State: VermontGMCB Filing Company: TVHP

TOI/Sub-TOI: ML02 Multi-Line - Other/ML02.000 Multi-Line - Other

Product Name: Q3 2022 TVHP Large Group Rating Program Filing

Project Name/Number: /

Filing at a Glance

Company: TVHP

Product Name: Q3 2022 TVHP Large Group Rating Program Filing

State: VermontGMCB

TOI: ML02 Multi-Line - Other

Sub-TOI: ML02.000 Multi-Line - Other

Filing Type: GMCB Trend / Admin Charge

Date Submitted: 02/17/2022

SERFF Tr Num: BCVT-133154563

SERFF Status: Pending Industry Response

State Tr Num: State Status: Co Tr Num:

Effective On Approval

Date Requested:

Author(s): Jude Daye, Martine Brisson-Lemieux, Andrew Proulx, Matthew Goodrich

Reviewer(s): Thomas Crompton (primary), David Dillon, Jacqueline Lee, Christina McLaughlin, Michael

Barber, Laura Beliveau

Disposition Date:
Disposition Status:
Effective Date:

State Filing Description:

State: VermontGMCB Filing Company: TVHP

TOI/Sub-TOI: ML02 Multi-Line - Other/ML02.000 Multi-Line - Other

Product Name: Q3 2022 TVHP Large Group Rating Program Filing

Project Name/Number: /

General Information

Project Name: Status of Filing in Domicile:
Project Number: Date Approved in Domicile:
Requested Filing Mode: Review & Approval Domicile Status Comments:

Explanation for Combination/Other: Market Type: Group

Submission Type: New Submission Group Market Size: Large Group Market Type: Employer Overall Rate Impact:

Filing Status Changed: 02/22/2022

State Status Changed: Deemer Date:

Created By: Matthew Goodrich Submitted By: Matthew Goodrich

Corresponding Filing Tracking Number:

Filing Description: February 17, 2022

Thomas Crompton
Health Systems Finance Associate Director
Green Mountain Care Board
144 State Street
Montpelier, Vermont 05602

Subject:Blue Cross and Blue Shield of Vermont - NAIC # 53295 The Vermont Health Plan - NAIC # 95696 Q3 2022 Large Group Rating Program Filing

Dear Mr. Crompton:

Attached for the Green Mountain Care Board's review and approval is Blue Cross and Blue Shield of Vermont's and The Vermont Health Plan's Q3 2022 Large Group Rating Program Filing. As directed by the Board, this filing combines the various factor filings for large group rating components (trend, large claims, benefit relativity, administrative fees and contribution to reserve, and the formula itself) into a single filing.

Please let me know if we can answer any questions or provide further information during your review.

Sincerely,

Ruth Greene

cc:Paul Schultz/BCBSVT

Martine Lemieux/BCBSVT

Company and Contact

Filing Contact Information

Jude Daye, Executive Assistant dayej@bcbsvt.com

State: VermontGMCB Filing Company: TVHP

TOI/Sub-TOI: ML02 Multi-Line - Other/ML02.000 Multi-Line - Other
Product Name: Q3 2022 TVHP Large Group Rating Program Filing

Project Name/Number: /

445 Industrial Lane 802-371-3244 [Phone]

Montpelier, VT 05601

Filing Company Information

TVHP CoCode: 95696 State of Domicile: Vermont PO BOX 186 Group Code: Company Type: HMO Montpelier, VT 05601 Group Name: State ID Number:

(802) 371-3450 ext. [Phone] FEIN Number: 03-0354356

State: VermontGMCB Filing Company: TVHP

TOI/Sub-TOI: ML02 Multi-Line - Other/ML02.000 Multi-Line - Other

Product Name: Q3 2022 TVHP Large Group Rating Program Filing

Project Name/Number: /

Filing Fees

State Fees

Fee Required? No Retaliatory? No

Fee Explanation:

SERFF Tracking #: BCVT-133154563 State Tracking #: Company Tracking #: Company Tracking #:

State: VermontGMCB Filing Company: TVHP

TOI/Sub-TOI: ML02 Multi-Line - Other/ML02.000 Multi-Line - Other

Product Name: Q3 2022 TVHP Large Group Rating Program Filing

Project Name/Number: /

Correspondence Summary

Objection Letters and Response Letters

Objection Letters

StatusCreated ByCreated OnDate SubmittedPending
ResponseThomas Crompton02/22/202202/22/2022

Response Letters

Responded By Created On Date Submitted

State: VermontGMCB Filing Company: TVHP

TOI/Sub-TOI: ML02 Multi-Line - Other/ML02.000 Multi-Line - Other

Product Name: Q3 2022 TVHP Large Group Rating Program Filing

Project Name/Number: /

Objection Letter

Objection Letter Status Pending Response

Objection Letter Date 02/22/2022
Submitted Date 02/22/2022
Respond By Date 02/25/2022

Dear Jude Daye,

Introduction:

Please note that a filing fee of \$150 is required. The submission stated that no filing fee is required.

See "Filing Rules" and "General Instructions" in SERFF and shown below:

Fees

Fee Information:

Date Last Modified: 04/18/2018 08:32 AM

Is there a fee? Yes Is this state retaliatory? Yes

EFT is: Not Accepted Payment is: Due at Submission

How are fees calculated?

Vermont is a retaliatory state, and the filing fee is either \$150 per filing, or the retaliatory fee, whichever is greater. The fee is non-refundable.

Remittance Instructions:

Send checks payable to; State of Vermont - Green Mountain Care Board.

Must include SERFF filing number on check in memo section on check as "GMCB SERFF# ______".

Please send checks to, GMCB Attention: Janeen Morrison, 144 State Street, Montpelier, VT 05620

Conclusion:

Sincerely,

Thomas Crompton

State: VermontGMCB Filing Company: TVHP

TOI/Sub-TOI: ML02 Multi-Line - Other/ML02.000 Multi-Line - Other

Product Name: Q3 2022 TVHP Large Group Rating Program Filing

Project Name/Number: /

Rate Information

Rate data applies to filing.

Filing Method:

Rate Change Type: %

Overall Percentage of Last Rate Revision: %

Effective Date of Last Rate Revision:

Filing Method of Last Filing:

SERFF Tracking Number of Last Filing:

Company Rate Information

	Overall %	Overall %	Written Premium	Number of Policy	Written	Maximum %	Minimum %
Company	Indicated	Rate	Change for	Holders Affected	Premium for	Change	Change
Name:	Change:	Impact:	this Program:	for this Program:	this Program:	(where req'd):	(where req'd):
TVHP	7.900%	%		198	\$2,573,224	%	%

SERFF Tracking #:	BCVT-133154563	State Tracking #:	Company Tracking #:

State: VermontGMCB Filing Company: TVHP

TOI/Sub-TOI: ML02 Multi-Line - Other/ML02.000 Multi-Line - Other

Product Name: Q3 2022 TVHP Large Group Rating Program Filing

Project Name/Number: /

Supporting Document Schedules

Satisfied - Item:	Actuarial Memorandum
Comments:	
Attachment(s):	Q3 2022 TVHP Large Group Rating Program Filing - Actuarial Memorandum (REDACTED).pdf
Item Status:	
Status Date:	
Bypassed - Item:	Civil Union Rating Requirements
Bypass Reason:	Not required.
Attachment(s):	
Item Status:	
Status Date:	
Satisfied - Item:	Filing Compliance Certification
Comments:	
Attachment(s):	Q3 2022 TVHP Large Group Rating Program Filing - Rate Filing Certification.pdf
Item Status:	
Status Date:	
Bypassed - Item:	Third Party Filing Authorization
Bypass Reason:	TVHP does not use a Third Party to submit filings.
Attachment(s):	
Item Status:	
Status Date:	
Satisfied - Item:	Cover Letter
Comments:	
Attachment(s):	Q3 2022 TVHP Large Group Rating Program Filing - Cover Letter.pdf
Item Status:	·
Status Date:	
Satisfied - Item:	F106 Form
Comments:	
Attachment(s):	Q3 2022 TVHP Lg Grp Filing - F106 Form.pdf
Item Status:	
Status Date:	

SERFF Tracking #: BCVT-133154563 State Tracking #: Company Tracking #: **VermontGMCB** Filing Company: **TVHP** State: TOI/Sub-TOI: ML02 Multi-Line - Other/ML02.000 Multi-Line - Other Q3 2022 TVHP Large Group Rating Program Filing Product Name: Project Name/Number: Satisfied - Item: Plain Language Summary Comments: Attachment(s): Q3 2022 TVHP Large Group Rating Program Filing - Plain Language Summary.pdf **Item Status:** Status Date: Satisfied - Item: **Exhibits** Comments: Attachment(s): Q3 2022 TVHP Large Group Rating Program Filing - Exhibits (REDACTED).pdf **Item Status:** Status Date: Satisfied - Item: Appendix A Comments: Attachment(s): Q3 2022 TVHP Large Group Rating Program Filing - Appendix A.pdf Item Status: **Status Date:** Satisfied - Item: VT Rx Data Template Comments: VT Rx Data Template - TVHP - Q3 2022 Large Group.xlsx Attachment(s): VT Rx Data Template - TVHP - Q3 2022 Large Group.pdf **Item Status:**

Status Date:

State: VermontGMCB Filing Company: TVHP

TOI/Sub-TOI: ML02 Multi-Line - Other/ML02.000 Multi-Line - Other

Product Name: Q3 2022 TVHP Large Group Rating Program Filing

Project Name/Number:

Attachment VT Rx Data Template - TVHP - Q3 2022 Large Group.xlsx is not a PDF document and cannot be reproduced here.

1.	PURPOSE	2
2.	OVERVIEW AND RATE IMPACT	2
2.1.	Overview	2
2.2.	Historical Financial Results	2
2.3.	Impact of Formula and Factor Changes	4
3.	FORMULA DESCRIPTION	5
4.	TREND FACTORS	8
4.1.	Medical Trend Development	8
4.2.	Retail Pharmacy Trend	14
4.3.	Overall Total Trend	17
4.4.	Leveraged Trends	17
4.5.	Medicare Secondary Trends	18
4.6.	Vision Trend	18
4.7.	Prior Experience Period Trend Factors	19
5.	BENEFIT FACTORS	19
5.1.	Models for Active Employees	20
5.2.	Tier Factors	23
5.3.	Models For Age 65+ Medicare Secondary Plans	24
5.4.	Formulary & Pharmacy Options	25
5.5.	Riders	26
5.6.	Rate Smoothing Charges	26
6.	OTHER FACTORS APPLICABLE TO ALL LARGE GROUPS	27
6.1.	Manual Rate	27
6.2.	Large Claims Factors	29
6.3.	Administrative Charges	29
6.4.	Net Cost of Reinsurance	32
6.5.	Pharmacy Rebates	33
6.6.	OneCare Coordination Fee	33
6.7.	Contribution to Reserve	33
6.8.	State Mandates and Assessments	33
6.9.	Federal Assessments	35
7.	FACTORS APPLICABLE ONLY TO SPECIFIC PRODUCTS	35
7.1.	Stop Loss Coverage for Cost Plus products	
8.	MEDICAL LOSS RATIO PROJECTION	
9.	ACT 193 INFORMATION	
10.	ACTUARIAL OPINION	38
11.	DISCLOSURES	39

1. Purpose

Blue Cross and Blue Shield of Vermont (Blue Cross) and The Vermont Health Plan (TVHP) perform large group rating on a case-by-case basis. We accomplish rating through a formulaic approach that blends recent group experience with a manual rate according to a credibility formula. We may adjust formula results for underwriting judgment and/or management decisions. This filing establishes the formula, manual rate, and accompanying factors that we will use for renewals beginning upon approval of this filing, most notably January 2023 renewals.

Once approved, we will use this filing for insured large group and grandfathered small group renewals (we will refer to them collectively as large groups for the remainder of the filing) until superseded by a subsequent filing. In the event that renewals require factors with effective dates or experience periods beyond those explicitly presented in this filing, we will calculate appropriate factors using the same base data and methodology used in this filing. This filing will apply beginning with rates communicated within seven business days after the date of its approval and continuing until at most seven business days after the date of approval of the next Blue Cross and TVHP Large Group Rating Program filings. The term "communicated," for this purpose, means a written proposal delivered to a large group account.

2. Overview and Rate Impact

2.1. Overview

This filing includes a description of the renewal formula and the development of each of the factors used in it. We use this formula for insured products, including Cost Plus. Blue Cross projects that this filing will affect 6,396 members (3,563 subscribers) in 38 groups. These totals are as of December 31, 2021 and include members of both Blue Cross and TVHP. We will refer to the combined population as Blue Cross throughout this memorandum.

We will describe in detail the formula used in the renewals. We will then detail the factors applicable to all insured large groups. The factors in the build-up of the projected claims cost include the trend factors, benefit relativities, manual rate, and large claims factors. In addition to the projected claims cost, we will explain the calculation of administrative charges, the net cost of reinsurance, contribution to reserve, and state and federal assessments, all of which are included in the rate development.

Finally, we will discuss factors applicable only to specific products. Cost Plus customers purchase Individual and Aggregate Stop Loss (ISL and ASL) from Blue Cross. Cost Plus products are not available through TVHP.

2.2. Historical Financial Results

Below is the combined medical and pharmacy experience for the prior five calendar years. This includes Blue Cross and TVHP insured large group experience. Additionally, we show loss & expense ratios for Cost Plus groups.

	Insured Large Group Experience							
						Target		
					Loss &	Loss and		
	Incurred	Administrative	Earned		Expense	Expense	Member	
Year	Claims	Charges	Premium	Gain/(Loss)	Ratio	Ratio	Months	
2017	\$86,520,109	\$10,424,245	\$92,106,277	(\$4,838,077)	105.3%	98.0%	197,954	
2018	\$81,698,684	\$12,621,438	\$86,961,470	(\$7,358,653)	108.5%	98.0%	176,430	
2019	\$83,943,117	\$10,154,503	\$88,800,868	(\$5,296,752)	106.0%	98.5%	166,597	
2020	\$46,676,144	\$9,376,855	\$56,468,497	\$415,498	99.3%	98.5%	97,941	
2021 ¹	\$42,184,467	\$7,166,723	\$43,451,198	(\$5,899,992)	113.6%	98.5%	71,773	

Cost Plus Experience					
Loss & Expense					
Year	Ratio	Member Months			
2017	95.4%	514,809			
2018	99.8%	5,045			
2019	89.2%	4,893			
2020	93.3%	2,632			
2021	148.8%	2,485			

The incurred claims, administrative expenses, and earned premium are from Blue Cross GAAP financials. The claims include capitations, fee-for-services claims, certain assessments, and other claims expenses.

The chart below shows the expected and actual contribution to reserves from the previous five years for Insured Large Groups. The expected contribution to reserves reflects ordered reductions to CTR as well as modifications to actuarial factors that were not recommended by the independent reviewing actuary.

Expected and Actual Contribution to Reserves							
Year	Year Filed Expected Actual						
2017	2017 2.0% 2.0% -5.3%						
2018	2018 2.0% 0.8% -8.5%						
2019	2019 1.5% -2.2% -6.0%						
2020	2020 1.5% 0.8% 0.7%						
2021	1.5%	0.1%	-13.6%				

We note the high variance between the expected and actual contribution to reserves prior to 2020, in which the results included the effects of the deferral of non-emergent care in the early stages of the pandemic. Recent filings have included increases to the manual rate that were a correction to experience through 2019, as well as numerous enhancements to the rating methodology to make rates more accurate on a group-by-group basis and in aggregate. Unfavorable 2021 results were driven by an

_

¹ 2021 underwriting results are preliminary as of December 31, 2021.

increase in high cost claims and COVID-19 costs. Overall, the performance of actual results to expected indicate a consistent absence of conservatism in the factors underlying the filing.

2.3. Impact of Formula and Factor Changes

To compute the impact of changes to the rating formula and the various factors in this filing on large group premium rates, we use the concept of a "pure manual premium," which is the premium that can be developed for each group in the existing block of business using none of their own experience data². Two renewals are developed for each group: the first renewal applies the approved factors currently in force (BCVT-132713612 and BCVT-132713919) with an effective date of January 1, 2022. The second renewal uses the factors and formulas detailed in this filing with a January 1, 2023 effective date. By nature of the differing effective dates, the latter renewal includes an additional year of health care cost trend.

Impact of Formula and Factor Changes						
Renewal Year	2022	2023	Component Increase	Premium		
Filing Year	Q3 2021	Q3 2022	iliciease	Impact		
Manual Claims (a)	\$41,735,042	\$45,068,894	8.0%	7.3%		
Projected Rebates	-\$2,646,726	-\$2,819,567	6.5%	-0.4%		
Admin	\$3,882,767	\$4,171,999	7.4%	0.6%		
Reserve	\$677,275	\$730,778	7.9%	0.1%		
Mandates and						
Assessments	\$1,030,869	\$1,057,883	2.6%	0.1%		
Additional Items (b)	\$1,230,828	\$1,323,594	7.5%	0.2%		
Total	\$45,910,054	\$49,533,582		7.9%		

- (a) The manual claims increase includes changes in the membership, industry, and update in benefit relativities from groups underlying the manual rate. We normalize the demographic factors and industry factors to the membership in each respective filing.
- (b) Additional Items include net cost of reinsurance, Cost Plus stop loss, broker commissions, the OneCare Coordination Fee, and fees paid to outside vendors.

The above approach has been used to generate a proxy increase for a hypothetical group that is renewing with zero experience credibility, exactly average demographics and industry, and no underwriting judgment or management discretion applied to the proposed or in-force rates. The actual rate increase experienced by any specific group will be based on the group's own circumstances, including its claims data, demographic makeup, large claims experience, and so forth.

This total impact of formula and factor changes should not be interpreted as the new formula resulting in a 7.9 percent premium increase for any specific group.

² This excludes three groups with fewer than 12 months of enrollment in the experience period used to develop the manual rate.

3. Formula Description

We develop rates for active and Medicare Primary subscribers separately based on their own experience. Both the formula and factors described in this filing are the same for both populations except where noted. Medicare Primary rate tiers are not offered on TVHP.

Benefit-Adjusted Projected Single Claims Rate

Exhibit 1A contains a sample calculation of the benefit-adjusted single claims rate. Page 1 of the exhibit applies to active members and page 2 applies to Medicare Primary members. For each case, we start the rating with a twelve-month experience period with at least two months of runout³. We develop the experience rate for medical and pharmacy claims separately. We determine a pooling point based on the size of the case at the end of the runout period and split the experience period claims (line A) into amounts above (line B) and below (referred to as capped claims, line D) the pooling point. We exclude certain COVID-19 related claims (line C) from the development. Exhibit 6C contains a list of excluded primary diagnosis and procedure codes, which we will update as new information becomes available. Section 6.7 provides further details on the exclusion of COVID-19 related claims.

We apply completion factors (line E) developed from the monthly financial reporting process (best estimates before margin) to capped claims to produce completed capped claims (line F). We use the formula and factors described in Milliman's 2021 *Health Cost Guidelines – Reinsurance* to calculate expected claims above the pooling limit (line G). We add the expected claims above the pooling limit to the completed capped claims to produce large-claim-adjusted experience period claims. Medicare Primary members generally do not have claims near the group's pooling point, so we do not pool their claims.

We then multiply the large-claim-adjusted experience claims by an adjustment factor (line H) to reflect structural changes between the experience period and the rating period. This adjustment modifies the experience to reflect such things as mandated benefit changes, contractual provision changes, etc., that, in the judgment of the underwriter, are necessary to make the experience appropriate for the estimation of the expected claims in the rating period.

We divide the result (line I) by the number of member months during the experience period (line J) to produce the adjusted experience period claims per member per month (line K).

We then divide the adjusted experience period claims per member per month (PMPM) by a seasonally-adjusted benefit relativity value to neutralize any effect of seasonality and benefits on the paid claims. To determine this factor, we first determine a benefit relativity factor for each benefit plan (using the factors described in section 5) and contract tier type (single, 2-person, family, etc.). Based on the seasonal patterns observed as part of the reserving process for each calendar month, we determine seasonal factors for CDHPs and for non-CDHPs and normalize them so that they total to 12. We combine these factors to calculate seasonal benefit relativity factors for each combination of benefit plan, contract tier type, and month. We apply these factors to the number of contracts for each benefit plan, contract tier type, and month in the experience period. We total the results and divide the resultant sum

³ For first year renewals where twelve months of experience is not available, we typically use claims incurred in nine months with no runout.

by the number of member months in the experience period. We apply the seasonal factors regardless of the length of experience period, but if there is a 12-month experience period and there are no changes in benefits or enrollment, the normalization of the seasonality factors would cause the seasonal adjustment to be 1.000. This produces the average experience period seasonally-adjusted benefit relativity factor (line L).

We adjust for any change in the demographics of the group between the experience period and the rating period by calculating the average demographic factor for each period and applying the ratio of projection to experience (line M). We multiply the adjusted experience period claims PMPM (line K) by the demographic normalization factor and divide by the average experience period seasonally-adjusted benefit relativity factor (line L) to produce the benefit-adjusted experience period single claims rate (line N), which is the expected cost for a single contract in the experience, neutral of benefit and seasonality. We then multiply this by a trend factor (line Q, as discussed in section 4) to project the claims from the experience period to the rating period.

We blend the projected single contract rate (line R) with the adjusted manual rate (line S, as described in section 6.1) using the credibility formula described below.

We calculate the credibility factor (line T) as follows:

$$Credibility = \sqrt{\frac{Member\ Months}{Upper\ Bound}}$$

The pooling point determines the upper bound. We base the pooling limit on the group's membership in the current month. Please see the abbreviated table below for details. The underwriter may apply discretion in the event the current month's membership is not appropriate for determining a pooling limit (e.g. a significant change in enrollment due to an acquisition or layoff).

Membership (Current Months)	Pooling Point	Upper Bound Member Months
Medicare	8,325	
0 to 299	\$70,000	14,002
300 to 499	\$90,000	16,127
500 to 999	\$110,000	17,923

If member months are greater than the upper bound, the credibility factor will be 1. We pool Cost Plus products at their attachment point. Exhibit 6A provides a complete list of upper bound member months by pooling point, while Exhibit 6B details pooling points by current month membership. To blend the projected single contract rate with the adjusted manual rate, we use the following equation:

Benefit-Adjusted Projected Single Claims Rate = Projected Single Contract Rate \times (Credibility) + Adjusted Manual Rate \times (1 - Credibility)

Multiple Experience Periods

Blue Cross uses multiple experience periods (when available) to develop the benefit-adjusted projected single claims rate. Following the methodology described above, we calculate an experience rate for the first and second year preceding the experience period. We then apply the credibility formula recursively to the residual portion of the rate. The table below provides a demonstration of the application of the credibility formula for a group with 50 percent credibility in each experience year.

Experience Period	Proportion of Rate
YE 202206	50.0%
YE 202106	25.0%
YE 202006	12.5%
Manual Rate	12.5%

Three years of experience is the maximum that we will use. In the absence of extenuating circumstances, all renewals will use the maximum number of years available. In the event we do not consider historical experience appropriate or reliable for rating periods (e.g. a significant change in enrollment due to an acquisition or layoff), the underwriter will use fewer years of experience and document the rationale for such a change.

Exhibit 1B provides a detailed sample calculation of the benefit-adjusted projected single claims rate using three years of experience.

If the credibility of the first year of experience is in excess of 66.67%, the underwriter shall develop rates using a 3-2-1 blend of experience periods and not utilize the manual rate.

Required premium by Plan, Tier Type

Exhibit 1C provides a sample calculation of premium. For each plan and contract tier type anticipated in the rating period, we calculate projected claims (line B1) as the product of the benefit-adjusted projected single claims rate (S) and the benefit relativity factor (as described in section 5) for the plan and contract tier (line A). For any premium components that are exclusively applicable to either active or Medicare Primary members, we only include the component in the respective rate tier(s) to which it applies.

We use the members per contract tier during the last month of the runout period as the basis for the projected members per tier in the rating period. The underwriter will adjust this ratio if, in their opinion, the result is not representative of the expected values in the rating period.⁴

Underwriting Judgment Adjustments

If, in the underwriter's professional judgment, the standard formula would not produce appropriate rates for the case being rated, the underwriter will make such modifications as needed to produce

⁴ E.g., the number of contracts in a particular tier may be small (or even 0). In such instances, the underwriter should use appropriate values based on total block of business or other appropriate sources.

appropriate rates. The underwriter will document in the case file the reason(s) for the adjustment(s) and the method of determining the appropriate adjustment(s).

Management Discretionary Adjustments

For marketing or other reasons, management may decide to modify the rates on a specific case or block of cases. The underwriter will document in the case file the adjustment(s) made, along with a description of the nature of the adjustment(s).

4. Trend Factors

The source of data for trend development is the Blue Cross data warehouse, except where noted below. To ensure the accuracy of claims information, we reconcile the data used against internal reserving, enrollment, and other financial reports. The data includes claims from Blue Cross Cost Plus groups, Blue Cross ASO groups of under 1,001 members, Blue Cross insured large groups, Blue Cross insured small groups with more than 10 members, Blue Cross insured association health plans with more than 10 members, and TVHP insured large groups. The data also excludes insured large groups with much higher costs than average that have left Blue Cross in 2020 and 2021. The above lines of business cover substantially similar populations under similar benefit packages. Combining these homogeneous populations creates greater consistency and credibility within the trend factor development.

We exclude large ASO groups and ASO groups with special pricing arrangements. Blue Cross experienced large membership movement out of the small group market during the trend experience period. Due to significant changes in membership, we exclude all membership from small groups that were not continuously with Blue Cross throughout the trend experience period. We exclude claims from Medicare Primary members. Medicare Primary trend is discussed in section 4.5. We exclude compounds, vaccines, and over-the-counter drugs from the pharmacy cost trend development.

We use claims incurred from September 1, 2017 to August 31, 2021, paid through October 31, 2021. We apply completion factors to estimate the ultimate incurred claims for each period shown in the exhibits.

4.1. Medical Trend Development

Medical trend is composed of three pieces: cost, utilization, and intensity. In our analysis, we combine utilization and intensity within the utilization metric and analyze the unit cost separately. For fee-for-service claims, we combine plan payment with member cost sharing to calculate the allowed charges. For claims under a capitation arrangement, we combine a fee-for-service equivalent amount with the member cost sharing to calculate allowed charges.

4.1.1. Unit Cost

Observations of recent contracting and provider budgetary changes are the main source of unit cost trends. During the year ended August 2021, roughly 52 percent of total claims dollars were provided by Vermont facilities and providers directly affected by the hospital budget review process of the Green Mountain Care Board (GMCB). For hospitals under the jurisdiction of GMCB review, we start with the assumption that the GMCB will approve hospital budgets for October 1, 2022 and October 1, 2023 that support identical commercial increases as those approved for October 1, 2021. The Blue Cross provider

contracting team continually communicates with certain hospitals. Accordingly, we have adjusted projected increases based on recent information from the hospitals. In the event that Blue Cross is made aware of budget increases that would materially diverge from this assumption, Blue Cross will file an interim trend filing to best align the cost trend used in pricing with expected cost trend.

For other providers within the Blue Cross service area, we work with the Blue Cross contracting team to include expected increases to fee schedules.

The provider contracting and actuarial departments worked together to assess the impact these increases would have on contracts for Blue Cross Managed Care, Blue Cross Non-Managed Care, and TVHP Managed Care contracts. For marketing reasons, Blue Cross negotiates different unit cost increases for each of the three contracts. To reflect these differences, we calculate a cost trend for each contract.

Finally, we derive unit cost increases for providers outside the Blue Cross service area from the Fall 2021 Blue Trend Survey, which is a proprietary and confidential dissemination of the BlueCross BlueShield Association.

Exhibit 2A shows the details of the cost increases by contract and type of claim.

We use the expected increases to trend the contract-normalized claims to the projection period.

The chart below summarizes the results of the analysis:

Medical Unit Cost Trend – CY 2022							
Blue Cross Blue Cross Non- TVHP Manag Managed Care Managed Care Care							
Vermont facilities and providers impacted by GMCB's Hospital Budget Review	5.0%	5.1%	5.0%				
Other facilities and providers	4.8%	5.0%	5.0%				
Total	4.9%	5.1%	5.0%				

Medical Unit Cost Trend – CY 2023						
	Blue Cross Non- Managed Care	TVHP Managed Care				
Vermont facilities and providers impacted by GMCB's Hospital Budget Review	5.9%	5.9%	5.9%			
Other facilities and providers	4.7%	4.7%	4.7%			
Total	5.4%	5.4%	5.4%			

4.1.2. Utilization & Intensity

To examine historical utilization trend patterns, we first normalize claims for unit cost increases. We measure contract changes for the entirety of the experience period explicitly for each facility within our service area as well as the three largest physician groups. We normalize claims to the August 2021

contract at each unique provider by applying a factor equal to the product of the impact of each contracting change from the experience month through August 2021. We assume that the derived trend for other claims increases monthly on a continuous basis.

To measure the increases for fee schedules and other chargemasters, we apply each schedule to a market basket of services defined using Current Procedural Terminology (CPT) codes & CPT modifier combinations that are present in each of the effective periods covered by the schedules. Using the same experience period data used throughout the trend analysis, we compare total allowed costs for the selected CPT & CPT modifier combinations under each schedule to estimate the percentage increase. For contracts under diagnosis-related group (DRG) arrangements, we compare the charge for the 1.000 DRG service for each period. Finally, for services under a discount of charge arrangement, we use the contracted chargemaster increase provided by our provider contracting department.

This accounts for 85 percent of allowed claims dollars during the experience period. Costs for other claims are primarily for out-of-area services. To derive contracting changes for these claims, we use data from the Fall 2021 Blue Trend Survey, which is a proprietary and confidential dissemination of the BlueCross BlueShield Association.

To ensure that random high claims do not skew the trend calculation, we removed all claims of members who exceeded \$500,000 in allowed medical claims in a year ended August. As the utilization component includes intensity, an increase in high-cost claimants can disproportionately impact the year-over-over and regression calculations.

Exhibit 2B shows the resulting array of allowed PMPM claims costs both before and after normalization for contract changes. We also apply normalization factors to the array of allowed PMPM claim costs for:

- Changes in demographics, using factors from the SOA's report Health Care Costs From Birth to Death⁵
- Normalizing each month to the average number of working days per month in the year ended August 2021, as defined by our reserving models.
- Programs to combat fraud, waste, and abuse (FWA). Due to the migration to a new operating platform, Blue Cross FWA programs slowed in 2019. Further, DFR ordered the suspension of all routine provider audits from March 18, 2020, through August 3, 2020. In the fourth quarter of 2020, we did not engage in routine audits of the University of Vermont Health Network providers while they dealt with a cyberattack. The COVID-19 pandemic is still ongoing and while Blue Cross continues to work on FWA programs, the overall recoveries continue to be dampened as the health care industry as a whole continues to deal with the impacts of this pandemic. To control for the historical changes in recoveries we normalize claims on a monthly basis based on each respective month's recovery rate.

Exhibit 2B, page 2 shows the development of the factors.

⁵ https://www.soa.org/Research/Research-Projects/Health/research-health-care-birth-death.aspx

4.1.2.1. Facility Claims

Using the array of PMPM claim costs net of high claimants and adjusted for contract, aging, number of working days, FWA, and one-time events, we performed 24-month regressions, 36-month regressions, 48-month regressions and time series calculations.

The year ended August 2021 over year ended February 2020 annualized trend, after the adjustments described above, is -6.7 percent. Though some services saw an escalation in services due to returning care that was deferred in the spring of 2020, many services were below their pre-pandemic levels in the year ended August 2021. We anticipate that facility services will remain at the current level through May 2022 and then rebound to the February 2020 level through the end of calendar year 2023. We consider a 0.0 percent trend rate for post-rebound claims, which is lower than the prior approved trend and in line with other Blue Cross lines of business, to be a reasonable long-term selection for these claims. We provide the historical facility utilization trends through August 2021, and our selected trends for future periods in the table below.

Facility Claims				
Year Ended	РМРМ	Annualized Trend		
February 2019	\$306.73			
February 2020	\$299.16	-2.5%		
August 2021	\$283.18	-3.6%		
December 2022	\$292.50	2.5%		
December 2023	\$299.16	2.3%		

Exhibit 2B, pages 4 to 6, shows the normalized facility time series and regressions. Note that these were not used to inform our trend assumption as they are heavily influenced by the impact of the COVID-19 pandemic on claims patterns.

4.1.2.2. Professional and Ancillary

The COVID-19 pandemic created significant variability in professional claims utilization. Though some categories of services have seen an increase in utilization to make up for services that were deferred in the spring of 2020, other service types have not returned to their pre-pandemic level of volume. This has resulted in a change in the mix and intensity of services, as the services that have seen the most immediate return are likely for more severe conditions, which may have been further exacerbated by the limited access to care in the spring of 2020.

Mental health services, which were seeing an escalation in services prior to the COVID-19 pandemic, continues to see rapid growth in the number of visits. Given the varying experience of mental health and other professional services over the past 18 months of the trend experience period, we select a separate utilization trend for mental health professional services and other professional services.

	Mental Health and Substance Abuse		All Other Professional	
	Visits per 1,000 Annualized		Visits per 1,000	Annualized
Year Ended	member per month Increase		member per month	Increase
February 2019	123.25		754.85	
February 2020	139.77	13.4%	757.87	0.4%
August 2021	161.61	10.2%	718.46	-3.5%

We provide in the table below the normalized claims cost, which includes adjustments for utilization, intensity, and mix of services. We consider the drop in utilization to be attributable largely to supply constraints and the reluctance of some members to seek care during the pandemic. We anticipate that non-mental health professional services will remain at the current level through May 2022 and then rebound to the February 2020 level through the end of calendar year 2023. We consider a 0.0 percent trend rate for post-rebound claims, which is lower than the prior approved trend and in line with other Blue Cross lines of business, to be a reasonable long-term selection for these claims.

For mental health claims, based on the historical patterns above and the work in Vermont to expand access to mental health services, especially during and after the pandemic, a 10 percent increase best projects the utilization of professional mental health services.

We provide the historical professional utilization trends through August 2021 and our selected trends for future periods in the table below.

Professional Trend						
	Mental Health		All Other		Total Professional	
Year Ended	РМРМ	Annualized Trend	РМРМ	Annualized Trend	РМРМ	Annualized Trend
February 2019	\$11.55		\$127.25		\$138.80	
February 2020	\$13.10	13.4%	\$122.82	-3.5%	\$135.92	-2.1%
August 2021	\$15.21	10.5%	\$119.08	-2.0%	\$134.29	-0.8%
December 2022	\$17.27	10.0%	\$121.26	1.4%	\$138.53	2.4%
December 2023	\$19.00	10.0%	\$122.82	1.3%	\$141.82	2.4%

Exhibit 2B, pages 7 to 12, shows the normalized professional time series and regressions. Note that these were not used to inform our trend assumption as they are heavily influenced by the impact of the COVID-19 pandemic on claims patterns.

4.1.2.3. Pharmaceuticals

The recent acceleration in cost for pharmaceuticals processed through the medical benefit warrants a separate analysis for these claims. Pharmaceuticals processed through the medical benefits include a wide variety of drugs. We split the experience into four categories: Injections with a biosimilar option, biosimilars, other injections costing at least \$1,000, and all other pharmaceuticals. The introduction of biosimilars considerably changes the cost per service for injections. To reflect this change in mix, we project the overall number of services for injections and their biosimilar options and project the growth

in the share of services that will be with biosimilar. We apply the overall outpatient cost trend to each category to project the cost per services. With varying utilization of services trends, the average projected cost per service reflects the change in mix, which is included in the total utilization trend below.

Exhibit 2C, pages 1 to 5 show the experience services per 1,000 members for each of the four pharmaceutical categories and the 24 and 36-month regressions. Exhibit 2C, page 6, shows the result of this calculation.

The 'All Other' category includes drugs used during other outpatient and office procedures and are expected to trend at the same rate as the overall facility services.

The high-cost injections experienced a large increase in services in the second half of 2019 before returning to historical levels. We expect these injections to remain at the level of the most recent 12-month period.

Services per 1,000 for High-Cost injections		
YE 201808	2.76	
YE 201908	4.27	
YE 202008	3.70	
YE 202108	3.20	

The combination of Injections with a biosimilar equivalent and the biosimilars have been increasing steadily and we expect it to continue to grow at a 10 percent rate through calendar year 2023.

Trend for Injections with Biosimilar Equivalent and Biosimilars		
Most Recent Year over Year	3.5%	
Two-Year	13.1%	
36-month regression on Monthly data	14.0%	
24-month regression on Monthly data	4.0%	
24-month regression on rolling 12 data	7.8%	

The biosimilars utilization as a percentage of total services for injections with biosimilar equivalent and biosimilars has been increasing logarithmically over the past few years.

Percentage of Biosimilar Services		
YE 201808	0.0%	
YE 201908	10.4%	
YE 202008	19.3%	
YE 202108	47.6%	

We do not expect the percentage to continue to double through calendar year 2023. The recent large increase in the percentage of biosimilars is due to the introduction of two new biosimilars, taking the overall number included in this category to five. We expect that the percentage of biosimilars will grow

by about 10 percent per year. At this rate, we calculate that the percentage of biosimilars will be about 70 percent for calendar year 2023, which is aligned with the most recent percentage for drugs that have had a biosimilar for at least 18 months.

Combining all of the categories calculates an overall 7.4 percent trend for pharmaceuticals, which is lower than the prior filing (13.8 percent). This drop is driven by the rapidly increasing availability and utilization of biosimilars.

4.1.3. Total Medical Trend

The total medical trend factors are the product of the utilization trend and the unit cost trend factors.

Annual Medical Trend – BCBSVT Managed Care				
Category	Facility Professional Pharmaceuticals Total			Total
Unit Cost	5.4%	4.2%	5.3%	
Utilization	2.4%	2.4%	1.9%	
Total Medical Trend	7.8%	6.7%	7.3%	7.5%

	BCBSVT Managed	BCBSVT Non-	TVHP Managed
Component	Care	Managed Care	Care
Total Annual Medical Trend	7.5%	7.6%	7.6%

These represent the annualized trend from year-ended August 2021 to calendar year 2023. Due to the non-uniform trend assumptions for facility and all other professional services, we will apply monthly trend factors to bring the renewal experience period through the rating period. The monthly factors are shown on Exhibit 2G.

4.2. Retail Pharmacy Trend

Similar to previous Large Group Rating Program filings, we base our cost trend calculation on Average Wholesale Price (AWP) and apply a separate factor in the rating formula to account for contracting changes. We analyze the components of trend (cost and utilization) separately for brand and generic drugs. We estimate the impact of brand drugs going generic based on the brand drugs that are likely to lose patent in the projection period. Specialty drugs are very high cost drugs with low utilization. Because of their relative infrequency, we consider it more appropriate to look at the overall PMPM trends for these drugs rather than separate cost and utilization components. We calculate the overall pharmacy trend by combining the separate projections.

Non-Specialty Drug Utilization

Exhibit 2D provides the monthly and the 12-month rolling data for non-specialty drugs, along with the corresponding year-over-year and exponential regression trends. There are separate developments for generic cost, brand cost, and overall non-specialty utilization. We use the number of days supply in the utilization development, rather than the number of scripts, to normalize for changes in the days supply per script (e.g. increased use of 90-day fills). Because there are several popular brand drugs that have become generic during the experience period, or will become generic during the projection period, we combine the data for generic and brand drugs for the purpose of analyzing utilization patterns.

Vaccines and devices have been moving from the medical benefit to the pharmacy benefit. These two categories are excluded from the non-specialty trend calculations as they would skew the results. We adjust the data for pharmacy working days, which are different from medical working days.

Due to COVID-19, many members refilled their prescription early in March 2020. This changed the pattern of monthly days supply per member. To adjust for this one-time event, we smooth monthly days supply per member for the periods from March 2020 to May 2020 and June 2020 to August 2020 by using the monthly spread from the same months in 2019.

Exhibit 2D, page 3, shows monthly cost per day supply, adjustment calculation, the 24-month regressions and the 36-month regressions.

Non-specialty utilization has been increasing at a two to three percent rate from March 2020 through June 2021 before decreasing slightly in the last two months of the experience. We select a 1.3 percent non-specialty utilization trend, which is approximately the average of the regressions on monthly, rolling costs, year-over-year and two-year trends.

Generic Cost Trend

In the previous filing, we used the generic drugs that have been in the market for at least three years to determine the generic cost trend. We modified the definition of *new generic* to be at the drug name level and not NDC level, which reduced the number of new generics. This change in definition and the use of all generics instead of only the generics that have been in the market for at least three years reduced the differences between the regressions and year over year results.

Exhibit 3D, page 1, shows monthly Average Wholesale Price (AWP) cost per days supply and the 24-month regressions. We select 2.8 percent for the generic cost trend, which is the average of the 24-month regressions and the year over year result. The rolling annual trends have been between 2.3 and 3.0 percent for the last six 12-month periods. We consider 2.8 percent to be a reasonable long-term outlook for generic cost trend.

Brands that are going generic will become subject to generic discounts. We do not expect that the AWP for these drugs will significantly change from the experience period due to the lack of generic competition for the main drugs in this category. We adjust the price to reflect the different experienced effective discounts between brands and generics. We also adjust the price of the new generics to reflect the difference in effective discounts as compared to the generics that have been in the market for at least three years.

Brand Cost Trend

The monthly AWP cost per day supply for brand drugs is impacted by the mix of new and older brands. Brands that have been in the market for one to two years are, on average, less expensive than older brands. To account for this change in mix, we perform a 24-month regression on monthly AWP cost per day supply for brand drugs that have been in the experience for at least four years.

Exhibit 2D, page 2, shows the monthly cost per day supply and the 24-month regressions.

We select 10.0 percent for the brand cost trend, which is slightly lower than the average of the 24-month regression result on monthly data, the 24-month regression on rolling 12-month data, and the

most recent year over year trend. This result is consistent with recent filings, and we consider it to be an adequate, yet not excessive, outlook of future trends.

Compounds are one-off prescriptions that are constructed at the pharmacy from component ingredients. Because they are not sold on a wholesale basis, there is no official AWP. Therefore, the concept of cost trend does not apply to compounds.

Vaccines, excluding COVID-19 vaccines, experienced major cost increases through the fall of 2019, and then slowed in 2020 before picking back up in 2021. We expect this up and down pattern to continue through 2022 include a 10 percent cost trend for vaccines.

We also do not expect over-the-counter drugs to follow the overall Brand cost trend. Based on historical data, we select a 0 percent cost trend for OTC drugs.

The cost of pharmaceutical devices has been increasing rapidly over the previous years due to the introduction of new and more expensive options. To calculate both the cost increases and impact of mix through 2022, we observe the increases by device and their respective market share. With the rollout of Vermont Blue Rx, some devices will no longer be covered and members will be directed to clinically equivalent preferred options. We adjusted the projected mix to reflect this change. We select an overall cost trend for devices of 17.4 percent. Details of the calculation are on page 4 of Exhibit 2D.

Specialty Drugs

Exhibit 2E shows the calculation of specialty trend for all specialty drugs. We select a 16.9 percent specialty trend, which is informed by the average trend produced by a 24-month regression on monthly cost, a 24-month regression on rolling 12-month cost, and the most recent year over year increase. For our regressions, we chose 24 points of monthly data to best capture the most recent history of drug costs. The selected trend of 16.9 percent is lower than the previous Large Group filings and filings for other Blue Cross business.

Total Pharmacy Trend

Instead of explicitly projecting a generic dispensing rate, we separate the drugs into eight categories:

- Generics: Drugs that have been generic since at least September 2018
- New generics: Generic drugs that have been on the market for fewer than 36 months (launched September 2018 through August 2021)
- Brands going Generic: brands that we expect to become available in generic form in the projection period, based on a list from our pharmacy benefit manager
- Vaccines
- Over the Counter (OTC)
- Compounds
- Devices, such as continuous glucose monitoring and insulin pens
- All other Brands

As shown on Exhibit 2F, we trend the days supply for each category forward at the same rate of 1.3 percent and calculate the total non-specialty allowed drug trend as 3.0 percent⁶.

Using the PMPM claims as weights between non-specialty and specialty claims for the 12 months ended August 2021, we apply the annual trends for 28 months. For drug claims in the year ended August 2021, we apply to AWP the contracted discounts and dispensing fees for both the experience period and CY 2023 to calculate the total effective trend based on anticipated discount improvements:

Allowed Pharmacy Trend		
Category Annual Trend		
Generic	-1.5%	
Brand	11.5%	
Brands Going Generic	-29.4%	
Specialty	16.9%	
Total (Contract Adjusted) ⁷	9.9%	

Please note that we apply contract changes separately from trend in order to accurately capture the timing for each renewal.

Exhibit 3K contains the contract adjustment factors that we will apply to the drug claims in a group's renewal. These factors assume that both the experience period and rating period are 12 months. For cases where this is not true, or for periods not provided in the exhibit, we will calculate an appropriate factor using an analogous methodology.

4.3. Overall Total Trend

Using the claims experience⁸ for the groups included in the manual rate (see section 6.1), we calculate the overall allowed trend as follows:

Category	Allowed PMPM	Allowed Trend
Medical	\$607.98	7.5%
Pharmacy	\$115.38	9.9%
Total	\$723.36	7.9%

4.4. Leveraged Trends

The above trends are based on allowed charges and do not account for the leveraging effect of deductibles and copays. Following the methodology used in the Q3 2019 filing, we measured the correlation between the leverage factors calculated using the method described above and the actuarial values (AVs) of the benefits and fit a curve to the results. For medical leverage, we fit a line to all medical products, including the medical portion of integrated CDHP benefits. For drug leverage, we found that using different lines for different types of drug benefits produced the best fits. We produced three lines:

⁶ The non-specialty trend prior to contract adjustments is

⁷ The total trend prior to the contract adjustment is

⁸ We use claims incurred September 1, 2020 through August 31, 2021, projected to calendar year 2023.

one for drug cards, one for CDHPs with wellness drugs covered at 100 percent, and one for all other CDHPs. The formulas for leverage are below:

Leverage Formulas		
Medical	-0.0631 x (AV) + 1.0641	
Drug Card	-0.0845 x (AV) + 1.0850	
Drug - CDHP 100% Wellness	-0.0517 x (AV) + 1.0529	
Drug - All Other CDHP	-0.0802 x (AV) + 1.0805	

Exhibits 3I and 3J provide examples of leverage factors.

Applying the leverage factors for benefits present in the year ended August 2021 for the groups included in the manual rate, we calculate the following paid trends:

Category	Paid PMPM	Paid Trend
Medical	\$ 503.82	9.0%
Pharmacy	\$ 103.11	10.6%
Total	\$ 606.94	9.3% ⁹

4.5. **Medicare Secondary Trends**

Medicare Secondary plans cover two categories of services: Medicare-covered services which are subject to member cost share (deductible/coinsurance) and services which are not covered by Medicare. We do not adjust services subject to Medicare cost sharing for network, as Medicare sets the allowed charges, whereas we do adjust the services not covered by Medicare using the contract factors described above to bring all charges to a single network.

For Medicare claims, we use cost and utilization trends from the 2022 TVHP Medigap Blue rate filing (BCVT-132956934).

Category	Allowed Trend
Inpatient	0.3%
Outpatient	4.0%
Professional	4.0%

The trends used for services not covered by Medicare are the same as the trends developed for use with active benefits. We use the same pharmacy trends for Medicare Secondary plans as we use for active plans.

4.6. **Vision Trend**

All large groups benefits include vision exams for both adult and children. Large groups can also purchase a rider to cover frames and lenses. Due to the different coverage options and limitation in the

⁹ The paid trend without the pharmacy contract adjustment is

vision data to identify the cost of the exam and the materials, we calculate the trends for the large groups with exam only coverage.

Year Ended	Paid PMPM	
August 2019	\$0.58	
August 2020	\$0.43	
August 2021	\$0.43	

We expect 2022 and 2023 to remain at the level experienced in the most recent two years ended August; we therefore select a 0.0 percent overall vision paid trend.

While the data for groups with coverage for exam and materials is not fully credible for trend development, we observed the following PMPM paid claims results. We believe that the overall 0.0 percent trend for vision benefits is therefore reasonable for both exam and material benefits.

Year Ended	Average Membership	Paid PMPM	
August 2019	1,594	\$3.84	
August 2020	1,544	\$2.71	
August 2021	1,784	\$2.37	

4.7. Prior Experience Period Trend Factors

We trend prior experience periods to the most current experience period using observed trends and apply the trend factors in section 4 to trend from the most current experience period to the rating period. Exhibit 2G contains the trend factors applicable to prior periods. For months following our trend base (that is, after August 2021), the observed trend is set to the trend factors in section 4. There are separate observed trend factors for active medical, Medicare Primary medical, and pharmacy.

To develop the observed medical trend factors, we calculate a monthly utilization trend. We apply actual cost increases to calculate the total observed medical trend. The observed pharmacy trend is the allowed claims trend of the trend experience base described in section 4. Historical trend factors for Medicare Primary medical claims are the approved trends for prior periods from the 2022 TVHP Medigap Blue Rate Filing (SERFF# BCVT-132956934).

5. Benefit Factors

To determine standardized claims rate relationships, also called relativities, Blue Cross creates models that simulate the impact of member benefits for all types of plans. The models determine the allowed charges for the 12 months of claims included in the study and "re-adjudicate" the claims, thereby simulating the impact of member cost sharing for a given benefit plan.

The claims data used in the models is from Blue Cross's data warehouse. To ensure accuracy, the claims data has been reconciled against internal reserving, enrollment, and other financial reports. The starting point of the analysis is allowed charges as determined by the Blue Cross claims adjudication system. The claims data includes benefit service codes that enable us to identify the services and benefit structures (copays, deductibles, and coinsurance) for each claim.

The models use incurred allowed charges from September 2020 to August 2021, paid through October 2021. We trend the allowed charges 28 months to the 12-month period that begins January 1, 2023. The majority of the business that will be renewed using these relativity factors has a January 1 renewal date; the rating formula adjusts the trend for non-January renewals (see section 6.1). We do not adjust the claims for the impact of deferred and returning care due to COVID-19. The trend factors we apply to the claims reflect the change in claims patterns anticipated from year-ended August 2021 through calendar year 2023, which includes the impacts of returning care in the experience and the expected return to pre-pandemic levels of utilization by 2023.). We exclude direct costs for COVID-19.

The data includes claims from Blue Cross Cost Plus groups, Blue Cross ASO groups, Blue Cross insured large groups, Blue Cross insured small groups, and TVHP insured large groups. Combining these homogeneous populations creates greater consistency and credibility within the relativity factor development. We combine CDHP and non-CDHP claims. We exclude claims from certain large ASO groups, as the rich benefits offered by those groups are not in line with the leaner offerings of most insured large groups. We also exclude groups that have special benefits. This predominantly refers to groups that have specific reimbursement with particular providers outside of Blue Cross's contracts and/or claims processing function. We exclude claims from groups that do not have pharmacy coverage through Blue Cross. We create separate models for active members and Medicare Primary members.

For each benefit plan, the models produce the simulated PMPM values of the benefits. We divide the PMPM for each plan by the average trended paid claims rate from the model experience period to produce its benefit relativity value (BRV). We calculate relativities for medical-only plans, Rx-only plans, and integrated CDHP plans for both active employees and Medicare Primary employees.

5.1. Models for Active Employees

Benefit Relativity Model: Medical

We use the total medical trend by type of service to project to the rating period. We calculate cost trends for each type of service using the discrete unit cost trend method above, while applying the separate utilization trends developed for facility and professional services (see section 4.1.2).

Using the contracted reimbursement schedules, we calculate network factors that represent the different network contracts. Using these factors, we can include all claims in each of the three networks by adjusting each claim to the basis of a single network. This enables us to combine all the experience for each plan design.

We categorize claims according to how benefits are paid and generate one record for each member, date of service, and type of service. We assign each record a cost share (deductible/coinsurance, copay, covered in full) for each plan modeled. For all products, we assign claims for preventive mandated benefits a "covered in full" cost share independently of the product that is being modeled.

The model tests one benefit design at a time. It determines the member portion of the allowed charges, and from this, a total simulated paid PMPM for each benefit design. The model considers the impact of copay, deductible, coinsurance, out-of-pocket maximum, and preventive mandated benefits. If the average allowed cost of a category is less than the assigned copay, we assume that the member paid the full cost of the service.

Blue Cross offers products on several different networks based on the three provider contracts (Blue Cross Managed Care, Blue Cross Non-Managed Care, and TVHP Managed Care). Depending on the network, there may be more than one tier of coverage (generally referred to as in-network and out-of-network) and different networks may have different providers in each tier. Below is a chart showing which providers are in which tiers on many of Blue Cross's common networks. Providers who accept the indicated provider contract are considered to be in-network. For providers in the BlueCard® network and non-participating providers, 'In' indicates coverage for these providers on the in-network tier of coverage, and 'Out' indicates coverage for these providers on the out-of-network tier of coverage.

Network Name	Provider Contract	BlueCard Providers	Non-Participating Providers
НМО	TVHP Managed Care	N/A	N/A
POS	TVHP Managed Care	Out	Out
VHP Select	Blue Cross Managed Care	N/A	N/A
VHP	Blue Cross Managed Care	Out	Out
EPO PCP	Blue Cross Managed Care	In	N/A
VHP Open Access	Blue Cross Managed Care	In	Out
EPO	Blue Cross Non-Managed Care	In	N/A
PPO	Blue Cross Non-Managed Care	In	Out
Indemnity	Blue Cross Non-Managed Care	In	In

If Blue Cross were to quote a product not on one of the networks listed above, or one featuring different provider networks for selected services, we would modify the base data in the BRV models to correspond to the desired changes (for example, excluding certain providers or modifying allowed amounts) before simulating the benefit impact.

We use BRVs in two places in the rating formula described in Section 3. We calculate the average experience period seasonally-adjusted benefit relativity factor (line K in Exhibit 1A) using BRVs for the benefits in the experience period and the projected claims for the rating period (line B1 in Exhibit 1C) using BRVs for the benefits in the rating period.

Exhibits 3B and 3C display the relativities for active employees for some medical products currently in our book of business.

Benefit Induced Utilization: Medical

We use factors for the impact of induced utilization (IU) developed by the federal Department of Health and Human Services (HHS) for use with Qualified Health Plans, to which we found the curve of best fit IU = AV^2 – AV + 1.24, where AV is the actuarial value of the benefit plan. HHS created their IU factors for combined medical/pharmacy AV, but as we develop BRVs separately for medical and pharmacy plans, we will apply the formula to medical-only AVs. We normalize the curve such that the average AV underlying the base BRV experience period returns a utilization adjustment of 1.00. In other words, if a simulated benefit has an AV less than the average AV, then utilization will be reduced (i.e. factor < 1.00). If a simulated benefit has an AV greater than the average AV, then the benefit will have induced utilization (i.e. factor > 1.00).

Benefit Relativity Model: Pharmacy

We use the total trend by type of drug, for brand, generic, and specialty drugs as described above (section 4.2) to project to the rating period.

Within the model, we assign all pharmacy scripts, including specialty, to one of six categories: retail generic, retail preferred brand, retail non-preferred brand, mail generic, mail preferred brand, and mail non-preferred brand. We apply flags to identify several categories of drugs that are either required to be covered in full (ACA contraceptives and vaccines) or for which a group may purchase a rider to offer additional coverage (some fertility drugs) or exclusion (lifestyle drugs). We also flag drugs for which a group may offer special cost-sharing arrangements, such a diabetic medications and wellness drugs. We assign these flags by National Drug Codes as reported to us by our current PBM.

We adjust the experience period data to reflect the major brands that are expected to become generic between 2020 and 2023. The list comes from a report provided by our current PBM.

For these brands, in the first six months (the exclusivity period), we reduce the Average Wholesale Price (AWP) by 10 percent and keep the brand discount. For the months after the exclusivity period, we reduce the AWP by 10 percent and change the discount to the generic discount. The 10 percent reduction in AWP is based on industry standard assumptions, supported by our own analysis of AWP changes for drugs that have moved from brand to generic over the past several years.

We generate one record for each member and date of service combination. One record can have more than one script category. The model tests one benefit design at a time. It determines the member portion of the allowed charges and a total simulated paid PMPM for each benefit design. The model considers the impact of the deductible, coinsurance, copays, and out-of-pocket maximum (OOPM). The model excludes contraceptives and vaccines from the cost sharing. If the average allowed cost of a category is less than the applied copay, we assume that the member pays only the full cost of the script. With Vermont Act 171, all pharmacy benefits effective January 1, 2022 or later will have an OOPM of \$1,400. It is possible that this limit will increase effective January 1, 2023, following the IRS rules for Health Savings Accounts and High Deductible Health Plans. The exhibits include the \$1,400 OOPM on pharmacy benefits.

Exhibit 3D displays the relativities for active employees for some pharmacy products currently in our book of business.

Benefit Induced Utilization: Pharmacy

We performed an independent analysis to measure the correlation between the benefit design and the quantity of pharmacy prescriptions consumed. We adjust the pharmacy benefits in two ways. First, the generic utilization varies with the benefit design. We use claims and membership data from September 2018 through August 2021 to create a table to adjust the base generic utilization up or down depending on the difference in the generic and brand copays of the member's drug plan. Exhibit 3A displays the adjustments by brand/generic copay differential for generic and brand scripts.

Second, we perform a separate analysis to adjust for the overall pharmacy benefit. We assign a modeled actuarial value to every benefit in the experience period. The correlation uses the actuarial value as the independent variable and days supply as the dependent variable. A linear equation best fits the data.

We normalize the curve such that the actuarial value underlying the base BRV benefit returns a utilization adjustment of 1.00. The resulting formula is

Although we use two steps to calculate the induced utilization, we are not adjusting the data twice. The adjustment for difference in generic/brand copays changes the mixture of scripts (i.e., generic dispensing rate) without adjusting the overall frequency of scripts. The richness or leanness of the plan, as measured by the actuarial value, drives an adjustment to the overall frequency of scripts without changing the mixture of scripts.

In prior filings, we included an adjustment for the type of benefit being modeled (CDHP vs. drug card). Claims incurred on a CDHP historically had a lower cost per script than claims incurred on a drug card, but the model includes claims from both CDHPs and drug cards. We calculate a factor for each benefit type by taking the ratio of the cost per script for that type and the cost per script from all claims in the model. Based on the data in the model for this filing, there is no longer a disparity in cost per script between the two benefit types. Rather than eliminate this adjustment altogether, we intend to phase it out over the course of the next two filings to avoid significant pricing changes. For CDHPs, the factor for this filing is

Benefit Relativity Model: Integrated (CDHP)

The CDHP model combines both the medical and pharmacy models described above. There is one record for each member, date of service and type of service combination. The model calculates separate medical and pharmacy actuarial values and makes the appropriate utilization adjustment for each.

Exhibit 3E displays the relativities for active employees for some CDHP products currently in our book of business.

5.2. Tier Factors

Each BRV model generates a BRV for different contract tiers as well as the overall PMPM described in the sections above. The models perform this calculation by re-adjudicating claims across families in addition to member-based readjudication. We apply the tiered BRVs to each benefit's member distribution by tier to calculate the average BRV for the experience benefits and to the group's member distribution by tier to calculate the average BRV for the rating benefits.

Blue Cross and TVHP sell products with rate tiers for multiple members. We develop tier factors to spread the required total premium across the different rate tiers. We refer to products that have family limits in addition to individual limits as stacked, and to products with only family limits as aggregate. For products renewing after January 1, 2016, members on aggregate plans are subject to the federal maximum allowed individual out-of-pocket, even if the aggregate out-of-pocket maximum is higher. We refer to these plans as hybrid.

To calculate the tier factors, We used the BRV models to calculate member paid amounts for each member in the model and used every combination of members to create "families" in the following categories:

- One Adult
- Two Adults
- One Adult and One Child, ..., One Adult and Seven Children
- Two Adults and One Child, ..., Two Adults and Seven Children

For each category of family, we calculated the average plan paid amount subject to the family cost sharing. Then we combined the categories of families into rate tiers using the proportion of each category in the experience period membership as a weight. The ratio of plan paid amount for each rate tier to the plan paid amount for the single rate tier is the tier factor. For aggregate and hybrid factors, we grouped products together into three ranges of out-of-pocket maximums and calculated tier factors for each range. We calculated different factors for products with separate medical and drug benefits and for products with integrated benefits (CDHPs). The hybrid factors assume a \$8,700 individual out-of-pocket maximum, which is the 2022 individual out-of-pocket maximum set by HHS. To limit rate disruption to our customers, in cases where the tier factor changed by more than +/- 0.04 from the previous approved factor, we limited the change to +/- 0.04. Exhibit 3L contains the tier factors calculated for each range and type of benefit.

There are separate factors for stacked plans with family multipliers of two, two-and-a-half, and three for deductibles and out-of-pocket maximums. The aggregate and hybrid factors assume a family multiplier of two. If a group requests a benefit with a non-standard multiplier, out-of-pocket maximum, tier structure, or individual out-of-pocket maximum (for a hybrid plan) that is not in the exhibit, we will use identical data, assumptions and methodology as described above to calculate appropriate tier factors for the requested benefit.

5.3. Models For Age 65+ Medicare Secondary Plans

Benefit Relativity Model: Medical

Medicare Primary rate tiers are only available on the Blue Cross Non-Managed Care network. To develop benefit relativity values for Medicare Secondary plans, we use the same method as we do for the active factors. For the claims base, we use allowed charges incurred between September 2020 and August 2021, paid through October 2021, for members whose primary insurance is Medicare. Given the scarcity of Medicare Primary members in the BRV experience (fewer than 1,000 member months), we also include Medicare Primary members from groups who we exclude from the development of the active BRVs (e.g., large ASO groups). If the underwriter believes that these claims are not representative of a given group's characteristics (for example, due to demographics or morbidity), we will develop relativities using an analogous method with more representative experience. As with the models for active employees, we exclude direct costs for COVID-19 but do not separately adjust for the impact of deferred and returning care.

Medicare Secondary plans cover two categories of services: Medicare-covered services which are subject to member cost share (deductible/coinsurance) and services which are not covered by Medicare. We do not adjust services subject to Medicare cost sharing for network, as Medicare determines the allowed charges, whereas we adjust the services not covered by Medicare using the contract factors described above to bring all charges to a single network.

We trend the allowed charges to the 12-month period that begins January 1, 2023. We use the total medical trend by type of service as described in section 4.5.

As with the active benefits, the model simulates the effects of a benefit design on the trended allowed charges and calculates a simulated paid PMPM. The model divides this paid PMPM by the Medicare Primary manual rate (without the adjustment for changes to the pharmacy contract) to produce the

benefit relativity value. Unlike the active benefits, we do not make an adjustment for induced utilization due to the richness of the benefit. As Medicare is the primary insurance for these plans and Medicare-covered claims make up 85 percent of the trended allowed charges, we do not believe that the richness of the secondary insurance will have any influence on utilization.

Exhibit 3F displays the relativities for some Medicare Secondary medical products currently in our book of business.

Benefit Relativity Model: Pharmacy

To calculate relativities for pharmacy benefits for plans that are secondary to Medicare, we use the same methodology as for active employees. We use allowed charges incurred between September 2020 and August 2021, paid through October 2021, for members whose primary insurance is Medicare (including members in large ASO groups, as with the medical experience). If the underwriter believes that these claims are not representative of a given group's characteristics (for example, due to demographics or morbidity), we will develop relativities using an analogous method with more representative experience.

We trend the allowed charges to the 12-month period that begins January 1, 2023 using the same trends as used for active members. We assign pharmacy scripts to the same categories as for the active members and adjust allowed charges for brands going generic between the experience period and the rating period. The model produces a simulated paid PMPM for each benefit design and adjusts for the impact of induced utilization on the mixture and frequency of scripts as described for the active relativities above. We divide the adjusted paid PMPM by the Medicare Primary manual rate (without the adjustment for changes to the pharmacy contract) to produce the relativity.

Exhibit 3G displays the relativities for some Medicare Secondary pharmacy products currently in our book of business.

Benefit Relativity Model: Integrated (CDHP)

The Medicare Secondary CDHP model combines both the medical and pharmacy Medicare Secondary models described above. We create one record for each member, date of service, and type of service combination. The model calculates separate medical and pharmacy actuarial values and makes the appropriate utilization adjustments for each.

Exhibit 3H displays the relativities for some Medicare Secondary CDHP products currently in our book of business.

5.4. Formulary & Pharmacy Options

Blue Cross and TVHP offer groups a selection of formularies. Groups can select either the Blue Cross Formulary or the National Performance Formulary. Groups electing the National Performance Formulary receive greater rebates than those on the Blue Cross Formulary. To calculate the impact of the change, we identify rebate-eligible claims for the large groups impacted by this filing. We calculate rebate totals under the contracted terms of each formulary. For groups changing formularies, we apply the below factors to projected rebates. We adjust the factors proportionately if the experience period includes a mix of formularies.

Experience Formulary	Rating Formulary Rebate Multipli	
Blue Cross Formulary	National Performance	
National Performance	Blue Cross Formulary	

The National Performance Formulary covers different drugs than the Blue Cross Formulary. To reflect the difference in covered drugs between the two formularies, we apply a factor to the drug BRV for the Blue Cross Formulary. Using the claims in the drug BRV model, we compare the average cost per script, including the impact of brand and generic dispensing rates, for both formularies. We compare the cost per script for each formulary to the cost per script for all claims in the model to calculate adjustment factors for each formulary.

Formulary	Adjustment Factor		
Blue Cross Formulary			
National Performance Formulary			

5.5. Riders

Blue Cross and TVHP file riders with the Vermont Department of Financial Regulation (DFR) that allow large groups to add or modify covered services. These riders include, but are not limited to, the Benefit Enhancement Rider, Acupuncture Benefits Rider, and Wellness Drug Rider. For riders that modify covered services, we use the benefit relativity model to price the rider. For riders that cover an optional service, we develop allowed charges from groups offering that coverage and adjust to the group's benefit or use a reasonable approximation of allowed charges if no experience data exists. If, in the underwriter's professional judgment, the election of a rider will create material anti-selection, the underwriter will modify the rate as necessary to reflect appropriate rates for the rider being rated, as described in section 3.

5.6. Rate Smoothing Charges

Blue Cross and TVHP offer groups the option to apply the composite rate change to each tier's rate change. There is no charge to smooth rate changes by tier within a benefit if the change by tiers varies by less than two percentage points. If the tiered rate changes vary between two and five percentage points, there is a charge of 0.2 percent applied to the total of the absolute values of the rate deviation by tier. Rate smoothing is not allowed if the rate increases by tier vary by more than five percentage points.

If a group offering multiple benefits elects to apply the same rate change across benefits, the charge begins at 0.2 percent of the total of the absolute values of the rate deviation by benefit and increases continuously by 0.1 percent for every percentage point deviation. Benefit smoothing is not allowed if the rate change by benefit varies by more than five percentage points.

6. Other Factors Applicable to All Large Groups

6.1. Manual Rate

The manual rate for active members is calculated from medical and pharmacy paid claims PMPM incurred between November 1, 2020 through October 31, 2021. Both medical and pharmacy claims include claims paid through December 31, 2021. We use claims from the groups impacted by this filing, trended to calendar year 2023 using the trends and pharmacy contract adjustments described in section 4. We cap claims at \$90,000¹⁰ and add expected claims above \$90,000. We calculate the expected large claims using the method described in section 6.2.

We calculate a separate manual rate for Medicare Primary members using the paid claims PMPM from the BRV experience period, trended to calendar year 2023 using the Medicare Primary trends described in section 4.5 and the pharmacy contract adjustments described in section 4.2. We make no adjustments to the Medicare Primary manual rate for large claims.

Calculation of the Manual Rate (Actives)					
Claim Type		Medical	Pharmacy		
Incurred and Paid Experience Paid Claims, capped at \$90,000	А	\$27,555,808	\$6,683,416		
COVID-19 Related Claims	В	\$2,210,189	\$80,855		
Estimated IBNR	С	\$140,486	\$361		
Expected Claims above \$90,000	D	\$6,454,791	\$430,827		
Experience Adjustment Factor	E	1.0000	1.0000		
Demographic Normalization	F	1.0073	1.0073		
Overall Paid Trend Factor	G	1.1995	1.2401		
Projected Total Paid Claims	H = (A - B + C + D) x E x F x G	\$38,594,461	\$8,786,383		
Total Member Months	1	71,568	71,568		
Medical/Pharmacy Manual Rate	J = H / I	\$539.27	\$122.77		
2023 Manual Rate	$K = J_1 + J_2$	\$662.04			
Q3 2021 Approved Manual Rate	L	\$612.01			
Manual Rate Increase	M = K / L -1	8.2%			

Calculation of the Manual Rate (Medicare Primary)						
Claim Type		Medical	Pharmacy			
BRV Experience Paid Claims	Α	\$10,304,718	\$19,345,477			
Paid Trend Factor	В	1.1275	1.1847			
Projected Total Paid Claims	$C = A \times B$	\$11,618,244	\$22,918,603			
Total Member Months	D	78,864 78,86				
Medical/Pharmacy Manual Rate	E = C / D	\$147.32	\$290.61			
2023 Manual Rate	2023 Manual Rate $F = E_1 + E_2$ \$437.93					
Q3 2021 Approved Manual Rate	G	\$450.97				
Manual Rate Increase	H = G / F -1	-2.9%				

¹⁰ Selected using the highest level a group in the manual rate membership base would be pooled at using the table in Exhibit 6B.

We use a different method of calculating the manual rate for active and Medicare Primary members. We develop the active manual rate from the experience of active members in the large groups covered by this filing. There are not enough Medicare Primary members in large groups to develop a credible manual rate with only large group experience, so we base the Medicare Primary manual rate on the larger set of claims in the BRV experience, which includes Medicare Primary members from ASO groups as well as large groups.

Changes in the experience base, an update to the trends detailed in this filing, and an additional year of trend cause the change in the active manual rate. As noted in the trend section, the "Update Experience Base" component results in a decease to the manual rate due to claims being lower than expected due to COVID-19. We expect these claims to rebound to normal levels, which results in an increase in the "Update Trend" line. Lastly, we trend the claims underlying the manual rate from 2022 to 2023.

Manual Rate Development	РМРМ	PMPM Change	Impact
2022 Manual Rate	\$612.01		
Update Experience Base		\$(24.48)	-4.0%
Update Trend		\$16.52	2.7%
Trend to 2023		\$57.99	9.5%
2023 Manual Rate	\$662.04		

We adjust the manual rate to reflect a group's particular characteristics, as demonstrated in Exhibit 4A. We make an adjustment for the average age/gender factor (line B) of the group. For active and Medicare primary members, we use factors from the SOA's report *Health Care Costs – From Birth to Death*¹¹. We normalize the factors such that the membership in the manual rate experience period has an age/gender factor of one. We assign an industry factor (line C) to each group based on the Standard Industrial Classification code. See Exhibit 4B for the schedule of industry factors. We normalize the industry factors such that the manual rate has a factor of one. We do not apply an industry adjustment to the manual rate for Medicare Primary members. We then multiply the manual rate by an adjustment factor to reflect structural changes between the experience period to the rating period. This adjustment modifies the manual claims to reflect such things as mandated benefit changes, contractual provision changes, etc., that, in the judgment of the underwriter, are necessary to make the manual rate appropriate for the estimation of the expected claims in the rating period.

For groups with a projection period other than calendar year 2023, we adjust the manual rate for trend to reflect the group's projection period (line D). Finally, we calculate a contract conversion factor (line E) based on member distribution and tier factors in order to convert from a PMPM to a single rate basis. This factor is necessary because the rating formula blends the adjusted manual rate (line S of Exhibit 1A) with the projected single contract rate (line R of Exhibit 1A), which is not on a PMPM basis.

¹¹ https://www.soa.org/Research/Research-Projects/Health/research-health-care-birth-death.aspx

The factors for the age curve are in Chart 1 (for actives) and Chart 21 (for Medicare Primary) of the databook linked on the page.

6.2. Large Claims Factors

Blue Cross and TVHP use the formula and factors in Milliman's 2021 *Health Cost Guidelines* – *Reinsurance* to calculate expected claims above the pooling limit. The contents of the *Guidelines* are proprietary and confidential. This filing provides a general description of the formula but will not include any of the factors.

The formula develops expected claim costs above a particular pooling point separately for children and adults on a PMPM basis. The basis for each rate is a starting claim cost that varies with the pooling point and the out-of-pocket limit for the benefit. Milliman calculates the starting claim costs using national data, and the formula applies factors to adjust to our Vermont service area and the details of our contracts with local providers. The formula applies an adjustment for demographics and a trend factor to adjust the starting claim costs for the experience period of the renewal. There are also adjustments to the starting claim costs for the network of the benefit to account for claims from out-of-network providers, if appropriate for the benefit. The formula includes an adjustment factor that controls for known, ongoing high claimants, which are typically added to premium through underwriting judgment. To avoid double-counting such claimants, we apply a five percent reduction to the estimated claims above the pooling point based on recent Blue Cross and TVHP large group experience.

We multiply the adjusted adult and child claim rates by benefit by the number of adult and child member months in the experience for that benefit to develop the total expected claims above the pooling level.

The guidelines included a refresh of the area factors. We are phasing in the area factors with a two-thirds weight of the 2021 factors and a one-third weight of the 2020 factors.

6.3. Administrative Charges

The sources of administrative expense data in this filing are the Blue Cross data warehouse and accounting records. The experience period for this filing is January 2020 to December 2020. We use actual Blue Cross and TVHP administrative expenses for the experience period on a GAAP reporting basis.

Experience Base of Actual Expenses

The Blue Cross cost accounting system allocates administrative expenses to lines of business. We use Blue Cross insured large group and TVHP insured large group information for the base administrative charges.

We allocate the cost accounting data by cost center into cost categories for purposes of determining administrative charges for each specific group account, given that account's characteristics. ¹² The group cost categories align with the rules used in the cost allocation model. The group cost categories include:

Account – those expenses that the system allocates to specific group accounts on a per group account basis.

¹² Per unit per month costs for Cost Plus members with Medicare Supplement plans are set equal to the corresponding values for conventionally funded Medicare Supplement members.

Member – those expenses that the system allocates on a per member basis.

Contract – those expenses that the system allocates on a per contract (subscriber) basis.

Medical Claims – those expenses that the system allocates on a per medical claim basis.

Invoice - those expenses that the system allocates on a per invoice basis.

Total Projected Claims – overhead expenses that we allocate using experience paid claims.

For each of the group cost categories described above, we tabulate the respective number of unit months during the experience period for Blue Cross and TVHP insured large groups. Groups can offer a choice of Blue Cross and TVHP products to their employees if they wish to offer options with different networks. We therefore combine expenses for both companies in this filing to ensure alignment of administrative expenses across the products within a group offering. The unit months include the number of account months, number of member months, number of contract months, and number of medical claims and invoices by month. For overhead expenses, we divide the experience administrative charges by experience paid claims to calculate a percent of claims factor.

The table below reflects reclassifications of the base data, including the removal of federal fees (we add these to premium rates separately; see section 6.9), GMCB billback (we add these to premium rates separately; see section 6.8), and fees paid to vendors for the administration of Health Savings Accounts and Health Reimbursement Accounts linked to our insurance products (participation in this service is optional; we assign these fees to groups who select the service). We also remove any expenses incurred due to one-time, non-recurring events, such as the expenses related to enabling full-time remote work, as these costs are not expected to continue to occur in the projection period. Finally, we adjusted the allocation of overhead among lines of business to reflect a consistent percentage of premium or premium equivalent, which is a more appropriate (i.e. lower, in the case of this filing) basis for pricing purposes.

Reconciliation of Experience Base Administrative Expense to Restated GAAP Expenses (dollars in thousands)								
Business Segment	Reported Expenses ¹³ (01/20 – 12/20)	Commissions ¹⁴	Reclassification Items ¹⁵	Reallocations	Adjusted Experience			
	(A)	(B)	(C)	(D)	(E) = (A) - (B) - (C) - (D)			
BCBSVT Insured	\$7,055	\$552	\$1,564	\$1,585	\$3,354			
TVHP Insured	\$2,322	\$143	\$589	\$281	\$1,310			
Large Group Subtotal	\$9,377	\$695	\$2,152	\$1,866	\$4,664			

We calculate per unit per month (PUPM) values using the adjusted experience period administrative expenses and unit counts. For the group segments included in this filing, there are five such PUPM values and one percent of claims value.

¹³ Reported Expenses are from Underwriting Results GAAP Basis, restated for the new allocation, for the Experience Base period.

¹⁴ Commissions are from Internal BCBSVT reports

¹⁵ Reclassification Items are from Internal BCBSVT reports, including the removal of one-time items

Projection Factors

We project actual administrative costs PUPM from the experience period to each of the rating periods based on a 2.2 percent annual trend. This projection factor makes a reasonable but modest provision for increases in overall operating costs PUPM. There are no known extraordinary or mandate-related costs at this time which require a separate provision for the rating periods involved in this filing.

To calculate the annual trend increase we assume that personnel costs (wages and benefits) will increase by three percent, the typical budgeted wage increase, and we assume other operating costs will remain flat. Based on year-to-date December 2020 information, we calculate that 73.6 percent of our administrative costs are for salaries and benefits. We therefore increase our total projected administrative expenses by the weighted average of 2.2 percent per annum. We assume no trend for 2021 and apply trend from 2021 to 2023, which broadly aligns with the decision to forgo salary increases in 2021. Blue Cross is closely monitoring the impacts of inflation on overall expenses, including personnel costs, to adequately balance the need for salary adjustments for employees and lower premiums for members.

Development of Administrative Charges Trend				
		Percent of Total		
Employee costs	A	55.4%		
Purchased services	В	24.7%		
Other operating costs	С	19.9%		
Subtotal administrative expenses	D = A + B + C	100.0%		
Total personnel costs	E = A / (A + C)	73.6%		
Trend for personnel costs	F	3.0%		
Total administrative charges trend	$G = \{(1+F) \times E + (1.00) \times (1-E)\} - 1$	2.2%		

We are experiencing overall growth in enterprise membership; however, customer demands have required we introduce new capabilities including arrangements with new vendors. This dynamic continues to shift the operating expenses among our businesses.

We calculate PMPM admin charges with experience period enrollment and projected 2022 enrollment. Using the lower 2022 enrollment increases the PMPM by 13.0 percent. A recent cost accounting exercise suggests that variable costs represent approximately 30 percent of total administrative expenses. Blue Cross is committed to providing insurance coverage for our members at the most affordable rates possible; as a result, even though it is impractical to react to enrollment shifts by immediately right-sizing staff, we nonetheless remove from our projection the entirety of variable costs associated with the reduced enrollment. We therefore apply a net increase of 10.4 percent to the base PUPM charges to account for the reduction in membership. The table below shows the calculation.

Development of Enterprise Membership Adjustment			
Members			
Experience Period	188,743		
Projected 2022 Enrollment	164,249		
Adjustment for Enterprise Membership	= 1+0.7(188,746/164,249-1) = 10.4%		

Required Administrative Increase

Using the methodology described above, the administrative charges increase by 9.2 percent:

	Administrative Charges – Reasons for Required Increase					
	Admin Charges Change Perce					
		PMPM	PMPM	Change		
1	Approved January 2022 admin from Q3 2021 filing	\$50.41				
2	Rebase experience and allocations	\$48.66	(\$1.75)	-3.5%		
3	Net enterprise membership adjustment	\$53.73	\$5.09	10.4%		
4	Additional year of trend	\$54.94 ¹⁶	\$1.19	2.2%		
	Total Increase		\$4.53	9.0%		

Charges for Group Accounts

Exhibit 5A shows the administrative charge PUPM values used by the rating formula to produce account-specific administrative charges. The formula applies these values to a group account's corresponding unit counts and expresses the resulting charges as an equivalent PMPM.

The administrative charges do not include amounts for special items or unique services not part of Blue Cross or TVHP's standard scope of administrative services (e.g., special booklets, certificates, or reports). Charges for such services will be determined and applied separately on an account-specific basis. The filed charges also do not include commissions based on the commission scale applicable to the account. The rating formula calculates and applies commissions separately.

6.4. Net Cost of Reinsurance

BCBSVT and TVHP purchased reinsurance for claims in excess of \$1,000,000 for 2022, and we expect to purchase similar reinsurance in future years with limits approximately equal to the 2022 limit. We estimate that the target loss ratio for the reinsurance is approximately 75 percent, which implies a cost of reinsurance of approximately 33 percent of claims above the reinsurance limit. For each pricing period starting quarter, we use the total allowed trend from 2022 to 2023 and a leverage factor for the \$1,000,000 reinsurance limit from Milliman's 2021 *Health Cost Guidelines – Reinsurance* to calculate the expected annual claim cost above the reinsurance limit, then multiply the cost by 33 percent to determine the annual cost of reinsurance. We divide this by 12 to produce the PMPM cost of reinsurance. The table below shows these PMPM's based on pricing period starting quarter. If a renewal requires a factor for a pricing period not in the table, identical data, assumptions, and methodology as described above will be used to calculate the net cost of reinsurance.

Pricing Period Starting Quarter								
Q3 2022								
\$1.90								

¹⁶ In a national survey of Blue Plans Commercial insured lines, the median PMPM for 2020 was \$56.67, which is slightly higher than our projected 2023 PMPM. (https://sherlockco.com/docs/navigator/June2021/Blue%20Late-June%20Navigator%202021.pdf).

6.5. Pharmacy Rebates

We calculate pharmacy rebates by taking the experience period rebates and trending them using the total trend for brands eligible for rebates (see table below). We subject the trended rebates to the minimum guarantees for the rating period. There is a lag between the receipt of pharmacy rebates and the time of the original claims. For months in the experience for which we do not have detailed rebate information, we include an estimated rebate amount in the calculation.

Claim Type	Experience Period Allowed Charges		Projected Allowed Charges after Contra Changes			:t	
Brand Going Generic							
Brand							
Specialty							
Total							
Total Trend for Drugs Eligible for rebates						12.0%	

6.6. OneCare Coordination Fee

Blue Cross and TVHP pay OneCare Vermont a care coordination fee for attributed members. This payment directly supports ACO providers, including community providers, as they deploy new care models. This model mirrors the investment Medicaid has made in the ACO provider network and supports the comprehensive care models being tested within the ACO program. The monthly charge for members attributed to OneCare is \$3.25. We will update this estimate if we receive additional information.

6.7. Contribution to Reserve

As recommended by management, we include the following contribution to reserve factors in the rate calculation:

Contribution to Reserve				
Blue Cross Insured Groups	1.5% of premium			
TVHP Insured Groups	2.0% of premium			
BCBSVT Cost Plus Groups	0.375% of equivalent premium			

A memo from Blue Cross senior management regarding the contribution to reserve factors can be found as Attachment A. We consider the above-listed contribution to reserve factors to be reasonable..

6.8. State Mandates and Assessments

Vermont Vaccine Purchasing Program Payments

The Vermont Vaccine Purchasing Program¹⁷ offers health care providers state-supplied vaccines at no charge by collecting payments from Health plans, insurers, and other payers. This assessment is a PMPM

_

¹⁷ http://www.vtvaccine.org/

charge applied to members residing in Vermont who are ages 0 to 64. On April 26, 2021, the Vermont Vaccine Purchasing Program released a memo that included the anticipated rates for April 1, 2022 – March 31, 2023: "For planning purposes, the best estimate at this time for the SFY2023 assessment rate is \$10.91 per child covered life per month and \$1.60 per adult covered life per month. The SFY2023 assessment rate will be reviewed for final determination in April 2022." We will update these rates once the actual rates are known.

New Hampshire Purchasing Program Payments

The New Hampshire Purchasing Program¹⁸ offers health care providers state-supplied vaccines at no charge by collecting payments from health plans, insurers, and other payers. The assessment for 2022 is \$6.85 for each child that is a New Hampshire resident. The current best estimate of the 2023 rate is \$7.15 per assessable life per month. We will use the new rate once it is approved.

New York State Health Care Reform Act

Blue Cross and TVHP pay the New York GME Covered Lives Assessment¹⁹ for all members who are New York residents as part of the New York State Health Care Reform Act. The assessment varies based on the county of residence. We will use the new rates once they are approved.

Maine Guaranteed Access Reinsurance Association

Blue Cross and TVHP pay the Maine Guaranteed Access Reinsurance Association Assessment²⁰. The 2019 assessment is \$4.00 per member per month for each member that is a Maine resident. We will use any new rates once they are approved.

Health Care Claims Tax

The Health Care Claims Tax of 0.999 percent applies to all claims or capitations incurred by members with Vermont zip codes. We use the percentage of current members with Vermont ZIP codes to estimate the percentage of rating period claims expected to be incurred by Vermont members. Act 73 of 2013 sunset the 0.199 percent assessment for the Health IT-Fund. Given this fee has routinely been extended close to its sunset date, we will include it in the calculation and update the charge if new information becomes available.

Blueprint

Blue Cross and TVHP participate in the Vermont Blueprint for Health program. The current assessments for this program, applied to members who are attributed to a Blueprint provider as of the month the renewal is produced, are \$2.77 PMPM for the Community Health Team and \$3.00 PMPM for the Patient Centered Medical Homes (PCMH). PCMH are eligible for up to \$0.50 for performance. We project that our total PMPM for PCMH will be \$3.21. We base the projected performance payment on the average payment for large groups in the year ended October 2021. We will incorporate any updates made to the Blueprint Manual²¹ in renewals.

¹⁸ https://nhvaccine.org/

¹⁹ https://www.health.ny.gov/regulations/hcra/gmecl.htm

²⁰ http://www.mgara.org/

²¹ http://blueprintforhealth.vermont.gov/

Green Mountain Care Board Billback

The Green Mountain Care Board assesses Blue Cross and TVHP a billback. We apply billback amounts from the administrative charges experience period described in section 6.3 to projected member months to develop the charge of \$2.31 PMPM.

Other Assessments

We include other state mandates and assessments in the calculation as applicable.

6.9. Federal Assessments

Patient-Centered Outcomes Research Institute Fee:

This fee is part of the Affordable Care Act and applies to all plan years ended after September 30, 2012 and before October 1, 2029. We provide the estimated fees in the table below. We will update this estimate if we receive additional information.

PCORI	
Plan Year Ending Between	Fee Amount
October 2021 - September 2022	\$2.79 PMPY
October 2022 - September 2023	\$2.93 PMPY
October 2023 - September 2024	\$3.07 PMPY

Other Assessments

We include other federal mandates and assessments in the calculation as applicable.

7. Factors applicable only to specific Products

7.1. Stop Loss Coverage for Cost Plus products

Cost Plus groups assume the risk for the claims incurred by their members. To protect themselves from high claims, they must purchase both Individual Stop Loss (ISL) and Aggregate Stop Loss (ASL) from BCBSVT²².

7.1.1. Individual Stop Loss

We develop ISL charges using the same formula and factors as described in section 6.2. We develop the charges for the rating period, rather than the experience period. They include a load for a 70 percent loss ratio. We use stacked tier factors to spread the charges across the different contract tiers, even when the benefit itself is aggregate, as the accumulation of the family cost sharing for the benefit does not have a meaningful impact on claims above the ISL attachment point.

²² With the exception that with the approval of Blue Cross's Executive staff, Cost Plus groups can shop their stop loss in accordance with strict guidelines set forth by Blue Cross.

7.1.2. Aggregate Stop Loss

<u>Distribution of Individual Claims by Amount</u>

We stochastically model the distribution of individual claims by amount by using the membership and claims from fully insured large group, fully insured association health plans, small groups, and certain ASO groups. We sum allowed charges and paid claim amounts for each member. We then sort into categories by the amount of allowed charges. The categories used are:

- \$0 up to \$50
- \$50 up to \$100
- \$100 up to \$200 ... \$1,900 up to \$2,000
- \$2,000 up to \$2,500 ... \$9,500 up to \$10,000
- \$10,000 up to \$15,000 ... \$995,000 up to \$1,000,000

We calculate paid-to-allowed ratios for each category. We average each year's ratios for each category and smooth the resulting ratios at allowed amounts greater than \$1,000. We trend allowed claims to 2023 and apply the paid-to-allowed benefit factor to create a simulated paid claims amount, which we use in the stochastic modeling.

For each number of members (N) 5,10, 15, 20, 25, 50, 100, 150, 200 to 1000 (by increments of 100), 1,500, 2,000 to 5,000 (by increments of 1,000) and 10,000 to 20,000, we run 20,000 simulations. Each simulation assigns a random number to every member and selects the (N) lowest members. For each specific stop loss level, we calculate the expected claims amount and standard deviation of the distribution of claims less than the specific stop loss level.

Expected Claims Factors

For each number of members (N) noted above and for each ISL limit, we calculate a preliminary expected fraction of aggregate claims in excess of 110%, 115%, 120%, 125%, 130%, 140% and 150% of expected aggregate claims. We then adjust for uncertainty in the projection of expected claims as described in the table below:

Expected to projected expected		107.5%	102.5%	97.5%	
	>107.5%	-	-	-	< 92.5%
		102.5%	97.5%	92.5%	
Fraction of projections	F ₁ *	F ₂ *	F ₃ *	F ₄ *	F ₅ *

^{*} Estimated for distribution

We then divide the factors developed by 0.7 to produce an expected loss ratio (net of the provision for default) of 70 percent.

To protect against potential default situations (i.e. to cover the risk of the group failing to fund claims), the proposed ASL rates include an additional fixed risk charge of 0.5 percent of expected claims under

the ISL limit for groups with fewer than 20,000 members, and a reduced fixed risk charge of 0.4 percent of expected claims under the ISL limit for groups of 20,000 members or more.

The final factors are applicable to total expected claims under ISL.

To ensure that the factors on each line are strictly decreasing with increasing stop loss percentage, in cases where the ratio for a 150% stop loss percentage is less than 0.0001:

- we increase the calculated value for 150% by 0.00001
- we increase the calculated value for 140% by 0.00002
- we increase the calculated value for 130% by 0.00003
- we increase the calculated value for 125% by 0.00004
- we increase the calculated value for 120% by 0.00005
- we increase the calculated value for 115% by 0.00006
- we increase the calculated value for 110% by 0.00007.

Exhibit 6D provides the tables of factors.

If the expected number of members (N) in the rating period is not one of the values in either table, we determine the value by interpolating linearly between the entries in the table for the numbers of members immediately below and above N.

If a group requests an ISL limit that is not in the exhibit, an aggregate attachment point that is not in the exhibit, if there are more than 20,000 members, or if the contract period is not 12 months, we will use identical data, assumptions, and methodology as described above to calculate the appropriate Aggregate Stop Loss Rating Factor for the required attachment point.

8. Medical Loss Ratio Projection

We use the factors and formula in this filing to project a Medical Loss Ratio (MLR) for 2023. Using the manual rate as a proxy for projected claims, we project a 2023 MLR of 89.3 percent for Blue Cross and 88.5 percent for TVHP. The Blue Cross credibility-adjusted MLR for Large Group was 95.3 percent in 2019 and 90.1 percent in 2020. The TVHP credibility-adjusted MLR for Large Group 94.5 percent in 2019 and 97.0 percent in 2020. Exhibit 4C provides the development of the projected MLR. The calculations represent estimates assuming that all pricing assumptions hold true, and assuming no change from 2020 values for various quantities (e.g. HCQ, commissions).

9. Act 193 Information

This information is included template filed in SERFF with this filing (VT Rx Data Template - BCBSVT - Q3 2022 Large Group.xlsx).

The data in the template is based on actual and projected experience for the groups included in the manual rate.

10. Actuarial Opinion

I, Martine Lemieux, Manager, Actuarial Services, am an employee of Blue Cross Blue Shield of Vermont and a member of the American Academy of Actuaries. I have experience in the area of insured health care programs.

Section 11 lists applicable limitations and disclosures.

It is my opinion that the rating formula and factors presented in this filing are reasonable and have been prepared in accordance with applicable Actuarial Standards of Practice. The formula and factors will produce premium rates that are reasonable in relation to the benefits provided and will not be excessive inadequate or unfairly discriminatory.

I am an Associate of the Society of Actuaries and a Member of the American Academy of Actuaries, and I meet the Academy's Qualification Standards to render this opinion.

Martine Lemieux, A.S.A., M.A.A.A.

February 17, 2022

11. Disclosures

Information Date: The analysis provided in the report is based on information as known on February 16, 2022.

Scope: The purpose of this filing is to establish the formula, manual rate, and accompanying factors that will be used for renewals of Blue Cross and Blue Shield of Vermont and The Vermont Health Plan large group plans. This filing is not intended to be used for other purposes.

Intended Users: This material has been prepared for the GMCB. Blue Cross understands that this memorandum and accompanying exhibits will be posted publicly.

Uncertainty or Risk: Future events may affect the results presented in the memorandum.

Reliance on Other Sources for Data and Other Information: This analysis relies upon data from the Blue Cross data warehouse. I have reviewed the data for reasonableness, but no audit was performed. This analysis relies upon several sources of information that are cited as footnotes at their respective references. If any of the sources we have relied upon are incorrect or inaccurate, it may affect the accuracy of the results presented in the report.

Subsequent Events: New information related to the COVID-19 pandemic continues to emerge on a regular basis. Subsequent events may affect the projected MLR presented herein. The degree to which future events may materially change the MLR is unknown.

I HEREBY CERTIFY that I have reviewed the applicable filing requirements for this filing, and, to the best of my knowledge, the filing complies with all applicable statutory and regulatory provisions for the state of Vermont

Ruth Greene

Vice President, Treasurer & Chief Financial Officer

Date

Feb 17, 2022

BERLIN HQ 445 INDUSTRIAL LANE BERLIN, VERMONT 05641 P.O. BOX 186 MONTPELIER VT 05601-0186 800 247 2583 800 922 8778 802 255 4550

February 17, 2022

Thomas Crompton
Health Systems Finance Associate Director
Green Mountain Care Board
144 State Street
Montpelier, Vermont 05602

Subject:

Blue Cross and Blue Shield of Vermont - NAIC # 53295

The Vermont Health Plan - NAIC # 95696 Q3 2022 Large Group Rating Program Filing

Dear Mr. Crompton:

Attached for the Green Mountain Care Board's review and approval is Blue Cross and Blue Shield of Vermont's and The Vermont Health Plan's Q3 2022 Large Group Rating Program Filing. As directed by the Board, this filing combines the various factor filings for large group rating components (trend, large claims, benefit relativity, administrative fees and contribution to reserve, and the formula itself) into a single filing.

Please let me know if we can answer any questions or provide further information during your review.

Sincerely,

Ruth Greene

CC:

Paul Schultz/BCBSVT

Martine Lemieux/BCBSVT



Vermont Department of Financial Regulation

Health Filing Form F-106

-		
NAIC#: 95696 Transmittal Date: 02/17/2	2022	
Company Name: The Vermont Health Plan Address: PO Box 186 City, State, Zip: Montpelier, VT 05601-0186		
Phone: () (802) 371-3734	Contact Person: Greg Boulbol	
3 2022 TVHP Large Group Rating Program Filing Amends a previously filing Dens	artmental File No.:	Approval Date:
Type of Filing:Form(s)XRate(s)	s product filing. If one of the following c	ategories does not describe the product filin
Accident OnlyAD&DAdvertising BlanketCancer ExpenseConversionCritical IllnessDental Comments: -Health	Disability —Home Health Only —Hospital IndemnityLimited Benefit Care Qualified Non-Qualified Major MedicalMedicare Supplement	MiscellaneousNursing Home OnlyOrgan TransplantPrescription DrugStudent/AthleteStop Loss/Excess RiskTravelVisionX Other (explain)
	State of Domicile: 150.00 Ibmitted with this filing: 150.00 ile's retaliatory fee? YesNo X_ as determined, show all calculations (us	· · · · · · · · · · · · · · · · · · ·
5. Fee calculated by: (Print Name) G	e g Boulbol (Si	gnature) /S/ Gregory J Boulbol

BLUE CROSS BLUE SHIELD OF VERMONT & THE VERMONT HEALTH PLAN Q3 2022 LARGE GROUP RATING PROGRAM FILING PLAIN LANGUAGE SUMMARY

Our mission and vision. Blue Cross and Blue Shield of Vermont (Blue Cross) is committed to giving our members access to high-value health care while responsibly managing healthcare costs. To that end, we seek to improve the health of Vermonters by promoting preventive care and healthy lifestyles. We use our strong care management program to assure better care for our members and avoid unnecessary costs. And we work with providers on strategies to improve health care services and reduce health care costs

Blue Cross's vision is a transformed health care system in which every Vermonter has health care coverage, and receives timely, effective, affordable care. To achieve that vision, Blue Cross must be financially sound. That means we need to charge rates that cover the cost of providing health care to our members.

Rate request summary. Blue Cross and TVHP create large group premiums on a case-by-case basis. The rating process uses a formula that blends recent claims experience for each group with a manual rate. This filing establishes the rating formula, manual rate and factors that will be used to create large group renewals.

- There are an estimated 3,300 contracts (6,000 members) currently enrolled in one of 35 Blue Cross large group plans that will be affected by this filing.
- TVHP has an estimated 200 contracts (400 members) enrolled in three large group plans that will be affected by this filing.
- The formula and factors in this filing will produce a premium increase of 7.9 percent for a group that is manually-rated using none of its own experience data.
- The result for any specific group may differ from a 7.9 percent increase, depending on the group's own claims experience.

Reasons for the change in factors. The primary reasons for premium increases due to the change in factors is that the cost of providing health care to our members is increasing. Specifically:

- Blue Cross and TVHP are proposing a paid trend of 9.0 percent for medical claims, which
 includes hospital unit cost increases and anticipated changes in the use of services. The medical
 trend is driven primarily by large increases that were approved for Vermont hospitals in the
 most recent round of budget reviews and by expected large increases in the next round of
 budget reviews.
- Blue Cross and TVHP are proposing a pharmacy trend of 10.6 percent. Increases in the cost and availability of high-cost "specialty" medications are the biggest driver of pharmacy trend.

Other items also contribute to the change in factors, including:

- Due to increases in base administrative expenses, premiums went up 0.6 percent.
- The contribution to reserves established in this filing is required to maintain a level of
 policyholder reserves that is in compliance with that ordered by the Vermont Department of
 Financial Regulation.

Our efforts to reduce premium increases. We know that paying for health insurance is a struggle for many, and we strive to keep premiums as low as possible. The proposed factors reflect our efforts to reduce rate increases, which included the launch of Vermont Blue Rx, an innovative prescription drug benefit service that will improve the consumer experience, drive better health outcomes and lower costs for members, providers, and employers.

BLUE CROSS BLUE SHIELD OF VERMONT & THE VERMONT HEALTH PLAN Q3 2022 LARGE GROUP RATING PROGRAM FILING PLAIN LANGUAGE SUMMARY

Our experience in this market. Over the past five years, Blue Cross has lost almost \$23 million on this line of business. Blue Cross has not included any additional contribution to member reserves to offset this loss.

Our health care system must be adequately funded in order to keep it strong and accessible. Since the factors that determine premiums are primarily the cost and utilization of health care, we believe that there is no way to further reduce the filed factors without underfunding the health care coverage on which Vermonters rely.

Public comment. Members of the public can submit comments to the Green Mountain Care Board about this rate request. For more information, please visit the Board's Public Comment page: https://ratereview.vermont.gov/public_comment

BLUE CROSS AND BLUE SHIELD OF VERMONT and THE VERMONT HEALTH PLAN Q3 2022 LARGE GROUP RATING PROGRAM FILING

TABLE OF CONTENTS

Exhibit 1	Examp	ole Calculations
	1A	Example Calculation of Projected Single Claims Rate
	1B	Example Calculation of Projected Single Claims Rate with Multiple Experience Periods
	1C	Example Calculation of Required Premium by Product and Tier
Exhibit 2	Trend	
	2A	Medical Cost Trend Calculation - CONFIDENTIAL
	2B	Medical Utilization Trend Calculation
	2C	Medical Utilization Trend Calculation, Phamraceuticals
	2D	Pharmacy Trend Development
	2E	Pharmacy Trend Development; Specialty Trend Calculations
	2F	Pharmacy Trend Development; Summary
	2G	Monthly Trend Factors
Exhibit 3	Benefi	t Factors
	3A	Generic Drug Utilization Adjustments - CONFIDENTIAL
	3B	Benefit Plan Relative Value Factors; Vermont Freedom Plan (VFP) and Comprehensive (COMP)
	3C	Benefit Plan Relative Value Factors; Vermont Health Partnership (VHP) Medical Plans
	3D	Benefit Plan Relative Value Factors; Prescription Drug Cards
	3E	Benefit Plan Relative Value Factors; Comprehensive Consumer Driven Health Plans (CDHPs)
	3F	Benefit Plan Relative Value Factors; Medicare Secondary Vermont Freedom Plan (VFP) and Indemnity J-Plan (JPLAN)
	3G	Benefit Plan Relative Value Factors; Medicare Secondary Consumer Driven Health Plans (CDHPs)
	3H	Benefit Plan Relative Value Factors; Medicare Secondary Prescription Drug Cards
	31	Benefit Leverage Factors; Vermont Freedom Plan (VFP) and Comprehensive (COMP)
	3J	Benefit Leverage Factors; Prescription Drug Cards
	3K	Pharmacy Contract Adjustment Factors - CONFIDENTIAL
	3L	Tier Factors
Exhibit 4	Manua	al Rate
	4A	Example of Manual Rate Adjustment
	4B	Industry Factors
	4C	Projected 2023 MLR Calculation
Exhibit 5	Admin	istrative Charges
	5A	Administrative Charges PUPM
Exhibit 6	Other	Factors
	6A	Credibility Table
	6B	Pooling Point By Membership
	6C	COVID-19 Diagnosis and Procedure Codes

6D

Aggregate Stop Loss Rate Factors

Example Calculation of Projected Single Claims Rate for Active Members

Benefit-Adjusted Projected Single Claims Rate:

	Medical	Pharmacy	Total	
Experience Period Paid Claims	\$1,600,000	\$320,000		Α
Experience Period Claims Amount above \$70,000 Pooling Limit	\$182,000	\$36,400		В
COVID-19 Related Claims	\$14,000	\$2,000		С
Capped Claims	\$1,404,000	\$281,600		D = A - B - C
Completion Factor	1.005	1.001		E
Completed Capped Claims	\$1,410,000	\$281,882		$F = D \times E$
Expected Claims above \$70,000 Pooling Limit	\$168,000	\$33,600		G
Experience Adjustment Factor	1.000	1.000		Н
Adjusted Experience Period Claims	\$1,578,000	\$315,482		I = (F + G) x H
Experience Period Member Months	4,000	4,000		J
Adjusted Experience Period Claims PMPM	\$394.50	\$78.87		K = I ÷ J
Average Experience Period Seasonally Adjusted Benefit Relativity Factor Demographic Normalization Benefit-Adjusted Experience Period Single Claims Rate Trend Trend Months Trend Factor	0.768 1.000 \$513.46 1.090 18 1.138	0.768 1.000 \$102.65 1.106 18 1.163		L M N = K ÷ L * M O P Q = O ^ (P/12)
Projected Single Contract Rate	\$584.31	\$119.40	\$703.71	$R = N \times Q$
Adjusted Manual Rate Credibility factor Benefit-Adjusted Projected Single Claims Rate		· 	\$795.12 53% \$746.26	S T U = (R x T) + { S x (1 — T)}
Credibility Calculation				
Active Member Months			4,000	a
Member Months for Full Credibility at \$70,000 Pooling Limit			14,002	b
Credibility			53%	c = (a / b) ^ 0.5

Example Calculation of Projected Single Claims Rate for Medicare Primary Members

Benefit-Adjusted Projected Single Claims Rate:

	Medical	Pharmacy	Total	
Experience Period Paid Claims	\$16,000	\$24,000		Α
COVID-19 Related Claims	\$400	\$0		В
Capped Claims	\$15,600	\$24,000		C = A — B
Completion Factor	1.011	1.001		D
Completed Capped Claims	\$15,800	\$24,024		$E = C \times D$
Experience Adjustment Factor ¹	1.000	1.000		F
Adjusted Experience Period Claims	\$15,800	\$24,024		$G = E \times F$
Experience Period Member Months	96	96		Н
Adjusted Experience Period Claims PMPM	\$164.58	\$250.25		$I = G \div H$
Average Experience Period Seasonal Adjusted Benefit Relativity Factor	0.900	0.900		J
Demographic Normalization	1.000	1.000		K
Benefit-Adjusted Experience Period Single Claims Rate	\$182.87	\$278.06		L = I ÷ J * K
Trend	1.043	1.106		M
Trend Months	18	18		N
Trend Factor	1.065	1.163		$O = M ^ (N/12)$
Projected Single Contract Rate	\$194.79	\$323.42	\$518.21	$P = L \times O$
Adjusted Manual Rate			\$534.31	Q
Credibility factor			11%	R
Benefit-Adjusted Projected Single Claims Rate			\$532.58	$S = (P \times R) + \{ Q \times (1 - R) \}$
Credibility Calculation				
Medicare Primary Member Months			96	a
Member Months for Full Credibility			8,325	b
Credibility			11%	$c = (a / b) ^ 0.5$

Example Calculation of Projected Single Claims Rate for Active Members with Multiple Experience Periods

Benefit-Adjusted Projected Single Claims Rate:

Period	Α		В	1	C			
Category	Medical	Pharamcy	Medical	Pharamcy	Medical	Pharamcy	Manual	
Experience Period Start	7/1/2021	7/1/2021	7/1/2020	7/1/2020	3/1/2019	7/1/2019		
Experience Period End	6/30/2022	6/30/2022	6/30/2021	6/30/2021	2/29/2020	6/30/2020		
Paid Claims in Experience Period	\$1,600,000	\$320,000	\$1,500,000	\$300,000	\$1,360,000	\$272,000		Α
Claims over \$70,000 Pooling Limit	\$182,000	\$36,400	\$321,000	\$64,200	\$80,000	\$16,000		В
COVID-19 Related Claims	\$14,000	\$0	\$8,000	\$2,000	\$0	\$0		С
Capped Claims	\$1,404,000	\$283,600	\$1,171,000	\$233,800	\$1,280,000	\$256,000		D = A - B - C
Completion Factor	1.005	1.001	1.001	1.000	1.000	1.000		E
Completed Capped Claims	\$1,410,000	\$283,884	\$1,170,000	\$234,000	\$1,280,000	\$256,000		$F = D \times E$
Expected Claims above \$70,000 Pooling Limit	\$168,000	\$33,600	\$212,000	\$42,400	\$200,000	\$40,000		G
Experience Adjustment Factor	1.000	1.000	1.000	1.000	1.000	1.000		Н
Adjusted Experience Period Claims	\$1,578,000	\$317,484	\$1,382,000	\$276,400	\$1,480,000	\$296,000		I = (F + G) x H
Experience Period Member Months	4,000	4,000	4,100	4,100	3,900	3,900		J
Adjusted Experience Period Claims PMPM	\$394.50	\$79.37	\$337.07	\$67.41	\$379.49	\$75.90		K = I ÷ J
Average Experience Period Med/Rx Total Seasonally Adjusted								
Benefit Relativity Factor	0.768	0.768	0.750	0.750	0.760	0.760		L
Demographic Normalization	1.000	1.000	1.002	1.002	0.998	0.998		M
Benefit-Adjusted Experience Period Single Claims Rate	\$513.46	\$103.30	\$450.33	\$90.07	\$498.33	\$99.67		$N = K \div L \times M$
Trend to Period A			1.051	1.110	1.114	1.198		0
Trend	1.090	1.106	1.090	1.106	1.090	1.106		P
Trend Months	18	18	18	18	18	18		Q
Trend Factor	1.138	1.163	1.196	1.291	1.268	1.394		$R = O \times P \wedge (Q/12)$
Projected Single Contract Rate	\$584.31	\$120.16	\$538.76	\$116.23	\$631.98	\$138.92	\$795.12	$S = N \times R$
Credibility Calculation	Δ		В	,	C		Manual	
Starting Residual	100.	.0%	46.0	6%	21.4	4%	10.1%	$T = 1 - \sum Y$
Active Member Months	4,0	00	4,100	4,100	3,900	3,900		U
Member Months for Full Credibility at \$70,000 Pooling Limit	14,0	002	14,002	14,002	14,002	14,002		V
Credibility	53.4	4%	54.1%	54.1%	52.8%	52.8%		$W = (T / U) ^ 0.5$
Med/Rx Weights ¹	77.2%	22.8%	77.2%	22.8%	77.2%	22.8%		X
Rating Credibility	53.4	4%	25.2	2%	11.3	3%	10.1%	$\mathbf{Y} = \sum T \times W \times X_i$
Projected Single Contract Rate	\$584.31	\$120.16	\$538.76	\$116.23	\$631.98	\$138.92	\$795.12	Z
Credibility	53.4		25.2		11.3		10.1%	α
Benefit-Adjusted Projected Single Claims Rate	\$312.31	\$64.22	\$135.72	\$29.28	\$71.25	\$15.66	\$80.21	$\beta = Z \times \alpha$
∑ Benefit-Adjusted Projected Single Claims Rate	\$708.64							$\gamma = \sum \beta$

⁽¹⁾ Claim weights underlying BRV model

Example Calculation of Required Premium by Product and Tier Illustrative Only

From Exhibit 1A: Active Benefit-Adjusted Projected Single Claims Rate (S)

Medicare Primary Benefit-Adjusted Projected Single Claims Rate (S)

\$746.26 \$532.58

Plan A			Single	2-Person	Family	Medicare Primary
Members per contract			1.000	2.000	3.940	1.000
BRV:	Α		0.929	1.859	2.585	0.984
Projected Claims:	B1 = A x S		\$693.50	\$1,387.00	\$1,929.16	\$524.06
OneCare Coordination Fee	B2		\$3.25	\$6.50	\$12.81	
Projected Rx Rebate:	В3		-\$14.00	-\$28.00	-\$55.16	-\$14.00
Net Cost of Reinsurance:	B4		\$2.09	\$4.18	\$8.23	
Mandates and Assessments						
Vaccines for Vemonters	C1		\$2.50	\$5.00	\$9.85	\$2.50
Blueprint for Health	C2		\$6.01	\$12.02	\$23.68	
Health Care Claims Tax	C3 = 0.999% * B1		\$6.93	\$13.86	\$19.27	\$5.24
GMCB Billback	C4		\$2.31	\$4.62	\$9.10	\$2.31
NH Vaccines	C5		\$0.01	\$0.02	\$0.04	
NY GME	C6		\$0.02	\$0.04	\$0.08	
MGARA	C7		\$0.03	\$0.06	\$0.12	\$0.03
PCORI	C8		\$0.26	\$0.51	\$1.01	\$0.26
Administrative Charge	D		\$50.00	\$100.00	\$197.00	\$50.00
Commission (% premium)	E	3.00%				
Contribution to Reserve	F	1.50%				
Required Premium:	$H = [\sum(B_i) + \sum(C_i) + D] / ($	1 - E - F)	\$788.38	\$1,576.77	\$2,256.74	\$597.27
Plan B			Single	2-Person	Family	Medicare Secondary
					·	Secondary
Members per contract	Α		Single 1.000 1.023	2.000	3.938	Secondary
	А		1.000		·	Secondary
Members per contract BRV:	A B1 = A x S		1.000	2.000 2.046	3.938 2.846	1.000 1.046
Members per contract			1.000 1.023	2.000	3.938	Secondary
Members per contract BRV: Projected Claims:	B1 = A x S		1.000 1.023 \$763.43	2.000 2.046 \$1,526.85	3.938 2.846 \$2,123.67	1.000 1.046
Members per contract BRV: Projected Claims: OneCare Coordination Fee	B1 = A x S B2		1.000 1.023 \$763.43 \$3.25	2.000 2.046 \$1,526.85 \$6.50	3.938 2.846 \$2,123.67 \$12.81	1.000 1.046 \$557.08
Members per contract BRV: Projected Claims: OneCare Coordination Fee Projected Rx Rebate:	B1 = A x S B2 B3		1.000 1.023 \$763.43 \$3.25 -\$14.00	2.000 2.046 \$1,526.85 \$6.50 -\$28.00	3.938 2.846 \$2,123.67 \$12.81 -\$55.16	1.000 1.046 \$557.08
Members per contract BRV: Projected Claims: OneCare Coordination Fee Projected Rx Rebate: Net Cost of Reinsurance:	B1 = A x S B2 B3		1.000 1.023 \$763.43 \$3.25 -\$14.00	2.000 2.046 \$1,526.85 \$6.50 -\$28.00	3.938 2.846 \$2,123.67 \$12.81 -\$55.16	1.000 1.046 \$557.08
Members per contract BRV: Projected Claims: OneCare Coordination Fee Projected Rx Rebate: Net Cost of Reinsurance: Mandates and Assessments	B1 = A x S B2 B3 B4		1.000 1.023 \$763.43 \$3.25 -\$14.00 \$1.71	2.000 2.046 \$1,526.85 \$6.50 -\$28.00 \$3.42	3.938 2.846 \$2,123.67 \$12.81 -\$55.16 \$6.74	1.000 1.046 \$557.08 -\$14.00
Members per contract BRV: Projected Claims: OneCare Coordination Fee Projected Rx Rebate: Net Cost of Reinsurance: Mandates and Assessments Vaccines for Vemonters	B1 = A x S B2 B3 B4		1.000 1.023 \$763.43 \$3.25 -\$14.00 \$1.71	2.000 2.046 \$1,526.85 \$6.50 -\$28.00 \$3.42	3.938 2.846 \$2,123.67 \$12.81 -\$55.16 \$6.74	1.000 1.046 \$557.08 -\$14.00
Members per contract BRV: Projected Claims: OneCare Coordination Fee Projected Rx Rebate: Net Cost of Reinsurance: Mandates and Assessments Vaccines for Vemonters Blueprint for Health	B1 = A x S B2 B3 B4		1.000 1.023 \$763.43 \$3.25 -\$14.00 \$1.71	2.000 2.046 \$1,526.85 \$6.50 -\$28.00 \$3.42 \$5.00 \$12.02	3.938 2.846 \$2,123.67 \$12.81 -\$55.16 \$6.74 \$9.85 \$23.68	1.000 1.046 \$557.08 -\$14.00
Members per contract BRV: Projected Claims: OneCare Coordination Fee Projected Rx Rebate: Net Cost of Reinsurance: Mandates and Assessments Vaccines for Vemonters Blueprint for Health Health Care Claims Tax	B1 = A x S B2 B3 B4 C1 C2 C3 = 0.999% * B1		1.000 1.023 \$763.43 \$3.25 -\$14.00 \$1.71 \$2.50 \$6.01 \$7.63	2.000 2.046 \$1,526.85 \$6.50 -\$28.00 \$3.42 \$5.00 \$12.02 \$15.25	3.938 2.846 \$2,123.67 \$12.81 -\$55.16 \$6.74 \$9.85 \$23.68 \$21.22	\$econdary 1.000 1.046 \$557.08 -\$14.00 \$2.50 \$5.57
Members per contract BRV: Projected Claims: OneCare Coordination Fee Projected Rx Rebate: Net Cost of Reinsurance: Mandates and Assessments Vaccines for Vemonters Blueprint for Health Health Care Claims Tax GMCB Billback	B1 = A x S B2 B3 B4 C1 C2 C3 = 0.999% * B1 C4		1.000 1.023 \$763.43 \$3.25 -\$14.00 \$1.71 \$2.50 \$6.01 \$7.63 \$2.31	2.000 2.046 \$1,526.85 \$6.50 -\$28.00 \$3.42 \$5.00 \$12.02 \$15.25 \$4.62	\$2,123.67 \$12.81 -\$55.16 \$6.74 \$9.85 \$23.68 \$21.22 \$9.10	\$econdary 1.000 1.046 \$557.08 -\$14.00 \$2.50 \$5.57
Members per contract BRV: Projected Claims: OneCare Coordination Fee Projected Rx Rebate: Net Cost of Reinsurance: Mandates and Assessments Vaccines for Vemonters Blueprint for Health Health Care Claims Tax GMCB Billback NH Vaccines	B1 = A x S B2 B3 B4 C1 C2 C3 = 0.999% * B1 C4 C5		1.000 1.023 \$763.43 \$3.25 -\$14.00 \$1.71 \$2.50 \$6.01 \$7.63 \$2.31 \$0.01	2.000 2.046 \$1,526.85 \$6.50 -\$28.00 \$3.42 \$5.00 \$12.02 \$15.25 \$4.62 \$0.02	\$2,123.67 \$12.81 -\$55.16 \$6.74 \$9.85 \$23.68 \$21.22 \$9.10 \$0.04	\$econdary 1.000 1.046 \$557.08 -\$14.00 \$2.50 \$5.57
Members per contract BRV: Projected Claims: OneCare Coordination Fee Projected Rx Rebate: Net Cost of Reinsurance: Mandates and Assessments Vaccines for Vemonters Blueprint for Health Health Care Claims Tax GMCB Billback NH Vaccines NY GME	B1 = A x S B2 B3 B4 C1 C2 C3 = 0.999% * B1 C4 C5 C6		1.000 1.023 \$763.43 \$3.25 -\$14.00 \$1.71 \$2.50 \$6.01 \$7.63 \$2.31 \$0.01 \$0.02	2.000 2.046 \$1,526.85 \$6.50 -\$28.00 \$3.42 \$5.00 \$12.02 \$15.25 \$4.62 \$0.02 \$0.04	\$2,123.67 \$12.81 -\$55.16 \$6.74 \$9.85 \$23.68 \$21.22 \$9.10 \$0.04 \$0.08	\$2.50 \$557.08 \$2.50
Members per contract BRV: Projected Claims: OneCare Coordination Fee Projected Rx Rebate: Net Cost of Reinsurance: Mandates and Assessments Vaccines for Vemonters Blueprint for Health Health Care Claims Tax GMCB Billback NH Vaccines NY GME MGARA	B1 = A x S B2 B3 B4 C1 C2 C3 = 0.999% * B1 C4 C5 C6		1.000 1.023 \$763.43 \$3.25 -\$14.00 \$1.71 \$2.50 \$6.01 \$7.63 \$2.31 \$0.01 \$0.02	2.000 2.046 \$1,526.85 \$6.50 -\$28.00 \$3.42 \$5.00 \$12.02 \$15.25 \$4.62 \$0.02 \$0.04	\$2,123.67 \$12.81 -\$55.16 \$6.74 \$9.85 \$23.68 \$21.22 \$9.10 \$0.04 \$0.08	\$econdary 1.000 1.046 \$557.08 -\$14.00 \$2.50 \$5.57 \$2.31
Members per contract BRV: Projected Claims: OneCare Coordination Fee Projected Rx Rebate: Net Cost of Reinsurance: Mandates and Assessments Vaccines for Vemonters Blueprint for Health Health Care Claims Tax GMCB Billback NH Vaccines NY GME MGARA PCORI	B1 = A x S B2 B3 B4 C1 C2 C3 = 0.999% * B1 C4 C5 C6 C7 C8	3.00%	1.000 1.023 \$763.43 \$3.25 -\$14.00 \$1.71 \$2.50 \$6.01 \$7.63 \$2.31 \$0.01 \$0.02	2.000 2.046 \$1,526.85 \$6.50 -\$28.00 \$3.42 \$5.00 \$12.02 \$15.25 \$4.62 \$0.02 \$0.04	\$2,123.67 \$12.81 -\$55.16 \$6.74 \$9.85 \$23.68 \$21.22 \$9.10 \$0.04 \$0.08	\$2.50 \$557.08 \$2.50 \$5.57 \$2.31
Members per contract BRV: Projected Claims: OneCare Coordination Fee Projected Rx Rebate: Net Cost of Reinsurance: Mandates and Assessments Vaccines for Vemonters Blueprint for Health Health Care Claims Tax GMCB Billback NH Vaccines NY GME MGARA PCORI Administrative Charge	B1 = A x S B2 B3 B4 C1 C2 C3 = 0.999% * B1 C4 C5 C6 C7 C8 D	3.00% 1.50%	1.000 1.023 \$763.43 \$3.25 -\$14.00 \$1.71 \$2.50 \$6.01 \$7.63 \$2.31 \$0.01 \$0.02	2.000 2.046 \$1,526.85 \$6.50 -\$28.00 \$3.42 \$5.00 \$12.02 \$15.25 \$4.62 \$0.02 \$0.04	\$2,123.67 \$12.81 -\$55.16 \$6.74 \$9.85 \$23.68 \$21.22 \$9.10 \$0.04 \$0.08	\$2.50 \$557.08 \$2.50 \$5.57 \$2.31

UNIT COST TREND SUMMARY

	i	In-retired.			lanation.	In-nel-or	0	0	0.4	Outration:	0.44:- :	Dfi '	Deefi '	Dfi '	Deefeeden !	Deef-eelee '	Desfersions!			Takal		
		Inpatient GMCB	Inpatient NH	Inpatient BlueCard	Inpatient Other	Inpatient Total	Outpatient GMCB	Outpatient NH	Outpatient BlueCard	Outpatient Other	Outpatient Total	Professional GMCB	Professional Community	Professional NH	Professional BlueCard	Professional Other	Professional Total	VT / GMCB	NH	Total BlueCard	Other	Total
ĺ	Exp Period	GIVICE	INH	Biuecaru	Other	27,144,930	GIVICB	NH	Bidecard	Other	72,773,568	GIVICE	Community	NH	Bidecard	Otilei	42,526,212	VI / GIVICE	INFI	Biuecaru	Other	142,444,710
	CY 2021					27,540,735					73,979,236						43,019,437					144,539,408
	YE 202206					28,319,332					75,825,125						43,897,195					148,041,652
	CY 2022		i i			29,042,049					77,608,260	i i				1	44,922,510					151,572,819
VHP	CY 2023					30,801,527					82,091,103						46,820,960					159,713,590
>	Exp % of Total					100.0%					100.0%						100.0%					100.0%
	Prj % of Total					100.0%					100.0%						100.0%					100.0%
	CY 2022 / CY 2021					5.5%					4.9%						4.4%					4.9%
	CY 2023 / CY 2022					6.1%					5.8%						4.2%					5.4%
	Annual Cost Trend					5.8%					5.4%						4.4%					5.2%
						27444020					70 770 550						40 505 040			_		442 444 740
	Exp Period CY 2021					27,144,930 27,600,292					72,773,568 74,055,997						42,526,212 43,047,690					142,444,710 144,703,978
	YE 202206					28,358,535					76,125,260						43,972,940					148,456,735
	CY 2022					29,034,800					78,036,384						44,999,667					152,070,852
0	CY 2023					30,792,368					82,546,553						46,901,975					160,240,897
ONI	Exp % of Total					100.0%					100.0%						100.0%					100.0%
	Pri % of Total					100.0%					100.0%						100.0%					100.0%
	CY 2022 / CY 2021					5.2%					5.4%						4.5%					5.1%
	CY 2023 / CY 2022					6.1%					5.8%						4.2%					5.4%
	Annual Cost Trend					5.6%					5.5%						4.4%					5.2%
	Exp Period					27,144,930					72,773,568						42,526,212					142,444,710
	CY 2021					27,564,519					74,024,673						43,047,690	77.050.040				144,636,882
	YE 202206					28,387,683					75,955,008						43,972,940	77,652,246				148,315,630
۵.	CY 2022 CY 2023					29,111,573 30,874,515					77,740,415 82,229,866						44,999,667 46.901.975					151,851,655 160,006,356
TVHP	Exp % of Total					100.0%					100.0%						100.0%					100.0%
_	Pri % of Total					100.0%					100.0%						100.0%					100.0%
	CY 2022 / CY 2021					5.6%					5.0%						4.5%		_			5.0%
	CY 2023 / CY 2022					6.1%					5.8%						4.2%					5.4%
	Annual Cost Trend					5.8%					5.4%						4.4%					5.2%

		Origin	al Allowed Claims (a	djusted to the VHP ne	etwork)	Adju	ısted Claims - Norma	lized for Contract Cha	inges	Adj	usted Claims - Norma	lized for Contract Cha	inges
Month	Membership	Facility	Professional, Mental Health	Professional, All Other	Total Allowed Claims	Facility	Professional, Mental Health	Professional, All Other	Total Allowed Claims	Facility	Professional, Mental Health	Professional, All Other	Total Allowed Claims
Sep-17	21,670	\$4,873,351	\$202,248	\$2,552,144	\$7,627,742	\$5,789,982	\$214,679	\$2,454,807	\$8,459,468	\$267.19	\$9.91	\$113.28	\$390.38
Oct-17	21,666	\$5,866,027	\$223,565	\$2,903,375	\$8,992,968	\$6,847,884	\$237,368	\$2,804,158	\$9,889,410	\$316.07	\$10.96	\$129.43	\$456.45
Nov-17	21,746	\$5,524,634	\$217,063	\$3,035,974	\$8,777,671	\$6,476,956	\$230,598	\$2,942,035	\$9,649,589	\$297.85	\$10.60	\$135.29	\$443.74
Dec-17	21,727	\$6,043,446	\$180,770	\$2,756,707	\$8,980,924	\$7,049,796	\$192,141	\$2,696,153	\$9,938,089	\$324.47	\$8.84	\$124.09	\$457.41
Jan-18	22,079	\$6,432,189	\$233,798	\$3,053,187	\$9,719,174	\$7,428,194	\$248,570	\$3,014,874	\$10,691,638	\$336.44	\$11.26	\$136.55	\$484.24
Feb-18	22.144	\$5,838,546	\$202,848	\$2,676,977	\$8,718,370	\$6,729,227	\$215,754	\$2,647,288	\$9,592,269	\$303.88	\$9.74	\$119.55	\$433.18
Mar-18	22,136	\$5,912,143	\$234,297	\$2,961,811	\$9,108,251	\$6,814,176	\$248,972	\$2,919,344	\$9,982,491	\$307.83	\$11.25	\$131.88	\$450.96
Apr-18	22,176	\$5,880,973	\$242,389	\$2,745,810	\$8,869,172	\$6,736,007	\$257,531	\$2,677,634	\$9,671,173	\$303.75	\$11.61	\$120.74	\$436.11
May-18	22,355	\$6,354,474	\$264,620	\$3,028,440	\$9,647,534	\$7,288,825	\$280,930	\$2,951,981	\$10,521,735	\$326.05	\$12.57	\$132.05	\$470.67
Jun-18	22,397	\$5,545,495	\$240,803	\$2,685,785	\$8,472,082	\$6,375,363	\$255,546	\$2,610,008	\$9,240,917	\$284.65	\$11.41	\$116.53	\$412.60
Jul-18	22,587	\$5,404,531	\$219,513	\$2,763,340	\$8,387,385	\$6,163,783	\$232,872	\$2,708,776	\$9,105,430	\$272.89	\$10.31	\$119.93	\$403.13
Aug-18	22,671	\$6,122,928	\$231,691	\$2,897,134	\$9,251,753	\$6,984,417	\$245,724	\$2,833,744	\$10,063,884	\$308.08	\$10.84	\$124.99	\$443.91
Sep-18	22,650	\$5,263,811	\$221,301	\$2,704,967	\$8,190,078	\$6,014,319	\$234,619	\$2,641,621	\$8,890,558	\$265.53	\$10.36	\$116.63	\$392.52
Oct-18	22,781	\$6,236,288	\$282,262	\$3,257,101	\$9,775,651	\$7,070,506	\$296,589	\$3,145,385	\$10,512,479	\$310.37	\$13.02	\$138.07	\$461.46
Nov-18	23,112	\$5,649,215	\$254,640	\$2,949,513	\$8,853,368	\$6,404,813	\$267,491	\$2,847,692	\$9,519,995	\$277.12	\$11.57	\$123.21	\$411.91
Dec-18	23,083	\$6,740,217	\$225,330	\$3,161,477	\$10,127,024	\$7,626,881	\$236,573	\$3,103,507	\$10,966,960	\$330.41	\$10.25	\$134.45	\$475.11
Jan-19	24,461	\$7,776,783	\$300,528	\$3,462,681	\$11,539,992	\$8,700,275	\$315,443	\$3,340,086	\$12,355,804	\$355.68	\$12.90	\$136.55	\$505.12
Feb-19	24,499	\$6,650,398	\$267,463	\$3,017,913	\$9,935,774	\$7,444,490	\$280,680	\$2,902,984	\$10,628,154	\$303.87	\$11.46	\$118.49	\$433.82
Mar-19	24,539	\$6,972,567	\$300,256	\$3,244,397	\$10,517,221	\$7,786,116	\$314,995	\$3,105,878	\$11,206,989	\$317.30	\$12.84	\$126.57	\$456.70
Apr-19	24,481	\$6,828,842	\$316,053	\$3,340,412	\$10,485,307	\$7,631,941	\$331,451	\$3,193,577	\$11,156,969	\$311.75	\$13.54	\$130.45	\$455.74
May-19	24,525	\$6,666,694	\$340,084	\$3,350,627	\$10,357,404	\$7,420,785	\$356,543	\$3,176,118	\$10,953,446	\$302.58	\$14.54	\$129.51	\$446.62
Jun-19	24,502	\$6,705,514	\$287,335	\$2,891,726	\$9,884,576	\$7,477,960	\$301,153	\$2,746,763	\$10,525,876	\$305.20	\$12.29	\$112.10	\$429.59
Jul-19	24,662	\$7,113,535	\$306,098	\$3,165,984	\$10,585,617	\$7,922,880	\$320,655	\$3,004,689	\$11,248,225	\$321.26	\$13.00	\$121.83	\$456.10
Aug-19	24,669	\$6,249,835	\$283,475	\$3,087,975	\$9,621,284	\$6,975,088	\$296,862	\$2,944,570	\$10,216,520	\$282.75	\$12.03	\$119.36	\$414.14
Sep-19	24,629	\$6,186,177	\$300,226	\$3,039,152	\$9,525,554	\$6,866,483	\$314,310	\$2,876,608	\$10,057,401	\$278.80	\$12.76	\$116.80	\$408.36
Oct-19	24,629	\$7,211,031	\$358,298	\$3,532,629	\$11,101,959	\$7,939,360	\$374,989	\$3,331,150	\$11,645,499	\$321.56	\$15.19	\$134.92	\$471.67
Nov-19	24,961	\$6,358,983	\$286,305	\$3,093,902	\$9,739,190	\$6,953,514	\$299,466	\$2,943,727	\$10,196,707	\$278.58	\$12.00	\$117.93	\$408.51
Dec-19	24,950	\$6,572,771	\$280,305	\$3,165,966	\$10.018.923	\$7,182,159	\$293,051	\$3,026,373	\$10,501,584	\$287.86	\$11.75	\$121.30	\$420.91
Jan-20	25,746	\$6,717,341	\$363,466	\$3,411,736	\$10,492,543	\$7,224,284	\$380,077	\$3,193,939	\$10,798,300	\$280.60	\$14.76	\$124.06	\$419.42
Feb-20	25,637	\$6,980,659	\$302,357	\$3,142,586	\$10,492,543	\$7,484,341	\$316,050	\$2,976,586	\$10,776,977	\$291.94	\$12.33	\$116.11	\$420.37
Mar-20	25,637	\$5,202,034	\$329,823	\$2,683,509	\$8,215,366	\$5,589,588	\$344,738	\$2,465,341	\$8,399,667	\$218.04	\$13.45	\$96.17	\$327.65
Apr-20	25,560	\$4,091,495	\$363,449	\$1,784,224	\$6,239,168	\$4,352,034	\$379,821	\$1,487,926	\$6,219,781	\$170.27	\$14.86	\$58.21	\$243.34
	25,418	\$5,298,589	\$336,726	\$2,340,247	\$7,975,562	\$5,646,585	\$351,793	\$2,099,329	\$8,097,707	\$222.15	\$13.84	\$82.59	\$318.58
May-20 Jun-20	25,418	\$7,220,990	\$360,348	\$3,156,637	\$10,737,975	\$7,738,559	\$376,515	\$2,928,835	\$11,043,909	\$304.97	\$14.84	\$115.42	\$435.23
Jun-20 Jul-20	25,375	\$7,286,610	\$354,606	\$3,120,723	\$10,761,939	\$7,783,724	\$370,313	\$2,883,855	\$11,043,909	\$308.38	\$14.67	\$114.25	\$437.30
		\$6,778,663	\$337,427	\$3,053,873	\$10,761,959	\$7,196,701	\$352,398	\$2,831,222	\$10,380,321	\$285.66	\$13.99	\$112.38	\$412.03
Aug-20	25,193	\$7,087,683	\$368,680	\$3,377,373	\$10,833,736	\$7,539,923	\$385,049	\$3,135,045	\$11,060,017	\$298.68	\$15.25	\$124.19	\$438.12
Sep-20	25,244	\$6,651,057	\$395,397	\$3,394,239	\$10,440,693	\$6,924,861	\$407,561	\$3,102,662	\$10,435,083	\$273.79	\$16.11	\$122.67	\$412.57
Oct-20	25,293								\$8,778,660	\$228.28	\$14.63		\$346.01
Nov-20	25,371	\$5,567,784	\$360,181	\$2,892,894	\$8,820,859	\$5,791,780	\$371,204	\$2,615,676				\$103.10	
Dec-20	25,360	\$6,846,321	\$380,416	\$3,295,219	\$10,521,956	\$7,149,540	\$392,027	\$3,014,639	\$10,556,206	\$281.92	\$15.46	\$118.87	\$416.25
Jan-21	26,304	\$6,914,876	\$389,397	\$3,213,883 \$3,237,882	\$10,518,155	\$7,056,320 \$7,385,684	\$401,137	\$2,889,543 \$2,920,389	\$10,347,000	\$268.26 \$281.13	\$15.25 \$14.89	\$109.85	\$393.36 \$407.19
Feb-21	26,271	\$7,283,037	\$380,009		\$10,900,928		\$391,250		\$10,697,323			\$111.16	
Mar-21	26,232	\$7,687,803	\$459,304	\$3,821,182	\$11,968,289	\$7,799,646	\$472,679	\$3,435,828	\$11,708,154	\$297.33	\$18.02	\$130.98	\$446.33
Apr-21	26,221	\$7,894,383	\$412,026	\$3,622,991	\$11,929,400	\$8,004,589	\$423,757	\$3,278,831	\$11,707,177	\$305.27	\$16.16	\$125.05	\$446.48
May-21	26,287	\$8,417,295	\$380,035	\$3,663,544	\$12,460,874	\$8,537,004	\$380,500	\$3,303,979	\$12,221,483	\$324.76	\$14.47	\$125.69	\$464.92
Jun-21	26,396	\$7,599,922	\$394,737	\$3,615,610	\$11,610,269	\$7,690,453	\$395,090	\$3,237,404	\$11,322,946	\$291.35	\$14.97	\$122.65	\$428.96
Jul-21	26,610	\$7,056,423	\$356,589	\$3,433,540	\$10,846,552	\$7,085,155	\$356,721	\$3,078,021	\$10,519,897	\$266.26	\$13.41	\$115.67	\$395.34
Aug-21	26,603	\$7,254,245	\$364,051	\$3,493,906	\$11,112,202	\$7,280,668	\$364,051	\$3,129,855	\$10,774,574	\$273.68	\$13.68	\$117.65	\$405.01

	ASF Norma	lization Factors	Working Day Nor	malization Factor	FWA Normalization	Te	Total Normalization Factor			
Month	Monthly ASF	ASF Normalization	Working Days	Working Day Normalization	Factor	Facility	Professional, Mental Health	Professional, All Other		
Sep-17	0.9772	1.0018	20	1.0542	0.9997	1.0558	1.0558	1.0558		
Oct-17	0.9774	1.0016	22	0.9583	0.9997	0.9596	0.9596	0.9596		
Nov-17	0.9777	1.0013	20	1.0542	0.9997	1.0552	1.0552	1.0552		
Dec-17	0.9792	0.9997	20	1.0542	0.9997	1.0535	1.0535	1.0535		
Jan-18	0.9709	1.0083	22	0.9583	1.0030	0.9692	0.9692	0.9692		
Feb-18	0.9713	1.0078	20	1.0542	1.0030	1.0655	1.0655	1.0655		
Mar-18	0.9731	1.0059	22	0.9583	1.0030	0.9669	0.9669	0.9669		
Apr-18	0.9728	1.0062	21	1.0040	1.0030	1.0132	1.0132	1.0132		
May-18	0.9736	1.0055	22	0.9583	1.0030	0.9665	0.9665	0.9665		
Jun-18	0.9745	1.0046	21	1.0040	1.0030	1.0116	1.0116	1.0116		
Jul-18	0.9744	1.0046	21	1.0040	1.0030	1.0116	1.0116	1.0116		
Aug-18	0.9752	1.0038	23	0.9167	1.0030	0.9229	0.9229	0.9229		
Sep-18	0.9780	1.0010	19	1.1096	1.0030	1.1140	1.1140	1.1140		
Oct-18	0.9776	1.0014	23	0.9167	1.0030	0.9207	0.9207	0.9207		
Nov-18	0.9762	1.0027	20	1.0542	1.0030	1.0602	1.0602	1.0602		
Dec-18	0.9775	1.0015	19	1.1096	1.0030	1.1146	1.1146	1.1146		
Jan-19	0.9725	1.0065	22	0.9583	0.9965	0.9613	0.9613	0.9613		
Feb-19	0.9726	1.0065	20	1.0542	0.9965	1.0573	1.0573	1.0573		
Mar-19	0.9730	1.0061	21	1.0040	0.9965	1.0066	1.0066	1.0066		
Apr-19	0.9741	1.0049	22	0.9583	0.9965	0.9597	0.9597	0.9597		
May-19	0.9752	1.0038	22	0.9583	0.9965	0.9587	0.9587	0.9587		
Jun-19	0.9750	1.0040	20	1.0542	0.9965	1.0547	1.0547	1.0547		
Jul-19	0.9755	1.0035	21	1.0040	0.9965	1.0040	1.0040	1.0040		
Aug-19	0.9744	1.0046	22	0.9583	0.9965	0.9594	0.9594	0.9594		
Sep-19	0.9740	1.0050	21	1.0040	0.9965	1.0055	1.0055	1.0055		
Oct-19	0.9742	1.0049	22	0.9583	0.9965	0.9597	0.9597	0.9597		
Nov-19	0.9726	1.0065	19	1.1096	0.9965	1.1130	1.1130	1.1130		
Dec-19	0.9747	1.0043	21	1.0040	0.9965	1.0048	1.0048	1.0048		
Jan-20	0.9701	1.0091	22	0.9583	0.9941	0.9613	0.9613	0.9613		
Feb-20	0.9704	1.0088	20	1.0542	0.9941	1.0571	1.0571	1.0571		
Mar-20	0.9724	1.0067	22	0.9583	0.9941	0.9590	0.9590	0.9590		
Apr-20	0.9726	1.0065	22	0.9583	0.9941	0.9589	0.9589	0.9589		
May-20	0.9749	1.0042	20	1.0542	0.9941	1.0523	1.0523	1.0523		
Jun-20	0.9745	1.0045	22	0.9583	0.9941	0.9570	0.9570	0.9570		
Jul-20	0.9756	1.0034	22	0.9583	0.9941	0.9559	0.9559	0.9559		
Aug-20	0.9764	1.0026	21	1.0040	0.9941	1.0006	1.0006	1.0006		
Sep-20	0.9761	1.0029	21	1.0040	0.9941	1.0009	1.0009	1.0009		
Oct-20	0.9763	1.0026	22	0.9583	0.9941	0.9552	0.9552	0.9552		
Nov-20	0.9765	1.0024	19	1.1096	0.9941	1.1058	1.1058	1.1058		
Dec-20	0.9757	1.0033	21	1.0040	0.9941	1.0013	1.0013	1.0013		
Jan-21	0.9736	1.0054	20	1.0542	1.0000	1.0599	1.0599	1.0599		
Feb-21	0.9737	1.0054	20	1.0542	1.0000	1.0599	1.0599	1.0599		
Mar-21	0.9752	1.0038	23	0.9167	1.0000	0.9201	0.9201	0.9201		
Apr-21	0.9757	1.0033	22	0.9583	1.0000	0.9615	0.9615	0.9615		
May-21	0.9767	1.0023	20	1.0542	1.0000	1.0566	1.0566	1.0566		
Jun-21	0.9774	1.0016	22	0.9583	1.0000	0.9599	0.9599	0.9599		
Jul-21	0.9776	1.0014	21	1.0040	1.0000	1.0054	1.0054	1.0054		
Aug-21	0.9789	1.0000	22	0.9583	1.0000	0.9583	0.9583	0.9583		

YE August 2021 Average: 21.1 Annual Trend:

Calendar Year	Percent of claims recovered as part of FWA programs
2017	1.09%
2018	1.42%
2019	0.77%
2020	0.52%
2021	1.12%

	N	Nonthly Adjusted A	llowed Claims PMF	PM	Rolling Adjusted Allowed Claims PMPM						
		Professional,	Professional, All	Total Allowed		Professional,	Professional, All	Total Allowe			
Month	Facility	Mental Health	Other	Claims	Facility	Mental Health	Other	Claims			
Sep-17	\$282.09	\$10.46	\$119.60	\$412.14							
Oct-17	\$303.29	\$10.51	\$124.19	\$438.00							
Nov-17	\$314.29	\$11.19	\$142.76	\$468.24							
Dec-17	\$341.83	\$9.32	\$130.73	\$481.88							
Jan-18	\$326.06	\$10.91	\$132.34	\$469.31							
Feb-18	\$323.80	\$10.38	\$127.38	\$461.57							
Mar-18	\$297.64	\$10.88	\$127.52	\$436.03							
Apr-18	\$307.77	\$11.77	\$122.34	\$441.88							
May-18	\$315.12	\$12.15	\$127.62	\$454.89							
Jun-18	\$287.94	\$11.54	\$117.88	\$417.36							
Jul-18	\$276.05	\$10.43	\$121.32	\$407.80							
Aug-18	\$284.31	\$10.00	\$115.35	\$409.67	\$304.89	\$10.80	\$125.70	\$441.38			
Sep-18	\$295.81	\$11.54	\$129.93	\$437.27	\$305.97	\$10.89	\$126.55	\$443.41			
Oct-18	\$285.74	\$11.99	\$127.11	\$424.84	\$304.46	\$11.01	\$126.79	\$442.27			
Nov-18	\$293.80	\$12.27	\$130.63	\$436.70	\$302.75	\$11.11	\$125.83	\$439.69			
Dec-18	\$368.27	\$11.42	\$149.86	\$529.55	\$305.21	\$11.28	\$127.49	\$443.97			
Jan-19	\$341.91	\$12.40	\$131.26	\$485.56	\$306.81	\$11.41	\$127.43	\$445.65			
Feb-19	\$321.29	\$12.11	\$125.29	\$458.69	\$306.73	\$11.55	\$127.25	\$445.53			
Mar-19	\$319.38	\$12.92	\$127.40	\$459.70	\$308.58	\$11.73	\$127.24	\$447.55			
Apr-19	\$299.19	\$12.99	\$125.20	\$437.39	\$307.82	\$11.83	\$127.45	\$447.10			
May-19	\$290.08	\$13.94	\$124.15	\$428.17	\$305.70	\$11.99	\$127.15	\$444.84			
Jun-19	\$321.90	\$12.96	\$118.24	\$453.10	\$308.50	\$12.11	\$127.11	\$447.72			
Jul-19	\$322.54	\$13.05	\$122.32	\$457.92	\$312.27	\$12.33	\$127.16	\$451.75			
Aug-19	\$271.27	\$11.55	\$114.52	\$397.34	\$310.96	\$12.44	\$127.00	\$450.40			
Sep-19	\$280.34	\$12.83	\$117.44	\$410.61	\$309.54	\$12.55	\$125.96	\$448.05			
Oct-19	\$308.59	\$14.58	\$129.48	\$452.64	\$311.32	\$12.76	\$126.17	\$450.25			
Nov-19	\$310.05	\$13.35	\$131.26	\$454.66	\$312.59	\$12.85	\$126.25	\$451.69			
Dec-19	\$289.25	\$11.80	\$121.88	\$422.93	\$306.27	\$12.87	\$124.04	\$443.18			
Jan-20	\$269.74	\$14.19	\$119.26	\$403.19	\$300.17	\$13.03	\$123.03	\$436.22			
Feb-20	\$308.61	\$13.03	\$122.74	\$444.39	\$299.16	\$13.10	\$123.83	\$435.08			
Mar-20	\$209.11	\$12.90	\$92.23	\$314.23	\$289.78	\$13.10	\$119.82	\$422.70			
Apr-20	\$163.26	\$14.25	\$55.82	\$233.33	\$278.24	\$13.21	\$113.93	\$405.38			
May-20	\$233.76	\$14.56	\$86.91	\$335.24	\$273.52	\$13.26	\$110.82	\$397.60			
Jun-20	\$291.84	\$14.20	\$110.45	\$416.50	\$273.32	\$13.36	\$110.82	\$394.68			
Jul-20	\$294.78	\$14.02	\$109.22	\$418.02	\$268.91	\$13.44	\$109.11	\$391.47			
Aug-20	\$285.84	\$14.00	\$112.45	\$412.28	\$270.13	\$13.65	\$108.95	\$392.73			
Sep-20	\$298.96	\$15.27	\$124.30	\$438.53	\$270.13	\$13.85	\$109.54	\$395.08			
Oct-20				\$394.08				\$390.33			
Nov-20	\$261.51 \$252.43	\$15.39 \$16.18	\$117.17	\$382.61	\$267.86 \$263.12	\$13.92 \$14.15	\$108.56 \$107.15	\$384.42			
Dec-20	\$252.43	\$15.48	\$114.00 \$119.03	\$416.80	\$263.12	\$14.15	\$107.15	\$383.96			
				\$416.80				\$385.18			
Jan-21 Feb-21	\$284.33	\$16.16	\$116.43	\$431.57	\$263.84	\$14.62	\$106.71	\$385.18			
	\$297.96	\$15.78	\$117.82	\$431.57	\$263.02	\$14.85	\$106.32	\$384.20			
Mar-21	\$273.59	\$16.58	\$120.52	\$410.68	\$268.43	\$15.17	\$108.71	\$408.67			
Apr-21	\$293.53	\$15.54	\$120.23	\$429.30	\$279.31	\$15.27	\$114.09	\$408.67			
May-21	\$343.14	\$15.29	\$132.80	\$491.23	\$288.50	\$15.33	\$117.93	\$421.76			
Jun-21	\$279.66	\$14.37	\$117.72		\$287.47	\$15.34	\$118.52				
Jul-21 Aug-21	\$267.69 \$262.28	\$13.48 \$13.11	\$116.29 \$112.75	\$397.46 \$388.14	\$285.19 \$283.18	\$15.29 \$15.21	\$119.09 \$119.08	\$419.57 \$417.48			

Annual Trend	4.8%	11.5%	9.3%	6.3%
Two-Year Trend	-4.6%	10.6%	-3.2%	-3.7%

Utilization Trend Calculation - Facility - 48 Month

		Adjusted	Logistic F	Regression	Linear R	egression		Vinters' olicative	Holt-Winte	ers' Additive	Double Ex	n Smoothin
		Allowed Claims	Fitted	Rolling 12	Fitted	Rolling 12	Fitted	Rolling 12	Fitted	Rolling 12	Fitted	Rolling :
Month	Membership	PMPM	PMPM	PMPM	PMPM	PMPM	PMPM	PMPM	PMPM	PMPM	PMPM	PMPN
Sep-17	21,670	\$282.09	\$313.41		\$313.92		\$282.09		\$282.11		\$299.57	
Oct-17	21.666	\$303.29	\$312.40		\$313.02		\$298.72		\$282.59		\$295.28	
Nov-17	21,746	\$314.29	\$311.35		\$312.08		\$313.31		\$306.16		\$296.07	
Dec-17	21,727	\$341.83	\$310.35		\$311.18		\$348.44		\$342.09		\$299.05	
Jan-18	22,079	\$326.06	\$309.31		\$310.24		\$319.51		\$326.98		\$307.29	
Feb-18	22,144	\$323.80	\$308.28		\$309.31		\$325.62		\$333.51		\$311.03	
Mar-18	22,136	\$297.64	\$307.35		\$308.46		\$291.92		\$285.86		\$313.74	
Apr-18	22,176	\$307.77	\$306.32		\$307.53		\$274.00		\$288.69		\$310.62	
May-18	22,355	\$315.12	\$305.33		\$306.63		\$315.14		\$337.40		\$310.07	
Jun-18	22,397	\$287.94	\$303.33		\$305.69		\$329.28		\$314.99		\$311.11	
Jul-18	22,587	\$276.05	\$303.33		\$304.79		\$287.00		\$282.92		\$306.39	
Aug-18	22,671	\$284.31	\$302.32	\$307.79	\$303.85	\$308.84	\$263.07	\$303.89	\$261.73	\$303.68	\$299.94	\$305.
Sep-18	22,650	\$295.81	\$302.32	\$306.78	\$302.92	\$307.93	\$286.41	\$304.18	\$287.07	\$304.02	\$296.20	\$304.
Oct-18	22,781	\$285.74	\$300.33	\$305.77	\$302.92	\$307.01	\$312.64	\$305.34	\$296.33	\$305.10	\$295.44	\$304.
Nov-18	23,112	\$293.80	\$299.33	\$304.77	\$302.01	\$306.09	\$298.80	\$304.13	\$288.64	\$303.60	\$292.76	\$304.
				\$304.77		\$305.18	\$325.56	\$304.13	\$321.60	\$303.00	\$292.76	\$304.
Dec-18 Jan-19	23,083 24.461	\$368.27 \$341.91	\$298.36 \$297.37	\$302.75	\$300.17 \$299.24	\$304.23	\$340.09	\$304.40	\$353.40	\$304.63	\$307.11	\$303.
				\$302.75		\$304.23	\$340.09	\$304.40		\$304.63	\$307.11	\$303.
Feb-19	24,499	\$321.29	\$296.38	\$301.74	\$298.30	\$303.30	\$341.04	\$305.95	\$349.39 \$283.37	\$305.90	\$314.33	\$304.
Mar-19	24,539	\$319.38	\$295.48		\$297.46							
Apr-19	24,481	\$299.19	\$294.50	\$299.75 \$298.76	\$296.53	\$301.45	\$295.07 \$305.79	\$307.48	\$310.43	\$307.66	\$317.31	\$305.
May-19	24,525	\$290.08	\$293.54		\$295.62	\$300.53		\$306.72	\$328.85	\$307.14	\$314.09	\$305.
Jun-19	24,502	\$321.90	\$292.56	\$297.79	\$294.69	\$299.62	\$299.65	\$304.33	\$289.95	\$305.04	\$309.45	\$305.
Jul-19	24,662	\$322.54	\$291.62	\$296.82	\$293.78	\$298.70	\$316.54	\$306.76	\$316.86	\$307.81	\$312.09	\$305.
Aug-19	24,669	\$271.27	\$290.64	\$295.86	\$292.85	\$297.80	\$309.78	\$310.45	\$308.26	\$311.47	\$314.44	\$307.
Sep-19	24,629	\$280.34	\$289.67	\$294.91	\$291.91	\$296.90	\$279.33	\$309.69	\$274.09	\$310.20	\$305.84	\$307.
Oct-19	24,690	\$308.59	\$288.74	\$293.96	\$291.01	\$296.00	\$292.59	\$308.01	\$280.85	\$308.80	\$300.43	\$308.
Nov-19	24,961	\$310.05	\$287.77	\$293.01	\$290.07	\$295.10	\$319.96	\$309.75	\$311.48	\$310.62	\$301.69	\$308.
Dec-19	24,950	\$289.25	\$286.84	\$292.07	\$289.17	\$294.20	\$350.23	\$311.94	\$337.88	\$312.06	\$303.08	\$309.
Jan-20	25,746	\$269.74	\$285.89	\$291.10	\$288.23	\$293.27	\$274.25	\$306.35	\$274.41	\$305.39	\$299.98	\$309.
Feb-20	25,637	\$308.61	\$284.93	\$290.14	\$287.30	\$292.34	\$267.29	\$300.13	\$277.16	\$299.34	\$293.35	\$307.
Mar-20	25,636	\$209.11	\$284.04	\$289.18	\$286.43	\$291.41	\$279.23	\$298.96	\$270.63	\$298.19	\$295.78	\$305.
Apr-20	25,560	\$163.26	\$283.09	\$288.22	\$285.49	\$290.49	\$201.48	\$290.97	\$200.16	\$288.85	\$277.34	\$302.
May-20	25,418	\$233.76	\$282.18	\$287.28	\$284.59	\$289.58	\$170.21	\$279.57	\$192.83	\$277.48	\$252.32	\$296.
Jun-20	25,375	\$291.84	\$281.24	\$286.34	\$283.65	\$288.66	\$234.93	\$274.19	\$233.51	\$272.77	\$245.80	\$291.
Jul-20	25,241	\$294.78	\$280.33	\$285.41	\$282.75	\$287.75	\$280.40	\$271.25	\$286.76	\$270.35	\$252.42	\$286.
Aug-20	25,193	\$285.84	\$279.39	\$284.49	\$281.81	\$286.84	\$276.27	\$268.53	\$280.48	\$268.10	\$258.76	\$282.
Sep-20	25,244	\$298.96	\$278.46	\$283.56	\$280.88	\$285.94	\$293.26	\$269.71	\$288.63	\$269.32	\$262.40	\$278.
Oct-20	25,293	\$261.51	\$277.56	\$282.64	\$279.97	\$285.03	\$313.43	\$271.49	\$299.50	\$270.90	\$268.29	\$275.
Nov-20	25,371	\$252.43	\$276.63	\$281.72	\$279.04	\$284.12	\$276.75	\$267.96	\$264.44	\$267.03	\$265.62	\$272.
Dec-20	25,360	\$282.29	\$275.74	\$280.81	\$278.13	\$283.21	\$280.87	\$262.30	\$280.22	\$262.34	\$261.56	\$269.
Jan-21	26,304	\$284.33	\$274.82	\$279.86	\$277.20	\$282.27	\$266.89	\$261.69	\$267.40	\$261.76	\$264.35	\$266.
Feb-21	26.271	\$297.96	\$273.90	\$278.93	\$276.26	\$281.33	\$284.46	\$263.18	\$291.75	\$263.04	\$267.22	\$264.
Mar-21	26,232	\$273.59	\$273.07	\$278.00	\$275.42	\$280.40	\$257.02	\$261.31	\$260.01	\$262.15	\$272.51	\$262.
Apr-21	26.221	\$293.53	\$272.16	\$277.08	\$274.49	\$279.47	\$254.30	\$265.68	\$264.64	\$267.51	\$272.01	\$262.
May-21	26,287	\$343.14	\$271.28	\$276.17	\$273.58	\$278.55	\$312.44	\$277.54	\$323.16	\$278.41	\$275.74	\$263.
Jun-21	26,396	\$279.66	\$270.38	\$275.26	\$272.65	\$277.63	\$350.15	\$287.23	\$343.03	\$287.60	\$289.17	\$267
Jul-21	26,610	\$267.69	\$269.50	\$274.35	\$271.74	\$276.71	\$279.07	\$287.08	\$274.69	\$286.57	\$287.44	\$270.
Aug-21	26,603	\$262.28	\$268.60	\$273.45	\$270.81	\$275.79	\$253.24	\$285.07	\$253.38	\$284.23	\$283.50	\$272.
Sep-21	26,603	J202.20	\$267.71	\$272.56	\$269.87	\$274.88	\$268.48	\$283.00	\$265.06	\$282.25	\$279.05	\$273.
Oct-21	26,603		\$266.84	\$271.68	\$268.97	\$273.97	\$274.42	\$279.84	\$265.58	\$279.46	\$278.75	\$274.
				\$271.68		\$273.97	\$274.42	\$279.84	\$265.58	\$279.46	\$278.75	\$275.
Nov-21	26,603		\$265.95		\$268.03			\$280.68				
Dec-21	26,603		\$265.09	\$269.93	\$267.13	\$272.16	\$319.67	+=====	\$296.29	\$281.09	\$278.15	\$277.
Jan-22	26,603		\$264.21	\$269.04	\$266.19	\$271.25	\$304.78	\$287.09	\$281.42	\$282.25	\$277.84	\$278.
Feb-22	26,603		\$263.32	\$268.16	\$265.26	\$270.33	\$306.80	\$288.96	\$288.87	\$282.02	\$277.54	\$279.
Mar-22	26,603		\$262.53	\$267.29	\$264.42	\$269.42	\$266.74	\$289.73	\$250.92	\$281.23	\$277.24	\$279.
Apr-22	26,603		\$261.65	\$266.42	\$263.48	\$268.50	\$252.22	\$289.52	\$241.97	\$279.32	\$276.94	\$279.
May-22	26,603		\$260.81	\$265.55	\$262.58	\$267.59	\$271.43	\$286.12	\$271.59	\$275.06	\$276.64	\$280.
Jun-22	26,603		\$259.94	\$264.68	\$261.64	\$266.68	\$268.14	\$279.33	\$271.44	\$269.14	\$276.34	\$278.
Jul-22	26,603		\$259.10	\$263.81	\$260.74	\$265.76	\$266.09	\$278.25	\$266.41	\$268.45	\$276.04	\$278.
Aug-22	26,603		\$258.23	\$262.95	\$259.80	\$264.84	\$252.84	\$278.21	\$252.11	\$268.35	\$275.74	\$277.
Sep-22	26,603		\$250.23	\$262.09	\$258.87	\$263.93	\$258.79	\$277.40	\$254.90	\$267.50	\$275.44	\$277.
				\$261.23		\$263.93	\$264.49	\$277.40	\$255.43	\$266.65	\$275.44	\$276.
Oct-22	26,603		\$256.54		\$257.96							
Nov-22	26,603		\$255.68	\$260.37	\$257.03	\$262.09	\$276.52	\$275.71	\$258.32	\$265.81	\$274.84	\$276.
Dec-22	26,603		\$254.86	\$259.52	\$256.12	\$261.17	\$308.02	\$274.74	\$286.13	\$264.96	\$274.54	\$276.
Jan-23	26,603		\$254.01	\$258.67	\$255.19	\$260.26	\$293.65	\$273.81	\$271.27	\$264.11	\$274.24	\$275.
Feb-23	26,603		\$253.16	\$257.82	\$254.26	\$259.34	\$295.56	\$272.87	\$278.71	\$263.27	\$273.94	\$275.
Mar-23	26,603		\$252.39	\$256.98	\$253.41	\$258.42	\$256.94	\$272.06	\$240.76	\$262.42	\$273.64	\$275.
Apr-23	26,603		\$251.55	\$256.14	\$252.48	\$257.51	\$242.92	\$271.28	\$231.82	\$261.58	\$273.34	\$274.
May-23	26,603		\$250.74	\$255.30	\$251.57	\$256.59	\$261.39	\$270.44	\$261.44	\$260.73	\$273.03	\$274.
				\$254.46		\$255.67	\$258.19	\$269.62	\$261.44	\$259.88	\$273.03	\$274.
Jun-23	26,603		\$249.90	\$254.46	\$250.64	\$255.67	\$256.19	\$269.62	\$251.29	\$259.88	\$272.73	\$274.
Jul-23	26,603		\$249.09		\$249.73							
Aug-23	26,603		\$248.26	\$252.80	\$248.80	\$253.84	\$243.40	\$268.00	\$241.95	\$258.19	\$272.13	\$273.
Sep-23	26,603		\$247.43	\$251.97	\$247.86	\$252.92	\$249.09	\$267.20	\$244.74	\$257.34	\$271.83	\$273.
Oct-23	26,603		\$246.63	\$251.14	\$246.96	\$252.00	\$254.55	\$266.37	\$245.27	\$256.50	\$271.53	\$273.
Nov-23	26,603		\$245.81	\$250.32	\$246.02	\$251.09	\$266.10	\$265.50	\$248.17	\$255.65	\$271.23	\$272.
NOV-25				\$249.50	\$245.12	\$250.17	\$296.38	\$264.53	\$275.98	\$254.80	\$270.93	

Utilization Trend	-3.85%	-4.09%	-3.15%	-4.57%	-0.01%
RMSE (root mean square error)	31.25	31.21	29.27	26.47	32.96

Utilization Trend Calculation - Facility - 36 Month

		Adjusted	Logistic	tegression	Linear P	tegression		Winters' plicative	Holt-Winte	ers' Additive	Double Exp Smoothing		
		Allowed Claims	Fitted	Rolling 12	Fitted	Rolling 12	Fitted	Rolling 12	Fitted	Rolling 12	Fitted	Rolling 1	
Month	Membership	PMPM	PMPM	PMPM	PMPM	PMPM	PMPM	PMPM	PMPM	PMPM	PMPM	PMPM	
Sep-18	22,650	\$295.81	\$306.08		\$308.43		\$294.69		\$295.57		\$297.17		
Oct-18	22,781	\$285.74	\$304.88		\$307.29		\$296.12		\$289.36		\$295.35		
Nov-18	23,112	\$293.80	\$303.65		\$306.11		\$301.97		\$286.40		\$291.14		
Dec-18	23,083	\$368.27	\$302.47		\$304.97		\$346.33		\$320.62		\$290.25		
Jan-19	24,461	\$341.91	\$301.25		\$303.79		\$322.10		\$347.05		\$311.03		
Feb-19	24,499	\$321.29	\$300.03		\$302.61		\$319.68		\$353.30		\$319.89		
Mar-19	24,539	\$319.38	\$298.94		\$301.54		\$287.08		\$283.85		\$320.94		
Apr-19	24,481	\$299.19	\$297.73		\$300.36		\$254.60		\$299.10		\$321.16		
May-19	24,525	\$290.08	\$296.57		\$299.22		\$264.15		\$336.23		\$315.50		
Jun-19	24,502	\$321.90	\$295.37		\$298.04		\$316.93		\$305.35		\$308.39		
Jul-19	24,662	\$322.54	\$294.22		\$296.89		\$320.69		\$316.81		\$311.93		
Aug-19	24,669	\$271.27	\$293.03	\$299.40	\$295.71	\$301.97	\$275.66	\$299.81	\$299.89	\$311.42	\$314.91	\$308.4	
Sep-19	24,629	\$280.34	\$291.85	\$298.24	\$294.53	\$300.83	\$281.54	\$298.66	\$279.94	\$309.98	\$302.56	\$308.8	
Oct-19	24,690	\$308.59	\$290.71	\$297.08	\$293.39	\$299.70	\$280.84	\$297.35	\$273.87	\$308.54	\$295.44	\$308.7	
Nov-19	24,961	\$310.05	\$289.54	\$295.93	\$292.21	\$298.55	\$286.80	\$296.09	\$303.92	\$309.89	\$298.02	\$309.2	
Dec-19	24,950	\$289.25	\$288.41	\$294.78	\$291.07	\$297.42	\$334.38	\$295.40	\$337.08	\$311.35	\$300.55	\$309.9	
Jan-20	25,746	\$269.74	\$287.24	\$293.59	\$289.89	\$296.24	\$310.76	\$294.53	\$281.32	\$305.80	\$296.63	\$308.7	
Feb-20	25,637	\$308.61	\$286.08	\$292.42	\$288.70	\$295.07	\$305.16	\$293.38	\$281.97	\$299.84	\$288.01	\$306.0	
Mar-20	25,636	\$209.11	\$285.00	\$291.25	\$287.60	\$293.90	\$279.38	\$292.70	\$262.98	\$298.00	\$292.45	\$303.6	
Apr-20	25,560	\$163.26	\$283.86	\$290.09	\$286.42	\$292.74	\$250.41	\$292.20	\$201.24	\$289.67	\$267.51	\$299.1	
May-20	25,418	\$233.76	\$282.75	\$288.94	\$285.28	\$291.58	\$256.07	\$291.44	\$205.50	\$278.77	\$234.85	\$292.3	
Jun-20	25,375	\$291.84	\$281.61	\$287.80	\$284.10	\$290.43	\$302.56	\$290.30	\$238.58	\$273.23	\$229.64	\$285.8	
Jul-20	25,241	\$294.78	\$280.51	\$286.67	\$282.95	\$289.28	\$305.52	\$289.10	\$281.60	\$270.38	\$242.57	\$280.0	
Aug-20	25,193	\$285.84	\$279.37	\$285.55	\$281.77	\$288.13	\$261.52	\$287.90	\$271.07	\$268.03	\$253.90	\$275.0	
Sep-20	25,244	\$298.96	\$278.25	\$284.43	\$280.59	\$286.98	\$267.64	\$286.73	\$288.47	\$268.77	\$260.50	\$271.6	
Oct-20	25,293	\$261.51	\$277.16	\$283.32	\$279.45	\$285.84	\$272.00	\$285.98	\$291.11	\$270.21	\$269.62	\$269.5	
Nov-20		\$252.43	\$277.16	\$282.20		\$284.68	\$276.79	\$285.15	\$265.81	\$267.08	\$266.18	\$266.9	
Dec-20	25,371			\$282.20	\$278.27	\$283.53	\$310.01		\$282.14	\$262.61		\$263.6	
	25,360	\$282.29	\$274.96		\$277.13			\$283.19			\$260.95		
Jan-21	26,304	\$284.33	\$273.86	\$279.95	\$275.95	\$282.35	\$288.22	\$281.30	\$267.66	\$261.47	\$265.50	\$261.0	
Feb-21	26,271	\$297.96	\$272.75	\$278.82	\$274.77	\$281.16	\$290.61	\$280.10	\$292.64	\$262.43	\$269.77	\$259.5	
Mar-21	26,232	\$273.59	\$271.76	\$277.70	\$273.70	\$279.99	\$253.23	\$277.86	\$255.30	\$261.77	\$277.12	\$258.2	
Apr-21	26,221	\$293.53	\$270.66	\$276.59	\$272.52	\$278.82	\$222.79	\$275.45	\$255.70	\$266.28	\$275.94	\$259.0	
May-21	26,287	\$343.14	\$269.60	\$275.48	\$271.38	\$277.65	\$239.57	\$273.99	\$325.30	\$276.32	\$280.75	\$262.8	
Jun-21	26,396	\$279.66	\$268.52	\$274.39	\$270.20	\$276.49	\$285.87	\$272.66	\$349.54	\$285.67	\$298.77	\$268.6	
Jul-21	26,610	\$267.69	\$267.47	\$273.30	\$269.05	\$275.32	\$288.63	\$271.36	\$286.65	\$286.08	\$294.70	\$273.0	
Aug-21	26,603	\$262.28	\$266.39	\$272.22	\$267.87	\$274.17	\$252.82	\$270.57	\$248.46	\$284.09	\$287.97	\$275.8	
Sep-21	26,603		\$265.31	\$271.15	\$266.69	\$273.02	\$259.80	\$269.89	\$265.03	\$282.12	\$281.06	\$277.5	
Oct-21	26,603		\$264.28	\$270.08	\$265.55	\$271.87	\$256.57	\$268.60	\$258.62	\$279.41	\$280.99	\$278.4	
Nov-21	26,603		\$263.21	\$269.03	\$264.37	\$270.72	\$258.66	\$267.11	\$258.79	\$278.77	\$280.93	\$279.6	
Dec-21	26,603		\$262.18	\$267.98	\$263.23	\$269.58	\$289.59	\$265.56	\$286.65	\$279.16	\$280.86	\$281.2	
Jan-22	26,603		\$261.13	\$266.92	\$262.05	\$268.43	\$273.01	\$264.31	\$272.05	\$279.51	\$280.79	\$282.	
Feb-22	26,603		\$260.07	\$265.86	\$260.87	\$267.27	\$277.18	\$263.21	\$282.70	\$278.69	\$280.73	\$283.	
Mar-22	26,603		\$259.12	\$264.81	\$259.80	\$266.12	\$243.88	\$262.42	\$240.78	\$277.45	\$280.66	\$283.6	
Apr-22	26,603		\$258.08	\$263.77	\$258.62	\$264.96	\$223.67	\$262.45	\$225.44	\$274.90	\$280.59	\$284.0	
May-22	26,603		\$257.07	\$262.73	\$257.48	\$263.81	\$245.16	\$262.89	\$262.45	\$269.71	\$280.52	\$284.0	
Jun-22	26,603		\$256.03	\$261.70	\$256.30	\$262.66	\$269.83	\$261.57	\$271.27	\$263.24	\$280.46	\$282.	
Jul-22	26,603		\$255.03	\$260.66	\$255.15	\$261.50	\$269.83	\$260.00	\$268.49	\$261.73	\$280.39	\$281.	
Aug-22	26,603		\$254.00	\$259.63	\$253.97	\$260.34	\$241.14	\$259.03	\$246.63	\$261.57	\$280.32	\$280.0	
Sep-22	26,603		\$252.98	\$258.60	\$252.79	\$259.18	\$246.03	\$257.88	\$251.31	\$260.43	\$280.26	\$280.6	
Oct-22	26,603		\$251.99	\$257.58	\$251.65	\$258.02	\$242.92	\$256.74	\$244.91	\$259.29	\$280.19	\$280.	
Nov-22	26,603		\$250.98	\$256.56	\$250.47	\$256.86	\$244.84	\$255.59	\$245.07	\$258.15	\$280.12	\$280.4	
Dec-22	26,603		\$250.00	\$255.54	\$249.33	\$255.71	\$274.04	\$254.29	\$272.93	\$257.00	\$280.06	\$280.	
Jan-23	26,603		\$248.99	\$254.53	\$248.15	\$254.55	\$258.29	\$253.07	\$258.34	\$255.86	\$279.99	\$280.	
Feb-23	26,603		\$247.98	\$253.52	\$246.96	\$253.39	\$262.16	\$251.82	\$268.98	\$254.72	\$279.92	\$280.	
Mar-23	26,603		\$247.08	\$252.52	\$245.90	\$252.23	\$230.61	\$250.71	\$227.07	\$253.57	\$279.86	\$280.	
Apr-23				\$252.52		\$252.23	\$211.45	\$249.69	\$211.72	\$253.37	\$279.86	\$280.	
	26,603	ļ	\$246.08		\$244.72								
May-23	26,603		\$245.12	\$250.52	\$243.58	\$249.91	\$231.70	\$248.57	\$248.74	\$251.29	\$279.72	\$280.	
Jun-23	26,603		\$244.13	\$249.53	\$242.39	\$248.75	\$254.95	\$247.33	\$257.56	\$250.15	\$279.65	\$280.	
Jul-23	26,603	ļ	\$243.18	\$248.54	\$241.25	\$247.60	\$254.87	\$246.08	\$254.78	\$249.00	\$279.59	\$279.	
Aug-23	26,603		\$242.20	\$247.56	\$240.07	\$246.44	\$227.71	\$244.96	\$232.92	\$247.86	\$279.52	\$279.	
Sep-23	26,603		\$241.22	\$246.58	\$238.89	\$245.28	\$232.27	\$243.82	\$237.60	\$246.72	\$279.45	\$279.	
Oct-23	26,603	ļ	\$240.28	\$245.60	\$237.75	\$244.12	\$229.27	\$242.68	\$231.20	\$245.58	\$279.39	\$279.	
Nov-23	26,603		\$239.31	\$244.63	\$236.57	\$242.96	\$231.01	\$241.53	\$231.36	\$244.43	\$279.32	\$279.	
Dec-23	26,603	J	\$238.37	\$243.66	\$235.43	\$241.80	\$258.50	\$240.23	\$259.22	\$243.29	\$279.25	\$279.	

Utilization Trend	-4.64%	-5.24%	-4.97%	-6.43%	0.59%
PMSE (root mean square error)	34.27	24.26	34 53	29.70	26.25

Utilization Trend Calculation - Facility - 24 Month

							Holt-V	Vinters'				
		Adjusted	Logistic F	tegression	Linear R	egression	Multip	licative	Holt-Winte	rs' Additive	Double Exp Smoothing	
		Allowed Claims	Fitted	Rolling 12	Fitted	Rolling 1						
Month	Membership	PMPM	PMPM									
Sep-19	24,629	\$280.34	\$266.92		\$271.31		\$281.46		\$280.37		\$277.23	
Oct-19	24,690	\$308.59	\$267.53		\$271.78		\$294.24		\$275.72		\$277.55	
Nov-19	24,961	\$310.05	\$268.16		\$272.26		\$294.38		\$304.76		\$279.04	
Dec-19	24,950	\$289.25	\$268.77		\$272.73		\$284.70		\$314.59		\$280.54	
Jan-20	25,746	\$269.74	\$269.40		\$273.21		\$269.43		\$280.53		\$281.13	
Feb-20	25,637	\$308.61	\$270.04		\$273.70		\$303.70		\$295.98		\$280.89	
Mar-20	25,636	\$209.11	\$270.63		\$274.15		\$216.24		\$246.65		\$282.27	
Apr-20	25,560	\$163.26	\$271.27		\$274.63		\$178.16		\$196.15		\$279.47	
May-20	25,418	\$233.76	\$271.89		\$275.10		\$243.61		\$223.27		\$274.85	
Jun-20	25,375	\$291.84	\$272.53		\$275.58		\$287.94		\$230.98		\$273.30	
Jul-20	25,241	\$294.78	\$273.15		\$276.05		\$289.83		\$287.26		\$274.21	
Aug-20	25,193	\$285.84	\$273.79	\$270.35	\$276.54	\$273.93	\$281.55	\$268.53	\$287.60	\$268.44	\$275.21	\$277.9
Sep-20	25,244	\$298.96	\$274.44	\$270.97	\$277.02	\$274.40	\$285.83	\$268.92	\$314.11	\$271.27	\$275.80	\$277.8
Oct-20	25,293	\$261.51	\$275.06	\$271.59	\$277.49	\$274.87	\$307.45	\$270.07	\$294.36	\$272.83	\$276.92	\$277.8
Nov-20	25,371	\$252.43	\$275.71	\$272.22	\$277.97	\$275.34	\$308.19	\$271.25	\$257.68	\$268.96	\$276.45	\$277.6
Dec-20	25,360	\$282.29	\$276.34	\$272.84 \$273.49	\$278.44	\$275.82 \$276.30	\$291.98 \$274.00	\$271.88 \$272.27	\$256.91 \$273.50	\$264.22 \$263.65	\$275.62 \$276.05	\$277.: \$276.:
Jan-21	26,304	\$284.33	\$276.99		\$278.93		\$274.00				\$276.05	
Feb-21 Mar-21	26,271	\$297.96	\$277.65	\$274.14 \$274.78	\$279.41	\$276.79 \$277.27	\$311.30	\$272.98 \$272.83	\$310.55 \$236.00	\$264.96 \$264.02	\$276.55	\$276.4
Mar-21 Apr-21	26,232 26,221	\$273.59 \$293.53	\$278.24 \$278.89	\$275.42	\$279.85 \$280.33	\$277.75	\$172.76	\$272.83	\$260.60	\$264.02	\$277.60	\$275.
				\$276.06		\$277.73	\$242.47	\$272.16	\$353.59	\$280.35	\$277.60	\$276.
May-21 Jun-21	26,287 26.396	\$343.14 \$279.66	\$279.53 \$280.19	\$276.00	\$280.80 \$281.28	\$278.70	\$295.65	\$271.98	\$340.47	\$280.35	\$281.29	\$276.8
Jun-21 Jul-21	26,396	\$267.69	\$280.19	\$277.35	\$281.28	\$279.18	\$298.35	\$273.50	\$275.17	\$288.48	\$281.42	\$277.
Aug-21	26,603	\$267.09	\$281.49	\$277.99	\$282.24	\$279.65	\$289.66	\$274.23	\$260.47	\$286.16	\$281.05	\$277.
Sep-21	26,603	\$202.20	\$282.15	\$278.62	\$282.72	\$280.13	\$299.07	\$275.40	\$290.51	\$284.28	\$280.47	\$278.
Oct-21	26,603		\$282.79	\$279.26	\$283.19	\$280.60	\$288.42	\$273.93	\$285.87	\$283.61	\$280.65	\$278.
Nov-21	26,603		\$283.46	\$279.90	\$283.67	\$281.07	\$283.96	\$272.02	\$282.02	\$285.55	\$280.84	\$278.
Dec-21	26,603		\$284.11	\$280.54	\$284.14	\$281.53	\$293.36	\$272.21	\$286.51	\$287.92	\$281.03	\$279.
Jan-22	26,603		\$284.78	\$281.19	\$284.62	\$282.01	\$286.36	\$273.25	\$277.74	\$288.27	\$281.21	\$279.
Feb-22	26,603		\$285.45	\$281.84	\$285.11	\$282.48	\$311.58	\$273.31	\$303.95	\$287.74	\$281.40	\$280.
Mar-22	26,603		\$286.06	\$282.48	\$285.54	\$282.96	\$253.55	\$276.41	\$241.97	\$288.18	\$281.59	\$280.
Apr-22	26,603		\$286.73	\$283.13	\$286.03	\$283.43	\$244.63	\$282.29	\$228.98	\$285.50	\$281.77	\$280.
May-22	26,603		\$287.38	\$283.79	\$286.50	\$283.90	\$304.63	\$287.43	\$289.00	\$280.18	\$281.96	\$281.
Jun-22	26,603		\$288.06	\$284.44	\$286.98	\$284.37	\$293.79	\$287.28	\$286.26	\$275.71	\$282.15	\$281.
Jul-22	26,603		\$288.72	\$285.10	\$287.45	\$284.85	\$288.34	\$286.45	\$281.71	\$276.25	\$282.33	\$281.
Aug-22	26,603		\$289.40	\$285.76	\$287.93	\$285.32	\$281.29	\$285.75	\$274.49	\$277.42	\$282.52	\$281.
Sep-22	26,603		\$290.08	\$286.42	\$288,42	\$285.80	\$306.22	\$286.34	\$302.72	\$278.44	\$282.71	\$281.
Oct-22	26,603		\$290.74	\$287.08	\$288.89	\$286.27	\$295.31	\$286.92	\$298.09	\$279.45	\$282.89	\$281.
Nov-22	26,603		\$291.43	\$287.74	\$289.37	\$286.75	\$290.72	\$287.48	\$294.24	\$280.47	\$283.08	\$282.
Dec-22	26,603		\$292.09	\$288.41	\$289.84	\$287.22	\$300.34	\$288.06	\$298.73	\$281.49	\$283.27	\$282.
Jan-23	26,603		\$292.78	\$289.08	\$290.32	\$287.70	\$293.16	\$288.63	\$289.96	\$282.51	\$283.45	\$282.
Feb-23	26,603		\$293.47	\$289.74	\$290.81	\$288.17	\$318.96	\$289.25	\$316.17	\$283.53	\$283.64	\$282.
Mar-23	26,603		\$294.09	\$290.41	\$291.24	\$288.65	\$259.55	\$289.75	\$254.19	\$284.54	\$283.83	\$282.
Apr-23	26,603		\$294.79	\$291.09	\$291.73	\$289.12	\$250.41	\$290.23	\$241.20	\$285.56	\$284.01	\$282.9
May-23	26,603		\$295.46	\$291.76	\$292.20	\$289.60	\$311.81	\$290.82	\$301.22	\$286.58	\$284.20	\$283.
Jun-23	26,603		\$296.16	\$292.43	\$292.68	\$290.07	\$300.70	\$291.40	\$298.47	\$287.60	\$284.39	\$283.
Jul-23	26,603		\$296.83	\$293.11	\$293.15	\$290.55	\$295.11	\$291.96	\$293.92	\$288.62	\$284.57	\$283.
Aug-23	26,603		\$297.53	\$293.79	\$293.63	\$291.02	\$287.87	\$292.51	\$286.70	\$289.63	\$284.76	\$283.
Sep-23	26,603		\$298.23	\$294.47	\$294.12	\$291.50	\$313.38	\$293.11	\$314.94	\$290.65	\$284.95	\$283.
Oct-23	26,603		\$298.91	\$295.15	\$294.58	\$291.97	\$302.20	\$293.68	\$310.30	\$291.67	\$285.13	\$284.
Nov-23	26,603		\$299.62	\$295.83	\$295.07	\$292.45	\$297.49	\$294.25	\$306.45	\$292.69	\$285.32	\$284.
Dec-23	26,603		\$300.30	\$296.51	\$295.54	\$292.92	\$307.32	\$294.83	\$310.95	\$293.71	\$285.51	\$284.

Utilization Trend	2.80%	2.01%	3.15%	1.12%	1.00%
RMSE (root mean square error)	35.40	35.29	39.11	26.62	36.09

Utilization Trend Calculation - Professional - Mental Health - 48 Month

		Adjusted	Logistic	Regression	Linear P	egression		Vinters' olicative	Holt-Winte	ers' Additive	Double Ev	p Smoothin
		Allowed Claims	Fitted	Rolling 12	Fitted	Rolling 12	Fitted	Rolling 12	Fitted	Rolling 12	Fitted	Rolling
Month	Membership	PMPM	PMPM	PMPM	PMPM	PMPM	PMPM	PMPM	PMPM	PMPM	PMPM	PMPN
Sep-17	21,670	\$10.46	\$10.46		\$10.34		\$10.34		\$10.32		\$10.80	
Oct-17	21,666	\$10.51	\$10.56		\$10.45		\$10.79		\$11.00		\$10.68	
Nov-17	21,746	\$11.19	\$10.65		\$10.57		\$11.00		\$10.81		\$10.64	
Dec-17	21.727	\$9.32	\$10.75		\$10.68		\$9.79		\$9.81		\$11.00	
Jan-18	22,079	\$10.91	\$10.84		\$10.80		\$11.10		\$10.90		\$10.10	
Feb-18	22,144	\$10.38	\$10.94		\$10.92		\$10.63		\$10.32		\$10.52	
Mar-18	22,136	\$10.88	\$11.03		\$11.02		\$11.10		\$10.85		\$10.45	
Apr-18	22,176	\$11.77	\$11.03		\$11.14		\$11.72		\$11.18		\$10.70	
May-18	22,355	\$12.15	\$11.23		\$11.25		\$12.21		\$11.91		\$11.36	
Jun-18	22,397	\$11.54	\$11.33		\$11.37		\$11.48		\$11.34		\$11.94	
Jul-18	22,587	\$10.43	\$11.43		\$11.48		\$10.82		\$10.95		\$11.90	
Aug-18	22,671	\$10.00	\$11.54	\$11.00	\$11.59	\$10.97	\$9.88	\$10.91	\$10.03	\$10.79	\$11.20	\$10.9
Sep-18	22,650	\$11.54	\$11.64	\$11.00	\$11.71	\$11.09	\$11.10	\$10.97	\$11.82	\$10.73	\$10.54	\$10.5
Oct-18	22,630	\$11.99	\$11.74	\$11.03	\$11.71	\$11.00	\$11.58	\$11.03	\$12.23	\$11.02	\$11.05	\$10.9
				\$11.19		\$11.20	\$12.25	\$11.05	\$12.20	\$11.02	\$11.61	\$11.0
Nov-18	23,112	\$12.27	\$11.85	\$11.29	\$11.94	\$11.52	\$10.61	\$11.21	\$11.00	\$11.13	\$12.09	\$11.0
Dec-18	23,083	\$11.42	\$11.95		\$12.05							
Jan-19	24,461	\$12.40	\$12.06	\$11.50	\$12.17	\$11.55	\$12.79	\$11.36	\$12.68	\$11.39 \$11.52	\$11.86 \$12.27	\$11.2
Feb-19	24,499	\$12.11	\$12.17	\$11.60	\$12.28	\$11.66	\$12.13	\$11.48	\$11.91			\$11.4
Mar-19	24,539	\$12.92	\$12.27	\$11.71	\$12.39	\$11.78	\$12.78	\$11.63	\$12.53	\$11.66	\$12.32	\$11.5
Apr-19	24,481	\$12.99	\$12.38	\$11.81	\$12.51	\$11.89	\$13.75	\$11.81	\$13.10	\$11.83	\$12.80	\$11.7
May-19	24,525	\$13.94	\$12.49	\$11.92	\$12.62	\$12.01	\$13.92	\$11.96	\$13.38	\$11.96	\$13.09	\$11.9
Jun-19	24,502	\$12.96	\$12.61	\$12.02	\$12.73	\$12.12	\$13.15	\$12.10	\$13.02	\$12.10	\$13.78	\$12.0
Jul-19	24,662	\$13.05	\$12.72	\$12.13	\$12.85	\$12.23	\$12.12	\$12.20	\$12.46	\$12.22	\$13.57	\$12.
Aug-19	24,669	\$11.55	\$12.83	\$12.24	\$12.96	\$12.35	\$11.76	\$12.35	\$12.26	\$12.39	\$13.47	\$12.
Sep-19	24,629	\$12.83	\$12.95	\$12.35	\$13.08	\$12.46	\$13.13	\$12.51	\$13.60	\$12.54	\$12.50	\$12.
Oct-19	24,690	\$14.58	\$13.06	\$12.45	\$13.19	\$12.57	\$13.31	\$12.65	\$13.69	\$12.66	\$12.69	\$12.0
Nov-19	24,961	\$13.35	\$13.18	\$12.56	\$13.31	\$12.68	\$14.28	\$12.82	\$14.40	\$12.85	\$13.81	\$12.8
Dec-19	24,950	\$11.80	\$13.30	\$12.67	\$13.42	\$12.79	\$12.26	\$12.95	\$12.47	\$12.96	\$13.72	\$12.9
Jan-20	25,746	\$14.19	\$13.42	\$12.79	\$13.54	\$12.91	\$13.65	\$13.02	\$13.44	\$13.02	\$12.74	\$13.0
Feb-20	25,637	\$13.03	\$13.54	\$12.90	\$13.65	\$13.03	\$13.45	\$13.13	\$13.34	\$13.14	\$13.57	\$13.1
Mar-20	25,636	\$12.90	\$13.66	\$13.02	\$13.76	\$13.14	\$14.03	\$13.24	\$13.63	\$13.24	\$13.36	\$13.
Apr-20	25,560	\$14.25	\$13.78	\$13.14	\$13.88	\$13.26	\$14.22	\$13.28	\$13.47	\$13.27	\$13.14	\$13.2
May-20	25,418	\$14.56	\$13.90	\$13.25	\$13.99	\$13.37	\$14.99	\$13.37	\$14.32	\$13.35	\$13.80	\$13.3
Jun-20	25,375	\$14.20	\$14.03	\$13.37	\$14.11	\$13.48	\$13.91	\$13.44	\$13.76	\$13.41	\$14.36	\$13.4
Jul-20	25,241	\$14.02	\$14.15	\$13.49	\$14.22	\$13.60	\$13.35	\$13.53	\$13.52	\$13.49	\$14.44	\$13.4
Aug-20	25,193	\$14.00	\$14.28	\$13.61	\$14.33	\$13.71	\$12.46	\$13.59	\$13.26	\$13.58	\$14.36	\$13.5
Sep-20	25,244	\$15.27	\$14.41	\$13.73	\$14.45	\$13.82	\$14.72	\$13.72	\$15.55	\$13.74	\$14.27	\$13.0
Oct-20	25,293	\$15.39	\$14.54	\$13.85	\$14.56	\$13.93	\$15.80	\$13.93	\$15.96	\$13.93	\$14.95	\$13.8
Nov-20	25,233	\$16.18	\$14.67	\$13.97	\$14.68	\$14.05	\$15.38	\$14.02	\$15.72	\$14.04	\$15.39	\$14.0
Dec-20	25,360	\$15.48	\$14.80	\$14.10	\$14.79	\$14.16	\$13.98	\$14.16	\$14.77	\$14.22	\$16.07	\$14.
Jan-21	26,304	\$16.16	\$14.93	\$14.22	\$14.73	\$14.28	\$16.90	\$14.44	\$16.64	\$14.50	\$16.01	\$14.4
Feb-21	26,271	\$15.78	\$15.07	\$14.35	\$15.02	\$14.20	\$15.73	\$14.63	\$15.74	\$14.70	\$16.33	\$14.7
Mar-21	26,271	\$15.78	\$15.07	\$14.48	\$15.02	\$14.59	\$16.38	\$14.83	\$16.26	\$14.70	\$16.35	\$14.9
Apr-21	26,232	\$15.58	\$15.19	\$14.62	\$15.13	\$14.63	\$17.70	\$15.13	\$16.28	\$15.20	\$16.26	\$15.2
				\$14.02		\$14.03	\$17.50	\$15.34	\$16.78	\$15.20	\$16.03	\$15.4
May-21	26,287	\$15.29	\$15.47	\$14.75	\$15.36	\$14.74	\$17.50	\$15.50	\$14.93	\$15.37	\$15.23	\$15.4
Jun-21	26,396	\$14.37	\$15.61		\$15.47			+-0.00	+			
Jul-21	26,610	\$13.48	\$15.74	\$15.01	\$15.59	\$14.97	\$14.55	\$15.59	\$14.04	\$15.50	\$15.03	\$15.6
Aug-21	26,603	\$13.11	\$15.89	\$15.15	\$15.70	\$15.08	\$13.13	\$15.63	\$13.09	\$15.48	\$14.06	\$15.
Sep-21	26,603		\$16.03	\$15.28	\$15.82	\$15.20	\$14.39	\$15.60	\$14.91	\$15.42	\$13.31	\$15.
Oct-21	26,603		\$16.17	\$15.41	\$15.93	\$15.31	\$14.93	\$15.53	\$15.50	\$15.39	\$13.03	\$15.
Nov-21	26,603		\$16.32	\$15.55	\$16.05	\$15.42	\$15.02	\$15.50	\$15.63	\$15.38	\$12.75	\$15.:
Dec-21	26,603		\$16.46	\$15.69	\$16.16	\$15.53	\$13.56	\$15.46	\$14.38	\$15.35	\$12.47	\$14.8
Jan-22	26,603		\$16.61	\$15.83	\$16.28	\$15.65	\$15.02	\$15.30	\$15.79	\$15.28	\$12.19	\$14.5
Feb-22	26,603		\$16.76	\$15.97	\$16.39	\$15.76	\$14.45	\$15.19	\$15.19	\$15.23	\$11.91	\$14.
Mar-22	26,603		\$16.90	\$16.11	\$16.50	\$15.88	\$15.06	\$15.08	\$15.68	\$15.18	\$11.63	\$13.
Apr-22	26,603		\$17.06	\$16.25	\$16.61	\$15.99	\$15.52	\$14.91	\$16.00	\$15.12	\$11.35	\$13.
May-22	26,603		\$17.00	\$16.40	\$16.01	\$16.10	\$16.16	\$14.80	\$16.34	\$15.12	\$11.07	\$12.8
				\$16.40		\$16.10	\$15.57	\$14.78	\$15.62	\$15.12	\$10.79	\$12.4
Jun-22	26,603		\$17.36	\$16.54	\$16.84	\$16.22	\$15.57	\$14.78	\$15.62	\$15.18 \$15.27	\$10.79	\$12.4
Jul-22	26,603		\$17.51	+-0.00	\$16.96	7-0.00	+	4-110-	+		+	·
Aug-22	26,603		\$17.67	\$16.84	\$17.07	\$16.44	\$14.27	\$14.91	\$14.51	\$15.39	\$10.23	\$11.
Sep-22	26,603		\$17.83	\$16.99	\$17.19	\$16.56	\$15.64	\$15.02	\$16.31	\$15.50	\$9.95	\$11.4
Oct-22	26,603		\$17.99	\$17.14	\$17.30	\$16.67	\$16.22	\$15.12	\$16.90	\$15.62	\$9.67	\$11.
Nov-22	26,603		\$18.15	\$17.29	\$17.42	\$16.79	\$16.31	\$15.23	\$17.03	\$15.74	\$9.39	\$10.9
Dec-22	26,603		\$18.31	\$17.45	\$17.53	\$16.90	\$14.72	\$15.33	\$15.78	\$15.85	\$9.11	\$10.6
Jan-23	26,603		\$18.48	\$17.60	\$17.64	\$17.01	\$16.29	\$15.43	\$17.19	\$15.97	\$8.83	\$10.
Feb-23	26,603		\$18.65	\$17.76	\$17.76	\$17.13	\$15.66	\$15.53	\$16.60	\$16.09	\$8.55	\$10.0
Mar-23	26,603		\$18.80	\$17.76	\$17.76	\$17.13	\$16.31	\$15.64	\$17.08	\$16.09	\$8.27	\$9.8
Apr-23	26,603		\$18.97	\$18.08	\$17.98	\$17.36	\$16.81	\$15.75	\$17.40	\$16.32	\$7.99	\$9.5
May-23	26,603		\$19.14	\$18.24	\$18.09	\$17.47	\$17.49	\$15.86	\$17.74	\$16.44	\$7.71	\$9.2
Jun-23	26,603		\$19.31	\$18.40	\$18.21	\$17.58	\$16.84	\$15.96	\$17.02	\$16.56	\$7.43	\$8.9
Jul-23	26,603		\$19.48	\$18.57	\$18.32	\$17.70	\$16.21	\$16.07	\$16.50	\$16.67	\$7.15	\$8.6
Aug-23	26,603		\$19.66	\$18.73	\$18.44	\$17.81	\$15.42	\$16.16	\$15.91	\$16.79	\$6.87	\$8.4
Sep-23	26,603		\$19.84	\$18.90	\$18.56	\$17.93	\$16.90	\$16.27	\$17.72	\$16.91	\$6.59	\$8.1
Oct-23	26,603		\$20.01	\$19.07	\$18.67	\$18.04	\$17.51	\$16.37	\$18.31	\$17.02	\$6.31	\$7.8
Nov-23	26,603		\$20.01	\$19.07	\$18.67	\$18.04	\$17.60	\$16.48	\$18.43	\$17.02	\$6.03	\$7.5
			520.20	213.24	\$18.78	210.13	\$17.0U	210.40	210.45	⊋1/.14	30.03	۵/.5

Utilization Trend	11.22%	8.56%	2.55%	4.77%	-27.80%
RMSE (root mean square error)	0.94	0.91	0.76	0.53	0.92

Utilization Trend Calculation - Professional - Mental Health - 36 Month

								Winters'					
		Adjusted		Regression		tegression		plicative		ers' Additive		p Smoothin	
		Allowed Claims	Fitted	Rolling 12	Fitted	Rolling 12	Fitted	Rolling 12	Fitted	Rolling 12	Fitted	Rolling 1	
Month	Membership	PMPM	PMPM	PMPM	PMPM	PMPM	PMPM	PMPM	PMPM	PMPM	PMPM	PMPM	
Sep-18	22,650	\$11.54	\$11.99		\$11.95		\$11.47		\$11.47		\$12.25		
Oct-18	22,781	\$11.99	\$12.08		\$12.05		\$12.26		\$12.29		\$11.93		
Nov-18	23,112	\$12.27	\$12.18		\$12.16		\$12.09		\$12.03		\$12.04		
Dec-18	23,083	\$11.42	\$12.27		\$12.26		\$11.30		\$11.16		\$12.27		
Jan-19	24,461	\$12.40	\$12.36		\$12.37		\$12.84		\$12.69		\$11.81		
Feb-19	24,499	\$12.11	\$12.46		\$12.47		\$12.27		\$11.88		\$12.21		
Mar-19	24,539	\$12.92	\$12.54		\$12.57		\$12.89		\$12.53		\$12.22		
Apr-19	24,481	\$12.99	\$12.64		\$12.67		\$13.43		\$12.92		\$12.75		
May-19	24,525	\$13.94	\$12.74		\$12.77		\$13.93		\$13.31		\$13.06		
Jun-19	24,502	\$12.96	\$12.84		\$12.88		\$13.05		\$12.98		\$13.81		
Jul-19	24,662	\$13.05	\$12.93		\$12.98		\$12.80		\$12.64		\$13.51		
Aug-19	24,669	\$11.55	\$13.03	\$12.51	\$13.09	\$12.53	\$11.64	\$12.51	\$12.29	\$12.36	\$13.38	\$12.6	
Sep-19	24,629	\$12.83	\$13.13	\$12.61	\$13.19	\$12.63	\$12.40	\$12.59	\$13.50	\$12.53	\$12.28	\$12.6	
Oct-19	24,690	\$14.58	\$13.23	\$12.70	\$13.30	\$12.73	\$13.26	\$12.67	\$13.82	\$12.66	\$12.56	\$12.6	
Nov-19	24,961	\$13.35	\$13.33	\$12.80	\$13.40	\$12.83	\$13.92	\$12.82	\$14.28	\$12.84	\$13.89	\$12.8	
Dec-19	24,950	\$11.80	\$13.43	\$12.89	\$13.50	\$12.94	\$12.68	\$12.93	\$12.61	\$12.96	\$13.73	\$12.9	
Jan-20	25,746	\$14.19	\$13.54	\$12.99	\$13.61	\$13.04	\$13.68	\$13.00	\$13.41	\$13.02	\$12.59	\$13.0	
Feb-20	25,637	\$13.03	\$13.64	\$13.09	\$13.71	\$13.15	\$13.57	\$13.11	\$13.33	\$13.14	\$13.59	\$13.1	
Mar-20	25,636	\$12.90	\$13.74	\$13.19	\$13.81	\$13.25	\$14.17	\$13.22	\$13.61	\$13.23	\$13.32	\$13.2	
Apr-20	25,560	\$14.25	\$13.85	\$13.29	\$13.92	\$13.35	\$14.01	\$13.27	\$13.25	\$13.26	\$13.08	\$13.2	
May-20	25,418	\$14.56	\$13.95	\$13.39	\$14.02	\$13.46	\$15.01	\$13.36	\$14.27	\$13.34	\$13.86	\$13.3	
Jun-20	25,375	\$14.20	\$14.06	\$13.49	\$14.13	\$13.56	\$13.84	\$13.43	\$13.71	\$13.40	\$14.46	\$13.3	
Jul-20	25,241	\$14.02	\$14.16	\$13.59	\$14.23	\$13.66	\$13.89	\$13.52	\$13.72	\$13.49	\$14.49	\$13.4	
Aug-20	25,193	\$14.00	\$14.27	\$13.70	\$14.33	\$13.77	\$12.44	\$13.58	\$13.29	\$13.57	\$14.36	\$13.5	
Sep-20	25,244	\$15.27	\$14.38	\$13.80	\$14.44	\$13.87	\$14.19	\$13.72	\$15.49	\$13.73	\$14.24	\$13.6	
Oct-20	25,293	\$15.39	\$14.49	\$13.90	\$14.54	\$13.97	\$15.76	\$13.93	\$16.11	\$13.92	\$15.01	\$13.8	
Nov-20	25,371	\$16.18	\$14.60	\$14.01	\$14.65	\$14.07	\$14.95	\$14.02	\$15.57	\$14.03	\$15.46	\$14.0	
Dec-20	25,360	\$15.48	\$14.71	\$14.11	\$14.75	\$14.18	\$14.14	\$14.14	\$14.95	\$14.22	\$16.18	\$14.2	
Jan-21	26,304	\$16.16	\$14.83	\$14.22	\$14.86	\$14.28	\$16.98	\$14.42	\$16.66	\$14.50	\$16.03	\$14.5	
Feb-21	26,271	\$15.78	\$14.94	\$14.33	\$14.96	\$14.39	\$15.78	\$14.61	\$15.71	\$14.70	\$16.36	\$14.7	
Mar-21	26,232	\$16.58	\$15.04	\$14.44	\$15.06	\$14.49	\$16.39	\$14.80	\$16.25	\$14.93	\$16.23	\$14.9	
Apr-21	26,221	\$15.54	\$15.16	\$14.56	\$15.16	\$14.60	\$17.62	\$15.10	\$16.60	\$15.21	\$16.66	\$15.2	
May-21	26.287	\$15.29	\$15.27	\$14.67	\$15.26	\$14.70	\$17.51	\$15.32	\$16.21	\$15.37	\$16.14	\$15.4	
Jun-21	26,396	\$14.37	\$15.39	\$14.78	\$15.20	\$14.81	\$15.82	\$15.48	\$14.83	\$15.46	\$15.68	\$15.5	
Jul-21	26,610	\$13.48	\$15.51	\$14.89	\$15.47	\$14.91	\$15.02	\$15.57	\$14.19	\$15.49	\$14.82	\$15.6	
Aug-21	26,603	\$13.11	\$15.63	\$15.00	\$15.58	\$15.01	\$13.36	\$15.63	\$13.07	\$15.47	\$13.79	\$15.5	
Sep-21	26,603	313.11	\$15.75	\$15.12	\$15.68	\$15.12	\$14.15	\$15.62	\$14.82	\$15.41	\$13.05	\$15.4	
Oct-21	26,603		\$15.75	\$15.23	\$15.00	\$15.22	\$14.69	\$15.53	\$15.59	\$15.41	\$12.69	\$15.4	
Nov-21	26,603		\$15.99	\$15.34	\$15.79	\$15.32	\$14.62	\$15.50	\$15.53	\$15.36	\$12.34	\$14.9	
Dec-21	26,603		\$16.11	\$15.46	\$15.89	\$15.42	\$13.44	\$15.44	\$14.50	\$15.33	\$11.98	\$14.6	
Jan-22	26,603		\$16.23	\$15.58	\$16.10	\$15.53	\$14.74	\$15.25	\$15.84	\$15.26	\$11.62	\$14.2	
				\$15.69		\$15.63	\$14.74	\$15.23	\$15.23	\$15.20	\$11.02	\$14.2	
Feb-22 Mar-22	26,603 26,603		\$16.36 \$16.47	\$15.89	\$16.20 \$16.30	\$15.63	\$14.23	\$15.12	\$15.23	\$15.22	\$10.90	\$13.8	
			\$16.47 \$16.60	\$15.81 \$15.93	\$16.30 \$16.41	\$15.74	\$14.85	\$15.00	\$15.72	\$15.18 \$15.11	\$10.90	\$13.4 \$12.9	
Apr-22	26,603 26,603			\$15.93	\$16.41	\$15.84	\$15.07	\$14.79	\$15.84	\$15.11	\$10.54	\$12.9	
May-22			\$16.72	\$16.05		\$15.94	\$15.67		\$15.42	\$15.11	\$9.82	\$12.4	
Jun-22	26,603		\$16.85	\$16.17	\$16.61	\$16.04 \$16.15	\$15.16	\$14.58 \$14.57	\$15.42 \$15.09	\$15.16 \$15.24	\$9.82	\$11.9	
Jul-22	26,603		\$16.98		\$16.72		\$14.87			\$15.24 \$15.35		\$11.4	
Aug-22	26,603		\$17.11	\$16.42 \$16.55	\$16.82	\$16.25		\$14.65	\$14.46		\$9.11		
Sep-22	26,603		\$17.24		\$16.93	\$16.36	\$15.34	\$14.75	\$16.18	\$15.47	\$8.75	\$10.7	
Oct-22	26,603		\$17.37	\$16.67	\$17.03	\$16.46	\$15.92	\$14.85	\$16.94	\$15.58	\$8.39	\$10.3	
Nov-22	26,603		\$17.51	\$16.80	\$17.13	\$16.56	\$15.84	\$14.95	\$16.89	\$15.69	\$8.03	\$10.0	
Dec-22	26,603		\$17.64	\$16.93	\$17.24	\$16.67	\$14.55	\$15.04	\$15.86	\$15.81	\$7.67	\$9.6	
Jan-23	26,603		\$17.78	\$17.05	\$17.34	\$16.77	\$15.95	\$15.15	\$17.20	\$15.92	\$7.31	\$9.28	
Feb-23	26,603		\$17.91	\$17.18	\$17.45	\$16.87	\$15.40	\$15.24	\$16.59	\$16.03	\$6.95	\$8.93	
Mar-23	26,603		\$18.04	\$17.31	\$17.54	\$16.98	\$16.05	\$15.34	\$17.08	\$16.14	\$6.59	\$8.57	
Apr-23	26,603		\$18.18	\$17.44	\$17.65	\$17.08	\$16.28	\$15.44	\$17.20	\$16.26	\$6.23	\$8.21	
May-23	26,603		\$18.31	\$17.58	\$17.75	\$17.18	\$16.93	\$15.55	\$17.54	\$16.37	\$5.87	\$7.85	
Jun-23	26,603		\$18.45	\$17.71	\$17.75	\$17.29	\$16.36	\$15.65	\$16.78	\$16.48	\$5.52	\$7.49	
				\$17.71		\$17.29	\$16.05	\$15.05	\$16.76	\$16.60	\$5.16	\$7.43	
Jul-23	26,603		\$18.59		\$17.96								
Aug-23	26,603		\$18.74	\$17.98	\$18.06	\$17.50	\$15.41	\$15.84	\$15.82	\$16.71	\$4.80	\$6.77	
Sep-23	26,603		\$18.88	\$18.12	\$18.17	\$17.60	\$16.54	\$15.94	\$17.53	\$16.82	\$4.44	\$6.41	
Oct-23	26,603		\$19.02	\$18.25	\$18.27	\$17.70	\$17.16	\$16.04	\$18.30	\$16.94	\$4.08	\$6.05	
Nov-23	26,603		\$19.17	\$18.39	\$18.38	\$17.81	\$17.06	\$16.14	\$18.25	\$17.05	\$3.72	\$5.70	
Dec-23	26,603		\$19.31	\$18.53	\$18.48	\$17.91	\$15.66	\$16.24	\$17.21	\$17.16	\$3.36	\$5.34	

Utilization Trend	9.47%	7.85%	1.64%	4.56%	-36.77%
RMSE (root mean square error)	0.96	0.94	0.88	0.57	0.91

Utilization Trend Calculation - Professional - Mental Health - 24 Month

							Holt-V	Vinters'				
		Adjusted		Regression		egression		olicative		ers' Additive		Smoothin
		Allowed Claims	Fitted	Rolling 12	Fitted	Rolling 1						
Month	Membership	PMPM	PMPM	PMPM	PMPM	PMPM	PMPM	PMPM	PMPM	PMPM	PMPM	PMPM
Sep-19	24,629	\$12.83	\$13.41		\$13.43		\$11.91		\$12.98		\$13.48	
Oct-19	24,690	\$14.58	\$13.49		\$13.52		\$13.62		\$13.81		\$13.07	
Nov-19	24,961	\$13.35	\$13.57		\$13.61		\$13.16		\$14.12		\$14.14	
Dec-19	24,950	\$11.80	\$13.66		\$13.69		\$11.96		\$12.46		\$13.74	
Jan-20	25,746	\$14.19	\$13.74		\$13.78		\$14.12		\$13.53		\$12.40	
Feb-20	25,637	\$13.03	\$13.83		\$13.87		\$13.14		\$13.22		\$13.52	
Mar-20	25,636	\$12.90	\$13.91		\$13.95		\$13.16		\$13.42		\$13.22	
Apr-20	25,560	\$14.25	\$13.99		\$14.04		\$14.18		\$13.21 \$13.97		\$12.97	
May-20	25,418	\$14.56	\$14.08		\$14.13		\$14.36 \$13.92				\$13.85 \$14.48	
Jun-20	25,375	\$14.20	\$14.16		\$14.21		\$13.92		\$13.74 \$13.53		\$14.48 \$14.49	
Jul-20	25,241	\$14.02	\$14.25	4.0.00	\$14.30		\$13.69					
Aug-20	25,193	\$14.00	\$14.34	\$13.87 \$13.95	\$14.39	\$13.91 \$14.00	\$15.72	\$13.42 \$13.75	\$13.68 \$15.97	\$13.47 \$13.72	\$14.32 \$14.19	\$13.6 \$13.7
Sep-20	25,244	\$15.27	\$14.43	\$13.95	\$14.48	\$14.00	\$15.92	\$13.75	\$15.97	\$13.72	\$14.19	\$13.8
Oct-20	25,293	\$15.39	\$14.51	\$14.04	\$14.56		\$17.88				\$15.04	\$13.8
Nov-20 Dec-20	25,371	\$16.18	\$14.60	\$14.12	\$14.65	\$14.17 \$14.26	\$14.36	\$14.36 \$14.55	\$15.48 \$14.84	\$14.05 \$14.24	\$15.51	\$13.5
	25,360	\$15.48	\$14.69	\$14.21	\$14.74		\$14.36	\$14.55	\$14.84	\$14.24		\$14.1
Jan-21	26,304	\$16.16	\$14.78	\$14.30	\$14.82	\$14.35 \$14.43	\$17.19	\$14.82	\$15.59	\$14.53	\$16.03 \$16.37	\$14.7
Feb-21	26,271	\$15.78	\$14.87	\$14.39	\$14.91	\$14.43	\$15.63	\$15.03	\$15.59	\$14.73	\$16.37	\$14.5
Mar-21	26,232 26,221	\$16.58	\$14.96	\$14.47	\$14.99 \$15.08	\$14.52	\$15.47	\$15.22	\$16.05	\$14.95	\$16.20	\$15.3
Apr-21		\$15.54	\$15.05			\$14.61						
May-21	26,287	\$15.29	\$15.14	\$14.65 \$14.74	\$15.17	\$14.70	\$16.98 \$16.05	\$15.68 \$15.86	\$15.88 \$14.82	\$15.39 \$15.48	\$16.07 \$15.59	\$15.4 \$15.5
Jun-21	26,396	\$14.37	\$15.23	\$14.74	\$15.25	\$14.78	\$15.26	\$15.86	\$14.82	\$15.48	\$15.59	\$15.5
Jul-21	26,610	\$13.48	\$15.32	\$14.83	\$15.34	\$14.87	\$15.26	\$15.98		\$15.51	\$14.68	\$15.5
Aug-21	26,603	\$13.11	\$15.42	\$14.92	\$15.43	\$14.96	\$15.66	\$16.05	\$13.43 \$15.28	\$15.48	\$13.62	\$15.4
Sep-21	26,603		\$15.52	\$15.01	\$15.52							
Oct-21	26,603		\$15.61		\$15.60	\$15.13	\$16.29	\$15.90	\$16.21	\$15.41	\$12.50	\$15.1
Nov-21	26,603		\$15.71	\$15.19	\$15.69	\$15.21	\$15.74	\$15.86	\$15.98	\$15.45	\$12.09	\$14.9
Dec-21	26,603		\$15.80	\$15.29	\$15.78	\$15.30	\$14.13	\$15.83	\$14.86	\$15.45	\$11.68	\$14.5
Jan-22	26,603		\$15.90	\$15.38	\$15.86	\$15.39	\$15.25	\$15.67	\$16.39	\$15.42	\$11.27	\$14.1
Feb-22	26,603		\$16.00	\$15.47	\$15.95	\$15.47	\$14.10	\$15.54	\$15.62	\$15.42	\$10.86	\$13.6
Mar-22	26,603		\$16.09	\$15.57	\$16.03	\$15.56	\$13.99	\$15.42	\$15.94	\$15.41	\$10.45	\$13.1
Apr-22	26,603		\$16.19	\$15.66	\$16.12	\$15.65	\$13.71	\$15.14	\$16.10	\$15.37	\$10.04	\$12.6
May-22	26,603		\$16.28	\$15.75	\$16.21	\$15.73	\$13.41	\$14.85	\$16.13	\$15.39	\$9.63	\$12.1
Jun-22	26,603		\$16.38	\$15.85	\$16.29	\$15.82	\$12.55	\$14.56	\$15.48	\$15.45	\$9.22	\$11.5
Jul-22	26,603		\$16.48	\$15.95	\$16.38	\$15.90	\$11.85	\$14.27	\$14.94	\$15.53	\$8.82	\$11.0
Aug-22	26,603		\$16.58	\$16.04	\$16.47	\$15.99	\$11.50	\$14.01	\$14.74	\$15.64	\$8.41	\$10.6
Sep-22	26,603		\$16.69	\$16.14	\$16.56	\$16.08	\$13.11 \$13.60	\$13.80	\$16.81 \$17.74	\$15.77 \$15.89	\$8.00 \$7.59	\$10.2 \$9.8
Oct-22	26,603		\$16.79	\$16.24 \$16.34	\$16.64	\$16.16 \$16.25	\$13.60	\$13.58 \$13.36	\$17.74	\$15.89 \$16.02	\$7.59	\$9.8 \$9.4
Nov-22	26,603		\$16.89		\$16.73							\$9.4 \$9.0
Dec-22	26,603		\$16.99	\$16.44 \$16.54	\$16.82	\$16.34 \$16.42	\$11.73 \$12.63	\$13.16 \$12.94	\$16.39 \$17.93	\$16.15 \$16.28	\$6.77 \$6.36	\$9.0 \$8.6
Jan-23	26,603		\$17.10	\$16.64	\$16.90	\$16.42	\$12.63	\$12.94	\$17.93	\$16.28	\$5.95	\$8.0
Feb-23 Mar-23	26,603		\$17.20 \$17.30	\$16.64	\$16.99 \$17.07	\$16.51	\$11.54	\$12.73	\$17.15	\$16.41	\$5.55	\$8.2 \$7.7
	26,603						\$11.51	\$12.53		\$16.53	\$5.54	\$7.7
Apr-23	26,603		\$17.41 \$17.51	\$16.84 \$16.94	\$17.16 \$17.25	\$16.68 \$16.77	\$11.25	\$12.32 \$12.12	\$17.63 \$17.66	\$16.66	\$5.13 \$4.72	\$7.3
May-23	26,603			\$16.94 \$17.05		\$16.77	\$10.96	\$12.12 \$11.93	\$17.66	\$16.79 \$16.92	\$4.72	\$6.9 \$6.5
Jun-23	26,603		\$17.62	\$17.05 \$17.15	\$17.33	\$16.86	\$10.22	\$11.93 \$11.74	\$17.01	\$16.92 \$17.05	\$4.31	\$6.5 \$6.1
Jul-23	26,603 26,603		\$17.73	\$17.15 \$17.26	\$17.42	\$16.94	\$9.62	\$11.74 \$11.56	\$16.48 \$16.28	\$17.05 \$17.17	\$3.90	\$5.7
Aug-23			\$17.84 \$17.95	\$17.26 \$17.36	\$17.51	\$17.03 \$17.12	\$9.30 \$10.56	\$11.56 \$11.34	\$16.28 \$18.35	\$17.17	\$3.49	\$5.7
Sep-23	26,603				\$17.60							
Oct-23	26,603		\$18.06	\$17.47	\$17.68	\$17.20	\$10.91	\$11.12	\$19.28	\$17.43	\$2.67	\$4.9
Nov-23	26,603		\$18.17	\$17.57	\$17.77	\$17.29	\$10.47	\$10.90	\$19.06	\$17.56	\$2.26	\$4.5
Dec-23	26,603		\$18.28	\$17.68	\$17.85	\$17.38	\$9.34	\$10.70	\$17.93	\$17.69	\$1.86	\$4.1

Utilization Trend	7.54%	6.64%	-15.93%	5.87%	-43,42%	
RMSE (root mean square error)	1.06	1.05	1.03	0.63	0.94	

Utilization Trend Calculation - Professional - All Other - 48 Month

		Adjusted	Logistic Regression Linear Regression		egression	Holt-Winters' Multiplicative Holt-Wint			/inters' Additive Double Exp Smoothin			
		Allowed Claims	Fitted	Rolling 12	Fitted	Rolling 12	Fitted	Rolling 12	Fitted	Rolling 12	Fitted	Rolling
Month	Membership	PMPM	PMPM	PMPM	PMPM	PMPM	PMPM	PMPM	PMPM	PMPM	PMPM	PMPN
Sep-17	21,670	\$119.60	\$129.01		\$129.22		\$119.59		\$119.60		\$128.02	
Oct-17	21,666	\$124.19	\$128.58		\$128.84		\$124.79		\$121.28		\$123.98	
Nov-17	21,746	\$142.76	\$128.14		\$128.45		\$136.67		\$129.38		\$123.80	
Dec-17	21,727	\$130.73	\$127.72		\$128.08		\$139.49		\$143.48		\$133.20	
Jan-18	22,079	\$132.34	\$127.28		\$127.69		\$126.26		\$125.20		\$132.90	
		\$132.34					\$120.20		\$125.20		\$132.90	
Feb-18	22,144		\$126.85		\$127.30							
Mar-18	22,136	\$127.52	\$126.46		\$126.95		\$125.01		\$121.01		\$131.09	
Apr-18	22,176	\$122.34	\$126.03		\$126.56		\$114.66		\$116.52		\$129.64	
May-18	22,355	\$127.62	\$125.61		\$126.19		\$125.78		\$134.34		\$126.05	
Jun-18	22,397	\$117.88	\$125.18		\$125.80		\$124.19		\$125.85		\$126.51	
Jul-18	22,587	\$121.32	\$124.77		\$125.43		\$122.83		\$119.11		\$121.87	
Aug-18	22,671	\$115.35	\$124.35	\$126.64	\$125.04	\$127.11	\$114.86	\$125.04	\$117.81	\$125.33	\$120.79	\$127.
Sep-18	22,650	\$129.93	\$123.92	\$126.22	\$124.65	\$126.73	\$122.45	\$125.26	\$120.61	\$125.40	\$117.18	\$126.
Oct-18	22,781	\$127.11	\$123.52	\$125.80	\$124.03	\$126.35	\$134.19	\$126.06	\$131.61	\$126.26	\$122.50	\$126.
				\$125.38		\$125.97	\$141.65	\$126.54	\$132.31	\$126.53	\$124.49	\$126
Nov-18	23,112	\$130.63	\$123.09		\$123.89				+		+	
Dec-18	23,083	\$149.86	\$122.69	\$124.96	\$123.51	\$125.59	\$129.47	\$125.75	\$131.36	\$125.58	\$127.57	\$126.
Jan-19	24,461	\$131.26	\$122.27	\$124.53	\$123.12	\$125.20	\$140.80	\$127.06	\$144.32	\$127.29	\$139.28	\$126.
Feb-19	24,499	\$125.29	\$121.85	\$124.10	\$122.74	\$124.81	\$128.24	\$127.17	\$129.78	\$127.23	\$136.98	\$127.
Mar-19	24,539	\$127.40	\$121.48	\$123.68	\$122.39	\$124.42	\$123.67	\$127.03	\$118.92	\$126.99	\$132.28	\$127.
Apr-19	24,481	\$125.20	\$121.06	\$123.27	\$122.00	\$124.04	\$114.73	\$126.94	\$116.40	\$126.89	\$130.30	\$127.
May-19	24,525	\$124.15	\$120.66	\$122.85	\$121.62	\$123.66	\$127.79	\$127.10	\$137.20	\$127.20	\$127.89	\$127.
Jun-19	24,502	\$118.24	\$120.00	\$122.45	\$121.02	\$123.28	\$121.15	\$126.82	\$122.39	\$126.89	\$125.84	\$127
Jul-19	24,662	\$122.32	\$119.86	\$122.04	\$121.25	\$123.28	\$122.94	\$126.80	\$119.47	\$126.86	\$121.58	\$127.
				\$121.63		\$122.50	\$115.81	\$126.80	\$118.82	\$126.89	\$121.38	\$127
Aug-19	24,669	\$114.52	\$119.45		\$120.47							
Sep-19	24,629	\$117.44	\$119.04	\$121.24	\$120.08	\$122.15	\$122.38	\$126.76	\$119.78	\$126.77	\$116.90	\$127.
Oct-19	24,690	\$129.48	\$118.65	\$120.84	\$119.71	\$121.78	\$122.41	\$125.81	\$119.13	\$125.75	\$115.92	\$126.
Nov-19	24,961	\$131.26	\$118.24	\$120.44	\$119.32	\$121.40	\$141.22	\$125.88	\$134.66	\$125.99	\$121.62	\$126
Dec-19	24,950	\$121.88	\$117.85	\$120.05	\$118.94	\$121.03	\$132.01	\$126.11	\$132.00	\$126.08	\$126.20	\$126.
Jan-20	25,746	\$119.26	\$117.45	\$119.64	\$118.56	\$120.65	\$117.18	\$124.13	\$116.35	\$123.73	\$124.28	\$125.
Feb-20	25,637	\$122.74	\$117.05	\$119.23	\$118.17	\$120.26	\$115.04	\$123.01	\$117.75	\$122.72	\$121.72	\$123.
Mar-20	25,636	\$92.23	\$116.68	\$118.83	\$117.81	\$119.88	\$119.77	\$122.68	\$116.36	\$122.49	\$121.92	\$122.
Apr-20	25,560	\$55.82	\$116.28	\$118.43	\$117.42	\$119.49	\$88.15	\$120.39	\$81.23	\$119.47	\$106.51	\$120.
		\$86.91		\$118.04		\$119.11	\$63.02	\$114.94	\$67.79	\$113.66	\$78.45	\$116.
May-20	25,418		\$115.90	\$118.04	\$117.04	\$119.11	\$80.17	\$114.94	\$85.08	\$113.66	\$78.45	\$110.
Jun-20	25,375	\$110.45	\$115.50		\$116.65							·
Jul-20	25,241	\$109.22	\$115.12	\$117.25	\$116.28	\$118.36	\$108.93	\$110.37	\$111.66	\$109.92	\$89.27	\$110.
Aug-20	25,193	\$112.45	\$114.73	\$116.86	\$115.89	\$117.98	\$103.17	\$109.33	\$105.71	\$108.84	\$96.67	\$108.
Sep-20	25,244	\$124.30	\$114.34	\$116.48	\$115.50	\$117.60	\$117.91	\$108.98	\$117.71	\$108.69	\$103.25	\$106.
Oct-20	25,293	\$117.17	\$113.96	\$116.09	\$115.13	\$117.23	\$128.36	\$109.50	\$125.99	\$109.28	\$113.54	\$106.
Nov-20	25,371	\$114.00	\$113.57	\$115.70	\$114.74	\$116.85	\$129.95	\$108.61	\$122.37	\$108.29	\$116.31	\$106.
Dec-20	25,360	\$119.03	\$113.20	\$115.32	\$114.36	\$116.47	\$115.82	\$107.29	\$114.73	\$106.89	\$116.29	\$105.
Jan-21	26,304	\$116.43	\$112.81	\$114.92	\$113.98	\$116.08	\$113.05	\$106.95	\$113.48	\$106.66	\$118.69	\$105
Feb-21	26,271	\$117.82	\$112.61	\$114.53	\$113.59	\$115.69	\$112.45	\$106.75	\$114.93	\$106.44	\$118.03	\$104.
												\$104.
Mar-21	26,232	\$120.52	\$112.08	\$114.14	\$113.24	\$115.30	\$112.42	\$106.15	\$111.44	\$106.04	\$119.30	
Apr-21	26,221	\$120.23	\$111.70	\$113.76	\$112.85	\$114.92	\$106.29	\$107.65	\$109.52	\$108.40	\$120.90	\$105.
May-21	26,287	\$132.80	\$111.33	\$113.37	\$112.47	\$114.54	\$128.43	\$113.10	\$132.23	\$113.78	\$121.62	\$109.
Jun-21	26,396	\$117.72	\$110.95	\$112.99	\$112.09	\$114.15	\$128.23	\$117.10	\$131.04	\$117.60	\$128.34	\$113.
Jul-21	26,610	\$116.29	\$110.58	\$112.61	\$111.71	\$113.77	\$121.47	\$118.13	\$118.98	\$118.20	\$124.66	\$116
Aug-21	26,603	\$112.75	\$110.21	\$112.24	\$111.32	\$113.39	\$111.45	\$118.77	\$112.80	\$118.75	\$121.44	\$118.
Sep-21	26,603		\$109.83	\$111.87	\$110.94	\$113.01	\$119.46	\$118.90	\$118.01	\$118.77	\$117.51	\$119.
Oct-21	26,603	ļ	\$109.47	\$111.49	\$110.56	\$112.64	\$123.17	\$118.50	\$119.71	\$118.27	\$117.45	\$120.
				\$111.49		\$112.04	\$123.17	\$118.88	\$119.71	\$118.50	\$117.43	\$120.
Nov-21	26,603		\$109.09		\$110.17							
Dec-21	26,603		\$108.73	\$110.76	\$109.80	\$111.89	\$134.47	\$120.43	\$125.64	\$119.40	\$117.33	\$120.
Jan-22	26,603	ļ	\$108.36	\$110.39	\$109.41	\$111.50	\$128.41	\$121.71	\$120.11	\$119.95	\$117.27	\$120.
Feb-22	26,603		\$107.99	\$110.02	\$109.02	\$111.12	\$124.86	\$122.74	\$118.61	\$120.25	\$117.21	\$120.
Mar-22	26,603		\$107.66	\$109.65	\$108.67	\$110.75	\$120.33	\$123.39	\$112.24	\$120.31	\$117.15	\$119.
Apr-22	26,603	ļ	\$107.30	\$109.29	\$108.28	\$110.73	\$107.79	\$123.49	\$101.25	\$119.61	\$117.09	\$119
				\$109.29		\$10.37	\$107.79	\$123.49	\$101.25	\$119.01	\$117.03	\$119.
May-22	26,603		\$106.94		\$107.91							
Jun-22	26,603	ļ	\$106.58	\$108.56	\$107.52	\$109.61	\$112.39	\$121.21	\$111.47	\$116.41	\$116.97	\$118.
Jul-22	26,603		\$106.23	\$108.20	\$107.14	\$109.23	\$114.51	\$120.63	\$112.70	\$115.89	\$116.91	\$117.
Aug-22	26,603		\$105.86	\$107.84	\$106.76	\$108.85	\$109.33	\$120.45	\$109.21	\$115.59	\$116.85	\$117
Sep-22	26,603	ļ	\$105.50	\$107.48	\$106.37	\$108.47	\$115.97	\$120.16	\$114.47	\$115.30	\$116.79	\$117
Oct-22	26,603		\$105.15	\$107.12	\$105.99	\$108.09	\$119.56	\$119.86	\$116.17	\$115.00	\$116.73	\$117
Nov-22	26,603	ļ	\$104.80	\$106.76	\$105.60	\$107.71	\$130.01	\$119.53	\$121.36	\$114.71	\$116.67	\$117.
Dec-22	26,603		\$104.45	\$106.40	\$105.23	\$107.33	\$130.51	\$119.20	\$122.10	\$114.41	\$116.61	\$116.
Jan-23	26,603		\$104.09	\$106.05	\$104.84	\$106.94	\$124.62	\$118.89	\$116.56	\$114.12	\$116.55	\$116.
Feb-23	26,603	ļ	\$103.74	\$105.69	\$104.45	\$106.56	\$121.16	\$118.58	\$115.07	\$113.82	\$116.48	\$116.
Mar-23		ļ	\$103.74	\$105.34		\$106.18	\$116.76	\$118.28	\$108.70	\$113.53	\$116.42	\$116
	26,603	ļ			\$104.10	+	·	+ 00	+=====		+	
Apr-23	26,603		\$103.07	\$104.99	\$103.72	\$105.80	\$104.58	\$118.02	\$97.71	\$113.23	\$116.36	\$116
May-23	26,603		\$102.73	\$104.63	\$103.34	\$105.42	\$113.30	\$117.73	\$109.70	\$112.94	\$116.30	\$116
Jun-23	26,603		\$102.38	\$104.28	\$102.95	\$105.04	\$109.03	\$117.45	\$107.93	\$112.64	\$116.24	\$116.
Jul-23	26,603	ļ	\$102.04	\$103.94	\$102.58	\$104.66	\$111.08	\$117.16	\$109.16	\$112.35	\$116.18	\$116.
		ļ		\$103.59		\$104.00	\$106.04	\$116.89	\$105.66	\$112.33	\$116.18	\$116.
Aug-23	26,603		\$101.69	+	\$102.19	, - oo	+···	+	+	+	+	7
Sep-23	26,603	J	\$101.34	\$103.24	\$101.80	\$103.90	\$112.48	\$116.59	\$110.93	\$111.75	\$116.06	\$116.
Oct-23	26,603	ļ	\$101.01	\$102.90	\$101.43	\$103.52	\$115.95	\$116.29	\$112.62	\$111.46	\$116.00	\$116.
Nov-23	26,603		\$100.67	\$102.55	\$101.04	\$103.14	\$126.08	\$115.97	\$117.82	\$111.16	\$115.94	\$116.
					₹101.0 4	\$103.14	7120.00	7225.57	7221.02	V		

Utilization Trend	-3.93%	-4.13%	-1.14%	-2.90%	-0.90%	
RMSE (root mean square error)	12.86	12.84	10.95	9.97	13.06	

Utilization Trend Calculation - Professional - All Other - 36 Month

								Vinters'					
						Linear Regression Multiplicative				ers' Additive	Double Exp Smoothing		
		Allowed Claims	Fitted	Rolling 12	Fitted	Rolling 12	Fitted	Rolling 12	Fitted	Rolling 12	Fitted	Rolling 1	
Month	Membership	PMPM	PMPM	PMPM	PMPM	PMPM	PMPM	PMPM	PMPM	PMPM	PMPM	PMPM	
Sep-18 Oct-18	22,650 22,781	\$129.93 \$127.11	\$125.32 \$124.85		\$126.48 \$126.03		\$129.93 \$133.22		\$129.92 \$130.62		\$129.39 \$129.19		
Nov-18	22,781	\$127.11 \$130.63	\$124.85		\$126.03		\$133.22		\$130.62		\$129.19		
Dec-18	23,112	\$130.63	\$124.36		\$125.56		\$132.19		\$135.58		\$127.46		
Jan-19	24,461	\$131.26	\$123.41		\$123.11		\$142.04		\$141.91		\$140.96		
Feb-19	24,499	\$125.29	\$122.93		\$124.04		\$126.66		\$130.90		\$136.68		
Mar-19	24,439	\$123.29	\$122.50		\$124.17		\$116.51		\$116.72		\$130.53		
Apr-19	24,481	\$125.20	\$122.02		\$123.73		\$108.83		\$114.43		\$128.29		
May-19	24,525	\$124.15	\$121.56		\$122.83		\$131.55		\$139.41		\$125.80		
Jun-19	24,502	\$118.24	\$121.09		\$122.36		\$133.97		\$125.02		\$123.89		
Jul-19	24,662	\$122.32	\$120.63		\$121.91		\$123.22		\$118.71		\$119.45		
Aug-19	24,669	\$114.52	\$120.17	\$122.68	\$121.44	\$123.92	\$116.64	\$127.11	\$119.61	\$127.47	\$119.59	\$128.	
Sep-19	24,629	\$117.44	\$119.70	\$122.22	\$120.97	\$123.47	\$125.57	\$126.75	\$121.14	\$126.74	\$115.25	\$127.	
Oct-19	24,690	\$129.48	\$119.25	\$121.77	\$120.52	\$123.02	\$120.49	\$125.72	\$118.13	\$125.71	\$114.79	\$125.	
Nov-19	24,961	\$131.26	\$118.78	\$121.31	\$120.05	\$122.57	\$134.15	\$125.93	\$130.18	\$125.92	\$121.99	\$125.	
Dec-19	24,950	\$121.88	\$118.34	\$120.86	\$119.60	\$122.12	\$143.22	\$126.13	\$136.22	\$126.04	\$127.26	\$125.	
Jan-20	25,746	\$119.26	\$117.88	\$120.39	\$119.13	\$121.65	\$108.43	\$124.08	\$113.94	\$123.68	\$124.61	\$124.	
Feb-20	25,637	\$122.74	\$117.42	\$119.92	\$118.66	\$121.19	\$114.50	\$123.04	\$118.88	\$122.67	\$121.50	\$122.	
Mar-20	25,636	\$92.23	\$116.99	\$119.46	\$118.23	\$120.72	\$114.23	\$122.82	\$114.17	\$122.43	\$121.84	\$122.	
Apr-20	25,560	\$55.82	\$116.53	\$119.00	\$117.76	\$120.26	\$80.03	\$120.32	\$79.26	\$119.41	\$103.88	\$119.	
May-20	25,418	\$86.91	\$116.10	\$118.55	\$117.31	\$119.80	\$59.44	\$114.26	\$70.00	\$113.61	\$72.26	\$115.	
Jun-20	25,375	\$110.45	\$115.64	\$118.10	\$116.84	\$119.35	\$91.73	\$110.77	\$87.71	\$110.51	\$73.80	\$111.	
Jul-20	25,241	\$109.22	\$115.21	\$117.65	\$116.38	\$118.89	\$114.15	\$110.04	\$110.89	\$109.87	\$89.79	\$108.	
Aug-20	25,193	\$112.45	\$114.76	\$117.20	\$115.92	\$118.44	\$104.23	\$109.02	\$106.50	\$108.80	\$98.75	\$107.	
Sep-20	25,244	\$124.30	\$114.31	\$116.76	\$115.45	\$117.98	\$122.49	\$108.79	\$119.06	\$108.65	\$106.03	\$106.	
Oct-20	25,293	\$117.17	\$113.88	\$116.32	\$115.00	\$117.53	\$127.89	\$109.43	\$125.00	\$109.24	\$117.26	\$106.	
Nov-20	25,371	\$114.00	\$113.44	\$115.88	\$114.53	\$117.07	\$121.75	\$108.43	\$117.88	\$108.24	\$119.15	\$106.	
Dec-20	25,360	\$119.03	\$113.01	\$115.44	\$114.08	\$116.61	\$123.72	\$106.86	\$118.95	\$106.84	\$118.02	\$105.	
Jan-21	26,304	\$116.43	\$112.57	\$114.99	\$113.61	\$116.14	\$106.52	\$106.70	\$111.08	\$106.61	\$120.10	\$105.	
Feb-21	26,271	\$117.82	\$112.14	\$114.54	\$113.14	\$115.68	\$111.69	\$106.47	\$116.05	\$106.39	\$119.48	\$105.	
Mar-21	26,232	\$120.52	\$111.74	\$114.10	\$112.72	\$115.21	\$108.19	\$105.97	\$109.25	\$105.99	\$119.73	\$104.	
Apr-21	26,221	\$120.23	\$111.31	\$113.66	\$112.25	\$114.75	\$102.17	\$107.80	\$107.55	\$108.34	\$121.30	\$106.	
May-21	26,287	\$132.80	\$110.89	\$113.22 \$112.78	\$111.80 \$111.33	\$114.28 \$113.82	\$129.48 \$141.34	\$113.64 \$117.80	\$134.45 \$133.67	\$113.73 \$117.56	\$121.83 \$129.45	\$110. \$115.	
Jun-21 Jul-21	26,396	\$117.72	\$110.46	\$112.78	\$111.33	\$113.82	\$141.34	\$117.80	\$133.67	\$117.56	\$129.45	\$115.	
	26,610 26,603	\$116.29 \$112.75	\$110.04 \$109.61	\$111.93	\$110.88	\$113.30	\$111.66	\$110.50	\$113.59	\$118.71	\$120.60	\$110.	
Aug-21 Sep-21	26,603	\$112.75	\$109.61	\$111.50	\$110.41	\$112.45	\$122.85	\$119.07	\$119.37	\$118.71	\$120.00	\$119.	
Oct-21	26,603		\$109.19	\$111.08	\$109.94	\$111.99	\$125.86	\$118.98	\$120.06	\$118.35	\$115.76	\$120.	
Nov-21	26,603		\$108.78	\$110.66	\$109.49	\$111.54	\$130.41	\$119.72	\$120.00	\$118.59	\$115.70	\$120.	
Dec-21	26,603		\$108.33	\$110.00	\$109.02	\$111.09	\$141.36	\$121.22	\$125.73	\$119.16	\$114.90	\$119.	
Jan-22	26,603		\$107.53	\$109.82	\$108.37	\$110.63	\$127.09	\$122.92	\$117.79	\$119.72	\$114.47	\$119.	
Feb-22	26,603		\$107.11	\$109.40	\$107.63	\$110.17	\$122.25	\$123.80	\$117.42	\$119.83	\$114.05	\$119.	
Mar-22	26,603		\$106.73	\$108.99	\$107.21	\$109.71	\$112.81	\$124.16	\$108.86	\$119.78	\$113.62	\$118.	
Apr-22	26,603		\$106.32	\$108.57	\$106.74	\$109.25	\$96.28	\$123.65	\$95.89	\$118.79	\$113.19	\$117.	
May-22	26,603		\$105.91	\$108.16	\$106.29	\$108.80	\$103.73	\$121.50	\$110.10	\$116.78	\$112.76	\$117.	
Jun-22	26,603		\$105.50	\$107.75	\$105.82	\$108.34	\$109.30	\$118.85	\$110.95	\$114.90	\$112.34	\$115.	
Jul-22	26,603		\$105.11	\$107.34	\$105.37	\$107.88	\$113.49	\$118.09	\$111.42	\$114.33	\$111.91	\$114.	
Aug-22	26,603		\$104.70	\$106.93	\$104.90	\$107.42	\$109.01	\$117.87	\$108.72	\$113.92	\$111.48	\$113.	
Sep-22	26,603		\$104.29	\$106.52	\$104.43	\$106.96	\$118.76	\$117.53	\$115.33	\$113.59	\$111.05	\$113.	
Oct-22	26,603		\$103.90	\$106.12	\$103.98	\$106.50	\$121.66	\$117.18	\$116.03	\$113.25	\$110.62	\$112.	
Nov-22	26,603		\$103.49	\$105.71	\$103.51	\$106.05	\$126.05	\$116.82	\$116.74	\$112.92	\$110.20	\$112.	
Dec-22	26,603		\$103.10	\$105.31	\$103.06	\$105.59	\$136.61	\$116.42	\$121.70	\$112.58	\$109.77	\$112.	
Jan-23	26,603		\$102.70	\$104.90	\$102.59	\$105.13	\$122.82	\$116.07	\$113.76	\$112.24	\$109.34	\$111.	
Feb-23	26,603		\$102.70	\$104.50	\$102.12	\$104.67	\$118.13	\$115.72	\$113.39	\$111.91	\$108.91	\$111.	
Mar-23	26,603		\$101.94	\$104.11	\$101.70	\$104.21	\$109.00	\$115.40	\$104.83	\$111.57	\$108.49	\$110.	
Apr-23	26,603		\$101.55	\$103.71	\$101.70	\$103.75	\$93.02	\$115.13	\$91.86	\$111.24	\$108.06	\$110.	
May-23	26,603		\$101.33	\$103.71	\$100.78	\$103.75	\$100.20	\$114.84	\$106.07	\$110.90	\$107.63	\$109.	
Jun-23	26,603		\$101.16	\$103.31	\$100.78	\$103.29	\$100.20	\$114.53	\$106.07	\$110.56	\$107.03	\$109.	
Jun-23 Jul-23	26,603		\$100.77	\$102.52	\$100.31	\$102.83	\$105.57	\$114.53	\$106.92	\$110.56	\$107.20	\$109.	
				\$102.53		\$102.37	\$109.61	\$114.20 \$113.89	\$107.39	\$110.23	\$106.77	\$109.	
Aug-23	26,603		\$100.00		\$99.39								
Sep-23	26,603		\$99.61	\$101.74	\$98.92	\$101.45	\$114.68	\$113.55	\$111.30	\$109.56	\$105.92	\$108.	
Oct-23	26,603		\$99.24	\$101.36	\$98.47	\$101.00	\$117.47	\$113.20	\$112.00	\$109.22	\$105.49	\$107.	
Nov-23	26,603		\$98.85	\$100.97	\$98.00	\$100.54	\$121.69	\$112.84	\$112.71	\$108.88	\$105.06	\$107.	
Dec-23	26,603		\$98.48	\$100.58	\$97.55	\$100.08	\$131.87	\$112.44	\$117.67	\$108.55	\$104.64	\$106	

Utilization Trend	-4.47%	-5.04%	-2.42%	-3.76%	-4.75%
RMSE (root mean square error)	14.29	14.28	12.11	10.36	14.16

Utilization Trend Calculation - Professional - All Other - 24 Month

							Holt-W	/inters'				
		Adjusted	Logistic R	egression	Linear Re	egression	Multip	licative	Holt-Winte	rs' Additive	Double Exp	Smoothin
		Allowed Claims	Fitted	Rolling 12	Fitted	Rolling 1						
Month	Membership	PMPM	PMPM	PMPM	PMPM	PMPM	PMPM	PMPM	PMPM	PMPM	PMPM	PMPM
Sep-19	24,629	\$117.44	\$108.18		\$110.91		\$118.37		\$117.45		\$119.69	
Oct-19	24,690	\$129.48	\$108.55		\$111.18		\$126.16		\$119.88		\$116.29	
Nov-19	24,961	\$131.26	\$108.94		\$111.46		\$127.31		\$128.77		\$125.50	
Dec-19	24,950	\$121.88	\$109.32		\$111.74		\$121.04		\$129.08		\$130.79	
Jan-20	25,746	\$119.26	\$109.71		\$112.02		\$118.59		\$119.27		\$124.74	
Feb-20	25,637	\$122.74	\$110.11		\$112.30		\$121.92		\$121.68		\$119.99	
Mar-20	25,636	\$92.23	\$110.47		\$112.56		\$95.91		\$108.83		\$121.21	
Apr-20	25,560	\$55.82	\$110.87		\$112.85		\$63.14		\$73.88		\$96.16	
May-20	25,418	\$86.91	\$111.26		\$113.12		\$92.57		\$77.62		\$56.38	
Jun-20	25,375	\$110.45	\$111.66		\$113.40		\$112.35		\$91.10		\$69.19	
Jul-20	25,241	\$109.22	\$112.04		\$113.67		\$110.92		\$109.09		\$96.48	
Aug-20	25,193	\$112.45	\$112.44	\$110.31	\$113.95	\$112.44	\$113.69	\$110.04	\$109.05	\$108.70	\$107.05	\$106.8
Sep-20	25,244	\$124.30	\$112.85	\$110.69	\$114.24	\$112.71	\$123.77	\$110.51	\$130.71	\$109.82	\$113.70	\$106.4
Oct-20	25,293	\$117.17	\$113.24	\$111.08	\$114.51	\$112.98	\$134.39	\$111.23	\$126.75	\$110.41	\$125.69	\$107.2
Nov-20	25,371	\$114.00	\$113.65	\$111.46	\$114.79	\$113.26	\$135.73	\$111.95	\$116.46	\$109.41	\$123.45	\$107.0
Dec-20	25,360	\$119.03	\$114.04	\$111.85	\$115.06	\$113.53	\$127.07	\$112.46	\$111.80	\$108.00	\$118.91	\$106.
Jan-21	26,304	\$116.43	\$114.45	\$112.26	\$115.35	\$113.82	\$124.26	\$112.96	\$116.39	\$107.78	\$120.76	\$105.8
Feb-21	26,271	\$117.82	\$114.86	\$112.66	\$115.63	\$114.10	\$127.67	\$113.47	\$118.85	\$107.56	\$118.88	\$105.
Mar-21	26,232	\$120.52	\$115.23	\$113.06	\$115.88	\$114.38	\$97.80	\$113.60	\$103.89	\$107.14	\$118.98	\$105.
Apr-21	26,221	\$120.23	\$115.64	\$113.47	\$116.16	\$114.66	\$61.67	\$113.37	\$102.15	\$109.48	\$121.09	\$107.
May-21	26,287	\$132.80	\$116.05	\$113.87	\$116.44	\$114.94	\$94.26	\$113.45	\$142.06	\$114.88	\$121.45	\$113.
Jun-21	26,396	\$117.72	\$116.46	\$114.27	\$116.72	\$115.22	\$117.84	\$113.92	\$137.05	\$118.73	\$131.95	\$118.
Jul-21	26,610	\$116.29	\$116.87	\$114.67	\$116.99	\$115.50	\$116.51	\$114.38	\$116.39	\$119.31	\$122.90	\$120.
Aug-21	26,603	\$112.75	\$117.29	\$115.08	\$117.27	\$115.77	\$119.78	\$114.90	\$116.12	\$119.87	\$117.75	\$121.
Sep-21	26,603		\$117.71	\$115.48	\$117.56	\$116.05	\$131.51 \$132.38	\$115.59	\$131.00	\$119.94	\$112.78	\$121.
Oct-21	26,603		\$118.11	\$115.88 \$116.28	\$117.83	\$116.32 \$116.59	\$132.38 \$131.35	\$115.50 \$115.21	\$133.43 \$132.72	\$120.53 \$121.88	\$111.13 \$109.49	\$119.
Nov-21	26,603		\$118.54		\$118.11							
Dec-21	26,603		\$118.95	\$116.69	\$118.38	\$116.87	\$130.49	\$115.54	\$130.53	\$123.41	\$107.84	\$117.
Jan-22	26,603		\$119.38	\$117.10 \$117.51	\$118.67	\$117.14 \$117.42	\$127.77 \$130.37	\$115.85 \$116.08	\$127.90	\$124.37 \$125.32	\$106.20 \$104.55	\$116. \$115.
Feb-22	26,603		\$119.80	\$117.51	\$118.95	\$117.42	\$130.37	\$116.08	\$130.31 \$116.39	\$125.32	\$104.55	\$115.
Mar-22	26,603		\$120.19		\$119.20		\$117.88					
Apr-22	26,603		\$120.62	\$118.33 \$118.75	\$119.48	\$117.97 \$118.24	\$100.09	\$120.88 \$123.18	\$98.02 \$119.83	\$125.97 \$124.13	\$101.26 \$99.62	\$112. \$110.
May-22 Jun-22	26,603 26.603		\$121.04 \$121.48	\$118.75	\$119.76 \$120.04	\$118.24	\$122.19	\$123.18	\$119.83	\$124.13	\$99.62	\$110.
Jun-22 Jul-22	26,603		\$121.48	\$119.16	\$120.04	\$118.80	\$122.58	\$123.70	\$122.69	\$123.58	\$96.33	\$107.
Jui-22 Aug-22	26,603		\$121.90	\$119.56	\$120.31	\$119.07	\$122.02	\$124.21	\$122.59	\$123.36	\$94.69	\$103.
Sep-22	26,603		\$122.34	\$120.01	\$120.39	\$119.35	\$138.52	\$124.98	\$140.77	\$124.12	\$93.04	\$103.
Oct-22	26,603		\$123.20	\$120.45	\$120.00	\$119.63	\$139.40	\$125.56	\$143.20	\$125.74	\$91.40	\$100.
Nov-22	26,603		\$123.20	\$121.28	\$121.13	\$119.90	\$138.29	\$126.14	\$142.49	\$126.56	\$89.75	\$98.8
Dec-22	26,603		\$123.04	\$121.70	\$121.70	\$120.18	\$137.35	\$126.71	\$140.29	\$127.37	\$88.11	\$97.1
Jan-23	26,603		\$124.52	\$122.13	\$121.70	\$120.46	\$134.46	\$127.27	\$137.66	\$128.18	\$86.46	\$95.5
Feb-23	26,603		\$124.96	\$122.56	\$122.27	\$120.73	\$137.16	\$127.84	\$140.08	\$129.00	\$84.82	\$93.8
Mar-23	26,603		\$125.37	\$122.99	\$122.52	\$121.01	\$124.00	\$128.35	\$126.15	\$129.81	\$83.17	\$92.2
Apr-23	26,603		\$125.82	\$123.43	\$122.80	\$121.29	\$105.26	\$128.78	\$107.79	\$130.63	\$81.53	\$90.5
May-23	26,603		\$126.25	\$123.86	\$123.08	\$121.56	\$128.48	\$129.30	\$129.60	\$131.44	\$79.89	\$88.9
Jun-23	26,603		\$126.23	\$124.30	\$123.36	\$121.84	\$130.44	\$129.83	\$133.81	\$132.25	\$78.24	\$87.2
Jul-23	26,603		\$120.71	\$124.73	\$123.63	\$122.12	\$128.84	\$130.35	\$132.46	\$133.07	\$76.60	\$85.6
Aug-23	26,603		\$127.60	\$125.17	\$123.03	\$122.39	\$128.22	\$130.87	\$132.28	\$133.88	\$74.95	\$84.0
Sep-23	26,603		\$128.06	\$125.61	\$124.20	\$122.67	\$145.52	\$131.45	\$150.53	\$134.69	\$73.31	\$82.3
Oct-23	26,603		\$128.50	\$126.05	\$124.47	\$122.95	\$146.42	\$132.04	\$152.96	\$135.51	\$71.66	\$80.7
Nov-23	26,603		\$128.97	\$126.50	\$124.47	\$123.22	\$145.23	\$132.62	\$152.25	\$136.32	\$70.02	\$79.0
Dec-23	26,603		\$128.97	\$126.50	\$124.75	\$123.50	\$143.23	\$132.02	\$152.25	\$130.32	\$68.37	\$77.4

Utilization Trend	4.29%	2.81%	6.53%	5.94%	-17.50%	
RMSE (root mean square error)	15.72	15.65	16.59	10.19	16.23	

MEDICAL UTILIZATION TREND CALCULATION - PHARMACEUTICALS

Services Trend - Pharmaceuticals Processed through the Medical Benefit

			MONTHLY DA	A - TOTAL SERVICES								
Month	Members	Biosimilar Equivalent	Injections with Biosimilar Equivalent	Other High Cost Injections	All Other Pharmaceuticals	Total Services	Members	Biosimilar Equivalent	ROLLI Injections with Biosimilar Equivalent	NG 12 Other High Cost Injections	All Other Pharmaceuticals	Total Service
Sep-17	21,670	0.00	24.00	45.00	2,362.00	2,431.00						
Oct-17	21,666	0.00	19.00	48.00	2,536.00	2,603.00						
Nov-17	21,746	0.00	27.00	67.00	2,415.00	2,509.00						
Dec-17	21,727	0.00	25.00	57.00	2,660.00	2,742.00						
an-18	22,079	0.00	35.00	72.00	2,559.00	2,666.00						
eb-18	22,144	0.00	19.00	55.00	2,406.00	2,480.00						
Mar-18	22,136	0.00	28.00	66.00	2,518.00	2,612.00						
pr-18	22,176	0.00	23.00	53.00	2,126.00	2,202.00						
1ay-18	22,355	0.00	32.00	64.00	2,399.00	2,495.00						
un-18	22,397	0.00	27.00	59.00	2,265.00	2,351.00						
Jul-18	22,587	0.00	31.00	80.00	2,172.00	2,283.00						
lug-18	22,671	0.00	24.00	66.00	2,208.00	2,298.00	265,354	0.00	314.00	732.00	28,626.00	29,672.0
ep-18	22,650	0.00	21.00	62.00	2,227.00	2,310.00	266,334	0.00	311.00	749.00	28,491.00	29,551.
Oct-18	22,781	0.00	31.00	71.00	2,604.00	2,706.00	267,449	0.00	323.00	772.00	28,559.00	29,654.0
Nov-18	23,112	0.00	29.00	72.00	2,538.00	2,639.00	268,815	0.00	325.00	777.00	28,682.00	29,784.0
Dec-18	23,083	0.00	35.00	84.00	2,670.00	2,789.00	270,171	0.00	335.00	804.00	28,692.00	29,831.0
an-19	24,461	0.00	38.00	103.00	3,081.08	3,222.09	272,553	0.00	338.00	835.00	29,214.08	30,387.
eb-19	24,499	0.00	31.00	73.00	2,262.07	2.366.07	274,908	0.00	350.00	853.00	29,070.15	30,273.:
/ar-19	24,539	1.00	40.00	82.00	2,542.07	2,665.07	277,311	1.00	362.00	869.00	29,094.22	30,326.
pr-19	24,481	3.00	24.00	140.00	2,584.07	2,751.07	279,616	4.00	363.00	956.01	29,552.29	30,875.
fay-19	24,525	4.00	33.00	172.01	2,539.08	2.748.09	281,786	8.00	364.00	1.064.01	29,692.38	31,128.
un-19	24,502	14.00	28.00	131.00	2,503.08	2,676.09	283,891	22.00	365.00	1,136.02	29,930.46	31,453.
lul-19	24,662	14.00	32.00	113.00	2,647.09	2,806.10	285,966	36.00	366.01	1,169.02	30,405.55	31,976.
ug-19	24,669	7.00	29.00	126.00	2,635.09	2,797.09	287,964	43.00	371.01	1,229.02	30,832.64	32,475.
ep-19	24,629	7.00	34.00	145.00	2,567.03	2,753.03	289,943	50.00	384.01	1,312.02	31,172.67	32,918.
Oct-19	24,690	10.00	42.00	140.00	2,701.01	2,893.01	291.852	60.00	395.01	1.381.02	31,269.68	33,105.
lov-19	24,961	8.00	40.00	115.00	2,700.00	2,863.00	293,701	68.00	406.01	1,424.02	31,431.68	33,329.
ec-19	24,950	3.00	42.00	105.00	2,626.00	2,776.00	295,568	71.00	413.01	1,445.02	31,387.68	33,316.
an-20	25,746	13.00	41.00	94.00	2,561.00	2,709.00	296,853	84.00	416.01	1,436.02	30,867.60	32,803.
eb-20	25,637	7.00	28.00	69.00	2,762.00	2,866.00	297,991	91.00	413.01	1,432.02	31,367.53	33,303.
/ar-20	25,636	8.00	29.00	71.00	2.018.04	2.126.04	299.088	98.00	402.01	1,421.02	30.843.49	32,764.
pr-20	25,560	7.00	38.00	64.00	1,248.08	1,357.09	300,167	102.00	416.01	1,345.02	29,507.50	31,370.
tay-20	25,418	12.00	30.00	77.00	2.061.05	2.180.05	301,060	110.00	413.01	1,250.02	29,029.47	30,802.
un-20	25,416	7.00	39.00	90.00	2,061.05	2,180.05	301,080	103.00	424.01	1,250.02	29,029.47	31.033.
ul-20	25,241	12.00	33.00	91.01	2,802.19	2,907.00	302,512	103.00	424.01	1,187.02	29,452.49	31,165.
ug-20	25,241	10.00	38.01	59.01	2,529.56	2,936.20	303,036	101.00	434.01	1,120.02	29,346.97	31,005
ug-20 ep-20	25,193	10.00	25.01	76.03	2,615.10	2,726.14	303,651	107.01	425.02	1,051.05	29,395.03	30,978.
ep-20 Oct-20	25,244	12.00	32.01	71.02		2,726.14		109.01	425.02	982.07		
oct-20 lov-20		12.00	24.01	71.02 65.03	2,768.80		304,254	112.01	415.03 399.03	982.07	29,462.83	30,968.
	25,371				2,139.08 2.741.96	2,239.12	304,664				28,901.91	30,345.
ec-20	25,360	20.00	31.01	66.01		2,858.98	305,074	129.01	388.04	893.11	29,017.87	30,428
an-21	26,304	27.01	28.01	79.04	2,498.08	2,632.13	305,632	143.02	375.05	878.14	28,954.95	30,351.
eb-21	26,271	22.00	21.00	77.02	2,593.64	2,713.66	306,266	158.02	368.05	886.16	28,786.59	30,198
lar-21	26,232	31.01	25.00	93.03	3,033.93	3,182.97	306,862	181.03	364.06	908.18	29,802.49	31,255
pr-21	26,221	36.02	30.03	84.06	3,046.98	3,197.10	307,523	210.05	356.08	928.24	31,601.39	33,095
1ay-21	26,287	28.03	17.03	76.17	3,125.21	3,246.44	308,392	226.08	343.11	927.42	32,665.55	34,162
un-21	26,396	20.01	25.09	100.37	3,125.47	3,270.94	309,413	239.09	329.20	937.79	33,020.02	34,526.
Jul-21	26,610	28.05	23.19	109.11	2,816.74	2,977.09	310,782	255.13	319.39	955.89	33,034.56	34,564.
ug-21	26,603	28.08	19.30	100.88	2,669.06	2,817.32	312,192	273.21	300.68	997.77	33,174.06	34,745.

MEDICAL UTILIZATION TREND CALCULATION - PHARMACEUTICALS

Services Trend - Pharmaceuticals Processed through the Medical Benefit

	MONTHLY DATA - TOTAL SERVICES								ROLLII	NG 12		
Month	Members	Biosimilar Equivalent	Injections with Biosimilar Equivalent	Other High Cost Injections	All Other Pharmaceuticals	Total Services	Members	Biosimilar Equivalent	Injections with Biosimilar Equivalent	Other High Cost Injections	All Other Pharmaceuticals	Total Services
Sep-17	21,670	0.00	1.11	2.08	109.00	112.18						
Oct-17	21,666	0.00	0.88	2.22	117.05	120.14						
Nov-17	21,746	0.00	1.24	3.08	111.05	115.38						
Dec-17	21,727	0.00	1.15	2.62	122.43	126.20						
Jan-18	22,079	0.00	1.59	3.26	115.90	120.75						
Feb-18	22,144	0.00	0.86	2.48	108.65	111.99						
Mar-18	22,136	0.00	1.26	2.98	113.75	118.00						
Apr-18	22,176	0.00	1.04	2.39	95.87	99.30						
May-18	22,355	0.00	1.43	2.86	107.31	111.61						
Jun-18	22,397	0.00	1.21	2.63	101.13	104.97						
Jul-18	22,587	0.00	1.37	3.54	96.16	101.08						
Aug-18	22,671	0.00	1.06	2.91	97.39	101.36	265,354	0.00	1.18	2.76	107.88	111.82
Sep-18	22,650	0.00	0.93	2.74	98.32	101.99	266,334	0.00	1.17	2.81	106.97	110.95
Oct-18	22.781	0.00	1.36	3.12	114.31	118.78	267,449	0.00	1.21	2.89	106.78	110.88
Nov-18	23,112	0.00	1.25	3.12	109.81	114.18	268,815	0.00	1.21	2.89	106.70	110.80
Dec-18	23,083	0.00	1.52	3.64	115.67	120.82	270,171	0.00	1.24	2.98	106.20	110.42
Jan-19	24,461	0.00	1.55	4.21	125.96	131.72	272,553	0.00	1.24	3.06	107.19	111.49
Feb-19	24,499	0.00	1.27	2.98	92.33	96.58	274,908	0.00	1.27	3.10	105.75	110.12
Mar-19	24,539	0.04	1.63	3.34	103.59	108.61	277,311	0.00	1.31	3.13	104.92	109.36
Apr-19	24,339	0.12	0.98	5.72	105.55	112.38	279,616	0.00	1.30	3.42	104.92	110.42
May-19	24,461	0.12	1.35	7.01	103.53	112.05	281,786	0.01	1.29	3.78	105.37	110.42
		0.16	1.14	5.35	103.55	109.22	283,891	0.08	1.29	4.00	105.37	110.47
Jun-19	24,502					109.22		0.08				110.79
Jul-19	24,662	0.57	1.30	4.58	107.33		285,966		1.28	4.09	106.33	
Aug-19	24,669	0.28	1.18	5.11	106.82	113.38	287,964	0.15	1.29	4.27	107.07	112.78
Sep-19	24,629	0.28	1.38	5.89	104.23	111.78	289,943	0.17	1.32	4.53	107.51	113.54
Oct-19	24,690	0.41	1.70	5.67	109.40	117.17	291,852	0.21	1.35	4.73	107.14	113.43
Nov-19	24,961	0.32	1.60	4.61	108.17	114.70	293,701	0.23	1.38	4.85	107.02	113.48
Dec-19	24,950	0.12	1.68	4.21	105.25	111.26	295,568	0.24	1.40	4.89	106.19	112.72
Jan-20	25,746	0.50	1.59	3.65	99.47	105.22	296,853	0.28	1.40	4.84	103.98	110.50
Feb-20	25,637	0.27	1.09	2.69	107.73	111.79	297,991	0.31	1.39	4.81	105.26	111.76
Mar-20	25,636	0.31	1.13	2.77	78.72	82.93	299,088	0.33	1.34	4.75	103.13	109.55
Apr-20	25,560	0.27	1.49	2.50	48.83	53.09	300,167	0.34	1.39	4.48	98.30	104.51
May-20	25,418	0.47	1.18	3.03	81.09	85.77	301,060	0.37	1.37	4.15	96.42	102.31
Jun-20	25,375	0.28	1.54	3.55	109.20	114.56	301,933	0.34	1.40	4.00	97.03	102.78
Jul-20	25,241	0.48	1.31	3.61	111.02	116.41	302,512	0.33	1.40	3.92	97.36	103.02
Aug-20	25,193	0.40	1.51	2.34	100.41	104.66	303,036	0.34	1.43	3.70	96.84	102.31
Sep-20	25,244	0.40	0.99	3.01	103.59	107.99	303,651	0.35	1.40	3.46	96.81	102.02
Oct-20	25,293	0.47	1.27	2.81	109.47	114.02	304,254	0.36	1.36	3.23	96.84	101.79
Nov-20	25,371	0.43	0.95	2.56	84.31	88.26	304,664	0.37	1.31	3.06	94.86	99.60
Dec-20	25,360	0.79	1.22	2.60	108.12	112.74	305,074	0.42	1.27	2.93	95.12	99.74
Jan-21	26,304	1.03	1.06	3.00	94.97	100.07	305,632	0.47	1.23	2.87	94.74	99.31
Feb-21	26.271	0.84	0.80	2.93	98.73	103.29	306,266	0.52	1.20	2.89	93.99	98.60
Mar-21	26.232	1.18	0.95	3.55	115.66	121.34	306,862	0.59	1.19	2.96	97.12	101.86
Apr-21	26,221	1.37	1.15	3.21	116.20	121.93	307,523	0.68	1.16	3.02	102.76	107.62
May-21	26,221	1.07	0.65	2.90	118.89	123.50	308,392	0.73	1.11	3.01	105.92	110.78
Jun-21	26,396	0.76	0.95	3.80	118.41	123.92	309,413	0.77	1.06	3.03	106.72	111.59
Jul-21	26,610	1.05	0.87	4.10	105.85	111.88	310,782	0.82	1.03	3.08	106.29	111.22
Aug-21	26,603	1.06	0.87	3.79	100.33	105.90	312,192	0.82	0.96	3.20	106.29	111.30

Annual Trend	155.0%	-32.8%	-13.5%	9.7%	8.8%
Two-Year Trend	142.1%	-13.5%	-13 5%	-0.4%	-0.7%

MEDICAL UTILIZATION TREND CALCULATION - PHARMACEUTICALS

Utilization Trend Calculation - Pharmaceuticals - Bisimilars and Injections with Biosimilar Equivalent

	O.I.	ization frend Can	culation i nun	Logistic Regression -					
							egression -		egression -
		Monthly	Rolling Services	Montnly -	36 months	Montnly -	24 months	Kolling -	24 months
		Services per	per 1,000	Fitted	Rolling 12	Fitted	Rolling 12	Fitted	Rolling 12
Month	Membership	1,000 Members	Members	PMPM	PMPM	PMPM	PMPM	PMPM	PMPM
Sep-17	21.670	1.11		1.19		1.59		1.38	
Oct-17	21,666	0.88		1.21		1.59		1.38	
Nov-17	21,746	1.24		1.22		1.60		1.39	
Dec-17	21,727	1.15		1.23		1.60		1.40	
Jan-18	22,079	1.59		1.25		1.61		1.41	
Feb-18	22,144	0.86		1.26		1.61		1.42	
Mar-18	22,136	1.26		1.28		1.62		1.43	
Apr-18	22,176	1.04		1.29		1.63		1.44	
May-18	22,355	1.43		1.30		1.63		1.45	
Jun-18	22,397	1.21		1.32		1.64		1.46	
Jul-18 Aug-18	22,587 22,671	1.37 1.06	1.18	1.33 1.35	1.27	1.64 1.65	1.62	1.46 1.47	1.42
Sep-18	22,650	0.93	1.17	1.36	1.27	1.65	1.62	1.47	1.42
Oct-18	22,781	1.36	1.21	1.38	1.30	1.66	1.63	1.48	1.44
Nov-18	23,112	1.25	1.21	1.39	1.31	1.66	1.63	1.50	1.45
Dec-18	23,083	1.52	1.24	1.41	1.33	1.67	1.64	1.51	1.46
Jan-19	24,461	1.55	1.24	1.42	1.34	1.67	1.64	1.52	1.47
Feb-19	24,499	1.27	1.27	1.44	1.36	1.68	1.65	1.53	1.48
Mar-19	24,539	1.67	1.31	1.45	1.37	1.69	1.66	1.54	1.49
Apr-19	24,481	1.10	1.31	1.47	1.39	1.69	1.66	1.55	1.50
May-19	24,525	1.51	1.32	1.49	1.40	1.70	1.67	1.56	1.51
Jun-19	24,502	1.71	1.36	1.50	1.42	1.70	1.67	1.57	1.52
Jul-19	24,662	1.87	1.41	1.52	1.43	1.71	1.68	1.58	1.53
Aug-19	24,669	1.46	1.44	1.54	1.45	1.71	1.68	1.59	1.54
Sep-19	24,629	1.66	1.50	1.55	1.47	1.72	1.69	1.60	1.55
Oct-19	24,690	2.11	1.56	1.57	1.48	1.73	1.69	1.61	1.56
Nov-19 Dec-19	24,961 24,950	1.92 1.80	1.61 1.64	1.59 1.61	1.50	1.73	1.70	1.62 1.63	1.57
Jan-20	25,746	2.10	1.68	1.62	1.53	1.74	1.71	1.64	1.57
Feb-20	25,637	1.37	1.69	1.64	1.55	1.75	1.72	1.65	1.60
Mar-20	25,636	1.44	1.67	1.66	1.56	1.75	1.72	1.66	1.61
Apr-20	25,560	1.76	1.73	1.68	1.58	1.76	1.73	1.67	1.62
May-20	25,418	1.65	1.74	1.70	1.60	1.77	1.73	1.68	1.63
Jun-20	25,375	1.81	1.75	1.72	1.62	1.77	1.74	1.69	1.64
Jul-20	25,241	1.78	1.74	1.73	1.63	1.78	1.75	1.70	1.65
Aug-20	25,193	1.91	1.78	1.75	1.65	1.78	1.75	1.71	1.66
Sep-20	25,244	1.39	1.75	1.77	1.67	1.79	1.76	1.73	1.67
Oct-20	25,293	1.74	1.72	1.79	1.69	1.80	1.76	1.74	1.68
Nov-20	25,371	1.38	1.68	1.81	1.71	1.80	1.77	1.75	1.69
Dec-20	25,360 26.304	2.01	1.69	1.83	1.73 1.75	1.81	1.77 1.78	1.76	1.70 1.71
Jan-21 Feb-21	26,304	2.09 1.64	1.70	1.85 1.87	1.76	1.81	1.79	1.77	1.72
Feb-21 Mar-21	26,271	2.14	1.72	1.87	1.78	1.82	1.79	1.78	1.72
Apr-21	26,232	2.52	1.84	1.03	1.80	1.83	1.80	1.80	1.74
May-21	26,287	1.71	1.85	1.93	1.82	1.84	1.80	1.81	1.75
Jun-21	26,396	1.71	1.84	1.96	1.84	1.84	1.81	1.83	1.76
Jul-21	26,610	1.93	1.85	1.98	1.86	1.85	1.82	1.84	1.78
Aug-21	26,603	1.78	1.84	2.00	1.89	1.86	1.82	1.85	1.79
Sep-21	26,603			2.02	1.91	1.86	1.83	1.86	1.80
Oct-21	26,603			2.04	1.93	1.87	1.83	1.87	1.81
Nov-21	26,603			2.07	1.95	1.87	1.84	1.88	1.82
Dec-21	26,603			2.09	1.97	1.88	1.85	1.90	1.83
Jan-22	26,603			2.11	1.99	1.89	1.85	1.91	1.84
Feb-22	26,603			2.14	2.01	1.89	1.86	1.92	1.86
Mar-22	26,603			2.16	2.03	1.90	1.87	1.93	1.87
Apr-22	26,603			2.18	2.06	1.91	1.87	1.94	1.88
May-22	26,603			2.21	2.08	1.91	1.88	1.96	1.89
Jun-22	26,603			2.23	2.10	1.92	1.88	1.97	1.90
Jul-22	26,603			2.26	2.13	1.92	1.89	1.98	1.91
Aug-22	26,603			2.28	2.15	1.93	1.90	1.99	1.93
Sep-22	26,603			2.31	2.17	1.94	1.90	2.01	1.94
Oct-22	26,603			2.33	2.20	1.94	1.91	2.02	1.95
Nov-22	26,603			2.36	2.22	1.95	1.92	2.03	1.96
Dec-22	26,603			2.38	2.24	1.96	1.92	2.04	1.98
Jan-23	26,603			2.41		1.96		2.06	
Feb-23	26,603			2.44	2.29	1.97	1.93	2.07	2.00
Mar-23	26,603			2.46	2.32	1.98	1.94	2.08	2.01
Apr-23	26,603			2.49	2.35 2.37	1.98	1.95 1.95	2.10	2.03
May-23	26,603			2.52	2.37	1.99	1.95	2.11	
Jun-23	26,603			2.54		2.00		2.12	2.05
Jul-23	26,603			2.57	2.42	2.00	1.97	2.14	2.06
Aug-23	26,603			2.60		2.01		2.15	
Sep-23	26,603			2.63	2.48	2.02	1.98	2.16	2.09
Oct-23	26,603			2.66	2.50	2.02	1.99	2.18	2.10
Nov-23 Dec-23	26,603			2.69	2.53 2.56	2.03	1.99 2.00	2.19	2.12
	26,603			2.72	Z.5b	2.04	2.00	2.20	2.13

Utilization Trend	14.0%	4.0%	7.8%
RMSE (root mean square error)	0.27	0.27	0.05

MEDICAL UTILIZATION TREND CALCULATION - PHARMACEUTICALS

Utilization Trend Calculation - Pharmaceuticals - High Cost Injections

		Othi			Logistic Regression -				
					egression - 36 months		legression - - 24 months		egression - 24 months
		Monthly	Rolling Services						
		Services per	per 1,000	Fitted	Rolling 12	Fitted	Rolling 12	Fitted	Rolling 12
Month	Membership	1,000 Members	Members	PMPM	PMPM	PMPM	PMPM	PMPM	PMPM
Sep-17	21,670	2.08		4.55		5.02		9.53	
Oct-17	21.666	2.22		4.52		4.96		9.29	
Nov-17	21,746	3.08		4.48		4.91		9.04	
Dec-17	21,727	2.62		4.44		4.85		8.80	
Jan-18	22,079	3.26		4.40		4.79		8.56	
Feb-18	22,144	2.48		4.37		4.74		8.33	
Mar-18	22,136	2.98		4.33		4.69		8.13	
Apr-18	22,176	2.39		4.30		4.63		7.91	
May-18	22,355	2.86		4.26		4.03		7.71	
Jun-18	22,397	2.63		4.23		4.53		7.50	
Jul-18	22,587	3.54		4.19		4.48		7.30	
Aug-18	22,671	2.91	2.76	4.16	4.35	4.43	4.71	7.11	8.26
Sep-18	22,650	2.74	2.81	4.12	4.32	4.38	4.66	6.92	8.04
Oct-18	22,781	3.12	2.89	4.09	4.28	4.33	4.61	6.74	7.83
Nov-18	23,112	3.12	2.89	4.06	4.24	4.28	4.56	6.56	7.62
Dec-18	23,112	3.64	2.89	4.06	4.21	4.28	4.50	6.39	7.42
Jan-19	24,461	4.21	3.06	3.99	4.17	4.18	4.45	6.21	7.22
Jan-19 Feb-19	24,461	2.98	3.10	3.99	4.17	4.18	4.40	6.05	7.22
Mar-19	24,499	3.34	3.10	3.90	4.10	4.13	4.45	5.90	6.84
Mar-19 Apr-19	24,539 24,481	3.34 5.72	3.13	3.93 3.89	4.10	4.09	4.35	5.90	6.66
Apr-19 May-19	24,481	7.01	3.42	3.89	4.07	4.04	4.30	5.74	6.48
May-19 Jun-19	24,525	5.35	4.00	3.85	4.04	3.95	4.25	5.59	6.31
Jun-19 Jul-19	24,502	5.35 4.58	4.00	3.83	3.97	3.95	4.20	5.44	6.14
Jul-19 Aug-19	24,662	4.58 5.11	4.09	3.80	3.97	3.91	4.15	5.30 5.16	5.98
					3.94		4.11		5.83
Sep-19 Oct-19	24,629 24,690	5.89 5.67	4.53 4.73	3.74 3.71	3.91	3.82 3.77	4.05	5.02 4.89	5.83
			4.73		3.88		3.97		5.68
Nov-19	24,961	4.61		3.67	3.85	3.73	3.97	4.76	5.53
Dec-19	24,950	4.21	4.89	3.64	3.78	3.69	3.93	4.63	
Jan-20	25,746	3.65	4.84	3.61	3.78	3.64	3.88	4.51	5.24 5.10
Feb-20	25,637	2.69	4.81	3.58		3.60		4.39	
Mar-20	25,636	2.77	4.75	3.56	3.72	3.56	3.80	4.28	4.97
Apr-20	25,560	2.50	4.48	3.53	3.69	3.52	3.75	4.16	4.84
May-20	25,418	3.03	4.15	3.50	3.66	3.48	3.71	4.05	4.71 4.58
Jun-20	25,375	3.55	4.00	3.47		3.44	3.67	3.94	
Jul-20	25,241	3.61	3.92	3.44	3.60	3.40	3.63	3.84	4.46
Aug-20	25,193	2.34	3.70	3.41	3.57	3.36	3.59	3.74	4.35
Sep-20	25,244	3.01	3.46	3.38	3.54	3.33	3.54	3.64	4.23
Oct-20	25,293	2.81	3.23	3.36	3.51	3.29	3.51	3.54	4.12
Nov-20	25,371	2.56	3.06	3.33	3.48	3.25	3.47	3.45	4.02
Dec-20	25,360	2.60	2.93	3.30	3.46	3.21	3.43	3.36	3.91
Jan-21	26,304	3.00	2.87	3.27	3.43	3.18	3.39	3.27	3.80
Feb-21	26,271	2.93	2.89	3.25	3.40	3.14	3.35	3.18	3.70
Mar-21	26,232	3.55	2.96	3.22	3.37	3.11	3.31	3.10	3.60
Apr-21	26,221	3.21	3.02	3.19	3.34	3.07	3.27	3.02	3.51
May-21	26,287	2.90	3.01	3.17	3.31	3.04	3.23	2.94	3.41
Jun-21	26,396	3.80	3.03	3.14	3.29	3.00	3.20	2.86	3.32
Jul-21	26,610	4.10	3.08	3.12	3.26	2.97	3.16	2.79	3.23
Aug-21	26,603	3.79	3.20	3.09	3.23	2.93	3.12	2.71	3.15
Sep-21	26,603			3.06	3.21	2.90	3.09	2.64	3.07
Oct-21	26,603			3.04	3.18	2.87	3.05	2.57	2.99
Nov-21	26,603			3.01	3.16	2.83	3.02	2.50	2.91
Dec-21	26,603			2.99	3.13	2.80	2.99	2.44	2.83
Jan-22	26,603			2.97	3.10	2.77	2.95	2.37	2.76
Feb-22	26,603			2.94	3.08	2.74	2.92	2.31	2.69
Mar-22	26,603			2.92	3.05	2.71	2.89	2.25	2.62
Apr-22	26,603			2.89	3.03	2 68	2.85	2.19	2.55
May-22	26,603			2.87	3.00	2.65	2.82	2.13	2.48
Jun-22	26,603			2.85	2.98	2.62	2.79	2.08	2.41
Jun-22 Jul-22	26,603			2.85	2.96	2.52	2.79	2.08	2.35
	26,603			2.82	2.98	2.59	2.76	1.97	2.35
Aug-22					2.93		2.73		2.29
Sep-22	26,603			2.78	2.91	2.53		1.91	
Oct-22	26,603			2.75		2.50	2.66	1.86	2.17
Nov-22	26,603			2.73	2.86	2.47	2.63	1.81	2.11
Dec-22	26,603			2.71	2.84	2.44	2.60	1.77	2.06
Jan-23	26,603			2.69	2.81	2.42	2.57	1.72	2.00
Feb-23	26,603			2.66	2.79	2.39	2.55	1.67	1.95
Mar-23	26,603			2.64	2.77	2.36	2.52	1.63	1.90
Apr-23	26,603			2.62	2.74	2.34	2.49	1.59	1.85
May-23	26,603			2.60	2.72	2.31	2.46	1.55	1.80
Jun-23	26,603			2.58	2.70	2.28	2.43	1.51	1.75
Jul-23	26,603			2.56	2.68	2.26	2.40	1.47	1.71
Aug-23	26,603			2.54	2.66	2.23	2.38	1.43	1.66
Sep-23	26,603			2.54	2.63	2.23	2.35	1.43	1.62
Oct-23	26,603			2.52	2.61	2.20	2.32	1.35	1.57
						2.10		1.33	
				2.47	2 50	2.10	2.20	4.22	1 52
Nov-23 Dec-23	26,603 26,603			2.47	2.59 2.57	2.16 2.13	2.30 2.27	1.32 1.28	1.53 1.49

Utilization Trend	-9.39%	-12.77%	-27.39%
RMSE (root mean square error)	1.06	0.84	0.29

MEDICAL UTILIZATION TREND CALCULATION - PHARMACEUTICALS

Utilization Trend Calculation - Pharmaceuticals - Other Pharmaceuticals

					egression - 36 months		egression - 24 months		egression - 24 months
		Monthly Services per	Rolling Services per 1,000	Fitted PMPM	Rolling 12 PMPM	Fitted PMPM	Rolling 12 PMPM	Fitted PMPM	Rolling 12 PMPM
Month Sep-17	Membership 21,670	1,000 Members 109.00	Members	104.29		79.86		106.23	
Oct-17	21,666	117.05		104.23		80.36		106.23	
Nov-17	21,746	111.05		104.16		80.89		105.92	
Dec-17	21,727	122.43		104.09		81.40		105.76	
Jan-18	22,079	115.90		104.02		81.93		105.61	
Feb-18	22,144	108.65		103.95		82.46		105.45	
Mar-18	22,136	113.75		103.89		82.94		105.31	
Apr-18	22,176	95.87		103.82		83.48		105.15	
May-18	22,355	107.31		103.75		84.01		105.00	
Jun-18	22,397	101.13		103.68		84.56		104.85	
Jul-18	22,587 22.671	96.16 97.39	107.88	103.61	103.91	85.09 85.64	82 75	104.70 104.54	105 37
Aug-18 Sep-18	22,650	98.32	106.97	103.54	103.91	86.20	83.27	104.34	105.37
Oct-18	22,781	114.31	106.78	103.48	103.83	86.74	83.81	104.38	105.22
Nov-18	23.112	109.81	106.70	103.41	103.71	87.31	84.34	104.08	104.91
Dec-18	23,083	115.67	106.20	103.27	103.64	87.86	84.88	103.93	104.76
Jan-19	24.461	125.96	107.19	103.20	103.57	88.43	85.44	103.78	104.60
Feb-19	24,499	92.33	105.75	103.13	103.50	89.00	86.00	103.62	104.45
Mar-19	24,539	103.59	104.92	103.07	103.43	89.53	86.55	103.48	104.29
Apr-19	24,481	105.55	105.69	103.00	103.37	90.11	87.11	103.33	104.14
May-19	24,525	103.53	105.37	102.94	103.30	90.68	87.66	103.18	103.99
Jun-19	24,502	102.16	105.43	102.87	103.23	91.27	88.22	103.03	103.84
Jul-19	24,662	107.33	106.33	102.80	103.16	91.84	88.78	102.88	103.69
Aug-19	24,669	106.82	107.07	102.73 102.66	103.10 103.03	92.44 93.04	89.34 89.90	102.73 102.57	103.54
Sep-19 Oct-19	24,629 24,690	104.23	107.51	102.66	103.03	93.04	90.46	102.57	103.39
Oct-19 Nov-19	24,690 24,961	109.40 108.17	107.14	102.50	102.96	93.63 94.24	91.03	102.43	103.24
Dec-19	24,950	105.25	106.19	102.46	102.83	94.83	91.60	102.27	102.95
Jan-20	25,746	99.47	103.98	102.39	102.76	95.45	92.19	101.98	102.80
Feb-20	25,637	107.73	105.26	102.33	102.70	96.07	92.79	101.82	102.64
Mar-20	25,636	78.72	103.13	102.26	102.63	96.65	93.39	101.68	102.49
Apr-20	25,560	48.83	98.30	102.19	102.56	97.28	93.99	101.53	102.34
May-20	25,418	81.09	96.42	102.13	102.49	97.90	94.59	101.39	102.19
Jun-20	25,375	109.20	97.03	102.06	102.43	98.53	95.19	101.23	102.05
Jul-20	25,241	111.02	97.36	101.99	102.36	99.15	95.79	101.09	101.90
Aug-20	25,193	100.41	96.84	101.93	102.29	99.80	96.40	100.94	101.75
Sep-20	25,244	103.59	96.81	101.86	102.23	100.45	97.01 97.62	100.79	101.60
Oct-20 Nov-20	25,293 25,371	109.47 84.31	96.84 94.86	101.79 101.72	102.16	101.08 101.74	98.24	100.64 100.49	101.46
Dec-20	25,371	108.12	95.12	101.72	102.03	101.74	98.86	100.49	101.16
Jan-21	26,304	94.97	95.12	101.00	101.96	102.38	99.51	100.33	101.10
Feh-21	26,271	98.73	93.99	101.53	101.89	103.72	100.16	100.05	100.86
Mar-21	26,232	115.66	97.12	101.46	101.82	104.33	100.81	99.92	100.71
Apr-21	26,221	116.20	102.76	101.39	101.76	105.01	101.46	99.77	100.57
May-21	26,287	118.89	105.92	101.33	101.69	105.67	102.11	99.63	100.42
Jun-21	26,396	118.41	106.72	101.26	101.62	106.35	102.77	99.48	100.27
Jul-21	26,610	105.85	106.29	101.19	101.55	107.02	103.42	99.34	100.12
Aug-21	26,603	100.33	106.26	101.13	101.49	107.72	104.08	99.19	99.98
Sep-21	26,603			101.06	101.42	108.42	104.74	99.04	99.83
Oct-21	26,603			100.99	101.36 101.29	109.10	105.41 106.07	98.90	99.69 99.55
Nov-21	26,603			100.93	101.29	109.81	106.07	98.75	99.55
Dec-21 Jan-22	26,603			100.86	101.22	110.51	105.74	98.61 98.46	99.40
Jan-22 Feb-22	26,603			100.79	101.16	111.23	107.42	98.46 98.32	99.26 99.11
	26,603				101.09		108.10		99.11
Mar-22	26,603 26,603			100.67 100.60	101.03	112.61	108.79	98.18 98.04	98.97
Apr-22 May-22	26,603 26,603			100.60	100.96	113.34	110.18	98.04	98.83
May-22 Jun-22	26,603 26,603			100.53	100.89	114.05	110.18	97.90 97.75	98.54
Jun-22 Jul-22	26,603 26,603			100.47	100.83	114.80 115.52	110.88	97.75 97.61	98.54
Aug-22	26,603			100.40	100.76	116.52	112.30	97.61	98.40
Sep-22	26,603			100.33	100.70	115.27	113.02	97.47	98.25
Oct-22	26,603			100.27	100.63	117.03	113.02	97.32	98.11
Nov-22	26,603			100.20	100.50	118.53	114.47	97.18	97.82
Dec-22	26,603			100.13	100.43	119.28	115.20	96.90	97.68
Jan-23	26,603			100.07	100.37	120.05	115.93	96.75	97.54
Feb-23	26,603			99.94	100.30	120.84	116.67	96.61	97.40
Mar-23	26,603			99.88	100.24	121.55	117.42	96.48	97.25
Apr-23	26,603			99.81	100.17	122.34	118.17	96.34	97.11
May-23	26,603			99.74	100.10	123.11	118.92	96.34	96.97
lun-23	26,603			99.74	100.04	123.11	119.68	96.20	96.83
Jul-23	26,603			99.61	99.97	124.69	120.45	95.92	96.69
Aug-23	26,603			99.55	99.91	125.50	121.21	95.78	96.55
Sep-23	26,603			99.48	99.84	126.32	121.99	95.63	96.41
Oct-23	26,603			99.42	99.78	127.11	122.77	95.50	96.27
Nov-23	26,603			99.35	99.71	127.94	123.55	95.35	96.13
	26,603			99.29	99.65	128.75	124.34	95.22	95.99

Utilization Trend	-0.78%	7.92%	-1.73%
RMSE (root mean square error)	13.57	14.68	4.79

MEDICAL UTILIZATION TREND CALCULATION - PHARMACEUTICALS

Bisimilars and Injections with Biosimilas Equivalent - Mix of Services

Services Per 1,000 Members	Biosimilar Equivalent	Injections with Biosimilar Equivalent	Total	Percentage of Biosimilars
YE 201808	0.00	1.18	1.18	0.0%
YE 201908	0.15	1.29	1.44	10.4%
YE 202008	0.34	1.43	1.78	19.3%
YE 202108	0.88	0.96	1.84	47.6%
YE 202212	1.27	0.82	2.09	60.9%
YE 202312	1.63	0.67	2.30	70.9%

Selected Service per 1,000 Trend 10% Expected Growth in Biosimilar Percentage 10%

Overall Trend - Pharmaceuticals Processed through the Medical Benefit


		Biosimilar Equivalent	Injections with Biosimilar Equivalent	Other High Cost Injections	All Other Pharmaceuticals	Total Services
	PMPM	\$4.24	\$7.18	\$24.26	\$12.76	\$48.44
YE 202108	Services per 1,000	0.88	0.96	3.20	106.26	111.30
	Cost Per Service	\$4,848.60	\$7,450.81	\$7,590.53	\$120.07	\$435.21
	Cost per Service Trend	4.9%	4.9%	4.9%	4.9%	4.3%
From YF 202108	Number of Services Trend	64.7%	-19.9%	0.0%	2.5%	2.5%
to YF 2022108	YE 202212 Cost Per Service	\$5,170.72	\$7,945.81	\$8,094.80	\$128.04	\$460.53
10 12 202212	YE 202212 Services per 1,000	1.27	0.82	3.20	109.76	115.04
	YE 202212 PMPM	\$6.58	\$6.48	\$25.87	\$14.05	\$52.98
	Cost per Service Trend	5.8%	5.8%	5.8%	5.8%	5.3%
From YF 202212	Number of Services Trend	28.0%	-18.2%	0.0%	2.3%	2.4%
to YF 202312	YE 202312 Cost Per Service	\$5,469.39	\$8,404.78	\$8,562.38	\$135.44	\$484.81
10 12 202522	YE 202312 Services per 1,000	1.63	0.67	3.20	112.26	117.75
	YE 202312 PMPM	\$8.91	\$5.61	\$27.37	\$15.20	\$57.09

Components	Trend	
Pure Cost	5.4%	
Utilization and Mix	1.8%	
Total	7.20/	

Generic Drugs - Cost Trend

		Monthly	Data			Rolling	12		Exponential Fit		
Incurred				Monthly Cost				Rolling 12			
Date	Supply	AWP Cost	Cost/ Supply	Trend	Supply	AWP Cost	Cost/ Supply	Cost Trend	Monthly Data	Rolling 12 Data	
Sep-17	530,993	\$2,092,125	\$3.94								
Oct-17	572,440	\$2,268,130	\$3.96						\$3.80	\$3.77	
Nov-17	561,280	\$2,175,657	\$3.88						\$3.81	\$3.78	
Dec-17	582,224	\$2,313,798	\$3.97						\$3.81	\$3.79	
Jan-18	584,146	\$2,249,721	\$3.85						\$3.82	\$3.80	
Feb-18	511,143	\$1,991,045	\$3.90						\$3.83	\$3.80	
Mar-18	581,523	\$2,248,310	\$3.87						\$3.84	\$3.81	
Apr-18	558,253	\$2,136,868	\$3.83						\$3.85	\$3.82	
May-18	589,604	\$2,276,095	\$3.86						\$3.86	\$3.83	
Jun-18	554,460	\$2,146,142	\$3.87						\$3.87	\$3.84	
Jul-18	573,193	\$2,264,371	\$3.95						\$3.87	\$3.84	
Aug-18	593,223	\$2,343,513	\$3.95		6,792,482	\$26,505,776	\$3.90		\$3.88	\$3.85	
Sep-18	539,218	\$2,105,025	\$3.90	-0.9%	6,800,707	\$26,518,676	\$3.90		\$3.89	\$3.86	
Oct-18	618,004	\$2,418,512	\$3.91	-1.2%	6,846,271	\$26,669,057	\$3.90		\$3.90	\$3.87	
Nov-18	587,068	\$2,303,108	\$3.92	1.2%	6,872,059	\$26,796,508	\$3.90		\$3.91	\$3.88	
Dec-18	620,202	\$2,415,131	\$3.89	-2.0%	6,910,037	\$26,897,841	\$3.89		\$3.92	\$3.88	
Jan-19	638,354	\$2,547,958	\$3.99	3.6%	6,964,245	\$27,196,078	\$3.91		\$3.93	\$3.89	
Feb-19	574,996	\$2,293,169	\$3.99	2.4%	7,028,098	\$27,498,202	\$3.91		\$3.94	\$3.90	
Mar-19	646,894	\$2,553,847	\$3.95	2.1%	7,093,469	\$27,803,739	\$3.92		\$3.94	\$3.91	
Apr-19	644,565	\$2,553,392	\$3.96	3.5%	7,179,781	\$28,220,263	\$3.93		\$3.95	\$3.92	
May-19	641,753	\$2,558,223	\$3.99	3.3%	7,231,930	\$28,502,391	\$3.94		\$3.96	\$3.92	
Jun-19	618,623	\$2,422,672	\$3.92	1.2%	7,296,093	\$28,778,921	\$3.94		\$3.97	\$3.93	
Jul-19	656,633	\$2,587,258	\$3.94	-0.3%	7,379,533	\$29,101,809	\$3.94		\$3.98	\$3.94	
Aug-19	633,275	\$2,556,365	\$4.04	2.2%	7,419,585	\$29,314,660	\$3.95	1.2%	\$3.99	\$3.95	
Sep-19	623,948	\$2,520,638	\$4.04	3.5%	7,504,315	\$29,730,274	\$3.96	1.6%	\$4.00	\$3.96	
Oct-19	677,086	\$2,713,765	\$4.01	2.4%	7,563,397	\$30,025,527	\$3.97	1.9%	\$4.01	\$3.96	
Nov-19	615,541	\$2,487,400	\$4.04	3.0%	7,591,870	\$30,209,819	\$3.98	2.0%	\$4.02	\$3.97	
Dec-19	698,083	\$2,850,096	\$4.08	4.8%	7,669,751	\$30,644,783	\$4.00	2.6%	\$4.02	\$3.98	
Jan-20	692,039	\$2,770,054	\$4.00	0.3%	7,723,436	\$30,866,879	\$4.00	2.3%	\$4.03	\$3.99	
Feb-20	624,626	\$2,578,623	\$4.13	3.5%	7,773,066	\$31,152,334	\$4.01	2.4%	\$4.04	\$4.00	
Mar-20	796,496	\$3,171,644	\$3.98	0.9%	7,922,668	\$31,770,131	\$4.01	2.3%	\$4.05	\$4.01	
Apr-20	644,728	\$2,564,188	\$3.98	0.4%	7,922,831	\$31,780,926	\$4.01	2.1%	\$4.06	\$4.01	
May-20	617,848	\$2,509,226	\$4.06	1.9%	7,898,926	\$31,731,929	\$4.02	1.9%	\$4.07	\$4.02	
Jun-20	687,347	\$2,703,855	\$3.93	0.4%	7,967,650	\$32,013,112	\$4.02	1.9%	\$4.08	\$4.03	
Jul-20	684,543	\$2,826,044	\$4.13	4.8%	7,995,560	\$32,251,898	\$4.03	2.3%	\$4.09	\$4.04	
Aug-20	669,075	\$2,723,399	\$4.07	0.8%	8,031,360	\$32,418,932	\$4.04	2.2%	\$4.10	\$4.05	
Sep-20	675,725	\$2,742,413	\$4.06	0.5%	8,083,137	\$32,640,708	\$4.04	1.9%	\$4.11	\$4.06	
Oct-20	689,087	\$2,868,515	\$4.16	3.9%	8,095,138	\$32,795,458	\$4.05	2.1%	\$4.11	\$4.06	
Nov-20	684,546	\$2,833,902	\$4.14	2.4%	8,164,143	\$33,141,960	\$4.06	2.0%	\$4.12	\$4.07	
Dec-20	749,027	\$3,154,531	\$4.21	3.2%	8,215,087	\$33,446,396	\$4.07	1.9%	\$4.13	\$4.08	
Jan-21	703,896	\$2,936,183	\$4.17	4.2%	8,226,944	\$33,612,524	\$4.09	2.2%	\$4.14	\$4.09	
Feb-21	650,150	\$2,690,164	\$4.14	0.2%	8,252,468	\$33,724,065	\$4.09	2.0%	\$4.15	\$4.10	
Mar-21	781,327	\$3,224,370	\$4.13	3.6%	8,237,299	\$33,776,791	\$4.10	2.3%	\$4.16	\$4.11	
Apr-21	728,267	\$3,042,239	\$4.18	5.0%	8,320,838	\$34,254,842	\$4.12	2.6%	\$4.17	\$4.11	
May-21	705,474	\$2,941,573	\$4.17	2.7%	8,408,464	\$34,687,188	\$4.13	2.7%	\$4.18	\$4.12	
Jun-21	760,414	\$3,226,882	\$4.24	7.9%	8,481,531	\$35,210,215	\$4.15	3.3%	\$4.19	\$4.13	
Jul-21	689,497	\$2,887,366	\$4.19	1.4%	8,486,485	\$35,271,537	\$4.16	3.0%	\$4.20	\$4.14	
Aug-21	736,902	\$3,095,281	\$4.20	3.2%	8,554,312	\$35,643,419	\$4.17	3.2%	\$4.21	\$4.15	

3.2% 2.7% 2.5%



Regressions

24 Months on Monthly 1.000 0.163 0.000 0.574 0.589 0.013 31.587 22.000

 24 Months on Annual

 1.000
 0.205

 0.000
 0.117


 0.967
 0.003

 654.629
 22.000

Brand Drugs - Cost Trend

٦	-	Month	ly Data			Rolling	12	-	Exponential Fit		
Incurred				Monthly Cost				Rolling 12			
Date	Supply	AWP Cost	Cost/ Supply	Trend	Supply	AWP Cost	Cost/ Supply	Cost Trend	Monthly Data	Rolling 12 Data	
Sep-17	48,392	\$812,410	\$16.79								
Oct-17	56,861	\$893,173	\$15.71						\$13.42	\$14.91	
Nov-17	54,061	\$859,319	\$15.90						\$13.56	\$15.01	
Dec-17	60,361	\$941,578	\$15.60						\$13.70	\$15.10	
Jan-18	51,049	\$815,271	\$15.97						\$13.84	\$15.20	
Feb-18	45,828	\$794,469	\$17.34						\$13.99	\$15.30	
Mar-18	53,487	\$869,628	\$16.26						\$14.13	\$15.39	
Apr-18	50,963	\$890,070	\$17.47						\$14.28	\$15.49	
May-18	53,261	\$912,217	\$17.13						\$14.42	\$15.59	
Jun-18	53,506	\$918,013	\$17.16		527,769	\$8,706,149			\$14.58	\$15.69	
Jul-18	49,887	\$879,853	\$17.64		577,656	\$9,586,002			\$14.73	\$15.79	
Aug-18	55,208	\$1,028,147	\$18.62		632,864	\$10,614,149	\$16.77		\$14.88	\$15.89	
Sep-18	50,828	\$859,722	\$16.91	0.8%	635,300	\$10,661,461	\$16.78		\$15.04	\$16.00	
Oct-18	57,743	\$1,065,945	\$18.46	17.5%	636,182	\$10,834,232	\$17.03		\$15.20	\$16.10	
Nov-18	55,619	\$971,705	\$17.47	9.9%	637,740	\$10,946,618	\$17.16		\$15.36	\$16.20	
Dec-18	60,839	\$1,046,899	\$17.21	10.3%	638,218	\$11,051,939	\$17.32		\$15.52	\$16.30	
Jan-19	54,694	\$926,425	\$16.94	6.1%	641,863	\$11,163,093	\$17.39		\$15.68	\$16.41	
Feb-19	51,544	\$897,996	\$17.42	0.5%	647,579	\$11,266,620	\$17.40		\$15.85	\$16.52	
Mar-19	53,228	\$895,117	\$16.82	3.4%	647,320	\$11,292,109	\$17.44		\$16.00	\$16.61	
Apr-19	50,809	\$953,382	\$18.76	7.4%	647,166	\$11,355,421	\$17.55		\$16.17	\$16.72	
May-19	55,701	\$1,007,392	\$18.09	5.6%	649,606	\$11,450,597	\$17.63		\$16.34	\$16.83	
Jun-19	50,375	\$932,998	\$18.52	7.9%	646,475	\$11,465,581	\$17.74		\$16.51	\$16.94	
Jul-19	54,509	\$1,029,924	\$18.89	7.1%	651,097	\$11,615,652	\$17.84		\$16.68	\$17.05	
Aug-19	54,039	\$1,003,030	\$18.56	-0.3%	649,928	\$11,590,535	\$17.83	6.3%	\$16.86	\$17.16	
Sep-19	53,738	\$972,854	\$18.10	7.0%	652,838	\$11,703,667	\$17.93	6.8%	\$17.04	\$17.27	
Oct-19	54,691	\$891,845	\$16.31	-11.7%	649,786	\$11,529,567	\$17.74	4.2%	\$17.22	\$17.38	
Nov-19	55,624	\$938,885	\$16.88	-3.4%	649,791	\$11,496,747	\$17.69	3.1%	\$17.40	\$17.49	
Dec-19	62,178	\$1,105,094	\$17.77	3.3%	651,130	\$11,554,942	\$17.75	2.5%	\$17.58	\$17.60	
Jan-20	50,438	\$851,312	\$16.88	-0.4%	646,874	\$11,479,829	\$17.75	2.0%	\$17.77	\$17.72	
Feb-20	51,408	\$934,897	\$18.19	4.4%	646,738	\$11,516,730	\$17.81	2.4%	\$17.95	\$17.83	
Mar-20	63,108	\$1,097,676	\$17.39	3.4%	656,618	\$11,719,289	\$17.85	2.3%	\$18.13	\$17.94	
Apr-20	45,623	\$850,246	\$18.64	-0.7%	651,432	\$11,616,153	\$17.83	1.6%	\$18.33	\$18.06	
May-20	47,886	\$935,997	\$19.55	8.1%	643,617	\$11,544,757	\$17.94	1.8%	\$18.51	\$18.17	
Jun-20	47,339	\$925,625	\$19.55	5.6%	640,581	\$11,537,385	\$18.01	1.6%	\$18.71	\$18.29	
Jul-20	49,209	\$984,928	\$20.02	5.9%	635,281	\$11,492,390	\$18.09	1.4%	\$18.90	\$18.41	
Aug-20	50,010	\$974,031	\$19.48	4.9%	631,252	\$11,463,390	\$18.16	1.8%	\$19.11	\$18.53	
Sep-20	45,985	\$891,503	\$19.39	7.1%	623,499	\$11,382,039	\$18.26	1.8%	\$19.31	\$18.65	
Oct-20	51,787	\$944,481	\$18.24	11.8%	620,595	\$11,434,675	\$18.43	3.8%	\$19.51	\$18.77	
Nov-20	48,235	\$890,290	\$18.46	9.4%	613,206	\$11,386,081	\$18.57	4.9%	\$19.72	\$18.89	
Dec-20	57,380	\$1,095,787	\$19.10	7.4%	608,408	\$11,376,773	\$18.70	5.4%	\$19.92	\$19.01	
Jan-21	46,696	\$942,944	\$20.19	19.6%	604,666	\$11,468,405	\$18.97	6.9%	\$20.13	\$19.13	
Feb-21	43,818	\$906,421	\$20.69	13.7%	597,076	\$11,439,929	\$19.16	7.6%	\$20.35	\$19.26	
Mar-21	52,506	\$1,143,426	\$21.78	25.2%	586,474	\$11,485,679	\$19.58	9.7%	\$20.54	\$19.37	
Apr-21	50,987	\$1,086,613	\$21.31	14.4%	591,838	\$11,722,046	\$19.81	11.1%	\$20.76	\$19.50	
May-21	48,883	\$1,056,035	\$21.60	10.5%	592,835	\$11,842,084	\$19.98	11.4%	\$20.97	\$19.62	
Jun-21	53,577	\$1,135,567	\$21.20	8.4%	599,073	\$12,052,026	\$20.12	11.7%	\$21.20	\$19.75	
Jul-21	44,715	\$905,976	\$20.26	1.2%	594,579	\$11,973,074	\$20.14	11.3%	\$21.41	\$19.87	
Aug-21	48,500	\$1,043,877	\$21.52	10.5%	593,069	\$12,042,919	\$20.31	11.8%	\$21.64	\$20.00	






Regressions


24 Months on Monthly
1.000 0.000
0.000 1.820
0.757 0.043
68.374 22.000

24 Months on Annual 1.000 0.002 0.000 0.718 0.883 0.017 165.931 22.000

Non-Specialty Drugs - Utilization Trend


		Monthly Data			Rolling 12		Normaliz	ation for Pharm	acy Days		Smo	othed		Exponential	Fit - 24 months	Exponential	Fit - 36 months
					_			Normalization	6				0.1140				
			Supply per			Supply per		for Pharmacy	Supply - Adjusted for	Smoothing	Smoothed	Smoothed	Rolling 12 Utilization				
Incurred Date	Membership	Supply	Member	Membership	Supply	Member	Pharmacy Days	Days	Pharmacy Days	Factor	Monthly Supply		Trend	Monthly Data	Rolling 12 Data	Monthly Data	Rolling 12 Data
Sep-17	21,670	600,815	27.73	Wembership	Зирріу	Hichiber	30.00	0.983	28.20	Tuctor	28.20	ronning Suppry	TTCTIO	Wildling Data	noming 12 Duto	Hiomany Data	noning 11 Duto
Oct-17	21,666	652,193	30.10				31.12	1.02	29.51		29.51			30.10	28.08	28.77	28.19
Nov-17	21,746	636,082	29.25				30.29	0.99	29.46		29.46			30.10	28.14	28.80	28.24
Dec-17	21,727	665,388	30.62				29.45	0.97	31.73		31.73			30.10	28.19	28.84	28.29
Jan-18	22,079	654,620	29.65				30.69	1.01	29.47		29.47			30.10	28.24	28.87	28.34
Feb-18	22,144	573,772	25.91				27.98	0.92	28.25		28.25			30.10	28.29	28.91	28.39
Mar-18	22,136	656,043	29.64				31.13	1.02	29.04		29.04			30.10	28.34	28.94	28.43
Apr-18	22,176	629,529	28.39				30.27	0.99	28.62		28.62			30.10	28.39	28.98	28.48
May-18	22,355	663,421	29.68				31.49	1.03	28.75		28.75			30.10	28.45	29.01	28.53
Jun-18	22,397	629,295	28.10				30.00	0.98	28.57		28.57			30.10	28.50	29.05	28.58
Jul-18	22,587	643,766	28.50				30.66	1.01	28.36		28.36			30.10	28.55	29.08	28.63
Aug-18	22,671	669,851	29.55	265,354	7,674,775	28.92	31.71	1.04	28.43		28.43	29.03		30.10	28.60	29.12	28.68
Sep-18	22,650	611,074	26.98	266,334	7,685,034	28.85	29.44	0.97	27.95		27.95	29.00		30.10	28.66	29.15	28.73
Oct-18	22,781	690,387	30.31	267,449	7,723,228	28.88	31.76	1.04	29.11		29.11	28.97		30.10	28.71	29.19	28.78
Nov-18	23,112	664,691	28.76	268,815	7,751,837	28.84	30.27	0.99	28.99		28.99	28.93		30.10	28.76	29.23	28.83
Dec-18	23,083	706,963	30.63	270,171	7,793,412	28.85	29.95	0.98	31.20		31.20	28.90		30.10	28.82	29.26	28.88
Jan-19	24,461	715,248	29.24	272,553	7,854,040	28.82	30.60	1.00	29.15		29.15	28.88		30.10	28.87	29.30	28.93
Feb-19	24,499	649,897	26.53	274,908	7,930,165	28.85	27.98	0.92	28.93		28.93	28.93		30.10	28.92	29.33	28.98
Mar-19	24,539	726,627	29.61	277,311	8,000,749	28.85	30.52	1.00	29.60	0.3387	29.60	28.98		30.10	28.97	29.36	29.03
Apr-19	24,481	720,859	29.45	279,616	8,092,079	28.94	30.97	1.02	29.01	0.3319	29.01	29.01		30.10	29.03	29.40	29.08
May-19	24,525	725,633	29.59	281,786	8,154,291	28.94	31.34	1.03	28.80	0.3295	28.80	29.02		30.10	29.08	29.44	29.13
Jun-19	24,502	697,049	28.45	283,891	8,222,045	28.96	29.44	0.97	29.48	0.3391	29.48	29.09		30.10	29.13	29.47	29.18
Jul-19	24,662	737,412	29.90	285,966	8,315,691	29.08	31.32	1.03	29.12	0.3351	29.12	29.15		30.10	29.19	29.51	29.23
Aug-19	24,669	712,871	28.90	287,964	8,358,711	29.03	31.13	1.02	28.32	0.3258	28.32	29.14	0.4%	30.11	29.24	29.54	29.28
Sep-19	24,629	705,775	28.66	289,943	8,453,412	29.16	29.90	0.98	29.24		29.24	29.24	0.8%	30.11	29.30	29.58	29.33
Oct-19	24,690	760,262	30.79	291,852	8,523,287	29.20	31.49	1.03	29.83		29.83	29.30	1.1%	30.11	29.35	29.62	29.38
Nov-19	24,961	697,905	27.96	293,701	8,556,501	29.13	28.83	0.94	29.59		29.59	29.35	1.4%	30.11	29.40	29.65	29.43
Dec-19	24,950	790,878	31.70	295,568	8,640,416	29.23	30.66	1.01	31.54		31.54	29.39	1.7%	30.11	29.46	29.69	29.48
Jan-20	25,746	764,315	29.69	296,853	8,689,483	29.27	30.52	1.00	29.68		29.68	29.43	1.9%	30.11	29.51	29.72	29.54
Feb-20	25,637	699,021	27.27	297,991	8,738,607	29.33	28.56	0.94	29.13		29.13	29.45	1.8%	30.11	29.57	29.76	29.59
Mar-20	25,636	890,637	34.74	299,088	8,902,617	29.77	31.49	1.03	33.66	1.0160	31.37	29.60	2.1%	30.11	29.62	29.79	29.64
Apr-20	25,560	712,537	27.88	300,167	8,894,295	29.63	30.64 30.15	1.00	27.76 27.41	0.9956	29.90	29.67	2.3%	30.11	29.68 29.73	29.83	29.69
May-20	25,418	688,538	27.09	301,060	8,857,200	29.42		0.99		0.9885	29.22	29.71		30.11		29.87	29.74
Jun-20 Jul-20	25,375 25,241	758,658 756,671	29.90 29.98	301,933 302.512	8,918,809 8,938,068	29.54 29.55	30.97 31.46	1.02	29.45 29.07	1.0174	30.78 30.89	29.81 29.96	2.5%	30.11 30.11	29.79 29.84	29.90 29.94	29.79 29.84
Jui-20 Aug-20	25,241 25,193	743,709	29.98	302,512	8,968,906	29.55	30.85	1.03	29.07	0.9774	30.89 29.45	30.05	3.1%	30.11	29.84	29.94	29.84
Sep-20	25,193	744,158	29.52	303,651	9,007,289	29.66	30.73	1.01	29.20	0.5774	29.43	30.05	2.8%	30.11	29.90	30.01	29.95
Oct-20	25,244	765,651	30.27	304,254	9,007,289	29.62	30.77	1.01	30.02		30.02	30.05	2.6%	30.11	30.01	30.01	30.00
Nov-20	25,293	756,224	29.81	304,664	9,012,678	29.02	29.34	0.96	30.99		30.99	30.18	2.9%	30.11	30.01	30.05	30.05
Dec-20	25,360	833,533	32.87	305,074	9,113,652	29.87	31.12	1.02	32.23		32.23	30.24	2.9%	30.11	30.12	30.12	30.10
Jan-21	26,304	773,674	29.41	305,632	9,123,011	29.85	29.41	0.96	30.51		30.51	30.31	3.0%	30.11	30.17	30.12	30.16
Feb-21	26,271	714,404	27.19	306,266	9,138,394	29.84	27.98	0.92	29.65		29.65	30.36	3.1%	30.11	30.23	30.20	30.21
Mar-21	26,232	860,492	32.80	306,862	9,108,249	29.68	32.13	1.05	31.15		31.15	30.34	2.5%	30.11	30.28	30.23	30.26
Apr-21	26,221	803,954	30.66	307,523	9,199,666	29.92	30.55	1.00	30.62		30.62	30.40	2.4%	30.11	30.34	30.27	30.31
May-21	26,287	778,956	29.63	308,392	9,290,084	30.12	30.48	1.00	29.66		29.66	30.43	2.4%	30.11	30.39	30.30	30.36
Jun-21	26,396	841,066	31.86	309,413	9,372,492	30.29	31.18	1.02	31.18		31.18	30.47	2.2%	30.11	30.45	30.34	30.42
Jul-21	26,610	751,341	28.24	310,782	9,367,162	30.14	30.94	1.01	27.84		27.84	30.21	0.8%	30.11	30.50	30.38	30.47
Aug-21	26,603	802,152	30.15	312,192	9,425,605	30.19	31.49	1.03	29.21		29.21	30.19	0.5%	30.11	30.56	30.41	30.52





Regressions	24 Months	on Monthly
	1.000	29.938
	0.000	1.455
	0.000	0.034


24 Months	on Annual	36 Months	on Monthly	36 Months on Annual		
1.000	2.090	1.000	5.218	1.000	2.454	
0.000	0.189	0.000	0.757	0.000	0.102	
0.900	0.004	0.135	0.033	0.946	0.004	
197.907	22.000	5.298	34.000	596.588	34.000	



Average 17.4% Selected 17.4%

PHARMACY TREND DEVELOPMENT - SPECIALTY TREND CALCULATION

		Monthly Data			Rolling 12		Exponential Fit		
		Contract Adicus:	Total		Contract Adicas - 4	Dalling 12			
Incurred Date	Members	Contract Adjusted Allowed Charges	Specialty PMPM	Members	Contract Adjusted Allowed Charges	Rolling 12 PMPM	Monthly Data	Rolling 12 Dat	
Sep-17	21,670	\$652,536	\$30.11	IVICIIDEIS	Allowed Charges	1 1411 141	\$36.22	\$33.28	
Oct-17	21,666	\$659,654	\$30.45				\$36.68	\$33.71	
Nov-17	21,746	\$695,613	\$31.99				\$37.17	\$34.17	
Dec-17	21,740	\$584,905	\$26.92				\$37.64	\$34.61	
Jan-18	22,079	\$731,509	\$33.13				\$37.04	\$35.08	
Feb-18	22,079	\$604,025	\$27.28						
Mar-18		\$860,741	\$38.88				\$38.64 \$39.10	\$35.55	
Apr-18	22,136 22,176	\$810,379	\$36.54				\$39.10	\$35.99 \$36.47	
May-18	22,355	\$838,544	\$37.51				\$40.12	\$36.95	
Jun-18	22,397	\$763,938	\$34.11				\$40.65	\$37.45	
Jul-18	22,587	\$769,740	\$34.08				\$41.17	\$37.94	
Aug-18	22,671	\$858,267	\$37.86	265,354	\$8,829,851	\$33.28	\$41.71	\$38.45	
Sep-18	22,650	\$749,573	\$33.09	266,334	\$8,926,887	\$33.52	\$42.26	\$38.96	
Oct-18	22,781	\$964,492	\$42.34	267,449	\$9,231,726	\$34.52	\$42.80	\$39.47	
Nov-18	23,112	\$804,182	\$34.79	268,815	\$9,340,295	\$34.75	\$43.36	\$40.01	
Dec-18	23,083	\$881,860	\$38.20	270,171	\$9,637,249	\$35.67	\$43.92	\$40.53	
Jan-19	24,461	\$1,007,651	\$41.19	272,553	\$9,913,392	\$36.37	\$44.49	\$41.07	
Feb-19	24,499	\$980,452	\$40.02	274,908	\$10,289,819	\$37.43	\$45.08	\$41.63	
Mar-19	24,539	\$945,107	\$38.51	277,311	\$10,374,184	\$37.41	\$45.62	\$42.13	
Apr-19	24,481	\$1,107,489	\$45.24	279,616	\$10,671,295	\$38.16	\$46.22	\$42.70	
May-19	24,525	\$1,277,961	\$52.11	281,786	\$11,110,712	\$39.43	\$46.81	\$43.26	
Jun-19	24,502	\$1,053,167	\$42.98	283,891	\$11,399,941	\$40.16	\$47.42	\$43.84	
Jul-19	24,662	\$1,159,844	\$47.03	285,966	\$11,790,045	\$41.23	\$48.03	\$44.41	
Aug-19	24,669	\$1,372,253	\$55.63	287,964	\$12,304,031	\$42.73	\$48.66	\$45.01	
Sep-19	24,629	\$1,244,323	\$50.52	289,943	\$12,798,781	\$44.14	\$49.30	\$45.62	
Oct-19	24,690	\$1,256,065	\$50.87	291,852	\$13,090,354	\$44.85	\$49.93	\$46.22	
Nov-19	24,961	\$1,143,054	\$45.79	293,701	\$13,429,226	\$45.72	\$50.59	\$46.84	
Dec-19	24,950	\$1,379,680	\$55.30	295,568	\$13,927,046	\$47.12	\$51.23	\$47.45	
Jan-20	25,746	\$1,415,859	\$54.99	296,853	\$14,335,254	\$48.29	\$51.91	\$48.09	
Feb-20	25,637	\$1,313,531	\$51.24	297,991	\$14,668,332	\$49.22	\$52.59	\$48.74	
Mar-20	25,636	\$1,569,948	\$61.24	299,088	\$15,293,174	\$51.13	\$53.24	\$49.35	
Apr-20	25,560	\$1,354,267	\$52.98	300,167	\$15,539,952	\$51.77	\$53.94	\$50.02	
May-20	25,418	\$1,314,073	\$51.70	301,060	\$15,576,063	\$51.74	\$54.63	\$50.67	
Jun-20	25,375	\$1,304,785	\$51.42	301,933	\$15,827,682	\$52.42	\$55.35	\$51.35	
Jul-20	25,241	\$1,492,818	\$59.14	302,512	\$16,160,656	\$53.42	\$56.06	\$52.02	
Aug-20	25,193	\$1,290,017	\$51.21	303,036	\$16,078,420	\$53.06	\$56.80	\$52.72	
Sep-20	25,244	\$1,425,486	\$56.47	303,651	\$16,259,582	\$53.55	\$57.54	\$53.44	
Oct-20	25,293	\$1,490,279	\$58.92	304,254	\$16,493,797	\$54.21	\$58.28	\$54.13	
Nov-20	25,371	\$1,429,842	\$56.36	304,664	\$16,780,585	\$55.08	\$59.05	\$54.86	
Dec-20	25,360	\$1,466,845	\$57.84	305,074	\$16,867,750	\$55.29	\$59.80	\$55.58	
Jan-21	26,304	\$1,430,699	\$54.39	305,632	\$16,882,590	\$55.24	\$60.59	\$56.33	
Feb-21	26,271	\$1,574,934	\$59.95	306,266	\$17,143,994	\$55.24	\$61.39	\$57.09	
Mar-21	26,271	\$1,807,901	\$68.92	306,266		\$55.98 \$56.64	\$62.12	\$57.09	
Apr-21		\$1,807,901 \$1,778,983			\$17,381,947		\$62.12		
	26,221		\$67.85	307,523	\$17,806,663	\$57.90	,	\$58.56	
May-21	26,287	\$1,701,653	\$64.73	308,392	\$18,194,243	\$59.00	\$63.74	\$59.33	
Jun-21	26,396	\$1,877,971	\$71.15	309,413	\$18,767,429	\$60.65	\$64.58	\$60.13	
Jul-21	26,610	\$1,555,115	\$58.44	310,782	\$18,829,725	\$60.59	\$65.40	\$60.91	
Aug-21	26,603	\$1,845,677	\$69.38	312,192	\$19,385,386	\$62.09	\$66.26	\$61.73	



24 Months	on Monthly
1.000	0.000
0.000	3.146
0.614	0.074
34.982	22.000

24 Months o	n Rolling 12
1.000	0.000
0.000	0.828
0.960	0.019
528.484	22.000

PHARMACY TREND DEVELOPMENT SUMMARY

		Generic	New Generics	Brands Going Generic	Brand	Vaccines	Over the Counter	Devices	Compounds	Non-Specialty Total	Specialty	Total Pharmac
Experience Period Member Months	m								•			312,192
Experience Period Days Supply	a	7,900,571	653,741	93,630	649,011	7,367	121,934	150,407	6,718	9,583,379	102,106	9,685,485
Experience Period Allowed Charge per Supply	b										\$193.16	
Experience Period Total Allowed Charges	c = a x b									\$18,960,758	\$19,723,088	\$38,683,845
Experience Period PMPM	d = c / m									\$60.73	\$63.18	\$123.91
Utilization Trend	e	1.3%	1.3%	1.3%	1.3%	1.3%	1.3%	1.3%	1.3%	1.3%		
Calculated Annual Trend	f	2.8%	2.8%	0.0%	10.0%	10.0%	0.0%	17.4%	0.0%		16.9%	
Impact on Cost of Brands going Generic	g											
Projected Generic/New Generic Mix	h											
Projected Allowed Charge per Supply	j=b x ((1+f)^(28/12)) x g											
Projected Total Allowed Charges before Contract Changes	k = j x a x ((1+e)^(28/12)) x i											
Projection Period PMPM	I = k/ m											
Annual Trend before Contract Changes	n = (I/d)^(12/28)-1		1.5%	-29.4%			11.5%		_		16.9%	
Reduction of Projected Claims due to Contract Changes	0											
Projected Total Allowed Charges after Contract Changes	p = o x k											
Projected PMPM after Contract Changes	q = p / m											
Impact of Contract Changes on Projected Pharmacy PMPM	r = q / I		<u> </u>	,			·					
Effective Annual Trend	s = (q/d)^(12/28)-1	1								3.0%	1	9.9%

MONTHLY TREND FACTORS

Nonth	
September 2018 1.0420 1.0420 1.0512 1.0018 1.0024	Medical
October 2018 1.0957 1.0997 1.0660 1.0143 1.01197 1.0141 December 2018 1.3013 1.3015 1.1017 1.1129 1.0197 1.0341 December 2018 1.3373 1.3375 1.3512 1.0323 1.0966 Earburay 2019 1.2199 1.2319 1.2322 1.0552 1.0416 March 2019 1.2244 1.2365 1.2367 1.0550 1.0411 May 2019 1.1972 1.2090 1.2093 1.0839 1.0491 June 2019 1.1933 1.2556 1.2559 1.0924 1.0516 July 2019 1.0002 1.3130 1.3133 1.1104 1.0516 July 2019 1.3002 1.3130 1.3133 1.1104 1.0511 July 2019 1.2002 1.2333 1.1462 1.1428 1.1263 1.0567 September 2019 1.1535 1.1670 1.1673 1.1463 1.0562 September 2019 1.2578 1.2726 1.2728	
November 2018 1.1015 1.1017 1.1129 1.0137 1.0341 1.0366 January 2019 1.3124 1.3126 1.3260 1.0409 1.0311 Agri 2019 1.2124 1.2139 1.2312 1.0552 1.0416 March 2019 1.2244 1.2365 1.2367 1.0550 1.0416 March 2019 1.2044 1.2365 1.2367 1.0550 1.0416 March 2019 1.2042 1.2060 1.2093 1.0839 1.0461 May 2019 1.1972 1.2090 1.2093 1.0839 1.0461 June 2019 1.2433 1.2556 1.2559 1.0924 1.0516 July 2019 1.1093 1.1293 1.1265 1.2559 1.0924 1.0516 August 2019 1.1293 1.1426 1.1428 1.1263 1.0667 August 2019 1.1293 1.1426 1.1428 1.1263 1.0567 August 2019 1.1293 1.1426 1.1428 1.1263 1.0567 October 2019 1.2775 1.2926 1.2728 1.1519 1.0617 December 2019 1.2775 1.2926 1.2928 1.1596 1.0643 December 2019 1.2108 1.2250 1.2253 1.1782 1.0668 January 2020 1.2040 1.2182 1.2184 1.1894 1.0701 February 2020 1.2628 1.2768 1.2780 1.2009 1.0733 June 2020 1.2628 1.2768 1.2780 1.2009 1.0733 June 2020 1.2443 1.2582 1.2593 1.2344 1.0765 April 2020 0.7984 0.7163 0.7170 1.2336 1.0798 August 2020 1.2443 1.2582 1.2593 1.2472 1.0663 August 2020 1.2443 1.2582 1.2593 1.2472 1.0663 August 2020 1.2443 1.2582 1.2593 1.2472 1.0663 August 2020 1.2466 1.2311 1.2322 1.2390 1.0995 September 2020 1.2666 1.2311 1.2322 1.2390 1.0995 August 2020 1.2666 1.2311 1.2322 1.2390 1.0995 August 2020 1.2666 1.2311 1.2322 1.2390 1.0995 August 2020 1.2464 1.2580 1.2592 1.2442 1.0866 August 2020 1.2468 1.3590 1.3595 1.3666 1.3077 1.1182 August 2021 1.3571 1.3466 1.3440 1.3450 1.3598 1.1395 August 2021 1.3575 1.3666 1.3460 1.3460 1.3460 1.3460 1.3460 1.3460 1.3461 1.1283 August 2021 1.3575 1.3666 1.3666 1.3977 1.1382 1.1395 1.3666	
December 2018	
January 2019	
February 2019	
March 2019	
April 2019 1.2062 1.2181 1.2183 1.0651 1.0466 May 2019 1.1977 1.2090 1.2093 1.0839 1.0491 June 2019 1.2433 1.2556 1.2559 1.0924 1.0516 July 2019 1.3002 1.3130 1.3133 1.1104 1.0541 August 2019 1.1253 1.1476 1.1478 1.1463 1.0567 September 2019 1.1535 1.1670 1.1673 1.1463 1.0592 October 2019 1.2758 1.2726 1.2728 1.1519 1.0612 November 2019 1.2775 1.2926 1.2928 1.1596 1.0643 December 2019 1.2108 1.2250 1.2253 1.1782 1.0643 December 2019 1.2108 1.2250 1.2283 1.1894 1.0701 February 2020 1.2628 1.2788 1.2780 1.2099 1.0733 March 2020 0.9276 0.9379 0.9388 1.234 1.0765 April	
Nay 2019	
June 2019	
July 2019	
Jugust 2019 1.1293 1.1426 1.1428 1.1263 1.0567 September 2019 1.1535 1.1670 1.1673 1.1463 1.0592 October 2019 1.2778 1.2726 1.2728 1.1519 1.0617 November 2019 1.2775 1.2926 1.2928 1.1596 1.0648 January 2020 1.2040 1.2182 1.2184 1.1894 1.0701 February 2020 1.2628 1.2768 1.2780 1.2009 1.0733 March 2020 0.9276 0.9379 0.9388 1.2324 1.0765 April 2020 0.7084 0.7163 0.7170 1.2336 1.0798 May 2020 0.9780 0.9889 0.9898 1.2278 1.0831 July 2020 1.2443 1.2582 1.2593 1.2347 1.0663 July 2020 1.2442 1.2580 1.2592 1.2442 1.0861 July 2020 1.2442 1.2580 1.2592 1.2442 1.0861 July 2020	
September 2019	
October 2019 1.2578 1.2775 1.2926 1.2728 1.1519 1.0617 November 2019 1.2775 1.2926 1.2928 1.1596 1.0643 December 2019 1.2108 1.2250 1.2253 1.1782 1.0668 January 2020 1.2040 1.2182 1.2184 1.1894 1.0701 February 2020 1.2628 1.2768 1.2760 1.0099 1.0733 March 2020 0.9276 0.9379 0.9388 1.2324 1.0765 April 2020 0.0784 0.7163 0.7170 1.2336 1.0798 May 2020 0.9780 0.9889 0.9888 1.2278 1.081 Jule 2020 1.2443 1.2582 1.2593 1.2347 1.0863 July 2020 1.2442 1.2580 1.2592 1.2442 1.0896 August 2020 1.2166 1.2311 1.2322 1.2390 1.0929 September 2020 1.2661 1.2811 1.2823 1.2428 1.0962	
November 2019	
December 2019	
January 2020	
February 2020	
March 2020 0.9276 0.9379 0.9388 1.2324 1.0765 April 2020 0.7084 0.7163 0.7170 1.2336 1.0788 May 2020 0.9780 0.9889 0.9898 1.2278 1.0831 July 2020 1.2443 1.2582 1.2593 1.2347 1.0863 July 2020 1.2442 1.2580 1.2592 1.2442 1.0866 August 2020 1.2661 1.2311 1.2322 1.2390 1.0929 September 2020 1.2661 1.2811 1.2823 1.2428 1.0962 October 2020 1.1645 1.1784 1.1795 1.2533 1.0995 November 2020 1.13135 1.1470 1.1480 1.2661 1.1028 December 2020 1.2562 1.2711 1.2723 1.2678 1.1062 January 2021 1.3171 1.3346 1.3340 1.2690 1.1092 February 2021 1.3601 1.3782 1.3776 1.2761 1.1122 May	
April 2020 0.7084 0.7163 0.7170 1.2336 1.0798 May 2020 0.9780 0.9889 0.9898 1.2278 1.0831 July 2020 1.2443 1.2582 1.2593 1.2347 1.0863 July 2020 1.2442 1.2580 1.2592 1.2442 1.0896 August 2020 1.2166 1.2311 1.2322 1.2390 1.0929 September 2020 1.2661 1.2811 1.2823 1.2428 1.0962 October 2020 1.1645 1.1784 1.1795 1.2533 1.0995 November 2020 1.2562 1.2711 1.2723 1.2678 1.1062 December 2020 1.2562 1.2711 1.2723 1.2678 1.1062 January 2021 1.3171 1.3346 1.3340 1.2690 1.1092 February 2021 1.3601 1.3782 1.3776 1.2761 1.1122 March 2021 1.3611 1.3792 1.3785 1.3077 1.1182 May 2	
May 2020 0.9780 0.9889 0.9898 1.2278 1.0831 June 2020 1.2443 1.2582 1.2593 1.2347 1.0863 July 2020 1.2442 1.2580 1.2592 1.2442 1.0896 August 2020 1.2166 1.2311 1.2322 1.2390 1.0929 September 2020 1.2661 1.2811 1.2823 1.2428 1.0962 October 2020 1.1645 1.1784 1.1795 1.2533 1.0995 November 2020 1.1345 1.1470 1.1480 1.2641 1.1022 December 2020 1.2562 1.2711 1.2723 1.2678 1.1062 January 2021 1.3171 1.3346 1.3340 1.2690 1.1092 February 2021 1.3601 1.3782 1.3776 1.2761 1.1122 March 2021 1.3270 1.3447 1.3440 1.2837 1.1152 April 2021 1.5489 1.5695 1.5687 1.3254 1.1213 July	
June 2020	
July 2020 1.2442 1.2580 1.2592 1.2442 1.0896 August 2020 1.2166 1.2311 1.2322 1.2390 1.0929 September 2020 1.2661 1.2811 1.2823 1.2428 1.0962 October 2020 1.1645 1.1784 1.1795 1.2533 1.0995 November 2020 1.2562 1.2711 1.2723 1.2678 1.1062 January 2021 1.3171 1.3346 1.3340 1.2690 1.1092 February 2021 1.3601 1.3782 1.3776 1.2761 1.1122 March 2021 1.3601 1.3782 1.3776 1.2761 1.1122 Mary 2021 1.3611 1.3792 1.3785 1.3077 1.1182 May 2021 1.5489 1.5695 1.5687 1.3254 1.1213 July 2021 1.3523 1.3703 1.3696 1.3541 1.1243 July 2021 1.3520 1.3466 1.3460 1.3451 1.1273 August 202	
August 2020 1.2166 1.2311 1.2322 1.2390 1.0929 September 2020 1.2661 1.2811 1.2823 1.2428 1.0962 October 2020 1.1645 1.1784 1.1795 1.2533 1.0995 November 2020 1.1335 1.1470 1.1480 1.2641 1.1028 December 2020 1.2562 1.2711 1.2723 1.2678 1.1062 January 2021 1.3171 1.3346 1.3340 1.2690 1.1092 February 2021 1.3601 1.3782 1.3776 1.2761 1.1122 March 2021 1.3601 1.3782 1.3776 1.2761 1.1122 May 2021 1.3611 1.3792 1.3785 1.3077 1.1182 May 2021 1.5489 1.5695 1.5687 1.3254 1.1213 Jule 2021 1.3523 1.3703 1.3696 1.3541 1.1243 July 2021 1.3260 1.3466 1.3460 1.3451 1.1273 August	
September 2020 1.2661 1.2811 1.2823 1.2428 1.0962 October 2020 1.1645 1.1784 1.1795 1.2533 1.0995 November 2020 1.1335 1.1470 1.1480 1.2641 1.1028 December 2020 1.2562 1.2711 1.2723 1.2678 1.1062 January 2021 1.3171 1.3346 1.3340 1.2690 1.1092 February 2021 1.3601 1.3782 1.3776 1.2761 1.1122 March 2021 1.3270 1.3447 1.3440 1.2837 1.1152 April 2021 1.3611 1.3792 1.3785 1.3077 1.1182 May 2021 1.5489 1.5695 1.5687 1.3254 1.1213 June 2021 1.3523 1.3703 1.3696 1.3541 1.1243 July 2021 1.3260 1.3466 1.3460 1.3451 1.1273 August 2021 1.3303 1.3510 1.3504 1.3723 1.1355 Octob	
October 2020 1.1645 1.1784 1.1795 1.2533 1.0995 November 2020 1.1335 1.1470 1.1480 1.2641 1.1028 December 2020 1.2562 1.2711 1.2723 1.2678 1.1062 January 2021 1.3171 1.3346 1.3340 1.2690 1.1092 February 2021 1.3601 1.3782 1.3776 1.2761 1.1122 March 2021 1.3270 1.3447 1.3440 1.2837 1.1152 April 2021 1.3611 1.3792 1.3785 1.3077 1.1182 May 2021 1.5489 1.5695 1.5687 1.3254 1.1213 June 2021 1.3523 1.3703 1.3696 1.3541 1.1243 July 2021 1.3260 1.3466 1.3460 1.3451 1.1273 August 2021 1.2725 1.2923 1.2917 1.3598 1.1304 September 2021 1.3303 1.3510 1.3504 1.3723 1.1335 Octob	
November 2020 1.1335 1.1470 1.1480 1.2641 1.1028 December 2020 1.2562 1.2711 1.2723 1.2678 1.1062 January 2021 1.3171 1.3346 1.3340 1.2690 1.1092 February 2021 1.3601 1.3782 1.3776 1.2761 1.1122 March 2021 1.3270 1.3447 1.3440 1.2837 1.1152 April 2021 1.3611 1.3792 1.3785 1.3077 1.1182 May 2021 1.5489 1.5695 1.5687 1.3254 1.1213 June 2021 1.3523 1.3703 1.3696 1.3541 1.1243 July 2021 1.3260 1.3466 1.3460 1.3451 1.1273 August 2021 1.2725 1.2923 1.2917 1.3598 1.1304 September 2021 1.3303 1.3510 1.3504 1.3723 1.1335 October 2021 1.34437 1.3646 1.3640 1.3848 1.1365 Nove	
December 2020 1.2562 1.2711 1.2723 1.2678 1.1062 January 2021 1.3171 1.3346 1.3340 1.2690 1.1092 February 2021 1.3601 1.3782 1.3776 1.2761 1.1122 March 2021 1.3270 1.3447 1.3440 1.2837 1.1152 April 2021 1.3611 1.3792 1.3785 1.3077 1.1182 May 2021 1.5489 1.5695 1.5687 1.3254 1.1213 June 2021 1.3523 1.3703 1.3696 1.3541 1.1243 July 2021 1.3260 1.3466 1.3460 1.3451 1.1273 August 2021 1.2725 1.2923 1.2917 1.3598 1.1304 September 2021 1.3303 1.3510 1.3504 1.3723 1.1335 October 2021 1.3447 1.3646 1.3640 1.3848 1.1365 November 2021 1.3463 1.3673 1.3666 1.3975 1.1396 Decem	
January 2021	
February 2021 1.3601 1.3782 1.3776 1.2761 1.1122 March 2021 1.3270 1.3447 1.3440 1.2837 1.1152 April 2021 1.3611 1.3792 1.3785 1.3077 1.1182 May 2021 1.5489 1.5695 1.5687 1.3254 1.1213 June 2021 1.3523 1.3703 1.3696 1.3541 1.1243 July 2021 1.3260 1.3466 1.3460 1.3451 1.1273 August 2021 1.2725 1.2923 1.2917 1.3598 1.1304 September 2021 1.3303 1.3510 1.3504 1.3723 1.1335 October 2021 1.3437 1.3646 1.3640 1.3848 1.1365 November 2021 1.3463 1.3673 1.3666 1.3975 1.1396 December 2021 1.3463 1.3700 1.3693 1.4102 1.4142 January 2022 1.3755 1.3983 1.3962 1.4231 1.458 Februa	
March 2021 1.3270 1.3447 1.3440 1.2837 1.1152 April 2021 1.3611 1.3792 1.3785 1.3077 1.1182 May 2021 1.5489 1.5695 1.5687 1.3254 1.1213 June 2021 1.3523 1.3703 1.3696 1.3541 1.1243 July 2021 1.3260 1.3466 1.3460 1.3451 1.1273 August 2021 1.2725 1.2923 1.2917 1.3598 1.1304 September 2021 1.3303 1.3510 1.3504 1.3723 1.1335 October 2021 1.3437 1.3646 1.3640 1.3848 1.1365 November 2021 1.3463 1.3673 1.3666 1.3975 1.1396 December 2021 1.3490 1.3700 1.3693 1.4102 1.1427 January 2022 1.3787 1.4015 1.3995 1.4361 1.1489 February 2022 1.3815 1.4043 1.4023 1.4493 1.1520 April	
April 2021 1.3611 1.3792 1.3785 1.3077 1.1182 May 2021 1.5489 1.5695 1.5687 1.3254 1.1213 June 2021 1.3523 1.3703 1.3696 1.3541 1.1243 July 2021 1.3260 1.3466 1.3460 1.3451 1.1273 August 2021 1.2725 1.2923 1.2917 1.3598 1.1304 September 2021 1.3303 1.3510 1.3504 1.3723 1.1335 October 2021 1.3437 1.3646 1.3640 1.3848 1.1365 November 2021 1.3463 1.3673 1.3666 1.3975 1.1396 December 2021 1.3490 1.3700 1.3693 1.4102 1.1427 January 2022 1.3755 1.3983 1.3962 1.4231 1.1458 February 2022 1.3787 1.4015 1.3995 1.4361 1.1489 March 2022 1.3815 1.4043 1.4023 1.4493 1.1520 April 2022 1.3843 1.4071 1.4051 1.4625 1.1551 <	
May 2021 1.5489 1.5695 1.5687 1.3254 1.1213 June 2021 1.3523 1.3703 1.3696 1.3541 1.1243 July 2021 1.3260 1.3466 1.3460 1.3451 1.1273 August 2021 1.2725 1.2923 1.2917 1.3598 1.1304 September 2021 1.3303 1.3510 1.3504 1.3723 1.1335 October 2021 1.3437 1.3646 1.3640 1.3848 1.1365 November 2021 1.3463 1.3673 1.3666 1.3975 1.1396 December 2021 1.3490 1.3700 1.3693 1.4102 1.1427 January 2022 1.3755 1.3983 1.3962 1.4231 1.1458 February 2022 1.3787 1.4015 1.3995 1.4361 1.1489 March 2022 1.3815 1.4043 1.4023 1.4493 1.1520 April 2022 1.3843 1.4071 1.4051 1.4625 1.1551 May 2022 1.3843 1.4071 1.4190 1.4759 1.1583 <tr< td=""><td></td></tr<>	
June 2021 1.3523 1.3703 1.3696 1.3541 1.1243 July 2021 1.3260 1.3466 1.3460 1.3451 1.1273 August 2021 1.2725 1.2923 1.2917 1.3598 1.304 September 2021 1.3303 1.3510 1.3504 1.3723 1.1335 October 2021 1.3437 1.3646 1.3640 1.3848 1.1365 November 2021 1.3463 1.3673 1.3666 1.3975 1.1396 December 2021 1.3490 1.3700 1.3693 1.4102 1.1427 January 2022 1.3755 1.3983 1.3962 1.4231 1.1458 February 2022 1.3787 1.4015 1.3995 1.4361 1.1489 March 2022 1.3815 1.4043 1.4023 1.4493 1.1520 April 2022 1.3843 1.4071 1.4051 1.4625 1.1551 May 2022 1.3980 1.4211 1.4190 1.4759 1.1583 June 2022 1.4594 1.4835 1.4813 1.4894 1.1614 <tr< td=""><td></td></tr<>	
July 2021 1.3260 1.3466 1.3460 1.3451 1.1273 August 2021 1.2725 1.2923 1.2917 1.3598 1.1304 September 2021 1.3303 1.3510 1.3504 1.3723 1.335 October 2021 1.3437 1.3646 1.3640 1.3848 1.1365 November 2021 1.3463 1.3673 1.3666 1.3975 1.1396 December 2021 1.3490 1.3700 1.3693 1.4102 1.1427 January 2022 1.3755 1.3983 1.3962 1.4231 1.1458 February 2022 1.3787 1.4015 1.3995 1.4361 1.1489 March 2022 1.3815 1.4043 1.4023 1.4493 1.1520 April 2022 1.3843 1.4071 1.4051 1.4625 1.551 May 2022 1.3980 1.4211 1.4190 1.4759 1.1583 June 2022 1.4594 1.4835 1.4813 1.4894 1.1614 July 2022 1.4728 1.4972 1.4950 1.5030 1.1646	
August 2021 1.2725 1.2923 1.2917 1.3598 1.1304 September 2021 1.3303 1.3510 1.3504 1.3723 1.1335 October 2021 1.3437 1.3646 1.3640 1.3848 1.1365 November 2021 1.3463 1.3673 1.3666 1.3975 1.1396 December 2021 1.3490 1.3700 1.3693 1.4102 1.427 January 2022 1.3755 1.3983 1.3962 1.4231 1.1458 February 2022 1.3787 1.4015 1.3995 1.4361 1.1489 March 2022 1.3815 1.4043 1.4023 1.4493 1.1520 April 2022 1.3843 1.4071 1.4051 1.4625 1.1551 May 2022 1.3980 1.4211 1.4190 1.4759 1.1583 June 2022 1.4594 1.4835 1.4813 1.4894 1.1614 July 2022 1.4728 1.4972 1.4950 1.5030 1.1646 August 2022 1.4648 1.4890 1.4869 1.5306 1.1709 <td></td>	
September 2021 1.3303 1.3510 1.3504 1.3723 1.1335 October 2021 1.3437 1.3646 1.3640 1.3848 1.1365 November 2021 1.3463 1.3673 1.3666 1.3975 1.1396 December 2021 1.3490 1.3700 1.3693 1.4102 1.1427 January 2022 1.3755 1.3983 1.3962 1.4231 1.1458 February 2022 1.3787 1.4015 1.3995 1.4361 1.1489 March 2022 1.3815 1.4043 1.4023 1.4493 1.1520 April 2022 1.3843 1.4071 1.4051 1.4625 1.1551 May 2022 1.3890 1.4211 1.4190 1.4759 1.1583 June 2022 1.4594 1.4835 1.4813 1.4894 1.1614 July 2022 1.4728 1.4972 1.4950 1.5030 1.1646 August 2022 1.4648 1.4890 1.4869 1.5306 1.1709	
October 2021 1.3437 1.3646 1.3640 1.3848 1.1365 November 2021 1.3463 1.3673 1.3666 1.3975 1.1396 December 2021 1.3490 1.3700 1.3693 1.4102 1.1427 January 2022 1.3755 1.3983 1.3962 1.4231 1.458 February 2022 1.3787 1.4015 1.3995 1.4361 1.1489 March 2022 1.3815 1.4043 1.4023 1.4493 1.1520 April 2022 1.3843 1.4071 1.4051 1.4625 1.1551 May 2022 1.3980 1.4211 1.4190 1.4759 1.1583 June 2022 1.4594 1.4835 1.4813 1.4894 1.1614 July 2022 1.4728 1.4972 1.4950 1.5030 1.1646 August 2022 1.4648 1.4890 1.4869 1.5306 1.1709	
November 2021 1.3463 1.3673 1.3666 1.3975 1.1396 December 2021 1.3490 1.3700 1.3693 1.4102 1.1427 January 2022 1.3755 1.3983 1.3962 1.4231 1.1458 February 2022 1.3787 1.4015 1.3995 1.4361 1.1489 March 2022 1.3815 1.4043 1.4023 1.4493 1.1520 April 2022 1.3843 1.4071 1.4051 1.4625 1.1551 May 2022 1.3980 1.4211 1.4190 1.4759 1.1583 June 2022 1.4594 1.4835 1.4813 1.4894 1.1614 July 2022 1.4728 1.4972 1.4950 1.5030 1.1646 August 2022 1.4757 1.5002 1.4980 1.5167 1.1677 September 2022 1.4648 1.4890 1.4869 1.5306 1.1709	
December 2021 1.3490 1.3700 1.3693 1.4102 1.1427 January 2022 1.3755 1.3983 1.3962 1.4231 1.1458 February 2022 1.3787 1.4015 1.3995 1.4361 1.1489 March 2022 1.3815 1.4043 1.4023 1.4493 1.1520 April 2022 1.3843 1.4071 1.4051 1.4625 1.1551 May 2022 1.3980 1.4211 1.4190 1.4759 1.1583 June 2022 1.4594 1.4835 1.4813 1.4894 1.1614 July 2022 1.4728 1.4972 1.4950 1.5030 1.1646 August 2022 1.4757 1.5002 1.4980 1.5167 1.1677 September 2022 1.4648 1.4890 1.4869 1.5306 1.1709	
January 2022 1.3755 1.3983 1.3962 1.4231 1.1458 February 2022 1.3787 1.4015 1.3995 1.4361 1.1489 March 2022 1.3815 1.4043 1.4023 1.4493 1.1520 April 2022 1.3843 1.4071 1.4051 1.4625 1.1551 May 2022 1.3980 1.4211 1.4190 1.4759 1.1583 June 2022 1.4594 1.4835 1.4813 1.4894 1.1614 July 2022 1.4728 1.4972 1.4950 1.5030 1.1646 August 2022 1.4757 1.5002 1.4980 1.5167 1.1677 September 2022 1.4648 1.4890 1.4869 1.5306 1.1709	
February 2022 1.3787 1.4015 1.3995 1.4361 1.1489 March 2022 1.3815 1.4043 1.4023 1.4493 1.1520 April 2022 1.3843 1.4071 1.4051 1.4625 1.1551 May 2022 1.3980 1.4211 1.4190 1.4759 1.1583 June 2022 1.4594 1.4835 1.4813 1.4894 1.1614 July 2022 1.4728 1.4972 1.4950 1.5030 1.1646 August 2022 1.4757 1.5002 1.4980 1.5167 1.1677 September 2022 1.4648 1.4890 1.4869 1.5306 1.1709	
March 2022 1.3815 1.4043 1.4023 1.4493 1.1520 April 2022 1.3843 1.4071 1.4051 1.4625 1.1551 May 2022 1.3980 1.4211 1.4190 1.4759 1.1583 June 2022 1.4594 1.4835 1.4813 1.4894 1.1614 July 2022 1.4728 1.4972 1.4950 1.5030 1.1646 August 2022 1.4757 1.5002 1.4980 1.5167 1.1677 September 2022 1.4648 1.4890 1.4869 1.5306 1.1709	
April 2022 1.3843 1.4071 1.4051 1.4625 1.1551 May 2022 1.3980 1.4211 1.4190 1.4759 1.1583 June 2022 1.4594 1.4835 1.4813 1.4894 1.1614 July 2022 1.4728 1.4972 1.4950 1.5030 1.1646 August 2022 1.4757 1.5002 1.4980 1.5167 1.1677 September 2022 1.4648 1.4890 1.4869 1.5306 1.1709	
May 2022 1.3980 1.4211 1.4190 1.4759 1.1583 June 2022 1.4594 1.4835 1.4813 1.4894 1.1614 July 2022 1.4728 1.4972 1.4950 1.5030 1.1646 August 2022 1.4757 1.5002 1.4980 1.5167 1.1677 September 2022 1.4648 1.4890 1.4869 1.5306 1.1709	
June 2022 1.4594 1.4835 1.4813 1.4894 1.1614 July 2022 1.4728 1.4972 1.4950 1.5030 1.1646 August 2022 1.4757 1.5002 1.4980 1.5167 1.1677 September 2022 1.4648 1.4890 1.4869 1.5306 1.1709	
July 2022 1.4728 1.4972 1.4950 1.5030 1.1646 August 2022 1.4757 1.5002 1.4980 1.5167 1.1677 September 2022 1.4648 1.4890 1.4869 1.5306 1.1709	
August 2022 1.4757 1.5002 1.4980 1.5167 1.1677 September 2022 1.4648 1.4890 1.4869 1.5306 1.1709	
September 2022 1.4648 1.4890 1.4869 1.5306 1.1709	
October 2022 1.4795 1.5039 1.5018 1.5446 1.1741	
November 2022 1.4823 1.5068 1.5046 1.5587 1.1772	
December 2022 1.4852 1.5097 1.5076 1.5730 1.1804	
January 2023 1.5220 1.5471 1.5449 1.5873 1.1836	
February 2023 1.5251 1.5503 1.5480 1.6019 1.1868	
March 2023 1.5281 1.5534 1.5511 1.6165 1.1901	
April 2023 1.5312 1.5565 1.5542 1.6313 1.1933	
May 2023 1.5415 1.5669 1.5466 1.6462 1.1965	
June 2023 1.5446 1.5701 1.5678 1.6612 1.1998	
July 2023 1.5587 1.5846 1.5823 1.6764 1.2030	
August 2023 1.5619 1.5878 1.5855 1.6918 1.2063	
September 2023 1.5505 1.5762 1.5739 1.7072 1.2095	
October 2023 1.5659 1.5919 1.5896 1.7228 1.2128	
November 2023 1.5690 1.5950 1.5927 1.7386 1.2161	
December 2023 1.5721 1.5981 1.5958 1.7545 1.2194	
January 2024 1.6117 1.6384 1.6359 1.7705 1.2227	
February 2024 1.6151 1.6418 1.6394 1.7867 1.2260	
March 2024 1.6183 1.6451 1.6427 1.8030 1.2293	
April 2024 1.6216 1.6485 1.6460 1.8195 1.2327	
May 2024 1.6249 1.6518 1.6493 1.8361 1.2360	
June 2024 1.6283 1.6552 1.6527 1.8529 1.2394	

Vermont Freedom Plan (VFP) and Comprehensive (COMP)

				In-Network	Benefits				Out	of-Network Bene	efits	Relativity Factor
					Office	Specialist		AMB			Out-of-	
index	Product	Deductible	Coinsurance	Out-of-Pocket	Copay	Copay	ER ¹ Copay	Copay	Deductible	Coinsurance	Pocket	Active
1	VFP	\$200	20%	\$800	\$20	\$20			\$400	30%	\$1,600	0.9766
2	VFP	\$300	10%	\$1,300	\$10	\$30	\$100	\$50	\$600	30%	\$2,600	0.9617
3	VFP	\$500	20%	\$1,500	\$20	\$20			\$1,000	30%	\$3,000	0.9228
4	VFP	\$500	20%	\$1,500	\$20	\$40	\$250	\$250	\$1,000	30%	\$3,000	0.9221
5	VFP	\$500	20%	\$1,750	\$20	\$20			\$1,000	30%	\$3,500	0.9131
6	VFP	\$1,000	20%	\$2,300	\$20	\$20	\$100		\$2,000	30%	\$4,600	0.8838
7	VFP	\$1,000	0%	\$2,350	\$25	\$25	\$50	\$50	\$2,000	30%	\$3,500	0.9239
8	VFP	\$1,000	20%	\$3,500	\$25	\$40			\$2,000	30%	\$7,000	0.8294
9	VFP	\$1,000	0%	\$2,000	\$30	\$50	\$150		\$2,000	30%	\$4,000	0.9036
10	VFP	\$1,500	20%	\$3,000	\$25	\$45	\$250	\$250	\$3,000	30%	\$6,000	0.8387
11	VFP	\$2,000	30%	\$3,500	\$20	\$20	\$500		\$3,000	50%	\$6,000	0.8136
12	VFP	\$2,000	20%	\$4,000	\$40	\$40	\$150		\$4,000	30%	\$8,000	0.7981
13	VFP	\$2,500	20%	\$5,000	\$20	\$20			\$5,000	30%	\$10,000	0.7728
14	VFP	\$2,500	20%	\$5,150	\$20	\$40			\$5,000	30%	\$10,300	0.7521
15	VFP	\$2,500	20%	\$6,000	\$20	\$30			\$5,000	30%	\$12,000	0.7452
16	VFP	\$3,000	0%	\$3,000	\$30	\$40	\$200		\$6,000	30%	\$6,000	0.8251
17	VFP	\$3,000	0%	\$4,000	\$30	\$50	\$150		\$6,000	30%	\$8,000	0.8029
18	VFP	\$4,000	0%	\$5,000	\$30	\$50	\$150		\$8,000	30%	\$10,000	0.7689
19	VFP	\$4,000	20%	\$6,000	\$40	\$40	\$150		\$8,000	30%	\$12,000	0.7309
20	VFP	\$5,000	0%	\$5,000	\$25	\$25			\$10,000	30%	\$10,000	0.7292
21	COMP	\$2,000	10%	\$3,000								0.7920
22	COMP	\$3,000	0%	\$3,000								0.7651
23	COMP	\$5,000	0%	\$5,000								0.6790
24	COMP	\$6,550	0%	\$6,550								0.6325
25	COMP	\$6,850	0%	\$6,850								0.6247
26	COMP	\$7,350	0%	\$7,350								0.6126

1. ER Copay: the displayed member copay goes toward the facility allowed charges. Associated physician and ancillary charges are then covered at 100%.

BlueCare LO Options (LO) and Open Access (OAP) Medical Plans

				In-Network	Benefits			Out-of-Network Benefits			Relativity Factor	
					Office	Specialist		AMB			Out-of-	
index	Product	Deductible	Coinsurance	Out-of-Pocket	Copay	Copay	ER1 Copay	Copay	Deductible	Coinsurance	Pocket	Active
1	LO	\$2,500	20%	\$5,000	\$20	\$20						0.6939
2	OAP	\$3,000	0%	\$4,100	\$30	\$30	\$100		\$6,000	30%	\$8,200	0.7457

- 1. ER Copay: the displayed member copay goes toward the facility allowed charges. Associated physician and ancillary charges are then covered at 100%.
- 2. For the LO product, Office and Specialist Copay can be under the deductible.
- 3. LO does not have Out-of-Network benefits.

Vermont Health Partnership (VHP) Medical Plans

				VHP In	-Network E	Benefits			VHF	Out-of-Network	Benefits	Relativity Factor
index	Product	IP	OP	PCP	SCP	ER	AMB	ООРМ	Deductible	Coinsurance	Out-of-Pocket	Active
1	VHP ¹	\$0	\$0	\$10	\$20	\$50	\$50	\$8,700	\$500	30%	\$17,400	0.9432
2	VHP ¹	\$250	\$100	\$15	\$25	\$50	\$50	\$8,700	\$500	30%	\$17,400	0.9294
3	VHP ¹	\$250	\$125	\$20	\$40	\$150	\$0	\$8,700	\$500	30%	\$17,400	0.9073
4	VHP ¹	\$250	\$250	\$20	\$20	\$200	\$100	\$8,700	\$1,000	30%	\$17,400	0.9152
5	VHP ¹	\$500	\$250	\$20	\$30	\$100	\$0	\$8,700	\$500	30%	\$17,400	0.9125
6	VHP ¹	\$750	\$750	\$20	\$30	\$50	\$50	\$8,700	\$500	30%	\$17,400	0.9010

PCP	Primary Care Physician Copay
SCP	Specialist Physician Copay
IP	Inpatient Care Deductible (max of 3/yr per family)
OP	Outpatient Surgery Copay
ER	Emergency Room Copay
AMB	Ambulance Copay
OOPM	Per ACA, all copays accumulate toward the Out of Pocket Maximum

- 1. All VHP Plans have a DME rider benefit of: \$100 deductible, 20% coinsurance, built into the relativity.
- 2. ER Copay: the displayed member copay goes toward the facility allowed charges.

Associated physician and ancillary charges are the covered at 100%.

BlueCare (HMO) Medical Plans

					In-Netw	ork Benefit	:s			Relativity Factor
index	Product	IP	OP	HOSP	PCP	SCP	ER	AMB	ООРМ	Active
1	HMO	\$2,000	\$1,000		\$20	\$30	\$50	\$50	\$8,700	0.9095
2	HMO			\$3,000	\$20	\$30	\$100	\$50	\$8,700	0.8746
3	НМО	\$500	\$200		\$25	\$40	\$150	\$50	\$8,700	0.9160

PCP	Primary Care Physician Copay
SCP	Specialist Physician Copay
IP	Inpatient Care Deductible (max of 2/yr per family)
OP	Outpatient Surgery Copay
HOSP	Combined Inpatient Care & Outpatient Surgery Deductible (max of 2/yr per family)
ER	Emergency Room Copay
AMB	Ambulance Copay
ООРМ	Per ACA, all copays accumulate toward the Out of Pocket Maximum

- 1. All **HMO** Plans have a DME rider benefit of: \$0 deductible, 20% coinsurance, built into the relativity.
- 2. ER Copay: the displayed member copay goes toward the facility allowed charges.
 - Associated physician and ancillary charges are the covered at 100%.
- 3. HMO Plans do not have Out-of-Network benefits.

Prescription Drug Cards

					Copay (\$) /	Coinsurance (%)		,		Relativity
						•		Mail Order			
				Retail	Retail Non-		Mail Order	Non-			
			Retail	Preferred	Preferred	Mail Order	Preferred	Preferred		Diabetic	
Index	Туре	Deductible	Generic	Brand	Brand	Generic	Brand	Brand	OOPM	Supplies	Active
1	CM1	\$100	\$5	40%	60%	\$10	40%	60%	\$1,400	SAAO	0.2274
2	CM2	\$0	\$5	\$50	50%	\$10	\$100	50%	\$1,400	SAAO	0.2388
3	CM2	\$100	\$5	\$50	50%	\$10	\$100	50%	\$1,400	SAAO	0.2308
4	COI	\$0	30%	30%	40%	30%	30%	40%	\$1,400	SAAO	0.2340
5	COI	\$0	50%	50%	50%	50%	50%	50%	\$1,400	SAAO	0.2240
6	COP	\$0	\$10	\$20	\$40	\$20	\$40	\$80	\$1,400	SAAO	0.2748
7	COP	\$0	\$10	\$25	\$50	\$20	\$50	\$100	\$1,400	SAAO	0.2674
8	COP	\$0	\$10	\$30	\$50	\$20	\$60	\$100	\$1,400	SAAO	0.2612
9	COP	\$0	\$10	\$30	\$60	\$20	\$60	\$120	\$1,400	SAAO	0.2606
10	COP	\$0	\$10	\$35	\$60	\$20	\$70	\$120	\$1,400	SAAO	0.2544
11	COP	\$0	\$15	\$25	\$40	\$30	\$50	\$80	\$1,400	SAAO	0.2699
12	COP	\$0	\$15	\$30	\$45	\$30	\$60	\$90	\$1,400	SAAO	0.2632
13	COP	\$0	\$15	\$35	\$50	\$30	\$70	\$100	\$1,400	SAAO	0.2566
14	COP	\$0	\$20	\$40	\$60	\$40	\$80	\$120	\$1,400	SAAO	0.2527
15	COP	\$0	\$20	\$40	\$80	\$40	\$80	\$160	\$1,400	SAAO	0.2518
16	COP	\$0	\$25	\$50	\$75	\$50	\$100	\$150	\$1,400	SAAO	0.2435
17	COP	\$0	\$5	\$15	\$30	\$10	\$30	\$60	\$1,400	SAAO	0.2829
18	COP	\$0	\$5	\$30	\$50	\$10	\$60	\$100	\$1,400	SAAO	0.2616
19	COP	\$50	\$10	\$25	\$50	\$20	\$50	\$100	\$1,400	SAAO	0.2637
20	COP	\$50	\$5	\$10	\$25	\$10	\$20	\$50	\$1,400	SAAO	0.2853
21	COP	\$100	\$10	\$15	\$30	\$20	\$30	\$60	\$1,400	SAAO	0.2749
22	COP	\$100	\$10	\$25	\$45	\$20	\$50	\$90	\$1,400	SAAO	0.2607
23	COP	\$100	\$10	\$30	\$45	\$20	\$60	\$90	\$1,400	SAAO	0.2545
24	COP	\$100	\$10	\$30	\$50	\$20	\$60	\$100	\$1,400	100%	0.2586
25	COP	\$100	\$10	\$30	\$50	\$20	\$60	\$100	\$1,400	SAAO	0.2542
26	COP	\$100	\$10	\$40	\$60	\$20	\$80	\$120	\$1,400	SAAO	0.2417
27	COP	\$100	\$15	\$30	\$45	\$30	\$60	\$90	\$1,400	SAAO	0.2571
28	COP	\$100	\$15	\$40	\$60	\$30	\$80	\$120	\$1,400	SAAO	0.2442
29	COP	\$100	\$5	\$20	\$40	\$10	\$40	\$80	\$1,400	SAAO	0.2661
30	COP	\$150	\$20	\$80	\$100	\$40	\$160	\$200	\$1,400	SAAO	0.2194

^{*} Type: COI = coinsurance; COP = copay; CM1 = combined (COP/COI); CM2 = combined (COP/COP/COI)

^{*} Diabetic: If "100%" then Diabetic medications and supplies are covered at 100% of allowed charges;

If "SAAO" then Diabetic medications and supplies are subject to cost sharing same as any other prescription drug.

BCBSVT Indemnity Consumer Driven Health Plans (CDHPs)

					In-Network				Relativity Facto
					RX OOPM		Drugs After	Diabetic	
index	Product	Deductible	Coinsurance	Out-of-Pocket	Limit ¹	Wellness Rx ²	Deductible ³	Supplies	Active
1	CDHP	\$1,500	0%	\$1,500	\$1,400	N/A	N/A	SAAO	1.1066
2	CDHP	\$1,500	20%	\$2,500	\$1,400	N/A	N/A	SAAO	1.0461
3	CDHP	\$2,000	0%	\$2,000	\$1,400	N/A	N/A	SAAO	1.0605
4	CDHP	\$2,000	20%	\$4,000	\$1,400	N/A	N/A	SAAO	0.9820
5	CDHP	\$2,500	0%	\$2,500	\$1,400	0%	N/A	SAAO	1.0358
6	CDHP	\$2,500	0%	\$2,500	\$1,400	N/A	N/A	SAAO	1.0225
7	CDHP	\$2,500	0%	\$3,500	\$1,400	0%	\$10/\$30/\$50	SAAO	1.0309
8	CDHP	\$2,500	10%	\$3,500	\$1,400	0%	N/A	SAAO	1.0012
9	CDHP	\$2,500	20%	\$3,500	\$1,400	N/A	N/A	SAAO	0.9770
10	CDHP	\$2,500	20%	\$5,000	\$1,400	0%	N/A	SAAO	0.9595
11	CDHP	\$2,600	20%	\$5,000	\$1,400	0%	N/A	SAAO	0.9560
12	CDHP	\$2,700	20%	\$5,000	\$1,400	0%	N/A	SAAO	0.9527
13	CDHP	\$3,000	0%	\$3,000	\$1,400	N/A	\$10/\$35/\$50	SAAO	0.9901
14	CDHP	\$3,000	0%	\$3,000	\$1,400	0%	N/A	SAAO	1.0046
15	CDHP	\$3,000	0%	\$3,000	\$1,400	N/A	N/A	SAAO	0.9901
16	CDHP	\$3,000	20%	\$5,000	\$1,400	0%	N/A	SAAO	0.9435
17	CDHP	\$3,500	0%	\$3,500	\$1,400	0%	N/A	SAAO	0.9775
18	CDHP	\$4,000	0%	\$4,000	\$1,400	0%	N/A	SAAO	0.9534
19	CDHP	\$4,000	20%	\$6,650	\$1,400	0%	N/A	SAAO	0.8930
20	CDHP	\$5,000	0%	\$5,000	\$1,400	0%	N/A	SAAO	0.9127
21	CDHP	\$5,000	0%	\$5,000	\$1,400	N/A	N/A	SAAO	0.8954
22	CDHP	\$6,000	0%	\$6,000	\$1,400	0%	N/A	SAAO	0.8796
23	CDHP	\$6,350	0%	\$6,350	\$1,400	0%	N/A	SAAO	0.8693
24	CDHP	\$6,450	0%	\$6,450	\$1,400	N/A	N/A	SAAO	0.8479
25	CDHP	\$6,550	0%	\$6,550	\$1,400	0%	N/A	SAAO	0.8636
26	CDHP	\$6,550	0%	\$6,550	\$1,400	N/A	N/A	SAAO	0.8450
27	CDHP	\$6,650	0%	\$6,650	\$1,400	0%	N/A	SAAO	0.8609
28	CDHP	\$6,650	0%	\$6,650	\$1,400	N/A	N/A	SAAO	0.8422
29	CDHP	\$6,850	0%	\$6,850	\$1,400	0%	N/A	SAAO	0.8555
30	CDHP	\$7,350	0%	\$7,350	\$1.400	0%	N/A	SAAO	0.8427

^{1.} The Rx OOPM Limit is as described in Vermont Act 171.

^{2.} Wellness Rx: if applicable, cost sharing rules apply before the deductible is satisfied.

The member's cost share for Wellness Rx accumulates toward the Out-of-Pocket Maximum.

^{3.} All other drugs are subject to deductible. Once the deductible is met, drugs are subject to the Drugs After Deductible cost share until the Out-of-Pocket Maximum is met.

TVHP HMO Consumer Driven Health Plans (CDHPs)

					In-Network				Relativity Facto
					RX OOPM		Drugs After	Diabetic	
index	Product	Deductible	Coinsurance	Out-of-Pocket	Limit ¹	Wellness Rx ²	Deductible ³	Supplies	Active
1	CDHP	\$1,500	0%	\$1,500	\$1,400	N/A	N/A	SAAO	1.0281
2	CDHP	\$1,500	20%	\$2,500	\$1,400	N/A	N/A	SAAO	0.9701
3	CDHP	\$2,000	0%	\$2,000	\$1,400	N/A	N/A	SAAO	0.9835
4	CDHP	\$2,000	20%	\$4,000	\$1,400	N/A	N/A	SAAO	0.9092
5	CDHP	\$2,500	0%	\$2,500	\$1,400	0%	N/A	SAAO	0.9606
6	CDHP	\$2,500	0%	\$2,500	\$1,400	N/A	N/A	SAAO	0.9469
7	CDHP	\$2,500	0%	\$3,500	\$1,400	0%	\$10/\$30/\$50	SAAO	0.9557
8	CDHP	\$2,500	10%	\$3,500	\$1,400	0%	N/A	SAAO	0.9279
9	CDHP	\$2,500	20%	\$3,500	\$1,400	N/A	N/A	SAAO	0.9036
10	CDHP	\$2,500	20%	\$5,000	\$1,400	0%	N/A	SAAO	0.8888
11	CDHP	\$2,600	20%	\$5,000	\$1,400	0%	N/A	SAAO	0.8855
12	CDHP	\$2,700	20%	\$5,000	\$1,400	0%	N/A	SAAO	0.8822
13	CDHP	\$3,000	0%	\$3,000	\$1,400	N/A	\$10/\$35/\$50	SAAO	0.9157
14	CDHP	\$3,000	0%	\$3,000	\$1,400	0%	N/A	SAAO	0.9307
15	CDHP	\$3,000	0%	\$3,000	\$1,400	N/A	N/A	SAAO	0.9157
16	CDHP	\$3,000	20%	\$5,000	\$1,400	0%	N/A	SAAO	0.8733
17	CDHP	\$3,500	0%	\$3,500	\$1,400	0%	N/A	SAAO	0.9048
18	CDHP	\$4,000	0%	\$4,000	\$1,400	0%	N/A	SAAO	0.8821
19	CDHP	\$4,000	20%	\$6,650	\$1,400	0%	N/A	SAAO	0.8259
20	CDHP	\$5,000	0%	\$5,000	\$1,400	0%	N/A	SAAO	0.8439
21	CDHP	\$5,000	0%	\$5,000	\$1,400	N/A	N/A	SAAO	0.8262
22	CDHP	\$6,000	0%	\$6,000	\$1,400	0%	N/A	SAAO	0.8128
23	CDHP	\$6,350	0%	\$6,350	\$1,400	0%	N/A	SAAO	0.8031
24	CDHP	\$6,450	0%	\$6,450	\$1,400	N/A	N/A	SAAO	0.7816
25	CDHP	\$6,550	0%	\$6,550	\$1,400	0%	N/A	SAAO	0.7978
26	CDHP	\$6,550	0%	\$6,550	\$1,400	N/A	N/A	SAAO	0.7789
27	CDHP	\$6,650	0%	\$6,650	\$1,400	0%	N/A	SAAO	0.7952
28	CDHP	\$6,650	0%	\$6,650	\$1,400	N/A	N/A	SAAO	0.7764
29	CDHP	\$6,850	0%	\$6,850	\$1,400	0%	N/A	SAAO	0.7902
30	CDHP	\$7,350	0%	\$7,350	\$1,400	0%	N/A	SAAO	0.7783

^{1.} The Rx OOPM Limit is as described in Vermont Act 171.

 $[\]textbf{2. Wellness Rx:} \ \text{if applicable, cost sharing rules apply } \textit{before } \ \text{the deductible is satisfied}.$

^{3.} All other drugs are subject to deductible. Once the deductible is met, drugs are subject to the Drugs After Deductible cost share until the Out-of-Pocket Maximum is met.

Medicare Secondary Vermont Freedom Plan (VFP) and Indemnity J-Plan (JPLAN)

				In-Network	Benefits				Out-	of-Network Bene	fits	Relativity Factor
index	Product	Deductible	Coinsurance	Out-of-Pocket	Office Copay	Specialist Copay	ER ¹ Copay	AMB Copay	Deductible	Coinsurance	Out-of- Pocket	Medicare Secondary
1	JPLAN ²	\$100	20%	\$8,700	\$10	\$10						0.3394
2	JPLAN ²	\$100	20%	\$8,700	\$20	\$20						0.3275
3	VFP	\$0	0%	\$0	\$20	\$20	\$50		\$250	20%	\$1,000	0.3603
4	VFP	\$100	20%	\$500	\$10	\$10			\$200	30%	\$1,000	0.3117
5	VFP	\$1,000	0%	\$2,350	\$25	\$25	\$50	\$50	\$2,000	30%	\$3,500	0.2389
6	VFP	\$1,000	20%	\$3,500	\$25	\$40			\$2,000	30%	\$7,000	0.2028
7	VFP	\$500	20%	\$1,600	\$10	\$10			\$1,000	30%	\$3,000	0.2580

^{1.} ER Copay: the displayed member copay goes toward the facility allowed charges. Associated physician and ancillary charges are then covered at 100%.

^{2.} The J Plan deductible applies only to infusion therapy, DME and prosthetics ambulance.

Medicare Secondary Prescription Drug Cards

					Copay (\$) /	Coinsurance (Relativity	
								Mail Order			
				Retail	Retail Non-		Mail Order	Non-			
			Retail	Preferred	Preferred	Mail Order	Preferred	Preferred		Diabetic	Medicare
Index	Туре	Deductible	Generic	Brand	Brand	Generic	Brand	Brand	OOPM	Supplies	Secondary
1	COP	\$0	\$10	\$20	\$40	\$20	\$40	\$80	\$1,400	SAAO	0.6963
2	COP	\$0	\$15	\$30	\$45	\$30	\$60	\$90	\$1,400	SAAO	0.6573
3	COP	\$0	\$5	\$30	\$50	\$10	\$60	\$100	\$1,400	SAAO	0.6756
4	COP	\$50	\$5	\$10	\$25	\$10	\$20	\$50	\$1,400	SAAO	0.7402
5	COP	\$100	\$10	\$30	\$45	\$20	\$60	\$90	\$1,400	SAAO	0.6489
6	COP	\$100	\$15	\$30	\$45	\$30	\$60	\$90	\$1,400	SAAO	0.6470

^{*} Type: COI = coinsurance; COP = copay; CM1 = combined (COP/COP/COI)

^{*} Diabetic: If "100%" then Diabetic medications and supplies are covered at 100% of allowed charges;

If "SAAO" then Diabetic medications and supplies are subject to cost sharing same as any other prescription drug.

Medicare Secondary Consumer Driven Health Plans (CDHPs)

					In-Network				Relativity Factor
					RX OOPM		Drugs After	Diabetic	
index	Product	Deductible	Coinsurance	Out-of-Pocket	Limit ¹	Wellness Rx ²	Deductible ³	Supplies	Medicare Secondary
1	CDHP	\$2,500	0%	\$2,500	\$1,400	0%	N/A	SAAO	0.8072
2	CDHP	\$3,500	0%	\$3,500	\$1,400	0%	N/A	SAAO	0.7710
3	CDHP	\$5,000	0%	\$5,000	\$1,400	N/A	\$5/\$20/\$40	SAAO	0.6473

- 1. The Rx OOPM Limit is as described in Vermont Act 171.
- 2. Wellness Rx: if applicable, cost sharing rules apply before the deductible is satisfied.

 The member's cost share for Wellness Rx accumulates toward the Out-of-Pocket Maximum.
- 3. All other drugs are subject to deductible. Once the deductible is met, drugs are subject to the Drugs After Deductible cost share until the Out-of-Pocket Maximum is met.

Vermont Freedom Plan (VFP) and Comprehensive (COMP)

				In-Ne	Out-of-Network Benefits							
						Specialist					Out-of-	Leverage
index	Product	Deductible	Coinsurance	Out-of-Pocket	Office Copay	Copay	ER ¹ Copay	AMB Copay	Deductible	Coinsurance	Pocket	Factor
1	VFP	\$200	20%	\$800	\$20	\$20			\$400	30%	\$1,600	1.0044
2	VFP	\$300	10%	\$1,300	\$10	\$30	\$100	\$50	\$600	30%	\$2,600	1.0049
3	VFP	\$500	20%	\$1,500	\$20	\$20			\$1,000	30%	\$3,000	1.0064
4	VFP	\$1,000	20%	\$3,500	\$25	\$40			\$2,000	30%	\$7,000	1.0101
5	VFP	\$1,000	0%	\$2,000	\$30	\$50	\$150		\$2,000	30%	\$4,000	1.0071
6	VFP	\$1,500	20%	\$3,000	\$25	\$45	\$250	\$250	\$3,000	30%	\$6,000	1.0097
7	VFP	\$2,000	30%	\$3,500	\$20	\$20	\$500		\$3,000	50%	\$6,000	1.0107
8	VFP	\$3,000	0%	\$4,000	\$30	\$50	\$150		\$6,000	30%	\$8,000	1.0112
9	VFP	\$4,000	0%	\$5,000	\$30	\$50	\$150		\$8,000	30%	\$10,000	1.0127
10	VFP	\$5,000	0%	\$5,000	\$25	\$25			\$10,000	30%	\$10,000	1.0146
11	COMP	\$2,000	10%	\$3,000								1.0118
12	COMP	\$5,000	0%	\$5,000								1.0172

1. ER Copay: the displayed member copay goes toward the facility allowed charges. Associated physician and ancillary charges are the covered at 100%.

Vermont Health Partnership (VHP) Medical Plans

				VHP In-N	Network Benef	its			VHP O			
index	Product	Inpatient Care Deductible ²	Outpatient Surgery Copay	Office Copay	Specialist Copay	ER ³ Copay	AMB Copay	Out-of- Pocket	Deductible	Coinsurance	Out-of- Pocket	Leverage Factor
1	VHP ¹	\$0	\$0	\$10	\$20	\$50	\$50	\$8,700	\$500	30%	\$17,400	1.0023
2	VHP ¹	\$250	\$100	\$15	\$25	\$50	\$50	\$8,700	\$500	30%	\$17,400	1.0028
3	VHP ¹	\$250	\$250	\$20	\$20	\$200	\$100	\$8,700	\$1,000	30%	\$17,400	1.0033
4	VHP ¹	\$750	\$750	\$20	\$30	\$50	\$50	\$8,700	\$500	30%	\$17,400	1.0040

- 1. All **VHP** Plans have a DME rider benefit of: \$100 deductible, 20% coinsurance, built into the relativity.
- 2. Maximum of 3/yr per family
- 3. ER Copay: the displayed member copay goes toward the facility allowed charges. Associated physician and ancillary charges are then covered at 100%.

BlueCare LO Options (LO) and Open Access (OAP) Medical Plans

				In-Ne	twork Benefits				Out-of-Network Benefits			
						Specialist					Out-of-	Leverage
index	Product	Deductible	Coinsurance	Out-of-Pocket	Office Copay	Copay	ER ¹ Copay	AMB Copay	Deductible	Coinsurance	Pocket	Factor
1	LO ²	\$2,500	20%	\$5,000	\$20	\$20						1.0137
2	OAP	\$3,000	0%	\$4,100	\$30	\$30	\$100		\$6,000	30%	\$8,200	1.0112

- 1. ER Copay: the displayed member copay goes toward the facility allowed charges. Associated physician and ancillary charges are then covered at 100%.
- 2. For the LO product, Office and Specialist Copay can be under the deductible.
- 3. LO does not have Out-of-Network benefits.

BlueCare (HMO) Medical Plans

					In-Network B	enefits				
		Inpatient Care	Outpatient	Combined Inpatient / Outpatient		Specialist				Leverage
index	Product	Deductible ²	Surgery Copay	Deductible ²	Office Copay	Copay	ER ³ Copay	AMB Copay	Out-of-Pocket	Factor
1	HMO ¹	\$2,000	\$1,000		\$20	\$30	\$50	\$50	\$8,700	1.0042
2	HMO ¹			\$3,000	\$20	\$30	\$100	\$50	\$8,700	1.0056
_										

- 1. All **HMO** Plans have a DME rider benefit of: \$0 deductible, 20% coinsurance, built into the relativity.
- 2. Maximum of 2/yr per family
- 3. ER Copay: the displayed member copay goes toward the facility allowed charges. Associated physician and ancillary charges are the covered at 100%.
- 4. HMO Plans do not have Out-of-Network benefits.

BCBSVT Comprehensive Consumer Driven Health Plans (CDHPs)

			In-Network							ge Factor
					RX OOPM	Wellness	Drugs After	Diabetic		
index	Product	Deductible	Coinsurance	Out-of-Pocket	Limit ¹	Rx ²	Deductible ³	Supplies	Medical	Rx
1	CDHP	\$1,500	0%	\$1,500	\$1,400	N/A	N/A	SAAO	1.0079	1.0073
2	CDHP	\$2,500	20%	\$5,000	\$1,400	0%	N/A	SAAO	1.0146	1.0048
3	CDHP	\$3,000	0%	\$3,000	\$1,400	N/A	N/A	SAAO	1.0123	1.0088
4	CDHP	\$5,000	0%	\$5,000	\$1,400	0%	N/A	SAAO	1.0169	1.0050
5	CDHP	\$6,000	0%	\$6,000	\$1,400	0%	N/A	SAAO	1.0185	1.0051
6	CDHP	\$6,850	0%	\$6,850	\$1,400	0%	N/A	SAAO	1.0198	1.0051

TVHP HMO Consumer Driven Health Plans (CDHPs)

			In-Network							e Factor
index	Product	Deductible	Coinsurance	Out-of-Pocket	RX OOPM	Wellness Rx ²	Drugs After Deductible ³	Diabetic Supplies	Medical	Rx
1	CDHP	\$1,500	0%	\$1,500	\$1,400	N/A	N/A	SAAO	1.0083	1.0073
2	CDHP	\$2,500	20%	\$5,000	\$1,400	0%	N/A	SAAO	1.0154	1.0058
3	CDHP	\$3,000	0%	\$3,000	\$1,400	N/A	N/A	SAAO	1.0131	1.0089
4	CDHP	\$5,000	0%	\$5,000	\$1,400	0%	N/A	SAAO	1.0178	1.0060
5	CDHP	\$6,000	0%	\$6,000	\$1,400	0%	N/A	SAAO	1.0195	1.0062
6	CDHP	\$6,850	0%	\$6,850	\$1,400	0%	N/A	SAAO	1.0208	1.0063

- 1. The Rx OOPM Limit is as described in Vermont Act 171.
- 2. Wellness Rx: if applicable, cost sharing rules apply before the deductible is satisfied.

 The member's cost share for Wellness Rx accumulates toward the Out-of-Pocket Maximum.
- 3. All other drugs are subject to deductible. Once the deductible is met, drugs are subject to the Drugs After Deductible cost share until the Out-of-Pocket Maximum is met.

Prescription Drug Cards

					Copay (\$) /	Coinsurance (%)				
								Mail Order			
				Retail	Retail Non-		Mail Order	Non-			
			Retail	Preferred	Preferred	Mail Order	Preferred	Preferred		Diabetic	Leverage
Index	Туре	Deductible	Generic	Brand	Brand	Generic	Brand	Brand	ООРМ	Supplies	Factor
1	CM1	\$100	\$5	40%	60%	\$10	40%	60%	\$1,400	SAAO	1.0075
2	CM2	\$0	\$5	\$50	50%	\$10	\$100	50%	\$1,400	SAAO	1.0052
3	CM2	\$100	\$5	\$50	50%	\$10	\$100	50%	\$1,400	SAAO	1.0063
4	COI	\$0	30%	30%	40%	30%	30%	40%	\$1,400	SAAO	1.0067
5	COI	\$0	50%	50%	50%	50%	50%	50%	\$1,400	SAAO	1.0080
6	COP	\$0	\$10	\$20	\$40	\$20	\$40	\$80	\$1,400	SAAO	1.0043
7	COP	\$0	\$10	\$25	\$50	\$20	\$50	\$100	\$1,400	SAAO	1.0046
8	COP	\$0	\$10	\$30	\$50	\$20	\$60	\$100	\$1,400	SAAO	1.0048
9	COP	\$0	\$10	\$30	\$60	\$20	\$60	\$120	\$1,400	SAAO	1.0049
10	COP	\$0	\$10	\$35	\$60	\$20	\$70	\$120	\$1,400	SAAO	1.0051
11	COP	\$0	\$15	\$25	\$40	\$30	\$50	\$80	\$1,400	SAAO	1.0049
12	COP	\$0	\$15	\$30	\$45	\$30	\$60	\$90	\$1,400	SAAO	1.0052
13	COP	\$0	\$15	\$35	\$50	\$30	\$70	\$100	\$1,400	SAAO	1.0054
14	COP	\$0	\$20	\$40	\$60	\$40	\$80	\$120	\$1,400	SAAO	1.0059
15	COP	\$0	\$20	\$40	\$80	\$40	\$80	\$160	\$1,400	SAAO	1.0060
16	COP	\$0	\$25	\$50	\$75	\$50	\$100	\$150	\$1,400	SAAO	1.0065
17	COP	\$0	\$5	\$15	\$30	\$10	\$30	\$60	\$1,400	SAAO	1.0034
18	COP	\$0	\$5	\$30	\$50	\$10	\$60	\$100	\$1,400	SAAO	1.0042
19	COP	\$50	\$10	\$25	\$50	\$20	\$50	\$100	\$1,400	SAAO	1.0051
20	COP	\$50	\$5	\$10	\$25	\$10	\$20	\$50	\$1,400	SAAO	1.0037
21	COP	\$100	\$10	\$15	\$30	\$20	\$30	\$60	\$1,400	SAAO	1.0049
22	COP	\$100	\$10	\$25	\$45	\$20	\$50	\$90	\$1,400	SAAO	1.0055
23	COP	\$100	\$10	\$30	\$45	\$20	\$60	\$90	\$1,400	SAAO	1.0056
24	COP	\$100	\$10	\$30	\$50	\$20	\$60	\$100	\$1,400	100%	1.0051
25	COP	\$100	\$10	\$30	\$50	\$20	\$60	\$100	\$1,400	SAAO	1.0057
26	COP	\$100	\$10	\$40	\$60	\$20	\$80	\$120	\$1,400	SAAO	1.0061
27	COP	\$100	\$15	\$30	\$45	\$30	\$60	\$90	\$1,400	SAAO	1.0059
28	COP	\$100	\$15	\$40	\$60	\$30	\$80	\$120	\$1,400	SAAO	1.0064
29	COP	\$100	\$5	\$20	\$40	\$10	\$40	\$80	\$1,400	SAAO	1.0048
30	COP	\$150	\$20	\$80	\$100	\$40	\$160	\$200	\$1,400	SAAO	1.0079

^{*} Type: COI = coinsurance; COP = copay; CM1 = combined (COP/COI/COI); CM2 = combined (COP/COP/COI)

^{*} Diabetic: If "100%" then Diabetic medications and supplies are covered at 100% of allowed charges;

If "SAAO" then Diabetic medications and supplies are subject to cost sharing same as any other prescription drug.

Tier Factors for Benefits with Separate Medical and Pharmacy Deductibles

		2-Ti	er		3-Tier		4-Tier			
Out-of-Pocket								Subscriber &	Subscriber &	
Range	Type	Single	Family	Single	2-Person	Family	Single	Spouse	Children	Family
NA/Stacked	2x Family	1.000	2.341	1.000	2.000	2.782	1.000	2.000	1.706	2.871
NA/Stacked	2.5x Family	1.000	2.335	1.000	2.000	2.771	1.000	2.000	1.704	2.860
NA/Stacked	3x Family	1.000	2.333	1.000	2.000	2.768	1.000	2.000	1.704	2.856
\$0 - \$3,499	Hybrid	1.000	2.290	1.000	1.847	2.725	1.000	1.932	1.650	2.812
\$3,500 - \$4,999	Hybrid	1.000	2.243	1.000	1.787	2.663	1.000	1.877	1.619	2.748
\$5,000 - \$9,150	Hybrid	1.000	2.251	1.000	1.801	2.677	1.000	1.893	1.635	2.766

Tier Factors for Benefits with Integrated Medical and Pharmacy Deductibles

		2-Ti	er		3-Tier			4-	Tier	
Out-of-Pocket								Subscriber &	Subscriber &	
Range	Type	Single	Family	Single	2-Person	Family	Single	Spouse	Children	Family
NA/Stacked	2x Family	1.000	2.341	1.000	2.000	2.782	1.000	2.000	1.706	2.871
NA/Stacked	2.5x Family	1.000	2.335	1.000	2.000	2.771	1.000	2.000	1.704	2.860
NA/Stacked	3x Family	1.000	2.333	1.000	2.000	2.768	1.000	2.000	1.704	2.856
\$0 - \$3,499	Aggregate	1.000	2.229	1.000	1.764	2.697	1.000	1.850	1.577	2.791
\$3,500 - \$4,999	Aggregate	1.000	2.185	1.000	1.753	2.609	1.000	1.839	1.537	2.699
\$5,000 - \$9,150	Aggregate	1.000	2.158	1.000	1.702	2.589	1.000	1.794	1.523	2.678
\$0 - \$3,499	Hybrid	1.000	2.229	1.000	1.783	2.697	1.000	1.870	1.577	2.791
\$3,500 - \$4,999	Hybrid	1.000	2.209	1.000	1.760	2.632	1.000	1.854	1.559	2.722
\$5,000 - \$9,150	Hybrid	1.000	2.206	1.000	1.778	2.625	1.000	1.865	1.557	2.714

Example of Manual Rate Adjustment

Manual Rate	\$662.04
Average Age/Gender Factor	1.000
Average Industry Factor	1.000
Projection Period	1/1/2023
Trend Factor	8.60%

Group Information	Active	Medi	care Primary
Age/Gender Factor		0.940	1.030
Industry Factor		0.965	1.000
Projection Period		7/1/2023	

Contract Conversion	Contract Distribution	Members	Tier Factor	"Contract Tiers"
Single	25	25	1	25
Two-Person	25	50	2.000	50
Family	50	197	2.782	139.09
	100	272		214.09

		Active	Medicare Primary
Manual Rate	Α	\$662.04	\$497.79
Adjustment for Age/Gender	B = 0.94 / 1	0.9400	1.0300
Adjustment for Industry	C = 0.965 / 1	0.9650	1.0000
Adjustment for Trend	D = 8.6% for 6 months	1.0421	1.0421
Contract Conversion Factor	E = 214.09 / 272	1.2705	1.0000
Adjusted Manual Rate	$F = A \times B \times C \times D \times E$	\$795.12	\$534.31

Industry Factors

2-Digit SIC Code Industry Description	Normalized Factor
01 Agricultural Production - Crops	0.94
02 Agricultural Production - Livestock And Animal Specialties	0.95
07 Agricultural Services	0.94
08 Forestry	0.95
09 Fishing, Hunting And Trapping	1.02
10 Metal Mining	1.08
12 Coal Mining	1.09
13 Oil And Gas Extraction	0.99
14 Mining And Quarrying Of Nonmetallic Minerals, Except Fuels	1.05
15 Building Cnstrctn - General Contractors & Operative Builders	0.96
16 Heavy Cnstrctn, Except Building Construction - Contractors	0.95
17 Construction - Special Trade Contractors	0.99
20 Food And Kindred Products	0.93
21 Tobacco Products	0.9
22 Textile Mill Products	0.93
23 Apparel, Finished Prdcts From Fabrics & Similar Materials	0.94
24 Lumber And Wood Products, Except Furniture	0.9
25 Furniture And Fixtures	0.9.
26 Paper And Allied Products	0.9.
27 Printing, Publishing And Allied Industries	0.9
28 Chemicals And Allied Products	0.9
29 Petroleum Refining And Related Industries	0.9
30 Rubber And Miscellaneous Plastic Products	0.9
31 Leather And Leather Products	0.9
	0.9
32 Stone, Clay, Glass, And Concrete Products	
33 Primary Metal Industries	0.9
34 Fabricated Metal Prdcts, Except Machinery & Transport Eqpmnt	0.9
35 Industrial And Commercial Machinery And Computer Equipment	0.9
36 Electronic, Elctrcl Eqpmnt & Cmpnts, Excpt Computer Eqpmnt	0.9
37 Transportation Equipment	0.9
38 Mesr/Anlyz/Cntrl Instrmnts; Photo/Med/Opt Gds; Watchs/Clocks	0.9
39 Miscellaneous Manufacturing Industries	0.9
40 Railroad Transportation	0.9
41 Local, Suburban Transit & Interurbn Hgwy Passenger Transport	1.0
42 Motor Freight Transportation	1.0
43 United States Postal Service	0.9
44 Water Transportation	0.9
45 Transportation By Air	0.9
46 Pipelines, Except Natural Gas	0.9
47 Transportation Services	0.9
48 Communications	0.8
49 Electric, Gas And Sanitary Services	0.9
50 Wholesale Trade - Durable Goods	0.9
51 Wholesale Trade - Nondurable Goods	0.9
52 Building Matrials, Hrdwr, Garden Supply & Mobile Home Dealrs	0.9
53 General Merchandise Stores	0.9
54 Food Stores	0.9
55 Automotive Dealers And Gasoline Service Stations	1.0
56 Apparel And Accessory Stores	0.9
57 Home Furniture, Furnishings And Equipment Stores	0.9
58 Eating And Drinking Places	1.0
59 Miscellaneous Retail	0.9
60 Depository Institutions	0.9
61 Nondepository Credit Institutions	0.8
62 Security & Commodity Brokers, Dealers, Exchanges & Services	0.9
63 Insurance Carriers	0.9
64 Insurance Agents, Brokers And Service	0.9
65 Real Estate	0.9
67 Holding And Other Investment Offices	0.9
70 Hotels, Rooming Houses, Camps, And Other Lodging Places	1.0
72 Personal Services	0.9
73 Business Services	0.9
75 Automotive Repair, Services And Parking	0.9
76 Miscellaneous Repair Services	0.9
78 Motion Pictures	0.9
79 Amusement And Recreation Services	1.0

Industry Factors

2-Digit	Normalized
SIC Code Industry Description	Factor
80 Health Services	1.0784
81 Legal Services	0.9729
82 Educational Services	0.9309
83 Social Services	1.0784
84 Museums, Art Galleries And Botanical And Zoological Gardens	0.9377
86 Membership Organizations	0.9852
87 Engineering, Accounting, Research, Management & Related Svcs	0.8901
88 Private Households	0.9377
89 Services, Not Elsewhere Classified	0.9416
91 Executive, Legislative & General Government, Except Finance	1.0784
92 Justice, Public Order And Safety	1.0784
93 Public Finance, Taxation And Monetary Policy	0.9940
94 Administration Of Human Resource Programs	1.0002
95 Administration Of Environmental Quality And Housing Programs	0.9924
96 Administration Of Economic Programs	0.9940
97 National Security And International Affairs	1.0245
99 Nonclassifiable Establishments	0.9377

PROJECTED 2023 MLR CALCULATION

BCBSVT

(A)	Manual Rate	\$662.04	Exhibit 4A
(B)	Rebates	\$39.62	Actuarial Memorandum, Section 2.3
(C)	Estimated HCQ	\$2.70	2020 MLR Filing, untrended
(D)	State Mandates and Assessments	\$14.61	Calculation as described on Exhibit 1C, using latest actual PMPM as needed
(E)	MLR Numerator	\$639.72	= (A) - (B) + (C) + (D)
(F)	Projected Claims	\$637.03	= (A) - (B) + (D)
(G)	Net Cost of Reinsurance	\$2.09	Actuarial Memorandum, Section 6.4
(H)	Administrative Charge	\$58.63	Calculation as of January 2023, from Exhibit 5A
(1)	GMCB Billbacks	\$2.31	Actuarial Memorandum, Section 6.8
(J)	Patient-Centered Outcomes Research Institute	\$0.26	Actuarial Memorandum, Section 6.9
(K)	Subtotal	\$700.31	= (F) + (G) + (H) + (I) + (J)
(L)	Total Premium	\$716.44	= (K) / (1 - 0.008 - 0.015)
(M)	Commissions	\$5.38	= (L) x 0.8% (from 2020 MLR filing)
(N)	Contribution to Reserve	\$10.75	= (L) x 1.5% (from Actuarial Memorandum, Section 6.6)
(O)	MLR Denominator	\$716.44	= (L)
(P)	MLR	89.3%	= (E) / (O)

TVHP

			IVHP
(A)	Manual Rate	\$662.04	Exhibit 4A
(B)	Rebates	\$39.62	Actuarial Memorandum, Section 2.3
(C)	Estimated HCQ	\$6.43	2020 MLR Filing, untrended
(D)	State Mandates and Assessments	\$14.61	Calculation as described on Exhibit 1C, using latest actual PMPM as needed
(E)	MLR Numerator	\$643.46	= (A) - (B) + (C) + (D)
(F)	Projected Claims	\$637.03	= (A) - (B) + (D)
(G)	Net Cost of Reinsurance	\$2.09	Actuarial Memorandum, Section 6.4
(H)	Administrative Charge	\$58.63	Calculation as of January 2023, from Exhibit 5A
(1)	GMCB Billbacks	\$2.31	Actuarial Memorandum, Section 6.8
(J)	Patient-Centered Outcomes Research Institute	\$0.26	Actuarial Memorandum, Section 6.9
(K)	Subtotal	\$700.31	= (F) + (G) + (H) + (I) + (J)
(L)	Total Premium	\$727.00	= (J) / (1 - 0.017 - 0.020)
(M)	Commissions	\$12.15	= (L) x 1.7% (from 2020 MLR filing)
(N)	Contribution to Reserve	\$14.54	= (L) x 2.0% (from Actuarial Memorandum, Section 6.6)
(O)	MLR Denominator	\$727.00	= (L)
(P)	MLR	88.5%	= (E) / (O)

BLUE CROSS AND BLUE SHIELD OF VERMONT and THE VERMONT HEALTH PLAN Q3 2022 LARGE GROUP RATING PROGRAM FILING ADMINISTRATIVE CHARGES DEVELOPMENT

Administrative Charges PUPM

Unit		Account	Member	Contract	Invoice Counts	Medical Claim	Projected Claims	Large Group Subtotal	CP Medsup
Administrative Expenses	Α	\$892,082	\$1,281,805	\$367,509	\$4,368	\$453,491	\$1,664,443	\$4,663,698	
Unit Months	В	548	97,941	55,163	776	84,355	48,726,879		
Expense PUPM	C = A / B	\$1,627.89	\$13.09	\$6.66	\$5.63	\$5.38			\$38.62
Increase for Membership	D	10.4%	10.4%	10.4%	10.4%	10.4%			10.4%
Updated Expense PUPM	E = (1+D) x C	\$1,797.82	\$14.45	\$7.36	\$6.22	\$5.94	3.42%		\$42.65
Annual Trend 2021	F	0.0%	0.0%	0.0%	0.0%	0.0%			0.0%
Monthly Trend Factor	$G = (1+F)^{(1/12)}$	1.0000	1.0000	1.0000	1.0000	1.0000			1.0000
Months of Trend to First Effective Period in 2021	Н	12	12	12	12	12			12
Annual Trend 2022	1	2.2%	2.2%	2.2%	2.2%	2.2%			2.2%
Monthly Trend Factor	$J = (1+I)^{(1/12)}$	1.0018	1.0018	1.0018	1.0018	1.0018			1.0018
Months of Trend to First Effective Period in 2022	K	12	12	12	12	12			12

Projection Periods								
Effective Date		Account	Member	Contract	Invoice Counts	Medical Claim	Projected Claims	CP Medsup
Jan-22	$L = E \times G^{(H)} \times J^{(K)}$	\$1,837.52	\$14.77	\$7.52	\$6.35	\$6.07	3.42%	\$43.59
Feb-22	$M = L \times J$	\$1,840.87	\$14.80	\$7.53	\$6.37	\$6.08	3.42%	\$43.67
Mar-22	$N = M \times J$	\$1,844.22	\$14.83	\$7.55	\$6.38	\$6.09	3.42%	\$43.75
Apr-22		\$1,847.58	\$14.85	\$7.56	\$6.39	\$6.10	3.42%	\$43.83
May-22		\$1,850.95	\$14.88	\$7.57	\$6.40	\$6.11	3.42%	\$43.91
Jun-22		\$1,854.32	\$14.91	\$7.59	\$6.41	\$6.12	3.42%	\$43.99
Jul-22		\$1,857.70	\$14.94	\$7.60	\$6.42	\$6.13	3.42%	\$44.07
Aug-22		\$1,861.08	\$14.96	\$7.62	\$6.44	\$6.15	3.42%	\$44.15
Sep-22		\$1,864.48	\$14.99	\$7.63	\$6.45	\$6.16	3.42%	\$44.23
Oct-22		\$1,867.87	\$15.02	\$7.64	\$6.46	\$6.17	3.42%	\$44.31
Nov-22		\$1,871.27	\$15.04	\$7.66	\$6.47	\$6.18	3.42%	\$44.40
Dec-22		\$1,874.68	\$15.07	\$7.67	\$6.48	\$6.19	3.42%	\$44.48
Jan-23		\$1,878.10	\$15.10	\$7.69	\$6.49	\$6.20	3.42%	\$44.56
Feb-23		\$1,881.52	\$15.13	\$7.70	\$6.51	\$6.21	3.42%	\$44.64
Mar-23		\$1,884.95	\$15.15	\$7.71	\$6.52	\$6.22	3.42%	\$44.72
Apr-23		\$1,888.38	\$15.18	\$7.73	\$6.53	\$6.24	3.42%	\$44.80
May-23		\$1,891.82	\$15.21	\$7.74	\$6.54	\$6.25	3.42%	\$44.88
Jun-23		\$1,895.27	\$15.24	\$7.76	\$6.55	\$6.26	3.42%	\$44.96
Jul-23		\$1,898.72	\$15.27	\$7.77	\$6.57	\$6.27	3.42%	\$45.05
Aug-23		\$1,902.18	\$15.29	\$7.78	\$6.58	\$6.28	3.42%	\$45.13
Sep-23		\$1,905.65	\$15.32	\$7.80	\$6.59	\$6.29	3.42%	\$45.21
Oct-23		\$1,909.12	\$15.35	\$7.81	\$6.60	\$6.30	3.42%	\$45.29

MEMBER MONTHS FOR FULL CREDIBILITY BY POOLING POINT

Pooling Limit	Member Months
\$30,000	8,325
\$35,000	9,182
\$40,000	9,990
\$45,000	10,747
\$50,000	11,462
\$55,000	12,142
\$60,000	12,786
\$65,000	13,406
\$70,000	14,002
\$75,000	14,573
\$80,000	15,117
\$85,000	15,633
\$90,000	16,127
\$95,000	16,600
\$100,000	17,055
\$105,000	17,497
\$110,000	17,923
\$115,000	18,338
\$120,000	18,745
\$125,000	19,140
\$130,000	19,523
\$135,000	19,897
\$140,000	•
	20,266
\$145,000	20,624
\$150,000	20,974
\$155,000	21,313
\$160,000	21,643
\$165,000	21,969
\$170,000	22,289
\$175,000	22,600
\$180,000	22,905
\$185,000	23,199
\$190,000	23,486
\$195,000	23,766
\$200,000	24,039
\$205,000	24,307
\$210,000	24,570
\$215,000	24,827
\$220,000	25,077
\$225,000	25,323
\$230,000	25,563
\$235,000	25,799
\$240,000	26,032
\$245,000	26,259
\$250,000	26,480
\$255,000	26,695
\$260,000	26,905
\$265,000	27,111
\$270,000	27,316
\$275,000	27,517
\$280,000	27,712
\$285,000	27,903
\$290,000	28,086
\$295,000	28,262
\$300,000	28,438

POOLING POINT by MEMBERSHIP

Membership (Current Month)	Pooling Limit
0 to 299	\$70,000
300 to 499	\$90,000
500 to 999	\$110,000
1,000 to 1,499	\$145,000
1,500 to 1,999	\$170,000
2,000 to 2,499	\$190,000
2,500 to 2,999	\$215,000
3,000 to 3,999	\$235,000
4,000 to 4,999	\$275,000
5,000 to 7,499	\$300,000
7,500 to 9,999	\$350,000
10,000+	\$400,000

COVID-19 DIAGNOSIS and PROCEDURE CODES

Diagnosis, Procedure, or Vaccine	Diagnosis or Procedure Code
Coronavirus Diagnosis Code	B34.2
Coronavirus Diagnosis Code	B97.21
Coronavirus Diagnosis Code	B97.29
Coronavirus Diagnosis Code	U07.1
Suspected COVID-19, Exposure to Infectious Disease	Z03.818
Suspected exposure to COVID-19	Z20.822
Suspected COVID-19, Exposure to Infectious Disease	Z20.828
Screening for Infectious Disease	Z11.59
COVID-19 Test	U0001
COVID-19 Test	U0002
COVID-19 Test	U0003
COVID-19 Test	U0004
COVID-19 Test	U0005
COVID-19 Test	87635
Specimen Collection	C9803
Specimen Collection	G2023
Specimen Collection	G2024
COVID-19 Test	0202U
COVID-19 Test	0223U
COVID-19 Test	87426
COVID-19 Test	0225U
COVID-19 Test	87636
COVID-19 Test	87637
COVID-19 Test	87811
COVID-19 Test	0240U
COVID-19 Test	0241U
COVID-19 Antibody Test	86328
COVID-19 Antibody Test	86769
COVID-19 Antibody Test	0224U
COVID-19 Antibody Test	86408
COVID-19 Antibody Test	86409
COVID-19 Antibody Test	86413
COVID-19 Antibody Test	0226U
Paxlovid	J8499
Evusheld and Evusheld Administration	Q0220
Evusheld and Evusheld Administration	M0220
Evusheld and Evusheld Administration	M0221
Pfizer-BioNTech COVID-19 Vaccine	91300
Pfizer-BioNTech COVID-19 Vaccine	0001A
Pfizer-BioNTech COVID-19 Vaccine	0002A
Moderna, Inc. Moderna COVID-19 Vaccine	91301
Moderna, Inc. Moderna COVID-19 Vaccine	0011A
Moderna, Inc. Moderna COVID-19 Vaccine	0012A
J&J COVID-19 Vaccine	0031A
J&J COVID-19 Vaccine	91303

AGGREGATE STOP LOSS RATE FACTORS*

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$30,000	5	6	55.709%	53.526%	51.411%	49.359%	47.369%	43.556%	39.944%
\$30,000	10	6	38.213%	35.490%	32.911%	30.482%	28.192%	24.049%	20.504%
\$30,000	15	6	29.289%	26.693%	24.305%	22.111%	20.096%	16.558%	13.576%
\$30,000	20	6	24.815%	22.274%	19.951%	17.832%	15.903%	12.574%	9.884%
\$30,000	25	6	21.689%	19.178%	16.911%	14.878%	13.058%	9.991%	7.591%
\$30,000	50	6	14.105%	11.798%	9.820%	8.135%	6.717%	4.536%	3.055%
\$30,000	100	6	8.821%	6.807%	5.211%	3.970%	3.020%	1.771%	1.108%
\$30,000	150	6	6.692%	4.873%	3.512%	2.520%	1.824%	1.030%	0.691%
\$30,000	200	6	5.490%	3.827%	2.651%	1.852%	1.325%	0.771%	0.579%
\$30,000	300	6	4.133%	2.694%	1.758%	1.183%	0.850%	0.576%	0.514%
\$30,000	400	6	3.337%	2.068%	1.308%	0.886%	0.669%	0.526%	0.503%
\$30,000	500	6	2.838%	1.691%	1.056%	0.737%	0.593%	0.512%	0.502%
\$30,000	600	6	2.486%	1.443%	0.904%	0.656%	0.555%	0.506%	0.501%
\$30,000	700	6	2.187%	1.243%	0.789%	0.601%	0.531%	0.504%	0.501%
\$30,000	800	6	1.962%	1.099%	0.713%	0.566%	0.519%	0.503%	0.501%
\$30,000	900	6	1.795%	0.996%	0.661%	0.544%	0.511%	0.502%	0.501%
\$30,000	1,000	6	1.640%	0.910%	0.623%	0.531%	0.508%	0.502%	0.501%
\$30,000	1,500	6	1.156%	0.675%	0.538%	0.509%	0.503%	0.502%	0.501%
\$30,000	2,000	6	0.912%	0.585%	0.516%	0.505%	0.503%	0.502%	0.501%
\$30,000	3,000	6	0.676%	0.525%	0.506%	0.504%	0.503%	0.502%	0.501%
\$30,000	4,000	6	0.579%	0.510%	0.505%	0.504%	0.503%	0.502%	0.501%
\$30,000	5,000	6	0.538%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$30,000	10,000	6	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$30,000	20,000	6	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$35,000	5	6	57.713%	55.610%	53.575%	51.601%	49.687%	46.022%	42.553%
\$35,000	10	6	40.421%	37.781%	35.238%	32.802%	30.495%	26.272%	22.537%
\$35,000	15	6	30.941%	28.305%	25.875%	23.640%	21.581%	17.965%	14.924%
\$35,000	20	6	26.195%	23.650%	21.320%	19.177%	17.218%	13.808%	11.002%
\$35,000	25	6	22.936%	20.413%	18.123%	16.053%	14.187%	11.009%	8.481%
\$35,000	50	6	14.947%	12.614%	10.595%	8.865%	7.390%	5.094%	3.494%
\$35,000	100	6	9.389%	7.334%	5.686%	4.384%	3.372%	2.012%	1.260%
\$35,000	150	6	7.131%	5.266%	3.847%	2.797%	2.043%	1.155%	0.753%
\$35,000	200	6	5.860%	4.147%	2.911%	2.055%	1.478%	0.846%	0.609%
\$35,000	300	6	4.418%	2.926%	1.933%	1.308%	0.931%	0.604%	0.521%
\$35,000	400	6	3.572%	2.248%	1.435%	0.967%	0.715%	0.537%	0.505%
\$35,000	500	6	3.040%	1.839%	1.153%	0.793%	0.620%	0.517%	0.502%
\$35,000	600	6	2.663%	1.567%	0.979%	0.694%	0.573%	0.509%	0.501%
\$35,000	700	6	2.346%	1.349%	0.848%	0.628%	0.543%	0.505%	0.501%
\$35,000	800	6	2.108%	1.191%	0.760%	0.586%	0.526%	0.503%	0.501%
\$35,000	900	6	1.931%	1.077%	0.699%	0.559%	0.516%	0.502%	0.501%
\$35,000	1,000	6	1.767%	0.981%	0.655%	0.542%	0.511%	0.502%	0.501%
\$35,000	1,500	6	1.249%	0.715%	0.550%	0.511%	0.504%	0.502%	0.501%

^{*} Applied to projected claims under ISL

AGGREGATE STOP LOSS RATE FACTORS*

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$35,000	2,000	6	0.980%	0.608%	0.521%	0.506%	0.503%	0.502%	0.501%
\$35,000	3,000	6	0.714%	0.533%	0.507%	0.504%	0.503%	0.502%	0.501%
\$35,000	4,000	6	0.600%	0.513%	0.505%	0.504%	0.503%	0.502%	0.501%
\$35,000	5,000	6	0.549%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$35,000	10,000	6	0.508%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$35,000	20,000	6	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$40,000	5	6	59.322%	57.285%	55.312%	53.401%	51.549%	47.998%	44.648%
\$40,000	10	6	42.242%	39.696%	37.240%	34.877%	32.601%	28.343%	24.539%
\$40,000	15	6	32.494%	29.832%	27.363%	25.077%	22.972%	19.258%	16.130%
\$40,000	20	6	27.459%	24.896%	22.542%	20.388%	18.416%	14.948%	12.057%
\$40,000	25	6	24.054%	21.526%	19.218%	17.123%	15.222%	11.960%	9.330%
\$40,000	50	6	15.709%	13.352%	11.304%	9.533%	8.010%	5.613%	3.911%
\$40,000	100	6	9.903%	7.813%	6.119%	4.766%	3.702%	2.244%	1.409%
\$40,000	150	6	7.528%	5.624%	4.158%	3.058%	2.253%	1.278%	0.818%
\$40,000	200	6	6.194%	4.440%	3.153%	2.247%	1.624%	0.923%	0.641%
\$40,000	300	6	4.675%	3.138%	2.096%	1.425%	1.012%	0.634%	0.529%
\$40,000	400	6	3.783%	2.415%	1.556%	1.046%	0.762%	0.550%	0.507%
\$40,000	500	6	3.223%	1.976%	1.245%	0.847%	0.649%	0.523%	0.503%
\$40,000	600	6	2.825%	1.682%	1.051%	0.734%	0.591%	0.512%	0.502%
\$40,000	700	6	2.491%	1.448%	0.906%	0.657%	0.555%	0.506%	0.501%
\$40,000	800	6	2.242%	1.277%	0.807%	0.607%	0.534%	0.504%	0.501%
\$40,000	900	6	2.055%	1.154%	0.738%	0.575%	0.521%	0.503%	0.501%
\$40,000	1,000	6	1.884%	1.050%	0.687%	0.555%	0.515%	0.502%	0.501%
\$40,000	1,500	6	1.336%	0.755%	0.563%	0.514%	0.504%	0.502%	0.501%
\$40,000	2,000	6	1.044%	0.631%	0.526%	0.507%	0.503%	0.502%	0.501%
\$40,000	3,000	6	0.751%	0.541%	0.508%	0.504%	0.503%	0.502%	0.501%
\$40,000	4,000	6	0.620%	0.515%	0.505%	0.504%	0.503%	0.502%	0.501%
\$40,000	5,000	6	0.561%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$40,000	10,000	6	0.508%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$40,000	20,000	6	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$45,000	5	6	60.641%	58.656%	56.736%	54.877%	53.072%	49.620%	46.363%
\$45,000	10	6	43.791%	41.318%	38.942%	36.657%	34.453%	30.273%	26.431%
\$45,000	15	6	33.951%	31.290%	28.793%	26.466%	24.315%	20.496%	17.258%
\$45,000	20	6	28.641%	26.056%	23.677%	21.502%	19.510%	15.999%	13.044%
\$45,000	25	6	25.070%	22.540%	20.224%	18.106%	16.178%	12.851%	10.137%
\$45,000	50	6	16.415%	14.041%	11.962%	10.156%	8.594%	6.107%	4.311%
\$45,000	100	6	10.380%	8.258%	6.525%	5.128%	4.018%	2.468%	1.557%
\$45,000	150	6	7.894%	5.954%	4.448%	3.306%	2.455%	1.401%	0.886%
\$45,000	200	6	6.499%	4.711%	3.382%	2.430%	1.766%	1.002%	0.676%
\$45,000	300	6	4.911%	3.335%	2.252%	1.540%	1.093%	0.667%	0.540%
\$45,000	400	6	3.976%	2.569%	1.670%	1.124%	0.811%	0.565%	0.511%
\$45,000	500	6	3.390%	2.105%	1.334%	0.903%	0.680%	0.531%	0.504%

^{*} Applied to projected claims under ISL

AGGREGATE STOP LOSS RATE FACTORS*

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$45,000	600	6	2.973%	1.791%	1.121%	0.774%	0.611%	0.516%	0.503%
\$45,000	700	6	2.624%	1.541%	0.963%	0.686%	0.569%	0.508%	0.501%
\$45,000	800	6	2.364%	1.359%	0.854%	0.630%	0.543%	0.505%	0.501%
\$45,000	900	6	2.169%	1.226%	0.777%	0.592%	0.527%	0.503%	0.501%
\$45,000	1,000	6	1.991%	1.115%	0.720%	0.568%	0.519%	0.502%	0.501%
\$45,000	1,500	6	1.417%	0.795%	0.577%	0.518%	0.505%	0.502%	0.501%
\$45,000	2,000	6	1.106%	0.655%	0.533%	0.508%	0.503%	0.502%	0.501%
\$45,000	3,000	6	0.786%	0.550%	0.509%	0.504%	0.503%	0.502%	0.501%
\$45,000	4,000	6	0.641%	0.518%	0.506%	0.504%	0.503%	0.502%	0.501%
\$45,000	5,000	6	0.573%	0.510%	0.505%	0.504%	0.503%	0.502%	0.501%
\$45,000	10,000	6	0.508%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$45,000	20,000	6	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$50,000	5	6	61.692%	59.749%	57.871%	56.049%	54.283%	50.910%	47.723%
\$50,000	10	6	45.038%	42.628%	40.316%	38.090%	35.944%	31.878%	28.111%
\$50,000	15	6	35.228%	32.579%	30.082%	27.742%	25.559%	21.647%	18.303%
\$50,000	20	6	29.701%	27.097%	24.702%	22.501%	20.478%	16.919%	13.918%
\$50,000	25	6	25.961%	23.425%	21.097%	18.966%	17.021%	13.643%	10.865%
\$50,000	50	6	17.038%	14.655%	12.551%	10.714%	9.119%	6.559%	4.678%
\$50,000	100	6	10.796%	8.648%	6.882%	5.447%	4.299%	2.672%	1.695%
\$50,000	150	6	8.213%	6.244%	4.704%	3.527%	2.640%	1.516%	0.952%
\$50,000	200	6	6.763%	4.948%	3.585%	2.595%	1.896%	1.076%	0.713%
\$50,000	300	6	5.115%	3.508%	2.391%	1.645%	1.168%	0.699%	0.551%
\$50,000	400	6	4.137%	2.700%	1.768%	1.192%	0.855%	0.578%	0.513%
\$50,000	500	6	3.535%	2.218%	1.413%	0.954%	0.710%	0.538%	0.506%
\$50,000	600	6	3.101%	1.886%	1.184%	0.811%	0.631%	0.520%	0.503%
\$50,000	700	6	2.740%	1.622%	1.014%	0.714%	0.582%	0.510%	0.502%
\$50,000	800	6	2.472%	1.432%	0.896%	0.651%	0.552%	0.506%	0.501%
\$50,000	900	6	2.269%	1.292%	0.812%	0.609%	0.534%	0.504%	0.501%
\$50,000	1,000	6	2.085%	1.174%	0.750%	0.581%	0.524%	0.503%	0.501%
\$50,000	1,500	6	1.488%	0.831%	0.591%	0.522%	0.506%	0.502%	0.501%
\$50,000	2,000	6	1.161%	0.678%	0.539%	0.509%	0.504%	0.502%	0.501%
\$50,000	3,000	6	0.819%	0.558%	0.511%	0.504%	0.503%	0.502%	0.501%
\$50,000	4,000	6	0.661%	0.522%	0.506%	0.504%	0.503%	0.502%	0.501%
\$50,000	5,000	6	0.584%	0.511%	0.505%	0.504%	0.503%	0.502%	0.501%
\$50,000	10,000	6	0.509%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$50,000	20,000	6	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$55,000	5	6	62.568%	60.660%	58.814%	57.024%	55.291%	51.981%	48.852%
\$55,000	10	6	46.078%	43.722%	41.459%	39.281%	37.182%	33.213%	29.542%
\$55,000	15	6	36.334%	33.720%	31.239%	28.901%	26.707%	22.736%	19.303%
\$55,000	20	6	30.661%	28.049%	25.636%	23.408%	21.354%	17.738%	14.690%
\$55,000	25	6	26.759%	24.211%	21.869%	19.723%	17.764%	14.344%	11.517%
\$55,000	50	6	17.592%	15.196%	13.076%	11.214%	9.590%	6.963%	5.014%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$55,000	100	6	11.167%	8.999%	7.202%	5.736%	4.554%	2.861%	1.825%
\$55,000	150	6	8.498%	6.504%	4.935%	3.727%	2.810%	1.624%	1.015%
\$55,000	200	6	6.997%	5.158%	3.767%	2.746%	2.014%	1.145%	0.748%
\$55,000	300	6	5.293%	3.660%	2.513%	1.739%	1.236%	0.731%	0.563%
\$55,000	400	6	4.284%	2.821%	1.860%	1.257%	0.899%	0.593%	0.517%
\$55,000	500	6	3.663%	2.318%	1.486%	1.002%	0.738%	0.545%	0.507%
\$55,000	600	6	3.214%	1.971%	1.241%	0.846%	0.650%	0.524%	0.504%
\$55,000	700	6	2.841%	1.694%	1.060%	0.740%	0.594%	0.512%	0.502%
\$55,000	800	6	2.567%	1.498%	0.935%	0.671%	0.561%	0.507%	0.501%
\$55,000	900	6	2.357%	1.350%	0.846%	0.625%	0.540%	0.504%	0.501%
\$55,000	1,000	6	2.168%	1.227%	0.778%	0.594%	0.528%	0.503%	0.501%
\$55,000	1,500	6	1.550%	0.864%	0.604%	0.526%	0.507%	0.502%	0.501%
\$55,000	2,000	6	1.210%	0.699%	0.546%	0.511%	0.504%	0.502%	0.501%
\$55,000	3,000	6	0.849%	0.567%	0.512%	0.504%	0.503%	0.502%	0.501%
\$55,000	4,000	6	0.680%	0.525%	0.506%	0.504%	0.503%	0.502%	0.501%
\$55,000	5,000	6	0.595%	0.512%	0.505%	0.504%	0.503%	0.502%	0.501%
\$55,000	10,000	6	0.509%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$55,000	20,000	6	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$60,000	5	6	63.343%	61.465%	59.646%	57.884%	56.180%	52.923%	49.842%
\$60,000	10	6	46.983%	44.671%	42.450%	40.312%	38.253%	34.368%	30.777%
\$60,000	15	6	37.299%	34.737%	32.296%	29.978%	27.785%	23.792%	20.304%
\$60,000	20	6	31.558%	28.950%	26.527%	24.278%	22.199%	18.525%	15.421%
\$60,000	25	6	27.509%	24.946%	22.589%	20.432%	18.453%	14.996%	12.131%
\$60,000	50	6	18.098%	15.691%	13.558%	11.677%	10.027%	7.342%	5.334%
\$60,000	100	6	11.506%	9.324%	7.500%	6.006%	4.795%	3.042%	1.951%
\$60,000	150	6	8.763%	6.749%	5.154%	3.917%	2.974%	1.732%	1.079%
\$60,000	200	6	7.214%	5.354%	3.938%	2.888%	2.129%	1.212%	0.784%
\$60,000	300	6	5.458%	3.801%	2.628%	1.828%	1.301%	0.762%	0.575%
\$60,000	400	6	4.421%	2.934%	1.948%	1.321%	0.942%	0.609%	0.522%
\$60,000	500	6	3.782%	2.414%	1.555%	1.048%	0.766%	0.553%	0.509%
\$60,000	600	6	3.320%	2.051%	1.297%	0.880%	0.669%	0.528%	0.505%
\$60,000	700	6	2.936%	1.764%	1.105%	0.766%	0.608%	0.515%	0.502%
\$60,000	800	6	2.657%	1.561%	0.974%	0.691%	0.570%	0.508%	0.501%
\$60,000	900	6	2.441%	1.407%	0.879%	0.641%	0.547%	0.505%	0.501%
\$60,000	1,000	6	2.245%	1.278%	0.806%	0.607%	0.533%	0.503%	0.501%
\$60,000	1,500	6	1.608%	0.895%	0.618%	0.530%	0.508%	0.502%	0.501%
\$60,000	2,000	6	1.255%	0.719%	0.552%	0.512%	0.504%	0.502%	0.501%
\$60,000	3,000	6	0.878%	0.575%	0.513%	0.505%	0.503%	0.502%	0.501%
\$60,000	4,000	6	0.698%	0.529%	0.507%	0.504%	0.503%	0.502%	0.501%
\$60,000	5,000	6	0.606%	0.513%	0.505%	0.504%	0.503%	0.502%	0.501%
\$60,000	10,000	6	0.510%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$60,000	20,000	6	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$65,000	5	6	64.025%	62.171%	60.377%	58.641%	56.961%	53.749%	50.712%
\$65,000	10	6	47.779%	45.505%	43.320%	41.216%	39.192%	35.383%	31.859%
\$65,000	15	6	38.147%	35.632%	33.240%	30.962%	28.791%	24.796%	21.281%
\$65,000	20	6	32.394%	29.802%	27.377%	25.116%	23.020%	19.291%	16.129%
\$65,000	25	6	28.224%	25.650%	23.279%	21.107%	19.111%	15.613%	12.712%
\$65,000	50	6	18.574%	16.157%	14.010%	12.116%	10.444%	7.705%	5.642%
\$65,000	100	6	11.824%	9.628%	7.784%	6.264%	5.025%	3.219%	2.079%
\$65,000	150	6	9.012%	6.982%	5.364%	4.100%	3.130%	1.839%	1.144%
\$65,000	200	6	7.420%	5.541%	4.101%	3.026%	2.241%	1.279%	0.822%
\$65,000	300	6	5.613%	3.936%	2.737%	1.914%	1.364%	0.794%	0.587%
\$65,000	400	6	4.552%	3.042%	2.032%	1.382%	0.985%	0.625%	0.527%
\$65,000	500	6	3.894%	2.504%	1.621%	1.093%	0.794%	0.561%	0.510%
\$65,000	600	6	3.420%	2.128%	1.351%	0.915%	0.688%	0.533%	0.506%
\$65,000	700	6	3.026%	1.830%	1.149%	0.791%	0.621%	0.517%	0.503%
\$65,000	800	6	2.741%	1.621%	1.011%	0.712%	0.580%	0.509%	0.501%
\$65,000	900	6	2.520%	1.461%	0.911%	0.657%	0.554%	0.506%	0.501%
\$65,000	1,000	6	2.319%	1.327%	0.834%	0.620%	0.539%	0.504%	0.501%
\$65,000	1,500	6	1.663%	0.925%	0.631%	0.535%	0.509%	0.502%	0.501%
\$65,000	2,000	6	1.299%	0.739%	0.559%	0.514%	0.504%	0.502%	0.501%
\$65,000	3,000	6	0.906%	0.584%	0.515%	0.505%	0.503%	0.502%	0.501%
\$65,000	4,000	6	0.716%	0.533%	0.507%	0.504%	0.503%	0.502%	0.501%
\$65,000	5,000	6	0.617%	0.515%	0.505%	0.504%	0.503%	0.502%	0.501%
\$65,000	10,000	6	0.511%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$65,000	20,000	6	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$70,000	5	6	64.608%	62.775%	61.001%	59.288%	57.629%	54.455%	51.456%
\$70,000	10	6	48.451%	46.208%	44.053%	41.980%	39.987%	36.242%	32.776%
\$70,000	15	6	38.871%	36.399%	34.049%	31.811%	29.677%	25.714%	22.186%
\$70,000	20	6	33.147%	30.574%	28.157%	25.896%	23.790%	20.020%	16.802%
\$70,000	25	6	28.878%	26.303%	23.923%	21.732%	19.721%	16.184%	13.243%
\$70,000	50	6	19.017%	16.591%	14.433%	12.524%	10.835%	8.048%	5.936%
\$70,000	100	6	12.119%	9.911%	8.051%	6.509%	5.243%	3.388%	2.203%
\$70,000	150	6	9.243%	7.199%	5.562%	4.273%	3.279%	1.944%	1.210%
\$70,000	200	6	7.611%	5.715%	4.254%	3.155%	2.347%	1.345%	0.859%
\$70,000	300	6	5.758%	4.062%	2.840%	1.995%	1.425%	0.825%	0.600%
\$70,000	400	6	4.675%	3.144%	2.112%	1.442%	1.026%	0.642%	0.532%
\$70,000	500	6	3.992%	2.582%	1.680%	1.132%	0.819%	0.568%	0.511%
\$70,000	600	6	3.514%	2.202%	1.404%	0.948%	0.707%	0.538%	0.506%
\$70,000	700	6	3.111%	1.894%	1.191%	0.817%	0.635%	0.520%	0.503%
\$70,000	800	6	2.820%	1.677%	1.047%	0.731%	0.590%	0.511%	0.502%
\$70,000	900	6	2.594%	1.512%	0.942%	0.673%	0.561%	0.507%	0.501%
\$70,000	1,000	6	2.388%	1.374%	0.861%	0.633%	0.544%	0.504%	0.501%
\$70,000	1,500	6	1.715%	0.955%	0.644%	0.540%	0.510%	0.502%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$70,000	2,000	6	1.340%	0.758%	0.566%	0.516%	0.505%	0.502%	0.501%
\$70,000	3,000	6	0.933%	0.592%	0.517%	0.505%	0.503%	0.502%	0.501%
\$70,000	4,000	6	0.734%	0.536%	0.507%	0.504%	0.503%	0.502%	0.501%
\$70,000	5,000	6	0.628%	0.516%	0.505%	0.504%	0.503%	0.502%	0.501%
\$70,000	10,000	6	0.511%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$70,000	20,000	6	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$75,000	5	6	65.130%	63.316%	61.562%	59.868%	58.228%	55.088%	52.123%
\$75,000	10	6	49.051%	46.835%	44.707%	42.661%	40.697%	37.007%	33.595%
\$75,000	15	6	39.526%	37.092%	34.779%	32.576%	30.478%	26.578%	23.057%
\$75,000	20	6	33.840%	31.295%	28.894%	26.642%	24.534%	20.738%	17.471%
\$75,000	25	6	29.505%	26.937%	24.557%	22.350%	20.321%	16.746%	13.763%
\$75,000	50	6	19.441%	17.009%	14.842%	12.918%	11.213%	8.386%	6.228%
\$75,000	100	6	12.400%	10.179%	8.305%	6.744%	5.455%	3.554%	2.327%
\$75,000	150	6	9.462%	7.405%	5.751%	4.441%	3.423%	2.046%	1.276%
\$75,000	200	6	7.791%	5.882%	4.401%	3.280%	2.450%	1.410%	0.897%
\$75,000	300	6	5.896%	4.183%	2.940%	2.074%	1.485%	0.856%	0.614%
\$75,000	400	6	4.793%	3.243%	2.189%	1.499%	1.067%	0.659%	0.537%
\$75,000	500	6	4.094%	2.665%	1.742%	1.176%	0.847%	0.577%	0.514%
\$75,000	600	6	3.605%	2.273%	1.455%	0.981%	0.727%	0.543%	0.507%
\$75,000	700	6	3.193%	1.956%	1.233%	0.842%	0.649%	0.523%	0.503%
\$75,000	800	6	2.897%	1.732%	1.082%	0.752%	0.600%	0.513%	0.502%
\$75,000	900	6	2.665%	1.562%	0.973%	0.690%	0.569%	0.508%	0.501%
\$75,000	1,000	6	2.455%	1.420%	0.887%	0.647%	0.550%	0.505%	0.501%
\$75,000	1,500	6	1.765%	0.984%	0.657%	0.545%	0.512%	0.502%	0.501%
\$75,000	2,000	6	1.379%	0.777%	0.573%	0.518%	0.505%	0.502%	0.501%
\$75,000	3,000	6	0.959%	0.601%	0.519%	0.505%	0.503%	0.502%	0.501%
\$75,000	4,000	6	0.751%	0.540%	0.508%	0.504%	0.503%	0.502%	0.501%
\$75,000	5,000	6	0.639%	0.518%	0.506%	0.504%	0.503%	0.502%	0.501%
\$75,000	10,000	6	0.512%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$75,000	20,000	6	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$80,000	5	6	65.611%	63.815%	62.079%	60.402%	58.778%	55.669%	52.736%
\$80,000	10	6	49.595%	47.405%	45.301%	43.280%	41.342%	37.702%	34.337%
\$80,000	15	6	40.129%	37.731%	35.451%	33.281%	31.214%	27.380%	23.899%
\$80,000	20	6	34.493%	31.980%	29.604%	27.365%	25.263%	21.454%	18.151%
\$80,000	25	6	30.117%	27.558%	25.182%	22.971%	20.924%	17.313%	14.287%
\$80,000	50	6	19.849%	17.414%	15.239%	13.301%	11.580%	8.719%	6.519%
\$80,000	100	6	12.670%	10.439%	8.552%	6.973%	5.665%	3.718%	2.450%
\$80,000	150	6	9.670%	7.602%	5.934%	4.603%	3.563%	2.147%	1.344%
\$80,000	200	6	7.965%	6.042%	4.544%	3.402%	2.552%	1.475%	0.934%
\$80,000	300	6	6.028%	4.301%	3.037%	2.152%	1.545%	0.888%	0.628%
\$80,000	400	6	4.906%	3.338%	2.265%	1.556%	1.107%	0.677%	0.542%
\$80,000	500	6	4.192%	2.745%	1.803%	1.219%	0.875%	0.587%	0.516%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$80,000	600	6	3.692%	2.342%	1.505%	1.015%	0.747%	0.549%	0.509%
\$80,000	700	6	3.271%	2.016%	1.275%	0.868%	0.663%	0.527%	0.504%
\$80,000	800	6	2.970%	1.786%	1.117%	0.772%	0.611%	0.514%	0.502%
\$80,000	900	6	2.734%	1.611%	1.003%	0.706%	0.577%	0.509%	0.502%
\$80,000	1,000	6	2.519%	1.464%	0.914%	0.661%	0.556%	0.506%	0.501%
\$80,000	1,500	6	1.814%	1.012%	0.671%	0.550%	0.513%	0.502%	0.501%
\$80,000	2,000	6	1.417%	0.796%	0.580%	0.520%	0.506%	0.502%	0.501%
\$80,000	3,000	6	0.985%	0.610%	0.521%	0.506%	0.503%	0.502%	0.501%
\$80,000	4,000	6	0.768%	0.545%	0.508%	0.504%	0.503%	0.502%	0.501%
\$80,000	5,000	6	0.650%	0.520%	0.506%	0.504%	0.503%	0.502%	0.501%
\$80,000	10,000	6	0.513%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$80,000	20,000	6	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$90,000	5	6	66.409%	64.641%	62.937%	61.288%	59.690%	56.633%	53.756%
\$90,000	10	6	50.521%	48.374%	46.312%	44.334%	42.442%	38.884%	35.602%
\$90,000	15	6	41.162%	38.823%	36.600%	34.486%	32.475%	28.752%	25.369%
\$90,000	20	6	35.620%	33.172%	30.857%	28.666%	26.593%	22.796%	19.457%
\$90,000	25	6	31.230%	28.701%	26.337%	24.132%	22.074%	18.409%	15.294%
\$90,000	50	6	20.598%	18.156%	15.970%	14.012%	12.267%	9.344%	7.077%
\$90,000	100	6	13.171%	10.923%	9.014%	7.405%	6.063%	4.038%	2.694%
\$90,000	150	6	10.061%	7.973%	6.278%	4.913%	3.834%	2.345%	1.478%
\$90,000	200	6	8.289%	6.342%	4.813%	3.636%	2.746%	1.603%	1.008%
\$90,000	300	6	6.277%	4.520%	3.222%	2.299%	1.659%	0.949%	0.656%
\$90,000	400	6	5.116%	3.518%	2.409%	1.664%	1.185%	0.712%	0.554%
\$90,000	500	6	4.375%	2.896%	1.918%	1.302%	0.930%	0.607%	0.521%
\$90,000	600	6	3.849%	2.466%	1.596%	1.075%	0.784%	0.558%	0.510%
\$90,000	700	6	3.418%	2.131%	1.355%	0.918%	0.691%	0.534%	0.505%
\$90,000	800	6	3.107%	1.888%	1.186%	0.813%	0.633%	0.519%	0.502%
\$90,000	900	6	2.862%	1.705%	1.063%	0.740%	0.593%	0.512%	0.502%
\$90,000	1,000	6	2.638%	1.549%	0.966%	0.688%	0.569%	0.508%	0.501%
\$90,000	1,500	6	1.904%	1.067%	0.698%	0.560%	0.516%	0.502%	0.501%
\$90,000	2,000	6	1.489%	0.833%	0.594%	0.524%	0.507%	0.502%	0.501%
\$90,000	3,000	6	1.033%	0.627%	0.525%	0.506%	0.503%	0.502%	0.501%
\$90,000	4,000	6	0.801%	0.553%	0.510%	0.504%	0.503%	0.502%	0.501%
\$90,000	5,000	6	0.671%	0.523%	0.506%	0.504%	0.503%	0.502%	0.501%
\$90,000	10,000	6	0.514%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$90,000	20,000	6	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$100,000	5	6	67.065%	65.323%	63.642%	62.017%	60.440%	57.427%	54.593%
\$100,000	10	6	51.281%	49.168%	47.140%	45.200%	43.344%	39.854%	36.639%
\$100,000	15	6	42.014%	39.723%	37.546%	35.476%	33.512%	29.876%	26.575%
\$100,000	20	6	36.543%	34.149%	31.888%	29.748%	27.721%	23.983%	20.647%
\$100,000	25	6	32.168%	29.685%	27.348%	25.158%	23.107%	19.428%	16.245%
\$100,000	50	6	21.266%	18.824%	16.627%	14.656%	12.888%	9.915%	7.592%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$100,000	100	6	13.624%	11.367%	9.437%	7.801%	6.431%	4.341%	2.928%
\$100,000	150	6	10.416%	8.311%	6.591%	5.196%	4.083%	2.530%	1.606%
\$100,000	200	6	8.583%	6.617%	5.060%	3.851%	2.928%	1.725%	1.082%
\$100,000	300	6	6.504%	4.721%	3.394%	2.438%	1.767%	1.009%	0.686%
\$100,000	400	6	5.308%	3.683%	2.543%	1.767%	1.260%	0.748%	0.567%
\$100,000	500	6	4.542%	3.035%	2.025%	1.380%	0.983%	0.628%	0.527%
\$100,000	600	6	3.997%	2.585%	1.686%	1.137%	0.823%	0.570%	0.513%
\$100,000	700	6	3.551%	2.235%	1.429%	0.965%	0.719%	0.542%	0.506%
\$100,000	800	6	3.230%	1.981%	1.249%	0.851%	0.655%	0.524%	0.503%
\$100,000	900	6	2.978%	1.790%	1.119%	0.773%	0.610%	0.515%	0.502%
\$100,000	1,000	6	2.746%	1.626%	1.016%	0.715%	0.582%	0.510%	0.502%
\$100,000	1,500	6	1.987%	1.118%	0.724%	0.571%	0.520%	0.503%	0.501%
\$100,000	2,000	6	1.555%	0.868%	0.609%	0.529%	0.508%	0.502%	0.501%
\$100,000	3,000	6	1.078%	0.644%	0.529%	0.507%	0.503%	0.502%	0.501%
\$100,000	4,000	6	0.832%	0.561%	0.511%	0.504%	0.503%	0.502%	0.501%
\$100,000	5,000	6	0.692%	0.527%	0.506%	0.504%	0.503%	0.502%	0.501%
\$100,000	10,000	6	0.516%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$100,000	20,000	6	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$110,000	5	6	67.609%	65.888%	64.227%	62.620%	61.061%	58.084%	55.284%
\$110,000	10	6	51.909%	49.823%	47.825%	45.915%	44.088%	40.653%	37.494%
\$110,000	15	6	42.717%	40.464%	38.324%	36.292%	34.365%	30.798%	27.565%
\$110,000	20	6	37.301%	34.952%	32.733%	30.635%	28.648%	24.986%	21.691%
\$110,000	25	6	32.943%	30.505%	28.208%	26.044%	24.015%	20.345%	17.133%
\$110,000	50	6	21.878%	19.435%	17.230%	15.247%	13.463%	10.446%	8.069%
\$110,000	100	6	14.034%	11.770%	9.820%	8.164%	6.765%	4.621%	3.146%
\$110,000	150	6	10.738%	8.618%	6.875%	5.453%	4.309%	2.699%	1.725%
\$110,000	200	6	8.853%	6.868%	5.286%	4.051%	3.097%	1.840%	1.155%
\$110,000	300	6	6.710%	4.903%	3.551%	2.567%	1.869%	1.066%	0.715%
\$110,000	400	6	5.483%	3.835%	2.668%	1.864%	1.332%	0.783%	0.582%
\$110,000	500	6	4.693%	3.161%	2.124%	1.453%	1.034%	0.649%	0.534%
\$110,000	600	6	4.130%	2.694%	1.768%	1.195%	0.861%	0.582%	0.516%
\$110,000	700	6	3.671%	2.330%	1.498%	1.011%	0.746%	0.550%	0.508%
\$110,000	800	6	3.342%	2.067%	1.308%	0.888%	0.676%	0.529%	0.504%
\$110,000	900	6	3.083%	1.868%	1.171%	0.804%	0.627%	0.519%	0.503%
\$110,000	1,000	6	2.844%	1.697%	1.062%	0.742%	0.595%	0.513%	0.502%
\$110,000	1,500	6	2.061%	1.165%	0.748%	0.582%	0.524%	0.503%	0.501%
\$110,000	2,000	6	1.614%	0.900%	0.623%	0.533%	0.509%	0.502%	0.501%
\$110,000	3,000	6	1.119%	0.660%	0.533%	0.507%	0.503%	0.502%	0.501%
\$110,000	4,000	6	0.860%	0.569%	0.512%	0.505%	0.503%	0.502%	0.501%
\$110,000	5,000	6	0.712%	0.531%	0.507%	0.504%	0.503%	0.502%	0.501%
\$110,000	10,000	6	0.518%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$110,000	20,000	6	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$120,000	5	6	68.074%	66.371%	64.726%	63.134%	61.591%	58.644%	55.872%
\$120,000	10	6	52.442%	50.381%	48.407%	46.523%	44.719%	41.330%	38.218%
\$120,000	15	6	43.305%	41.083%	38.975%	36.974%	35.079%	31.568%	28.390%
\$120,000	20	6	37.942%	35.629%	33.446%	31.381%	29.428%	25.829%	22.592%
\$120,000	25	6	33.596%	31.196%	28.938%	26.808%	24.808%	21.166%	17.954%
\$120,000	50	6	22.443%	20.000%	17.788%	15.790%	13.993%	10.939%	8.513%
\$120,000	100	6	14.415%	12.143%	10.181%	8.505%	7.083%	4.886%	3.358%
\$120,000	150	6	11.039%	8.904%	7.141%	5.694%	4.524%	2.860%	1.840%
\$120,000	200	6	9.105%	7.101%	5.498%	4.239%	3.259%	1.951%	1.226%
\$120,000	300	6	6.901%	5.073%	3.698%	2.689%	1.966%	1.122%	0.745%
\$120,000	400	6	5.647%	3.978%	2.786%	1.957%	1.401%	0.818%	0.597%
\$120,000	500	6	4.833%	3.279%	2.218%	1.523%	1.084%	0.669%	0.541%
\$120,000	600	6	4.253%	2.795%	1.844%	1.250%	0.897%	0.595%	0.520%
\$120,000	700	6	3.781%	2.418%	1.562%	1.055%	0.774%	0.558%	0.510%
\$120,000	800	6	3.444%	2.147%	1.363%	0.924%	0.697%	0.534%	0.505%
\$120,000	900	6	3.179%	1.941%	1.221%	0.835%	0.644%	0.523%	0.504%
\$120,000	1,000	6	2.933%	1.763%	1.105%	0.767%	0.609%	0.515%	0.502%
\$120,000	1,500	6	2.130%	1.209%	0.772%	0.593%	0.529%	0.503%	0.501%
\$120,000	2,000	6	1.668%	0.931%	0.636%	0.538%	0.510%	0.502%	0.501%
\$120,000	3,000	6	1.156%	0.676%	0.538%	0.508%	0.503%	0.502%	0.501%
\$120,000	4,000	6	0.887%	0.577%	0.514%	0.505%	0.503%	0.502%	0.501%
\$120,000	5,000	6	0.731%	0.535%	0.507%	0.504%	0.503%	0.502%	0.501%
\$120,000	10,000	6	0.520%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$120,000	20,000	6	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$130,000	5	6	68.497%	66.809%	65.179%	63.600%	62.070%	59.152%	56.405%
\$130,000	10	6	52.911%	50.871%	48.920%	47.058%	45.275%	41.926%	38.855%
\$130,000	15	6	43.821%	41.627%	39.545%	37.572%	35.705%	32.243%	29.111%
\$130,000	20	6	38.501%	36.220%	34.068%	32.033%	30.109%	26.566%	23.380%
\$130,000	25	6	34.171%	31.805%	29.580%	27.483%	25.517%	21.919%	18.724%
\$130,000	50	6	22.980%	20.540%	18.322%	16.313%	14.501%	11.416%	8.941%
\$130,000	100	6	14.778%	12.499%	10.527%	8.835%	7.393%	5.144%	3.568%
\$130,000	150	6	11.329%	9.180%	7.397%	5.929%	4.734%	3.020%	1.955%
\$130,000	200	6	9.347%	7.326%	5.702%	4.421%	3.418%	2.061%	1.299%
\$130,000	300	6	7.084%	5.239%	3.841%	2.809%	2.063%	1.180%	0.776%
\$130,000	400	6	5.804%	4.115%	2.900%	2.049%	1.471%	0.853%	0.613%
\$130,000	500	6	4.966%	3.393%	2.309%	1.591%	1.133%	0.690%	0.549%
\$130,000	600	6	4.371%	2.893%	1.918%	1.303%	0.933%	0.609%	0.524%
\$130,000	700	6	3.880%	2.497%	1.620%	1.094%	0.798%	0.565%	0.511%
\$130,000	800	6	3.540%	2.223%	1.417%	0.959%	0.718%	0.540%	0.506%
\$130,000	900	6	3.270%	2.010%	1.268%	0.864%	0.661%	0.527%	0.504%
\$130,000	1,000	6	3.018%	1.826%	1.147%	0.792%	0.622%	0.518%	0.503%
\$130,000	1,500	6	2.194%	1.251%	0.796%	0.604%	0.533%	0.504%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$130,000	2,000	6	1.720%	0.960%	0.650%	0.543%	0.512%	0.502%	0.501%
\$130,000	3,000	6	1.192%	0.691%	0.542%	0.509%	0.503%	0.502%	0.501%
\$130,000	4,000	6	0.913%	0.585%	0.515%	0.505%	0.503%	0.502%	0.501%
\$130,000	5,000	6	0.749%	0.539%	0.508%	0.504%	0.503%	0.502%	0.501%
\$130,000	10,000	6	0.522%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$130,000	20,000	6	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$140,000	5	6	68.853%	67.178%	65.560%	63.992%	62.474%	59.579%	56.852%
\$140,000	10	6	53.294%	51.271%	49.339%	47.494%	45.727%	42.411%	39.374%
\$140,000	15	6	44.230%	42.057%	39.997%	38.046%	36.201%	32.779%	29.684%
\$140,000	20	6	38.952%	36.698%	34.570%	32.558%	30.658%	27.159%	24.014%
\$140,000	25	6	34.635%	32.297%	30.098%	28.029%	26.090%	22.538%	19.376%
\$140,000	50	6	23.440%	21.005%	18.784%	16.768%	14.945%	11.835%	9.317%
\$140,000	100	6	15.096%	12.811%	10.831%	9.125%	7.665%	5.376%	3.757%
\$140,000	150	6	11.588%	9.426%	7.628%	6.140%	4.926%	3.166%	2.062%
\$140,000	200	6	9.561%	7.529%	5.886%	4.584%	3.562%	2.164%	1.367%
\$140,000	300	6	7.246%	5.386%	3.969%	2.918%	2.150%	1.233%	0.805%
\$140,000	400	6	5.943%	4.237%	3.001%	2.130%	1.534%	0.886%	0.629%
\$140,000	500	6	5.084%	3.493%	2.390%	1.652%	1.178%	0.709%	0.556%
\$140,000	600	6	4.474%	2.978%	1.984%	1.350%	0.966%	0.621%	0.528%
\$140,000	700	6	3.973%	2.572%	1.676%	1.132%	0.822%	0.573%	0.513%
\$140,000	800	6	3.625%	2.289%	1.465%	0.991%	0.737%	0.546%	0.507%
\$140,000	900	6	3.349%	2.071%	1.310%	0.891%	0.676%	0.530%	0.505%
\$140,000	1,000	6	3.092%	1.881%	1.184%	0.815%	0.635%	0.521%	0.503%
\$140,000	1,500	6	2.250%	1.288%	0.816%	0.614%	0.537%	0.504%	0.501%
\$140,000	2,000	6	1.765%	0.986%	0.663%	0.548%	0.514%	0.502%	0.501%
\$140,000	3,000	6	1.224%	0.705%	0.546%	0.510%	0.504%	0.502%	0.501%
\$140,000	4,000	6	0.935%	0.593%	0.517%	0.505%	0.503%	0.502%	0.501%
\$140,000	5,000	6	0.765%	0.543%	0.508%	0.504%	0.503%	0.502%	0.501%
\$140,000	10,000	6	0.523%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$140,000	20,000	6	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$150,000	5	6	69.149%	67.484%	65.876%	64.318%	62.808%	59.934%	57.224%
\$150,000	10	6	53.633%	51.625%	49.709%	47.879%	46.126%	42.840%	39.831%
\$150,000	15	6	44.585%	42.432%	40.391%	38.459%	36.632%	33.244%	30.181%
\$150,000	20	6	39.345%	37.112%	35.005%	33.015%	31.134%	27.674%	24.564%
\$150,000	25	6	35.037%	32.723%	30.547%	28.502%	26.586%	23.074%	19.952%
\$150,000	50	6	23.861%	21.433%	19.214%	17.193%	15.361%	12.226%	9.675%
\$150,000	100	6	15.393%	13.104%	11.116%	9.395%	7.920%	5.596%	3.937%
\$150,000	150	6	11.834%	9.661%	7.847%	6.342%	5.109%	3.308%	2.167%
\$150,000	200	6	9.763%	7.720%	6.061%	4.740%	3.701%	2.264%	1.433%
\$150,000	300	6	7.400%	5.526%	4.091%	3.022%	2.236%	1.285%	0.834%
\$150,000	400	6	6.073%	4.351%	3.096%	2.208%	1.595%	0.918%	0.644%
\$150,000	500	6	5.195%	3.587%	2.466%	1.711%	1.221%	0.728%	0.563%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$150,000	600	6	4.570%	3.059%	2.047%	1.396%	0.997%	0.634%	0.532%
\$150,000	700	6	4.059%	2.643%	1.728%	1.170%	0.846%	0.581%	0.515%
\$150,000	800	6	3.705%	2.353%	1.511%	1.022%	0.756%	0.552%	0.508%
\$150,000	900	6	3.424%	2.129%	1.351%	0.917%	0.692%	0.534%	0.506%
\$150,000	1,000	6	3.161%	1.934%	1.220%	0.837%	0.646%	0.524%	0.504%
\$150,000	1,500	6	2.302%	1.323%	0.837%	0.624%	0.541%	0.505%	0.501%
\$150,000	2,000	6	1.807%	1.012%	0.675%	0.553%	0.515%	0.502%	0.501%
\$150,000	3,000	6	1.254%	0.718%	0.551%	0.511%	0.504%	0.502%	0.501%
\$150,000	4,000	6	0.957%	0.600%	0.518%	0.505%	0.503%	0.502%	0.501%
\$150,000	5,000	6	0.781%	0.547%	0.509%	0.504%	0.503%	0.502%	0.501%
\$150,000	10,000	6	0.525%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$150,000	20,000	6	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$160,000	5	6	69.420%	67.764%	66.164%	64.615%	63.114%	60.257%	57.564%
\$160,000	10	6	53.948%	51.954%	50.053%	48.237%	46.497%	43.238%	40.254%
\$160,000	15	6	44.918%	42.782%	40.759%	38.845%	37.035%	33.678%	30.643%
\$160,000	20	6	39.712%	37.500%	35.412%	33.441%	31.579%	28.153%	25.076%
\$160,000	25	6	35.412%	33.121%	30.965%	28.943%	27.047%	23.572%	20.487%
\$160,000	50	6	24.267%	21.851%	19.637%	17.616%	15.779%	12.619%	10.042%
\$160,000	100	6	15.687%	13.394%	11.398%	9.666%	8.175%	5.815%	4.119%
\$160,000	150	6	12.076%	9.894%	8.065%	6.543%	5.292%	3.451%	2.272%
\$160,000	200	6	9.960%	7.907%	6.234%	4.895%	3.837%	2.365%	1.501%
\$160,000	300	6	7.551%	5.663%	4.213%	3.126%	2.322%	1.338%	0.865%
\$160,000	400	6	6.200%	4.463%	3.191%	2.285%	1.655%	0.951%	0.661%
\$160,000	500	6	5.304%	3.681%	2.541%	1.769%	1.264%	0.747%	0.571%
\$160,000	600	6	4.663%	3.138%	2.109%	1.442%	1.028%	0.647%	0.537%
\$160,000	700	6	4.144%	2.712%	1.781%	1.207%	0.871%	0.590%	0.518%
\$160,000	800	6	3.784%	2.416%	1.557%	1.053%	0.776%	0.558%	0.509%
\$160,000	900	6	3.497%	2.186%	1.391%	0.943%	0.707%	0.539%	0.507%
\$160,000	1,000	6	3.229%	1.985%	1.256%	0.859%	0.659%	0.527%	0.504%
\$160,000	1,500	6	2.354%	1.358%	0.857%	0.634%	0.546%	0.505%	0.501%
\$160,000	2,000	6	1.849%	1.037%	0.687%	0.558%	0.517%	0.503%	0.501%
\$160,000	3,000	6	1.284%	0.732%	0.555%	0.512%	0.504%	0.502%	0.501%
\$160,000	4,000	6	0.978%	0.607%	0.520%	0.506%	0.503%	0.502%	0.501%
\$160,000	5,000	6	0.796%	0.551%	0.509%	0.504%	0.503%	0.502%	0.501%
\$160,000	10,000	6	0.527%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$160,000	20,000	6	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$170,000	5	6	69.672%	68.025%	66.433%	64.893%	63.400%	60.559%	57.881%
\$170,000	10	6	54.244%	52.264%	50.377%	48.574%	46.846%	43.613%	40.652%
\$170,000	15	6	45.230%	43.111%	41.105%	39.208%	37.413%	34.085%	31.078%
\$170,000	20	6	40.060%	37.866%	35.796%	33.843%	31.999%	28.606%	25.559%
\$170,000	25	6	35.768%	33.497%	31.360%	29.359%	27.482%	24.042%	20.993%
\$170,000	50	6	24.666%	22.264%	20.061%	18.044%	16.203%	13.024%	10.420%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$170,000	100	6	15.982%	13.684%	11.681%	9.940%	8.434%	6.038%	4.306%
\$170,000	150	6	12.316%	10.128%	8.284%	6.746%	5.477%	3.598%	2.381%
\$170,000	200	6	10.156%	8.094%	6.408%	5.051%	3.976%	2.468%	1.572%
\$170,000	300	6	7.704%	5.803%	4.338%	3.232%	2.411%	1.393%	0.897%
\$170,000	400	6	6.327%	4.576%	3.287%	2.363%	1.717%	0.986%	0.678%
\$170,000	500	6	5.413%	3.774%	2.617%	1.829%	1.308%	0.767%	0.580%
\$170,000	600	6	4.758%	3.218%	2.172%	1.489%	1.061%	0.661%	0.542%
\$170,000	700	6	4.229%	2.783%	1.834%	1.245%	0.896%	0.600%	0.521%
\$170,000	800	6	3.863%	2.480%	1.604%	1.085%	0.796%	0.565%	0.511%
\$170,000	900	6	3.571%	2.244%	1.433%	0.971%	0.724%	0.543%	0.508%
\$170,000	1,000	6	3.297%	2.038%	1.293%	0.882%	0.672%	0.530%	0.505%
\$170,000	1,500	6	2.406%	1.394%	0.878%	0.645%	0.551%	0.506%	0.501%
\$170,000	2,000	6	1.892%	1.062%	0.700%	0.563%	0.519%	0.503%	0.501%
\$170,000	3,000	6	1.314%	0.746%	0.560%	0.513%	0.504%	0.502%	0.501%
\$170,000	4,000	6	1.000%	0.615%	0.522%	0.506%	0.503%	0.502%	0.501%
\$170,000	5,000	6	0.812%	0.555%	0.510%	0.504%	0.503%	0.502%	0.501%
\$170,000	10,000	6	0.529%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$170,000	20,000	6	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$180,000	5	6	69.903%	68.264%	66.680%	65.147%	63.661%	60.835%	58.171%
\$180,000	10	6	54.512%	52.543%	50.669%	48.877%	47.161%	43.950%	41.012%
\$180,000	15	6	45.509%	43.405%	41.413%	39.532%	37.749%	34.449%	31.465%
\$180,000	20	6	40.373%	38.196%	36.143%	34.205%	32.377%	29.013%	25.994%
\$180,000	25	6	36.089%	33.837%	31.719%	29.736%	27.876%	24.467%	21.450%
\$180,000	50	6	25.038%	22.654%	20.461%	18.450%	16.613%	13.419%	10.789%
\$180,000	100	6	16.265%	13.963%	11.953%	10.202%	8.684%	6.254%	4.489%
\$180,000	150	6	12.544%	10.350%	8.493%	6.942%	5.656%	3.742%	2.489%
\$180,000	200	6	10.343%	8.273%	6.575%	5.203%	4.111%	2.569%	1.642%
\$180,000	300	6	7.851%	5.939%	4.459%	3.336%	2.498%	1.449%	0.930%
\$180,000	400	6	6.447%	4.684%	3.379%	2.439%	1.777%	1.021%	0.695%
\$180,000	500	6	5.516%	3.864%	2.691%	1.886%	1.352%	0.788%	0.588%
\$180,000	600	6	4.848%	3.294%	2.233%	1.534%	1.093%	0.674%	0.547%
\$180,000	700	6	4.310%	2.850%	1.886%	1.282%	0.921%	0.609%	0.523%
\$180,000	800	6	3.931%	2.535%	1.644%	1.112%	0.812%	0.570%	0.511%
\$180,000	900	6	3.640%	2.299%	1.473%	0.997%	0.740%	0.548%	0.509%
\$180,000	1,000	6	3.362%	2.089%	1.328%	0.904%	0.686%	0.534%	0.505%
\$180,000	1,500	6	2.455%	1.428%	0.899%	0.656%	0.556%	0.507%	0.501%
\$180,000	2,000	6	1.932%	1.087%	0.713%	0.569%	0.521%	0.503%	0.501%
\$180,000	3,000	6	1.343%	0.760%	0.565%	0.514%	0.504%	0.502%	0.501%
\$180,000	4,000	6	1.020%	0.622%	0.523%	0.506%	0.503%	0.502%	0.501%
\$180,000	5,000	6	0.827%	0.559%	0.511%	0.504%	0.503%	0.502%	0.501%
\$180,000	10,000	6	0.531%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$180,000	20,000	6	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$190,000	5	6	70.099%	68.468%	66.889%	65.362%	63.884%	61.070%	58.417%
\$190,000	10	6	54.745%	52.788%	50.924%	49.142%	47.436%	44.245%	41.325%
\$190,000	15	6	45.756%	43.663%	41.685%	39.816%	38.045%	34.768%	31.805%
\$190,000	20	6	40.644%	38.482%	36.442%	34.519%	32.703%	29.365%	26.369%
\$190,000	25	6	36.368%	34.131%	32.029%	30.062%	28.216%	24.834%	21.843%
\$190,000	50	6	25.364%	22.994%	20.814%	18.810%	16.978%	13.777%	11.126%
\$190,000	100	6	16.514%	14.210%	12.194%	10.435%	8.907%	6.449%	4.654%
\$190,000	150	6	12.746%	10.548%	8.680%	7.118%	5.818%	3.871%	2.588%
\$190,000	200	6	10.510%	8.433%	6.725%	5.339%	4.232%	2.660%	1.706%
\$190,000	300	6	7.982%	6.060%	4.567%	3.429%	2.577%	1.501%	0.960%
\$190,000	400	6	6.553%	4.780%	3.462%	2.507%	1.831%	1.052%	0.712%
\$190,000	500	6	5.608%	3.944%	2.756%	1.938%	1.391%	0.806%	0.596%
\$190,000	600	6	4.928%	3.362%	2.287%	1.575%	1.122%	0.687%	0.552%
\$190,000	700	6	4.382%	2.910%	1.932%	1.315%	0.944%	0.618%	0.526%
\$190,000	800	6	3.996%	2.588%	1.684%	1.139%	0.830%	0.576%	0.513%
\$190,000	900	6	3.702%	2.348%	1.508%	1.021%	0.754%	0.552%	0.510%
\$190,000	1,000	6	3.418%	2.133%	1.359%	0.924%	0.697%	0.537%	0.506%
\$190,000	1,500	6	2.497%	1.458%	0.917%	0.666%	0.560%	0.507%	0.501%
\$190,000	2,000	6	1.967%	1.110%	0.724%	0.573%	0.522%	0.503%	0.501%
\$190,000	3,000	6	1.369%	0.772%	0.569%	0.515%	0.505%	0.502%	0.501%
\$190,000	4,000	6	1.039%	0.629%	0.525%	0.506%	0.503%	0.502%	0.501%
\$190,000	5,000	6	0.841%	0.563%	0.511%	0.504%	0.503%	0.502%	0.501%
\$190,000	10,000	6	0.532%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$190,000	20,000	6	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$200,000	5	6	70.253%	68.627%	67.054%	65.532%	64.059%	61.255%	58.612%
\$200,000	10	6	54.939%	52.991%	51.136%	49.361%	47.664%	44.490%	41.585%
\$200,000	15	6	45.967%	43.886%	41.918%	40.061%	38.299%	35.042%	32.096%
\$200,000	20	6	40.875%	38.725%	36.697%	34.786%	32.982%	29.664%	26.689%
\$200,000	25	6	36.606%	34.383%	32.295%	30.341%	28.507%	25.148%	22.181%
\$200,000	50	6	25.650%	23.296%	21.128%	19.134%	17.309%	14.108%	11.442%
\$200,000	100	6	16.743%	14.439%	12.417%	10.652%	9.114%	6.633%	4.808%
\$200,000	150	6	12.934%	10.731%	8.856%	7.283%	5.970%	3.994%	2.683%
\$200,000	200	6	10.664%	8.581%	6.864%	5.467%	4.347%	2.748%	1.768%
\$200,000	300	6	8.103%	6.173%	4.668%	3.516%	2.651%	1.549%	0.989%
\$200,000	400	6	6.651%	4.869%	3.538%	2.571%	1.882%	1.082%	0.728%
\$200,000	500	6	5.693%	4.018%	2.818%	1.987%	1.428%	0.825%	0.603%
\$200,000	600	6	5.002%	3.426%	2.339%	1.613%	1.149%	0.700%	0.556%
\$200,000	700	6	4.449%	2.966%	1.976%	1.347%	0.965%	0.626%	0.529%
\$200,000	800	6	4.057%	2.638%	1.722%	1.165%	0.847%	0.582%	0.514%
\$200,000	900	6	3.752%	2.388%	1.537%	1.039%	0.765%	0.555%	0.510%
\$200,000	1,000	6	3.471%	2.174%	1.388%	0.943%	0.709%	0.540%	0.506%
\$200,000	1,500	6	2.537%	1.486%	0.934%	0.675%	0.565%	0.508%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$200,000	2,000	6	2.000%	1.130%	0.735%	0.578%	0.524%	0.503%	0.501%
\$200,000	3,000	6	1.393%	0.784%	0.574%	0.517%	0.505%	0.502%	0.501%
\$200,000	4,000	6	1.056%	0.635%	0.527%	0.507%	0.503%	0.502%	0.501%
\$200,000	5,000	6	0.854%	0.567%	0.512%	0.505%	0.503%	0.502%	0.501%
\$200,000	10,000	6	0.534%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$200,000	20,000	6	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$225,000	5	6	70.558%	68.943%	67.380%	65.868%	64.406%	61.622%	58.999%
\$225,000	10	6	55.320%	53.391%	51.554%	49.796%	48.116%	44.976%	42.104%
\$225,000	15	6	46.396%	44.338%	42.394%	40.559%	38.817%	35.601%	32.692%
\$225,000	20	6	41.354%	39.230%	37.227%	35.339%	33.559%	30.286%	27.353%
\$225,000	25	6	37.106%	34.910%	32.851%	30.926%	29.117%	25.806%	22.888%
\$225,000	50	6	26.262%	23.947%	21.812%	19.846%	18.042%	14.860%	12.183%
\$225,000	100	6	17.267%	14.968%	12.937%	11.156%	9.600%	7.071%	5.185%
\$225,000	150	6	13.367%	11.154%	9.265%	7.669%	6.330%	4.288%	2.915%
\$225,000	200	6	11.024%	8.927%	7.191%	5.768%	4.617%	2.957%	1.922%
\$225,000	300	6	8.384%	6.436%	4.905%	3.724%	2.827%	1.668%	1.062%
\$225,000	400	6	6.877%	5.075%	3.719%	2.723%	2.006%	1.156%	0.768%
\$225,000	500	6	5.892%	4.193%	2.964%	2.104%	1.518%	0.872%	0.624%
\$225,000	600	6	5.175%	3.575%	2.459%	1.706%	1.217%	0.730%	0.568%
\$225,000	700	6	4.605%	3.097%	2.080%	1.424%	1.018%	0.647%	0.536%
\$225,000	800	6	4.198%	2.754%	1.811%	1.229%	0.889%	0.597%	0.519%
\$225,000	900	6	3.884%	2.494%	1.615%	1.093%	0.799%	0.566%	0.513%
\$225,000	1,000	6	3.594%	2.271%	1.458%	0.989%	0.737%	0.548%	0.508%
\$225,000	1,500	6	2.629%	1.551%	0.975%	0.697%	0.576%	0.510%	0.501%
\$225,000	2,000	6	2.075%	1.178%	0.760%	0.589%	0.528%	0.504%	0.501%
\$225,000	3,000	6	1.449%	0.812%	0.584%	0.520%	0.505%	0.502%	0.501%
\$225,000	4,000	6	1.096%	0.651%	0.531%	0.507%	0.503%	0.502%	0.501%
\$225,000	5,000	6	0.883%	0.576%	0.513%	0.505%	0.503%	0.502%	0.501%
\$225,000	10,000	6	0.538%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$225,000	20,000	6	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$250,000	5	6	70.790%	69.183%	67.628%	66.124%	64.671%	61.902%	59.294%
\$250,000	10	6	55.618%	53.704%	51.881%	50.136%	48.470%	45.357%	42.511%
\$250,000	15	6	46.728%	44.688%	42.762%	40.945%	39.219%	36.034%	33.154%
\$250,000	20	6	41.719%	39.615%	37.632%	35.763%	34.001%	30.762%	27.861%
\$250,000	25	6	37.496%	35.322%	33.286%	31.383%	29.592%	26.320%	23.440%
\$250,000	50	6	26.748%	24.464%	22.359%	20.422%	18.644%	15.494%	12.829%
\$250,000	100	6	17.715%	15.425%	13.395%	11.603%	10.034%	7.465%	5.532%
\$250,000	150	6	13.741%	11.524%	9.623%	8.010%	6.650%	4.556%	3.129%
\$250,000	200	6	11.343%	9.237%	7.483%	6.041%	4.865%	3.154%	2.067%
\$250,000	300	6	8.635%	6.674%	5.122%	3.915%	2.993%	1.782%	1.133%
\$250,000	400	6	7.080%	5.261%	3.884%	2.863%	2.121%	1.227%	0.808%
\$250,000	500	6	6.069%	4.352%	3.099%	2.213%	1.602%	0.918%	0.645%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$250,000	600	6	5.329%	3.708%	2.569%	1.792%	1.281%	0.760%	0.580%
\$250,000	700	6	4.743%	3.215%	2.174%	1.495%	1.068%	0.668%	0.544%
\$250,000	800	6	4.323%	2.859%	1.892%	1.287%	0.929%	0.612%	0.524%
\$250,000	900	6	4.000%	2.589%	1.687%	1.142%	0.832%	0.577%	0.516%
\$250,000	1,000	6	3.703%	2.359%	1.522%	1.032%	0.764%	0.556%	0.510%
\$250,000	1,500	6	2.710%	1.610%	1.012%	0.719%	0.587%	0.512%	0.502%
\$250,000	2,000	6	2.140%	1.220%	0.783%	0.600%	0.533%	0.504%	0.501%
\$250,000	3,000	6	1.497%	0.837%	0.594%	0.523%	0.506%	0.502%	0.501%
\$250,000	4,000	6	1.132%	0.666%	0.535%	0.508%	0.503%	0.502%	0.501%
\$250,000	5,000	6	0.910%	0.584%	0.515%	0.505%	0.503%	0.502%	0.501%
\$250,000	10,000	6	0.543%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$250,000	20,000	6	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$275,000	5	6	70.997%	69.397%	67.850%	66.353%	64.908%	62.152%	59.558%
\$275,000	10	6	55.880%	53.979%	52.167%	50.434%	48.780%	45.690%	42.866%
\$275,000	15	6	47.024%	45.000%	43.090%	41.287%	39.575%	36.417%	33.563%
\$275,000	20	6	42.036%	39.949%	37.983%	36.131%	34.384%	31.175%	28.303%
\$275,000	25	6	37.837%	35.682%	33.666%	31.782%	30.007%	26.769%	23.922%
\$275,000	50	6	27.169%	24.912%	22.833%	20.921%	19.167%	16.059%	13.419%
\$275,000	100	6	18.126%	15.849%	13.824%	12.032%	10.451%	7.848%	5.875%
\$275,000	150	6	14.092%	11.874%	9.964%	8.337%	6.958%	4.821%	3.341%
\$275,000	200	6	11.647%	9.535%	7.768%	6.307%	5.109%	3.352%	2.216%
\$275,000	300	6	8.876%	6.903%	5.334%	4.103%	3.156%	1.898%	1.207%
\$275,000	400	6	7.276%	5.442%	4.044%	3.001%	2.238%	1.300%	0.851%
\$275,000	500	6	6.239%	4.506%	3.232%	2.321%	1.687%	0.967%	0.668%
\$275,000	600	6	5.477%	3.839%	2.677%	1.877%	1.346%	0.791%	0.593%
\$275,000	700	6	4.877%	3.329%	2.267%	1.565%	1.120%	0.690%	0.553%
\$275,000	800	6	4.445%	2.961%	1.972%	1.346%	0.970%	0.628%	0.529%
\$275,000	900	6	4.114%	2.683%	1.758%	1.193%	0.866%	0.590%	0.520%
\$275,000	1,000	6	3.801%	2.439%	1.581%	1.073%	0.789%	0.564%	0.511%
\$275,000	1,500	6	2.790%	1.668%	1.050%	0.741%	0.599%	0.514%	0.502%
\$275,000	2,000	6	2.205%	1.263%	0.807%	0.612%	0.538%	0.505%	0.501%
\$275,000	3,000	6	1.544%	0.862%	0.604%	0.526%	0.507%	0.502%	0.501%
\$275,000	4,000	6	1.168%	0.681%	0.540%	0.509%	0.504%	0.502%	0.501%
\$275,000	5,000	6	0.937%	0.593%	0.517%	0.505%	0.503%	0.502%	0.501%
\$275,000	10,000	6	0.547%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$275,000	20,000	6	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$300,000	5	6	71.180%	69.586%	68.046%	66.555%	65.117%	62.372%	59.790%
\$300,000	10	6	56.115%	54.226%	52.425%	50.702%	49.058%	45.990%	43.185%
\$300,000	15	6	47.292%	45.282%	43.387%	41.597%	39.898%	36.764%	33.932%
\$300,000	20	6	42.320%	40.248%	38.298%	36.461%	34.728%	31.545%	28.698%
\$300,000	25	6	38.144%	36.005%	34.007%	32.139%	30.380%	27.172%	24.354%
\$300,000	50	6	27.548%	25.314%	23.258%	21.368%	19.636%	16.566%	13.960%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$300,000	100	6	18.507%	16.248%	14.234%	12.444%	10.861%	8.229%	6.217%
\$300,000	150	6	14.426%	12.211%	10.297%	8.657%	7.264%	5.085%	3.558%
\$300,000	200	6	11.941%	9.827%	8.047%	6.571%	5.353%	3.552%	2.370%
\$300,000	300	6	9.113%	7.130%	5.545%	4.293%	3.321%	2.016%	1.285%
\$300,000	400	6	7.469%	5.622%	4.205%	3.141%	2.355%	1.376%	0.895%
\$300,000	500	6	6.406%	4.659%	3.364%	2.431%	1.774%	1.017%	0.694%
\$300,000	600	6	5.623%	3.970%	2.785%	1.963%	1.412%	0.825%	0.607%
\$300,000	700	6	5.009%	3.442%	2.359%	1.637%	1.173%	0.713%	0.562%
\$300,000	800	6	4.564%	3.063%	2.053%	1.406%	1.013%	0.646%	0.536%
\$300,000	900	6	4.226%	2.777%	1.831%	1.244%	0.901%	0.603%	0.524%
\$300,000	1,000	6	3.906%	2.525%	1.646%	1.119%	0.818%	0.574%	0.514%
\$300,000	1,500	6	2.868%	1.727%	1.089%	0.764%	0.611%	0.517%	0.503%
\$300,000	2,000	6	2.268%	1.305%	0.831%	0.624%	0.544%	0.506%	0.501%
\$300,000	3,000	6	1.591%	0.888%	0.615%	0.529%	0.507%	0.502%	0.501%
\$300,000	4,000	6	1.203%	0.696%	0.544%	0.510%	0.504%	0.502%	0.501%
\$300,000	5,000	6	0.964%	0.602%	0.519%	0.505%	0.503%	0.502%	0.501%
\$300,000	10,000	6	0.552%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$300,000	20,000	6	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$325,000	5	6	71.343%	69.755%	68.220%	66.736%	65.303%	62.570%	59.999%
\$325,000	10	6	56.328%	54.450%	52.658%	50.945%	49.310%	46.261%	43.474%
\$325,000	15	6	47.534%	45.537%	43.656%	41.877%	40.190%	37.078%	34.266%
\$325,000	20	6	42.574%	40.516%	38.579%	36.755%	35.035%	31.876%	29.052%
\$325,000	25	6	38.420%	36.297%	34.316%	32.462%	30.716%	27.537%	24.744%
\$325,000	50	6	27.891%	25.679%	23.643%	21.775%	20.062%	17.026%	14.452%
\$325,000	100	6	18.862%	16.623%	14.624%	12.841%	11.258%	8.609%	6.564%
\$325,000	150	6	14.750%	12.539%	10.625%	8.977%	7.570%	5.352%	3.783%
\$325,000	200	6	12.229%	10.114%	8.325%	6.834%	5.599%	3.756%	2.530%
\$325,000	300	6	9.345%	7.353%	5.754%	4.483%	3.489%	2.140%	1.368%
\$325,000	400	6	7.661%	5.801%	4.366%	3.281%	2.475%	1.455%	0.942%
\$325,000	500	6	6.571%	4.811%	3.497%	2.542%	1.864%	1.071%	0.721%
\$325,000	600	6	5.768%	4.100%	2.895%	2.051%	1.481%	0.861%	0.623%
\$325,000	700	6	5.141%	3.556%	2.453%	1.710%	1.228%	0.739%	0.573%
\$325,000	800	6	4.684%	3.166%	2.134%	1.468%	1.057%	0.665%	0.542%
\$325,000	900	6	4.339%	2.873%	1.904%	1.298%	0.938%	0.618%	0.528%
\$325,000	1,000	6	4.011%	2.612%	1.712%	1.166%	0.849%	0.585%	0.517%
\$325,000	1,500	6	2.946%	1.786%	1.128%	0.788%	0.625%	0.520%	0.503%
\$325,000	2,000	6	2.331%	1.348%	0.856%	0.637%	0.549%	0.506%	0.501%
\$325,000	3,000	6	1.637%	0.913%	0.626%	0.533%	0.508%	0.502%	0.501%
\$325,000	4,000	6	1.239%	0.712%	0.549%	0.511%	0.504%	0.502%	0.501%
\$325,000	5,000	6	0.991%	0.611%	0.521%	0.506%	0.503%	0.502%	0.501%
\$325,000	10,000	6	0.557%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$325,000	20,000	6	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$350,000	5	6	71.492%	69.909%	68.380%	66.901%	65.473%	62.749%	60.188%
\$350,000	10	6	56.517%	54.648%	52.864%	51.160%	49.533%	46.501%	43.729%
\$350,000	15	6	47.744%	45.759%	43.889%	42.120%	40.444%	37.352%	34.556%
\$350,000	20	6	42.790%	40.744%	38.819%	37.007%	35.298%	32.160%	29.355%
\$350,000	25	6	38.655%	36.546%	34.578%	32.737%	31.003%	27.849%	25.078%
\$350,000	50	6	28.188%	25.995%	23.978%	22.128%	20.431%	17.426%	14.880%
\$350,000	100	6	19.174%	16.958%	14.975%	13.203%	11.625%	8.972%	6.898%
\$350,000	150	6	15.049%	12.848%	10.934%	9.281%	7.863%	5.615%	4.004%
\$350,000	200	6	12.500%	10.384%	8.590%	7.087%	5.836%	3.954%	2.686%
\$350,000	300	6	9.563%	7.564%	5.952%	4.665%	3.651%	2.260%	1.453%
\$350,000	400	6	7.842%	5.972%	4.521%	3.417%	2.591%	1.534%	0.989%
\$350,000	500	6	6.727%	4.955%	3.625%	2.650%	1.952%	1.124%	0.749%
\$350,000	600	6	5.906%	4.225%	3.002%	2.138%	1.549%	0.898%	0.639%
\$350,000	700	6	5.265%	3.666%	2.544%	1.782%	1.282%	0.765%	0.584%
\$350,000	800	6	4.798%	3.265%	2.213%	1.529%	1.100%	0.684%	0.550%
\$350,000	900	6	4.446%	2.964%	1.976%	1.351%	0.975%	0.632%	0.533%
\$350,000	1,000	6	4.112%	2.696%	1.776%	1.212%	0.880%	0.597%	0.520%
\$350,000	1,500	6	3.021%	1.844%	1.167%	0.812%	0.638%	0.523%	0.504%
\$350,000	2,000	6	2.391%	1.389%	0.880%	0.649%	0.555%	0.507%	0.501%
\$350,000	3,000	6	1.682%	0.938%	0.637%	0.537%	0.510%	0.502%	0.501%
\$350,000	4,000	6	1.273%	0.727%	0.555%	0.512%	0.504%	0.502%	0.501%
\$350,000	5,000	6	1.017%	0.620%	0.523%	0.506%	0.503%	0.502%	0.501%
\$350,000	10,000	6	0.562%	0.509%	0.505%	0.504%	0.503%	0.502%	0.501%
\$350,000	20,000	6	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$375,000	5	6	71.601%	70.021%	68.496%	67.021%	65.598%	62.881%	60.327%
\$375,000	10	6	56.672%	54.810%	53.033%	51.336%	49.716%	46.697%	43.938%
\$375,000	15	6	47.914%	45.938%	44.077%	42.316%	40.649%	37.572%	34.790%
\$375,000	20	6	42.968%	40.931%	39.016%	37.213%	35.513%	32.391%	29.602%
\$375,000	25	6	38.848%	36.751%	34.795%	32.963%	31.240%	28.105%	25.352%
\$375,000	50	6	28.429%	26.250%	24.248%	22.413%	20.728%	17.747%	15.223%
\$375,000	100	6	19.423%	17.226%	15.260%	13.501%	11.930%	9.278%	7.189%
\$375,000	150	6	15.294%	13.102%	11.192%	9.536%	8.110%	5.837%	4.195%
\$375,000	200	6	12.723%	10.609%	8.812%	7.299%	6.036%	4.123%	2.823%
\$375,000	300	6	9.746%	7.742%	6.120%	4.820%	3.791%	2.365%	1.528%
\$375,000	400	6	7.995%	6.118%	4.654%	3.535%	2.693%	1.604%	1.032%
\$375,000	500	6	6.860%	5.079%	3.736%	2.745%	2.029%	1.172%	0.775%
\$375,000	600	6	6.024%	4.333%	3.095%	2.215%	1.609%	0.932%	0.655%
\$375,000	700	6	5.372%	3.760%	2.623%	1.845%	1.331%	0.790%	0.594%
\$375,000	800	6	4.895%	3.350%	2.282%	1.582%	1.139%	0.702%	0.557%
\$375,000	900	6	4.538%	3.042%	2.038%	1.397%	1.008%	0.646%	0.537%
\$375,000	1,000	6	4.198%	2.767%	1.831%	1.253%	0.908%	0.607%	0.523%
\$375,000	1,500	6	3.085%	1.893%	1.201%	0.833%	0.650%	0.527%	0.505%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$375,000	2,000	6	2.441%	1.424%	0.901%	0.660%	0.560%	0.508%	0.502%
\$375,000	3,000	6	1.719%	0.960%	0.647%	0.541%	0.511%	0.502%	0.501%
\$375,000	4,000	6	1.302%	0.741%	0.559%	0.513%	0.504%	0.502%	0.501%
\$375,000	5,000	6	1.039%	0.629%	0.525%	0.506%	0.503%	0.502%	0.501%
\$375,000	10,000	6	0.567%	0.509%	0.505%	0.504%	0.503%	0.502%	0.501%
\$375,000	20,000	6	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$400,000	5	6	71.698%	70.122%	68.600%	67.129%	65.709%	62.998%	60.452%
\$400,000	10	6	56.809%	54.954%	53.183%	51.492%	49.877%	46.870%	44.122%
\$400,000	15	6	48.062%	46.094%	44.241%	42.486%	40.826%	37.762%	34.992%
\$400,000	20	6	43.118%	41.090%	39.182%	37.387%	35.695%	32.587%	29.810%
\$400,000	25	6	39.010%	36.922%	34.976%	33.152%	31.436%	28.318%	25.579%
\$400,000	50	6	28.625%	26.459%	24.469%	22.646%	20.972%	18.011%	15.506%
\$400,000	100	6	19.630%	17.449%	15.498%	13.752%	12.190%	9.544%	7.449%
\$400,000	150	6	15.503%	13.319%	11.416%	9.760%	8.329%	6.035%	4.368%
\$400,000	200	6	12.918%	10.806%	9.007%	7.489%	6.216%	4.275%	2.948%
\$400,000	300	6	9.906%	7.900%	6.269%	4.959%	3.916%	2.463%	1.597%
\$400,000	400	6	8.131%	6.248%	4.774%	3.642%	2.786%	1.669%	1.073%
\$400,000	500	6	6.979%	5.191%	3.836%	2.831%	2.101%	1.217%	0.800%
\$400,000	600	6	6.131%	4.431%	3.180%	2.286%	1.665%	0.964%	0.671%
\$400,000	700	6	5.468%	3.846%	2.695%	1.903%	1.375%	0.813%	0.604%
\$400,000	800	6	4.983%	3.427%	2.345%	1.631%	1.175%	0.719%	0.563%
\$400,000	900	6	4.620%	3.113%	2.094%	1.439%	1.038%	0.659%	0.541%
\$400,000	1,000	6	4.275%	2.832%	1.882%	1.290%	0.935%	0.617%	0.526%
\$400,000	1,500	6	3.143%	1.938%	1.232%	0.852%	0.661%	0.530%	0.505%
\$400,000	2,000	6	2.487%	1.457%	0.921%	0.671%	0.565%	0.509%	0.502%
\$400,000	3,000	6	1.752%	0.979%	0.656%	0.544%	0.512%	0.502%	0.501%
\$400,000	4,000	6	1.328%	0.753%	0.563%	0.514%	0.504%	0.502%	0.501%
\$400,000	5,000	6	1.059%	0.636%	0.527%	0.507%	0.503%	0.502%	0.501%
\$400,000	10,000	6	0.571%	0.509%	0.505%	0.504%	0.503%	0.502%	0.501%
\$400,000	20,000	6	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$425,000	5	6	71.772%	70.198%	68.678%	67.211%	65.794%	63.088%	60.546%
\$425,000	10	6	56.918%	55.068%	53.301%	51.615%	50.005%	47.007%	44.268%
\$425,000	15	6	48.180%	46.218%	44.371%	42.622%	40.967%	37.914%	35.153%
\$425,000	20	6	43.234%	41.212%	39.311%	37.522%	35.836%	32.739%	29.973%
\$425,000	25	6	39.134%	37.054%	35.115%	33.297%	31.588%	28.482%	25.756%
\$425,000	50	6	28.774%	26.618%	24.637%	22.823%	21.158%	18.214%	15.722%
\$425,000	100	6	19.796%	17.628%	15.689%	13.954%	12.402%	9.766%	7.671%
\$425,000	150	6	15.675%	13.500%	11.603%	9.951%	8.517%	6.210%	4.524%
\$425,000	200	6	13.084%	10.975%	9.176%	7.655%	6.374%	4.412%	3.060%
\$425,000	300	6	10.041%	8.033%	6.397%	5.078%	4.024%	2.547%	1.658%
\$425,000	400	6	8.247%	6.360%	4.878%	3.735%	2.867%	1.726%	1.110%
\$425,000	500	6	7.081%	5.288%	3.923%	2.907%	2.165%	1.258%	0.823%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$425,000	600	6	6.222%	4.515%	3.253%	2.347%	1.714%	0.993%	0.685%
\$425,000	700	6	5.552%	3.920%	2.757%	1.954%	1.415%	0.834%	0.613%
\$425,000	800	6	5.059%	3.494%	2.401%	1.674%	1.207%	0.734%	0.569%
\$425,000	900	6	4.692%	3.174%	2.143%	1.476%	1.065%	0.671%	0.545%
\$425,000	1,000	6	4.342%	2.888%	1.927%	1.323%	0.958%	0.626%	0.529%
\$425,000	1,500	6	3.193%	1.977%	1.260%	0.870%	0.672%	0.533%	0.506%
\$425,000	2,000	6	2.527%	1.485%	0.939%	0.680%	0.570%	0.510%	0.502%
\$425,000	3,000	6	1.781%	0.996%	0.664%	0.547%	0.512%	0.502%	0.501%
\$425,000	4,000	6	1.350%	0.764%	0.567%	0.515%	0.505%	0.502%	0.501%
\$425,000	5,000	6	1.076%	0.643%	0.529%	0.507%	0.503%	0.502%	0.501%
\$425,000	10,000	6	0.575%	0.510%	0.505%	0.504%	0.503%	0.502%	0.501%
\$425,000	20,000	6	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$450,000	5	6	71.833%	70.262%	68.744%	67.279%	65.864%	63.162%	60.625%
\$450,000	10	6	57.004%	55.157%	53.394%	51.712%	50.106%	47.115%	44.383%
\$450,000	15	6	48.278%	46.321%	44.479%	42.735%	41.085%	38.039%	35.286%
\$450,000	20	6	43.332%	41.316%	39.420%	37.636%	35.954%	32.866%	30.108%
\$450,000	25	6	39.238%	37.164%	35.231%	33.418%	31.714%	28.619%	25.902%
\$450,000	50	6	28.891%	26.742%	24.769%	22.963%	21.304%	18.372%	15.892%
\$450,000	100	6	19.927%	17.769%	15.840%	14.114%	12.569%	9.945%	7.855%
\$450,000	150	6	15.811%	13.645%	11.753%	10.105%	8.672%	6.356%	4.656%
\$450,000	200	6	13.218%	11.114%	9.315%	7.793%	6.508%	4.529%	3.157%
\$450,000	300	6	10.154%	8.145%	6.505%	5.179%	4.118%	2.621%	1.712%
\$450,000	400	6	8.345%	6.456%	4.967%	3.816%	2.937%	1.776%	1.143%
\$450,000	500	6	7.169%	5.371%	3.999%	2.972%	2.220%	1.294%	0.843%
\$450,000	600	6	6.300%	4.587%	3.317%	2.401%	1.757%	1.019%	0.698%
\$450,000	700	6	5.623%	3.984%	2.812%	1.998%	1.449%	0.852%	0.621%
\$450,000	800	6	5.124%	3.551%	2.448%	1.711%	1.234%	0.748%	0.574%
\$450,000	900	6	4.752%	3.226%	2.185%	1.508%	1.088%	0.682%	0.549%
\$450,000	1,000	6	4.399%	2.937%	1.966%	1.352%	0.978%	0.635%	0.532%
\$450,000	1,500	6	3.235%	2.010%	1.284%	0.885%	0.681%	0.535%	0.506%
\$450,000	2,000	6	2.561%	1.509%	0.953%	0.688%	0.573%	0.511%	0.502%
\$450,000	3,000	6	1.805%	1.011%	0.671%	0.550%	0.513%	0.502%	0.501%
\$450,000	4,000	6	1.369%	0.773%	0.570%	0.516%	0.505%	0.502%	0.501%
\$450,000	5,000	6	1.091%	0.649%	0.530%	0.507%	0.503%	0.502%	0.501%
\$450,000	10,000	6	0.579%	0.510%	0.505%	0.504%	0.503%	0.502%	0.501%
\$450,000	20,000	6	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$475,000	5	6	71.890%	70.321%	68.805%	67.342%	65.929%	63.230%	60.697%
\$475,000	10	6	57.083%	55.239%	53.480%	51.801%	50.198%	47.213%	44.487%
\$475,000	15	6	48.363%	46.411%	44.573%	42.832%	41.186%	38.148%	35.401%
\$475,000	20	6	43.413%	41.401%	39.510%	37.730%	36.052%	32.972%	30.220%
\$475,000	25	6	39.324%	37.256%	35.328%	33.520%	31.820%	28.733%	26.024%
\$475,000	50	6	28.985%	26.843%	24.876%	23.076%	21.423%	18.502%	16.031%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$475,000	100	6	20.037%	17.888%	15.967%	14.248%	12.711%	10.098%	8.013%
\$475,000	150	6	15.928%	13.770%	11.884%	10.240%	8.810%	6.489%	4.776%
\$475,000	200	6	13.335%	11.234%	9.438%	7.915%	6.627%	4.635%	3.246%
\$475,000	300	6	10.254%	8.246%	6.603%	5.271%	4.203%	2.689%	1.763%
\$475,000	400	6	8.434%	6.544%	5.049%	3.890%	3.003%	1.824%	1.174%
\$475,000	500	6	7.249%	5.446%	4.068%	3.033%	2.272%	1.328%	0.863%
\$475,000	600	6	6.370%	4.653%	3.375%	2.450%	1.797%	1.043%	0.710%
\$475,000	700	6	5.688%	4.043%	2.861%	2.039%	1.480%	0.870%	0.629%
\$475,000	800	6	5.182%	3.603%	2.492%	1.745%	1.260%	0.761%	0.579%
\$475,000	900	6	4.806%	3.274%	2.224%	1.538%	1.109%	0.692%	0.553%
\$475,000	1,000	6	4.451%	2.981%	2.001%	1.378%	0.996%	0.643%	0.535%
\$475,000	1,500	6	3.273%	2.040%	1.305%	0.899%	0.689%	0.538%	0.507%
\$475,000	2,000	6	2.592%	1.531%	0.967%	0.695%	0.577%	0.512%	0.502%
\$475,000	3,000	6	1.828%	1.024%	0.677%	0.552%	0.514%	0.502%	0.501%
\$475,000	4,000	6	1.386%	0.781%	0.573%	0.517%	0.505%	0.502%	0.501%
\$475,000	5,000	6	1.104%	0.654%	0.532%	0.507%	0.503%	0.502%	0.501%
\$475,000	10,000	6	0.582%	0.510%	0.505%	0.504%	0.503%	0.502%	0.501%
\$475,000	20,000	6	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$500,000	5	6	71.947%	70.380%	68.866%	67.404%	65.994%	63.298%	60.769%
\$500,000	10	6	57.159%	55.318%	53.562%	51.886%	50.287%	47.307%	44.587%
\$500,000	15	6	48.441%	46.492%	44.658%	42.921%	41.278%	38.246%	35.506%
\$500,000	20	6	43.485%	41.477%	39.589%	37.813%	36.139%	33.066%	30.321%
\$500,000	25	6	39.401%	37.338%	35.414%	33.610%	31.914%	28.836%	26.134%
\$500,000	50	6	29.069%	26.933%	24.972%	23.177%	21.529%	18.617%	16.155%
\$500,000	100	6	20.136%	17.995%	16.081%	14.370%	12.838%	10.237%	8.160%
\$500,000	150	6	16.034%	13.885%	12.006%	10.367%	8.938%	6.617%	4.895%
\$500,000	200	6	13.443%	11.348%	9.554%	8.030%	6.742%	4.738%	3.335%
\$500,000	300	6	10.350%	8.342%	6.697%	5.361%	4.287%	2.756%	1.815%
\$500,000	400	6	8.521%	6.629%	5.130%	3.965%	3.068%	1.871%	1.207%
\$500,000	500	6	7.325%	5.520%	4.136%	3.093%	2.323%	1.362%	0.883%
\$500,000	600	6	6.438%	4.717%	3.432%	2.498%	1.837%	1.067%	0.723%
\$500,000	700	6	5.750%	4.100%	2.910%	2.079%	1.512%	0.888%	0.637%
\$500,000	800	6	5.239%	3.653%	2.535%	1.780%	1.286%	0.774%	0.585%
\$500,000	900	6	4.859%	3.321%	2.263%	1.567%	1.131%	0.702%	0.557%
\$500,000	1,000	6	4.502%	3.025%	2.037%	1.404%	1.015%	0.651%	0.538%
\$500,000	1,500	6	3.311%	2.070%	1.326%	0.913%	0.697%	0.540%	0.508%
\$500,000	2,000	6	2.622%	1.552%	0.981%	0.703%	0.581%	0.512%	0.502%
\$500,000	3,000	6	1.850%	1.037%	0.684%	0.555%	0.515%	0.502%	0.501%
\$500,000	4,000	6	1.403%	0.790%	0.577%	0.518%	0.505%	0.502%	0.501%
\$500,000	5,000	6	1.118%	0.660%	0.533%	0.508%	0.503%	0.502%	0.501%
\$500,000	10,000	6	0.585%	0.511%	0.505%	0.504%	0.503%	0.502%	0.501%
\$500,000	20,000	6	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$30,000	5	7	52.893%	50.582%	48.346%	46.179%	44.080%	40.063%	36.261%
\$30,000	10	7	35.133%	32.385%	29.808%	27.407%	25.186%	21.249%	17.919%
\$30,000	15	7	27.437%	24.840%	22.451%	20.266%	18.263%	14.748%	11.832%
\$30,000	20	7	22.915%	20.368%	18.057%	15.966%	14.085%	10.892%	8.364%
\$30,000	25	7	19.983%	17.483%	15.247%	13.250%	11.489%	8.563%	6.337%
\$30,000	50	7	13.061%	10.766%	8.816%	7.177%	5.812%	3.780%	2.463%
\$30,000	100	7	8.196%	6.210%	4.654%	3.468%	2.580%	1.470%	0.922%
\$30,000	150	7	6.160%	4.386%	3.095%	2.182%	1.557%	0.882%	0.625%
\$30,000	200	7	4.984%	3.387%	2.289%	1.564%	1.107%	0.675%	0.541%
\$30,000	300	7	3.747%	2.379%	1.524%	1.020%	0.747%	0.546%	0.507%
\$30,000	400	7	3.043%	1.836%	1.144%	0.783%	0.613%	0.514%	0.502%
\$30,000	500	7	2.578%	1.503%	0.935%	0.667%	0.556%	0.506%	0.501%
\$30,000	600	7	2.225%	1.263%	0.796%	0.600%	0.530%	0.503%	0.501%
\$30,000	700	7	1.973%	1.101%	0.711%	0.563%	0.517%	0.502%	0.501%
\$30,000	800	7	1.763%	0.975%	0.649%	0.540%	0.510%	0.502%	0.501%
\$30,000	900	7	1.603%	0.887%	0.613%	0.529%	0.508%	0.502%	0.501%
\$30,000	1,000	7	1.463%	0.815%	0.584%	0.520%	0.506%	0.502%	0.501%
\$30,000	1,500	7	1.035%	0.626%	0.524%	0.506%	0.503%	0.502%	0.501%
\$30,000	2,000	7	0.811%	0.555%	0.510%	0.504%	0.503%	0.502%	0.501%
\$30,000	3,000	7	0.623%	0.516%	0.505%	0.504%	0.503%	0.502%	0.501%
\$30,000	4,000	7	0.554%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$30,000	5,000	7	0.527%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$30,000	10,000	7	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$30,000	20,000	7	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$35,000	5	7	54.952%	52.731%	50.583%	48.507%	46.492%	42.633%	38.997%
\$35,000	10	7	37.330%	34.596%	32.002%	29.565%	27.274%	23.162%	19.649%
\$35,000	15	7	28.992%	26.374%	23.966%	21.754%	19.727%	16.158%	13.151%
\$35,000	20	7	24.263%	21.709%	19.381%	17.263%	15.344%	12.048%	9.392%
\$35,000	25	7	21.176%	18.656%	16.390%	14.359%	12.546%	9.504%	7.158%
\$35,000	50	7	13.871%	11.544%	9.549%	7.856%	6.428%	4.271%	2.836%
\$35,000	100	7	8.729%	6.698%	5.090%	3.842%	2.891%	1.666%	1.035%
\$35,000	150	7	6.566%	4.743%	3.394%	2.421%	1.742%	0.978%	0.669%
\$35,000	200	7	5.316%	3.669%	2.515%	1.733%	1.228%	0.728%	0.560%
\$35,000	300	7	3.999%	2.579%	1.669%	1.118%	0.807%	0.562%	0.510%
\$35,000	400	7	3.256%	1.994%	1.251%	0.847%	0.646%	0.521%	0.503%
\$35,000	500	7	2.764%	1.635%	1.017%	0.711%	0.577%	0.509%	0.501%
\$35,000	600	7	2.388%	1.372%	0.857%	0.629%	0.542%	0.504%	0.501%
\$35,000	700	7	2.121%	1.194%	0.759%	0.583%	0.524%	0.503%	0.501%
\$35,000	800	7	1.899%	1.055%	0.686%	0.554%	0.514%	0.502%	0.501%
\$35,000	900	7	1.730%	0.957%	0.642%	0.538%	0.510%	0.502%	0.501%
\$35,000	1,000	7	1.580%	0.876%	0.608%	0.527%	0.507%	0.502%	0.501%
\$35,000	1,500	7	1.115%	0.657%	0.532%	0.507%	0.503%	0.502%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$35,000	2,000	7	0.867%	0.570%	0.512%	0.504%	0.503%	0.502%	0.501%
\$35,000	3,000	7	0.653%	0.521%	0.506%	0.504%	0.503%	0.502%	0.501%
\$35,000	4,000	7	0.569%	0.509%	0.505%	0.504%	0.503%	0.502%	0.501%
\$35,000	5,000	7	0.535%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$35,000	10,000	7	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$35,000	20,000	7	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$40,000	5	7	56.651%	54.504%	52.431%	50.422%	48.472%	44.750%	41.243%
\$40,000	10	7	39.275%	36.596%	34.033%	31.591%	29.280%	25.054%	21.378%
\$40,000	15	7	30.453%	27.805%	25.365%	23.117%	21.054%	17.423%	14.362%
\$40,000	20	7	25.469%	22.917%	20.582%	18.448%	16.502%	13.126%	10.375%
\$40,000	25	7	22.255%	19.724%	17.443%	15.386%	13.533%	10.395%	7.945%
\$40,000	50	7	14.611%	12.258%	10.225%	8.487%	7.008%	4.745%	3.202%
\$40,000	100	7	9.221%	7.150%	5.495%	4.197%	3.191%	1.861%	1.152%
\$40,000	150	7	6.939%	5.074%	3.676%	2.650%	1.921%	1.078%	0.718%
\$40,000	200	7	5.624%	3.933%	2.728%	1.898%	1.348%	0.783%	0.582%
\$40,000	300	7	4.235%	2.769%	1.812%	1.218%	0.871%	0.583%	0.516%
\$40,000	400	7	3.450%	2.141%	1.352%	0.909%	0.681%	0.529%	0.504%
\$40,000	500	7	2.931%	1.758%	1.095%	0.755%	0.599%	0.513%	0.502%
\$40,000	600	7	2.536%	1.474%	0.918%	0.660%	0.555%	0.505%	0.501%
\$40,000	700	7	2.256%	1.282%	0.807%	0.605%	0.532%	0.503%	0.501%
\$40,000	800	7	2.023%	1.131%	0.724%	0.569%	0.519%	0.503%	0.501%
\$40,000	900	7	1.844%	1.023%	0.673%	0.549%	0.514%	0.502%	0.501%
\$40,000	1,000	7	1.687%	0.934%	0.633%	0.535%	0.509%	0.502%	0.501%
\$40,000	1,500	7	1.190%	0.688%	0.541%	0.509%	0.503%	0.502%	0.501%
\$40,000	2,000	7	0.921%	0.587%	0.515%	0.505%	0.503%	0.502%	0.501%
\$40,000	3,000	7	0.683%	0.526%	0.506%	0.504%	0.503%	0.502%	0.501%
\$40,000	4,000	7	0.585%	0.511%	0.505%	0.504%	0.503%	0.502%	0.501%
\$40,000	5,000	7	0.544%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$40,000	10,000	7	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$40,000	20,000	7	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$45,000	5	7	58.123%	56.041%	54.026%	52.073%	50.181%	46.577%	43.172%
\$45,000	10	7	40.970%	38.381%	35.887%	33.484%	31.178%	26.917%	23.125%
\$45,000	15	7	31.864%	29.187%	26.708%	24.420%	22.308%	18.595%	15.471%
\$45,000	20	7	26.588%	24.028%	21.683%	19.537%	17.570%	14.138%	11.309%
\$45,000	25	7	23.245%	20.713%	18.415%	16.335%	14.456%	11.244%	8.693%
\$45,000	50	7	15.294%	12.922%	10.854%	9.077%	7.558%	5.199%	3.557%
\$45,000	100	7	9.680%	7.575%	5.880%	4.536%	3.481%	2.055%	1.272%
\$45,000	150	7	7.291%	5.389%	3.946%	2.875%	2.100%	1.182%	0.771%
\$45,000	200	7	5.916%	4.185%	2.934%	2.060%	1.470%	0.842%	0.607%
\$45,000	300	7	4.458%	2.953%	1.951%	1.317%	0.935%	0.606%	0.522%
\$45,000	400	7	3.634%	2.284%	1.451%	0.973%	0.718%	0.538%	0.506%
\$45,000	500	7	3.089%	1.875%	1.173%	0.801%	0.622%	0.517%	0.502%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$45,000	600	7	2.676%	1.571%	0.978%	0.692%	0.570%	0.507%	0.501%
\$45,000	700	7	2.383%	1.368%	0.856%	0.629%	0.541%	0.504%	0.501%
\$45,000	800	7	2.139%	1.205%	0.763%	0.586%	0.524%	0.503%	0.501%
\$45,000	900	7	1.952%	1.088%	0.704%	0.562%	0.517%	0.503%	0.501%
\$45,000	1,000	7	1.787%	0.991%	0.658%	0.544%	0.512%	0.502%	0.501%
\$45,000	1,500	7	1.262%	0.719%	0.551%	0.511%	0.504%	0.502%	0.501%
\$45,000	2,000	7	0.974%	0.604%	0.519%	0.505%	0.503%	0.502%	0.501%
\$45,000	3,000	7	0.713%	0.532%	0.507%	0.504%	0.503%	0.502%	0.501%
\$45,000	4,000	7	0.602%	0.513%	0.505%	0.504%	0.503%	0.502%	0.501%
\$45,000	5,000	7	0.553%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$45,000	10,000	7	0.508%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$45,000	20,000	7	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$50,000	5	7	59.365%	57.333%	55.366%	53.461%	51.621%	48.108%	44.790%
\$50,000	10	7	42.411%	39.893%	37.468%	35.130%	32.875%	28.626%	24.778%
\$50,000	15	7	33.165%	30.484%	27.975%	25.642%	23.488%	19.686%	16.480%
\$50,000	20	7	27.612%	25.035%	22.674%	20.508%	18.525%	15.053%	12.163%
\$50,000	25	7	24.138%	21.607%	19.297%	17.199%	15.302%	12.032%	9.399%
\$50,000	50	7	15.914%	13.522%	11.429%	9.618%	8.067%	5.621%	3.896%
\$50,000	100	7	10.099%	7.967%	6.234%	4.851%	3.754%	2.243%	1.391%
\$50,000	150	7	7.609%	5.676%	4.197%	3.085%	2.270%	1.281%	0.824%
\$50,000	200	7	6.181%	4.417%	3.127%	2.214%	1.587%	0.902%	0.633%
\$50,000	300	7	4.663%	3.124%	2.082%	1.412%	1.000%	0.629%	0.529%
\$50,000	400	7	3.803%	2.417%	1.546%	1.035%	0.754%	0.548%	0.508%
\$50,000	500	7	3.233%	1.984%	1.247%	0.846%	0.647%	0.522%	0.503%
\$50,000	600	7	2.803%	1.663%	1.036%	0.724%	0.585%	0.509%	0.501%
\$50,000	700	7	2.498%	1.447%	0.904%	0.653%	0.551%	0.505%	0.501%
\$50,000	800	7	2.244%	1.274%	0.800%	0.603%	0.531%	0.503%	0.501%
\$50,000	900	7	2.051%	1.149%	0.736%	0.574%	0.522%	0.503%	0.501%
\$50,000	1,000	7	1.878%	1.045%	0.683%	0.553%	0.515%	0.502%	0.501%
\$50,000	1,500	7	1.329%	0.750%	0.561%	0.514%	0.504%	0.502%	0.501%
\$50,000	2,000	7	1.023%	0.621%	0.523%	0.506%	0.503%	0.502%	0.501%
\$50,000	3,000	7	0.742%	0.538%	0.508%	0.504%	0.503%	0.502%	0.501%
\$50,000	4,000	7	0.619%	0.515%	0.505%	0.504%	0.503%	0.502%	0.501%
\$50,000	5,000	7	0.562%	0.509%	0.505%	0.504%	0.503%	0.502%	0.501%
\$50,000	10,000	7	0.508%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$50,000	20,000	7	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$55,000	5	7	60.381%	58.388%	56.460%	54.597%	52.796%	49.355%	46.111%
\$55,000	10	7	43.604%	41.142%	38.773%	36.489%	34.293%	30.129%	26.277%
\$55,000	15	7	34.332%	31.656%	29.141%	26.783%	24.589%	20.694%	17.405%
\$55,000	20	7	28.551%	25.959%	23.572%	21.383%	19.379%	15.870%	12.932%
\$55,000	25	7	24.928%	22.394%	20.077%	17.969%	16.054%	12.740%	10.047%
\$55,000	50	7	16.464%	14.054%	11.943%	10.104%	8.522%	6.007%	4.206%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$55,000	100	7	10.475%	8.319%	6.554%	5.135%	4.003%	2.421%	1.506%
\$55,000	150	7	7.893%	5.934%	4.424%	3.277%	2.426%	1.376%	0.876%
\$55,000	200	7	6.419%	4.626%	3.302%	2.354%	1.697%	0.960%	0.658%
\$55,000	300	7	4.844%	3.275%	2.201%	1.498%	1.060%	0.651%	0.535%
\$55,000	400	7	3.953%	2.536%	1.633%	1.093%	0.790%	0.558%	0.509%
\$55,000	500	7	3.361%	2.081%	1.314%	0.887%	0.670%	0.528%	0.504%
\$55,000	600	7	2.915%	1.744%	1.088%	0.754%	0.600%	0.512%	0.502%
\$55,000	700	7	2.600%	1.518%	0.946%	0.675%	0.561%	0.506%	0.501%
\$55,000	800	7	2.338%	1.336%	0.836%	0.619%	0.537%	0.504%	0.501%
\$55,000	900	7	2.139%	1.206%	0.765%	0.587%	0.526%	0.503%	0.501%
\$55,000	1,000	7	1.959%	1.094%	0.708%	0.563%	0.518%	0.503%	0.501%
\$55,000	1,500	7	1.389%	0.779%	0.571%	0.516%	0.505%	0.502%	0.501%
\$55,000	2,000	7	1.068%	0.638%	0.527%	0.506%	0.503%	0.502%	0.501%
\$55,000	3,000	7	0.769%	0.545%	0.508%	0.504%	0.503%	0.502%	0.501%
\$55,000	4,000	7	0.635%	0.518%	0.506%	0.504%	0.503%	0.502%	0.501%
\$55,000	5,000	7	0.571%	0.510%	0.505%	0.504%	0.503%	0.502%	0.501%
\$55,000	10,000	7	0.508%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$55,000	20,000	7	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$60,000	5	7	61.217%	59.256%	57.362%	55.533%	53.765%	50.382%	47.200%
\$60,000	10	7	44.591%	42.176%	39.852%	37.615%	35.465%	31.388%	27.608%
\$60,000	15	7	35.370%	32.709%	30.194%	27.834%	25.621%	21.651%	18.267%
\$60,000	20	7	29.407%	26.798%	24.391%	22.176%	20.149%	16.595%	13.618%
\$60,000	25	7	25.635%	23.093%	20.766%	18.648%	16.720%	13.376%	10.633%
\$60,000	50	7	16.952%	14.533%	12.405%	10.547%	8.939%	6.365%	4.498%
\$60,000	100	7	10.817%	8.638%	6.846%	5.396%	4.234%	2.587%	1.616%
\$60,000	150	7	8.153%	6.171%	4.632%	3.453%	2.572%	1.469%	0.927%
\$60,000	200	7	6.634%	4.817%	3.465%	2.486%	1.799%	1.016%	0.684%
\$60,000	300	7	5.008%	3.413%	2.310%	1.578%	1.116%	0.674%	0.542%
\$60,000	400	7	4.081%	2.638%	1.707%	1.143%	0.820%	0.566%	0.511%
\$60,000	500	7	3.477%	2.171%	1.377%	0.927%	0.693%	0.533%	0.505%
\$60,000	600	7	3.017%	1.819%	1.137%	0.782%	0.615%	0.515%	0.502%
\$60,000	700	7	2.692%	1.583%	0.987%	0.697%	0.571%	0.508%	0.501%
\$60,000	800	7	2.424%	1.394%	0.869%	0.636%	0.544%	0.505%	0.501%
\$60,000	900	7	2.220%	1.258%	0.793%	0.599%	0.531%	0.504%	0.501%
\$60,000	1,000	7	2.033%	1.140%	0.731%	0.573%	0.521%	0.503%	0.501%
\$60,000	1,500	7	1.445%	0.806%	0.581%	0.519%	0.505%	0.502%	0.501%
\$60,000	2,000	7	1.110%	0.654%	0.531%	0.507%	0.503%	0.502%	0.501%
\$60,000	3,000	7	0.794%	0.551%	0.509%	0.504%	0.503%	0.502%	0.501%
\$60,000	4,000	7	0.650%	0.520%	0.506%	0.504%	0.503%	0.502%	0.501%
\$60,000	5,000	7	0.580%	0.510%	0.505%	0.504%	0.503%	0.502%	0.501%
\$60,000	10,000	7	0.509%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$60,000	20,000	7	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$65,000	5	7	61.932%	60.000%	58.134%	56.334%	54.591%	51.260%	48.130%
\$65,000	10	7	45.422%	43.046%	40.759%	38.564%	36.450%	32.448%	28.746%
\$65,000	15	7	36.265%	33.636%	31.138%	28.779%	26.567%	22.557%	19.092%
\$65,000	20	7	30.191%	27.572%	25.148%	22.917%	20.866%	17.264%	14.246%
\$65,000	25	7	26.279%	23.729%	21.395%	19.266%	17.325%	13.956%	11.174%
\$65,000	50	7	17.392%	14.966%	12.825%	10.949%	9.321%	6.698%	4.773%
\$65,000	100	7	11.128%	8.932%	7.116%	5.638%	4.448%	2.747%	1.724%
\$65,000	150	7	8.389%	6.388%	4.825%	3.619%	2.711%	1.558%	0.978%
\$65,000	200	7	6.831%	4.993%	3.615%	2.609%	1.896%	1.071%	0.711%
\$65,000	300	7	5.159%	3.541%	2.412%	1.655%	1.170%	0.697%	0.550%
\$65,000	400	7	4.205%	2.738%	1.782%	1.193%	0.852%	0.577%	0.513%
\$65,000	500	7	3.584%	2.253%	1.436%	0.966%	0.715%	0.539%	0.506%
\$65,000	600	7	3.112%	1.890%	1.184%	0.810%	0.629%	0.518%	0.502%
\$65,000	700	7	2.777%	1.645%	1.026%	0.719%	0.582%	0.509%	0.502%
\$65,000	800	7	2.503%	1.448%	0.902%	0.652%	0.551%	0.505%	0.501%
\$65,000	900	7	2.293%	1.307%	0.820%	0.612%	0.536%	0.504%	0.501%
\$65,000	1,000	7	2.101%	1.183%	0.754%	0.582%	0.524%	0.503%	0.501%
\$65,000	1,500	7	1.496%	0.832%	0.591%	0.522%	0.506%	0.502%	0.501%
\$65,000	2,000	7	1.149%	0.670%	0.535%	0.508%	0.503%	0.502%	0.501%
\$65,000	3,000	7	0.817%	0.557%	0.510%	0.504%	0.503%	0.502%	0.501%
\$65,000	4,000	7	0.665%	0.522%	0.506%	0.504%	0.503%	0.502%	0.501%
\$65,000	5,000	7	0.589%	0.511%	0.505%	0.504%	0.503%	0.502%	0.501%
\$65,000	10,000	7	0.509%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$65,000	20,000	7	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$70,000	5	7	62.546%	60.638%	58.798%	57.022%	55.301%	52.014%	48.928%
\$70,000	10	7	46.137%	43.795%	41.542%	39.381%	37.297%	33.363%	29.729%
\$70,000	15	7	37.042%	34.453%	31.988%	29.648%	27.436%	23.419%	19.902%
\$70,000	20	7	30.924%	28.304%	25.868%	23.622%	21.554%	17.905%	14.840%
\$70,000	25	7	26.892%	24.332%	21.991%	19.849%	17.896%	14.502%	11.688%
\$70,000	50	7	17.807%	15.373%	13.223%	11.333%	9.685%	7.014%	5.041%
\$70,000	100	7	11.420%	9.209%	7.371%	5.869%	4.653%	2.901%	1.831%
\$70,000	150	7	8.612%	6.595%	5.008%	3.778%	2.845%	1.645%	1.029%
\$70,000	200	7	7.017%	5.159%	3.758%	2.728%	1.990%	1.125%	0.738%
\$70,000	300	7	5.302%	3.663%	2.509%	1.729%	1.223%	0.720%	0.559%
\$70,000	400	7	4.323%	2.834%	1.855%	1.244%	0.885%	0.588%	0.516%
\$70,000	500	7	3.685%	2.332%	1.493%	1.004%	0.738%	0.546%	0.507%
\$70,000	600	7	3.202%	1.959%	1.230%	0.838%	0.644%	0.521%	0.503%
\$70,000	700	7	2.858%	1.705%	1.064%	0.741%	0.592%	0.511%	0.502%
\$70,000	800	7	2.578%	1.501%	0.934%	0.669%	0.559%	0.506%	0.501%
\$70,000	900	7	2.363%	1.354%	0.847%	0.625%	0.541%	0.505%	0.501%
\$70,000	1,000	7	2.165%	1.225%	0.777%	0.592%	0.528%	0.503%	0.501%
\$70,000	1,500	7	1.545%	0.858%	0.602%	0.525%	0.507%	0.502%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$70,000	2,000	7	1.186%	0.686%	0.540%	0.509%	0.503%	0.502%	0.501%
\$70,000	3,000	7	0.840%	0.563%	0.511%	0.504%	0.503%	0.502%	0.501%
\$70,000	4,000	7	0.680%	0.525%	0.506%	0.504%	0.503%	0.502%	0.501%
\$70,000	5,000	7	0.598%	0.513%	0.505%	0.504%	0.503%	0.502%	0.501%
\$70,000	10,000	7	0.509%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$70,000	20,000	7	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$75,000	5	7	63.102%	61.217%	59.399%	57.644%	55.942%	52.697%	49.650%
\$75,000	10	7	46.785%	44.472%	42.252%	40.119%	38.064%	34.189%	30.616%
\$75,000	15	7	37.741%	35.192%	32.766%	30.457%	28.263%	24.245%	20.703%
\$75,000	20	7	31.611%	29.001%	26.565%	24.307%	22.222%	18.532%	15.417%
\$75,000	25	7	27.481%	24.915%	22.565%	20.412%	18.446%	15.022%	12.181%
\$75,000	50	7	18.199%	15.761%	13.600%	11.698%	10.032%	7.320%	5.303%
\$75,000	100	7	11.697%	9.474%	7.617%	6.092%	4.851%	3.052%	1.937%
\$75,000	150	7	8.824%	6.792%	5.184%	3.932%	2.975%	1.731%	1.080%
\$75,000	200	7	7.194%	5.317%	3.895%	2.843%	2.081%	1.178%	0.765%
\$75,000	300	7	5.439%	3.779%	2.603%	1.801%	1.275%	0.744%	0.567%
\$75,000	400	7	4.435%	2.925%	1.925%	1.293%	0.917%	0.599%	0.519%
\$75,000	500	7	3.782%	2.409%	1.549%	1.041%	0.760%	0.552%	0.509%
\$75,000	600	7	3.288%	2.025%	1.275%	0.866%	0.660%	0.525%	0.503%
\$75,000	700	7	2.935%	1.762%	1.101%	0.762%	0.604%	0.513%	0.502%
\$75,000	800	7	2.650%	1.551%	0.965%	0.686%	0.566%	0.507%	0.501%
\$75,000	900	7	2.429%	1.400%	0.874%	0.638%	0.547%	0.506%	0.501%
\$75,000	1,000	7	2.226%	1.265%	0.799%	0.602%	0.532%	0.504%	0.501%
\$75,000	1,500	7	1.591%	0.883%	0.612%	0.528%	0.507%	0.502%	0.501%
\$75,000	2,000	7	1.223%	0.702%	0.545%	0.510%	0.503%	0.502%	0.501%
\$75,000	3,000	7	0.862%	0.570%	0.512%	0.505%	0.503%	0.502%	0.501%
\$75,000	4,000	7	0.694%	0.528%	0.506%	0.504%	0.503%	0.502%	0.501%
\$75,000	5,000	7	0.607%	0.514%	0.505%	0.504%	0.503%	0.502%	0.501%
\$75,000	10,000	7	0.510%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$75,000	20,000	7	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$80,000	5	7	63.623%	61.758%	59.961%	58.224%	56.540%	53.333%	50.322%
\$80,000	10	7	47.390%	45.104%	42.914%	40.806%	38.778%	34.959%	31.441%
\$80,000	15	7	38.392%	35.881%	33.491%	31.219%	29.056%	25.058%	21.503%
\$80,000	20	7	32.271%	29.676%	27.249%	24.989%	22.891%	19.162%	16.002%
\$80,000	25	7	28.058%	25.491%	23.133%	20.970%	18.991%	15.535%	12.663%
\$80,000	50	7	18.583%	16.143%	13.973%	12.059%	10.378%	7.627%	5.567%
\$80,000	100	7	11.969%	9.733%	7.860%	6.314%	5.048%	3.203%	2.047%
\$80,000	150	7	9.032%	6.986%	5.357%	4.086%	3.105%	1.819%	1.134%
\$80,000	200	7	7.368%	5.474%	4.031%	2.957%	2.173%	1.232%	0.793%
\$80,000	300	7	5.573%	3.894%	2.697%	1.874%	1.328%	0.769%	0.577%
\$80,000	400	7	4.545%	3.016%	1.995%	1.343%	0.949%	0.611%	0.523%
\$80,000	500	7	3.876%	2.485%	1.605%	1.079%	0.784%	0.560%	0.511%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$80,000	600	7	3.372%	2.090%	1.321%	0.894%	0.676%	0.529%	0.504%
\$80,000	700	7	3.011%	1.819%	1.139%	0.785%	0.615%	0.516%	0.502%
\$80,000	800	7	2.719%	1.601%	0.997%	0.703%	0.574%	0.509%	0.501%
\$80,000	900	7	2.494%	1.445%	0.901%	0.652%	0.552%	0.507%	0.501%
\$80,000	1,000	7	2.286%	1.305%	0.821%	0.613%	0.536%	0.504%	0.501%
\$80,000	1,500	7	1.637%	0.908%	0.623%	0.532%	0.508%	0.502%	0.501%
\$80,000	2,000	7	1.258%	0.717%	0.550%	0.511%	0.504%	0.502%	0.501%
\$80,000	3,000	7	0.884%	0.576%	0.514%	0.505%	0.503%	0.502%	0.501%
\$80,000	4,000	7	0.708%	0.531%	0.507%	0.504%	0.503%	0.502%	0.501%
\$80,000	5,000	7	0.616%	0.515%	0.505%	0.504%	0.503%	0.502%	0.501%
\$80,000	10,000	7	0.510%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$80,000	20,000	7	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$90,000	5	7	64.522%	62.695%	60.933%	59.227%	57.576%	54.435%	51.485%
\$90,000	10	7	48.449%	46.214%	44.072%	42.010%	40.030%	36.311%	32.889%
\$90,000	15	7	39.554%	37.110%	34.787%	32.578%	30.482%	26.582%	23.044%
\$90,000	20	7	33.497%	30.948%	28.550%	26.304%	24.201%	20.419%	17.172%
\$90,000	25	7	29.174%	26.614%	24.246%	22.064%	20.058%	16.536%	13.594%
\$90,000	50	7	19.322%	16.877%	14.695%	12.756%	11.046%	8.228%	6.085%
\$90,000	100	7	12.492%	10.233%	8.333%	6.748%	5.435%	3.504%	2.269%
\$90,000	150	7	9.435%	7.360%	5.697%	4.385%	3.366%	1.996%	1.246%
\$90,000	200	7	7.704%	5.780%	4.297%	3.179%	2.356%	1.343%	0.851%
\$90,000	300	7	5.833%	4.117%	2.883%	2.020%	1.437%	0.820%	0.598%
\$90,000	400	7	4.758%	3.193%	2.133%	1.443%	1.017%	0.637%	0.531%
\$90,000	500	7	4.054%	2.629%	1.713%	1.153%	0.830%	0.573%	0.513%
\$90,000	600	7	3.536%	2.218%	1.411%	0.952%	0.710%	0.538%	0.506%
\$90,000	700	7	3.157%	1.930%	1.214%	0.831%	0.641%	0.521%	0.503%
\$90,000	800	7	2.855%	1.701%	1.060%	0.739%	0.592%	0.512%	0.502%
\$90,000	900	7	2.621%	1.534%	0.956%	0.680%	0.565%	0.509%	0.502%
\$90,000	1,000	7	2.402%	1.384%	0.867%	0.635%	0.546%	0.505%	0.501%
\$90,000	1,500	7	1.725%	0.958%	0.645%	0.540%	0.510%	0.502%	0.501%
\$90,000	2,000	7	1.328%	0.750%	0.561%	0.513%	0.504%	0.502%	0.501%
\$90,000	3,000	7	0.928%	0.590%	0.516%	0.505%	0.503%	0.502%	0.501%
\$90,000	4,000	7	0.738%	0.537%	0.507%	0.504%	0.503%	0.502%	0.501%
\$90,000	5,000	7	0.635%	0.518%	0.506%	0.504%	0.503%	0.502%	0.501%
\$90,000	10,000	7	0.512%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$90,000	20,000	7	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$100,000	5	7	65.259%	63.461%	61.726%	60.046%	58.423%	55.336%	52.435%
\$100,000	10	7	49.310%	47.118%	45.013%	42.990%	41.052%	37.414%	34.069%
\$100,000	15	7	40.521%	38.130%	35.862%	33.708%	31.664%	27.861%	24.407%
\$100,000	20	7	34.534%	32.046%	29.696%	27.477%	25.387%	21.592%	18.290%
\$100,000	25	7	30.174%	27.634%	25.271%	23.078%	21.050%	17.470%	14.453%
\$100,000	50	7	19.996%	17.549%	15.354%	13.400%	11.666%	8.789%	6.577%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$100,000	100	7	12.968%	10.688%	8.766%	7.149%	5.799%	3.788%	2.485%
\$100,000	150	7	9.803%	7.703%	6.011%	4.665%	3.612%	2.169%	1.358%
\$100,000	200	7	8.011%	6.063%	4.544%	3.388%	2.530%	1.453%	0.911%
\$100,000	300	7	6.073%	4.326%	3.058%	2.159%	1.543%	0.872%	0.621%
\$100,000	400	7	4.956%	3.360%	2.263%	1.540%	1.084%	0.664%	0.540%
\$100,000	500	7	4.224%	2.769%	1.819%	1.228%	0.879%	0.590%	0.518%
\$100,000	600	7	3.687%	2.336%	1.497%	1.008%	0.745%	0.548%	0.508%
\$100,000	700	7	3.293%	2.034%	1.287%	0.876%	0.667%	0.528%	0.504%
\$100,000	800	7	2.982%	1.795%	1.121%	0.775%	0.611%	0.516%	0.502%
\$100,000	900	7	2.738%	1.618%	1.008%	0.709%	0.579%	0.511%	0.502%
\$100,000	1,000	7	2.510%	1.458%	0.912%	0.658%	0.556%	0.507%	0.501%
\$100,000	1,500	7	1.808%	1.006%	0.668%	0.548%	0.513%	0.502%	0.501%
\$100,000	2,000	7	1.393%	0.782%	0.572%	0.516%	0.505%	0.502%	0.501%
\$100,000	3,000	7	0.970%	0.604%	0.519%	0.505%	0.503%	0.502%	0.501%
\$100,000	4,000	7	0.766%	0.544%	0.508%	0.504%	0.503%	0.502%	0.501%
\$100,000	5,000	7	0.654%	0.521%	0.506%	0.504%	0.503%	0.502%	0.501%
\$100,000	10,000	7	0.513%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$100,000	20,000	7	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$110,000	5	7	65.859%	64.086%	62.371%	60.714%	59.113%	56.068%	53.208%
\$110,000	10	7	50.018%	47.860%	45.786%	43.796%	41.891%	38.320%	35.037%
\$110,000	15	7	41.314%	38.969%	36.744%	34.635%	32.632%	28.909%	25.533%
\$110,000	20	7	35.394%	32.958%	30.658%	28.484%	26.427%	22.651%	19.326%
\$110,000	25	7	31.047%	28.535%	26.187%	24.000%	21.966%	18.342%	15.263%
\$110,000	50	7	20.608%	18.159%	15.958%	13.990%	12.235%	9.310%	7.038%
\$110,000	100	7	13.401%	11.106%	9.158%	7.516%	6.137%	4.055%	2.690%
\$110,000	150	7	10.135%	8.017%	6.297%	4.921%	3.836%	2.332%	1.467%
\$110,000	200	7	8.288%	6.318%	4.769%	3.581%	2.691%	1.557%	0.971%
\$110,000	300	7	6.289%	4.518%	3.217%	2.287%	1.643%	0.925%	0.643%
\$110,000	400	7	5.134%	3.512%	2.384%	1.631%	1.149%	0.692%	0.549%
\$110,000	500	7	4.379%	2.897%	1.917%	1.300%	0.927%	0.608%	0.523%
\$110,000	600	7	3.823%	2.445%	1.577%	1.062%	0.779%	0.558%	0.511%
\$110,000	700	7	3.417%	2.131%	1.354%	0.919%	0.693%	0.535%	0.505%
\$110,000	800	7	3.098%	1.882%	1.179%	0.809%	0.630%	0.520%	0.503%
\$110,000	900	7	2.844%	1.695%	1.057%	0.737%	0.593%	0.513%	0.502%
\$110,000	1,000	7	2.608%	1.527%	0.954%	0.681%	0.566%	0.508%	0.501%
\$110,000	1,500	7	1.883%	1.051%	0.690%	0.557%	0.516%	0.502%	0.501%
\$110,000	2,000	7	1.453%	0.811%	0.583%	0.519%	0.505%	0.502%	0.501%
\$110,000	3,000	7	1.009%	0.618%	0.523%	0.506%	0.503%	0.502%	0.501%
\$110,000	4,000	7	0.792%	0.550%	0.509%	0.504%	0.503%	0.502%	0.501%
\$110,000	5,000	7	0.671%	0.524%	0.506%	0.504%	0.503%	0.502%	0.501%
\$110,000	10,000	7	0.514%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$110,000	20,000	7	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$120,000	5	7	66.365%	64.611%	62.914%	61.276%	59.694%	56.685%	53.859%
\$120,000	10	7	50.606%	48.474%	46.426%	44.464%	42.586%	39.071%	35.842%
\$120,000	15	7	41.980%	39.673%	37.486%	35.413%	33.445%	29.787%	26.478%
\$120,000	20	7	36.129%	33.737%	31.478%	29.344%	27.325%	23.606%	20.289%
\$120,000	25	7	31.806%	29.333%	27.012%	24.838%	22.810%	19.170%	16.044%
\$120,000	50	7	21.162%	18.715%	16.510%	14.530%	12.762%	9.795%	7.467%
\$120,000	100	7	13.791%	11.487%	9.516%	7.852%	6.447%	4.305%	2.883%
\$120,000	150	7	10.435%	8.301%	6.558%	5.155%	4.042%	2.485%	1.572%
\$120,000	200	7	8.539%	6.550%	4.976%	3.761%	2.842%	1.657%	1.031%
\$120,000	300	7	6.486%	4.693%	3.366%	2.408%	1.737%	0.976%	0.666%
\$120,000	400	7	5.297%	3.652%	2.497%	1.717%	1.211%	0.719%	0.559%
\$120,000	500	7	4.519%	3.015%	2.010%	1.368%	0.974%	0.625%	0.529%
\$120,000	600	7	3.941%	2.540%	1.647%	1.110%	0.809%	0.567%	0.512%
\$120,000	700	7	3.531%	2.220%	1.419%	0.961%	0.718%	0.542%	0.507%
\$120,000	800	7	3.204%	1.963%	1.234%	0.843%	0.649%	0.524%	0.503%
\$120,000	900	7	2.941%	1.767%	1.104%	0.765%	0.607%	0.516%	0.503%
\$120,000	1,000	7	2.699%	1.592%	0.995%	0.704%	0.576%	0.510%	0.502%
\$120,000	1,500	7	1.952%	1.094%	0.711%	0.565%	0.519%	0.503%	0.501%
\$120,000	2,000	7	1.508%	0.840%	0.594%	0.522%	0.506%	0.502%	0.501%
\$120,000	3,000	7	1.045%	0.631%	0.526%	0.506%	0.503%	0.502%	0.501%
\$120,000	4,000	7	0.817%	0.557%	0.510%	0.504%	0.503%	0.502%	0.501%
\$120,000	5,000	7	0.688%	0.527%	0.506%	0.504%	0.503%	0.502%	0.501%
\$120,000	10,000	7	0.515%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$120,000	20,000	7	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$130,000	5	7	66.805%	65.066%	63.385%	61.763%	60.198%	57.219%	54.422%
\$130,000	10	7	51.115%	49.004%	46.980%	45.043%	43.189%	39.721%	36.537%
\$130,000	15	7	42.545%	40.270%	38.114%	36.073%	34.133%	30.531%	27.278%
\$130,000	20	7	36.753%	34.396%	32.173%	30.073%	28.087%	24.430%	21.155%
\$130,000	25	7	32.452%	30.018%	27.731%	25.582%	23.570%	19.934%	16.779%
\$130,000	50	7	21.674%	19.226%	17.016%	15.031%	13.250%	10.246%	7.872%
\$130,000	100	7	14.149%	11.837%	9.848%	8.163%	6.735%	4.541%	3.066%
\$130,000	150	7	10.706%	8.561%	6.799%	5.371%	4.233%	2.628%	1.671%
\$130,000	200	7	8.768%	6.762%	5.166%	3.927%	2.984%	1.751%	1.089%
\$130,000	300	7	6.665%	4.854%	3.503%	2.520%	1.825%	1.026%	0.689%
\$130,000	400	7	5.446%	3.782%	2.602%	1.798%	1.271%	0.746%	0.569%
\$130,000	500	7	4.649%	3.123%	2.097%	1.432%	1.019%	0.643%	0.535%
\$130,000	600	7	4.055%	2.634%	1.717%	1.160%	0.841%	0.578%	0.515%
\$130,000	700	7	3.636%	2.304%	1.480%	1.002%	0.743%	0.549%	0.508%
\$130,000	800	7	3.302%	2.039%	1.287%	0.876%	0.668%	0.529%	0.504%
\$130,000	900	7	3.031%	1.834%	1.149%	0.791%	0.621%	0.519%	0.503%
\$130,000	1,000	7	2.782%	1.653%	1.033%	0.725%	0.587%	0.511%	0.502%
\$130,000	1,500	7	2.016%	1.134%	0.732%	0.574%	0.522%	0.503%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$130,000	2,000	7	1.560%	0.867%	0.605%	0.526%	0.507%	0.502%	0.501%
\$130,000	3,000	7	1.079%	0.645%	0.529%	0.507%	0.503%	0.502%	0.501%
\$130,000	4,000	7	0.841%	0.563%	0.511%	0.504%	0.503%	0.502%	0.501%
\$130,000	5,000	7	0.704%	0.530%	0.507%	0.504%	0.503%	0.502%	0.501%
\$130,000	10,000	7	0.517%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$130,000	20,000	7	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$140,000	5	7	67.161%	65.435%	63.768%	62.159%	60.607%	57.653%	54.880%
\$140,000	10	7	51.530%	49.438%	47.433%	45.516%	43.682%	40.253%	37.107%
\$140,000	15	7	43.011%	40.762%	38.633%	36.616%	34.699%	31.145%	27.936%
\$140,000	20	7	37.259%	34.932%	32.738%	30.666%	28.706%	25.102%	21.875%
\$140,000	25	7	32.981%	30.581%	28.325%	26.205%	24.216%	20.600%	17.436%
\$140,000	50	7	22.132%	19.685%	17.475%	15.481%	13.691%	10.656%	8.246%
\$140,000	100	7	14.466%	12.147%	10.147%	8.442%	6.995%	4.758%	3.237%
\$140,000	150	7	10.945%	8.790%	7.013%	5.565%	4.405%	2.758%	1.764%
\$140,000	200	7	8.969%	6.949%	5.336%	4.076%	3.112%	1.838%	1.143%
\$140,000	300	7	6.826%	4.998%	3.627%	2.623%	1.906%	1.073%	0.713%
\$140,000	400	7	5.580%	3.898%	2.698%	1.872%	1.327%	0.773%	0.579%
\$140,000	500	7	4.765%	3.222%	2.176%	1.491%	1.061%	0.660%	0.541%
\$140,000	600	7	4.158%	2.719%	1.781%	1.205%	0.872%	0.590%	0.519%
\$140,000	700	7	3.730%	2.380%	1.535%	1.039%	0.766%	0.557%	0.510%
\$140,000	800	7	3.390%	2.108%	1.335%	0.907%	0.686%	0.533%	0.505%
\$140,000	900	7	3.111%	1.896%	1.191%	0.817%	0.635%	0.522%	0.504%
\$140,000	1,000	7	2.856%	1.708%	1.069%	0.746%	0.598%	0.513%	0.502%
\$140,000	1,500	7	2.074%	1.171%	0.751%	0.583%	0.525%	0.503%	0.501%
\$140,000	2,000	7	1.607%	0.893%	0.616%	0.529%	0.508%	0.502%	0.501%
\$140,000	3,000	7	1.111%	0.657%	0.532%	0.507%	0.503%	0.502%	0.501%
\$140,000	4,000	7	0.862%	0.569%	0.512%	0.504%	0.503%	0.502%	0.501%
\$140,000	5,000	7	0.719%	0.534%	0.507%	0.504%	0.503%	0.502%	0.501%
\$140,000	10,000	7	0.518%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$140,000	20,000	7	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$150,000	5	7	67.453%	65.737%	64.081%	62.484%	60.942%	58.009%	55.256%
\$150,000	10	7	51.872%	49.795%	47.807%	45.906%	44.089%	40.692%	37.577%
\$150,000	15	7	43.399%	41.172%	39.066%	37.070%	35.173%	31.657%	28.485%
\$150,000	20	7	37.677%	35.375%	33.204%	31.155%	29.218%	25.657%	22.471%
\$150,000	25	7	33.422%	31.048%	28.819%	26.726%	24.762%	21.179%	18.019%
\$150,000	50	7	22.547%	20.104%	17.891%	15.893%	14.095%	11.037%	8.597%
\$150,000	100	7	14.751%	12.426%	10.417%	8.697%	7.233%	4.959%	3.398%
\$150,000	150	7	11.162%	8.998%	7.208%	5.744%	4.565%	2.880%	1.853%
\$150,000	200	7	9.149%	7.116%	5.490%	4.212%	3.230%	1.919%	1.195%
\$150,000	300	7	6.969%	5.126%	3.738%	2.717%	1.982%	1.117%	0.735%
\$150,000	400	7	5.699%	4.002%	2.784%	1.940%	1.378%	0.798%	0.589%
\$150,000	500	7	4.867%	3.310%	2.246%	1.544%	1.100%	0.677%	0.547%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$150,000	600	7	4.249%	2.795%	1.839%	1.246%	0.899%	0.600%	0.522%
\$150,000	700	7	3.806%	2.441%	1.580%	1.069%	0.784%	0.562%	0.511%
\$150,000	800	7	3.469%	2.170%	1.379%	0.935%	0.703%	0.538%	0.506%
\$150,000	900	7	3.183%	1.951%	1.229%	0.840%	0.648%	0.525%	0.504%
\$150,000	1,000	7	2.923%	1.758%	1.102%	0.765%	0.608%	0.515%	0.502%
\$150,000	1,500	7	2.126%	1.204%	0.769%	0.591%	0.527%	0.504%	0.501%
\$150,000	2,000	7	1.649%	0.916%	0.626%	0.532%	0.508%	0.502%	0.501%
\$150,000	3,000	7	1.139%	0.668%	0.535%	0.508%	0.503%	0.502%	0.501%
\$150,000	4,000	7	0.883%	0.575%	0.513%	0.505%	0.503%	0.502%	0.501%
\$150,000	5,000	7	0.734%	0.537%	0.507%	0.504%	0.503%	0.502%	0.501%
\$150,000	10,000	7	0.520%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$150,000	20,000	7	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$160,000	5	7	67.724%	66.018%	64.372%	62.785%	61.254%	58.338%	55.605%
\$160,000	10	7	52.186%	50.123%	48.150%	46.264%	44.463%	41.095%	38.009%
\$160,000	15	7	43.759%	41.552%	39.466%	37.489%	35.610%	32.130%	28.992%
\$160,000	20	7	38.064%	35.786%	33.637%	31.608%	29.692%	26.171%	23.023%
\$160,000	25	7	33.831%	31.483%	29.278%	27.209%	25.268%	21.727%	18.588%
\$160,000	50	7	22.950%	20.515%	18.303%	16.301%	14.496%	11.417%	8.946%
\$160,000	100	7	15.032%	12.703%	10.686%	8.953%	7.473%	5.164%	3.563%
\$160,000	150	7	11.378%	9.204%	7.403%	5.923%	4.725%	3.004%	1.944%
\$160,000	200	7	9.325%	7.282%	5.642%	4.347%	3.348%	2.001%	1.249%
\$160,000	300	7	7.110%	5.253%	3.848%	2.811%	2.058%	1.162%	0.759%
\$160,000	400	7	5.815%	4.104%	2.870%	2.008%	1.429%	0.824%	0.600%
\$160,000	500	7	4.967%	3.396%	2.316%	1.597%	1.140%	0.695%	0.553%
\$160,000	600	7	4.338%	2.870%	1.897%	1.287%	0.927%	0.612%	0.525%
\$160,000	700	7	3.887%	2.507%	1.629%	1.103%	0.806%	0.569%	0.513%
\$160,000	800	7	3.545%	2.231%	1.423%	0.964%	0.720%	0.544%	0.507%
\$160,000	900	7	3.254%	2.006%	1.267%	0.864%	0.662%	0.528%	0.505%
\$160,000	1,000	7	2.989%	1.808%	1.135%	0.785%	0.618%	0.517%	0.503%
\$160,000	1,500	7	2.177%	1.237%	0.787%	0.599%	0.531%	0.504%	0.501%
\$160,000	2,000	7	1.691%	0.939%	0.636%	0.536%	0.509%	0.502%	0.501%
\$160,000	3,000	7	1.167%	0.680%	0.539%	0.509%	0.503%	0.502%	0.501%
\$160,000	4,000	7	0.903%	0.582%	0.515%	0.505%	0.503%	0.502%	0.501%
\$160,000	5,000	7	0.748%	0.540%	0.508%	0.504%	0.503%	0.502%	0.501%
\$160,000	10,000	7	0.521%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$160,000	20,000	7	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$170,000	5	7	67.973%	66.276%	64.639%	63.062%	61.540%	58.642%	55.925%
\$170,000	10	7	52.472%	50.423%	48.464%	46.592%	44.806%	41.463%	38.404%
\$170,000	15	7	44.086%	41.898%	39.830%	37.870%	36.008%	32.560%	29.452%
\$170,000	20	7	38.411%	36.153%	34.023%	32.014%	30.116%	26.631%	23.517%
\$170,000	25	7	34.200%	31.875%	29.692%	27.646%	25.725%	22.223%	19.116%
\$170,000	50	7	23.333%	20.907%	18.699%	16.695%	14.885%	11.783%	9.285%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$170,000	100	7	15.302%	12.971%	10.947%	9.201%	7.704%	5.363%	3.726%
\$170,000	150	7	11.585%	9.403%	7.591%	6.098%	4.882%	3.126%	2.034%
\$170,000	200	7	9.496%	7.443%	5.791%	4.480%	3.463%	2.083%	1.303%
\$170,000	300	7	7.245%	5.377%	3.955%	2.902%	2.134%	1.207%	0.783%
\$170,000	400	7	5.928%	4.204%	2.955%	2.075%	1.480%	0.850%	0.611%
\$170,000	500	7	5.064%	3.479%	2.384%	1.650%	1.178%	0.712%	0.560%
\$170,000	600	7	4.424%	2.943%	1.952%	1.328%	0.955%	0.623%	0.528%
\$170,000	700	7	3.966%	2.571%	1.677%	1.137%	0.828%	0.577%	0.515%
\$170,000	800	7	3.619%	2.290%	1.466%	0.992%	0.737%	0.549%	0.509%
\$170,000	900	7	3.322%	2.059%	1.304%	0.888%	0.675%	0.532%	0.506%
\$170,000	1,000	7	3.053%	1.856%	1.168%	0.804%	0.629%	0.520%	0.503%
\$170,000	1,500	7	2.226%	1.270%	0.805%	0.607%	0.534%	0.504%	0.501%
\$170,000	2,000	7	1.730%	0.962%	0.646%	0.539%	0.510%	0.502%	0.501%
\$170,000	3,000	7	1.194%	0.691%	0.542%	0.509%	0.503%	0.502%	0.501%
\$170,000	4,000	7	0.923%	0.588%	0.516%	0.505%	0.503%	0.502%	0.501%
\$170,000	5,000	7	0.762%	0.543%	0.508%	0.504%	0.503%	0.502%	0.501%
\$170,000	10,000	7	0.523%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$170,000	20,000	7	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$180,000	5	7	68.204%	66.516%	64.888%	63.320%	61.806%	58.924%	56.224%
\$180,000	10	7	52.743%	50.706%	48.761%	46.901%	45.129%	41.811%	38.777%
\$180,000	15	7	44.391%	42.221%	40.170%	38.225%	36.379%	32.963%	29.882%
\$180,000	20	7	38.735%	36.495%	34.384%	32.392%	30.512%	27.060%	23.977%
\$180,000	25	7	34.545%	32.241%	30.079%	28.053%	26.152%	22.687%	19.614%
\$180,000	50	7	23.710%	21.293%	19.091%	17.088%	15.274%	12.152%	9.628%
\$180,000	100	7	15.569%	13.237%	11.206%	9.448%	7.936%	5.564%	3.891%
\$180,000	150	7	11.792%	9.603%	7.780%	6.274%	5.040%	3.250%	2.128%
\$180,000	200	7	9.667%	7.605%	5.940%	4.615%	3.581%	2.168%	1.360%
\$180,000	300	7	7.381%	5.502%	4.064%	2.995%	2.211%	1.254%	0.808%
\$180,000	400	7	6.041%	4.304%	3.039%	2.143%	1.533%	0.877%	0.623%
\$180,000	500	7	5.161%	3.563%	2.453%	1.703%	1.218%	0.731%	0.567%
\$180,000	600	7	4.509%	3.015%	2.009%	1.369%	0.983%	0.634%	0.532%
\$180,000	700	7	4.044%	2.636%	1.726%	1.171%	0.850%	0.585%	0.517%
\$180,000	800	7	3.693%	2.349%	1.509%	1.021%	0.756%	0.554%	0.510%
\$180,000	900	7	3.390%	2.112%	1.341%	0.912%	0.689%	0.535%	0.506%
\$180,000	1,000	7	3.116%	1.904%	1.201%	0.824%	0.639%	0.522%	0.503%
\$180,000	1,500	7	2.275%	1.302%	0.823%	0.616%	0.538%	0.505%	0.501%
\$180,000	2,000	7	1.770%	0.985%	0.657%	0.543%	0.511%	0.502%	0.501%
\$180,000	3,000	7	1.221%	0.703%	0.546%	0.510%	0.504%	0.502%	0.501%
\$180,000	4,000	7	0.943%	0.594%	0.517%	0.505%	0.503%	0.502%	0.501%
\$180,000	5,000	7	0.776%	0.547%	0.509%	0.504%	0.503%	0.502%	0.501%
\$180,000	10,000	7	0.524%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$180,000	20,000	7	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$190,000	5	7	68.417%	66.737%	65.118%	63.558%	62.051%	59.184%	56.498%
\$190,000	10	7	52.992%	50.967%	49.034%	47.187%	45.426%	42.131%	39.121%
\$190,000	15	7	44.670%	42.515%	40.480%	38.549%	36.717%	33.330%	30.273%
\$190,000	20	7	39.028%	36.805%	34.711%	32.735%	30.871%	27.450%	24.395%
\$190,000	25	7	34.859%	32.574%	30.431%	28.423%	26.540%	23.108%	20.067%
\$190,000	50	7	24.064%	21.659%	19.463%	17.464%	15.648%	12.511%	9.963%
\$190,000	100	7	15.822%	13.489%	11.452%	9.685%	8.161%	5.760%	4.053%
\$190,000	150	7	11.991%	9.799%	7.965%	6.446%	5.196%	3.375%	2.222%
\$190,000	200	7	9.832%	7.762%	6.086%	4.749%	3.697%	2.253%	1.417%
\$190,000	300	7	7.512%	5.622%	4.170%	3.086%	2.286%	1.301%	0.833%
\$190,000	400	7	6.149%	4.400%	3.121%	2.210%	1.585%	0.905%	0.636%
\$190,000	500	7	5.253%	3.644%	2.519%	1.755%	1.257%	0.750%	0.574%
\$190,000	600	7	4.591%	3.085%	2.064%	1.410%	1.011%	0.645%	0.536%
\$190,000	700	7	4.119%	2.698%	1.773%	1.205%	0.872%	0.592%	0.520%
\$190,000	800	7	3.757%	2.401%	1.547%	1.046%	0.771%	0.558%	0.510%
\$190,000	900	7	3.455%	2.163%	1.378%	0.936%	0.703%	0.539%	0.507%
\$190,000	1,000	7	3.177%	1.951%	1.233%	0.844%	0.650%	0.525%	0.504%
\$190,000	1,500	7	2.322%	1.334%	0.842%	0.625%	0.541%	0.505%	0.501%
\$190,000	2,000	7	1.809%	1.007%	0.667%	0.547%	0.513%	0.502%	0.501%
\$190,000	3,000	7	1.247%	0.714%	0.549%	0.511%	0.504%	0.502%	0.501%
\$190,000	4,000	7	0.962%	0.601%	0.518%	0.505%	0.503%	0.502%	0.501%
\$190,000	5,000	7	0.790%	0.550%	0.509%	0.504%	0.503%	0.502%	0.501%
\$190,000	10,000	7	0.526%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$190,000	20,000	7	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$200,000	5	7	68.603%	66.930%	65.318%	63.765%	62.265%	59.410%	56.738%
\$200,000	10	7	53.215%	51.200%	49.278%	47.442%	45.692%	42.417%	39.427%
\$200,000	15	7	44.919%	42.779%	40.757%	38.839%	37.019%	33.657%	30.623%
\$200,000	20	7	39.285%	37.079%	34.999%	33.038%	31.188%	27.793%	24.764%
\$200,000	25	7	35.138%	32.869%	30.742%	28.751%	26.884%	23.481%	20.467%
\$200,000	50	7	24.387%	21.996%	19.808%	17.813%	15.999%	12.853%	10.281%
\$200,000	100	7	16.058%	13.725%	11.684%	9.908%	8.375%	5.947%	4.210%
\$200,000	150	7	12.179%	9.985%	8.141%	6.612%	5.347%	3.496%	2.314%
\$200,000	200	7	9.987%	7.912%	6.224%	4.875%	3.809%	2.335%	1.472%
\$200,000	300	7	7.635%	5.736%	4.271%	3.172%	2.358%	1.346%	0.859%
\$200,000	400	7	6.251%	4.491%	3.198%	2.274%	1.636%	0.932%	0.649%
\$200,000	500	7	5.340%	3.720%	2.582%	1.805%	1.295%	0.769%	0.582%
\$200,000	600	7	4.669%	3.151%	2.117%	1.449%	1.039%	0.657%	0.540%
\$200,000	700	7	4.190%	2.757%	1.819%	1.238%	0.894%	0.600%	0.522%
\$200,000	800	7	3.825%	2.456%	1.588%	1.074%	0.788%	0.564%	0.512%
\$200,000	900	7	3.517%	2.212%	1.413%	0.959%	0.717%	0.543%	0.508%
\$200,000	1,000	7	3.234%	1.995%	1.263%	0.863%	0.661%	0.527%	0.504%
\$200,000	1,500	7	2.367%	1.364%	0.859%	0.634%	0.545%	0.505%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$200,000	2,000	7	1.845%	1.029%	0.677%	0.551%	0.514%	0.502%	0.501%
\$200,000	3,000	7	1.272%	0.726%	0.553%	0.512%	0.504%	0.502%	0.501%
\$200,000	4,000	7	0.980%	0.607%	0.520%	0.505%	0.503%	0.502%	0.501%
\$200,000	5,000	7	0.803%	0.554%	0.510%	0.504%	0.503%	0.502%	0.501%
\$200,000	10,000	7	0.528%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$200,000	20,000	7	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$225,000	5	7	68.969%	67.310%	65.712%	64.173%	62.686%	59.858%	57.211%
\$225,000	10	7	53.657%	51.664%	49.762%	47.949%	46.219%	42.986%	40.037%
\$225,000	15	7	45.418%	43.307%	41.311%	39.419%	37.624%	34.312%	31.322%
\$225,000	20	7	39.805%	37.628%	35.578%	33.645%	31.824%	28.484%	25.503%
\$225,000	25	7	35.699%	33.464%	31.372%	29.414%	27.576%	24.233%	21.273%
\$225,000	50	7	25.066%	22.709%	20.547%	18.567%	16.761%	13.609%	11.004%
\$225,000	100	7	16.577%	14.245%	12.198%	10.405%	8.851%	6.371%	4.569%
\$225,000	150	7	12.594%	10.394%	8.533%	6.980%	5.688%	3.771%	2.524%
\$225,000	200	7	10.333%	8.244%	6.534%	5.158%	4.063%	2.525%	1.601%
\$225,000	300	7	7.908%	5.988%	4.497%	3.366%	2.521%	1.452%	0.920%
\$225,000	400	7	6.480%	4.699%	3.376%	2.422%	1.754%	0.998%	0.682%
\$225,000	500	7	5.534%	3.892%	2.724%	1.919%	1.383%	0.813%	0.600%
\$225,000	600	7	4.842%	3.299%	2.237%	1.539%	1.103%	0.685%	0.551%
\$225,000	700	7	4.348%	2.888%	1.922%	1.312%	0.944%	0.619%	0.529%
\$225,000	800	7	3.972%	2.577%	1.681%	1.137%	0.829%	0.578%	0.515%
\$225,000	900	7	3.652%	2.320%	1.492%	1.012%	0.749%	0.553%	0.510%
\$225,000	1,000	7	3.360%	2.091%	1.331%	0.906%	0.686%	0.534%	0.505%
\$225,000	1,500	7	2.464%	1.431%	0.899%	0.655%	0.554%	0.506%	0.501%
\$225,000	2,000	7	1.924%	1.076%	0.701%	0.560%	0.517%	0.503%	0.501%
\$225,000	3,000	7	1.326%	0.751%	0.562%	0.514%	0.504%	0.502%	0.501%
\$225,000	4,000	7	1.021%	0.622%	0.523%	0.506%	0.503%	0.502%	0.501%
\$225,000	5,000	7	0.833%	0.562%	0.511%	0.504%	0.503%	0.502%	0.501%
\$225,000	10,000	7	0.532%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$225,000	20,000	7	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$250,000	5	7	69.251%	67.603%	66.017%	64.488%	63.012%	60.203%	57.577%
\$250,000	10	7	53.995%	52.018%	50.133%	48.337%	46.623%	43.422%	40.506%
\$250,000	15	7	45.796%	43.706%	41.731%	39.858%	38.083%	34.810%	31.854%
\$250,000	20	7	40.197%	38.043%	36.016%	34.105%	32.306%	29.007%	26.064%
\$250,000	25	7	36.134%	33.926%	31.860%	29.926%	28.113%	24.814%	21.897%
\$250,000	50	7	25.603%	23.281%	21.150%	19.194%	17.402%	14.258%	11.642%
\$250,000	100	7	17.022%	14.695%	12.643%	10.841%	9.273%	6.751%	4.891%
\$250,000	150	7	12.958%	10.752%	8.878%	7.307%	5.994%	4.022%	2.720%
\$250,000	200	7	10.636%	8.537%	6.810%	5.412%	4.294%	2.699%	1.725%
\$250,000	300	7	8.146%	6.210%	4.697%	3.542%	2.671%	1.551%	0.980%
\$250,000	400	7	6.681%	4.884%	3.537%	2.557%	1.863%	1.061%	0.713%
\$250,000	500	7	5.705%	4.045%	2.852%	2.023%	1.463%	0.855%	0.619%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$250,000	600	7	4.995%	3.430%	2.344%	1.622%	1.162%	0.712%	0.561%
\$250,000	700	7	4.487%	3.005%	2.014%	1.381%	0.992%	0.637%	0.536%
\$250,000	800	7	4.101%	2.685%	1.763%	1.196%	0.868%	0.592%	0.519%
\$250,000	900	7	3.764%	2.409%	1.558%	1.057%	0.778%	0.560%	0.512%
\$250,000	1,000	7	3.469%	2.178%	1.394%	0.948%	0.711%	0.540%	0.507%
\$250,000	1,500	7	2.549%	1.490%	0.935%	0.674%	0.563%	0.508%	0.501%
\$250,000	2,000	7	1.992%	1.119%	0.723%	0.569%	0.520%	0.503%	0.501%
\$250,000	3,000	7	1.374%	0.774%	0.570%	0.516%	0.504%	0.502%	0.501%
\$250,000	4,000	7	1.056%	0.635%	0.527%	0.507%	0.503%	0.502%	0.501%
\$250,000	5,000	7	0.859%	0.569%	0.512%	0.505%	0.503%	0.502%	0.501%
\$250,000	10,000	7	0.536%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$250,000	20,000	7	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$275,000	5	7	69.435%	67.795%	66.217%	64.695%	63.226%	60.432%	57.819%
\$275,000	10	7	54.232%	52.268%	50.395%	48.613%	46.910%	43.733%	40.842%
\$275,000	15	7	46.068%	43.996%	42.035%	40.178%	38.417%	35.173%	32.242%
\$275,000	20	7	40.481%	38.345%	36.335%	34.441%	32.657%	29.390%	26.477%
\$275,000	25	7	36.462%	34.274%	32.229%	30.315%	28.520%	25.255%	22.372%
\$275,000	50	7	26.034%	23.741%	21.638%	19.707%	17.934%	14.815%	12.198%
\$275,000	100	7	17.411%	15.091%	13.038%	11.229%	9.652%	7.096%	5.188%
\$275,000	150	7	13.280%	11.069%	9.187%	7.600%	6.270%	4.253%	2.902%
\$275,000	200	7	10.906%	8.799%	7.059%	5.643%	4.503%	2.862%	1.846%
\$275,000	300	7	8.357%	6.409%	4.878%	3.703%	2.808%	1.645%	1.039%
\$275,000	400	7	6.859%	5.048%	3.682%	2.679%	1.964%	1.123%	0.745%
\$275,000	500	7	5.857%	4.181%	2.967%	2.116%	1.536%	0.895%	0.637%
\$275,000	600	7	5.129%	3.547%	2.441%	1.699%	1.218%	0.739%	0.572%
\$275,000	700	7	4.610%	3.109%	2.098%	1.443%	1.036%	0.656%	0.542%
\$275,000	800	7	4.215%	2.780%	1.837%	1.250%	0.904%	0.607%	0.524%
\$275,000	900	7	3.869%	2.494%	1.623%	1.102%	0.807%	0.570%	0.515%
\$275,000	1,000	7	3.566%	2.255%	1.450%	0.985%	0.733%	0.547%	0.508%
\$275,000	1,500	7	2.622%	1.543%	0.968%	0.692%	0.572%	0.509%	0.501%
\$275,000	2,000	7	2.052%	1.157%	0.743%	0.578%	0.523%	0.503%	0.501%
\$275,000	3,000	7	1.416%	0.795%	0.577%	0.518%	0.505%	0.502%	0.501%
\$275,000	4,000	7	1.087%	0.647%	0.530%	0.507%	0.503%	0.502%	0.501%
\$275,000	5,000	7	0.883%	0.576%	0.514%	0.505%	0.503%	0.502%	0.501%
\$275,000	10,000	7	0.539%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$275,000	20,000	7	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$300,000	5	7	69.569%	67.935%	66.363%	64.848%	63.384%	60.601%	57.999%
\$300,000	10	7	54.421%	52.467%	50.605%	48.832%	47.140%	43.982%	41.111%
\$300,000	15	7	46.288%	44.229%	42.281%	40.436%	38.687%	35.466%	32.557%
\$300,000	20	7	40.711%	38.589%	36.593%	34.713%	32.943%	29.702%	26.812%
\$300,000	25	7	36.731%	34.559%	32.531%	30.632%	28.854%	25.616%	22.760%
\$300,000	50	7	26.387%	24.119%	22.038%	20.129%	18.377%	15.290%	12.686%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$300,000	100	7	17.756%	15.444%	13.393%	11.582%	9.997%	7.416%	5.471%
\$300,000	150	7	13.569%	11.362%	9.472%	7.872%	6.528%	4.474%	3.080%
\$300,000	200	7	11.152%	9.041%	7.291%	5.859%	4.702%	3.020%	1.965%
\$300,000	300	7	8.552%	6.594%	5.049%	3.856%	2.940%	1.738%	1.097%
\$300,000	400	7	7.024%	5.201%	3.818%	2.796%	2.061%	1.183%	0.777%
\$300,000	500	7	5.998%	4.309%	3.076%	2.205%	1.606%	0.934%	0.656%
\$300,000	600	7	5.255%	3.657%	2.533%	1.772%	1.272%	0.765%	0.583%
\$300,000	700	7	4.723%	3.206%	2.176%	1.502%	1.078%	0.675%	0.549%
\$300,000	800	7	4.321%	2.869%	1.907%	1.301%	0.939%	0.620%	0.529%
\$300,000	900	7	3.965%	2.573%	1.683%	1.144%	0.834%	0.580%	0.518%
\$300,000	1,000	7	3.657%	2.327%	1.503%	1.021%	0.756%	0.554%	0.510%
\$300,000	1,500	7	2.689%	1.592%	0.999%	0.709%	0.581%	0.511%	0.501%
\$300,000	2,000	7	2.106%	1.192%	0.761%	0.586%	0.526%	0.503%	0.501%
\$300,000	3,000	7	1.454%	0.814%	0.585%	0.520%	0.505%	0.502%	0.501%
\$300,000	4,000	7	1.116%	0.659%	0.533%	0.508%	0.503%	0.502%	0.501%
\$300,000	5,000	7	0.905%	0.583%	0.515%	0.505%	0.503%	0.502%	0.501%
\$300,000	10,000	7	0.543%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$300,000	20,000	7	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$325,000	5	7	69.700%	68.072%	66.506%	64.996%	63.537%	60.765%	58.173%
\$325,000	10	7	54.595%	52.651%	50.798%	49.035%	47.352%	44.212%	41.360%
\$325,000	15	7	46.491%	44.445%	42.508%	40.674%	38.936%	35.737%	32.847%
\$325,000	20	7	40.922%	38.814%	36.831%	34.964%	33.205%	29.988%	27.120%
\$325,000	25	7	36.978%	34.822%	32.809%	30.925%	29.160%	25.948%	23.118%
\$325,000	50	7	26.711%	24.465%	22.405%	20.516%	18.783%	15.731%	13.150%
\$325,000	100	7	18.090%	15.791%	13.745%	11.936%	10.345%	7.744%	5.762%
\$325,000	150	7	13.856%	11.651%	9.758%	8.147%	6.788%	4.701%	3.264%
\$325,000	200	7	11.397%	9.283%	7.524%	6.078%	4.903%	3.182%	2.089%
\$325,000	300	7	8.747%	6.782%	5.223%	4.011%	3.076%	1.833%	1.159%
\$325,000	400	7	7.188%	5.355%	3.956%	2.915%	2.160%	1.246%	0.811%
\$325,000	500	7	6.139%	4.437%	3.186%	2.295%	1.678%	0.975%	0.676%
\$325,000	600	7	5.381%	3.768%	2.627%	1.846%	1.329%	0.794%	0.595%
\$325,000	700	7	4.836%	3.304%	2.255%	1.563%	1.123%	0.695%	0.556%
\$325,000	800	7	4.426%	2.958%	1.979%	1.354%	0.976%	0.635%	0.534%
\$325,000	900	7	4.063%	2.653%	1.744%	1.188%	0.863%	0.590%	0.521%
\$325,000	1,000	7	3.741%	2.395%	1.553%	1.054%	0.777%	0.559%	0.510%
\$325,000	1,500	7	2.757%	1.641%	1.031%	0.728%	0.590%	0.512%	0.502%
\$325,000	2,000	7	2.161%	1.228%	0.781%	0.595%	0.529%	0.503%	0.501%
\$325,000	3,000	7	1.493%	0.834%	0.592%	0.522%	0.506%	0.502%	0.501%
\$325,000	4,000	7	1.145%	0.670%	0.536%	0.508%	0.503%	0.502%	0.501%
\$325,000	5,000	7	0.927%	0.590%	0.517%	0.505%	0.503%	0.502%	0.501%
\$325,000	10,000	7	0.546%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$325,000	20,000	7	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$350,000	5	7	69.825%	68.202%	66.641%	65.136%	63.682%	60.920%	58.338%
\$350,000	10	7	54.749%	52.814%	50.970%	49.215%	47.539%	44.415%	41.580%
\$350,000	15	7	46.668%	44.632%	42.705%	40.881%	39.153%	35.973%	33.099%
\$350,000	20	7	41.102%	39.006%	37.033%	35.178%	33.429%	30.232%	27.384%
\$350,000	25	7	37.190%	35.047%	33.047%	31.176%	29.424%	26.234%	23.425%
\$350,000	50	7	26.991%	24.764%	22.722%	20.851%	19.134%	16.113%	13.558%
\$350,000	100	7	18.396%	16.110%	14.074%	12.268%	10.676%	8.057%	6.047%
\$350,000	150	7	14.126%	11.923%	10.031%	8.411%	7.038%	4.919%	3.446%
\$350,000	200	7	11.628%	9.512%	7.746%	6.288%	5.096%	3.340%	2.211%
\$350,000	300	7	8.932%	6.959%	5.388%	4.161%	3.207%	1.928%	1.221%
\$350,000	400	7	7.344%	5.501%	4.087%	3.029%	2.256%	1.308%	0.846%
\$350,000	500	7	6.275%	4.560%	3.293%	2.385%	1.750%	1.016%	0.697%
\$350,000	600	7	5.501%	3.874%	2.717%	1.920%	1.385%	0.823%	0.608%
\$350,000	700	7	4.944%	3.398%	2.332%	1.622%	1.167%	0.716%	0.564%
\$350,000	800	7	4.527%	3.043%	2.047%	1.405%	1.012%	0.650%	0.539%
\$350,000	900	7	4.155%	2.730%	1.804%	1.230%	0.892%	0.601%	0.524%
\$350,000	1,000	7	3.828%	2.466%	1.606%	1.091%	0.800%	0.567%	0.512%
\$350,000	1,500	7	2.822%	1.689%	1.062%	0.746%	0.600%	0.514%	0.502%
\$350,000	2,000	7	2.214%	1.263%	0.800%	0.604%	0.533%	0.504%	0.501%
\$350,000	3,000	7	1.531%	0.854%	0.600%	0.525%	0.506%	0.502%	0.501%
\$350,000	4,000	7	1.174%	0.682%	0.540%	0.509%	0.503%	0.502%	0.501%
\$350,000	5,000	7	0.949%	0.598%	0.518%	0.505%	0.503%	0.502%	0.501%
\$350,000	10,000	7	0.550%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$350,000	20,000	7	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$375,000	5	7	69.928%	68.310%	66.754%	65.253%	63.803%	61.050%	58.475%
\$375,000	10	7	54.883%	52.955%	51.118%	49.370%	47.702%	44.592%	41.771%
\$375,000	15	7	46.826%	44.799%	42.880%	41.065%	39.346%	36.182%	33.324%
\$375,000	20	7	41.260%	39.173%	37.211%	35.365%	33.626%	30.447%	27.615%
\$375,000	25	7	37.376%	35.246%	33.258%	31.397%	29.656%	26.486%	23.697%
\$375,000	50	7	27.241%	25.030%	23.005%	21.149%	19.447%	16.453%	13.922%
\$375,000	100	7	18.676%	16.406%	14.380%	12.581%	10.989%	8.358%	6.326%
\$375,000	150	7	14.384%	12.185%	10.292%	8.667%	7.283%	5.133%	3.628%
\$375,000	200	7	11.851%	9.734%	7.961%	6.492%	5.285%	3.496%	2.334%
\$375,000	300	7	9.110%	7.129%	5.548%	4.306%	3.337%	2.023%	1.285%
\$375,000	400	7	7.495%	5.643%	4.217%	3.142%	2.351%	1.370%	0.884%
\$375,000	500	7	6.407%	4.680%	3.399%	2.474%	1.821%	1.059%	0.720%
\$375,000	600	7	5.617%	3.978%	2.806%	1.993%	1.442%	0.853%	0.622%
\$375,000	700	7	5.049%	3.490%	2.408%	1.682%	1.211%	0.737%	0.573%
\$375,000	800	7	4.625%	3.127%	2.115%	1.457%	1.048%	0.665%	0.545%
\$375,000	900	7	4.246%	2.807%	1.863%	1.274%	0.922%	0.612%	0.527%
\$375,000	1,000	7	3.913%	2.536%	1.659%	1.128%	0.824%	0.575%	0.514%
\$375,000	1,500	7	2.886%	1.737%	1.093%	0.764%	0.609%	0.516%	0.502%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$375,000	2,000	7	2.265%	1.297%	0.820%	0.613%	0.536%	0.504%	0.501%
\$375,000	3,000	7	1.568%	0.874%	0.608%	0.527%	0.507%	0.502%	0.501%
\$375,000	4,000	7	1.202%	0.694%	0.543%	0.510%	0.504%	0.502%	0.501%
\$375,000	5,000	7	0.971%	0.605%	0.520%	0.505%	0.503%	0.502%	0.501%
\$375,000	10,000	7	0.554%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$375,000	20,000	7	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$400,000	5	7	70.008%	68.394%	66.842%	65.344%	63.898%	61.151%	58.584%
\$400,000	10	7	54.987%	53.065%	51.235%	49.493%	47.831%	44.733%	41.924%
\$400,000	15	7	46.955%	44.936%	43.025%	41.217%	39.506%	36.357%	33.511%
\$400,000	20	7	41.386%	39.309%	37.355%	35.517%	33.787%	30.623%	27.806%
\$400,000	25	7	37.529%	35.409%	33.431%	31.580%	29.848%	26.696%	23.924%
\$400,000	50	7	27.458%	25.262%	23.251%	21.409%	19.720%	16.750%	14.240%
\$400,000	100	7	18.925%	16.671%	14.657%	12.867%	11.280%	8.643%	6.592%
\$400,000	150	7	14.622%	12.428%	10.535%	8.907%	7.515%	5.337%	3.801%
\$400,000	200	7	12.057%	9.939%	8.162%	6.684%	5.464%	3.644%	2.453%
\$400,000	300	7	9.276%	7.290%	5.701%	4.444%	3.461%	2.117%	1.348%
\$400,000	400	7	7.636%	5.778%	4.340%	3.251%	2.444%	1.432%	0.922%
\$400,000	500	7	6.530%	4.794%	3.499%	2.559%	1.890%	1.101%	0.742%
\$400,000	600	7	5.727%	4.077%	2.891%	2.063%	1.498%	0.882%	0.637%
\$400,000	700	7	5.148%	3.577%	2.481%	1.739%	1.255%	0.759%	0.582%
\$400,000	800	7	4.717%	3.207%	2.180%	1.507%	1.084%	0.681%	0.551%
\$400,000	900	7	4.332%	2.880%	1.920%	1.316%	0.951%	0.623%	0.531%
\$400,000	1,000	7	3.995%	2.604%	1.710%	1.164%	0.848%	0.584%	0.517%
\$400,000	1,500	7	2.947%	1.783%	1.124%	0.782%	0.619%	0.518%	0.502%
\$400,000	2,000	7	2.315%	1.331%	0.840%	0.623%	0.540%	0.504%	0.501%
\$400,000	3,000	7	1.603%	0.893%	0.616%	0.530%	0.508%	0.502%	0.501%
\$400,000	4,000	7	1.229%	0.706%	0.547%	0.511%	0.504%	0.502%	0.501%
\$400,000	5,000	7	0.992%	0.612%	0.521%	0.506%	0.503%	0.502%	0.501%
\$400,000	10,000	7	0.558%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$400,000	20,000	7	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$425,000	5	7	70.081%	68.470%	66.921%	65.427%	63.983%	61.243%	58.682%
\$425,000	10	7	55.077%	53.161%	51.336%	49.600%	47.942%	44.855%	42.057%
\$425,000	15	7	47.055%	45.043%	43.139%	41.337%	39.632%	36.495%	33.660%
\$425,000	20	7	41.485%	39.415%	37.468%	35.638%	33.914%	30.764%	27.959%
\$425,000	25	7	37.655%	35.544%	33.574%	31.731%	30.007%	26.870%	24.111%
\$425,000	50	7	27.642%	25.459%	23.461%	21.631%	19.952%	17.003%	14.510%
\$425,000	100	7	19.135%	16.896%	14.895%	13.115%	11.533%	8.898%	6.834%
\$425,000	150	7	14.830%	12.643%	10.752%	9.122%	7.726%	5.525%	3.962%
\$425,000	200	7	12.238%	10.121%	8.341%	6.856%	5.626%	3.780%	2.562%
\$425,000	300	7	9.424%	7.433%	5.837%	4.569%	3.573%	2.202%	1.408%
\$425,000	400	7	7.761%	5.897%	4.450%	3.350%	2.530%	1.491%	0.959%
\$425,000	500	7	6.639%	4.896%	3.588%	2.635%	1.953%	1.141%	0.764%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$425,000	600	7	5.825%	4.166%	2.968%	2.127%	1.548%	0.910%	0.651%
\$425,000	700	7	5.237%	3.656%	2.547%	1.791%	1.295%	0.779%	0.590%
\$425,000	800	7	4.801%	3.279%	2.240%	1.553%	1.118%	0.696%	0.557%
\$425,000	900	7	4.410%	2.946%	1.973%	1.355%	0.978%	0.635%	0.535%
\$425,000	1,000	7	4.068%	2.665%	1.757%	1.198%	0.871%	0.592%	0.519%
\$425,000	1,500	7	3.002%	1.825%	1.153%	0.799%	0.628%	0.520%	0.502%
\$425,000	2,000	7	2.359%	1.361%	0.858%	0.632%	0.544%	0.505%	0.501%
\$425,000	3,000	7	1.635%	0.910%	0.624%	0.532%	0.508%	0.502%	0.501%
\$425,000	4,000	7	1.254%	0.717%	0.550%	0.511%	0.504%	0.502%	0.501%
\$425,000	5,000	7	1.011%	0.619%	0.523%	0.506%	0.503%	0.502%	0.501%
\$425,000	10,000	7	0.562%	0.509%	0.505%	0.504%	0.503%	0.502%	0.501%
\$425,000	20,000	7	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$450,000	5	7	70.146%	68.539%	66.992%	65.500%	64.059%	61.324%	58.768%
\$450,000	10	7	55.152%	53.239%	51.419%	49.686%	48.033%	44.954%	42.164%
\$450,000	15	7	47.136%	45.129%	43.230%	41.433%	39.733%	36.605%	33.778%
\$450,000	20	7	41.565%	39.500%	37.559%	35.734%	34.015%	30.875%	28.080%
\$450,000	25	7	37.748%	35.645%	33.681%	31.844%	30.127%	27.001%	24.253%
\$450,000	50	7	27.785%	25.611%	23.622%	21.801%	20.131%	17.197%	14.718%
\$450,000	100	7	19.288%	17.061%	15.070%	13.300%	11.724%	9.093%	7.022%
\$450,000	150	7	14.988%	12.808%	10.920%	9.291%	7.891%	5.675%	4.091%
\$450,000	200	7	12.376%	10.261%	8.479%	6.990%	5.753%	3.887%	2.648%
\$450,000	300	7	9.539%	7.545%	5.944%	4.667%	3.661%	2.270%	1.456%
\$450,000	400	7	7.859%	5.991%	4.538%	3.429%	2.598%	1.537%	0.988%
\$450,000	500	7	6.724%	4.976%	3.659%	2.695%	2.003%	1.173%	0.782%
\$450,000	600	7	5.900%	4.236%	3.028%	2.176%	1.588%	0.933%	0.662%
\$450,000	700	7	5.307%	3.718%	2.599%	1.832%	1.326%	0.796%	0.597%
\$450,000	800	7	4.865%	3.335%	2.286%	1.589%	1.144%	0.708%	0.562%
\$450,000	900	7	4.470%	2.997%	2.013%	1.385%	0.999%	0.643%	0.538%
\$450,000	1,000	7	4.125%	2.712%	1.793%	1.224%	0.889%	0.599%	0.521%
\$450,000	1,500	7	3.046%	1.858%	1.175%	0.813%	0.636%	0.522%	0.503%
\$450,000	2,000	7	2.395%	1.386%	0.872%	0.639%	0.548%	0.505%	0.501%
\$450,000	3,000	7	1.660%	0.925%	0.630%	0.534%	0.509%	0.502%	0.501%
\$450,000	4,000	7	1.274%	0.726%	0.553%	0.512%	0.504%	0.502%	0.501%
\$450,000	5,000	7	1.027%	0.625%	0.525%	0.506%	0.503%	0.502%	0.501%
\$450,000	10,000	7	0.565%	0.509%	0.505%	0.504%	0.503%	0.502%	0.501%
\$450,000	20,000	7	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$475,000	5	7	70.182%	68.576%	67.031%	65.541%	64.102%	61.370%	58.818%
\$475,000	10	7	55.196%	53.286%	51.470%	49.740%	48.089%	45.016%	42.232%
\$475,000	15	7	47.182%	45.178%	43.282%	41.489%	39.793%	36.671%	33.850%
\$475,000	20	7	41.613%	39.553%	37.615%	35.795%	34.080%	30.948%	28.160%
\$475,000	25	7	37.806%	35.707%	33.749%	31.916%	30.203%	27.085%	24.346%
\$475,000	50	7	27.886%	25.720%	23.738%	21.924%	20.260%	17.339%	14.870%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$475,000	100	7	19.408%	17.191%	15.210%	13.447%	11.877%	9.253%	7.179%
\$475,000	150	7	15.116%	12.943%	11.059%	9.431%	8.030%	5.804%	4.202%
\$475,000	200	7	12.491%	10.378%	8.595%	7.103%	5.861%	3.979%	2.723%
\$475,000	300	7	9.635%	7.640%	6.034%	4.750%	3.736%	2.327%	1.498%
\$475,000	400	7	7.940%	6.070%	4.611%	3.495%	2.655%	1.577%	1.014%
\$475,000	500	7	6.795%	5.043%	3.719%	2.747%	2.046%	1.200%	0.797%
\$475,000	600	7	5.964%	4.295%	3.080%	2.219%	1.623%	0.953%	0.671%
\$475,000	700	7	5.366%	3.771%	2.642%	1.867%	1.353%	0.810%	0.603%
\$475,000	800	7	4.920%	3.383%	2.325%	1.620%	1.166%	0.719%	0.566%
\$475,000	900	7	4.521%	3.040%	2.048%	1.411%	1.017%	0.651%	0.541%
\$475,000	1,000	7	4.172%	2.751%	1.824%	1.247%	0.904%	0.605%	0.523%
\$475,000	1,500	7	3.083%	1.886%	1.194%	0.825%	0.643%	0.523%	0.503%
\$475,000	2,000	7	2.426%	1.408%	0.885%	0.646%	0.551%	0.506%	0.501%
\$475,000	3,000	7	1.682%	0.937%	0.636%	0.536%	0.509%	0.502%	0.501%
\$475,000	4,000	7	1.292%	0.734%	0.556%	0.513%	0.504%	0.502%	0.501%
\$475,000	5,000	7	1.040%	0.630%	0.526%	0.506%	0.503%	0.502%	0.501%
\$475,000	10,000	7	0.567%	0.509%	0.505%	0.504%	0.503%	0.502%	0.501%
\$475,000	20,000	7	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$500,000	5	7	70.210%	68.605%	67.062%	65.574%	64.136%	61.406%	58.857%
\$500,000	10	7	55.232%	53.325%	51.511%	49.783%	48.135%	45.067%	42.288%
\$500,000	15	7	47.215%	45.214%	43.321%	41.531%	39.838%	36.721%	33.905%
\$500,000	20	7	41.647%	39.590%	37.656%	35.838%	34.127%	31.000%	28.217%
\$500,000	25	7	37.846%	35.751%	33.797%	31.968%	30.258%	27.147%	24.413%
\$500,000	50	7	27.958%	25.799%	23.822%	22.013%	20.355%	17.442%	14.981%
\$500,000	100	7	19.502%	17.293%	15.319%	13.562%	11.998%	9.382%	7.308%
\$500,000	150	7	15.216%	13.050%	11.170%	9.544%	8.143%	5.911%	4.295%
\$500,000	200	7	12.583%	10.473%	8.690%	7.196%	5.951%	4.056%	2.787%
\$500,000	300	7	9.714%	7.718%	6.109%	4.820%	3.798%	2.376%	1.534%
\$500,000	400	7	8.009%	6.136%	4.673%	3.551%	2.704%	1.611%	1.036%
\$500,000	500	7	6.854%	5.099%	3.769%	2.790%	2.083%	1.224%	0.811%
\$500,000	600	7	6.018%	4.345%	3.123%	2.256%	1.653%	0.970%	0.680%
\$500,000	700	7	5.416%	3.815%	2.680%	1.897%	1.376%	0.822%	0.609%
\$500,000	800	7	4.967%	3.424%	2.358%	1.646%	1.186%	0.728%	0.570%
\$500,000	900	7	4.563%	3.076%	2.077%	1.433%	1.033%	0.658%	0.543%
\$500,000	1,000	7	4.212%	2.785%	1.851%	1.266%	0.917%	0.610%	0.525%
\$500,000	1,500	7	3.114%	1.910%	1.211%	0.835%	0.648%	0.524%	0.503%
\$500,000	2,000	7	2.451%	1.425%	0.896%	0.652%	0.553%	0.506%	0.501%
\$500,000	3,000	7	1.700%	0.947%	0.640%	0.538%	0.510%	0.502%	0.501%
\$500,000	4,000	7	1.306%	0.741%	0.558%	0.513%	0.504%	0.502%	0.501%
\$500,000	5,000	7	1.051%	0.634%	0.527%	0.507%	0.503%	0.502%	0.501%
\$500,000	10,000	7	0.570%	0.509%	0.505%	0.504%	0.503%	0.502%	0.501%
\$500,000	20,000	7	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$30,000	5	8	48.865%	46.428%	44.073%	41.797%	39.597%	35.400%	31.445%
\$30,000	10	8	32.320%	29.624%	27.127%	24.829%	22.721%	19.003%	15.861%
\$30,000	15	8	25.534%	22.990%	20.651%	18.507%	16.553%	13.159%	10.371%
\$30,000	20	8	21.460%	18.930%	16.649%	14.595%	12.762%	9.693%	7.314%
\$30,000	25	8	18.748%	16.263%	14.056%	12.109%	10.404%	7.622%	5.533%
\$30,000	50	8	12.020%	9.774%	7.891%	6.332%	5.061%	3.219%	2.065%
\$30,000	100	8	7.703%	5.765%	4.275%	3.151%	2.324%	1.313%	0.833%
\$30,000	150	8	5.835%	4.100%	2.853%	1.986%	1.408%	0.805%	0.590%
\$30,000	200	8	4.774%	3.199%	2.131%	1.442%	1.019%	0.631%	0.526%
\$30,000	300	8	3.555%	2.218%	1.404%	0.943%	0.701%	0.535%	0.505%
\$30,000	400	8	2.876%	1.702%	1.052%	0.730%	0.588%	0.511%	0.501%
\$30,000	500	8	2.440%	1.402%	0.873%	0.638%	0.546%	0.505%	0.501%
\$30,000	600	8	2.113%	1.185%	0.754%	0.583%	0.524%	0.503%	0.501%
\$30,000	700	8	1.853%	1.025%	0.675%	0.551%	0.513%	0.502%	0.501%
\$30,000	800	8	1.670%	0.921%	0.627%	0.533%	0.508%	0.502%	0.501%
\$30,000	900	8	1.514%	0.837%	0.592%	0.521%	0.506%	0.502%	0.501%
\$30,000	1,000	8	1.387%	0.773%	0.567%	0.514%	0.504%	0.502%	0.501%
\$30,000	1,500	8	0.988%	0.608%	0.520%	0.506%	0.503%	0.502%	0.501%
\$30,000	2,000	8	0.787%	0.548%	0.509%	0.504%	0.503%	0.502%	0.501%
\$30,000	3,000	8	0.613%	0.514%	0.505%	0.504%	0.503%	0.502%	0.501%
\$30,000	4,000	8	0.548%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$30,000	5,000	8	0.524%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$30,000	10,000	8	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$30,000	20,000	8	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$35,000	5	8	51.005%	48.669%	46.415%	44.241%	42.135%	38.118%	34.350%
\$35,000	10	8	34.358%	31.635%	29.094%	26.734%	24.545%	20.679%	17.417%
\$35,000	15	8	26.972%	24.420%	22.076%	19.921%	17.940%	14.470%	11.591%
\$35,000	20	8	22.726%	20.183%	17.878%	15.792%	13.915%	10.737%	8.229%
\$35,000	25	8	19.872%	17.369%	15.131%	13.140%	11.382%	8.480%	6.264%
\$35,000	50	8	12.767%	10.484%	8.555%	6.940%	5.607%	3.641%	2.375%
\$35,000	100	8	8.193%	6.212%	4.673%	3.488%	2.602%	1.487%	0.932%
\$35,000	150	8	6.228%	4.444%	3.136%	2.211%	1.578%	0.890%	0.625%
\$35,000	200	8	5.102%	3.476%	2.350%	1.605%	1.132%	0.678%	0.540%
\$35,000	300	8	3.799%	2.410%	1.540%	1.032%	0.755%	0.549%	0.508%
\$35,000	400	8	3.079%	1.851%	1.148%	0.784%	0.615%	0.516%	0.502%
\$35,000	500	8	2.620%	1.527%	0.947%	0.674%	0.562%	0.507%	0.502%
\$35,000	600	8	2.270%	1.286%	0.808%	0.607%	0.533%	0.504%	0.501%
\$35,000	700	8	1.992%	1.109%	0.715%	0.566%	0.519%	0.503%	0.501%
\$35,000	800	8	1.797%	0.992%	0.658%	0.545%	0.512%	0.502%	0.501%
\$35,000	900	8	1.633%	0.899%	0.617%	0.529%	0.507%	0.502%	0.501%
\$35,000	1,000	8	1.496%	0.826%	0.587%	0.519%	0.505%	0.502%	0.501%
\$35,000	1,500	8	1.063%	0.635%	0.526%	0.506%	0.503%	0.502%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$35,000	2,000	8	0.839%	0.562%	0.511%	0.504%	0.503%	0.502%	0.501%
\$35,000	3,000	8	0.640%	0.518%	0.505%	0.504%	0.503%	0.502%	0.501%
\$35,000	4,000	8	0.562%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$35,000	5,000	8	0.531%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$35,000	10,000	8	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$35,000	20,000	8	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$40,000	5	8	52.784%	50.532%	48.362%	46.264%	44.233%	40.370%	36.744%
\$40,000	10	8	36.224%	33.511%	30.957%	28.558%	26.315%	22.294%	18.869%
\$40,000	15	8	28.290%	25.716%	23.351%	21.176%	19.178%	15.657%	12.703%
\$40,000	20	8	23.855%	21.306%	18.986%	16.880%	14.970%	11.702%	9.088%
\$40,000	25	8	20.885%	18.367%	16.105%	14.084%	12.283%	9.276%	6.950%
\$40,000	50	8	13.440%	11.128%	9.160%	7.498%	6.113%	4.038%	2.671%
\$40,000	100	8	8.637%	6.618%	5.034%	3.801%	2.861%	1.653%	1.030%
\$40,000	150	8	6.584%	4.757%	3.398%	2.423%	1.741%	0.976%	0.663%
\$40,000	200	8	5.399%	3.730%	2.553%	1.760%	1.243%	0.727%	0.556%
\$40,000	300	8	4.021%	2.586%	1.669%	1.118%	0.808%	0.565%	0.511%
\$40,000	400	8	3.264%	1.989%	1.240%	0.839%	0.643%	0.521%	0.503%
\$40,000	500	8	2.784%	1.643%	1.018%	0.712%	0.579%	0.510%	0.502%
\$40,000	600	8	2.414%	1.382%	0.862%	0.633%	0.544%	0.505%	0.501%
\$40,000	700	8	2.119%	1.187%	0.755%	0.584%	0.525%	0.503%	0.501%
\$40,000	800	8	1.914%	1.060%	0.690%	0.557%	0.515%	0.502%	0.501%
\$40,000	900	8	1.740%	0.958%	0.642%	0.537%	0.509%	0.502%	0.501%
\$40,000	1,000	8	1.595%	0.878%	0.607%	0.525%	0.506%	0.502%	0.501%
\$40,000	1,500	8	1.134%	0.662%	0.533%	0.508%	0.503%	0.502%	0.501%
\$40,000	2,000	8	0.889%	0.576%	0.514%	0.505%	0.503%	0.502%	0.501%
\$40,000	3,000	8	0.666%	0.522%	0.506%	0.504%	0.503%	0.502%	0.501%
\$40,000	4,000	8	0.575%	0.510%	0.505%	0.504%	0.503%	0.502%	0.501%
\$40,000	5,000	8	0.538%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$40,000	10,000	8	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$40,000	20,000	8	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$45,000	5	8	54.302%	52.121%	50.017%	47.982%	46.016%	42.283%	38.765%
\$45,000	10	8	37.923%	35.251%	32.701%	30.288%	28.018%	23.892%	20.308%
\$45,000	15	8	29.534%	26.930%	24.534%	22.332%	20.309%	16.742%	13.742%
\$45,000	20	8	24.887%	22.339%	20.011%	17.888%	15.955%	12.618%	9.914%
\$45,000	25	8	21.818%	19.292%	17.013%	14.964%	13.130%	10.038%	7.611%
\$45,000	50	8	14.060%	11.724%	9.722%	8.020%	6.592%	4.424%	2.964%
\$45,000	100	8	9.053%	7.002%	5.375%	4.097%	3.111%	1.820%	1.132%
\$45,000	150	8	6.915%	5.053%	3.648%	2.627%	1.901%	1.063%	0.703%
\$45,000	200	8	5.677%	3.970%	2.749%	1.910%	1.354%	0.778%	0.575%
\$45,000	300	8	4.222%	2.747%	1.789%	1.199%	0.859%	0.580%	0.514%
\$45,000	400	8	3.437%	2.121%	1.330%	0.894%	0.674%	0.528%	0.504%
\$45,000	500	8	2.937%	1.753%	1.087%	0.751%	0.599%	0.513%	0.502%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$45,000	600	8	2.549%	1.473%	0.915%	0.659%	0.556%	0.506%	0.501%
\$45,000	700	8	2.238%	1.264%	0.796%	0.602%	0.532%	0.504%	0.501%
\$45,000	800	8	2.024%	1.126%	0.723%	0.570%	0.520%	0.503%	0.501%
\$45,000	900	8	1.842%	1.016%	0.668%	0.547%	0.512%	0.502%	0.501%
\$45,000	1,000	8	1.689%	0.929%	0.629%	0.532%	0.508%	0.502%	0.501%
\$45,000	1,500	8	1.202%	0.690%	0.541%	0.509%	0.504%	0.502%	0.501%
\$45,000	2,000	8	0.939%	0.592%	0.517%	0.505%	0.503%	0.502%	0.501%
\$45,000	3,000	8	0.693%	0.527%	0.506%	0.504%	0.503%	0.502%	0.501%
\$45,000	4,000	8	0.590%	0.511%	0.505%	0.504%	0.503%	0.502%	0.501%
\$45,000	5,000	8	0.546%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$45,000	10,000	8	0.508%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$45,000	20,000	8	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$50,000	5	8	55.563%	53.439%	51.388%	49.407%	47.498%	43.866%	40.437%
\$50,000	10	8	39.369%	36.766%	34.263%	31.867%	29.589%	25.407%	21.725%
\$50,000	15	8	30.680%	28.053%	25.626%	23.391%	21.336%	17.717%	14.669%
\$50,000	20	8	25.821%	23.269%	20.933%	18.800%	16.851%	13.462%	10.685%
\$50,000	25	8	22.664%	20.136%	17.842%	15.771%	13.911%	10.753%	8.243%
\$50,000	50	8	14.630%	12.272%	10.243%	8.509%	7.044%	4.790%	3.248%
\$50,000	100	8	9.438%	7.360%	5.693%	4.374%	3.348%	1.983%	1.232%
\$50,000	150	8	7.222%	5.326%	3.882%	2.819%	2.055%	1.150%	0.746%
\$50,000	200	8	5.933%	4.191%	2.932%	2.052%	1.459%	0.828%	0.595%
\$50,000	300	8	4.414%	2.903%	1.906%	1.282%	0.913%	0.598%	0.518%
\$50,000	400	8	3.596%	2.244%	1.417%	0.948%	0.705%	0.536%	0.506%
\$50,000	500	8	3.078%	1.856%	1.155%	0.790%	0.619%	0.517%	0.503%
\$50,000	600	8	2.673%	1.560%	0.968%	0.687%	0.568%	0.508%	0.501%
\$50,000	700	8	2.349%	1.337%	0.836%	0.620%	0.539%	0.505%	0.501%
\$50,000	800	8	2.125%	1.189%	0.755%	0.583%	0.525%	0.503%	0.501%
\$50,000	900	8	1.935%	1.072%	0.695%	0.557%	0.515%	0.502%	0.501%
\$50,000	1,000	8	1.777%	0.979%	0.651%	0.540%	0.510%	0.502%	0.501%
\$50,000	1,500	8	1.266%	0.717%	0.549%	0.511%	0.504%	0.502%	0.501%
\$50,000	2,000	8	0.987%	0.608%	0.520%	0.505%	0.503%	0.502%	0.501%
\$50,000	3,000	8	0.720%	0.532%	0.507%	0.504%	0.503%	0.502%	0.501%
\$50,000	4,000	8	0.604%	0.513%	0.505%	0.504%	0.503%	0.502%	0.501%
\$50,000	5,000	8	0.554%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$50,000	10,000	8	0.508%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$50,000	20,000	8	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$55,000	5	8	56.634%	54.555%	52.549%	50.616%	48.753%	45.198%	41.849%
\$55,000	10	8	40.592%	38.051%	35.612%	33.267%	31.012%	26.807%	23.072%
\$55,000	15	8	31.750%	29.108%	26.655%	24.389%	22.302%	18.619%	15.512%
\$55,000	20	8	26.680%	24.117%	21.772%	19.626%	17.663%	14.235%	11.399%
\$55,000	25	8	23.429%	20.902%	18.597%	16.506%	14.624%	11.416%	8.838%
\$55,000	50	8	15.146%	12.775%	10.723%	8.961%	7.464%	5.136%	3.523%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$55,000	100	8	9.788%	7.686%	5.985%	4.629%	3.568%	2.135%	1.327%
\$55,000	150	8	7.496%	5.572%	4.096%	2.997%	2.198%	1.232%	0.789%
\$55,000	200	8	6.164%	4.394%	3.099%	2.184%	1.558%	0.879%	0.616%
\$55,000	300	8	4.586%	3.045%	2.015%	1.359%	0.965%	0.616%	0.524%
\$55,000	400	8	3.741%	2.358%	1.498%	1.001%	0.735%	0.544%	0.507%
\$55,000	500	8	3.206%	1.952%	1.220%	0.828%	0.639%	0.521%	0.503%
\$55,000	600	8	2.786%	1.640%	1.017%	0.713%	0.581%	0.510%	0.502%
\$55,000	700	8	2.450%	1.404%	0.875%	0.639%	0.547%	0.506%	0.501%
\$55,000	800	8	2.219%	1.249%	0.787%	0.597%	0.530%	0.504%	0.501%
\$55,000	900	8	2.021%	1.124%	0.720%	0.567%	0.519%	0.503%	0.501%
\$55,000	1,000	8	1.858%	1.026%	0.672%	0.548%	0.512%	0.502%	0.501%
\$55,000	1,500	8	1.326%	0.744%	0.558%	0.513%	0.504%	0.502%	0.501%
\$55,000	2,000	8	1.032%	0.624%	0.524%	0.506%	0.503%	0.502%	0.501%
\$55,000	3,000	8	0.745%	0.537%	0.507%	0.504%	0.503%	0.502%	0.501%
\$55,000	4,000	8	0.619%	0.514%	0.505%	0.504%	0.503%	0.502%	0.501%
\$55,000	5,000	8	0.562%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$55,000	10,000	8	0.508%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$55,000	20,000	8	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$60,000	5	8	57.551%	55.511%	53.545%	51.653%	49.827%	46.337%	43.055%
\$60,000	10	8	41.642%	39.154%	36.768%	34.475%	32.268%	28.106%	24.334%
\$60,000	15	8	32.745%	30.100%	27.632%	25.340%	23.223%	19.474%	16.302%
\$60,000	20	8	27.481%	24.909%	22.550%	20.388%	18.412%	14.955%	12.068%
\$60,000	25	8	24.130%	21.600%	19.290%	17.188%	15.288%	12.033%	9.401%
\$60,000	50	8	15.618%	13.236%	11.164%	9.378%	7.853%	5.463%	3.785%
\$60,000	100	8	10.111%	7.989%	6.258%	4.871%	3.778%	2.282%	1.421%
\$60,000	150	8	7.747%	5.799%	4.294%	3.164%	2.333%	1.313%	0.831%
\$60,000	200	8	6.376%	4.581%	3.255%	2.310%	1.653%	0.929%	0.639%
\$60,000	300	8	4.745%	3.178%	2.117%	1.433%	1.015%	0.635%	0.529%
\$60,000	400	8	3.875%	2.464%	1.575%	1.052%	0.766%	0.553%	0.509%
\$60,000	500	8	3.326%	2.043%	1.282%	0.866%	0.659%	0.526%	0.504%
\$60,000	600	8	2.892%	1.716%	1.065%	0.740%	0.594%	0.512%	0.502%
\$60,000	700	8	2.544%	1.468%	0.912%	0.657%	0.555%	0.507%	0.502%
\$60,000	800	8	2.305%	1.305%	0.818%	0.612%	0.536%	0.504%	0.501%
\$60,000	900	8	2.101%	1.174%	0.746%	0.578%	0.522%	0.503%	0.501%
\$60,000	1,000	8	1.934%	1.071%	0.694%	0.556%	0.515%	0.502%	0.501%
\$60,000	1,500	8	1.382%	0.770%	0.567%	0.515%	0.505%	0.502%	0.501%
\$60,000	2,000	8	1.075%	0.640%	0.528%	0.507%	0.503%	0.502%	0.501%
\$60,000	3,000	8	0.770%	0.543%	0.508%	0.504%	0.503%	0.502%	0.501%
\$60,000	4,000	8	0.633%	0.516%	0.505%	0.504%	0.503%	0.502%	0.501%
\$60,000	5,000	8	0.570%	0.509%	0.505%	0.504%	0.503%	0.502%	0.501%
\$60,000	10,000	8	0.509%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$60,000	20,000	8	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$65,000	5	8	58.344%	56.337%	54.406%	52.548%	50.751%	47.318%	44.092%
\$65,000	10	8	42.534%	40.093%	37.750%	35.500%	33.336%	29.256%	25.499%
\$65,000	15	8	33.646%	31.013%	28.542%	26.238%	24.096%	20.286%	17.051%
\$65,000	20	8	28.219%	25.641%	23.271%	21.091%	19.098%	15.609%	12.688%
\$65,000	25	8	24.769%	22.236%	19.921%	17.813%	15.902%	12.604%	9.927%
\$65,000	50	8	16.043%	13.652%	11.568%	9.760%	8.210%	5.767%	4.031%
\$65,000	100	8	10.405%	8.265%	6.509%	5.096%	3.975%	2.423%	1.514%
\$65,000	150	8	7.977%	6.008%	4.478%	3.319%	2.461%	1.392%	0.874%
\$65,000	200	8	6.571%	4.755%	3.401%	2.428%	1.744%	0.977%	0.662%
\$65,000	300	8	4.892%	3.300%	2.212%	1.503%	1.064%	0.654%	0.535%
\$65,000	400	8	3.998%	2.562%	1.647%	1.100%	0.796%	0.561%	0.511%
\$65,000	500	8	3.437%	2.128%	1.340%	0.902%	0.680%	0.530%	0.505%
\$65,000	600	8	2.988%	1.786%	1.110%	0.765%	0.606%	0.514%	0.502%
\$65,000	700	8	2.629%	1.527%	0.947%	0.676%	0.563%	0.508%	0.502%
\$65,000	800	8	2.384%	1.357%	0.847%	0.626%	0.541%	0.505%	0.501%
\$65,000	900	8	2.175%	1.220%	0.770%	0.589%	0.526%	0.503%	0.501%
\$65,000	1,000	8	2.002%	1.112%	0.714%	0.564%	0.517%	0.503%	0.501%
\$65,000	1,500	8	1.433%	0.795%	0.576%	0.518%	0.505%	0.502%	0.501%
\$65,000	2,000	8	1.115%	0.655%	0.532%	0.507%	0.503%	0.502%	0.501%
\$65,000	3,000	8	0.794%	0.549%	0.509%	0.504%	0.503%	0.502%	0.501%
\$65,000	4,000	8	0.647%	0.519%	0.506%	0.504%	0.503%	0.502%	0.501%
\$65,000	5,000	8	0.579%	0.510%	0.505%	0.504%	0.503%	0.502%	0.501%
\$65,000	10,000	8	0.509%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$65,000	20,000	8	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$70,000	5	8	59.030%	57.052%	55.152%	53.321%	51.547%	48.164%	44.987%
\$70,000	10	8	43.301%	40.898%	38.593%	36.378%	34.250%	30.245%	26.551%
\$70,000	15	8	34.460%	31.846%	29.385%	27.078%	24.925%	21.066%	17.769%
\$70,000	20	8	28.908%	26.323%	23.939%	21.744%	19.733%	16.207%	13.258%
\$70,000	25	8	25.355%	22.818%	20.499%	18.385%	16.461%	13.131%	10.413%
\$70,000	50	8	16.436%	14.038%	11.943%	10.118%	8.547%	6.055%	4.268%
\$70,000	100	8	10.676%	8.518%	6.743%	5.307%	4.162%	2.557%	1.605%
\$70,000	150	8	8.189%	6.201%	4.649%	3.466%	2.583%	1.468%	0.917%
\$70,000	200	8	6.749%	4.914%	3.536%	2.539%	1.831%	1.025%	0.685%
\$70,000	300	8	5.027%	3.413%	2.302%	1.569%	1.110%	0.672%	0.541%
\$70,000	400	8	4.103%	2.646%	1.709%	1.141%	0.821%	0.568%	0.512%
\$70,000	500	8	3.536%	2.205%	1.394%	0.937%	0.700%	0.535%	0.506%
\$70,000	600	8	3.076%	1.850%	1.152%	0.789%	0.619%	0.517%	0.503%
\$70,000	700	8	2.707%	1.582%	0.981%	0.693%	0.571%	0.509%	0.502%
\$70,000	800	8	2.456%	1.405%	0.875%	0.639%	0.547%	0.506%	0.501%
\$70,000	900	8	2.242%	1.263%	0.793%	0.599%	0.530%	0.504%	0.501%
\$70,000	1,000	8	2.065%	1.151%	0.734%	0.573%	0.520%	0.503%	0.501%
\$70,000	1,500	8	1.480%	0.818%	0.585%	0.520%	0.506%	0.502%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$70,000	2,000	8	1.152%	0.670%	0.536%	0.508%	0.503%	0.502%	0.501%
\$70,000	3,000	8	0.816%	0.554%	0.510%	0.504%	0.503%	0.502%	0.501%
\$70,000	4,000	8	0.661%	0.521%	0.506%	0.504%	0.503%	0.502%	0.501%
\$70,000	5,000	8	0.587%	0.511%	0.505%	0.504%	0.503%	0.502%	0.501%
\$70,000	10,000	8	0.510%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$70,000	20,000	8	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$75,000	5	8	59.622%	57.671%	55.796%	53.987%	52.233%	48.892%	45.758%
\$75,000	10	8	43.960%	41.590%	39.316%	37.133%	35.035%	31.094%	27.462%
\$75,000	15	8	35.180%	32.593%	30.149%	27.849%	25.692%	21.802%	18.453%
\$75,000	20	8	29.547%	26.960%	24.563%	22.357%	20.326%	16.764%	13.783%
\$75,000	25	8	25.898%	23.355%	21.032%	18.911%	16.976%	13.616%	10.865%
\$75,000	50	8	16.802%	14.399%	12.294%	10.454%	8.864%	6.328%	4.493%
\$75,000	100	8	10.927%	8.755%	6.962%	5.507%	4.339%	2.686%	1.695%
\$75,000	150	8	8.385%	6.382%	4.810%	3.605%	2.699%	1.543%	0.960%
\$75,000	200	8	6.916%	5.062%	3.663%	2.643%	1.914%	1.071%	0.707%
\$75,000	300	8	5.152%	3.520%	2.386%	1.632%	1.155%	0.691%	0.547%
\$75,000	400	8	4.205%	2.729%	1.771%	1.184%	0.849%	0.577%	0.514%
\$75,000	500	8	3.628%	2.276%	1.445%	0.970%	0.719%	0.540%	0.507%
\$75,000	600	8	3.156%	1.910%	1.192%	0.813%	0.632%	0.520%	0.503%
\$75,000	700	8	2.779%	1.633%	1.013%	0.710%	0.579%	0.511%	0.502%
\$75,000	800	8	2.521%	1.450%	0.901%	0.653%	0.553%	0.506%	0.501%
\$75,000	900	8	2.303%	1.303%	0.816%	0.610%	0.534%	0.504%	0.501%
\$75,000	1,000	8	2.123%	1.187%	0.753%	0.581%	0.523%	0.503%	0.501%
\$75,000	1,500	8	1.524%	0.840%	0.593%	0.523%	0.506%	0.502%	0.501%
\$75,000	2,000	8	1.187%	0.684%	0.540%	0.509%	0.503%	0.502%	0.501%
\$75,000	3,000	8	0.838%	0.560%	0.510%	0.504%	0.503%	0.502%	0.501%
\$75,000	4,000	8	0.673%	0.523%	0.506%	0.504%	0.503%	0.502%	0.501%
\$75,000	5,000	8	0.595%	0.512%	0.505%	0.504%	0.503%	0.502%	0.501%
\$75,000	10,000	8	0.510%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$75,000	20,000	8	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$80,000	5	8	60.139%	58.210%	56.357%	54.567%	52.832%	49.528%	46.432%
\$80,000	10	8	44.546%	42.205%	39.959%	37.803%	35.734%	31.849%	28.273%
\$80,000	15	8	35.831%	33.280%	30.861%	28.574%	26.425%	22.521%	19.126%
\$80,000	20	8	30.156%	27.570%	25.168%	22.951%	20.904%	17.305%	14.291%
\$80,000	25	8	26.423%	23.874%	21.545%	19.416%	17.468%	14.082%	11.302%
\$80,000	50	8	17.155%	14.748%	12.634%	10.779%	9.171%	6.596%	4.715%
\$80,000	100	8	11.168%	8.983%	7.174%	5.700%	4.511%	2.813%	1.785%
\$80,000	150	8	8.572%	6.556%	4.965%	3.739%	2.812%	1.618%	1.004%
\$80,000	200	8	7.075%	5.205%	3.788%	2.746%	1.995%	1.117%	0.731%
\$80,000	300	8	5.271%	3.622%	2.467%	1.693%	1.198%	0.710%	0.554%
\$80,000	400	8	4.303%	2.809%	1.832%	1.226%	0.876%	0.586%	0.516%
\$80,000	500	8	3.714%	2.344%	1.494%	1.003%	0.739%	0.546%	0.508%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$80,000	600	8	3.232%	1.968%	1.231%	0.837%	0.645%	0.523%	0.503%
\$80,000	700	8	2.847%	1.683%	1.044%	0.727%	0.588%	0.512%	0.502%
\$80,000	800	8	2.583%	1.494%	0.927%	0.666%	0.559%	0.507%	0.502%
\$80,000	900	8	2.362%	1.342%	0.838%	0.620%	0.539%	0.505%	0.501%
\$80,000	1,000	8	2.177%	1.222%	0.771%	0.589%	0.526%	0.503%	0.501%
\$80,000	1,500	8	1.565%	0.862%	0.602%	0.525%	0.507%	0.502%	0.501%
\$80,000	2,000	8	1.220%	0.698%	0.544%	0.510%	0.504%	0.502%	0.501%
\$80,000	3,000	8	0.858%	0.565%	0.511%	0.504%	0.503%	0.502%	0.501%
\$80,000	4,000	8	0.686%	0.525%	0.506%	0.504%	0.503%	0.502%	0.501%
\$80,000	5,000	8	0.602%	0.512%	0.505%	0.504%	0.503%	0.502%	0.501%
\$80,000	10,000	8	0.510%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$80,000	20,000	8	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$90,000	5	8	61.044%	59.156%	57.338%	55.579%	53.878%	50.640%	47.607%
\$90,000	10	8	45.564%	43.273%	41.076%	38.969%	36.952%	33.165%	29.684%
\$90,000	15	8	36.978%	34.496%	32.141%	29.910%	27.793%	23.906%	20.466%
\$90,000	20	8	31.303%	28.730%	26.334%	24.106%	22.039%	18.370%	15.280%
\$90,000	25	8	27.435%	24.878%	22.533%	20.388%	18.416%	14.976%	12.139%
\$90,000	50	8	17.833%	15.422%	13.289%	11.410%	9.772%	7.125%	5.157%
\$90,000	100	8	11.635%	9.426%	7.587%	6.079%	4.851%	3.069%	1.970%
\$90,000	150	8	8.933%	6.892%	5.269%	4.005%	3.038%	1.770%	1.096%
\$90,000	200	8	7.383%	5.482%	4.031%	2.949%	2.161%	1.214%	0.782%
\$90,000	300	8	5.504%	3.821%	2.628%	1.817%	1.287%	0.750%	0.569%
\$90,000	400	8	4.493%	2.966%	1.951%	1.311%	0.932%	0.605%	0.521%
\$90,000	500	8	3.881%	2.477%	1.591%	1.067%	0.778%	0.557%	0.511%
\$90,000	600	8	3.380%	2.081%	1.309%	0.885%	0.672%	0.530%	0.505%
\$90,000	700	8	2.979%	1.780%	1.107%	0.763%	0.606%	0.516%	0.503%
\$90,000	800	8	2.703%	1.579%	0.979%	0.694%	0.572%	0.509%	0.502%
\$90,000	900	8	2.474%	1.418%	0.882%	0.642%	0.548%	0.506%	0.501%
\$90,000	1,000	8	2.282%	1.291%	0.809%	0.606%	0.533%	0.504%	0.501%
\$90,000	1,500	8	1.644%	0.904%	0.619%	0.531%	0.508%	0.502%	0.501%
\$90,000	2,000	8	1.283%	0.727%	0.553%	0.512%	0.504%	0.502%	0.501%
\$90,000	3,000	8	0.898%	0.577%	0.513%	0.505%	0.503%	0.502%	0.501%
\$90,000	4,000	8	0.711%	0.530%	0.506%	0.504%	0.503%	0.502%	0.501%
\$90,000	5,000	8	0.618%	0.514%	0.505%	0.504%	0.503%	0.502%	0.501%
\$90,000	10,000	8	0.511%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$90,000	20,000	8	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$100,000	5	8	61.819%	59.965%	58.175%	56.444%	54.772%	51.591%	48.611%
\$100,000	10	8	46.437%	44.188%	42.033%	39.968%	37.994%	34.291%	30.893%
\$100,000	15	8	37.957%	35.534%	33.237%	31.062%	29.000%	25.181%	21.747%
\$100,000	20	8	32.339%	29.804%	27.428%	25.204%	23.134%	19.428%	16.260%
\$100,000	25	8	28.383%	25.834%	23.482%	21.313%	19.321%	15.831%	12.930%
\$100,000	50	8	18.467%	16.050%	13.904%	12.010%	10.347%	7.637%	5.597%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$100,000	100	8	12.075%	9.847%	7.982%	6.445%	5.182%	3.325%	2.159%
\$100,000	150	8	9.275%	7.211%	5.561%	4.263%	3.259%	1.923%	1.192%
\$100,000	200	8	7.671%	5.743%	4.263%	3.144%	2.322%	1.312%	0.835%
\$100,000	300	8	5.722%	4.010%	2.782%	1.936%	1.376%	0.793%	0.586%
\$100,000	400	8	4.673%	3.116%	2.068%	1.396%	0.989%	0.627%	0.528%
\$100,000	500	8	4.033%	2.599%	1.681%	1.128%	0.816%	0.568%	0.513%
\$100,000	600	8	3.521%	2.190%	1.386%	0.934%	0.700%	0.537%	0.506%
\$100,000	700	8	3.106%	1.875%	1.170%	0.800%	0.625%	0.520%	0.504%
\$100,000	800	8	2.818%	1.662%	1.031%	0.722%	0.586%	0.512%	0.502%
\$100,000	900	8	2.581%	1.492%	0.926%	0.665%	0.558%	0.507%	0.502%
\$100,000	1,000	8	2.383%	1.358%	0.847%	0.624%	0.540%	0.504%	0.501%
\$100,000	1,500	8	1.719%	0.946%	0.637%	0.537%	0.510%	0.502%	0.501%
\$100,000	2,000	8	1.345%	0.755%	0.563%	0.514%	0.504%	0.502%	0.501%
\$100,000	3,000	8	0.937%	0.589%	0.515%	0.505%	0.503%	0.502%	0.501%
\$100,000	4,000	8	0.737%	0.536%	0.507%	0.504%	0.503%	0.502%	0.501%
\$100,000	5,000	8	0.634%	0.517%	0.505%	0.504%	0.503%	0.502%	0.501%
\$100,000	10,000	8	0.513%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$100,000	20,000	8	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$110,000	5	8	62.481%	60.653%	58.886%	57.179%	55.531%	52.400%	49.464%
\$110,000	10	8	47.183%	44.970%	42.850%	40.823%	38.885%	35.253%	31.928%
\$110,000	15	8	38.800%	36.425%	34.179%	32.051%	30.035%	26.303%	22.922%
\$110,000	20	8	33.244%	30.758%	28.416%	26.213%	24.154%	20.437%	17.220%
\$110,000	25	8	29.252%	26.721%	24.373%	22.192%	20.181%	16.646%	13.680%
\$110,000	50	8	19.055%	16.631%	14.475%	12.569%	10.886%	8.118%	6.013%
\$110,000	100	8	12.482%	10.239%	8.353%	6.787%	5.495%	3.571%	2.342%
\$110,000	150	8	9.595%	7.512%	5.836%	4.507%	3.471%	2.071%	1.288%
\$110,000	200	8	7.940%	5.989%	4.481%	3.330%	2.476%	1.408%	0.889%
\$110,000	300	8	5.925%	4.188%	2.930%	2.052%	1.464%	0.836%	0.603%
\$110,000	400	8	4.843%	3.261%	2.181%	1.479%	1.047%	0.650%	0.535%
\$110,000	500	8	4.181%	2.719%	1.772%	1.192%	0.857%	0.581%	0.516%
\$110,000	600	8	3.655%	2.295%	1.461%	0.982%	0.729%	0.545%	0.508%
\$110,000	700	8	3.226%	1.966%	1.231%	0.837%	0.645%	0.524%	0.505%
\$110,000	800	8	2.927%	1.741%	1.082%	0.751%	0.601%	0.514%	0.503%
\$110,000	900	8	2.682%	1.564%	0.969%	0.688%	0.568%	0.509%	0.502%
\$110,000	1,000	8	2.477%	1.423%	0.885%	0.643%	0.548%	0.505%	0.501%
\$110,000	1,500	8	1.791%	0.986%	0.656%	0.544%	0.512%	0.502%	0.501%
\$110,000	2,000	8	1.403%	0.783%	0.573%	0.517%	0.505%	0.502%	0.501%
\$110,000	3,000	8	0.976%	0.602%	0.518%	0.505%	0.503%	0.502%	0.501%
\$110,000	4,000	8	0.762%	0.541%	0.508%	0.504%	0.503%	0.502%	0.501%
\$110,000	5,000	8	0.650%	0.519%	0.506%	0.504%	0.503%	0.502%	0.501%
\$110,000	10,000	8	0.514%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$110,000	20,000	8	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$120,000	5	8	63.051%	61.244%	59.497%	57.811%	56.183%	53.092%	50.195%
\$120,000	10	8	47.823%	45.640%	43.551%	41.556%	39.647%	36.077%	32.813%
\$120,000	15	8	39.523%	37.189%	34.984%	32.897%	30.918%	27.257%	23.946%
\$120,000	20	8	34.021%	31.583%	29.282%	27.114%	25.076%	21.370%	18.130%
\$120,000	25	8	30.038%	27.532%	25.194%	23.016%	21.000%	17.427%	14.404%
\$120,000	50	8	19.594%	17.162%	14.996%	13.080%	11.382%	8.563%	6.402%
\$120,000	100	8	12.858%	10.606%	8.701%	7.109%	5.790%	3.809%	2.519%
\$120,000	150	8	9.895%	7.796%	6.094%	4.738%	3.675%	2.215%	1.382%
\$120,000	200	8	8.188%	6.219%	4.684%	3.507%	2.622%	1.503%	0.944%
\$120,000	300	8	6.116%	4.355%	3.070%	2.164%	1.550%	0.881%	0.623%
\$120,000	400	8	5.000%	3.394%	2.287%	1.559%	1.104%	0.673%	0.542%
\$120,000	500	8	4.318%	2.831%	1.857%	1.253%	0.897%	0.595%	0.520%
\$120,000	600	8	3.777%	2.391%	1.532%	1.029%	0.757%	0.553%	0.509%
\$120,000	700	8	3.336%	2.051%	1.290%	0.873%	0.665%	0.529%	0.505%
\$120,000	800	8	3.027%	1.815%	1.131%	0.779%	0.615%	0.517%	0.503%
\$120,000	900	8	2.775%	1.629%	1.010%	0.711%	0.579%	0.510%	0.502%
\$120,000	1,000	8	2.564%	1.482%	0.921%	0.661%	0.555%	0.506%	0.501%
\$120,000	1,500	8	1.856%	1.025%	0.674%	0.550%	0.514%	0.502%	0.501%
\$120,000	2,000	8	1.457%	0.810%	0.583%	0.519%	0.505%	0.502%	0.501%
\$120,000	3,000	8	1.012%	0.614%	0.521%	0.505%	0.503%	0.502%	0.501%
\$120,000	4,000	8	0.786%	0.547%	0.508%	0.504%	0.503%	0.502%	0.501%
\$120,000	5,000	8	0.666%	0.522%	0.506%	0.504%	0.503%	0.502%	0.501%
\$120,000	10,000	8	0.515%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$120,000	20,000	8	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$130,000	5	8	63.548%	61.758%	60.029%	58.363%	56.752%	53.696%	50.833%
\$130,000	10	8	48.394%	46.238%	44.177%	42.209%	40.328%	36.810%	33.601%
\$130,000	15	8	40.165%	37.869%	35.700%	33.647%	31.702%	28.104%	24.853%
\$130,000	20	8	34.719%	32.322%	30.061%	27.934%	25.928%	22.256%	19.012%
\$130,000	25	8	30.763%	28.291%	25.971%	23.803%	21.791%	18.194%	15.124%
\$130,000	50	8	20.107%	17.672%	15.496%	13.566%	11.853%	8.991%	6.782%
\$130,000	100	8	13.216%	10.958%	9.037%	7.423%	6.079%	4.045%	2.699%
\$130,000	150	8	10.185%	8.070%	6.345%	4.965%	3.873%	2.359%	1.479%
\$130,000	200	8	8.426%	6.441%	4.882%	3.680%	2.768%	1.599%	1.001%
\$130,000	300	8	6.297%	4.516%	3.206%	2.275%	1.633%	0.925%	0.643%
\$130,000	400	8	5.149%	3.522%	2.391%	1.638%	1.161%	0.698%	0.551%
\$130,000	500	8	4.448%	2.938%	1.940%	1.312%	0.937%	0.609%	0.524%
\$130,000	600	8	3.886%	2.478%	1.596%	1.072%	0.783%	0.560%	0.510%
\$130,000	700	8	3.440%	2.132%	1.347%	0.909%	0.686%	0.534%	0.506%
\$130,000	800	8	3.122%	1.887%	1.180%	0.808%	0.631%	0.520%	0.504%
\$130,000	900	8	2.862%	1.692%	1.051%	0.733%	0.590%	0.512%	0.502%
\$130,000	1,000	8	2.646%	1.540%	0.957%	0.680%	0.564%	0.507%	0.502%
\$130,000	1,500	8	1.919%	1.062%	0.691%	0.557%	0.516%	0.502%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$130,000	2,000	8	1.509%	0.836%	0.593%	0.522%	0.506%	0.502%	0.501%
\$130,000	3,000	8	1.046%	0.627%	0.523%	0.506%	0.503%	0.502%	0.501%
\$130,000	4,000	8	0.810%	0.553%	0.509%	0.504%	0.503%	0.502%	0.501%
\$130,000	5,000	8	0.681%	0.524%	0.506%	0.504%	0.503%	0.502%	0.501%
\$130,000	10,000	8	0.517%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$130,000	20,000	8	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$140,000	5	8	63.985%	62.211%	60.499%	58.847%	57.253%	54.228%	51.394%
\$140,000	10	8	48.899%	46.766%	44.730%	42.786%	40.928%	37.456%	34.296%
\$140,000	15	8	40.738%	38.476%	36.337%	34.315%	32.400%	28.856%	25.659%
\$140,000	20	8	35.345%	32.983%	30.758%	28.665%	26.693%	23.073%	19.845%
\$140,000	25	8	31.418%	28.980%	26.687%	24.538%	22.534%	18.931%	15.828%
\$140,000	50	8	20.594%	18.158%	15.975%	14.029%	12.301%	9.403%	7.150%
\$140,000	100	8	13.557%	11.294%	9.359%	7.725%	6.358%	4.276%	2.877%
\$140,000	150	8	10.462%	8.333%	6.587%	5.184%	4.067%	2.500%	1.575%
\$140,000	200	8	8.656%	6.655%	5.074%	3.848%	2.911%	1.695%	1.059%
\$140,000	300	8	6.471%	4.670%	3.337%	2.381%	1.715%	0.970%	0.664%
\$140,000	400	8	5.294%	3.647%	2.492%	1.715%	1.217%	0.723%	0.560%
\$140,000	500	8	4.574%	3.042%	2.021%	1.371%	0.977%	0.624%	0.529%
\$140,000	600	8	3.997%	2.567%	1.663%	1.118%	0.812%	0.569%	0.513%
\$140,000	700	8	3.542%	2.211%	1.403%	0.946%	0.708%	0.539%	0.507%
\$140,000	800	8	3.215%	1.957%	1.227%	0.837%	0.646%	0.524%	0.504%
\$140,000	900	8	2.947%	1.754%	1.091%	0.756%	0.602%	0.514%	0.503%
\$140,000	1,000	8	2.725%	1.596%	0.992%	0.699%	0.573%	0.508%	0.502%
\$140,000	1,500	8	1.980%	1.100%	0.710%	0.564%	0.518%	0.503%	0.501%
\$140,000	2,000	8	1.559%	0.862%	0.603%	0.526%	0.507%	0.502%	0.501%
\$140,000	3,000	8	1.080%	0.639%	0.526%	0.506%	0.503%	0.502%	0.501%
\$140,000	4,000	8	0.833%	0.559%	0.510%	0.504%	0.503%	0.502%	0.501%
\$140,000	5,000	8	0.696%	0.527%	0.506%	0.504%	0.503%	0.502%	0.501%
\$140,000	10,000	8	0.518%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$140,000	20,000	8	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$150,000	5	8	64.367%	62.606%	60.908%	59.270%	57.690%	54.690%	51.881%
\$150,000	10	8	49.333%	47.220%	45.206%	43.282%	41.445%	38.012%	34.892%
\$150,000	15	8	41.233%	38.998%	36.887%	34.890%	33.000%	29.501%	26.349%
\$150,000	20	8	35.873%	33.542%	31.346%	29.283%	27.339%	23.771%	20.579%
\$150,000	25	8	31.971%	29.565%	27.300%	25.176%	23.188%	19.594%	16.473%
\$150,000	50	8	21.028%	18.594%	16.405%	14.447%	12.703%	9.774%	7.481%
\$150,000	100	8	13.860%	11.592%	9.647%	7.996%	6.610%	4.484%	3.040%
\$150,000	150	8	10.709%	8.567%	6.803%	5.381%	4.243%	2.631%	1.665%
\$150,000	200	8	8.865%	6.849%	5.250%	4.003%	3.044%	1.786%	1.116%
\$150,000	300	8	6.628%	4.811%	3.456%	2.480%	1.792%	1.014%	0.685%
\$150,000	400	8	5.427%	3.760%	2.584%	1.787%	1.269%	0.747%	0.569%
\$150,000	500	8	4.688%	3.137%	2.095%	1.426%	1.015%	0.638%	0.533%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$150,000	600	8	4.097%	2.648%	1.724%	1.161%	0.839%	0.578%	0.515%
\$150,000	700	8	3.634%	2.283%	1.455%	0.980%	0.728%	0.544%	0.508%
\$150,000	800	8	3.297%	2.020%	1.271%	0.864%	0.662%	0.528%	0.505%
\$150,000	900	8	3.023%	1.811%	1.128%	0.777%	0.613%	0.516%	0.503%
\$150,000	1,000	8	2.796%	1.647%	1.024%	0.717%	0.582%	0.510%	0.502%
\$150,000	1,500	8	2.035%	1.133%	0.727%	0.571%	0.521%	0.503%	0.501%
\$150,000	2,000	8	1.603%	0.886%	0.613%	0.529%	0.507%	0.502%	0.501%
\$150,000	3,000	8	1.111%	0.651%	0.529%	0.507%	0.503%	0.502%	0.501%
\$150,000	4,000	8	0.854%	0.565%	0.511%	0.504%	0.503%	0.502%	0.501%
\$150,000	5,000	8	0.711%	0.530%	0.507%	0.504%	0.503%	0.502%	0.501%
\$150,000	10,000	8	0.520%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$150,000	20,000	8	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$160,000	5	8	64.703%	62.953%	61.267%	59.641%	58.074%	55.097%	52.308%
\$160,000	10	8	49.710%	47.615%	45.619%	43.712%	41.893%	38.496%	35.411%
\$160,000	15	8	41.664%	39.453%	37.365%	35.390%	33.522%	30.064%	26.950%
\$160,000	20	8	36.336%	34.031%	31.861%	29.824%	27.904%	24.381%	21.231%
\$160,000	25	8	32.457%	30.077%	27.840%	25.743%	23.776%	20.205%	17.081%
\$160,000	50	8	21.439%	19.007%	16.816%	14.848%	13.090%	10.131%	7.800%
\$160,000	100	8	14.142%	11.869%	9.916%	8.251%	6.847%	4.684%	3.199%
\$160,000	150	8	10.938%	8.786%	7.008%	5.568%	4.411%	2.758%	1.755%
\$160,000	200	8	9.062%	7.034%	5.418%	4.152%	3.173%	1.876%	1.172%
\$160,000	300	8	6.777%	4.945%	3.572%	2.576%	1.868%	1.058%	0.707%
\$160,000	400	8	5.552%	3.868%	2.673%	1.856%	1.320%	0.771%	0.578%
\$160,000	500	8	4.795%	3.228%	2.166%	1.479%	1.051%	0.653%	0.538%
\$160,000	600	8	4.192%	2.725%	1.782%	1.202%	0.866%	0.586%	0.518%
\$160,000	700	8	3.720%	2.352%	1.504%	1.013%	0.748%	0.550%	0.510%
\$160,000	800	8	3.375%	2.080%	1.312%	0.891%	0.677%	0.531%	0.506%
\$160,000	900	8	3.095%	1.864%	1.163%	0.798%	0.624%	0.518%	0.503%
\$160,000	1,000	8	2.863%	1.696%	1.055%	0.734%	0.590%	0.511%	0.502%
\$160,000	1,500	8	2.086%	1.166%	0.743%	0.578%	0.523%	0.503%	0.501%
\$160,000	2,000	8	1.645%	0.909%	0.622%	0.532%	0.508%	0.502%	0.501%
\$160,000	3,000	8	1.140%	0.662%	0.532%	0.507%	0.503%	0.502%	0.501%
\$160,000	4,000	8	0.875%	0.571%	0.512%	0.504%	0.503%	0.502%	0.501%
\$160,000	5,000	8	0.724%	0.533%	0.507%	0.504%	0.503%	0.502%	0.501%
\$160,000	10,000	8	0.521%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$160,000	20,000	8	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$170,000	5	8	65.008%	63.269%	61.594%	59.979%	58.423%	55.466%	52.696%
\$170,000	10	8	50.048%	47.969%	45.989%	44.099%	42.295%	38.931%	35.877%
\$170,000	15	8	42.051%	39.862%	37.794%	35.839%	33.990%	30.568%	27.488%
\$170,000	20	8	36.752%	34.470%	32.325%	30.309%	28.411%	24.929%	21.816%
\$170,000	25	8	32.894%	30.539%	28.327%	26.255%	24.311%	20.771%	17.656%
\$170,000	50	8	21.834%	19.406%	17.216%	15.238%	13.468%	10.478%	8.113%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$170,000	100	8	14.412%	12.135%	10.173%	8.497%	7.077%	4.878%	3.356%
\$170,000	150	8	11.156%	8.995%	7.203%	5.747%	4.571%	2.882%	1.843%
\$170,000	200	8	9.252%	7.210%	5.580%	4.295%	3.298%	1.963%	1.228%
\$170,000	300	8	6.923%	5.076%	3.685%	2.670%	1.944%	1.101%	0.729%
\$170,000	400	8	5.673%	3.973%	2.759%	1.924%	1.371%	0.796%	0.588%
\$170,000	500	8	4.900%	3.316%	2.236%	1.531%	1.088%	0.668%	0.543%
\$170,000	600	8	4.284%	2.801%	1.840%	1.243%	0.893%	0.596%	0.520%
\$170,000	700	8	3.804%	2.418%	1.553%	1.045%	0.768%	0.556%	0.511%
\$170,000	800	8	3.451%	2.138%	1.353%	0.917%	0.692%	0.535%	0.507%
\$170,000	900	8	3.165%	1.916%	1.198%	0.819%	0.636%	0.521%	0.504%
\$170,000	1,000	8	2.928%	1.744%	1.086%	0.752%	0.599%	0.512%	0.502%
\$170,000	1,500	8	2.136%	1.197%	0.760%	0.585%	0.525%	0.503%	0.501%
\$170,000	2,000	8	1.686%	0.931%	0.632%	0.535%	0.509%	0.502%	0.501%
\$170,000	3,000	8	1.168%	0.674%	0.535%	0.508%	0.503%	0.502%	0.501%
\$170,000	4,000	8	0.895%	0.577%	0.513%	0.504%	0.503%	0.502%	0.501%
\$170,000	5,000	8	0.738%	0.536%	0.507%	0.504%	0.503%	0.502%	0.501%
\$170,000	10,000	8	0.523%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$170,000	20,000	8	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$180,000	5	8	65.298%	63.569%	61.905%	60.300%	58.755%	55.816%	53.064%
\$180,000	10	8	50.361%	48.298%	46.333%	44.457%	42.668%	39.333%	36.308%
\$180,000	15	8	42.410%	40.240%	38.192%	36.255%	34.423%	31.035%	27.984%
\$180,000	20	8	37.135%	34.874%	32.752%	30.757%	28.879%	25.432%	22.355%
\$180,000	25	8	33.299%	30.966%	28.778%	26.728%	24.805%	21.303%	18.209%
\$180,000	50	8	22.217%	19.792%	17.603%	15.622%	13.839%	10.817%	8.423%
\$180,000	100	8	14.672%	12.391%	10.422%	8.735%	7.302%	5.067%	3.512%
\$180,000	150	8	11.364%	9.196%	7.392%	5.920%	4.727%	3.004%	1.932%
\$180,000	200	8	9.433%	7.380%	5.735%	4.435%	3.419%	2.049%	1.285%
\$180,000	300	8	7.062%	5.201%	3.795%	2.763%	2.018%	1.144%	0.752%
\$180,000	400	8	5.790%	4.076%	2.844%	1.991%	1.422%	0.821%	0.598%
\$180,000	500	8	5.001%	3.400%	2.303%	1.581%	1.125%	0.683%	0.548%
\$180,000	600	8	4.373%	2.874%	1.896%	1.283%	0.919%	0.606%	0.523%
\$180,000	700	8	3.877%	2.477%	1.595%	1.073%	0.785%	0.560%	0.511%
\$180,000	800	8	3.523%	2.195%	1.393%	0.943%	0.707%	0.539%	0.507%
\$180,000	900	8	3.231%	1.966%	1.233%	0.840%	0.647%	0.523%	0.504%
\$180,000	1,000	8	2.991%	1.791%	1.116%	0.770%	0.608%	0.514%	0.502%
\$180,000	1,500	8	2.184%	1.228%	0.776%	0.592%	0.528%	0.503%	0.501%
\$180,000	2,000	8	1.725%	0.953%	0.642%	0.539%	0.510%	0.502%	0.501%
\$180,000	3,000	8	1.196%	0.685%	0.539%	0.508%	0.503%	0.502%	0.501%
\$180,000	4,000	8	0.914%	0.583%	0.514%	0.505%	0.503%	0.502%	0.501%
\$180,000	5,000	8	0.751%	0.539%	0.507%	0.504%	0.503%	0.502%	0.501%
\$180,000	10,000	8	0.524%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$180,000	20,000	8	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$190,000	5	8	65.577%	63.859%	62.205%	60.610%	59.074%	56.154%	53.418%
\$190,000	10	8	50.660%	48.612%	46.660%	44.798%	43.023%	39.715%	36.716%
\$190,000	15	8	42.752%	40.600%	38.569%	36.650%	34.834%	31.476%	28.454%
\$190,000	20	8	37.501%	35.260%	33.158%	31.181%	29.322%	25.909%	22.864%
\$190,000	25	8	33.682%	31.371%	29.204%	27.175%	25.273%	21.807%	18.743%
\$190,000	50	8	22.590%	20.172%	17.984%	16.001%	14.209%	11.157%	8.732%
\$190,000	100	8	14.928%	12.641%	10.665%	8.968%	7.522%	5.255%	3.666%
\$190,000	150	8	11.567%	9.393%	7.579%	6.091%	4.882%	3.126%	2.021%
\$190,000	200	8	9.610%	7.548%	5.888%	4.572%	3.539%	2.135%	1.343%
\$190,000	300	8	7.200%	5.326%	3.905%	2.855%	2.093%	1.189%	0.776%
\$190,000	400	8	5.907%	4.178%	2.929%	2.059%	1.475%	0.847%	0.610%
\$190,000	500	8	5.100%	3.485%	2.371%	1.633%	1.162%	0.699%	0.553%
\$190,000	600	8	4.461%	2.947%	1.951%	1.323%	0.947%	0.616%	0.526%
\$190,000	700	8	3.956%	2.541%	1.642%	1.106%	0.805%	0.566%	0.513%
\$190,000	800	8	3.595%	2.251%	1.433%	0.969%	0.723%	0.543%	0.508%
\$190,000	900	8	3.296%	2.016%	1.267%	0.861%	0.659%	0.526%	0.504%
\$190,000	1,000	8	3.053%	1.837%	1.147%	0.789%	0.618%	0.516%	0.502%
\$190,000	1,500	8	2.231%	1.258%	0.793%	0.600%	0.531%	0.503%	0.501%
\$190,000	2,000	8	1.764%	0.975%	0.652%	0.542%	0.511%	0.502%	0.501%
\$190,000	3,000	8	1.223%	0.697%	0.542%	0.509%	0.503%	0.502%	0.501%
\$190,000	4,000	8	0.934%	0.589%	0.515%	0.505%	0.503%	0.502%	0.501%
\$190,000	5,000	8	0.764%	0.542%	0.508%	0.504%	0.503%	0.502%	0.501%
\$190,000	10,000	8	0.526%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$190,000	20,000	8	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$200,000	5	8	65.820%	64.111%	62.465%	60.878%	59.351%	56.446%	53.725%
\$200,000	10	8	50.922%	48.887%	46.947%	45.098%	43.334%	40.051%	37.075%
\$200,000	15	8	43.054%	40.918%	38.903%	36.998%	35.196%	31.866%	28.869%
\$200,000	20	8	37.825%	35.602%	33.518%	31.558%	29.714%	26.331%	23.314%
\$200,000	25	8	34.021%	31.728%	29.580%	27.569%	25.685%	22.251%	19.219%
\$200,000	50	8	22.927%	20.519%	18.332%	16.349%	14.551%	11.477%	9.020%
\$200,000	100	8	15.164%	12.873%	10.891%	9.186%	7.728%	5.433%	3.813%
\$200,000	150	8	11.753%	9.576%	7.752%	6.249%	5.026%	3.241%	2.107%
\$200,000	200	8	9.772%	7.701%	6.029%	4.701%	3.650%	2.216%	1.398%
\$200,000	300	8	7.328%	5.441%	4.007%	2.942%	2.165%	1.232%	0.800%
\$200,000	400	8	6.015%	4.274%	3.009%	2.125%	1.525%	0.873%	0.621%
\$200,000	500	8	5.194%	3.565%	2.435%	1.683%	1.198%	0.715%	0.558%
\$200,000	600	8	4.545%	3.015%	2.004%	1.362%	0.974%	0.626%	0.529%
\$200,000	700	8	4.031%	2.601%	1.687%	1.137%	0.825%	0.572%	0.514%
\$200,000	800	8	3.663%	2.304%	1.471%	0.995%	0.738%	0.548%	0.509%
\$200,000	900	8	3.358%	2.064%	1.300%	0.882%	0.670%	0.528%	0.505%
\$200,000	1,000	8	3.111%	1.881%	1.177%	0.806%	0.627%	0.518%	0.503%
\$200,000	1,500	8	2.276%	1.287%	0.809%	0.607%	0.534%	0.504%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$200,000	2,000	8	1.800%	0.996%	0.662%	0.546%	0.512%	0.502%	0.501%
\$200,000	3,000	8	1.248%	0.708%	0.545%	0.510%	0.504%	0.502%	0.501%
\$200,000	4,000	8	0.952%	0.595%	0.517%	0.505%	0.503%	0.502%	0.501%
\$200,000	5,000	8	0.777%	0.545%	0.508%	0.504%	0.503%	0.502%	0.501%
\$200,000	10,000	8	0.528%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$200,000	20,000	8	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$225,000	5	8	66.322%	64.631%	63.002%	61.435%	59.923%	57.052%	54.362%
\$225,000	10	8	51.481%	49.472%	47.558%	45.735%	43.996%	40.766%	37.838%
\$225,000	15	8	43.691%	41.589%	39.605%	37.733%	35.959%	32.687%	29.743%
\$225,000	20	8	38.506%	36.321%	34.274%	32.350%	30.539%	27.219%	24.261%
\$225,000	25	8	34.734%	32.480%	30.373%	28.401%	26.554%	23.187%	20.222%
\$225,000	50	8	23.664%	21.286%	19.116%	17.136%	15.336%	12.224%	9.701%
\$225,000	100	8	15.694%	13.396%	11.402%	9.680%	8.198%	5.844%	4.157%
\$225,000	150	8	12.174%	9.988%	8.146%	6.614%	5.358%	3.506%	2.309%
\$225,000	200	8	10.137%	8.051%	6.352%	4.995%	3.912%	2.410%	1.531%
\$225,000	300	8	7.617%	5.705%	4.242%	3.142%	2.331%	1.336%	0.860%
\$225,000	400	8	6.259%	4.491%	3.193%	2.275%	1.644%	0.938%	0.650%
\$225,000	500	8	5.403%	3.746%	2.583%	1.797%	1.282%	0.755%	0.573%
\$225,000	600	8	4.731%	3.172%	2.127%	1.455%	1.037%	0.651%	0.538%
\$225,000	700	8	4.201%	2.740%	1.791%	1.210%	0.873%	0.588%	0.518%
\$225,000	800	8	3.808%	2.418%	1.554%	1.050%	0.772%	0.557%	0.510%
\$225,000	900	8	3.496%	2.172%	1.376%	0.930%	0.698%	0.535%	0.506%
\$225,000	1,000	8	3.243%	1.982%	1.246%	0.849%	0.650%	0.523%	0.503%
\$225,000	1,500	8	2.375%	1.354%	0.846%	0.625%	0.541%	0.504%	0.501%
\$225,000	2,000	8	1.882%	1.045%	0.685%	0.554%	0.515%	0.502%	0.501%
\$225,000	3,000	8	1.306%	0.734%	0.554%	0.512%	0.504%	0.502%	0.501%
\$225,000	4,000	8	0.994%	0.609%	0.520%	0.505%	0.503%	0.502%	0.501%
\$225,000	5,000	8	0.807%	0.552%	0.509%	0.504%	0.503%	0.502%	0.501%
\$225,000	10,000	8	0.532%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$225,000	20,000	8	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$250,000	5	8	66.739%	65.063%	63.449%	61.897%	60.399%	57.556%	54.890%
\$250,000	10	8	51.946%	49.960%	48.067%	46.265%	44.548%	41.362%	38.475%
\$250,000	15	8	44.232%	42.158%	40.201%	38.355%	36.605%	33.383%	30.482%
\$250,000	20	8	39.086%	36.934%	34.917%	33.023%	31.239%	27.972%	25.064%
\$250,000	25	8	35.338%	33.118%	31.045%	29.105%	27.288%	23.979%	21.070%
\$250,000	50	8	24.315%	21.974%	19.827%	17.864%	16.067%	12.946%	10.379%
\$250,000	100	8	16.186%	13.888%	11.881%	10.145%	8.642%	6.237%	4.491%
\$250,000	150	8	12.569%	10.375%	8.518%	6.961%	5.676%	3.763%	2.506%
\$250,000	200	8	10.481%	8.379%	6.658%	5.271%	4.161%	2.598%	1.662%
\$250,000	300	8	7.885%	5.952%	4.462%	3.331%	2.491%	1.437%	0.920%
\$250,000	400	8	6.485%	4.695%	3.368%	2.418%	1.757%	1.002%	0.682%
\$250,000	500	8	5.599%	3.916%	2.723%	1.906%	1.364%	0.794%	0.588%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$250,000	600	8	4.907%	3.320%	2.244%	1.543%	1.099%	0.677%	0.547%
\$250,000	700	8	4.359%	2.870%	1.891%	1.282%	0.920%	0.605%	0.522%
\$250,000	800	8	3.949%	2.532%	1.638%	1.107%	0.808%	0.568%	0.513%
\$250,000	900	8	3.625%	2.273%	1.448%	0.978%	0.726%	0.543%	0.507%
\$250,000	1,000	8	3.366%	2.076%	1.312%	0.890%	0.674%	0.528%	0.504%
\$250,000	1,500	8	2.470%	1.418%	0.883%	0.643%	0.549%	0.505%	0.501%
\$250,000	2,000	8	1.959%	1.092%	0.708%	0.564%	0.518%	0.502%	0.501%
\$250,000	3,000	8	1.360%	0.759%	0.562%	0.514%	0.504%	0.502%	0.501%
\$250,000	4,000	8	1.035%	0.624%	0.523%	0.506%	0.503%	0.502%	0.501%
\$250,000	5,000	8	0.836%	0.560%	0.510%	0.504%	0.503%	0.502%	0.501%
\$250,000	10,000	8	0.537%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$250,000	20,000	8	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$275,000	5	8	67.099%	65.436%	63.835%	62.296%	60.810%	57.990%	55.347%
\$275,000	10	8	52.340%	50.372%	48.498%	46.714%	45.014%	41.865%	39.014%
\$275,000	15	8	44.701%	42.651%	40.718%	38.893%	37.164%	33.984%	31.120%
\$275,000	20	8	39.587%	37.463%	35.472%	33.602%	31.842%	28.619%	25.755%
\$275,000	25	8	35.852%	33.662%	31.616%	29.703%	27.912%	24.651%	21.789%
\$275,000	50	8	24.880%	22.574%	20.458%	18.516%	16.735%	13.618%	11.033%
\$275,000	100	8	16.644%	14.349%	12.334%	10.583%	9.063%	6.617%	4.814%
\$275,000	150	8	12.935%	10.734%	8.864%	7.289%	5.977%	4.012%	2.701%
\$275,000	200	8	10.798%	8.685%	6.945%	5.533%	4.397%	2.779%	1.791%
\$275,000	300	8	8.133%	6.182%	4.667%	3.510%	2.644%	1.537%	0.980%
\$275,000	400	8	6.694%	4.885%	3.532%	2.554%	1.866%	1.066%	0.715%
\$275,000	500	8	5.781%	4.075%	2.855%	2.010%	1.443%	0.834%	0.605%
\$275,000	600	8	5.070%	3.460%	2.356%	1.627%	1.160%	0.704%	0.556%
\$275,000	700	8	4.508%	2.993%	1.986%	1.351%	0.967%	0.623%	0.527%
\$275,000	800	8	4.082%	2.639%	1.719%	1.163%	0.845%	0.580%	0.517%
\$275,000	900	8	3.746%	2.370%	1.517%	1.024%	0.754%	0.551%	0.509%
\$275,000	1,000	8	3.482%	2.166%	1.375%	0.930%	0.697%	0.534%	0.505%
\$275,000	1,500	8	2.558%	1.479%	0.920%	0.662%	0.557%	0.506%	0.501%
\$275,000	2,000	8	2.032%	1.137%	0.731%	0.573%	0.521%	0.503%	0.501%
\$275,000	3,000	8	1.413%	0.784%	0.571%	0.516%	0.505%	0.502%	0.501%
\$275,000	4,000	8	1.073%	0.638%	0.527%	0.506%	0.503%	0.502%	0.501%
\$275,000	5,000	8	0.864%	0.568%	0.512%	0.504%	0.503%	0.502%	0.501%
\$275,000	10,000	8	0.541%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$275,000	20,000	8	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$300,000	5	8	67.388%	65.735%	64.145%	62.615%	61.138%	58.335%	55.709%
\$300,000	10	8	52.641%	50.687%	48.827%	47.056%	45.369%	42.248%	39.423%
\$300,000	15	8	45.053%	43.021%	41.104%	39.295%	37.582%	34.432%	31.595%
\$300,000	20	8	39.958%	37.854%	35.881%	34.030%	32.286%	29.096%	26.263%
\$300,000	25	8	36.235%	34.066%	32.041%	30.148%	28.375%	25.149%	22.321%
\$300,000	50	8	25.294%	23.016%	20.924%	19.002%	17.238%	14.140%	11.551%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$300,000	100	8	17.002%	14.711%	12.694%	10.931%	9.397%	6.919%	5.074%
\$300,000	150	8	13.222%	11.016%	9.138%	7.549%	6.220%	4.212%	2.860%
\$300,000	200	8	11.046%	8.923%	7.170%	5.739%	4.584%	2.923%	1.895%
\$300,000	300	8	8.329%	6.366%	4.832%	3.654%	2.768%	1.620%	1.032%
\$300,000	400	8	6.859%	5.036%	3.665%	2.666%	1.956%	1.120%	0.743%
\$300,000	500	8	5.927%	4.205%	2.963%	2.096%	1.508%	0.867%	0.620%
\$300,000	600	8	5.201%	3.574%	2.447%	1.697%	1.211%	0.727%	0.564%
\$300,000	700	8	4.628%	3.093%	2.066%	1.409%	1.008%	0.639%	0.532%
\$300,000	800	8	4.191%	2.728%	1.786%	1.211%	0.876%	0.591%	0.520%
\$300,000	900	8	3.845%	2.449%	1.575%	1.063%	0.779%	0.558%	0.510%
\$300,000	1,000	8	3.574%	2.238%	1.427%	0.964%	0.717%	0.539%	0.506%
\$300,000	1,500	8	2.631%	1.530%	0.950%	0.678%	0.564%	0.507%	0.501%
\$300,000	2,000	8	2.091%	1.175%	0.751%	0.582%	0.524%	0.503%	0.501%
\$300,000	3,000	8	1.455%	0.806%	0.579%	0.518%	0.505%	0.502%	0.501%
\$300,000	4,000	8	1.106%	0.651%	0.530%	0.507%	0.503%	0.502%	0.501%
\$300,000	5,000	8	0.888%	0.575%	0.513%	0.505%	0.503%	0.502%	0.501%
\$300,000	10,000	8	0.545%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$300,000	20,000	8	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$325,000	5	8	67.641%	65.997%	64.415%	62.893%	61.424%	58.637%	56.026%
\$325,000	10	8	52.895%	50.952%	49.104%	47.345%	45.669%	42.570%	39.767%
\$325,000	15	8	45.351%	43.333%	41.431%	39.635%	37.935%	34.810%	31.996%
\$325,000	20	8	40.268%	38.181%	36.224%	34.388%	32.658%	29.496%	26.688%
\$325,000	25	8	36.557%	34.406%	32.398%	30.522%	28.764%	25.568%	22.768%
\$325,000	50	8	25.636%	23.381%	21.311%	19.409%	17.662%	14.589%	12.011%
\$325,000	100	8	17.324%	15.039%	13.024%	11.254%	9.707%	7.201%	5.321%
\$325,000	150	8	13.484%	11.275%	9.389%	7.790%	6.445%	4.400%	3.012%
\$325,000	200	8	11.271%	9.141%	7.377%	5.929%	4.757%	3.058%	1.995%
\$325,000	300	8	8.507%	6.533%	4.984%	3.789%	2.885%	1.700%	1.082%
\$325,000	400	8	7.008%	5.175%	3.788%	2.770%	2.041%	1.173%	0.772%
\$325,000	500	8	6.060%	4.324%	3.063%	2.176%	1.570%	0.901%	0.635%
\$325,000	600	8	5.321%	3.678%	2.533%	1.763%	1.259%	0.750%	0.573%
\$325,000	700	8	4.737%	3.186%	2.140%	1.464%	1.046%	0.655%	0.537%
\$325,000	800	8	4.290%	2.811%	1.849%	1.255%	0.906%	0.602%	0.523%
\$325,000	900	8	3.928%	2.516%	1.624%	1.096%	0.799%	0.564%	0.511%
\$325,000	1,000	8	3.658%	2.305%	1.476%	0.996%	0.737%	0.544%	0.507%
\$325,000	1,500	8	2.695%	1.576%	0.979%	0.694%	0.571%	0.508%	0.501%
\$325,000	2,000	8	2.145%	1.210%	0.769%	0.590%	0.527%	0.503%	0.501%
\$325,000	3,000	8	1.493%	0.825%	0.586%	0.520%	0.505%	0.502%	0.501%
\$325,000	4,000	8	1.134%	0.662%	0.533%	0.507%	0.503%	0.502%	0.501%
\$325,000	5,000	8	0.910%	0.582%	0.514%	0.505%	0.503%	0.502%	0.501%
\$325,000	10,000	8	0.549%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$325,000	20,000	8	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$350,000	5	8	67.886%	66.250%	64.676%	63.162%	61.701%	58.928%	56.331%
\$350,000	10	8	53.142%	51.210%	49.373%	47.625%	45.960%	42.883%	40.101%
\$350,000	15	8	45.636%	43.632%	41.744%	39.960%	38.273%	35.171%	32.380%
\$350,000	20	8	40.566%	38.495%	36.553%	34.731%	33.016%	29.879%	27.096%
\$350,000	25	8	36.869%	34.735%	32.743%	30.883%	29.140%	25.972%	23.200%
\$350,000	50	8	25.966%	23.733%	21.684%	19.802%	18.074%	15.031%	12.470%
\$350,000	100	8	17.653%	15.374%	13.362%	11.591%	10.034%	7.497%	5.584%
\$350,000	150	8	13.754%	11.542%	9.649%	8.042%	6.683%	4.601%	3.175%
\$350,000	200	8	11.503%	9.367%	7.592%	6.129%	4.939%	3.203%	2.103%
\$350,000	300	8	8.692%	6.709%	5.144%	3.931%	3.008%	1.787%	1.137%
\$350,000	400	8	7.164%	5.319%	3.917%	2.880%	2.131%	1.229%	0.803%
\$350,000	500	8	6.197%	4.449%	3.168%	2.261%	1.637%	0.937%	0.651%
\$350,000	600	8	5.446%	3.788%	2.624%	1.834%	1.311%	0.776%	0.583%
\$350,000	700	8	4.849%	3.283%	2.217%	1.521%	1.087%	0.672%	0.543%
\$350,000	800	8	4.393%	2.896%	1.915%	1.303%	0.938%	0.615%	0.527%
\$350,000	900	8	4.020%	2.592%	1.681%	1.135%	0.825%	0.572%	0.513%
\$350,000	1,000	8	3.745%	2.374%	1.527%	1.031%	0.758%	0.551%	0.508%
\$350,000	1,500	8	2.761%	1.625%	1.010%	0.710%	0.580%	0.509%	0.502%
\$350,000	2,000	8	2.199%	1.245%	0.789%	0.600%	0.530%	0.503%	0.501%
\$350,000	3,000	8	1.532%	0.845%	0.594%	0.522%	0.506%	0.502%	0.501%
\$350,000	4,000	8	1.163%	0.674%	0.536%	0.508%	0.503%	0.502%	0.501%
\$350,000	5,000	8	0.932%	0.589%	0.515%	0.505%	0.503%	0.502%	0.501%
\$350,000	10,000	8	0.553%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$350,000	20,000	8	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$375,000	5	8	68.118%	66.489%	64.924%	63.417%	61.963%	59.203%	56.620%
\$375,000	10	8	53.378%	51.457%	49.630%	47.891%	46.238%	43.181%	40.418%
\$375,000	15	8	45.894%	43.903%	42.027%	40.255%	38.579%	35.498%	32.727%
\$375,000	20	8	40.839%	38.783%	36.854%	35.045%	33.342%	30.229%	27.468%
\$375,000	25	8	37.156%	35.038%	33.062%	31.216%	29.486%	26.345%	23.597%
\$375,000	50	8	26.275%	24.062%	22.032%	20.168%	18.458%	15.446%	12.910%
\$375,000	100	8	17.973%	15.704%	13.696%	11.925%	10.363%	7.799%	5.852%
\$375,000	150	8	14.020%	11.808%	9.909%	8.293%	6.923%	4.805%	3.344%
\$375,000	200	8	11.732%	9.591%	7.807%	6.332%	5.125%	3.352%	2.216%
\$375,000	300	8	8.877%	6.885%	5.305%	4.076%	3.135%	1.877%	1.195%
\$375,000	400	8	7.320%	5.463%	4.047%	2.992%	2.224%	1.288%	0.837%
\$375,000	500	8	6.334%	4.573%	3.275%	2.348%	1.705%	0.976%	0.670%
\$375,000	600	8	5.570%	3.898%	2.715%	1.905%	1.365%	0.802%	0.594%
\$375,000	700	8	4.960%	3.379%	2.295%	1.580%	1.130%	0.691%	0.549%
\$375,000	800	8	4.493%	2.981%	1.980%	1.350%	0.971%	0.628%	0.531%
\$375,000	900	8	4.112%	2.667%	1.738%	1.175%	0.851%	0.582%	0.515%
\$375,000	1,000	8	3.831%	2.444%	1.578%	1.066%	0.780%	0.557%	0.509%
\$375,000	1,500	8	2.827%	1.673%	1.040%	0.727%	0.588%	0.511%	0.502%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$375,000	2,000	8	2.253%	1.281%	0.809%	0.609%	0.534%	0.504%	0.501%
\$375,000	3,000	8	1.571%	0.866%	0.603%	0.525%	0.507%	0.502%	0.501%
\$375,000	4,000	8	1.192%	0.687%	0.540%	0.509%	0.503%	0.502%	0.501%
\$375,000	5,000	8	0.954%	0.596%	0.517%	0.505%	0.503%	0.502%	0.501%
\$375,000	10,000	8	0.558%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$375,000	20,000	8	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$400,000	5	8	68.317%	66.695%	65.137%	63.636%	62.188%	59.440%	56.869%
\$400,000	10	8	53.590%	51.677%	49.859%	48.130%	46.487%	43.447%	40.702%
\$400,000	15	8	46.122%	44.142%	42.278%	40.515%	38.850%	35.788%	33.034%
\$400,000	20	8	41.082%	39.038%	37.123%	35.325%	33.633%	30.541%	27.800%
\$400,000	25	8	37.410%	35.306%	33.343%	31.509%	29.792%	26.675%	23.947%
\$400,000	50	8	26.552%	24.357%	22.344%	20.496%	18.802%	15.818%	13.307%
\$400,000	100	8	18.266%	16.011%	14.008%	12.239%	10.675%	8.092%	6.114%
\$400,000	150	8	14.270%	12.059%	10.155%	8.532%	7.153%	5.006%	3.509%
\$400,000	200	8	11.949%	9.806%	8.013%	6.526%	5.306%	3.499%	2.330%
\$400,000	300	8	9.054%	7.054%	5.461%	4.217%	3.258%	1.967%	1.253%
\$400,000	400	8	7.469%	5.601%	4.173%	3.101%	2.314%	1.345%	0.871%
\$400,000	500	8	6.465%	4.694%	3.379%	2.433%	1.772%	1.015%	0.688%
\$400,000	600	8	5.689%	4.004%	2.804%	1.975%	1.418%	0.829%	0.606%
\$400,000	700	8	5.066%	3.472%	2.370%	1.638%	1.171%	0.710%	0.556%
\$400,000	800	8	4.589%	3.062%	2.044%	1.397%	1.003%	0.641%	0.536%
\$400,000	900	8	4.201%	2.740%	1.795%	1.214%	0.877%	0.591%	0.518%
\$400,000	1,000	8	3.907%	2.506%	1.623%	1.096%	0.799%	0.563%	0.510%
\$400,000	1,500	8	2.891%	1.720%	1.071%	0.744%	0.597%	0.513%	0.502%
\$400,000	2,000	8	2.305%	1.316%	0.828%	0.619%	0.538%	0.504%	0.501%
\$400,000	3,000	8	1.608%	0.886%	0.611%	0.527%	0.507%	0.502%	0.501%
\$400,000	4,000	8	1.221%	0.699%	0.544%	0.509%	0.503%	0.502%	0.501%
\$400,000	5,000	8	0.975%	0.603%	0.519%	0.505%	0.503%	0.502%	0.501%
\$400,000	10,000	8	0.562%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$400,000	20,000	8	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$425,000	5	8	68.487%	66.871%	65.318%	63.822%	62.380%	59.642%	57.081%
\$425,000	10	8	53.761%	51.856%	50.046%	48.324%	46.688%	43.664%	40.933%
\$425,000	15	8	46.314%	44.344%	42.489%	40.734%	39.078%	36.031%	33.293%
\$425,000	20	8	41.288%	39.255%	37.350%	35.562%	33.879%	30.805%	28.081%
\$425,000	25	8	37.624%	35.532%	33.580%	31.757%	30.050%	26.952%	24.243%
\$425,000	50	8	26.789%	24.609%	22.610%	20.775%	19.094%	16.135%	13.644%
\$425,000	100	8	18.519%	16.278%	14.285%	12.517%	10.953%	8.359%	6.355%
\$425,000	150	8	14.495%	12.285%	10.378%	8.749%	7.362%	5.189%	3.662%
\$425,000	200	8	12.142%	9.999%	8.201%	6.703%	5.470%	3.636%	2.436%
\$425,000	300	8	9.215%	7.210%	5.605%	4.347%	3.373%	2.051%	1.309%
\$425,000	400	8	7.604%	5.728%	4.287%	3.201%	2.398%	1.400%	0.903%
\$425,000	500	8	6.583%	4.802%	3.473%	2.512%	1.834%	1.052%	0.707%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$425,000	600	8	5.796%	4.100%	2.885%	2.040%	1.467%	0.855%	0.618%
\$425,000	700	8	5.162%	3.556%	2.438%	1.691%	1.210%	0.729%	0.564%
\$425,000	800	8	4.676%	3.137%	2.102%	1.440%	1.033%	0.655%	0.541%
\$425,000	900	8	4.282%	2.808%	1.846%	1.250%	0.902%	0.601%	0.520%
\$425,000	1,000	8	3.983%	2.568%	1.669%	1.128%	0.820%	0.570%	0.512%
\$425,000	1,500	8	2.950%	1.764%	1.100%	0.761%	0.605%	0.514%	0.502%
\$425,000	2,000	8	2.353%	1.348%	0.847%	0.628%	0.542%	0.504%	0.501%
\$425,000	3,000	8	1.642%	0.905%	0.619%	0.530%	0.508%	0.502%	0.501%
\$425,000	4,000	8	1.247%	0.710%	0.548%	0.510%	0.504%	0.502%	0.501%
\$425,000	5,000	8	0.995%	0.610%	0.520%	0.505%	0.503%	0.502%	0.501%
\$425,000	10,000	8	0.566%	0.509%	0.505%	0.504%	0.503%	0.502%	0.501%
\$425,000	20,000	8	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$450,000	5	8	68.628%	67.016%	65.468%	63.977%	62.539%	59.809%	57.256%
\$450,000	10	8	53.890%	51.992%	50.187%	48.471%	46.842%	43.828%	41.109%
\$450,000	15	8	46.466%	44.503%	42.655%	40.907%	39.257%	36.223%	33.496%
\$450,000	20	8	41.450%	39.425%	37.528%	35.746%	34.071%	31.011%	28.300%
\$450,000	25	8	37.796%	35.713%	33.770%	31.955%	30.256%	27.174%	24.479%
\$450,000	50	8	26.977%	24.807%	22.820%	20.996%	19.325%	16.384%	13.910%
\$450,000	100	8	18.713%	16.485%	14.501%	12.740%	11.176%	8.577%	6.555%
\$450,000	150	8	14.675%	12.468%	10.562%	8.927%	7.533%	5.343%	3.791%
\$450,000	200	8	12.300%	10.158%	8.357%	6.851%	5.609%	3.751%	2.527%
\$450,000	300	8	9.348%	7.339%	5.725%	4.456%	3.470%	2.123%	1.358%
\$450,000	400	8	7.715%	5.834%	4.383%	3.285%	2.469%	1.448%	0.932%
\$450,000	500	8	6.680%	4.891%	3.550%	2.578%	1.888%	1.083%	0.724%
\$450,000	600	8	5.882%	4.178%	2.952%	2.094%	1.509%	0.876%	0.628%
\$450,000	700	8	5.241%	3.624%	2.495%	1.736%	1.243%	0.744%	0.570%
\$450,000	800	8	4.748%	3.199%	2.151%	1.476%	1.059%	0.666%	0.545%
\$450,000	900	8	4.348%	2.863%	1.889%	1.281%	0.923%	0.609%	0.523%
\$450,000	1,000	8	4.044%	2.618%	1.708%	1.155%	0.838%	0.576%	0.513%
\$450,000	1,500	8	2.997%	1.799%	1.123%	0.774%	0.613%	0.516%	0.502%
\$450,000	2,000	8	2.392%	1.375%	0.862%	0.635%	0.545%	0.505%	0.501%
\$450,000	3,000	8	1.670%	0.920%	0.625%	0.532%	0.508%	0.502%	0.501%
\$450,000	4,000	8	1.268%	0.720%	0.551%	0.511%	0.504%	0.502%	0.501%
\$450,000	5,000	8	1.012%	0.616%	0.521%	0.506%	0.503%	0.502%	0.501%
\$450,000	10,000	8	0.570%	0.509%	0.505%	0.504%	0.503%	0.502%	0.501%
\$450,000	20,000	8	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$475,000	5	8	68.750%	67.142%	65.599%	64.111%	62.677%	59.954%	57.408%
\$475,000	10	8	54.004%	52.111%	50.312%	48.601%	46.977%	43.973%	41.264%
\$475,000	15	8	46.602%	44.646%	42.804%	41.062%	39.419%	36.395%	33.679%
\$475,000	20	8	41.595%	39.577%	37.688%	35.913%	34.244%	31.196%	28.497%
\$475,000	25	8	37.948%	35.874%	33.938%	32.131%	30.438%	27.370%	24.687%
\$475,000	50	8	27.141%	24.982%	23.004%	21.190%	19.528%	16.604%	14.144%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$475,000	100	8	18.885%	16.668%	14.696%	12.941%	11.381%	8.778%	6.745%
\$475,000	150	8	14.838%	12.637%	10.731%	9.093%	7.693%	5.489%	3.916%
\$475,000	200	8	12.447%	10.306%	8.503%	6.992%	5.740%	3.861%	2.616%
\$475,000	300	8	9.473%	7.460%	5.840%	4.560%	3.564%	2.193%	1.407%
\$475,000	400	8	7.819%	5.934%	4.474%	3.365%	2.537%	1.495%	0.960%
\$475,000	500	8	6.772%	4.976%	3.626%	2.642%	1.940%	1.114%	0.741%
\$475,000	600	8	5.965%	4.253%	3.016%	2.147%	1.550%	0.898%	0.639%
\$475,000	700	8	5.315%	3.690%	2.550%	1.779%	1.276%	0.760%	0.577%
\$475,000	800	8	4.816%	3.257%	2.198%	1.512%	1.084%	0.678%	0.549%
\$475,000	900	8	4.411%	2.916%	1.931%	1.311%	0.943%	0.617%	0.526%
\$475,000	1,000	8	4.103%	2.667%	1.745%	1.181%	0.856%	0.583%	0.515%
\$475,000	1,500	8	3.042%	1.834%	1.146%	0.788%	0.620%	0.517%	0.502%
\$475,000	2,000	8	2.429%	1.401%	0.878%	0.643%	0.548%	0.505%	0.501%
\$475,000	3,000	8	1.697%	0.935%	0.632%	0.534%	0.509%	0.502%	0.501%
\$475,000	4,000	8	1.288%	0.729%	0.554%	0.512%	0.504%	0.502%	0.501%
\$475,000	5,000	8	1.027%	0.622%	0.523%	0.506%	0.503%	0.502%	0.501%
\$475,000	10,000	8	0.573%	0.509%	0.505%	0.504%	0.503%	0.502%	0.501%
\$475,000	20,000	8	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$500,000	5	8	68.851%	67.246%	65.706%	64.222%	62.791%	60.073%	57.533%
\$500,000	10	8	54.100%	52.211%	50.417%	48.710%	47.091%	44.096%	41.395%
\$500,000	15	8	46.722%	44.771%	42.934%	41.198%	39.560%	36.546%	33.839%
\$500,000	20	8	41.724%	39.713%	37.829%	36.060%	34.397%	31.360%	28.671%
\$500,000	25	8	38.081%	36.014%	34.086%	32.284%	30.598%	27.542%	24.870%
\$500,000	50	8	27.286%	25.135%	23.166%	21.360%	19.706%	16.796%	14.349%
\$500,000	100	8	19.034%	16.829%	14.866%	13.120%	11.564%	8.961%	6.923%
\$500,000	150	8	14.981%	12.785%	10.882%	9.243%	7.840%	5.623%	4.031%
\$500,000	200	8	12.577%	10.439%	8.636%	7.121%	5.862%	3.964%	2.699%
\$500,000	300	8	9.585%	7.570%	5.945%	4.657%	3.650%	2.259%	1.455%
\$500,000	400	8	7.915%	6.026%	4.559%	3.440%	2.601%	1.539%	0.988%
\$500,000	500	8	6.856%	5.054%	3.696%	2.702%	1.990%	1.144%	0.758%
\$500,000	600	8	6.041%	4.321%	3.076%	2.196%	1.589%	0.920%	0.650%
\$500,000	700	8	5.383%	3.750%	2.601%	1.820%	1.306%	0.775%	0.584%
\$500,000	800	8	4.879%	3.312%	2.243%	1.545%	1.107%	0.689%	0.553%
\$500,000	900	8	4.469%	2.965%	1.970%	1.340%	0.963%	0.625%	0.528%
\$500,000	1,000	8	4.157%	2.712%	1.779%	1.206%	0.872%	0.589%	0.517%
\$500,000	1,500	8	3.083%	1.865%	1.167%	0.801%	0.627%	0.519%	0.503%
\$500,000	2,000	8	2.463%	1.425%	0.892%	0.650%	0.552%	0.506%	0.501%
\$500,000	3,000	8	1.721%	0.949%	0.638%	0.536%	0.509%	0.502%	0.501%
\$500,000	4,000	8	1.306%	0.738%	0.556%	0.512%	0.504%	0.502%	0.501%
\$500,000	5,000	8	1.041%	0.627%	0.524%	0.506%	0.503%	0.502%	0.501%
\$500,000	10,000	8	0.577%	0.510%	0.505%	0.504%	0.503%	0.502%	0.501%
\$500,000	20,000	8	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$30,000	5	9	47.782%	45.282%	42.858%	40.509%	38.237%	33.892%	29.791%
\$30,000	10	9	31.241%	28.581%	26.128%	23.868%	21.782%	18.093%	14.953%
\$30,000	15	9	24.812%	22.230%	19.863%	17.709%	15.753%	12.387%	9.669%
\$30,000	20	9	20.824%	18.272%	15.978%	13.934%	12.120%	9.089%	6.763%
\$30,000	25	9	18.242%	15.742%	13.527%	11.579%	9.880%	7.123%	5.088%
\$30,000	50	9	11.658%	9.415%	7.551%	6.021%	4.779%	2.985%	1.884%
\$30,000	100	9	7.363%	5.442%	3.984%	2.902%	2.120%	1.195%	0.773%
\$30,000	150	9	5.580%	3.880%	2.674%	1.854%	1.312%	0.764%	0.578%
\$30,000	200	9	4.546%	3.006%	1.984%	1.337%	0.952%	0.616%	0.524%
\$30,000	300	9	3.421%	2.108%	1.323%	0.889%	0.668%	0.524%	0.503%
\$30,000	400	9	2.738%	1.605%	0.996%	0.701%	0.573%	0.508%	0.501%
\$30,000	500	9	2.327%	1.322%	0.827%	0.614%	0.536%	0.504%	0.501%
\$30,000	600	9	1.998%	1.110%	0.713%	0.564%	0.518%	0.502%	0.501%
\$30,000	700	9	1.776%	0.978%	0.650%	0.540%	0.510%	0.502%	0.501%
\$30,000	800	9	1.596%	0.878%	0.607%	0.526%	0.507%	0.502%	0.501%
\$30,000	900	9	1.436%	0.796%	0.575%	0.517%	0.505%	0.502%	0.501%
\$30,000	1,000	9	1.323%	0.743%	0.557%	0.512%	0.504%	0.502%	0.501%
\$30,000	1,500	9	0.941%	0.592%	0.516%	0.505%	0.503%	0.502%	0.501%
\$30,000	2,000	9	0.750%	0.538%	0.507%	0.504%	0.503%	0.502%	0.501%
\$30,000	3,000	9	0.593%	0.511%	0.505%	0.504%	0.503%	0.502%	0.501%
\$30,000	4,000	9	0.540%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$30,000	5,000	9	0.520%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$30,000	10,000	9	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$30,000	20,000	9	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$35,000	5	9	49.925%	47.519%	45.194%	42.947%	40.769%	36.610%	32.696%
\$35,000	10	9	33.112%	30.410%	27.898%	25.577%	23.437%	19.642%	16.411%
\$35,000	15	9	26.172%	23.587%	21.213%	19.035%	17.045%	13.586%	10.760%
\$35,000	20	9	22.005%	19.442%	17.121%	15.035%	13.171%	10.038%	7.588%
\$35,000	25	9	19.294%	16.773%	14.528%	12.539%	10.785%	7.917%	5.759%
\$35,000	50	9	12.356%	10.078%	8.169%	6.583%	5.281%	3.369%	2.157%
\$35,000	100	9	7.835%	5.869%	4.356%	3.218%	2.378%	1.349%	0.857%
\$35,000	150	9	5.946%	4.196%	2.935%	2.058%	1.467%	0.839%	0.608%
\$35,000	200	9	4.847%	3.258%	2.179%	1.480%	1.049%	0.656%	0.537%
\$35,000	300	9	3.663%	2.296%	1.456%	0.975%	0.719%	0.536%	0.504%
\$35,000	400	9	2.938%	1.751%	1.089%	0.753%	0.598%	0.513%	0.502%
\$35,000	500	9	2.503%	1.442%	0.897%	0.649%	0.550%	0.505%	0.501%
\$35,000	600	9	2.151%	1.206%	0.764%	0.586%	0.525%	0.503%	0.501%
\$35,000	700	9	1.915%	1.061%	0.689%	0.554%	0.514%	0.502%	0.501%
\$35,000	800	9	1.722%	0.947%	0.637%	0.536%	0.509%	0.502%	0.501%
\$35,000	900	9	1.552%	0.855%	0.598%	0.523%	0.506%	0.502%	0.501%
\$35,000	1,000	9	1.429%	0.794%	0.575%	0.517%	0.505%	0.502%	0.501%
\$35,000	1,500	9	1.012%	0.616%	0.521%	0.505%	0.503%	0.502%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$35,000	2,000	9	0.799%	0.550%	0.509%	0.504%	0.503%	0.502%	0.501%
\$35,000	3,000	9	0.617%	0.514%	0.505%	0.504%	0.503%	0.502%	0.501%
\$35,000	4,000	9	0.552%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$35,000	5,000	9	0.526%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$35,000	10,000	9	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$35,000	20,000	9	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$40,000	5	9	51.656%	49.332%	47.088%	44.918%	42.816%	38.808%	35.039%
\$40,000	10	9	34.824%	32.111%	29.567%	27.194%	24.989%	21.065%	17.730%
\$40,000	15	9	27.356%	24.764%	22.383%	20.190%	18.177%	14.657%	11.748%
\$40,000	20	9	23.038%	20.464%	18.126%	16.013%	14.114%	10.890%	8.348%
\$40,000	25	9	20.212%	17.679%	15.415%	13.394%	11.598%	8.637%	6.381%
\$40,000	50	9	12.976%	10.670%	8.719%	7.088%	5.738%	3.726%	2.419%
\$40,000	100	9	8.253%	6.249%	4.692%	3.507%	2.617%	1.497%	0.941%
\$40,000	150	9	6.274%	4.483%	3.174%	2.248%	1.613%	0.914%	0.641%
\$40,000	200	9	5.116%	3.484%	2.359%	1.615%	1.143%	0.696%	0.552%
\$40,000	300	9	3.880%	2.467%	1.581%	1.058%	0.769%	0.551%	0.506%
\$40,000	400	9	3.117%	1.884%	1.177%	0.805%	0.625%	0.517%	0.502%
\$40,000	500	9	2.661%	1.553%	0.964%	0.683%	0.566%	0.507%	0.501%
\$40,000	600	9	2.288%	1.296%	0.813%	0.608%	0.534%	0.503%	0.501%
\$40,000	700	9	2.040%	1.137%	0.727%	0.569%	0.518%	0.502%	0.501%
\$40,000	800	9	1.837%	1.013%	0.667%	0.546%	0.512%	0.502%	0.501%
\$40,000	900	9	1.656%	0.911%	0.621%	0.531%	0.508%	0.502%	0.501%
\$40,000	1,000	9	1.526%	0.843%	0.593%	0.522%	0.506%	0.502%	0.501%
\$40,000	1,500	9	1.078%	0.640%	0.527%	0.506%	0.503%	0.502%	0.501%
\$40,000	2,000	9	0.845%	0.562%	0.511%	0.504%	0.503%	0.502%	0.501%
\$40,000	3,000	9	0.641%	0.518%	0.506%	0.504%	0.503%	0.502%	0.501%
\$40,000	4,000	9	0.564%	0.509%	0.505%	0.504%	0.503%	0.502%	0.501%
\$40,000	5,000	9	0.532%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$40,000	10,000	9	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$40,000	20,000	9	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$45,000	5	9	53.141%	50.887%	48.710%	46.605%	44.567%	40.687%	37.043%
\$45,000	10	9	36.423%	33.716%	31.167%	28.769%	26.519%	22.469%	19.011%
\$45,000	15	9	28.459%	25.853%	23.452%	21.242%	19.212%	15.657%	12.686%
\$45,000	20	9	23.978%	21.399%	19.049%	16.919%	14.996%	11.698%	9.071%
\$45,000	25	9	21.061%	18.519%	16.237%	14.191%	12.369%	9.326%	6.982%
\$45,000	50	9	13.556%	11.230%	9.245%	7.572%	6.177%	4.075%	2.684%
\$45,000	100	9	8.644%	6.608%	5.012%	3.783%	2.851%	1.646%	1.029%
\$45,000	150	9	6.584%	4.759%	3.407%	2.435%	1.759%	0.995%	0.678%
\$45,000	200	9	5.371%	3.701%	2.534%	1.750%	1.239%	0.738%	0.569%
\$45,000	300	9	4.084%	2.631%	1.701%	1.140%	0.821%	0.567%	0.510%
\$45,000	400	9	3.286%	2.011%	1.264%	0.858%	0.654%	0.523%	0.503%
\$45,000	500	9	2.807%	1.658%	1.030%	0.720%	0.583%	0.510%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$45,000	600	9	2.417%	1.382%	0.863%	0.632%	0.543%	0.504%	0.501%
\$45,000	700	9	2.157%	1.211%	0.766%	0.586%	0.524%	0.503%	0.501%
\$45,000	800	9	1.944%	1.078%	0.698%	0.558%	0.516%	0.502%	0.501%
\$45,000	900	9	1.754%	0.967%	0.646%	0.539%	0.510%	0.502%	0.501%
\$45,000	1,000	9	1.617%	0.891%	0.613%	0.528%	0.507%	0.502%	0.501%
\$45,000	1,500	9	1.142%	0.665%	0.533%	0.507%	0.503%	0.502%	0.501%
\$45,000	2,000	9	0.890%	0.576%	0.513%	0.505%	0.503%	0.502%	0.501%
\$45,000	3,000	9	0.666%	0.522%	0.506%	0.504%	0.503%	0.502%	0.501%
\$45,000	4,000	9	0.577%	0.510%	0.505%	0.504%	0.503%	0.502%	0.501%
\$45,000	5,000	9	0.538%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$45,000	10,000	9	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$45,000	20,000	9	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$50,000	5	9	54.429%	52.232%	50.112%	48.061%	46.080%	42.307%	38.769%
\$50,000	10	9	37.879%	35.208%	32.663%	30.255%	27.988%	23.858%	20.270%
\$50,000	15	9	29.496%	26.867%	24.440%	22.208%	20.161%	16.566%	13.554%
\$50,000	20	9	24.826%	22.246%	19.892%	17.749%	15.806%	12.457%	9.756%
\$50,000	25	9	21.832%	19.286%	16.990%	14.927%	13.085%	9.980%	7.556%
\$50,000	50	9	14.096%	11.753%	9.742%	8.034%	6.598%	4.414%	2.948%
\$50,000	100	9	9.004%	6.941%	5.310%	4.043%	3.073%	1.793%	1.117%
\$50,000	150	9	6.872%	5.015%	3.625%	2.614%	1.900%	1.074%	0.717%
\$50,000	200	9	5.607%	3.905%	2.700%	1.879%	1.334%	0.782%	0.587%
\$50,000	300	9	4.267%	2.780%	1.812%	1.217%	0.870%	0.582%	0.513%
\$50,000	400	9	3.445%	2.132%	1.347%	0.910%	0.684%	0.530%	0.504%
\$50,000	500	9	2.944%	1.758%	1.094%	0.756%	0.601%	0.512%	0.501%
\$50,000	600	9	2.537%	1.464%	0.911%	0.656%	0.554%	0.505%	0.501%
\$50,000	700	9	2.266%	1.282%	0.804%	0.604%	0.531%	0.503%	0.501%
\$50,000	800	9	2.045%	1.140%	0.729%	0.571%	0.520%	0.502%	0.501%
\$50,000	900	9	1.848%	1.021%	0.671%	0.548%	0.512%	0.502%	0.501%
\$50,000	1,000	9	1.703%	0.939%	0.633%	0.534%	0.509%	0.502%	0.501%
\$50,000	1,500	9	1.202%	0.689%	0.540%	0.509%	0.503%	0.502%	0.501%
\$50,000	2,000	9	0.934%	0.589%	0.516%	0.505%	0.503%	0.502%	0.501%
\$50,000	3,000	9	0.690%	0.526%	0.506%	0.504%	0.503%	0.502%	0.501%
\$50,000	4,000	9	0.590%	0.511%	0.505%	0.504%	0.503%	0.502%	0.501%
\$50,000	5,000	9	0.545%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$50,000	10,000	9	0.508%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$50,000	20,000	9	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$55,000	5	9	55.539%	53.392%	51.318%	49.315%	47.382%	43.700%	40.250%
\$55,000	10	9	39.144%	36.534%	34.026%	31.628%	29.349%	25.182%	21.508%
\$55,000	15	9	30.474%	27.822%	25.373%	23.115%	21.042%	17.401%	14.346%
\$55,000	20	9	25.593%	23.016%	20.658%	18.504%	16.547%	13.157%	10.397%
\$55,000	25	9	22.535%	19.988%	17.684%	15.608%	13.745%	10.591%	8.096%
\$55,000	50	9	14.589%	12.233%	10.199%	8.462%	6.993%	4.736%	3.200%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$55,000	100	9	9.331%	7.246%	5.585%	4.285%	3.280%	1.933%	1.204%
\$55,000	150	9	7.134%	5.248%	3.828%	2.781%	2.034%	1.151%	0.757%
\$55,000	200	9	5.822%	4.091%	2.855%	2.000%	1.425%	0.825%	0.605%
\$55,000	300	9	4.440%	2.921%	1.919%	1.293%	0.921%	0.600%	0.518%
\$55,000	400	9	3.588%	2.243%	1.425%	0.960%	0.713%	0.537%	0.505%
\$55,000	500	9	3.067%	1.849%	1.154%	0.791%	0.619%	0.515%	0.502%
\$55,000	600	9	2.645%	1.540%	0.957%	0.681%	0.564%	0.507%	0.501%
\$55,000	700	9	2.366%	1.348%	0.842%	0.621%	0.538%	0.503%	0.501%
\$55,000	800	9	2.137%	1.199%	0.760%	0.584%	0.524%	0.503%	0.501%
\$55,000	900	9	1.933%	1.072%	0.695%	0.557%	0.515%	0.502%	0.501%
\$55,000	1,000	9	1.781%	0.983%	0.653%	0.541%	0.510%	0.502%	0.501%
\$55,000	1,500	9	1.257%	0.713%	0.548%	0.510%	0.504%	0.502%	0.501%
\$55,000	2,000	9	0.975%	0.603%	0.519%	0.505%	0.503%	0.502%	0.501%
\$55,000	3,000	9	0.714%	0.531%	0.507%	0.504%	0.503%	0.502%	0.501%
\$55,000	4,000	9	0.604%	0.513%	0.505%	0.504%	0.503%	0.502%	0.501%
\$55,000	5,000	9	0.552%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$55,000	10,000	9	0.508%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$55,000	20,000	9	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$60,000	5	9	56.514%	54.408%	52.375%	50.415%	48.520%	44.920%	41.544%
\$60,000	10	9	40.243%	37.688%	35.235%	32.877%	30.615%	26.422%	22.709%
\$60,000	15	9	31.402%	28.738%	26.266%	23.988%	21.884%	18.193%	15.087%
\$60,000	20	9	26.310%	23.728%	21.362%	19.201%	17.233%	13.815%	11.010%
\$60,000	25	9	23.187%	20.641%	18.334%	16.250%	14.369%	11.169%	8.621%
\$60,000	50	9	15.048%	12.678%	10.627%	8.865%	7.370%	5.048%	3.445%
\$60,000	100	9	9.642%	7.536%	5.850%	4.517%	3.479%	2.074%	1.293%
\$60,000	150	9	7.379%	5.469%	4.020%	2.943%	2.163%	1.227%	0.797%
\$60,000	200	9	6.023%	4.267%	3.002%	2.117%	1.514%	0.868%	0.624%
\$60,000	300	9	4.600%	3.054%	2.021%	1.367%	0.971%	0.618%	0.523%
\$60,000	400	9	3.721%	2.347%	1.500%	1.009%	0.742%	0.545%	0.507%
\$60,000	500	9	3.180%	1.934%	1.211%	0.825%	0.637%	0.519%	0.502%
\$60,000	600	9	2.745%	1.611%	1.001%	0.705%	0.576%	0.508%	0.501%
\$60,000	700	9	2.457%	1.410%	0.878%	0.639%	0.545%	0.504%	0.501%
\$60,000	800	9	2.222%	1.254%	0.789%	0.597%	0.529%	0.503%	0.501%
\$60,000	900	9	2.011%	1.120%	0.719%	0.567%	0.518%	0.502%	0.501%
\$60,000	1,000	9	1.853%	1.025%	0.672%	0.548%	0.512%	0.502%	0.501%
\$60,000	1,500	9	1.308%	0.736%	0.555%	0.512%	0.504%	0.502%	0.501%
\$60,000	2,000	9	1.014%	0.616%	0.522%	0.506%	0.503%	0.502%	0.501%
\$60,000	3,000	9	0.737%	0.536%	0.507%	0.504%	0.503%	0.502%	0.501%
\$60,000	4,000	9	0.617%	0.514%	0.505%	0.504%	0.503%	0.502%	0.501%
\$60,000	5,000	9	0.560%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$60,000	10,000	9	0.508%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$60,000	20,000	9	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$65,000	5	9	57.342%	55.270%	53.274%	51.349%	49.488%	45.955%	42.641%
\$65,000	10	9	41.191%	38.686%	36.281%	33.970%	31.750%	27.578%	23.835%
\$65,000	15	9	32.263%	29.600%	27.119%	24.816%	22.692%	18.942%	15.781%
\$65,000	20	9	26.973%	24.383%	22.009%	19.839%	17.861%	14.420%	11.575%
\$65,000	25	9	23.785%	21.244%	18.934%	16.842%	14.949%	11.711%	9.117%
\$65,000	50	9	15.474%	13.095%	11.028%	9.244%	7.725%	5.346%	3.681%
\$65,000	100	9	9.934%	7.810%	6.100%	4.738%	3.670%	2.211%	1.382%
\$65,000	150	9	7.610%	5.680%	4.203%	3.097%	2.289%	1.303%	0.839%
\$65,000	200	9	6.214%	4.434%	3.142%	2.230%	1.600%	0.912%	0.644%
\$65,000	300	9	4.752%	3.180%	2.120%	1.439%	1.020%	0.637%	0.529%
\$65,000	400	9	3.847%	2.446%	1.572%	1.057%	0.771%	0.553%	0.509%
\$65,000	500	9	3.288%	2.016%	1.266%	0.859%	0.656%	0.523%	0.502%
\$65,000	600	9	2.840%	1.680%	1.044%	0.729%	0.587%	0.510%	0.501%
\$65,000	700	9	2.544%	1.470%	0.913%	0.657%	0.553%	0.505%	0.501%
\$65,000	800	9	2.302%	1.307%	0.818%	0.610%	0.534%	0.503%	0.501%
\$65,000	900	9	2.086%	1.167%	0.742%	0.577%	0.521%	0.503%	0.501%
\$65,000	1,000	9	1.922%	1.066%	0.692%	0.555%	0.514%	0.502%	0.501%
\$65,000	1,500	9	1.358%	0.759%	0.563%	0.514%	0.504%	0.502%	0.501%
\$65,000	2,000	9	1.052%	0.630%	0.525%	0.506%	0.503%	0.502%	0.501%
\$65,000	3,000	9	0.760%	0.541%	0.508%	0.504%	0.503%	0.502%	0.501%
\$65,000	4,000	9	0.630%	0.516%	0.505%	0.504%	0.503%	0.502%	0.501%
\$65,000	5,000	9	0.567%	0.509%	0.505%	0.504%	0.503%	0.502%	0.501%
\$65,000	10,000	9	0.509%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$65,000	20,000	9	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$70,000	5	9	58.042%	56.001%	54.036%	52.139%	50.309%	46.832%	43.571%
\$70,000	10	9	42.004%	39.540%	37.175%	34.905%	32.724%	28.622%	24.873%
\$70,000	15	9	33.046%	30.394%	27.911%	25.596%	23.452%	19.649%	16.431%
\$70,000	20	9	27.588%	24.987%	22.604%	20.422%	18.433%	14.971%	12.095%
\$70,000	25	9	24.324%	21.790%	19.478%	17.379%	15.478%	12.211%	9.576%
\$70,000	50	9	15.859%	13.473%	11.393%	9.592%	8.051%	5.622%	3.903%
\$70,000	100	9	10.196%	8.059%	6.327%	4.942%	3.847%	2.338%	1.468%
\$70,000	150	9	7.819%	5.872%	4.370%	3.239%	2.407%	1.375%	0.879%
\$70,000	200	9	6.387%	4.587%	3.271%	2.334%	1.681%	0.955%	0.663%
\$70,000	300	9	4.890%	3.297%	2.212%	1.507%	1.068%	0.656%	0.535%
\$70,000	400	9	3.963%	2.539%	1.640%	1.103%	0.800%	0.562%	0.510%
\$70,000	500	9	3.388%	2.092%	1.319%	0.892%	0.675%	0.527%	0.503%
\$70,000	600	9	2.927%	1.744%	1.085%	0.753%	0.599%	0.512%	0.501%
\$70,000	700	9	2.624%	1.525%	0.947%	0.674%	0.561%	0.506%	0.501%
\$70,000	800	9	2.376%	1.356%	0.846%	0.623%	0.539%	0.504%	0.501%
\$70,000	900	9	2.155%	1.210%	0.765%	0.586%	0.525%	0.503%	0.501%
\$70,000	1,000	9	1.986%	1.105%	0.711%	0.563%	0.517%	0.502%	0.501%
\$70,000	1,500	9	1.404%	0.781%	0.571%	0.516%	0.505%	0.502%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$70,000	2,000	9	1.088%	0.643%	0.529%	0.507%	0.503%	0.502%	0.501%
\$70,000	3,000	9	0.781%	0.546%	0.509%	0.504%	0.503%	0.502%	0.501%
\$70,000	4,000	9	0.643%	0.518%	0.506%	0.504%	0.503%	0.502%	0.501%
\$70,000	5,000	9	0.575%	0.509%	0.505%	0.504%	0.503%	0.502%	0.501%
\$70,000	10,000	9	0.509%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$70,000	20,000	9	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$75,000	5	9	58.665%	56.651%	54.713%	52.841%	51.037%	47.609%	44.394%
\$75,000	10	9	42.718%	40.290%	37.960%	35.725%	33.580%	29.550%	25.843%
\$75,000	15	9	33.762%	31.127%	28.652%	26.337%	24.183%	20.332%	17.060%
\$75,000	20	9	28.163%	25.557%	23.163%	20.971%	18.969%	15.483%	12.580%
\$75,000	25	9	24.827%	22.295%	19.982%	17.875%	15.969%	12.679%	10.007%
\$75,000	50	9	16.216%	13.824%	11.734%	9.920%	8.360%	5.885%	4.117%
\$75,000	100	9	10.440%	8.292%	6.541%	5.133%	4.014%	2.460%	1.552%
\$75,000	150	9	8.013%	6.050%	4.527%	3.373%	2.518%	1.444%	0.918%
\$75,000	200	9	6.549%	4.732%	3.393%	2.434%	1.758%	0.996%	0.682%
\$75,000	300	9	5.019%	3.405%	2.298%	1.572%	1.114%	0.675%	0.542%
\$75,000	400	9	4.063%	2.619%	1.698%	1.143%	0.825%	0.569%	0.512%
\$75,000	500	9	3.481%	2.163%	1.370%	0.924%	0.693%	0.532%	0.503%
\$75,000	600	9	3.009%	1.804%	1.125%	0.776%	0.611%	0.514%	0.502%
\$75,000	700	9	2.698%	1.577%	0.979%	0.691%	0.569%	0.506%	0.501%
\$75,000	800	9	2.445%	1.402%	0.873%	0.636%	0.544%	0.504%	0.501%
\$75,000	900	9	2.219%	1.251%	0.787%	0.596%	0.528%	0.503%	0.501%
\$75,000	1,000	9	2.046%	1.141%	0.729%	0.570%	0.519%	0.502%	0.501%
\$75,000	1,500	9	1.448%	0.802%	0.578%	0.518%	0.505%	0.502%	0.501%
\$75,000	2,000	9	1.121%	0.656%	0.532%	0.508%	0.503%	0.502%	0.501%
\$75,000	3,000	9	0.802%	0.551%	0.509%	0.504%	0.503%	0.502%	0.501%
\$75,000	4,000	9	0.655%	0.520%	0.506%	0.504%	0.503%	0.502%	0.501%
\$75,000	5,000	9	0.582%	0.510%	0.505%	0.504%	0.503%	0.502%	0.501%
\$75,000	10,000	9	0.509%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$75,000	20,000	9	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$80,000	5	9	59.222%	57.232%	55.316%	53.468%	51.686%	48.301%	45.127%
\$80,000	10	9	43.357%	40.961%	38.662%	36.458%	34.344%	30.379%	26.729%
\$80,000	15	9	34.421%	31.808%	29.347%	27.039%	24.884%	21.000%	17.679%
\$80,000	20	9	28.710%	26.106%	23.704%	21.500%	19.484%	15.971%	13.041%
\$80,000	25	9	25.307%	22.775%	20.460%	18.349%	16.432%	13.121%	10.423%
\$80,000	50	9	16.556%	14.157%	12.058%	10.234%	8.658%	6.139%	4.327%
\$80,000	100	9	10.672%	8.513%	6.745%	5.315%	4.174%	2.578%	1.634%
\$80,000	150	9	8.194%	6.217%	4.675%	3.500%	2.623%	1.512%	0.957%
\$80,000	200	9	6.703%	4.869%	3.509%	2.529%	1.834%	1.037%	0.701%
\$80,000	300	9	5.139%	3.507%	2.380%	1.633%	1.158%	0.694%	0.549%
\$80,000	400	9	4.164%	2.700%	1.759%	1.185%	0.852%	0.578%	0.514%
\$80,000	500	9	3.568%	2.231%	1.418%	0.955%	0.712%	0.537%	0.504%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$80,000	600	9	3.086%	1.861%	1.162%	0.798%	0.623%	0.516%	0.502%
\$80,000	700	9	2.768%	1.627%	1.010%	0.708%	0.577%	0.508%	0.501%
\$80,000	800	9	2.510%	1.447%	0.899%	0.650%	0.550%	0.505%	0.501%
\$80,000	900	9	2.279%	1.290%	0.808%	0.605%	0.531%	0.503%	0.501%
\$80,000	1,000	9	2.102%	1.176%	0.747%	0.577%	0.521%	0.503%	0.501%
\$80,000	1,500	9	1.489%	0.823%	0.586%	0.520%	0.506%	0.502%	0.501%
\$80,000	2,000	9	1.153%	0.669%	0.535%	0.508%	0.504%	0.502%	0.501%
\$80,000	3,000	9	0.822%	0.557%	0.510%	0.504%	0.503%	0.502%	0.501%
\$80,000	4,000	9	0.668%	0.522%	0.506%	0.504%	0.503%	0.502%	0.501%
\$80,000	5,000	9	0.589%	0.511%	0.505%	0.504%	0.503%	0.502%	0.501%
\$80,000	10,000	9	0.510%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$80,000	20,000	9	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$90,000	5	9	60.180%	58.233%	56.355%	54.548%	52.804%	49.491%	46.388%
\$90,000	10	9	44.469%	42.127%	39.883%	37.733%	35.672%	31.816%	28.270%
\$90,000	15	9	35.587%	33.038%	30.624%	28.345%	26.201%	22.301%	18.908%
\$90,000	20	9	29.747%	27.156%	24.755%	22.537%	20.494%	16.913%	13.925%
\$90,000	25	9	26.230%	23.694%	21.371%	19.251%	17.315%	13.964%	11.217%
\$90,000	50	9	17.197%	14.788%	12.673%	10.829%	9.222%	6.629%	4.736%
\$90,000	100	9	11.109%	8.929%	7.133%	5.665%	4.482%	2.810%	1.798%
\$90,000	150	9	8.536%	6.533%	4.958%	3.744%	2.826%	1.645%	1.036%
\$90,000	200	9	6.993%	5.129%	3.731%	2.710%	1.978%	1.118%	0.741%
\$90,000	300	9	5.364%	3.699%	2.535%	1.752%	1.243%	0.733%	0.563%
\$90,000	400	9	4.353%	2.854%	1.875%	1.266%	0.906%	0.597%	0.519%
\$90,000	500	9	3.732%	2.360%	1.510%	1.017%	0.748%	0.548%	0.506%
\$90,000	600	9	3.231%	1.970%	1.235%	0.842%	0.647%	0.521%	0.502%
\$90,000	700	9	2.899%	1.721%	1.070%	0.741%	0.593%	0.510%	0.501%
\$90,000	800	9	2.632%	1.532%	0.951%	0.676%	0.561%	0.506%	0.501%
\$90,000	900	9	2.391%	1.365%	0.850%	0.625%	0.539%	0.504%	0.501%
\$90,000	1,000	9	2.207%	1.243%	0.781%	0.592%	0.527%	0.503%	0.501%
\$90,000	1,500	9	1.566%	0.863%	0.602%	0.525%	0.507%	0.502%	0.501%
\$90,000	2,000	9	1.213%	0.694%	0.542%	0.510%	0.504%	0.502%	0.501%
\$90,000	3,000	9	0.860%	0.567%	0.512%	0.505%	0.503%	0.502%	0.501%
\$90,000	4,000	9	0.692%	0.527%	0.506%	0.504%	0.503%	0.502%	0.501%
\$90,000	5,000	9	0.603%	0.512%	0.505%	0.504%	0.503%	0.502%	0.501%
\$90,000	10,000	9	0.511%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$90,000	20,000	9	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$100,000	5	9	60.974%	59.059%	57.215%	55.440%	53.728%	50.474%	47.428%
\$100,000	10	9	45.386%	43.089%	40.889%	38.783%	36.769%	33.001%	29.540%
\$100,000	15	9	36.560%	34.072%	31.718%	29.491%	27.377%	23.497%	20.085%
\$100,000	20	9	30.692%	28.123%	25.733%	23.513%	21.460%	17.817%	14.761%
\$100,000	25	9	27.093%	24.556%	22.227%	20.092%	18.141%	14.749%	11.952%
\$100,000	50	9	17.786%	15.371%	13.246%	11.380%	9.749%	7.095%	5.127%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$100,000	100	9	11.510%	9.315%	7.493%	5.991%	4.773%	3.033%	1.958%
\$100,000	150	9	8.848%	6.824%	5.220%	3.972%	3.017%	1.774%	1.116%
\$100,000	200	9	7.258%	5.367%	3.936%	2.879%	2.114%	1.198%	0.782%
\$100,000	300	9	5.568%	3.875%	2.677%	1.862%	1.325%	0.771%	0.578%
\$100,000	400	9	4.524%	2.996%	1.983%	1.344%	0.959%	0.617%	0.524%
\$100,000	500	9	3.881%	2.478%	1.596%	1.075%	0.785%	0.559%	0.508%
\$100,000	600	9	3.364%	2.070%	1.304%	0.884%	0.671%	0.526%	0.503%
\$100,000	700	9	3.021%	1.810%	1.128%	0.775%	0.610%	0.513%	0.501%
\$100,000	800	9	2.745%	1.611%	1.000%	0.702%	0.574%	0.508%	0.501%
\$100,000	900	9	2.495%	1.436%	0.891%	0.645%	0.547%	0.505%	0.501%
\$100,000	1,000	9	2.305%	1.307%	0.816%	0.608%	0.533%	0.504%	0.501%
\$100,000	1,500	9	1.639%	0.901%	0.618%	0.530%	0.508%	0.502%	0.501%
\$100,000	2,000	9	1.269%	0.718%	0.550%	0.511%	0.504%	0.502%	0.501%
\$100,000	3,000	9	0.897%	0.578%	0.514%	0.505%	0.503%	0.502%	0.501%
\$100,000	4,000	9	0.716%	0.531%	0.507%	0.504%	0.503%	0.502%	0.501%
\$100,000	5,000	9	0.618%	0.514%	0.505%	0.504%	0.503%	0.502%	0.501%
\$100,000	10,000	9	0.512%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$100,000	20,000	9	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$110,000	5	9	61.685%	59.798%	57.984%	56.237%	54.552%	51.350%	48.354%
\$110,000	10	9	46.185%	43.927%	41.766%	39.700%	37.728%	34.033%	30.646%
\$110,000	15	9	37.402%	34.966%	32.665%	30.487%	28.420%	24.605%	21.200%
\$110,000	20	9	31.552%	29.019%	26.650%	24.441%	22.387%	18.712%	15.590%
\$110,000	25	9	27.916%	25.385%	23.053%	20.907%	18.941%	15.505%	12.658%
\$110,000	50	9	18.343%	15.928%	13.792%	11.911%	10.255%	7.548%	5.516%
\$110,000	100	9	11.889%	9.680%	7.836%	6.306%	5.054%	3.251%	2.118%
\$110,000	150	9	9.141%	7.097%	5.465%	4.187%	3.201%	1.899%	1.194%
\$110,000	200	9	7.507%	5.593%	4.131%	3.043%	2.247%	1.278%	0.825%
\$110,000	300	9	5.759%	4.041%	2.812%	1.968%	1.405%	0.810%	0.594%
\$110,000	400	9	4.683%	3.130%	2.088%	1.420%	1.012%	0.638%	0.531%
\$110,000	500	9	4.020%	2.590%	1.679%	1.132%	0.820%	0.570%	0.511%
\$110,000	600	9	3.488%	2.165%	1.370%	0.926%	0.695%	0.532%	0.504%
\$110,000	700	9	3.133%	1.895%	1.183%	0.807%	0.627%	0.516%	0.502%
\$110,000	800	9	2.850%	1.687%	1.048%	0.729%	0.587%	0.510%	0.501%
\$110,000	900	9	2.593%	1.504%	0.932%	0.665%	0.556%	0.506%	0.501%
\$110,000	1,000	9	2.397%	1.368%	0.851%	0.625%	0.540%	0.504%	0.501%
\$110,000	1,500	9	1.707%	0.939%	0.634%	0.536%	0.510%	0.502%	0.501%
\$110,000	2,000	9	1.323%	0.743%	0.558%	0.513%	0.505%	0.502%	0.501%
\$110,000	3,000	9	0.933%	0.590%	0.516%	0.505%	0.503%	0.502%	0.501%
\$110,000	4,000	9	0.739%	0.536%	0.507%	0.504%	0.503%	0.502%	0.501%
\$110,000	5,000	9	0.632%	0.516%	0.505%	0.504%	0.503%	0.502%	0.501%
\$110,000	10,000	9	0.513%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$110,000	20,000	9	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$120,000	5	9	62.319%	60.457%	58.669%	56.946%	55.284%	52.128%	49.176%
\$120,000	10	9	46.900%	44.676%	42.550%	40.518%	38.581%	34.952%	31.630%
\$120,000	15	9	38.146%	35.756%	33.499%	31.363%	29.338%	25.603%	22.246%
\$120,000	20	9	32.320%	29.833%	27.497%	25.309%	23.261%	19.578%	16.412%
\$120,000	25	9	28.681%	26.166%	23.838%	21.688%	19.709%	16.236%	13.336%
\$120,000	50	9	18.866%	16.451%	14.307%	12.413%	10.740%	7.983%	5.893%
\$120,000	100	9	12.246%	10.025%	8.158%	6.605%	5.324%	3.462%	2.273%
\$120,000	150	9	9.420%	7.357%	5.700%	4.394%	3.379%	2.022%	1.272%
\$120,000	200	9	7.745%	5.810%	4.319%	3.202%	2.378%	1.358%	0.868%
\$120,000	300	9	5.942%	4.200%	2.943%	2.071%	1.484%	0.851%	0.611%
\$120,000	400	9	4.836%	3.259%	2.189%	1.495%	1.063%	0.659%	0.538%
\$120,000	500	9	4.146%	2.691%	1.754%	1.184%	0.854%	0.581%	0.513%
\$120,000	600	9	3.607%	2.258%	1.436%	0.968%	0.720%	0.539%	0.505%
\$120,000	700	9	3.241%	1.977%	1.238%	0.840%	0.645%	0.520%	0.502%
\$120,000	800	9	2.950%	1.760%	1.095%	0.757%	0.600%	0.513%	0.502%
\$120,000	900	9	2.686%	1.570%	0.971%	0.686%	0.566%	0.507%	0.501%
\$120,000	1,000	9	2.485%	1.427%	0.885%	0.642%	0.547%	0.505%	0.501%
\$120,000	1,500	9	1.773%	0.976%	0.650%	0.542%	0.511%	0.502%	0.501%
\$120,000	2,000	9	1.375%	0.767%	0.566%	0.516%	0.505%	0.502%	0.501%
\$120,000	3,000	9	0.969%	0.601%	0.519%	0.505%	0.503%	0.502%	0.501%
\$120,000	4,000	9	0.762%	0.542%	0.508%	0.504%	0.503%	0.502%	0.501%
\$120,000	5,000	9	0.647%	0.518%	0.506%	0.504%	0.503%	0.502%	0.501%
\$120,000	10,000	9	0.514%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$120,000	20,000	9	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$130,000	5	9	62.877%	61.039%	59.272%	57.571%	55.929%	52.813%	49.899%
\$130,000	10	9	47.530%	45.336%	43.239%	41.239%	39.330%	35.758%	32.494%
\$130,000	15	9	38.798%	36.448%	34.230%	32.129%	30.140%	26.475%	23.183%
\$130,000	20	9	32.991%	30.549%	28.252%	26.094%	24.066%	20.393%	17.205%
\$130,000	25	9	29.375%	26.884%	24.567%	22.418%	20.436%	16.935%	13.984%
\$130,000	50	9	19.359%	16.942%	14.791%	12.882%	11.196%	8.396%	6.252%
\$130,000	100	9	12.580%	10.346%	8.462%	6.887%	5.583%	3.664%	2.424%
\$130,000	150	9	9.681%	7.602%	5.921%	4.591%	3.549%	2.143%	1.350%
\$130,000	200	9	7.967%	6.014%	4.497%	3.353%	2.503%	1.436%	0.912%
\$130,000	300	9	6.111%	4.348%	3.066%	2.169%	1.559%	0.890%	0.629%
\$130,000	400	9	4.976%	3.378%	2.283%	1.565%	1.113%	0.681%	0.545%
\$130,000	500	9	4.269%	2.791%	1.830%	1.238%	0.889%	0.594%	0.516%
\$130,000	600	9	3.718%	2.345%	1.498%	1.009%	0.745%	0.546%	0.506%
\$130,000	700	9	3.341%	2.053%	1.290%	0.873%	0.663%	0.524%	0.503%
\$130,000	800	9	3.043%	1.829%	1.140%	0.783%	0.614%	0.515%	0.502%
\$130,000	900	9	2.772%	1.631%	1.009%	0.707%	0.575%	0.509%	0.501%
\$130,000	1,000	9	2.565%	1.482%	0.918%	0.658%	0.553%	0.506%	0.501%
\$130,000	1,500	9	1.833%	1.010%	0.666%	0.547%	0.513%	0.502%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$130,000	2,000	9	1.423%	0.790%	0.575%	0.518%	0.506%	0.502%	0.501%
\$130,000	3,000	9	1.002%	0.613%	0.521%	0.506%	0.503%	0.502%	0.501%
\$130,000	4,000	9	0.785%	0.547%	0.509%	0.504%	0.503%	0.502%	0.501%
\$130,000	5,000	9	0.661%	0.521%	0.506%	0.504%	0.503%	0.502%	0.501%
\$130,000	10,000	9	0.515%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$130,000	20,000	9	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$140,000	5	9	63.374%	61.557%	59.809%	58.126%	56.501%	53.420%	50.540%
\$140,000	10	9	48.082%	45.913%	43.842%	41.870%	39.986%	36.463%	33.251%
\$140,000	15	9	39.373%	37.058%	34.872%	32.803%	30.846%	27.241%	24.004%
\$140,000	20	9	33.587%	31.183%	28.924%	26.800%	24.800%	21.154%	17.964%
\$140,000	25	9	30.005%	27.542%	25.243%	23.104%	21.124%	17.605%	14.615%
\$140,000	50	9	19.822%	17.406%	15.247%	13.323%	11.623%	8.789%	6.596%
\$140,000	100	9	12.898%	10.650%	8.750%	7.156%	5.831%	3.859%	2.571%
\$140,000	150	9	9.924%	7.831%	6.130%	4.776%	3.712%	2.259%	1.426%
\$140,000	200	9	8.174%	6.204%	4.666%	3.497%	2.623%	1.514%	0.955%
\$140,000	300	9	6.267%	4.487%	3.183%	2.262%	1.631%	0.930%	0.646%
\$140,000	400	9	5.108%	3.489%	2.373%	1.633%	1.162%	0.702%	0.553%
\$140,000	500	9	4.385%	2.886%	1.903%	1.290%	0.925%	0.606%	0.520%
\$140,000	600	9	3.822%	2.428%	1.558%	1.049%	0.770%	0.554%	0.508%
\$140,000	700	9	3.437%	2.127%	1.340%	0.904%	0.680%	0.529%	0.503%
\$140,000	800	9	3.130%	1.894%	1.183%	0.808%	0.627%	0.518%	0.502%
\$140,000	900	9	2.853%	1.688%	1.046%	0.727%	0.585%	0.510%	0.502%
\$140,000	1,000	9	2.641%	1.535%	0.949%	0.674%	0.560%	0.507%	0.501%
\$140,000	1,500	9	1.891%	1.044%	0.682%	0.554%	0.515%	0.503%	0.501%
\$140,000	2,000	9	1.469%	0.813%	0.583%	0.520%	0.506%	0.502%	0.501%
\$140,000	3,000	9	1.034%	0.624%	0.524%	0.506%	0.503%	0.502%	0.501%
\$140,000	4,000	9	0.806%	0.552%	0.509%	0.504%	0.503%	0.502%	0.501%
\$140,000	5,000	9	0.675%	0.523%	0.506%	0.504%	0.503%	0.502%	0.501%
\$140,000	10,000	9	0.516%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$140,000	20,000	9	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$150,000	5	9	63.804%	62.004%	60.273%	58.605%	56.996%	53.944%	51.093%
\$150,000	10	9	48.555%	46.408%	44.360%	42.411%	40.548%	37.068%	33.898%
\$150,000	15	9	39.868%	37.582%	35.424%	33.382%	31.452%	27.898%	24.707%
\$150,000	20	9	34.101%	31.728%	29.501%	27.406%	25.435%	21.831%	18.652%
\$150,000	25	9	30.553%	28.119%	25.843%	23.718%	21.747%	18.220%	15.205%
\$150,000	50	9	20.241%	17.826%	15.661%	13.728%	12.013%	9.148%	6.916%
\$150,000	100	9	13.191%	10.931%	9.016%	7.405%	6.063%	4.045%	2.712%
\$150,000	150	9	10.150%	8.043%	6.325%	4.951%	3.865%	2.370%	1.500%
\$150,000	200	9	8.364%	6.379%	4.823%	3.631%	2.736%	1.588%	0.998%
\$150,000	300	9	6.411%	4.615%	3.292%	2.349%	1.699%	0.968%	0.664%
\$150,000	400	9	5.228%	3.591%	2.456%	1.696%	1.207%	0.722%	0.560%
\$150,000	500	9	4.490%	2.972%	1.970%	1.339%	0.958%	0.619%	0.524%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$150,000	600	9	3.917%	2.504%	1.614%	1.087%	0.793%	0.561%	0.510%
\$150,000	700	9	3.523%	2.194%	1.387%	0.934%	0.698%	0.533%	0.504%
\$150,000	800	9	3.209%	1.953%	1.223%	0.833%	0.640%	0.521%	0.503%
\$150,000	900	9	2.926%	1.742%	1.079%	0.746%	0.594%	0.512%	0.502%
\$150,000	1,000	9	2.710%	1.583%	0.978%	0.689%	0.567%	0.508%	0.501%
\$150,000	1,500	9	1.944%	1.076%	0.697%	0.560%	0.517%	0.503%	0.501%
\$150,000	2,000	9	1.510%	0.834%	0.592%	0.523%	0.507%	0.502%	0.501%
\$150,000	3,000	9	1.063%	0.635%	0.526%	0.507%	0.503%	0.502%	0.501%
\$150,000	4,000	9	0.826%	0.558%	0.510%	0.504%	0.503%	0.502%	0.501%
\$150,000	5,000	9	0.688%	0.525%	0.506%	0.504%	0.503%	0.502%	0.501%
\$150,000	10,000	9	0.518%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$150,000	20,000	9	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$160,000	5	9	64.202%	62.417%	60.700%	59.047%	57.452%	54.427%	51.601%
\$160,000	10	9	48.996%	46.870%	44.843%	42.915%	41.071%	37.630%	34.500%
\$160,000	15	9	40.328%	38.069%	35.935%	33.918%	32.012%	28.505%	25.356%
\$160,000	20	9	34.576%	32.231%	30.032%	27.965%	26.020%	22.466%	19.315%
\$160,000	25	9	31.058%	28.654%	26.403%	24.301%	22.342%	18.820%	15.790%
\$160,000	50	9	20.644%	18.231%	16.061%	14.120%	12.393%	9.499%	7.230%
\$160,000	100	9	13.472%	11.203%	9.273%	7.647%	6.289%	4.230%	2.854%
\$160,000	150	9	10.367%	8.249%	6.515%	5.122%	4.016%	2.480%	1.575%
\$160,000	200	9	8.545%	6.547%	4.976%	3.763%	2.847%	1.662%	1.043%
\$160,000	300	9	6.548%	4.738%	3.397%	2.435%	1.766%	1.006%	0.683%
\$160,000	400	9	5.341%	3.690%	2.536%	1.758%	1.252%	0.743%	0.568%
\$160,000	500	9	4.589%	3.055%	2.035%	1.386%	0.991%	0.632%	0.528%
\$160,000	600	9	3.999%	2.570%	1.662%	1.120%	0.814%	0.567%	0.511%
\$160,000	700	9	3.603%	2.257%	1.432%	0.963%	0.715%	0.538%	0.505%
\$160,000	800	9	3.282%	2.009%	1.261%	0.856%	0.653%	0.524%	0.503%
\$160,000	900	9	2.995%	1.792%	1.112%	0.764%	0.603%	0.513%	0.502%
\$160,000	1,000	9	2.774%	1.629%	1.007%	0.705%	0.574%	0.509%	0.502%
\$160,000	1,500	9	1.993%	1.107%	0.712%	0.566%	0.519%	0.503%	0.501%
\$160,000	2,000	9	1.549%	0.854%	0.600%	0.525%	0.507%	0.502%	0.501%
\$160,000	3,000	9	1.091%	0.645%	0.529%	0.507%	0.503%	0.502%	0.501%
\$160,000	4,000	9	0.845%	0.563%	0.511%	0.504%	0.503%	0.502%	0.501%
\$160,000	5,000	9	0.700%	0.528%	0.506%	0.504%	0.503%	0.502%	0.501%
\$160,000	10,000	9	0.519%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$160,000	20,000	9	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$170,000	5	9	64.557%	62.786%	61.083%	59.441%	57.859%	54.859%	52.057%
\$170,000	10	9	49.396%	47.289%	45.281%	43.371%	41.545%	38.139%	35.044%
\$170,000	15	9	40.750%	38.515%	36.402%	34.408%	32.523%	29.058%	25.948%
\$170,000	20	9	35.006%	32.688%	30.514%	28.471%	26.549%	23.042%	19.929%
\$170,000	25	9	31.520%	29.144%	26.921%	24.843%	22.902%	19.393%	16.355%
\$170,000	50	9	21.035%	18.622%	16.449%	14.502%	12.766%	9.840%	7.538%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$170,000	100	9	13.744%	11.470%	9.526%	7.885%	6.511%	4.414%	2.996%
\$170,000	150	9	10.580%	8.450%	6.702%	5.290%	4.165%	2.590%	1.652%
\$170,000	200	9	8.723%	6.713%	5.126%	3.894%	2.958%	1.736%	1.089%
\$170,000	300	9	6.682%	4.859%	3.500%	2.521%	1.833%	1.045%	0.703%
\$170,000	400	9	5.454%	3.788%	2.616%	1.820%	1.297%	0.765%	0.577%
\$170,000	500	9	4.687%	3.137%	2.099%	1.433%	1.023%	0.645%	0.533%
\$170,000	600	9	4.088%	2.642%	1.716%	1.157%	0.838%	0.575%	0.513%
\$170,000	700	9	3.683%	2.320%	1.478%	0.993%	0.733%	0.542%	0.506%
\$170,000	800	9	3.355%	2.065%	1.299%	0.880%	0.667%	0.527%	0.504%
\$170,000	900	9	3.064%	1.843%	1.145%	0.783%	0.613%	0.515%	0.502%
\$170,000	1,000	9	2.838%	1.675%	1.036%	0.721%	0.582%	0.510%	0.502%
\$170,000	1,500	9	2.043%	1.137%	0.727%	0.572%	0.521%	0.503%	0.501%
\$170,000	2,000	9	1.589%	0.875%	0.608%	0.528%	0.508%	0.502%	0.501%
\$170,000	3,000	9	1.119%	0.656%	0.532%	0.508%	0.503%	0.502%	0.501%
\$170,000	4,000	9	0.865%	0.568%	0.512%	0.504%	0.503%	0.502%	0.501%
\$170,000	5,000	9	0.713%	0.530%	0.507%	0.504%	0.503%	0.502%	0.501%
\$170,000	10,000	9	0.520%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$170,000	20,000	9	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$180,000	5	9	64.874%	63.114%	61.423%	59.792%	58.222%	55.243%	52.461%
\$180,000	10	9	49.752%	47.661%	45.671%	43.776%	41.966%	38.591%	35.528%
\$180,000	15	9	41.123%	38.909%	36.817%	34.842%	32.977%	29.550%	26.473%
\$180,000	20	9	35.386%	33.091%	30.940%	28.918%	27.018%	23.551%	20.474%
\$180,000	25	9	31.931%	29.581%	27.382%	25.329%	23.408%	19.925%	16.887%
\$180,000	50	9	21.402%	18.990%	16.814%	14.861%	13.116%	10.162%	7.828%
\$180,000	100	9	13.994%	11.717%	9.763%	8.107%	6.718%	4.587%	3.132%
\$180,000	150	9	10.775%	8.635%	6.874%	5.448%	4.305%	2.695%	1.726%
\$180,000	200	9	8.886%	6.867%	5.265%	4.018%	3.062%	1.809%	1.133%
\$180,000	300	9	6.807%	4.971%	3.597%	2.601%	1.898%	1.083%	0.723%
\$180,000	400	9	5.558%	3.879%	2.692%	1.878%	1.341%	0.787%	0.586%
\$180,000	500	9	4.777%	3.214%	2.159%	1.478%	1.055%	0.658%	0.537%
\$180,000	600	9	4.170%	2.709%	1.767%	1.192%	0.860%	0.583%	0.515%
\$180,000	700	9	3.758%	2.379%	1.520%	1.021%	0.750%	0.547%	0.507%
\$180,000	800	9	3.422%	2.117%	1.335%	0.903%	0.680%	0.530%	0.504%
\$180,000	900	9	3.127%	1.890%	1.177%	0.802%	0.623%	0.517%	0.503%
\$180,000	1,000	9	2.897%	1.718%	1.064%	0.736%	0.590%	0.512%	0.502%
\$180,000	1,500	9	2.088%	1.166%	0.742%	0.578%	0.524%	0.503%	0.501%
\$180,000	2,000	9	1.625%	0.895%	0.616%	0.531%	0.509%	0.502%	0.501%
\$180,000	3,000	9	1.145%	0.666%	0.535%	0.508%	0.503%	0.502%	0.501%
\$180,000	4,000	9	0.883%	0.574%	0.513%	0.505%	0.503%	0.502%	0.501%
\$180,000	5,000	9	0.726%	0.533%	0.507%	0.504%	0.503%	0.502%	0.501%
\$180,000	10,000	9	0.522%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$180,000	20,000	9	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$190,000	5	9	65.161%	63.412%	61.732%	60.111%	58.551%	55.591%	52.828%
\$190,000	10	9	50.074%	47.998%	46.025%	44.143%	42.349%	39.003%	35.968%
\$190,000	15	9	41.463%	39.267%	37.193%	35.237%	33.389%	29.995%	26.949%
\$190,000	20	9	35.730%	33.457%	31.326%	29.324%	27.443%	24.012%	20.968%
\$190,000	25	9	32.305%	29.977%	27.801%	25.770%	23.870%	20.419%	17.392%
\$190,000	50	9	21.751%	19.342%	17.163%	15.207%	13.454%	10.474%	8.111%
\$190,000	100	9	14.234%	11.955%	9.993%	8.322%	6.919%	4.756%	3.266%
\$190,000	150	9	10.963%	8.814%	7.042%	5.600%	4.440%	2.797%	1.799%
\$190,000	200	9	9.043%	7.016%	5.400%	4.138%	3.165%	1.879%	1.177%
\$190,000	300	9	6.927%	5.080%	3.692%	2.681%	1.961%	1.121%	0.743%
\$190,000	400	9	5.659%	3.968%	2.765%	1.937%	1.384%	0.808%	0.594%
\$190,000	500	9	4.865%	3.289%	2.217%	1.522%	1.085%	0.671%	0.542%
\$190,000	600	9	4.250%	2.775%	1.817%	1.227%	0.883%	0.591%	0.517%
\$190,000	700	9	3.830%	2.436%	1.562%	1.049%	0.767%	0.552%	0.508%
\$190,000	800	9	3.488%	2.168%	1.371%	0.926%	0.693%	0.533%	0.505%
\$190,000	900	9	3.188%	1.936%	1.208%	0.820%	0.633%	0.519%	0.503%
\$190,000	1,000	9	2.954%	1.760%	1.091%	0.752%	0.597%	0.513%	0.502%
\$190,000	1,500	9	2.133%	1.194%	0.757%	0.585%	0.526%	0.503%	0.501%
\$190,000	2,000	9	1.661%	0.914%	0.625%	0.533%	0.509%	0.502%	0.501%
\$190,000	3,000	9	1.170%	0.677%	0.538%	0.509%	0.504%	0.502%	0.501%
\$190,000	4,000	9	0.902%	0.579%	0.514%	0.505%	0.503%	0.502%	0.501%
\$190,000	5,000	9	0.738%	0.535%	0.507%	0.504%	0.503%	0.502%	0.501%
\$190,000	10,000	9	0.523%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$190,000	20,000	9	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$200,000	5	9	65.411%	63.672%	62.000%	60.389%	58.838%	55.895%	53.148%
\$200,000	10	9	50.355%	48.292%	46.333%	44.463%	42.681%	39.361%	36.351%
\$200,000	15	9	41.759%	39.580%	37.522%	35.581%	33.749%	30.384%	27.364%
\$200,000	20	9	36.031%	33.777%	31.664%	29.679%	27.814%	24.416%	21.401%
\$200,000	25	9	32.629%	30.321%	28.165%	26.153%	24.270%	20.852%	17.846%
\$200,000	50	9	22.065%	19.661%	17.481%	15.522%	13.761%	10.758%	8.369%
\$200,000	100	9	14.453%	12.172%	10.203%	8.519%	7.102%	4.911%	3.390%
\$200,000	150	9	11.135%	8.978%	7.195%	5.740%	4.565%	2.892%	1.868%
\$200,000	200	9	9.188%	7.152%	5.525%	4.248%	3.261%	1.945%	1.219%
\$200,000	300	9	7.039%	5.182%	3.781%	2.756%	2.021%	1.157%	0.763%
\$200,000	400	9	5.754%	4.051%	2.834%	1.991%	1.425%	0.829%	0.603%
\$200,000	500	9	4.947%	3.359%	2.272%	1.563%	1.115%	0.684%	0.547%
\$200,000	600	9	4.325%	2.836%	1.864%	1.260%	0.905%	0.599%	0.520%
\$200,000	700	9	3.897%	2.490%	1.602%	1.075%	0.783%	0.557%	0.509%
\$200,000	800	9	3.549%	2.216%	1.405%	0.947%	0.706%	0.537%	0.505%
\$200,000	900	9	3.245%	1.979%	1.237%	0.838%	0.643%	0.521%	0.503%
\$200,000	1,000	9	3.008%	1.800%	1.117%	0.767%	0.605%	0.515%	0.502%
\$200,000	1,500	9	2.174%	1.221%	0.772%	0.591%	0.528%	0.504%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$200,000	2,000	9	1.694%	0.932%	0.633%	0.536%	0.510%	0.502%	0.501%
\$200,000	3,000	9	1.194%	0.687%	0.541%	0.509%	0.504%	0.502%	0.501%
\$200,000	4,000	9	0.919%	0.585%	0.515%	0.505%	0.503%	0.502%	0.501%
\$200,000	5,000	9	0.750%	0.538%	0.507%	0.504%	0.503%	0.502%	0.501%
\$200,000	10,000	9	0.525%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$200,000	20,000	9	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$225,000	5	9	65.963%	64.245%	62.593%	61.001%	59.468%	56.562%	53.849%
\$225,000	10	9	50.963%	48.929%	46.998%	45.156%	43.400%	40.133%	37.175%
\$225,000	15	9	42.390%	40.244%	38.220%	36.312%	34.512%	31.206%	28.242%
\$225,000	20	9	36.670%	34.455%	32.378%	30.429%	28.599%	25.266%	22.313%
\$225,000	25	9	33.316%	31.050%	28.934%	26.963%	25.117%	21.768%	18.825%
\$225,000	50	9	22.758%	20.371%	18.200%	16.237%	14.462%	11.415%	8.967%
\$225,000	100	9	14.940%	12.656%	10.671%	8.965%	7.517%	5.261%	3.675%
\$225,000	150	9	11.518%	9.347%	7.543%	6.060%	4.853%	3.112%	2.028%
\$225,000	200	9	9.509%	7.455%	5.803%	4.495%	3.478%	2.096%	1.319%
\$225,000	300	9	7.290%	5.411%	3.982%	2.926%	2.160%	1.242%	0.809%
\$225,000	400	9	5.964%	4.238%	2.990%	2.115%	1.520%	0.879%	0.625%
\$225,000	500	9	5.129%	3.516%	2.398%	1.658%	1.183%	0.715%	0.558%
\$225,000	600	9	4.491%	2.975%	1.971%	1.337%	0.956%	0.619%	0.525%
\$225,000	700	9	4.041%	2.605%	1.687%	1.132%	0.819%	0.567%	0.511%
\$225,000	800	9	3.686%	2.323%	1.481%	0.997%	0.736%	0.545%	0.507%
\$225,000	900	9	3.374%	2.077%	1.304%	0.879%	0.665%	0.527%	0.504%
\$225,000	1,000	9	3.129%	1.890%	1.177%	0.802%	0.624%	0.518%	0.503%
\$225,000	1,500	9	2.266%	1.281%	0.805%	0.606%	0.534%	0.504%	0.501%
\$225,000	2,000	9	1.768%	0.974%	0.651%	0.543%	0.512%	0.502%	0.501%
\$225,000	3,000	9	1.248%	0.710%	0.548%	0.511%	0.504%	0.502%	0.501%
\$225,000	4,000	9	0.958%	0.597%	0.517%	0.505%	0.503%	0.502%	0.501%
\$225,000	5,000	9	0.776%	0.544%	0.508%	0.504%	0.503%	0.502%	0.501%
\$225,000	10,000	9	0.528%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$225,000	20,000	9	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$250,000	5	9	66.422%	64.721%	63.084%	61.510%	59.992%	57.117%	54.433%
\$250,000	10	9	51.468%	49.459%	47.550%	45.731%	43.997%	40.775%	37.860%
\$250,000	15	9	42.919%	40.801%	38.805%	36.925%	35.151%	31.895%	28.977%
\$250,000	20	9	37.208%	35.025%	32.979%	31.059%	29.259%	25.980%	23.078%
\$250,000	25	9	33.897%	31.665%	29.585%	27.646%	25.832%	22.541%	19.652%
\$250,000	50	9	23.374%	21.011%	18.858%	16.903%	15.124%	12.046%	9.550%
\$250,000	100	9	15.397%	13.108%	11.114%	9.389%	7.914%	5.598%	3.951%
\$250,000	150	9	11.876%	9.695%	7.872%	6.365%	5.130%	3.328%	2.189%
\$250,000	200	9	9.808%	7.739%	6.065%	4.731%	3.686%	2.245%	1.418%
\$250,000	300	9	7.522%	5.626%	4.172%	3.089%	2.295%	1.325%	0.855%
\$250,000	400	9	6.160%	4.412%	3.137%	2.234%	1.613%	0.928%	0.648%
\$250,000	500	9	5.298%	3.663%	2.517%	1.749%	1.249%	0.746%	0.570%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$250,000	600	9	4.646%	3.104%	2.071%	1.410%	1.006%	0.639%	0.532%
\$250,000	700	9	4.179%	2.718%	1.771%	1.191%	0.857%	0.580%	0.514%
\$250,000	800	9	3.812%	2.423%	1.554%	1.046%	0.766%	0.553%	0.509%
\$250,000	900	9	3.492%	2.169%	1.367%	0.919%	0.688%	0.533%	0.505%
\$250,000	1,000	9	3.242%	1.976%	1.235%	0.838%	0.642%	0.523%	0.504%
\$250,000	1,500	9	2.351%	1.338%	0.837%	0.621%	0.540%	0.505%	0.501%
\$250,000	2,000	9	1.837%	1.014%	0.670%	0.550%	0.514%	0.502%	0.501%
\$250,000	3,000	9	1.298%	0.733%	0.555%	0.512%	0.504%	0.502%	0.501%
\$250,000	4,000	9	0.994%	0.609%	0.520%	0.505%	0.503%	0.502%	0.501%
\$250,000	5,000	9	0.802%	0.551%	0.509%	0.504%	0.503%	0.502%	0.501%
\$250,000	10,000	9	0.532%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$250,000	20,000	9	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$275,000	5	9	66.805%	65.119%	63.496%	61.935%	60.430%	57.580%	54.920%
\$275,000	10	9	51.895%	49.908%	48.017%	46.217%	44.501%	41.319%	38.441%
\$275,000	15	9	43.371%	41.277%	39.306%	37.448%	35.698%	32.484%	29.604%
\$275,000	20	9	37.673%	35.516%	33.496%	31.602%	29.825%	26.593%	23.733%
\$275,000	25	9	34.393%	32.192%	30.142%	28.229%	26.441%	23.199%	20.356%
\$275,000	50	9	23.927%	21.593%	19.464%	17.522%	15.748%	12.658%	10.128%
\$275,000	100	9	15.829%	13.537%	11.535%	9.796%	8.297%	5.926%	4.224%
\$275,000	150	9	12.210%	10.022%	8.183%	6.656%	5.396%	3.541%	2.348%
\$275,000	200	9	10.088%	8.008%	6.315%	4.958%	3.887%	2.393%	1.516%
\$275,000	300	9	7.740%	5.829%	4.354%	3.245%	2.425%	1.407%	0.902%
\$275,000	400	9	6.345%	4.577%	3.277%	2.349%	1.703%	0.978%	0.672%
\$275,000	500	9	5.457%	3.801%	2.630%	1.835%	1.314%	0.777%	0.582%
\$275,000	600	9	4.790%	3.226%	2.165%	1.480%	1.055%	0.659%	0.538%
\$275,000	700	9	4.308%	2.824%	1.852%	1.249%	0.895%	0.593%	0.517%
\$275,000	800	9	3.930%	2.519%	1.624%	1.093%	0.796%	0.563%	0.511%
\$275,000	900	9	3.602%	2.254%	1.428%	0.958%	0.711%	0.539%	0.506%
\$275,000	1,000	9	3.346%	2.056%	1.290%	0.872%	0.662%	0.527%	0.505%
\$275,000	1,500	9	2.430%	1.392%	0.868%	0.636%	0.546%	0.506%	0.501%
\$275,000	2,000	9	1.901%	1.053%	0.688%	0.556%	0.516%	0.503%	0.501%
\$275,000	3,000	9	1.346%	0.755%	0.562%	0.514%	0.504%	0.502%	0.501%
\$275,000	4,000	9	1.029%	0.622%	0.523%	0.506%	0.503%	0.502%	0.501%
\$275,000	5,000	9	0.827%	0.557%	0.510%	0.504%	0.503%	0.502%	0.501%
\$275,000	10,000	9	0.536%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$275,000	20,000	9	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$300,000	5	9	67.078%	65.402%	63.789%	62.238%	60.743%	57.911%	55.268%
\$300,000	10	9	52.206%	50.234%	48.357%	46.571%	44.870%	41.715%	38.864%
\$300,000	15	9	43.713%	41.637%	39.684%	37.843%	36.110%	32.928%	30.076%
\$300,000	20	9	38.024%	35.888%	33.887%	32.012%	30.254%	27.056%	24.229%
\$300,000	25	9	34.769%	32.590%	30.562%	28.670%	26.900%	23.696%	20.886%
\$300,000	50	9	24.349%	22.042%	19.936%	18.013%	16.250%	13.162%	10.614%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$300,000	100	9	16.187%	13.894%	11.886%	10.140%	8.625%	6.210%	4.464%
\$300,000	150	9	12.487%	10.294%	8.445%	6.900%	5.621%	3.723%	2.488%
\$300,000	200	9	10.321%	8.234%	6.525%	5.150%	4.058%	2.521%	1.604%
\$300,000	300	9	7.923%	6.000%	4.509%	3.378%	2.537%	1.479%	0.944%
\$300,000	400	9	6.502%	4.717%	3.397%	2.448%	1.782%	1.022%	0.694%
\$300,000	500	9	5.594%	3.920%	2.727%	1.911%	1.371%	0.804%	0.594%
\$300,000	600	9	4.913%	3.331%	2.247%	1.542%	1.098%	0.678%	0.545%
\$300,000	700	9	4.418%	2.916%	1.923%	1.299%	0.929%	0.606%	0.521%
\$300,000	800	9	4.025%	2.595%	1.680%	1.130%	0.819%	0.570%	0.512%
\$300,000	900	9	3.696%	2.329%	1.481%	0.993%	0.732%	0.545%	0.508%
\$300,000	1,000	9	3.436%	2.125%	1.338%	0.902%	0.679%	0.531%	0.506%
\$300,000	1,500	9	2.498%	1.439%	0.895%	0.649%	0.552%	0.506%	0.501%
\$300,000	2,000	9	1.956%	1.086%	0.704%	0.563%	0.518%	0.503%	0.501%
\$300,000	3,000	9	1.387%	0.774%	0.569%	0.516%	0.505%	0.502%	0.501%
\$300,000	4,000	9	1.059%	0.633%	0.526%	0.506%	0.503%	0.502%	0.501%
\$300,000	5,000	9	0.850%	0.563%	0.511%	0.504%	0.503%	0.502%	0.501%
\$300,000	10,000	9	0.539%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$300,000	20,000	9	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$325,000	5	9	67.303%	65.635%	64.030%	62.487%	61.000%	58.184%	55.554%
\$325,000	10	9	52.446%	50.486%	48.620%	46.845%	45.155%	42.023%	39.192%
\$325,000	15	9	43.986%	41.924%	39.985%	38.158%	36.439%	33.281%	30.452%
\$325,000	20	9	38.296%	36.176%	34.190%	32.330%	30.585%	27.415%	24.613%
\$325,000	25	9	35.061%	32.899%	30.888%	29.011%	27.257%	24.081%	21.298%
\$325,000	50	9	24.679%	22.394%	20.309%	18.403%	16.655%	13.583%	11.033%
\$325,000	100	9	16.486%	14.197%	12.185%	10.432%	8.908%	6.458%	4.674%
\$325,000	150	9	12.721%	10.525%	8.668%	7.112%	5.815%	3.881%	2.611%
\$325,000	200	9	10.517%	8.422%	6.703%	5.313%	4.204%	2.632%	1.682%
\$325,000	300	9	8.078%	6.145%	4.640%	3.493%	2.634%	1.543%	0.983%
\$325,000	400	9	6.634%	4.836%	3.500%	2.532%	1.850%	1.060%	0.714%
\$325,000	500	9	5.711%	4.021%	2.810%	1.977%	1.421%	0.830%	0.605%
\$325,000	600	9	5.017%	3.420%	2.318%	1.596%	1.137%	0.695%	0.551%
\$325,000	700	9	4.512%	2.994%	1.983%	1.342%	0.958%	0.618%	0.524%
\$325,000	800	9	4.111%	2.666%	1.733%	1.166%	0.843%	0.578%	0.514%
\$325,000	900	9	3.776%	2.392%	1.526%	1.023%	0.751%	0.550%	0.509%
\$325,000	1,000	9	3.511%	2.183%	1.379%	0.929%	0.694%	0.535%	0.507%
\$325,000	1,500	9	2.554%	1.478%	0.919%	0.661%	0.557%	0.507%	0.501%
\$325,000	2,000	9	2.003%	1.115%	0.719%	0.568%	0.520%	0.503%	0.501%
\$325,000	3,000	9	1.422%	0.791%	0.574%	0.517%	0.505%	0.502%	0.501%
\$325,000	4,000	9	1.085%	0.643%	0.528%	0.507%	0.503%	0.502%	0.501%
\$325,000	5,000	9	0.869%	0.569%	0.512%	0.504%	0.503%	0.502%	0.501%
\$325,000	10,000	9	0.542%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$325,000	20,000	9	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$350,000	5	9	67.521%	65.861%	64.264%	62.728%	61.248%	58.446%	55.830%
\$350,000	10	9	52.676%	50.727%	48.872%	47.107%	45.427%	42.317%	39.506%
\$350,000	15	9	44.245%	42.197%	40.272%	38.458%	36.751%	33.617%	30.809%
\$350,000	20	9	38.553%	36.448%	34.476%	32.630%	30.900%	27.754%	24.975%
\$350,000	25	9	35.338%	33.192%	31.198%	29.336%	27.596%	24.447%	21.688%
\$350,000	50	9	24.990%	22.727%	20.664%	18.776%	17.043%	13.996%	11.453%
\$350,000	100	9	16.785%	14.503%	12.490%	10.731%	9.198%	6.718%	4.894%
\$350,000	150	9	12.960%	10.760%	8.897%	7.330%	6.018%	4.047%	2.741%
\$350,000	200	9	10.715%	8.614%	6.886%	5.482%	4.357%	2.749%	1.766%
\$350,000	300	9	8.235%	6.292%	4.775%	3.612%	2.734%	1.610%	1.024%
\$350,000	400	9	6.767%	4.957%	3.604%	2.619%	1.920%	1.102%	0.735%
\$350,000	500	9	5.829%	4.124%	2.896%	2.046%	1.474%	0.857%	0.618%
\$350,000	600	9	5.123%	3.510%	2.391%	1.651%	1.177%	0.713%	0.558%
\$350,000	700	9	4.606%	3.074%	2.046%	1.388%	0.989%	0.631%	0.528%
\$350,000	800	9	4.197%	2.736%	1.786%	1.204%	0.868%	0.587%	0.516%
\$350,000	900	9	3.856%	2.456%	1.573%	1.055%	0.770%	0.556%	0.510%
\$350,000	1,000	9	3.586%	2.242%	1.421%	0.957%	0.711%	0.539%	0.507%
\$350,000	1,500	9	2.611%	1.518%	0.943%	0.673%	0.563%	0.508%	0.501%
\$350,000	2,000	9	2.049%	1.144%	0.733%	0.574%	0.522%	0.503%	0.501%
\$350,000	3,000	9	1.456%	0.808%	0.581%	0.519%	0.505%	0.502%	0.501%
\$350,000	4,000	9	1.110%	0.652%	0.530%	0.507%	0.503%	0.502%	0.501%
\$350,000	5,000	9	0.887%	0.574%	0.513%	0.504%	0.503%	0.502%	0.501%
\$350,000	10,000	9	0.546%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$350,000	20,000	9	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$375,000	5	9	67.728%	66.076%	64.486%	62.957%	61.484%	58.696%	56.091%
\$375,000	10	9	52.896%	50.958%	49.113%	47.358%	45.688%	42.597%	39.804%
\$375,000	15	9	44.496%	42.462%	40.549%	38.747%	37.052%	33.940%	31.152%
\$375,000	20	9	38.803%	36.712%	34.754%	32.921%	31.204%	28.082%	25.326%
\$375,000	25	9	35.607%	33.478%	31.498%	29.651%	27.925%	24.801%	22.065%
\$375,000	50	9	25.295%	23.053%	21.010%	19.140%	17.425%	14.405%	11.879%
\$375,000	100	9	17.087%	14.814%	12.805%	11.041%	9.499%	6.995%	5.131%
\$375,000	150	9	13.206%	11.005%	9.135%	7.558%	6.232%	4.223%	2.879%
\$375,000	200	9	10.920%	8.814%	7.076%	5.659%	4.518%	2.875%	1.858%
\$375,000	300	9	8.397%	6.445%	4.915%	3.736%	2.840%	1.681%	1.070%
\$375,000	400	9	6.905%	5.083%	3.714%	2.711%	1.996%	1.147%	0.759%
\$375,000	500	9	5.950%	4.231%	2.986%	2.117%	1.529%	0.886%	0.631%
\$375,000	600	9	5.232%	3.604%	2.468%	1.710%	1.220%	0.733%	0.566%
\$375,000	700	9	4.703%	3.156%	2.111%	1.436%	1.022%	0.645%	0.532%
\$375,000	800	9	4.286%	2.810%	1.843%	1.244%	0.894%	0.596%	0.519%
\$375,000	900	9	3.931%	2.516%	1.617%	1.084%	0.788%	0.561%	0.510%
\$375,000	1,000	9	3.663%	2.303%	1.465%	0.986%	0.728%	0.544%	0.508%
\$375,000	1,500	9	2.669%	1.560%	0.969%	0.687%	0.569%	0.509%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$375,000	2,000	9	2.097%	1.174%	0.749%	0.581%	0.524%	0.503%	0.501%
\$375,000	3,000	9	1.492%	0.826%	0.588%	0.521%	0.506%	0.502%	0.501%
\$375,000	4,000	9	1.136%	0.663%	0.533%	0.507%	0.503%	0.502%	0.501%
\$375,000	5,000	9	0.907%	0.580%	0.514%	0.504%	0.503%	0.502%	0.501%
\$375,000	10,000	9	0.549%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$375,000	20,000	9	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$400,000	5	9	67.912%	66.266%	64.683%	63.160%	61.694%	58.917%	56.324%
\$400,000	10	9	53.092%	51.163%	49.327%	47.581%	45.920%	42.847%	40.071%
\$400,000	15	9	44.728%	42.706%	40.804%	39.014%	37.330%	34.237%	31.468%
\$400,000	20	9	39.037%	36.958%	35.012%	33.192%	31.486%	28.385%	25.650%
\$400,000	25	9	35.853%	33.738%	31.772%	29.938%	28.224%	25.124%	22.408%
\$400,000	50	9	25.572%	23.350%	21.324%	19.470%	17.770%	14.780%	12.273%
\$400,000	100	9	17.368%	15.105%	13.103%	11.338%	9.789%	7.263%	5.364%
\$400,000	150	9	13.440%	11.239%	9.363%	7.776%	6.439%	4.396%	3.014%
\$400,000	200	9	11.114%	9.005%	7.259%	5.830%	4.673%	2.997%	1.948%
\$400,000	300	9	8.551%	6.592%	5.050%	3.856%	2.944%	1.753%	1.115%
\$400,000	400	9	7.037%	5.204%	3.820%	2.801%	2.070%	1.192%	0.783%
\$400,000	500	9	6.066%	4.335%	3.073%	2.188%	1.583%	0.916%	0.645%
\$400,000	600	9	5.336%	3.695%	2.543%	1.768%	1.263%	0.753%	0.574%
\$400,000	700	9	4.796%	3.235%	2.175%	1.484%	1.055%	0.659%	0.537%
\$400,000	800	9	4.372%	2.881%	1.899%	1.284%	0.921%	0.607%	0.522%
\$400,000	900	9	4.010%	2.581%	1.665%	1.117%	0.809%	0.568%	0.512%
\$400,000	1,000	9	3.737%	2.362%	1.508%	1.015%	0.746%	0.549%	0.509%
\$400,000	1,500	9	2.726%	1.601%	0.995%	0.701%	0.575%	0.510%	0.501%
\$400,000	2,000	9	2.144%	1.204%	0.765%	0.588%	0.526%	0.503%	0.501%
\$400,000	3,000	9	1.527%	0.844%	0.594%	0.523%	0.506%	0.502%	0.501%
\$400,000	4,000	9	1.162%	0.673%	0.536%	0.508%	0.503%	0.502%	0.501%
\$400,000	5,000	9	0.926%	0.586%	0.515%	0.505%	0.503%	0.502%	0.501%
\$400,000	10,000	9	0.553%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$400,000	20,000	9	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$425,000	5	9	68.077%	66.437%	64.860%	63.343%	61.882%	59.116%	56.533%
\$425,000	10	9	53.274%	51.354%	49.526%	47.788%	46.135%	43.079%	40.318%
\$425,000	15	9	44.940%	42.929%	41.037%	39.258%	37.583%	34.509%	31.756%
\$425,000	20	9	39.251%	37.184%	35.250%	33.440%	31.746%	28.664%	25.947%
\$425,000	25	9	36.075%	33.973%	32.019%	30.196%	28.494%	25.415%	22.718%
\$425,000	50	9	25.826%	23.622%	21.613%	19.773%	18.087%	15.124%	12.638%
\$425,000	100	9	17.631%	15.381%	13.386%	11.624%	10.071%	7.526%	5.596%
\$425,000	150	9	13.666%	11.467%	9.587%	7.990%	6.643%	4.568%	3.151%
\$425,000	200	9	11.304%	9.192%	7.439%	5.999%	4.827%	3.120%	2.040%
\$425,000	300	9	8.701%	6.736%	5.182%	3.975%	3.048%	1.825%	1.161%
\$425,000	400	9	7.165%	5.322%	3.924%	2.889%	2.143%	1.237%	0.807%
\$425,000	500	9	6.179%	4.436%	3.158%	2.257%	1.638%	0.947%	0.659%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$425,000	600	9	5.438%	3.784%	2.617%	1.825%	1.306%	0.774%	0.583%
\$425,000	700	9	4.887%	3.313%	2.237%	1.531%	1.089%	0.674%	0.543%
\$425,000	800	9	4.455%	2.951%	1.953%	1.323%	0.947%	0.617%	0.525%
\$425,000	900	9	4.087%	2.644%	1.713%	1.150%	0.831%	0.575%	0.514%
\$425,000	1,000	9	3.809%	2.420%	1.551%	1.044%	0.765%	0.554%	0.511%
\$425,000	1,500	9	2.781%	1.641%	1.020%	0.715%	0.581%	0.511%	0.502%
\$425,000	2,000	9	2.189%	1.234%	0.781%	0.595%	0.529%	0.503%	0.501%
\$425,000	3,000	9	1.561%	0.862%	0.602%	0.525%	0.506%	0.502%	0.501%
\$425,000	4,000	9	1.187%	0.684%	0.539%	0.509%	0.503%	0.502%	0.501%
\$425,000	5,000	9	0.945%	0.592%	0.516%	0.505%	0.503%	0.502%	0.501%
\$425,000	10,000	9	0.556%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$425,000	20,000	9	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$450,000	5	9	68.203%	66.566%	64.994%	63.482%	62.025%	59.267%	56.692%
\$450,000	10	9	53.421%	51.507%	49.686%	47.954%	46.307%	43.264%	40.515%
\$450,000	15	9	45.109%	43.105%	41.222%	39.451%	37.784%	34.724%	31.984%
\$450,000	20	9	39.418%	37.360%	35.435%	33.633%	31.948%	28.881%	26.178%
\$450,000	25	9	36.245%	34.153%	32.209%	30.395%	28.702%	25.639%	22.956%
\$450,000	50	9	26.027%	23.836%	21.840%	20.012%	18.337%	15.394%	12.926%
\$450,000	100	9	17.843%	15.603%	13.616%	11.857%	10.304%	7.746%	5.795%
\$450,000	150	9	13.855%	11.658%	9.776%	8.172%	6.815%	4.716%	3.270%
\$450,000	200	9	11.464%	9.350%	7.593%	6.144%	4.961%	3.228%	2.123%
\$450,000	300	9	8.828%	6.858%	5.296%	4.076%	3.137%	1.887%	1.202%
\$450,000	400	9	7.275%	5.423%	4.012%	2.965%	2.206%	1.276%	0.828%
\$450,000	500	9	6.274%	4.522%	3.231%	2.317%	1.684%	0.972%	0.670%
\$450,000	600	9	5.525%	3.860%	2.679%	1.873%	1.342%	0.792%	0.590%
\$450,000	700	9	4.965%	3.380%	2.290%	1.572%	1.118%	0.686%	0.548%
\$450,000	800	9	4.527%	3.010%	2.000%	1.357%	0.971%	0.627%	0.528%
\$450,000	900	9	4.153%	2.698%	1.754%	1.179%	0.850%	0.582%	0.515%
\$450,000	1,000	9	3.865%	2.464%	1.584%	1.066%	0.778%	0.557%	0.511%
\$450,000	1,500	9	2.829%	1.675%	1.042%	0.727%	0.587%	0.512%	0.502%
\$450,000	2,000	9	2.229%	1.260%	0.795%	0.601%	0.531%	0.504%	0.501%
\$450,000	3,000	9	1.591%	0.878%	0.608%	0.527%	0.507%	0.502%	0.501%
\$450,000	4,000	9	1.210%	0.694%	0.542%	0.509%	0.503%	0.502%	0.501%
\$450,000	5,000	9	0.962%	0.598%	0.517%	0.505%	0.503%	0.502%	0.501%
\$450,000	10,000	9	0.560%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$450,000	20,000	9	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$475,000	5	9	68.309%	66.677%	65.109%	63.600%	62.147%	59.395%	56.826%
\$475,000	10	9	53.536%	51.627%	49.811%	48.084%	46.443%	43.410%	40.670%
\$475,000	15	9	45.242%	43.245%	41.369%	39.604%	37.943%	34.893%	32.164%
\$475,000	20	9	39.552%	37.501%	35.583%	33.788%	32.109%	29.055%	26.363%
\$475,000	25	9	36.381%	34.297%	32.360%	30.553%	28.866%	25.816%	23.146%
\$475,000	50	9	26.185%	24.005%	22.018%	20.200%	18.533%	15.607%	13.152%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$475,000	100	9	18.011%	15.781%	13.801%	12.046%	10.493%	7.929%	5.962%
\$475,000	150	9	14.008%	11.813%	9.930%	8.322%	6.958%	4.839%	3.371%
\$475,000	200	9	11.595%	9.481%	7.720%	6.266%	5.073%	3.320%	2.195%
\$475,000	300	9	8.930%	6.958%	5.389%	4.160%	3.211%	1.940%	1.237%
\$475,000	400	9	7.364%	5.505%	4.086%	3.028%	2.258%	1.309%	0.847%
\$475,000	500	9	6.354%	4.594%	3.293%	2.367%	1.723%	0.994%	0.681%
\$475,000	600	9	5.598%	3.925%	2.733%	1.915%	1.372%	0.808%	0.597%
\$475,000	700	9	5.030%	3.436%	2.336%	1.607%	1.144%	0.698%	0.552%
\$475,000	800	9	4.587%	3.061%	2.040%	1.387%	0.992%	0.635%	0.531%
\$475,000	900	9	4.210%	2.745%	1.790%	1.205%	0.867%	0.588%	0.517%
\$475,000	1,000	9	3.918%	2.507%	1.616%	1.089%	0.793%	0.562%	0.512%
\$475,000	1,500	9	2.869%	1.705%	1.061%	0.738%	0.592%	0.513%	0.502%
\$475,000	2,000	9	2.262%	1.282%	0.808%	0.607%	0.534%	0.504%	0.501%
\$475,000	3,000	9	1.615%	0.891%	0.614%	0.529%	0.507%	0.502%	0.501%
\$475,000	4,000	9	1.228%	0.702%	0.545%	0.510%	0.503%	0.502%	0.501%
\$475,000	5,000	9	0.976%	0.603%	0.518%	0.505%	0.503%	0.502%	0.501%
\$475,000	10,000	9	0.562%	0.509%	0.505%	0.504%	0.503%	0.502%	0.501%
\$475,000	20,000	9	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$500,000	5	9	68.411%	66.782%	65.217%	63.712%	62.262%	59.517%	56.954%
\$500,000	10	9	53.638%	51.734%	49.923%	48.200%	46.564%	43.539%	40.808%
\$500,000	15	9	45.362%	43.371%	41.501%	39.741%	38.086%	35.047%	32.326%
\$500,000	20	9	39.671%	37.627%	35.715%	33.926%	32.253%	29.210%	26.529%
\$500,000	25	9	36.502%	34.426%	32.496%	30.695%	29.014%	25.976%	23.315%
\$500,000	50	9	26.321%	24.151%	22.173%	20.363%	18.704%	15.793%	13.350%
\$500,000	100	9	18.156%	15.937%	13.964%	12.214%	10.664%	8.097%	6.118%
\$500,000	150	9	14.144%	11.954%	10.072%	8.461%	7.091%	4.956%	3.467%
\$500,000	200	9	11.714%	9.601%	7.837%	6.378%	5.179%	3.407%	2.263%
\$500,000	300	9	9.024%	7.050%	5.476%	4.239%	3.280%	1.990%	1.271%
\$500,000	400	9	7.445%	5.581%	4.154%	3.087%	2.307%	1.340%	0.865%
\$500,000	500	9	6.428%	4.661%	3.351%	2.415%	1.761%	1.016%	0.691%
\$500,000	600	9	5.666%	3.985%	2.783%	1.956%	1.402%	0.824%	0.604%
\$500,000	700	9	5.091%	3.489%	2.378%	1.640%	1.168%	0.709%	0.557%
\$500,000	800	9	4.644%	3.109%	2.079%	1.416%	1.011%	0.642%	0.534%
\$500,000	900	9	4.262%	2.789%	1.824%	1.229%	0.884%	0.594%	0.519%
\$500,000	1,000	9	3.968%	2.547%	1.647%	1.110%	0.807%	0.566%	0.513%
\$500,000	1,500	9	2.905%	1.732%	1.079%	0.749%	0.598%	0.513%	0.502%
\$500,000	2,000	9	2.292%	1.303%	0.820%	0.613%	0.536%	0.504%	0.501%
\$500,000	3,000	9	1.638%	0.903%	0.619%	0.530%	0.508%	0.502%	0.501%
\$500,000	4,000	9	1.246%	0.709%	0.547%	0.510%	0.504%	0.502%	0.501%
\$500,000	5,000	9	0.989%	0.607%	0.519%	0.505%	0.503%	0.502%	0.501%
\$500,000	10,000	9	0.565%	0.509%	0.505%	0.504%	0.503%	0.502%	0.501%
\$500,000	20,000	9	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$30,000	5	10	46.096%	43.532%	41.047%	38.638%	36.299%	31.831%	27.652%
\$30,000	10	10	29.684%	27.055%	24.635%	22.416%	20.384%	16.786%	13.735%
\$30,000	15	10	23.150%	20.585%	18.253%	16.142%	14.244%	11.014%	8.452%
\$30,000	20	10	19.488%	16.978%	14.740%	12.750%	11.001%	8.131%	5.957%
\$30,000	25	10	17.060%	14.602%	12.440%	10.551%	8.916%	6.309%	4.428%
\$30,000	50	10	10.945%	8.740%	6.922%	5.450%	4.268%	2.616%	1.638%
\$30,000	100	10	6.870%	5.015%	3.620%	2.610%	1.895%	1.070%	0.713%
\$30,000	150	10	5.222%	3.585%	2.448%	1.688%	1.197%	0.714%	0.555%
\$30,000	200	10	4.259%	2.779%	1.814%	1.217%	0.871%	0.583%	0.513%
\$30,000	300	10	3.149%	1.900%	1.182%	0.805%	0.624%	0.514%	0.501%
\$30,000	400	10	2.513%	1.448%	0.898%	0.647%	0.548%	0.504%	0.501%
\$30,000	500	10	2.127%	1.195%	0.758%	0.583%	0.524%	0.503%	0.501%
\$30,000	600	10	1.824%	1.011%	0.667%	0.547%	0.512%	0.502%	0.501%
\$30,000	700	10	1.582%	0.879%	0.611%	0.528%	0.507%	0.502%	0.501%
\$30,000	800	10	1.407%	0.789%	0.576%	0.518%	0.505%	0.502%	0.501%
\$30,000	900	10	1.269%	0.723%	0.552%	0.512%	0.504%	0.502%	0.501%
\$30,000	1,000	10	1.156%	0.675%	0.537%	0.508%	0.503%	0.502%	0.501%
\$30,000	1,500	10	0.844%	0.564%	0.511%	0.504%	0.503%	0.502%	0.501%
\$30,000	2,000	10	0.688%	0.526%	0.506%	0.504%	0.503%	0.502%	0.501%
\$30,000	3,000	10	0.564%	0.509%	0.505%	0.504%	0.503%	0.502%	0.501%
\$30,000	4,000	10	0.527%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$30,000	5,000	10	0.513%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$30,000	10,000	10	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$30,000	20,000	10	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$35,000	5	10	48.408%	45.946%	43.563%	41.254%	39.018%	34.746%	30.705%
\$35,000	10	10	31.400%	28.730%	26.265%	24.001%	21.925%	18.262%	15.161%
\$35,000	15	10	24.481%	21.918%	19.575%	17.443%	15.506%	12.180%	9.502%
\$35,000	20	10	20.657%	18.128%	15.859%	13.836%	12.038%	9.051%	6.757%
\$35,000	25	10	18.109%	15.629%	13.433%	11.501%	9.811%	7.085%	5.072%
\$35,000	50	10	11.649%	9.400%	7.531%	5.999%	4.755%	2.970%	1.880%
\$35,000	100	10	7.331%	5.428%	3.975%	2.901%	2.126%	1.203%	0.779%
\$35,000	150	10	5.577%	3.888%	2.693%	1.875%	1.334%	0.777%	0.580%
\$35,000	200	10	4.558%	3.022%	1.999%	1.350%	0.959%	0.614%	0.522%
\$35,000	300	10	3.378%	2.073%	1.298%	0.874%	0.661%	0.521%	0.502%
\$35,000	400	10	2.701%	1.578%	0.977%	0.687%	0.566%	0.506%	0.501%
\$35,000	500	10	2.290%	1.301%	0.816%	0.609%	0.534%	0.504%	0.501%
\$35,000	600	10	1.970%	1.098%	0.709%	0.563%	0.517%	0.502%	0.501%
\$35,000	700	10	1.711%	0.951%	0.642%	0.539%	0.510%	0.502%	0.501%
\$35,000	800	10	1.522%	0.847%	0.598%	0.525%	0.507%	0.502%	0.501%
\$35,000	900	10	1.374%	0.772%	0.569%	0.516%	0.505%	0.502%	0.501%
\$35,000	1,000	10	1.250%	0.715%	0.550%	0.511%	0.504%	0.502%	0.501%
\$35,000	1,500	10	0.905%	0.582%	0.514%	0.505%	0.503%	0.502%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$35,000	2,000	10	0.729%	0.534%	0.507%	0.504%	0.503%	0.502%	0.501%
\$35,000	3,000	10	0.582%	0.510%	0.505%	0.504%	0.503%	0.502%	0.501%
\$35,000	4,000	10	0.534%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$35,000	5,000	10	0.517%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$35,000	10,000	10	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$35,000	20,000	10	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$40,000	5	10	50.319%	47.941%	45.641%	43.416%	41.263%	37.141%	33.255%
\$40,000	10	10	33.036%	30.331%	27.824%	25.508%	23.374%	19.619%	16.441%
\$40,000	15	10	25.676%	23.115%	20.771%	18.623%	16.659%	13.266%	10.496%
\$40,000	20	10	21.721%	19.179%	16.890%	14.835%	12.999%	9.917%	7.510%
\$40,000	25	10	19.061%	16.565%	14.340%	12.370%	10.639%	7.812%	5.687%
\$40,000	50	10	12.291%	10.008%	8.094%	6.507%	5.212%	3.314%	2.122%
\$40,000	100	10	7.749%	5.807%	4.306%	3.176%	2.349%	1.338%	0.851%
\$40,000	150	10	5.897%	4.166%	2.921%	2.053%	1.466%	0.841%	0.607%
\$40,000	200	10	4.825%	3.243%	2.169%	1.476%	1.045%	0.647%	0.532%
\$40,000	300	10	3.585%	2.232%	1.408%	0.943%	0.701%	0.530%	0.503%
\$40,000	400	10	2.872%	1.701%	1.053%	0.728%	0.586%	0.510%	0.501%
\$40,000	500	10	2.438%	1.400%	0.873%	0.637%	0.545%	0.505%	0.501%
\$40,000	600	10	2.102%	1.180%	0.751%	0.580%	0.523%	0.503%	0.501%
\$40,000	700	10	1.830%	1.019%	0.674%	0.551%	0.514%	0.502%	0.501%
\$40,000	800	10	1.629%	0.904%	0.622%	0.532%	0.509%	0.502%	0.501%
\$40,000	900	10	1.471%	0.820%	0.586%	0.521%	0.506%	0.502%	0.501%
\$40,000	1,000	10	1.338%	0.755%	0.563%	0.514%	0.504%	0.502%	0.501%
\$40,000	1,500	10	0.964%	0.601%	0.518%	0.505%	0.503%	0.502%	0.501%
\$40,000	2,000	10	0.768%	0.543%	0.508%	0.504%	0.503%	0.502%	0.501%
\$40,000	3,000	10	0.599%	0.512%	0.505%	0.504%	0.503%	0.502%	0.501%
\$40,000	4,000	10	0.542%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$40,000	5,000	10	0.520%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$40,000	10,000	10	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$40,000	20,000	10	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$45,000	5	10	51.930%	49.622%	47.393%	45.239%	43.151%	39.157%	35.402%
\$45,000	10	10	34.569%	31.863%	29.327%	26.968%	24.784%	20.915%	17.639%
\$45,000	15	10	26.784%	24.213%	21.860%	19.699%	17.727%	14.281%	11.434%
\$45,000	20	10	22.694%	20.154%	17.849%	15.770%	13.902%	10.739%	8.237%
\$45,000	25	10	19.939%	17.431%	15.186%	13.187%	11.419%	8.503%	6.284%
\$45,000	50	10	12.884%	10.575%	8.624%	6.994%	5.648%	3.652%	2.367%
\$45,000	100	10	8.138%	6.161%	4.620%	3.442%	2.567%	1.473%	0.927%
\$45,000	150	10	6.193%	4.425%	3.135%	2.223%	1.595%	0.907%	0.635%
\$45,000	200	10	5.072%	3.451%	2.332%	1.597%	1.130%	0.682%	0.543%
\$45,000	300	10	3.779%	2.384%	1.515%	1.012%	0.741%	0.541%	0.505%
\$45,000	400	10	3.031%	1.816%	1.127%	0.771%	0.607%	0.513%	0.502%
\$45,000	500	10	2.576%	1.495%	0.929%	0.665%	0.558%	0.507%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$45,000	600	10	2.225%	1.259%	0.794%	0.599%	0.531%	0.503%	0.501%
\$45,000	700	10	1.941%	1.086%	0.706%	0.564%	0.518%	0.503%	0.501%
\$45,000	800	10	1.729%	0.960%	0.646%	0.541%	0.511%	0.502%	0.501%
\$45,000	900	10	1.562%	0.867%	0.605%	0.526%	0.507%	0.502%	0.501%
\$45,000	1,000	10	1.421%	0.795%	0.578%	0.518%	0.505%	0.502%	0.501%
\$45,000	1,500	10	1.021%	0.621%	0.522%	0.506%	0.503%	0.502%	0.501%
\$45,000	2,000	10	0.807%	0.553%	0.509%	0.504%	0.503%	0.502%	0.501%
\$45,000	3,000	10	0.618%	0.515%	0.505%	0.504%	0.503%	0.502%	0.501%
\$45,000	4,000	10	0.551%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$45,000	5,000	10	0.524%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$45,000	10,000	10	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$45,000	20,000	10	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$50,000	5	10	53.310%	51.063%	48.896%	46.798%	44.762%	40.881%	37.235%
\$50,000	10	10	35.988%	33.298%	30.762%	28.383%	26.162%	22.185%	18.797%
\$50,000	15	10	27.827%	25.236%	22.862%	20.689%	18.700%	15.219%	12.306%
\$50,000	20	10	23.596%	21.054%	18.741%	16.647%	14.750%	11.516%	8.933%
\$50,000	25	10	20.743%	18.225%	15.965%	13.943%	12.143%	9.148%	6.848%
\$50,000	50	10	13.421%	11.094%	9.112%	7.444%	6.053%	3.971%	2.604%
\$50,000	100	10	8.492%	6.486%	4.908%	3.690%	2.772%	1.603%	1.004%
\$50,000	150	10	6.468%	4.667%	3.338%	2.385%	1.721%	0.974%	0.665%
\$50,000	200	10	5.300%	3.644%	2.486%	1.712%	1.215%	0.718%	0.555%
\$50,000	300	10	3.958%	2.527%	1.618%	1.079%	0.782%	0.552%	0.507%
\$50,000	400	10	3.176%	1.925%	1.199%	0.813%	0.629%	0.518%	0.502%
\$50,000	500	10	2.702%	1.583%	0.982%	0.693%	0.571%	0.509%	0.501%
\$50,000	600	10	2.338%	1.334%	0.835%	0.618%	0.538%	0.504%	0.501%
\$50,000	700	10	2.043%	1.148%	0.738%	0.577%	0.523%	0.503%	0.501%
\$50,000	800	10	1.821%	1.013%	0.671%	0.550%	0.514%	0.502%	0.501%
\$50,000	900	10	1.647%	0.913%	0.624%	0.533%	0.509%	0.502%	0.501%
\$50,000	1,000	10	1.498%	0.834%	0.592%	0.523%	0.506%	0.502%	0.501%
\$50,000	1,500	10	1.075%	0.641%	0.527%	0.506%	0.503%	0.502%	0.501%
\$50,000	2,000	10	0.845%	0.564%	0.511%	0.504%	0.503%	0.502%	0.501%
\$50,000	3,000	10	0.636%	0.518%	0.505%	0.504%	0.503%	0.502%	0.501%
\$50,000	4,000	10	0.560%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$50,000	5,000	10	0.528%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$50,000	10,000	10	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$50,000	20,000	10	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$55,000	5	10	54.503%	52.310%	50.192%	48.139%	46.151%	42.367%	38.811%
\$55,000	10	10	37.279%	34.623%	32.102%	29.722%	27.486%	23.434%	19.938%
\$55,000	15	10	28.817%	26.206%	23.805%	21.609%	19.598%	16.076%	13.117%
\$55,000	20	10	24.424%	21.881%	19.561%	17.452%	15.537%	12.245%	9.590%
\$55,000	25	10	21.480%	18.958%	16.683%	14.641%	12.816%	9.752%	7.375%
\$55,000	50	10	13.910%	11.569%	9.563%	7.862%	6.433%	4.273%	2.833%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$55,000	100	10	8.820%	6.787%	5.176%	3.925%	2.969%	1.729%	1.081%
\$55,000	150	10	6.721%	4.890%	3.528%	2.538%	1.841%	1.040%	0.696%
\$55,000	200	10	5.511%	3.825%	2.632%	1.823%	1.296%	0.755%	0.569%
\$55,000	300	10	4.124%	2.661%	1.716%	1.145%	0.822%	0.565%	0.510%
\$55,000	400	10	3.311%	2.027%	1.268%	0.854%	0.651%	0.522%	0.503%
\$55,000	500	10	2.819%	1.666%	1.034%	0.721%	0.584%	0.511%	0.502%
\$55,000	600	10	2.441%	1.404%	0.875%	0.638%	0.547%	0.505%	0.501%
\$55,000	700	10	2.137%	1.208%	0.770%	0.591%	0.528%	0.503%	0.501%
\$55,000	800	10	1.907%	1.063%	0.695%	0.560%	0.517%	0.503%	0.501%
\$55,000	900	10	1.726%	0.957%	0.644%	0.539%	0.511%	0.502%	0.501%
\$55,000	1,000	10	1.570%	0.871%	0.607%	0.528%	0.508%	0.502%	0.501%
\$55,000	1,500	10	1.127%	0.661%	0.533%	0.507%	0.503%	0.502%	0.501%
\$55,000	2,000	10	0.882%	0.574%	0.513%	0.505%	0.503%	0.502%	0.501%
\$55,000	3,000	10	0.655%	0.520%	0.506%	0.504%	0.503%	0.502%	0.501%
\$55,000	4,000	10	0.570%	0.509%	0.505%	0.504%	0.503%	0.502%	0.501%
\$55,000	5,000	10	0.533%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$55,000	10,000	10	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$55,000	20,000	10	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$60,000	5	10	55.559%	53.411%	51.333%	49.321%	47.378%	43.677%	40.198%
\$60,000	10	10	38.431%	35.832%	33.349%	30.982%	28.742%	24.649%	21.069%
\$60,000	15	10	29.760%	27.130%	24.706%	22.479%	20.441%	16.865%	13.863%
\$60,000	20	10	25.194%	22.644%	20.320%	18.198%	16.269%	12.929%	10.215%
\$60,000	25	10	22.165%	19.640%	17.357%	15.298%	13.448%	10.328%	7.884%
\$60,000	50	10	14.365%	12.013%	9.985%	8.255%	6.796%	4.565%	3.056%
\$60,000	100	10	9.125%	7.068%	5.429%	4.147%	3.158%	1.854%	1.158%
\$60,000	150	10	6.958%	5.101%	3.709%	2.687%	1.959%	1.105%	0.729%
\$60,000	200	10	5.711%	3.997%	2.773%	1.930%	1.375%	0.793%	0.584%
\$60,000	300	10	4.272%	2.780%	1.805%	1.205%	0.859%	0.576%	0.512%
\$60,000	400	10	3.438%	2.123%	1.335%	0.896%	0.673%	0.528%	0.503%
\$60,000	500	10	2.928%	1.745%	1.084%	0.749%	0.599%	0.514%	0.502%
\$60,000	600	10	2.539%	1.471%	0.914%	0.658%	0.555%	0.506%	0.501%
\$60,000	700	10	2.226%	1.265%	0.800%	0.605%	0.534%	0.504%	0.501%
\$60,000	800	10	1.988%	1.113%	0.720%	0.570%	0.520%	0.503%	0.501%
\$60,000	900	10	1.800%	1.000%	0.663%	0.546%	0.513%	0.502%	0.501%
\$60,000	1,000	10	1.637%	0.908%	0.623%	0.533%	0.509%	0.502%	0.501%
\$60,000	1,500	10	1.175%	0.681%	0.538%	0.508%	0.504%	0.502%	0.501%
\$60,000	2,000	10	0.917%	0.585%	0.515%	0.505%	0.503%	0.502%	0.501%
\$60,000	3,000	10	0.672%	0.524%	0.506%	0.504%	0.503%	0.502%	0.501%
\$60,000	4,000	10	0.579%	0.510%	0.505%	0.504%	0.503%	0.502%	0.501%
\$60,000	5,000	10	0.538%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$60,000	10,000	10	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$60,000	20,000	10	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$65,000	5	10	56.483%	54.372%	52.330%	50.355%	48.448%	44.819%	41.408%
\$65,000	10	10	39.449%	36.907%	34.475%	32.144%	29.916%	25.804%	22.174%
\$65,000	15	10	30.652%	28.014%	25.570%	23.317%	21.247%	17.613%	14.560%
\$65,000	20	10	25.913%	23.356%	21.022%	18.894%	16.953%	13.573%	10.807%
\$65,000	25	10	22.798%	20.273%	17.983%	15.909%	14.041%	10.870%	8.368%
\$65,000	50	10	14.788%	12.425%	10.379%	8.623%	7.138%	4.844%	3.270%
\$65,000	100	10	9.409%	7.331%	5.666%	4.355%	3.338%	1.975%	1.234%
\$65,000	150	10	7.179%	5.299%	3.880%	2.829%	2.072%	1.170%	0.763%
\$65,000	200	10	5.898%	4.158%	2.905%	2.033%	1.452%	0.831%	0.600%
\$65,000	300	10	4.416%	2.898%	1.894%	1.268%	0.900%	0.590%	0.515%
\$65,000	400	10	3.556%	2.214%	1.399%	0.936%	0.696%	0.533%	0.504%
\$65,000	500	10	3.030%	1.820%	1.132%	0.777%	0.613%	0.517%	0.502%
\$65,000	600	10	2.630%	1.535%	0.952%	0.678%	0.564%	0.507%	0.501%
\$65,000	700	10	2.309%	1.320%	0.831%	0.620%	0.540%	0.504%	0.501%
\$65,000	800	10	2.064%	1.160%	0.744%	0.580%	0.524%	0.503%	0.501%
\$65,000	900	10	1.870%	1.041%	0.683%	0.554%	0.515%	0.502%	0.501%
\$65,000	1,000	10	1.701%	0.943%	0.638%	0.538%	0.511%	0.502%	0.501%
\$65,000	1,500	10	1.221%	0.701%	0.544%	0.510%	0.504%	0.502%	0.501%
\$65,000	2,000	10	0.950%	0.596%	0.517%	0.505%	0.503%	0.502%	0.501%
\$65,000	3,000	10	0.690%	0.527%	0.506%	0.504%	0.503%	0.502%	0.501%
\$65,000	4,000	10	0.589%	0.511%	0.505%	0.504%	0.503%	0.502%	0.501%
\$65,000	5,000	10	0.543%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$65,000	10,000	10	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$65,000	20,000	10	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$70,000	5	10	57.285%	55.205%	53.193%	51.253%	49.378%	45.808%	42.460%
\$70,000	10	10	40.346%	37.852%	35.466%	33.180%	30.987%	26.890%	23.221%
\$70,000	15	10	31.490%	28.849%	26.395%	24.121%	22.024%	18.324%	15.216%
\$70,000	20	10	26.593%	24.028%	21.682%	19.544%	17.592%	14.178%	11.367%
\$70,000	25	10	23.386%	20.858%	18.563%	16.478%	14.593%	11.379%	8.826%
\$70,000	50	10	15.181%	12.807%	10.744%	8.967%	7.457%	5.109%	3.477%
\$70,000	100	10	9.673%	7.576%	5.887%	4.552%	3.508%	2.092%	1.309%
\$70,000	150	10	7.385%	5.486%	4.041%	2.964%	2.181%	1.235%	0.797%
\$70,000	200	10	6.073%	4.311%	3.032%	2.133%	1.527%	0.869%	0.616%
\$70,000	300	10	4.551%	3.009%	1.979%	1.328%	0.940%	0.604%	0.519%
\$70,000	400	10	3.666%	2.300%	1.460%	0.975%	0.719%	0.539%	0.505%
\$70,000	500	10	3.125%	1.891%	1.179%	0.804%	0.627%	0.520%	0.503%
\$70,000	600	10	2.716%	1.595%	0.989%	0.697%	0.573%	0.509%	0.501%
\$70,000	700	10	2.387%	1.372%	0.861%	0.634%	0.546%	0.505%	0.501%
\$70,000	800	10	2.134%	1.205%	0.767%	0.590%	0.528%	0.503%	0.501%
\$70,000	900	10	1.935%	1.080%	0.702%	0.561%	0.518%	0.503%	0.501%
\$70,000	1,000	10	1.761%	0.977%	0.653%	0.543%	0.512%	0.502%	0.501%
\$70,000	1,500	10	1.263%	0.719%	0.550%	0.511%	0.504%	0.502%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$70,000	2,000	10	0.981%	0.607%	0.520%	0.505%	0.503%	0.502%	0.501%
\$70,000	3,000	10	0.707%	0.530%	0.507%	0.504%	0.503%	0.502%	0.501%
\$70,000	4,000	10	0.598%	0.512%	0.505%	0.504%	0.503%	0.502%	0.501%
\$70,000	5,000	10	0.548%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$70,000	10,000	10	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$70,000	20,000	10	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$75,000	5	10	57.981%	55.928%	53.945%	52.033%	50.185%	46.668%	43.374%
\$75,000	10	10	41.133%	38.681%	36.335%	34.088%	31.933%	27.890%	24.210%
\$75,000	15	10	32.266%	29.629%	27.170%	24.883%	22.766%	19.009%	15.842%
\$75,000	20	10	27.231%	24.658%	22.299%	20.149%	18.185%	14.744%	11.894%
\$75,000	25	10	23.930%	21.399%	19.098%	17.005%	15.103%	11.856%	9.256%
\$75,000	50	10	15.546%	13.161%	11.084%	9.291%	7.760%	5.360%	3.677%
\$75,000	100	10	9.920%	7.806%	6.097%	4.738%	3.669%	2.206%	1.382%
\$75,000	150	10	7.579%	5.661%	4.193%	3.093%	2.286%	1.298%	0.831%
\$75,000	200	10	6.237%	4.454%	3.151%	2.228%	1.599%	0.907%	0.632%
\$75,000	300	10	4.677%	3.114%	2.060%	1.386%	0.979%	0.618%	0.523%
\$75,000	400	10	3.767%	2.380%	1.517%	1.013%	0.741%	0.545%	0.507%
\$75,000	500	10	3.213%	1.957%	1.224%	0.831%	0.642%	0.523%	0.503%
\$75,000	600	10	2.795%	1.652%	1.025%	0.716%	0.582%	0.510%	0.502%
\$75,000	700	10	2.460%	1.421%	0.889%	0.648%	0.553%	0.506%	0.501%
\$75,000	800	10	2.201%	1.247%	0.789%	0.600%	0.531%	0.504%	0.501%
\$75,000	900	10	1.995%	1.116%	0.720%	0.569%	0.520%	0.503%	0.501%
\$75,000	1,000	10	1.816%	1.009%	0.668%	0.549%	0.514%	0.503%	0.501%
\$75,000	1,500	10	1.303%	0.738%	0.556%	0.512%	0.504%	0.502%	0.501%
\$75,000	2,000	10	1.011%	0.617%	0.522%	0.506%	0.503%	0.502%	0.501%
\$75,000	3,000	10	0.724%	0.534%	0.507%	0.504%	0.503%	0.502%	0.501%
\$75,000	4,000	10	0.607%	0.514%	0.505%	0.504%	0.503%	0.502%	0.501%
\$75,000	5,000	10	0.553%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$75,000	10,000	10	0.508%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$75,000	20,000	10	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$80,000	5	10	58.601%	56.571%	54.615%	52.727%	50.904%	47.433%	44.187%
\$80,000	10	10	41.837%	39.422%	37.111%	34.898%	32.778%	28.802%	25.147%
\$80,000	15	10	32.998%	30.372%	27.913%	25.621%	23.488%	19.686%	16.460%
\$80,000	20	10	27.846%	25.267%	22.898%	20.734%	18.752%	15.286%	12.399%
\$80,000	25	10	24.447%	21.913%	19.604%	17.502%	15.589%	12.309%	9.669%
\$80,000	50	10	15.893%	13.498%	11.409%	9.601%	8.051%	5.605%	3.873%
\$80,000	100	10	10.155%	8.027%	6.298%	4.916%	3.824%	2.317%	1.456%
\$80,000	150	10	7.762%	5.828%	4.339%	3.217%	2.388%	1.361%	0.866%
\$80,000	200	10	6.393%	4.590%	3.265%	2.320%	1.670%	0.945%	0.649%
\$80,000	300	10	4.797%	3.214%	2.138%	1.442%	1.017%	0.633%	0.527%
\$80,000	400	10	3.864%	2.457%	1.573%	1.051%	0.764%	0.552%	0.508%
\$80,000	500	10	3.297%	2.021%	1.267%	0.857%	0.656%	0.527%	0.504%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$80,000	600	10	2.870%	1.707%	1.059%	0.735%	0.591%	0.512%	0.502%
\$80,000	700	10	2.529%	1.468%	0.917%	0.662%	0.559%	0.507%	0.501%
\$80,000	800	10	2.263%	1.287%	0.811%	0.610%	0.535%	0.504%	0.501%
\$80,000	900	10	2.052%	1.152%	0.738%	0.576%	0.523%	0.503%	0.501%
\$80,000	1,000	10	1.868%	1.040%	0.682%	0.554%	0.516%	0.503%	0.501%
\$80,000	1,500	10	1.341%	0.756%	0.562%	0.514%	0.504%	0.502%	0.501%
\$80,000	2,000	10	1.040%	0.628%	0.525%	0.506%	0.503%	0.502%	0.501%
\$80,000	3,000	10	0.740%	0.538%	0.507%	0.504%	0.503%	0.502%	0.501%
\$80,000	4,000	10	0.616%	0.515%	0.505%	0.504%	0.503%	0.502%	0.501%
\$80,000	5,000	10	0.558%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$80,000	10,000	10	0.508%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$80,000	20,000	10	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$90,000	5	10	59.631%	57.644%	55.730%	53.884%	52.101%	48.708%	45.540%
\$90,000	10	10	43.006%	40.650%	38.398%	36.242%	34.180%	30.314%	26.760%
\$90,000	15	10	34.263%	31.684%	29.246%	26.955%	24.809%	20.953%	17.637%
\$90,000	20	10	28.964%	26.385%	24.003%	21.809%	19.793%	16.273%	13.319%
\$90,000	25	10	25.381%	22.838%	20.513%	18.391%	16.463%	13.133%	10.430%
\$90,000	50	10	16.524%	14.115%	12.009%	10.179%	8.594%	6.072%	4.256%
\$90,000	100	10	10.587%	8.432%	6.672%	5.251%	4.118%	2.532%	1.602%
\$90,000	150	10	8.101%	6.135%	4.611%	3.449%	2.580%	1.480%	0.934%
\$90,000	200	10	6.678%	4.844%	3.479%	2.495%	1.806%	1.019%	0.684%
\$90,000	300	10	5.018%	3.399%	2.283%	1.549%	1.091%	0.663%	0.537%
\$90,000	400	10	4.043%	2.601%	1.678%	1.122%	0.808%	0.564%	0.511%
\$90,000	500	10	3.452%	2.140%	1.349%	0.908%	0.684%	0.534%	0.505%
\$90,000	600	10	3.008%	1.808%	1.125%	0.772%	0.610%	0.515%	0.502%
\$90,000	700	10	2.655%	1.556%	0.971%	0.690%	0.572%	0.509%	0.501%
\$90,000	800	10	2.377%	1.363%	0.854%	0.630%	0.544%	0.505%	0.501%
\$90,000	900	10	2.157%	1.219%	0.773%	0.591%	0.528%	0.503%	0.501%
\$90,000	1,000	10	1.965%	1.098%	0.710%	0.565%	0.519%	0.503%	0.501%
\$90,000	1,500	10	1.412%	0.790%	0.575%	0.517%	0.505%	0.502%	0.501%
\$90,000	2,000	10	1.094%	0.648%	0.530%	0.507%	0.503%	0.502%	0.501%
\$90,000	3,000	10	0.770%	0.545%	0.509%	0.504%	0.503%	0.502%	0.501%
\$90,000	4,000	10	0.634%	0.517%	0.506%	0.504%	0.503%	0.502%	0.501%
\$90,000	5,000	10	0.568%	0.509%	0.505%	0.504%	0.503%	0.502%	0.501%
\$90,000	10,000	10	0.508%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$90,000	20,000	10	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$100,000	5	10	60.474%	58.523%	56.643%	54.830%	53.079%	49.753%	46.645%
\$100,000	10	10	43.952%	41.645%	39.439%	37.331%	35.316%	31.541%	28.071%
\$100,000	15	10	35.313%	32.793%	30.406%	28.142%	26.006%	22.127%	18.765%
\$100,000	20	10	29.973%	27.405%	25.025%	22.813%	20.775%	17.188%	14.176%
\$100,000	25	10	26.236%	23.685%	21.342%	19.203%	17.255%	13.889%	11.132%
\$100,000	50	10	17.098%	14.683%	12.563%	10.714%	9.102%	6.513%	4.630%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$100,000	100	10	10.984%	8.807%	7.019%	5.566%	4.399%	2.742%	1.749%
\$100,000	150	10	8.413%	6.421%	4.866%	3.670%	2.764%	1.601%	1.004%
\$100,000	200	10	6.942%	5.081%	3.683%	2.662%	1.938%	1.094%	0.721%
\$100,000	300	10	5.221%	3.571%	2.420%	1.654%	1.164%	0.694%	0.548%
\$100,000	400	10	4.202%	2.730%	1.775%	1.188%	0.850%	0.576%	0.513%
\$100,000	500	10	3.595%	2.251%	1.428%	0.958%	0.712%	0.541%	0.507%
\$100,000	600	10	3.136%	1.903%	1.188%	0.810%	0.629%	0.520%	0.503%
\$100,000	700	10	2.772%	1.640%	1.022%	0.718%	0.585%	0.511%	0.502%
\$100,000	800	10	2.483%	1.436%	0.896%	0.651%	0.553%	0.506%	0.501%
\$100,000	900	10	2.255%	1.282%	0.807%	0.607%	0.534%	0.504%	0.501%
\$100,000	1,000	10	2.054%	1.154%	0.738%	0.576%	0.524%	0.503%	0.501%
\$100,000	1,500	10	1.477%	0.823%	0.587%	0.520%	0.506%	0.502%	0.501%
\$100,000	2,000	10	1.144%	0.669%	0.536%	0.508%	0.503%	0.502%	0.501%
\$100,000	3,000	10	0.800%	0.552%	0.510%	0.504%	0.503%	0.502%	0.501%
\$100,000	4,000	10	0.651%	0.520%	0.506%	0.504%	0.503%	0.502%	0.501%
\$100,000	5,000	10	0.579%	0.510%	0.505%	0.504%	0.503%	0.502%	0.501%
\$100,000	10,000	10	0.508%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$100,000	20,000	10	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$110,000	5	10	61.210%	59.290%	57.440%	55.657%	53.933%	50.665%	47.608%
\$110,000	10	10	44.773%	42.508%	40.343%	38.277%	36.302%	32.603%	29.206%
\$110,000	15	10	36.234%	33.769%	31.434%	29.217%	27.119%	23.260%	19.869%
\$110,000	20	10	30.916%	28.370%	25.996%	23.786%	21.738%	18.095%	15.016%
\$110,000	25	10	27.055%	24.501%	22.146%	19.990%	18.024%	14.617%	11.810%
\$110,000	50	10	17.633%	15.217%	13.086%	11.216%	9.582%	6.937%	4.987%
\$110,000	100	10	11.356%	9.163%	7.350%	5.866%	4.669%	2.948%	1.896%
\$110,000	150	10	8.709%	6.694%	5.111%	3.886%	2.947%	1.724%	1.080%
\$110,000	200	10	7.192%	5.307%	3.880%	2.826%	2.070%	1.172%	0.762%
\$110,000	300	10	5.413%	3.735%	2.554%	1.756%	1.238%	0.726%	0.560%
\$110,000	400	10	4.360%	2.859%	1.873%	1.257%	0.895%	0.591%	0.517%
\$110,000	500	10	3.730%	2.357%	1.505%	1.008%	0.742%	0.549%	0.509%
\$110,000	600	10	3.257%	1.994%	1.250%	0.847%	0.649%	0.524%	0.503%
\$110,000	700	10	2.882%	1.719%	1.073%	0.746%	0.599%	0.514%	0.502%
\$110,000	800	10	2.583%	1.505%	0.938%	0.672%	0.563%	0.507%	0.501%
\$110,000	900	10	2.346%	1.343%	0.841%	0.623%	0.540%	0.505%	0.501%
\$110,000	1,000	10	2.138%	1.207%	0.766%	0.588%	0.528%	0.504%	0.501%
\$110,000	1,500	10	1.540%	0.855%	0.600%	0.524%	0.507%	0.502%	0.501%
\$110,000	2,000	10	1.192%	0.689%	0.542%	0.509%	0.504%	0.502%	0.501%
\$110,000	3,000	10	0.829%	0.560%	0.511%	0.504%	0.503%	0.502%	0.501%
\$110,000	4,000	10	0.669%	0.523%	0.506%	0.504%	0.503%	0.502%	0.501%
\$110,000	5,000	10	0.589%	0.511%	0.505%	0.504%	0.503%	0.502%	0.501%
\$110,000	10,000	10	0.509%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$110,000	20,000	10	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$120,000	5	10	61.846%	59.951%	58.127%	56.367%	54.668%	51.451%	48.436%
\$120,000	10	10	45.497%	43.267%	41.138%	39.108%	37.167%	33.535%	30.200%
\$120,000	15	10	37.048%	34.630%	32.339%	30.169%	28.114%	24.322%	20.930%
\$120,000	20	10	31.782%	29.270%	26.911%	24.708%	22.660%	18.986%	15.842%
\$120,000	25	10	27.834%	25.286%	22.928%	20.759%	18.778%	15.325%	12.468%
\$120,000	50	10	18.140%	15.724%	13.584%	11.696%	10.042%	7.348%	5.335%
\$120,000	100	10	11.709%	9.505%	7.668%	6.158%	4.931%	3.152%	2.045%
\$120,000	150	10	8.990%	6.957%	5.348%	4.093%	3.126%	1.846%	1.155%
\$120,000	200	10	7.428%	5.523%	4.069%	2.986%	2.199%	1.250%	0.804%
\$120,000	300	10	5.593%	3.892%	2.682%	1.855%	1.310%	0.760%	0.573%
\$120,000	400	10	4.507%	2.982%	1.968%	1.325%	0.939%	0.607%	0.522%
\$120,000	500	10	3.858%	2.459%	1.578%	1.057%	0.772%	0.557%	0.511%
\$120,000	600	10	3.371%	2.081%	1.311%	0.884%	0.669%	0.529%	0.504%
\$120,000	700	10	2.986%	1.796%	1.122%	0.774%	0.613%	0.517%	0.502%
\$120,000	800	10	2.679%	1.573%	0.980%	0.694%	0.572%	0.509%	0.501%
\$120,000	900	10	2.433%	1.402%	0.875%	0.639%	0.547%	0.505%	0.501%
\$120,000	1,000	10	2.217%	1.259%	0.794%	0.601%	0.533%	0.504%	0.501%
\$120,000	1,500	10	1.600%	0.887%	0.613%	0.528%	0.507%	0.502%	0.501%
\$120,000	2,000	10	1.238%	0.709%	0.548%	0.511%	0.504%	0.502%	0.501%
\$120,000	3,000	10	0.858%	0.568%	0.512%	0.505%	0.503%	0.502%	0.501%
\$120,000	4,000	10	0.686%	0.527%	0.506%	0.504%	0.503%	0.502%	0.501%
\$120,000	5,000	10	0.600%	0.513%	0.505%	0.504%	0.503%	0.502%	0.501%
\$120,000	10,000	10	0.509%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$120,000	20,000	10	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$130,000	5	10	62.397%	60.525%	58.723%	56.985%	55.307%	52.132%	49.155%
\$130,000	10	10	46.138%	43.940%	41.843%	39.843%	37.933%	34.359%	31.080%
\$130,000	15	10	37.768%	35.392%	33.141%	31.011%	28.994%	25.278%	21.932%
\$130,000	20	10	32.563%	30.092%	27.761%	25.575%	23.531%	19.849%	16.663%
\$130,000	25	10	28.565%	26.030%	23.677%	21.506%	19.512%	16.016%	13.109%
\$130,000	50	10	18.624%	16.206%	14.058%	12.156%	10.484%	7.746%	5.678%
\$130,000	100	10	12.044%	9.829%	7.971%	6.438%	5.182%	3.349%	2.187%
\$130,000	150	10	9.254%	7.206%	5.573%	4.291%	3.297%	1.964%	1.230%
\$130,000	200	10	7.650%	5.727%	4.248%	3.139%	2.324%	1.328%	0.848%
\$130,000	300	10	5.763%	4.040%	2.804%	1.951%	1.383%	0.795%	0.586%
\$130,000	400	10	4.647%	3.098%	2.058%	1.390%	0.984%	0.624%	0.527%
\$130,000	500	10	3.974%	2.551%	1.646%	1.102%	0.799%	0.564%	0.512%
\$130,000	600	10	3.480%	2.165%	1.370%	0.922%	0.691%	0.534%	0.505%
\$130,000	700	10	3.086%	1.870%	1.171%	0.804%	0.628%	0.520%	0.503%
\$130,000	800	10	2.772%	1.640%	1.021%	0.716%	0.583%	0.510%	0.501%
\$130,000	900	10	2.516%	1.460%	0.909%	0.656%	0.554%	0.506%	0.501%
\$130,000	1,000	10	2.294%	1.310%	0.823%	0.614%	0.538%	0.505%	0.501%
\$130,000	1,500	10	1.658%	0.919%	0.627%	0.533%	0.508%	0.502%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$130,000	2,000	10	1.284%	0.730%	0.554%	0.512%	0.504%	0.502%	0.501%
\$130,000	3,000	10	0.886%	0.577%	0.514%	0.505%	0.503%	0.502%	0.501%
\$130,000	4,000	10	0.704%	0.530%	0.507%	0.504%	0.503%	0.502%	0.501%
\$130,000	5,000	10	0.610%	0.514%	0.505%	0.504%	0.503%	0.502%	0.501%
\$130,000	10,000	10	0.510%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$130,000	20,000	10	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$140,000	5	10	62.879%	61.027%	59.244%	57.523%	55.866%	52.725%	49.782%
\$140,000	10	10	46.690%	44.519%	42.450%	40.477%	38.592%	35.068%	31.837%
\$140,000	15	10	38.391%	36.050%	33.833%	31.738%	29.754%	26.103%	22.812%
\$140,000	20	10	33.234%	30.802%	28.508%	26.349%	24.318%	20.636%	17.435%
\$140,000	25	10	29.217%	26.699%	24.359%	22.193%	20.195%	16.665%	13.711%
\$140,000	50	10	19.063%	16.646%	14.491%	12.577%	10.892%	8.114%	6.002%
\$140,000	100	10	12.355%	10.129%	8.254%	6.697%	5.418%	3.534%	2.322%
\$140,000	150	10	9.497%	7.435%	5.781%	4.475%	3.456%	2.076%	1.302%
\$140,000	200	10	7.853%	5.913%	4.413%	3.281%	2.442%	1.402%	0.890%
\$140,000	300	10	5.917%	4.175%	2.917%	2.041%	1.451%	0.829%	0.601%
\$140,000	400	10	4.775%	3.206%	2.142%	1.453%	1.028%	0.641%	0.532%
\$140,000	500	10	4.085%	2.641%	1.713%	1.149%	0.829%	0.573%	0.514%
\$140,000	600	10	3.579%	2.243%	1.426%	0.958%	0.712%	0.539%	0.506%
\$140,000	700	10	3.176%	1.938%	1.217%	0.831%	0.643%	0.523%	0.503%
\$140,000	800	10	2.856%	1.701%	1.060%	0.737%	0.593%	0.512%	0.502%
\$140,000	900	10	2.592%	1.513%	0.940%	0.672%	0.561%	0.507%	0.501%
\$140,000	1,000	10	2.365%	1.358%	0.850%	0.627%	0.542%	0.505%	0.501%
\$140,000	1,500	10	1.712%	0.949%	0.640%	0.537%	0.510%	0.502%	0.501%
\$140,000	2,000	10	1.326%	0.749%	0.561%	0.514%	0.504%	0.502%	0.501%
\$140,000	3,000	10	0.913%	0.585%	0.516%	0.505%	0.503%	0.502%	0.501%
\$140,000	4,000	10	0.721%	0.533%	0.507%	0.504%	0.503%	0.502%	0.501%
\$140,000	5,000	10	0.621%	0.515%	0.505%	0.504%	0.503%	0.502%	0.501%
\$140,000	10,000	10	0.510%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$140,000	20,000	10	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$150,000	5	10	63.285%	61.450%	59.682%	57.978%	56.337%	53.226%	50.310%
\$150,000	10	10	47.155%	45.008%	42.962%	41.012%	39.149%	35.667%	32.478%
\$150,000	15	10	38.922%	36.610%	34.423%	32.357%	30.402%	26.804%	23.562%
\$150,000	20	10	33.810%	31.410%	29.149%	27.021%	25.015%	21.350%	18.142%
\$150,000	25	10	29.789%	27.294%	24.969%	22.812%	20.817%	17.269%	14.274%
\$150,000	50	10	19.462%	17.046%	14.885%	12.963%	11.265%	8.453%	6.303%
\$150,000	100	10	12.637%	10.402%	8.514%	6.937%	5.635%	3.705%	2.449%
\$150,000	150	10	9.716%	7.643%	5.970%	4.644%	3.603%	2.181%	1.370%
\$150,000	200	10	8.036%	6.082%	4.564%	3.411%	2.552%	1.471%	0.930%
\$150,000	300	10	6.058%	4.300%	3.022%	2.124%	1.515%	0.862%	0.615%
\$150,000	400	10	4.891%	3.305%	2.221%	1.512%	1.069%	0.658%	0.537%
\$150,000	500	10	4.186%	2.724%	1.775%	1.193%	0.858%	0.582%	0.516%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$150,000	600	10	3.669%	2.314%	1.477%	0.992%	0.733%	0.544%	0.507%
\$150,000	700	10	3.259%	2.002%	1.260%	0.858%	0.657%	0.526%	0.504%
\$150,000	800	10	2.932%	1.757%	1.096%	0.758%	0.603%	0.514%	0.502%
\$150,000	900	10	2.662%	1.562%	0.970%	0.688%	0.568%	0.508%	0.501%
\$150,000	1,000	10	2.430%	1.402%	0.876%	0.639%	0.547%	0.506%	0.501%
\$150,000	1,500	10	1.761%	0.977%	0.652%	0.541%	0.511%	0.502%	0.501%
\$150,000	2,000	10	1.366%	0.768%	0.568%	0.516%	0.505%	0.502%	0.501%
\$150,000	3,000	10	0.938%	0.594%	0.517%	0.505%	0.503%	0.502%	0.501%
\$150,000	4,000	10	0.736%	0.537%	0.507%	0.504%	0.503%	0.502%	0.501%
\$150,000	5,000	10	0.631%	0.517%	0.505%	0.504%	0.503%	0.502%	0.501%
\$150,000	10,000	10	0.511%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$150,000	20,000	10	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$160,000	5	10	63.643%	61.823%	60.069%	58.379%	56.753%	53.668%	50.777%
\$160,000	10	10	47.569%	45.442%	43.418%	41.487%	39.645%	36.200%	33.048%
\$160,000	15	10	39.400%	37.115%	34.955%	32.915%	30.986%	27.437%	24.237%
\$160,000	20	10	34.331%	31.960%	29.730%	27.630%	25.652%	22.023%	18.815%
\$160,000	25	10	30.317%	27.850%	25.546%	23.402%	21.412%	17.858%	14.830%
\$160,000	50	10	19.846%	17.430%	15.263%	13.335%	11.625%	8.782%	6.596%
\$160,000	100	10	12.909%	10.667%	8.765%	7.171%	5.848%	3.878%	2.578%
\$160,000	150	10	9.927%	7.844%	6.154%	4.809%	3.747%	2.284%	1.438%
\$160,000	200	10	8.213%	6.246%	4.712%	3.539%	2.661%	1.541%	0.971%
\$160,000	300	10	6.196%	4.422%	3.126%	2.207%	1.579%	0.896%	0.630%
\$160,000	400	10	5.004%	3.402%	2.298%	1.570%	1.111%	0.676%	0.543%
\$160,000	500	10	4.282%	2.804%	1.836%	1.237%	0.886%	0.591%	0.519%
\$160,000	600	10	3.756%	2.382%	1.528%	1.026%	0.753%	0.550%	0.508%
\$160,000	700	10	3.338%	2.063%	1.303%	0.884%	0.672%	0.530%	0.504%
\$160,000	800	10	3.005%	1.811%	1.132%	0.779%	0.614%	0.516%	0.502%
\$160,000	900	10	2.728%	1.609%	1.000%	0.704%	0.575%	0.509%	0.501%
\$160,000	1,000	10	2.492%	1.445%	0.901%	0.652%	0.552%	0.506%	0.501%
\$160,000	1,500	10	1.808%	1.005%	0.665%	0.546%	0.512%	0.502%	0.501%
\$160,000	2,000	10	1.404%	0.787%	0.574%	0.517%	0.505%	0.502%	0.501%
\$160,000	3,000	10	0.962%	0.602%	0.519%	0.505%	0.503%	0.502%	0.501%
\$160,000	4,000	10	0.752%	0.541%	0.508%	0.504%	0.503%	0.502%	0.501%
\$160,000	5,000	10	0.641%	0.518%	0.506%	0.504%	0.503%	0.502%	0.501%
\$160,000	10,000	10	0.511%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$160,000	20,000	10	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$170,000	5	10	63.952%	62.144%	60.403%	58.725%	57.113%	54.051%	51.181%
\$170,000	10	10	47.931%	45.823%	43.818%	41.904%	40.080%	36.668%	33.550%
\$170,000	15	10	39.826%	37.564%	35.429%	33.411%	31.506%	28.001%	24.838%
\$170,000	20	10	34.803%	32.459%	30.255%	28.182%	26.229%	22.646%	19.454%
\$170,000	25	10	30.801%	28.363%	26.084%	23.958%	21.976%	18.426%	15.379%
\$170,000	50	10	20.214%	17.798%	15.626%	13.690%	11.972%	9.097%	6.879%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$170,000	100	10	13.169%	10.919%	9.006%	7.398%	6.054%	4.047%	2.707%
\$170,000	150	10	10.130%	8.036%	6.332%	4.968%	3.887%	2.385%	1.506%
\$170,000	200	10	8.383%	6.404%	4.854%	3.664%	2.766%	1.610%	1.013%
\$170,000	300	10	6.327%	4.539%	3.225%	2.288%	1.641%	0.929%	0.646%
\$170,000	400	10	5.112%	3.494%	2.372%	1.626%	1.151%	0.693%	0.549%
\$170,000	500	10	4.374%	2.880%	1.895%	1.280%	0.915%	0.601%	0.521%
\$170,000	600	10	3.838%	2.449%	1.577%	1.060%	0.774%	0.556%	0.509%
\$170,000	700	10	3.415%	2.122%	1.344%	0.910%	0.687%	0.533%	0.505%
\$170,000	800	10	3.075%	1.864%	1.167%	0.800%	0.624%	0.518%	0.502%
\$170,000	900	10	2.792%	1.655%	1.029%	0.720%	0.582%	0.510%	0.501%
\$170,000	1,000	10	2.551%	1.487%	0.927%	0.665%	0.558%	0.507%	0.501%
\$170,000	1,500	10	1.852%	1.031%	0.677%	0.551%	0.514%	0.502%	0.501%
\$170,000	2,000	10	1.441%	0.805%	0.581%	0.519%	0.505%	0.502%	0.501%
\$170,000	3,000	10	0.986%	0.610%	0.521%	0.506%	0.503%	0.502%	0.501%
\$170,000	4,000	10	0.768%	0.544%	0.508%	0.504%	0.503%	0.502%	0.501%
\$170,000	5,000	10	0.651%	0.520%	0.506%	0.504%	0.503%	0.502%	0.501%
\$170,000	10,000	10	0.512%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$170,000	20,000	10	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$180,000	5	10	64.219%	62.423%	60.692%	59.027%	57.425%	54.383%	51.533%
\$180,000	10	10	48.253%	46.163%	44.174%	42.276%	40.468%	37.085%	33.998%
\$180,000	15	10	40.206%	37.966%	35.852%	33.856%	31.972%	28.504%	25.375%
\$180,000	20	10	35.226%	32.906%	30.727%	28.677%	26.746%	23.205%	20.047%
\$180,000	25	10	31.236%	28.826%	26.574%	24.469%	22.501%	18.960%	15.904%
\$180,000	50	10	20.564%	18.150%	15.973%	14.030%	12.303%	9.403%	7.152%
\$180,000	100	10	13.416%	11.158%	9.236%	7.613%	6.253%	4.208%	2.832%
\$180,000	150	10	10.322%	8.219%	6.502%	5.121%	4.022%	2.482%	1.573%
\$180,000	200	10	8.545%	6.555%	4.991%	3.784%	2.868%	1.678%	1.053%
\$180,000	300	10	6.450%	4.649%	3.320%	2.365%	1.701%	0.962%	0.662%
\$180,000	400	10	5.214%	3.582%	2.443%	1.680%	1.191%	0.710%	0.555%
\$180,000	500	10	4.462%	2.953%	1.951%	1.321%	0.943%	0.611%	0.524%
\$180,000	600	10	3.917%	2.513%	1.625%	1.093%	0.795%	0.562%	0.511%
\$180,000	700	10	3.487%	2.178%	1.384%	0.936%	0.702%	0.537%	0.505%
\$180,000	800	10	3.142%	1.914%	1.201%	0.821%	0.635%	0.521%	0.502%
\$180,000	900	10	2.852%	1.699%	1.057%	0.735%	0.590%	0.512%	0.501%
\$180,000	1,000	10	2.608%	1.527%	0.951%	0.677%	0.563%	0.508%	0.501%
\$180,000	1,500	10	1.895%	1.057%	0.690%	0.556%	0.515%	0.503%	0.501%
\$180,000	2,000	10	1.476%	0.823%	0.588%	0.521%	0.506%	0.502%	0.501%
\$180,000	3,000	10	1.009%	0.618%	0.523%	0.506%	0.503%	0.502%	0.501%
\$180,000	4,000	10	0.783%	0.548%	0.509%	0.504%	0.503%	0.502%	0.501%
\$180,000	5,000	10	0.660%	0.521%	0.506%	0.504%	0.503%	0.502%	0.501%
\$180,000	10,000	10	0.513%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$180,000	20,000	10	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$190,000	5	10	64.445%	62.659%	60.938%	59.282%	57.690%	54.664%	51.832%
\$190,000	10	10	48.527%	46.451%	44.475%	42.592%	40.796%	37.439%	34.378%
\$190,000	15	10	40.533%	38.311%	36.216%	34.238%	32.372%	28.937%	25.837%
\$190,000	20	10	35.590%	33.292%	31.134%	29.103%	27.191%	23.687%	20.562%
\$190,000	25	10	31.610%	29.225%	26.996%	24.913%	22.962%	19.437%	16.380%
\$190,000	50	10	20.884%	18.470%	16.292%	14.343%	12.606%	9.683%	7.403%
\$190,000	100	10	13.643%	11.379%	9.447%	7.811%	6.437%	4.359%	2.949%
\$190,000	150	10	10.500%	8.388%	6.660%	5.262%	4.149%	2.575%	1.637%
\$190,000	200	10	8.691%	6.693%	5.115%	3.893%	2.960%	1.742%	1.092%
\$190,000	300	10	6.564%	4.751%	3.408%	2.437%	1.759%	0.994%	0.677%
\$190,000	400	10	5.307%	3.663%	2.509%	1.731%	1.229%	0.727%	0.562%
\$190,000	500	10	4.542%	3.020%	2.003%	1.360%	0.969%	0.621%	0.527%
\$190,000	600	10	3.982%	2.566%	1.664%	1.120%	0.812%	0.566%	0.511%
\$190,000	700	10	3.553%	2.230%	1.421%	0.960%	0.716%	0.541%	0.506%
\$190,000	800	10	3.204%	1.961%	1.233%	0.840%	0.646%	0.523%	0.503%
\$190,000	900	10	2.908%	1.740%	1.083%	0.750%	0.597%	0.513%	0.501%
\$190,000	1,000	10	2.660%	1.564%	0.974%	0.689%	0.569%	0.509%	0.501%
\$190,000	1,500	10	1.935%	1.082%	0.702%	0.561%	0.517%	0.503%	0.501%
\$190,000	2,000	10	1.509%	0.840%	0.595%	0.523%	0.506%	0.502%	0.501%
\$190,000	3,000	10	1.030%	0.626%	0.525%	0.506%	0.503%	0.502%	0.501%
\$190,000	4,000	10	0.797%	0.552%	0.509%	0.504%	0.503%	0.502%	0.501%
\$190,000	5,000	10	0.670%	0.523%	0.506%	0.504%	0.503%	0.502%	0.501%
\$190,000	10,000	10	0.513%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$190,000	20,000	10	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$200,000	5	10	64.639%	62.861%	61.148%	59.501%	57.917%	54.905%	52.089%
\$200,000	10	10	48.761%	46.698%	44.734%	42.863%	41.078%	37.743%	34.705%
\$200,000	15	10	40.815%	38.609%	36.530%	34.567%	32.716%	29.310%	26.236%
\$200,000	20	10	35.906%	33.627%	31.486%	29.473%	27.577%	24.104%	21.010%
\$200,000	25	10	31.934%	29.570%	27.361%	25.298%	23.366%	19.864%	16.811%
\$200,000	50	10	21.175%	18.763%	16.585%	14.631%	12.885%	9.942%	7.635%
\$200,000	100	10	13.850%	11.581%	9.642%	7.994%	6.608%	4.501%	3.060%
\$200,000	150	10	10.663%	8.544%	6.805%	5.394%	4.266%	2.662%	1.697%
\$200,000	200	10	8.825%	6.819%	5.230%	3.993%	3.047%	1.802%	1.129%
\$200,000	300	10	6.668%	4.844%	3.489%	2.504%	1.812%	1.023%	0.693%
\$200,000	400	10	5.393%	3.738%	2.570%	1.778%	1.264%	0.744%	0.568%
\$200,000	500	10	4.615%	3.082%	2.052%	1.395%	0.994%	0.631%	0.530%
\$200,000	600	10	4.049%	2.621%	1.705%	1.149%	0.831%	0.573%	0.513%
\$200,000	700	10	3.614%	2.279%	1.456%	0.983%	0.730%	0.545%	0.506%
\$200,000	800	10	3.260%	2.004%	1.262%	0.858%	0.656%	0.525%	0.503%
\$200,000	900	10	2.959%	1.777%	1.108%	0.765%	0.604%	0.514%	0.502%
\$200,000	1,000	10	2.707%	1.598%	0.995%	0.701%	0.574%	0.510%	0.501%
\$200,000	1,500	10	1.971%	1.104%	0.714%	0.565%	0.518%	0.503%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$200,000	2,000	10	1.539%	0.856%	0.601%	0.525%	0.507%	0.502%	0.501%
\$200,000	3,000	10	1.050%	0.633%	0.527%	0.507%	0.503%	0.502%	0.501%
\$200,000	4,000	10	0.810%	0.555%	0.510%	0.504%	0.503%	0.502%	0.501%
\$200,000	5,000	10	0.678%	0.525%	0.506%	0.504%	0.503%	0.502%	0.501%
\$200,000	10,000	10	0.514%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$200,000	20,000	10	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$225,000	5	10	65.066%	63.305%	61.610%	59.982%	58.415%	55.435%	52.650%
\$225,000	10	10	49.264%	47.228%	45.290%	43.445%	41.684%	38.397%	35.407%
\$225,000	15	10	41.414%	39.244%	37.198%	35.269%	33.451%	30.103%	27.084%
\$225,000	20	10	36.586%	34.346%	32.244%	30.268%	28.406%	25.001%	21.970%
\$225,000	25	10	32.632%	30.311%	28.146%	26.123%	24.231%	20.800%	17.786%
\$225,000	50	10	21.849%	19.445%	17.268%	15.308%	13.546%	10.557%	8.189%
\$225,000	100	10	14.330%	12.055%	10.096%	8.424%	7.012%	4.836%	3.328%
\$225,000	150	10	11.044%	8.908%	7.146%	5.707%	4.544%	2.873%	1.846%
\$225,000	200	10	9.136%	7.113%	5.500%	4.233%	3.255%	1.946%	1.223%
\$225,000	300	10	6.909%	5.063%	3.679%	2.663%	1.940%	1.096%	0.731%
\$225,000	400	10	5.591%	3.912%	2.714%	1.890%	1.347%	0.785%	0.583%
\$225,000	500	10	4.785%	3.226%	2.166%	1.479%	1.053%	0.655%	0.537%
\$225,000	600	10	4.202%	2.748%	1.801%	1.218%	0.876%	0.588%	0.517%
\$225,000	700	10	3.756%	2.390%	1.537%	1.037%	0.763%	0.555%	0.509%
\$225,000	800	10	3.389%	2.103%	1.331%	0.902%	0.681%	0.531%	0.504%
\$225,000	900	10	3.077%	1.865%	1.166%	0.798%	0.622%	0.517%	0.502%
\$225,000	1,000	10	2.816%	1.677%	1.046%	0.729%	0.588%	0.512%	0.502%
\$225,000	1,500	10	2.055%	1.157%	0.741%	0.577%	0.522%	0.503%	0.501%
\$225,000	2,000	10	1.608%	0.893%	0.616%	0.530%	0.508%	0.502%	0.501%
\$225,000	3,000	10	1.096%	0.651%	0.532%	0.508%	0.503%	0.502%	0.501%
\$225,000	4,000	10	0.842%	0.564%	0.511%	0.504%	0.503%	0.502%	0.501%
\$225,000	5,000	10	0.700%	0.529%	0.507%	0.504%	0.503%	0.502%	0.501%
\$225,000	10,000	10	0.516%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$225,000	20,000	10	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$250,000	5	10	65.442%	63.696%	62.016%	60.404%	58.850%	55.897%	53.141%
\$250,000	10	10	49.719%	47.706%	45.789%	43.966%	42.225%	38.979%	36.030%
\$250,000	15	10	41.934%	39.793%	37.776%	35.875%	34.084%	30.784%	27.811%
\$250,000	20	10	37.174%	34.967%	32.897%	30.951%	29.119%	25.768%	22.789%
\$250,000	25	10	33.238%	30.954%	28.825%	26.836%	24.977%	21.608%	18.650%
\$250,000	50	10	22.465%	20.079%	17.911%	15.951%	14.181%	11.154%	8.735%
\$250,000	100	10	14.785%	12.502%	10.529%	8.837%	7.399%	5.161%	3.594%
\$250,000	150	10	11.401%	9.255%	7.473%	6.006%	4.816%	3.083%	1.997%
\$250,000	200	10	9.434%	7.398%	5.761%	4.467%	3.460%	2.093%	1.320%
\$250,000	300	10	7.136%	5.272%	3.862%	2.818%	2.066%	1.171%	0.772%
\$250,000	400	10	5.777%	4.076%	2.851%	1.998%	1.429%	0.826%	0.600%
\$250,000	500	10	4.944%	3.362%	2.274%	1.560%	1.111%	0.679%	0.544%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$250,000	600	10	4.343%	2.866%	1.893%	1.283%	0.920%	0.605%	0.521%
\$250,000	700	10	3.879%	2.488%	1.609%	1.086%	0.793%	0.563%	0.510%
\$250,000	800	10	3.508%	2.195%	1.396%	0.944%	0.706%	0.538%	0.505%
\$250,000	900	10	3.185%	1.947%	1.222%	0.831%	0.640%	0.521%	0.502%
\$250,000	1,000	10	2.917%	1.750%	1.093%	0.757%	0.601%	0.514%	0.502%
\$250,000	1,500	10	2.132%	1.207%	0.768%	0.589%	0.527%	0.503%	0.501%
\$250,000	2,000	10	1.673%	0.929%	0.632%	0.535%	0.509%	0.502%	0.501%
\$250,000	3,000	10	1.140%	0.669%	0.537%	0.509%	0.503%	0.502%	0.501%
\$250,000	4,000	10	0.872%	0.573%	0.513%	0.505%	0.503%	0.502%	0.501%
\$250,000	5,000	10	0.721%	0.533%	0.507%	0.504%	0.503%	0.502%	0.501%
\$250,000	10,000	10	0.518%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$250,000	20,000	10	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$275,000	5	10	65.761%	64.027%	62.362%	60.763%	59.220%	56.291%	53.559%
\$275,000	10	10	50.100%	48.106%	46.209%	44.403%	42.680%	39.469%	36.555%
\$275,000	15	10	42.375%	40.260%	38.267%	36.391%	34.622%	31.363%	28.431%
\$275,000	20	10	37.681%	35.504%	33.460%	31.541%	29.734%	26.431%	23.495%
\$275,000	25	10	33.758%	31.506%	29.408%	27.448%	25.618%	22.302%	19.395%
\$275,000	50	10	23.021%	20.660%	18.510%	16.557%	14.785%	11.734%	9.270%
\$275,000	100	10	15.215%	12.928%	10.942%	9.234%	7.775%	5.480%	3.857%
\$275,000	150	10	11.742%	9.587%	7.786%	6.295%	5.079%	3.292%	2.149%
\$275,000	200	10	9.719%	7.672%	6.015%	4.696%	3.661%	2.242%	1.418%
\$275,000	300	10	7.354%	5.475%	4.041%	2.971%	2.192%	1.247%	0.814%
\$275,000	400	10	5.957%	4.236%	2.987%	2.107%	1.512%	0.869%	0.618%
\$275,000	500	10	5.098%	3.494%	2.381%	1.642%	1.169%	0.705%	0.553%
\$275,000	600	10	4.482%	2.983%	1.984%	1.350%	0.966%	0.622%	0.526%
\$275,000	700	10	4.006%	2.591%	1.685%	1.139%	0.827%	0.574%	0.513%
\$275,000	800	10	3.624%	2.286%	1.462%	0.986%	0.732%	0.544%	0.507%
\$275,000	900	10	3.291%	2.027%	1.277%	0.865%	0.659%	0.525%	0.503%
\$275,000	1,000	10	3.014%	1.823%	1.141%	0.786%	0.617%	0.517%	0.502%
\$275,000	1,500	10	2.206%	1.255%	0.795%	0.602%	0.532%	0.504%	0.501%
\$275,000	2,000	10	1.735%	0.965%	0.648%	0.541%	0.511%	0.502%	0.501%
\$275,000	3,000	10	1.182%	0.687%	0.542%	0.510%	0.504%	0.502%	0.501%
\$275,000	4,000	10	0.902%	0.582%	0.514%	0.505%	0.503%	0.502%	0.501%
\$275,000	5,000	10	0.742%	0.538%	0.508%	0.504%	0.503%	0.502%	0.501%
\$275,000	10,000	10	0.520%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$275,000	20,000	10	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$300,000	5	10	66.028%	64.305%	62.651%	61.063%	59.530%	56.619%	53.908%
\$300,000	10	10	50.400%	48.421%	46.539%	44.747%	43.038%	39.856%	36.968%
\$300,000	15	10	42.717%	40.621%	38.648%	36.791%	35.040%	31.812%	28.913%
\$300,000	20	10	38.084%	35.929%	33.907%	32.008%	30.222%	26.957%	24.056%
\$300,000	25	10	34.169%	31.943%	29.869%	27.933%	26.125%	22.850%	19.984%
\$300,000	50	10	23.476%	21.140%	19.011%	17.071%	15.303%	12.242%	9.750%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$300,000	100	10	15.589%	13.301%	11.305%	9.582%	8.104%	5.765%	4.090%
\$300,000	150	10	12.034%	9.875%	8.057%	6.548%	5.310%	3.478%	2.288%
\$300,000	200	10	9.966%	7.910%	6.238%	4.897%	3.839%	2.375%	1.508%
\$300,000	300	10	7.547%	5.653%	4.201%	3.109%	2.307%	1.318%	0.853%
\$300,000	400	10	6.117%	4.379%	3.109%	2.207%	1.588%	0.910%	0.637%
\$300,000	500	10	5.237%	3.615%	2.480%	1.717%	1.223%	0.730%	0.562%
\$300,000	600	10	4.607%	3.088%	2.067%	1.412%	1.008%	0.640%	0.531%
\$300,000	700	10	4.119%	2.683%	1.755%	1.188%	0.859%	0.585%	0.516%
\$300,000	800	10	3.726%	2.368%	1.521%	1.026%	0.756%	0.552%	0.508%
\$300,000	900	10	3.385%	2.099%	1.327%	0.897%	0.676%	0.529%	0.504%
\$300,000	1,000	10	3.100%	1.887%	1.185%	0.812%	0.631%	0.520%	0.503%
\$300,000	1,500	10	2.272%	1.299%	0.819%	0.613%	0.537%	0.504%	0.501%
\$300,000	2,000	10	1.790%	0.997%	0.663%	0.546%	0.512%	0.502%	0.501%
\$300,000	3,000	10	1.220%	0.703%	0.547%	0.511%	0.504%	0.502%	0.501%
\$300,000	4,000	10	0.929%	0.590%	0.516%	0.505%	0.503%	0.502%	0.501%
\$300,000	5,000	10	0.761%	0.542%	0.508%	0.504%	0.503%	0.502%	0.501%
\$300,000	10,000	10	0.522%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$300,000	20,000	10	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$325,000	5	10	66.269%	64.556%	62.912%	61.332%	59.807%	56.913%	54.220%
\$325,000	10	10	50.647%	48.680%	46.810%	45.029%	43.332%	40.172%	37.307%
\$325,000	15	10	42.992%	40.913%	38.954%	37.113%	35.376%	32.173%	29.300%
\$325,000	20	10	38.418%	36.281%	34.277%	32.393%	30.624%	27.390%	24.516%
\$325,000	25	10	34.509%	32.304%	30.250%	28.333%	26.542%	23.301%	20.468%
\$325,000	50	10	23.857%	21.546%	19.437%	17.513%	15.755%	12.696%	10.188%
\$325,000	100	10	15.914%	13.628%	11.628%	9.893%	8.399%	6.023%	4.306%
\$325,000	150	10	12.288%	10.125%	8.297%	6.774%	5.517%	3.648%	2.417%
\$325,000	200	10	10.181%	8.119%	6.435%	5.078%	4.000%	2.496%	1.593%
\$325,000	300	10	7.717%	5.810%	4.342%	3.232%	2.411%	1.384%	0.890%
\$325,000	400	10	6.260%	4.508%	3.219%	2.297%	1.659%	0.949%	0.655%
\$325,000	500	10	5.360%	3.723%	2.568%	1.786%	1.273%	0.754%	0.572%
\$325,000	600	10	4.716%	3.182%	2.141%	1.467%	1.047%	0.656%	0.537%
\$325,000	700	10	4.218%	2.764%	1.817%	1.232%	0.889%	0.595%	0.519%
\$325,000	800	10	3.815%	2.440%	1.574%	1.061%	0.778%	0.558%	0.510%
\$325,000	900	10	3.466%	2.163%	1.372%	0.926%	0.693%	0.534%	0.505%
\$325,000	1,000	10	3.174%	1.944%	1.224%	0.836%	0.645%	0.523%	0.503%
\$325,000	1,500	10	2.329%	1.337%	0.842%	0.624%	0.541%	0.505%	0.501%
\$325,000	2,000	10	1.838%	1.025%	0.677%	0.552%	0.514%	0.502%	0.501%
\$325,000	3,000	10	1.253%	0.718%	0.552%	0.512%	0.504%	0.502%	0.501%
\$325,000	4,000	10	0.953%	0.598%	0.518%	0.505%	0.503%	0.502%	0.501%
\$325,000	5,000	10	0.778%	0.546%	0.509%	0.504%	0.503%	0.502%	0.501%
\$325,000	10,000	10	0.524%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$325,000	20,000	10	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$350,000	5	10	66.465%	64.759%	63.122%	61.550%	60.032%	57.151%	54.471%
\$350,000	10	10	50.839%	48.882%	47.022%	45.250%	43.562%	40.421%	37.573%
\$350,000	15	10	43.214%	41.147%	39.202%	37.372%	35.647%	32.465%	29.613%
\$350,000	20	10	38.696%	36.574%	34.585%	32.714%	30.959%	27.749%	24.898%
\$350,000	25	10	34.793%	32.604%	30.566%	28.664%	26.888%	23.675%	20.869%
\$350,000	50	10	24.173%	21.884%	19.794%	17.887%	16.141%	13.097%	10.582%
\$350,000	100	10	16.204%	13.920%	11.916%	10.174%	8.666%	6.262%	4.506%
\$350,000	150	10	12.514%	10.348%	8.512%	6.978%	5.705%	3.803%	2.537%
\$350,000	200	10	10.373%	8.307%	6.612%	5.241%	4.146%	2.608%	1.672%
\$350,000	300	10	7.869%	5.953%	4.471%	3.345%	2.507%	1.446%	0.925%
\$350,000	400	10	6.389%	4.625%	3.320%	2.381%	1.726%	0.986%	0.673%
\$350,000	500	10	5.472%	3.822%	2.650%	1.851%	1.322%	0.778%	0.581%
\$350,000	600	10	4.816%	3.267%	2.210%	1.519%	1.084%	0.672%	0.542%
\$350,000	700	10	4.308%	2.838%	1.874%	1.273%	0.917%	0.606%	0.522%
\$350,000	800	10	3.889%	2.499%	1.617%	1.090%	0.796%	0.563%	0.511%
\$350,000	900	10	3.540%	2.222%	1.414%	0.953%	0.709%	0.538%	0.505%
\$350,000	1,000	10	3.243%	1.997%	1.261%	0.859%	0.658%	0.526%	0.504%
\$350,000	1,500	10	2.381%	1.373%	0.862%	0.635%	0.546%	0.505%	0.501%
\$350,000	2,000	10	1.881%	1.052%	0.690%	0.557%	0.515%	0.502%	0.501%
\$350,000	3,000	10	1.283%	0.732%	0.557%	0.513%	0.504%	0.502%	0.501%
\$350,000	4,000	10	0.975%	0.606%	0.520%	0.506%	0.503%	0.502%	0.501%
\$350,000	5,000	10	0.793%	0.550%	0.509%	0.504%	0.503%	0.502%	0.501%
\$350,000	10,000	10	0.526%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$350,000	20,000	10	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$375,000	5	10	66.656%	64.957%	63.328%	61.762%	60.251%	57.382%	54.716%
\$375,000	10	10	51.023%	49.074%	47.224%	45.461%	43.781%	40.657%	37.825%
\$375,000	15	10	43.426%	41.371%	39.437%	37.619%	35.904%	32.742%	29.909%
\$375,000	20	10	38.957%	36.848%	34.872%	33.014%	31.271%	28.085%	25.255%
\$375,000	25	10	35.057%	32.885%	30.861%	28.974%	27.211%	24.023%	21.243%
\$375,000	50	10	24.470%	22.201%	20.131%	18.242%	16.509%	13.486%	10.975%
\$375,000	100	10	16.489%	14.210%	12.205%	10.457%	8.939%	6.505%	4.713%
\$375,000	150	10	12.739%	10.572%	8.730%	7.184%	5.898%	3.962%	2.661%
\$375,000	200	10	10.565%	8.495%	6.791%	5.407%	4.296%	2.723%	1.754%
\$375,000	300	10	8.023%	6.099%	4.602%	3.460%	2.605%	1.513%	0.964%
\$375,000	400	10	6.519%	4.744%	3.423%	2.467%	1.796%	1.027%	0.693%
\$375,000	500	10	5.586%	3.923%	2.734%	1.917%	1.372%	0.803%	0.591%
\$375,000	600	10	4.916%	3.352%	2.280%	1.572%	1.122%	0.688%	0.548%
\$375,000	700	10	4.398%	2.913%	1.933%	1.316%	0.946%	0.617%	0.526%
\$375,000	800	10	3.970%	2.566%	1.667%	1.125%	0.818%	0.571%	0.513%
\$375,000	900	10	3.614%	2.281%	1.457%	0.981%	0.726%	0.543%	0.507%
\$375,000	1,000	10	3.312%	2.050%	1.298%	0.882%	0.671%	0.530%	0.504%
\$375,000	1,500	10	2.433%	1.408%	0.884%	0.646%	0.551%	0.506%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$375,000	2,000	10	1.924%	1.078%	0.703%	0.563%	0.517%	0.503%	0.501%
\$375,000	3,000	10	1.313%	0.746%	0.561%	0.514%	0.504%	0.502%	0.501%
\$375,000	4,000	10	0.997%	0.614%	0.522%	0.506%	0.503%	0.502%	0.501%
\$375,000	5,000	10	0.809%	0.554%	0.510%	0.504%	0.503%	0.502%	0.501%
\$375,000	10,000	10	0.528%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$375,000	20,000	10	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$400,000	5	10	66.823%	65.131%	63.508%	61.948%	60.443%	57.585%	54.931%
\$400,000	10	10	51.192%	49.252%	47.410%	45.655%	43.982%	40.874%	38.057%
\$400,000	15	10	43.622%	41.578%	39.655%	37.847%	36.142%	32.997%	30.182%
\$400,000	20	10	39.196%	37.100%	35.136%	33.290%	31.558%	28.393%	25.582%
\$400,000	25	10	35.299%	33.141%	31.130%	29.255%	27.505%	24.340%	21.582%
\$400,000	50	10	24.731%	22.481%	20.429%	18.555%	16.837%	13.837%	11.338%
\$400,000	100	10	16.761%	14.487%	12.485%	10.732%	9.207%	6.745%	4.920%
\$400,000	150	10	12.957%	10.787%	8.940%	7.385%	6.087%	4.119%	2.787%
\$400,000	200	10	10.748%	8.674%	6.963%	5.568%	4.443%	2.837%	1.837%
\$400,000	300	10	8.171%	6.240%	4.729%	3.573%	2.701%	1.580%	1.004%
\$400,000	400	10	6.645%	4.861%	3.525%	2.554%	1.866%	1.068%	0.714%
\$400,000	500	10	5.696%	4.022%	2.818%	1.984%	1.423%	0.829%	0.602%
\$400,000	600	10	5.013%	3.436%	2.348%	1.625%	1.160%	0.705%	0.555%
\$400,000	700	10	4.486%	2.987%	1.990%	1.359%	0.976%	0.628%	0.530%
\$400,000	800	10	4.049%	2.631%	1.716%	1.159%	0.841%	0.579%	0.515%
\$400,000	900	10	3.686%	2.339%	1.499%	1.009%	0.743%	0.548%	0.508%
\$400,000	1,000	10	3.379%	2.103%	1.335%	0.906%	0.685%	0.534%	0.505%
\$400,000	1,500	10	2.483%	1.443%	0.905%	0.658%	0.556%	0.507%	0.501%
\$400,000	2,000	10	1.965%	1.104%	0.716%	0.568%	0.519%	0.503%	0.501%
\$400,000	3,000	10	1.342%	0.760%	0.566%	0.516%	0.505%	0.502%	0.501%
\$400,000	4,000	10	1.018%	0.621%	0.523%	0.506%	0.503%	0.502%	0.501%
\$400,000	5,000	10	0.825%	0.559%	0.510%	0.504%	0.503%	0.502%	0.501%
\$400,000	10,000	10	0.530%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$400,000	20,000	10	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$425,000	5	10	66.969%	65.282%	63.666%	62.111%	60.610%	57.763%	55.119%
\$425,000	10	10	51.339%	49.407%	47.572%	45.824%	44.158%	41.064%	38.260%
\$425,000	15	10	43.792%	41.757%	39.844%	38.045%	36.348%	33.219%	30.419%
\$425,000	20	10	39.405%	37.320%	35.367%	33.531%	31.809%	28.662%	25.869%
\$425,000	25	10	35.513%	33.367%	31.368%	29.505%	27.765%	24.621%	21.883%
\$425,000	50	10	24.967%	22.733%	20.697%	18.837%	17.133%	14.157%	11.674%
\$425,000	100	10	17.011%	14.745%	12.746%	10.993%	9.461%	6.977%	5.122%
\$425,000	150	10	13.159%	10.990%	9.138%	7.576%	6.267%	4.272%	2.912%
\$425,000	200	10	10.920%	8.845%	7.127%	5.722%	4.586%	2.950%	1.922%
\$425,000	300	10	8.312%	6.375%	4.851%	3.682%	2.796%	1.645%	1.044%
\$425,000	400	10	6.766%	4.972%	3.624%	2.638%	1.934%	1.110%	0.736%
\$425,000	500	10	5.800%	4.116%	2.898%	2.048%	1.473%	0.856%	0.614%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$425,000	600	10	5.105%	3.516%	2.415%	1.676%	1.198%	0.723%	0.562%
\$425,000	700	10	4.570%	3.058%	2.046%	1.400%	1.005%	0.640%	0.534%
\$425,000	800	10	4.124%	2.693%	1.764%	1.193%	0.863%	0.587%	0.518%
\$425,000	900	10	3.755%	2.395%	1.540%	1.038%	0.761%	0.553%	0.509%
\$425,000	1,000	10	3.444%	2.154%	1.372%	0.930%	0.699%	0.537%	0.506%
\$425,000	1,500	10	2.531%	1.477%	0.926%	0.669%	0.562%	0.508%	0.501%
\$425,000	2,000	10	2.005%	1.129%	0.730%	0.574%	0.522%	0.503%	0.501%
\$425,000	3,000	10	1.370%	0.774%	0.571%	0.517%	0.505%	0.502%	0.501%
\$425,000	4,000	10	1.039%	0.629%	0.525%	0.506%	0.503%	0.502%	0.501%
\$425,000	5,000	10	0.840%	0.563%	0.511%	0.504%	0.503%	0.502%	0.501%
\$425,000	10,000	10	0.532%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$425,000	20,000	10	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$450,000	5	10	67.094%	65.412%	63.801%	62.250%	60.754%	57.915%	55.280%
\$450,000	10	10	51.457%	49.531%	47.702%	45.960%	44.300%	41.217%	38.424%
\$450,000	15	10	43.927%	41.900%	39.995%	38.204%	36.514%	33.397%	30.611%
\$450,000	20	10	39.571%	37.495%	35.551%	33.724%	32.009%	28.879%	26.100%
\$450,000	25	10	35.688%	33.552%	31.563%	29.710%	27.979%	24.852%	22.131%
\$450,000	50	10	25.163%	22.943%	20.920%	19.073%	17.380%	14.426%	11.959%
\$450,000	100	10	17.224%	14.969%	12.973%	11.220%	9.685%	7.186%	5.306%
\$450,000	150	10	13.336%	11.169%	9.314%	7.747%	6.429%	4.413%	3.027%
\$450,000	200	10	11.074%	8.997%	7.275%	5.862%	4.717%	3.055%	2.002%
\$450,000	300	10	8.438%	6.496%	4.964%	3.782%	2.883%	1.707%	1.082%
\$450,000	400	10	6.875%	5.073%	3.715%	2.714%	1.998%	1.150%	0.757%
\$450,000	500	10	5.894%	4.201%	2.972%	2.109%	1.520%	0.880%	0.626%
\$450,000	600	10	5.189%	3.589%	2.475%	1.724%	1.234%	0.739%	0.569%
\$450,000	700	10	4.646%	3.123%	2.097%	1.439%	1.032%	0.652%	0.538%
\$450,000	800	10	4.191%	2.749%	1.807%	1.224%	0.884%	0.595%	0.520%
\$450,000	900	10	3.818%	2.445%	1.579%	1.064%	0.777%	0.558%	0.510%
\$450,000	1,000	10	3.502%	2.200%	1.405%	0.951%	0.713%	0.541%	0.507%
\$450,000	1,500	10	2.575%	1.508%	0.945%	0.680%	0.567%	0.509%	0.501%
\$450,000	2,000	10	2.042%	1.152%	0.742%	0.580%	0.524%	0.503%	0.501%
\$450,000	3,000	10	1.395%	0.786%	0.576%	0.518%	0.505%	0.502%	0.501%
\$450,000	4,000	10	1.058%	0.637%	0.527%	0.507%	0.503%	0.502%	0.501%
\$450,000	5,000	10	0.853%	0.567%	0.512%	0.504%	0.503%	0.502%	0.501%
\$450,000	10,000	10	0.534%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$450,000	20,000	10	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$475,000	5	10	67.204%	65.527%	63.920%	62.373%	60.881%	58.050%	55.423%
\$475,000	10	10	51.563%	49.642%	47.818%	46.081%	44.426%	41.355%	38.571%
\$475,000	15	10	44.050%	42.030%	40.132%	38.348%	36.664%	33.559%	30.784%
\$475,000	20	10	39.718%	37.651%	35.714%	33.895%	32.187%	29.071%	26.305%
\$475,000	25	10	35.845%	33.719%	31.739%	29.894%	28.171%	25.060%	22.353%
\$475,000	50	10	25.339%	23.131%	21.120%	19.284%	17.602%	14.667%	12.216%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$475,000	100	10	17.418%	15.173%	13.183%	11.433%	9.896%	7.387%	5.485%
\$475,000	150	10	13.499%	11.334%	9.478%	7.906%	6.581%	4.546%	3.138%
\$475,000	200	10	11.217%	9.139%	7.414%	5.994%	4.840%	3.154%	2.079%
\$475,000	300	10	8.556%	6.610%	5.070%	3.876%	2.965%	1.767%	1.120%
\$475,000	400	10	6.977%	5.168%	3.800%	2.788%	2.059%	1.188%	0.779%
\$475,000	500	10	5.983%	4.281%	3.042%	2.166%	1.564%	0.904%	0.638%
\$475,000	600	10	5.267%	3.658%	2.533%	1.769%	1.268%	0.756%	0.576%
\$475,000	700	10	4.716%	3.184%	2.146%	1.475%	1.058%	0.663%	0.542%
\$475,000	800	10	4.254%	2.802%	1.848%	1.254%	0.904%	0.602%	0.522%
\$475,000	900	10	3.869%	2.487%	1.609%	1.084%	0.790%	0.561%	0.511%
\$475,000	1,000	10	3.557%	2.244%	1.437%	0.972%	0.725%	0.545%	0.508%
\$475,000	1,500	10	2.616%	1.538%	0.963%	0.690%	0.572%	0.510%	0.502%
\$475,000	2,000	10	2.075%	1.174%	0.754%	0.585%	0.526%	0.503%	0.501%
\$475,000	3,000	10	1.419%	0.798%	0.581%	0.519%	0.506%	0.502%	0.501%
\$475,000	4,000	10	1.076%	0.644%	0.529%	0.507%	0.503%	0.502%	0.501%
\$475,000	5,000	10	0.866%	0.570%	0.512%	0.504%	0.503%	0.502%	0.501%
\$475,000	10,000	10	0.536%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$475,000	20,000	10	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$500,000	5	10	67.290%	65.617%	64.013%	62.469%	60.980%	58.156%	55.535%
\$500,000	10	10	51.647%	49.731%	47.912%	46.179%	44.528%	41.466%	38.690%
\$500,000	15	10	44.152%	42.138%	40.247%	38.468%	36.789%	33.694%	30.929%
\$500,000	20	10	39.841%	37.780%	35.850%	34.037%	32.336%	29.231%	26.476%
\$500,000	25	10	35.977%	33.858%	31.886%	30.048%	28.332%	25.234%	22.540%
\$500,000	50	10	25.490%	23.293%	21.292%	19.465%	17.791%	14.873%	12.436%
\$500,000	100	10	17.588%	15.352%	13.370%	11.623%	10.087%	7.568%	5.651%
\$500,000	150	10	13.644%	11.482%	9.626%	8.050%	6.719%	4.666%	3.238%
\$500,000	200	10	11.345%	9.266%	7.538%	6.113%	4.952%	3.244%	2.149%
\$500,000	300	10	8.662%	6.712%	5.166%	3.962%	3.040%	1.821%	1.155%
\$500,000	400	10	7.068%	5.254%	3.877%	2.855%	2.114%	1.224%	0.800%
\$500,000	500	10	6.064%	4.354%	3.106%	2.218%	1.605%	0.927%	0.649%
\$500,000	600	10	5.337%	3.720%	2.584%	1.810%	1.299%	0.771%	0.582%
\$500,000	700	10	4.778%	3.238%	2.190%	1.508%	1.082%	0.673%	0.546%
\$500,000	800	10	4.310%	2.849%	1.886%	1.281%	0.922%	0.609%	0.525%
\$500,000	900	10	3.921%	2.530%	1.642%	1.107%	0.804%	0.566%	0.512%
\$500,000	1,000	10	3.606%	2.283%	1.466%	0.992%	0.737%	0.549%	0.509%
\$500,000	1,500	10	2.653%	1.564%	0.980%	0.699%	0.577%	0.511%	0.502%
\$500,000	2,000	10	2.106%	1.194%	0.765%	0.590%	0.528%	0.503%	0.501%
\$500,000	3,000	10	1.441%	0.809%	0.585%	0.521%	0.506%	0.502%	0.501%
\$500,000	4,000	10	1.092%	0.650%	0.531%	0.507%	0.503%	0.502%	0.501%
\$500,000	5,000	10	0.878%	0.574%	0.513%	0.505%	0.503%	0.502%	0.501%
\$500,000	10,000	10	0.537%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$500,000	20,000	10	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$30,000	5	11	43.714%	41.107%	38.587%	36.147%	33.781%	29.291%	25.259%
\$30,000	10	11	28.261%	25.648%	23.255%	21.062%	19.042%	15.479%	12.490%
\$30,000	15	11	21.944%	19.400%	17.105%	15.041%	13.196%	10.088%	7.658%
\$30,000	20	11	18.615%	16.136%	13.932%	11.984%	10.273%	7.487%	5.399%
\$30,000	25	11	16.073%	13.667%	11.564%	9.738%	8.165%	5.681%	3.934%
\$30,000	50	11	10.232%	8.112%	6.386%	4.996%	3.893%	2.380%	1.501%
\$30,000	100	11	6.562%	4.739%	3.390%	2.426%	1.758%	0.996%	0.675%
\$30,000	150	11	4.950%	3.351%	2.256%	1.543%	1.096%	0.672%	0.544%
\$30,000	200	11	4.014%	2.585%	1.673%	1.125%	0.815%	0.569%	0.514%
\$30,000	300	11	3.030%	1.822%	1.135%	0.780%	0.613%	0.516%	0.502%
\$30,000	400	11	2.433%	1.400%	0.876%	0.640%	0.547%	0.505%	0.501%
\$30,000	500	11	2.027%	1.136%	0.730%	0.573%	0.521%	0.503%	0.501%
\$30,000	600	11	1.742%	0.966%	0.649%	0.541%	0.511%	0.502%	0.501%
\$30,000	700	11	1.528%	0.850%	0.599%	0.524%	0.506%	0.502%	0.501%
\$30,000	800	11	1.359%	0.765%	0.567%	0.515%	0.504%	0.502%	0.501%
\$30,000	900	11	1.232%	0.708%	0.547%	0.510%	0.504%	0.502%	0.501%
\$30,000	1,000	11	1.124%	0.662%	0.534%	0.508%	0.503%	0.502%	0.501%
\$30,000	1,500	11	0.803%	0.553%	0.510%	0.504%	0.503%	0.502%	0.501%
\$30,000	2,000	11	0.660%	0.522%	0.506%	0.504%	0.503%	0.502%	0.501%
\$30,000	3,000	11	0.554%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$30,000	4,000	11	0.522%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$30,000	5,000	11	0.512%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$30,000	10,000	11	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$30,000	20,000	11	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$35,000	5	11	45.900%	43.399%	40.982%	38.641%	36.382%	32.090%	28.054%
\$35,000	10	11	29.822%	27.178%	24.745%	22.511%	20.459%	16.844%	13.798%
\$35,000	15	11	23.206%	20.651%	18.336%	16.244%	14.358%	11.147%	8.599%
\$35,000	20	11	19.716%	17.220%	14.985%	12.999%	11.241%	8.335%	6.118%
\$35,000	25	11	17.028%	14.597%	12.457%	10.586%	8.962%	6.362%	4.485%
\$35,000	50	11	10.870%	8.714%	6.938%	5.492%	4.328%	2.704%	1.724%
\$35,000	100	11	6.997%	5.130%	3.727%	2.702%	1.976%	1.123%	0.739%
\$35,000	150	11	5.284%	3.636%	2.486%	1.718%	1.223%	0.729%	0.564%
\$35,000	200	11	4.289%	2.808%	1.842%	1.243%	0.893%	0.595%	0.521%
\$35,000	300	11	3.249%	1.984%	1.243%	0.845%	0.647%	0.523%	0.503%
\$35,000	400	11	2.615%	1.524%	0.949%	0.678%	0.564%	0.507%	0.501%
\$35,000	500	11	2.186%	1.237%	0.783%	0.596%	0.529%	0.503%	0.501%
\$35,000	600	11	1.880%	1.047%	0.687%	0.555%	0.515%	0.502%	0.501%
\$35,000	700	11	1.650%	0.915%	0.626%	0.533%	0.508%	0.502%	0.501%
\$35,000	800	11	1.467%	0.818%	0.586%	0.520%	0.505%	0.502%	0.501%
\$35,000	900	11	1.329%	0.751%	0.562%	0.514%	0.504%	0.502%	0.501%
\$35,000	1,000	11	1.211%	0.698%	0.544%	0.510%	0.504%	0.502%	0.501%
\$35,000	1,500	11	0.857%	0.568%	0.512%	0.505%	0.503%	0.502%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$35,000	2,000	11	0.695%	0.528%	0.507%	0.504%	0.503%	0.502%	0.501%
\$35,000	3,000	11	0.569%	0.509%	0.505%	0.504%	0.503%	0.502%	0.501%
\$35,000	4,000	11	0.528%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$35,000	5,000	11	0.515%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$35,000	10,000	11	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$35,000	20,000	11	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$40,000	5	11	47.773%	45.358%	43.024%	40.777%	38.609%	34.482%	30.606%
\$40,000	10	11	31.374%	28.691%	26.207%	23.919%	21.816%	18.118%	15.002%
\$40,000	15	11	24.368%	21.812%	19.485%	17.371%	15.450%	12.162%	9.515%
\$40,000	20	11	20.739%	18.231%	15.973%	13.950%	12.151%	9.143%	6.815%
\$40,000	25	11	17.914%	15.461%	13.293%	11.385%	9.715%	7.013%	5.025%
\$40,000	50	11	11.457%	9.266%	7.452%	5.957%	4.746%	3.014%	1.945%
\$40,000	100	11	7.398%	5.492%	4.040%	2.964%	2.188%	1.250%	0.806%
\$40,000	150	11	5.592%	3.903%	2.705%	1.885%	1.347%	0.788%	0.588%
\$40,000	200	11	4.543%	3.018%	2.004%	1.359%	0.971%	0.624%	0.530%
\$40,000	300	11	3.452%	2.137%	1.349%	0.910%	0.684%	0.532%	0.505%
\$40,000	400	11	2.783%	1.643%	1.022%	0.718%	0.582%	0.509%	0.502%
\$40,000	500	11	2.333%	1.334%	0.837%	0.621%	0.539%	0.504%	0.501%
\$40,000	600	11	2.007%	1.125%	0.726%	0.571%	0.520%	0.503%	0.501%
\$40,000	700	11	1.762%	0.978%	0.654%	0.543%	0.511%	0.502%	0.501%
\$40,000	800	11	1.568%	0.870%	0.606%	0.527%	0.507%	0.502%	0.501%
\$40,000	900	11	1.419%	0.794%	0.577%	0.518%	0.505%	0.502%	0.501%
\$40,000	1,000	11	1.293%	0.735%	0.556%	0.512%	0.504%	0.502%	0.501%
\$40,000	1,500	11	0.909%	0.584%	0.515%	0.505%	0.503%	0.502%	0.501%
\$40,000	2,000	11	0.730%	0.536%	0.507%	0.504%	0.503%	0.502%	0.501%
\$40,000	3,000	11	0.585%	0.511%	0.505%	0.504%	0.503%	0.502%	0.501%
\$40,000	4,000	11	0.535%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$40,000	5,000	11	0.517%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$40,000	10,000	11	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$40,000	20,000	11	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$45,000	5	11	49.382%	47.039%	44.784%	42.614%	40.519%	36.526%	32.789%
\$45,000	10	11	32.877%	30.165%	27.640%	25.302%	23.146%	19.335%	16.131%
\$45,000	15	11	25.443%	22.882%	20.544%	18.414%	16.469%	13.119%	10.388%
\$45,000	20	11	21.682%	19.168%	16.890%	14.838%	13.003%	9.910%	7.485%
\$45,000	25	11	18.725%	16.262%	14.072%	12.133%	10.422%	7.631%	5.546%
\$45,000	50	11	11.992%	9.776%	7.928%	6.394%	5.138%	3.311%	2.163%
\$45,000	100	11	7.768%	5.830%	4.334%	3.214%	2.393%	1.378%	0.877%
\$45,000	150	11	5.873%	4.148%	2.908%	2.046%	1.467%	0.849%	0.614%
\$45,000	200	11	4.776%	3.214%	2.157%	1.472%	1.048%	0.655%	0.540%
\$45,000	300	11	3.637%	2.280%	1.449%	0.974%	0.721%	0.541%	0.507%
\$45,000	400	11	2.937%	1.754%	1.092%	0.757%	0.601%	0.513%	0.502%
\$45,000	500	11	2.466%	1.424%	0.890%	0.647%	0.550%	0.505%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$45,000	600	11	2.123%	1.198%	0.764%	0.588%	0.526%	0.503%	0.501%
\$45,000	700	11	1.865%	1.039%	0.682%	0.553%	0.514%	0.502%	0.501%
\$45,000	800	11	1.661%	0.920%	0.627%	0.533%	0.508%	0.502%	0.501%
\$45,000	900	11	1.504%	0.837%	0.593%	0.522%	0.506%	0.502%	0.501%
\$45,000	1,000	11	1.369%	0.770%	0.568%	0.515%	0.504%	0.502%	0.501%
\$45,000	1,500	11	0.960%	0.601%	0.519%	0.505%	0.503%	0.502%	0.501%
\$45,000	2,000	11	0.764%	0.543%	0.508%	0.504%	0.503%	0.502%	0.501%
\$45,000	3,000	11	0.601%	0.513%	0.505%	0.504%	0.503%	0.502%	0.501%
\$45,000	4,000	11	0.542%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$45,000	5,000	11	0.521%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$45,000	10,000	11	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$45,000	20,000	11	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$50,000	5	11	50.736%	48.459%	46.271%	44.164%	42.125%	38.249%	34.626%
\$50,000	10	11	34.262%	31.553%	29.009%	26.637%	24.430%	20.507%	17.201%
\$50,000	15	11	26.439%	23.865%	21.509%	19.360%	17.406%	14.009%	11.205%
\$50,000	20	11	22.541%	20.022%	17.732%	15.659%	13.798%	10.633%	8.127%
\$50,000	25	11	19.476%	17.003%	14.798%	12.834%	11.088%	8.217%	6.046%
\$50,000	50	11	12.485%	10.248%	8.370%	6.805%	5.509%	3.600%	2.377%
\$50,000	100	11	8.110%	6.143%	4.612%	3.450%	2.589%	1.502%	0.950%
\$50,000	150	11	6.132%	4.376%	3.099%	2.198%	1.582%	0.908%	0.640%
\$50,000	200	11	4.992%	3.397%	2.302%	1.580%	1.123%	0.687%	0.551%
\$50,000	300	11	3.807%	2.414%	1.545%	1.037%	0.759%	0.551%	0.509%
\$50,000	400	11	3.077%	1.858%	1.159%	0.796%	0.621%	0.516%	0.502%
\$50,000	500	11	2.587%	1.508%	0.939%	0.672%	0.561%	0.507%	0.501%
\$50,000	600	11	2.228%	1.265%	0.800%	0.604%	0.533%	0.504%	0.501%
\$50,000	700	11	1.958%	1.095%	0.710%	0.564%	0.518%	0.502%	0.501%
\$50,000	800	11	1.746%	0.968%	0.648%	0.541%	0.510%	0.502%	0.501%
\$50,000	900	11	1.581%	0.877%	0.609%	0.527%	0.507%	0.502%	0.501%
\$50,000	1,000	11	1.438%	0.804%	0.580%	0.519%	0.505%	0.502%	0.501%
\$50,000	1,500	11	1.007%	0.617%	0.523%	0.506%	0.503%	0.502%	0.501%
\$50,000	2,000	11	0.796%	0.552%	0.510%	0.504%	0.503%	0.502%	0.501%
\$50,000	3,000	11	0.617%	0.515%	0.505%	0.504%	0.503%	0.502%	0.501%
\$50,000	4,000	11	0.550%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$50,000	5,000	11	0.524%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$50,000	10,000	11	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$50,000	20,000	11	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$55,000	5	11	51.884%	49.666%	47.532%	45.473%	43.483%	39.707%	36.177%
\$55,000	10	11	35.512%	32.817%	30.277%	27.888%	25.648%	21.631%	18.217%
\$55,000	15	11	27.360%	24.769%	22.391%	20.224%	18.252%	14.815%	11.958%
\$55,000	20	11	23.323%	20.801%	18.503%	16.416%	14.529%	11.309%	8.734%
\$55,000	25	11	20.169%	17.689%	15.468%	13.483%	11.712%	8.770%	6.521%
\$55,000	50	11	12.948%	10.691%	8.788%	7.193%	5.862%	3.880%	2.588%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$55,000	100	11	8.425%	6.433%	4.873%	3.673%	2.774%	1.623%	1.023%
\$55,000	150	11	6.372%	4.589%	3.279%	2.344%	1.693%	0.967%	0.668%
\$55,000	200	11	5.194%	3.568%	2.438%	1.682%	1.196%	0.719%	0.563%
\$55,000	300	11	3.955%	2.531%	1.630%	1.093%	0.793%	0.560%	0.510%
\$55,000	400	11	3.206%	1.954%	1.223%	0.834%	0.642%	0.521%	0.503%
\$55,000	500	11	2.699%	1.587%	0.987%	0.698%	0.573%	0.508%	0.501%
\$55,000	600	11	2.324%	1.329%	0.835%	0.621%	0.539%	0.504%	0.501%
\$55,000	700	11	2.045%	1.149%	0.737%	0.575%	0.521%	0.502%	0.501%
\$55,000	800	11	1.824%	1.013%	0.669%	0.548%	0.512%	0.502%	0.501%
\$55,000	900	11	1.652%	0.917%	0.626%	0.533%	0.508%	0.502%	0.501%
\$55,000	1,000	11	1.503%	0.837%	0.593%	0.522%	0.506%	0.502%	0.501%
\$55,000	1,500	11	1.052%	0.634%	0.527%	0.507%	0.503%	0.502%	0.501%
\$55,000	2,000	11	0.828%	0.560%	0.511%	0.504%	0.503%	0.502%	0.501%
\$55,000	3,000	11	0.633%	0.518%	0.506%	0.504%	0.503%	0.502%	0.501%
\$55,000	4,000	11	0.558%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$55,000	5,000	11	0.528%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$55,000	10,000	11	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$55,000	20,000	11	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$60,000	5	11	52.905%	50.735%	48.647%	46.630%	44.683%	40.995%	37.545%
\$60,000	10	11	36.663%	34.007%	31.480%	29.086%	26.835%	22.763%	19.243%
\$60,000	15	11	28.247%	25.639%	23.244%	21.054%	19.058%	15.573%	12.678%
\$60,000	20	11	24.055%	21.530%	19.230%	17.130%	15.223%	11.957%	9.318%
\$60,000	25	11	20.820%	18.336%	16.099%	14.096%	12.303%	9.298%	6.980%
\$60,000	50	11	13.385%	11.112%	9.184%	7.561%	6.200%	4.151%	2.794%
\$60,000	100	11	8.721%	6.708%	5.121%	3.889%	2.952%	1.741%	1.097%
\$60,000	150	11	6.601%	4.791%	3.451%	2.484%	1.803%	1.026%	0.696%
\$60,000	200	11	5.383%	3.730%	2.569%	1.782%	1.268%	0.751%	0.575%
\$60,000	300	11	4.100%	2.648%	1.716%	1.152%	0.829%	0.571%	0.513%
\$60,000	400	11	3.326%	2.045%	1.285%	0.872%	0.663%	0.525%	0.503%
\$60,000	500	11	2.803%	1.662%	1.034%	0.723%	0.585%	0.510%	0.502%
\$60,000	600	11	2.416%	1.390%	0.870%	0.639%	0.547%	0.505%	0.501%
\$60,000	700	11	2.126%	1.201%	0.764%	0.587%	0.526%	0.503%	0.501%
\$60,000	800	11	1.900%	1.058%	0.690%	0.556%	0.515%	0.502%	0.501%
\$60,000	900	11	1.721%	0.955%	0.642%	0.538%	0.510%	0.502%	0.501%
\$60,000	1,000	11	1.565%	0.870%	0.606%	0.526%	0.507%	0.502%	0.501%
\$60,000	1,500	11	1.096%	0.651%	0.531%	0.508%	0.503%	0.502%	0.501%
\$60,000	2,000	11	0.859%	0.569%	0.513%	0.505%	0.503%	0.502%	0.501%
\$60,000	3,000	11	0.650%	0.520%	0.506%	0.504%	0.503%	0.502%	0.501%
\$60,000	4,000	11	0.566%	0.509%	0.505%	0.504%	0.503%	0.502%	0.501%
\$60,000	5,000	11	0.532%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$60,000	10,000	11	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$60,000	20,000	11	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$65,000	5	11	53.801%	51.672%	49.621%	47.642%	45.735%	42.121%	38.739%
\$65,000	10	11	37.683%	35.081%	32.589%	30.206%	27.955%	23.857%	20.257%
\$65,000	15	11	29.096%	26.473%	24.062%	21.851%	19.827%	16.290%	13.353%
\$65,000	20	11	24.744%	22.214%	19.907%	17.801%	15.878%	12.569%	9.875%
\$65,000	25	11	21.430%	18.939%	16.690%	14.670%	12.858%	9.800%	7.420%
\$65,000	50	11	13.796%	11.508%	9.558%	7.907%	6.518%	4.409%	2.991%
\$65,000	100	11	8.995%	6.963%	5.351%	4.090%	3.122%	1.855%	1.169%
\$65,000	150	11	6.811%	4.979%	3.612%	2.616%	1.906%	1.083%	0.724%
\$65,000	200	11	5.558%	3.879%	2.691%	1.876%	1.338%	0.783%	0.588%
\$65,000	300	11	4.236%	2.758%	1.798%	1.209%	0.865%	0.583%	0.516%
\$65,000	400	11	3.439%	2.131%	1.344%	0.908%	0.683%	0.530%	0.504%
\$65,000	500	11	2.901%	1.733%	1.079%	0.749%	0.598%	0.513%	0.502%
\$65,000	600	11	2.502%	1.449%	0.905%	0.656%	0.554%	0.506%	0.501%
\$65,000	700	11	2.204%	1.251%	0.791%	0.599%	0.530%	0.503%	0.501%
\$65,000	800	11	1.971%	1.102%	0.711%	0.565%	0.518%	0.502%	0.501%
\$65,000	900	11	1.787%	0.993%	0.660%	0.545%	0.511%	0.502%	0.501%
\$65,000	1,000	11	1.624%	0.902%	0.619%	0.531%	0.508%	0.502%	0.501%
\$65,000	1,500	11	1.138%	0.668%	0.536%	0.509%	0.504%	0.502%	0.501%
\$65,000	2,000	11	0.890%	0.578%	0.514%	0.505%	0.503%	0.502%	0.501%
\$65,000	3,000	11	0.666%	0.523%	0.506%	0.504%	0.503%	0.502%	0.501%
\$65,000	4,000	11	0.574%	0.510%	0.505%	0.504%	0.503%	0.502%	0.501%
\$65,000	5,000	11	0.537%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$65,000	10,000	11	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$65,000	20,000	11	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$70,000	5	11	54.582%	52.488%	50.470%	48.524%	46.652%	43.102%	39.777%
\$70,000	10	11	38.593%	36.040%	33.591%	31.246%	29.010%	24.899%	21.258%
\$70,000	15	11	29.910%	27.278%	24.853%	22.620%	20.569%	16.976%	13.987%
\$70,000	20	11	25.393%	22.856%	20.537%	18.423%	16.492%	13.145%	10.400%
\$70,000	25	11	22.001%	19.503%	17.244%	15.211%	13.381%	10.275%	7.840%
\$70,000	50	11	14.182%	11.883%	9.912%	8.235%	6.819%	4.656%	3.181%
\$70,000	100	11	9.253%	7.202%	5.567%	4.281%	3.284%	1.964%	1.240%
\$70,000	150	11	7.008%	5.156%	3.763%	2.739%	2.005%	1.139%	0.753%
\$70,000	200	11	5.722%	4.022%	2.806%	1.966%	1.405%	0.816%	0.601%
\$70,000	300	11	4.362%	2.861%	1.876%	1.263%	0.900%	0.595%	0.519%
\$70,000	400	11	3.545%	2.213%	1.401%	0.944%	0.704%	0.536%	0.505%
\$70,000	500	11	2.993%	1.801%	1.123%	0.774%	0.610%	0.515%	0.502%
\$70,000	600	11	2.584%	1.506%	0.939%	0.673%	0.562%	0.508%	0.501%
\$70,000	700	11	2.277%	1.299%	0.818%	0.611%	0.535%	0.504%	0.501%
\$70,000	800	11	2.040%	1.144%	0.733%	0.573%	0.521%	0.503%	0.501%
\$70,000	900	11	1.849%	1.029%	0.677%	0.551%	0.513%	0.502%	0.501%
\$70,000	1,000	11	1.680%	0.933%	0.633%	0.535%	0.509%	0.502%	0.501%
\$70,000	1,500	11	1.178%	0.684%	0.541%	0.510%	0.504%	0.502%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$70,000	2,000	11	0.919%	0.588%	0.516%	0.505%	0.503%	0.502%	0.501%
\$70,000	3,000	11	0.682%	0.526%	0.506%	0.504%	0.503%	0.502%	0.501%
\$70,000	4,000	11	0.582%	0.511%	0.505%	0.504%	0.503%	0.502%	0.501%
\$70,000	5,000	11	0.541%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$70,000	10,000	11	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$70,000	20,000	11	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$75,000	5	11	55.284%	53.220%	51.231%	49.318%	47.475%	43.981%	40.708%
\$75,000	10	11	39.427%	36.917%	34.511%	32.210%	30.010%	25.908%	22.241%
\$75,000	15	11	30.696%	28.066%	25.626%	23.373%	21.297%	17.647%	14.598%
\$75,000	20	11	26.013%	23.465%	21.134%	19.008%	17.070%	13.688%	10.901%
\$75,000	25	11	22.537%	20.035%	17.769%	15.721%	13.877%	10.729%	8.246%
\$75,000	50	11	14.551%	12.239%	10.250%	8.551%	7.110%	4.895%	3.368%
\$75,000	100	11	9.498%	7.432%	5.776%	4.465%	3.442%	2.071%	1.311%
\$75,000	150	11	7.198%	5.327%	3.910%	2.861%	2.102%	1.194%	0.782%
\$75,000	200	11	5.881%	4.159%	2.919%	2.055%	1.471%	0.849%	0.614%
\$75,000	300	11	4.484%	2.962%	1.952%	1.317%	0.936%	0.608%	0.523%
\$75,000	400	11	3.647%	2.291%	1.457%	0.980%	0.725%	0.541%	0.506%
\$75,000	500	11	3.082%	1.867%	1.167%	0.799%	0.624%	0.518%	0.503%
\$75,000	600	11	2.663%	1.561%	0.972%	0.691%	0.570%	0.509%	0.502%
\$75,000	700	11	2.348%	1.346%	0.845%	0.624%	0.540%	0.504%	0.501%
\$75,000	800	11	2.106%	1.186%	0.755%	0.583%	0.524%	0.503%	0.501%
\$75,000	900	11	1.908%	1.065%	0.695%	0.558%	0.516%	0.502%	0.501%
\$75,000	1,000	11	1.735%	0.964%	0.647%	0.540%	0.510%	0.502%	0.501%
\$75,000	1,500	11	1.218%	0.701%	0.546%	0.511%	0.504%	0.502%	0.501%
\$75,000	2,000	11	0.948%	0.598%	0.518%	0.505%	0.503%	0.502%	0.501%
\$75,000	3,000	11	0.697%	0.529%	0.507%	0.504%	0.503%	0.502%	0.501%
\$75,000	4,000	11	0.591%	0.512%	0.505%	0.504%	0.503%	0.502%	0.501%
\$75,000	5,000	11	0.546%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$75,000	10,000	11	0.508%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$75,000	20,000	11	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$80,000	5	11	55.901%	53.863%	51.901%	50.015%	48.198%	44.753%	41.525%
\$80,000	10	11	40.169%	37.696%	35.329%	33.068%	30.907%	26.850%	23.172%
\$80,000	15	11	31.426%	28.806%	26.363%	24.093%	21.996%	18.294%	15.187%
\$80,000	20	11	26.601%	24.040%	21.698%	19.558%	17.609%	14.196%	11.377%
\$80,000	25	11	23.037%	20.531%	18.257%	16.201%	14.343%	11.160%	8.636%
\$80,000	50	11	14.900%	12.577%	10.571%	8.852%	7.390%	5.125%	3.549%
\$80,000	100	11	9.727%	7.648%	5.969%	4.637%	3.591%	2.176%	1.380%
\$80,000	150	11	7.374%	5.485%	4.047%	2.976%	2.195%	1.248%	0.811%
\$80,000	200	11	6.029%	4.288%	3.026%	2.141%	1.536%	0.881%	0.628%
\$80,000	300	11	4.599%	3.057%	2.025%	1.370%	0.971%	0.621%	0.526%
\$80,000	400	11	3.742%	2.367%	1.511%	1.015%	0.747%	0.547%	0.507%
\$80,000	500	11	3.166%	1.930%	1.209%	0.825%	0.637%	0.521%	0.503%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$80,000	600	11	2.736%	1.613%	1.005%	0.709%	0.579%	0.510%	0.502%
\$80,000	700	11	2.414%	1.391%	0.871%	0.637%	0.546%	0.505%	0.501%
\$80,000	800	11	2.168%	1.227%	0.777%	0.592%	0.527%	0.503%	0.501%
\$80,000	900	11	1.964%	1.099%	0.712%	0.565%	0.518%	0.502%	0.501%
\$80,000	1,000	11	1.785%	0.994%	0.661%	0.545%	0.511%	0.502%	0.501%
\$80,000	1,500	11	1.255%	0.718%	0.551%	0.512%	0.504%	0.502%	0.501%
\$80,000	2,000	11	0.976%	0.607%	0.521%	0.506%	0.503%	0.502%	0.501%
\$80,000	3,000	11	0.713%	0.533%	0.507%	0.504%	0.503%	0.502%	0.501%
\$80,000	4,000	11	0.600%	0.513%	0.505%	0.504%	0.503%	0.502%	0.501%
\$80,000	5,000	11	0.551%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$80,000	10,000	11	0.508%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$80,000	20,000	11	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$90,000	5	11	56.978%	54.985%	53.070%	51.230%	49.457%	46.093%	42.941%
\$90,000	10	11	41.455%	39.045%	36.745%	34.551%	32.455%	28.513%	24.904%
\$90,000	15	11	32.745%	30.157%	27.724%	25.446%	23.324%	19.540%	16.323%
\$90,000	20	11	27.683%	25.116%	22.752%	20.588%	18.606%	15.141%	12.262%
\$90,000	25	11	23.959%	21.446%	19.158%	17.083%	15.200%	11.964%	9.368%
\$90,000	50	11	15.538%	13.194%	11.157%	9.405%	7.907%	5.554%	3.894%
\$90,000	100	11	10.145%	8.039%	6.325%	4.954%	3.868%	2.372%	1.509%
\$90,000	150	11	7.699%	5.778%	4.303%	3.192%	2.369%	1.352%	0.869%
\$90,000	200	11	6.302%	4.528%	3.224%	2.300%	1.658%	0.945%	0.655%
\$90,000	300	11	4.811%	3.233%	2.163%	1.469%	1.039%	0.647%	0.534%
\$90,000	400	11	3.920%	2.508%	1.613%	1.083%	0.788%	0.559%	0.510%
\$90,000	500	11	3.320%	2.046%	1.288%	0.873%	0.664%	0.527%	0.505%
\$90,000	600	11	2.872%	1.712%	1.067%	0.744%	0.596%	0.514%	0.502%
\$90,000	700	11	2.535%	1.475%	0.921%	0.663%	0.557%	0.507%	0.501%
\$90,000	800	11	2.282%	1.302%	0.819%	0.612%	0.535%	0.504%	0.501%
\$90,000	900	11	2.066%	1.164%	0.746%	0.579%	0.523%	0.503%	0.501%
\$90,000	1,000	11	1.879%	1.049%	0.687%	0.555%	0.514%	0.502%	0.501%
\$90,000	1,500	11	1.324%	0.750%	0.562%	0.515%	0.505%	0.502%	0.501%
\$90,000	2,000	11	1.028%	0.626%	0.525%	0.506%	0.503%	0.502%	0.501%
\$90,000	3,000	11	0.742%	0.539%	0.508%	0.504%	0.503%	0.502%	0.501%
\$90,000	4,000	11	0.616%	0.515%	0.505%	0.504%	0.503%	0.502%	0.501%
\$90,000	5,000	11	0.560%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$90,000	10,000	11	0.508%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$90,000	20,000	11	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$100,000	5	11	57.837%	55.881%	54.005%	52.201%	50.463%	47.162%	44.073%
\$100,000	10	11	42.506%	40.152%	37.907%	35.768%	33.720%	29.878%	26.369%
\$100,000	15	11	33.866%	31.327%	28.925%	26.661%	24.539%	20.714%	17.411%
\$100,000	20	11	28.659%	26.092%	23.722%	21.533%	19.524%	16.000%	13.059%
\$100,000	25	11	24.797%	22.278%	19.977%	17.881%	15.978%	12.697%	10.039%
\$100,000	50	11	16.107%	13.750%	11.689%	9.907%	8.377%	5.951%	4.219%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$100,000	100	11	10.525%	8.395%	6.653%	5.247%	4.126%	2.560%	1.635%
\$100,000	150	11	7.998%	6.050%	4.542%	3.397%	2.537%	1.454%	0.926%
\$100,000	200	11	6.552%	4.748%	3.410%	2.448%	1.776%	1.008%	0.683%
\$100,000	300	11	5.006%	3.397%	2.292%	1.564%	1.105%	0.673%	0.542%
\$100,000	400	11	4.077%	2.634%	1.705%	1.145%	0.827%	0.570%	0.513%
\$100,000	500	11	3.462%	2.156%	1.364%	0.920%	0.690%	0.534%	0.506%
\$100,000	600	11	2.997%	1.804%	1.126%	0.778%	0.614%	0.517%	0.503%
\$100,000	700	11	2.647%	1.553%	0.969%	0.688%	0.569%	0.509%	0.501%
\$100,000	800	11	2.387%	1.372%	0.859%	0.631%	0.543%	0.505%	0.501%
\$100,000	900	11	2.162%	1.225%	0.779%	0.594%	0.528%	0.503%	0.501%
\$100,000	1,000	11	1.966%	1.102%	0.714%	0.566%	0.518%	0.502%	0.501%
\$100,000	1,500	11	1.388%	0.781%	0.574%	0.518%	0.505%	0.502%	0.501%
\$100,000	2,000	11	1.076%	0.645%	0.530%	0.507%	0.503%	0.502%	0.501%
\$100,000	3,000	11	0.771%	0.546%	0.509%	0.504%	0.503%	0.502%	0.501%
\$100,000	4,000	11	0.633%	0.517%	0.506%	0.504%	0.503%	0.502%	0.501%
\$100,000	5,000	11	0.570%	0.509%	0.505%	0.504%	0.503%	0.502%	0.501%
\$100,000	10,000	11	0.508%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$100,000	20,000	11	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$110,000	5	11	58.549%	56.626%	54.781%	53.007%	51.297%	48.049%	45.014%
\$110,000	10	11	43.399%	41.092%	38.895%	36.800%	34.791%	31.037%	27.609%
\$110,000	15	11	34.836%	32.351%	29.996%	27.766%	25.663%	21.827%	18.474%
\$110,000	20	11	29.558%	27.003%	24.632%	22.435%	20.399%	16.814%	13.816%
\$110,000	25	11	25.582%	23.059%	20.750%	18.636%	16.710%	13.387%	10.675%
\$110,000	50	11	16.638%	14.269%	12.190%	10.385%	8.823%	6.331%	4.532%
\$110,000	100	11	10.874%	8.726%	6.957%	5.523%	4.371%	2.742%	1.760%
\$110,000	150	11	8.279%	6.306%	4.769%	3.592%	2.700%	1.558%	0.986%
\$110,000	200	11	6.788%	4.959%	3.589%	2.593%	1.892%	1.072%	0.714%
\$110,000	300	11	5.190%	3.553%	2.418%	1.659%	1.171%	0.702%	0.552%
\$110,000	400	11	4.231%	2.760%	1.798%	1.210%	0.868%	0.584%	0.516%
\$110,000	500	11	3.597%	2.260%	1.438%	0.967%	0.717%	0.541%	0.508%
\$110,000	600	11	3.116%	1.892%	1.185%	0.812%	0.632%	0.521%	0.503%
\$110,000	700	11	2.752%	1.628%	1.016%	0.714%	0.581%	0.511%	0.501%
\$110,000	800	11	2.485%	1.440%	0.900%	0.652%	0.551%	0.506%	0.501%
\$110,000	900	11	2.250%	1.284%	0.811%	0.609%	0.534%	0.504%	0.501%
\$110,000	1,000	11	2.048%	1.153%	0.741%	0.577%	0.522%	0.503%	0.501%
\$110,000	1,500	11	1.449%	0.812%	0.585%	0.521%	0.506%	0.502%	0.501%
\$110,000	2,000	11	1.123%	0.663%	0.535%	0.508%	0.504%	0.502%	0.501%
\$110,000	3,000	11	0.798%	0.553%	0.510%	0.505%	0.503%	0.502%	0.501%
\$110,000	4,000	11	0.650%	0.520%	0.506%	0.504%	0.503%	0.502%	0.501%
\$110,000	5,000	11	0.580%	0.510%	0.505%	0.504%	0.503%	0.502%	0.501%
\$110,000	10,000	11	0.509%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$110,000	20,000	11	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$120,000	5	11	59.152%	57.258%	55.438%	53.689%	52.003%	48.800%	45.810%
\$120,000	10	11	44.174%	41.908%	39.751%	37.692%	35.718%	32.040%	28.681%
\$120,000	15	11	35.683%	33.247%	30.939%	28.755%	26.686%	22.874%	19.497%
\$120,000	20	11	30.384%	27.852%	25.488%	23.287%	21.243%	17.609%	14.546%
\$120,000	25	11	26.328%	23.805%	21.487%	19.361%	17.417%	14.049%	11.289%
\$120,000	50	11	17.140%	14.761%	12.669%	10.842%	9.255%	6.700%	4.841%
\$120,000	100	11	11.203%	9.039%	7.247%	5.786%	4.607%	2.920%	1.885%
\$120,000	150	11	8.544%	6.552%	4.988%	3.781%	2.859%	1.663%	1.047%
\$120,000	200	11	7.015%	5.162%	3.762%	2.735%	2.005%	1.138%	0.746%
\$120,000	300	11	5.367%	3.704%	2.541%	1.753%	1.239%	0.732%	0.563%
\$120,000	400	11	4.378%	2.882%	1.890%	1.275%	0.910%	0.599%	0.520%
\$120,000	500	11	3.725%	2.361%	1.511%	1.014%	0.744%	0.548%	0.509%
\$120,000	600	11	3.229%	1.976%	1.242%	0.846%	0.651%	0.525%	0.504%
\$120,000	700	11	2.852%	1.700%	1.062%	0.740%	0.594%	0.513%	0.502%
\$120,000	800	11	2.579%	1.505%	0.939%	0.673%	0.560%	0.507%	0.501%
\$120,000	900	11	2.334%	1.340%	0.843%	0.625%	0.541%	0.504%	0.501%
\$120,000	1,000	11	2.126%	1.203%	0.767%	0.589%	0.526%	0.503%	0.501%
\$120,000	1,500	11	1.508%	0.842%	0.597%	0.524%	0.507%	0.502%	0.501%
\$120,000	2,000	11	1.167%	0.682%	0.540%	0.509%	0.504%	0.502%	0.501%
\$120,000	3,000	11	0.825%	0.561%	0.512%	0.505%	0.503%	0.502%	0.501%
\$120,000	4,000	11	0.666%	0.523%	0.506%	0.504%	0.503%	0.502%	0.501%
\$120,000	5,000	11	0.590%	0.511%	0.505%	0.504%	0.503%	0.502%	0.501%
\$120,000	10,000	11	0.509%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$120,000	20,000	11	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$130,000	5	11	59.682%	57.811%	56.015%	54.287%	52.621%	49.458%	46.508%
\$130,000	10	11	44.852%	42.621%	40.500%	38.470%	36.530%	32.917%	29.618%
\$130,000	15	11	36.428%	34.034%	31.768%	29.626%	27.596%	23.840%	20.468%
\$130,000	20	11	31.143%	28.641%	26.295%	24.098%	22.050%	18.390%	15.267%
\$130,000	25	11	27.038%	24.521%	22.197%	20.062%	18.104%	14.695%	11.883%
\$130,000	50	11	17.620%	15.234%	13.129%	11.283%	9.672%	7.061%	5.143%
\$130,000	100	11	11.518%	9.337%	7.528%	6.042%	4.838%	3.094%	2.009%
\$130,000	150	11	8.797%	6.788%	5.199%	3.964%	3.016%	1.768%	1.109%
\$130,000	200	11	7.232%	5.356%	3.931%	2.874%	2.117%	1.203%	0.779%
\$130,000	300	11	5.537%	3.850%	2.659%	1.845%	1.306%	0.763%	0.574%
\$130,000	400	11	4.519%	2.998%	1.979%	1.338%	0.953%	0.615%	0.525%
\$130,000	500	11	3.839%	2.450%	1.576%	1.056%	0.769%	0.554%	0.510%
\$130,000	600	11	3.336%	2.058%	1.297%	0.881%	0.670%	0.530%	0.505%
\$130,000	700	11	2.947%	1.770%	1.107%	0.766%	0.607%	0.516%	0.502%
\$130,000	800	11	2.667%	1.568%	0.978%	0.694%	0.570%	0.508%	0.501%
\$130,000	900	11	2.413%	1.394%	0.875%	0.641%	0.547%	0.505%	0.501%
\$130,000	1,000	11	2.200%	1.251%	0.793%	0.601%	0.531%	0.503%	0.501%
\$130,000	1,500	11	1.563%	0.872%	0.610%	0.528%	0.507%	0.502%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$130,000	2,000	11	1.209%	0.700%	0.546%	0.511%	0.504%	0.502%	0.501%
\$130,000	3,000	11	0.852%	0.568%	0.513%	0.505%	0.503%	0.502%	0.501%
\$130,000	4,000	11	0.683%	0.526%	0.506%	0.504%	0.503%	0.502%	0.501%
\$130,000	5,000	11	0.600%	0.513%	0.505%	0.504%	0.503%	0.502%	0.501%
\$130,000	10,000	11	0.510%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$130,000	20,000	11	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$140,000	5	11	60.154%	58.304%	56.528%	54.819%	53.171%	50.043%	47.127%
\$140,000	10	11	45.446%	43.246%	41.154%	39.151%	37.241%	33.685%	30.436%
\$140,000	15	11	37.085%	34.727%	32.498%	30.392%	28.396%	24.703%	21.370%
\$140,000	20	11	31.820%	29.355%	27.034%	24.851%	22.808%	19.138%	15.974%
\$140,000	25	11	27.692%	25.190%	22.868%	20.723%	18.756%	15.312%	12.447%
\$140,000	50	11	18.066%	15.673%	13.558%	11.697%	10.066%	7.407%	5.432%
\$140,000	100	11	11.814%	9.619%	7.791%	6.285%	5.058%	3.261%	2.131%
\$140,000	150	11	9.035%	7.010%	5.400%	4.138%	3.165%	1.871%	1.171%
\$140,000	200	11	7.435%	5.540%	4.091%	3.008%	2.224%	1.266%	0.813%
\$140,000	300	11	5.696%	3.987%	2.772%	1.932%	1.371%	0.795%	0.587%
\$140,000	400	11	4.650%	3.108%	2.064%	1.400%	0.995%	0.630%	0.529%
\$140,000	500	11	3.952%	2.540%	1.642%	1.101%	0.797%	0.563%	0.513%
\$140,000	600	11	3.437%	2.135%	1.352%	0.915%	0.690%	0.535%	0.506%
\$140,000	700	11	3.037%	1.836%	1.151%	0.792%	0.621%	0.519%	0.503%
\$140,000	800	11	2.750%	1.627%	1.015%	0.715%	0.580%	0.510%	0.502%
\$140,000	900	11	2.488%	1.445%	0.906%	0.657%	0.555%	0.506%	0.501%
\$140,000	1,000	11	2.270%	1.297%	0.819%	0.613%	0.536%	0.504%	0.501%
\$140,000	1,500	11	1.615%	0.900%	0.621%	0.532%	0.508%	0.502%	0.501%
\$140,000	2,000	11	1.249%	0.718%	0.552%	0.512%	0.504%	0.502%	0.501%
\$140,000	3,000	11	0.877%	0.576%	0.514%	0.505%	0.503%	0.502%	0.501%
\$140,000	4,000	11	0.699%	0.529%	0.507%	0.504%	0.503%	0.502%	0.501%
\$140,000	5,000	11	0.610%	0.514%	0.505%	0.504%	0.503%	0.502%	0.501%
\$140,000	10,000	11	0.510%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$140,000	20,000	11	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$150,000	5	11	60.579%	58.746%	56.988%	55.295%	53.662%	50.566%	47.679%
\$150,000	10	11	45.975%	43.803%	41.735%	39.756%	37.872%	34.365%	31.159%
\$150,000	15	11	37.669%	35.344%	33.147%	31.072%	29.105%	25.467%	22.186%
\$150,000	20	11	32.415%	29.985%	27.694%	25.533%	23.504%	19.834%	16.651%
\$150,000	25	11	28.283%	25.799%	23.488%	21.343%	19.368%	15.899%	12.989%
\$150,000	50	11	18.479%	16.081%	13.957%	12.082%	10.435%	7.734%	5.708%
\$150,000	100	11	12.089%	9.882%	8.037%	6.513%	5.264%	3.422%	2.249%
\$150,000	150	11	9.255%	7.217%	5.586%	4.302%	3.305%	1.969%	1.233%
\$150,000	200	11	7.625%	5.712%	4.241%	3.135%	2.326%	1.327%	0.846%
\$150,000	300	11	5.844%	4.116%	2.877%	2.015%	1.434%	0.826%	0.599%
\$150,000	400	11	4.774%	3.210%	2.145%	1.459%	1.036%	0.645%	0.534%
\$150,000	500	11	4.058%	2.625%	1.705%	1.144%	0.824%	0.571%	0.515%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$150,000	600	11	3.530%	2.208%	1.403%	0.948%	0.709%	0.539%	0.507%
\$150,000	700	11	3.120%	1.899%	1.192%	0.817%	0.634%	0.522%	0.503%
\$150,000	800	11	2.827%	1.683%	1.051%	0.735%	0.590%	0.512%	0.502%
\$150,000	900	11	2.558%	1.494%	0.936%	0.672%	0.562%	0.507%	0.501%
\$150,000	1,000	11	2.335%	1.340%	0.843%	0.625%	0.541%	0.504%	0.501%
\$150,000	1,500	11	1.663%	0.927%	0.633%	0.536%	0.509%	0.502%	0.501%
\$150,000	2,000	11	1.286%	0.735%	0.558%	0.514%	0.505%	0.502%	0.501%
\$150,000	3,000	11	0.900%	0.583%	0.516%	0.505%	0.503%	0.502%	0.501%
\$150,000	4,000	11	0.714%	0.532%	0.507%	0.504%	0.503%	0.502%	0.501%
\$150,000	5,000	11	0.620%	0.515%	0.505%	0.504%	0.503%	0.502%	0.501%
\$150,000	10,000	11	0.511%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$150,000	20,000	11	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$160,000	5	11	60.967%	59.151%	57.407%	55.729%	54.110%	51.042%	48.181%
\$160,000	10	11	46.463%	44.316%	42.269%	40.312%	38.450%	34.987%	31.820%
\$160,000	15	11	38.202%	35.905%	33.738%	31.688%	29.748%	26.159%	22.924%
\$160,000	20	11	32.957%	30.558%	28.296%	26.162%	24.154%	20.500%	17.307%
\$160,000	25	11	28.831%	26.367%	24.070%	21.934%	19.959%	16.467%	13.520%
\$160,000	50	11	18.867%	16.468%	14.335%	12.448%	10.784%	8.047%	5.977%
\$160,000	100	11	12.347%	10.130%	8.270%	6.729%	5.461%	3.578%	2.364%
\$160,000	150	11	9.461%	7.411%	5.764%	4.458%	3.439%	2.064%	1.294%
\$160,000	200	11	7.804%	5.875%	4.384%	3.256%	2.425%	1.387%	0.879%
\$160,000	300	11	5.984%	4.238%	2.978%	2.095%	1.495%	0.856%	0.612%
\$160,000	400	11	4.891%	3.308%	2.222%	1.517%	1.076%	0.661%	0.539%
\$160,000	500	11	4.157%	2.706%	1.766%	1.186%	0.851%	0.579%	0.517%
\$160,000	600	11	3.618%	2.277%	1.452%	0.979%	0.727%	0.545%	0.508%
\$160,000	700	11	3.198%	1.958%	1.232%	0.842%	0.647%	0.525%	0.504%
\$160,000	800	11	2.900%	1.737%	1.085%	0.755%	0.600%	0.513%	0.502%
\$160,000	900	11	2.623%	1.540%	0.964%	0.688%	0.569%	0.508%	0.501%
\$160,000	1,000	11	2.396%	1.381%	0.868%	0.637%	0.546%	0.505%	0.501%
\$160,000	1,500	11	1.709%	0.952%	0.645%	0.540%	0.510%	0.502%	0.501%
\$160,000	2,000	11	1.322%	0.751%	0.563%	0.515%	0.505%	0.502%	0.501%
\$160,000	3,000	11	0.923%	0.590%	0.517%	0.506%	0.503%	0.502%	0.501%
\$160,000	4,000	11	0.729%	0.535%	0.507%	0.504%	0.503%	0.502%	0.501%
\$160,000	5,000	11	0.629%	0.517%	0.506%	0.504%	0.503%	0.502%	0.501%
\$160,000	10,000	11	0.511%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$160,000	20,000	11	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$170,000	5	11	61.316%	59.514%	57.785%	56.119%	54.513%	51.471%	48.633%
\$170,000	10	11	46.902%	44.777%	42.749%	40.813%	38.972%	35.547%	32.415%
\$170,000	15	11	38.688%	36.417%	34.276%	32.251%	30.334%	26.790%	23.598%
\$170,000	20	11	33.453%	31.082%	28.846%	26.739%	24.756%	21.133%	17.942%
\$170,000	25	11	29.343%	26.902%	24.621%	22.498%	20.530%	17.023%	14.046%
\$170,000	50	11	19.240%	16.838%	14.699%	12.801%	11.122%	8.351%	6.241%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$170,000	100	11	12.594%	10.367%	8.495%	6.937%	5.652%	3.731%	2.478%
\$170,000	150	11	9.659%	7.598%	5.933%	4.607%	3.569%	2.157%	1.354%
\$170,000	200	11	7.978%	6.034%	4.523%	3.375%	2.522%	1.447%	0.913%
\$170,000	300	11	6.119%	4.356%	3.077%	2.173%	1.556%	0.887%	0.626%
\$170,000	400	11	5.003%	3.402%	2.298%	1.573%	1.115%	0.677%	0.544%
\$170,000	500	11	4.254%	2.785%	1.826%	1.228%	0.878%	0.588%	0.519%
\$170,000	600	11	3.703%	2.344%	1.501%	1.011%	0.746%	0.550%	0.509%
\$170,000	700	11	3.274%	2.015%	1.271%	0.866%	0.661%	0.528%	0.504%
\$170,000	800	11	2.971%	1.789%	1.119%	0.775%	0.610%	0.515%	0.502%
\$170,000	900	11	2.687%	1.585%	0.993%	0.703%	0.576%	0.509%	0.501%
\$170,000	1,000	11	2.455%	1.421%	0.891%	0.649%	0.551%	0.505%	0.501%
\$170,000	1,500	11	1.753%	0.978%	0.656%	0.544%	0.512%	0.502%	0.501%
\$170,000	2,000	11	1.357%	0.768%	0.569%	0.517%	0.505%	0.502%	0.501%
\$170,000	3,000	11	0.946%	0.598%	0.519%	0.506%	0.503%	0.502%	0.501%
\$170,000	4,000	11	0.743%	0.539%	0.508%	0.504%	0.503%	0.502%	0.501%
\$170,000	5,000	11	0.639%	0.518%	0.506%	0.504%	0.503%	0.502%	0.501%
\$170,000	10,000	11	0.512%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$170,000	20,000	11	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$180,000	5	11	61.623%	59.835%	58.117%	56.463%	54.868%	51.849%	49.031%
\$180,000	10	11	47.284%	45.178%	43.166%	41.249%	39.426%	36.035%	32.934%
\$180,000	15	11	39.117%	36.869%	34.751%	32.748%	30.851%	27.347%	24.193%
\$180,000	20	11	33.899%	31.553%	29.342%	27.260%	25.299%	21.715%	18.542%
\$180,000	25	11	29.810%	27.396%	25.134%	23.026%	21.068%	17.561%	14.559%
\$180,000	50	11	19.593%	17.189%	15.045%	13.137%	11.445%	8.642%	6.497%
\$180,000	100	11	12.830%	10.596%	8.712%	7.138%	5.836%	3.881%	2.591%
\$180,000	150	11	9.846%	7.776%	6.095%	4.750%	3.695%	2.248%	1.414%
\$180,000	200	11	8.144%	6.186%	4.657%	3.491%	2.619%	1.506%	0.947%
\$180,000	300	11	6.247%	4.470%	3.171%	2.249%	1.616%	0.918%	0.640%
\$180,000	400	11	5.111%	3.493%	2.371%	1.628%	1.155%	0.694%	0.550%
\$180,000	500	11	4.345%	2.860%	1.883%	1.269%	0.905%	0.597%	0.522%
\$180,000	600	11	3.784%	2.408%	1.548%	1.042%	0.765%	0.556%	0.511%
\$180,000	700	11	3.347%	2.071%	1.310%	0.891%	0.676%	0.531%	0.505%
\$180,000	800	11	3.038%	1.839%	1.153%	0.795%	0.621%	0.517%	0.503%
\$180,000	900	11	2.748%	1.628%	1.020%	0.719%	0.584%	0.511%	0.502%
\$180,000	1,000	11	2.512%	1.460%	0.915%	0.661%	0.556%	0.506%	0.501%
\$180,000	1,500	11	1.796%	1.003%	0.668%	0.549%	0.513%	0.502%	0.501%
\$180,000	2,000	11	1.391%	0.784%	0.575%	0.518%	0.505%	0.502%	0.501%
\$180,000	3,000	11	0.967%	0.605%	0.520%	0.506%	0.503%	0.502%	0.501%
\$180,000	4,000	11	0.758%	0.542%	0.508%	0.504%	0.503%	0.502%	0.501%
\$180,000	5,000	11	0.648%	0.520%	0.506%	0.504%	0.503%	0.502%	0.501%
\$180,000	10,000	11	0.512%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$180,000	20,000	11	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$190,000	5	11	61.896%	60.119%	58.412%	56.768%	55.183%	52.183%	49.384%
\$190,000	10	11	47.619%	45.529%	43.532%	41.632%	39.826%	36.465%	33.392%
\$190,000	15	11	39.495%	37.269%	35.171%	33.187%	31.309%	27.840%	24.720%
\$190,000	20	11	34.301%	31.978%	29.788%	27.728%	25.790%	22.244%	19.100%
\$190,000	25	11	30.233%	27.844%	25.605%	23.515%	21.569%	18.070%	15.056%
\$190,000	50	11	19.931%	17.526%	15.376%	13.460%	11.758%	8.925%	6.747%
\$190,000	100	11	13.057%	10.816%	8.920%	7.332%	6.014%	4.028%	2.704%
\$190,000	150	11	10.025%	7.946%	6.251%	4.890%	3.818%	2.338%	1.474%
\$190,000	200	11	8.302%	6.332%	4.788%	3.604%	2.714%	1.567%	0.982%
\$190,000	300	11	6.369%	4.579%	3.262%	2.323%	1.674%	0.949%	0.654%
\$190,000	400	11	5.213%	3.580%	2.442%	1.682%	1.194%	0.711%	0.556%
\$190,000	500	11	4.434%	2.933%	1.938%	1.310%	0.932%	0.607%	0.525%
\$190,000	600	11	3.855%	2.465%	1.588%	1.069%	0.781%	0.560%	0.511%
\$190,000	700	11	3.416%	2.124%	1.347%	0.915%	0.690%	0.535%	0.506%
\$190,000	800	11	3.104%	1.887%	1.185%	0.815%	0.632%	0.519%	0.503%
\$190,000	900	11	2.806%	1.670%	1.047%	0.734%	0.592%	0.512%	0.502%
\$190,000	1,000	11	2.567%	1.498%	0.938%	0.673%	0.562%	0.506%	0.501%
\$190,000	1,500	11	1.837%	1.027%	0.680%	0.553%	0.514%	0.502%	0.501%
\$190,000	2,000	11	1.423%	0.800%	0.581%	0.520%	0.506%	0.502%	0.501%
\$190,000	3,000	11	0.988%	0.612%	0.522%	0.506%	0.503%	0.502%	0.501%
\$190,000	4,000	11	0.772%	0.546%	0.509%	0.504%	0.503%	0.502%	0.501%
\$190,000	5,000	11	0.658%	0.521%	0.506%	0.504%	0.503%	0.502%	0.501%
\$190,000	10,000	11	0.513%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$190,000	20,000	11	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$200,000	5	11	62.137%	60.370%	58.672%	57.037%	55.461%	52.479%	49.696%
\$200,000	10	11	47.917%	45.841%	43.858%	41.973%	40.181%	36.846%	33.798%
\$200,000	15	11	39.830%	37.623%	35.542%	33.575%	31.713%	28.276%	25.186%
\$200,000	20	11	34.661%	32.358%	30.188%	28.147%	26.228%	22.718%	19.605%
\$200,000	25	11	30.615%	28.247%	26.031%	23.961%	22.029%	18.542%	15.526%
\$200,000	50	11	20.247%	17.841%	15.686%	13.763%	12.050%	9.193%	6.982%
\$200,000	100	11	13.267%	11.021%	9.115%	7.514%	6.181%	4.166%	2.812%
\$200,000	150	11	10.191%	8.105%	6.399%	5.022%	3.934%	2.424%	1.532%
\$200,000	200	11	8.451%	6.470%	4.912%	3.713%	2.805%	1.626%	1.018%
\$200,000	300	11	6.483%	4.681%	3.349%	2.394%	1.730%	0.979%	0.668%
\$200,000	400	11	5.310%	3.662%	2.509%	1.734%	1.231%	0.728%	0.562%
\$200,000	500	11	4.517%	3.002%	1.992%	1.348%	0.959%	0.617%	0.527%
\$200,000	600	11	3.928%	2.524%	1.631%	1.098%	0.800%	0.566%	0.513%
\$200,000	700	11	3.481%	2.175%	1.383%	0.938%	0.703%	0.538%	0.507%
\$200,000	800	11	3.165%	1.933%	1.216%	0.833%	0.642%	0.521%	0.503%
\$200,000	900	11	2.861%	1.710%	1.073%	0.749%	0.599%	0.513%	0.502%
\$200,000	1,000	11	2.618%	1.534%	0.959%	0.685%	0.567%	0.507%	0.501%
\$200,000	1,500	11	1.875%	1.050%	0.691%	0.558%	0.516%	0.502%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$200,000	2,000	11	1.454%	0.816%	0.587%	0.522%	0.506%	0.502%	0.501%
\$200,000	3,000	11	1.008%	0.619%	0.524%	0.507%	0.504%	0.502%	0.501%
\$200,000	4,000	11	0.786%	0.549%	0.509%	0.504%	0.503%	0.502%	0.501%
\$200,000	5,000	11	0.667%	0.523%	0.506%	0.504%	0.503%	0.502%	0.501%
\$200,000	10,000	11	0.514%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$200,000	20,000	11	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$225,000	5	11	62.625%	60.878%	59.199%	57.583%	56.025%	53.079%	50.327%
\$225,000	10	11	48.540%	46.492%	44.538%	42.683%	40.920%	37.639%	34.643%
\$225,000	15	11	40.523%	38.354%	36.309%	34.377%	32.548%	29.175%	26.145%
\$225,000	20	11	35.403%	33.140%	31.010%	29.009%	27.130%	23.692%	20.648%
\$225,000	25	11	31.407%	29.085%	26.914%	24.890%	22.997%	19.564%	16.567%
\$225,000	50	11	20.939%	18.538%	16.378%	14.439%	12.708%	9.798%	7.523%
\$225,000	100	11	13.731%	11.475%	9.550%	7.925%	6.561%	4.479%	3.061%
\$225,000	150	11	10.561%	8.458%	6.729%	5.322%	4.201%	2.622%	1.668%
\$225,000	200	11	8.775%	6.774%	5.187%	3.956%	3.012%	1.765%	1.103%
\$225,000	300	11	6.737%	4.908%	3.543%	2.554%	1.857%	1.051%	0.704%
\$225,000	400	11	5.522%	3.845%	2.660%	1.851%	1.317%	0.768%	0.578%
\$225,000	500	11	4.701%	3.157%	2.112%	1.438%	1.020%	0.640%	0.535%
\$225,000	600	11	4.089%	2.654%	1.730%	1.166%	0.843%	0.580%	0.516%
\$225,000	700	11	3.626%	2.288%	1.464%	0.990%	0.735%	0.547%	0.509%
\$225,000	800	11	3.300%	2.036%	1.286%	0.876%	0.667%	0.527%	0.504%
\$225,000	900	11	2.984%	1.800%	1.132%	0.784%	0.617%	0.517%	0.502%
\$225,000	1,000	11	2.730%	1.614%	1.009%	0.712%	0.580%	0.509%	0.501%
\$225,000	1,500	11	1.960%	1.102%	0.717%	0.568%	0.519%	0.503%	0.501%
\$225,000	2,000	11	1.523%	0.852%	0.602%	0.526%	0.507%	0.502%	0.501%
\$225,000	3,000	11	1.052%	0.635%	0.528%	0.507%	0.504%	0.502%	0.501%
\$225,000	4,000	11	0.817%	0.557%	0.510%	0.504%	0.503%	0.502%	0.501%
\$225,000	5,000	11	0.688%	0.527%	0.506%	0.504%	0.503%	0.502%	0.501%
\$225,000	10,000	11	0.515%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$225,000	20,000	11	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$250,000	5	11	63.030%	61.300%	59.636%	58.034%	56.492%	53.576%	50.849%
\$250,000	10	11	49.058%	47.033%	45.104%	43.274%	41.535%	38.297%	35.343%
\$250,000	15	11	41.086%	38.949%	36.933%	35.028%	33.226%	29.905%	26.925%
\$250,000	20	11	36.008%	33.777%	31.681%	29.713%	27.864%	24.485%	21.497%
\$250,000	25	11	32.052%	29.768%	27.635%	25.647%	23.788%	20.419%	17.468%
\$250,000	50	11	21.561%	19.173%	17.015%	15.071%	13.326%	10.373%	8.045%
\$250,000	100	11	14.155%	11.894%	9.955%	8.309%	6.918%	4.776%	3.299%
\$250,000	150	11	10.903%	8.785%	7.034%	5.606%	4.457%	2.813%	1.805%
\$250,000	200	11	9.075%	7.056%	5.445%	4.186%	3.210%	1.901%	1.189%
\$250,000	300	11	6.969%	5.119%	3.727%	2.707%	1.979%	1.123%	0.741%
\$250,000	400	11	5.715%	4.015%	2.801%	1.963%	1.400%	0.810%	0.595%
\$250,000	500	11	4.870%	3.301%	2.226%	1.523%	1.081%	0.666%	0.543%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$250,000	600	11	4.238%	2.777%	1.824%	1.232%	0.887%	0.595%	0.521%
\$250,000	700	11	3.760%	2.395%	1.541%	1.042%	0.768%	0.557%	0.511%
\$250,000	800	11	3.425%	2.132%	1.353%	0.919%	0.692%	0.533%	0.505%
\$250,000	900	11	3.097%	1.885%	1.188%	0.818%	0.636%	0.521%	0.503%
\$250,000	1,000	11	2.835%	1.689%	1.057%	0.739%	0.593%	0.511%	0.502%
\$250,000	1,500	11	2.040%	1.152%	0.743%	0.579%	0.523%	0.503%	0.501%
\$250,000	2,000	11	1.587%	0.886%	0.616%	0.531%	0.508%	0.502%	0.501%
\$250,000	3,000	11	1.094%	0.652%	0.532%	0.508%	0.504%	0.502%	0.501%
\$250,000	4,000	11	0.847%	0.565%	0.512%	0.505%	0.503%	0.502%	0.501%
\$250,000	5,000	11	0.708%	0.531%	0.507%	0.504%	0.503%	0.502%	0.501%
\$250,000	10,000	11	0.517%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$250,000	20,000	11	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$275,000	5	11	63.370%	61.653%	60.002%	58.413%	56.884%	53.992%	51.289%
\$275,000	10	11	49.506%	47.500%	45.593%	43.784%	42.067%	38.865%	35.948%
\$275,000	15	11	41.582%	39.472%	37.481%	35.600%	33.821%	30.545%	27.607%
\$275,000	20	11	36.534%	34.332%	32.264%	30.324%	28.502%	25.175%	22.233%
\$275,000	25	11	32.616%	30.363%	28.263%	26.307%	24.477%	21.164%	18.264%
\$275,000	50	11	22.128%	19.763%	17.615%	15.672%	13.921%	10.936%	8.558%
\$275,000	100	11	14.560%	12.292%	10.342%	8.678%	7.265%	5.070%	3.537%
\$275,000	150	11	11.232%	9.098%	7.329%	5.882%	4.709%	3.004%	1.944%
\$275,000	200	11	9.361%	7.329%	5.697%	4.411%	3.405%	2.039%	1.280%
\$275,000	300	11	7.191%	5.321%	3.903%	2.856%	2.100%	1.196%	0.780%
\$275,000	400	11	5.899%	4.178%	2.937%	2.072%	1.483%	0.853%	0.613%
\$275,000	500	11	5.030%	3.439%	2.336%	1.607%	1.142%	0.692%	0.553%
\$275,000	600	11	4.381%	2.895%	1.914%	1.298%	0.932%	0.612%	0.526%
\$275,000	700	11	3.881%	2.492%	1.612%	1.090%	0.798%	0.566%	0.513%
\$275,000	800	11	3.543%	2.225%	1.419%	0.962%	0.717%	0.540%	0.507%
\$275,000	900	11	3.204%	1.966%	1.244%	0.852%	0.655%	0.525%	0.504%
\$275,000	1,000	11	2.934%	1.762%	1.104%	0.767%	0.607%	0.514%	0.502%
\$275,000	1,500	11	2.115%	1.200%	0.769%	0.591%	0.527%	0.503%	0.501%
\$275,000	2,000	11	1.648%	0.920%	0.631%	0.536%	0.510%	0.503%	0.501%
\$275,000	3,000	11	1.135%	0.668%	0.536%	0.509%	0.504%	0.502%	0.501%
\$275,000	4,000	11	0.875%	0.574%	0.513%	0.505%	0.503%	0.502%	0.501%
\$275,000	5,000	11	0.728%	0.535%	0.507%	0.504%	0.503%	0.502%	0.501%
\$275,000	10,000	11	0.519%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$275,000	20,000	11	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$300,000	5	11	63.658%	61.952%	60.312%	58.734%	57.216%	54.344%	51.660%
\$300,000	10	11	49.879%	47.889%	46.001%	44.209%	42.508%	39.336%	36.452%
\$300,000	15	11	41.999%	39.910%	37.940%	36.079%	34.319%	31.080%	28.177%
\$300,000	20	11	36.967%	34.788%	32.744%	30.826%	29.026%	25.742%	22.837%
\$300,000	25	11	33.085%	30.859%	28.786%	26.855%	25.049%	21.782%	18.924%
\$300,000	50	11	22.620%	20.277%	18.148%	16.214%	14.464%	11.461%	9.049%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$300,000	100	11	14.934%	12.663%	10.704%	9.024%	7.591%	5.350%	3.767%
\$300,000	150	11	11.535%	9.391%	7.604%	6.139%	4.944%	3.188%	2.078%
\$300,000	200	11	9.622%	7.579%	5.930%	4.619%	3.587%	2.171%	1.368%
\$300,000	300	11	7.394%	5.507%	4.067%	2.995%	2.215%	1.267%	0.818%
\$300,000	400	11	6.065%	4.328%	3.063%	2.173%	1.561%	0.895%	0.631%
\$300,000	500	11	5.174%	3.563%	2.438%	1.685%	1.199%	0.719%	0.562%
\$300,000	600	11	4.510%	3.003%	1.998%	1.360%	0.975%	0.629%	0.532%
\$300,000	700	11	3.997%	2.586%	1.682%	1.139%	0.830%	0.577%	0.516%
\$300,000	800	11	3.650%	2.309%	1.480%	1.002%	0.742%	0.547%	0.508%
\$300,000	900	11	3.301%	2.040%	1.295%	0.884%	0.674%	0.530%	0.505%
\$300,000	1,000	11	3.024%	1.829%	1.149%	0.793%	0.621%	0.517%	0.502%
\$300,000	1,500	11	2.183%	1.244%	0.793%	0.602%	0.531%	0.503%	0.501%
\$300,000	2,000	11	1.703%	0.951%	0.645%	0.541%	0.511%	0.503%	0.501%
\$300,000	3,000	11	1.172%	0.684%	0.541%	0.510%	0.504%	0.502%	0.501%
\$300,000	4,000	11	0.902%	0.582%	0.515%	0.505%	0.503%	0.502%	0.501%
\$300,000	5,000	11	0.747%	0.539%	0.508%	0.504%	0.503%	0.502%	0.501%
\$300,000	10,000	11	0.521%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$300,000	20,000	11	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$325,000	5	11	63.892%	62.196%	60.565%	58.996%	57.487%	54.631%	51.964%
\$325,000	10	11	50.183%	48.208%	46.335%	44.558%	42.871%	39.724%	36.866%
\$325,000	15	11	42.348%	40.277%	38.324%	36.480%	34.736%	31.529%	28.654%
\$325,000	20	11	37.323%	35.164%	33.139%	31.241%	29.459%	26.211%	23.337%
\$325,000	25	11	33.477%	31.274%	29.224%	27.313%	25.528%	22.300%	19.476%
\$325,000	50	11	23.045%	20.727%	18.616%	16.696%	14.953%	11.946%	9.507%
\$325,000	100	11	15.275%	13.005%	11.037%	9.344%	7.893%	5.613%	3.983%
\$325,000	150	11	11.815%	9.662%	7.860%	6.377%	5.163%	3.364%	2.207%
\$325,000	200	11	9.860%	7.808%	6.144%	4.813%	3.758%	2.297%	1.454%
\$325,000	300	11	7.581%	5.679%	4.220%	3.126%	2.324%	1.335%	0.858%
\$325,000	400	11	6.217%	4.464%	3.179%	2.266%	1.634%	0.935%	0.650%
\$325,000	500	11	5.303%	3.677%	2.532%	1.757%	1.253%	0.745%	0.573%
\$325,000	600	11	4.627%	3.102%	2.076%	1.418%	1.015%	0.645%	0.538%
\$325,000	700	11	4.102%	2.673%	1.747%	1.185%	0.860%	0.588%	0.519%
\$325,000	800	11	3.746%	2.386%	1.537%	1.040%	0.765%	0.555%	0.510%
\$325,000	900	11	3.389%	2.108%	1.342%	0.915%	0.692%	0.535%	0.506%
\$325,000	1,000	11	3.106%	1.891%	1.191%	0.819%	0.635%	0.520%	0.503%
\$325,000	1,500	11	2.244%	1.285%	0.816%	0.613%	0.536%	0.504%	0.501%
\$325,000	2,000	11	1.753%	0.980%	0.659%	0.546%	0.513%	0.503%	0.501%
\$325,000	3,000	11	1.207%	0.699%	0.546%	0.511%	0.504%	0.502%	0.501%
\$325,000	4,000	11	0.926%	0.589%	0.516%	0.505%	0.503%	0.502%	0.501%
\$325,000	5,000	11	0.764%	0.543%	0.508%	0.504%	0.503%	0.502%	0.501%
\$325,000	10,000	11	0.523%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$325,000	20,000	11	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$350,000	5	11	64.101%	62.413%	60.789%	59.228%	57.727%	54.885%	52.231%
\$350,000	10	11	50.450%	48.486%	46.626%	44.862%	43.185%	40.060%	37.223%
\$350,000	15	11	42.648%	40.592%	38.653%	36.823%	35.092%	31.911%	29.060%
\$350,000	20	11	37.620%	35.477%	33.469%	31.587%	29.819%	26.600%	23.751%
\$350,000	25	11	33.804%	31.620%	29.588%	27.694%	25.926%	22.729%	19.934%
\$350,000	50	11	23.397%	21.103%	19.011%	17.105%	15.373%	12.372%	9.918%
\$350,000	100	11	15.573%	13.304%	11.332%	9.627%	8.163%	5.847%	4.178%
\$350,000	150	11	12.058%	9.901%	8.085%	6.587%	5.356%	3.523%	2.325%
\$350,000	200	11	10.069%	8.008%	6.333%	4.985%	3.909%	2.411%	1.534%
\$350,000	300	11	7.742%	5.829%	4.355%	3.243%	2.421%	1.397%	0.894%
\$350,000	400	11	6.348%	4.583%	3.281%	2.348%	1.700%	0.972%	0.668%
\$350,000	500	11	5.416%	3.776%	2.614%	1.822%	1.301%	0.769%	0.583%
\$350,000	600	11	4.729%	3.188%	2.145%	1.470%	1.052%	0.661%	0.544%
\$350,000	700	11	4.194%	2.749%	1.806%	1.227%	0.888%	0.599%	0.523%
\$350,000	800	11	3.823%	2.448%	1.582%	1.070%	0.784%	0.560%	0.511%
\$350,000	900	11	3.465%	2.168%	1.385%	0.943%	0.709%	0.540%	0.507%
\$350,000	1,000	11	3.177%	1.945%	1.228%	0.842%	0.648%	0.523%	0.503%
\$350,000	1,500	11	2.298%	1.321%	0.837%	0.624%	0.540%	0.504%	0.501%
\$350,000	2,000	11	1.797%	1.006%	0.671%	0.551%	0.514%	0.503%	0.501%
\$350,000	3,000	11	1.238%	0.713%	0.550%	0.512%	0.505%	0.502%	0.501%
\$350,000	4,000	11	0.948%	0.597%	0.518%	0.505%	0.503%	0.502%	0.501%
\$350,000	5,000	11	0.780%	0.547%	0.509%	0.504%	0.503%	0.502%	0.501%
\$350,000	10,000	11	0.525%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$350,000	20,000	11	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$375,000	5	11	64.288%	62.607%	60.990%	59.436%	57.941%	55.112%	52.471%
\$375,000	10	11	50.693%	48.741%	46.892%	45.138%	43.472%	40.366%	37.548%
\$375,000	15	11	42.920%	40.877%	38.951%	37.132%	35.414%	32.256%	29.426%
\$375,000	20	11	37.890%	35.761%	33.767%	31.899%	30.145%	26.951%	24.125%
\$375,000	25	11	34.102%	31.934%	29.919%	28.040%	26.286%	23.117%	20.348%
\$375,000	50	11	23.713%	21.439%	19.367%	17.478%	15.758%	12.770%	10.313%
\$375,000	100	11	15.854%	13.588%	11.615%	9.900%	8.425%	6.077%	4.373%
\$375,000	150	11	12.287%	10.128%	8.303%	6.792%	5.544%	3.678%	2.445%
\$375,000	200	11	10.268%	8.200%	6.514%	5.150%	4.056%	2.524%	1.615%
\$375,000	300	11	7.895%	5.972%	4.484%	3.356%	2.516%	1.459%	0.932%
\$375,000	400	11	6.474%	4.697%	3.380%	2.429%	1.764%	1.008%	0.687%
\$375,000	500	11	5.526%	3.872%	2.695%	1.886%	1.349%	0.794%	0.593%
\$375,000	600	11	4.827%	3.272%	2.212%	1.521%	1.088%	0.678%	0.551%
\$375,000	700	11	4.282%	2.822%	1.863%	1.268%	0.915%	0.609%	0.526%
\$375,000	800	11	3.904%	2.513%	1.631%	1.104%	0.807%	0.567%	0.513%
\$375,000	900	11	3.538%	2.226%	1.427%	0.970%	0.726%	0.545%	0.509%
\$375,000	1,000	11	3.245%	1.998%	1.264%	0.865%	0.662%	0.526%	0.504%
\$375,000	1,500	11	2.349%	1.356%	0.858%	0.635%	0.545%	0.504%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$375,000	2,000	11	1.838%	1.032%	0.684%	0.556%	0.516%	0.503%	0.501%
\$375,000	3,000	11	1.267%	0.726%	0.555%	0.513%	0.505%	0.502%	0.501%
\$375,000	4,000	11	0.969%	0.604%	0.519%	0.505%	0.503%	0.502%	0.501%
\$375,000	5,000	11	0.795%	0.551%	0.509%	0.504%	0.503%	0.502%	0.501%
\$375,000	10,000	11	0.527%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$375,000	20,000	11	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$400,000	5	11	64.457%	62.782%	61.171%	59.623%	58.134%	55.316%	52.686%
\$400,000	10	11	50.909%	48.966%	47.127%	45.383%	43.725%	40.636%	37.836%
\$400,000	15	11	43.164%	41.132%	39.218%	37.410%	35.702%	32.564%	29.753%
\$400,000	20	11	38.134%	36.018%	34.036%	32.180%	30.437%	27.267%	24.461%
\$400,000	25	11	34.366%	32.213%	30.212%	28.347%	26.606%	23.461%	20.714%
\$400,000	50	11	23.993%	21.738%	19.684%	17.811%	16.105%	13.135%	10.682%
\$400,000	100	11	16.112%	13.853%	11.879%	10.161%	8.674%	6.298%	4.562%
\$400,000	150	11	12.503%	10.342%	8.512%	6.987%	5.725%	3.827%	2.563%
\$400,000	200	11	10.454%	8.379%	6.684%	5.307%	4.197%	2.632%	1.694%
\$400,000	300	11	8.040%	6.108%	4.607%	3.464%	2.607%	1.520%	0.969%
\$400,000	400	11	6.594%	4.807%	3.476%	2.509%	1.828%	1.046%	0.706%
\$400,000	500	11	5.630%	3.965%	2.773%	1.949%	1.397%	0.819%	0.604%
\$400,000	600	11	4.920%	3.353%	2.278%	1.571%	1.124%	0.694%	0.557%
\$400,000	700	11	4.365%	2.892%	1.918%	1.307%	0.942%	0.620%	0.530%
\$400,000	800	11	3.980%	2.576%	1.679%	1.138%	0.828%	0.575%	0.515%
\$400,000	900	11	3.608%	2.282%	1.468%	0.998%	0.743%	0.550%	0.510%
\$400,000	1,000	11	3.310%	2.048%	1.301%	0.888%	0.675%	0.530%	0.505%
\$400,000	1,500	11	2.398%	1.390%	0.878%	0.645%	0.550%	0.505%	0.501%
\$400,000	2,000	11	1.878%	1.056%	0.696%	0.561%	0.518%	0.503%	0.501%
\$400,000	3,000	11	1.295%	0.739%	0.559%	0.514%	0.505%	0.502%	0.501%
\$400,000	4,000	11	0.989%	0.611%	0.521%	0.506%	0.503%	0.502%	0.501%
\$400,000	5,000	11	0.809%	0.555%	0.510%	0.504%	0.503%	0.502%	0.501%
\$400,000	10,000	11	0.529%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$400,000	20,000	11	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$425,000	5	11	64.605%	62.935%	61.330%	59.787%	58.304%	55.495%	52.875%
\$425,000	10	11	51.097%	49.164%	47.333%	45.598%	43.948%	40.874%	38.088%
\$425,000	15	11	43.377%	41.355%	39.450%	37.652%	35.954%	32.834%	30.039%
\$425,000	20	11	38.348%	36.245%	34.274%	32.429%	30.696%	27.547%	24.758%
\$425,000	25	11	34.598%	32.458%	30.470%	28.616%	26.887%	23.763%	21.037%
\$425,000	50	11	24.244%	22.007%	19.969%	18.112%	16.420%	13.471%	11.027%
\$425,000	100	11	16.353%	14.102%	12.129%	10.408%	8.914%	6.513%	4.747%
\$425,000	150	11	12.707%	10.546%	8.712%	7.176%	5.901%	3.972%	2.679%
\$425,000	200	11	10.632%	8.551%	6.847%	5.458%	4.334%	2.738%	1.771%
\$425,000	300	11	8.179%	6.239%	4.726%	3.569%	2.697%	1.580%	1.006%
\$425,000	400	11	6.709%	4.912%	3.569%	2.588%	1.891%	1.083%	0.725%
\$425,000	500	11	5.730%	4.055%	2.849%	2.010%	1.444%	0.844%	0.615%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$425,000	600	11	5.009%	3.430%	2.341%	1.619%	1.159%	0.711%	0.564%
\$425,000	700	11	4.443%	2.958%	1.970%	1.345%	0.968%	0.631%	0.534%
\$425,000	800	11	4.052%	2.636%	1.724%	1.170%	0.850%	0.582%	0.518%
\$425,000	900	11	3.667%	2.330%	1.502%	1.020%	0.757%	0.554%	0.511%
\$425,000	1,000	11	3.372%	2.097%	1.335%	0.911%	0.689%	0.533%	0.506%
\$425,000	1,500	11	2.444%	1.422%	0.898%	0.656%	0.555%	0.506%	0.501%
\$425,000	2,000	11	1.917%	1.080%	0.708%	0.566%	0.519%	0.503%	0.501%
\$425,000	3,000	11	1.322%	0.752%	0.564%	0.515%	0.505%	0.502%	0.501%
\$425,000	4,000	11	1.008%	0.617%	0.522%	0.506%	0.503%	0.502%	0.501%
\$425,000	5,000	11	0.823%	0.559%	0.511%	0.504%	0.503%	0.502%	0.501%
\$425,000	10,000	11	0.530%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$425,000	20,000	11	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$450,000	5	11	64.708%	63.042%	61.441%	59.902%	58.423%	55.622%	53.009%
\$450,000	10	11	51.239%	49.313%	47.489%	45.761%	44.116%	41.055%	38.280%
\$450,000	15	11	43.541%	41.529%	39.631%	37.841%	36.150%	33.045%	30.263%
\$450,000	20	11	38.515%	36.420%	34.459%	32.623%	30.898%	27.765%	24.991%
\$450,000	25	11	34.785%	32.656%	30.679%	28.834%	27.114%	24.009%	21.298%
\$450,000	50	11	24.452%	22.229%	20.205%	18.361%	16.681%	13.752%	11.320%
\$450,000	100	11	16.560%	14.316%	12.348%	10.624%	9.127%	6.705%	4.912%
\$450,000	150	11	12.883%	10.722%	8.885%	7.343%	6.055%	4.099%	2.783%
\$450,000	200	11	10.785%	8.701%	6.989%	5.590%	4.454%	2.832%	1.840%
\$450,000	300	11	8.298%	6.352%	4.831%	3.661%	2.777%	1.634%	1.040%
\$450,000	400	11	6.810%	5.004%	3.652%	2.658%	1.949%	1.117%	0.744%
\$450,000	500	11	5.818%	4.134%	2.917%	2.065%	1.486%	0.867%	0.626%
\$450,000	600	11	5.086%	3.498%	2.397%	1.663%	1.192%	0.726%	0.570%
\$450,000	700	11	4.511%	3.016%	2.017%	1.380%	0.992%	0.641%	0.537%
\$450,000	800	11	4.116%	2.689%	1.765%	1.199%	0.869%	0.589%	0.520%
\$450,000	900	11	3.725%	2.377%	1.537%	1.045%	0.772%	0.559%	0.512%
\$450,000	1,000	11	3.425%	2.140%	1.367%	0.931%	0.701%	0.537%	0.506%
\$450,000	1,500	11	2.486%	1.451%	0.916%	0.666%	0.559%	0.506%	0.501%
\$450,000	2,000	11	1.950%	1.101%	0.719%	0.571%	0.521%	0.503%	0.501%
\$450,000	3,000	11	1.346%	0.763%	0.568%	0.516%	0.505%	0.502%	0.501%
\$450,000	4,000	11	1.025%	0.624%	0.524%	0.506%	0.503%	0.502%	0.501%
\$450,000	5,000	11	0.835%	0.562%	0.511%	0.504%	0.503%	0.502%	0.501%
\$450,000	10,000	11	0.532%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$450,000	20,000	11	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$475,000	5	11	64.792%	63.129%	61.532%	59.996%	58.520%	55.725%	53.119%
\$475,000	10	11	51.366%	49.446%	47.628%	45.906%	44.267%	41.215%	38.451%
\$475,000	15	11	43.683%	41.678%	39.788%	38.004%	36.320%	33.227%	30.456%
\$475,000	20	11	38.660%	36.574%	34.621%	32.791%	31.074%	27.955%	25.193%
\$475,000	25	11	34.948%	32.829%	30.860%	29.024%	27.312%	24.222%	21.525%
\$475,000	50	11	24.636%	22.426%	20.413%	18.580%	16.911%	14.001%	11.582%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$475,000	100	11	16.744%	14.509%	12.545%	10.821%	9.321%	6.883%	5.067%
\$475,000	150	11	13.042%	10.880%	9.042%	7.495%	6.196%	4.218%	2.881%
\$475,000	200	11	10.924%	8.837%	7.117%	5.710%	4.564%	2.920%	1.905%
\$475,000	300	11	8.407%	6.455%	4.926%	3.745%	2.851%	1.685%	1.073%
\$475,000	400	11	6.900%	5.088%	3.726%	2.723%	2.001%	1.149%	0.762%
\$475,000	500	11	5.898%	4.206%	2.979%	2.116%	1.526%	0.889%	0.636%
\$475,000	600	11	5.156%	3.560%	2.449%	1.704%	1.222%	0.741%	0.576%
\$475,000	700	11	4.574%	3.070%	2.060%	1.412%	1.015%	0.651%	0.541%
\$475,000	800	11	4.173%	2.737%	1.803%	1.226%	0.888%	0.596%	0.522%
\$475,000	900	11	3.777%	2.420%	1.570%	1.067%	0.787%	0.564%	0.514%
\$475,000	1,000	11	3.475%	2.179%	1.396%	0.950%	0.712%	0.540%	0.507%
\$475,000	1,500	11	2.523%	1.477%	0.932%	0.675%	0.564%	0.507%	0.501%
\$475,000	2,000	11	1.980%	1.120%	0.729%	0.575%	0.523%	0.503%	0.501%
\$475,000	3,000	11	1.368%	0.774%	0.572%	0.517%	0.506%	0.502%	0.501%
\$475,000	4,000	11	1.041%	0.629%	0.525%	0.506%	0.503%	0.502%	0.501%
\$475,000	5,000	11	0.847%	0.566%	0.512%	0.504%	0.503%	0.502%	0.501%
\$475,000	10,000	11	0.534%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$475,000	20,000	11	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$500,000	5	11	64.870%	63.211%	61.617%	60.085%	58.612%	55.822%	53.222%
\$500,000	10	11	51.490%	49.575%	47.764%	46.046%	44.412%	41.371%	38.616%
\$500,000	15	11	43.817%	41.818%	39.934%	38.156%	36.478%	33.397%	30.636%
\$500,000	20	11	38.796%	36.717%	34.772%	32.949%	31.238%	28.132%	25.382%
\$500,000	25	11	35.099%	32.989%	31.028%	29.200%	27.495%	24.419%	21.736%
\$500,000	50	11	24.807%	22.608%	20.606%	18.783%	17.124%	14.232%	11.827%
\$500,000	100	11	16.919%	14.692%	12.733%	11.012%	9.509%	7.058%	5.221%
\$500,000	150	11	13.194%	11.033%	9.194%	7.642%	6.336%	4.335%	2.979%
\$500,000	200	11	11.056%	8.968%	7.242%	5.826%	4.672%	3.007%	1.970%
\$500,000	300	11	8.511%	6.555%	5.019%	3.828%	2.923%	1.735%	1.106%
\$500,000	400	11	6.988%	5.169%	3.798%	2.785%	2.053%	1.181%	0.780%
\$500,000	500	11	5.974%	4.274%	3.038%	2.164%	1.565%	0.910%	0.646%
\$500,000	600	11	5.224%	3.620%	2.499%	1.743%	1.251%	0.755%	0.582%
\$500,000	700	11	4.634%	3.122%	2.102%	1.443%	1.037%	0.660%	0.544%
\$500,000	800	11	4.228%	2.784%	1.839%	1.253%	0.906%	0.603%	0.525%
\$500,000	900	11	3.828%	2.462%	1.602%	1.090%	0.801%	0.569%	0.515%
\$500,000	1,000	11	3.523%	2.218%	1.424%	0.969%	0.723%	0.544%	0.508%
\$500,000	1,500	11	2.559%	1.503%	0.948%	0.684%	0.568%	0.507%	0.501%
\$500,000	2,000	11	2.010%	1.139%	0.739%	0.580%	0.524%	0.504%	0.501%
\$500,000	3,000	11	1.389%	0.785%	0.576%	0.519%	0.506%	0.502%	0.501%
\$500,000	4,000	11	1.056%	0.635%	0.527%	0.507%	0.503%	0.502%	0.501%
\$500,000	5,000	11	0.858%	0.569%	0.512%	0.505%	0.503%	0.502%	0.501%
\$500,000	10,000	11	0.536%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$500,000	20,000	11	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$30,000	5	12	42.348%	39.652%	37.037%	34.510%	32.066%	27.540%	23.548%
\$30,000	10	12	27.128%	24.525%	22.135%	19.939%	17.918%	14.380%	11.453%
\$30,000	15	12	21.592%	19.041%	16.743%	14.680%	12.835%	9.745%	7.344%
\$30,000	20	12	18.094%	15.611%	13.415%	11.484%	9.801%	7.083%	5.074%
\$30,000	25	12	15.649%	13.241%	11.138%	9.329%	7.781%	5.367%	3.674%
\$30,000	50	12	10.175%	8.015%	6.256%	4.849%	3.739%	2.235%	1.381%
\$30,000	100	12	6.411%	4.593%	3.257%	2.301%	1.641%	0.922%	0.638%
\$30,000	150	12	4.802%	3.214%	2.139%	1.445%	1.018%	0.634%	0.530%
\$30,000	200	12	3.924%	2.502%	1.602%	1.071%	0.778%	0.554%	0.508%
\$30,000	300	12	2.910%	1.733%	1.077%	0.747%	0.598%	0.513%	0.502%
\$30,000	400	12	2.348%	1.335%	0.834%	0.617%	0.537%	0.503%	0.501%
\$30,000	500	12	1.971%	1.096%	0.707%	0.562%	0.516%	0.502%	0.501%
\$30,000	600	12	1.690%	0.931%	0.631%	0.534%	0.509%	0.502%	0.501%
\$30,000	700	12	1.489%	0.824%	0.587%	0.520%	0.505%	0.502%	0.501%
\$30,000	800	12	1.346%	0.754%	0.562%	0.514%	0.504%	0.502%	0.501%
\$30,000	900	12	1.220%	0.697%	0.543%	0.509%	0.504%	0.502%	0.501%
\$30,000	1,000	12	1.120%	0.657%	0.532%	0.507%	0.503%	0.502%	0.501%
\$30,000	1,500	12	0.815%	0.555%	0.510%	0.504%	0.503%	0.502%	0.501%
\$30,000	2,000	12	0.671%	0.523%	0.506%	0.504%	0.503%	0.502%	0.501%
\$30,000	3,000	12	0.555%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$30,000	4,000	12	0.523%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$30,000	5,000	12	0.512%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$30,000	10,000	12	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$30,000	20,000	12	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$35,000	5	12	44.610%	42.019%	39.519%	37.102%	34.761%	30.292%	26.170%
\$35,000	10	12	28.687%	26.052%	23.636%	21.412%	19.368%	15.768%	12.748%
\$35,000	15	12	22.873%	20.309%	17.984%	15.886%	14.002%	10.800%	8.270%
\$35,000	20	12	19.184%	16.678%	14.448%	12.475%	10.742%	7.908%	5.775%
\$35,000	25	12	16.607%	14.173%	12.037%	10.178%	8.575%	6.034%	4.214%
\$35,000	50	12	10.819%	8.620%	6.815%	5.347%	4.173%	2.548%	1.591%
\$35,000	100	12	6.842%	4.976%	3.578%	2.561%	1.844%	1.031%	0.687%
\$35,000	150	12	5.134%	3.492%	2.357%	1.605%	1.129%	0.678%	0.543%
\$35,000	200	12	4.191%	2.715%	1.759%	1.176%	0.844%	0.573%	0.512%
\$35,000	300	12	3.120%	1.887%	1.178%	0.806%	0.628%	0.519%	0.502%
\$35,000	400	12	2.525%	1.454%	0.902%	0.651%	0.551%	0.504%	0.501%
\$35,000	500	12	2.124%	1.190%	0.756%	0.583%	0.524%	0.503%	0.501%
\$35,000	600	12	1.824%	1.007%	0.666%	0.547%	0.512%	0.502%	0.501%
\$35,000	700	12	1.609%	0.886%	0.612%	0.528%	0.507%	0.502%	0.501%
\$35,000	800	12	1.456%	0.807%	0.581%	0.519%	0.505%	0.502%	0.501%
\$35,000	900	12	1.318%	0.740%	0.557%	0.512%	0.504%	0.502%	0.501%
\$35,000	1,000	12	1.210%	0.693%	0.542%	0.509%	0.503%	0.502%	0.501%
\$35,000	1,500	12	0.872%	0.571%	0.513%	0.505%	0.503%	0.502%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$35,000	2,000	12	0.708%	0.530%	0.507%	0.504%	0.503%	0.502%	0.501%
\$35,000	3,000	12	0.570%	0.509%	0.505%	0.504%	0.503%	0.502%	0.501%
\$35,000	4,000	12	0.529%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$35,000	5,000	12	0.515%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$35,000	10,000	12	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$35,000	20,000	12	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$40,000	5	12	46.501%	44.006%	41.598%	39.267%	37.011%	32.721%	28.698%
\$40,000	10	12	30.166%	27.495%	25.028%	22.762%	20.679%	17.013%	13.935%
\$40,000	15	12	24.035%	21.467%	19.127%	17.000%	15.079%	11.788%	9.147%
\$40,000	20	12	20.191%	17.667%	15.409%	13.400%	11.627%	8.687%	6.442%
\$40,000	25	12	17.488%	15.029%	12.862%	10.966%	9.314%	6.660%	4.731%
\$40,000	50	12	11.415%	9.180%	7.331%	5.815%	4.587%	2.852%	1.802%
\$40,000	100	12	7.242%	5.333%	3.884%	2.811%	2.043%	1.142%	0.743%
\$40,000	150	12	5.437%	3.751%	2.564%	1.761%	1.239%	0.726%	0.559%
\$40,000	200	12	4.442%	2.921%	1.914%	1.285%	0.915%	0.598%	0.518%
\$40,000	300	12	3.312%	2.033%	1.277%	0.865%	0.660%	0.526%	0.503%
\$40,000	400	12	2.687%	1.566%	0.969%	0.685%	0.566%	0.506%	0.501%
\$40,000	500	12	2.263%	1.279%	0.804%	0.605%	0.532%	0.503%	0.501%
\$40,000	600	12	1.946%	1.080%	0.701%	0.560%	0.516%	0.502%	0.501%
\$40,000	700	12	1.719%	0.946%	0.637%	0.536%	0.509%	0.502%	0.501%
\$40,000	800	12	1.557%	0.859%	0.601%	0.525%	0.506%	0.502%	0.501%
\$40,000	900	12	1.409%	0.783%	0.571%	0.516%	0.504%	0.502%	0.501%
\$40,000	1,000	12	1.293%	0.729%	0.553%	0.511%	0.504%	0.502%	0.501%
\$40,000	1,500	12	0.927%	0.588%	0.516%	0.505%	0.503%	0.502%	0.501%
\$40,000	2,000	12	0.745%	0.538%	0.507%	0.504%	0.503%	0.502%	0.501%
\$40,000	3,000	12	0.586%	0.511%	0.505%	0.504%	0.503%	0.502%	0.501%
\$40,000	4,000	12	0.536%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$40,000	5,000	12	0.518%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$40,000	10,000	12	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$40,000	20,000	12	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$45,000	5	12	48.138%	45.722%	43.388%	41.131%	38.952%	34.813%	30.927%
\$45,000	10	12	31.579%	28.876%	26.364%	24.046%	21.917%	18.166%	15.009%
\$45,000	15	12	25.091%	22.526%	20.182%	18.039%	16.085%	12.718%	9.995%
\$45,000	20	12	21.118%	18.586%	16.309%	14.269%	12.456%	9.429%	7.079%
\$45,000	25	12	18.294%	15.815%	13.622%	11.693%	10.003%	7.256%	5.228%
\$45,000	50	12	11.970%	9.708%	7.819%	6.259%	4.988%	3.152%	2.015%
\$45,000	100	12	7.615%	5.669%	4.176%	3.057%	2.239%	1.257%	0.803%
\$45,000	150	12	5.723%	3.997%	2.763%	1.915%	1.352%	0.778%	0.579%
\$45,000	200	12	4.679%	3.117%	2.066%	1.395%	0.988%	0.626%	0.526%
\$45,000	300	12	3.492%	2.172%	1.373%	0.925%	0.693%	0.535%	0.505%
\$45,000	400	12	2.838%	1.673%	1.035%	0.721%	0.583%	0.509%	0.501%
\$45,000	500	12	2.393%	1.365%	0.853%	0.628%	0.542%	0.504%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$45,000	600	12	2.061%	1.150%	0.736%	0.575%	0.521%	0.503%	0.501%
\$45,000	700	12	1.823%	1.005%	0.664%	0.546%	0.512%	0.502%	0.501%
\$45,000	800	12	1.652%	0.910%	0.622%	0.531%	0.508%	0.502%	0.501%
\$45,000	900	12	1.495%	0.826%	0.587%	0.520%	0.505%	0.502%	0.501%
\$45,000	1,000	12	1.371%	0.765%	0.565%	0.514%	0.504%	0.502%	0.501%
\$45,000	1,500	12	0.980%	0.605%	0.519%	0.505%	0.503%	0.502%	0.501%
\$45,000	2,000	12	0.781%	0.546%	0.509%	0.504%	0.503%	0.502%	0.501%
\$45,000	3,000	12	0.603%	0.513%	0.505%	0.504%	0.503%	0.502%	0.501%
\$45,000	4,000	12	0.544%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$45,000	5,000	12	0.521%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$45,000	10,000	12	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$45,000	20,000	12	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$50,000	5	12	49.550%	47.198%	44.927%	42.736%	40.622%	36.606%	32.836%
\$50,000	10	12	32.913%	30.191%	27.648%	25.286%	23.103%	19.254%	16.011%
\$50,000	15	12	26.055%	23.487%	21.137%	18.985%	17.013%	13.586%	10.793%
\$50,000	20	12	21.961%	19.423%	17.131%	15.069%	13.226%	10.120%	7.682%
\$50,000	25	12	19.027%	16.535%	14.321%	12.364%	10.639%	7.817%	5.702%
\$50,000	50	12	12.475%	10.191%	8.267%	6.674%	5.365%	3.440%	2.223%
\$50,000	100	12	7.957%	5.980%	4.448%	3.287%	2.428%	1.371%	0.866%
\$50,000	150	12	5.989%	4.226%	2.953%	2.065%	1.464%	0.832%	0.600%
\$50,000	200	12	4.894%	3.298%	2.209%	1.500%	1.060%	0.655%	0.535%
\$50,000	300	12	3.657%	2.300%	1.464%	0.984%	0.728%	0.544%	0.506%
\$50,000	400	12	2.976%	1.774%	1.099%	0.757%	0.601%	0.512%	0.501%
\$50,000	500	12	2.511%	1.445%	0.899%	0.652%	0.552%	0.506%	0.501%
\$50,000	600	12	2.165%	1.215%	0.770%	0.590%	0.527%	0.503%	0.501%
\$50,000	700	12	1.917%	1.061%	0.691%	0.556%	0.515%	0.502%	0.501%
\$50,000	800	12	1.738%	0.958%	0.643%	0.538%	0.510%	0.502%	0.501%
\$50,000	900	12	1.575%	0.867%	0.603%	0.525%	0.506%	0.502%	0.501%
\$50,000	1,000	12	1.444%	0.800%	0.578%	0.517%	0.505%	0.502%	0.501%
\$50,000	1,500	12	1.030%	0.623%	0.523%	0.506%	0.503%	0.502%	0.501%
\$50,000	2,000	12	0.816%	0.555%	0.510%	0.504%	0.503%	0.502%	0.501%
\$50,000	3,000	12	0.619%	0.515%	0.505%	0.504%	0.503%	0.502%	0.501%
\$50,000	4,000	12	0.551%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$50,000	5,000	12	0.525%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$50,000	10,000	12	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$50,000	20,000	12	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$55,000	5	12	50.781%	48.483%	46.268%	44.134%	42.077%	38.162%	34.492%
\$55,000	10	12	34.155%	31.435%	28.882%	26.493%	24.267%	20.313%	16.984%
\$55,000	15	12	26.962%	24.385%	22.022%	19.856%	17.873%	14.410%	11.548%
\$55,000	20	12	22.745%	20.205%	17.901%	15.823%	13.956%	10.780%	8.270%
\$55,000	25	12	19.716%	17.213%	14.979%	12.997%	11.244%	8.354%	6.162%
\$55,000	50	12	12.941%	10.638%	8.686%	7.062%	5.719%	3.717%	2.427%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$55,000	100	12	8.273%	6.269%	4.702%	3.506%	2.610%	1.484%	0.931%
\$55,000	150	12	6.235%	4.440%	3.131%	2.207%	1.572%	0.886%	0.623%
\$55,000	200	12	5.096%	3.469%	2.345%	1.602%	1.131%	0.685%	0.545%
\$55,000	300	12	3.812%	2.421%	1.552%	1.041%	0.763%	0.554%	0.508%
\$55,000	400	12	3.105%	1.869%	1.161%	0.793%	0.619%	0.516%	0.502%
\$55,000	500	12	2.621%	1.522%	0.945%	0.676%	0.563%	0.507%	0.501%
\$55,000	600	12	2.263%	1.279%	0.805%	0.606%	0.533%	0.504%	0.501%
\$55,000	700	12	2.006%	1.115%	0.717%	0.567%	0.518%	0.502%	0.501%
\$55,000	800	12	1.820%	1.005%	0.664%	0.546%	0.512%	0.502%	0.501%
\$55,000	900	12	1.650%	0.907%	0.620%	0.530%	0.507%	0.502%	0.501%
\$55,000	1,000	12	1.512%	0.834%	0.591%	0.521%	0.505%	0.502%	0.501%
\$55,000	1,500	12	1.078%	0.640%	0.528%	0.507%	0.503%	0.502%	0.501%
\$55,000	2,000	12	0.850%	0.564%	0.511%	0.504%	0.503%	0.502%	0.501%
\$55,000	3,000	12	0.636%	0.517%	0.505%	0.504%	0.503%	0.502%	0.501%
\$55,000	4,000	12	0.559%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$55,000	5,000	12	0.529%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$55,000	10,000	12	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$55,000	20,000	12	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$60,000	5	12	51.883%	49.634%	47.471%	45.387%	43.377%	39.553%	35.971%
\$60,000	10	12	35.327%	32.626%	30.074%	27.675%	25.426%	21.384%	17.958%
\$60,000	15	12	27.834%	25.243%	22.862%	20.680%	18.682%	15.188%	12.277%
\$60,000	20	12	23.478%	20.937%	18.625%	16.533%	14.644%	11.412%	8.833%
\$60,000	25	12	20.369%	17.859%	15.606%	13.601%	11.823%	8.872%	6.610%
\$60,000	50	12	13.381%	11.063%	9.086%	7.434%	6.059%	3.989%	2.630%
\$60,000	100	12	8.571%	6.542%	4.943%	3.715%	2.786%	1.597%	0.998%
\$60,000	150	12	6.464%	4.641%	3.299%	2.343%	1.677%	0.940%	0.647%
\$60,000	200	12	5.285%	3.629%	2.474%	1.699%	1.201%	0.715%	0.556%
\$60,000	300	12	3.956%	2.536%	1.636%	1.098%	0.797%	0.564%	0.511%
\$60,000	400	12	3.225%	1.959%	1.221%	0.829%	0.638%	0.520%	0.502%
\$60,000	500	12	2.724%	1.595%	0.991%	0.700%	0.574%	0.509%	0.502%
\$60,000	600	12	2.355%	1.340%	0.839%	0.622%	0.539%	0.504%	0.501%
\$60,000	700	12	2.089%	1.167%	0.744%	0.579%	0.522%	0.503%	0.501%
\$60,000	800	12	1.896%	1.050%	0.686%	0.555%	0.514%	0.502%	0.501%
\$60,000	900	12	1.721%	0.946%	0.637%	0.536%	0.509%	0.502%	0.501%
\$60,000	1,000	12	1.577%	0.868%	0.604%	0.525%	0.506%	0.502%	0.501%
\$60,000	1,500	12	1.124%	0.658%	0.532%	0.507%	0.503%	0.502%	0.501%
\$60,000	2,000	12	0.882%	0.574%	0.513%	0.505%	0.503%	0.502%	0.501%
\$60,000	3,000	12	0.653%	0.520%	0.506%	0.504%	0.503%	0.502%	0.501%
\$60,000	4,000	12	0.568%	0.509%	0.505%	0.504%	0.503%	0.502%	0.501%
\$60,000	5,000	12	0.533%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$60,000	10,000	12	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$60,000	20,000	12	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$65,000	5	12	52.876%	50.673%	48.554%	46.515%	44.545%	40.800%	37.297%
\$65,000	10	12	36.423%	33.755%	31.217%	28.817%	26.559%	22.465%	18.944%
\$65,000	15	12	28.681%	26.076%	23.677%	21.477%	19.460%	15.929%	12.978%
\$65,000	20	12	24.172%	21.629%	19.316%	17.210%	15.300%	12.023%	9.381%
\$65,000	25	12	20.990%	18.474%	16.209%	14.182%	12.379%	9.371%	7.045%
\$65,000	50	12	13.797%	11.467%	9.471%	7.790%	6.386%	4.256%	2.831%
\$65,000	100	12	8.853%	6.804%	5.176%	3.918%	2.958%	1.711%	1.064%
\$65,000	150	12	6.685%	4.836%	3.464%	2.477%	1.781%	0.995%	0.673%
\$65,000	200	12	5.468%	3.786%	2.600%	1.796%	1.270%	0.745%	0.568%
\$65,000	300	12	4.089%	2.642%	1.714%	1.151%	0.830%	0.574%	0.513%
\$65,000	400	12	3.341%	2.047%	1.280%	0.865%	0.658%	0.524%	0.503%
\$65,000	500	12	2.825%	1.667%	1.036%	0.725%	0.586%	0.511%	0.502%
\$65,000	600	12	2.444%	1.400%	0.873%	0.638%	0.546%	0.505%	0.501%
\$65,000	700	12	2.169%	1.218%	0.771%	0.590%	0.527%	0.503%	0.501%
\$65,000	800	12	1.970%	1.094%	0.708%	0.564%	0.517%	0.502%	0.501%
\$65,000	900	12	1.790%	0.985%	0.655%	0.542%	0.510%	0.502%	0.501%
\$65,000	1,000	12	1.640%	0.902%	0.618%	0.529%	0.507%	0.502%	0.501%
\$65,000	1,500	12	1.169%	0.676%	0.537%	0.508%	0.503%	0.502%	0.501%
\$65,000	2,000	12	0.915%	0.584%	0.515%	0.505%	0.503%	0.502%	0.501%
\$65,000	3,000	12	0.670%	0.523%	0.506%	0.504%	0.503%	0.502%	0.501%
\$65,000	4,000	12	0.577%	0.510%	0.505%	0.504%	0.503%	0.502%	0.501%
\$65,000	5,000	12	0.538%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$65,000	10,000	12	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$65,000	20,000	12	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$70,000	5	12	53.742%	51.580%	49.501%	47.497%	45.563%	41.888%	38.451%
\$70,000	10	12	37.392%	34.771%	32.262%	29.873%	27.613%	23.498%	19.902%
\$70,000	15	12	29.462%	26.846%	24.429%	22.209%	20.175%	16.605%	13.611%
\$70,000	20	12	24.808%	22.263%	19.945%	17.830%	15.904%	12.588%	9.891%
\$70,000	25	12	21.555%	19.033%	16.758%	14.717%	12.893%	9.833%	7.451%
\$70,000	50	12	14.177%	11.839%	9.828%	8.121%	6.692%	4.508%	3.025%
\$70,000	100	12	9.109%	7.042%	5.390%	4.105%	3.118%	1.820%	1.130%
\$70,000	150	12	6.886%	5.016%	3.618%	2.602%	1.880%	1.050%	0.698%
\$70,000	200	12	5.635%	3.930%	2.717%	1.887%	1.336%	0.775%	0.580%
\$70,000	300	12	4.217%	2.745%	1.790%	1.204%	0.865%	0.585%	0.516%
\$70,000	400	12	3.447%	2.129%	1.337%	0.900%	0.678%	0.529%	0.504%
\$70,000	500	12	2.917%	1.735%	1.080%	0.749%	0.598%	0.513%	0.502%
\$70,000	600	12	2.527%	1.457%	0.906%	0.655%	0.553%	0.506%	0.501%
\$70,000	700	12	2.242%	1.265%	0.796%	0.602%	0.531%	0.503%	0.501%
\$70,000	800	12	2.038%	1.136%	0.730%	0.573%	0.520%	0.503%	0.501%
\$70,000	900	12	1.853%	1.022%	0.672%	0.548%	0.512%	0.502%	0.501%
\$70,000	1,000	12	1.698%	0.934%	0.632%	0.534%	0.508%	0.502%	0.501%
\$70,000	1,500	12	1.211%	0.694%	0.542%	0.509%	0.504%	0.502%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$70,000	2,000	12	0.945%	0.593%	0.517%	0.505%	0.503%	0.502%	0.501%
\$70,000	3,000	12	0.686%	0.526%	0.506%	0.504%	0.503%	0.502%	0.501%
\$70,000	4,000	12	0.586%	0.511%	0.505%	0.504%	0.503%	0.502%	0.501%
\$70,000	5,000	12	0.543%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$70,000	10,000	12	0.508%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$70,000	20,000	12	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$75,000	5	12	54.535%	52.409%	50.365%	48.395%	46.492%	42.882%	39.503%
\$75,000	10	12	38.280%	35.706%	33.241%	30.879%	28.629%	24.503%	20.869%
\$75,000	15	12	30.227%	27.602%	25.171%	22.929%	20.874%	17.260%	14.220%
\$75,000	20	12	25.423%	22.874%	20.546%	18.421%	16.483%	13.132%	10.386%
\$75,000	25	12	22.101%	19.574%	17.291%	15.236%	13.395%	10.286%	7.850%
\$75,000	50	12	14.546%	12.198%	10.175%	8.446%	6.993%	4.755%	3.219%
\$75,000	100	12	9.355%	7.273%	5.601%	4.289%	3.276%	1.929%	1.196%
\$75,000	150	12	7.080%	5.191%	3.768%	2.726%	1.977%	1.105%	0.725%
\$75,000	200	12	5.796%	4.068%	2.831%	1.976%	1.402%	0.806%	0.592%
\$75,000	300	12	4.339%	2.845%	1.865%	1.257%	0.900%	0.597%	0.520%
\$75,000	400	12	3.550%	2.209%	1.393%	0.936%	0.698%	0.534%	0.505%
\$75,000	500	12	3.007%	1.801%	1.122%	0.774%	0.611%	0.516%	0.502%
\$75,000	600	12	2.607%	1.513%	0.939%	0.672%	0.561%	0.507%	0.501%
\$75,000	700	12	2.312%	1.311%	0.822%	0.614%	0.536%	0.504%	0.501%
\$75,000	800	12	2.104%	1.177%	0.751%	0.582%	0.524%	0.503%	0.501%
\$75,000	900	12	1.914%	1.058%	0.689%	0.555%	0.514%	0.502%	0.501%
\$75,000	1,000	12	1.754%	0.965%	0.646%	0.539%	0.509%	0.502%	0.501%
\$75,000	1,500	12	1.251%	0.711%	0.548%	0.510%	0.504%	0.502%	0.501%
\$75,000	2,000	12	0.975%	0.603%	0.519%	0.505%	0.503%	0.502%	0.501%
\$75,000	3,000	12	0.703%	0.529%	0.507%	0.504%	0.503%	0.502%	0.501%
\$75,000	4,000	12	0.595%	0.512%	0.505%	0.504%	0.503%	0.502%	0.501%
\$75,000	5,000	12	0.548%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$75,000	10,000	12	0.508%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$75,000	20,000	12	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$80,000	5	12	55.251%	53.157%	51.144%	49.202%	47.329%	43.776%	40.449%
\$80,000	10	12	39.090%	36.558%	34.134%	31.813%	29.591%	25.473%	21.812%
\$80,000	15	12	30.964%	28.338%	25.895%	23.637%	21.558%	17.897%	14.808%
\$80,000	20	12	26.018%	23.461%	21.121%	18.983%	17.033%	13.652%	10.862%
\$80,000	25	12	22.623%	20.093%	17.801%	15.736%	13.879%	10.726%	8.239%
\$80,000	50	12	14.901%	12.544%	10.508%	8.762%	7.284%	4.996%	3.411%
\$80,000	100	12	9.594%	7.496%	5.806%	4.470%	3.432%	2.038%	1.264%
\$80,000	150	12	7.270%	5.362%	3.917%	2.849%	2.076%	1.162%	0.754%
\$80,000	200	12	5.954%	4.205%	2.944%	2.065%	1.469%	0.838%	0.605%
\$80,000	300	12	4.458%	2.942%	1.939%	1.310%	0.935%	0.610%	0.523%
\$80,000	400	12	3.650%	2.288%	1.449%	0.971%	0.719%	0.539%	0.506%
\$80,000	500	12	3.093%	1.865%	1.165%	0.798%	0.624%	0.518%	0.503%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$80,000	600	12	2.684%	1.567%	0.972%	0.689%	0.568%	0.508%	0.501%
\$80,000	700	12	2.380%	1.357%	0.848%	0.627%	0.541%	0.504%	0.501%
\$80,000	800	12	2.167%	1.217%	0.773%	0.592%	0.527%	0.503%	0.501%
\$80,000	900	12	1.973%	1.094%	0.707%	0.562%	0.516%	0.502%	0.501%
\$80,000	1,000	12	1.808%	0.996%	0.660%	0.544%	0.511%	0.502%	0.501%
\$80,000	1,500	12	1.290%	0.729%	0.553%	0.512%	0.504%	0.502%	0.501%
\$80,000	2,000	12	1.004%	0.613%	0.521%	0.506%	0.503%	0.502%	0.501%
\$80,000	3,000	12	0.719%	0.532%	0.507%	0.504%	0.503%	0.502%	0.501%
\$80,000	4,000	12	0.604%	0.513%	0.505%	0.504%	0.503%	0.502%	0.501%
\$80,000	5,000	12	0.553%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$80,000	10,000	12	0.508%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$80,000	20,000	12	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$90,000	5	12	56.457%	54.418%	52.454%	50.562%	48.737%	45.278%	42.036%
\$90,000	10	12	40.482%	38.022%	35.668%	33.417%	31.265%	27.240%	23.565%
\$90,000	15	12	32.295%	29.680%	27.235%	24.959%	22.847%	19.091%	15.913%
\$90,000	20	12	27.104%	24.533%	22.168%	20.003%	18.029%	14.592%	11.737%
\$90,000	25	12	23.563%	21.028%	18.724%	16.639%	14.756%	11.535%	8.963%
\$90,000	50	12	15.545%	13.171%	11.112%	9.339%	7.820%	5.443%	3.772%
\$90,000	100	12	10.029%	7.905%	6.182%	4.804%	3.721%	2.242%	1.396%
\$90,000	150	12	7.615%	5.675%	4.190%	3.078%	2.262%	1.272%	0.811%
\$90,000	200	12	6.239%	4.455%	3.152%	2.229%	1.595%	0.900%	0.632%
\$90,000	300	12	4.675%	3.121%	2.077%	1.408%	1.002%	0.635%	0.531%
\$90,000	400	12	3.833%	2.433%	1.554%	1.040%	0.760%	0.551%	0.508%
\$90,000	500	12	3.251%	1.985%	1.245%	0.847%	0.650%	0.524%	0.504%
\$90,000	600	12	2.825%	1.667%	1.034%	0.722%	0.584%	0.511%	0.501%
\$90,000	700	12	2.505%	1.441%	0.897%	0.651%	0.551%	0.505%	0.501%
\$90,000	800	12	2.283%	1.292%	0.813%	0.611%	0.534%	0.504%	0.501%
\$90,000	900	12	2.081%	1.160%	0.740%	0.576%	0.521%	0.503%	0.501%
\$90,000	1,000	12	1.908%	1.054%	0.687%	0.554%	0.514%	0.502%	0.501%
\$90,000	1,500	12	1.363%	0.762%	0.565%	0.514%	0.504%	0.502%	0.501%
\$90,000	2,000	12	1.059%	0.633%	0.526%	0.506%	0.503%	0.502%	0.501%
\$90,000	3,000	12	0.749%	0.539%	0.508%	0.504%	0.503%	0.502%	0.501%
\$90,000	4,000	12	0.622%	0.515%	0.505%	0.504%	0.503%	0.502%	0.501%
\$90,000	5,000	12	0.563%	0.509%	0.505%	0.504%	0.503%	0.502%	0.501%
\$90,000	10,000	12	0.508%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$90,000	20,000	12	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$100,000	5	12	57.438%	55.440%	53.517%	51.665%	49.880%	46.494%	43.322%
\$100,000	10	12	41.645%	39.243%	36.948%	34.754%	32.663%	28.745%	25.148%
\$100,000	15	12	33.462%	30.872%	28.443%	26.169%	24.043%	20.212%	16.949%
\$100,000	20	12	28.094%	25.515%	23.130%	20.940%	18.940%	15.441%	12.532%
\$100,000	25	12	24.402%	21.860%	19.548%	17.448%	15.539%	12.268%	9.632%
\$100,000	50	12	16.126%	13.740%	11.662%	9.865%	8.318%	5.864%	4.117%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$100,000	100	12	10.420%	8.274%	6.522%	5.110%	3.989%	2.433%	1.526%
\$100,000	150	12	7.923%	5.957%	4.435%	3.286%	2.433%	1.379%	0.869%
\$100,000	200	12	6.494%	4.680%	3.341%	2.381%	1.711%	0.962%	0.660%
\$100,000	300	12	4.872%	3.285%	2.203%	1.501%	1.066%	0.661%	0.539%
\$100,000	400	12	3.990%	2.559%	1.646%	1.102%	0.798%	0.561%	0.510%
\$100,000	500	12	3.393%	2.095%	1.320%	0.893%	0.675%	0.530%	0.505%
\$100,000	600	12	2.952%	1.760%	1.093%	0.754%	0.600%	0.513%	0.502%
\$100,000	700	12	2.618%	1.519%	0.944%	0.674%	0.562%	0.507%	0.501%
\$100,000	800	12	2.387%	1.361%	0.852%	0.629%	0.542%	0.505%	0.501%
\$100,000	900	12	2.177%	1.221%	0.773%	0.590%	0.526%	0.503%	0.501%
\$100,000	1,000	12	1.997%	1.108%	0.713%	0.565%	0.517%	0.502%	0.501%
\$100,000	1,500	12	1.430%	0.794%	0.576%	0.517%	0.505%	0.502%	0.501%
\$100,000	2,000	12	1.110%	0.653%	0.531%	0.507%	0.503%	0.502%	0.501%
\$100,000	3,000	12	0.778%	0.546%	0.509%	0.504%	0.503%	0.502%	0.501%
\$100,000	4,000	12	0.639%	0.518%	0.506%	0.504%	0.503%	0.502%	0.501%
\$100,000	5,000	12	0.573%	0.509%	0.505%	0.504%	0.503%	0.502%	0.501%
\$100,000	10,000	12	0.509%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$100,000	20,000	12	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$110,000	5	12	58.271%	56.308%	54.418%	52.599%	50.849%	47.523%	44.412%
\$110,000	10	12	42.640%	40.287%	38.042%	35.899%	33.857%	30.029%	26.524%
\$110,000	15	12	34.486%	31.942%	29.540%	27.277%	25.151%	21.292%	17.954%
\$110,000	20	12	29.012%	26.432%	24.038%	21.832%	19.803%	16.238%	13.277%
\$110,000	25	12	25.179%	22.630%	20.307%	18.193%	16.267%	12.951%	10.261%
\$110,000	50	12	16.662%	14.267%	12.173%	10.356%	8.783%	6.263%	4.446%
\$110,000	100	12	10.782%	8.617%	6.839%	5.396%	4.242%	2.620%	1.655%
\$110,000	150	12	8.210%	6.222%	4.668%	3.484%	2.598%	1.485%	0.928%
\$110,000	200	12	6.733%	4.893%	3.521%	2.529%	1.827%	1.024%	0.690%
\$110,000	300	12	5.056%	3.440%	2.325%	1.590%	1.129%	0.688%	0.548%
\$110,000	400	12	4.145%	2.683%	1.739%	1.166%	0.837%	0.574%	0.513%
\$110,000	500	12	3.526%	2.198%	1.391%	0.937%	0.701%	0.537%	0.506%
\$110,000	600	12	3.070%	1.847%	1.151%	0.787%	0.616%	0.516%	0.502%
\$110,000	700	12	2.722%	1.593%	0.990%	0.698%	0.573%	0.508%	0.501%
\$110,000	800	12	2.484%	1.426%	0.889%	0.648%	0.550%	0.505%	0.501%
\$110,000	900	12	2.267%	1.279%	0.804%	0.604%	0.531%	0.503%	0.501%
\$110,000	1,000	12	2.081%	1.160%	0.740%	0.576%	0.521%	0.503%	0.501%
\$110,000	1,500	12	1.493%	0.826%	0.588%	0.521%	0.505%	0.502%	0.501%
\$110,000	2,000	12	1.158%	0.672%	0.536%	0.508%	0.503%	0.502%	0.501%
\$110,000	3,000	12	0.807%	0.553%	0.510%	0.504%	0.503%	0.502%	0.501%
\$110,000	4,000	12	0.656%	0.520%	0.506%	0.504%	0.503%	0.502%	0.501%
\$110,000	5,000	12	0.583%	0.510%	0.505%	0.504%	0.503%	0.502%	0.501%
\$110,000	10,000	12	0.509%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$110,000	20,000	12	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$120,000	5	12	58.990%	57.056%	55.196%	53.406%	51.683%	48.409%	45.350%
\$120,000	10	12	43.501%	41.191%	38.988%	36.890%	34.888%	31.139%	27.713%
\$120,000	15	12	35.379%	32.888%	30.527%	28.291%	26.172%	22.310%	18.931%
\$120,000	20	12	29.861%	27.289%	24.895%	22.680%	20.630%	17.008%	13.982%
\$120,000	25	12	25.913%	23.361%	21.027%	18.895%	16.953%	13.599%	10.859%
\$120,000	50	12	17.166%	14.765%	12.656%	10.817%	9.221%	6.646%	4.763%
\$120,000	100	12	11.123%	8.941%	7.140%	5.669%	4.484%	2.801%	1.783%
\$120,000	150	12	8.478%	6.470%	4.888%	3.671%	2.755%	1.587%	0.988%
\$120,000	200	12	6.957%	5.095%	3.694%	2.671%	1.940%	1.088%	0.721%
\$120,000	300	12	5.229%	3.587%	2.442%	1.677%	1.191%	0.716%	0.558%
\$120,000	400	12	4.289%	2.800%	1.827%	1.228%	0.877%	0.587%	0.517%
\$120,000	500	12	3.649%	2.294%	1.459%	0.981%	0.726%	0.544%	0.508%
\$120,000	600	12	3.180%	1.929%	1.206%	0.819%	0.632%	0.520%	0.502%
\$120,000	700	12	2.820%	1.662%	1.033%	0.722%	0.584%	0.510%	0.501%
\$120,000	800	12	2.575%	1.488%	0.926%	0.666%	0.558%	0.506%	0.501%
\$120,000	900	12	2.351%	1.334%	0.834%	0.618%	0.537%	0.504%	0.501%
\$120,000	1,000	12	2.159%	1.209%	0.765%	0.587%	0.525%	0.503%	0.501%
\$120,000	1,500	12	1.551%	0.855%	0.599%	0.524%	0.506%	0.502%	0.501%
\$120,000	2,000	12	1.203%	0.690%	0.541%	0.509%	0.504%	0.502%	0.501%
\$120,000	3,000	12	0.834%	0.560%	0.511%	0.504%	0.503%	0.502%	0.501%
\$120,000	4,000	12	0.672%	0.523%	0.506%	0.504%	0.503%	0.502%	0.501%
\$120,000	5,000	12	0.593%	0.511%	0.505%	0.504%	0.503%	0.502%	0.501%
\$120,000	10,000	12	0.510%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$120,000	20,000	12	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$130,000	5	12	59.641%	57.733%	55.899%	54.136%	52.436%	49.208%	46.196%
\$130,000	10	12	44.275%	42.003%	39.838%	37.778%	35.810%	32.131%	28.775%
\$130,000	15	12	36.189%	33.744%	31.429%	29.230%	27.138%	23.291%	19.894%
\$130,000	20	12	30.658%	28.102%	25.717%	23.500%	21.440%	17.773%	14.683%
\$130,000	25	12	26.624%	24.075%	21.735%	19.586%	17.629%	14.236%	11.450%
\$130,000	50	12	17.653%	15.248%	13.123%	11.265%	9.648%	7.021%	5.077%
\$130,000	100	12	11.451%	9.255%	7.432%	5.936%	4.723%	2.981%	1.912%
\$130,000	150	12	8.733%	6.707%	5.100%	3.855%	2.910%	1.690%	1.051%
\$130,000	200	12	7.172%	5.289%	3.862%	2.811%	2.052%	1.153%	0.753%
\$130,000	300	12	5.395%	3.729%	2.556%	1.764%	1.253%	0.744%	0.569%
\$130,000	400	12	4.426%	2.912%	1.914%	1.289%	0.917%	0.601%	0.520%
\$130,000	500	12	3.767%	2.388%	1.526%	1.024%	0.751%	0.551%	0.509%
\$130,000	600	12	3.284%	2.008%	1.259%	0.850%	0.649%	0.523%	0.503%
\$130,000	700	12	2.913%	1.729%	1.076%	0.746%	0.596%	0.512%	0.501%
\$130,000	800	12	2.661%	1.548%	0.961%	0.685%	0.567%	0.507%	0.501%
\$130,000	900	12	2.430%	1.387%	0.865%	0.633%	0.543%	0.505%	0.501%
\$130,000	1,000	12	2.233%	1.256%	0.791%	0.598%	0.529%	0.503%	0.501%
\$130,000	1,500	12	1.606%	0.884%	0.611%	0.527%	0.507%	0.502%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$130,000	2,000	12	1.246%	0.709%	0.547%	0.510%	0.504%	0.502%	0.501%
\$130,000	3,000	12	0.861%	0.567%	0.512%	0.504%	0.503%	0.502%	0.501%
\$130,000	4,000	12	0.689%	0.526%	0.506%	0.504%	0.503%	0.502%	0.501%
\$130,000	5,000	12	0.603%	0.513%	0.505%	0.504%	0.503%	0.502%	0.501%
\$130,000	10,000	12	0.511%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$130,000	20,000	12	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$140,000	5	12	60.225%	58.341%	56.530%	54.790%	53.111%	49.925%	46.955%
\$140,000	10	12	44.962%	42.724%	40.594%	38.567%	36.630%	33.011%	29.717%
\$140,000	15	12	36.912%	34.509%	32.233%	30.070%	28.014%	24.212%	20.808%
\$140,000	20	12	31.397%	28.866%	26.497%	24.284%	22.221%	18.527%	15.380%
\$140,000	25	12	27.306%	24.765%	22.420%	20.260%	18.287%	14.854%	12.021%
\$140,000	50	12	18.118%	15.709%	13.574%	11.698%	10.060%	7.385%	5.385%
\$140,000	100	12	11.767%	9.558%	7.716%	6.196%	4.955%	3.159%	2.041%
\$140,000	150	12	8.979%	6.935%	5.306%	4.036%	3.062%	1.792%	1.114%
\$140,000	200	12	7.378%	5.476%	4.026%	2.948%	2.163%	1.218%	0.788%
\$140,000	300	12	5.553%	3.866%	2.668%	1.850%	1.315%	0.774%	0.580%
\$140,000	400	12	4.557%	3.021%	1.998%	1.350%	0.958%	0.616%	0.524%
\$140,000	500	12	3.875%	2.473%	1.587%	1.064%	0.775%	0.557%	0.510%
\$140,000	600	12	3.385%	2.085%	1.312%	0.883%	0.667%	0.527%	0.503%
\$140,000	700	12	3.003%	1.796%	1.119%	0.770%	0.608%	0.514%	0.502%
\$140,000	800	12	2.744%	1.607%	0.997%	0.704%	0.576%	0.509%	0.501%
\$140,000	900	12	2.507%	1.439%	0.895%	0.649%	0.550%	0.505%	0.501%
\$140,000	1,000	12	2.305%	1.303%	0.817%	0.610%	0.533%	0.503%	0.501%
\$140,000	1,500	12	1.660%	0.913%	0.623%	0.531%	0.508%	0.502%	0.501%
\$140,000	2,000	12	1.288%	0.727%	0.553%	0.512%	0.504%	0.502%	0.501%
\$140,000	3,000	12	0.887%	0.575%	0.513%	0.505%	0.503%	0.502%	0.501%
\$140,000	4,000	12	0.705%	0.530%	0.507%	0.504%	0.503%	0.502%	0.501%
\$140,000	5,000	12	0.613%	0.514%	0.505%	0.504%	0.503%	0.502%	0.501%
\$140,000	10,000	12	0.511%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$140,000	20,000	12	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$150,000	5	12	60.745%	58.882%	57.092%	55.371%	53.711%	50.561%	47.626%
\$150,000	10	12	45.566%	43.358%	41.259%	39.259%	37.348%	33.783%	30.542%
\$150,000	15	12	37.538%	35.169%	32.926%	30.794%	28.771%	25.027%	21.644%
\$150,000	20	12	32.050%	29.550%	27.202%	24.999%	22.937%	19.232%	16.045%
\$150,000	25	12	27.930%	25.399%	23.055%	20.890%	18.905%	15.436%	12.559%
\$150,000	50	12	18.541%	16.129%	13.986%	12.098%	10.442%	7.725%	5.676%
\$150,000	100	12	12.058%	9.837%	7.978%	6.438%	5.171%	3.327%	2.164%
\$150,000	150	12	9.203%	7.143%	5.496%	4.205%	3.207%	1.890%	1.177%
\$150,000	200	12	7.567%	5.648%	4.178%	3.077%	2.268%	1.282%	0.822%
\$150,000	300	12	5.699%	3.994%	2.772%	1.932%	1.375%	0.803%	0.592%
\$150,000	400	12	4.680%	3.122%	2.078%	1.408%	0.998%	0.631%	0.529%
\$150,000	500	12	3.982%	2.559%	1.650%	1.106%	0.801%	0.566%	0.512%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$150,000	600	12	3.479%	2.157%	1.362%	0.914%	0.684%	0.532%	0.504%
\$150,000	700	12	3.087%	1.859%	1.160%	0.794%	0.621%	0.516%	0.502%
\$150,000	800	12	2.821%	1.663%	1.032%	0.724%	0.585%	0.510%	0.502%
\$150,000	900	12	2.578%	1.488%	0.925%	0.664%	0.557%	0.506%	0.501%
\$150,000	1,000	12	2.371%	1.348%	0.842%	0.622%	0.538%	0.504%	0.501%
\$150,000	1,500	12	1.709%	0.941%	0.635%	0.535%	0.509%	0.502%	0.501%
\$150,000	2,000	12	1.327%	0.745%	0.558%	0.513%	0.504%	0.502%	0.501%
\$150,000	3,000	12	0.912%	0.583%	0.515%	0.505%	0.503%	0.502%	0.501%
\$150,000	4,000	12	0.722%	0.533%	0.507%	0.504%	0.503%	0.502%	0.501%
\$150,000	5,000	12	0.623%	0.515%	0.505%	0.504%	0.503%	0.502%	0.501%
\$150,000	10,000	12	0.512%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$150,000	20,000	12	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$160,000	5	12	61.218%	59.373%	57.602%	55.898%	54.255%	51.137%	48.235%
\$160,000	10	12	46.109%	43.927%	41.854%	39.878%	37.992%	34.475%	31.278%
\$160,000	15	12	38.096%	35.757%	33.542%	31.438%	29.442%	25.752%	22.411%
\$160,000	20	12	32.637%	30.170%	27.848%	25.661%	23.607%	19.901%	16.691%
\$160,000	25	12	28.507%	25.991%	23.651%	21.487%	19.495%	15.994%	13.074%
\$160,000	50	12	18.936%	16.520%	14.370%	12.471%	10.801%	8.046%	5.955%
\$160,000	100	12	12.327%	10.098%	8.223%	6.664%	5.376%	3.487%	2.283%
\$160,000	150	12	9.414%	7.340%	5.675%	4.363%	3.343%	1.985%	1.238%
\$160,000	200	12	7.743%	5.809%	4.321%	3.198%	2.368%	1.343%	0.856%
\$160,000	300	12	5.836%	4.114%	2.871%	2.010%	1.434%	0.832%	0.604%
\$160,000	400	12	4.793%	3.217%	2.153%	1.463%	1.036%	0.647%	0.534%
\$160,000	500	12	4.081%	2.639%	1.709%	1.147%	0.826%	0.574%	0.514%
\$160,000	600	12	3.567%	2.225%	1.410%	0.945%	0.702%	0.536%	0.505%
\$160,000	700	12	3.166%	1.918%	1.199%	0.817%	0.634%	0.519%	0.502%
\$160,000	800	12	2.893%	1.715%	1.065%	0.742%	0.595%	0.512%	0.502%
\$160,000	900	12	2.645%	1.535%	0.953%	0.679%	0.564%	0.507%	0.501%
\$160,000	1,000	12	2.433%	1.389%	0.866%	0.634%	0.543%	0.504%	0.501%
\$160,000	1,500	12	1.756%	0.967%	0.646%	0.539%	0.510%	0.502%	0.501%
\$160,000	2,000	12	1.365%	0.762%	0.564%	0.514%	0.504%	0.502%	0.501%
\$160,000	3,000	12	0.936%	0.590%	0.516%	0.505%	0.503%	0.502%	0.501%
\$160,000	4,000	12	0.737%	0.536%	0.507%	0.504%	0.503%	0.502%	0.501%
\$160,000	5,000	12	0.634%	0.517%	0.505%	0.504%	0.503%	0.502%	0.501%
\$160,000	10,000	12	0.513%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$160,000	20,000	12	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$170,000	5	12	61.646%	59.818%	58.064%	56.374%	54.746%	51.658%	48.784%
\$170,000	10	12	46.601%	44.442%	42.393%	40.439%	38.573%	35.100%	31.942%
\$170,000	15	12	38.601%	36.289%	34.099%	32.020%	30.050%	26.407%	23.110%
\$170,000	20	12	33.171%	30.736%	28.443%	26.278%	24.239%	20.541%	17.318%
\$170,000	25	12	29.048%	26.547%	24.217%	22.057%	20.065%	16.538%	13.579%
\$170,000	50	12	19.307%	16.888%	14.731%	12.821%	11.137%	8.352%	6.221%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$170,000	100	12	12.580%	10.343%	8.455%	6.879%	5.572%	3.642%	2.397%
\$170,000	150	12	9.609%	7.523%	5.841%	4.511%	3.472%	2.076%	1.297%
\$170,000	200	12	7.907%	5.960%	4.456%	3.313%	2.463%	1.403%	0.890%
\$170,000	300	12	5.964%	4.227%	2.964%	2.084%	1.490%	0.860%	0.617%
\$170,000	400	12	4.898%	3.306%	2.224%	1.516%	1.073%	0.662%	0.539%
\$170,000	500	12	4.172%	2.714%	1.766%	1.186%	0.852%	0.582%	0.517%
\$170,000	600	12	3.648%	2.289%	1.455%	0.975%	0.720%	0.541%	0.506%
\$170,000	700	12	3.239%	1.974%	1.237%	0.840%	0.647%	0.522%	0.502%
\$170,000	800	12	2.960%	1.764%	1.097%	0.760%	0.604%	0.513%	0.502%
\$170,000	900	12	2.707%	1.579%	0.980%	0.694%	0.571%	0.508%	0.501%
\$170,000	1,000	12	2.491%	1.429%	0.889%	0.646%	0.548%	0.505%	0.501%
\$170,000	1,500	12	1.799%	0.992%	0.658%	0.544%	0.511%	0.502%	0.501%
\$170,000	2,000	12	1.400%	0.779%	0.570%	0.516%	0.505%	0.502%	0.501%
\$170,000	3,000	12	0.959%	0.598%	0.517%	0.505%	0.503%	0.502%	0.501%
\$170,000	4,000	12	0.752%	0.540%	0.508%	0.504%	0.503%	0.502%	0.501%
\$170,000	5,000	12	0.643%	0.518%	0.506%	0.504%	0.503%	0.502%	0.501%
\$170,000	10,000	12	0.514%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$170,000	20,000	12	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$180,000	5	12	62.047%	60.234%	58.495%	56.820%	55.205%	52.145%	49.297%
\$180,000	10	12	47.063%	44.927%	42.899%	40.964%	39.119%	35.687%	32.564%
\$180,000	15	12	39.075%	36.789%	34.622%	32.566%	30.620%	27.020%	23.765%
\$180,000	20	12	33.673%	31.268%	29.002%	26.863%	24.846%	21.168%	17.940%
\$180,000	25	12	29.563%	27.084%	24.767%	22.616%	20.625%	17.086%	14.092%
\$180,000	50	12	19.667%	17.248%	15.085%	13.165%	11.467%	8.654%	6.486%
\$180,000	100	12	12.827%	10.582%	8.681%	7.089%	5.765%	3.795%	2.512%
\$180,000	150	12	9.800%	7.702%	6.004%	4.656%	3.599%	2.166%	1.356%
\$180,000	200	12	8.066%	6.108%	4.588%	3.425%	2.557%	1.463%	0.924%
\$180,000	300	12	6.088%	4.337%	3.056%	2.158%	1.547%	0.889%	0.630%
\$180,000	400	12	5.001%	3.393%	2.294%	1.569%	1.110%	0.678%	0.545%
\$180,000	500	12	4.262%	2.787%	1.822%	1.225%	0.877%	0.591%	0.519%
\$180,000	600	12	3.728%	2.352%	1.501%	1.005%	0.738%	0.546%	0.507%
\$180,000	700	12	3.311%	2.029%	1.274%	0.864%	0.660%	0.525%	0.503%
\$180,000	800	12	3.025%	1.813%	1.129%	0.779%	0.614%	0.515%	0.502%
\$180,000	900	12	2.768%	1.622%	1.007%	0.709%	0.578%	0.509%	0.501%
\$180,000	1,000	12	2.548%	1.468%	0.912%	0.658%	0.554%	0.505%	0.501%
\$180,000	1,500	12	1.842%	1.017%	0.670%	0.548%	0.513%	0.502%	0.501%
\$180,000	2,000	12	1.434%	0.796%	0.576%	0.517%	0.505%	0.502%	0.501%
\$180,000	3,000	12	0.981%	0.605%	0.519%	0.505%	0.503%	0.502%	0.501%
\$180,000	4,000	12	0.767%	0.543%	0.508%	0.504%	0.503%	0.502%	0.501%
\$180,000	5,000	12	0.653%	0.520%	0.506%	0.504%	0.503%	0.502%	0.501%
\$180,000	10,000	12	0.515%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$180,000	20,000	12	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$190,000	5	12	62.407%	60.608%	58.882%	57.219%	55.616%	52.581%	49.756%
\$190,000	10	12	47.475%	45.360%	43.350%	41.433%	39.607%	36.210%	33.119%
\$190,000	15	12	39.501%	37.237%	35.090%	33.056%	31.130%	27.569%	24.351%
\$190,000	20	12	34.124%	31.745%	29.502%	27.387%	25.394%	21.749%	18.525%
\$190,000	25	12	30.026%	27.571%	25.273%	23.134%	21.147%	17.603%	14.583%
\$190,000	50	12	20.007%	17.587%	15.419%	13.489%	11.779%	8.939%	6.737%
\$190,000	100	12	13.062%	10.809%	8.897%	7.291%	5.949%	3.942%	2.622%
\$190,000	150	12	9.981%	7.872%	6.160%	4.795%	3.722%	2.254%	1.414%
\$190,000	200	12	8.217%	6.248%	4.713%	3.532%	2.646%	1.521%	0.958%
\$190,000	300	12	6.208%	4.442%	3.144%	2.230%	1.602%	0.917%	0.642%
\$190,000	400	12	5.099%	3.477%	2.361%	1.619%	1.147%	0.693%	0.551%
\$190,000	500	12	4.347%	2.858%	1.876%	1.264%	0.902%	0.600%	0.521%
\$190,000	600	12	3.804%	2.413%	1.545%	1.034%	0.756%	0.551%	0.508%
\$190,000	700	12	3.380%	2.082%	1.311%	0.887%	0.673%	0.528%	0.503%
\$190,000	800	12	3.088%	1.859%	1.159%	0.797%	0.624%	0.517%	0.502%
\$190,000	900	12	2.826%	1.664%	1.033%	0.724%	0.585%	0.510%	0.502%
\$190,000	1,000	12	2.602%	1.506%	0.935%	0.670%	0.559%	0.506%	0.501%
\$190,000	1,500	12	1.882%	1.041%	0.681%	0.553%	0.514%	0.502%	0.501%
\$190,000	2,000	12	1.467%	0.812%	0.582%	0.519%	0.505%	0.502%	0.501%
\$190,000	3,000	12	1.003%	0.613%	0.521%	0.506%	0.503%	0.502%	0.501%
\$190,000	4,000	12	0.782%	0.547%	0.509%	0.504%	0.503%	0.502%	0.501%
\$190,000	5,000	12	0.662%	0.521%	0.506%	0.504%	0.503%	0.502%	0.501%
\$190,000	10,000	12	0.515%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$190,000	20,000	12	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$200,000	5	12	62.725%	60.938%	59.223%	57.572%	55.980%	52.967%	50.162%
\$200,000	10	12	47.844%	45.747%	43.754%	41.852%	40.042%	36.678%	33.615%
\$200,000	15	12	39.880%	37.636%	35.508%	33.492%	31.585%	28.057%	24.873%
\$200,000	20	12	34.527%	32.171%	29.950%	27.856%	25.884%	22.275%	19.069%
\$200,000	25	12	30.439%	28.006%	25.730%	23.606%	21.628%	18.086%	15.047%
\$200,000	50	12	20.323%	17.902%	15.732%	13.793%	12.073%	9.207%	6.977%
\$200,000	100	12	13.285%	11.025%	9.103%	7.482%	6.127%	4.085%	2.730%
\$200,000	150	12	10.151%	8.034%	6.309%	4.928%	3.839%	2.338%	1.470%
\$200,000	200	12	8.359%	6.380%	4.831%	3.635%	2.732%	1.577%	0.991%
\$200,000	300	12	6.319%	4.541%	3.228%	2.298%	1.655%	0.945%	0.655%
\$200,000	400	12	5.191%	3.556%	2.424%	1.668%	1.181%	0.708%	0.557%
\$200,000	500	12	4.427%	2.924%	1.927%	1.300%	0.926%	0.609%	0.524%
\$200,000	600	12	3.875%	2.470%	1.587%	1.063%	0.773%	0.556%	0.509%
\$200,000	700	12	3.444%	2.132%	1.346%	0.909%	0.686%	0.532%	0.504%
\$200,000	800	12	3.146%	1.903%	1.189%	0.814%	0.633%	0.519%	0.503%
\$200,000	900	12	2.881%	1.703%	1.059%	0.738%	0.593%	0.511%	0.502%
\$200,000	1,000	12	2.653%	1.543%	0.957%	0.682%	0.564%	0.507%	0.501%
\$200,000	1,500	12	1.920%	1.063%	0.692%	0.557%	0.515%	0.502%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$200,000	2,000	12	1.499%	0.828%	0.588%	0.521%	0.505%	0.502%	0.501%
\$200,000	3,000	12	1.023%	0.620%	0.522%	0.506%	0.503%	0.502%	0.501%
\$200,000	4,000	12	0.796%	0.550%	0.509%	0.504%	0.503%	0.502%	0.501%
\$200,000	5,000	12	0.672%	0.523%	0.506%	0.504%	0.503%	0.502%	0.501%
\$200,000	10,000	12	0.516%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$200,000	20,000	12	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$225,000	5	12	63.391%	61.630%	59.939%	58.311%	56.741%	53.774%	51.011%
\$225,000	10	12	48.631%	46.571%	44.611%	42.744%	40.967%	37.670%	34.665%
\$225,000	15	12	40.685%	38.480%	36.391%	34.415%	32.545%	29.088%	25.972%
\$225,000	20	12	35.378%	33.067%	30.891%	28.841%	26.913%	23.384%	20.247%
\$225,000	25	12	31.304%	28.921%	26.695%	24.617%	22.674%	19.159%	16.107%
\$225,000	50	12	21.032%	18.613%	16.436%	14.484%	12.742%	9.819%	7.533%
\$225,000	100	12	13.794%	11.521%	9.576%	7.926%	6.538%	4.422%	2.986%
\$225,000	150	12	10.540%	8.404%	6.651%	5.237%	4.111%	2.539%	1.610%
\$225,000	200	12	8.682%	6.684%	5.103%	3.873%	2.933%	1.712%	1.072%
\$225,000	300	12	6.574%	4.767%	3.422%	2.456%	1.779%	1.013%	0.687%
\$225,000	400	12	5.401%	3.738%	2.571%	1.780%	1.264%	0.747%	0.571%
\$225,000	500	12	4.610%	3.076%	2.047%	1.387%	0.984%	0.631%	0.531%
\$225,000	600	12	4.031%	2.597%	1.680%	1.126%	0.813%	0.567%	0.511%
\$225,000	700	12	3.590%	2.247%	1.427%	0.962%	0.717%	0.540%	0.505%
\$225,000	800	12	3.280%	2.005%	1.258%	0.856%	0.656%	0.525%	0.503%
\$225,000	900	12	3.005%	1.796%	1.119%	0.773%	0.610%	0.514%	0.502%
\$225,000	1,000	12	2.770%	1.626%	1.009%	0.710%	0.578%	0.508%	0.501%
\$225,000	1,500	12	2.007%	1.117%	0.719%	0.568%	0.519%	0.502%	0.501%
\$225,000	2,000	12	1.569%	0.865%	0.602%	0.525%	0.506%	0.502%	0.501%
\$225,000	3,000	12	1.071%	0.638%	0.527%	0.506%	0.503%	0.502%	0.501%
\$225,000	4,000	12	0.828%	0.559%	0.510%	0.504%	0.503%	0.502%	0.501%
\$225,000	5,000	12	0.693%	0.527%	0.506%	0.504%	0.503%	0.502%	0.501%
\$225,000	10,000	12	0.518%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$225,000	20,000	12	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$250,000	5	12	63.893%	62.152%	60.479%	58.868%	57.316%	54.384%	51.651%
\$250,000	10	12	49.232%	47.200%	45.266%	43.425%	41.672%	38.426%	35.467%
\$250,000	15	12	41.302%	39.127%	37.067%	35.122%	33.280%	29.877%	26.814%
\$250,000	20	12	36.020%	33.744%	31.602%	29.585%	27.690%	24.224%	21.146%
\$250,000	25	12	31.957%	29.614%	27.427%	25.386%	23.480%	20.021%	16.990%
\$250,000	50	12	21.624%	19.209%	17.031%	15.072%	13.315%	10.347%	8.015%
\$250,000	100	12	14.222%	11.939%	9.980%	8.306%	6.891%	4.717%	3.217%
\$250,000	150	12	10.872%	8.721%	6.947%	5.506%	4.351%	2.719%	1.737%
\$250,000	200	12	8.959%	6.944%	5.340%	4.083%	3.112%	1.835%	1.149%
\$250,000	300	12	6.795%	4.967%	3.595%	2.601%	1.895%	1.078%	0.720%
\$250,000	400	12	5.583%	3.897%	2.702%	1.882%	1.341%	0.784%	0.586%
\$250,000	500	12	4.768%	3.209%	2.153%	1.465%	1.038%	0.653%	0.539%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$250,000	600	12	4.172%	2.713%	1.768%	1.187%	0.853%	0.581%	0.514%
\$250,000	700	12	3.716%	2.349%	1.502%	1.011%	0.747%	0.549%	0.507%
\$250,000	800	12	3.395%	2.094%	1.319%	0.895%	0.679%	0.530%	0.504%
\$250,000	900	12	3.113%	1.877%	1.173%	0.805%	0.628%	0.518%	0.502%
\$250,000	1,000	12	2.871%	1.700%	1.056%	0.736%	0.591%	0.510%	0.501%
\$250,000	1,500	12	2.082%	1.163%	0.743%	0.578%	0.522%	0.503%	0.501%
\$250,000	2,000	12	1.631%	0.897%	0.616%	0.529%	0.507%	0.502%	0.501%
\$250,000	3,000	12	1.113%	0.654%	0.531%	0.507%	0.503%	0.502%	0.501%
\$250,000	4,000	12	0.857%	0.567%	0.512%	0.504%	0.503%	0.502%	0.501%
\$250,000	5,000	12	0.713%	0.531%	0.507%	0.504%	0.503%	0.502%	0.501%
\$250,000	10,000	12	0.521%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$250,000	20,000	12	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$275,000	5	12	64.299%	62.574%	60.915%	59.318%	57.781%	54.877%	52.169%
\$275,000	10	12	49.723%	47.714%	45.800%	43.981%	42.250%	39.044%	36.122%
\$275,000	15	12	41.812%	39.661%	37.628%	35.707%	33.889%	30.530%	27.511%
\$275,000	20	12	36.551%	34.304%	32.190%	30.202%	28.334%	24.919%	21.890%
\$275,000	25	12	32.508%	30.198%	28.044%	26.034%	24.158%	20.755%	17.770%
\$275,000	50	12	22.163%	19.760%	17.583%	15.621%	13.853%	10.848%	8.468%
\$275,000	100	12	14.611%	12.323%	10.351%	8.660%	7.223%	4.997%	3.443%
\$275,000	150	12	11.180%	9.017%	7.227%	5.763%	4.583%	2.893%	1.863%
\$275,000	200	12	9.215%	7.186%	5.561%	4.279%	3.283%	1.955%	1.225%
\$275,000	300	12	6.998%	5.153%	3.758%	2.738%	2.006%	1.143%	0.753%
\$275,000	400	12	5.751%	4.044%	2.825%	1.980%	1.415%	0.821%	0.602%
\$275,000	500	12	4.912%	3.332%	2.251%	1.540%	1.092%	0.675%	0.547%
\$275,000	600	12	4.300%	2.821%	1.852%	1.246%	0.892%	0.595%	0.518%
\$275,000	700	12	3.833%	2.444%	1.572%	1.059%	0.776%	0.558%	0.509%
\$275,000	800	12	3.501%	2.177%	1.379%	0.934%	0.701%	0.536%	0.505%
\$275,000	900	12	3.213%	1.953%	1.225%	0.836%	0.645%	0.522%	0.503%
\$275,000	1,000	12	2.964%	1.768%	1.101%	0.762%	0.604%	0.513%	0.502%
\$275,000	1,500	12	2.149%	1.207%	0.766%	0.588%	0.526%	0.503%	0.501%
\$275,000	2,000	12	1.687%	0.928%	0.629%	0.533%	0.508%	0.502%	0.501%
\$275,000	3,000	12	1.152%	0.669%	0.535%	0.508%	0.503%	0.502%	0.501%
\$275,000	4,000	12	0.884%	0.575%	0.513%	0.505%	0.503%	0.502%	0.501%
\$275,000	5,000	12	0.732%	0.535%	0.507%	0.504%	0.503%	0.502%	0.501%
\$275,000	10,000	12	0.523%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$275,000	20,000	12	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$300,000	5	12	64.656%	62.944%	61.298%	59.713%	58.188%	55.308%	52.622%
\$300,000	10	12	50.141%	48.150%	46.254%	44.454%	42.741%	39.569%	36.679%
\$300,000	15	12	42.248%	40.119%	38.107%	36.207%	34.409%	31.087%	28.105%
\$300,000	20	12	37.014%	34.791%	32.701%	30.737%	28.893%	25.520%	22.533%
\$300,000	25	12	32.983%	30.701%	28.575%	26.591%	24.740%	21.384%	18.442%
\$300,000	50	12	22.650%	20.262%	18.093%	16.131%	14.355%	11.324%	8.900%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$300,000	100	12	14.971%	12.680%	10.696%	8.992%	7.536%	5.264%	3.660%
\$300,000	150	12	11.466%	9.294%	7.490%	6.005%	4.804%	3.063%	1.987%
\$300,000	200	12	9.452%	7.410%	5.768%	4.463%	3.446%	2.071%	1.302%
\$300,000	300	12	7.185%	5.324%	3.909%	2.866%	2.111%	1.207%	0.786%
\$300,000	400	12	5.905%	4.182%	2.941%	2.072%	1.486%	0.858%	0.618%
\$300,000	500	12	5.045%	3.447%	2.344%	1.611%	1.144%	0.697%	0.556%
\$300,000	600	12	4.418%	2.921%	1.930%	1.303%	0.931%	0.609%	0.523%
\$300,000	700	12	3.933%	2.526%	1.634%	1.101%	0.802%	0.566%	0.511%
\$300,000	800	12	3.600%	2.255%	1.436%	0.971%	0.724%	0.542%	0.506%
\$300,000	900	12	3.305%	2.025%	1.274%	0.867%	0.662%	0.526%	0.504%
\$300,000	1,000	12	3.050%	1.833%	1.144%	0.787%	0.617%	0.515%	0.502%
\$300,000	1,500	12	2.212%	1.248%	0.788%	0.598%	0.530%	0.503%	0.501%
\$300,000	2,000	12	1.739%	0.957%	0.642%	0.538%	0.509%	0.502%	0.501%
\$300,000	3,000	12	1.189%	0.684%	0.539%	0.509%	0.504%	0.502%	0.501%
\$300,000	4,000	12	0.910%	0.583%	0.515%	0.505%	0.503%	0.502%	0.501%
\$300,000	5,000	12	0.750%	0.538%	0.507%	0.504%	0.503%	0.502%	0.501%
\$300,000	10,000	12	0.525%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$300,000	20,000	12	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$325,000	5	12	64.979%	63.278%	61.643%	60.069%	58.556%	55.697%	53.029%
\$325,000	10	12	50.520%	48.545%	46.666%	44.881%	43.185%	40.042%	37.180%
\$325,000	15	12	42.645%	40.534%	38.541%	36.660%	34.879%	31.591%	28.641%
\$325,000	20	12	37.430%	35.229%	33.159%	31.216%	29.392%	26.057%	23.107%
\$325,000	25	12	33.405%	31.148%	29.047%	27.086%	25.256%	21.941%	19.036%
\$325,000	50	12	23.088%	20.720%	18.562%	16.606%	14.828%	11.781%	9.321%
\$325,000	100	12	15.308%	13.016%	11.023%	9.305%	7.832%	5.519%	3.871%
\$325,000	150	12	11.729%	9.553%	7.736%	6.236%	5.014%	3.230%	2.111%
\$325,000	200	12	9.671%	7.620%	5.963%	4.640%	3.601%	2.185%	1.379%
\$325,000	300	12	7.360%	5.487%	4.055%	2.990%	2.214%	1.272%	0.822%
\$325,000	400	12	6.051%	4.312%	3.051%	2.162%	1.555%	0.895%	0.635%
\$325,000	500	12	5.170%	3.556%	2.433%	1.680%	1.194%	0.720%	0.565%
\$325,000	600	12	4.528%	3.015%	2.004%	1.358%	0.969%	0.623%	0.527%
\$325,000	700	12	4.034%	2.610%	1.697%	1.146%	0.831%	0.576%	0.513%
\$325,000	800	12	3.692%	2.330%	1.491%	1.007%	0.746%	0.549%	0.508%
\$325,000	900	12	3.392%	2.093%	1.321%	0.897%	0.679%	0.531%	0.504%
\$325,000	1,000	12	3.130%	1.894%	1.185%	0.811%	0.630%	0.518%	0.502%
\$325,000	1,500	12	2.271%	1.287%	0.811%	0.608%	0.534%	0.503%	0.501%
\$325,000	2,000	12	1.788%	0.986%	0.654%	0.542%	0.511%	0.502%	0.501%
\$325,000	3,000	12	1.223%	0.699%	0.544%	0.510%	0.504%	0.502%	0.501%
\$325,000	4,000	12	0.934%	0.591%	0.516%	0.505%	0.503%	0.502%	0.501%
\$325,000	5,000	12	0.767%	0.542%	0.508%	0.504%	0.503%	0.502%	0.501%
\$325,000	10,000	12	0.527%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$325,000	20,000	12	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$350,000	5	12	65.268%	63.577%	61.953%	60.388%	58.885%	56.044%	53.393%
\$350,000	10	12	50.861%	48.901%	47.036%	45.265%	43.583%	40.466%	37.628%
\$350,000	15	12	43.000%	40.905%	38.929%	37.064%	35.299%	32.040%	29.118%
\$350,000	20	12	37.806%	35.624%	33.573%	31.649%	29.842%	26.541%	23.623%
\$350,000	25	12	33.782%	31.547%	29.467%	27.526%	25.715%	22.436%	19.564%
\$350,000	50	12	23.484%	21.138%	18.998%	17.050%	15.276%	12.221%	9.736%
\$350,000	100	12	15.626%	13.333%	11.336%	9.603%	8.119%	5.767%	4.077%
\$350,000	150	12	11.982%	9.801%	7.974%	6.458%	5.217%	3.394%	2.234%
\$350,000	200	12	9.880%	7.821%	6.151%	4.812%	3.752%	2.298%	1.457%
\$350,000	300	12	7.529%	5.644%	4.196%	3.112%	2.315%	1.337%	0.858%
\$350,000	400	12	6.191%	4.438%	3.159%	2.250%	1.624%	0.933%	0.653%
\$350,000	500	12	5.292%	3.662%	2.520%	1.748%	1.245%	0.744%	0.574%
\$350,000	600	12	4.636%	3.107%	2.077%	1.413%	1.007%	0.639%	0.533%
\$350,000	700	12	4.132%	2.692%	1.761%	1.191%	0.860%	0.587%	0.517%
\$350,000	800	12	3.782%	2.402%	1.545%	1.044%	0.769%	0.556%	0.510%
\$350,000	900	12	3.476%	2.159%	1.368%	0.927%	0.697%	0.535%	0.505%
\$350,000	1,000	12	3.209%	1.954%	1.227%	0.836%	0.643%	0.521%	0.503%
\$350,000	1,500	12	2.329%	1.326%	0.833%	0.619%	0.538%	0.504%	0.501%
\$350,000	2,000	12	1.836%	1.014%	0.668%	0.547%	0.512%	0.502%	0.501%
\$350,000	3,000	12	1.257%	0.714%	0.549%	0.511%	0.504%	0.502%	0.501%
\$350,000	4,000	12	0.958%	0.599%	0.518%	0.505%	0.503%	0.502%	0.501%
\$350,000	5,000	12	0.785%	0.547%	0.508%	0.504%	0.503%	0.502%	0.501%
\$350,000	10,000	12	0.530%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$350,000	20,000	12	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$375,000	5	12	65.502%	63.820%	62.203%	60.647%	59.151%	56.326%	53.689%
\$375,000	10	12	51.141%	49.192%	47.339%	45.579%	43.911%	40.815%	37.997%
\$375,000	15	12	43.295%	41.214%	39.253%	37.400%	35.648%	32.414%	29.515%
\$375,000	20	12	38.125%	35.958%	33.924%	32.015%	30.223%	26.950%	24.060%
\$375,000	25	12	34.101%	31.883%	29.821%	27.897%	26.102%	22.853%	20.009%
\$375,000	50	12	23.824%	21.499%	19.377%	17.442%	15.675%	12.620%	10.118%
\$375,000	100	12	15.909%	13.617%	11.617%	9.875%	8.378%	5.996%	4.268%
\$375,000	150	12	12.209%	10.024%	8.190%	6.662%	5.404%	3.546%	2.351%
\$375,000	200	12	10.070%	8.003%	6.323%	4.968%	3.894%	2.403%	1.531%
\$375,000	300	12	7.683%	5.787%	4.326%	3.224%	2.409%	1.398%	0.894%
\$375,000	400	12	6.320%	4.555%	3.260%	2.332%	1.689%	0.969%	0.670%
\$375,000	500	12	5.405%	3.760%	2.601%	1.812%	1.294%	0.767%	0.584%
\$375,000	600	12	4.737%	3.192%	2.145%	1.464%	1.044%	0.655%	0.539%
\$375,000	700	12	4.224%	2.768%	1.820%	1.234%	0.889%	0.598%	0.520%
\$375,000	800	12	3.859%	2.465%	1.591%	1.076%	0.788%	0.561%	0.510%
\$375,000	900	12	3.554%	2.221%	1.413%	0.957%	0.715%	0.540%	0.506%
\$375,000	1,000	12	3.282%	2.010%	1.266%	0.861%	0.657%	0.524%	0.503%
\$375,000	1,500	12	2.383%	1.362%	0.854%	0.629%	0.543%	0.504%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$375,000	2,000	12	1.880%	1.040%	0.680%	0.552%	0.514%	0.502%	0.501%
\$375,000	3,000	12	1.288%	0.728%	0.553%	0.512%	0.504%	0.502%	0.501%
\$375,000	4,000	12	0.981%	0.606%	0.520%	0.505%	0.503%	0.502%	0.501%
\$375,000	5,000	12	0.801%	0.551%	0.509%	0.504%	0.503%	0.502%	0.501%
\$375,000	10,000	12	0.532%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$375,000	20,000	12	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$400,000	5	12	65.694%	64.018%	62.408%	60.859%	59.370%	56.557%	53.932%
\$400,000	10	12	51.363%	49.423%	47.581%	45.830%	44.172%	41.093%	38.292%
\$400,000	15	12	43.537%	41.469%	39.519%	37.677%	35.936%	32.722%	29.844%
\$400,000	20	12	38.392%	36.239%	34.218%	32.322%	30.543%	27.294%	24.426%
\$400,000	25	12	34.368%	32.167%	30.119%	28.210%	26.428%	23.205%	20.384%
\$400,000	50	12	24.106%	21.801%	19.697%	17.775%	16.020%	12.972%	10.461%
\$400,000	100	12	16.160%	13.871%	11.869%	10.122%	8.613%	6.205%	4.445%
\$400,000	150	12	12.414%	10.226%	8.385%	6.849%	5.577%	3.687%	2.461%
\$400,000	200	12	10.244%	8.170%	6.480%	5.113%	4.025%	2.501%	1.601%
\$400,000	300	12	7.823%	5.918%	4.445%	3.328%	2.498%	1.456%	0.929%
\$400,000	400	12	6.438%	4.662%	3.352%	2.409%	1.749%	1.004%	0.688%
\$400,000	500	12	5.508%	3.851%	2.677%	1.872%	1.339%	0.790%	0.593%
\$400,000	600	12	4.828%	3.271%	2.208%	1.513%	1.078%	0.670%	0.544%
\$400,000	700	12	4.308%	2.839%	1.875%	1.274%	0.916%	0.609%	0.524%
\$400,000	800	12	3.936%	2.528%	1.639%	1.109%	0.810%	0.568%	0.512%
\$400,000	900	12	3.626%	2.279%	1.455%	0.985%	0.731%	0.545%	0.507%
\$400,000	1,000	12	3.351%	2.063%	1.303%	0.884%	0.670%	0.527%	0.504%
\$400,000	1,500	12	2.432%	1.397%	0.874%	0.639%	0.547%	0.505%	0.501%
\$400,000	2,000	12	1.921%	1.065%	0.692%	0.557%	0.515%	0.503%	0.501%
\$400,000	3,000	12	1.316%	0.741%	0.558%	0.513%	0.504%	0.502%	0.501%
\$400,000	4,000	12	1.002%	0.613%	0.521%	0.506%	0.503%	0.502%	0.501%
\$400,000	5,000	12	0.816%	0.555%	0.510%	0.504%	0.503%	0.502%	0.501%
\$400,000	10,000	12	0.534%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$400,000	20,000	12	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$425,000	5	12	65.868%	64.198%	62.594%	61.051%	59.568%	56.767%	54.152%
\$425,000	10	12	51.561%	49.630%	47.797%	46.055%	44.406%	41.342%	38.556%
\$425,000	15	12	43.760%	41.702%	39.762%	37.931%	36.199%	33.004%	30.143%
\$425,000	20	12	38.633%	36.492%	34.483%	32.599%	30.831%	27.603%	24.757%
\$425,000	25	12	34.610%	32.422%	30.387%	28.492%	26.721%	23.520%	20.720%
\$425,000	50	12	24.358%	22.071%	19.984%	18.076%	16.333%	13.299%	10.786%
\$425,000	100	12	16.390%	14.106%	12.103%	10.352%	8.835%	6.404%	4.614%
\$425,000	150	12	12.605%	10.416%	8.569%	7.024%	5.741%	3.822%	2.568%
\$425,000	200	12	10.405%	8.327%	6.626%	5.249%	4.150%	2.596%	1.669%
\$425,000	300	12	7.954%	6.041%	4.558%	3.427%	2.583%	1.513%	0.964%
\$425,000	400	12	6.547%	4.763%	3.440%	2.482%	1.808%	1.037%	0.705%
\$425,000	500	12	5.605%	3.938%	2.748%	1.929%	1.383%	0.812%	0.603%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$425,000	600	12	4.914%	3.345%	2.268%	1.559%	1.112%	0.685%	0.550%
\$425,000	700	12	4.385%	2.905%	1.927%	1.313%	0.943%	0.619%	0.527%
\$425,000	800	12	4.009%	2.588%	1.685%	1.142%	0.831%	0.576%	0.515%
\$425,000	900	12	3.694%	2.333%	1.495%	1.012%	0.748%	0.550%	0.509%
\$425,000	1,000	12	3.414%	2.113%	1.339%	0.907%	0.683%	0.530%	0.504%
\$425,000	1,500	12	2.479%	1.429%	0.894%	0.649%	0.551%	0.506%	0.501%
\$425,000	2,000	12	1.958%	1.088%	0.704%	0.561%	0.517%	0.503%	0.501%
\$425,000	3,000	12	1.343%	0.754%	0.562%	0.514%	0.504%	0.502%	0.501%
\$425,000	4,000	12	1.021%	0.620%	0.523%	0.506%	0.503%	0.502%	0.501%
\$425,000	5,000	12	0.830%	0.558%	0.510%	0.504%	0.503%	0.502%	0.501%
\$425,000	10,000	12	0.536%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$425,000	20,000	12	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$450,000	5	12	66.021%	64.357%	62.758%	61.221%	59.743%	56.952%	54.346%
\$450,000	10	12	51.746%	49.823%	47.997%	46.263%	44.622%	41.572%	38.799%
\$450,000	15	12	43.968%	41.919%	39.990%	38.167%	36.444%	33.266%	30.421%
\$450,000	20	12	38.855%	36.725%	34.726%	32.854%	31.095%	27.887%	25.059%
\$450,000	25	12	34.832%	32.657%	30.633%	28.749%	26.989%	23.809%	21.027%
\$450,000	50	12	24.589%	22.317%	20.246%	18.351%	16.621%	13.604%	11.093%
\$450,000	100	12	16.605%	14.327%	12.324%	10.572%	9.049%	6.597%	4.781%
\$450,000	150	12	12.786%	10.596%	8.744%	7.192%	5.898%	3.953%	2.671%
\$450,000	200	12	10.556%	8.474%	6.764%	5.378%	4.268%	2.688%	1.735%
\$450,000	300	12	8.076%	6.157%	4.664%	3.520%	2.663%	1.567%	0.998%
\$450,000	400	12	6.649%	4.857%	3.522%	2.550%	1.863%	1.070%	0.722%
\$450,000	500	12	5.696%	4.019%	2.816%	1.983%	1.425%	0.833%	0.612%
\$450,000	600	12	4.995%	3.414%	2.324%	1.603%	1.145%	0.699%	0.555%
\$450,000	700	12	4.458%	2.967%	1.976%	1.349%	0.969%	0.630%	0.531%
\$450,000	800	12	4.076%	2.645%	1.728%	1.173%	0.852%	0.583%	0.517%
\$450,000	900	12	3.757%	2.385%	1.533%	1.038%	0.764%	0.555%	0.510%
\$450,000	1,000	12	3.474%	2.160%	1.372%	0.929%	0.696%	0.534%	0.505%
\$450,000	1,500	12	2.522%	1.459%	0.912%	0.658%	0.555%	0.506%	0.501%
\$450,000	2,000	12	1.993%	1.110%	0.715%	0.566%	0.518%	0.503%	0.501%
\$450,000	3,000	12	1.368%	0.766%	0.567%	0.515%	0.505%	0.502%	0.501%
\$450,000	4,000	12	1.039%	0.627%	0.525%	0.506%	0.503%	0.502%	0.501%
\$450,000	5,000	12	0.844%	0.562%	0.511%	0.504%	0.503%	0.502%	0.501%
\$450,000	10,000	12	0.538%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$450,000	20,000	12	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$475,000	5	12	66.167%	64.508%	62.914%	61.382%	59.910%	57.128%	54.530%
\$475,000	10	12	51.921%	50.006%	48.188%	46.461%	44.827%	41.790%	39.029%
\$475,000	15	12	44.161%	42.122%	40.201%	38.387%	36.671%	33.509%	30.678%
\$475,000	20	12	39.056%	36.936%	34.947%	33.084%	31.334%	28.143%	25.332%
\$475,000	25	12	35.034%	32.870%	30.857%	28.983%	27.233%	24.071%	21.306%
\$475,000	50	12	24.801%	22.544%	20.486%	18.604%	16.886%	13.889%	11.386%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$475,000	100	12	16.809%	14.537%	12.537%	10.783%	9.254%	6.784%	4.944%
\$475,000	150	12	12.959%	10.769%	8.912%	7.354%	6.050%	4.081%	2.773%
\$475,000	200	12	10.702%	8.617%	6.899%	5.503%	4.383%	2.778%	1.800%
\$475,000	300	12	8.195%	6.269%	4.768%	3.612%	2.742%	1.621%	1.032%
\$475,000	400	12	6.748%	4.948%	3.602%	2.618%	1.918%	1.102%	0.739%
\$475,000	500	12	5.783%	4.097%	2.882%	2.036%	1.465%	0.855%	0.622%
\$475,000	600	12	5.073%	3.481%	2.379%	1.646%	1.177%	0.714%	0.560%
\$475,000	700	12	4.529%	3.027%	2.024%	1.385%	0.994%	0.640%	0.534%
\$475,000	800	12	4.141%	2.700%	1.770%	1.203%	0.872%	0.590%	0.519%
\$475,000	900	12	3.811%	2.429%	1.565%	1.059%	0.777%	0.558%	0.510%
\$475,000	1,000	12	3.532%	2.206%	1.405%	0.950%	0.709%	0.537%	0.505%
\$475,000	1,500	12	2.564%	1.488%	0.930%	0.668%	0.560%	0.507%	0.501%
\$475,000	2,000	12	2.028%	1.131%	0.726%	0.571%	0.520%	0.503%	0.501%
\$475,000	3,000	12	1.392%	0.778%	0.571%	0.516%	0.505%	0.502%	0.501%
\$475,000	4,000	12	1.057%	0.634%	0.526%	0.506%	0.503%	0.502%	0.501%
\$475,000	5,000	12	0.857%	0.566%	0.512%	0.504%	0.503%	0.502%	0.501%
\$475,000	10,000	12	0.540%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$475,000	20,000	12	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$500,000	5	12	66.304%	64.650%	63.060%	61.532%	60.065%	57.291%	54.701%
\$500,000	10	12	52.080%	50.171%	48.360%	46.639%	45.012%	41.987%	39.237%
\$500,000	15	12	44.335%	42.304%	40.391%	38.584%	36.875%	33.727%	30.908%
\$500,000	20	12	39.234%	37.123%	35.143%	33.288%	31.545%	28.370%	25.574%
\$500,000	25	12	35.212%	33.058%	31.054%	29.190%	27.448%	24.301%	21.551%
\$500,000	50	12	24.987%	22.742%	20.696%	18.826%	17.118%	14.140%	11.650%
\$500,000	100	12	16.991%	14.727%	12.730%	10.976%	9.443%	6.958%	5.097%
\$500,000	150	12	13.116%	10.927%	9.067%	7.502%	6.190%	4.201%	2.869%
\$500,000	200	12	10.836%	8.749%	7.025%	5.621%	4.491%	2.864%	1.864%
\$500,000	300	12	8.303%	6.373%	4.864%	3.697%	2.817%	1.672%	1.064%
\$500,000	400	12	6.839%	5.032%	3.676%	2.681%	1.968%	1.133%	0.755%
\$500,000	500	12	5.863%	4.168%	2.942%	2.084%	1.502%	0.875%	0.631%
\$500,000	600	12	5.144%	3.543%	2.429%	1.685%	1.206%	0.728%	0.566%
\$500,000	700	12	4.593%	3.082%	2.068%	1.418%	1.018%	0.649%	0.538%
\$500,000	800	12	4.200%	2.750%	1.809%	1.231%	0.891%	0.597%	0.521%
\$500,000	900	12	3.867%	2.474%	1.599%	1.083%	0.792%	0.563%	0.511%
\$500,000	1,000	12	3.584%	2.247%	1.435%	0.970%	0.721%	0.540%	0.506%
\$500,000	1,500	12	2.602%	1.515%	0.946%	0.677%	0.564%	0.507%	0.501%
\$500,000	2,000	12	2.059%	1.151%	0.737%	0.575%	0.522%	0.503%	0.501%
\$500,000	3,000	12	1.414%	0.789%	0.575%	0.517%	0.505%	0.502%	0.501%
\$500,000	4,000	12	1.074%	0.640%	0.528%	0.507%	0.503%	0.502%	0.501%
\$500,000	5,000	12	0.870%	0.570%	0.512%	0.504%	0.503%	0.502%	0.501%
\$500,000	10,000	12	0.542%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$500,000	20,000	12	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$30,000	5	13	41.680%	38.918%	36.249%	33.673%	31.221%	26.746%	22.803%
\$30,000	10	13	27.063%	24.433%	22.021%	19.815%	17.785%	14.240%	11.337%
\$30,000	15	13	21.323%	18.751%	16.439%	14.368%	12.522%	9.435%	7.052%
\$30,000	20	13	17.858%	15.361%	13.154%	11.220%	9.536%	6.822%	4.844%
\$30,000	25	13	15.585%	13.155%	11.043%	9.224%	7.673%	5.254%	3.582%
\$30,000	50	13	9.888%	7.764%	6.041%	4.672%	3.603%	2.153%	1.339%
\$30,000	100	13	6.124%	4.354%	3.061%	2.152%	1.536%	0.868%	0.615%
\$30,000	150	13	4.550%	3.024%	2.002%	1.352%	0.962%	0.618%	0.525%
\$30,000	200	13	3.738%	2.369%	1.513%	1.016%	0.745%	0.545%	0.507%
\$30,000	300	13	2.754%	1.628%	1.013%	0.708%	0.577%	0.508%	0.501%
\$30,000	400	13	2.185%	1.238%	0.783%	0.594%	0.529%	0.503%	0.501%
\$30,000	500	13	1.826%	1.019%	0.674%	0.551%	0.514%	0.502%	0.501%
\$30,000	600	13	1.577%	0.881%	0.613%	0.529%	0.508%	0.502%	0.501%
\$30,000	700	13	1.381%	0.779%	0.572%	0.517%	0.505%	0.502%	0.501%
\$30,000	800	13	1.246%	0.717%	0.551%	0.511%	0.504%	0.502%	0.501%
\$30,000	900	13	1.137%	0.669%	0.536%	0.508%	0.503%	0.502%	0.501%
\$30,000	1,000	13	1.044%	0.632%	0.526%	0.506%	0.503%	0.502%	0.501%
\$30,000	1,500	13	0.761%	0.543%	0.508%	0.504%	0.503%	0.502%	0.501%
\$30,000	2,000	13	0.635%	0.517%	0.505%	0.504%	0.503%	0.502%	0.501%
\$30,000	3,000	13	0.545%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$30,000	4,000	13	0.518%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$30,000	5,000	13	0.511%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$30,000	10,000	13	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$30,000	20,000	13	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$35,000	5	13	43.936%	41.294%	38.743%	36.276%	33.888%	29.350%	25.280%
\$35,000	10	13	28.537%	25.899%	23.477%	21.255%	19.216%	15.628%	12.629%
\$35,000	15	13	22.565%	19.983%	17.655%	15.554%	13.662%	10.469%	7.966%
\$35,000	20	13	18.910%	16.393%	14.161%	12.186%	10.453%	7.626%	5.518%
\$35,000	25	13	16.525%	14.072%	11.923%	10.060%	8.456%	5.916%	4.113%
\$35,000	50	13	10.527%	8.363%	6.590%	5.164%	4.028%	2.456%	1.540%
\$35,000	100	13	6.535%	4.715%	3.364%	2.394%	1.722%	0.966%	0.657%
\$35,000	150	13	4.861%	3.284%	2.205%	1.500%	1.065%	0.659%	0.537%
\$35,000	200	13	3.995%	2.575%	1.664%	1.116%	0.807%	0.562%	0.510%
\$35,000	300	13	2.951%	1.772%	1.105%	0.760%	0.602%	0.512%	0.502%
\$35,000	400	13	2.344%	1.343%	0.841%	0.621%	0.539%	0.504%	0.501%
\$35,000	500	13	1.960%	1.101%	0.714%	0.566%	0.519%	0.502%	0.501%
\$35,000	600	13	1.696%	0.947%	0.642%	0.539%	0.510%	0.502%	0.501%
\$35,000	700	13	1.487%	0.833%	0.593%	0.523%	0.506%	0.502%	0.501%
\$35,000	800	13	1.342%	0.762%	0.566%	0.515%	0.504%	0.502%	0.501%
\$35,000	900	13	1.223%	0.706%	0.547%	0.510%	0.504%	0.502%	0.501%
\$35,000	1,000	13	1.122%	0.663%	0.534%	0.508%	0.503%	0.502%	0.501%
\$35,000	1,500	13	0.810%	0.555%	0.510%	0.504%	0.503%	0.502%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$35,000	2,000	13	0.665%	0.522%	0.506%	0.504%	0.503%	0.502%	0.501%
\$35,000	3,000	13	0.557%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$35,000	4,000	13	0.523%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$35,000	5,000	13	0.513%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$35,000	10,000	13	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$35,000	20,000	13	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$40,000	5	13	45.851%	43.308%	40.851%	38.477%	36.179%	31.800%	27.697%
\$40,000	10	13	29.923%	27.264%	24.810%	22.561%	20.499%	16.877%	13.819%
\$40,000	15	13	23.699%	21.113%	18.768%	16.644%	14.723%	11.441%	8.828%
\$40,000	20	13	19.870%	17.342%	15.085%	13.080%	11.307%	8.380%	6.165%
\$40,000	25	13	17.383%	14.913%	12.735%	10.836%	9.188%	6.546%	4.628%
\$40,000	50	13	11.121%	8.926%	7.106%	5.627%	4.439%	2.755%	1.740%
\$40,000	100	13	6.914%	5.052%	3.651%	2.627%	1.905%	1.067%	0.705%
\$40,000	150	13	5.151%	3.527%	2.400%	1.646%	1.168%	0.702%	0.552%
\$40,000	200	13	4.239%	2.772%	1.812%	1.219%	0.873%	0.584%	0.515%
\$40,000	300	13	3.134%	1.907%	1.196%	0.814%	0.629%	0.517%	0.502%
\$40,000	400	13	2.490%	1.442%	0.898%	0.649%	0.550%	0.506%	0.501%
\$40,000	500	13	2.083%	1.178%	0.754%	0.583%	0.524%	0.503%	0.501%
\$40,000	600	13	1.805%	1.009%	0.671%	0.550%	0.513%	0.502%	0.501%
\$40,000	700	13	1.585%	0.885%	0.614%	0.529%	0.507%	0.502%	0.501%
\$40,000	800	13	1.431%	0.806%	0.582%	0.519%	0.505%	0.502%	0.501%
\$40,000	900	13	1.303%	0.742%	0.559%	0.513%	0.504%	0.502%	0.501%
\$40,000	1,000	13	1.197%	0.694%	0.543%	0.509%	0.503%	0.502%	0.501%
\$40,000	1,500	13	0.857%	0.569%	0.512%	0.504%	0.503%	0.502%	0.501%
\$40,000	2,000	13	0.696%	0.528%	0.506%	0.504%	0.503%	0.502%	0.501%
\$40,000	3,000	13	0.570%	0.509%	0.505%	0.504%	0.503%	0.502%	0.501%
\$40,000	4,000	13	0.529%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$40,000	5,000	13	0.515%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$40,000	10,000	13	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$40,000	20,000	13	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$45,000	5	13	47.496%	45.033%	42.657%	40.360%	38.137%	33.911%	29.950%
\$45,000	10	13	31.266%	28.573%	26.086%	23.799%	21.705%	18.016%	14.907%
\$45,000	15	13	24.737%	22.153%	19.793%	17.653%	15.706%	12.358%	9.649%
\$45,000	20	13	20.767%	18.228%	15.953%	13.920%	12.114%	9.100%	6.789%
\$45,000	25	13	18.183%	15.697%	13.495%	11.564%	9.879%	7.150%	5.131%
\$45,000	50	13	11.677%	9.452%	7.593%	6.066%	4.829%	3.047%	1.941%
\$45,000	100	13	7.269%	5.370%	3.925%	2.855%	2.085%	1.172%	0.756%
\$45,000	150	13	5.426%	3.760%	2.588%	1.790%	1.271%	0.749%	0.570%
\$45,000	200	13	4.470%	2.961%	1.957%	1.321%	0.941%	0.608%	0.522%
\$45,000	300	13	3.306%	2.038%	1.285%	0.869%	0.658%	0.523%	0.503%
\$45,000	400	13	2.627%	1.539%	0.956%	0.679%	0.564%	0.507%	0.501%
\$45,000	500	13	2.199%	1.253%	0.794%	0.602%	0.531%	0.503%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$45,000	600	13	1.907%	1.071%	0.700%	0.561%	0.516%	0.502%	0.501%
\$45,000	700	13	1.677%	0.936%	0.636%	0.536%	0.509%	0.502%	0.501%
\$45,000	800	13	1.516%	0.849%	0.599%	0.524%	0.506%	0.502%	0.501%
\$45,000	900	13	1.379%	0.778%	0.571%	0.516%	0.505%	0.502%	0.501%
\$45,000	1,000	13	1.267%	0.725%	0.553%	0.511%	0.504%	0.502%	0.501%
\$45,000	1,500	13	0.904%	0.583%	0.515%	0.505%	0.503%	0.502%	0.501%
\$45,000	2,000	13	0.727%	0.535%	0.507%	0.504%	0.503%	0.502%	0.501%
\$45,000	3,000	13	0.583%	0.511%	0.505%	0.504%	0.503%	0.502%	0.501%
\$45,000	4,000	13	0.535%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$45,000	5,000	13	0.517%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$45,000	10,000	13	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$45,000	20,000	13	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$50,000	5	13	48.919%	46.524%	44.214%	41.982%	39.827%	35.731%	31.890%
\$50,000	10	13	32.555%	29.839%	27.323%	25.001%	22.862%	19.092%	15.927%
\$50,000	15	13	25.675%	23.096%	20.732%	18.578%	16.614%	13.210%	10.432%
\$50,000	20	13	21.596%	19.053%	16.762%	14.706%	12.871%	9.785%	7.386%
\$50,000	25	13	18.922%	16.425%	14.202%	12.243%	10.524%	7.718%	5.612%
\$50,000	50	13	12.189%	9.940%	8.045%	6.479%	5.197%	3.328%	2.141%
\$50,000	100	13	7.599%	5.668%	4.183%	3.072%	2.261%	1.277%	0.812%
\$50,000	150	13	5.681%	3.979%	2.768%	1.931%	1.375%	0.797%	0.590%
\$50,000	200	13	4.683%	3.139%	2.095%	1.420%	1.009%	0.634%	0.529%
\$50,000	300	13	3.466%	2.160%	1.371%	0.924%	0.688%	0.530%	0.504%
\$50,000	400	13	2.754%	1.630%	1.013%	0.710%	0.577%	0.509%	0.501%
\$50,000	500	13	2.307%	1.326%	0.835%	0.621%	0.539%	0.504%	0.501%
\$50,000	600	13	2.002%	1.129%	0.729%	0.573%	0.521%	0.502%	0.501%
\$50,000	700	13	1.764%	0.985%	0.658%	0.544%	0.511%	0.502%	0.501%
\$50,000	800	13	1.595%	0.892%	0.617%	0.529%	0.507%	0.502%	0.501%
\$50,000	900	13	1.451%	0.814%	0.585%	0.520%	0.505%	0.502%	0.501%
\$50,000	1,000	13	1.333%	0.756%	0.563%	0.514%	0.504%	0.502%	0.501%
\$50,000	1,500	13	0.949%	0.598%	0.518%	0.505%	0.503%	0.502%	0.501%
\$50,000	2,000	13	0.758%	0.542%	0.508%	0.504%	0.503%	0.502%	0.501%
\$50,000	3,000	13	0.597%	0.513%	0.505%	0.504%	0.503%	0.502%	0.501%
\$50,000	4,000	13	0.541%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$50,000	5,000	13	0.520%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$50,000	10,000	13	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$50,000	20,000	13	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$55,000	5	13	50.148%	47.813%	45.558%	43.384%	41.285%	37.300%	33.561%
\$55,000	10	13	33.762%	31.046%	28.511%	26.159%	23.979%	20.124%	16.880%
\$55,000	15	13	26.546%	23.963%	21.595%	19.431%	17.454%	14.003%	11.172%
\$55,000	20	13	22.371%	19.824%	17.521%	15.445%	13.583%	10.434%	7.956%
\$55,000	25	13	19.611%	17.106%	14.866%	12.880%	11.133%	8.256%	6.071%
\$55,000	50	13	12.660%	10.389%	8.465%	6.864%	5.542%	3.595%	2.337%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$55,000	100	13	7.903%	5.945%	4.426%	3.278%	2.429%	1.381%	0.869%
\$55,000	150	13	5.921%	4.187%	2.940%	2.067%	1.478%	0.847%	0.612%
\$55,000	200	13	4.882%	3.306%	2.226%	1.517%	1.075%	0.661%	0.537%
\$55,000	300	13	3.614%	2.277%	1.453%	0.978%	0.719%	0.538%	0.505%
\$55,000	400	13	2.874%	1.718%	1.069%	0.741%	0.592%	0.512%	0.502%
\$55,000	500	13	2.408%	1.395%	0.875%	0.641%	0.547%	0.505%	0.501%
\$55,000	600	13	2.092%	1.186%	0.759%	0.586%	0.525%	0.503%	0.501%
\$55,000	700	13	1.846%	1.034%	0.681%	0.552%	0.514%	0.502%	0.501%
\$55,000	800	13	1.670%	0.933%	0.635%	0.535%	0.509%	0.502%	0.501%
\$55,000	900	13	1.520%	0.850%	0.599%	0.524%	0.506%	0.502%	0.501%
\$55,000	1,000	13	1.397%	0.786%	0.574%	0.516%	0.504%	0.502%	0.501%
\$55,000	1,500	13	0.992%	0.613%	0.521%	0.505%	0.503%	0.502%	0.501%
\$55,000	2,000	13	0.788%	0.549%	0.509%	0.504%	0.503%	0.502%	0.501%
\$55,000	3,000	13	0.612%	0.514%	0.505%	0.504%	0.503%	0.502%	0.501%
\$55,000	4,000	13	0.548%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$55,000	5,000	13	0.523%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$55,000	10,000	13	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$55,000	20,000	13	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$60,000	5	13	51.234%	48.947%	46.743%	44.619%	42.569%	38.677%	35.028%
\$60,000	10	13	34.899%	32.192%	29.657%	27.281%	25.071%	21.130%	17.798%
\$60,000	15	13	27.367%	24.773%	22.397%	20.219%	18.227%	14.745%	11.862%
\$60,000	20	13	23.086%	20.539%	18.226%	16.134%	14.249%	11.046%	8.500%
\$60,000	25	13	20.250%	17.739%	15.484%	13.479%	11.705%	8.763%	6.506%
\$60,000	50	13	13.098%	10.805%	8.857%	7.226%	5.870%	3.850%	2.527%
\$60,000	100	13	8.187%	6.203%	4.657%	3.475%	2.592%	1.484%	0.928%
\$60,000	150	13	6.143%	4.382%	3.102%	2.199%	1.578%	0.897%	0.634%
\$60,000	200	13	5.067%	3.464%	2.351%	1.610%	1.141%	0.690%	0.546%
\$60,000	300	13	3.752%	2.386%	1.532%	1.030%	0.751%	0.546%	0.506%
\$60,000	400	13	2.985%	1.800%	1.122%	0.772%	0.608%	0.515%	0.502%
\$60,000	500	13	2.503%	1.461%	0.914%	0.661%	0.555%	0.506%	0.501%
\$60,000	600	13	2.175%	1.241%	0.788%	0.599%	0.530%	0.503%	0.501%
\$60,000	700	13	1.922%	1.080%	0.703%	0.561%	0.517%	0.502%	0.501%
\$60,000	800	13	1.740%	0.973%	0.653%	0.541%	0.510%	0.502%	0.501%
\$60,000	900	13	1.585%	0.884%	0.613%	0.528%	0.507%	0.502%	0.501%
\$60,000	1,000	13	1.456%	0.816%	0.586%	0.520%	0.505%	0.502%	0.501%
\$60,000	1,500	13	1.033%	0.628%	0.525%	0.506%	0.503%	0.502%	0.501%
\$60,000	2,000	13	0.818%	0.557%	0.510%	0.504%	0.503%	0.502%	0.501%
\$60,000	3,000	13	0.626%	0.516%	0.505%	0.504%	0.503%	0.502%	0.501%
\$60,000	4,000	13	0.555%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$60,000	5,000	13	0.527%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$60,000	10,000	13	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$60,000	20,000	13	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$65,000	5	13	52.224%	49.981%	47.823%	45.743%	43.739%	39.928%	36.361%
\$65,000	10	13	35.974%	33.292%	30.758%	28.377%	26.146%	22.138%	18.708%
\$65,000	15	13	28.158%	25.551%	23.160%	20.966%	18.957%	15.445%	12.519%
\$65,000	20	13	23.755%	21.207%	18.887%	16.781%	14.877%	11.625%	9.019%
\$65,000	25	13	20.852%	18.332%	16.064%	14.045%	12.244%	9.244%	6.925%
\$65,000	50	13	13.510%	11.199%	9.230%	7.570%	6.183%	4.096%	2.713%
\$65,000	100	13	8.456%	6.451%	4.879%	3.667%	2.751%	1.586%	0.989%
\$65,000	150	13	6.355%	4.569%	3.260%	2.327%	1.677%	0.949%	0.659%
\$65,000	200	13	5.245%	3.616%	2.473%	1.703%	1.207%	0.720%	0.556%
\$65,000	300	13	3.884%	2.492%	1.610%	1.083%	0.784%	0.556%	0.508%
\$65,000	400	13	3.091%	1.880%	1.176%	0.803%	0.625%	0.518%	0.502%
\$65,000	500	13	2.594%	1.525%	0.953%	0.681%	0.564%	0.507%	0.501%
\$65,000	600	13	2.256%	1.294%	0.817%	0.612%	0.535%	0.504%	0.501%
\$65,000	700	13	1.996%	1.125%	0.726%	0.570%	0.520%	0.503%	0.501%
\$65,000	800	13	1.807%	1.012%	0.671%	0.548%	0.512%	0.502%	0.501%
\$65,000	900	13	1.647%	0.918%	0.627%	0.532%	0.508%	0.502%	0.501%
\$65,000	1,000	13	1.514%	0.846%	0.597%	0.523%	0.506%	0.502%	0.501%
\$65,000	1,500	13	1.073%	0.644%	0.529%	0.507%	0.503%	0.502%	0.501%
\$65,000	2,000	13	0.846%	0.565%	0.511%	0.504%	0.503%	0.502%	0.501%
\$65,000	3,000	13	0.640%	0.519%	0.506%	0.504%	0.503%	0.502%	0.501%
\$65,000	4,000	13	0.562%	0.509%	0.505%	0.504%	0.503%	0.502%	0.501%
\$65,000	5,000	13	0.530%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$65,000	10,000	13	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$65,000	20,000	13	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$70,000	5	13	53.108%	50.907%	48.789%	46.749%	44.783%	41.044%	37.548%
\$70,000	10	13	36.957%	34.308%	31.790%	29.410%	27.173%	23.118%	19.602%
\$70,000	15	13	28.914%	26.296%	23.885%	21.671%	19.645%	16.100%	13.135%
\$70,000	20	13	24.378%	21.831%	19.504%	17.388%	15.469%	12.175%	9.518%
\$70,000	25	13	21.416%	18.890%	16.614%	14.578%	12.756%	9.703%	7.329%
\$70,000	50	13	13.893%	11.570%	9.581%	7.895%	6.480%	4.333%	2.894%
\$70,000	100	13	8.710%	6.686%	5.091%	3.850%	2.905%	1.686%	1.051%
\$70,000	150	13	6.555%	4.748%	3.411%	2.451%	1.775%	1.002%	0.684%
\$70,000	200	13	5.414%	3.762%	2.592%	1.795%	1.273%	0.751%	0.568%
\$70,000	300	13	4.009%	2.593%	1.685%	1.134%	0.817%	0.566%	0.511%
\$70,000	400	13	3.192%	1.957%	1.228%	0.835%	0.642%	0.521%	0.503%
\$70,000	500	13	2.680%	1.586%	0.991%	0.702%	0.574%	0.509%	0.501%
\$70,000	600	13	2.332%	1.345%	0.847%	0.626%	0.540%	0.504%	0.501%
\$70,000	700	13	2.066%	1.170%	0.749%	0.580%	0.523%	0.503%	0.501%
\$70,000	800	13	1.870%	1.050%	0.689%	0.555%	0.514%	0.502%	0.501%
\$70,000	900	13	1.706%	0.951%	0.642%	0.538%	0.509%	0.502%	0.501%
\$70,000	1,000	13	1.569%	0.875%	0.609%	0.527%	0.506%	0.502%	0.501%
\$70,000	1,500	13	1.112%	0.659%	0.533%	0.507%	0.503%	0.502%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$70,000	2,000	13	0.874%	0.573%	0.513%	0.504%	0.503%	0.502%	0.501%
\$70,000	3,000	13	0.654%	0.521%	0.506%	0.504%	0.503%	0.502%	0.501%
\$70,000	4,000	13	0.569%	0.509%	0.505%	0.504%	0.503%	0.502%	0.501%
\$70,000	5,000	13	0.534%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$70,000	10,000	13	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$70,000	20,000	13	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$75,000	5	13	53.906%	51.742%	49.660%	47.657%	45.722%	42.049%	38.618%
\$75,000	10	13	37.858%	35.254%	32.763%	30.396%	28.156%	24.078%	20.503%
\$75,000	15	13	29.650%	27.019%	24.591%	22.357%	20.310%	16.724%	13.721%
\$75,000	20	13	24.972%	22.421%	20.089%	17.963%	16.033%	12.706%	10.001%
\$75,000	25	13	21.950%	19.421%	17.140%	15.087%	13.249%	10.149%	7.721%
\$75,000	50	13	14.261%	11.924%	9.916%	8.206%	6.766%	4.565%	3.071%
\$75,000	100	13	8.954%	6.912%	5.294%	4.028%	3.054%	1.784%	1.111%
\$75,000	150	13	6.746%	4.919%	3.557%	2.571%	1.870%	1.055%	0.710%
\$75,000	200	13	5.575%	3.902%	2.707%	1.883%	1.339%	0.783%	0.580%
\$75,000	300	13	4.122%	2.685%	1.753%	1.181%	0.847%	0.574%	0.512%
\$75,000	400	13	3.289%	2.032%	1.280%	0.866%	0.659%	0.525%	0.503%
\$75,000	500	13	2.761%	1.645%	1.028%	0.722%	0.584%	0.510%	0.502%
\$75,000	600	13	2.405%	1.395%	0.875%	0.640%	0.546%	0.505%	0.501%
\$75,000	700	13	2.133%	1.213%	0.772%	0.590%	0.527%	0.503%	0.501%
\$75,000	800	13	1.931%	1.086%	0.707%	0.562%	0.517%	0.502%	0.501%
\$75,000	900	13	1.762%	0.983%	0.656%	0.543%	0.511%	0.502%	0.501%
\$75,000	1,000	13	1.622%	0.904%	0.622%	0.531%	0.507%	0.502%	0.501%
\$75,000	1,500	13	1.149%	0.674%	0.537%	0.508%	0.503%	0.502%	0.501%
\$75,000	2,000	13	0.901%	0.582%	0.514%	0.505%	0.503%	0.502%	0.501%
\$75,000	3,000	13	0.668%	0.523%	0.506%	0.504%	0.503%	0.502%	0.501%
\$75,000	4,000	13	0.577%	0.510%	0.505%	0.504%	0.503%	0.502%	0.501%
\$75,000	5,000	13	0.538%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$75,000	10,000	13	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$75,000	20,000	13	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$80,000	5	13	54.639%	52.508%	50.459%	48.488%	46.584%	42.970%	39.595%
\$80,000	10	13	38.685%	36.126%	33.676%	31.333%	29.104%	25.010%	21.399%
\$80,000	15	13	30.368%	27.729%	25.286%	23.033%	20.964%	17.333%	14.286%
\$80,000	20	13	25.545%	22.988%	20.650%	18.514%	16.572%	13.217%	10.470%
\$80,000	25	13	22.463%	19.931%	17.646%	15.579%	13.725%	10.583%	8.106%
\$80,000	50	13	14.613%	12.265%	10.240%	8.509%	7.046%	4.793%	3.248%
\$80,000	100	13	9.189%	7.132%	5.491%	4.200%	3.201%	1.883%	1.173%
\$80,000	150	13	6.931%	5.085%	3.700%	2.689%	1.965%	1.111%	0.737%
\$80,000	200	13	5.732%	4.038%	2.820%	1.971%	1.406%	0.815%	0.593%
\$80,000	300	13	4.239%	2.781%	1.826%	1.232%	0.881%	0.585%	0.515%
\$80,000	400	13	3.384%	2.104%	1.330%	0.898%	0.676%	0.529%	0.504%
\$80,000	500	13	2.840%	1.701%	1.064%	0.743%	0.595%	0.512%	0.502%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$80,000	600	13	2.476%	1.443%	0.904%	0.655%	0.552%	0.506%	0.501%
\$80,000	700	13	2.198%	1.255%	0.796%	0.600%	0.530%	0.504%	0.501%
\$80,000	800	13	1.990%	1.123%	0.725%	0.570%	0.519%	0.503%	0.501%
\$80,000	900	13	1.816%	1.015%	0.671%	0.549%	0.512%	0.502%	0.501%
\$80,000	1,000	13	1.672%	0.932%	0.634%	0.535%	0.508%	0.502%	0.501%
\$80,000	1,500	13	1.185%	0.690%	0.542%	0.509%	0.503%	0.502%	0.501%
\$80,000	2,000	13	0.927%	0.590%	0.516%	0.505%	0.503%	0.502%	0.501%
\$80,000	3,000	13	0.682%	0.526%	0.506%	0.504%	0.503%	0.502%	0.501%
\$80,000	4,000	13	0.584%	0.511%	0.505%	0.504%	0.503%	0.502%	0.501%
\$80,000	5,000	13	0.542%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$80,000	10,000	13	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$80,000	20,000	13	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$90,000	5	13	55.912%	53.838%	51.847%	49.926%	48.075%	44.565%	41.287%
\$90,000	10	13	40.121%	37.638%	35.264%	32.993%	30.821%	26.751%	23.098%
\$90,000	15	13	31.712%	29.075%	26.616%	24.334%	22.227%	18.497%	15.360%
\$90,000	20	13	26.634%	24.061%	21.706%	19.552%	17.589%	14.186%	11.371%
\$90,000	25	13	23.412%	20.885%	18.591%	16.504%	14.620%	11.411%	8.848%
\$90,000	50	13	15.269%	12.903%	10.850%	9.087%	7.583%	5.236%	3.600%
\$90,000	100	13	9.633%	7.548%	5.866%	4.531%	3.485%	2.080%	1.298%
\$90,000	150	13	7.280%	5.401%	3.974%	2.917%	2.150%	1.223%	0.795%
\$90,000	200	13	6.023%	4.293%	3.034%	2.140%	1.535%	0.880%	0.622%
\$90,000	300	13	4.457%	2.962%	1.964%	1.332%	0.949%	0.610%	0.522%
\$90,000	400	13	3.560%	2.242%	1.428%	0.961%	0.713%	0.539%	0.506%
\$90,000	500	13	2.987%	1.810%	1.136%	0.785%	0.617%	0.516%	0.502%
\$90,000	600	13	2.608%	1.536%	0.961%	0.685%	0.566%	0.507%	0.501%
\$90,000	700	13	2.319%	1.335%	0.841%	0.622%	0.538%	0.504%	0.501%
\$90,000	800	13	2.099%	1.192%	0.762%	0.586%	0.525%	0.503%	0.501%
\$90,000	900	13	1.918%	1.076%	0.701%	0.560%	0.516%	0.502%	0.501%
\$90,000	1,000	13	1.767%	0.985%	0.658%	0.543%	0.510%	0.502%	0.501%
\$90,000	1,500	13	1.253%	0.719%	0.552%	0.511%	0.504%	0.502%	0.501%
\$90,000	2,000	13	0.977%	0.607%	0.520%	0.505%	0.503%	0.502%	0.501%
\$90,000	3,000	13	0.710%	0.532%	0.507%	0.504%	0.503%	0.502%	0.501%
\$90,000	4,000	13	0.599%	0.513%	0.505%	0.504%	0.503%	0.502%	0.501%
\$90,000	5,000	13	0.550%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$90,000	10,000	13	0.508%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$90,000	20,000	13	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$100,000	5	13	56.912%	54.885%	52.936%	51.058%	49.247%	45.820%	42.617%
\$100,000	10	13	41.269%	38.848%	36.533%	34.324%	32.207%	28.236%	24.605%
\$100,000	15	13	32.868%	30.250%	27.799%	25.508%	23.373%	19.563%	16.341%
\$100,000	20	13	27.606%	25.019%	22.644%	20.471%	18.489%	15.038%	12.176%
\$100,000	25	13	24.249%	21.721%	19.416%	17.317%	15.412%	12.151%	9.518%
\$100,000	50	13	15.839%	13.460%	11.386%	9.596%	8.062%	5.636%	3.924%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$100,000	100	13	10.021%	7.913%	6.200%	4.827%	3.743%	2.264%	1.418%
\$100,000	150	13	7.586%	5.681%	4.220%	3.124%	2.320%	1.329%	0.851%
\$100,000	200	13	6.277%	4.517%	3.224%	2.293%	1.654%	0.942%	0.650%
\$100,000	300	13	4.647%	3.122%	2.088%	1.424%	1.013%	0.636%	0.530%
\$100,000	400	13	3.715%	2.365%	1.517%	1.019%	0.749%	0.549%	0.508%
\$100,000	500	13	3.118%	1.908%	1.201%	0.824%	0.639%	0.521%	0.503%
\$100,000	600	13	2.727%	1.621%	1.014%	0.714%	0.580%	0.509%	0.501%
\$100,000	700	13	2.427%	1.408%	0.884%	0.643%	0.547%	0.505%	0.501%
\$100,000	800	13	2.196%	1.254%	0.796%	0.601%	0.531%	0.503%	0.501%
\$100,000	900	13	2.009%	1.133%	0.730%	0.572%	0.520%	0.502%	0.501%
\$100,000	1,000	13	1.851%	1.036%	0.682%	0.553%	0.513%	0.502%	0.501%
\$100,000	1,500	13	1.313%	0.747%	0.561%	0.514%	0.504%	0.502%	0.501%
\$100,000	2,000	13	1.022%	0.624%	0.524%	0.506%	0.503%	0.502%	0.501%
\$100,000	3,000	13	0.736%	0.537%	0.508%	0.504%	0.503%	0.502%	0.501%
\$100,000	4,000	13	0.613%	0.515%	0.505%	0.504%	0.503%	0.502%	0.501%
\$100,000	5,000	13	0.558%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$100,000	10,000	13	0.508%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$100,000	20,000	13	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$110,000	5	13	57.753%	55.764%	53.849%	52.006%	50.231%	46.869%	43.730%
\$110,000	10	13	42.248%	39.878%	37.615%	35.453%	33.384%	29.508%	25.960%
\$110,000	15	13	33.910%	31.325%	28.889%	26.604%	24.464%	20.599%	17.293%
\$110,000	20	13	28.514%	25.921%	23.528%	21.336%	19.334%	15.834%	12.918%
\$110,000	25	13	25.032%	22.493%	20.175%	18.065%	16.144%	12.837%	10.146%
\$110,000	50	13	16.362%	13.974%	11.882%	10.068%	8.505%	6.014%	4.233%
\$110,000	100	13	10.374%	8.245%	6.506%	5.101%	3.982%	2.437%	1.536%
\$110,000	150	13	7.869%	5.940%	4.448%	3.318%	2.479%	1.431%	0.908%
\$110,000	200	13	6.510%	4.725%	3.400%	2.437%	1.766%	1.003%	0.680%
\$110,000	300	13	4.822%	3.270%	2.205%	1.512%	1.075%	0.663%	0.538%
\$110,000	400	13	3.857%	2.479%	1.601%	1.076%	0.785%	0.560%	0.510%
\$110,000	500	13	3.239%	1.999%	1.264%	0.863%	0.661%	0.526%	0.503%
\$110,000	600	13	2.835%	1.700%	1.065%	0.743%	0.594%	0.512%	0.502%
\$110,000	700	13	2.525%	1.477%	0.925%	0.664%	0.556%	0.506%	0.501%
\$110,000	800	13	2.285%	1.314%	0.829%	0.617%	0.537%	0.504%	0.501%
\$110,000	900	13	2.093%	1.186%	0.758%	0.584%	0.524%	0.503%	0.501%
\$110,000	1,000	13	1.930%	1.083%	0.706%	0.562%	0.516%	0.502%	0.501%
\$110,000	1,500	13	1.370%	0.775%	0.571%	0.516%	0.504%	0.502%	0.501%
\$110,000	2,000	13	1.064%	0.640%	0.528%	0.507%	0.503%	0.502%	0.501%
\$110,000	3,000	13	0.761%	0.543%	0.508%	0.504%	0.503%	0.502%	0.501%
\$110,000	4,000	13	0.628%	0.517%	0.506%	0.504%	0.503%	0.502%	0.501%
\$110,000	5,000	13	0.566%	0.509%	0.505%	0.504%	0.503%	0.502%	0.501%
\$110,000	10,000	13	0.508%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$110,000	20,000	13	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$120,000	5	13	58.486%	56.529%	54.645%	52.831%	51.086%	47.781%	44.697%
\$120,000	10	13	43.107%	40.780%	38.563%	36.442%	34.413%	30.620%	27.149%
\$120,000	15	13	34.843%	32.306%	29.900%	27.630%	25.494%	21.614%	18.244%
\$120,000	20	13	29.369%	26.782%	24.384%	22.177%	20.153%	16.599%	13.628%
\$120,000	25	13	25.776%	23.230%	20.898%	18.769%	16.837%	13.488%	10.741%
\$120,000	50	13	16.843%	14.449%	12.344%	10.509%	8.920%	6.373%	4.529%
\$120,000	100	13	10.701%	8.556%	6.793%	5.362%	4.212%	2.606%	1.654%
\$120,000	150	13	8.132%	6.181%	4.662%	3.502%	2.632%	1.530%	0.965%
\$120,000	200	13	6.725%	4.917%	3.563%	2.573%	1.873%	1.064%	0.710%
\$120,000	300	13	4.984%	3.408%	2.315%	1.596%	1.137%	0.690%	0.548%
\$120,000	400	13	3.982%	2.580%	1.676%	1.128%	0.818%	0.570%	0.512%
\$120,000	500	13	3.352%	2.086%	1.325%	0.902%	0.683%	0.532%	0.504%
\$120,000	600	13	2.937%	1.774%	1.114%	0.771%	0.609%	0.514%	0.502%
\$120,000	700	13	2.617%	1.542%	0.964%	0.686%	0.566%	0.508%	0.501%
\$120,000	800	13	2.369%	1.370%	0.862%	0.634%	0.543%	0.504%	0.501%
\$120,000	900	13	2.172%	1.236%	0.785%	0.597%	0.528%	0.503%	0.501%
\$120,000	1,000	13	2.003%	1.129%	0.730%	0.572%	0.519%	0.502%	0.501%
\$120,000	1,500	13	1.423%	0.801%	0.581%	0.519%	0.505%	0.502%	0.501%
\$120,000	2,000	13	1.105%	0.656%	0.533%	0.507%	0.503%	0.502%	0.501%
\$120,000	3,000	13	0.785%	0.549%	0.509%	0.504%	0.503%	0.502%	0.501%
\$120,000	4,000	13	0.642%	0.519%	0.506%	0.504%	0.503%	0.502%	0.501%
\$120,000	5,000	13	0.575%	0.510%	0.505%	0.504%	0.503%	0.502%	0.501%
\$120,000	10,000	13	0.508%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$120,000	20,000	13	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$130,000	5	13	59.123%	57.191%	55.334%	53.548%	51.829%	48.572%	45.536%
\$130,000	10	13	43.861%	41.573%	39.393%	37.308%	35.315%	31.595%	28.190%
\$130,000	15	13	35.666%	33.175%	30.814%	28.574%	26.453%	22.578%	19.180%
\$130,000	20	13	30.166%	27.594%	25.202%	22.991%	20.948%	17.344%	14.317%
\$130,000	25	13	26.481%	23.934%	21.591%	19.445%	17.497%	14.105%	11.311%
\$130,000	50	13	17.298%	14.898%	12.781%	10.929%	9.317%	6.720%	4.821%
\$130,000	100	13	11.010%	8.850%	7.066%	5.611%	4.434%	2.771%	1.771%
\$130,000	150	13	8.381%	6.410%	4.867%	3.680%	2.781%	1.628%	1.023%
\$130,000	200	13	6.929%	5.100%	3.721%	2.705%	1.979%	1.125%	0.743%
\$130,000	300	13	5.138%	3.539%	2.422%	1.678%	1.197%	0.718%	0.558%
\$130,000	400	13	4.107%	2.682%	1.753%	1.182%	0.853%	0.582%	0.515%
\$130,000	500	13	3.460%	2.169%	1.385%	0.940%	0.706%	0.538%	0.506%
\$130,000	600	13	3.034%	1.846%	1.162%	0.800%	0.625%	0.517%	0.502%
\$130,000	700	13	2.705%	1.605%	1.003%	0.708%	0.576%	0.509%	0.501%
\$130,000	800	13	2.449%	1.425%	0.894%	0.650%	0.550%	0.505%	0.501%
\$130,000	900	13	2.246%	1.285%	0.812%	0.610%	0.534%	0.503%	0.501%
\$130,000	1,000	13	2.073%	1.174%	0.753%	0.583%	0.523%	0.503%	0.501%
\$130,000	1,500	13	1.474%	0.827%	0.591%	0.522%	0.505%	0.502%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$130,000	2,000	13	1.144%	0.672%	0.537%	0.508%	0.503%	0.502%	0.501%
\$130,000	3,000	13	0.808%	0.555%	0.510%	0.504%	0.503%	0.502%	0.501%
\$130,000	4,000	13	0.656%	0.521%	0.506%	0.504%	0.503%	0.502%	0.501%
\$130,000	5,000	13	0.583%	0.511%	0.505%	0.504%	0.503%	0.502%	0.501%
\$130,000	10,000	13	0.509%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$130,000	20,000	13	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$140,000	5	13	59.693%	57.785%	55.952%	54.189%	52.493%	49.279%	46.286%
\$140,000	10	13	44.536%	42.284%	40.136%	38.083%	36.123%	32.468%	29.119%
\$140,000	15	13	36.402%	33.954%	31.634%	29.433%	27.342%	23.490%	20.086%
\$140,000	20	13	30.912%	28.360%	25.982%	23.774%	21.723%	18.076%	14.995%
\$140,000	25	13	27.156%	24.610%	22.261%	20.104%	18.135%	14.702%	11.862%
\$140,000	50	13	17.734%	15.333%	13.207%	11.337%	9.703%	7.060%	5.112%
\$140,000	100	13	11.306%	9.132%	7.330%	5.852%	4.651%	2.935%	1.888%
\$140,000	150	13	8.619%	6.630%	5.064%	3.853%	2.927%	1.725%	1.083%
\$140,000	200	13	7.124%	5.274%	3.873%	2.833%	2.082%	1.186%	0.776%
\$140,000	300	13	5.285%	3.666%	2.526%	1.757%	1.257%	0.747%	0.570%
\$140,000	400	13	4.227%	2.780%	1.828%	1.236%	0.888%	0.596%	0.519%
\$140,000	500	13	3.563%	2.250%	1.443%	0.978%	0.729%	0.544%	0.507%
\$140,000	600	13	3.127%	1.916%	1.210%	0.829%	0.640%	0.521%	0.503%
\$140,000	700	13	2.789%	1.666%	1.042%	0.729%	0.586%	0.510%	0.501%
\$140,000	800	13	2.525%	1.478%	0.926%	0.666%	0.558%	0.506%	0.501%
\$140,000	900	13	2.317%	1.333%	0.840%	0.623%	0.539%	0.504%	0.501%
\$140,000	1,000	13	2.140%	1.217%	0.776%	0.593%	0.527%	0.503%	0.501%
\$140,000	1,500	13	1.522%	0.852%	0.601%	0.525%	0.506%	0.502%	0.501%
\$140,000	2,000	13	1.181%	0.688%	0.542%	0.509%	0.504%	0.502%	0.501%
\$140,000	3,000	13	0.831%	0.562%	0.511%	0.505%	0.503%	0.502%	0.501%
\$140,000	4,000	13	0.670%	0.524%	0.506%	0.504%	0.503%	0.502%	0.501%
\$140,000	5,000	13	0.592%	0.512%	0.505%	0.504%	0.503%	0.502%	0.501%
\$140,000	10,000	13	0.509%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$140,000	20,000	13	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$150,000	5	13	60.200%	58.314%	56.500%	54.759%	53.083%	49.907%	46.950%
\$150,000	10	13	45.132%	42.911%	40.791%	38.766%	36.835%	33.235%	29.936%
\$150,000	15	13	37.040%	34.627%	32.343%	30.176%	28.117%	24.315%	20.917%
\$150,000	20	13	31.579%	29.052%	26.693%	24.492%	22.441%	18.769%	15.638%
\$150,000	25	13	27.779%	25.238%	22.886%	20.721%	18.736%	15.261%	12.378%
\$150,000	50	13	18.136%	15.731%	13.600%	11.715%	10.061%	7.378%	5.385%
\$150,000	100	13	11.579%	9.395%	7.576%	6.078%	4.854%	3.092%	2.001%
\$150,000	150	13	8.840%	6.834%	5.248%	4.014%	3.065%	1.819%	1.140%
\$150,000	200	13	7.305%	5.437%	4.015%	2.954%	2.180%	1.244%	0.808%
\$150,000	300	13	5.419%	3.782%	2.622%	1.832%	1.313%	0.775%	0.582%
\$150,000	400	13	4.338%	2.871%	1.899%	1.287%	0.923%	0.608%	0.522%
\$150,000	500	13	3.657%	2.324%	1.498%	1.014%	0.751%	0.551%	0.508%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$150,000	600	13	3.211%	1.981%	1.254%	0.857%	0.656%	0.524%	0.503%
\$150,000	700	13	2.866%	1.722%	1.079%	0.750%	0.597%	0.512%	0.502%
\$150,000	800	13	2.595%	1.527%	0.956%	0.682%	0.565%	0.507%	0.501%
\$150,000	900	13	2.383%	1.377%	0.865%	0.636%	0.545%	0.504%	0.501%
\$150,000	1,000	13	2.202%	1.257%	0.798%	0.603%	0.531%	0.503%	0.501%
\$150,000	1,500	13	1.567%	0.876%	0.611%	0.528%	0.507%	0.502%	0.501%
\$150,000	2,000	13	1.215%	0.703%	0.547%	0.510%	0.504%	0.502%	0.501%
\$150,000	3,000	13	0.853%	0.568%	0.512%	0.505%	0.503%	0.502%	0.501%
\$150,000	4,000	13	0.684%	0.527%	0.506%	0.504%	0.503%	0.502%	0.501%
\$150,000	5,000	13	0.601%	0.513%	0.505%	0.504%	0.503%	0.502%	0.501%
\$150,000	10,000	13	0.509%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$150,000	20,000	13	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$160,000	5	13	60.644%	58.776%	56.982%	55.258%	53.599%	50.457%	47.531%
\$160,000	10	13	45.666%	43.471%	41.377%	39.377%	37.472%	33.920%	30.665%
\$160,000	15	13	37.605%	35.226%	32.972%	30.835%	28.806%	25.061%	21.690%
\$160,000	20	13	32.177%	29.682%	27.346%	25.156%	23.111%	19.430%	16.261%
\$160,000	25	13	28.358%	25.827%	23.478%	21.311%	19.311%	15.798%	12.872%
\$160,000	50	13	18.511%	16.104%	13.966%	12.069%	10.400%	7.681%	5.644%
\$160,000	100	13	11.836%	9.642%	7.808%	6.291%	5.048%	3.244%	2.112%
\$160,000	150	13	9.045%	7.024%	5.420%	4.165%	3.197%	1.907%	1.196%
\$160,000	200	13	7.475%	5.591%	4.149%	3.069%	2.274%	1.301%	0.840%
\$160,000	300	13	5.546%	3.892%	2.713%	1.904%	1.368%	0.803%	0.594%
\$160,000	400	13	4.443%	2.958%	1.967%	1.337%	0.956%	0.621%	0.526%
\$160,000	500	13	3.748%	2.396%	1.550%	1.050%	0.774%	0.558%	0.510%
\$160,000	600	13	3.292%	2.043%	1.297%	0.884%	0.671%	0.528%	0.504%
\$160,000	700	13	2.940%	1.776%	1.114%	0.771%	0.608%	0.514%	0.502%
\$160,000	800	13	2.662%	1.574%	0.985%	0.698%	0.573%	0.508%	0.501%
\$160,000	900	13	2.444%	1.419%	0.890%	0.648%	0.551%	0.505%	0.501%
\$160,000	1,000	13	2.259%	1.295%	0.820%	0.613%	0.535%	0.503%	0.501%
\$160,000	1,500	13	1.609%	0.899%	0.620%	0.531%	0.508%	0.502%	0.501%
\$160,000	2,000	13	1.248%	0.718%	0.551%	0.511%	0.504%	0.502%	0.501%
\$160,000	3,000	13	0.874%	0.574%	0.514%	0.505%	0.503%	0.502%	0.501%
\$160,000	4,000	13	0.697%	0.529%	0.507%	0.504%	0.503%	0.502%	0.501%
\$160,000	5,000	13	0.610%	0.514%	0.505%	0.504%	0.503%	0.502%	0.501%
\$160,000	10,000	13	0.510%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$160,000	20,000	13	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$170,000	5	13	61.045%	59.194%	57.417%	55.709%	54.065%	50.954%	48.056%
\$170,000	10	13	46.155%	43.984%	41.912%	39.936%	38.053%	34.545%	31.329%
\$170,000	15	13	38.119%	35.768%	33.543%	31.432%	29.430%	25.738%	22.409%
\$170,000	20	13	32.723%	30.262%	27.952%	25.780%	23.744%	20.065%	16.874%
\$170,000	25	13	28.900%	26.384%	24.042%	21.875%	19.868%	16.322%	13.354%
\$170,000	50	13	18.870%	16.461%	14.315%	12.408%	10.727%	7.973%	5.898%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$170,000	100	13	12.079%	9.877%	8.029%	6.495%	5.233%	3.390%	2.221%
\$170,000	150	13	9.237%	7.205%	5.584%	4.310%	3.322%	1.994%	1.252%
\$170,000	200	13	7.636%	5.738%	4.278%	3.179%	2.366%	1.358%	0.873%
\$170,000	300	13	5.668%	3.998%	2.801%	1.974%	1.422%	0.831%	0.606%
\$170,000	400	13	4.543%	3.042%	2.034%	1.385%	0.990%	0.634%	0.530%
\$170,000	500	13	3.826%	2.458%	1.596%	1.080%	0.793%	0.563%	0.510%
\$170,000	600	13	3.368%	2.102%	1.338%	0.910%	0.686%	0.532%	0.505%
\$170,000	700	13	3.010%	1.828%	1.149%	0.792%	0.619%	0.516%	0.502%
\$170,000	800	13	2.725%	1.620%	1.014%	0.714%	0.580%	0.509%	0.501%
\$170,000	900	13	2.503%	1.460%	0.915%	0.661%	0.557%	0.505%	0.501%
\$170,000	1,000	13	2.314%	1.332%	0.841%	0.624%	0.539%	0.504%	0.501%
\$170,000	1,500	13	1.649%	0.921%	0.630%	0.534%	0.508%	0.502%	0.501%
\$170,000	2,000	13	1.280%	0.732%	0.556%	0.513%	0.504%	0.502%	0.501%
\$170,000	3,000	13	0.895%	0.581%	0.515%	0.505%	0.503%	0.502%	0.501%
\$170,000	4,000	13	0.711%	0.532%	0.507%	0.504%	0.503%	0.502%	0.501%
\$170,000	5,000	13	0.619%	0.516%	0.505%	0.504%	0.503%	0.502%	0.501%
\$170,000	10,000	13	0.510%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$170,000	20,000	13	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$180,000	5	13	61.412%	59.576%	57.814%	56.121%	54.490%	51.407%	48.535%
\$180,000	10	13	46.601%	44.450%	42.399%	40.444%	38.582%	35.112%	31.933%
\$180,000	15	13	38.587%	36.263%	34.063%	31.976%	29.999%	26.353%	23.067%
\$180,000	20	13	33.221%	30.792%	28.510%	26.361%	24.340%	20.671%	17.469%
\$180,000	25	13	29.404%	26.905%	24.575%	22.412%	20.404%	16.834%	13.825%
\$180,000	50	13	19.214%	16.803%	14.651%	12.736%	11.042%	8.259%	6.148%
\$180,000	100	13	12.311%	10.102%	8.242%	6.694%	5.413%	3.533%	2.329%
\$180,000	150	13	9.421%	7.378%	5.742%	4.450%	3.444%	2.080%	1.309%
\$180,000	200	13	7.790%	5.879%	4.403%	3.286%	2.455%	1.415%	0.905%
\$180,000	300	13	5.785%	4.101%	2.887%	2.043%	1.474%	0.859%	0.619%
\$180,000	400	13	4.640%	3.123%	2.098%	1.433%	1.023%	0.648%	0.534%
\$180,000	500	13	3.908%	2.524%	1.645%	1.114%	0.815%	0.570%	0.512%
\$180,000	600	13	3.441%	2.159%	1.378%	0.936%	0.701%	0.536%	0.505%
\$180,000	700	13	3.078%	1.879%	1.183%	0.813%	0.630%	0.518%	0.502%
\$180,000	800	13	2.786%	1.664%	1.042%	0.730%	0.588%	0.510%	0.502%
\$180,000	900	13	2.560%	1.500%	0.940%	0.675%	0.563%	0.506%	0.501%
\$180,000	1,000	13	2.367%	1.367%	0.862%	0.634%	0.544%	0.504%	0.501%
\$180,000	1,500	13	1.689%	0.943%	0.640%	0.538%	0.510%	0.502%	0.501%
\$180,000	2,000	13	1.311%	0.747%	0.561%	0.514%	0.504%	0.502%	0.501%
\$180,000	3,000	13	0.915%	0.587%	0.516%	0.505%	0.503%	0.502%	0.501%
\$180,000	4,000	13	0.724%	0.535%	0.507%	0.504%	0.503%	0.502%	0.501%
\$180,000	5,000	13	0.627%	0.517%	0.506%	0.504%	0.503%	0.502%	0.501%
\$180,000	10,000	13	0.511%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$180,000	20,000	13	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$190,000	5	13	61.737%	59.914%	58.166%	56.486%	54.868%	51.809%	48.960%
\$190,000	10	13	46.999%	44.867%	42.834%	40.898%	39.056%	35.620%	32.473%
\$190,000	15	13	39.012%	36.711%	34.533%	32.468%	30.513%	26.910%	23.661%
\$190,000	20	13	33.672%	31.272%	29.016%	26.892%	24.891%	21.239%	18.033%
\$190,000	25	13	29.869%	27.389%	25.074%	22.918%	20.912%	17.327%	14.285%
\$190,000	50	13	19.542%	17.131%	14.973%	13.049%	11.346%	8.536%	6.390%
\$190,000	100	13	12.536%	10.319%	8.449%	6.887%	5.590%	3.674%	2.436%
\$190,000	150	13	9.599%	7.546%	5.895%	4.586%	3.562%	2.165%	1.365%
\$190,000	200	13	7.937%	6.014%	4.523%	3.389%	2.541%	1.470%	0.938%
\$190,000	300	13	5.896%	4.199%	2.969%	2.109%	1.525%	0.886%	0.632%
\$190,000	400	13	4.732%	3.201%	2.160%	1.479%	1.055%	0.661%	0.539%
\$190,000	500	13	3.987%	2.588%	1.692%	1.147%	0.836%	0.577%	0.514%
\$190,000	600	13	3.512%	2.214%	1.418%	0.961%	0.716%	0.540%	0.506%
\$190,000	700	13	3.142%	1.927%	1.217%	0.833%	0.641%	0.521%	0.503%
\$190,000	800	13	2.845%	1.707%	1.070%	0.746%	0.597%	0.511%	0.502%
\$190,000	900	13	2.615%	1.539%	0.964%	0.688%	0.569%	0.507%	0.501%
\$190,000	1,000	13	2.418%	1.402%	0.882%	0.645%	0.548%	0.505%	0.501%
\$190,000	1,500	13	1.727%	0.965%	0.650%	0.541%	0.511%	0.502%	0.501%
\$190,000	2,000	13	1.341%	0.761%	0.566%	0.515%	0.504%	0.502%	0.501%
\$190,000	3,000	13	0.934%	0.594%	0.518%	0.505%	0.503%	0.502%	0.501%
\$190,000	4,000	13	0.737%	0.538%	0.508%	0.504%	0.503%	0.502%	0.501%
\$190,000	5,000	13	0.636%	0.518%	0.506%	0.504%	0.503%	0.502%	0.501%
\$190,000	10,000	13	0.511%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$190,000	20,000	13	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$200,000	5	13	62.035%	60.225%	58.488%	56.820%	55.214%	52.177%	49.348%
\$200,000	10	13	47.364%	45.249%	43.233%	41.315%	39.489%	36.085%	32.968%
\$200,000	15	13	39.403%	37.123%	34.966%	32.921%	30.987%	27.422%	24.207%
\$200,000	20	13	34.091%	31.716%	29.484%	27.383%	25.404%	21.780%	18.577%
\$200,000	25	13	30.303%	27.845%	25.548%	23.401%	21.402%	17.811%	14.741%
\$200,000	50	13	19.859%	17.447%	15.285%	13.354%	11.641%	8.806%	6.628%
\$200,000	100	13	12.755%	10.531%	8.652%	7.075%	5.763%	3.813%	2.542%
\$200,000	150	13	9.772%	7.711%	6.046%	4.720%	3.678%	2.249%	1.422%
\$200,000	200	13	8.080%	6.145%	4.640%	3.490%	2.627%	1.526%	0.971%
\$200,000	300	13	6.004%	4.295%	3.050%	2.174%	1.576%	0.914%	0.645%
\$200,000	400	13	4.822%	3.276%	2.221%	1.525%	1.087%	0.674%	0.544%
\$200,000	500	13	4.063%	2.650%	1.739%	1.180%	0.857%	0.585%	0.515%
\$200,000	600	13	3.580%	2.268%	1.456%	0.986%	0.732%	0.544%	0.507%
\$200,000	700	13	3.204%	1.975%	1.249%	0.853%	0.653%	0.524%	0.503%
\$200,000	800	13	2.901%	1.748%	1.097%	0.762%	0.605%	0.513%	0.502%
\$200,000	900	13	2.667%	1.577%	0.988%	0.701%	0.575%	0.508%	0.501%
\$200,000	1,000	13	2.467%	1.436%	0.903%	0.655%	0.553%	0.505%	0.501%
\$200,000	1,500	13	1.764%	0.986%	0.660%	0.545%	0.512%	0.502%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$200,000	2,000	13	1.370%	0.775%	0.572%	0.517%	0.505%	0.502%	0.501%
\$200,000	3,000	13	0.953%	0.600%	0.519%	0.506%	0.503%	0.502%	0.501%
\$200,000	4,000	13	0.750%	0.541%	0.508%	0.504%	0.503%	0.502%	0.501%
\$200,000	5,000	13	0.645%	0.520%	0.506%	0.504%	0.503%	0.502%	0.501%
\$200,000	10,000	13	0.512%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$200,000	20,000	13	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$225,000	5	13	62.670%	60.886%	59.175%	57.531%	55.949%	52.960%	50.172%
\$225,000	10	13	48.150%	46.071%	44.092%	42.211%	40.421%	37.081%	34.028%
\$225,000	15	13	40.246%	38.011%	35.897%	33.894%	32.004%	28.519%	25.376%
\$225,000	20	13	34.985%	32.663%	30.481%	28.428%	26.496%	22.955%	19.797%
\$225,000	25	13	31.227%	28.823%	26.574%	24.464%	22.489%	18.912%	15.812%
\$225,000	50	13	20.585%	18.174%	16.001%	14.058%	12.324%	9.431%	7.184%
\$225,000	100	13	13.257%	11.019%	9.119%	7.512%	6.166%	4.139%	2.794%
\$225,000	150	13	10.164%	8.084%	6.391%	5.028%	3.947%	2.446%	1.558%
\$225,000	200	13	8.406%	6.448%	4.910%	3.725%	2.825%	1.657%	1.051%
\$225,000	300	13	6.253%	4.515%	3.237%	2.325%	1.694%	0.981%	0.678%
\$225,000	400	13	5.026%	3.448%	2.360%	1.631%	1.163%	0.706%	0.557%
\$225,000	500	13	4.237%	2.794%	1.848%	1.258%	0.908%	0.604%	0.521%
\$225,000	600	13	3.734%	2.391%	1.546%	1.045%	0.769%	0.555%	0.510%
\$225,000	700	13	3.345%	2.084%	1.325%	0.901%	0.680%	0.530%	0.504%
\$225,000	800	13	3.029%	1.844%	1.160%	0.799%	0.625%	0.517%	0.502%
\$225,000	900	13	2.787%	1.663%	1.043%	0.732%	0.591%	0.510%	0.501%
\$225,000	1,000	13	2.578%	1.514%	0.950%	0.681%	0.565%	0.507%	0.501%
\$225,000	1,500	13	1.850%	1.037%	0.685%	0.555%	0.515%	0.502%	0.501%
\$225,000	2,000	13	1.437%	0.809%	0.584%	0.520%	0.506%	0.502%	0.501%
\$225,000	3,000	13	0.998%	0.616%	0.523%	0.506%	0.503%	0.502%	0.501%
\$225,000	4,000	13	0.780%	0.548%	0.509%	0.504%	0.503%	0.502%	0.501%
\$225,000	5,000	13	0.665%	0.523%	0.506%	0.504%	0.503%	0.502%	0.501%
\$225,000	10,000	13	0.513%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$225,000	20,000	13	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$250,000	5	13	63.174%	61.411%	59.721%	58.095%	56.532%	53.579%	50.824%
\$250,000	10	13	48.766%	46.715%	44.765%	42.912%	41.150%	37.860%	34.857%
\$250,000	15	13	40.897%	38.697%	36.615%	34.647%	32.789%	29.366%	26.280%
\$250,000	20	13	35.681%	33.399%	31.256%	29.240%	27.343%	23.869%	20.775%
\$250,000	25	13	31.949%	29.589%	27.381%	25.311%	23.369%	19.835%	16.741%
\$250,000	50	13	21.204%	18.794%	16.615%	14.660%	12.909%	9.972%	7.668%
\$250,000	100	13	13.684%	11.436%	9.519%	7.889%	6.518%	4.428%	3.024%
\$250,000	150	13	10.500%	8.407%	6.691%	5.301%	4.186%	2.625%	1.685%
\$250,000	200	13	8.688%	6.713%	5.148%	3.933%	3.003%	1.779%	1.126%
\$250,000	300	13	6.466%	4.706%	3.401%	2.458%	1.800%	1.044%	0.709%
\$250,000	400	13	5.201%	3.598%	2.481%	1.726%	1.232%	0.738%	0.569%
\$250,000	500	13	4.388%	2.919%	1.946%	1.329%	0.957%	0.623%	0.527%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$250,000	600	13	3.860%	2.492%	1.621%	1.096%	0.801%	0.565%	0.512%
\$250,000	700	13	3.467%	2.179%	1.392%	0.945%	0.707%	0.537%	0.506%
\$250,000	800	13	3.140%	1.928%	1.218%	0.835%	0.645%	0.521%	0.503%
\$250,000	900	13	2.891%	1.739%	1.092%	0.761%	0.606%	0.513%	0.502%
\$250,000	1,000	13	2.674%	1.583%	0.993%	0.705%	0.577%	0.508%	0.501%
\$250,000	1,500	13	1.924%	1.082%	0.708%	0.564%	0.518%	0.502%	0.501%
\$250,000	2,000	13	1.496%	0.839%	0.596%	0.524%	0.506%	0.502%	0.501%
\$250,000	3,000	13	1.038%	0.631%	0.527%	0.507%	0.503%	0.502%	0.501%
\$250,000	4,000	13	0.808%	0.556%	0.510%	0.504%	0.503%	0.502%	0.501%
\$250,000	5,000	13	0.684%	0.527%	0.506%	0.504%	0.503%	0.502%	0.501%
\$250,000	10,000	13	0.515%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$250,000	20,000	13	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$275,000	5	13	63.581%	61.835%	60.161%	58.551%	57.003%	54.079%	51.351%
\$275,000	10	13	49.264%	47.236%	45.310%	43.481%	41.739%	38.489%	35.528%
\$275,000	15	13	41.420%	39.247%	37.192%	35.252%	33.420%	30.046%	27.005%
\$275,000	20	13	36.245%	33.995%	31.882%	29.897%	28.029%	24.608%	21.567%
\$275,000	25	13	32.534%	30.210%	28.035%	25.998%	24.087%	20.607%	17.547%
\$275,000	50	13	21.741%	19.340%	17.159%	15.197%	13.433%	10.459%	8.104%
\$275,000	100	13	14.066%	11.812%	9.880%	8.232%	6.841%	4.699%	3.239%
\$275,000	150	13	10.806%	8.702%	6.967%	5.553%	4.411%	2.795%	1.808%
\$275,000	200	13	8.947%	6.956%	5.368%	4.127%	3.170%	1.894%	1.200%
\$275,000	300	13	6.659%	4.880%	3.551%	2.583%	1.899%	1.103%	0.741%
\$275,000	400	13	5.360%	3.736%	2.593%	1.813%	1.298%	0.769%	0.581%
\$275,000	500	13	4.526%	3.034%	2.036%	1.396%	1.004%	0.642%	0.534%
\$275,000	600	13	3.982%	2.591%	1.696%	1.149%	0.835%	0.577%	0.515%
\$275,000	700	13	3.578%	2.266%	1.455%	0.987%	0.732%	0.545%	0.507%
\$275,000	800	13	3.242%	2.006%	1.272%	0.869%	0.664%	0.526%	0.503%
\$275,000	900	13	2.984%	1.809%	1.140%	0.790%	0.621%	0.516%	0.502%
\$275,000	1,000	13	2.761%	1.646%	1.034%	0.727%	0.588%	0.510%	0.501%
\$275,000	1,500	13	1.991%	1.124%	0.729%	0.574%	0.522%	0.503%	0.501%
\$275,000	2,000	13	1.549%	0.867%	0.608%	0.528%	0.507%	0.502%	0.501%
\$275,000	3,000	13	1.075%	0.646%	0.531%	0.508%	0.503%	0.502%	0.501%
\$275,000	4,000	13	0.833%	0.563%	0.512%	0.505%	0.503%	0.502%	0.501%
\$275,000	5,000	13	0.702%	0.531%	0.507%	0.504%	0.503%	0.502%	0.501%
\$275,000	10,000	13	0.516%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$275,000	20,000	13	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$300,000	5	13	63.920%	62.188%	60.527%	58.930%	57.396%	54.495%	51.789%
\$300,000	10	13	49.681%	47.673%	45.767%	43.956%	42.233%	39.016%	36.089%
\$300,000	15	13	41.853%	39.703%	37.670%	35.753%	33.943%	30.609%	27.605%
\$300,000	20	13	36.715%	34.491%	32.405%	30.444%	28.599%	25.223%	22.225%
\$300,000	25	13	33.017%	30.722%	28.573%	26.564%	24.678%	21.247%	18.230%
\$300,000	50	13	22.215%	19.824%	17.652%	15.687%	13.916%	10.909%	8.516%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$300,000	100	13	14.406%	12.150%	10.208%	8.546%	7.136%	4.953%	3.442%
\$300,000	150	13	11.079%	8.966%	7.218%	5.784%	4.619%	2.956%	1.925%
\$300,000	200	13	9.182%	7.178%	5.571%	4.307%	3.325%	2.005%	1.271%
\$300,000	300	13	6.835%	5.038%	3.688%	2.699%	1.993%	1.160%	0.772%
\$300,000	400	13	5.506%	3.863%	2.698%	1.896%	1.361%	0.800%	0.595%
\$300,000	500	13	4.654%	3.142%	2.121%	1.459%	1.050%	0.662%	0.541%
\$300,000	600	13	4.095%	2.684%	1.767%	1.200%	0.868%	0.588%	0.519%
\$300,000	700	13	3.680%	2.348%	1.516%	1.027%	0.758%	0.553%	0.509%
\$300,000	800	13	3.336%	2.079%	1.323%	0.902%	0.683%	0.531%	0.504%
\$300,000	900	13	3.071%	1.875%	1.184%	0.817%	0.636%	0.520%	0.502%
\$300,000	1,000	13	2.841%	1.704%	1.073%	0.750%	0.600%	0.512%	0.502%
\$300,000	1,500	13	2.053%	1.163%	0.750%	0.583%	0.525%	0.503%	0.501%
\$300,000	2,000	13	1.599%	0.894%	0.619%	0.532%	0.508%	0.502%	0.501%
\$300,000	3,000	13	1.110%	0.659%	0.534%	0.508%	0.503%	0.502%	0.501%
\$300,000	4,000	13	0.858%	0.570%	0.513%	0.505%	0.503%	0.502%	0.501%
\$300,000	5,000	13	0.719%	0.534%	0.507%	0.504%	0.503%	0.502%	0.501%
\$300,000	10,000	13	0.517%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$300,000	20,000	13	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$325,000	5	13	64.206%	62.486%	60.836%	59.250%	57.727%	54.847%	52.159%
\$325,000	10	13	50.052%	48.061%	46.171%	44.378%	42.670%	39.483%	36.586%
\$325,000	15	13	42.241%	40.111%	38.097%	36.200%	34.409%	31.109%	28.140%
\$325,000	20	13	37.139%	34.938%	32.874%	30.935%	29.111%	25.774%	22.814%
\$325,000	25	13	33.443%	31.174%	29.049%	27.062%	25.198%	21.811%	18.834%
\$325,000	50	13	22.657%	20.282%	18.121%	16.161%	14.389%	11.358%	8.930%
\$325,000	100	13	14.727%	12.473%	10.522%	8.848%	7.422%	5.203%	3.643%
\$325,000	150	13	11.340%	9.218%	7.457%	6.005%	4.821%	3.114%	2.041%
\$325,000	200	13	9.406%	7.392%	5.768%	4.482%	3.478%	2.115%	1.345%
\$325,000	300	13	7.003%	5.191%	3.821%	2.811%	2.086%	1.217%	0.805%
\$325,000	400	13	5.647%	3.986%	2.801%	1.978%	1.424%	0.831%	0.609%
\$325,000	500	13	4.777%	3.246%	2.204%	1.522%	1.095%	0.683%	0.549%
\$325,000	600	13	4.203%	2.773%	1.837%	1.251%	0.902%	0.601%	0.522%
\$325,000	700	13	3.778%	2.427%	1.575%	1.068%	0.783%	0.561%	0.511%
\$325,000	800	13	3.425%	2.149%	1.373%	0.934%	0.702%	0.536%	0.505%
\$325,000	900	13	3.153%	1.939%	1.228%	0.844%	0.651%	0.524%	0.503%
\$325,000	1,000	13	2.917%	1.761%	1.110%	0.772%	0.612%	0.514%	0.502%
\$325,000	1,500	13	2.112%	1.201%	0.771%	0.593%	0.529%	0.503%	0.501%
\$325,000	2,000	13	1.646%	0.920%	0.631%	0.536%	0.509%	0.502%	0.501%
\$325,000	3,000	13	1.143%	0.673%	0.538%	0.509%	0.504%	0.502%	0.501%
\$325,000	4,000	13	0.881%	0.577%	0.514%	0.505%	0.503%	0.502%	0.501%
\$325,000	5,000	13	0.736%	0.538%	0.508%	0.504%	0.503%	0.502%	0.501%
\$325,000	10,000	13	0.519%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$325,000	20,000	13	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$350,000	5	13	64.452%	62.742%	61.101%	59.525%	58.010%	55.148%	52.477%
\$350,000	10	13	50.369%	48.393%	46.518%	44.739%	43.044%	39.882%	37.010%
\$350,000	15	13	42.576%	40.462%	38.466%	36.586%	34.811%	31.540%	28.600%
\$350,000	20	13	37.498%	35.317%	33.272%	31.351%	29.545%	26.241%	23.313%
\$350,000	25	13	33.803%	31.555%	29.451%	27.484%	25.638%	22.287%	19.344%
\$350,000	50	13	23.046%	20.687%	18.541%	16.586%	14.820%	11.776%	9.318%
\$350,000	100	13	15.019%	12.765%	10.809%	9.125%	7.686%	5.432%	3.832%
\$350,000	150	13	11.577%	9.450%	7.675%	6.208%	5.008%	3.262%	2.149%
\$350,000	200	13	9.611%	7.588%	5.951%	4.646%	3.621%	2.220%	1.416%
\$350,000	300	13	7.157%	5.332%	3.944%	2.916%	2.171%	1.271%	0.836%
\$350,000	400	13	5.777%	4.101%	2.896%	2.055%	1.483%	0.862%	0.622%
\$350,000	500	13	4.891%	3.343%	2.282%	1.581%	1.138%	0.702%	0.556%
\$350,000	600	13	4.304%	2.857%	1.902%	1.299%	0.935%	0.613%	0.527%
\$350,000	700	13	3.862%	2.494%	1.625%	1.102%	0.804%	0.568%	0.512%
\$350,000	800	13	3.507%	2.214%	1.420%	0.965%	0.721%	0.542%	0.506%
\$350,000	900	13	3.229%	1.997%	1.269%	0.869%	0.665%	0.528%	0.503%
\$350,000	1,000	13	2.988%	1.814%	1.146%	0.793%	0.623%	0.517%	0.502%
\$350,000	1,500	13	2.166%	1.237%	0.791%	0.602%	0.533%	0.503%	0.501%
\$350,000	2,000	13	1.689%	0.945%	0.642%	0.540%	0.511%	0.502%	0.501%
\$350,000	3,000	13	1.174%	0.686%	0.542%	0.510%	0.504%	0.502%	0.501%
\$350,000	4,000	13	0.903%	0.584%	0.516%	0.505%	0.503%	0.502%	0.501%
\$350,000	5,000	13	0.751%	0.542%	0.508%	0.504%	0.503%	0.502%	0.501%
\$350,000	10,000	13	0.521%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$350,000	20,000	13	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$375,000	5	13	64.666%	62.965%	61.332%	59.765%	58.258%	55.411%	52.754%
\$375,000	10	13	50.648%	48.684%	46.822%	45.055%	43.372%	40.232%	37.383%
\$375,000	15	13	42.871%	40.772%	38.791%	36.926%	35.164%	31.919%	29.004%
\$375,000	20	13	37.814%	35.651%	33.622%	31.717%	29.926%	26.651%	23.751%
\$375,000	25	13	34.117%	31.888%	29.802%	27.851%	26.022%	22.703%	19.789%
\$375,000	50	13	23.397%	21.057%	18.925%	16.981%	15.219%	12.175%	9.696%
\$375,000	100	13	15.293%	13.038%	11.081%	9.388%	7.937%	5.649%	4.015%
\$375,000	150	13	11.798%	9.667%	7.882%	6.401%	5.186%	3.404%	2.255%
\$375,000	200	13	9.803%	7.772%	6.123%	4.801%	3.757%	2.321%	1.485%
\$375,000	300	13	7.303%	5.466%	4.061%	3.016%	2.254%	1.323%	0.866%
\$375,000	400	13	5.900%	4.211%	2.987%	2.129%	1.540%	0.893%	0.636%
\$375,000	500	13	4.999%	3.435%	2.357%	1.639%	1.180%	0.722%	0.564%
\$375,000	600	13	4.398%	2.936%	1.964%	1.345%	0.967%	0.626%	0.531%
\$375,000	700	13	3.948%	2.563%	1.678%	1.139%	0.828%	0.576%	0.514%
\$375,000	800	13	3.584%	2.275%	1.465%	0.995%	0.739%	0.547%	0.507%
\$375,000	900	13	3.300%	2.053%	1.308%	0.894%	0.679%	0.531%	0.504%
\$375,000	1,000	13	3.055%	1.865%	1.180%	0.813%	0.634%	0.519%	0.502%
\$375,000	1,500	13	2.217%	1.271%	0.810%	0.611%	0.537%	0.504%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$375,000	2,000	13	1.731%	0.969%	0.653%	0.544%	0.512%	0.502%	0.501%
\$375,000	3,000	13	1.203%	0.699%	0.546%	0.511%	0.504%	0.502%	0.501%
\$375,000	4,000	13	0.924%	0.591%	0.517%	0.505%	0.503%	0.502%	0.501%
\$375,000	5,000	13	0.766%	0.545%	0.509%	0.504%	0.503%	0.502%	0.501%
\$375,000	10,000	13	0.522%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$375,000	20,000	13	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$400,000	5	13	64.863%	63.170%	61.544%	59.984%	58.485%	55.650%	53.007%
\$400,000	10	13	50.890%	48.938%	47.087%	45.330%	43.656%	40.536%	37.705%
\$400,000	15	13	43.117%	41.031%	39.063%	37.209%	35.459%	32.235%	29.342%
\$400,000	20	13	38.074%	35.926%	33.911%	32.019%	30.242%	26.990%	24.113%
\$400,000	25	13	34.373%	32.159%	30.088%	28.151%	26.335%	23.042%	20.153%
\$400,000	50	13	23.699%	21.379%	19.263%	17.329%	15.576%	12.536%	10.045%
\$400,000	100	13	15.541%	13.287%	11.327%	9.629%	8.167%	5.850%	4.186%
\$400,000	150	13	12.000%	9.867%	8.074%	6.580%	5.353%	3.537%	2.355%
\$400,000	200	13	9.979%	7.939%	6.280%	4.944%	3.885%	2.415%	1.551%
\$400,000	300	13	7.435%	5.590%	4.171%	3.110%	2.334%	1.373%	0.896%
\$400,000	400	13	6.012%	4.311%	3.071%	2.197%	1.594%	0.923%	0.650%
\$400,000	500	13	5.097%	3.521%	2.426%	1.692%	1.220%	0.741%	0.572%
\$400,000	600	13	4.484%	3.008%	2.021%	1.388%	0.997%	0.638%	0.535%
\$400,000	700	13	4.025%	2.627%	1.727%	1.174%	0.851%	0.584%	0.517%
\$400,000	800	13	3.655%	2.332%	1.506%	1.023%	0.756%	0.552%	0.509%
\$400,000	900	13	3.365%	2.104%	1.345%	0.917%	0.692%	0.535%	0.505%
\$400,000	1,000	13	3.115%	1.911%	1.211%	0.832%	0.645%	0.521%	0.503%
\$400,000	1,500	13	2.263%	1.302%	0.828%	0.620%	0.540%	0.504%	0.501%
\$400,000	2,000	13	1.768%	0.990%	0.664%	0.548%	0.513%	0.502%	0.501%
\$400,000	3,000	13	1.230%	0.710%	0.550%	0.512%	0.504%	0.502%	0.501%
\$400,000	4,000	13	0.944%	0.598%	0.519%	0.505%	0.503%	0.502%	0.501%
\$400,000	5,000	13	0.780%	0.549%	0.509%	0.504%	0.503%	0.502%	0.501%
\$400,000	10,000	13	0.524%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$400,000	20,000	13	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$425,000	5	13	65.040%	63.353%	61.734%	60.180%	58.687%	55.863%	53.231%
\$425,000	10	13	51.102%	49.159%	47.318%	45.570%	43.904%	40.801%	37.987%
\$425,000	15	13	43.328%	41.252%	39.295%	37.452%	35.712%	32.507%	29.632%
\$425,000	20	13	38.298%	36.162%	34.159%	32.279%	30.512%	27.282%	24.424%
\$425,000	25	13	34.591%	32.390%	30.332%	28.407%	26.603%	23.332%	20.464%
\$425,000	50	13	23.963%	21.660%	19.560%	17.639%	15.895%	12.863%	10.370%
\$425,000	100	13	15.767%	13.515%	11.552%	9.850%	8.380%	6.036%	4.345%
\$425,000	150	13	12.185%	10.049%	8.250%	6.746%	5.506%	3.661%	2.449%
\$425,000	200	13	10.139%	8.093%	6.424%	5.077%	4.004%	2.503%	1.613%
\$425,000	300	13	7.557%	5.704%	4.273%	3.198%	2.407%	1.420%	0.924%
\$425,000	400	13	6.115%	4.402%	3.149%	2.261%	1.645%	0.951%	0.663%
\$425,000	500	13	5.187%	3.600%	2.490%	1.742%	1.257%	0.760%	0.580%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$425,000	600	13	4.564%	3.076%	2.075%	1.428%	1.025%	0.650%	0.539%
\$425,000	700	13	4.097%	2.686%	1.772%	1.206%	0.873%	0.592%	0.519%
\$425,000	800	13	3.720%	2.385%	1.545%	1.049%	0.773%	0.558%	0.510%
\$425,000	900	13	3.427%	2.152%	1.379%	0.939%	0.706%	0.539%	0.505%
\$425,000	1,000	13	3.171%	1.954%	1.241%	0.851%	0.655%	0.524%	0.503%
\$425,000	1,500	13	2.306%	1.331%	0.844%	0.628%	0.544%	0.505%	0.501%
\$425,000	2,000	13	1.801%	1.010%	0.673%	0.551%	0.514%	0.502%	0.501%
\$425,000	3,000	13	1.254%	0.721%	0.554%	0.513%	0.504%	0.502%	0.501%
\$425,000	4,000	13	0.961%	0.604%	0.520%	0.506%	0.503%	0.502%	0.501%
\$425,000	5,000	13	0.793%	0.552%	0.510%	0.504%	0.503%	0.502%	0.501%
\$425,000	10,000	13	0.525%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$425,000	20,000	13	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$450,000	5	13	65.191%	63.510%	61.896%	60.348%	58.860%	56.046%	53.424%
\$450,000	10	13	51.281%	49.347%	47.513%	45.772%	44.114%	41.024%	38.224%
\$450,000	15	13	43.507%	41.440%	39.492%	37.658%	35.927%	32.737%	29.877%
\$450,000	20	13	38.494%	36.369%	34.376%	32.505%	30.748%	27.535%	24.694%
\$450,000	25	13	34.779%	32.589%	30.542%	28.627%	26.832%	23.580%	20.731%
\$450,000	50	13	24.192%	21.905%	19.819%	17.912%	16.179%	13.156%	10.664%
\$450,000	100	13	15.972%	13.724%	11.760%	10.053%	8.577%	6.212%	4.495%
\$450,000	150	13	12.353%	10.215%	8.410%	6.897%	5.646%	3.776%	2.537%
\$450,000	200	13	10.285%	8.233%	6.556%	5.198%	4.114%	2.586%	1.671%
\$450,000	300	13	7.668%	5.808%	4.366%	3.279%	2.475%	1.465%	0.951%
\$450,000	400	13	6.208%	4.486%	3.221%	2.321%	1.693%	0.977%	0.676%
\$450,000	500	13	5.269%	3.672%	2.550%	1.789%	1.293%	0.778%	0.588%
\$450,000	600	13	4.637%	3.138%	2.125%	1.466%	1.052%	0.662%	0.544%
\$450,000	700	13	4.163%	2.741%	1.815%	1.237%	0.894%	0.600%	0.522%
\$450,000	800	13	3.774%	2.427%	1.577%	1.070%	0.786%	0.561%	0.510%
\$450,000	900	13	3.483%	2.196%	1.411%	0.961%	0.719%	0.542%	0.506%
\$450,000	1,000	13	3.223%	1.993%	1.269%	0.869%	0.665%	0.526%	0.503%
\$450,000	1,500	13	2.345%	1.357%	0.860%	0.636%	0.547%	0.505%	0.501%
\$450,000	2,000	13	1.832%	1.029%	0.682%	0.555%	0.515%	0.502%	0.501%
\$450,000	3,000	13	1.276%	0.732%	0.557%	0.514%	0.504%	0.502%	0.501%
\$450,000	4,000	13	0.978%	0.610%	0.521%	0.506%	0.503%	0.502%	0.501%
\$450,000	5,000	13	0.805%	0.556%	0.511%	0.504%	0.503%	0.502%	0.501%
\$450,000	10,000	13	0.527%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$450,000	20,000	13	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$475,000	5	13	65.326%	63.650%	62.041%	60.498%	59.015%	56.210%	53.597%
\$475,000	10	13	51.444%	49.517%	47.691%	45.956%	44.305%	41.228%	38.440%
\$475,000	15	13	43.673%	41.614%	39.675%	37.849%	36.125%	32.950%	30.104%
\$475,000	20	13	38.679%	36.563%	34.580%	32.718%	30.969%	27.773%	24.947%
\$475,000	25	13	34.955%	32.774%	30.738%	28.832%	27.046%	23.812%	20.979%
\$475,000	50	13	24.405%	22.132%	20.060%	18.166%	16.444%	13.435%	10.946%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$475,000	100	13	16.165%	13.922%	11.959%	10.248%	8.767%	6.385%	4.641%
\$475,000	150	13	12.514%	10.374%	8.564%	7.043%	5.783%	3.889%	2.624%
\$475,000	200	13	10.423%	8.366%	6.682%	5.316%	4.219%	2.666%	1.728%
\$475,000	300	13	7.774%	5.907%	4.456%	3.357%	2.541%	1.509%	0.978%
\$475,000	400	13	6.297%	4.566%	3.290%	2.378%	1.739%	1.004%	0.689%
\$475,000	500	13	5.347%	3.741%	2.607%	1.835%	1.328%	0.796%	0.596%
\$475,000	600	13	4.707%	3.198%	2.173%	1.503%	1.078%	0.674%	0.548%
\$475,000	700	13	4.226%	2.794%	1.856%	1.267%	0.915%	0.608%	0.524%
\$475,000	800	13	3.831%	2.474%	1.612%	1.095%	0.802%	0.566%	0.511%
\$475,000	900	13	3.536%	2.239%	1.442%	0.982%	0.732%	0.546%	0.507%
\$475,000	1,000	13	3.272%	2.032%	1.296%	0.886%	0.675%	0.528%	0.504%
\$475,000	1,500	13	2.381%	1.383%	0.875%	0.644%	0.550%	0.505%	0.501%
\$475,000	2,000	13	1.862%	1.047%	0.691%	0.559%	0.517%	0.502%	0.501%
\$475,000	3,000	13	1.298%	0.742%	0.561%	0.515%	0.505%	0.502%	0.501%
\$475,000	4,000	13	0.994%	0.615%	0.523%	0.506%	0.503%	0.502%	0.501%
\$475,000	5,000	13	0.817%	0.559%	0.511%	0.504%	0.503%	0.502%	0.501%
\$475,000	10,000	13	0.528%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$475,000	20,000	13	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$500,000	5	13	65.455%	63.784%	62.180%	60.641%	59.163%	56.365%	53.761%
\$500,000	10	13	51.602%	49.682%	47.863%	46.135%	44.490%	41.425%	38.649%
\$500,000	15	13	43.834%	41.784%	39.853%	38.035%	36.318%	33.156%	30.324%
\$500,000	20	13	38.856%	36.749%	34.774%	32.921%	31.181%	28.000%	25.188%
\$500,000	25	13	35.123%	32.951%	30.924%	29.028%	27.251%	24.032%	21.214%
\$500,000	50	13	24.609%	22.350%	20.291%	18.410%	16.700%	13.708%	11.226%
\$500,000	100	13	16.353%	14.116%	12.155%	10.442%	8.956%	6.559%	4.791%
\$500,000	150	13	12.674%	10.533%	8.719%	7.191%	5.921%	4.005%	2.715%
\$500,000	200	13	10.561%	8.501%	6.809%	5.434%	4.326%	2.750%	1.788%
\$500,000	300	13	7.879%	6.006%	4.547%	3.436%	2.608%	1.553%	1.005%
\$500,000	400	13	6.385%	4.646%	3.359%	2.435%	1.785%	1.031%	0.702%
\$500,000	500	13	5.424%	3.809%	2.663%	1.880%	1.362%	0.814%	0.604%
\$500,000	600	13	4.774%	3.257%	2.221%	1.539%	1.105%	0.686%	0.553%
\$500,000	700	13	4.288%	2.845%	1.897%	1.297%	0.935%	0.616%	0.527%
\$500,000	800	13	3.888%	2.521%	1.647%	1.120%	0.819%	0.572%	0.513%
\$500,000	900	13	3.589%	2.281%	1.473%	1.003%	0.745%	0.549%	0.508%
\$500,000	1,000	13	3.321%	2.069%	1.323%	0.904%	0.686%	0.531%	0.504%
\$500,000	1,500	13	2.418%	1.408%	0.890%	0.651%	0.554%	0.506%	0.501%
\$500,000	2,000	13	1.891%	1.065%	0.700%	0.563%	0.518%	0.502%	0.501%
\$500,000	3,000	13	1.319%	0.752%	0.564%	0.516%	0.505%	0.502%	0.501%
\$500,000	4,000	13	1.010%	0.621%	0.524%	0.506%	0.503%	0.502%	0.501%
\$500,000	5,000	13	0.829%	0.562%	0.512%	0.505%	0.503%	0.502%	0.501%
\$500,000	10,000	13	0.530%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$500,000	20,000	13	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$30,000	5	14	40.478%	37.680%	34.978%	32.410%	29.994%	25.589%	21.765%
\$30,000	10	14	26.745%	24.144%	21.749%	19.548%	17.531%	14.025%	11.143%
\$30,000	15	14	20.806%	18.277%	16.003%	13.970%	12.160%	9.148%	6.820%
\$30,000	20	14	17.336%	14.882%	12.719%	10.833%	9.197%	6.566%	4.646%
\$30,000	25	14	15.160%	12.782%	10.722%	8.945%	7.434%	5.084%	3.452%
\$30,000	50	14	9.540%	7.445%	5.766%	4.433%	3.399%	2.009%	1.246%
\$30,000	100	14	5.879%	4.144%	2.893%	2.025%	1.440%	0.826%	0.600%
\$30,000	150	14	4.381%	2.879%	1.887%	1.267%	0.902%	0.593%	0.515%
\$30,000	200	14	3.608%	2.257%	1.432%	0.961%	0.712%	0.537%	0.506%
\$30,000	300	14	2.678%	1.570%	0.974%	0.690%	0.570%	0.508%	0.501%
\$30,000	400	14	2.116%	1.190%	0.757%	0.584%	0.525%	0.503%	0.501%
\$30,000	500	14	1.759%	0.977%	0.654%	0.543%	0.511%	0.502%	0.501%
\$30,000	600	14	1.539%	0.860%	0.604%	0.526%	0.507%	0.502%	0.501%
\$30,000	700	14	1.359%	0.770%	0.570%	0.516%	0.505%	0.502%	0.501%
\$30,000	800	14	1.213%	0.703%	0.547%	0.510%	0.504%	0.502%	0.501%
\$30,000	900	14	1.105%	0.656%	0.533%	0.508%	0.503%	0.502%	0.501%
\$30,000	1,000	14	1.010%	0.620%	0.524%	0.506%	0.503%	0.502%	0.501%
\$30,000	1,500	14	0.730%	0.535%	0.507%	0.504%	0.503%	0.502%	0.501%
\$30,000	2,000	14	0.617%	0.515%	0.505%	0.504%	0.503%	0.502%	0.501%
\$30,000	3,000	14	0.538%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$30,000	4,000	14	0.516%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$30,000	5,000	14	0.510%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$30,000	10,000	14	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$30,000	20,000	14	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$35,000	5	14	42.899%	40.225%	37.640%	35.138%	32.712%	28.210%	24.223%
\$35,000	10	14	28.288%	25.682%	23.289%	21.090%	19.062%	15.480%	12.489%
\$35,000	15	14	22.091%	19.550%	17.254%	15.179%	13.321%	10.194%	7.728%
\$35,000	20	14	18.413%	15.939%	13.743%	11.810%	10.123%	7.370%	5.309%
\$35,000	25	14	16.113%	13.706%	11.603%	9.775%	8.208%	5.729%	3.962%
\$35,000	50	14	10.157%	8.020%	6.286%	4.896%	3.797%	2.286%	1.427%
\$35,000	100	14	6.276%	4.490%	3.184%	2.256%	1.617%	0.916%	0.640%
\$35,000	150	14	4.691%	3.135%	2.085%	1.409%	0.997%	0.630%	0.526%
\$35,000	200	14	3.866%	2.461%	1.578%	1.058%	0.770%	0.553%	0.509%
\$35,000	300	14	2.878%	1.713%	1.064%	0.739%	0.593%	0.512%	0.502%
\$35,000	400	14	2.279%	1.295%	0.814%	0.610%	0.535%	0.504%	0.501%
\$35,000	500	14	1.897%	1.059%	0.693%	0.557%	0.515%	0.502%	0.501%
\$35,000	600	14	1.662%	0.927%	0.632%	0.535%	0.509%	0.502%	0.501%
\$35,000	700	14	1.468%	0.823%	0.590%	0.522%	0.506%	0.502%	0.501%
\$35,000	800	14	1.309%	0.747%	0.562%	0.514%	0.504%	0.502%	0.501%
\$35,000	900	14	1.192%	0.692%	0.543%	0.510%	0.504%	0.502%	0.501%
\$35,000	1,000	14	1.087%	0.650%	0.531%	0.507%	0.503%	0.502%	0.501%
\$35,000	1,500	14	0.775%	0.546%	0.509%	0.504%	0.503%	0.502%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$35,000	2,000	14	0.646%	0.519%	0.506%	0.504%	0.503%	0.502%	0.501%
\$35,000	3,000	14	0.549%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$35,000	4,000	14	0.520%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$35,000	5,000	14	0.511%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$35,000	10,000	14	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$35,000	20,000	14	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$40,000	5	14	44.949%	42.377%	39.888%	37.480%	35.154%	30.717%	26.606%
\$40,000	10	14	29.713%	27.087%	24.673%	22.457%	20.417%	16.798%	13.732%
\$40,000	15	14	23.250%	20.701%	18.387%	16.285%	14.383%	11.159%	8.583%
\$40,000	20	14	19.379%	16.889%	14.667%	12.698%	10.963%	8.109%	5.937%
\$40,000	25	14	16.965%	14.537%	12.403%	10.535%	8.914%	6.329%	4.448%
\$40,000	50	14	10.718%	8.545%	6.767%	5.328%	4.174%	2.555%	1.609%
\$40,000	100	14	6.639%	4.813%	3.456%	2.476%	1.787%	1.009%	0.684%
\$40,000	150	14	4.971%	3.371%	2.270%	1.545%	1.093%	0.670%	0.539%
\$40,000	200	14	4.091%	2.641%	1.709%	1.146%	0.825%	0.569%	0.512%
\$40,000	300	14	3.056%	1.844%	1.149%	0.787%	0.617%	0.517%	0.502%
\$40,000	400	14	2.426%	1.395%	0.871%	0.637%	0.546%	0.505%	0.501%
\$40,000	500	14	2.021%	1.135%	0.730%	0.573%	0.521%	0.503%	0.501%
\$40,000	600	14	1.772%	0.990%	0.661%	0.545%	0.512%	0.502%	0.501%
\$40,000	700	14	1.567%	0.875%	0.611%	0.528%	0.507%	0.502%	0.501%
\$40,000	800	14	1.397%	0.789%	0.577%	0.518%	0.505%	0.502%	0.501%
\$40,000	900	14	1.272%	0.727%	0.555%	0.512%	0.504%	0.502%	0.501%
\$40,000	1,000	14	1.160%	0.679%	0.540%	0.509%	0.503%	0.502%	0.501%
\$40,000	1,500	14	0.820%	0.558%	0.510%	0.504%	0.503%	0.502%	0.501%
\$40,000	2,000	14	0.675%	0.524%	0.506%	0.504%	0.503%	0.502%	0.501%
\$40,000	3,000	14	0.560%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$40,000	4,000	14	0.525%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$40,000	5,000	14	0.513%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$40,000	10,000	14	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$40,000	20,000	14	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$45,000	5	14	46.697%	44.206%	41.798%	39.476%	37.230%	32.938%	28.896%
\$45,000	10	14	31.063%	28.418%	25.969%	23.719%	21.653%	17.991%	14.876%
\$45,000	15	14	24.308%	21.757%	19.431%	17.309%	15.379%	12.068%	9.400%
\$45,000	20	14	20.274%	17.765%	15.523%	13.523%	11.749%	8.803%	6.542%
\$45,000	25	14	17.755%	15.310%	13.148%	11.244%	9.580%	6.903%	4.922%
\$45,000	50	14	11.236%	9.033%	7.219%	5.733%	4.535%	2.822%	1.794%
\$45,000	100	14	6.981%	5.120%	3.717%	2.690%	1.955%	1.104%	0.731%
\$45,000	150	14	5.236%	3.597%	2.450%	1.681%	1.189%	0.712%	0.555%
\$45,000	200	14	4.309%	2.817%	1.841%	1.239%	0.886%	0.589%	0.517%
\$45,000	300	14	3.222%	1.969%	1.232%	0.837%	0.644%	0.523%	0.503%
\$45,000	400	14	2.565%	1.491%	0.928%	0.666%	0.559%	0.506%	0.501%
\$45,000	500	14	2.137%	1.209%	0.769%	0.590%	0.527%	0.503%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$45,000	600	14	1.875%	1.051%	0.690%	0.557%	0.515%	0.503%	0.501%
\$45,000	700	14	1.660%	0.926%	0.633%	0.536%	0.509%	0.502%	0.501%
\$45,000	800	14	1.480%	0.831%	0.593%	0.523%	0.506%	0.502%	0.501%
\$45,000	900	14	1.347%	0.762%	0.567%	0.516%	0.505%	0.502%	0.501%
\$45,000	1,000	14	1.228%	0.708%	0.549%	0.511%	0.504%	0.502%	0.501%
\$45,000	1,500	14	0.864%	0.571%	0.513%	0.504%	0.503%	0.502%	0.501%
\$45,000	2,000	14	0.704%	0.529%	0.506%	0.504%	0.503%	0.502%	0.501%
\$45,000	3,000	14	0.572%	0.509%	0.505%	0.504%	0.503%	0.502%	0.501%
\$45,000	4,000	14	0.530%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$45,000	5,000	14	0.515%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$45,000	10,000	14	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$45,000	20,000	14	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$50,000	5	14	48.203%	45.781%	43.447%	41.195%	39.014%	34.845%	30.937%
\$50,000	10	14	32.351%	29.688%	27.212%	24.922%	22.817%	19.096%	15.926%
\$50,000	15	14	25.282%	22.732%	20.396%	18.259%	16.308%	12.934%	10.183%
\$50,000	20	14	21.110%	18.588%	16.324%	14.300%	12.495%	9.465%	7.127%
\$50,000	25	14	18.495%	16.031%	13.844%	11.911%	10.215%	7.452%	5.385%
\$50,000	50	14	11.721%	9.494%	7.646%	6.121%	4.881%	3.084%	1.980%
\$50,000	100	14	7.300%	5.409%	3.967%	2.896%	2.120%	1.201%	0.781%
\$50,000	150	14	5.483%	3.809%	2.622%	1.813%	1.286%	0.757%	0.572%
\$50,000	200	14	4.513%	2.984%	1.968%	1.330%	0.946%	0.611%	0.523%
\$50,000	300	14	3.377%	2.086%	1.312%	0.886%	0.672%	0.529%	0.505%
\$50,000	400	14	2.695%	1.583%	0.984%	0.696%	0.573%	0.508%	0.501%
\$50,000	500	14	2.247%	1.280%	0.808%	0.607%	0.533%	0.504%	0.501%
\$50,000	600	14	1.974%	1.112%	0.720%	0.568%	0.519%	0.503%	0.501%
\$50,000	700	14	1.749%	0.976%	0.655%	0.544%	0.512%	0.502%	0.501%
\$50,000	800	14	1.559%	0.872%	0.610%	0.528%	0.507%	0.502%	0.501%
\$50,000	900	14	1.420%	0.797%	0.579%	0.519%	0.505%	0.502%	0.501%
\$50,000	1,000	14	1.294%	0.738%	0.558%	0.513%	0.504%	0.502%	0.501%
\$50,000	1,500	14	0.907%	0.584%	0.515%	0.505%	0.503%	0.502%	0.501%
\$50,000	2,000	14	0.732%	0.536%	0.507%	0.504%	0.503%	0.502%	0.501%
\$50,000	3,000	14	0.585%	0.511%	0.505%	0.504%	0.503%	0.502%	0.501%
\$50,000	4,000	14	0.535%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$50,000	5,000	14	0.517%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$50,000	10,000	14	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$50,000	20,000	14	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$55,000	5	14	49.517%	47.159%	44.887%	42.692%	40.564%	36.508%	32.714%
\$55,000	10	14	33.579%	30.901%	28.404%	26.082%	23.934%	20.133%	16.903%
\$55,000	15	14	26.187%	23.631%	21.285%	19.138%	17.169%	13.744%	10.929%
\$55,000	20	14	21.886%	19.357%	17.073%	15.026%	13.191%	10.096%	7.680%
\$55,000	25	14	19.183%	16.706%	14.494%	12.536%	10.811%	7.973%	5.829%
\$55,000	50	14	12.175%	9.929%	8.050%	6.490%	5.211%	3.340%	2.163%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$55,000	100	14	7.605%	5.684%	4.208%	3.097%	2.283%	1.300%	0.833%
\$55,000	150	14	5.717%	4.012%	2.788%	1.943%	1.383%	0.803%	0.591%
\$55,000	200	14	4.705%	3.143%	2.091%	1.419%	1.006%	0.634%	0.530%
\$55,000	300	14	3.522%	2.198%	1.391%	0.936%	0.700%	0.536%	0.506%
\$55,000	400	14	2.818%	1.672%	1.040%	0.726%	0.588%	0.511%	0.502%
\$55,000	500	14	2.351%	1.349%	0.847%	0.626%	0.541%	0.504%	0.501%
\$55,000	600	14	2.069%	1.170%	0.750%	0.581%	0.524%	0.503%	0.501%
\$55,000	700	14	1.834%	1.025%	0.678%	0.552%	0.514%	0.502%	0.501%
\$55,000	800	14	1.635%	0.913%	0.628%	0.534%	0.509%	0.502%	0.501%
\$55,000	900	14	1.489%	0.832%	0.593%	0.523%	0.506%	0.502%	0.501%
\$55,000	1,000	14	1.357%	0.768%	0.569%	0.516%	0.505%	0.502%	0.501%
\$55,000	1,500	14	0.949%	0.598%	0.518%	0.505%	0.503%	0.502%	0.501%
\$55,000	2,000	14	0.761%	0.542%	0.508%	0.504%	0.503%	0.502%	0.501%
\$55,000	3,000	14	0.598%	0.512%	0.505%	0.504%	0.503%	0.502%	0.501%
\$55,000	4,000	14	0.541%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$55,000	5,000	14	0.520%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$55,000	10,000	14	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$55,000	20,000	14	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$60,000	5	14	50.670%	48.368%	46.148%	44.000%	41.918%	37.964%	34.261%
\$60,000	10	14	34.725%	32.044%	29.532%	27.186%	25.003%	21.110%	17.807%
\$60,000	15	14	27.012%	24.441%	22.085%	19.927%	17.947%	14.481%	11.614%
\$60,000	20	14	22.594%	20.061%	17.764%	15.694%	13.834%	10.682%	8.195%
\$60,000	25	14	19.811%	17.325%	15.094%	13.110%	11.359%	8.455%	6.242%
\$60,000	50	14	12.601%	10.336%	8.431%	6.841%	5.527%	3.590%	2.347%
\$60,000	100	14	7.890%	5.941%	4.434%	3.288%	2.439%	1.395%	0.887%
\$60,000	150	14	5.935%	4.202%	2.945%	2.068%	1.477%	0.849%	0.611%
\$60,000	200	14	4.885%	3.294%	2.209%	1.505%	1.066%	0.659%	0.538%
\$60,000	300	14	3.661%	2.306%	1.468%	0.986%	0.730%	0.544%	0.508%
\$60,000	400	14	2.935%	1.758%	1.095%	0.758%	0.604%	0.514%	0.502%
\$60,000	500	14	2.449%	1.416%	0.886%	0.646%	0.550%	0.505%	0.501%
\$60,000	600	14	2.158%	1.227%	0.780%	0.594%	0.529%	0.504%	0.501%
\$60,000	700	14	1.914%	1.073%	0.701%	0.562%	0.517%	0.503%	0.501%
\$60,000	800	14	1.708%	0.953%	0.646%	0.540%	0.510%	0.502%	0.501%
\$60,000	900	14	1.555%	0.867%	0.607%	0.527%	0.507%	0.502%	0.501%
\$60,000	1,000	14	1.418%	0.797%	0.579%	0.519%	0.505%	0.502%	0.501%
\$60,000	1,500	14	0.990%	0.612%	0.521%	0.506%	0.503%	0.502%	0.501%
\$60,000	2,000	14	0.789%	0.549%	0.509%	0.504%	0.503%	0.502%	0.501%
\$60,000	3,000	14	0.611%	0.514%	0.505%	0.504%	0.503%	0.502%	0.501%
\$60,000	4,000	14	0.547%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$60,000	5,000	14	0.523%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$60,000	10,000	14	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$60,000	20,000	14	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$65,000	5	14	51.689%	49.434%	47.257%	45.149%	43.112%	39.249%	35.622%
\$65,000	10	14	35.794%	33.126%	30.610%	28.251%	26.042%	22.071%	18.684%
\$65,000	15	14	27.792%	25.208%	22.837%	20.665%	18.673%	15.173%	12.260%
\$65,000	20	14	23.261%	20.723%	18.415%	16.329%	14.449%	11.246%	8.695%
\$65,000	25	14	20.406%	17.909%	15.665%	13.658%	11.882%	8.920%	6.638%
\$65,000	50	14	13.001%	10.719%	8.793%	7.174%	5.832%	3.831%	2.527%
\$65,000	100	14	8.155%	6.184%	4.648%	3.471%	2.591%	1.491%	0.941%
\$65,000	150	14	6.141%	4.382%	3.095%	2.189%	1.570%	0.897%	0.632%
\$65,000	200	14	5.057%	3.439%	2.324%	1.591%	1.126%	0.685%	0.547%
\$65,000	300	14	3.793%	2.410%	1.544%	1.036%	0.760%	0.553%	0.510%
\$65,000	400	14	3.045%	1.840%	1.149%	0.790%	0.620%	0.517%	0.503%
\$65,000	500	14	2.543%	1.480%	0.924%	0.665%	0.558%	0.507%	0.501%
\$65,000	600	14	2.241%	1.281%	0.810%	0.608%	0.534%	0.504%	0.501%
\$65,000	700	14	1.990%	1.119%	0.725%	0.571%	0.521%	0.503%	0.501%
\$65,000	800	14	1.777%	0.992%	0.664%	0.547%	0.512%	0.502%	0.501%
\$65,000	900	14	1.617%	0.900%	0.621%	0.532%	0.508%	0.502%	0.501%
\$65,000	1,000	14	1.475%	0.826%	0.590%	0.522%	0.506%	0.502%	0.501%
\$65,000	1,500	14	1.029%	0.627%	0.525%	0.506%	0.503%	0.502%	0.501%
\$65,000	2,000	14	0.816%	0.556%	0.510%	0.504%	0.503%	0.502%	0.501%
\$65,000	3,000	14	0.624%	0.516%	0.505%	0.504%	0.503%	0.502%	0.501%
\$65,000	4,000	14	0.554%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$65,000	5,000	14	0.526%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$65,000	10,000	14	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$65,000	20,000	14	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$70,000	5	14	52.592%	50.377%	48.237%	46.166%	44.169%	40.383%	36.823%
\$70,000	10	14	36.785%	34.135%	31.627%	29.263%	27.038%	23.009%	19.541%
\$70,000	15	14	28.529%	25.936%	23.548%	21.355%	19.349%	15.821%	12.871%
\$70,000	20	14	23.880%	21.340%	19.023%	16.927%	15.033%	11.786%	9.181%
\$70,000	25	14	20.958%	18.455%	16.200%	14.177%	12.380%	9.369%	7.029%
\$70,000	50	14	13.381%	11.085%	9.139%	7.496%	6.126%	4.064%	2.704%
\$70,000	100	14	8.406%	6.414%	4.851%	3.646%	2.738%	1.586%	0.997%
\$70,000	150	14	6.336%	4.553%	3.240%	2.305%	1.660%	0.945%	0.654%
\$70,000	200	14	5.219%	3.578%	2.436%	1.675%	1.187%	0.711%	0.556%
\$70,000	300	14	3.911%	2.504%	1.612%	1.081%	0.787%	0.561%	0.511%
\$70,000	400	14	3.149%	1.918%	1.201%	0.821%	0.637%	0.521%	0.503%
\$70,000	500	14	2.630%	1.541%	0.961%	0.685%	0.568%	0.508%	0.501%
\$70,000	600	14	2.320%	1.333%	0.839%	0.622%	0.539%	0.505%	0.501%
\$70,000	700	14	2.061%	1.163%	0.747%	0.581%	0.524%	0.503%	0.501%
\$70,000	800	14	1.842%	1.030%	0.682%	0.554%	0.514%	0.502%	0.501%
\$70,000	900	14	1.676%	0.932%	0.635%	0.536%	0.509%	0.502%	0.501%
\$70,000	1,000	14	1.529%	0.854%	0.601%	0.526%	0.507%	0.502%	0.501%
\$70,000	1,500	14	1.066%	0.641%	0.529%	0.507%	0.503%	0.502%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$70,000	2,000	14	0.842%	0.563%	0.511%	0.504%	0.503%	0.502%	0.501%
\$70,000	3,000	14	0.637%	0.518%	0.505%	0.504%	0.503%	0.502%	0.501%
\$70,000	4,000	14	0.561%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$70,000	5,000	14	0.529%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$70,000	10,000	14	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$70,000	20,000	14	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$75,000	5	14	53.406%	51.225%	49.117%	47.083%	45.122%	41.402%	37.902%
\$75,000	10	14	37.706%	35.088%	32.595%	30.233%	27.999%	23.935%	20.394%
\$75,000	15	14	29.241%	26.639%	24.234%	22.020%	19.993%	16.435%	13.451%
\$75,000	20	14	24.465%	21.923%	19.603%	17.497%	15.591%	12.305%	9.653%
\$75,000	25	14	21.484%	18.977%	16.713%	14.675%	12.860%	9.807%	7.414%
\$75,000	50	14	13.746%	11.436%	9.472%	7.808%	6.412%	4.293%	2.882%
\$75,000	100	14	8.649%	6.636%	5.050%	3.819%	2.884%	1.681%	1.053%
\$75,000	150	14	6.526%	4.720%	3.382%	2.420%	1.749%	0.994%	0.677%
\$75,000	200	14	5.377%	3.714%	2.546%	1.759%	1.247%	0.739%	0.566%
\$75,000	300	14	4.033%	2.601%	1.684%	1.130%	0.819%	0.571%	0.514%
\$75,000	400	14	3.248%	1.993%	1.252%	0.852%	0.654%	0.525%	0.504%
\$75,000	500	14	2.713%	1.600%	0.997%	0.704%	0.577%	0.509%	0.502%
\$75,000	600	14	2.395%	1.383%	0.868%	0.636%	0.545%	0.505%	0.501%
\$75,000	700	14	2.129%	1.206%	0.770%	0.591%	0.528%	0.503%	0.501%
\$75,000	800	14	1.904%	1.067%	0.700%	0.561%	0.517%	0.502%	0.501%
\$75,000	900	14	1.733%	0.965%	0.649%	0.541%	0.511%	0.502%	0.501%
\$75,000	1,000	14	1.582%	0.882%	0.613%	0.529%	0.508%	0.502%	0.501%
\$75,000	1,500	14	1.103%	0.655%	0.533%	0.508%	0.503%	0.502%	0.501%
\$75,000	2,000	14	0.869%	0.571%	0.512%	0.504%	0.503%	0.502%	0.501%
\$75,000	3,000	14	0.651%	0.520%	0.506%	0.504%	0.503%	0.502%	0.501%
\$75,000	4,000	14	0.568%	0.509%	0.505%	0.504%	0.503%	0.502%	0.501%
\$75,000	5,000	14	0.533%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$75,000	10,000	14	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$75,000	20,000	14	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$80,000	5	14	54.155%	52.006%	49.928%	47.927%	46.001%	42.337%	38.894%
\$80,000	10	14	38.562%	35.987%	33.523%	31.168%	28.936%	24.850%	21.252%
\$80,000	15	14	29.941%	27.326%	24.905%	22.671%	20.622%	17.029%	14.007%
\$80,000	20	14	25.025%	22.480%	20.156%	18.042%	16.123%	12.804%	10.110%
\$80,000	25	14	21.988%	19.475%	17.204%	15.156%	13.323%	10.229%	7.789%
\$80,000	50	14	14.096%	11.775%	9.792%	8.108%	6.688%	4.515%	3.056%
\$80,000	100	14	8.882%	6.852%	5.243%	3.987%	3.027%	1.775%	1.111%
\$80,000	150	14	6.709%	4.881%	3.520%	2.532%	1.837%	1.042%	0.701%
\$80,000	200	14	5.530%	3.845%	2.653%	1.841%	1.308%	0.767%	0.577%
\$80,000	300	14	4.149%	2.695%	1.755%	1.180%	0.850%	0.581%	0.517%
\$80,000	400	14	3.344%	2.067%	1.302%	0.883%	0.671%	0.530%	0.505%
\$80,000	500	14	2.794%	1.657%	1.033%	0.724%	0.587%	0.511%	0.502%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$80,000	600	14	2.467%	1.432%	0.897%	0.650%	0.552%	0.506%	0.501%
\$80,000	700	14	2.195%	1.249%	0.793%	0.602%	0.532%	0.504%	0.501%
\$80,000	800	14	1.965%	1.104%	0.719%	0.569%	0.519%	0.503%	0.501%
\$80,000	900	14	1.788%	0.997%	0.664%	0.547%	0.512%	0.502%	0.501%
\$80,000	1,000	14	1.633%	0.910%	0.625%	0.533%	0.509%	0.502%	0.501%
\$80,000	1,500	14	1.139%	0.670%	0.537%	0.509%	0.503%	0.502%	0.501%
\$80,000	2,000	14	0.895%	0.579%	0.514%	0.504%	0.503%	0.502%	0.501%
\$80,000	3,000	14	0.664%	0.522%	0.506%	0.504%	0.503%	0.502%	0.501%
\$80,000	4,000	14	0.575%	0.510%	0.505%	0.504%	0.503%	0.502%	0.501%
\$80,000	5,000	14	0.536%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$80,000	10,000	14	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$80,000	20,000	14	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$90,000	5	14	55.482%	53.385%	51.366%	49.425%	47.555%	43.990%	40.649%
\$90,000	10	14	40.091%	37.596%	35.202%	32.904%	30.702%	26.606%	22.948%
\$90,000	15	14	31.281%	28.649%	26.201%	23.934%	21.844%	18.165%	15.067%
\$90,000	20	14	26.080%	23.525%	21.192%	19.061%	17.118%	13.750%	10.983%
\$90,000	25	14	22.925%	20.408%	18.124%	16.059%	14.200%	11.036%	8.511%
\$90,000	50	14	14.756%	12.413%	10.398%	8.678%	7.213%	4.945%	3.391%
\$90,000	100	14	9.323%	7.263%	5.611%	4.311%	3.304%	1.962%	1.229%
\$90,000	150	14	7.053%	5.189%	3.784%	2.750%	2.009%	1.140%	0.750%
\$90,000	200	14	5.818%	4.095%	2.859%	2.002%	1.428%	0.823%	0.601%
\$90,000	300	14	4.371%	2.876%	1.892%	1.277%	0.915%	0.603%	0.524%
\$90,000	400	14	3.525%	2.207%	1.401%	0.946%	0.707%	0.539%	0.507%
\$90,000	500	14	2.946%	1.768%	1.104%	0.765%	0.608%	0.515%	0.502%
\$90,000	600	14	2.603%	1.526%	0.953%	0.680%	0.565%	0.508%	0.501%
\$90,000	700	14	2.321%	1.332%	0.840%	0.625%	0.541%	0.505%	0.501%
\$90,000	800	14	2.080%	1.175%	0.756%	0.585%	0.525%	0.503%	0.501%
\$90,000	900	14	1.893%	1.059%	0.694%	0.558%	0.516%	0.502%	0.501%
\$90,000	1,000	14	1.730%	0.964%	0.649%	0.542%	0.511%	0.502%	0.501%
\$90,000	1,500	14	1.208%	0.699%	0.546%	0.510%	0.504%	0.502%	0.501%
\$90,000	2,000	14	0.946%	0.596%	0.517%	0.505%	0.503%	0.502%	0.501%
\$90,000	3,000	14	0.691%	0.527%	0.506%	0.504%	0.503%	0.502%	0.501%
\$90,000	4,000	14	0.589%	0.511%	0.505%	0.504%	0.503%	0.502%	0.501%
\$90,000	5,000	14	0.544%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$90,000	10,000	14	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$90,000	20,000	14	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$100,000	5	14	56.625%	54.577%	52.609%	50.718%	48.890%	45.410%	42.160%
\$100,000	10	14	41.392%	38.962%	36.630%	34.396%	32.253%	28.219%	24.535%
\$100,000	15	14	32.517%	29.885%	27.426%	25.137%	23.016%	19.246%	16.070%
\$100,000	20	14	27.071%	24.505%	22.156%	20.001%	18.034%	14.620%	11.791%
\$100,000	25	14	23.783%	21.262%	18.966%	16.889%	15.007%	11.783%	9.184%
\$100,000	50	14	15.359%	13.002%	10.958%	9.203%	7.706%	5.351%	3.712%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$100,000	100	14	9.730%	7.643%	5.956%	4.617%	3.569%	2.144%	1.347%
\$100,000	150	14	7.372%	5.476%	4.032%	2.956%	2.176%	1.238%	0.801%
\$100,000	200	14	6.084%	4.327%	3.053%	2.155%	1.544%	0.882%	0.627%
\$100,000	300	14	4.577%	3.046%	2.023%	1.372%	0.979%	0.627%	0.531%
\$100,000	400	14	3.693%	2.338%	1.495%	1.007%	0.744%	0.549%	0.509%
\$100,000	500	14	3.087%	1.872%	1.173%	0.806%	0.629%	0.520%	0.503%
\$100,000	600	14	2.728%	1.614%	1.007%	0.710%	0.579%	0.510%	0.502%
\$100,000	700	14	2.437%	1.410%	0.885%	0.647%	0.550%	0.506%	0.501%
\$100,000	800	14	2.185%	1.242%	0.792%	0.601%	0.531%	0.503%	0.501%
\$100,000	900	14	1.989%	1.117%	0.723%	0.570%	0.520%	0.503%	0.501%
\$100,000	1,000	14	1.819%	1.016%	0.673%	0.550%	0.514%	0.502%	0.501%
\$100,000	1,500	14	1.272%	0.728%	0.555%	0.513%	0.504%	0.502%	0.501%
\$100,000	2,000	14	0.994%	0.612%	0.521%	0.505%	0.503%	0.502%	0.501%
\$100,000	3,000	14	0.717%	0.532%	0.507%	0.504%	0.503%	0.502%	0.501%
\$100,000	4,000	14	0.604%	0.513%	0.505%	0.504%	0.503%	0.502%	0.501%
\$100,000	5,000	14	0.552%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$100,000	10,000	14	0.508%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$100,000	20,000	14	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$110,000	5	14	57.575%	55.568%	53.642%	51.788%	49.996%	46.586%	43.410%
\$110,000	10	14	42.473%	40.093%	37.813%	35.631%	33.536%	29.595%	25.956%
\$110,000	15	14	33.589%	30.975%	28.519%	26.224%	24.085%	20.246%	16.994%
\$110,000	20	14	27.966%	25.388%	23.020%	20.844%	18.853%	15.386%	12.507%
\$110,000	25	14	24.546%	22.014%	19.711%	17.618%	15.719%	12.440%	9.783%
\$110,000	50	14	15.890%	13.515%	11.452%	9.668%	8.140%	5.716%	4.005%
\$110,000	100	14	10.091%	7.982%	6.264%	4.894%	3.810%	2.314%	1.459%
\$110,000	150	14	7.652%	5.730%	4.253%	3.143%	2.328%	1.329%	0.851%
\$110,000	200	14	6.317%	4.534%	3.226%	2.294%	1.651%	0.938%	0.652%
\$110,000	300	14	4.757%	3.196%	2.140%	1.458%	1.039%	0.649%	0.538%
\$110,000	400	14	3.831%	2.448%	1.574%	1.059%	0.775%	0.558%	0.511%
\$110,000	500	14	3.211%	1.964%	1.235%	0.843%	0.649%	0.524%	0.503%
\$110,000	600	14	2.836%	1.691%	1.057%	0.737%	0.593%	0.513%	0.502%
\$110,000	700	14	2.538%	1.478%	0.926%	0.669%	0.560%	0.507%	0.501%
\$110,000	800	14	2.277%	1.302%	0.826%	0.618%	0.537%	0.504%	0.501%
\$110,000	900	14	2.074%	1.170%	0.751%	0.582%	0.524%	0.503%	0.501%
\$110,000	1,000	14	1.898%	1.062%	0.695%	0.559%	0.517%	0.503%	0.501%
\$110,000	1,500	14	1.330%	0.755%	0.564%	0.515%	0.504%	0.502%	0.501%
\$110,000	2,000	14	1.038%	0.628%	0.524%	0.506%	0.503%	0.502%	0.501%
\$110,000	3,000	14	0.741%	0.537%	0.507%	0.504%	0.503%	0.502%	0.501%
\$110,000	4,000	14	0.618%	0.515%	0.505%	0.504%	0.503%	0.502%	0.501%
\$110,000	5,000	14	0.560%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$110,000	10,000	14	0.508%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$110,000	20,000	14	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$120,000	5	14	58.412%	56.441%	54.551%	52.727%	50.965%	47.618%	44.502%
\$120,000	10	14	43.425%	41.089%	38.854%	36.714%	34.664%	30.802%	27.241%
\$120,000	15	14	34.551%	31.971%	29.532%	27.243%	25.096%	21.221%	17.900%
\$120,000	20	14	28.806%	26.225%	23.837%	21.643%	19.630%	16.104%	13.173%
\$120,000	25	14	25.254%	22.712%	20.400%	18.293%	16.377%	13.055%	10.347%
\$120,000	50	14	16.375%	13.988%	11.904%	10.098%	8.539%	6.058%	4.281%
\$120,000	100	14	10.422%	8.295%	6.550%	5.151%	4.036%	2.477%	1.567%
\$120,000	150	14	7.909%	5.965%	4.459%	3.318%	2.472%	1.418%	0.901%
\$120,000	200	14	6.528%	4.723%	3.387%	2.423%	1.751%	0.992%	0.677%
\$120,000	300	14	4.921%	3.335%	2.250%	1.539%	1.095%	0.672%	0.546%
\$120,000	400	14	3.962%	2.554%	1.652%	1.112%	0.808%	0.568%	0.513%
\$120,000	500	14	3.322%	2.049%	1.293%	0.878%	0.669%	0.529%	0.504%
\$120,000	600	14	2.934%	1.762%	1.102%	0.764%	0.606%	0.515%	0.502%
\$120,000	700	14	2.628%	1.541%	0.965%	0.689%	0.570%	0.508%	0.501%
\$120,000	800	14	2.360%	1.358%	0.858%	0.633%	0.544%	0.505%	0.501%
\$120,000	900	14	2.150%	1.219%	0.777%	0.594%	0.529%	0.504%	0.501%
\$120,000	1,000	14	1.969%	1.106%	0.717%	0.567%	0.519%	0.503%	0.501%
\$120,000	1,500	14	1.382%	0.780%	0.573%	0.517%	0.505%	0.502%	0.501%
\$120,000	2,000	14	1.078%	0.644%	0.528%	0.506%	0.503%	0.502%	0.501%
\$120,000	3,000	14	0.764%	0.543%	0.508%	0.504%	0.503%	0.502%	0.501%
\$120,000	4,000	14	0.632%	0.517%	0.505%	0.504%	0.503%	0.502%	0.501%
\$120,000	5,000	14	0.568%	0.509%	0.505%	0.504%	0.503%	0.502%	0.501%
\$120,000	10,000	14	0.508%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$120,000	20,000	14	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$130,000	5	14	59.174%	57.237%	55.376%	53.579%	51.844%	48.555%	45.491%
\$130,000	10	14	44.286%	41.990%	39.795%	37.694%	35.680%	31.891%	28.400%
\$130,000	15	14	35.424%	32.888%	30.484%	28.209%	26.066%	22.175%	18.807%
\$130,000	20	14	29.609%	27.029%	24.633%	22.420%	20.384%	16.801%	13.813%
\$130,000	25	14	25.930%	23.385%	21.059%	18.939%	17.003%	13.645%	10.890%
\$130,000	50	14	16.837%	14.442%	12.339%	10.511%	8.926%	6.391%	4.552%
\$130,000	100	14	10.741%	8.594%	6.827%	5.400%	4.256%	2.638%	1.676%
\$130,000	150	14	8.154%	6.190%	4.658%	3.487%	2.613%	1.506%	0.950%
\$130,000	200	14	6.729%	4.904%	3.541%	2.547%	1.848%	1.046%	0.703%
\$130,000	300	14	5.077%	3.467%	2.355%	1.619%	1.151%	0.696%	0.553%
\$130,000	400	14	4.086%	2.653%	1.726%	1.163%	0.840%	0.578%	0.516%
\$130,000	500	14	3.426%	2.130%	1.349%	0.913%	0.690%	0.534%	0.505%
\$130,000	600	14	3.027%	1.830%	1.147%	0.790%	0.620%	0.518%	0.502%
\$130,000	700	14	2.713%	1.602%	1.003%	0.710%	0.580%	0.510%	0.501%
\$130,000	800	14	2.439%	1.412%	0.889%	0.649%	0.551%	0.505%	0.501%
\$130,000	900	14	2.224%	1.267%	0.803%	0.606%	0.533%	0.504%	0.501%
\$130,000	1,000	14	2.037%	1.148%	0.738%	0.576%	0.523%	0.503%	0.501%
\$130,000	1,500	14	1.433%	0.805%	0.582%	0.520%	0.506%	0.502%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$130,000	2,000	14	1.117%	0.659%	0.532%	0.507%	0.503%	0.502%	0.501%
\$130,000	3,000	14	0.787%	0.548%	0.509%	0.504%	0.503%	0.502%	0.501%
\$130,000	4,000	14	0.646%	0.519%	0.506%	0.504%	0.503%	0.502%	0.501%
\$130,000	5,000	14	0.576%	0.510%	0.505%	0.504%	0.503%	0.502%	0.501%
\$130,000	10,000	14	0.508%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$130,000	20,000	14	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$140,000	5	14	59.852%	57.943%	56.107%	54.335%	52.624%	49.386%	46.368%
\$140,000	10	14	45.050%	42.790%	40.631%	38.563%	36.582%	32.857%	29.427%
\$140,000	15	14	36.194%	33.700%	31.338%	29.093%	26.965%	23.073%	19.679%
\$140,000	20	14	30.353%	27.782%	25.386%	23.164%	21.108%	17.473%	14.426%
\$140,000	25	14	26.573%	24.023%	21.686%	19.548%	17.596%	14.200%	11.400%
\$140,000	50	14	17.271%	14.867%	12.751%	10.900%	9.292%	6.709%	4.813%
\$140,000	100	14	11.038%	8.876%	7.090%	5.637%	4.467%	2.795%	1.785%
\$140,000	150	14	8.381%	6.400%	4.845%	3.647%	2.746%	1.591%	1.000%
\$140,000	200	14	6.916%	5.073%	3.685%	2.665%	1.941%	1.100%	0.729%
\$140,000	300	14	5.224%	3.593%	2.456%	1.695%	1.206%	0.720%	0.561%
\$140,000	400	14	4.202%	2.748%	1.798%	1.212%	0.872%	0.588%	0.518%
\$140,000	500	14	3.525%	2.207%	1.402%	0.947%	0.710%	0.539%	0.506%
\$140,000	600	14	3.114%	1.895%	1.190%	0.815%	0.633%	0.520%	0.503%
\$140,000	700	14	2.795%	1.660%	1.039%	0.731%	0.590%	0.511%	0.502%
\$140,000	800	14	2.514%	1.464%	0.919%	0.665%	0.558%	0.506%	0.501%
\$140,000	900	14	2.293%	1.313%	0.829%	0.618%	0.538%	0.504%	0.501%
\$140,000	1,000	14	2.101%	1.189%	0.760%	0.586%	0.526%	0.503%	0.501%
\$140,000	1,500	14	1.481%	0.830%	0.592%	0.523%	0.506%	0.502%	0.501%
\$140,000	2,000	14	1.155%	0.675%	0.537%	0.508%	0.503%	0.502%	0.501%
\$140,000	3,000	14	0.809%	0.554%	0.510%	0.504%	0.503%	0.502%	0.501%
\$140,000	4,000	14	0.660%	0.522%	0.506%	0.504%	0.503%	0.502%	0.501%
\$140,000	5,000	14	0.584%	0.511%	0.505%	0.504%	0.503%	0.502%	0.501%
\$140,000	10,000	14	0.509%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$140,000	20,000	14	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$150,000	5	14	60.453%	58.569%	56.755%	55.004%	53.314%	50.122%	47.144%
\$150,000	10	14	45.729%	43.500%	41.371%	39.333%	37.380%	33.712%	30.334%
\$150,000	15	14	36.872%	34.418%	32.094%	29.884%	27.783%	23.914%	20.505%
\$150,000	20	14	31.040%	28.481%	26.092%	23.868%	21.802%	18.122%	15.018%
\$150,000	25	14	27.181%	24.631%	22.286%	20.131%	18.162%	14.728%	11.883%
\$150,000	50	14	17.677%	15.266%	13.139%	11.270%	9.640%	7.012%	5.066%
\$150,000	100	14	11.319%	9.144%	7.339%	5.864%	4.669%	2.948%	1.892%
\$150,000	150	14	8.595%	6.598%	5.022%	3.801%	2.874%	1.675%	1.049%
\$150,000	200	14	7.093%	5.231%	3.822%	2.779%	2.031%	1.152%	0.756%
\$150,000	300	14	5.362%	3.711%	2.551%	1.769%	1.259%	0.744%	0.570%
\$150,000	400	14	4.312%	2.837%	1.866%	1.260%	0.904%	0.599%	0.521%
\$150,000	500	14	3.618%	2.280%	1.454%	0.981%	0.730%	0.544%	0.507%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$150,000	600	14	3.196%	1.956%	1.231%	0.840%	0.647%	0.523%	0.503%
\$150,000	700	14	2.870%	1.715%	1.075%	0.751%	0.600%	0.513%	0.502%
\$150,000	800	14	2.583%	1.512%	0.948%	0.681%	0.565%	0.507%	0.501%
\$150,000	900	14	2.357%	1.356%	0.853%	0.630%	0.543%	0.505%	0.501%
\$150,000	1,000	14	2.161%	1.227%	0.780%	0.595%	0.529%	0.504%	0.501%
\$150,000	1,500	14	1.526%	0.853%	0.601%	0.526%	0.507%	0.502%	0.501%
\$150,000	2,000	14	1.190%	0.690%	0.541%	0.509%	0.503%	0.502%	0.501%
\$150,000	3,000	14	0.831%	0.560%	0.510%	0.504%	0.503%	0.502%	0.501%
\$150,000	4,000	14	0.674%	0.524%	0.506%	0.504%	0.503%	0.502%	0.501%
\$150,000	5,000	14	0.592%	0.512%	0.505%	0.504%	0.503%	0.502%	0.501%
\$150,000	10,000	14	0.509%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$150,000	20,000	14	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$160,000	5	14	60.971%	59.108%	57.311%	55.579%	53.908%	50.755%	47.811%
\$160,000	10	14	46.325%	44.125%	42.021%	40.010%	38.081%	34.463%	31.131%
\$160,000	15	14	37.474%	35.055%	32.762%	30.584%	28.513%	24.692%	21.281%
\$160,000	20	14	31.661%	29.122%	26.744%	24.525%	22.458%	18.750%	15.596%
\$160,000	25	14	27.744%	25.201%	22.850%	20.685%	18.700%	15.229%	12.343%
\$160,000	50	14	18.058%	15.642%	13.506%	11.622%	9.973%	7.304%	5.313%
\$160,000	100	14	11.582%	9.396%	7.574%	6.079%	4.862%	3.096%	1.998%
\$160,000	150	14	8.797%	6.785%	5.190%	3.949%	2.998%	1.756%	1.099%
\$160,000	200	14	7.260%	5.380%	3.951%	2.887%	2.117%	1.202%	0.782%
\$160,000	300	14	5.490%	3.821%	2.641%	1.838%	1.310%	0.767%	0.579%
\$160,000	400	14	4.414%	2.921%	1.930%	1.306%	0.934%	0.610%	0.524%
\$160,000	500	14	3.705%	2.349%	1.504%	1.013%	0.749%	0.549%	0.508%
\$160,000	600	14	3.272%	2.015%	1.271%	0.864%	0.660%	0.527%	0.504%
\$160,000	700	14	2.941%	1.767%	1.108%	0.770%	0.611%	0.515%	0.502%
\$160,000	800	14	2.648%	1.558%	0.976%	0.696%	0.572%	0.508%	0.501%
\$160,000	900	14	2.417%	1.397%	0.877%	0.642%	0.548%	0.506%	0.501%
\$160,000	1,000	14	2.216%	1.263%	0.800%	0.604%	0.533%	0.504%	0.501%
\$160,000	1,500	14	1.569%	0.876%	0.611%	0.529%	0.508%	0.502%	0.501%
\$160,000	2,000	14	1.224%	0.704%	0.546%	0.510%	0.504%	0.502%	0.501%
\$160,000	3,000	14	0.851%	0.566%	0.511%	0.504%	0.503%	0.502%	0.501%
\$160,000	4,000	14	0.687%	0.527%	0.506%	0.504%	0.503%	0.502%	0.501%
\$160,000	5,000	14	0.600%	0.512%	0.505%	0.504%	0.503%	0.502%	0.501%
\$160,000	10,000	14	0.510%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$160,000	20,000	14	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$170,000	5	14	61.430%	59.584%	57.804%	56.089%	54.436%	51.315%	48.402%
\$170,000	10	14	46.860%	44.684%	42.605%	40.616%	38.709%	35.137%	31.845%
\$170,000	15	14	38.021%	35.633%	33.369%	31.220%	29.177%	25.412%	22.021%
\$170,000	20	14	32.230%	29.718%	27.359%	25.148%	23.083%	19.362%	16.169%
\$170,000	25	14	28.280%	25.742%	23.395%	21.222%	19.225%	15.718%	12.792%
\$170,000	50	14	18.419%	15.999%	13.854%	11.959%	10.294%	7.587%	5.555%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$170,000	100	14	11.835%	9.637%	7.801%	6.287%	5.050%	3.240%	2.103%
\$170,000	150	14	8.992%	6.966%	5.354%	4.093%	3.120%	1.839%	1.150%
\$170,000	200	14	7.421%	5.525%	4.077%	2.992%	2.204%	1.253%	0.809%
\$170,000	300	14	5.613%	3.928%	2.730%	1.907%	1.361%	0.791%	0.588%
\$170,000	400	14	4.513%	3.002%	1.993%	1.352%	0.965%	0.621%	0.528%
\$170,000	500	14	3.790%	2.416%	1.552%	1.046%	0.768%	0.555%	0.509%
\$170,000	600	14	3.347%	2.071%	1.310%	0.888%	0.674%	0.530%	0.504%
\$170,000	700	14	3.010%	1.818%	1.141%	0.790%	0.621%	0.517%	0.502%
\$170,000	800	14	2.712%	1.604%	1.004%	0.711%	0.580%	0.509%	0.501%
\$170,000	900	14	2.476%	1.437%	0.901%	0.654%	0.554%	0.506%	0.501%
\$170,000	1,000	14	2.271%	1.299%	0.820%	0.614%	0.537%	0.505%	0.501%
\$170,000	1,500	14	1.611%	0.899%	0.620%	0.532%	0.509%	0.502%	0.501%
\$170,000	2,000	14	1.257%	0.719%	0.550%	0.511%	0.504%	0.502%	0.501%
\$170,000	3,000	14	0.872%	0.572%	0.512%	0.504%	0.503%	0.502%	0.501%
\$170,000	4,000	14	0.700%	0.529%	0.507%	0.504%	0.503%	0.502%	0.501%
\$170,000	5,000	14	0.608%	0.514%	0.505%	0.504%	0.503%	0.502%	0.501%
\$170,000	10,000	14	0.510%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$170,000	20,000	14	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$180,000	5	14	61.839%	60.008%	58.244%	56.543%	54.906%	51.816%	48.930%
\$180,000	10	14	47.339%	45.185%	43.127%	41.158%	39.272%	35.739%	32.484%
\$180,000	15	14	38.519%	36.160%	33.923%	31.799%	29.783%	26.069%	22.718%
\$180,000	20	14	32.752%	30.271%	27.936%	25.739%	23.679%	19.958%	16.735%
\$180,000	25	14	28.794%	26.267%	23.923%	21.749%	19.745%	16.205%	13.240%
\$180,000	50	14	18.772%	16.348%	14.194%	12.289%	10.612%	7.867%	5.796%
\$180,000	100	14	12.079%	9.871%	8.021%	6.489%	5.231%	3.383%	2.209%
\$180,000	150	14	9.182%	7.142%	5.514%	4.234%	3.242%	1.921%	1.203%
\$180,000	200	14	7.578%	5.667%	4.201%	3.097%	2.289%	1.304%	0.837%
\$180,000	300	14	5.733%	4.033%	2.817%	1.975%	1.411%	0.815%	0.598%
\$180,000	400	14	4.608%	3.082%	2.055%	1.397%	0.995%	0.632%	0.531%
\$180,000	500	14	3.871%	2.481%	1.601%	1.078%	0.788%	0.561%	0.511%
\$180,000	600	14	3.418%	2.127%	1.348%	0.912%	0.688%	0.534%	0.505%
\$180,000	700	14	3.077%	1.868%	1.175%	0.810%	0.632%	0.519%	0.503%
\$180,000	800	14	2.774%	1.648%	1.032%	0.726%	0.588%	0.510%	0.502%
\$180,000	900	14	2.533%	1.477%	0.925%	0.667%	0.559%	0.507%	0.501%
\$180,000	1,000	14	2.324%	1.335%	0.840%	0.623%	0.541%	0.505%	0.501%
\$180,000	1,500	14	1.651%	0.922%	0.630%	0.535%	0.510%	0.502%	0.501%
\$180,000	2,000	14	1.290%	0.734%	0.555%	0.512%	0.504%	0.502%	0.501%
\$180,000	3,000	14	0.892%	0.578%	0.514%	0.505%	0.503%	0.502%	0.501%
\$180,000	4,000	14	0.713%	0.532%	0.507%	0.504%	0.503%	0.502%	0.501%
\$180,000	5,000	14	0.616%	0.515%	0.505%	0.504%	0.503%	0.502%	0.501%
\$180,000	10,000	14	0.510%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$180,000	20,000	14	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$190,000	5	14	62.210%	60.393%	58.643%	56.956%	55.334%	52.270%	49.410%
\$190,000	10	14	47.772%	45.637%	43.599%	41.649%	39.781%	36.284%	33.062%
\$190,000	15	14	38.974%	36.640%	34.427%	32.326%	30.334%	26.667%	23.356%
\$190,000	20	14	33.230%	30.778%	28.469%	26.292%	24.243%	20.525%	17.287%
\$190,000	25	14	29.279%	26.766%	24.428%	22.257%	20.249%	16.682%	13.680%
\$190,000	50	14	19.112%	16.683%	14.522%	12.607%	10.917%	8.136%	6.031%
\$190,000	100	14	12.312%	10.094%	8.232%	6.683%	5.407%	3.522%	2.313%
\$190,000	150	14	9.363%	7.312%	5.668%	4.371%	3.361%	2.003%	1.255%
\$190,000	200	14	7.727%	5.803%	4.320%	3.198%	2.373%	1.355%	0.865%
\$190,000	300	14	5.846%	4.132%	2.900%	2.041%	1.461%	0.840%	0.608%
\$190,000	400	14	4.700%	3.158%	2.114%	1.441%	1.025%	0.644%	0.535%
\$190,000	500	14	3.943%	2.539%	1.643%	1.106%	0.805%	0.565%	0.511%
\$190,000	600	14	3.487%	2.180%	1.386%	0.936%	0.702%	0.537%	0.506%
\$190,000	700	14	3.141%	1.916%	1.207%	0.830%	0.643%	0.521%	0.503%
\$190,000	800	14	2.833%	1.691%	1.059%	0.741%	0.595%	0.511%	0.502%
\$190,000	900	14	2.588%	1.515%	0.948%	0.679%	0.565%	0.508%	0.502%
\$190,000	1,000	14	2.375%	1.369%	0.860%	0.633%	0.545%	0.506%	0.501%
\$190,000	1,500	14	1.690%	0.944%	0.640%	0.539%	0.510%	0.502%	0.501%
\$190,000	2,000	14	1.321%	0.748%	0.560%	0.513%	0.504%	0.502%	0.501%
\$190,000	3,000	14	0.912%	0.584%	0.515%	0.505%	0.503%	0.502%	0.501%
\$190,000	4,000	14	0.726%	0.535%	0.507%	0.504%	0.503%	0.502%	0.501%
\$190,000	5,000	14	0.624%	0.516%	0.505%	0.504%	0.503%	0.502%	0.501%
\$190,000	10,000	14	0.511%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$190,000	20,000	14	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$200,000	5	14	62.555%	60.751%	59.013%	57.338%	55.731%	52.690%	49.853%
\$200,000	10	14	48.173%	46.057%	44.036%	42.103%	40.253%	36.788%	33.596%
\$200,000	15	14	39.397%	37.086%	34.895%	32.815%	30.846%	27.220%	23.947%
\$200,000	20	14	33.673%	31.247%	28.964%	26.811%	24.778%	21.072%	17.825%
\$200,000	25	14	29.738%	27.242%	24.913%	22.746%	20.739%	17.153%	14.116%
\$200,000	50	14	19.440%	17.007%	14.839%	12.914%	11.213%	8.400%	6.261%
\$200,000	100	14	12.533%	10.308%	8.433%	6.869%	5.577%	3.656%	2.415%
\$200,000	150	14	9.536%	7.474%	5.816%	4.503%	3.475%	2.083%	1.307%
\$200,000	200	14	7.869%	5.933%	4.434%	3.295%	2.453%	1.405%	0.894%
\$200,000	300	14	5.955%	4.229%	2.981%	2.106%	1.510%	0.865%	0.619%
\$200,000	400	14	4.788%	3.232%	2.172%	1.485%	1.055%	0.655%	0.539%
\$200,000	500	14	4.019%	2.600%	1.689%	1.138%	0.824%	0.571%	0.513%
\$200,000	600	14	3.553%	2.233%	1.423%	0.960%	0.716%	0.541%	0.506%
\$200,000	700	14	3.202%	1.962%	1.238%	0.849%	0.654%	0.524%	0.503%
\$200,000	800	14	2.890%	1.732%	1.085%	0.756%	0.603%	0.513%	0.502%
\$200,000	900	14	2.640%	1.552%	0.971%	0.691%	0.571%	0.508%	0.502%
\$200,000	1,000	14	2.424%	1.403%	0.880%	0.643%	0.549%	0.506%	0.501%
\$200,000	1,500	14	1.727%	0.965%	0.650%	0.542%	0.511%	0.502%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$200,000	2,000	14	1.351%	0.763%	0.565%	0.514%	0.504%	0.502%	0.501%
\$200,000	3,000	14	0.931%	0.591%	0.516%	0.505%	0.503%	0.502%	0.501%
\$200,000	4,000	14	0.738%	0.538%	0.508%	0.504%	0.503%	0.502%	0.501%
\$200,000	5,000	14	0.632%	0.517%	0.505%	0.504%	0.503%	0.502%	0.501%
\$200,000	10,000	14	0.511%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$200,000	20,000	14	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$225,000	5	14	63.327%	61.550%	59.839%	58.194%	56.616%	53.628%	50.840%
\$225,000	10	14	49.041%	46.962%	44.979%	43.081%	41.267%	37.871%	34.745%
\$225,000	15	14	40.300%	38.035%	35.891%	33.856%	31.936%	28.397%	25.203%
\$225,000	20	14	34.618%	32.249%	30.018%	27.915%	25.930%	22.293%	19.054%
\$225,000	25	14	30.721%	28.276%	25.982%	23.839%	21.840%	18.239%	15.144%
\$225,000	50	14	20.179%	17.741%	15.560%	13.614%	11.885%	9.009%	6.795%
\$225,000	100	14	13.032%	10.787%	8.886%	7.292%	5.965%	3.966%	2.651%
\$225,000	150	14	9.924%	7.843%	6.156%	4.806%	3.742%	2.274%	1.431%
\$225,000	200	14	8.188%	6.230%	4.696%	3.518%	2.640%	1.527%	0.962%
\$225,000	300	14	6.204%	4.449%	3.169%	2.256%	1.626%	0.925%	0.645%
\$225,000	400	14	4.990%	3.403%	2.308%	1.587%	1.128%	0.686%	0.550%
\$225,000	500	14	4.192%	2.742%	1.797%	1.213%	0.873%	0.588%	0.517%
\$225,000	600	14	3.705%	2.353%	1.510%	1.018%	0.750%	0.552%	0.509%
\$225,000	700	14	3.343%	2.071%	1.313%	0.897%	0.681%	0.530%	0.504%
\$225,000	800	14	3.021%	1.830%	1.149%	0.793%	0.623%	0.516%	0.502%
\$225,000	900	14	2.761%	1.638%	1.026%	0.722%	0.586%	0.510%	0.502%
\$225,000	1,000	14	2.536%	1.481%	0.926%	0.667%	0.560%	0.508%	0.501%
\$225,000	1,500	14	1.813%	1.015%	0.674%	0.551%	0.514%	0.502%	0.501%
\$225,000	2,000	14	1.419%	0.796%	0.578%	0.518%	0.505%	0.502%	0.501%
\$225,000	3,000	14	0.975%	0.606%	0.519%	0.505%	0.503%	0.502%	0.501%
\$225,000	4,000	14	0.768%	0.545%	0.509%	0.504%	0.503%	0.502%	0.501%
\$225,000	5,000	14	0.650%	0.520%	0.506%	0.504%	0.503%	0.502%	0.501%
\$225,000	10,000	14	0.513%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$225,000	20,000	14	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$250,000	5	14	63.970%	62.216%	60.528%	58.908%	57.352%	54.406%	51.658%
\$250,000	10	14	49.758%	47.711%	45.757%	43.889%	42.105%	38.762%	35.691%
\$250,000	15	14	41.046%	38.820%	36.711%	34.715%	32.833%	29.362%	26.230%
\$250,000	20	14	35.395%	33.070%	30.881%	28.819%	26.873%	23.311%	20.129%
\$250,000	25	14	31.520%	29.121%	26.871%	24.764%	22.787%	19.200%	16.090%
\$250,000	50	14	20.835%	18.398%	16.206%	14.242%	12.491%	9.559%	7.286%
\$250,000	100	14	13.463%	11.205%	9.283%	7.666%	6.313%	4.251%	2.872%
\$250,000	150	14	10.266%	8.168%	6.458%	5.077%	3.983%	2.450%	1.549%
\$250,000	200	14	8.469%	6.492%	4.929%	3.719%	2.808%	1.641%	1.029%
\$250,000	300	14	6.424%	4.647%	3.338%	2.393%	1.732%	0.982%	0.672%
\$250,000	400	14	5.170%	3.557%	2.432%	1.682%	1.197%	0.717%	0.561%
\$250,000	500	14	4.344%	2.869%	1.895%	1.284%	0.919%	0.605%	0.522%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$250,000	600	14	3.832%	2.455%	1.585%	1.068%	0.780%	0.560%	0.510%
\$250,000	700	14	3.468%	2.168%	1.382%	0.941%	0.707%	0.537%	0.505%
\$250,000	800	14	3.135%	1.917%	1.208%	0.829%	0.642%	0.520%	0.502%
\$250,000	900	14	2.866%	1.716%	1.076%	0.751%	0.600%	0.513%	0.502%
\$250,000	1,000	14	2.634%	1.550%	0.970%	0.690%	0.571%	0.509%	0.502%
\$250,000	1,500	14	1.888%	1.061%	0.696%	0.561%	0.517%	0.503%	0.501%
\$250,000	2,000	14	1.480%	0.827%	0.589%	0.521%	0.506%	0.502%	0.501%
\$250,000	3,000	14	1.015%	0.620%	0.523%	0.506%	0.503%	0.502%	0.501%
\$250,000	4,000	14	0.795%	0.552%	0.510%	0.504%	0.503%	0.502%	0.501%
\$250,000	5,000	14	0.668%	0.523%	0.506%	0.504%	0.503%	0.502%	0.501%
\$250,000	10,000	14	0.514%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$250,000	20,000	14	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$275,000	5	14	64.487%	62.751%	61.081%	59.481%	57.943%	55.030%	52.316%
\$275,000	10	14	50.345%	48.324%	46.393%	44.549%	42.789%	39.490%	36.462%
\$275,000	15	14	41.664%	39.469%	37.389%	35.425%	33.573%	30.157%	27.075%
\$275,000	20	14	36.040%	33.750%	31.596%	29.566%	27.652%	24.152%	21.027%
\$275,000	25	14	32.174%	29.813%	27.601%	25.531%	23.584%	20.040%	16.934%
\$275,000	50	14	21.414%	18.980%	16.784%	14.806%	13.036%	10.058%	7.735%
\$275,000	100	14	13.845%	11.576%	9.639%	8.002%	6.626%	4.512%	3.077%
\$275,000	150	14	10.565%	8.457%	6.727%	5.321%	4.200%	2.613%	1.663%
\$275,000	200	14	8.721%	6.727%	5.141%	3.904%	2.966%	1.750%	1.095%
\$275,000	300	14	6.620%	4.825%	3.491%	2.520%	1.832%	1.038%	0.700%
\$275,000	400	14	5.332%	3.697%	2.547%	1.771%	1.262%	0.747%	0.571%
\$275,000	500	14	4.481%	2.982%	1.984%	1.348%	0.962%	0.621%	0.527%
\$275,000	600	14	3.952%	2.552%	1.658%	1.119%	0.813%	0.570%	0.513%
\$275,000	700	14	3.580%	2.257%	1.446%	0.983%	0.732%	0.545%	0.506%
\$275,000	800	14	3.238%	1.997%	1.263%	0.863%	0.661%	0.525%	0.503%
\$275,000	900	14	2.961%	1.786%	1.123%	0.778%	0.615%	0.516%	0.503%
\$275,000	1,000	14	2.721%	1.614%	1.010%	0.713%	0.583%	0.511%	0.502%
\$275,000	1,500	14	1.955%	1.102%	0.718%	0.570%	0.520%	0.503%	0.501%
\$275,000	2,000	14	1.534%	0.856%	0.601%	0.524%	0.506%	0.502%	0.501%
\$275,000	3,000	14	1.051%	0.634%	0.526%	0.506%	0.503%	0.502%	0.501%
\$275,000	4,000	14	0.820%	0.559%	0.511%	0.504%	0.503%	0.502%	0.501%
\$275,000	5,000	14	0.685%	0.526%	0.506%	0.504%	0.503%	0.502%	0.501%
\$275,000	10,000	14	0.515%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$275,000	20,000	14	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$300,000	5	14	64.917%	63.196%	61.542%	59.957%	58.433%	55.547%	52.860%
\$300,000	10	14	50.814%	48.812%	46.899%	45.074%	43.333%	40.067%	37.074%
\$300,000	15	14	42.154%	39.983%	37.926%	35.987%	34.159%	30.785%	27.741%
\$300,000	20	14	36.545%	34.283%	32.155%	30.150%	28.261%	24.807%	21.728%
\$300,000	25	14	32.682%	30.350%	28.167%	26.124%	24.203%	20.707%	17.629%
\$300,000	50	14	21.898%	19.471%	17.274%	15.292%	13.507%	10.494%	8.129%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$300,000	100	14	14.167%	11.892%	9.943%	8.291%	6.898%	4.742%	3.261%
\$300,000	150	14	10.821%	8.704%	6.959%	5.536%	4.393%	2.762%	1.769%
\$300,000	200	14	8.938%	6.932%	5.327%	4.070%	3.106%	1.849%	1.158%
\$300,000	300	14	6.790%	4.979%	3.626%	2.631%	1.920%	1.089%	0.726%
\$300,000	400	14	5.471%	3.818%	2.648%	1.849%	1.320%	0.775%	0.581%
\$300,000	500	14	4.598%	3.080%	2.062%	1.405%	1.001%	0.636%	0.532%
\$300,000	600	14	4.055%	2.636%	1.723%	1.165%	0.843%	0.580%	0.516%
\$300,000	700	14	3.676%	2.335%	1.503%	1.021%	0.755%	0.552%	0.508%
\$300,000	800	14	3.326%	2.065%	1.311%	0.893%	0.679%	0.529%	0.504%
\$300,000	900	14	3.042%	1.848%	1.164%	0.803%	0.629%	0.519%	0.503%
\$300,000	1,000	14	2.796%	1.669%	1.046%	0.734%	0.593%	0.513%	0.502%
\$300,000	1,500	14	2.012%	1.138%	0.737%	0.578%	0.523%	0.503%	0.501%
\$300,000	2,000	14	1.581%	0.881%	0.611%	0.528%	0.507%	0.502%	0.501%
\$300,000	3,000	14	1.083%	0.646%	0.529%	0.507%	0.503%	0.502%	0.501%
\$300,000	4,000	14	0.841%	0.565%	0.512%	0.504%	0.503%	0.502%	0.501%
\$300,000	5,000	14	0.699%	0.529%	0.507%	0.504%	0.503%	0.502%	0.501%
\$300,000	10,000	14	0.517%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$300,000	20,000	14	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$325,000	5	14	65.328%	63.621%	61.981%	60.411%	58.900%	56.039%	53.377%
\$325,000	10	14	51.258%	49.274%	47.379%	45.571%	43.846%	40.612%	37.649%
\$325,000	15	14	42.615%	40.466%	38.431%	36.515%	34.707%	31.372%	28.364%
\$325,000	20	14	37.016%	34.778%	32.674%	30.692%	28.826%	25.414%	22.376%
\$325,000	25	14	33.153%	30.848%	28.691%	26.673%	24.775%	21.325%	18.289%
\$325,000	50	14	22.375%	19.960%	17.765%	15.781%	13.990%	10.945%	8.536%
\$325,000	100	14	14.490%	12.209%	10.249%	8.584%	7.172%	4.979%	3.454%
\$325,000	150	14	11.075%	8.951%	7.191%	5.752%	4.587%	2.914%	1.880%
\$325,000	200	14	9.157%	7.138%	5.515%	4.237%	3.251%	1.952%	1.224%
\$325,000	300	14	6.960%	5.135%	3.761%	2.745%	2.012%	1.143%	0.754%
\$325,000	400	14	5.611%	3.940%	2.749%	1.929%	1.380%	0.804%	0.593%
\$325,000	500	14	4.716%	3.179%	2.141%	1.463%	1.042%	0.653%	0.538%
\$325,000	600	14	4.160%	2.722%	1.788%	1.212%	0.873%	0.590%	0.520%
\$325,000	700	14	3.773%	2.412%	1.560%	1.059%	0.779%	0.559%	0.510%
\$325,000	800	14	3.413%	2.134%	1.361%	0.925%	0.697%	0.534%	0.504%
\$325,000	900	14	3.123%	1.909%	1.206%	0.829%	0.643%	0.522%	0.503%
\$325,000	1,000	14	2.871%	1.724%	1.082%	0.755%	0.604%	0.515%	0.502%
\$325,000	1,500	14	2.069%	1.175%	0.756%	0.587%	0.527%	0.503%	0.501%
\$325,000	2,000	14	1.627%	0.906%	0.622%	0.531%	0.508%	0.502%	0.501%
\$325,000	3,000	14	1.114%	0.659%	0.533%	0.508%	0.503%	0.502%	0.501%
\$325,000	4,000	14	0.863%	0.571%	0.513%	0.505%	0.503%	0.502%	0.501%
\$325,000	5,000	14	0.714%	0.532%	0.507%	0.504%	0.503%	0.502%	0.501%
\$325,000	10,000	14	0.518%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$325,000	20,000	14	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$350,000	5	14	65.681%	63.986%	62.359%	60.801%	59.301%	56.462%	53.822%
\$350,000	10	14	51.645%	49.677%	47.797%	46.005%	44.294%	41.087%	38.151%
\$350,000	15	14	43.021%	40.891%	38.876%	36.979%	35.190%	31.888%	28.912%
\$350,000	20	14	37.426%	35.210%	33.126%	31.164%	29.319%	25.943%	22.939%
\$350,000	25	14	33.570%	31.287%	29.155%	27.157%	25.281%	21.870%	18.871%
\$350,000	50	14	22.812%	20.414%	18.227%	16.244%	14.449%	11.384%	8.937%
\$350,000	100	14	14.795%	12.513%	10.545%	8.866%	7.438%	5.210%	3.643%
\$350,000	150	14	11.316%	9.185%	7.414%	5.960%	4.776%	3.064%	1.991%
\$350,000	200	14	9.365%	7.334%	5.696%	4.399%	3.394%	2.055%	1.292%
\$350,000	300	14	7.121%	5.282%	3.889%	2.854%	2.100%	1.196%	0.783%
\$350,000	400	14	5.742%	4.056%	2.846%	2.005%	1.439%	0.834%	0.605%
\$350,000	500	14	4.827%	3.275%	2.217%	1.521%	1.083%	0.670%	0.544%
\$350,000	600	14	4.260%	2.803%	1.851%	1.257%	0.904%	0.601%	0.523%
\$350,000	700	14	3.856%	2.480%	1.610%	1.092%	0.800%	0.565%	0.511%
\$350,000	800	14	3.496%	2.200%	1.408%	0.955%	0.715%	0.540%	0.505%
\$350,000	900	14	3.199%	1.968%	1.246%	0.854%	0.658%	0.526%	0.504%
\$350,000	1,000	14	2.941%	1.777%	1.117%	0.776%	0.615%	0.517%	0.503%
\$350,000	1,500	14	2.122%	1.209%	0.776%	0.596%	0.530%	0.504%	0.501%
\$350,000	2,000	14	1.670%	0.930%	0.633%	0.535%	0.509%	0.502%	0.501%
\$350,000	3,000	14	1.144%	0.671%	0.537%	0.508%	0.503%	0.502%	0.501%
\$350,000	4,000	14	0.884%	0.578%	0.514%	0.505%	0.503%	0.502%	0.501%
\$350,000	5,000	14	0.728%	0.535%	0.507%	0.504%	0.503%	0.502%	0.501%
\$350,000	10,000	14	0.519%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$350,000	20,000	14	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$375,000	5	14	65.998%	64.314%	62.699%	61.152%	59.662%	56.842%	54.221%
\$375,000	10	14	51.991%	50.036%	48.170%	46.391%	44.693%	41.510%	38.598%
\$375,000	15	14	43.382%	41.268%	39.271%	37.392%	35.617%	32.345%	29.398%
\$375,000	20	14	37.787%	35.589%	33.523%	31.579%	29.752%	26.408%	23.435%
\$375,000	25	14	33.938%	31.677%	29.565%	27.585%	25.728%	22.353%	19.386%
\$375,000	50	14	23.216%	20.837%	18.662%	16.684%	14.890%	11.814%	9.335%
\$375,000	100	14	15.088%	12.806%	10.833%	9.142%	7.698%	5.438%	3.832%
\$375,000	150	14	11.546%	9.411%	7.628%	6.161%	4.959%	3.210%	2.101%
\$375,000	200	14	9.566%	7.526%	5.873%	4.559%	3.535%	2.157%	1.362%
\$375,000	300	14	7.275%	5.424%	4.014%	2.961%	2.189%	1.251%	0.812%
\$375,000	400	14	5.868%	4.168%	2.941%	2.081%	1.498%	0.865%	0.619%
\$375,000	500	14	4.936%	3.368%	2.291%	1.578%	1.124%	0.688%	0.550%
\$375,000	600	14	4.355%	2.882%	1.913%	1.302%	0.935%	0.613%	0.527%
\$375,000	700	14	3.943%	2.552%	1.664%	1.129%	0.824%	0.574%	0.513%
\$375,000	800	14	3.575%	2.264%	1.455%	0.986%	0.734%	0.546%	0.506%
\$375,000	900	14	3.272%	2.025%	1.286%	0.879%	0.673%	0.530%	0.505%
\$375,000	1,000	14	3.009%	1.829%	1.152%	0.797%	0.627%	0.520%	0.503%
\$375,000	1,500	14	2.173%	1.243%	0.795%	0.605%	0.534%	0.504%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$375,000	2,000	14	1.712%	0.954%	0.643%	0.539%	0.510%	0.502%	0.501%
\$375,000	3,000	14	1.173%	0.683%	0.540%	0.509%	0.504%	0.502%	0.501%
\$375,000	4,000	14	0.905%	0.584%	0.515%	0.505%	0.503%	0.502%	0.501%
\$375,000	5,000	14	0.742%	0.538%	0.508%	0.504%	0.503%	0.502%	0.501%
\$375,000	10,000	14	0.521%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$375,000	20,000	14	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$400,000	5	14	66.296%	64.621%	63.017%	61.479%	59.998%	57.197%	54.593%
\$400,000	10	14	52.307%	50.364%	48.510%	46.744%	45.057%	41.897%	39.006%
\$400,000	15	14	43.712%	41.612%	39.631%	37.768%	36.007%	32.762%	29.840%
\$400,000	20	14	38.114%	35.934%	33.884%	31.956%	30.145%	26.829%	23.884%
\$400,000	25	14	34.272%	32.029%	29.935%	27.972%	26.132%	22.788%	19.851%
\$400,000	50	14	23.588%	21.229%	19.070%	17.103%	15.312%	12.231%	9.728%
\$400,000	100	14	15.371%	13.089%	11.111%	9.410%	7.951%	5.659%	4.019%
\$400,000	150	14	11.767%	9.629%	7.836%	6.355%	5.137%	3.353%	2.210%
\$400,000	200	14	9.759%	7.710%	6.044%	4.715%	3.672%	2.258%	1.431%
\$400,000	300	14	7.423%	5.560%	4.135%	3.064%	2.276%	1.305%	0.841%
\$400,000	400	14	5.988%	4.275%	3.032%	2.155%	1.555%	0.895%	0.633%
\$400,000	500	14	5.039%	3.456%	2.364%	1.634%	1.165%	0.706%	0.557%
\$400,000	600	14	4.445%	2.957%	1.972%	1.346%	0.965%	0.625%	0.531%
\$400,000	700	14	4.026%	2.620%	1.716%	1.166%	0.848%	0.582%	0.515%
\$400,000	800	14	3.651%	2.325%	1.500%	1.016%	0.753%	0.551%	0.508%
\$400,000	900	14	3.342%	2.080%	1.324%	0.904%	0.688%	0.534%	0.505%
\$400,000	1,000	14	3.073%	1.878%	1.185%	0.818%	0.638%	0.523%	0.504%
\$400,000	1,500	14	2.222%	1.276%	0.814%	0.614%	0.538%	0.505%	0.501%
\$400,000	2,000	14	1.751%	0.977%	0.654%	0.543%	0.511%	0.502%	0.501%
\$400,000	3,000	14	1.201%	0.695%	0.544%	0.510%	0.504%	0.502%	0.501%
\$400,000	4,000	14	0.924%	0.590%	0.517%	0.505%	0.503%	0.502%	0.501%
\$400,000	5,000	14	0.756%	0.542%	0.508%	0.504%	0.503%	0.502%	0.501%
\$400,000	10,000	14	0.523%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$400,000	20,000	14	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$425,000	5	14	66.558%	64.892%	63.297%	61.768%	60.295%	57.509%	54.921%
\$425,000	10	14	52.587%	50.655%	48.812%	47.057%	45.380%	42.239%	39.367%
\$425,000	15	14	43.999%	41.912%	39.945%	38.095%	36.347%	33.125%	30.225%
\$425,000	20	14	38.401%	36.236%	34.200%	32.286%	30.489%	27.199%	24.277%
\$425,000	25	14	34.567%	32.341%	30.263%	28.314%	26.488%	23.173%	20.261%
\$425,000	50	14	23.919%	21.579%	19.437%	17.481%	15.699%	12.617%	10.101%
\$425,000	100	14	15.634%	13.353%	11.373%	9.663%	8.191%	5.868%	4.198%
\$425,000	150	14	11.974%	9.832%	8.032%	6.539%	5.306%	3.489%	2.316%
\$425,000	200	14	9.941%	7.883%	6.205%	4.863%	3.804%	2.355%	1.499%
\$425,000	300	14	7.562%	5.688%	4.249%	3.162%	2.359%	1.358%	0.871%
\$425,000	400	14	6.102%	4.377%	3.118%	2.225%	1.610%	0.926%	0.648%
\$425,000	500	14	5.136%	3.540%	2.433%	1.688%	1.204%	0.724%	0.564%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$425,000	600	14	4.530%	3.030%	2.029%	1.388%	0.994%	0.637%	0.535%
\$425,000	700	14	4.104%	2.685%	1.766%	1.201%	0.871%	0.591%	0.518%
\$425,000	800	14	3.722%	2.383%	1.542%	1.046%	0.771%	0.558%	0.509%
\$425,000	900	14	3.407%	2.131%	1.361%	0.928%	0.702%	0.538%	0.506%
\$425,000	1,000	14	3.133%	1.924%	1.217%	0.838%	0.650%	0.526%	0.504%
\$425,000	1,500	14	2.267%	1.307%	0.832%	0.623%	0.542%	0.505%	0.501%
\$425,000	2,000	14	1.789%	0.999%	0.665%	0.547%	0.512%	0.502%	0.501%
\$425,000	3,000	14	1.227%	0.707%	0.548%	0.511%	0.504%	0.502%	0.501%
\$425,000	4,000	14	0.943%	0.597%	0.518%	0.505%	0.503%	0.502%	0.501%
\$425,000	5,000	14	0.769%	0.545%	0.509%	0.504%	0.503%	0.502%	0.501%
\$425,000	10,000	14	0.524%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$425,000	20,000	14	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$450,000	5	14	66.777%	65.119%	63.532%	62.009%	60.544%	57.770%	55.195%
\$450,000	10	14	52.818%	50.894%	49.061%	47.314%	45.645%	42.521%	39.664%
\$450,000	15	14	44.236%	42.160%	40.204%	38.366%	36.628%	33.424%	30.542%
\$450,000	20	14	38.640%	36.487%	34.463%	32.560%	30.775%	27.505%	24.603%
\$450,000	25	14	34.815%	32.603%	30.538%	28.601%	26.787%	23.494%	20.603%
\$450,000	50	14	24.194%	21.872%	19.745%	17.802%	16.029%	12.955%	10.429%
\$450,000	100	14	15.861%	13.582%	11.599%	9.883%	8.402%	6.053%	4.357%
\$450,000	150	14	12.156%	10.011%	8.205%	6.702%	5.457%	3.611%	2.412%
\$450,000	200	14	10.099%	8.036%	6.348%	4.994%	3.921%	2.442%	1.561%
\$450,000	300	14	7.683%	5.801%	4.350%	3.249%	2.432%	1.406%	0.898%
\$450,000	400	14	6.202%	4.466%	3.195%	2.288%	1.659%	0.953%	0.661%
\$450,000	500	14	5.221%	3.614%	2.494%	1.735%	1.239%	0.741%	0.571%
\$450,000	600	14	4.605%	3.094%	2.079%	1.425%	1.021%	0.648%	0.539%
\$450,000	700	14	4.171%	2.741%	1.810%	1.233%	0.892%	0.598%	0.521%
\$450,000	800	14	3.784%	2.433%	1.580%	1.072%	0.788%	0.563%	0.510%
\$450,000	900	14	3.464%	2.176%	1.393%	0.950%	0.715%	0.542%	0.507%
\$450,000	1,000	14	3.186%	1.965%	1.246%	0.856%	0.660%	0.528%	0.504%
\$450,000	1,500	14	2.307%	1.334%	0.847%	0.631%	0.545%	0.506%	0.501%
\$450,000	2,000	14	1.821%	1.019%	0.674%	0.550%	0.514%	0.502%	0.501%
\$450,000	3,000	14	1.249%	0.717%	0.551%	0.512%	0.504%	0.502%	0.501%
\$450,000	4,000	14	0.959%	0.602%	0.519%	0.505%	0.503%	0.502%	0.501%
\$450,000	5,000	14	0.780%	0.548%	0.509%	0.504%	0.503%	0.502%	0.501%
\$450,000	10,000	14	0.526%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$450,000	20,000	14	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$475,000	5	14	66.982%	65.331%	63.751%	62.235%	60.776%	58.014%	55.452%
\$475,000	10	14	53.029%	51.114%	49.288%	47.550%	45.888%	42.779%	39.936%
\$475,000	15	14	44.457%	42.391%	40.446%	38.617%	36.889%	33.703%	30.837%
\$475,000	20	14	38.861%	36.719%	34.705%	32.813%	31.038%	27.787%	24.904%
\$475,000	25	14	35.046%	32.846%	30.793%	28.867%	27.065%	23.793%	20.921%
\$475,000	50	14	24.451%	22.145%	20.034%	18.103%	16.342%	13.280%	10.750%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$475,000	100	14	16.080%	13.804%	11.820%	10.100%	8.610%	6.237%	4.516%
\$475,000	150	14	12.334%	10.185%	8.375%	6.863%	5.607%	3.732%	2.508%
\$475,000	200	14	10.254%	8.185%	6.489%	5.123%	4.038%	2.529%	1.623%
\$475,000	300	14	7.802%	5.913%	4.449%	3.336%	2.505%	1.455%	0.926%
\$475,000	400	14	6.299%	4.554%	3.271%	2.351%	1.708%	0.981%	0.675%
\$475,000	500	14	5.306%	3.688%	2.555%	1.783%	1.275%	0.759%	0.578%
\$475,000	600	14	4.679%	3.158%	2.130%	1.463%	1.048%	0.659%	0.542%
\$475,000	700	14	4.237%	2.797%	1.853%	1.264%	0.913%	0.607%	0.523%
\$475,000	800	14	3.837%	2.476%	1.612%	1.094%	0.801%	0.567%	0.511%
\$475,000	900	14	3.519%	2.220%	1.425%	0.971%	0.728%	0.546%	0.508%
\$475,000	1,000	14	3.237%	2.005%	1.274%	0.874%	0.671%	0.531%	0.505%
\$475,000	1,500	14	2.345%	1.360%	0.863%	0.639%	0.549%	0.506%	0.501%
\$475,000	2,000	14	1.853%	1.038%	0.684%	0.554%	0.515%	0.502%	0.501%
\$475,000	3,000	14	1.271%	0.728%	0.555%	0.512%	0.504%	0.502%	0.501%
\$475,000	4,000	14	0.975%	0.608%	0.521%	0.506%	0.503%	0.502%	0.501%
\$475,000	5,000	14	0.792%	0.551%	0.509%	0.504%	0.503%	0.502%	0.501%
\$475,000	10,000	14	0.527%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$475,000	20,000	14	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$500,000	5	14	67.168%	65.523%	63.950%	62.439%	60.986%	58.235%	55.683%
\$500,000	10	14	53.220%	51.311%	49.494%	47.762%	46.108%	43.012%	40.182%
\$500,000	15	14	44.658%	42.601%	40.666%	38.846%	37.126%	33.956%	31.105%
\$500,000	20	14	39.061%	36.930%	34.926%	33.044%	31.278%	28.044%	25.177%
\$500,000	25	14	35.258%	33.069%	31.027%	29.111%	27.318%	24.066%	21.212%
\$500,000	50	14	24.683%	22.392%	20.296%	18.378%	16.628%	13.582%	11.054%
\$500,000	100	14	16.286%	14.013%	12.029%	10.306%	8.810%	6.416%	4.671%
\$500,000	150	14	12.503%	10.351%	8.536%	7.017%	5.752%	3.851%	2.602%
\$500,000	200	14	10.401%	8.327%	6.623%	5.247%	4.150%	2.614%	1.684%
\$500,000	300	14	7.917%	6.020%	4.546%	3.420%	2.576%	1.504%	0.955%
\$500,000	400	14	6.392%	4.638%	3.343%	2.412%	1.756%	1.009%	0.690%
\$500,000	500	14	5.386%	3.759%	2.613%	1.830%	1.310%	0.776%	0.585%
\$500,000	600	14	4.750%	3.218%	2.178%	1.500%	1.075%	0.671%	0.546%
\$500,000	700	14	4.300%	2.851%	1.895%	1.294%	0.934%	0.615%	0.526%
\$500,000	800	14	3.894%	2.523%	1.648%	1.119%	0.818%	0.572%	0.512%
\$500,000	900	14	3.571%	2.263%	1.456%	0.992%	0.741%	0.550%	0.509%
\$500,000	1,000	14	3.285%	2.043%	1.301%	0.892%	0.681%	0.534%	0.505%
\$500,000	1,500	14	2.382%	1.386%	0.878%	0.647%	0.553%	0.507%	0.501%
\$500,000	2,000	14	1.884%	1.057%	0.693%	0.558%	0.516%	0.503%	0.501%
\$500,000	3,000	14	1.293%	0.738%	0.558%	0.513%	0.504%	0.502%	0.501%
\$500,000	4,000	14	0.991%	0.613%	0.522%	0.506%	0.503%	0.502%	0.501%
\$500,000	5,000	14	0.803%	0.554%	0.510%	0.504%	0.503%	0.502%	0.501%
\$500,000	10,000	14	0.529%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$500,000	20,000	14	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$30,000	5	15	39.260%	36.413%	33.706%	31.153%	28.758%	24.419%	20.696%
\$30,000	10	15	25.813%	23.220%	20.831%	18.642%	16.648%	13.204%	10.374%
\$30,000	15	15	20.214%	17.668%	15.387%	13.356%	11.562%	8.588%	6.313%
\$30,000	20	15	16.865%	14.394%	12.222%	10.333%	8.697%	6.101%	4.241%
\$30,000	25	15	14.731%	12.335%	10.267%	8.494%	6.994%	4.694%	3.137%
\$30,000	50	15	9.339%	7.251%	5.580%	4.260%	3.238%	1.883%	1.156%
\$30,000	100	15	5.855%	4.121%	2.877%	2.011%	1.431%	0.817%	0.593%
\$30,000	150	15	4.419%	2.914%	1.916%	1.289%	0.917%	0.601%	0.519%
\$30,000	200	15	3.585%	2.248%	1.431%	0.965%	0.717%	0.539%	0.506%
\$30,000	300	15	2.636%	1.541%	0.959%	0.683%	0.565%	0.507%	0.501%
\$30,000	400	15	2.080%	1.167%	0.746%	0.578%	0.522%	0.503%	0.501%
\$30,000	500	15	1.732%	0.959%	0.645%	0.540%	0.511%	0.502%	0.501%
\$30,000	600	15	1.473%	0.820%	0.586%	0.520%	0.505%	0.502%	0.501%
\$30,000	700	15	1.298%	0.735%	0.556%	0.513%	0.504%	0.502%	0.501%
\$30,000	800	15	1.158%	0.673%	0.536%	0.508%	0.504%	0.502%	0.501%
\$30,000	900	15	1.040%	0.628%	0.524%	0.506%	0.503%	0.502%	0.501%
\$30,000	1,000	15	0.955%	0.598%	0.518%	0.505%	0.503%	0.502%	0.501%
\$30,000	1,500	15	0.709%	0.531%	0.507%	0.504%	0.503%	0.502%	0.501%
\$30,000	2,000	15	0.604%	0.513%	0.505%	0.504%	0.503%	0.502%	0.501%
\$30,000	3,000	15	0.532%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$30,000	4,000	15	0.514%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$30,000	5,000	15	0.509%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$30,000	10,000	15	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$30,000	20,000	15	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$35,000	5	15	41.637%	38.911%	36.274%	33.726%	31.295%	26.845%	22.932%
\$35,000	10	15	27.244%	24.650%	22.261%	20.062%	18.043%	14.512%	11.582%
\$35,000	15	15	21.394%	18.829%	16.523%	14.455%	12.616%	9.529%	7.135%
\$35,000	20	15	17.865%	15.370%	13.169%	11.236%	9.547%	6.827%	4.845%
\$35,000	25	15	15.633%	13.205%	11.097%	9.277%	7.720%	5.290%	3.600%
\$35,000	50	15	9.941%	7.813%	6.090%	4.712%	3.623%	2.146%	1.324%
\$35,000	100	15	6.257%	4.471%	3.169%	2.243%	1.608%	0.906%	0.631%
\$35,000	150	15	4.728%	3.170%	2.113%	1.431%	1.013%	0.637%	0.530%
\$35,000	200	15	3.840%	2.447%	1.573%	1.059%	0.774%	0.555%	0.509%
\$35,000	300	15	2.831%	1.680%	1.045%	0.729%	0.587%	0.510%	0.501%
\$35,000	400	15	2.245%	1.272%	0.801%	0.603%	0.531%	0.503%	0.501%
\$35,000	500	15	1.870%	1.038%	0.681%	0.553%	0.515%	0.502%	0.501%
\$35,000	600	15	1.594%	0.883%	0.611%	0.527%	0.507%	0.502%	0.501%
\$35,000	700	15	1.403%	0.785%	0.573%	0.517%	0.505%	0.502%	0.501%
\$35,000	800	15	1.251%	0.712%	0.548%	0.511%	0.504%	0.502%	0.501%
\$35,000	900	15	1.123%	0.660%	0.533%	0.507%	0.503%	0.502%	0.501%
\$35,000	1,000	15	1.029%	0.624%	0.524%	0.506%	0.503%	0.502%	0.501%
\$35,000	1,500	15	0.753%	0.541%	0.508%	0.504%	0.503%	0.502%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$35,000	2,000	15	0.630%	0.517%	0.505%	0.504%	0.503%	0.502%	0.501%
\$35,000	3,000	15	0.541%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$35,000	4,000	15	0.518%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$35,000	5,000	15	0.510%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$35,000	10,000	15	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$35,000	20,000	15	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$40,000	5	15	43.606%	40.979%	38.444%	35.994%	33.623%	29.124%	25.102%
\$40,000	10	15	28.551%	25.938%	23.537%	21.329%	19.297%	15.717%	12.705%
\$40,000	15	15	22.452%	19.881%	17.553%	15.456%	13.578%	10.405%	7.903%
\$40,000	20	15	18.777%	16.264%	14.035%	12.066%	10.334%	7.515%	5.425%
\$40,000	25	15	16.442%	13.990%	11.847%	9.988%	8.386%	5.848%	4.048%
\$40,000	50	15	10.481%	8.321%	6.553%	5.128%	3.984%	2.401%	1.492%
\$40,000	100	15	6.620%	4.794%	3.440%	2.465%	1.778%	0.998%	0.673%
\$40,000	150	15	5.009%	3.407%	2.299%	1.568%	1.109%	0.677%	0.543%
\$40,000	200	15	4.069%	2.628%	1.704%	1.148%	0.830%	0.572%	0.512%
\$40,000	300	15	3.009%	1.810%	1.128%	0.776%	0.611%	0.514%	0.502%
\$40,000	400	15	2.396%	1.372%	0.857%	0.629%	0.541%	0.504%	0.501%
\$40,000	500	15	1.996%	1.114%	0.718%	0.568%	0.520%	0.503%	0.501%
\$40,000	600	15	1.705%	0.944%	0.637%	0.536%	0.509%	0.502%	0.501%
\$40,000	700	15	1.501%	0.834%	0.592%	0.522%	0.506%	0.502%	0.501%
\$40,000	800	15	1.337%	0.751%	0.561%	0.514%	0.504%	0.502%	0.501%
\$40,000	900	15	1.201%	0.692%	0.542%	0.509%	0.504%	0.502%	0.501%
\$40,000	1,000	15	1.099%	0.650%	0.530%	0.507%	0.503%	0.502%	0.501%
\$40,000	1,500	15	0.796%	0.551%	0.509%	0.504%	0.503%	0.502%	0.501%
\$40,000	2,000	15	0.657%	0.521%	0.506%	0.504%	0.503%	0.502%	0.501%
\$40,000	3,000	15	0.551%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$40,000	4,000	15	0.521%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$40,000	5,000	15	0.512%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$40,000	10,000	15	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$40,000	20,000	15	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$45,000	5	15	45.306%	42.767%	40.317%	37.949%	35.656%	31.290%	27.209%
\$45,000	10	15	29.765%	27.130%	24.706%	22.476%	20.423%	16.805%	13.748%
\$45,000	15	15	23.411%	20.837%	18.498%	16.381%	14.472%	11.224%	8.640%
\$45,000	20	15	19.618%	17.096%	14.844%	12.841%	11.074%	8.171%	5.988%
\$45,000	25	15	17.183%	14.716%	12.544%	10.656%	9.013%	6.384%	4.487%
\$45,000	50	15	10.982%	8.793%	6.989%	5.517%	4.328%	2.652%	1.661%
\$45,000	100	15	6.958%	5.097%	3.699%	2.678%	1.947%	1.094%	0.720%
\$45,000	150	15	5.274%	3.632%	2.480%	1.704%	1.208%	0.719%	0.558%
\$45,000	200	15	4.291%	2.808%	1.838%	1.241%	0.891%	0.593%	0.517%
\$45,000	300	15	3.177%	1.935%	1.210%	0.825%	0.637%	0.519%	0.502%
\$45,000	400	15	2.538%	1.469%	0.913%	0.657%	0.553%	0.505%	0.501%
\$45,000	500	15	2.115%	1.188%	0.756%	0.584%	0.526%	0.503%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$45,000	600	15	1.810%	1.003%	0.664%	0.545%	0.512%	0.502%	0.501%
\$45,000	700	15	1.594%	0.882%	0.611%	0.528%	0.508%	0.502%	0.501%
\$45,000	800	15	1.420%	0.791%	0.575%	0.517%	0.505%	0.502%	0.501%
\$45,000	900	15	1.277%	0.725%	0.553%	0.512%	0.504%	0.502%	0.501%
\$45,000	1,000	15	1.167%	0.677%	0.538%	0.508%	0.503%	0.502%	0.501%
\$45,000	1,500	15	0.838%	0.563%	0.511%	0.504%	0.503%	0.502%	0.501%
\$45,000	2,000	15	0.684%	0.526%	0.506%	0.504%	0.503%	0.502%	0.501%
\$45,000	3,000	15	0.562%	0.509%	0.505%	0.504%	0.503%	0.502%	0.501%
\$45,000	4,000	15	0.526%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$45,000	5,000	15	0.514%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$45,000	10,000	15	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$45,000	20,000	15	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$50,000	5	15	46.805%	44.341%	41.963%	39.662%	37.440%	33.210%	29.229%
\$50,000	10	15	30.939%	28.279%	25.823%	23.563%	21.481%	17.808%	14.710%
\$50,000	15	15	24.294%	21.721%	19.375%	17.242%	15.311%	12.000%	9.343%
\$50,000	20	15	20.406%	17.874%	15.604%	13.575%	11.778%	8.795%	6.526%
\$50,000	25	15	17.873%	15.391%	13.199%	11.282%	9.607%	6.902%	4.918%
\$50,000	50	15	11.451%	9.236%	7.401%	5.888%	4.658%	2.899%	1.831%
\$50,000	100	15	7.272%	5.380%	3.943%	2.881%	2.110%	1.190%	0.769%
\$50,000	150	15	5.519%	3.841%	2.651%	1.836%	1.304%	0.764%	0.575%
\$50,000	200	15	4.494%	2.975%	1.966%	1.332%	0.952%	0.616%	0.524%
\$50,000	300	15	3.331%	2.051%	1.290%	0.873%	0.663%	0.525%	0.503%
\$50,000	400	15	2.668%	1.560%	0.968%	0.685%	0.565%	0.507%	0.501%
\$50,000	500	15	2.226%	1.259%	0.793%	0.600%	0.532%	0.504%	0.501%
\$50,000	600	15	1.908%	1.061%	0.691%	0.556%	0.515%	0.502%	0.501%
\$50,000	700	15	1.682%	0.930%	0.631%	0.535%	0.510%	0.502%	0.501%
\$50,000	800	15	1.498%	0.831%	0.590%	0.521%	0.506%	0.502%	0.501%
\$50,000	900	15	1.348%	0.759%	0.564%	0.514%	0.504%	0.502%	0.501%
\$50,000	1,000	15	1.231%	0.705%	0.546%	0.510%	0.504%	0.502%	0.501%
\$50,000	1,500	15	0.879%	0.575%	0.513%	0.505%	0.503%	0.502%	0.501%
\$50,000	2,000	15	0.711%	0.531%	0.507%	0.504%	0.503%	0.502%	0.501%
\$50,000	3,000	15	0.573%	0.510%	0.505%	0.504%	0.503%	0.502%	0.501%
\$50,000	4,000	15	0.530%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$50,000	5,000	15	0.516%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$50,000	10,000	15	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$50,000	20,000	15	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$55,000	5	15	48.126%	45.725%	43.406%	41.168%	39.006%	34.890%	31.015%
\$55,000	10	15	32.079%	29.392%	26.906%	24.610%	22.495%	18.751%	15.599%
\$55,000	15	15	25.111%	22.539%	20.186%	18.042%	16.092%	12.734%	10.010%
\$55,000	20	15	21.137%	18.599%	16.315%	14.266%	12.438%	9.386%	7.039%
\$55,000	25	15	18.518%	16.024%	13.815%	11.869%	10.166%	7.394%	5.334%
\$55,000	50	15	11.889%	9.652%	7.786%	6.241%	4.973%	3.139%	2.002%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$55,000	100	15	7.567%	5.647%	4.174%	3.075%	2.268%	1.287%	0.821%
\$55,000	150	15	5.747%	4.038%	2.812%	1.963%	1.399%	0.811%	0.594%
\$55,000	200	15	4.682%	3.132%	2.088%	1.420%	1.013%	0.641%	0.531%
\$55,000	300	15	3.474%	2.162%	1.368%	0.921%	0.690%	0.531%	0.504%
\$55,000	400	15	2.789%	1.646%	1.021%	0.714%	0.579%	0.508%	0.501%
\$55,000	500	15	2.329%	1.327%	0.830%	0.617%	0.538%	0.505%	0.501%
\$55,000	600	15	1.999%	1.116%	0.719%	0.567%	0.518%	0.503%	0.501%
\$55,000	700	15	1.764%	0.976%	0.651%	0.542%	0.512%	0.502%	0.501%
\$55,000	800	15	1.572%	0.869%	0.605%	0.526%	0.507%	0.502%	0.501%
\$55,000	900	15	1.416%	0.791%	0.575%	0.517%	0.505%	0.502%	0.501%
\$55,000	1,000	15	1.293%	0.732%	0.554%	0.512%	0.504%	0.502%	0.501%
\$55,000	1,500	15	0.919%	0.587%	0.516%	0.505%	0.503%	0.502%	0.501%
\$55,000	2,000	15	0.738%	0.536%	0.507%	0.504%	0.503%	0.502%	0.501%
\$55,000	3,000	15	0.585%	0.511%	0.505%	0.504%	0.503%	0.502%	0.501%
\$55,000	4,000	15	0.535%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$55,000	5,000	15	0.518%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$55,000	10,000	15	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$55,000	20,000	15	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$60,000	5	15	49.287%	46.939%	44.674%	42.490%	40.380%	36.360%	32.578%
\$60,000	10	15	33.174%	30.473%	27.957%	25.628%	23.476%	19.660%	16.441%
\$60,000	15	15	25.880%	23.306%	20.947%	18.792%	16.829%	13.430%	10.649%
\$60,000	20	15	21.824%	19.279%	16.984%	14.917%	13.061%	9.952%	7.533%
\$60,000	25	15	19.125%	16.623%	14.395%	12.426%	10.696%	7.865%	5.734%
\$60,000	50	15	12.297%	10.041%	8.149%	6.573%	5.272%	3.370%	2.169%
\$60,000	100	15	7.842%	5.899%	4.392%	3.261%	2.421%	1.382%	0.873%
\$60,000	150	15	5.960%	4.223%	2.965%	2.086%	1.492%	0.858%	0.615%
\$60,000	200	15	4.861%	3.282%	2.205%	1.506%	1.073%	0.666%	0.539%
\$60,000	300	15	3.609%	2.267%	1.442%	0.969%	0.717%	0.538%	0.505%
\$60,000	400	15	2.902%	1.728%	1.072%	0.742%	0.592%	0.511%	0.501%
\$60,000	500	15	2.425%	1.391%	0.867%	0.634%	0.545%	0.506%	0.501%
\$60,000	600	15	2.085%	1.170%	0.746%	0.579%	0.522%	0.503%	0.501%
\$60,000	700	15	1.842%	1.021%	0.672%	0.550%	0.514%	0.503%	0.501%
\$60,000	800	15	1.643%	0.907%	0.621%	0.531%	0.508%	0.502%	0.501%
\$60,000	900	15	1.480%	0.823%	0.588%	0.521%	0.506%	0.502%	0.501%
\$60,000	1,000	15	1.351%	0.759%	0.564%	0.514%	0.504%	0.502%	0.501%
\$60,000	1,500	15	0.958%	0.600%	0.519%	0.505%	0.503%	0.502%	0.501%
\$60,000	2,000	15	0.764%	0.543%	0.508%	0.504%	0.503%	0.502%	0.501%
\$60,000	3,000	15	0.596%	0.512%	0.505%	0.504%	0.503%	0.502%	0.501%
\$60,000	4,000	15	0.541%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$60,000	5,000	15	0.520%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$60,000	10,000	15	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$60,000	20,000	15	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$65,000	5	15	50.309%	48.007%	45.790%	43.652%	41.586%	37.649%	33.950%
\$65,000	10	15	34.201%	31.503%	28.973%	26.614%	24.428%	20.542%	17.244%
\$65,000	15	15	26.608%	24.029%	21.660%	19.493%	17.518%	14.089%	11.260%
\$65,000	20	15	22.460%	19.913%	17.611%	15.526%	13.649%	10.485%	8.006%
\$65,000	25	15	19.692%	17.182%	14.940%	12.954%	11.199%	8.310%	6.120%
\$65,000	50	15	12.680%	10.409%	8.492%	6.890%	5.558%	3.594%	2.333%
\$65,000	100	15	8.103%	6.138%	4.602%	3.439%	2.569%	1.476%	0.926%
\$65,000	150	15	6.158%	4.397%	3.111%	2.203%	1.582%	0.906%	0.636%
\$65,000	200	15	5.029%	3.424%	2.318%	1.589%	1.132%	0.692%	0.548%
\$65,000	300	15	3.736%	2.367%	1.513%	1.015%	0.745%	0.545%	0.507%
\$65,000	400	15	3.008%	1.806%	1.122%	0.770%	0.607%	0.513%	0.502%
\$65,000	500	15	2.516%	1.453%	0.902%	0.651%	0.552%	0.507%	0.501%
\$65,000	600	15	2.166%	1.221%	0.773%	0.590%	0.526%	0.503%	0.501%
\$65,000	700	15	1.915%	1.065%	0.693%	0.558%	0.516%	0.503%	0.501%
\$65,000	800	15	1.709%	0.944%	0.637%	0.536%	0.509%	0.502%	0.501%
\$65,000	900	15	1.540%	0.854%	0.600%	0.525%	0.507%	0.502%	0.501%
\$65,000	1,000	15	1.406%	0.786%	0.573%	0.517%	0.505%	0.502%	0.501%
\$65,000	1,500	15	0.995%	0.613%	0.521%	0.506%	0.503%	0.502%	0.501%
\$65,000	2,000	15	0.789%	0.549%	0.509%	0.504%	0.503%	0.502%	0.501%
\$65,000	3,000	15	0.608%	0.514%	0.505%	0.504%	0.503%	0.502%	0.501%
\$65,000	4,000	15	0.546%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$65,000	5,000	15	0.523%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$65,000	10,000	15	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$65,000	20,000	15	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$70,000	5	15	51.224%	48.965%	46.790%	44.693%	42.667%	38.803%	35.177%
\$70,000	10	15	35.181%	32.491%	29.960%	27.584%	25.371%	21.415%	18.037%
\$70,000	15	15	27.306%	24.718%	22.337%	20.159%	18.173%	14.714%	11.847%
\$70,000	20	15	23.058%	20.510%	18.199%	16.100%	14.206%	10.994%	8.460%
\$70,000	25	15	20.228%	17.707%	15.453%	13.453%	11.677%	8.734%	6.489%
\$70,000	50	15	13.047%	10.762%	8.823%	7.195%	5.837%	3.812%	2.495%
\$70,000	100	15	8.352%	6.365%	4.806%	3.612%	2.713%	1.569%	0.980%
\$70,000	150	15	6.348%	4.563%	3.253%	2.318%	1.670%	0.953%	0.657%
\$70,000	200	15	5.188%	3.559%	2.426%	1.671%	1.191%	0.718%	0.558%
\$70,000	300	15	3.857%	2.463%	1.583%	1.062%	0.773%	0.553%	0.508%
\$70,000	400	15	3.108%	1.880%	1.171%	0.799%	0.621%	0.515%	0.502%
\$70,000	500	15	2.602%	1.512%	0.938%	0.669%	0.559%	0.508%	0.501%
\$70,000	600	15	2.243%	1.271%	0.800%	0.602%	0.531%	0.504%	0.501%
\$70,000	700	15	1.985%	1.108%	0.714%	0.566%	0.519%	0.503%	0.501%
\$70,000	800	15	1.772%	0.980%	0.653%	0.542%	0.511%	0.502%	0.501%
\$70,000	900	15	1.598%	0.885%	0.613%	0.529%	0.508%	0.502%	0.501%
\$70,000	1,000	15	1.458%	0.812%	0.583%	0.519%	0.505%	0.502%	0.501%
\$70,000	1,500	15	1.031%	0.626%	0.525%	0.506%	0.503%	0.502%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$70,000	2,000	15	0.815%	0.556%	0.510%	0.504%	0.503%	0.502%	0.501%
\$70,000	3,000	15	0.620%	0.515%	0.505%	0.504%	0.503%	0.502%	0.501%
\$70,000	4,000	15	0.552%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$70,000	5,000	15	0.525%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$70,000	10,000	15	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$70,000	20,000	15	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$75,000	5	15	52.064%	49.845%	47.708%	45.647%	43.653%	39.858%	36.299%
\$75,000	10	15	36.113%	33.439%	30.911%	28.532%	26.300%	22.281%	18.827%
\$75,000	15	15	27.986%	25.382%	22.991%	20.798%	18.797%	15.305%	12.409%
\$75,000	20	15	23.627%	21.080%	18.759%	16.649%	14.742%	11.486%	8.901%
\$75,000	25	15	20.742%	18.211%	15.947%	13.934%	12.140%	9.146%	6.848%
\$75,000	50	15	13.403%	11.104%	9.144%	7.493%	6.110%	4.027%	2.658%
\$75,000	100	15	8.590%	6.583%	5.002%	3.779%	2.854%	1.661%	1.036%
\$75,000	150	15	6.530%	4.725%	3.389%	2.428%	1.757%	1.001%	0.680%
\$75,000	200	15	5.341%	3.690%	2.533%	1.752%	1.250%	0.745%	0.568%
\$75,000	300	15	3.974%	2.556%	1.652%	1.109%	0.801%	0.562%	0.510%
\$75,000	400	15	3.204%	1.952%	1.220%	0.828%	0.636%	0.518%	0.502%
\$75,000	500	15	2.685%	1.571%	0.973%	0.688%	0.567%	0.509%	0.502%
\$75,000	600	15	2.317%	1.320%	0.827%	0.615%	0.536%	0.504%	0.501%
\$75,000	700	15	2.053%	1.150%	0.735%	0.575%	0.522%	0.503%	0.501%
\$75,000	800	15	1.833%	1.016%	0.669%	0.548%	0.513%	0.502%	0.501%
\$75,000	900	15	1.653%	0.915%	0.626%	0.533%	0.509%	0.502%	0.501%
\$75,000	1,000	15	1.509%	0.838%	0.593%	0.522%	0.506%	0.502%	0.501%
\$75,000	1,500	15	1.066%	0.639%	0.528%	0.507%	0.503%	0.502%	0.501%
\$75,000	2,000	15	0.839%	0.562%	0.511%	0.504%	0.503%	0.502%	0.501%
\$75,000	3,000	15	0.633%	0.517%	0.505%	0.504%	0.503%	0.502%	0.501%
\$75,000	4,000	15	0.558%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$75,000	5,000	15	0.528%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$75,000	10,000	15	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$75,000	20,000	15	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$80,000	5	15	52.843%	50.659%	48.557%	46.528%	44.566%	40.832%	37.335%
\$80,000	10	15	36.991%	34.346%	31.829%	29.450%	27.211%	23.144%	19.621%
\$80,000	15	15	28.649%	26.028%	23.624%	21.417%	19.398%	15.871%	12.946%
\$80,000	20	15	24.175%	21.622%	19.293%	17.177%	15.257%	11.963%	9.330%
\$80,000	25	15	21.236%	18.698%	16.424%	14.398%	12.589%	9.548%	7.201%
\$80,000	50	15	13.750%	11.434%	9.456%	7.783%	6.376%	4.238%	2.817%
\$80,000	100	15	8.819%	6.794%	5.192%	3.944%	2.992%	1.753%	1.093%
\$80,000	150	15	6.706%	4.881%	3.522%	2.537%	1.844%	1.050%	0.705%
\$80,000	200	15	5.487%	3.816%	2.636%	1.832%	1.308%	0.773%	0.580%
\$80,000	300	15	4.079%	2.641%	1.714%	1.151%	0.827%	0.569%	0.511%
\$80,000	400	15	3.296%	2.022%	1.267%	0.857%	0.652%	0.522%	0.503%
\$80,000	500	15	2.766%	1.628%	1.008%	0.706%	0.576%	0.510%	0.502%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$80,000	600	15	2.389%	1.368%	0.854%	0.628%	0.541%	0.504%	0.501%
\$80,000	700	15	2.119%	1.191%	0.757%	0.584%	0.525%	0.503%	0.501%
\$80,000	800	15	1.892%	1.051%	0.686%	0.554%	0.515%	0.502%	0.501%
\$80,000	900	15	1.707%	0.945%	0.639%	0.538%	0.510%	0.502%	0.501%
\$80,000	1,000	15	1.557%	0.863%	0.603%	0.525%	0.507%	0.502%	0.501%
\$80,000	1,500	15	1.100%	0.652%	0.531%	0.507%	0.503%	0.502%	0.501%
\$80,000	2,000	15	0.864%	0.569%	0.512%	0.504%	0.503%	0.502%	0.501%
\$80,000	3,000	15	0.645%	0.519%	0.506%	0.504%	0.503%	0.502%	0.501%
\$80,000	4,000	15	0.564%	0.509%	0.505%	0.504%	0.503%	0.502%	0.501%
\$80,000	5,000	15	0.531%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$80,000	10,000	15	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$80,000	20,000	15	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$90,000	5	15	54.193%	52.071%	50.027%	48.052%	46.145%	42.519%	39.130%
\$90,000	10	15	38.554%	35.983%	33.523%	31.170%	28.932%	24.815%	21.191%
\$90,000	15	15	29.911%	27.266%	24.830%	22.592%	20.534%	16.932%	13.937%
\$90,000	20	15	25.190%	22.618%	20.276%	18.148%	16.209%	12.851%	10.140%
\$90,000	25	15	22.151%	19.606%	17.314%	15.262%	13.424%	10.307%	7.869%
\$90,000	50	15	14.398%	12.059%	10.045%	8.331%	6.879%	4.644%	3.126%
\$90,000	100	15	9.245%	7.188%	5.545%	4.253%	3.253%	1.930%	1.205%
\$90,000	150	15	7.033%	5.173%	3.773%	2.745%	2.010%	1.145%	0.754%
\$90,000	200	15	5.759%	4.052%	2.830%	1.985%	1.421%	0.829%	0.603%
\$90,000	300	15	4.287%	2.810%	1.842%	1.240%	0.885%	0.588%	0.516%
\$90,000	400	15	3.467%	2.153%	1.358%	0.913%	0.683%	0.530%	0.504%
\$90,000	500	15	2.914%	1.736%	1.077%	0.744%	0.594%	0.513%	0.502%
\$90,000	600	15	2.522%	1.459%	0.907%	0.654%	0.552%	0.506%	0.501%
\$90,000	700	15	2.240%	1.270%	0.799%	0.603%	0.532%	0.504%	0.501%
\$90,000	800	15	2.001%	1.117%	0.719%	0.567%	0.519%	0.503%	0.501%
\$90,000	900	15	1.807%	1.003%	0.665%	0.547%	0.513%	0.502%	0.501%
\$90,000	1,000	15	1.649%	0.913%	0.624%	0.532%	0.508%	0.502%	0.501%
\$90,000	1,500	15	1.164%	0.678%	0.539%	0.509%	0.503%	0.502%	0.501%
\$90,000	2,000	15	0.911%	0.584%	0.515%	0.505%	0.503%	0.502%	0.501%
\$90,000	3,000	15	0.670%	0.523%	0.506%	0.504%	0.503%	0.502%	0.501%
\$90,000	4,000	15	0.577%	0.510%	0.505%	0.504%	0.503%	0.502%	0.501%
\$90,000	5,000	15	0.538%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$90,000	10,000	15	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$90,000	20,000	15	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$100,000	5	15	55.330%	53.257%	51.260%	49.332%	47.470%	43.936%	40.635%
\$100,000	10	15	39.887%	37.387%	34.996%	32.702%	30.501%	26.390%	22.709%
\$100,000	15	15	31.090%	28.441%	25.981%	23.709%	21.613%	17.934%	14.850%
\$100,000	20	15	26.126%	23.540%	21.178%	19.035%	17.079%	13.673%	10.888%
\$100,000	25	15	22.975%	20.432%	18.126%	16.054%	14.189%	11.016%	8.499%
\$100,000	50	15	14.998%	12.638%	10.595%	8.846%	7.353%	5.034%	3.431%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$100,000	100	15	9.637%	7.552%	5.876%	4.547%	3.505%	2.106%	1.319%
\$100,000	150	15	7.334%	5.445%	4.008%	2.944%	2.172%	1.242%	0.806%
\$100,000	200	15	6.010%	4.272%	3.013%	2.131%	1.532%	0.886%	0.629%
\$100,000	300	15	4.479%	2.968%	1.964%	1.327%	0.943%	0.608%	0.522%
\$100,000	400	15	3.626%	2.277%	1.446%	0.970%	0.716%	0.538%	0.505%
\$100,000	500	15	3.052%	1.839%	1.144%	0.782%	0.613%	0.517%	0.503%
\$100,000	600	15	2.646%	1.546%	0.960%	0.681%	0.565%	0.507%	0.501%
\$100,000	700	15	2.352%	1.344%	0.841%	0.623%	0.540%	0.505%	0.501%
\$100,000	800	15	2.102%	1.181%	0.752%	0.581%	0.524%	0.503%	0.501%
\$100,000	900	15	1.900%	1.058%	0.691%	0.557%	0.516%	0.502%	0.501%
\$100,000	1,000	15	1.734%	0.960%	0.645%	0.539%	0.510%	0.502%	0.501%
\$100,000	1,500	15	1.225%	0.704%	0.547%	0.511%	0.504%	0.502%	0.501%
\$100,000	2,000	15	0.956%	0.599%	0.518%	0.505%	0.503%	0.502%	0.501%
\$100,000	3,000	15	0.695%	0.528%	0.506%	0.504%	0.503%	0.502%	0.501%
\$100,000	4,000	15	0.591%	0.512%	0.505%	0.504%	0.503%	0.502%	0.501%
\$100,000	5,000	15	0.545%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$100,000	10,000	15	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$100,000	20,000	15	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$110,000	5	15	56.292%	54.260%	52.301%	50.412%	48.589%	45.132%	41.904%
\$110,000	10	15	41.027%	38.587%	36.251%	34.013%	31.863%	27.822%	24.129%
\$110,000	15	15	32.157%	29.523%	27.059%	24.762%	22.638%	18.882%	15.710%
\$110,000	20	15	26.984%	24.387%	22.009%	19.836%	17.863%	14.419%	11.575%
\$110,000	25	15	23.714%	21.172%	18.860%	16.771%	14.885%	11.669%	9.090%
\$110,000	50	15	15.541%	13.163%	11.097%	9.320%	7.793%	5.400%	3.724%
\$110,000	100	15	9.994%	7.886%	6.179%	4.818%	3.740%	2.271%	1.431%
\$110,000	150	15	7.609%	5.694%	4.226%	3.128%	2.323%	1.335%	0.857%
\$110,000	200	15	6.240%	4.474%	3.183%	2.267%	1.637%	0.940%	0.655%
\$110,000	300	15	4.653%	3.113%	2.077%	1.409%	1.000%	0.630%	0.528%
\$110,000	400	15	3.770%	2.390%	1.528%	1.024%	0.748%	0.547%	0.507%
\$110,000	500	15	3.178%	1.934%	1.207%	0.820%	0.632%	0.521%	0.504%
\$110,000	600	15	2.759%	1.626%	1.010%	0.708%	0.578%	0.509%	0.502%
\$110,000	700	15	2.454%	1.414%	0.881%	0.643%	0.549%	0.505%	0.501%
\$110,000	800	15	2.194%	1.241%	0.784%	0.596%	0.529%	0.503%	0.501%
\$110,000	900	15	1.985%	1.110%	0.717%	0.568%	0.519%	0.502%	0.501%
\$110,000	1,000	15	1.812%	1.006%	0.665%	0.546%	0.512%	0.502%	0.501%
\$110,000	1,500	15	1.282%	0.730%	0.555%	0.513%	0.504%	0.502%	0.501%
\$110,000	2,000	15	0.998%	0.613%	0.521%	0.506%	0.503%	0.502%	0.501%
\$110,000	3,000	15	0.719%	0.533%	0.507%	0.504%	0.503%	0.502%	0.501%
\$110,000	4,000	15	0.604%	0.513%	0.505%	0.504%	0.503%	0.502%	0.501%
\$110,000	5,000	15	0.552%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$110,000	10,000	15	0.508%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$110,000	20,000	15	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$120,000	5	15	57.112%	55.114%	53.189%	51.332%	49.542%	46.151%	42.982%
\$120,000	10	15	41.995%	39.605%	37.316%	35.123%	33.018%	29.063%	25.418%
\$120,000	15	15	33.113%	30.498%	28.042%	25.740%	23.599%	19.776%	16.526%
\$120,000	20	15	27.783%	25.179%	22.783%	20.589%	18.587%	15.104%	12.218%
\$120,000	25	15	24.395%	21.849%	19.534%	17.432%	15.529%	12.275%	9.645%
\$120,000	50	15	16.042%	13.650%	11.565%	9.759%	8.204%	5.746%	4.001%
\$120,000	100	15	10.324%	8.197%	6.462%	5.070%	3.961%	2.429%	1.537%
\$120,000	150	15	7.864%	5.925%	4.428%	3.300%	2.464%	1.424%	0.907%
\$120,000	200	15	6.453%	4.662%	3.342%	2.395%	1.736%	0.993%	0.680%
\$120,000	300	15	4.813%	3.247%	2.183%	1.487%	1.054%	0.652%	0.535%
\$120,000	400	15	3.903%	2.496%	1.605%	1.076%	0.780%	0.556%	0.509%
\$120,000	500	15	3.293%	2.022%	1.267%	0.856%	0.651%	0.525%	0.504%
\$120,000	600	15	2.861%	1.700%	1.057%	0.734%	0.590%	0.511%	0.502%
\$120,000	700	15	2.546%	1.478%	0.919%	0.662%	0.557%	0.506%	0.501%
\$120,000	800	15	2.279%	1.296%	0.815%	0.610%	0.534%	0.504%	0.501%
\$120,000	900	15	2.063%	1.159%	0.742%	0.578%	0.523%	0.503%	0.501%
\$120,000	1,000	15	1.884%	1.048%	0.686%	0.554%	0.514%	0.502%	0.501%
\$120,000	1,500	15	1.334%	0.754%	0.563%	0.515%	0.504%	0.502%	0.501%
\$120,000	2,000	15	1.038%	0.628%	0.525%	0.506%	0.503%	0.502%	0.501%
\$120,000	3,000	15	0.741%	0.538%	0.507%	0.504%	0.503%	0.502%	0.501%
\$120,000	4,000	15	0.616%	0.515%	0.505%	0.504%	0.503%	0.502%	0.501%
\$120,000	5,000	15	0.559%	0.509%	0.505%	0.504%	0.503%	0.502%	0.501%
\$120,000	10,000	15	0.508%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$120,000	20,000	15	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$130,000	5	15	57.804%	55.834%	53.937%	52.108%	50.347%	47.010%	43.893%
\$130,000	10	15	42.834%	40.485%	38.237%	36.082%	34.017%	30.138%	26.564%
\$130,000	15	15	33.976%	31.390%	28.948%	26.654%	24.512%	20.642%	17.324%
\$130,000	20	15	28.537%	25.934%	23.526%	21.314%	19.284%	15.757%	12.829%
\$130,000	25	15	25.041%	22.489%	20.168%	18.050%	16.131%	12.842%	10.171%
\$130,000	50	15	16.505%	14.105%	12.003%	10.171%	8.590%	6.074%	4.268%
\$130,000	100	15	10.632%	8.487%	6.728%	5.308%	4.170%	2.581%	1.642%
\$130,000	150	15	8.103%	6.142%	4.621%	3.463%	2.601%	1.511%	0.957%
\$130,000	200	15	6.653%	4.840%	3.493%	2.518%	1.833%	1.046%	0.707%
\$130,000	300	15	4.965%	3.374%	2.285%	1.562%	1.108%	0.674%	0.542%
\$130,000	400	15	4.022%	2.592%	1.676%	1.122%	0.809%	0.564%	0.510%
\$130,000	500	15	3.401%	2.105%	1.325%	0.892%	0.671%	0.530%	0.505%
\$130,000	600	15	2.957%	1.770%	1.103%	0.760%	0.603%	0.513%	0.502%
\$130,000	700	15	2.633%	1.539%	0.956%	0.682%	0.566%	0.508%	0.501%
\$130,000	800	15	2.357%	1.349%	0.844%	0.624%	0.540%	0.504%	0.501%
\$130,000	900	15	2.135%	1.205%	0.766%	0.589%	0.527%	0.503%	0.501%
\$130,000	1,000	15	1.951%	1.089%	0.705%	0.562%	0.516%	0.502%	0.501%
\$130,000	1,500	15	1.384%	0.777%	0.571%	0.517%	0.505%	0.502%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$130,000	2,000	15	1.076%	0.642%	0.528%	0.507%	0.503%	0.502%	0.501%
\$130,000	3,000	15	0.763%	0.543%	0.508%	0.504%	0.503%	0.502%	0.501%
\$130,000	4,000	15	0.629%	0.517%	0.505%	0.504%	0.503%	0.502%	0.501%
\$130,000	5,000	15	0.567%	0.509%	0.505%	0.504%	0.503%	0.502%	0.501%
\$130,000	10,000	15	0.508%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$130,000	20,000	15	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$140,000	5	15	58.417%	56.472%	54.600%	52.796%	51.060%	47.771%	44.700%
\$140,000	10	15	43.589%	41.275%	39.063%	36.943%	34.914%	31.101%	27.592%
\$140,000	15	15	34.763%	32.219%	29.804%	27.526%	25.387%	21.499%	18.130%
\$140,000	20	15	29.271%	26.666%	24.256%	22.029%	19.979%	16.399%	13.428%
\$140,000	25	15	25.666%	23.109%	20.778%	18.647%	16.710%	13.386%	10.681%
\$140,000	50	15	16.945%	14.539%	12.422%	10.568%	8.960%	6.391%	4.531%
\$140,000	100	15	10.923%	8.765%	6.984%	5.538%	4.374%	2.732%	1.745%
\$140,000	150	15	8.332%	6.351%	4.808%	3.624%	2.736%	1.598%	1.010%
\$140,000	200	15	6.845%	5.011%	3.639%	2.638%	1.928%	1.100%	0.734%
\$140,000	300	15	5.111%	3.499%	2.384%	1.638%	1.161%	0.697%	0.550%
\$140,000	400	15	4.143%	2.689%	1.748%	1.172%	0.841%	0.574%	0.513%
\$140,000	500	15	3.505%	2.185%	1.382%	0.928%	0.692%	0.535%	0.506%
\$140,000	600	15	3.050%	1.838%	1.148%	0.787%	0.617%	0.516%	0.502%
\$140,000	700	15	2.716%	1.598%	0.993%	0.701%	0.575%	0.509%	0.501%
\$140,000	800	15	2.432%	1.400%	0.874%	0.639%	0.546%	0.505%	0.501%
\$140,000	900	15	2.204%	1.249%	0.790%	0.600%	0.531%	0.503%	0.501%
\$140,000	1,000	15	2.016%	1.129%	0.725%	0.570%	0.519%	0.502%	0.501%
\$140,000	1,500	15	1.431%	0.800%	0.580%	0.519%	0.505%	0.502%	0.501%
\$140,000	2,000	15	1.112%	0.656%	0.532%	0.507%	0.503%	0.502%	0.501%
\$140,000	3,000	15	0.785%	0.548%	0.509%	0.504%	0.503%	0.502%	0.501%
\$140,000	4,000	15	0.642%	0.519%	0.506%	0.504%	0.503%	0.502%	0.501%
\$140,000	5,000	15	0.574%	0.510%	0.505%	0.504%	0.503%	0.502%	0.501%
\$140,000	10,000	15	0.508%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$140,000	20,000	15	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$150,000	5	15	58.943%	57.020%	55.169%	53.388%	51.673%	48.425%	45.393%
\$150,000	10	15	44.242%	41.961%	39.779%	37.689%	35.690%	31.936%	28.483%
\$150,000	15	15	35.457%	32.953%	30.576%	28.327%	26.199%	22.308%	18.909%
\$150,000	20	15	29.946%	27.352%	24.939%	22.703%	20.639%	17.015%	13.995%
\$150,000	25	15	26.250%	23.693%	21.349%	19.207%	17.254%	13.897%	11.156%
\$150,000	50	15	17.349%	14.938%	12.807%	10.939%	9.309%	6.689%	4.780%
\$150,000	100	15	11.191%	9.020%	7.220%	5.753%	4.565%	2.875%	1.846%
\$150,000	150	15	8.545%	6.547%	4.982%	3.775%	2.864%	1.683%	1.063%
\$150,000	200	15	7.023%	5.170%	3.775%	2.752%	2.018%	1.151%	0.761%
\$150,000	300	15	5.248%	3.616%	2.479%	1.710%	1.213%	0.720%	0.559%
\$150,000	400	15	4.257%	2.782%	1.818%	1.221%	0.872%	0.584%	0.516%
\$150,000	500	15	3.602%	2.262%	1.436%	0.964%	0.712%	0.540%	0.508%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$150,000	600	15	3.137%	1.904%	1.192%	0.813%	0.630%	0.519%	0.503%
\$150,000	700	15	2.795%	1.654%	1.029%	0.721%	0.584%	0.511%	0.502%
\$150,000	800	15	2.504%	1.449%	0.903%	0.654%	0.552%	0.506%	0.501%
\$150,000	900	15	2.270%	1.292%	0.814%	0.611%	0.535%	0.504%	0.501%
\$150,000	1,000	15	2.076%	1.167%	0.745%	0.578%	0.522%	0.503%	0.501%
\$150,000	1,500	15	1.476%	0.823%	0.588%	0.521%	0.506%	0.502%	0.501%
\$150,000	2,000	15	1.146%	0.670%	0.536%	0.508%	0.503%	0.502%	0.501%
\$150,000	3,000	15	0.806%	0.554%	0.510%	0.504%	0.503%	0.502%	0.501%
\$150,000	4,000	15	0.654%	0.521%	0.506%	0.504%	0.503%	0.502%	0.501%
\$150,000	5,000	15	0.581%	0.511%	0.505%	0.504%	0.503%	0.502%	0.501%
\$150,000	10,000	15	0.509%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$150,000	20,000	15	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$160,000	5	15	59.423%	57.520%	55.689%	53.928%	52.232%	49.020%	46.023%
\$160,000	10	15	44.825%	42.572%	40.417%	38.355%	36.382%	32.681%	29.277%
\$160,000	15	15	36.080%	33.611%	31.271%	29.055%	26.950%	23.072%	19.657%
\$160,000	20	15	30.578%	27.998%	25.594%	23.352%	21.279%	17.621%	14.550%
\$160,000	25	15	26.811%	24.253%	21.902%	19.746%	17.781%	14.389%	11.611%
\$160,000	50	15	17.731%	15.313%	13.170%	11.289%	9.641%	6.977%	5.021%
\$160,000	100	15	11.442%	9.259%	7.443%	5.957%	4.748%	3.013%	1.943%
\$160,000	150	15	8.744%	6.730%	5.146%	3.918%	2.984%	1.764%	1.113%
\$160,000	200	15	7.190%	5.320%	3.904%	2.859%	2.105%	1.201%	0.788%
\$160,000	300	15	5.377%	3.728%	2.569%	1.780%	1.263%	0.744%	0.568%
\$160,000	400	15	4.364%	2.870%	1.885%	1.267%	0.902%	0.595%	0.519%
\$160,000	500	15	3.694%	2.334%	1.489%	0.998%	0.732%	0.545%	0.509%
\$160,000	600	15	3.219%	1.966%	1.234%	0.839%	0.644%	0.522%	0.503%
\$160,000	700	15	2.869%	1.708%	1.063%	0.741%	0.594%	0.512%	0.502%
\$160,000	800	15	2.571%	1.496%	0.931%	0.669%	0.559%	0.506%	0.501%
\$160,000	900	15	2.332%	1.333%	0.837%	0.622%	0.539%	0.504%	0.501%
\$160,000	1,000	15	2.133%	1.203%	0.764%	0.586%	0.525%	0.503%	0.501%
\$160,000	1,500	15	1.519%	0.845%	0.597%	0.524%	0.506%	0.502%	0.501%
\$160,000	2,000	15	1.179%	0.684%	0.540%	0.509%	0.503%	0.502%	0.501%
\$160,000	3,000	15	0.826%	0.559%	0.510%	0.504%	0.503%	0.502%	0.501%
\$160,000	4,000	15	0.666%	0.523%	0.506%	0.504%	0.503%	0.502%	0.501%
\$160,000	5,000	15	0.588%	0.511%	0.505%	0.504%	0.503%	0.502%	0.501%
\$160,000	10,000	15	0.509%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$160,000	20,000	15	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$170,000	5	15	59.859%	57.974%	56.160%	54.417%	52.739%	49.560%	46.594%
\$170,000	10	15	45.354%	43.126%	40.995%	38.958%	37.008%	33.354%	29.994%
\$170,000	15	15	36.648%	34.211%	31.903%	29.719%	27.641%	23.799%	20.379%
\$170,000	20	15	31.168%	28.609%	26.216%	23.977%	21.901%	18.216%	15.101%
\$170,000	25	15	27.352%	24.796%	22.440%	20.274%	18.298%	14.871%	12.054%
\$170,000	50	15	18.094%	15.671%	13.521%	11.625%	9.962%	7.257%	5.257%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$170,000	100	15	11.682%	9.487%	7.658%	6.155%	4.925%	3.147%	2.039%
\$170,000	150	15	8.931%	6.903%	5.301%	4.053%	3.100%	1.842%	1.162%
\$170,000	200	15	7.349%	5.462%	4.028%	2.962%	2.188%	1.249%	0.814%
\$170,000	300	15	5.499%	3.834%	2.655%	1.848%	1.312%	0.767%	0.577%
\$170,000	400	15	4.466%	2.953%	1.949%	1.313%	0.933%	0.605%	0.522%
\$170,000	500	15	3.783%	2.404%	1.540%	1.033%	0.753%	0.551%	0.510%
\$170,000	600	15	3.297%	2.026%	1.275%	0.864%	0.658%	0.525%	0.503%
\$170,000	700	15	2.940%	1.760%	1.097%	0.760%	0.604%	0.514%	0.502%
\$170,000	800	15	2.635%	1.541%	0.959%	0.683%	0.566%	0.507%	0.501%
\$170,000	900	15	2.391%	1.373%	0.860%	0.633%	0.544%	0.505%	0.501%
\$170,000	1,000	15	2.188%	1.239%	0.783%	0.595%	0.528%	0.503%	0.501%
\$170,000	1,500	15	1.560%	0.866%	0.605%	0.526%	0.507%	0.502%	0.501%
\$170,000	2,000	15	1.210%	0.697%	0.544%	0.510%	0.503%	0.502%	0.501%
\$170,000	3,000	15	0.846%	0.565%	0.511%	0.504%	0.503%	0.502%	0.501%
\$170,000	4,000	15	0.678%	0.525%	0.506%	0.504%	0.503%	0.502%	0.501%
\$170,000	5,000	15	0.596%	0.512%	0.505%	0.504%	0.503%	0.502%	0.501%
\$170,000	10,000	15	0.509%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$170,000	20,000	15	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$180,000	5	15	60.267%	58.398%	56.601%	54.874%	53.213%	50.064%	47.127%
\$180,000	10	15	45.840%	43.636%	41.526%	39.512%	37.584%	33.973%	30.654%
\$180,000	15	15	37.173%	34.765%	32.489%	30.331%	28.280%	24.488%	21.081%
\$180,000	20	15	31.722%	29.189%	26.810%	24.580%	22.505%	18.804%	15.652%
\$180,000	25	15	27.872%	25.323%	22.964%	20.793%	18.806%	15.350%	12.493%
\$180,000	50	15	18.446%	16.018%	13.861%	11.954%	10.276%	7.536%	5.493%
\$180,000	100	15	11.911%	9.706%	7.865%	6.345%	5.097%	3.280%	2.134%
\$180,000	150	15	9.110%	7.070%	5.451%	4.184%	3.212%	1.919%	1.212%
\$180,000	200	15	7.501%	5.600%	4.147%	3.063%	2.270%	1.298%	0.840%
\$180,000	300	15	5.615%	3.935%	2.738%	1.913%	1.362%	0.792%	0.587%
\$180,000	400	15	4.563%	3.033%	2.011%	1.358%	0.963%	0.616%	0.525%
\$180,000	500	15	3.860%	2.465%	1.585%	1.063%	0.771%	0.555%	0.511%
\$180,000	600	15	3.373%	2.084%	1.315%	0.890%	0.672%	0.529%	0.504%
\$180,000	700	15	3.009%	1.811%	1.131%	0.780%	0.615%	0.516%	0.502%
\$180,000	800	15	2.698%	1.586%	0.987%	0.698%	0.573%	0.508%	0.501%
\$180,000	900	15	2.449%	1.413%	0.883%	0.644%	0.549%	0.505%	0.501%
\$180,000	1,000	15	2.241%	1.274%	0.802%	0.604%	0.532%	0.503%	0.501%
\$180,000	1,500	15	1.600%	0.887%	0.614%	0.529%	0.508%	0.502%	0.501%
\$180,000	2,000	15	1.241%	0.711%	0.548%	0.510%	0.504%	0.502%	0.501%
\$180,000	3,000	15	0.866%	0.570%	0.512%	0.504%	0.503%	0.502%	0.501%
\$180,000	4,000	15	0.690%	0.527%	0.506%	0.504%	0.503%	0.502%	0.501%
\$180,000	5,000	15	0.603%	0.513%	0.505%	0.504%	0.503%	0.502%	0.501%
\$180,000	10,000	15	0.510%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$180,000	20,000	15	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$190,000	5	15	60.640%	58.787%	57.005%	55.293%	53.646%	50.524%	47.614%
\$190,000	10	15	46.286%	44.102%	42.014%	40.020%	38.112%	34.539%	31.256%
\$190,000	15	15	37.652%	35.272%	33.023%	30.890%	28.864%	25.121%	21.745%
\$190,000	20	15	32.233%	29.728%	27.368%	25.152%	23.084%	19.376%	16.195%
\$190,000	25	15	28.367%	25.827%	23.469%	21.295%	19.301%	15.818%	12.921%
\$190,000	50	15	18.779%	16.348%	14.187%	12.268%	10.577%	7.806%	5.724%
\$190,000	100	15	12.128%	9.915%	8.061%	6.526%	5.263%	3.408%	2.228%
\$190,000	150	15	9.280%	7.229%	5.595%	4.310%	3.322%	1.995%	1.261%
\$190,000	200	15	7.645%	5.731%	4.262%	3.159%	2.349%	1.345%	0.866%
\$190,000	300	15	5.725%	4.032%	2.818%	1.978%	1.410%	0.816%	0.597%
\$190,000	400	15	4.655%	3.110%	2.071%	1.402%	0.994%	0.628%	0.529%
\$190,000	500	15	3.940%	2.530%	1.633%	1.096%	0.792%	0.561%	0.512%
\$190,000	600	15	3.444%	2.140%	1.355%	0.915%	0.687%	0.532%	0.505%
\$190,000	700	15	3.074%	1.860%	1.164%	0.800%	0.625%	0.518%	0.502%
\$190,000	800	15	2.758%	1.629%	1.014%	0.713%	0.580%	0.510%	0.501%
\$190,000	900	15	2.504%	1.451%	0.905%	0.655%	0.554%	0.506%	0.501%
\$190,000	1,000	15	2.292%	1.308%	0.821%	0.613%	0.535%	0.504%	0.501%
\$190,000	1,500	15	1.638%	0.908%	0.623%	0.532%	0.508%	0.502%	0.501%
\$190,000	2,000	15	1.271%	0.724%	0.552%	0.511%	0.504%	0.502%	0.501%
\$190,000	3,000	15	0.885%	0.576%	0.513%	0.505%	0.503%	0.502%	0.501%
\$190,000	4,000	15	0.701%	0.529%	0.507%	0.504%	0.503%	0.502%	0.501%
\$190,000	5,000	15	0.611%	0.514%	0.505%	0.504%	0.503%	0.502%	0.501%
\$190,000	10,000	15	0.510%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$190,000	20,000	15	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$200,000	5	15	60.981%	59.141%	57.374%	55.675%	54.040%	50.944%	48.058%
\$200,000	10	15	46.695%	44.529%	42.460%	40.485%	38.594%	35.056%	31.807%
\$200,000	15	15	38.092%	35.737%	33.512%	31.402%	29.398%	25.700%	22.362%
\$200,000	20	15	32.698%	30.222%	27.885%	25.686%	23.630%	19.924%	16.722%
\$200,000	25	15	28.828%	26.300%	23.948%	21.774%	19.778%	16.272%	13.338%
\$200,000	50	15	19.093%	16.659%	14.494%	12.567%	10.865%	8.066%	5.950%
\$200,000	100	15	12.333%	10.112%	8.248%	6.699%	5.421%	3.533%	2.320%
\$200,000	150	15	9.440%	7.379%	5.733%	4.432%	3.427%	2.070%	1.309%
\$200,000	200	15	7.783%	5.856%	4.372%	3.253%	2.425%	1.393%	0.892%
\$200,000	300	15	5.831%	4.125%	2.896%	2.039%	1.458%	0.840%	0.607%
\$200,000	400	15	4.743%	3.184%	2.129%	1.446%	1.023%	0.639%	0.532%
\$200,000	500	15	4.018%	2.593%	1.680%	1.129%	0.813%	0.568%	0.514%
\$200,000	600	15	3.513%	2.194%	1.393%	0.939%	0.701%	0.536%	0.505%
\$200,000	700	15	3.136%	1.906%	1.195%	0.819%	0.635%	0.521%	0.503%
\$200,000	800	15	2.815%	1.670%	1.041%	0.728%	0.587%	0.511%	0.502%
\$200,000	900	15	2.557%	1.487%	0.927%	0.666%	0.559%	0.507%	0.501%
\$200,000	1,000	15	2.341%	1.341%	0.840%	0.622%	0.539%	0.504%	0.501%
\$200,000	1,500	15	1.675%	0.928%	0.631%	0.535%	0.509%	0.502%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$200,000	2,000	15	1.300%	0.737%	0.557%	0.513%	0.504%	0.502%	0.501%
\$200,000	3,000	15	0.903%	0.582%	0.515%	0.505%	0.503%	0.502%	0.501%
\$200,000	4,000	15	0.713%	0.532%	0.507%	0.504%	0.503%	0.502%	0.501%
\$200,000	5,000	15	0.618%	0.515%	0.505%	0.504%	0.503%	0.502%	0.501%
\$200,000	10,000	15	0.510%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$200,000	20,000	15	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$225,000	5	15	61.705%	59.894%	58.156%	56.486%	54.878%	51.834%	49.000%
\$225,000	10	15	47.566%	45.439%	43.411%	41.473%	39.621%	36.156%	32.980%
\$225,000	15	15	39.037%	36.736%	34.562%	32.498%	30.543%	26.938%	23.687%
\$225,000	20	15	33.701%	31.283%	29.003%	26.860%	24.847%	21.182%	17.967%
\$225,000	25	15	29.846%	27.359%	25.036%	22.876%	20.883%	17.343%	14.341%
\$225,000	50	15	19.812%	17.377%	15.199%	13.256%	11.531%	8.667%	6.479%
\$225,000	100	15	12.808%	10.571%	8.684%	7.104%	5.792%	3.831%	2.541%
\$225,000	150	15	9.814%	7.732%	6.055%	4.719%	3.675%	2.248%	1.428%
\$225,000	200	15	8.106%	6.153%	4.633%	3.475%	2.609%	1.509%	0.958%
\$225,000	300	15	6.080%	4.345%	3.081%	2.186%	1.571%	0.901%	0.634%
\$225,000	400	15	4.949%	3.359%	2.267%	1.549%	1.095%	0.668%	0.542%
\$225,000	500	15	4.197%	2.739%	1.791%	1.207%	0.863%	0.584%	0.518%
\$225,000	600	15	3.671%	2.318%	1.483%	0.999%	0.737%	0.546%	0.508%
\$225,000	700	15	3.277%	2.014%	1.269%	0.864%	0.660%	0.526%	0.504%
\$225,000	800	15	2.945%	1.765%	1.102%	0.763%	0.606%	0.514%	0.502%
\$225,000	900	15	2.676%	1.571%	0.979%	0.693%	0.572%	0.508%	0.501%
\$225,000	1,000	15	2.453%	1.416%	0.885%	0.644%	0.548%	0.505%	0.501%
\$225,000	1,500	15	1.759%	0.976%	0.652%	0.542%	0.511%	0.502%	0.501%
\$225,000	2,000	15	1.366%	0.769%	0.567%	0.515%	0.504%	0.502%	0.501%
\$225,000	3,000	15	0.945%	0.596%	0.517%	0.505%	0.503%	0.502%	0.501%
\$225,000	4,000	15	0.740%	0.538%	0.508%	0.504%	0.503%	0.502%	0.501%
\$225,000	5,000	15	0.635%	0.518%	0.506%	0.504%	0.503%	0.502%	0.501%
\$225,000	10,000	15	0.511%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$225,000	20,000	15	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$250,000	5	15	62.294%	60.508%	58.793%	57.147%	55.561%	52.559%	49.768%
\$250,000	10	15	48.289%	46.195%	44.201%	42.294%	40.475%	37.070%	33.952%
\$250,000	15	15	39.821%	37.564%	35.430%	33.406%	31.491%	27.961%	24.781%
\$250,000	20	15	34.536%	32.165%	29.933%	27.839%	25.873%	22.283%	19.097%
\$250,000	25	15	30.702%	28.263%	25.981%	23.853%	21.876%	18.328%	15.287%
\$250,000	50	15	20.459%	18.026%	15.839%	13.882%	12.138%	9.222%	6.970%
\$250,000	100	15	13.238%	10.990%	9.082%	7.477%	6.134%	4.109%	2.755%
\$250,000	150	15	10.154%	8.054%	6.352%	4.984%	3.906%	2.418%	1.544%
\$250,000	200	15	8.397%	6.423%	4.872%	3.681%	2.782%	1.621%	1.024%
\$250,000	300	15	6.305%	4.544%	3.249%	2.322%	1.679%	0.959%	0.661%
\$250,000	400	15	5.136%	3.519%	2.395%	1.646%	1.165%	0.698%	0.552%
\$250,000	500	15	4.360%	2.873%	1.894%	1.281%	0.913%	0.601%	0.523%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$250,000	600	15	3.814%	2.433%	1.567%	1.056%	0.772%	0.556%	0.510%
\$250,000	700	15	3.405%	2.113%	1.338%	0.908%	0.686%	0.532%	0.505%
\$250,000	800	15	3.062%	1.853%	1.161%	0.798%	0.625%	0.518%	0.502%
\$250,000	900	15	2.784%	1.649%	1.028%	0.721%	0.585%	0.511%	0.502%
\$250,000	1,000	15	2.553%	1.487%	0.927%	0.666%	0.558%	0.506%	0.501%
\$250,000	1,500	15	1.835%	1.020%	0.673%	0.550%	0.514%	0.502%	0.501%
\$250,000	2,000	15	1.427%	0.799%	0.578%	0.518%	0.505%	0.502%	0.501%
\$250,000	3,000	15	0.985%	0.609%	0.521%	0.505%	0.503%	0.502%	0.501%
\$250,000	4,000	15	0.767%	0.544%	0.508%	0.504%	0.503%	0.502%	0.501%
\$250,000	5,000	15	0.652%	0.521%	0.506%	0.504%	0.503%	0.502%	0.501%
\$250,000	10,000	15	0.513%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$250,000	20,000	15	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$275,000	5	15	62.780%	61.013%	59.318%	57.690%	56.122%	53.156%	50.399%
\$275,000	10	15	48.865%	46.798%	44.829%	42.949%	41.155%	37.798%	34.727%
\$275,000	15	15	40.457%	38.236%	36.133%	34.142%	32.260%	28.790%	25.667%
\$275,000	20	15	35.228%	32.895%	30.703%	28.649%	26.722%	23.201%	20.073%
\$275,000	25	15	31.397%	29.001%	26.762%	24.673%	22.724%	19.195%	16.138%
\$275,000	50	15	21.033%	18.603%	16.413%	14.445%	12.686%	9.729%	7.426%
\$275,000	100	15	13.625%	11.369%	9.445%	7.819%	6.449%	4.367%	2.956%
\$275,000	150	15	10.460%	8.346%	6.622%	5.228%	4.120%	2.576%	1.655%
\$275,000	200	15	8.653%	6.662%	5.087%	3.869%	2.940%	1.726%	1.087%
\$275,000	300	15	6.502%	4.720%	3.399%	2.446%	1.777%	1.015%	0.689%
\$275,000	400	15	5.301%	3.662%	2.509%	1.734%	1.230%	0.726%	0.562%
\$275,000	500	15	4.504%	2.992%	1.987%	1.349%	0.959%	0.619%	0.527%
\$275,000	600	15	3.932%	2.528%	1.637%	1.104%	0.803%	0.565%	0.512%
\$275,000	700	15	3.518%	2.201%	1.402%	0.949%	0.710%	0.539%	0.506%
\$275,000	800	15	3.165%	1.931%	1.213%	0.830%	0.643%	0.522%	0.503%
\$275,000	900	15	2.880%	1.719%	1.074%	0.747%	0.599%	0.513%	0.502%
\$275,000	1,000	15	2.643%	1.550%	0.967%	0.688%	0.568%	0.508%	0.501%
\$275,000	1,500	15	1.902%	1.061%	0.693%	0.558%	0.517%	0.502%	0.501%
\$275,000	2,000	15	1.481%	0.826%	0.589%	0.521%	0.506%	0.502%	0.501%
\$275,000	3,000	15	1.022%	0.623%	0.524%	0.506%	0.503%	0.502%	0.501%
\$275,000	4,000	15	0.791%	0.550%	0.509%	0.504%	0.503%	0.502%	0.501%
\$275,000	5,000	15	0.669%	0.524%	0.506%	0.504%	0.503%	0.502%	0.501%
\$275,000	10,000	15	0.514%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$275,000	20,000	15	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$300,000	5	15	63.148%	61.397%	59.718%	58.103%	56.549%	53.610%	50.880%
\$300,000	10	15	49.309%	47.265%	45.316%	43.456%	41.681%	38.362%	35.329%
\$300,000	15	15	40.962%	38.768%	36.690%	34.725%	32.868%	29.446%	26.369%
\$300,000	20	15	35.780%	33.477%	31.318%	29.294%	27.397%	23.930%	20.853%
\$300,000	25	15	31.951%	29.590%	27.385%	25.330%	23.411%	19.925%	16.875%
\$300,000	50	15	21.514%	19.091%	16.900%	14.928%	13.158%	10.172%	7.827%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$300,000	100	15	13.962%	11.700%	9.764%	8.122%	6.733%	4.600%	3.143%
\$300,000	150	15	10.729%	8.604%	6.860%	5.446%	4.314%	2.721%	1.757%
\$300,000	200	15	8.878%	6.873%	5.279%	4.036%	3.083%	1.822%	1.147%
\$300,000	300	15	6.673%	4.873%	3.531%	2.555%	1.864%	1.065%	0.714%
\$300,000	400	15	5.445%	3.786%	2.610%	1.812%	1.288%	0.753%	0.572%
\$300,000	500	15	4.628%	3.097%	2.069%	1.409%	1.001%	0.635%	0.533%
\$300,000	600	15	4.040%	2.616%	1.703%	1.150%	0.833%	0.575%	0.515%
\$300,000	700	15	3.616%	2.279%	1.458%	0.986%	0.733%	0.545%	0.507%
\$300,000	800	15	3.255%	1.999%	1.261%	0.860%	0.659%	0.526%	0.504%
\$300,000	900	15	2.964%	1.781%	1.115%	0.771%	0.611%	0.516%	0.502%
\$300,000	1,000	15	2.721%	1.607%	1.003%	0.708%	0.578%	0.509%	0.501%
\$300,000	1,500	15	1.961%	1.097%	0.711%	0.565%	0.519%	0.503%	0.501%
\$300,000	2,000	15	1.529%	0.851%	0.599%	0.524%	0.506%	0.502%	0.501%
\$300,000	3,000	15	1.054%	0.635%	0.527%	0.506%	0.503%	0.502%	0.501%
\$300,000	4,000	15	0.813%	0.556%	0.510%	0.504%	0.503%	0.502%	0.501%
\$300,000	5,000	15	0.684%	0.527%	0.506%	0.504%	0.503%	0.502%	0.501%
\$300,000	10,000	15	0.515%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$300,000	20,000	15	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$325,000	5	15	63.455%	61.717%	60.050%	58.447%	56.905%	53.988%	51.281%
\$325,000	10	15	49.674%	47.647%	45.714%	43.871%	42.112%	38.825%	35.823%
\$325,000	15	15	41.381%	39.209%	37.152%	35.209%	33.374%	29.991%	26.951%
\$325,000	20	15	36.247%	33.970%	31.838%	29.841%	27.968%	24.546%	21.512%
\$325,000	25	15	32.415%	30.082%	27.906%	25.880%	23.987%	20.548%	17.529%
\$325,000	50	15	21.940%	19.524%	17.336%	15.361%	13.584%	10.574%	8.196%
\$325,000	100	15	14.265%	11.998%	10.052%	8.395%	6.990%	4.816%	3.317%
\$325,000	150	15	10.972%	8.837%	7.078%	5.644%	4.491%	2.854%	1.851%
\$325,000	200	15	9.083%	7.066%	5.455%	4.191%	3.217%	1.914%	1.206%
\$325,000	300	15	6.828%	5.012%	3.651%	2.656%	1.945%	1.113%	0.740%
\$325,000	400	15	5.576%	3.899%	2.704%	1.886%	1.342%	0.779%	0.583%
\$325,000	500	15	4.741%	3.193%	2.146%	1.465%	1.041%	0.652%	0.538%
\$325,000	600	15	4.139%	2.698%	1.765%	1.194%	0.862%	0.585%	0.518%
\$325,000	700	15	3.707%	2.351%	1.511%	1.022%	0.755%	0.552%	0.509%
\$325,000	800	15	3.338%	2.062%	1.305%	0.888%	0.676%	0.531%	0.504%
\$325,000	900	15	3.040%	1.839%	1.153%	0.794%	0.623%	0.518%	0.503%
\$325,000	1,000	15	2.793%	1.659%	1.037%	0.727%	0.588%	0.511%	0.502%
\$325,000	1,500	15	2.015%	1.131%	0.728%	0.573%	0.522%	0.503%	0.501%
\$325,000	2,000	15	1.572%	0.874%	0.608%	0.527%	0.507%	0.502%	0.501%
\$325,000	3,000	15	1.084%	0.646%	0.530%	0.507%	0.503%	0.502%	0.501%
\$325,000	4,000	15	0.835%	0.562%	0.511%	0.504%	0.503%	0.502%	0.501%
\$325,000	5,000	15	0.698%	0.529%	0.507%	0.504%	0.503%	0.502%	0.501%
\$325,000	10,000	15	0.517%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$325,000	20,000	15	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$350,000	5	15	63.712%	61.985%	60.329%	58.736%	57.203%	54.307%	51.618%
\$350,000	10	15	49.984%	47.972%	46.054%	44.225%	42.480%	39.220%	36.245%
\$350,000	15	15	41.739%	39.585%	37.547%	35.623%	33.805%	30.456%	27.449%
\$350,000	20	15	36.651%	34.398%	32.289%	30.314%	28.463%	25.080%	22.083%
\$350,000	25	15	32.818%	30.510%	28.359%	26.357%	24.486%	21.088%	18.107%
\$350,000	50	15	22.332%	19.926%	17.743%	15.769%	13.987%	10.959%	8.552%
\$350,000	100	15	14.551%	12.281%	10.327%	8.658%	7.236%	5.028%	3.488%
\$350,000	150	15	11.205%	9.061%	7.286%	5.836%	4.662%	2.985%	1.944%
\$350,000	200	15	9.277%	7.249%	5.623%	4.341%	3.346%	2.005%	1.264%
\$350,000	300	15	6.976%	5.146%	3.767%	2.754%	2.024%	1.160%	0.766%
\$350,000	400	15	5.701%	4.008%	2.796%	1.957%	1.396%	0.805%	0.594%
\$350,000	500	15	4.849%	3.285%	2.219%	1.520%	1.081%	0.669%	0.544%
\$350,000	600	15	4.234%	2.775%	1.825%	1.236%	0.890%	0.596%	0.521%
\$350,000	700	15	3.792%	2.420%	1.561%	1.056%	0.777%	0.559%	0.510%
\$350,000	800	15	3.415%	2.122%	1.347%	0.915%	0.692%	0.535%	0.505%
\$350,000	900	15	3.111%	1.893%	1.189%	0.816%	0.635%	0.521%	0.503%
\$350,000	1,000	15	2.860%	1.709%	1.069%	0.746%	0.597%	0.513%	0.502%
\$350,000	1,500	15	2.066%	1.163%	0.745%	0.580%	0.525%	0.503%	0.501%
\$350,000	2,000	15	1.613%	0.897%	0.618%	0.531%	0.508%	0.502%	0.501%
\$350,000	3,000	15	1.113%	0.658%	0.533%	0.508%	0.503%	0.502%	0.501%
\$350,000	4,000	15	0.855%	0.568%	0.512%	0.504%	0.503%	0.502%	0.501%
\$350,000	5,000	15	0.712%	0.532%	0.507%	0.504%	0.503%	0.502%	0.501%
\$350,000	10,000	15	0.518%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$350,000	20,000	15	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$375,000	5	15	63.931%	62.213%	60.566%	58.982%	57.458%	54.579%	51.906%
\$375,000	10	15	50.257%	48.259%	46.353%	44.538%	42.805%	39.569%	36.618%
\$375,000	15	15	42.058%	39.921%	37.899%	35.992%	34.190%	30.871%	27.894%
\$375,000	20	15	37.018%	34.786%	32.698%	30.743%	28.910%	25.562%	22.598%
\$375,000	25	15	33.184%	30.898%	28.770%	26.789%	24.937%	21.577%	18.631%
\$375,000	50	15	22.705%	20.312%	18.136%	16.166%	14.381%	11.340%	8.904%
\$375,000	100	15	14.829%	12.556%	10.595%	8.914%	7.479%	5.236%	3.658%
\$375,000	150	15	11.432%	9.280%	7.492%	6.025%	4.834%	3.117%	2.039%
\$375,000	200	15	9.469%	7.429%	5.789%	4.490%	3.476%	2.097%	1.324%
\$375,000	300	15	7.122%	5.279%	3.883%	2.851%	2.103%	1.209%	0.793%
\$375,000	400	15	5.826%	4.117%	2.887%	2.029%	1.451%	0.833%	0.606%
\$375,000	500	15	4.955%	3.376%	2.291%	1.575%	1.120%	0.687%	0.550%
\$375,000	600	15	4.326%	2.852%	1.884%	1.278%	0.919%	0.607%	0.525%
\$375,000	700	15	3.868%	2.481%	1.606%	1.086%	0.796%	0.564%	0.511%
\$375,000	800	15	3.491%	2.182%	1.390%	0.943%	0.708%	0.540%	0.506%
\$375,000	900	15	3.181%	1.946%	1.226%	0.839%	0.648%	0.524%	0.504%
\$375,000	1,000	15	2.925%	1.757%	1.102%	0.765%	0.608%	0.515%	0.502%
\$375,000	1,500	15	2.116%	1.195%	0.762%	0.588%	0.527%	0.503%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$375,000	2,000	15	1.654%	0.919%	0.628%	0.534%	0.509%	0.502%	0.501%
\$375,000	3,000	15	1.141%	0.670%	0.536%	0.508%	0.503%	0.502%	0.501%
\$375,000	4,000	15	0.875%	0.574%	0.513%	0.505%	0.503%	0.502%	0.501%
\$375,000	5,000	15	0.726%	0.535%	0.507%	0.504%	0.503%	0.502%	0.501%
\$375,000	10,000	15	0.519%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$375,000	20,000	15	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$400,000	5	15	64.116%	62.406%	60.766%	59.190%	57.674%	54.809%	52.150%
\$400,000	10	15	50.498%	48.511%	46.617%	44.813%	43.090%	39.876%	36.947%
\$400,000	15	15	42.342%	40.220%	38.213%	36.320%	34.533%	31.241%	28.289%
\$400,000	20	15	37.345%	35.132%	33.062%	31.125%	29.309%	25.991%	23.057%
\$400,000	25	15	33.510%	31.244%	29.136%	27.174%	25.339%	22.012%	19.096%
\$400,000	50	15	23.049%	20.672%	18.507%	16.541%	14.758%	11.708%	9.249%
\$400,000	100	15	15.094%	12.819%	10.851%	9.160%	7.712%	5.437%	3.824%
\$400,000	150	15	11.646%	9.489%	7.689%	6.206%	4.999%	3.247%	2.133%
\$400,000	200	15	9.651%	7.602%	5.950%	4.636%	3.603%	2.188%	1.385%
\$400,000	300	15	7.262%	5.406%	3.994%	2.945%	2.180%	1.256%	0.820%
\$400,000	400	15	5.944%	4.221%	2.974%	2.099%	1.505%	0.861%	0.618%
\$400,000	500	15	5.055%	3.462%	2.361%	1.629%	1.160%	0.706%	0.557%
\$400,000	600	15	4.413%	2.926%	1.940%	1.320%	0.947%	0.618%	0.528%
\$400,000	700	15	3.948%	2.547%	1.655%	1.120%	0.818%	0.572%	0.513%
\$400,000	800	15	3.563%	2.239%	1.431%	0.970%	0.725%	0.545%	0.508%
\$400,000	900	15	3.247%	1.997%	1.262%	0.861%	0.660%	0.528%	0.504%
\$400,000	1,000	15	2.988%	1.804%	1.133%	0.785%	0.618%	0.517%	0.503%
\$400,000	1,500	15	2.163%	1.226%	0.779%	0.596%	0.530%	0.504%	0.501%
\$400,000	2,000	15	1.692%	0.941%	0.638%	0.537%	0.510%	0.502%	0.501%
\$400,000	3,000	15	1.168%	0.681%	0.540%	0.509%	0.504%	0.502%	0.501%
\$400,000	4,000	15	0.895%	0.580%	0.514%	0.505%	0.503%	0.502%	0.501%
\$400,000	5,000	15	0.740%	0.539%	0.508%	0.504%	0.503%	0.502%	0.501%
\$400,000	10,000	15	0.521%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$400,000	20,000	15	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$425,000	5	15	64.285%	62.583%	60.950%	59.381%	57.871%	55.020%	52.374%
\$425,000	10	15	50.721%	48.745%	46.861%	45.067%	43.355%	40.161%	37.251%
\$425,000	15	15	42.613%	40.504%	38.511%	36.632%	34.858%	31.590%	28.662%
\$425,000	20	15	37.653%	35.457%	33.404%	31.483%	29.681%	26.392%	23.485%
\$425,000	25	15	33.813%	31.566%	29.476%	27.531%	25.711%	22.415%	19.527%
\$425,000	50	15	23.374%	21.014%	18.863%	16.905%	15.124%	12.071%	9.593%
\$425,000	100	15	15.354%	13.079%	11.103%	9.404%	7.942%	5.640%	3.991%
\$425,000	150	15	11.855%	9.695%	7.885%	6.387%	5.163%	3.378%	2.230%
\$425,000	200	15	9.831%	7.774%	6.109%	4.781%	3.731%	2.281%	1.448%
\$425,000	300	15	7.399%	5.533%	4.105%	3.039%	2.258%	1.306%	0.848%
\$425,000	400	15	6.059%	4.324%	3.061%	2.169%	1.559%	0.890%	0.631%
\$425,000	500	15	5.154%	3.548%	2.431%	1.683%	1.200%	0.725%	0.565%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$425,000	600	15	4.500%	3.000%	1.998%	1.362%	0.976%	0.630%	0.532%
\$425,000	700	15	4.026%	2.611%	1.703%	1.154%	0.841%	0.580%	0.515%
\$425,000	800	15	3.634%	2.296%	1.472%	0.997%	0.742%	0.550%	0.509%
\$425,000	900	15	3.312%	2.048%	1.297%	0.884%	0.673%	0.531%	0.505%
\$425,000	1,000	15	3.049%	1.851%	1.165%	0.804%	0.629%	0.519%	0.503%
\$425,000	1,500	15	2.209%	1.256%	0.796%	0.604%	0.534%	0.504%	0.501%
\$425,000	2,000	15	1.729%	0.962%	0.648%	0.541%	0.511%	0.502%	0.501%
\$425,000	3,000	15	1.195%	0.692%	0.543%	0.510%	0.504%	0.502%	0.501%
\$425,000	4,000	15	0.913%	0.586%	0.515%	0.505%	0.503%	0.502%	0.501%
\$425,000	5,000	15	0.753%	0.542%	0.508%	0.504%	0.503%	0.502%	0.501%
\$425,000	10,000	15	0.522%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$425,000	20,000	15	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$450,000	5	15	64.420%	62.724%	61.097%	59.533%	58.029%	55.189%	52.555%
\$450,000	10	15	50.902%	48.935%	47.060%	45.274%	43.570%	40.393%	37.499%
\$450,000	15	15	42.840%	40.743%	38.762%	36.894%	35.132%	31.885%	28.976%
\$450,000	20	15	37.914%	35.733%	33.695%	31.788%	29.998%	26.734%	23.850%
\$450,000	25	15	34.069%	31.837%	29.764%	27.833%	26.027%	22.756%	19.892%
\$450,000	50	15	23.656%	21.314%	19.176%	17.228%	15.454%	12.400%	9.910%
\$450,000	100	15	15.589%	13.315%	11.335%	9.627%	8.154%	5.828%	4.148%
\$450,000	150	15	12.046%	9.882%	8.065%	6.555%	5.317%	3.501%	2.322%
\$450,000	200	15	9.998%	7.934%	6.258%	4.917%	3.852%	2.369%	1.509%
\$450,000	300	15	7.528%	5.652%	4.210%	3.130%	2.333%	1.353%	0.875%
\$450,000	400	15	6.168%	4.421%	3.143%	2.236%	1.612%	0.919%	0.645%
\$450,000	500	15	5.246%	3.627%	2.497%	1.734%	1.238%	0.743%	0.572%
\$450,000	600	15	4.580%	3.068%	2.052%	1.402%	1.004%	0.642%	0.536%
\$450,000	700	15	4.099%	2.672%	1.749%	1.187%	0.862%	0.588%	0.518%
\$450,000	800	15	3.701%	2.350%	1.511%	1.024%	0.759%	0.556%	0.510%
\$450,000	900	15	3.373%	2.096%	1.331%	0.905%	0.686%	0.534%	0.506%
\$450,000	1,000	15	3.106%	1.895%	1.195%	0.823%	0.639%	0.522%	0.504%
\$450,000	1,500	15	2.252%	1.284%	0.812%	0.611%	0.537%	0.504%	0.501%
\$450,000	2,000	15	1.764%	0.983%	0.657%	0.545%	0.512%	0.502%	0.501%
\$450,000	3,000	15	1.220%	0.703%	0.547%	0.510%	0.504%	0.502%	0.501%
\$450,000	4,000	15	0.931%	0.592%	0.517%	0.505%	0.503%	0.502%	0.501%
\$450,000	5,000	15	0.766%	0.545%	0.509%	0.504%	0.503%	0.502%	0.501%
\$450,000	10,000	15	0.524%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$450,000	20,000	15	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$475,000	5	15	64.524%	62.833%	61.211%	59.652%	58.153%	55.322%	52.696%
\$475,000	10	15	51.045%	49.085%	47.217%	45.439%	43.742%	40.578%	37.699%
\$475,000	15	15	43.030%	40.943%	38.972%	37.115%	35.361%	32.132%	29.241%
\$475,000	20	15	38.134%	35.966%	33.940%	32.045%	30.266%	27.023%	24.159%
\$475,000	25	15	34.285%	32.068%	30.008%	28.089%	26.295%	23.046%	20.203%
\$475,000	50	15	23.901%	21.574%	19.450%	17.513%	15.748%	12.697%	10.199%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$475,000	100	15	15.801%	13.530%	11.547%	9.831%	8.350%	6.003%	4.295%
\$475,000	150	15	12.221%	10.054%	8.230%	6.710%	5.460%	3.615%	2.410%
\$475,000	200	15	10.151%	8.080%	6.396%	5.044%	3.964%	2.452%	1.567%
\$475,000	300	15	7.645%	5.760%	4.307%	3.212%	2.402%	1.398%	0.901%
\$475,000	400	15	6.267%	4.510%	3.219%	2.299%	1.661%	0.946%	0.657%
\$475,000	500	15	5.329%	3.700%	2.557%	1.781%	1.273%	0.760%	0.580%
\$475,000	600	15	4.653%	3.131%	2.102%	1.439%	1.031%	0.654%	0.540%
\$475,000	700	15	4.166%	2.727%	1.792%	1.218%	0.883%	0.596%	0.520%
\$475,000	800	15	3.755%	2.393%	1.543%	1.045%	0.771%	0.559%	0.511%
\$475,000	900	15	3.428%	2.139%	1.362%	0.926%	0.699%	0.538%	0.507%
\$475,000	1,000	15	3.158%	1.935%	1.223%	0.840%	0.649%	0.524%	0.504%
\$475,000	1,500	15	2.291%	1.311%	0.827%	0.619%	0.540%	0.505%	0.501%
\$475,000	2,000	15	1.796%	1.002%	0.666%	0.548%	0.513%	0.502%	0.501%
\$475,000	3,000	15	1.242%	0.713%	0.550%	0.511%	0.504%	0.502%	0.501%
\$475,000	4,000	15	0.948%	0.597%	0.518%	0.505%	0.503%	0.502%	0.501%
\$475,000	5,000	15	0.778%	0.548%	0.509%	0.504%	0.503%	0.502%	0.501%
\$475,000	10,000	15	0.525%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$475,000	20,000	15	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$500,000	5	15	64.610%	62.925%	61.306%	59.751%	58.256%	55.434%	52.816%
\$500,000	10	15	51.166%	49.212%	47.351%	45.579%	43.888%	40.737%	37.870%
\$500,000	15	15	43.194%	41.115%	39.153%	37.305%	35.560%	32.347%	29.471%
\$500,000	20	15	38.330%	36.173%	34.158%	32.273%	30.504%	27.280%	24.434%
\$500,000	25	15	34.478%	32.273%	30.225%	28.317%	26.533%	23.304%	20.480%
\$500,000	50	15	24.118%	21.808%	19.698%	17.772%	16.016%	12.973%	10.471%
\$500,000	100	15	15.998%	13.731%	11.747%	10.023%	8.535%	6.168%	4.435%
\$500,000	150	15	12.386%	10.215%	8.386%	6.857%	5.595%	3.724%	2.494%
\$500,000	200	15	10.296%	8.219%	6.528%	5.164%	4.072%	2.533%	1.624%
\$500,000	300	15	7.756%	5.863%	4.399%	3.290%	2.468%	1.441%	0.926%
\$500,000	400	15	6.361%	4.594%	3.291%	2.358%	1.708%	0.972%	0.669%
\$500,000	500	15	5.407%	3.768%	2.614%	1.826%	1.307%	0.777%	0.587%
\$500,000	600	15	4.722%	3.190%	2.149%	1.474%	1.056%	0.665%	0.544%
\$500,000	700	15	4.229%	2.779%	1.832%	1.247%	0.902%	0.603%	0.522%
\$500,000	800	15	3.813%	2.440%	1.578%	1.069%	0.786%	0.564%	0.512%
\$500,000	900	15	3.480%	2.180%	1.392%	0.946%	0.710%	0.541%	0.507%
\$500,000	1,000	15	3.207%	1.973%	1.249%	0.856%	0.658%	0.527%	0.505%
\$500,000	1,500	15	2.328%	1.337%	0.842%	0.626%	0.543%	0.505%	0.501%
\$500,000	2,000	15	1.827%	1.020%	0.675%	0.551%	0.514%	0.502%	0.501%
\$500,000	3,000	15	1.263%	0.723%	0.553%	0.512%	0.504%	0.502%	0.501%
\$500,000	4,000	15	0.963%	0.603%	0.519%	0.505%	0.503%	0.502%	0.501%
\$500,000	5,000	15	0.790%	0.551%	0.510%	0.504%	0.503%	0.502%	0.501%
\$500,000	10,000	15	0.527%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$500,000	20,000	15	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$30,000	5	16	38.047%	35.163%	32.446%	29.897%	27.513%	23.235%	19.641%
\$30,000	10	16	25.132%	22.510%	20.110%	17.927%	15.941%	12.529%	9.792%
\$30,000	15	16	19.499%	16.971%	14.719%	12.719%	10.958%	8.069%	5.875%
\$30,000	20	16	16.402%	13.953%	11.819%	9.969%	8.372%	5.840%	4.047%
\$30,000	25	16	14.346%	11.976%	9.938%	8.206%	6.746%	4.514%	3.003%
\$30,000	50	16	9.054%	6.988%	5.338%	4.048%	3.062%	1.784%	1.108%
\$30,000	100	16	5.674%	3.954%	2.730%	1.889%	1.335%	0.778%	0.586%
\$30,000	150	16	4.219%	2.740%	1.776%	1.187%	0.848%	0.575%	0.511%
\$30,000	200	16	3.406%	2.108%	1.329%	0.896%	0.679%	0.531%	0.505%
\$30,000	300	16	2.510%	1.454%	0.907%	0.655%	0.554%	0.506%	0.501%
\$30,000	400	16	1.987%	1.109%	0.715%	0.565%	0.518%	0.502%	0.501%
\$30,000	500	16	1.682%	0.930%	0.630%	0.533%	0.508%	0.502%	0.501%
\$30,000	600	16	1.436%	0.801%	0.578%	0.518%	0.505%	0.502%	0.501%
\$30,000	700	16	1.262%	0.719%	0.551%	0.511%	0.504%	0.502%	0.501%
\$30,000	800	16	1.128%	0.662%	0.533%	0.508%	0.503%	0.502%	0.501%
\$30,000	900	16	1.022%	0.621%	0.523%	0.506%	0.503%	0.502%	0.501%
\$30,000	1,000	16	0.935%	0.591%	0.516%	0.505%	0.503%	0.502%	0.501%
\$30,000	1,500	16	0.699%	0.529%	0.507%	0.504%	0.503%	0.502%	0.501%
\$30,000	2,000	16	0.598%	0.512%	0.505%	0.504%	0.503%	0.502%	0.501%
\$30,000	3,000	16	0.530%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$30,000	4,000	16	0.513%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$30,000	5,000	16	0.509%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$30,000	10,000	16	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$30,000	20,000	16	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$35,000	5	16	40.425%	37.622%	34.918%	32.339%	29.906%	25.492%	21.655%
\$35,000	10	16	26.562%	23.947%	21.543%	19.341%	17.324%	13.825%	10.968%
\$35,000	15	16	20.658%	18.111%	15.829%	13.795%	11.987%	8.984%	6.670%
\$35,000	20	16	17.397%	14.922%	12.753%	10.860%	9.212%	6.553%	4.633%
\$35,000	25	16	15.208%	12.811%	10.731%	8.948%	7.435%	5.079%	3.442%
\$35,000	50	16	9.639%	7.530%	5.831%	4.482%	3.432%	2.035%	1.267%
\$35,000	100	16	6.067%	4.295%	3.009%	2.108%	1.499%	0.858%	0.620%
\$35,000	150	16	4.517%	2.982%	1.961%	1.318%	0.933%	0.604%	0.519%
\$35,000	200	16	3.647%	2.297%	1.462%	0.982%	0.728%	0.545%	0.507%
\$35,000	300	16	2.697%	1.586%	0.986%	0.697%	0.573%	0.509%	0.502%
\$35,000	400	16	2.142%	1.207%	0.766%	0.587%	0.526%	0.503%	0.501%
\$35,000	500	16	1.818%	1.009%	0.666%	0.546%	0.512%	0.502%	0.501%
\$35,000	600	16	1.553%	0.861%	0.602%	0.524%	0.506%	0.502%	0.501%
\$35,000	700	16	1.364%	0.766%	0.567%	0.515%	0.504%	0.502%	0.501%
\$35,000	800	16	1.220%	0.700%	0.545%	0.510%	0.504%	0.502%	0.501%
\$35,000	900	16	1.103%	0.652%	0.531%	0.507%	0.503%	0.502%	0.501%
\$35,000	1,000	16	1.007%	0.616%	0.522%	0.506%	0.503%	0.502%	0.501%
\$35,000	1,500	16	0.742%	0.538%	0.508%	0.504%	0.503%	0.502%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$35,000	2,000	16	0.622%	0.516%	0.505%	0.504%	0.503%	0.502%	0.501%
\$35,000	3,000	16	0.538%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$35,000	4,000	16	0.516%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$35,000	5,000	16	0.510%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$35,000	10,000	16	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$35,000	20,000	16	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$40,000	5	16	42.429%	39.737%	37.132%	34.613%	32.180%	27.688%	23.725%
\$40,000	10	16	27.853%	25.229%	22.823%	20.616%	18.589%	15.022%	12.084%
\$40,000	15	16	21.732%	19.175%	16.867%	14.801%	12.957%	9.855%	7.426%
\$40,000	20	16	18.312%	15.824%	13.622%	11.689%	9.996%	7.240%	5.199%
\$40,000	25	16	16.000%	13.585%	11.472%	9.645%	8.084%	5.623%	3.871%
\$40,000	50	16	10.179%	8.037%	6.291%	4.892%	3.788%	2.282%	1.427%
\$40,000	100	16	6.426%	4.610%	3.270%	2.317%	1.659%	0.940%	0.657%
\$40,000	150	16	4.789%	3.207%	2.134%	1.444%	1.018%	0.635%	0.529%
\$40,000	200	16	3.866%	2.470%	1.588%	1.064%	0.777%	0.560%	0.510%
\$40,000	300	16	2.868%	1.708%	1.063%	0.739%	0.594%	0.513%	0.502%
\$40,000	400	16	2.285%	1.300%	0.816%	0.610%	0.534%	0.504%	0.501%
\$40,000	500	16	1.944%	1.085%	0.703%	0.560%	0.516%	0.502%	0.501%
\$40,000	600	16	1.661%	0.920%	0.627%	0.532%	0.508%	0.502%	0.501%
\$40,000	700	16	1.460%	0.813%	0.584%	0.520%	0.505%	0.502%	0.501%
\$40,000	800	16	1.305%	0.739%	0.557%	0.513%	0.504%	0.502%	0.501%
\$40,000	900	16	1.179%	0.683%	0.539%	0.509%	0.504%	0.502%	0.501%
\$40,000	1,000	16	1.075%	0.642%	0.528%	0.507%	0.503%	0.502%	0.501%
\$40,000	1,500	16	0.783%	0.548%	0.509%	0.504%	0.503%	0.502%	0.501%
\$40,000	2,000	16	0.647%	0.519%	0.506%	0.504%	0.503%	0.502%	0.501%
\$40,000	3,000	16	0.548%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$40,000	4,000	16	0.520%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$40,000	5,000	16	0.511%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$40,000	10,000	16	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$40,000	20,000	16	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$45,000	5	16	44.180%	41.574%	39.058%	36.631%	34.290%	29.828%	25.751%
\$45,000	10	16	29.052%	26.412%	23.989%	21.764%	19.725%	16.129%	13.120%
\$45,000	15	16	22.722%	20.159%	17.836%	15.743%	13.862%	10.671%	8.147%
\$45,000	20	16	19.159%	16.660%	14.434%	12.461%	10.728%	7.893%	5.748%
\$45,000	25	16	16.738%	14.303%	12.164%	10.301%	8.694%	6.140%	4.294%
\$45,000	50	16	10.683%	8.509%	6.726%	5.282%	4.132%	2.526%	1.590%
\$45,000	100	16	6.759%	4.903%	3.518%	2.518%	1.817%	1.026%	0.697%
\$45,000	150	16	5.041%	3.418%	2.301%	1.568%	1.105%	0.668%	0.539%
\$45,000	200	16	4.062%	2.628%	1.703%	1.143%	0.825%	0.573%	0.513%
\$45,000	300	16	3.027%	1.825%	1.138%	0.782%	0.615%	0.517%	0.503%
\$45,000	400	16	2.418%	1.389%	0.867%	0.634%	0.544%	0.504%	0.501%
\$45,000	500	16	2.061%	1.158%	0.740%	0.575%	0.521%	0.502%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$45,000	600	16	1.763%	0.978%	0.652%	0.541%	0.510%	0.502%	0.501%
\$45,000	700	16	1.550%	0.860%	0.602%	0.525%	0.506%	0.502%	0.501%
\$45,000	800	16	1.386%	0.778%	0.570%	0.516%	0.505%	0.502%	0.501%
\$45,000	900	16	1.251%	0.714%	0.549%	0.511%	0.504%	0.502%	0.501%
\$45,000	1,000	16	1.141%	0.668%	0.535%	0.508%	0.503%	0.502%	0.501%
\$45,000	1,500	16	0.823%	0.559%	0.511%	0.504%	0.503%	0.502%	0.501%
\$45,000	2,000	16	0.672%	0.524%	0.506%	0.504%	0.503%	0.502%	0.501%
\$45,000	3,000	16	0.558%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$45,000	4,000	16	0.524%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$45,000	5,000	16	0.513%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$45,000	10,000	16	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$45,000	20,000	16	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$50,000	5	16	45.698%	43.168%	40.731%	38.385%	36.116%	31.786%	27.716%
\$50,000	10	16	30.196%	27.536%	25.085%	22.838%	20.773%	17.146%	14.092%
\$50,000	15	16	23.635%	21.067%	18.733%	16.622%	14.713%	11.449%	8.842%
\$50,000	20	16	19.945%	17.437%	15.192%	13.189%	11.420%	8.509%	6.278%
\$50,000	25	16	17.422%	14.968%	12.806%	10.912%	9.271%	6.634%	4.701%
\$50,000	50	16	11.146%	8.947%	7.128%	5.646%	4.455%	2.761%	1.750%
\$50,000	100	16	7.064%	5.173%	3.750%	2.709%	1.968%	1.110%	0.738%
\$50,000	150	16	5.271%	3.613%	2.457%	1.684%	1.187%	0.702%	0.551%
\$50,000	200	16	4.250%	2.780%	1.817%	1.222%	0.876%	0.590%	0.518%
\$50,000	300	16	3.173%	1.934%	1.210%	0.825%	0.638%	0.522%	0.503%
\$50,000	400	16	2.542%	1.474%	0.917%	0.659%	0.554%	0.506%	0.501%
\$50,000	500	16	2.171%	1.228%	0.777%	0.592%	0.527%	0.503%	0.501%
\$50,000	600	16	1.858%	1.033%	0.678%	0.550%	0.512%	0.502%	0.501%
\$50,000	700	16	1.635%	0.905%	0.621%	0.531%	0.508%	0.502%	0.501%
\$50,000	800	16	1.463%	0.816%	0.585%	0.519%	0.505%	0.502%	0.501%
\$50,000	900	16	1.319%	0.746%	0.559%	0.513%	0.504%	0.502%	0.501%
\$50,000	1,000	16	1.203%	0.695%	0.543%	0.509%	0.504%	0.502%	0.501%
\$50,000	1,500	16	0.863%	0.570%	0.513%	0.505%	0.503%	0.502%	0.501%
\$50,000	2,000	16	0.698%	0.529%	0.506%	0.504%	0.503%	0.502%	0.501%
\$50,000	3,000	16	0.568%	0.509%	0.505%	0.504%	0.503%	0.502%	0.501%
\$50,000	4,000	16	0.528%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$50,000	5,000	16	0.515%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$50,000	10,000	16	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$50,000	20,000	16	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$55,000	5	16	47.017%	44.556%	42.190%	39.906%	37.698%	33.482%	29.526%
\$55,000	10	16	31.301%	28.613%	26.138%	23.858%	21.768%	18.088%	14.989%
\$55,000	15	16	24.484%	21.919%	19.578%	17.451%	15.520%	12.200%	9.517%
\$55,000	20	16	20.683%	18.164%	15.900%	13.874%	12.077%	9.095%	6.786%
\$55,000	25	16	18.058%	15.590%	13.406%	11.488%	9.816%	7.109%	5.098%
\$55,000	50	16	11.578%	9.356%	7.504%	5.987%	4.758%	2.989%	1.906%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$55,000	100	16	7.347%	5.426%	3.968%	2.890%	2.113%	1.193%	0.781%
\$55,000	150	16	5.485%	3.795%	2.603%	1.795%	1.268%	0.736%	0.563%
\$55,000	200	16	4.426%	2.923%	1.925%	1.298%	0.926%	0.608%	0.523%
\$55,000	300	16	3.309%	2.037%	1.280%	0.867%	0.661%	0.528%	0.504%
\$55,000	400	16	2.656%	1.554%	0.965%	0.684%	0.566%	0.507%	0.501%
\$55,000	500	16	2.272%	1.294%	0.814%	0.608%	0.533%	0.503%	0.501%
\$55,000	600	16	1.946%	1.086%	0.704%	0.560%	0.516%	0.502%	0.501%
\$55,000	700	16	1.714%	0.949%	0.640%	0.537%	0.509%	0.502%	0.501%
\$55,000	800	16	1.535%	0.853%	0.599%	0.524%	0.506%	0.502%	0.501%
\$55,000	900	16	1.383%	0.777%	0.570%	0.516%	0.505%	0.502%	0.501%
\$55,000	1,000	16	1.261%	0.720%	0.551%	0.511%	0.504%	0.502%	0.501%
\$55,000	1,500	16	0.901%	0.582%	0.515%	0.505%	0.503%	0.502%	0.501%
\$55,000	2,000	16	0.722%	0.534%	0.507%	0.504%	0.503%	0.502%	0.501%
\$55,000	3,000	16	0.579%	0.510%	0.505%	0.504%	0.503%	0.502%	0.501%
\$55,000	4,000	16	0.532%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$55,000	5,000	16	0.517%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$55,000	10,000	16	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$55,000	20,000	16	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$60,000	5	16	48.192%	45.793%	43.485%	41.256%	39.098%	34.987%	31.130%
\$60,000	10	16	32.370%	29.666%	27.161%	24.848%	22.725%	18.982%	15.828%
\$60,000	15	16	25.279%	22.719%	20.375%	18.229%	16.283%	12.917%	10.170%
\$60,000	20	16	21.379%	18.849%	16.570%	14.527%	12.703%	9.653%	7.275%
\$60,000	25	16	18.658%	16.178%	13.975%	12.033%	10.334%	7.563%	5.483%
\$60,000	50	16	11.986%	9.743%	7.864%	6.313%	5.049%	3.211%	2.059%
\$60,000	100	16	7.613%	5.665%	4.177%	3.065%	2.254%	1.275%	0.825%
\$60,000	150	16	5.687%	3.969%	2.743%	1.903%	1.347%	0.771%	0.576%
\$60,000	200	16	4.591%	3.058%	2.029%	1.373%	0.976%	0.626%	0.528%
\$60,000	300	16	3.437%	2.134%	1.349%	0.910%	0.685%	0.533%	0.506%
\$60,000	400	16	2.764%	1.630%	1.012%	0.710%	0.578%	0.509%	0.501%
\$60,000	500	16	2.368%	1.358%	0.850%	0.626%	0.540%	0.504%	0.501%
\$60,000	600	16	2.030%	1.138%	0.730%	0.571%	0.519%	0.502%	0.501%
\$60,000	700	16	1.790%	0.992%	0.659%	0.544%	0.511%	0.502%	0.501%
\$60,000	800	16	1.604%	0.890%	0.614%	0.528%	0.507%	0.502%	0.501%
\$60,000	900	16	1.444%	0.807%	0.581%	0.519%	0.505%	0.502%	0.501%
\$60,000	1,000	16	1.317%	0.746%	0.560%	0.513%	0.504%	0.502%	0.501%
\$60,000	1,500	16	0.938%	0.594%	0.517%	0.505%	0.503%	0.502%	0.501%
\$60,000	2,000	16	0.747%	0.539%	0.508%	0.504%	0.503%	0.502%	0.501%
\$60,000	3,000	16	0.590%	0.511%	0.505%	0.504%	0.503%	0.502%	0.501%
\$60,000	4,000	16	0.537%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$60,000	5,000	16	0.519%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$60,000	10,000	16	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$60,000	20,000	16	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$65,000	5	16	49.247%	46.903%	44.643%	42.461%	40.348%	36.329%	32.559%
\$65,000	10	16	33.379%	30.672%	28.143%	25.805%	23.646%	19.834%	16.620%
\$65,000	15	16	26.020%	23.457%	21.108%	18.956%	16.993%	13.589%	10.790%
\$65,000	20	16	22.026%	19.491%	17.200%	15.138%	13.292%	10.182%	7.738%
\$65,000	25	16	19.216%	16.724%	14.507%	12.546%	10.818%	7.988%	5.850%
\$65,000	50	16	12.369%	10.110%	8.207%	6.625%	5.330%	3.427%	2.213%
\$65,000	100	16	7.863%	5.892%	4.375%	3.232%	2.390%	1.358%	0.870%
\$65,000	150	16	5.876%	4.133%	2.877%	2.007%	1.425%	0.808%	0.590%
\$65,000	200	16	4.746%	3.186%	2.129%	1.446%	1.026%	0.644%	0.534%
\$65,000	300	16	3.556%	2.227%	1.414%	0.951%	0.709%	0.540%	0.507%
\$65,000	400	16	2.865%	1.703%	1.058%	0.736%	0.591%	0.511%	0.502%
\$65,000	500	16	2.458%	1.419%	0.886%	0.643%	0.548%	0.505%	0.501%
\$65,000	600	16	2.109%	1.187%	0.756%	0.582%	0.523%	0.503%	0.501%
\$65,000	700	16	1.860%	1.034%	0.679%	0.551%	0.513%	0.502%	0.501%
\$65,000	800	16	1.668%	0.925%	0.629%	0.533%	0.508%	0.502%	0.501%
\$65,000	900	16	1.502%	0.837%	0.593%	0.522%	0.506%	0.502%	0.501%
\$65,000	1,000	16	1.369%	0.771%	0.569%	0.516%	0.504%	0.502%	0.501%
\$65,000	1,500	16	0.974%	0.606%	0.520%	0.505%	0.503%	0.502%	0.501%
\$65,000	2,000	16	0.771%	0.545%	0.508%	0.504%	0.503%	0.502%	0.501%
\$65,000	3,000	16	0.601%	0.513%	0.505%	0.504%	0.503%	0.502%	0.501%
\$65,000	4,000	16	0.542%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$65,000	5,000	16	0.522%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$65,000	10,000	16	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$65,000	20,000	16	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$70,000	5	16	50.206%	47.907%	45.691%	43.548%	41.476%	37.540%	33.845%
\$70,000	10	16	34.339%	31.636%	29.101%	26.741%	24.551%	20.667%	17.389%
\$70,000	15	16	26.725%	24.155%	21.798%	19.639%	17.665%	14.228%	11.383%
\$70,000	20	16	22.637%	20.101%	17.801%	15.725%	13.857%	10.693%	8.192%
\$70,000	25	16	19.744%	17.242%	15.014%	13.034%	11.284%	8.399%	6.206%
\$70,000	50	16	12.731%	10.459%	8.534%	6.925%	5.600%	3.639%	2.369%
\$70,000	100	16	8.101%	6.109%	4.565%	3.394%	2.523%	1.440%	0.916%
\$70,000	150	16	6.057%	4.291%	3.007%	2.109%	1.502%	0.846%	0.605%
\$70,000	200	16	4.893%	3.308%	2.225%	1.517%	1.074%	0.664%	0.540%
\$70,000	300	16	3.669%	2.315%	1.477%	0.993%	0.733%	0.546%	0.508%
\$70,000	400	16	2.961%	1.773%	1.103%	0.762%	0.604%	0.513%	0.502%
\$70,000	500	16	2.542%	1.478%	0.921%	0.662%	0.556%	0.506%	0.501%
\$70,000	600	16	2.184%	1.235%	0.782%	0.594%	0.527%	0.503%	0.501%
\$70,000	700	16	1.928%	1.074%	0.698%	0.559%	0.516%	0.502%	0.501%
\$70,000	800	16	1.729%	0.960%	0.645%	0.538%	0.509%	0.502%	0.501%
\$70,000	900	16	1.558%	0.866%	0.604%	0.525%	0.507%	0.502%	0.501%
\$70,000	1,000	16	1.419%	0.796%	0.578%	0.518%	0.505%	0.502%	0.501%
\$70,000	1,500	16	1.008%	0.618%	0.523%	0.506%	0.503%	0.502%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$70,000	2,000	16	0.794%	0.551%	0.509%	0.504%	0.503%	0.502%	0.501%
\$70,000	3,000	16	0.612%	0.514%	0.505%	0.504%	0.503%	0.502%	0.501%
\$70,000	4,000	16	0.548%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$70,000	5,000	16	0.524%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$70,000	10,000	16	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$70,000	20,000	16	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$75,000	5	16	51.074%	48.815%	46.636%	44.530%	42.496%	38.632%	35.005%
\$75,000	10	16	35.259%	32.564%	30.034%	27.662%	25.449%	21.494%	18.150%
\$75,000	15	16	27.399%	24.818%	22.451%	20.282%	18.299%	14.834%	11.946%
\$75,000	20	16	23.216%	20.678%	18.371%	16.282%	14.395%	11.182%	8.632%
\$75,000	25	16	20.245%	17.738%	15.498%	13.503%	11.731%	8.796%	6.552%
\$75,000	50	16	13.075%	10.790%	8.847%	7.215%	5.862%	3.846%	2.522%
\$75,000	100	16	8.327%	6.315%	4.747%	3.550%	2.652%	1.521%	0.962%
\$75,000	150	16	6.229%	4.443%	3.134%	2.209%	1.577%	0.884%	0.620%
\$75,000	200	16	5.035%	3.427%	2.320%	1.587%	1.124%	0.684%	0.547%
\$75,000	300	16	3.778%	2.401%	1.540%	1.034%	0.757%	0.553%	0.510%
\$75,000	400	16	3.053%	1.842%	1.148%	0.788%	0.617%	0.515%	0.502%
\$75,000	500	16	2.623%	1.534%	0.956%	0.680%	0.564%	0.507%	0.501%
\$75,000	600	16	2.256%	1.283%	0.808%	0.606%	0.532%	0.503%	0.501%
\$75,000	700	16	1.993%	1.114%	0.718%	0.567%	0.519%	0.502%	0.501%
\$75,000	800	16	1.789%	0.995%	0.661%	0.544%	0.511%	0.502%	0.501%
\$75,000	900	16	1.612%	0.895%	0.616%	0.529%	0.507%	0.502%	0.501%
\$75,000	1,000	16	1.468%	0.821%	0.587%	0.521%	0.505%	0.502%	0.501%
\$75,000	1,500	16	1.042%	0.631%	0.526%	0.506%	0.503%	0.502%	0.501%
\$75,000	2,000	16	0.818%	0.557%	0.510%	0.504%	0.503%	0.502%	0.501%
\$75,000	3,000	16	0.623%	0.516%	0.505%	0.504%	0.503%	0.502%	0.501%
\$75,000	4,000	16	0.553%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$75,000	5,000	16	0.527%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$75,000	10,000	16	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$75,000	20,000	16	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$80,000	5	16	51.871%	49.648%	47.502%	45.430%	43.433%	39.634%	36.066%
\$80,000	10	16	36.134%	33.457%	30.933%	28.558%	26.329%	22.321%	18.903%
\$80,000	15	16	28.055%	25.461%	23.079%	20.899%	18.905%	15.414%	12.488%
\$80,000	20	16	23.770%	21.229%	18.916%	16.816%	14.914%	11.657%	9.060%
\$80,000	25	16	20.727%	18.214%	15.963%	13.955%	12.164%	9.184%	6.891%
\$80,000	50	16	13.406%	11.108%	9.148%	7.496%	6.119%	4.050%	2.676%
\$80,000	100	16	8.543%	6.514%	4.922%	3.701%	2.779%	1.602%	1.007%
\$80,000	150	16	6.394%	4.589%	3.257%	2.308%	1.653%	0.923%	0.636%
\$80,000	200	16	5.172%	3.543%	2.412%	1.657%	1.173%	0.705%	0.554%
\$80,000	300	16	3.876%	2.478%	1.596%	1.071%	0.780%	0.558%	0.510%
\$80,000	400	16	3.142%	1.909%	1.192%	0.815%	0.631%	0.518%	0.503%
\$80,000	500	16	2.701%	1.589%	0.990%	0.699%	0.573%	0.508%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$80,000	600	16	2.325%	1.329%	0.834%	0.619%	0.537%	0.504%	0.501%
\$80,000	700	16	2.056%	1.154%	0.739%	0.576%	0.522%	0.503%	0.501%
\$80,000	800	16	1.848%	1.029%	0.677%	0.550%	0.513%	0.502%	0.501%
\$80,000	900	16	1.664%	0.924%	0.629%	0.533%	0.509%	0.502%	0.501%
\$80,000	1,000	16	1.517%	0.846%	0.597%	0.524%	0.506%	0.502%	0.501%
\$80,000	1,500	16	1.075%	0.644%	0.529%	0.507%	0.503%	0.502%	0.501%
\$80,000	2,000	16	0.841%	0.563%	0.511%	0.504%	0.503%	0.502%	0.501%
\$80,000	3,000	16	0.634%	0.518%	0.506%	0.504%	0.503%	0.502%	0.501%
\$80,000	4,000	16	0.559%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$80,000	5,000	16	0.530%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$80,000	10,000	16	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$80,000	20,000	16	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$90,000	5	16	53.268%	51.105%	49.019%	47.010%	45.070%	41.382%	37.919%
\$90,000	10	16	37.701%	35.093%	32.600%	30.229%	27.994%	23.927%	20.375%
\$90,000	15	16	29.305%	26.688%	24.275%	22.065%	20.040%	16.483%	13.497%
\$90,000	20	16	24.791%	22.242%	19.917%	17.794%	15.864%	12.541%	9.857%
\$90,000	25	16	21.614%	19.091%	16.825%	14.791%	12.971%	9.914%	7.532%
\$90,000	50	16	14.017%	11.695%	9.709%	8.022%	6.604%	4.439%	2.977%
\$90,000	100	16	8.942%	6.883%	5.252%	3.985%	3.020%	1.760%	1.099%
\$90,000	150	16	6.704%	4.865%	3.492%	2.499%	1.800%	1.002%	0.671%
\$90,000	200	16	5.430%	3.763%	2.589%	1.793%	1.272%	0.749%	0.570%
\$90,000	300	16	4.074%	2.637%	1.713%	1.152%	0.830%	0.573%	0.514%
\$90,000	400	16	3.308%	2.034%	1.278%	0.867%	0.660%	0.525%	0.503%
\$90,000	500	16	2.846%	1.694%	1.057%	0.737%	0.591%	0.511%	0.501%
\$90,000	600	16	2.455%	1.418%	0.885%	0.644%	0.547%	0.505%	0.501%
\$90,000	700	16	2.174%	1.230%	0.779%	0.594%	0.528%	0.503%	0.501%
\$90,000	800	16	1.955%	1.094%	0.709%	0.563%	0.516%	0.502%	0.501%
\$90,000	900	16	1.763%	0.980%	0.654%	0.542%	0.511%	0.502%	0.501%
\$90,000	1,000	16	1.607%	0.894%	0.617%	0.530%	0.508%	0.502%	0.501%
\$90,000	1,500	16	1.137%	0.668%	0.536%	0.508%	0.503%	0.502%	0.501%
\$90,000	2,000	16	0.885%	0.576%	0.513%	0.505%	0.503%	0.502%	0.501%
\$90,000	3,000	16	0.657%	0.521%	0.506%	0.504%	0.503%	0.502%	0.501%
\$90,000	4,000	16	0.570%	0.509%	0.505%	0.504%	0.503%	0.502%	0.501%
\$90,000	5,000	16	0.536%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$90,000	10,000	16	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$90,000	20,000	16	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$100,000	5	16	54.500%	52.388%	50.355%	48.397%	46.507%	42.912%	39.544%
\$100,000	10	16	39.089%	36.553%	34.123%	31.795%	29.572%	25.488%	21.865%
\$100,000	15	16	30.503%	27.874%	25.439%	23.195%	21.129%	17.496%	14.443%
\$100,000	20	16	25.752%	23.191%	20.847%	18.708%	16.756%	13.380%	10.621%
\$100,000	25	16	22.444%	19.914%	17.630%	15.576%	13.735%	10.616%	8.156%
\$100,000	50	16	14.585%	12.246%	10.233%	8.517%	7.064%	4.817%	3.274%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$100,000	100	16	9.309%	7.226%	5.561%	4.254%	3.249%	1.914%	1.194%
\$100,000	150	16	6.992%	5.121%	3.713%	2.682%	1.945%	1.083%	0.710%
\$100,000	200	16	5.668%	3.969%	2.756%	1.922%	1.368%	0.795%	0.588%
\$100,000	300	16	4.256%	2.786%	1.825%	1.230%	0.881%	0.590%	0.519%
\$100,000	400	16	3.462%	2.153%	1.361%	0.918%	0.690%	0.532%	0.505%
\$100,000	500	16	2.981%	1.794%	1.123%	0.774%	0.609%	0.515%	0.502%
\$100,000	600	16	2.577%	1.502%	0.936%	0.670%	0.558%	0.506%	0.501%
\$100,000	700	16	2.284%	1.302%	0.819%	0.613%	0.535%	0.504%	0.501%
\$100,000	800	16	2.056%	1.157%	0.741%	0.576%	0.521%	0.503%	0.501%
\$100,000	900	16	1.856%	1.035%	0.680%	0.552%	0.514%	0.502%	0.501%
\$100,000	1,000	16	1.693%	0.942%	0.638%	0.537%	0.509%	0.502%	0.501%
\$100,000	1,500	16	1.198%	0.694%	0.544%	0.510%	0.504%	0.502%	0.501%
\$100,000	2,000	16	0.928%	0.590%	0.516%	0.505%	0.503%	0.502%	0.501%
\$100,000	3,000	16	0.681%	0.526%	0.506%	0.504%	0.503%	0.502%	0.501%
\$100,000	4,000	16	0.583%	0.511%	0.505%	0.504%	0.503%	0.502%	0.501%
\$100,000	5,000	16	0.543%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$100,000	10,000	16	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$100,000	20,000	16	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$110,000	5	16	55.560%	53.492%	51.506%	49.591%	47.744%	44.226%	40.940%
\$110,000	10	16	40.290%	37.815%	35.445%	33.175%	31.005%	26.941%	23.285%
\$110,000	15	16	31.628%	28.998%	26.555%	24.281%	22.180%	18.459%	15.329%
\$110,000	20	16	26.652%	24.078%	21.712%	19.549%	17.584%	14.161%	11.335%
\$110,000	25	16	23.206%	20.673%	18.372%	16.302%	14.442%	11.270%	8.742%
\$110,000	50	16	15.106%	12.752%	10.717%	8.972%	7.490%	5.172%	3.557%
\$110,000	100	16	9.648%	7.544%	5.849%	4.509%	3.467%	2.065%	1.291%
\$110,000	150	16	7.257%	5.360%	3.920%	2.854%	2.083%	1.163%	0.750%
\$110,000	200	16	5.888%	4.161%	2.914%	2.046%	1.461%	0.840%	0.607%
\$110,000	300	16	4.427%	2.926%	1.932%	1.306%	0.932%	0.608%	0.524%
\$110,000	400	16	3.606%	2.265%	1.440%	0.969%	0.720%	0.540%	0.506%
\$110,000	500	16	3.106%	1.887%	1.185%	0.812%	0.629%	0.519%	0.503%
\$110,000	600	16	2.690%	1.582%	0.986%	0.697%	0.571%	0.508%	0.501%
\$110,000	700	16	2.387%	1.372%	0.859%	0.632%	0.543%	0.505%	0.501%
\$110,000	800	16	2.150%	1.217%	0.773%	0.591%	0.526%	0.503%	0.501%
\$110,000	900	16	1.943%	1.088%	0.706%	0.562%	0.517%	0.502%	0.501%
\$110,000	1,000	16	1.773%	0.988%	0.659%	0.544%	0.512%	0.502%	0.501%
\$110,000	1,500	16	1.256%	0.719%	0.552%	0.512%	0.504%	0.502%	0.501%
\$110,000	2,000	16	0.970%	0.604%	0.519%	0.505%	0.503%	0.502%	0.501%
\$110,000	3,000	16	0.704%	0.530%	0.507%	0.504%	0.503%	0.502%	0.501%
\$110,000	4,000	16	0.595%	0.512%	0.505%	0.504%	0.503%	0.502%	0.501%
\$110,000	5,000	16	0.550%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$110,000	10,000	16	0.508%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$110,000	20,000	16	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$120,000	5	16	56.468%	54.441%	52.492%	50.614%	48.801%	45.353%	42.134%
\$120,000	10	16	41.336%	38.914%	36.597%	34.379%	32.261%	28.274%	24.617%
\$120,000	15	16	32.665%	30.047%	27.597%	25.310%	23.181%	19.379%	16.164%
\$120,000	20	16	27.489%	24.898%	22.512%	20.327%	18.341%	14.877%	11.997%
\$120,000	25	16	23.905%	21.366%	19.057%	16.971%	15.092%	11.877%	9.291%
\$120,000	50	16	15.585%	13.218%	11.164%	9.396%	7.885%	5.507%	3.825%
\$120,000	100	16	9.964%	7.843%	6.121%	4.751%	3.675%	2.213%	1.386%
\$120,000	150	16	7.505%	5.584%	4.116%	3.018%	2.215%	1.241%	0.791%
\$120,000	200	16	6.095%	4.342%	3.064%	2.165%	1.552%	0.886%	0.627%
\$120,000	300	16	4.588%	3.058%	2.033%	1.380%	0.981%	0.627%	0.530%
\$120,000	400	16	3.738%	2.369%	1.516%	1.019%	0.750%	0.549%	0.508%
\$120,000	500	16	3.223%	1.975%	1.246%	0.849%	0.650%	0.523%	0.504%
\$120,000	600	16	2.797%	1.659%	1.034%	0.723%	0.584%	0.510%	0.502%
\$120,000	700	16	2.483%	1.438%	0.898%	0.652%	0.552%	0.506%	0.501%
\$120,000	800	16	2.237%	1.274%	0.804%	0.606%	0.532%	0.503%	0.501%
\$120,000	900	16	2.024%	1.138%	0.732%	0.573%	0.521%	0.503%	0.501%
\$120,000	1,000	16	1.848%	1.032%	0.680%	0.552%	0.514%	0.502%	0.501%
\$120,000	1,500	16	1.311%	0.744%	0.560%	0.514%	0.504%	0.502%	0.501%
\$120,000	2,000	16	1.010%	0.617%	0.522%	0.506%	0.503%	0.502%	0.501%
\$120,000	3,000	16	0.726%	0.535%	0.507%	0.504%	0.503%	0.502%	0.501%
\$120,000	4,000	16	0.607%	0.513%	0.505%	0.504%	0.503%	0.502%	0.501%
\$120,000	5,000	16	0.557%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$120,000	10,000	16	0.508%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$120,000	20,000	16	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$130,000	5	16	57.247%	55.254%	53.337%	51.490%	49.706%	46.318%	43.158%
\$130,000	10	16	42.255%	39.878%	37.605%	35.436%	33.359%	29.454%	25.854%
\$130,000	15	16	33.612%	31.016%	28.567%	26.274%	24.130%	20.268%	16.968%
\$130,000	20	16	28.277%	25.673%	23.271%	21.070%	19.058%	15.546%	12.627%
\$130,000	25	16	24.561%	22.015%	19.700%	17.602%	15.705%	12.450%	9.813%
\$130,000	50	16	16.026%	13.648%	11.576%	9.789%	8.252%	5.819%	4.080%
\$130,000	100	16	10.260%	8.121%	6.376%	4.979%	3.872%	2.354%	1.479%
\$130,000	150	16	7.737%	5.795%	4.301%	3.173%	2.341%	1.317%	0.832%
\$130,000	200	16	6.286%	4.510%	3.205%	2.277%	1.637%	0.931%	0.648%
\$130,000	300	16	4.736%	3.181%	2.128%	1.449%	1.029%	0.645%	0.536%
\$130,000	400	16	3.861%	2.467%	1.587%	1.067%	0.779%	0.558%	0.510%
\$130,000	500	16	3.331%	2.058%	1.303%	0.885%	0.669%	0.528%	0.505%
\$130,000	600	16	2.894%	1.730%	1.080%	0.750%	0.597%	0.512%	0.502%
\$130,000	700	16	2.572%	1.500%	0.935%	0.671%	0.561%	0.507%	0.501%
\$130,000	800	16	2.318%	1.327%	0.834%	0.620%	0.538%	0.504%	0.501%
\$130,000	900	16	2.098%	1.185%	0.757%	0.584%	0.525%	0.503%	0.501%
\$130,000	1,000	16	1.917%	1.073%	0.700%	0.560%	0.516%	0.503%	0.501%
\$130,000	1,500	16	1.362%	0.768%	0.568%	0.516%	0.504%	0.502%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$130,000	2,000	16	1.047%	0.631%	0.525%	0.506%	0.503%	0.502%	0.501%
\$130,000	3,000	16	0.747%	0.540%	0.508%	0.504%	0.503%	0.502%	0.501%
\$130,000	4,000	16	0.619%	0.515%	0.505%	0.504%	0.503%	0.502%	0.501%
\$130,000	5,000	16	0.564%	0.509%	0.505%	0.504%	0.503%	0.502%	0.501%
\$130,000	10,000	16	0.508%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$130,000	20,000	16	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$140,000	5	16	57.924%	55.961%	54.072%	52.251%	50.492%	47.158%	44.049%
\$140,000	10	16	43.062%	40.726%	38.493%	36.364%	34.325%	30.490%	26.961%
\$140,000	15	16	34.473%	31.907%	29.472%	27.180%	25.027%	21.134%	17.766%
\$140,000	20	16	29.025%	26.414%	24.001%	21.787%	19.751%	16.184%	13.226%
\$140,000	25	16	25.187%	22.635%	20.311%	18.200%	16.288%	12.995%	10.315%
\$140,000	50	16	16.442%	14.057%	11.968%	10.162%	8.602%	6.118%	4.326%
\$140,000	100	16	10.539%	8.384%	6.620%	5.199%	4.065%	2.493%	1.574%
\$140,000	150	16	7.956%	5.995%	4.477%	3.321%	2.463%	1.393%	0.874%
\$140,000	200	16	6.466%	4.670%	3.340%	2.386%	1.722%	0.978%	0.669%
\$140,000	300	16	4.876%	3.298%	2.220%	1.516%	1.077%	0.664%	0.542%
\$140,000	400	16	3.972%	2.556%	1.652%	1.110%	0.806%	0.566%	0.512%
\$140,000	500	16	3.436%	2.138%	1.359%	0.920%	0.690%	0.533%	0.506%
\$140,000	600	16	2.988%	1.799%	1.125%	0.776%	0.610%	0.514%	0.502%
\$140,000	700	16	2.655%	1.559%	0.972%	0.691%	0.570%	0.508%	0.501%
\$140,000	800	16	2.394%	1.378%	0.864%	0.635%	0.544%	0.504%	0.501%
\$140,000	900	16	2.168%	1.231%	0.782%	0.595%	0.529%	0.503%	0.501%
\$140,000	1,000	16	1.981%	1.113%	0.720%	0.568%	0.519%	0.503%	0.501%
\$140,000	1,500	16	1.410%	0.791%	0.577%	0.518%	0.505%	0.502%	0.501%
\$140,000	2,000	16	1.082%	0.645%	0.529%	0.507%	0.503%	0.502%	0.501%
\$140,000	3,000	16	0.768%	0.545%	0.509%	0.504%	0.503%	0.502%	0.501%
\$140,000	4,000	16	0.631%	0.517%	0.505%	0.504%	0.503%	0.502%	0.501%
\$140,000	5,000	16	0.571%	0.509%	0.505%	0.504%	0.503%	0.502%	0.501%
\$140,000	10,000	16	0.508%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$140,000	20,000	16	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$150,000	5	16	58.507%	56.568%	54.703%	52.904%	51.166%	47.878%	44.814%
\$150,000	10	16	43.754%	41.453%	39.256%	37.160%	35.152%	31.378%	27.911%
\$150,000	15	16	35.225%	32.694%	30.286%	28.004%	25.847%	21.937%	18.526%
\$150,000	20	16	29.711%	27.102%	24.684%	22.455%	20.400%	16.783%	13.782%
\$150,000	25	16	25.769%	23.210%	20.879%	18.754%	16.827%	13.498%	10.779%
\$150,000	50	16	16.824%	14.433%	12.331%	10.507%	8.926%	6.399%	4.556%
\$150,000	100	16	10.798%	8.631%	6.849%	5.407%	4.249%	2.627%	1.667%
\$150,000	150	16	8.156%	6.180%	4.641%	3.461%	2.578%	1.465%	0.917%
\$150,000	200	16	6.632%	4.819%	3.467%	2.489%	1.804%	1.022%	0.691%
\$150,000	300	16	5.004%	3.406%	2.306%	1.581%	1.122%	0.683%	0.549%
\$150,000	400	16	4.081%	2.645%	1.718%	1.157%	0.836%	0.576%	0.514%
\$150,000	500	16	3.533%	2.212%	1.413%	0.954%	0.710%	0.538%	0.507%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$150,000	600	16	3.075%	1.864%	1.168%	0.801%	0.624%	0.517%	0.503%
\$150,000	700	16	2.733%	1.615%	1.007%	0.710%	0.579%	0.510%	0.502%
\$150,000	800	16	2.464%	1.426%	0.892%	0.649%	0.550%	0.505%	0.501%
\$150,000	900	16	2.233%	1.273%	0.805%	0.606%	0.533%	0.504%	0.501%
\$150,000	1,000	16	2.041%	1.150%	0.739%	0.577%	0.522%	0.503%	0.501%
\$150,000	1,500	16	1.454%	0.813%	0.585%	0.520%	0.505%	0.502%	0.501%
\$150,000	2,000	16	1.116%	0.658%	0.532%	0.507%	0.503%	0.502%	0.501%
\$150,000	3,000	16	0.788%	0.550%	0.509%	0.504%	0.503%	0.502%	0.501%
\$150,000	4,000	16	0.643%	0.519%	0.506%	0.504%	0.503%	0.502%	0.501%
\$150,000	5,000	16	0.578%	0.510%	0.505%	0.504%	0.503%	0.502%	0.501%
\$150,000	10,000	16	0.508%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$150,000	20,000	16	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$160,000	5	16	59.025%	57.108%	55.263%	53.484%	51.767%	48.518%	45.495%
\$160,000	10	16	44.371%	42.100%	39.936%	37.868%	35.887%	32.168%	28.753%
\$160,000	15	16	35.887%	33.390%	31.015%	28.755%	26.610%	22.685%	19.257%
\$160,000	20	16	30.342%	27.743%	25.328%	23.091%	21.018%	17.359%	14.313%
\$160,000	25	16	26.323%	23.758%	21.417%	19.281%	17.337%	13.972%	11.220%
\$160,000	50	16	17.182%	14.786%	12.674%	10.833%	9.235%	6.667%	4.778%
\$160,000	100	16	11.044%	8.864%	7.066%	5.605%	4.425%	2.757%	1.757%
\$160,000	150	16	8.346%	6.355%	4.796%	3.595%	2.690%	1.536%	0.959%
\$160,000	200	16	6.790%	4.960%	3.588%	2.589%	1.883%	1.066%	0.713%
\$160,000	300	16	5.127%	3.510%	2.389%	1.644%	1.168%	0.703%	0.556%
\$160,000	400	16	4.186%	2.731%	1.784%	1.203%	0.866%	0.587%	0.517%
\$160,000	500	16	3.626%	2.284%	1.464%	0.988%	0.731%	0.544%	0.508%
\$160,000	600	16	3.158%	1.926%	1.210%	0.826%	0.638%	0.519%	0.503%
\$160,000	700	16	2.807%	1.668%	1.041%	0.729%	0.588%	0.511%	0.502%
\$160,000	800	16	2.532%	1.473%	0.920%	0.664%	0.557%	0.506%	0.501%
\$160,000	900	16	2.295%	1.314%	0.828%	0.617%	0.537%	0.504%	0.501%
\$160,000	1,000	16	2.098%	1.186%	0.758%	0.585%	0.525%	0.503%	0.501%
\$160,000	1,500	16	1.496%	0.834%	0.593%	0.523%	0.506%	0.502%	0.501%
\$160,000	2,000	16	1.148%	0.671%	0.536%	0.508%	0.503%	0.502%	0.501%
\$160,000	3,000	16	0.807%	0.555%	0.510%	0.504%	0.503%	0.502%	0.501%
\$160,000	4,000	16	0.654%	0.520%	0.506%	0.504%	0.503%	0.502%	0.501%
\$160,000	5,000	16	0.585%	0.511%	0.505%	0.504%	0.503%	0.502%	0.501%
\$160,000	10,000	16	0.509%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$160,000	20,000	16	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$170,000	5	16	59.498%	57.601%	55.774%	54.013%	52.315%	49.103%	46.115%
\$170,000	10	16	44.937%	42.692%	40.557%	38.516%	36.559%	32.890%	29.522%
\$170,000	15	16	36.489%	34.024%	31.681%	29.449%	27.327%	23.410%	19.968%
\$170,000	20	16	30.938%	28.354%	25.948%	23.708%	21.625%	17.930%	14.834%
\$170,000	25	16	26.857%	24.292%	21.940%	19.794%	17.836%	14.434%	11.649%
\$170,000	50	16	17.528%	15.125%	13.004%	11.150%	9.535%	6.928%	4.998%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$170,000	100	16	11.279%	9.087%	7.275%	5.795%	4.596%	2.884%	1.848%
\$170,000	150	16	8.531%	6.525%	4.948%	3.727%	2.800%	1.608%	1.002%
\$170,000	200	16	6.944%	5.097%	3.707%	2.688%	1.962%	1.110%	0.736%
\$170,000	300	16	5.246%	3.612%	2.470%	1.706%	1.213%	0.724%	0.563%
\$170,000	400	16	4.287%	2.815%	1.848%	1.249%	0.896%	0.598%	0.521%
\$170,000	500	16	3.715%	2.355%	1.515%	1.022%	0.752%	0.550%	0.510%
\$170,000	600	16	3.239%	1.987%	1.252%	0.852%	0.652%	0.522%	0.504%
\$170,000	700	16	2.879%	1.721%	1.075%	0.748%	0.598%	0.513%	0.502%
\$170,000	800	16	2.597%	1.518%	0.948%	0.678%	0.563%	0.507%	0.501%
\$170,000	900	16	2.355%	1.354%	0.851%	0.629%	0.542%	0.504%	0.501%
\$170,000	1,000	16	2.154%	1.221%	0.777%	0.594%	0.528%	0.503%	0.501%
\$170,000	1,500	16	1.538%	0.855%	0.601%	0.525%	0.507%	0.502%	0.501%
\$170,000	2,000	16	1.179%	0.684%	0.540%	0.509%	0.503%	0.502%	0.501%
\$170,000	3,000	16	0.825%	0.560%	0.511%	0.504%	0.503%	0.502%	0.501%
\$170,000	4,000	16	0.666%	0.522%	0.506%	0.504%	0.503%	0.502%	0.501%
\$170,000	5,000	16	0.592%	0.512%	0.505%	0.504%	0.503%	0.502%	0.501%
\$170,000	10,000	16	0.509%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$170,000	20,000	16	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$180,000	5	16	59.936%	58.056%	56.246%	54.501%	52.821%	49.642%	46.687%
\$180,000	10	16	45.456%	43.238%	41.127%	39.109%	37.175%	33.553%	30.227%
\$180,000	15	16	37.039%	34.604%	32.291%	30.086%	27.992%	24.106%	20.655%
\$180,000	20	16	31.504%	28.937%	26.541%	24.303%	22.215%	18.495%	15.351%
\$180,000	25	16	27.372%	24.809%	22.452%	20.293%	18.320%	14.886%	12.064%
\$180,000	50	16	17.861%	15.452%	13.324%	11.457%	9.827%	7.183%	5.214%
\$180,000	100	16	11.507%	9.304%	7.478%	5.981%	4.765%	3.010%	1.938%
\$180,000	150	16	8.709%	6.690%	5.097%	3.856%	2.910%	1.679%	1.045%
\$180,000	200	16	7.092%	5.230%	3.823%	2.785%	2.038%	1.155%	0.760%
\$180,000	300	16	5.361%	3.711%	2.550%	1.768%	1.258%	0.745%	0.571%
\$180,000	400	16	4.385%	2.896%	1.911%	1.293%	0.926%	0.609%	0.524%
\$180,000	500	16	3.794%	2.418%	1.560%	1.052%	0.770%	0.554%	0.510%
\$180,000	600	16	3.316%	2.046%	1.292%	0.877%	0.666%	0.525%	0.504%
\$180,000	700	16	2.948%	1.772%	1.108%	0.767%	0.608%	0.514%	0.502%
\$180,000	800	16	2.659%	1.562%	0.975%	0.692%	0.570%	0.508%	0.501%
\$180,000	900	16	2.412%	1.393%	0.873%	0.640%	0.547%	0.505%	0.501%
\$180,000	1,000	16	2.207%	1.256%	0.796%	0.603%	0.532%	0.504%	0.501%
\$180,000	1,500	16	1.577%	0.876%	0.610%	0.528%	0.507%	0.502%	0.501%
\$180,000	2,000	16	1.210%	0.697%	0.544%	0.510%	0.503%	0.502%	0.501%
\$180,000	3,000	16	0.844%	0.565%	0.512%	0.504%	0.503%	0.502%	0.501%
\$180,000	4,000	16	0.677%	0.525%	0.506%	0.504%	0.503%	0.502%	0.501%
\$180,000	5,000	16	0.599%	0.513%	0.505%	0.504%	0.503%	0.502%	0.501%
\$180,000	10,000	16	0.509%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$180,000	20,000	16	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$190,000	5	16	60.324%	58.460%	56.665%	54.934%	53.270%	50.121%	47.195%
\$190,000	10	16	45.924%	43.730%	41.641%	39.644%	37.731%	34.151%	30.861%
\$190,000	15	16	37.535%	35.128%	32.840%	30.662%	28.594%	24.751%	21.308%
\$190,000	20	16	32.026%	29.482%	27.097%	24.865%	22.778%	19.044%	15.860%
\$190,000	25	16	27.860%	25.304%	22.945%	20.778%	18.791%	15.324%	12.468%
\$190,000	50	16	18.176%	15.763%	13.629%	11.750%	10.109%	7.431%	5.426%
\$190,000	100	16	11.724%	9.512%	7.673%	6.160%	4.926%	3.132%	2.025%
\$190,000	150	16	8.880%	6.847%	5.239%	3.980%	3.015%	1.749%	1.089%
\$190,000	200	16	7.233%	5.357%	3.934%	2.878%	2.113%	1.200%	0.783%
\$190,000	300	16	5.469%	3.805%	2.626%	1.826%	1.302%	0.765%	0.579%
\$190,000	400	16	4.476%	2.972%	1.971%	1.336%	0.955%	0.620%	0.527%
\$190,000	500	16	3.876%	2.484%	1.607%	1.084%	0.790%	0.561%	0.512%
\$190,000	600	16	3.389%	2.102%	1.331%	0.901%	0.680%	0.529%	0.505%
\$190,000	700	16	3.014%	1.820%	1.139%	0.786%	0.618%	0.516%	0.503%
\$190,000	800	16	2.719%	1.604%	1.001%	0.707%	0.577%	0.509%	0.501%
\$190,000	900	16	2.467%	1.430%	0.895%	0.651%	0.551%	0.506%	0.501%
\$190,000	1,000	16	2.258%	1.289%	0.815%	0.612%	0.535%	0.504%	0.501%
\$190,000	1,500	16	1.616%	0.897%	0.618%	0.531%	0.508%	0.502%	0.501%
\$190,000	2,000	16	1.239%	0.709%	0.548%	0.510%	0.504%	0.502%	0.501%
\$190,000	3,000	16	0.862%	0.570%	0.513%	0.505%	0.503%	0.502%	0.501%
\$190,000	4,000	16	0.688%	0.527%	0.506%	0.504%	0.503%	0.502%	0.501%
\$190,000	5,000	16	0.606%	0.513%	0.505%	0.504%	0.503%	0.502%	0.501%
\$190,000	10,000	16	0.510%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$190,000	20,000	16	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$200,000	5	16	60.674%	58.824%	57.043%	55.326%	53.676%	50.553%	47.653%
\$200,000	10	16	46.343%	44.172%	42.102%	40.122%	38.229%	34.685%	31.429%
\$200,000	15	16	37.976%	35.593%	33.328%	31.173%	29.127%	25.329%	21.911%
\$200,000	20	16	32.492%	29.974%	27.605%	25.380%	23.298%	19.561%	16.348%
\$200,000	25	16	28.309%	25.763%	23.406%	21.234%	19.235%	15.740%	12.852%
\$200,000	50	16	18.471%	16.054%	13.914%	12.024%	10.372%	7.664%	5.627%
\$200,000	100	16	11.924%	9.706%	7.854%	6.326%	5.077%	3.250%	2.108%
\$200,000	150	16	9.038%	6.994%	5.372%	4.098%	3.116%	1.816%	1.131%
\$200,000	200	16	7.364%	5.476%	4.037%	2.965%	2.184%	1.242%	0.806%
\$200,000	300	16	5.570%	3.892%	2.698%	1.881%	1.343%	0.785%	0.587%
\$200,000	400	16	4.561%	3.043%	2.026%	1.376%	0.983%	0.630%	0.531%
\$200,000	500	16	3.952%	2.545%	1.652%	1.115%	0.809%	0.567%	0.513%
\$200,000	600	16	3.458%	2.155%	1.368%	0.924%	0.694%	0.532%	0.505%
\$200,000	700	16	3.075%	1.865%	1.169%	0.803%	0.627%	0.518%	0.503%
\$200,000	800	16	2.774%	1.643%	1.025%	0.720%	0.584%	0.510%	0.501%
\$200,000	900	16	2.517%	1.464%	0.915%	0.662%	0.556%	0.506%	0.501%
\$200,000	1,000	16	2.305%	1.320%	0.833%	0.620%	0.538%	0.504%	0.501%
\$200,000	1,500	16	1.651%	0.916%	0.626%	0.534%	0.509%	0.502%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$200,000	2,000	16	1.266%	0.721%	0.552%	0.511%	0.504%	0.502%	0.501%
\$200,000	3,000	16	0.879%	0.575%	0.514%	0.505%	0.503%	0.502%	0.501%
\$200,000	4,000	16	0.699%	0.529%	0.506%	0.504%	0.503%	0.502%	0.501%
\$200,000	5,000	16	0.613%	0.514%	0.505%	0.504%	0.503%	0.502%	0.501%
\$200,000	10,000	16	0.510%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$200,000	20,000	16	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$225,000	5	16	61.447%	59.626%	57.873%	56.188%	54.566%	51.503%	48.656%
\$225,000	10	16	47.258%	45.133%	43.105%	41.164%	39.311%	35.846%	32.660%
\$225,000	15	16	38.922%	36.590%	34.372%	32.268%	30.269%	26.570%	23.239%
\$225,000	20	16	33.493%	31.037%	28.722%	26.535%	24.476%	20.752%	17.512%
\$225,000	25	16	29.322%	26.806%	24.469%	22.298%	20.288%	16.736%	13.771%
\$225,000	50	16	19.148%	16.728%	14.575%	12.666%	10.981%	8.213%	6.106%
\$225,000	100	16	12.388%	10.155%	8.277%	6.719%	5.434%	3.535%	2.315%
\$225,000	150	16	9.410%	7.343%	5.687%	4.378%	3.358%	1.981%	1.236%
\$225,000	200	16	7.671%	5.756%	4.281%	3.172%	2.353%	1.346%	0.861%
\$225,000	300	16	5.803%	4.094%	2.865%	2.012%	1.442%	0.833%	0.607%
\$225,000	400	16	4.759%	3.208%	2.157%	1.472%	1.050%	0.657%	0.540%
\$225,000	500	16	4.127%	2.689%	1.758%	1.188%	0.857%	0.583%	0.517%
\$225,000	600	16	3.617%	2.279%	1.455%	0.981%	0.727%	0.541%	0.507%
\$225,000	700	16	3.218%	1.972%	1.241%	0.846%	0.651%	0.523%	0.504%
\$225,000	800	16	2.902%	1.737%	1.085%	0.754%	0.601%	0.512%	0.502%
\$225,000	900	16	2.634%	1.546%	0.965%	0.689%	0.569%	0.508%	0.501%
\$225,000	1,000	16	2.415%	1.394%	0.875%	0.640%	0.547%	0.506%	0.501%
\$225,000	1,500	16	1.733%	0.962%	0.646%	0.540%	0.511%	0.502%	0.501%
\$225,000	2,000	16	1.329%	0.750%	0.561%	0.514%	0.504%	0.502%	0.501%
\$225,000	3,000	16	0.920%	0.588%	0.516%	0.505%	0.503%	0.502%	0.501%
\$225,000	4,000	16	0.725%	0.534%	0.507%	0.504%	0.503%	0.502%	0.501%
\$225,000	5,000	16	0.630%	0.517%	0.505%	0.504%	0.503%	0.502%	0.501%
\$225,000	10,000	16	0.511%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$225,000	20,000	16	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$250,000	5	16	62.102%	60.306%	58.577%	56.918%	55.321%	52.306%	49.503%
\$250,000	10	16	48.026%	45.936%	43.941%	42.035%	40.213%	36.812%	33.686%
\$250,000	15	16	39.707%	37.416%	35.239%	33.176%	31.214%	27.597%	24.341%
\$250,000	20	16	34.330%	31.924%	29.657%	27.517%	25.502%	21.825%	18.581%
\$250,000	25	16	30.200%	27.727%	25.418%	23.263%	21.258%	17.687%	14.659%
\$250,000	50	16	19.769%	17.346%	15.183%	13.259%	11.550%	8.725%	6.559%
\$250,000	100	16	12.815%	10.568%	8.670%	7.086%	5.772%	3.806%	2.519%
\$250,000	150	16	9.754%	7.668%	5.984%	4.643%	3.591%	2.148%	1.343%
\$250,000	200	16	7.955%	6.018%	4.513%	3.369%	2.517%	1.450%	0.920%
\$250,000	300	16	6.023%	4.287%	3.027%	2.140%	1.541%	0.884%	0.630%
\$250,000	400	16	4.943%	3.364%	2.282%	1.567%	1.117%	0.686%	0.550%
\$250,000	500	16	4.292%	2.825%	1.861%	1.261%	0.906%	0.601%	0.522%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$250,000	600	16	3.767%	2.399%	1.542%	1.038%	0.763%	0.551%	0.509%
\$250,000	700	16	3.351%	2.074%	1.312%	0.891%	0.676%	0.529%	0.505%
\$250,000	800	16	3.024%	1.827%	1.144%	0.789%	0.619%	0.516%	0.502%
\$250,000	900	16	2.745%	1.625%	1.015%	0.716%	0.581%	0.510%	0.502%
\$250,000	1,000	16	2.517%	1.464%	0.916%	0.662%	0.556%	0.507%	0.501%
\$250,000	1,500	16	1.810%	1.006%	0.667%	0.548%	0.513%	0.502%	0.501%
\$250,000	2,000	16	1.388%	0.779%	0.571%	0.516%	0.504%	0.502%	0.501%
\$250,000	3,000	16	0.958%	0.601%	0.519%	0.505%	0.503%	0.502%	0.501%
\$250,000	4,000	16	0.750%	0.540%	0.508%	0.504%	0.503%	0.502%	0.501%
\$250,000	5,000	16	0.647%	0.519%	0.506%	0.504%	0.503%	0.502%	0.501%
\$250,000	10,000	16	0.512%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$250,000	20,000	16	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$275,000	5	16	62.634%	60.858%	59.150%	57.510%	55.933%	52.957%	50.191%
\$275,000	10	16	48.632%	46.570%	44.601%	42.721%	40.927%	37.575%	34.497%
\$275,000	15	16	40.319%	38.059%	35.915%	33.884%	31.953%	28.401%	25.206%
\$275,000	20	16	34.998%	32.633%	30.403%	28.301%	26.325%	22.717%	19.503%
\$275,000	25	16	30.913%	28.484%	26.212%	24.084%	22.097%	18.535%	15.476%
\$275,000	50	16	20.316%	17.892%	15.721%	13.784%	12.058%	9.184%	6.970%
\$275,000	100	16	13.193%	10.937%	9.022%	7.415%	6.077%	4.054%	2.712%
\$275,000	150	16	10.064%	7.965%	6.259%	4.889%	3.807%	2.307%	1.448%
\$275,000	200	16	8.212%	6.256%	4.726%	3.553%	2.672%	1.550%	0.978%
\$275,000	300	16	6.224%	4.465%	3.175%	2.259%	1.633%	0.934%	0.653%
\$275,000	400	16	5.110%	3.507%	2.397%	1.654%	1.180%	0.715%	0.560%
\$275,000	500	16	4.442%	2.950%	1.957%	1.330%	0.953%	0.619%	0.527%
\$275,000	600	16	3.903%	2.506%	1.621%	1.092%	0.797%	0.561%	0.511%
\$275,000	700	16	3.471%	2.167%	1.377%	0.933%	0.701%	0.535%	0.506%
\$275,000	800	16	3.133%	1.909%	1.198%	0.821%	0.637%	0.519%	0.503%
\$275,000	900	16	2.844%	1.696%	1.060%	0.742%	0.594%	0.512%	0.502%
\$275,000	1,000	16	2.608%	1.527%	0.955%	0.683%	0.566%	0.508%	0.502%
\$275,000	1,500	16	1.879%	1.047%	0.686%	0.555%	0.515%	0.502%	0.501%
\$275,000	2,000	16	1.443%	0.805%	0.581%	0.519%	0.505%	0.502%	0.501%
\$275,000	3,000	16	0.993%	0.613%	0.522%	0.506%	0.503%	0.502%	0.501%
\$275,000	4,000	16	0.773%	0.545%	0.508%	0.504%	0.503%	0.502%	0.501%
\$275,000	5,000	16	0.662%	0.522%	0.506%	0.504%	0.503%	0.502%	0.501%
\$275,000	10,000	16	0.513%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$275,000	20,000	16	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$300,000	5	16	63.070%	61.311%	59.620%	57.997%	56.436%	53.492%	50.755%
\$300,000	10	16	49.117%	47.077%	45.129%	43.271%	41.498%	38.186%	35.147%
\$300,000	15	16	40.812%	38.578%	36.462%	34.456%	32.552%	29.050%	25.903%
\$300,000	20	16	35.541%	33.208%	31.009%	28.939%	26.996%	23.444%	20.282%
\$300,000	25	16	31.497%	29.106%	26.868%	24.774%	22.814%	19.280%	16.218%
\$300,000	50	16	20.806%	18.384%	16.210%	14.262%	12.522%	9.607%	7.350%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$300,000	100	16	13.531%	11.268%	9.339%	7.712%	6.353%	4.282%	2.890%
\$300,000	150	16	10.342%	8.230%	6.507%	5.113%	4.005%	2.454%	1.548%
\$300,000	200	16	8.442%	6.471%	4.918%	3.720%	2.813%	1.644%	1.035%
\$300,000	300	16	6.402%	4.624%	3.311%	2.369%	1.719%	0.981%	0.675%
\$300,000	400	16	5.258%	3.635%	2.501%	1.733%	1.238%	0.743%	0.571%
\$300,000	500	16	4.575%	3.061%	2.043%	1.392%	0.997%	0.637%	0.533%
\$300,000	600	16	4.017%	2.597%	1.688%	1.138%	0.826%	0.569%	0.512%
\$300,000	700	16	3.577%	2.250%	1.437%	0.973%	0.724%	0.541%	0.507%
\$300,000	800	16	3.230%	1.982%	1.248%	0.852%	0.654%	0.523%	0.504%
\$300,000	900	16	2.932%	1.760%	1.102%	0.766%	0.607%	0.515%	0.502%
\$300,000	1,000	16	2.690%	1.585%	0.991%	0.702%	0.575%	0.510%	0.502%
\$300,000	1,500	16	1.942%	1.084%	0.704%	0.563%	0.518%	0.502%	0.501%
\$300,000	2,000	16	1.491%	0.830%	0.591%	0.522%	0.506%	0.502%	0.501%
\$300,000	3,000	16	1.025%	0.624%	0.524%	0.506%	0.503%	0.502%	0.501%
\$300,000	4,000	16	0.796%	0.551%	0.509%	0.504%	0.503%	0.502%	0.501%
\$300,000	5,000	16	0.677%	0.525%	0.506%	0.504%	0.503%	0.502%	0.501%
\$300,000	10,000	16	0.514%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$300,000	20,000	16	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$325,000	5	16	63.445%	61.698%	60.022%	58.413%	56.866%	53.949%	51.236%
\$325,000	10	16	49.530%	47.509%	45.579%	43.739%	41.985%	38.705%	35.700%
\$325,000	15	16	41.234%	39.021%	36.929%	34.943%	33.062%	29.602%	26.494%
\$325,000	20	16	36.006%	33.699%	31.526%	29.482%	27.566%	24.062%	20.945%
\$325,000	25	16	31.992%	29.632%	27.423%	25.357%	23.426%	19.935%	16.885%
\$325,000	50	16	21.251%	18.833%	16.657%	14.701%	12.950%	10.003%	7.700%
\$325,000	100	16	13.836%	11.568%	9.628%	7.985%	6.606%	4.492%	3.058%
\$325,000	150	16	10.593%	8.470%	6.732%	5.319%	4.187%	2.590%	1.644%
\$325,000	200	16	8.649%	6.664%	5.094%	3.873%	2.943%	1.731%	1.089%
\$325,000	300	16	6.564%	4.769%	3.434%	2.470%	1.797%	1.026%	0.697%
\$325,000	400	16	5.392%	3.751%	2.596%	1.806%	1.292%	0.769%	0.582%
\$325,000	500	16	4.695%	3.162%	2.122%	1.451%	1.038%	0.654%	0.538%
\$325,000	600	16	4.125%	2.686%	1.755%	1.185%	0.856%	0.579%	0.515%
\$325,000	700	16	3.672%	2.326%	1.492%	1.010%	0.746%	0.548%	0.508%
\$325,000	800	16	3.317%	2.050%	1.295%	0.882%	0.671%	0.527%	0.504%
\$325,000	900	16	3.012%	1.819%	1.141%	0.788%	0.619%	0.517%	0.503%
\$325,000	1,000	16	2.764%	1.638%	1.025%	0.721%	0.584%	0.511%	0.502%
\$325,000	1,500	16	1.998%	1.119%	0.722%	0.570%	0.520%	0.503%	0.501%
\$325,000	2,000	16	1.536%	0.853%	0.600%	0.525%	0.506%	0.502%	0.501%
\$325,000	3,000	16	1.055%	0.635%	0.527%	0.507%	0.503%	0.502%	0.501%
\$325,000	4,000	16	0.816%	0.556%	0.510%	0.504%	0.503%	0.502%	0.501%
\$325,000	5,000	16	0.691%	0.528%	0.506%	0.504%	0.503%	0.502%	0.501%
\$325,000	10,000	16	0.515%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$325,000	20,000	16	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$350,000	5	16	63.771%	62.037%	60.374%	58.776%	57.241%	54.347%	51.656%
\$350,000	10	16	49.890%	47.884%	45.971%	44.146%	42.409%	39.156%	36.179%
\$350,000	15	16	41.599%	39.406%	37.332%	35.364%	33.504%	30.080%	27.006%
\$350,000	20	16	36.411%	34.128%	31.977%	29.957%	28.063%	24.600%	21.521%
\$350,000	25	16	32.424%	30.091%	27.908%	25.866%	23.959%	20.514%	17.492%
\$350,000	50	16	21.662%	19.252%	17.078%	15.114%	13.356%	10.379%	8.036%
\$350,000	100	16	14.121%	11.850%	9.901%	8.244%	6.848%	4.695%	3.220%
\$350,000	150	16	10.829%	8.697%	6.944%	5.516%	4.362%	2.723%	1.738%
\$350,000	200	16	8.845%	6.848%	5.260%	4.020%	3.068%	1.816%	1.142%
\$350,000	300	16	6.715%	4.905%	3.552%	2.568%	1.874%	1.071%	0.720%
\$350,000	400	16	5.519%	3.861%	2.687%	1.878%	1.345%	0.794%	0.593%
\$350,000	500	16	4.807%	3.258%	2.198%	1.508%	1.077%	0.671%	0.544%
\$350,000	600	16	4.228%	2.771%	1.820%	1.231%	0.886%	0.590%	0.517%
\$350,000	700	16	3.762%	2.398%	1.545%	1.046%	0.769%	0.555%	0.510%
\$350,000	800	16	3.400%	2.114%	1.341%	0.911%	0.687%	0.531%	0.505%
\$350,000	900	16	3.087%	1.876%	1.178%	0.811%	0.631%	0.520%	0.503%
\$350,000	1,000	16	2.834%	1.689%	1.057%	0.739%	0.594%	0.513%	0.502%
\$350,000	1,500	16	2.052%	1.152%	0.739%	0.577%	0.523%	0.503%	0.501%
\$350,000	2,000	16	1.579%	0.876%	0.609%	0.528%	0.507%	0.502%	0.501%
\$350,000	3,000	16	1.083%	0.646%	0.530%	0.507%	0.503%	0.502%	0.501%
\$350,000	4,000	16	0.836%	0.562%	0.511%	0.504%	0.503%	0.502%	0.501%
\$350,000	5,000	16	0.705%	0.530%	0.507%	0.504%	0.503%	0.502%	0.501%
\$350,000	10,000	16	0.516%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$350,000	20,000	16	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$375,000	5	16	64.070%	62.346%	60.695%	59.108%	57.584%	54.710%	52.038%
\$375,000	10	16	50.219%	48.227%	46.329%	44.518%	42.794%	39.568%	36.616%
\$375,000	15	16	41.927%	39.751%	37.695%	35.743%	33.901%	30.509%	27.466%
\$375,000	20	16	36.776%	34.512%	32.382%	30.383%	28.508%	25.083%	22.038%
\$375,000	25	16	32.811%	30.501%	28.341%	26.322%	24.437%	21.033%	18.047%
\$375,000	50	16	22.056%	19.657%	17.487%	15.521%	13.755%	10.754%	8.376%
\$375,000	100	16	14.400%	12.125%	10.170%	8.501%	7.088%	4.898%	3.384%
\$375,000	150	16	11.057%	8.918%	7.150%	5.708%	4.535%	2.856%	1.833%
\$375,000	200	16	9.035%	7.027%	5.422%	4.165%	3.192%	1.901%	1.197%
\$375,000	300	16	6.862%	5.039%	3.669%	2.665%	1.951%	1.117%	0.744%
\$375,000	400	16	5.642%	3.969%	2.777%	1.950%	1.398%	0.821%	0.605%
\$375,000	500	16	4.916%	3.351%	2.273%	1.564%	1.117%	0.688%	0.550%
\$375,000	600	16	4.327%	2.853%	1.883%	1.276%	0.916%	0.601%	0.520%
\$375,000	700	16	3.842%	2.462%	1.592%	1.077%	0.789%	0.560%	0.510%
\$375,000	800	16	3.480%	2.177%	1.386%	0.940%	0.704%	0.535%	0.506%
\$375,000	900	16	3.160%	1.931%	1.216%	0.834%	0.644%	0.522%	0.504%
\$375,000	1,000	16	2.902%	1.739%	1.090%	0.758%	0.603%	0.515%	0.503%
\$375,000	1,500	16	2.104%	1.185%	0.757%	0.585%	0.525%	0.503%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$375,000	2,000	16	1.620%	0.898%	0.618%	0.531%	0.508%	0.502%	0.501%
\$375,000	3,000	16	1.111%	0.657%	0.533%	0.508%	0.503%	0.502%	0.501%
\$375,000	4,000	16	0.856%	0.567%	0.512%	0.504%	0.503%	0.502%	0.501%
\$375,000	5,000	16	0.718%	0.533%	0.507%	0.504%	0.503%	0.502%	0.501%
\$375,000	10,000	16	0.518%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$375,000	20,000	16	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$400,000	5	16	64.345%	62.632%	60.991%	59.414%	57.900%	55.045%	52.390%
\$400,000	10	16	50.525%	48.547%	46.661%	44.864%	43.153%	39.949%	37.021%
\$400,000	15	16	42.221%	40.061%	38.020%	36.083%	34.257%	30.894%	27.877%
\$400,000	20	16	37.100%	34.855%	32.743%	30.762%	28.904%	25.512%	22.498%
\$400,000	25	16	33.155%	30.865%	28.725%	26.726%	24.860%	21.493%	18.540%
\$400,000	50	16	22.418%	20.032%	17.868%	15.905%	14.135%	11.116%	8.706%
\$400,000	100	16	14.662%	12.387%	10.425%	8.747%	7.320%	5.094%	3.545%
\$400,000	150	16	11.272%	9.127%	7.346%	5.889%	4.700%	2.984%	1.927%
\$400,000	200	16	9.214%	7.196%	5.577%	4.302%	3.311%	1.984%	1.251%
\$400,000	300	16	7.003%	5.167%	3.781%	2.760%	2.027%	1.163%	0.768%
\$400,000	400	16	5.759%	4.072%	2.864%	2.019%	1.450%	0.847%	0.617%
\$400,000	500	16	5.019%	3.440%	2.345%	1.618%	1.156%	0.706%	0.556%
\$400,000	600	16	4.420%	2.931%	1.944%	1.321%	0.947%	0.613%	0.523%
\$400,000	700	16	3.924%	2.528%	1.642%	1.112%	0.812%	0.567%	0.512%
\$400,000	800	16	3.556%	2.237%	1.429%	0.969%	0.721%	0.540%	0.507%
\$400,000	900	16	3.229%	1.984%	1.252%	0.857%	0.657%	0.525%	0.504%
\$400,000	1,000	16	2.967%	1.787%	1.121%	0.776%	0.613%	0.517%	0.503%
\$400,000	1,500	16	2.153%	1.217%	0.774%	0.593%	0.528%	0.503%	0.501%
\$400,000	2,000	16	1.659%	0.920%	0.628%	0.534%	0.509%	0.502%	0.501%
\$400,000	3,000	16	1.137%	0.667%	0.536%	0.508%	0.503%	0.502%	0.501%
\$400,000	4,000	16	0.874%	0.573%	0.513%	0.505%	0.503%	0.502%	0.501%
\$400,000	5,000	16	0.732%	0.536%	0.507%	0.504%	0.503%	0.502%	0.501%
\$400,000	10,000	16	0.519%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$400,000	20,000	16	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$425,000	5	16	64.599%	62.896%	61.264%	59.696%	58.191%	55.352%	52.714%
\$425,000	10	16	50.811%	48.844%	46.971%	45.185%	43.486%	40.303%	37.396%
\$425,000	15	16	42.489%	40.343%	38.315%	36.392%	34.580%	31.243%	28.250%
\$425,000	20	16	37.399%	35.170%	33.074%	31.111%	29.268%	25.905%	22.919%
\$425,000	25	16	33.472%	31.201%	29.080%	27.099%	25.250%	21.915%	18.992%
\$425,000	50	16	22.755%	20.384%	18.229%	16.272%	14.503%	11.469%	9.031%
\$425,000	100	16	14.913%	12.638%	10.671%	8.985%	7.545%	5.286%	3.703%
\$425,000	150	16	11.477%	9.327%	7.534%	6.064%	4.860%	3.110%	2.020%
\$425,000	200	16	9.384%	7.359%	5.727%	4.436%	3.427%	2.067%	1.305%
\$425,000	300	16	7.138%	5.291%	3.890%	2.852%	2.101%	1.208%	0.793%
\$425,000	400	16	5.872%	4.171%	2.947%	2.086%	1.500%	0.873%	0.629%
\$425,000	500	16	5.118%	3.525%	2.414%	1.671%	1.194%	0.724%	0.562%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$425,000	600	16	4.509%	3.007%	2.003%	1.365%	0.977%	0.625%	0.526%
\$425,000	700	16	4.002%	2.592%	1.690%	1.146%	0.834%	0.574%	0.514%
\$425,000	800	16	3.628%	2.294%	1.471%	0.997%	0.739%	0.545%	0.508%
\$425,000	900	16	3.295%	2.034%	1.287%	0.879%	0.669%	0.528%	0.505%
\$425,000	1,000	16	3.029%	1.833%	1.151%	0.794%	0.623%	0.519%	0.504%
\$425,000	1,500	16	2.200%	1.248%	0.791%	0.600%	0.532%	0.504%	0.501%
\$425,000	2,000	16	1.696%	0.941%	0.637%	0.537%	0.510%	0.502%	0.501%
\$425,000	3,000	16	1.162%	0.678%	0.539%	0.509%	0.503%	0.502%	0.501%
\$425,000	4,000	16	0.893%	0.578%	0.514%	0.505%	0.503%	0.502%	0.501%
\$425,000	5,000	16	0.744%	0.539%	0.508%	0.504%	0.503%	0.502%	0.501%
\$425,000	10,000	16	0.520%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$425,000	20,000	16	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$450,000	5	16	64.820%	63.125%	61.500%	59.940%	58.444%	55.619%	52.995%
\$450,000	10	16	51.065%	49.108%	47.245%	45.470%	43.780%	40.617%	37.728%
\$450,000	15	16	42.724%	40.592%	38.575%	36.665%	34.865%	31.551%	28.578%
\$450,000	20	16	37.665%	35.450%	33.369%	31.421%	29.592%	26.253%	23.293%
\$450,000	25	16	33.758%	31.503%	29.397%	27.432%	25.598%	22.293%	19.395%
\$450,000	50	16	23.060%	20.705%	18.562%	16.611%	14.844%	11.803%	9.344%
\$450,000	100	16	15.147%	12.873%	10.901%	9.207%	7.756%	5.468%	3.854%
\$450,000	150	16	11.667%	9.513%	7.712%	6.227%	5.010%	3.230%	2.108%
\$450,000	200	16	9.544%	7.511%	5.868%	4.562%	3.538%	2.146%	1.358%
\$450,000	300	16	7.265%	5.407%	3.994%	2.940%	2.173%	1.252%	0.817%
\$450,000	400	16	5.977%	4.265%	3.026%	2.150%	1.550%	0.898%	0.640%
\$450,000	500	16	5.210%	3.605%	2.480%	1.721%	1.231%	0.741%	0.569%
\$450,000	600	16	4.592%	3.077%	2.058%	1.406%	1.006%	0.637%	0.530%
\$450,000	700	16	4.075%	2.652%	1.736%	1.179%	0.855%	0.582%	0.516%
\$450,000	800	16	3.696%	2.348%	1.510%	1.023%	0.755%	0.550%	0.509%
\$450,000	900	16	3.356%	2.082%	1.321%	0.900%	0.682%	0.532%	0.506%
\$450,000	1,000	16	3.086%	1.877%	1.181%	0.812%	0.633%	0.521%	0.504%
\$450,000	1,500	16	2.244%	1.277%	0.807%	0.608%	0.535%	0.504%	0.501%
\$450,000	2,000	16	1.730%	0.961%	0.646%	0.540%	0.511%	0.502%	0.501%
\$450,000	3,000	16	1.186%	0.688%	0.542%	0.509%	0.503%	0.502%	0.501%
\$450,000	4,000	16	0.910%	0.584%	0.515%	0.505%	0.503%	0.502%	0.501%
\$450,000	5,000	16	0.757%	0.542%	0.508%	0.504%	0.503%	0.502%	0.501%
\$450,000	10,000	16	0.522%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$450,000	20,000	16	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$475,000	5	16	65.022%	63.336%	61.718%	60.165%	58.676%	55.865%	53.253%
\$475,000	10	16	51.294%	49.347%	47.493%	45.729%	44.048%	40.901%	38.029%
\$475,000	15	16	42.935%	40.814%	38.808%	36.909%	35.121%	31.828%	28.874%
\$475,000	20	16	37.907%	35.705%	33.638%	31.703%	29.886%	26.571%	23.635%
\$475,000	25	16	34.017%	31.777%	29.686%	27.735%	25.916%	22.637%	19.762%
\$475,000	50	16	23.342%	21.005%	18.875%	16.934%	15.170%	12.130%	9.654%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$475,000	100	16	15.375%	13.101%	11.125%	9.424%	7.962%	5.647%	4.003%
\$475,000	150	16	11.852%	9.694%	7.886%	6.387%	5.157%	3.349%	2.197%
\$475,000	200	16	9.701%	7.661%	6.007%	4.687%	3.649%	2.227%	1.412%
\$475,000	300	16	7.388%	5.521%	4.095%	3.027%	2.244%	1.296%	0.842%
\$475,000	400	16	6.080%	4.357%	3.104%	2.214%	1.599%	0.924%	0.653%
\$475,000	500	16	5.300%	3.683%	2.545%	1.772%	1.268%	0.758%	0.576%
\$475,000	600	16	4.672%	3.146%	2.113%	1.446%	1.034%	0.649%	0.534%
\$475,000	700	16	4.146%	2.711%	1.781%	1.211%	0.877%	0.590%	0.518%
\$475,000	800	16	3.761%	2.400%	1.549%	1.050%	0.772%	0.555%	0.510%
\$475,000	900	16	3.416%	2.129%	1.354%	0.921%	0.694%	0.535%	0.506%
\$475,000	1,000	16	3.142%	1.920%	1.209%	0.829%	0.642%	0.523%	0.504%
\$475,000	1,500	16	2.287%	1.305%	0.823%	0.616%	0.538%	0.504%	0.501%
\$475,000	2,000	16	1.764%	0.980%	0.655%	0.544%	0.512%	0.502%	0.501%
\$475,000	3,000	16	1.209%	0.698%	0.545%	0.510%	0.504%	0.502%	0.501%
\$475,000	4,000	16	0.926%	0.589%	0.516%	0.505%	0.503%	0.502%	0.501%
\$475,000	5,000	16	0.769%	0.545%	0.509%	0.504%	0.503%	0.502%	0.501%
\$475,000	10,000	16	0.523%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$475,000	20,000	16	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$500,000	5	16	65.199%	63.519%	61.908%	60.361%	58.879%	56.079%	53.479%
\$500,000	10	16	51.492%	49.552%	47.707%	45.951%	44.277%	41.146%	38.289%
\$500,000	15	16	43.117%	41.006%	39.009%	37.121%	35.342%	32.067%	29.129%
\$500,000	20	16	38.111%	35.921%	33.865%	31.942%	30.136%	26.841%	23.924%
\$500,000	25	16	34.234%	32.007%	29.929%	27.991%	26.183%	22.927%	20.072%
\$500,000	50	16	23.587%	21.267%	19.149%	17.219%	15.462%	12.423%	9.937%
\$500,000	100	16	15.583%	13.308%	11.330%	9.622%	8.150%	5.811%	4.141%
\$500,000	150	16	12.021%	9.859%	8.044%	6.534%	5.292%	3.460%	2.281%
\$500,000	200	16	9.845%	7.798%	6.136%	4.804%	3.752%	2.302%	1.464%
\$500,000	300	16	7.501%	5.627%	4.188%	3.108%	2.311%	1.339%	0.866%
\$500,000	400	16	6.175%	4.442%	3.176%	2.274%	1.645%	0.949%	0.664%
\$500,000	500	16	5.383%	3.756%	2.605%	1.818%	1.302%	0.775%	0.583%
\$500,000	600	16	4.746%	3.209%	2.163%	1.483%	1.061%	0.660%	0.538%
\$500,000	700	16	4.210%	2.765%	1.822%	1.240%	0.897%	0.597%	0.520%
\$500,000	800	16	3.812%	2.442%	1.579%	1.070%	0.784%	0.558%	0.510%
\$500,000	900	16	3.470%	2.171%	1.384%	0.941%	0.706%	0.538%	0.507%
\$500,000	1,000	16	3.193%	1.959%	1.236%	0.846%	0.652%	0.526%	0.505%
\$500,000	1,500	16	2.326%	1.331%	0.839%	0.624%	0.541%	0.504%	0.501%
\$500,000	2,000	16	1.795%	0.998%	0.664%	0.547%	0.513%	0.502%	0.501%
\$500,000	3,000	16	1.230%	0.707%	0.547%	0.511%	0.504%	0.502%	0.501%
\$500,000	4,000	16	0.942%	0.594%	0.517%	0.505%	0.503%	0.502%	0.501%
\$500,000	5,000	16	0.780%	0.548%	0.509%	0.504%	0.503%	0.502%	0.501%
\$500,000	10,000	16	0.524%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$500,000	20,000	16	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$30,000	5	17	37.154%	34.287%	31.593%	29.067%	26.711%	22.547%	19.055%
\$30,000	10	17	24.567%	21.950%	19.558%	17.389%	15.424%	12.045%	9.347%
\$30,000	15	17	19.201%	16.681%	14.433%	12.447%	10.703%	7.849%	5.697%
\$30,000	20	17	16.021%	13.590%	11.476%	9.647%	8.080%	5.615%	3.875%
\$30,000	25	17	14.062%	11.688%	9.655%	7.927%	6.479%	4.274%	2.812%
\$30,000	50	17	8.892%	6.823%	5.187%	3.920%	2.954%	1.707%	1.057%
\$30,000	100	17	5.550%	3.846%	2.644%	1.825%	1.290%	0.751%	0.568%
\$30,000	150	17	4.208%	2.730%	1.769%	1.182%	0.847%	0.574%	0.512%
\$30,000	200	17	3.390%	2.081%	1.302%	0.876%	0.661%	0.523%	0.502%
\$30,000	300	17	2.524%	1.454%	0.901%	0.651%	0.551%	0.505%	0.501%
\$30,000	400	17	2.018%	1.126%	0.724%	0.570%	0.520%	0.503%	0.501%
\$30,000	500	17	1.689%	0.930%	0.630%	0.534%	0.508%	0.502%	0.501%
\$30,000	600	17	1.455%	0.807%	0.581%	0.519%	0.505%	0.502%	0.501%
\$30,000	700	17	1.290%	0.728%	0.553%	0.512%	0.504%	0.502%	0.501%
\$30,000	800	17	1.156%	0.671%	0.536%	0.508%	0.503%	0.502%	0.501%
\$30,000	900	17	1.050%	0.629%	0.524%	0.506%	0.503%	0.502%	0.501%
\$30,000	1,000	17	0.965%	0.600%	0.518%	0.505%	0.503%	0.502%	0.501%
\$30,000	1,500	17	0.716%	0.531%	0.507%	0.504%	0.503%	0.502%	0.501%
\$30,000	2,000	17	0.606%	0.513%	0.505%	0.504%	0.503%	0.502%	0.501%
\$30,000	3,000	17	0.534%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$30,000	4,000	17	0.515%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$30,000	5,000	17	0.510%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$30,000	10,000	17	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$30,000	20,000	17	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$35,000	5	17	39.642%	36.810%	34.099%	31.541%	29.138%	24.774%	21.017%
\$35,000	10	17	25.950%	23.344%	20.951%	18.754%	16.755%	13.295%	10.481%
\$35,000	15	17	20.350%	17.813%	15.539%	13.511%	11.718%	8.749%	6.477%
\$35,000	20	17	16.987%	14.533%	12.382%	10.503%	8.878%	6.286%	4.418%
\$35,000	25	17	14.917%	12.513%	10.442%	8.664%	7.156%	4.821%	3.230%
\$35,000	50	17	9.460%	7.349%	5.656%	4.329%	3.306%	1.943%	1.201%
\$35,000	100	17	5.921%	4.170%	2.909%	2.030%	1.443%	0.824%	0.598%
\$35,000	150	17	4.497%	2.969%	1.952%	1.311%	0.932%	0.604%	0.520%
\$35,000	200	17	3.628%	2.266%	1.432%	0.958%	0.709%	0.535%	0.504%
\$35,000	300	17	2.714%	1.587%	0.982%	0.692%	0.570%	0.508%	0.501%
\$35,000	400	17	2.177%	1.226%	0.776%	0.592%	0.528%	0.503%	0.501%
\$35,000	500	17	1.827%	1.008%	0.665%	0.546%	0.512%	0.502%	0.501%
\$35,000	600	17	1.574%	0.868%	0.604%	0.525%	0.506%	0.502%	0.501%
\$35,000	700	17	1.395%	0.777%	0.570%	0.516%	0.504%	0.502%	0.501%
\$35,000	800	17	1.251%	0.711%	0.548%	0.511%	0.504%	0.502%	0.501%
\$35,000	900	17	1.134%	0.661%	0.532%	0.507%	0.503%	0.502%	0.501%
\$35,000	1,000	17	1.041%	0.626%	0.523%	0.506%	0.503%	0.502%	0.501%
\$35,000	1,500	17	0.761%	0.541%	0.508%	0.504%	0.503%	0.502%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$35,000	2,000	17	0.632%	0.516%	0.505%	0.504%	0.503%	0.502%	0.501%
\$35,000	3,000	17	0.544%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$35,000	4,000	17	0.519%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$35,000	5,000	17	0.511%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$35,000	10,000	17	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$35,000	20,000	17	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$40,000	5	17	41.759%	39.035%	36.404%	33.856%	31.418%	26.948%	23.017%
\$40,000	10	17	27.178%	24.575%	22.180%	19.983%	17.968%	14.437%	11.535%
\$40,000	15	17	21.381%	18.834%	16.538%	14.475%	12.638%	9.575%	7.197%
\$40,000	20	17	17.853%	15.378%	13.192%	11.279%	9.607%	6.909%	4.930%
\$40,000	25	17	15.687%	13.263%	11.157%	9.338%	7.779%	5.337%	3.632%
\$40,000	50	17	9.981%	7.836%	6.098%	4.717%	3.641%	2.175%	1.347%
\$40,000	100	17	6.267%	4.474%	3.162%	2.229%	1.594%	0.901%	0.631%
\$40,000	150	17	4.764%	3.191%	2.126%	1.438%	1.017%	0.637%	0.530%
\$40,000	200	17	3.848%	2.441%	1.558%	1.041%	0.759%	0.548%	0.506%
\$40,000	300	17	2.887%	1.712%	1.060%	0.735%	0.591%	0.511%	0.501%
\$40,000	400	17	2.322%	1.321%	0.829%	0.617%	0.537%	0.504%	0.501%
\$40,000	500	17	1.953%	1.083%	0.701%	0.559%	0.516%	0.502%	0.501%
\$40,000	600	17	1.685%	0.927%	0.629%	0.533%	0.508%	0.502%	0.501%
\$40,000	700	17	1.494%	0.825%	0.587%	0.520%	0.505%	0.502%	0.501%
\$40,000	800	17	1.340%	0.751%	0.561%	0.514%	0.504%	0.502%	0.501%
\$40,000	900	17	1.214%	0.693%	0.542%	0.509%	0.503%	0.502%	0.501%
\$40,000	1,000	17	1.112%	0.652%	0.530%	0.507%	0.503%	0.502%	0.501%
\$40,000	1,500	17	0.805%	0.552%	0.509%	0.504%	0.503%	0.502%	0.501%
\$40,000	2,000	17	0.659%	0.521%	0.506%	0.504%	0.503%	0.502%	0.501%
\$40,000	3,000	17	0.555%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$40,000	4,000	17	0.523%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$40,000	5,000	17	0.513%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$40,000	10,000	17	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$40,000	20,000	17	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$45,000	5	17	43.574%	40.945%	38.401%	35.939%	33.550%	29.028%	24.991%
\$45,000	10	17	28.308%	25.691%	23.288%	21.083%	19.059%	15.492%	12.509%
\$45,000	15	17	22.316%	19.765%	17.447%	15.359%	13.489%	10.344%	7.871%
\$45,000	20	17	18.643%	16.154%	13.940%	11.990%	10.282%	7.498%	5.419%
\$45,000	25	17	16.388%	13.948%	11.810%	9.955%	8.360%	5.822%	4.019%
\$45,000	50	17	10.454%	8.281%	6.505%	5.082%	3.959%	2.403%	1.495%
\$45,000	100	17	6.584%	4.755%	3.398%	2.420%	1.741%	0.980%	0.667%
\$45,000	150	17	5.007%	3.395%	2.288%	1.559%	1.101%	0.672%	0.542%
\$45,000	200	17	4.050%	2.602%	1.677%	1.121%	0.810%	0.564%	0.509%
\$45,000	300	17	3.046%	1.829%	1.137%	0.779%	0.612%	0.515%	0.502%
\$45,000	400	17	2.456%	1.412%	0.881%	0.642%	0.548%	0.505%	0.501%
\$45,000	500	17	2.070%	1.156%	0.737%	0.574%	0.520%	0.503%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$45,000	600	17	1.786%	0.984%	0.654%	0.542%	0.510%	0.502%	0.501%
\$45,000	700	17	1.587%	0.873%	0.605%	0.525%	0.507%	0.502%	0.501%
\$45,000	800	17	1.424%	0.790%	0.575%	0.517%	0.505%	0.502%	0.501%
\$45,000	900	17	1.290%	0.726%	0.552%	0.511%	0.504%	0.502%	0.501%
\$45,000	1,000	17	1.180%	0.679%	0.537%	0.508%	0.503%	0.502%	0.501%
\$45,000	1,500	17	0.848%	0.564%	0.511%	0.504%	0.503%	0.502%	0.501%
\$45,000	2,000	17	0.686%	0.526%	0.506%	0.504%	0.503%	0.502%	0.501%
\$45,000	3,000	17	0.566%	0.509%	0.505%	0.504%	0.503%	0.502%	0.501%
\$45,000	4,000	17	0.528%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$45,000	5,000	17	0.515%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$45,000	10,000	17	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$45,000	20,000	17	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$50,000	5	17	45.137%	42.583%	40.113%	37.721%	35.405%	30.987%	26.868%
\$50,000	10	17	29.359%	26.723%	24.301%	22.076%	20.038%	16.443%	13.409%
\$50,000	15	17	23.168%	20.608%	18.280%	16.171%	14.275%	11.056%	8.505%
\$50,000	20	17	19.367%	16.864%	14.630%	12.650%	10.908%	8.046%	5.887%
\$50,000	25	17	17.027%	14.573%	12.410%	10.530%	8.900%	6.279%	4.392%
\$50,000	50	17	10.889%	8.692%	6.885%	5.424%	4.258%	2.620%	1.642%
\$50,000	100	17	6.882%	5.020%	3.625%	2.605%	1.885%	1.060%	0.705%
\$50,000	150	17	5.234%	3.586%	2.441%	1.676%	1.184%	0.708%	0.555%
\$50,000	200	17	4.230%	2.747%	1.786%	1.196%	0.858%	0.579%	0.512%
\$50,000	300	17	3.197%	1.942%	1.212%	0.823%	0.634%	0.520%	0.502%
\$50,000	400	17	2.581%	1.498%	0.933%	0.669%	0.559%	0.507%	0.501%
\$50,000	500	17	2.181%	1.225%	0.773%	0.589%	0.526%	0.503%	0.501%
\$50,000	600	17	1.883%	1.040%	0.680%	0.551%	0.513%	0.502%	0.501%
\$50,000	700	17	1.675%	0.919%	0.625%	0.532%	0.508%	0.502%	0.501%
\$50,000	800	17	1.506%	0.830%	0.589%	0.521%	0.506%	0.502%	0.501%
\$50,000	900	17	1.362%	0.759%	0.563%	0.514%	0.504%	0.502%	0.501%
\$50,000	1,000	17	1.245%	0.707%	0.546%	0.510%	0.504%	0.502%	0.501%
\$50,000	1,500	17	0.890%	0.576%	0.513%	0.505%	0.503%	0.502%	0.501%
\$50,000	2,000	17	0.714%	0.531%	0.507%	0.504%	0.503%	0.502%	0.501%
\$50,000	3,000	17	0.578%	0.510%	0.505%	0.504%	0.503%	0.502%	0.501%
\$50,000	4,000	17	0.533%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$50,000	5,000	17	0.517%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$50,000	10,000	17	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$50,000	20,000	17	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$55,000	5	17	46.495%	44.005%	41.597%	39.267%	37.013%	32.715%	28.658%
\$55,000	10	17	30.368%	27.705%	25.255%	23.003%	20.939%	17.307%	14.240%
\$55,000	15	17	23.945%	21.381%	19.045%	16.921%	15.005%	11.726%	9.103%
\$55,000	20	17	20.036%	17.523%	15.274%	13.268%	11.495%	8.564%	6.332%
\$55,000	25	17	17.621%	15.152%	12.975%	11.070%	9.408%	6.718%	4.754%
\$55,000	50	17	11.296%	9.077%	7.242%	5.749%	4.543%	2.830%	1.787%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$55,000	100	17	7.162%	5.271%	3.839%	2.783%	2.025%	1.140%	0.745%
\$55,000	150	17	5.446%	3.767%	2.586%	1.788%	1.266%	0.745%	0.570%
\$55,000	200	17	4.404%	2.890%	1.895%	1.274%	0.908%	0.596%	0.517%
\$55,000	300	17	3.336%	2.048%	1.284%	0.867%	0.658%	0.525%	0.503%
\$55,000	400	17	2.699%	1.581%	0.983%	0.696%	0.571%	0.509%	0.502%
\$55,000	500	17	2.284%	1.292%	0.809%	0.605%	0.532%	0.504%	0.501%
\$55,000	600	17	1.974%	1.095%	0.706%	0.562%	0.516%	0.502%	0.501%
\$55,000	700	17	1.758%	0.966%	0.645%	0.539%	0.510%	0.502%	0.501%
\$55,000	800	17	1.583%	0.870%	0.605%	0.526%	0.507%	0.502%	0.501%
\$55,000	900	17	1.432%	0.792%	0.574%	0.517%	0.505%	0.502%	0.501%
\$55,000	1,000	17	1.308%	0.735%	0.554%	0.512%	0.504%	0.502%	0.501%
\$55,000	1,500	17	0.932%	0.588%	0.516%	0.505%	0.503%	0.502%	0.501%
\$55,000	2,000	17	0.742%	0.537%	0.507%	0.504%	0.503%	0.502%	0.501%
\$55,000	3,000	17	0.591%	0.511%	0.505%	0.504%	0.503%	0.502%	0.501%
\$55,000	4,000	17	0.539%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$55,000	5,000	17	0.520%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$55,000	10,000	17	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$55,000	20,000	17	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$60,000	5	17	47.706%	45.272%	42.919%	40.645%	38.446%	34.250%	30.294%
\$60,000	10	17	31.360%	28.673%	26.189%	23.907%	21.811%	18.129%	15.023%
\$60,000	15	17	24.681%	22.117%	19.775%	17.641%	15.707%	12.382%	9.695%
\$60,000	20	17	20.678%	18.154%	15.888%	13.864%	12.065%	9.075%	6.770%
\$60,000	25	17	18.187%	15.708%	13.515%	11.587%	9.896%	7.147%	5.114%
\$60,000	50	17	11.685%	9.447%	7.587%	6.062%	4.823%	3.037%	1.934%
\$60,000	100	17	7.429%	5.511%	4.047%	2.955%	2.164%	1.221%	0.788%
\$60,000	150	17	5.650%	3.942%	2.728%	1.898%	1.348%	0.784%	0.586%
\$60,000	200	17	4.571%	3.029%	2.002%	1.351%	0.960%	0.616%	0.523%
\$60,000	300	17	3.470%	2.150%	1.355%	0.911%	0.683%	0.530%	0.504%
\$60,000	400	17	2.810%	1.661%	1.033%	0.723%	0.584%	0.511%	0.502%
\$60,000	500	17	2.381%	1.356%	0.845%	0.622%	0.539%	0.504%	0.501%
\$60,000	600	17	2.059%	1.148%	0.733%	0.573%	0.520%	0.503%	0.501%
\$60,000	700	17	1.837%	1.011%	0.665%	0.546%	0.512%	0.502%	0.501%
\$60,000	800	17	1.654%	0.908%	0.620%	0.531%	0.508%	0.502%	0.501%
\$60,000	900	17	1.497%	0.824%	0.586%	0.520%	0.505%	0.502%	0.501%
\$60,000	1,000	17	1.367%	0.762%	0.563%	0.514%	0.504%	0.502%	0.501%
\$60,000	1,500	17	0.971%	0.601%	0.518%	0.505%	0.503%	0.502%	0.501%
\$60,000	2,000	17	0.768%	0.543%	0.508%	0.504%	0.503%	0.502%	0.501%
\$60,000	3,000	17	0.603%	0.513%	0.505%	0.504%	0.503%	0.502%	0.501%
\$60,000	4,000	17	0.545%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$60,000	5,000	17	0.523%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$60,000	10,000	17	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$60,000	20,000	17	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$65,000	5	17	48.780%	46.394%	44.090%	41.865%	39.713%	35.603%	31.743%
\$65,000	10	17	32.322%	29.614%	27.103%	24.785%	22.660%	18.917%	15.766%
\$65,000	15	17	25.368%	22.806%	20.461%	18.321%	16.371%	13.007%	10.268%
\$65,000	20	17	21.281%	18.751%	16.474%	14.430%	12.609%	9.567%	7.198%
\$65,000	25	17	18.720%	16.238%	14.031%	12.081%	10.368%	7.565%	5.466%
\$65,000	50	17	12.047%	9.794%	7.912%	6.359%	5.089%	3.237%	2.079%
\$65,000	100	17	7.679%	5.738%	4.245%	3.122%	2.298%	1.302%	0.831%
\$65,000	150	17	5.841%	4.108%	2.863%	2.004%	1.428%	0.824%	0.603%
\$65,000	200	17	4.730%	3.161%	2.105%	1.426%	1.011%	0.636%	0.529%
\$65,000	300	17	3.598%	2.250%	1.425%	0.955%	0.709%	0.537%	0.505%
\$65,000	400	17	2.917%	1.738%	1.082%	0.750%	0.598%	0.513%	0.502%
\$65,000	500	17	2.474%	1.419%	0.881%	0.639%	0.546%	0.505%	0.501%
\$65,000	600	17	2.141%	1.199%	0.760%	0.584%	0.524%	0.503%	0.501%
\$65,000	700	17	1.912%	1.055%	0.686%	0.554%	0.514%	0.502%	0.501%
\$65,000	800	17	1.724%	0.947%	0.637%	0.536%	0.509%	0.502%	0.501%
\$65,000	900	17	1.560%	0.857%	0.599%	0.524%	0.506%	0.502%	0.501%
\$65,000	1,000	17	1.424%	0.789%	0.573%	0.516%	0.505%	0.502%	0.501%
\$65,000	1,500	17	1.010%	0.614%	0.521%	0.506%	0.503%	0.502%	0.501%
\$65,000	2,000	17	0.794%	0.549%	0.509%	0.504%	0.503%	0.502%	0.501%
\$65,000	3,000	17	0.616%	0.514%	0.505%	0.504%	0.503%	0.502%	0.501%
\$65,000	4,000	17	0.551%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$65,000	5,000	17	0.526%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$65,000	10,000	17	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$65,000	20,000	17	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$70,000	5	17	49.736%	47.394%	45.134%	42.951%	40.842%	36.809%	33.034%
\$70,000	10	17	33.243%	30.530%	27.998%	25.653%	23.491%	19.681%	16.475%
\$70,000	15	17	26.016%	23.450%	21.102%	18.956%	16.994%	13.599%	10.817%
\$70,000	20	17	21.847%	19.314%	17.029%	14.971%	13.129%	10.041%	7.616%
\$70,000	25	17	19.224%	16.737%	14.518%	12.549%	10.817%	7.965%	5.807%
\$70,000	50	17	12.384%	10.118%	8.216%	6.638%	5.341%	3.430%	2.220%
\$70,000	100	17	7.911%	5.951%	4.431%	3.280%	2.427%	1.381%	0.875%
\$70,000	150	17	6.020%	4.263%	2.992%	2.105%	1.505%	0.862%	0.620%
\$70,000	200	17	4.879%	3.286%	2.203%	1.499%	1.061%	0.656%	0.535%
\$70,000	300	17	3.716%	2.343%	1.492%	0.998%	0.734%	0.544%	0.506%
\$70,000	400	17	3.015%	1.811%	1.129%	0.777%	0.612%	0.516%	0.503%
\$70,000	500	17	2.560%	1.478%	0.915%	0.656%	0.553%	0.506%	0.501%
\$70,000	600	17	2.218%	1.248%	0.786%	0.596%	0.528%	0.503%	0.501%
\$70,000	700	17	1.982%	1.098%	0.707%	0.562%	0.517%	0.502%	0.501%
\$70,000	800	17	1.789%	0.983%	0.653%	0.542%	0.511%	0.502%	0.501%
\$70,000	900	17	1.619%	0.888%	0.611%	0.527%	0.507%	0.502%	0.501%
\$70,000	1,000	17	1.478%	0.816%	0.583%	0.519%	0.505%	0.502%	0.501%
\$70,000	1,500	17	1.046%	0.627%	0.524%	0.506%	0.503%	0.502%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$70,000	2,000	17	0.820%	0.556%	0.510%	0.504%	0.503%	0.502%	0.501%
\$70,000	3,000	17	0.628%	0.516%	0.505%	0.504%	0.503%	0.502%	0.501%
\$70,000	4,000	17	0.557%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$70,000	5,000	17	0.529%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$70,000	10,000	17	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$70,000	20,000	17	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$75,000	5	17	50.627%	48.326%	46.107%	43.964%	41.889%	37.931%	34.233%
\$75,000	10	17	34.137%	31.429%	28.890%	26.524%	24.328%	20.447%	17.179%
\$75,000	15	17	26.650%	24.077%	21.723%	19.566%	17.599%	14.175%	11.349%
\$75,000	20	17	22.394%	19.860%	17.567%	15.496%	13.637%	10.503%	8.026%
\$75,000	25	17	19.713%	17.218%	14.988%	13.006%	11.252%	8.353%	6.141%
\$75,000	50	17	12.713%	10.433%	8.512%	6.910%	5.588%	3.622%	2.361%
\$75,000	100	17	8.133%	6.154%	4.611%	3.434%	2.554%	1.460%	0.920%
\$75,000	150	17	6.190%	4.412%	3.117%	2.205%	1.580%	0.901%	0.637%
\$75,000	200	17	5.021%	3.406%	2.299%	1.570%	1.111%	0.677%	0.543%
\$75,000	300	17	3.831%	2.433%	1.557%	1.042%	0.760%	0.551%	0.508%
\$75,000	400	17	3.110%	1.881%	1.175%	0.805%	0.626%	0.519%	0.503%
\$75,000	500	17	2.642%	1.535%	0.950%	0.674%	0.561%	0.507%	0.501%
\$75,000	600	17	2.291%	1.296%	0.812%	0.608%	0.533%	0.504%	0.501%
\$75,000	700	17	2.049%	1.139%	0.727%	0.570%	0.520%	0.502%	0.501%
\$75,000	800	17	1.851%	1.020%	0.669%	0.548%	0.513%	0.502%	0.501%
\$75,000	900	17	1.677%	0.919%	0.624%	0.532%	0.508%	0.502%	0.501%
\$75,000	1,000	17	1.530%	0.842%	0.593%	0.522%	0.506%	0.502%	0.501%
\$75,000	1,500	17	1.082%	0.641%	0.528%	0.507%	0.503%	0.502%	0.501%
\$75,000	2,000	17	0.845%	0.563%	0.511%	0.504%	0.503%	0.502%	0.501%
\$75,000	3,000	17	0.641%	0.518%	0.506%	0.504%	0.503%	0.502%	0.501%
\$75,000	4,000	17	0.564%	0.509%	0.505%	0.504%	0.503%	0.502%	0.501%
\$75,000	5,000	17	0.532%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$75,000	10,000	17	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$75,000	20,000	17	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$80,000	5	17	51.454%	49.190%	47.008%	44.900%	42.857%	38.972%	35.340%
\$80,000	10	17	35.011%	32.306%	29.769%	27.391%	25.170%	21.218%	17.881%
\$80,000	15	17	27.281%	24.697%	22.331%	20.164%	18.188%	14.739%	11.874%
\$80,000	20	17	22.924%	20.389%	18.089%	16.006%	14.132%	10.954%	8.429%
\$80,000	25	17	20.188%	17.685%	15.444%	13.451%	11.678%	8.733%	6.472%
\$80,000	50	17	13.032%	10.738%	8.800%	7.175%	5.829%	3.811%	2.499%
\$80,000	100	17	8.347%	6.351%	4.786%	3.584%	2.678%	1.539%	0.965%
\$80,000	150	17	6.356%	4.558%	3.239%	2.302%	1.655%	0.941%	0.656%
\$80,000	200	17	5.160%	3.524%	2.393%	1.641%	1.162%	0.698%	0.550%
\$80,000	300	17	3.942%	2.521%	1.621%	1.085%	0.786%	0.558%	0.509%
\$80,000	400	17	3.202%	1.950%	1.221%	0.832%	0.641%	0.522%	0.504%
\$80,000	500	17	2.722%	1.592%	0.984%	0.692%	0.569%	0.508%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$80,000	600	17	2.361%	1.342%	0.838%	0.620%	0.538%	0.504%	0.501%
\$80,000	700	17	2.114%	1.179%	0.748%	0.579%	0.523%	0.503%	0.501%
\$80,000	800	17	1.912%	1.055%	0.686%	0.555%	0.515%	0.502%	0.501%
\$80,000	900	17	1.731%	0.950%	0.638%	0.536%	0.509%	0.502%	0.501%
\$80,000	1,000	17	1.581%	0.869%	0.604%	0.525%	0.506%	0.502%	0.501%
\$80,000	1,500	17	1.118%	0.654%	0.531%	0.507%	0.503%	0.502%	0.501%
\$80,000	2,000	17	0.870%	0.569%	0.512%	0.504%	0.503%	0.502%	0.501%
\$80,000	3,000	17	0.654%	0.520%	0.506%	0.504%	0.503%	0.502%	0.501%
\$80,000	4,000	17	0.571%	0.509%	0.505%	0.504%	0.503%	0.502%	0.501%
\$80,000	5,000	17	0.535%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$80,000	10,000	17	0.507%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$80,000	20,000	17	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$90,000	5	17	52.921%	50.724%	48.606%	46.555%	44.573%	40.816%	37.297%
\$90,000	10	17	36.649%	33.981%	31.452%	29.066%	26.825%	22.768%	19.287%
\$90,000	15	17	28.494%	25.888%	23.493%	21.301%	19.296%	15.798%	12.872%
\$90,000	20	17	23.926%	21.386%	19.075%	16.976%	15.076%	11.826%	9.216%
\$90,000	25	17	21.083%	18.567%	16.315%	14.297%	12.494%	9.466%	7.119%
\$90,000	50	17	13.639%	11.323%	9.351%	7.687%	6.296%	4.183%	2.776%
\$90,000	100	17	8.760%	6.730%	5.126%	3.878%	2.923%	1.697%	1.058%
\$90,000	150	17	6.672%	4.838%	3.474%	2.493%	1.803%	1.020%	0.693%
\$90,000	200	17	5.424%	3.751%	2.576%	1.780%	1.262%	0.743%	0.566%
\$90,000	300	17	4.146%	2.685%	1.742%	1.166%	0.837%	0.573%	0.512%
\$90,000	400	17	3.376%	2.082%	1.311%	0.887%	0.672%	0.529%	0.505%
\$90,000	500	17	2.875%	1.701%	1.052%	0.729%	0.587%	0.511%	0.502%
\$90,000	600	17	2.496%	1.433%	0.890%	0.646%	0.549%	0.505%	0.501%
\$90,000	700	17	2.238%	1.259%	0.791%	0.598%	0.530%	0.503%	0.501%
\$90,000	800	17	2.027%	1.125%	0.721%	0.569%	0.519%	0.503%	0.501%
\$90,000	900	17	1.837%	1.010%	0.665%	0.546%	0.512%	0.502%	0.501%
\$90,000	1,000	17	1.678%	0.922%	0.626%	0.532%	0.508%	0.502%	0.501%
\$90,000	1,500	17	1.187%	0.682%	0.539%	0.509%	0.503%	0.502%	0.501%
\$90,000	2,000	17	0.918%	0.584%	0.515%	0.505%	0.503%	0.502%	0.501%
\$90,000	3,000	17	0.681%	0.525%	0.506%	0.504%	0.503%	0.502%	0.501%
\$90,000	4,000	17	0.584%	0.511%	0.505%	0.504%	0.503%	0.502%	0.501%
\$90,000	5,000	17	0.543%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$90,000	10,000	17	0.508%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$90,000	20,000	17	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$100,000	5	17	54.186%	52.044%	49.976%	47.977%	46.050%	42.399%	38.976%
\$100,000	10	17	38.099%	35.503%	33.014%	30.640%	28.393%	24.295%	20.705%
\$100,000	15	17	29.659%	27.035%	24.612%	22.388%	20.353%	16.791%	13.810%
\$100,000	20	17	24.857%	22.311%	19.992%	17.883%	15.964%	12.657%	9.976%
\$100,000	25	17	21.914%	19.396%	17.128%	15.092%	13.263%	10.170%	7.740%
\$100,000	50	17	14.214%	11.879%	9.879%	8.181%	6.751%	4.550%	3.057%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$100,000	100	17	9.151%	7.092%	5.451%	4.161%	3.164%	1.857%	1.155%
\$100,000	150	17	6.970%	5.102%	3.697%	2.676%	1.946%	1.100%	0.732%
\$100,000	200	17	5.673%	3.966%	2.752%	1.916%	1.362%	0.790%	0.585%
\$100,000	300	17	4.345%	2.848%	1.864%	1.251%	0.892%	0.592%	0.517%
\$100,000	400	17	3.539%	2.207%	1.397%	0.942%	0.704%	0.536%	0.506%
\$100,000	500	17	3.017%	1.805%	1.119%	0.767%	0.606%	0.515%	0.502%
\$100,000	600	17	2.621%	1.520%	0.942%	0.672%	0.561%	0.506%	0.501%
\$100,000	700	17	2.354%	1.336%	0.833%	0.618%	0.538%	0.504%	0.501%
\$100,000	800	17	2.135%	1.193%	0.755%	0.583%	0.524%	0.503%	0.501%
\$100,000	900	17	1.935%	1.069%	0.693%	0.557%	0.515%	0.503%	0.501%
\$100,000	1,000	17	1.770%	0.973%	0.648%	0.540%	0.510%	0.502%	0.501%
\$100,000	1,500	17	1.253%	0.710%	0.547%	0.510%	0.504%	0.502%	0.501%
\$100,000	2,000	17	0.966%	0.600%	0.518%	0.505%	0.503%	0.502%	0.501%
\$100,000	3,000	17	0.707%	0.530%	0.507%	0.504%	0.503%	0.502%	0.501%
\$100,000	4,000	17	0.599%	0.512%	0.505%	0.504%	0.503%	0.502%	0.501%
\$100,000	5,000	17	0.550%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$100,000	10,000	17	0.508%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$100,000	20,000	17	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$110,000	5	17	55.273%	53.177%	51.152%	49.199%	47.322%	43.756%	40.420%
\$110,000	10	17	39.353%	36.821%	34.396%	32.072%	29.844%	25.726%	22.082%
\$110,000	15	17	30.758%	28.122%	25.680%	23.425%	21.355%	17.716%	14.676%
\$110,000	20	17	25.723%	23.165%	20.835%	18.717%	16.787%	13.431%	10.691%
\$110,000	25	17	22.685%	20.169%	17.891%	15.835%	13.984%	10.837%	8.334%
\$110,000	50	17	14.752%	12.401%	10.379%	8.650%	7.181%	4.905%	3.333%
\$110,000	100	17	9.518%	7.431%	5.755%	4.429%	3.396%	2.013%	1.251%
\$110,000	150	17	7.250%	5.350%	3.910%	2.850%	2.085%	1.178%	0.772%
\$110,000	200	17	5.907%	4.170%	2.920%	2.047%	1.459%	0.837%	0.605%
\$110,000	300	17	4.530%	3.000%	1.979%	1.334%	0.948%	0.612%	0.522%
\$110,000	400	17	3.691%	2.325%	1.481%	0.996%	0.736%	0.545%	0.508%
\$110,000	500	17	3.149%	1.904%	1.184%	0.806%	0.625%	0.519%	0.502%
\$110,000	600	17	2.736%	1.602%	0.992%	0.699%	0.573%	0.508%	0.501%
\$110,000	700	17	2.462%	1.408%	0.875%	0.638%	0.546%	0.505%	0.501%
\$110,000	800	17	2.234%	1.256%	0.789%	0.598%	0.530%	0.504%	0.501%
\$110,000	900	17	2.027%	1.125%	0.721%	0.568%	0.519%	0.503%	0.501%
\$110,000	1,000	17	1.855%	1.022%	0.670%	0.548%	0.513%	0.502%	0.501%
\$110,000	1,500	17	1.316%	0.738%	0.556%	0.512%	0.504%	0.502%	0.501%
\$110,000	2,000	17	1.012%	0.615%	0.521%	0.506%	0.503%	0.502%	0.501%
\$110,000	3,000	17	0.733%	0.535%	0.507%	0.504%	0.503%	0.502%	0.501%
\$110,000	4,000	17	0.613%	0.514%	0.505%	0.504%	0.503%	0.502%	0.501%
\$110,000	5,000	17	0.558%	0.508%	0.505%	0.504%	0.503%	0.502%	0.501%
\$110,000	10,000	17	0.508%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$110,000	20,000	17	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$120,000	5	17	56.232%	54.173%	52.188%	50.278%	48.441%	44.948%	41.691%
\$120,000	10	17	40.465%	37.989%	35.621%	33.351%	31.173%	27.086%	23.405%
\$120,000	15	17	31.796%	29.161%	26.709%	24.433%	22.329%	18.613%	15.508%
\$120,000	20	17	26.551%	23.982%	21.635%	19.501%	17.559%	14.165%	11.373%
\$120,000	25	17	23.413%	20.899%	18.613%	16.540%	14.668%	11.475%	8.908%
\$120,000	50	17	15.256%	12.893%	10.851%	9.096%	7.594%	5.248%	3.607%
\$120,000	100	17	9.861%	7.751%	6.044%	4.684%	3.617%	2.167%	1.350%
\$120,000	150	17	7.513%	5.585%	4.114%	3.018%	2.221%	1.257%	0.812%
\$120,000	200	17	6.126%	4.363%	3.079%	2.173%	1.555%	0.885%	0.627%
\$120,000	300	17	4.702%	3.143%	2.090%	1.414%	1.003%	0.633%	0.528%
\$120,000	400	17	3.832%	2.437%	1.562%	1.049%	0.770%	0.554%	0.510%
\$120,000	500	17	3.272%	1.996%	1.247%	0.843%	0.645%	0.523%	0.503%
\$120,000	600	17	2.843%	1.678%	1.041%	0.725%	0.586%	0.510%	0.501%
\$120,000	700	17	2.561%	1.476%	0.915%	0.658%	0.555%	0.505%	0.501%
\$120,000	800	17	2.327%	1.317%	0.822%	0.614%	0.536%	0.504%	0.501%
\$120,000	900	17	2.113%	1.178%	0.748%	0.579%	0.523%	0.503%	0.501%
\$120,000	1,000	17	1.934%	1.069%	0.693%	0.557%	0.515%	0.502%	0.501%
\$120,000	1,500	17	1.376%	0.766%	0.565%	0.515%	0.504%	0.502%	0.501%
\$120,000	2,000	17	1.057%	0.631%	0.525%	0.506%	0.503%	0.502%	0.501%
\$120,000	3,000	17	0.759%	0.541%	0.508%	0.504%	0.503%	0.502%	0.501%
\$120,000	4,000	17	0.628%	0.516%	0.505%	0.504%	0.503%	0.502%	0.501%
\$120,000	5,000	17	0.567%	0.509%	0.505%	0.504%	0.503%	0.502%	0.501%
\$120,000	10,000	17	0.509%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$120,000	20,000	17	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$130,000	5	17	57.047%	55.021%	53.071%	51.199%	49.394%	45.965%	42.775%
\$130,000	10	17	41.416%	38.990%	36.670%	34.445%	32.314%	28.307%	24.631%
\$130,000	15	17	32.740%	30.116%	27.662%	25.375%	23.248%	19.464%	16.288%
\$130,000	20	17	27.320%	24.740%	22.379%	20.225%	18.265%	14.838%	12.005%
\$130,000	25	17	24.079%	21.565%	19.270%	17.185%	15.300%	12.061%	9.443%
\$130,000	50	17	15.716%	13.342%	11.284%	9.505%	7.974%	5.567%	3.864%
\$130,000	100	17	10.178%	8.047%	6.312%	4.923%	3.824%	2.315%	1.446%
\$130,000	150	17	7.759%	5.806%	4.305%	3.177%	2.351%	1.335%	0.853%
\$130,000	200	17	6.334%	4.546%	3.230%	2.294%	1.647%	0.934%	0.649%
\$130,000	300	17	4.863%	3.278%	2.195%	1.491%	1.057%	0.654%	0.535%
\$130,000	400	17	3.958%	2.536%	1.633%	1.097%	0.799%	0.562%	0.511%
\$130,000	500	17	3.386%	2.083%	1.306%	0.880%	0.665%	0.528%	0.504%
\$130,000	600	17	2.943%	1.751%	1.087%	0.752%	0.599%	0.512%	0.502%
\$130,000	700	17	2.652%	1.540%	0.953%	0.678%	0.564%	0.507%	0.501%
\$130,000	800	17	2.413%	1.374%	0.855%	0.630%	0.543%	0.505%	0.501%
\$130,000	900	17	2.193%	1.229%	0.775%	0.591%	0.527%	0.503%	0.501%
\$130,000	1,000	17	2.008%	1.114%	0.715%	0.566%	0.518%	0.502%	0.501%
\$130,000	1,500	17	1.432%	0.792%	0.574%	0.517%	0.505%	0.502%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$130,000	2,000	17	1.099%	0.647%	0.529%	0.507%	0.503%	0.502%	0.501%
\$130,000	3,000	17	0.784%	0.547%	0.509%	0.504%	0.503%	0.502%	0.501%
\$130,000	4,000	17	0.642%	0.518%	0.506%	0.504%	0.503%	0.502%	0.501%
\$130,000	5,000	17	0.575%	0.509%	0.505%	0.504%	0.503%	0.502%	0.501%
\$130,000	10,000	17	0.509%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$130,000	20,000	17	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$140,000	5	17	57.765%	55.769%	53.851%	52.009%	50.232%	46.859%	43.725%
\$140,000	10	17	42.250%	39.867%	37.587%	35.402%	33.310%	29.380%	25.760%
\$140,000	15	17	33.597%	30.995%	28.545%	26.254%	24.111%	20.280%	17.030%
\$140,000	20	17	28.033%	25.448%	23.070%	20.896%	18.913%	15.449%	12.577%
\$140,000	25	17	24.686%	22.166%	19.865%	17.769%	15.871%	12.594%	9.933%
\$140,000	50	17	16.137%	13.755%	11.680%	9.881%	8.327%	5.867%	4.107%
\$140,000	100	17	10.469%	8.322%	6.563%	5.146%	4.020%	2.457%	1.540%
\$140,000	150	17	7.987%	6.012%	4.485%	3.328%	2.474%	1.410%	0.893%
\$140,000	200	17	6.527%	4.716%	3.373%	2.409%	1.735%	0.982%	0.671%
\$140,000	300	17	5.014%	3.404%	2.294%	1.565%	1.108%	0.675%	0.542%
\$140,000	400	17	4.081%	2.635%	1.705%	1.145%	0.829%	0.571%	0.513%
\$140,000	500	17	3.493%	2.165%	1.363%	0.916%	0.686%	0.532%	0.505%
\$140,000	600	17	3.036%	1.820%	1.132%	0.777%	0.612%	0.515%	0.502%
\$140,000	700	17	2.738%	1.601%	0.991%	0.698%	0.573%	0.508%	0.501%
\$140,000	800	17	2.494%	1.429%	0.886%	0.645%	0.549%	0.505%	0.501%
\$140,000	900	17	2.267%	1.277%	0.801%	0.603%	0.531%	0.504%	0.501%
\$140,000	1,000	17	2.078%	1.157%	0.737%	0.575%	0.522%	0.503%	0.501%
\$140,000	1,500	17	1.485%	0.819%	0.584%	0.520%	0.505%	0.502%	0.501%
\$140,000	2,000	17	1.139%	0.663%	0.533%	0.507%	0.503%	0.502%	0.501%
\$140,000	3,000	17	0.809%	0.553%	0.510%	0.504%	0.503%	0.502%	0.501%
\$140,000	4,000	17	0.657%	0.520%	0.506%	0.504%	0.503%	0.502%	0.501%
\$140,000	5,000	17	0.583%	0.510%	0.505%	0.504%	0.503%	0.502%	0.501%
\$140,000	10,000	17	0.510%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$140,000	20,000	17	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$150,000	5	17	58.390%	56.420%	54.531%	52.714%	50.960%	47.638%	44.552%
\$150,000	10	17	42.982%	40.636%	38.390%	36.241%	34.182%	30.319%	26.761%
\$150,000	15	17	34.361%	31.789%	29.356%	27.066%	24.918%	21.059%	17.745%
\$150,000	20	17	28.688%	26.103%	23.717%	21.526%	19.518%	16.016%	13.105%
\$150,000	25	17	25.248%	22.720%	20.411%	18.306%	16.393%	13.085%	10.386%
\$150,000	50	17	16.525%	14.136%	12.045%	10.229%	8.655%	6.149%	4.339%
\$150,000	100	17	10.737%	8.575%	6.795%	5.355%	4.204%	2.592%	1.631%
\$150,000	150	17	8.195%	6.202%	4.653%	3.470%	2.591%	1.483%	0.934%
\$150,000	200	17	6.705%	4.873%	3.508%	2.519%	1.819%	1.028%	0.693%
\$150,000	300	17	5.150%	3.518%	2.386%	1.634%	1.156%	0.696%	0.549%
\$150,000	400	17	4.194%	2.725%	1.773%	1.191%	0.858%	0.581%	0.515%
\$150,000	500	17	3.591%	2.240%	1.415%	0.949%	0.705%	0.537%	0.506%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$150,000	600	17	3.122%	1.882%	1.173%	0.802%	0.624%	0.517%	0.502%
\$150,000	700	17	2.817%	1.657%	1.026%	0.717%	0.582%	0.509%	0.501%
\$150,000	800	17	2.567%	1.479%	0.916%	0.660%	0.556%	0.506%	0.501%
\$150,000	900	17	2.335%	1.322%	0.826%	0.614%	0.536%	0.504%	0.501%
\$150,000	1,000	17	2.142%	1.197%	0.758%	0.584%	0.525%	0.503%	0.501%
\$150,000	1,500	17	1.534%	0.843%	0.593%	0.522%	0.506%	0.502%	0.501%
\$150,000	2,000	17	1.176%	0.678%	0.537%	0.508%	0.503%	0.502%	0.501%
\$150,000	3,000	17	0.832%	0.559%	0.510%	0.504%	0.503%	0.502%	0.501%
\$150,000	4,000	17	0.670%	0.523%	0.506%	0.504%	0.503%	0.502%	0.501%
\$150,000	5,000	17	0.591%	0.511%	0.505%	0.504%	0.503%	0.502%	0.501%
\$150,000	10,000	17	0.510%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$150,000	20,000	17	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$160,000	5	17	58.948%	57.002%	55.138%	53.342%	51.610%	48.333%	45.287%
\$160,000	10	17	43.641%	41.327%	39.112%	36.995%	34.966%	31.162%	27.659%
\$160,000	15	17	35.048%	32.511%	30.104%	27.825%	25.676%	21.805%	18.447%
\$160,000	20	17	29.304%	26.721%	24.333%	22.132%	20.103%	16.557%	13.609%
\$160,000	25	17	25.780%	23.244%	20.926%	18.815%	16.889%	13.553%	10.820%
\$160,000	50	17	16.891%	14.495%	12.394%	10.561%	8.970%	6.421%	4.566%
\$160,000	100	17	10.992%	8.817%	7.018%	5.555%	4.382%	2.724%	1.722%
\$160,000	150	17	8.392%	6.384%	4.814%	3.609%	2.704%	1.557%	0.976%
\$160,000	200	17	6.874%	5.024%	3.637%	2.625%	1.903%	1.075%	0.717%
\$160,000	300	17	5.278%	3.627%	2.473%	1.701%	1.204%	0.717%	0.556%
\$160,000	400	17	4.301%	2.811%	1.838%	1.236%	0.888%	0.590%	0.517%
\$160,000	500	17	3.682%	2.311%	1.466%	0.982%	0.724%	0.542%	0.507%
\$160,000	600	17	3.201%	1.942%	1.214%	0.826%	0.637%	0.520%	0.502%
\$160,000	700	17	2.890%	1.711%	1.060%	0.736%	0.591%	0.511%	0.501%
\$160,000	800	17	2.637%	1.528%	0.945%	0.675%	0.563%	0.507%	0.501%
\$160,000	900	17	2.399%	1.364%	0.850%	0.626%	0.541%	0.505%	0.501%
\$160,000	1,000	17	2.202%	1.235%	0.779%	0.593%	0.528%	0.503%	0.501%
\$160,000	1,500	17	1.580%	0.867%	0.603%	0.525%	0.506%	0.502%	0.501%
\$160,000	2,000	17	1.211%	0.692%	0.541%	0.509%	0.503%	0.502%	0.501%
\$160,000	3,000	17	0.854%	0.565%	0.511%	0.504%	0.503%	0.502%	0.501%
\$160,000	4,000	17	0.684%	0.525%	0.506%	0.504%	0.503%	0.502%	0.501%
\$160,000	5,000	17	0.599%	0.512%	0.505%	0.504%	0.503%	0.502%	0.501%
\$160,000	10,000	17	0.510%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$160,000	20,000	17	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$170,000	5	17	59.457%	57.534%	55.691%	53.915%	52.202%	48.967%	45.957%
\$170,000	10	17	44.245%	41.960%	39.774%	37.684%	35.684%	31.933%	28.480%
\$170,000	15	17	35.677%	33.176%	30.802%	28.543%	26.407%	22.528%	19.143%
\$170,000	20	17	29.895%	27.320%	24.933%	22.726%	20.683%	17.090%	14.105%
\$170,000	25	17	26.304%	23.759%	21.432%	19.313%	17.376%	14.008%	11.245%
\$170,000	50	17	17.243%	14.841%	12.730%	10.883%	9.275%	6.686%	4.791%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$170,000	100	17	11.236%	9.048%	7.233%	5.749%	4.555%	2.853%	1.811%
\$170,000	150	17	8.582%	6.559%	4.970%	3.744%	2.816%	1.630%	1.019%
\$170,000	200	17	7.037%	5.169%	3.762%	2.729%	1.986%	1.122%	0.742%
\$170,000	300	17	5.402%	3.734%	2.559%	1.767%	1.251%	0.739%	0.565%
\$170,000	400	17	4.404%	2.896%	1.902%	1.281%	0.917%	0.601%	0.520%
\$170,000	500	17	3.771%	2.380%	1.516%	1.015%	0.744%	0.548%	0.508%
\$170,000	600	17	3.279%	2.002%	1.254%	0.851%	0.651%	0.523%	0.503%
\$170,000	700	17	2.962%	1.764%	1.094%	0.756%	0.601%	0.513%	0.502%
\$170,000	800	17	2.705%	1.575%	0.974%	0.690%	0.570%	0.508%	0.501%
\$170,000	900	17	2.461%	1.407%	0.874%	0.638%	0.546%	0.505%	0.501%
\$170,000	1,000	17	2.260%	1.273%	0.799%	0.602%	0.532%	0.503%	0.501%
\$170,000	1,500	17	1.625%	0.891%	0.612%	0.528%	0.507%	0.502%	0.501%
\$170,000	2,000	17	1.244%	0.706%	0.545%	0.510%	0.503%	0.502%	0.501%
\$170,000	3,000	17	0.875%	0.571%	0.512%	0.504%	0.503%	0.502%	0.501%
\$170,000	4,000	17	0.697%	0.527%	0.506%	0.504%	0.503%	0.502%	0.501%
\$170,000	5,000	17	0.607%	0.513%	0.505%	0.504%	0.503%	0.502%	0.501%
\$170,000	10,000	17	0.511%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$170,000	20,000	17	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$180,000	5	17	59.920%	58.019%	56.195%	54.436%	52.741%	49.544%	46.565%
\$180,000	10	17	44.794%	42.534%	40.375%	38.310%	36.335%	32.633%	29.226%
\$180,000	15	17	36.253%	33.784%	31.442%	29.212%	27.099%	23.228%	19.822%
\$180,000	20	17	30.458%	27.894%	25.511%	23.300%	21.249%	17.618%	14.590%
\$180,000	25	17	26.811%	24.260%	21.925%	19.794%	17.847%	14.450%	11.653%
\$180,000	50	17	17.583%	15.176%	13.056%	11.196%	9.572%	6.947%	5.013%
\$180,000	100	17	11.476%	9.276%	7.444%	5.940%	4.726%	2.983%	1.901%
\$180,000	150	17	8.767%	6.730%	5.123%	3.877%	2.927%	1.702%	1.062%
\$180,000	200	17	7.195%	5.311%	3.885%	2.831%	2.068%	1.170%	0.768%
\$180,000	300	17	5.523%	3.838%	2.643%	1.832%	1.299%	0.761%	0.573%
\$180,000	400	17	4.505%	2.979%	1.966%	1.326%	0.947%	0.612%	0.523%
\$180,000	500	17	3.857%	2.448%	1.566%	1.048%	0.764%	0.553%	0.509%
\$180,000	600	17	3.355%	2.060%	1.294%	0.875%	0.665%	0.526%	0.503%
\$180,000	700	17	3.032%	1.815%	1.128%	0.775%	0.611%	0.515%	0.502%
\$180,000	800	17	2.770%	1.622%	1.003%	0.705%	0.577%	0.509%	0.501%
\$180,000	900	17	2.522%	1.448%	0.898%	0.650%	0.551%	0.506%	0.501%
\$180,000	1,000	17	2.317%	1.310%	0.820%	0.611%	0.535%	0.504%	0.501%
\$180,000	1,500	17	1.668%	0.914%	0.622%	0.531%	0.508%	0.502%	0.501%
\$180,000	2,000	17	1.277%	0.721%	0.550%	0.511%	0.504%	0.502%	0.501%
\$180,000	3,000	17	0.897%	0.577%	0.513%	0.505%	0.503%	0.502%	0.501%
\$180,000	4,000	17	0.710%	0.530%	0.507%	0.504%	0.503%	0.502%	0.501%
\$180,000	5,000	17	0.615%	0.514%	0.505%	0.504%	0.503%	0.502%	0.501%
\$180,000	10,000	17	0.512%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$180,000	20,000	17	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$190,000	5	17	60.332%	58.449%	56.642%	54.899%	53.221%	50.058%	47.107%
\$190,000	10	17	45.280%	43.044%	40.908%	38.866%	36.914%	33.255%	29.889%
\$190,000	15	17	36.773%	34.334%	32.019%	29.817%	27.732%	23.889%	20.472%
\$190,000	20	17	30.983%	28.436%	26.061%	23.849%	21.793%	18.136%	15.063%
\$190,000	25	17	27.294%	24.746%	22.402%	20.261%	18.303%	14.879%	12.047%
\$190,000	50	17	17.911%	15.500%	13.370%	11.499%	9.861%	7.202%	5.231%
\$190,000	100	17	11.707%	9.496%	7.648%	6.125%	4.893%	3.109%	1.991%
\$190,000	150	17	8.945%	6.895%	5.272%	4.007%	3.036%	1.773%	1.106%
\$190,000	200	17	7.347%	5.447%	4.002%	2.930%	2.148%	1.217%	0.793%
\$190,000	300	17	5.639%	3.938%	2.726%	1.896%	1.346%	0.784%	0.582%
\$190,000	400	17	4.602%	3.058%	2.027%	1.371%	0.976%	0.623%	0.526%
\$190,000	500	17	3.939%	2.514%	1.614%	1.080%	0.784%	0.559%	0.510%
\$190,000	600	17	3.428%	2.116%	1.332%	0.899%	0.678%	0.530%	0.504%
\$190,000	700	17	3.099%	1.866%	1.161%	0.794%	0.621%	0.517%	0.502%
\$190,000	800	17	2.833%	1.666%	1.031%	0.720%	0.585%	0.510%	0.501%
\$190,000	900	17	2.580%	1.488%	0.922%	0.662%	0.556%	0.506%	0.501%
\$190,000	1,000	17	2.371%	1.346%	0.840%	0.621%	0.539%	0.504%	0.501%
\$190,000	1,500	17	1.709%	0.937%	0.631%	0.534%	0.508%	0.502%	0.501%
\$190,000	2,000	17	1.309%	0.735%	0.554%	0.512%	0.504%	0.502%	0.501%
\$190,000	3,000	17	0.917%	0.584%	0.515%	0.505%	0.503%	0.502%	0.501%
\$190,000	4,000	17	0.723%	0.533%	0.507%	0.504%	0.503%	0.502%	0.501%
\$190,000	5,000	17	0.623%	0.515%	0.505%	0.504%	0.503%	0.502%	0.501%
\$190,000	10,000	17	0.512%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$190,000	20,000	17	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$200,000	5	17	60.697%	58.831%	57.038%	55.310%	53.647%	50.513%	47.588%
\$200,000	10	17	45.719%	43.504%	41.389%	39.368%	37.436%	33.817%	30.488%
\$200,000	15	17	37.245%	34.833%	32.543%	30.367%	28.309%	24.505%	21.091%
\$200,000	20	17	31.470%	28.944%	26.580%	24.371%	22.312%	18.641%	15.525%
\$200,000	25	17	27.752%	25.209%	22.864%	20.711%	18.742%	15.292%	12.425%
\$200,000	50	17	18.223%	15.809%	13.670%	11.790%	10.139%	7.445%	5.440%
\$200,000	100	17	11.926%	9.705%	7.843%	6.304%	5.054%	3.233%	2.080%
\$200,000	150	17	9.115%	7.053%	5.414%	4.132%	3.143%	1.844%	1.149%
\$200,000	200	17	7.492%	5.578%	4.116%	3.026%	2.226%	1.264%	0.818%
\$200,000	300	17	5.750%	4.034%	2.805%	1.958%	1.392%	0.806%	0.591%
\$200,000	400	17	4.695%	3.135%	2.087%	1.415%	1.006%	0.635%	0.529%
\$200,000	500	17	4.010%	2.571%	1.656%	1.108%	0.801%	0.563%	0.511%
\$200,000	600	17	3.497%	2.169%	1.370%	0.923%	0.692%	0.533%	0.504%
\$200,000	700	17	3.163%	1.914%	1.194%	0.813%	0.631%	0.519%	0.502%
\$200,000	800	17	2.893%	1.710%	1.058%	0.736%	0.592%	0.511%	0.502%
\$200,000	900	17	2.635%	1.526%	0.945%	0.674%	0.562%	0.507%	0.501%
\$200,000	1,000	17	2.423%	1.381%	0.859%	0.630%	0.543%	0.504%	0.501%
\$200,000	1,500	17	1.749%	0.959%	0.641%	0.537%	0.509%	0.502%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$200,000	2,000	17	1.340%	0.749%	0.559%	0.513%	0.504%	0.502%	0.501%
\$200,000	3,000	17	0.937%	0.590%	0.516%	0.505%	0.503%	0.502%	0.501%
\$200,000	4,000	17	0.735%	0.535%	0.507%	0.504%	0.503%	0.502%	0.501%
\$200,000	5,000	17	0.631%	0.516%	0.505%	0.504%	0.503%	0.502%	0.501%
\$200,000	10,000	17	0.513%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$200,000	20,000	17	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$225,000	5	17	61.451%	59.618%	57.854%	56.157%	54.527%	51.453%	48.582%
\$225,000	10	17	46.658%	44.489%	42.418%	40.442%	38.552%	35.014%	31.767%
\$225,000	15	17	38.258%	35.903%	33.666%	31.548%	29.545%	25.843%	22.496%
\$225,000	20	17	32.536%	30.069%	27.747%	25.562%	23.510%	19.830%	16.648%
\$225,000	25	17	28.791%	26.269%	23.933%	21.769%	19.772%	16.265%	13.325%
\$225,000	50	17	18.940%	16.521%	14.368%	12.465%	10.789%	8.022%	5.940%
\$225,000	100	17	12.429%	10.189%	8.297%	6.724%	5.433%	3.528%	2.297%
\$225,000	150	17	9.510%	7.424%	5.753%	4.432%	3.401%	2.020%	1.260%
\$225,000	200	17	7.831%	5.885%	4.385%	3.253%	2.414%	1.380%	0.881%
\$225,000	300	17	6.009%	4.261%	2.994%	2.107%	1.506%	0.864%	0.615%
\$225,000	400	17	4.909%	3.316%	2.230%	1.521%	1.079%	0.665%	0.539%
\$225,000	500	17	4.193%	2.720%	1.768%	1.186%	0.851%	0.580%	0.515%
\$225,000	600	17	3.658%	2.296%	1.460%	0.981%	0.727%	0.543%	0.506%
\$225,000	700	17	3.313%	2.028%	1.271%	0.860%	0.656%	0.525%	0.503%
\$225,000	800	17	3.032%	1.812%	1.124%	0.774%	0.612%	0.514%	0.502%
\$225,000	900	17	2.763%	1.618%	1.001%	0.705%	0.575%	0.509%	0.501%
\$225,000	1,000	17	2.542%	1.462%	0.907%	0.654%	0.553%	0.505%	0.501%
\$225,000	1,500	17	1.842%	1.012%	0.665%	0.545%	0.512%	0.502%	0.501%
\$225,000	2,000	17	1.412%	0.783%	0.570%	0.515%	0.504%	0.502%	0.501%
\$225,000	3,000	17	0.984%	0.605%	0.519%	0.505%	0.503%	0.502%	0.501%
\$225,000	4,000	17	0.766%	0.542%	0.508%	0.504%	0.503%	0.502%	0.501%
\$225,000	5,000	17	0.651%	0.519%	0.506%	0.504%	0.503%	0.502%	0.501%
\$225,000	10,000	17	0.514%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$225,000	20,000	17	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$250,000	5	17	62.061%	60.253%	58.514%	56.842%	55.239%	52.210%	49.385%
\$250,000	10	17	47.442%	45.310%	43.277%	41.336%	39.481%	36.009%	32.829%
\$250,000	15	17	39.097%	36.786%	34.594%	32.523%	30.565%	26.944%	23.679%
\$250,000	20	17	33.423%	31.012%	28.738%	26.594%	24.579%	20.918%	17.711%
\$250,000	25	17	29.699%	27.211%	24.895%	22.739%	20.739%	17.182%	14.187%
\$250,000	50	17	19.584%	17.163%	14.999%	13.077%	11.378%	8.557%	6.404%
\$250,000	100	17	12.871%	10.618%	8.703%	7.101%	5.776%	3.802%	2.503%
\$250,000	150	17	9.864%	7.758%	6.060%	4.706%	3.640%	2.184%	1.367%
\$250,000	200	17	8.131%	6.162%	4.631%	3.461%	2.590%	1.493%	0.945%
\$250,000	300	17	6.240%	4.465%	3.166%	2.246%	1.613%	0.918%	0.640%
\$250,000	400	17	5.100%	3.479%	2.361%	1.619%	1.148%	0.696%	0.550%
\$250,000	500	17	4.358%	2.854%	1.870%	1.258%	0.899%	0.597%	0.519%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$250,000	600	17	3.802%	2.412%	1.544%	1.036%	0.761%	0.553%	0.508%
\$250,000	700	17	3.445%	2.131%	1.343%	0.906%	0.682%	0.531%	0.504%
\$250,000	800	17	3.157%	1.905%	1.186%	0.810%	0.631%	0.518%	0.502%
\$250,000	900	17	2.878%	1.701%	1.054%	0.734%	0.590%	0.511%	0.502%
\$250,000	1,000	17	2.649%	1.537%	0.952%	0.678%	0.563%	0.507%	0.501%
\$250,000	1,500	17	1.925%	1.061%	0.688%	0.554%	0.514%	0.502%	0.501%
\$250,000	2,000	17	1.477%	0.815%	0.582%	0.518%	0.505%	0.502%	0.501%
\$250,000	3,000	17	1.027%	0.620%	0.523%	0.506%	0.503%	0.502%	0.501%
\$250,000	4,000	17	0.794%	0.549%	0.509%	0.504%	0.503%	0.502%	0.501%
\$250,000	5,000	17	0.670%	0.522%	0.506%	0.504%	0.503%	0.502%	0.501%
\$250,000	10,000	17	0.516%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$250,000	20,000	17	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$275,000	5	17	62.580%	60.794%	59.075%	57.426%	55.845%	52.854%	50.068%
\$275,000	10	17	48.109%	46.009%	44.007%	42.095%	40.271%	36.854%	33.727%
\$275,000	15	17	39.802%	37.528%	35.375%	33.343%	31.422%	27.869%	24.670%
\$275,000	20	17	34.165%	31.799%	29.568%	27.465%	25.493%	21.888%	18.686%
\$275,000	25	17	30.477%	28.034%	25.747%	23.609%	21.619%	18.050%	15.006%
\$275,000	50	17	20.165%	17.741%	15.572%	13.637%	11.917%	9.050%	6.841%
\$275,000	100	17	13.276%	11.012%	9.080%	7.454%	6.098%	4.063%	2.703%
\$275,000	150	17	10.189%	8.065%	6.343%	4.958%	3.863%	2.342%	1.472%
\$275,000	200	17	8.405%	6.414%	4.856%	3.656%	2.754%	1.603%	1.010%
\$275,000	300	17	6.452%	4.654%	3.326%	2.376%	1.715%	0.973%	0.666%
\$275,000	400	17	5.275%	3.630%	2.483%	1.713%	1.216%	0.726%	0.562%
\$275,000	500	17	4.509%	2.980%	1.967%	1.328%	0.947%	0.614%	0.525%
\$275,000	600	17	3.929%	2.514%	1.619%	1.086%	0.792%	0.561%	0.510%
\$275,000	700	17	3.569%	2.228%	1.412%	0.950%	0.708%	0.537%	0.505%
\$275,000	800	17	3.272%	1.993%	1.246%	0.846%	0.650%	0.522%	0.503%
\$275,000	900	17	2.984%	1.780%	1.104%	0.763%	0.604%	0.513%	0.502%
\$275,000	1,000	17	2.747%	1.608%	0.996%	0.701%	0.574%	0.508%	0.501%
\$275,000	1,500	17	2.001%	1.108%	0.711%	0.563%	0.517%	0.502%	0.501%
\$275,000	2,000	17	1.537%	0.845%	0.594%	0.522%	0.505%	0.502%	0.501%
\$275,000	3,000	17	1.067%	0.635%	0.526%	0.506%	0.503%	0.502%	0.501%
\$275,000	4,000	17	0.822%	0.556%	0.510%	0.504%	0.503%	0.502%	0.501%
\$275,000	5,000	17	0.688%	0.525%	0.506%	0.504%	0.503%	0.502%	0.501%
\$275,000	10,000	17	0.518%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$275,000	20,000	17	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$300,000	5	17	63.001%	61.231%	59.529%	57.899%	56.335%	53.374%	50.620%
\$300,000	10	17	48.659%	46.583%	44.606%	42.719%	40.918%	37.547%	34.462%
\$300,000	15	17	40.383%	38.138%	36.018%	34.017%	32.124%	28.626%	25.480%
\$300,000	20	17	34.774%	32.442%	30.245%	28.178%	26.240%	22.696%	19.533%
\$300,000	25	17	31.112%	28.708%	26.456%	24.347%	22.372%	18.813%	15.748%
\$300,000	50	17	20.675%	18.249%	16.075%	14.131%	12.394%	9.492%	7.237%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$300,000	100	17	13.633%	11.360%	9.415%	7.770%	6.391%	4.300%	2.887%
\$300,000	150	17	10.475%	8.338%	6.595%	5.187%	4.064%	2.490%	1.570%
\$300,000	200	17	8.645%	6.637%	5.055%	3.829%	2.901%	1.702%	1.070%
\$300,000	300	17	6.639%	4.822%	3.470%	2.494%	1.809%	1.026%	0.692%
\$300,000	400	17	5.429%	3.763%	2.594%	1.799%	1.279%	0.756%	0.574%
\$300,000	500	17	4.642%	3.092%	2.055%	1.392%	0.991%	0.632%	0.530%
\$300,000	600	17	4.048%	2.611%	1.691%	1.136%	0.824%	0.572%	0.513%
\$300,000	700	17	3.678%	2.314%	1.474%	0.991%	0.732%	0.544%	0.507%
\$300,000	800	17	3.373%	2.071%	1.301%	0.880%	0.669%	0.526%	0.503%
\$300,000	900	17	3.078%	1.850%	1.151%	0.790%	0.618%	0.516%	0.502%
\$300,000	1,000	17	2.835%	1.671%	1.036%	0.723%	0.584%	0.510%	0.501%
\$300,000	1,500	17	2.069%	1.150%	0.732%	0.572%	0.520%	0.502%	0.501%
\$300,000	2,000	17	1.590%	0.874%	0.605%	0.525%	0.506%	0.502%	0.501%
\$300,000	3,000	17	1.103%	0.649%	0.530%	0.507%	0.503%	0.502%	0.501%
\$300,000	4,000	17	0.847%	0.563%	0.511%	0.504%	0.503%	0.502%	0.501%
\$300,000	5,000	17	0.705%	0.529%	0.506%	0.504%	0.503%	0.502%	0.501%
\$300,000	10,000	17	0.520%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$300,000	20,000	17	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$325,000	5	17	63.346%	61.589%	59.902%	58.287%	56.737%	53.800%	51.073%
\$325,000	10	17	49.110%	47.055%	45.098%	43.231%	41.450%	38.116%	35.066%
\$325,000	15	17	40.858%	38.639%	36.545%	34.569%	32.700%	29.247%	26.146%
\$325,000	20	17	35.279%	32.976%	30.807%	28.770%	26.859%	23.367%	20.251%
\$325,000	25	17	31.640%	29.269%	27.049%	24.969%	23.019%	19.488%	16.423%
\$325,000	50	17	21.138%	18.713%	16.534%	14.583%	12.836%	9.900%	7.605%
\$325,000	100	17	13.954%	11.674%	9.718%	8.057%	6.659%	4.521%	3.061%
\$325,000	150	17	10.730%	8.581%	6.820%	5.393%	4.247%	2.626%	1.664%
\$325,000	200	17	8.859%	6.837%	5.235%	3.988%	3.035%	1.795%	1.129%
\$325,000	300	17	6.808%	4.975%	3.601%	2.603%	1.897%	1.077%	0.718%
\$325,000	400	17	5.567%	3.885%	2.695%	1.880%	1.338%	0.785%	0.586%
\$325,000	500	17	4.761%	3.194%	2.136%	1.452%	1.033%	0.649%	0.535%
\$325,000	600	17	4.154%	2.698%	1.757%	1.182%	0.854%	0.583%	0.516%
\$325,000	700	17	3.775%	2.392%	1.531%	1.029%	0.756%	0.551%	0.508%
\$325,000	800	17	3.464%	2.142%	1.350%	0.911%	0.687%	0.530%	0.504%
\$325,000	900	17	3.162%	1.913%	1.194%	0.815%	0.632%	0.519%	0.503%
\$325,000	1,000	17	2.913%	1.729%	1.073%	0.743%	0.594%	0.512%	0.502%
\$325,000	1,500	17	2.130%	1.188%	0.752%	0.580%	0.523%	0.503%	0.501%
\$325,000	2,000	17	1.638%	0.899%	0.615%	0.528%	0.507%	0.502%	0.501%
\$325,000	3,000	17	1.137%	0.662%	0.534%	0.508%	0.503%	0.502%	0.501%
\$325,000	4,000	17	0.870%	0.570%	0.512%	0.505%	0.503%	0.502%	0.501%
\$325,000	5,000	17	0.721%	0.532%	0.507%	0.504%	0.503%	0.502%	0.501%
\$325,000	10,000	17	0.522%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$325,000	20,000	17	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$350,000	5	17	63.627%	61.882%	60.208%	58.604%	57.066%	54.150%	51.445%
\$350,000	10	17	49.489%	47.452%	45.512%	43.662%	41.897%	38.596%	35.574%
\$350,000	15	17	41.257%	39.059%	36.988%	35.034%	33.185%	29.769%	26.706%
\$350,000	20	17	35.715%	33.435%	31.289%	29.278%	27.391%	23.941%	20.867%
\$350,000	25	17	32.091%	29.747%	27.553%	25.500%	23.574%	20.084%	17.033%
\$350,000	50	17	21.561%	19.142%	16.960%	15.002%	13.248%	10.282%	7.950%
\$350,000	100	17	14.245%	11.959%	9.994%	8.319%	6.904%	4.726%	3.223%
\$350,000	150	17	10.962%	8.803%	7.025%	5.582%	4.416%	2.753%	1.753%
\$350,000	200	17	9.055%	7.022%	5.403%	4.135%	3.163%	1.884%	1.186%
\$350,000	300	17	6.964%	5.116%	3.725%	2.706%	1.980%	1.126%	0.743%
\$350,000	400	17	5.694%	3.997%	2.789%	1.954%	1.395%	0.813%	0.599%
\$350,000	500	17	4.872%	3.288%	2.211%	1.508%	1.072%	0.666%	0.541%
\$350,000	600	17	4.252%	2.779%	1.819%	1.226%	0.883%	0.593%	0.519%
\$350,000	700	17	3.865%	2.464%	1.585%	1.065%	0.778%	0.557%	0.510%
\$350,000	800	17	3.548%	2.207%	1.397%	0.941%	0.704%	0.535%	0.505%
\$350,000	900	17	3.240%	1.973%	1.235%	0.840%	0.646%	0.521%	0.503%
\$350,000	1,000	17	2.985%	1.782%	1.107%	0.763%	0.604%	0.514%	0.502%
\$350,000	1,500	17	2.186%	1.224%	0.771%	0.588%	0.526%	0.503%	0.501%
\$350,000	2,000	17	1.682%	0.923%	0.626%	0.532%	0.508%	0.502%	0.501%
\$350,000	3,000	17	1.168%	0.675%	0.537%	0.509%	0.503%	0.502%	0.501%
\$350,000	4,000	17	0.893%	0.577%	0.514%	0.505%	0.503%	0.502%	0.501%
\$350,000	5,000	17	0.737%	0.535%	0.507%	0.504%	0.503%	0.502%	0.501%
\$350,000	10,000	17	0.524%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$350,000	20,000	17	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$375,000	5	17	63.868%	62.133%	60.469%	58.877%	57.348%	54.450%	51.763%
\$375,000	10	17	49.815%	47.794%	45.868%	44.033%	42.282%	39.008%	36.011%
\$375,000	15	17	41.603%	39.424%	37.372%	35.436%	33.604%	30.222%	27.190%
\$375,000	20	17	36.096%	33.837%	31.713%	29.724%	27.856%	24.443%	21.406%
\$375,000	25	17	32.486%	30.165%	27.994%	25.964%	24.059%	20.609%	17.588%
\$375,000	50	17	21.948%	19.540%	17.360%	15.396%	13.635%	10.649%	8.283%
\$375,000	100	17	14.516%	12.226%	10.252%	8.566%	7.136%	4.922%	3.379%
\$375,000	150	17	11.174%	9.008%	7.218%	5.758%	4.574%	2.874%	1.839%
\$375,000	200	17	9.238%	7.196%	5.562%	4.276%	3.285%	1.969%	1.241%
\$375,000	300	17	7.109%	5.250%	3.842%	2.804%	2.060%	1.175%	0.769%
\$375,000	400	17	5.812%	4.102%	2.877%	2.026%	1.450%	0.841%	0.611%
\$375,000	500	17	4.974%	3.376%	2.282%	1.561%	1.111%	0.683%	0.547%
\$375,000	600	17	4.342%	2.854%	1.877%	1.268%	0.910%	0.604%	0.522%
\$375,000	700	17	3.940%	2.525%	1.630%	1.095%	0.796%	0.562%	0.510%
\$375,000	800	17	3.624%	2.268%	1.440%	0.969%	0.721%	0.539%	0.505%
\$375,000	900	17	3.311%	2.027%	1.272%	0.863%	0.659%	0.524%	0.504%
\$375,000	1,000	17	3.051%	1.831%	1.140%	0.782%	0.614%	0.515%	0.502%
\$375,000	1,500	17	2.237%	1.257%	0.789%	0.597%	0.529%	0.503%	0.501%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$375,000	2,000	17	1.723%	0.946%	0.636%	0.535%	0.509%	0.502%	0.501%
\$375,000	3,000	17	1.197%	0.687%	0.541%	0.509%	0.504%	0.502%	0.501%
\$375,000	4,000	17	0.913%	0.583%	0.515%	0.505%	0.503%	0.502%	0.501%
\$375,000	5,000	17	0.751%	0.538%	0.507%	0.504%	0.503%	0.502%	0.501%
\$375,000	10,000	17	0.526%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$375,000	20,000	17	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$400,000	5	17	64.085%	62.359%	60.705%	59.122%	57.602%	54.720%	52.051%
\$400,000	10	17	50.115%	48.107%	46.195%	44.373%	42.634%	39.385%	36.411%
\$400,000	15	17	41.922%	39.761%	37.726%	35.806%	33.990%	30.639%	27.635%
\$400,000	20	17	36.448%	34.209%	32.104%	30.135%	28.284%	24.904%	21.901%
\$400,000	25	17	32.852%	30.553%	28.402%	26.392%	24.508%	21.095%	18.108%
\$400,000	50	17	22.318%	19.922%	17.749%	15.782%	14.015%	11.011%	8.615%
\$400,000	100	17	14.782%	12.488%	10.506%	8.808%	7.366%	5.117%	3.537%
\$400,000	150	17	11.382%	9.210%	7.408%	5.932%	4.732%	2.995%	1.927%
\$400,000	200	17	9.417%	7.365%	5.717%	4.414%	3.406%	2.055%	1.298%
\$400,000	300	17	7.250%	5.379%	3.956%	2.902%	2.140%	1.224%	0.796%
\$400,000	400	17	5.928%	4.205%	2.965%	2.097%	1.506%	0.869%	0.624%
\$400,000	500	17	5.073%	3.462%	2.351%	1.614%	1.149%	0.700%	0.554%
\$400,000	600	17	4.430%	2.928%	1.935%	1.309%	0.939%	0.615%	0.526%
\$400,000	700	17	4.020%	2.590%	1.679%	1.129%	0.818%	0.569%	0.512%
\$400,000	800	17	3.697%	2.327%	1.483%	0.997%	0.738%	0.544%	0.506%
\$400,000	900	17	3.379%	2.080%	1.310%	0.887%	0.672%	0.527%	0.504%
\$400,000	1,000	17	3.114%	1.880%	1.173%	0.801%	0.624%	0.517%	0.503%
\$400,000	1,500	17	2.287%	1.290%	0.807%	0.605%	0.532%	0.503%	0.501%
\$400,000	2,000	17	1.763%	0.969%	0.646%	0.539%	0.510%	0.502%	0.501%
\$400,000	3,000	17	1.224%	0.699%	0.545%	0.510%	0.504%	0.502%	0.501%
\$400,000	4,000	17	0.933%	0.590%	0.516%	0.505%	0.503%	0.502%	0.501%
\$400,000	5,000	17	0.766%	0.542%	0.508%	0.504%	0.503%	0.502%	0.501%
\$400,000	10,000	17	0.528%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$400,000	20,000	17	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$425,000	5	17	64.285%	62.567%	60.922%	59.348%	57.835%	54.969%	52.314%
\$425,000	10	17	50.385%	48.390%	46.490%	44.680%	42.951%	39.725%	36.772%
\$425,000	15	17	42.211%	40.067%	38.047%	36.142%	34.340%	31.015%	28.037%
\$425,000	20	17	36.762%	34.540%	32.452%	30.500%	28.666%	25.315%	22.342%
\$425,000	25	17	33.178%	30.897%	28.766%	26.773%	24.907%	21.527%	18.572%
\$425,000	50	17	22.663%	20.280%	18.116%	16.151%	14.380%	11.358%	8.936%
\$425,000	100	17	15.035%	12.738%	10.749%	9.040%	7.586%	5.305%	3.692%
\$425,000	150	17	11.580%	9.403%	7.591%	6.101%	4.886%	3.115%	2.014%
\$425,000	200	17	9.584%	7.526%	5.865%	4.547%	3.523%	2.139%	1.355%
\$425,000	300	17	7.385%	5.503%	4.067%	2.996%	2.219%	1.272%	0.824%
\$425,000	400	17	6.039%	4.305%	3.050%	2.167%	1.560%	0.898%	0.638%
\$425,000	500	17	5.168%	3.544%	2.419%	1.667%	1.187%	0.717%	0.561%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$425,000	600	17	4.514%	2.998%	1.990%	1.350%	0.967%	0.626%	0.529%
\$425,000	700	17	4.097%	2.653%	1.726%	1.162%	0.840%	0.577%	0.514%
\$425,000	800	17	3.768%	2.384%	1.524%	1.025%	0.754%	0.549%	0.507%
\$425,000	900	17	3.445%	2.132%	1.346%	0.910%	0.685%	0.530%	0.505%
\$425,000	1,000	17	3.176%	1.927%	1.204%	0.820%	0.634%	0.519%	0.503%
\$425,000	1,500	17	2.334%	1.321%	0.825%	0.613%	0.535%	0.503%	0.501%
\$425,000	2,000	17	1.801%	0.991%	0.656%	0.542%	0.511%	0.502%	0.501%
\$425,000	3,000	17	1.251%	0.711%	0.548%	0.511%	0.504%	0.502%	0.501%
\$425,000	4,000	17	0.952%	0.596%	0.518%	0.505%	0.503%	0.502%	0.501%
\$425,000	5,000	17	0.780%	0.545%	0.508%	0.504%	0.503%	0.502%	0.501%
\$425,000	10,000	17	0.530%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$425,000	20,000	17	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$450,000	5	17	64.477%	62.767%	61.131%	59.565%	58.058%	55.206%	52.566%
\$450,000	10	17	50.637%	48.653%	46.765%	44.965%	43.246%	40.042%	37.107%
\$450,000	15	17	42.484%	40.354%	38.349%	36.457%	34.667%	31.369%	28.413%
\$450,000	20	17	37.053%	34.847%	32.776%	30.839%	29.020%	25.695%	22.750%
\$450,000	25	17	33.479%	31.217%	29.102%	27.125%	25.276%	21.927%	19.000%
\$450,000	50	17	22.988%	20.620%	18.465%	16.506%	14.733%	11.697%	9.252%
\$450,000	100	17	15.277%	12.978%	10.986%	9.267%	7.800%	5.490%	3.845%
\$450,000	150	17	11.770%	9.590%	7.768%	6.264%	5.036%	3.234%	2.100%
\$450,000	200	17	9.747%	7.681%	6.011%	4.679%	3.640%	2.224%	1.412%
\$450,000	300	17	7.515%	5.624%	4.175%	3.089%	2.296%	1.322%	0.852%
\$450,000	400	17	6.148%	4.403%	3.133%	2.235%	1.615%	0.927%	0.652%
\$450,000	500	17	5.261%	3.625%	2.485%	1.719%	1.225%	0.735%	0.568%
\$450,000	600	17	4.596%	3.068%	2.046%	1.391%	0.995%	0.638%	0.533%
\$450,000	700	17	4.172%	2.715%	1.773%	1.196%	0.862%	0.584%	0.516%
\$450,000	800	17	3.837%	2.440%	1.565%	1.052%	0.772%	0.554%	0.508%
\$450,000	900	17	3.510%	2.183%	1.383%	0.933%	0.698%	0.534%	0.505%
\$450,000	1,000	17	3.236%	1.973%	1.235%	0.839%	0.644%	0.522%	0.503%
\$450,000	1,500	17	2.380%	1.352%	0.842%	0.622%	0.538%	0.504%	0.501%
\$450,000	2,000	17	1.839%	1.013%	0.667%	0.546%	0.512%	0.502%	0.501%
\$450,000	3,000	17	1.277%	0.723%	0.552%	0.512%	0.504%	0.502%	0.501%
\$450,000	4,000	17	0.971%	0.603%	0.519%	0.505%	0.503%	0.502%	0.501%
\$450,000	5,000	17	0.794%	0.549%	0.509%	0.504%	0.503%	0.502%	0.501%
\$450,000	10,000	17	0.531%	0.506%	0.505%	0.504%	0.503%	0.502%	0.501%
\$450,000	20,000	17	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$475,000	5	17	64.650%	62.948%	61.319%	59.760%	58.259%	55.420%	52.793%
\$475,000	10	17	50.868%	48.895%	47.017%	45.227%	43.517%	40.331%	37.415%
\$475,000	15	17	42.734%	40.618%	38.625%	36.745%	34.967%	31.691%	28.756%
\$475,000	20	17	37.321%	35.129%	33.073%	31.151%	29.345%	26.044%	23.123%
\$475,000	25	17	33.752%	31.506%	29.407%	27.444%	25.610%	22.289%	19.387%
\$475,000	50	17	23.288%	20.936%	18.792%	16.840%	15.070%	12.023%	9.558%

^{*} Applied to projected claims under ISL

ISL limit	Members	Months	110%	115%	120%	125%	130%	140%	150%
\$475,000	100	17	15.506%	13.208%	11.211%	9.484%	8.005%	5.668%	3.994%
\$475,000	150	17	11.950%	9.767%	7.936%	6.420%	5.180%	3.349%	2.185%
\$475,000	200	17	9.903%	7.830%	6.151%	4.806%	3.753%	2.306%	1.469%
\$475,000	300	17	7.639%	5.740%	4.279%	3.179%	2.371%	1.370%	0.881%
\$475,000	400	17	6.252%	4.496%	3.214%	2.301%	1.668%	0.957%	0.666%
\$475,000	500	17	5.351%	3.703%	2.549%	1.770%	1.263%	0.753%	0.575%
\$475,000	600	17	4.676%	3.136%	2.099%	1.431%	1.023%	0.649%	0.537%
\$475,000	700	17	4.244%	2.775%	1.819%	1.229%	0.884%	0.592%	0.518%
\$475,000	800	17	3.903%	2.493%	1.605%	1.079%	0.788%	0.559%	0.509%
\$475,000	900	17	3.572%	2.232%	1.418%	0.956%	0.712%	0.537%	0.506%
\$475,000	1,000	17	3.293%	2.017%	1.266%	0.857%	0.655%	0.524%	0.504%
\$475,000	1,500	17	2.425%	1.383%	0.860%	0.630%	0.542%	0.504%	0.501%
\$475,000	2,000	17	1.875%	1.035%	0.677%	0.550%	0.513%	0.502%	0.501%
\$475,000	3,000	17	1.303%	0.734%	0.556%	0.513%	0.504%	0.502%	0.501%
\$475,000	4,000	17	0.990%	0.609%	0.520%	0.505%	0.503%	0.502%	0.501%
\$475,000	5,000	17	0.807%	0.552%	0.509%	0.504%	0.503%	0.502%	0.501%
\$475,000	10,000	17	0.533%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$475,000	20,000	17	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%
\$500,000	5	17	64.813%	63.117%	61.495%	59.943%	58.448%	55.621%	53.006%
\$500,000	10	17	51.086%	49.122%	47.253%	45.473%	43.772%	40.603%	37.704%
\$500,000	15	17	42.967%	40.864%	38.883%	37.015%	35.247%	31.993%	29.077%
\$500,000	20	17	37.573%	35.394%	33.353%	31.443%	29.651%	26.372%	23.475%
\$500,000	25	17	34.005%	31.774%	29.690%	27.741%	25.920%	22.625%	19.747%
\$500,000	50	17	23.571%	21.234%	19.103%	17.159%	15.394%	12.343%	9.861%
\$500,000	100	17	15.728%	13.432%	11.430%	9.697%	8.208%	5.846%	4.142%
\$500,000	150	17	12.125%	9.939%	8.102%	6.576%	5.323%	3.465%	2.273%
\$500,000	200	17	10.055%	7.977%	6.288%	4.932%	3.866%	2.390%	1.527%
\$500,000	300	17	7.760%	5.853%	4.382%	3.268%	2.446%	1.419%	0.910%
\$500,000	400	17	6.353%	4.588%	3.293%	2.367%	1.720%	0.987%	0.680%
\$500,000	500	17	5.438%	3.779%	2.613%	1.820%	1.301%	0.771%	0.583%
\$500,000	600	17	4.753%	3.202%	2.152%	1.471%	1.051%	0.661%	0.541%
\$500,000	700	17	4.313%	2.833%	1.864%	1.261%	0.905%	0.600%	0.520%
\$500,000	800	17	3.966%	2.545%	1.644%	1.106%	0.805%	0.565%	0.511%
\$500,000	900	17	3.631%	2.279%	1.452%	0.978%	0.725%	0.541%	0.506%
\$500,000	1,000	17	3.348%	2.059%	1.295%	0.876%	0.665%	0.526%	0.504%
\$500,000	1,500	17	2.468%	1.412%	0.877%	0.639%	0.545%	0.504%	0.501%
\$500,000	2,000	17	1.909%	1.055%	0.687%	0.554%	0.514%	0.502%	0.501%
\$500,000	3,000	17	1.327%	0.746%	0.560%	0.514%	0.504%	0.502%	0.501%
\$500,000	4,000	17	1.007%	0.615%	0.522%	0.506%	0.503%	0.502%	0.501%
\$500,000	5,000	17	0.820%	0.556%	0.510%	0.504%	0.503%	0.502%	0.501%
\$500,000	10,000	17	0.535%	0.507%	0.505%	0.504%	0.503%	0.502%	0.501%
\$500,000	20,000	17	0.407%	0.406%	0.405%	0.404%	0.403%	0.402%	0.401%

^{*} Applied to projected claims under ISL

MEMORANDUM

To: Martine Lemieux, Manager, Actuarial Services

From: Ruth Greene, VP and CFO

BlueCross BlueShield

of Vermont

An Independent Licensee of the Blue Cross and Blue Shield Association

Date: February 16, 2022

Subject: Administrative Charges and Contribution to Policyholder Reserves for Q3 2022 Large

Group Rating Program Filings

Upon consideration of the points documented in this memorandum, I am recommending that you file as follows for the Q3 2022 Blue Cross and TVHP Large Group Rating Program Filings and the 2023 Association Health Plan Filing:

- 1. A contribution to policyholder reserves (CTR) of 1.5 percent for Blue Cross insured groups, 2.0 percent for TVHP insured groups, and 0.375 percent for Cost Plus groups; and
- 2. Exclude from the filing any explicit claims costs related to testing and treatment for the COVID-19 pandemic.

Overall CTR Philosophy

Blue Cross holds that a long-term CTR of 1.5 percent represents an adequate, yet not excessive, contribution to policyholder reserves. CTR at this level within a typical trend and growth environment allows us to navigate short-term fluctuations in order to maintain surplus levels that are within our established, modest target range.

Blue Cross believes that CTR should be managed to an adequate long-term level rather than fluctuating significantly from year to year with changes in membership and health care cost trend. For this reason, we file a CTR equal to our long-term target. It is our expectation that our future filings will also include contribution to policyholder reserves equal to this target. While the long-term CTR target may exceed or fall below that required to maintain our surplus position in any given year, maintaining an adequate long-term assumption will allow the market to avoid rate shocks in years of high growth in projected claims costs.

The impact of the ongoing pandemic on financial results is one example of a short-term fluctuation. In order to remain in the target range and provide stability to its policyholders, the Blue Cross CTR philosophy looks beyond a single year of experience to establish the required levels.

Should the outlook for the Blue Cross surplus level fail to fall within our target range, we would adjust our filed CTR accordingly. That is, in the event that surplus is projected to materially exceed our targeted range, we would reduce our filed CTR from the long-term rate, all else being equal. Similarly, in the

absence of mitigating factors, we would file a CTR that exceeds the long-term rate should surplus project to fall materially below our target range.

Adequately funded premiums are the foundation of solvency, the most important element of consumer protection. An adequate long-term contribution to policyholder reserves should exceed the minimum required to keep pace with increases in total claims costs. While best estimate assumptions are by definition expected to lead to equal likelihood of gains and losses, unexpected events or periods of sustained losses may lead to financial deterioration of sufficient magnitude to threaten a company's solvency.

Apart from modest investment income, CTR is the only source of funding that sustains policyholder reserves for Blue Cross. While any rating program filing is by definition an estimate of future costs and is therefore subject to gains or losses, Blue Cross files no additional margin beyond the required CTR. Any rate shortfall will first be paid out of CTR, while any shortfall beyond the approved CTR for a particular filing will be funded from existing policyholder reserves (i.e. surplus).

Maintaining an adequate surplus level is critical for any insurer. Consequences of low surplus include reduced flexibility in responding to customer needs (for instance, a restricted ability to give payment flexibility to customers during an economic crisis), a need for higher margins in rates in order to avoid further deterioration, and a reduced ability to attract or retain business or to support membership growth. Stability is particularly important in times of change, including the continuing evolution at both the federal and Vermont levels of the individual and small group market, the health care reform environment in Vermont, and the ongoing COVID-19 crisis.

Blue Cross must remain financially strong in order to continue to provide Vermonters with access to high quality care, outstanding member experiences, and responsible cost management. Realizing a sustainable CTR over time is key to achieving that goal.

Risk Based Capital Outlook

On February 7, 2019, the Commissioner of the Vermont Department of Financial Regulation (DFR) issued an order approving a target Risk Based Capital (RBC) range of 590 percent to 745 percent. The order states, in part:

"If BCBSVT's RBC ratio falls below or increases above the approved range, BCBSVT shall promptly develop a plan to move within the range within a reasonable time and shall submit such plan to the Commissioner."

Blue Cross's RBC is currently within the targeted range, however, uncertainties with regard to future growth of insured membership, continued economic and market volatility as well as a very challenging competitive environment make it difficult to predict where Blue Cross will be in the range by the end of 2023. We note that, all else being equal, it is better to be near the middle of the target RBC range rather than at an end point, as this minimizes the probability of falling out of the range and triggering a required corrective market action¹.

¹ The Axene Health Partners RBC study indicates that the point within the target RBC range from which it is least likely to fall outside the range within a one-year period is 690 percent.

We do not intend to waver from our CTR philosophy while within the target range, which will generally have the effect of very modestly increasing RBC when near the low end of the target range and very modestly decreasing RBC when approaching the high end of the target range.

COVID-19

During this difficult time, Blue Cross's primary responsibility to Vermonters is to maintain continuity of coverage and claims payments for the duration of the COVID-19 crisis. This understanding necessitates that we continue to rate appropriately so that we can provide flexibility to customers and providers who are struggling financially.

As discussed in our prior filings, Blue Cross has long maintained that a pandemic is one reason to hold surplus. Given that the designed function of policyholder reserves is to weather the types of uncertainties created by a pandemic without resorting to extreme rate fluctuations, any increased cost in 2021 and 2022 due explicitly to the COVID-19 pandemic has been and will be funded through policyholder reserves. For 2023, Blue Cross expects that COVID-19 vaccines will be recurring annually, and these endemic costs will be included in the claims projections. Other costs related to this pandemic, such as testing and treatment, will be funded through policyholder reserves. Said differently, I am comfortable that the filed CTR of 1.5 percent will yield our targeted financial outcome in the event that the COVID-19 pandemic is responsible for 2023 claims increases beyond those projected in the filing.

Federal Taxes

The Tax Cuts and Jobs Act resulted in the Blue Cross legal entity being no longer subject to federal income taxes (note that Blue Cross subsidiaries continue to be taxable). The savings resulting from the elimination of Blue Cross's annual federal tax obligation have been passed on directly to our customers in premium rates through the reduction of our long-term CTR to 1.5 percent from its historical level of 2.0 percent².

Conclusion

In consideration of all the above, I recommend that you file a 1.5 percent CTR for the Q3 2022 Blue Cross Large Group Rating Program Filing and the 2023 Association Health Plan Filing, a 2.0 percent CTR for the Q3 2022 TVHP Large Group Rating Program Filing, a 0.375 percent CTR for Cost Plus business. Further, I recommend that you exclude direct testing and treatment costs for COVID-19 from claims projections to reflect Blue Cross's intention to fund these items through policyholder reserves.

² Because TVHP remains taxable at the federal level, its long-term CTR target is 2 percent.

Please provide Company specific inputs for any cells shaded in blue.

Field Name	Description	Input
Insurance Company Name	Company Name	The Vermont Health Plan
HIOS ID	5 digit HIOS ID (if applicable)	99852
SERFF Filing Number	Filing number assigned by SERFF	BCVT-133154563
Market	Market type: Individual, Small Group, Large Group etc.	Large Group
Product Name	Product name entered in SERFF	Q3 2022 TVHP Large Group Rating Program Filing
Period Prior to Experience Period Start Date	Beginning date for the 12 month period preceding the base period experience (MM/DD/YYYY)	9/1/2019
Period Prior to Experience Period End Date	End date for the 12 month period preceding the base period experience (MM/DD/YYYY)	8/31/2020
Experience Period Start Date	Beginning date for base period experience (MM/DD/YYYY)	9/1/2020
Experience Period End Date	End date for base period experience (MM/DD/YYYY)	8/31/2021
Projection Period Start Date	Beginning effective date for proposed rates (MM/DD/YYYY)	1/1/2023
Projection Period End Date	Ending effective date for proposed rates (MM/DD/YYYY)	12/31/2023

Insurance Company Name The Vermont Health Plan HIOS ID 99852

SERFF Filing Number BCVT-133154563
Market Large Group

Product Name Q3 2022 TVHP Large Group Rating Program Filing

Prescription Drug Costs as Percentage of Premium¹

Enter PMPM drug costs incurred during the below periods for the following prescription drug tiers **dispensed only at a pharmacy, network pharmacy, or mail- order pharmacy.** Additionally, enter the total premium PMPM and member months for each period.

	Gross of Member	Cost Sharing and	d Rebates (Allow	ved Basis)			
		Experienc	e Period -1	Experier	ice Period	Projecti	on Period
		09/01/2019	-08/31/2020	09/01/2020	0-08/31/2021	01/01/2023-12/31/2023	
		Retail	Mail	Retail	Mail	Retail	Mail
	Non-Specialty Generic PMPM	\$16.99	\$1.03	\$16.77	\$0.97	\$15.62	\$0.90
(III)	Non-Specialty Brand PMPM	\$38.54	\$4.21	\$44.32	\$3.88	\$49.88	\$4.37
	Specialty PMPM	\$31.22	\$14.10	\$43.74	\$6.02	\$60.37	\$8.31
(B)	Medical Rx PMPM	\$49	9.37	\$7:	1.47	\$8	3.28
	Total (Medical and Rx) Premium PMPM	\$50	8.69	\$54	8.92	\$69	96.09
	Non-Specialty Generic % of Premium	3.34%	0.20%	3.06%	0.18%	2.24%	0.13%
(1)	Non-Specialty Brand % of Premium	7.58%	0.83%	8.07%	0.71%	7.17%	0.63%
	Specialty Total % of Premium	6.14%	2.77%	7.97%	1.10%	8.67%	1.19%
(B)	Medical Rx PMPM	9.7	'0%	13.	02%	11	.96%
	Non-Specialty Generic % of Premium Change vs Prior Period			-0.29%	-0.03%	-0.81%	-0.05%
(11)	Non-Specialty Brand % of Premium Change vs Prior Period			0.50%	-0.12%	-0.91%	-0.08%
	Specialty % of Premium Change vs Prior Period			1.83%	-1.67%	0.70%	0.10%
(B)	Medical Rx % of Premium Change vs Prior Period			3.3	31%	-1.	06%

N	let of Member Cost Sharing (Paid	Amount), Gross	of Rebates			
	Experien	ce Period -1	Experier	nce Period	Projection Period	
	Retail	Mail	Retail	Mail	Retail	Mail
Non-Specialty Generic PMPM	\$10.97	\$0.65	\$11.05	\$0.69	\$10.43	\$0.65
(III) Non-Specialty Brand PMPM	\$34.15	\$3.98	\$39.55	\$3.69	\$45.11	\$4.21
Specialty PMPM	\$30.54	\$13.58	\$42.60	\$5.78	\$59.60	\$8.08
(B) Medical Rx PMPM	\$4	17.12	\$6	\$69.22		33.05
Total Medical and Rx Premium PMPM	\$5	08.69	\$54	48.92	\$6	96.09
Non-Specialty Generic % of Premium	2.16%	0.13%	2.01%	0.12%	1.50%	0.09%
(I) Non-Specialty Brand % of Premium	6.71%	0.78%	7.20%	0.67%	6.48%	0.61%
Specialty Total % of Premium	6.00%	2.67%	7.76%	1.05%	8.56%	1.16%
(B) Medical Rx PMPM	9	.26%	12	.61%	11	93%
Non-Specialty Generic % of Premium Change vs Prior	Period		-0.14%	0.00%	-0.51%	-0.03%
(II) Non-Specialty Brand % of Premium Change vs Prior P			0.49%	-0.11%	-0.72%	-0.07%
Specialty % of Premium Change vs Prior Period			1.76%	-1.62%	0.80%	0.11%
(B) Medical Rx % of Premium Change vs Prior Period			3.:	35%	-0	.68%

¹ Vermont Statute 8 V.S.A. § 4062

(2)(A) In conjunction with a rate filing required by subsection (a) of this section, an insurer shall disclose to the Board:

- (i) for all covered prescription drugs, including generic drugs, brand-name drugs excluding specialty drugs, and specialty drugs dispensed at a pharmacy, network pharmacy, or mail-order pharmacy for outpatient use:
- (I) the percentage of the premium rate attributable to prescription drug costs for the prior year for each category of prescription drugs;
- (II) the year-over-year increase or decrease, expressed as a percentage, in per-member, per-month total health plan spending on each category of prescription drugs; and
- (III) the year-over-year increase or decrease in per-member, per-month costs for prescription drugs compared to other components of the premium rate.
- (B) The insurer shall provide, if available, the percentage of the premium rate attributable to prescription drugs administered by a health care provider in an outpatient setting that are part of the medical benefit as separate from the pharmacy benefit.

Insurance Company Name The Vermont Health Plan

HIOS ID 99852

SERFF Filing Number BCVT-133154563
Market Large Group

Product Name Q3 2022 TVHP Large Group Rating Program Filing

Vermont Statute 8 V.S.A. § 4062

(2)(A) In conjunction with a rate filing required by subsection (a) of this section, an insurer shall disclose to the Board:

(ii) the specialty tier formulary list.

Specialty Formulary List

Provide the specialty formulary information listed below.

Drug Name	Drug Tier	Formulary Name (if multiple formularies are used)
ABIRATERONE	ORAL-CHEMO	Blue Cross Formulary
ABIRATERONE	ORAL-CHEMO	National Performance Formulary
ABRAXANE	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ABRAXANE	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
ACTEMRA	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ACTEMRA	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
ACTHAR	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ACTHAR	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
ACTIMMUNE	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ACTIMMUNE	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
ADAKVEO	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ADAKVEO	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
ADCETRIS	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ADCETRIS	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
ADEFOV	GENERIC-SPECIALTY	Blue Cross Formulary
ADEFOV	GENERIC-SPECIALTY	National Performance Formulary
ADEMPAS	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ADEMPAS	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
ADRIAMYCIN	GENERIC-SPECIALTY	Blue Cross Formulary
ADRIAMYCIN	GENERIC-SPECIALTY GENERIC-SPECIALTY	National Performance Formulary
ADVATE	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ADVATE	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	National Performance Formulary
ADVATE	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ADTNOVATE	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
AFINITOR	ORAL-CHEMO	Blue Cross Formulary
AFINITOR	ORAL-CHEMO ORAL-CHEMO	
AFINITOR AFSTYLA	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary
	NON-PREFERRED-BRAND-SPECIALTY	,
AFSTYLA ALDURAZYME	PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary
ALDURAZYME ALDURAZYME	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	National Performance Formulary
ALECENSA	ORAL-CHEMO	Blue Cross Formulary
ALECENSA		National Performance Formulary
	ORAL-CHEMO	
ALFERON	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ALFERON	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
ALIMTA	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ALIMTA	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
ALIQOPA	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ALIQOPA	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
ALKERAN	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ALKERAN	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
ALKERAN	ORAL-CHEMO	Blue Cross Formulary
ALKERAN	ORAL-CHEMO	National Performance Formulary
ALPHANATE	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ALPHANATE	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
ALPHANINE	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ALPHANINE	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
ALPROLIX	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ALPROLIX	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
ALUNBRIG	ORAL-CHEMO	Blue Cross Formulary
ALUNBRIG	ORAL-CHEMO	National Performance Formulary
ALYQ	GENERIC-SPECIALTY	Blue Cross Formulary
ALYQ	GENERIC-SPECIALTY	National Performance Formulary
AMBRISENTAN	GENERIC-SPECIALTY	Blue Cross Formulary
AMBRISENTAN	GENERIC-SPECIALTY	National Performance Formulary
AMPYRA	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
AMPYRA	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
APOKYN	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
APOKYN	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
ARALAST	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary

ARALAST	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
ARANESP	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ARANESP	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
ARIKAYCE	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ARIKAYCE	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
ARIXTRA	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ARIXTRA	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
ARRANON	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ARRANON	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
ARSENIC	GENERIC-SPECIALTY	Blue Cross Formulary
ARSENIC	GENERIC-SPECIALTY	National Performance Formulary
ARZERRA	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ARZERRA	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
ASCENIV	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ASPARLAS	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ASPARLAS	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
ASTAGRAF	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ASTAGRAF	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
ATGAM	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ATGAM	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
AUBAGIO	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
AUBAGIO	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
AUSTEDO	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
AUSTEDO	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
AVASTIN	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
AVASTIN	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
AVONEX	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
AVONEX	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
AVSOLA	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
AVSOLA	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
AYVAKIT	ORAL-CHEMO	Blue Cross Formulary
AYVAKIT	ORAL-CHEMO	National Performance Formulary
AZACITIDINE	GENERIC-SPECIALTY	Blue Cross Formulary
AZACITIDINE	GENERIC-SPECIALTY	National Performance Formulary
BAFIERTAM	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
BAFIERTAM	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
BALVERSA	ORAL-CHEMO	Blue Cross Formulary
BALVERSA	ORAL-CHEMO	National Performance Formulary
BARACLUDE	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
BARACLUDE	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
BAVENCIO	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
BAVENCIO BAVENCIO	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary
		,
BAVENCIO	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
BAVENCIO BELEODAQ	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary
BAVENCIO BELEODAQ BELEODAQ	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary
BAVENCIO BELEODAQ BELEODAQ BELRAPZO	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
BAVENCIO BELEODAQ BELEODAQ BELRAPZO BENDEKA	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary
BAVENCIO BELEODAQ BELEODAQ BELRAPZO BENDEKA BENDEKA	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary
BAVENCIO BELEODAQ BELEODAQ BELRAPZO BENDEKA BENDEKA BENEFIX	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
BAVENCIO BELEODAQ BELEODAQ BELRAPZO BENDEKA BENDEKA BENEFIX BENEFIX	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
BAVENCIO BELEODAQ BELEODAQ BELRAPZO BENDEKA BENDEKA BENEFIX BENEFIX BENLYSTA	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary
BAVENCIO BELEODAQ BELEODAQ BELRAPZO BENDEKA BENDEKA BENEFIX BENEFIX BENEFIX BENLYSTA BENLYSTA BEOVU BERINERT	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
BAVENCIO BELEODAQ BELEODAQ BELRAPZO BENDEKA BENDEKA BENEFIX BENEFIX BENEFIX BENLYSTA BENLYSTA BEOVU	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary
BAVENCIO BELEODAQ BELEODAQ BELRAPZO BENDEKA BENDEKA BENEFIX BENEFIX BENEFIX BENLYSTA BENLYSTA BEOVU BERINERT	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary
BAVENCIO BELEODAQ BELEODAQ BELEODAQ BELRAPZO BENDEKA BENDEKA BENEFIX BENEFIX BENLYSTA BENLYSTA BENLYSTA BEOVU BERINERT BERINERT	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary
BAVENCIO BELEODAQ BELEODAQ BELEODAQ BELRAPZO BENDEKA BENDEKA BENEFIX BENEFIX BENEFIX BENLYSTA BENLYSTA BEOVU BERINERT BERINERT BESPONSA	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Slue Cross Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
BAVENCIO BELEODAQ BELEODAQ BELEODAQ BELRAPZO BENDEKA BENDEKA BENEFIX BENEFIX BENEFIX BENLYSTA BEOVU BERINERT BERINERT BESPONSA BESPONSA	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
BAVENCIO BELEODAQ BELEODAQ BELEODAQ BELRAPZO BENDEKA BENDEKA BENDEKIX BENEFIX BENLYSTA BENLYSTA BEOVU BERINERT BERINERT BESPONSA BESPONSA BESPONSA BETASERON	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary
BAVENCIO BELEODAQ BELEODAQ BELEODAQ BELRAPZO BENDEKA BENDEKA BENDEKX BENEFIX BENEFIX BENLYSTA BENLYSTA BEOVU BERINERT BERINERT BESPONSA BESPONSA BETASERON BETASERON	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
BAVENCIO BELEODAQ BELEODAQ BELEODAQ BELRAPZO BENDEKA BENDEKA BENEFIX BENEFIX BENEFIX BENLYSTA BEOVU BERINERT BESPONSA BESPONSA BESPONSA BETASERON BETASERON BETHKIS	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary
BAVENCIO BELEODAQ BELEODAQ BELEODAQ BELRAPZO BENDEKA BENDEKA BENEFIX BENEFIX BENEFIX BENLYSTA BEOVU BERINERT BESPONSA BESPONSA BESPONSA BETASERON BETASERON BETHKIS BETHKIS	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
BAVENCIO BELEODAQ BELEODAQ BELEODAQ BELRAPZO BENDEKA BENDEKA BENEFIX BENEFIX BENEFIX BENLYSTA BEOVU BERINERT BESPONSA BESPONSA BESPONSA BETASERON BETASERON BETHKIS BETHKIS BEVACIZUMAB	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
BAVENCIO BELEODAQ BELEODAQ BELEODAQ BELRAPZO BENDEKA BENDEKA BENEFIX BENEFIX BENEFIX BENLYSTA BEOVU BERINERT BERINERT BESPONSA BESPONSA BETASERON BETASERON BETHKIS BETHKIS BEVACIZUMAB BEVACIZUMAB	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
BAVENCIO BELEODAQ BELEODAQ BELEODAQ BELRAPZO BENDEKA BENDEKA BENDEKA BENEFIX BENEFIX BENLYSTA BENLYSTA BEOVU BERINERT BERINERT BESPONSA BESPONSA BETASERON BETASERON BETHKIS BETHKIS BETHKIS BEVACIZUMAB BEVACIZUMAB BEVACIZUMAB	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
BAVENCIO BELEODAQ BELEODAQ BELEODAQ BELRAPZO BENDEKA BENDEKA BENDEKA BENEFIX BENEFIX BENLYSTA BENLYSTA BEOVU BERINERT BERINERT BESPONSA BESPONSA BETASERON BETASERON BETHKIS BETHKIS BETHKIS BEVACIZUMAB BEVACIZUMAB BEVACIZUMAB BEVACIZUMAB	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY TIER 03	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
BAVENCIO BELEODAQ BELEODAQ BELEODAQ BELRAPZO BENDEKA BENDEKA BENDEKA BENEFIX BENEFIX BENLYSTA BENLYSTA BEOVU BERINERT BERINERT BESPONSA BESPONSA BETASERON BETASERON BETHKIS BETHKIS BETHKIS BEVACIZUMAB	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY TIER 03 TIER 03 ORAL-CHEMO	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
BAVENCIO BELEODAQ BELEODAQ BELEODAQ BELRAPZO BENDEKA BENDEKA BENDEKA BENEFIX BENEFIX BENLYSTA BENLYSTA BEOVU BERINERT BESPONSA BESPONSA BESPONSA BETASERON BETASERON BETHKIS BETHKIS BETHKIS BEVACIZUMAB BEXAROTENE	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
BAVENCIO BELEODAQ BELEODAQ BELEODAQ BELRAPZO BENDEKA BENDEKA BENDEKIX BENEFIX BENEFIX BENLYSTA BENLYSTA BEOVU BERINERT BESPONSA BESPONSA BESPONSA BETASERON BETASERON BETHKIS BETHKIS BEVACIZUMAB BEVACIZUMAB BEVACIZUMAB BEVACIZUMAB BEVACIZUMAB BEXAROTENE BEXAROTENE BEXAROTENE BELOOD BELEODACO BELE	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary
BAVENCIO BELEODAQ BELEODAQ BELEODAQ BELRAPZO BENDEKA BENDEKA BENDEKIX BENEFIX BENEFIX BENLYSTA BEOVU BERINERT BESPONSA BESPONSA BETASERON BETASERON BETHKIS BETHKIS BEVACIZUMAB BEVACIZUMAB BEVACIZUMAB BEXAROTENE BEXAROTENE BICNU BELEODAQ BELEODAQ BETASERON BETASERON BETASERON BETASERON	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary
BAVENCIO BELEODAQ BELEODAQ BELEODAQ BELRAPZO BENDEKA BENDEKA BENDEKA BENEFIX BENLYSTA BENLYSTA BENLYSTA BENLYSTA BERINERT BERINERT BERINERT BESPONSA BESPONSA BETASERON BETASERON BETHKIS BETHKIS BETHKIS BEVACIZUMAB BEVACIZUMAB BEVACIZUMAB BEVACIZUMAB BEVACIZUMAB BEVACIZUMAB BEXAROTENE BEXAROTENE BEXAROTENE BICNU BICNU BICNU	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
BAVENCIO BELEODAQ BELEODAQ BELEODAQ BELRAPZO BENDEKA BENDEKA BENDEKA BENEFIX BENEFIX BENLYSTA BENLYSTA BEOVU BERINERT BERINERT BESPONSA BESPONSA BETASERON BETASERON BETHKIS BETHKIS BEVACIZUMAB BEVACIZUMAB BEVACIZUMAB BEVACIZUMAB BEVACIZUMAB BEXAROTENE BEXAROTENE BICNU BICNU BICNU BIVIGAM BIVIGAM	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
BAVENCIO BELEODAQ BELEODAQ BELEODAQ BELRAPZO BENDEKA BENDEKA BENDEKA BENEFIX BENEFIX BENLYSTA BENLYSTA BEOVU BERINERT BESPONSA BESPONSA BETASERON BETASERON BETHISS BETHKIS BETHKIS BEVACIZUMAB BEVACIZUMAB BEVACIZUMAB BEVACIZUMAB BEXAROTENE BEXAROTENE BICNU BICNU BICNU BICNU BIVIGAM BIVIGAM BIVIGAM BIVIGAM BIVIGAM BIVIGAM BILENEEP	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary
BAVENCIO BELEODAQ BELEODAQ BELEODAQ BELRAPZO BENDEKA BENDEKA BENDEKA BENEFIX BENEFIX BENLYSTA BENLYSTA BEOVU BERINERT BESPONSA BESPONSA BESPONSA BETASERON BETHKIS BETHKIS BETHKIS BEVACIZUMAB	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
BAVENCIO BELEODAQ BELEODAQ BELEODAQ BELRAPZO BENDEKA BENDEKA BENDEKA BENEFIX BENEFIX BENLYSTA BENLYSTA BEOVU BERINERT BESPONSA BESPONSA BESPONSA BETASERON BETASERON BETHKIS BETHKIS BEVACIZUMAB BEVAC	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary

BORTEZOMIB BORTEZOMIB	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
BOSENTAN	GENERIC-SPECIALTY	National Performance Formulary Blue Cross Formulary
BOSENTAN	GENERIC-SPECIALTY GENERIC-SPECIALTY	National Performance Formulary
BOSULIF	ORAL-CHEMO	Blue Cross Formulary
BOSULIF	ORAL-CHEMO	National Performance Formulary
вотох	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
вотох	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
BRAFTOVI	ORAL-CHEMO	Blue Cross Formulary
BRAFTOVI	ORAL-CHEMO	National Performance Formulary
BRINEURA	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
BRINEURA	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
BRUKINSA	ORAL-CHEMO	Blue Cross Formulary
BRUKINSA	ORAL-CHEMO	National Performance Formulary
BUPHENYL	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
BUPHENYL	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
BUSULFAN	GENERIC-SPECIALTY	Blue Cross Formulary
BUSULFAN	GENERIC-SPECIALTY	National Performance Formulary
BUSULFEX	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
BUSULFEX	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
CABLIVI	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
CABLIVI	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
CABOMETYX	ORAL-CHEMO	Blue Cross Formulary
CALOUENCE	ORAL CHEMO	National Performance Formulary
CALQUENCE	ORAL-CHEMO ORAL-CHEMO	Blue Cross Formulary National Performance Formulary
CALQUENCE CAMPTOSAR	NON-PREFERRED-BRAND-SPECIALTY	,
CAMPTOSAR	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary
CAPECITABINE	ORAL-CHEMO	Blue Cross Formulary
CAPECITABINE	ORAL-CHEMO	National Performance Formulary
CAPRELSA	ORAL-CHEMO	Blue Cross Formulary
CAPRELSA	ORAL-CHEMO	National Performance Formulary
CARBAGLU	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
CARBAGLU	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
CARBOPLATIN	GENERIC-SPECIALTY	Blue Cross Formulary
CARBOPLATIN	GENERIC-SPECIALTY	National Performance Formulary
CARMUSTINE	GENERIC-SPECIALTY	Blue Cross Formulary
CARMUSTINE	GENERIC-SPECIALTY	National Performance Formulary
CAYSTON	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
CHISTON	TOTAL THE ENTED BIGHTS STECKETT	Blue Closs Formulary
CAYSTON	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
		,
CAYSTON	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
CAYSTON CELLCEPT	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
CAYSTON CELLCEPT CELLCEPT CERDELGA CERDELGA	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
CAYSTON CELLCEPT CELLCEPT CERDELGA CERDELGA CEREZYME	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
CAYSTON CELLCEPT CELLCEPT CERDELGA CERDELGA CEREZYME CEREZYME	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
CAYSTON CELLCEPT CELLCEPT CERDELGA CERDELGA CEREZYME CEREZYME CEREZYME CETROTIDE	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary Blue Cross Formulary
CAYSTON CELLCEPT CELLCEPT CERDELGA CERELGA CEREZYME CEREZYME CEREZYME CETROTIDE CHENODAL	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary
CAYSTON CELLCEPT CELLCEPT CERDELGA CERDELGA CEREZYME CEREZYME CEREZYME CETROTIDE CHENODAL CHENODAL	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary Blue Cross Formulary
CAYSTON CELLCEPT CELLCEPT CERDELGA CERDELGA CEREZYME CEREZYME CETROTIDE CHENODAL CHENODAL CHOLBAM	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
CAYSTON CELLCEPT CELLCEPT CERDELGA CERDELGA CEREZYME CEREZYME CETROTIDE CHENODAL CHOLBAM CHOLBAM	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
CAYSTON CELLCEPT CELLCEPT CERDELGA CERDELGA CEREZYME CEREZYME CEREZYME CERROTIDE CHENODAL CHOLBAM CHOLBAM CHOLBAM CHOLBAM	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY RON-PREFERRED-BRAND-SPECIALTY ON-PREFERRED-BRAND-SPECIALTY RON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY	National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
CAYSTON CELLCEPT CELLCEPT CERDELGA CERDELGA CEREZYME CEREZYME CETROTIDE CHENODAL CHOLBAM CHOLBAM CHOLBAM CHOR CHOR	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY	National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
CAYSTON CELLCEPT CELLCEPT CELLCEPT CERDELGA CERELGA CEREZYME CEREZYME CETROTIDE CHENODAL CHENODAL CHOLBAM CHOLBAM CHOR CHOR CHOR CHOR CIMZIA	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary
CAYSTON CELLCEPT CELLCEPT CERDELGA CERDELGA CEREZYME CEREZYME CEREZYME CETROTIDE CHENODAL CHENODAL CHOLBAM CHOLBAM CHOR CHOR CHOR CIMZIA	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
CAYSTON CELLCEPT CELLCEPT CERDELGA CERDELGA CEREZYME CEREZYME CETROTIDE CHENODAL CHENODAL CHOLBAM CHOLBAM CHOCK CHOR CHOR CIMZIA CIMZIA CINQAIR	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
CAYSTON CELLCEPT CELLCEPT CERDELGA CERDELGA CEREZYME CEREZYME CETROTIDE CHENODAL CHOLBAM CHOLBAM CHOLBAM CHOR CHOR CIMZIA CIMZIA CIMZIA CINQAIR CINQAIR	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
CAYSTON CELLCEPT CELLCEPT CERDELGA CERDELGA CEREZYME CEREZYME CETROTIDE CHENODAL CHOLBAM CHOLBAM CHOR CHOR CHOR CIMZIA CIMZIA CIMZIA CINQAIR CINQAIR CINQAIR CINQAIR	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
CAYSTON CELLCEPT CELLCEPT CERDELGA CERDELGA CEREZYME CEREZYME CETROTIDE CHENODAL CHOLBAM CHOLBAM CHOLBAM CHOR CHOR CIMZIA CIMZIA CIMZIA CINQAIR CINQAIR	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
CAYSTON CELLCEPT CELLCEPT CELLCEPT CERDELGA CERELGA CEREZYME CEREZYME CETROTIDE CHENODAL CHOLBAM CHOLBAM CHOLBAM CHOR CHOR CIMZIA CIMZIA CIMZIA CINQAIR CINQAIR CINCAIR	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
CAYSTON CELLCEPT CELLCEPT CELLCEPT CERDELGA CERELGA CEREZYME CEREZYME CETROTIDE CHENODAL CHOLBAM CHOLBAM CHOLBAM CHOR CHOR CIMZIA CIMZIA CIMZIA CINQAIR CINQAIR CINQAIR CINCYZE CINRYZE CISPLATIN	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
CAYSTON CELLCEPT CELLCEPT CELLCEPT CERDELGA CEREJGA CEREZYME CEREZYME CEREZYME CEREZYME CHENODAL CHENODAL CHOLBAM CHOLBAM CHOR CHOR CIMZIA CIMZIA CINQAIR CINQAIR CINQAIR CINRYZE CINRYZE CISPLATIN CISPLATIN	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY	National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
CAYSTON CELLCEPT CELLCEPT CERDELGA CERDELGA CEREZYME CEREZYME CEREZYME CETROTIDE CHENODAL CHOLBAM CHOLBAM CHOR CHOR CIMZIA CIMZIA CINQAIR CINQAIR CINQAIR CINRYZE CISPLATIN CISPLATIN	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ONN-PREFERRED-BRAND-SPECIALTY ONN-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ONN-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
CAYSTON CELLCEPT CELLCEPT CERDELGA CERDELGA CEREZYME CEREZYME CEREZYME CETROTIDE CHENODAL CHOLBAM CHOLBAM CHOLBAM CHOR CIMZIA CIMZIA CIMZIA CINQAIR CINQAIR CINCAIR CINRYZE CINRYZE CISPLATIN CISPLATIN CISPLATIN	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
CAYSTON CELLCEPT CELLCEPT CELLCEPT CERDELGA CERELGA CEREZYME CEREZYME CETROTIDE CHENODAL CHOLBAM CHOLBAM CHOLBAM CHOR CHOR CIMZIA CIMZIA CIMZIA CINQAIR CINQAIR CINQAIR CINRYZE CISPLATIN CISPLATIN CISPLATIN CISPLATIN CLADRIBINE CLADRIBINE CLADRIBINE CLADRIBINE CLADRIBINE CELADRIBINE CELACTIC CERLECT CE	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY	National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary
CAYSTON CELLCEPT CELLCEPT CELLCEPT CERDELGA CERELGA CEREZYME CEREZYME CETROTIDE CHENODAL CHOLBAM CHOLBAM CHOLBAM CHOR CHOR CIMZIA CIMZIA CINQAIR CINQAIR CINQAIR CINRYZE CINRYZE CISPLATIN CISPLATIN CISPLATIN CISPLATIN CISPLATIN CLADRIBINE CLADRIBINE	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY	National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
CAYSTON CELLCEPT CELLCEPT CELLCEPT CERDELGA CERELGA CEREZYME CEREZYME CETROTIDE CHENODAL CHOLBAM CHOLBAM CHOLBAM CHOR CHOR CIMZIA CIMZIA CIMZIA CINQAIR CINQAIR CINQAIR CINRYZE CISPLATIN CISPLATIN CISPLATIN CISPLATIN CLADRIBINE CLADRIBINE CLADRIBINE CLADRIBINE CLADRIBINE CELATIN CELATIN CELATIN CLADRIBINE CLADRIBINE CLADRIBINE CLADRIBINE CLADRIBINE CLADRIBINE CLADRIBINE	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY	National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary
CAYSTON CELLCEPT CELLCEPT CERDELGA CERDELGA CEREZYME CEREZYME CEREZYME CETROTIDE CHENODAL CHOLBAM CHOLBAM CHOLBAM CHOR CHOR CIMZIA CIMZIA CINZIA CINQAIR CINQAIR CINRYZE CISPLATIN CISPLATIN CISPLATIN CLADRIBINE CLADRIBINE CLADRIBINE CLOFARABINE	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary
CAYSTON CELLCEPT CELLCEPT CELLCEPT CERDELGA CEREZYME CEREZYME CEREZYME CETROTIDE CHENODAL CHENODAL CHOLBAM CHOLBAM CHOLBAM CHOR CHOR CIMZIA CINZIA CINZIA CINZIA CINQAIR CINQAIR CINRYZE CINRYZE CINRYZE CISPLATIN CISPLATIN CISPLATIN CISPLATIN CLADRIBINE CLADRIBINE CLADRIBINE CLOFARABINE CLOLAR CLOVIQUE	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY	National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
CAYSTON CELLCEPT CELLCEPT CELLCEPT CERDELGA CEREZYME CEREZYME CEREZYME CETROTIDE CHENODAL CHOLBAM CHOLBAM CHOLBAM CHOR CHOR CIMZIA CINZIA CINZIA CINZIA CINQAIR CINQAIR CINRYZE CISPLATIN CISPLATIN CISPLATIN CISPLATIN CLADRIBINE CLADRIBINE CLOFARABINE CLOLAR CLOLAR CLOLAR CLOVIQUE CLOVIQUE	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY	National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary
CAYSTON CELLCEPT CELLCEPT CELLCEPT CERDELGA CEREZYME CEREZYME CEREZYME CETROTIDE CHENODAL CHOLBAM CHOLBAM CHOLBAM CHOLBAM CHOR CIMZIA CIMZIA CINQAIR CINQAIR CINQAIR CINRYZE CINRYZE CISPLATIN CISPLATIN CISPLATIN CISPLATIN CLADRIBINE CLADRIBINE CLOFARABINE CLOFARABINE CLOLAR CLOVIQUE CLOVIQUE COMERCE CEREZYME CEREZYME CEREZYME CEREZYME CEREZYME CEREZYME CHONDAL CHORAL CHORAL CHORAL CLOVIQUE CLOVIQUE CLOVIQUE CCOMAGAE CLOVIQUE COMAGAE CLOVIQUE CCOMAGAE CCOMAGAE CLOVIQUE CCOMAGAE	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
CAYSTON CELLCEPT CELLCEPT CELLCEPT CERDELGA CEREZYME CEREZYME CEREZYME CETROTIDE CHENODAL CHENODAL CHOLBAM CHOLBAM CHOLBAM CHOR CIMZIA CIMZIA CIMZIA CINQAIR CINQAIR CINRYZE CINRYZE CISPLATIN CISPLATIN CISPLATIN CISPLATIN CISPLATIN CLADRIBINE CLADRIBINE CLADRIBINE CLOFARABINE CLOFARABINE CLOVIQUE CLOVIQUE COAGADEX COAGADEX CEREZYME CEREZYME CEREZYME CHENODAL CHENODAL CHENODAL CHORA CHORA CHORA CHORA CLOVIQUE CLOVIQUE COAGADEX	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary
CAYSTON CELLCEPT CELLCEPT CELLCEPT CERDELGA CEREJGA CEREZYME CEREZYME CEREZYME CEREZYME CEREZYME CEREZYME CEREZYME CHENODAL CHONODAL CHOLBAM CHOLBAM CHOLBAM CHOR CIMZIA CIMZIA CIMZIA CINQAIR CINQAIR CINQAIR CINRYZE CINRYZE CINRYZE CISPLATIN CISPLATIN CISPLATIN CISPLATIN CLADRIBINE CLADRIBINE CLADRIBINE CLOFARABINE CLOLAR CLOLAR CLOVIQUE CLOVIQUE COAGADEX COAGADEX COMETRIQ	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO	National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary
CAYSTON CELLCEPT CELLCEPT CELLCEPT CERDELGA CEREJGA CEREZYME CEREZYME CEREZYME CETROTIDE CHENODAL CHENODAL CHOLBAM CHOLBAM CHOLBAM CHOR CHOR CIMZIA CINZIA CINZIA CINZIA CINZIA CINAZIE CINRYZE CISPLATIN CISPLATIN CISPLATIN CISPLATIN CISPLATIN CLADRIBINE CLADRIBINE CLOFARABINE CLOFARABINE CLOLAR CLOVIQUE CLOVIQUE COAGADEX CORRESIME COAGADEX COAG	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary

COPAXONE	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
CODIKTRA	ORAL-CHEMO ORAL-CHEMO	Blue Cross Formulary
COPIKTRA CORIFACT	PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary
CORIFACT	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
COSENTYX	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
COSMEGEN	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
COSMEGEN	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
COTELLIC	ORAL-CHEMO	Blue Cross Formulary
COTELLIC	ORAL-CHEMO	National Performance Formulary
CRYSVITA	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
CRYSVITA	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
CUPRIMINE	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
CUPRIMINE	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
CUTAQUIG	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
CUVITRU	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
CUVITRU	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
CYCLOPHOSPH	GENERIC SPECIALTY	Blue Cross Formulary
CYCLOPHOSPH CYCLOPHOSPH	GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary
CYCLOPHOSPH	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
CYCLOPHOSPHA	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
CYCLOPHOSPHA	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
CYCLOSPORINE	GENERIC-SPECIALTY	Blue Cross Formulary
CYCLOSPORINE	GENERIC-SPECIALTY	National Performance Formulary
CYRAMZA	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
CYRAMZA	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
CYSTADANE	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
CYSTADANE	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
CYSTADROPS	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
CYSTADROPS	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
CYSTAGON	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
CYSTAGON	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
CYSTARAN	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
CYSTARAN CYTARABINE	NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY	National Performance Formulary Blue Cross Formulary
CYTARABINE	GENERIC-SPECIALTY GENERIC-SPECIALTY	National Performance Formulary
CYTOGAM	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
CYTOGAM	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
DACARBAZINE		Blue Cross Formulary
	GENERIC-SPECIALTY GENERIC-SPECIALTY	
DACARBAZINE	GENERIC-SPECIALTY	Blue Cross Formulary
DACARBAZINE DACARBAZINE	GENERIC-SPECIALTY GENERIC-SPECIALTY	Blue Cross Formulary National Performance Formulary
DACARBAZINE DACARBAZINE DACOGEN DACOGEN DACTINOMYCIN	GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary
DACARBAZINE DACARBAZINE DACOGEN DACOGEN DACTINOMYCIN DACTINOMYCIN	GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
DACARBAZINE DACARBAZINE DACOGEN DACOGEN DACTINOMYCIN DACTINOMYCIN DALFAMPRIDIN	GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary
DACARBAZINE DACARBAZINE DACOGEN DACOGEN DACTINOMYCIN DACTINOMYCIN DALFAMPRIDIN DALFAMPRIDIN	GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY	Blue Cross Formulary National Performance Formulary National Performance Formulary
DACARBAZINE DACARBAZINE DACOGEN DACOGEN DACTINOMYCIN DACTINOMYCIN DALFAMPRIDIN DALFAMPRIDIN DALFAMPRIDIN	GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary
DACARBAZINE DACARBAZINE DACOGEN DACOGEN DACTINOMYCIN DACTINOMYCIN DALFAMPRIDIN DALFAMPRIDIN DANYELZA DANYELZA	GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary National Performance Formulary
DACARBAZINE DACARBAZINE DACOGEN DACOGEN DACTINOMYCIN DACTINOMYCIN DALFAMPRIDIN DALFAMPRIDIN DANYELZA DANYELZA DARAPRIM	GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary
DACARBAZINE DACARBAZINE DACOGEN DACOGEN DACTINOMYCIN DACTINOMYCIN DALFAMPRIDIN DALFAMPRIDIN DANYELZA DANYELZA DARAPRIM DARAPRIM	GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
DACARBAZINE DACARBAZINE DACOGEN DACOGEN DACTINOMYCIN DACTINOMYCIN DALFAMPRIDIN DALFAMPRIDIN DANYELZA DANYELZA DARAPRIM DARAPRIM DARAPRIM DARAZALEX	GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary
DACARBAZINE DACARBAZINE DACOGEN DACOGEN DACTINOMYCIN DACTINOMYCIN DALFAMPRIDIN DALFAMPRIDIN DANYELZA DANYELZA DARAPRIM DARAPRIM	GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
DACARBAZINE DACARBAZINE DACOGEN DACOGEN DACTINOMYCIN DACTINOMYCIN DALFAMPRIDIN DALFAMPRIDIN DANYELZA DANYELZA DARAPRIM DARAPRIM DARAPRIM DARAPLEX DARZALEX DARZALEX	GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
DACARBAZINE DACARBAZINE DACOGEN DACOGEN DACOGEN DACTINOMYCIN DACTINOMYCIN DALFAMPRIDIN DALFAMPRIDIN DANYELZA DANYELZA DARAPRIM DARAPRIM DARAPRIM DARAPRIM DARAZALEX DANZALEX DAUNORUBICIN	GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
DACARBAZINE DACARBAZINE DACOGEN DACOGEN DACTINOMYCIN DACTINOMYCIN DALFAMPRIDIN DALFAMPRIDIN DANYELZA DANYELZA DARAPRIM DARAPRIM DARAPRIM DARAPRIM DARALEX DARZALEX DAUNORUBICIN	GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY	Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
DACARBAZINE DACARBAZINE DACOGEN DACOGEN DACTINOMYCIN DACTINOMYCIN DALFAMPRIDIN DALFAMPRIDIN DANYELZA DANYELZA DARAPRIM DARAPRIM DARAPRIM DARAZALEX DARAZALEX DAUNORUBICIN DAUNORUBICIN DAUNORUBICIN DAUNORUBICIN	GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY ON-PREFERED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO	Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
DACARBAZINE DACARBAZINE DACOGEN DACOGEN DACTINOMYCIN DACTINOMYCIN DALFAMPRIDIN DALFAMPRIDIN DANYELZA DANYELZA DARAPRIM DARAPRIM DARAPRIM DARALEX DARALEX DANORUBICIN DAUNORUBICIN DAUNORUBICIN DAUNORUBICIN DAUNORUBICIN DAUNISMO	GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ON-PREFERED-BRAND-SPECIALTY ON-PREFERED-BRAND-SPECIALTY OR-PREFERED-BRAND-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO ORAL-CHEMO	Blue Cross Formulary National Performance Formulary
DACARBAZINE DACARBAZINE DACOGEN DACOGEN DACTINOMYCIN DACTINOMYCIN DALFAMPRIDIN DALFAMPRIDIN DANYELZA DANYELZA DARAPRIM DARAPRIM DARZALEX DANZALEX DAUNORUBICIN DAUNORUBICIN DAURISMO DAURISMO DECITABINE	GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY OF SEMENIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY ON-PREFERED-BRAND-SPECIALTY ON-PREFERED-BRAND-SPECIALTY ON-PREFERED-BRAND-SPECIALTY ON-PREFERED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO GENERIC-SPECIALTY	Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
DACARBAZINE DACAGEN DACOGEN DACOGEN DACOGEN DACTINOMYCIN DACTINOMYCIN DALFAMPRIDIN DALFAMPRIDIN DANYELZA DANYELZA DARAPRIM DARAPRIM DARAPRIM DARAZALEX DAUNORUBICIN DAUNORUBICIN DAUNISMO DECITABINE DECITABINE DEPEN DEPEN	GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY ON-PREFERED-BRAND-SPECIALTY ORN-PREFERED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GRAL-CHEMO ORAL-CHEMO GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
DACARBAZINE DACARBAZINE DACOGEN DACOGEN DACOGEN DACTINOMYCIN DACTINOMYCIN DALFAMPRIDIN DALFAMPRIDIN DANYELZA DANYELZA DARAPRIM DARAPRIM DARAPRIM DARAZALEX DARZALEX DAUNORUBICIN DAUNORUBICIN DAUNORUBICIN DAUNISMO DECITABINE DECITABINE DEPEN DEPEN DEPEN DECITABINE	GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY ON-PREFERED-BRAND-SPECIALTY ON-PREFERED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY	Blue Cross Formulary National Performance Formulary
DACARBAZINE DACARBAZINE DACOGEN DACOGEN DACOGEN DACTINOMYCIN DACTINOMYCIN DALFAMPRIDIN DALFAMPRIDIN DANYELZA DANYELZA DARAPRIM DARAPRIM DARAPRIM DARAZALEX DARAZALEX DAUNORUBICIN DAUNORUBICIN DAUNORUBICIN DAUNISMO DAURISMO DECITABINE DECITABINE DEPEN DEPEN DEPEN DEPEN DEXRAZOXANE	GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GRAL-CHEMO ORAL-CHEMO GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY	Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary
DACARBAZINE DACARBAZINE DACOGEN DACOGEN DACTINOMYCIN DACTINOMYCIN DALFAMPRIDIN DALFAMPRIDIN DANYELZA DANYELZA DARAPRIM DARAPRIM DARAJEX DAUNORUBICIN DAUNISMO DAURISMO DECITABINE DECITABINE DECITABINE DEPEN DEPEN DEPEN DEPEN DEPEN DEPEN DEPEN DEXRAZOXANE DEXRAZOXANE	GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY ON-PREFERED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO ORAL-CHEMO GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY	Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
DACARBAZINE DACARBAZINE DACOGEN DACOGEN DACTINOMYCIN DACTINOMYCIN DALFAMPRIDIN DALFAMPRIDIN DANYELZA DANYELZA DARAPRIM DARAPRIM DARZALEX DARZALEX DAUNORUBICIN DAUNORUBICIN DAURISMO DECITABINE DEPEN DEPEN DEPEN DEXRAZOXANE DEXTENZA	GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY OGNERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
DACARBAZINE DACARBAZINE DACOGEN DACOGEN DACTINOMYCIN DACTINOMYCIN DALFAMPRIDIN DALFAMPRIDIN DANYELZA DANYELZA DARAPRIM DARAPRIM DARAJELX DARAJELX DARAJELX DAURORUBICIN DAURISMO DECITABINE DECITABINE DEPEN DEPEN DEPEN DEXRAZOXANE DEXTENZA DACTINOMYCIN DAURISMO DECITABINE DEPEN DEPEN DEPEN DEPEN DEXRAZOXANE DEXRAZOXANE DEXTENZA DIACOMIT	GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY OF SET OF SET OF SET OF SET OF SET OF SECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORNO-PREFERED-BRAND-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO ORAL-CHEMO GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
DACARBAZINE DACAGEN DACOGEN DACOGEN DACOGEN DACTINOMYCIN DACTINOMYCIN DALFAMPRIDIN DALFAMPRIDIN DANYELZA DANYELZA DARAPRIM DARAPRIM DARAPRIM DARAZALEX DARAZALEX DAUNORUBICIN DAUNISMO DAURISMO DECITABINE DECITABINE DEPEN DEPEN DEPEN DEPEN DEXRAZOXANE DEXTENZA DEXTENZA DIACOMIT DIACOMIT	GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
DACARBAZINE DACAGEN DACOGEN DACOGEN DACOGEN DACTINOMYCIN DACTINOMYCIN DALFAMPRIDIN DALFAMPRIDIN DANYELZA DANYELZA DARAPRIM DARAPRIM DARAPRIM DARAZALEX DAUNORUBICIN DAUNORUBICIN DAUNISMO DECITABINE DECITABINE DECITABINE DEPEN DEPEN DEPEN DEXTRAZOXANE DEXTENZA DEXTENZA DIACOMIT DIMETHYL	GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
DACARBAZINE DACAGEN DACOGEN DACOGEN DACOGEN DACTINOMYCIN DACTINOMYCIN DALFAMPRIDIN DALFAMPRIDIN DANYELZA DANYELZA DARAPRIM DARAPRIM DARAZALEX DARZALEX DARZALEX DAUNORUBICIN DAUNORUBICIN DAUNORUBICIN DAUNISMO DECITABINE DECITABINE DECITABINE DEPEN DEPEN DEPEN DEPEN DEXRAZOXANE DEXTENZA DIACOMIT DIACOMIT DIACOMIT DIACOMIT DIMETHYL DIMETHYL	GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERED-BRAND-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO ORAL-CHE	Blue Cross Formulary National Performance Formulary
DACARBAZINE DACARBAZINE DACOGEN DACOGEN DACTINOMYCIN DACTINOMYCIN DALFAMPRIDIN DALFAMPRIDIN DANYELZA DANYELZA DARAPRIM DARAPRIM DARAPRIM DARAZALEX DARAZALEX DAUNORUBICIN DAUNORUBICIN DAUNISMO DECITABINE DECITABINE DEPEN DEPEN DEPEN DEPEN DEXRAZOXANE DEXTRAZOXANE DEXTENZA DIACOMIT DIACOMIT DIMCTHYL DIMETHYL DIMETHYL DOCETAXEL	GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY	Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary
DACARBAZINE DACARBAZINE DACOGEN DACOGEN DACTINOMYCIN DACTINOMYCIN DALFAMPRIDIN DALFAMPRIDIN DANYELZA DANYELZA DARAPRIM DARAPRIM DARAZALEX DARAZALEX DAUNORUBICIN DAURISMO DAURISMO DECITABINE DEPEN DEPEN DEPEN DEPEN DEPEN DEPEN DEXAZOXANE DEXTRAZO DEXTENZA DIACOMIT DIACOMIT DIMETHYL DIMETHYL DOCETAXEL	GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY OFN-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY	Blue Cross Formulary National Performance Formulary
DACARBAZINE DACARBAZINE DACOGEN DACOGEN DACTINOMYCIN DACTINOMYCIN DALFAMPRIDIN DALFAMPRIDIN DANYELZA DANYELZA DARAPRIM DARAPRIM DARALEX DARALEX DAUNORUBICIN DAUNORUBICIN DAUNISMO DECITABINE DECITABINE DEPEN DEPEN DEPEN DEPEN DEXRAZOXANE DEXRAZOXANE DEXRAZOXANE DEXTENZA DIACOMIT DIMETHYL DIMETHYL DOCETAXEL DOCETAXEL	GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORN-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORN-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-SPECIALTY GENERIC-SPECIALTY ORN-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORN-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY OGENERIC-SPECIALTY GENERIC-SPECIALTY ORN-PREFERRED-BRAND-SPECIALTY ORN-PREFERRED-BRAND-SPECIALTY ORN-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY ORN-PREFERRED-BRAND-SPECIALTY ORN-PREFERRED-BRAND-SPECIALTY ORN-PREFERRED-BRAND-SPECIALTY ORN-PREFERRED-BRAND-SPECIALTY ORN-PREFERRED-BRAND-SPECIALTY ORN-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Slue Cross Formulary Rotal Performance Formulary Blue Cross Formulary Rotal Performance Formulary
DACARBAZINE DACARBAZINE DACOGEN DACOGEN DACTINOMYCIN DACTINOMYCIN DALFAMPRIDIN DALFAMPRIDIN DANYELZA DANYELZA DARAPRIM DARAPRIM DARAZALEX DARAZALEX DAUNORUBICIN DAUNORUBICIN DAURISMO DECITABINE DEPEN DEPEN DEPEN DEPEN DEPEN DEPEN DEXRAZOXANE DEXRAZOXANE DEXRAZOXANE DEXRAZOMIT DIACOMIT DIACOMIT DIMETHYL DIMETHYL DOCETAXEL	GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY OFN-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY	Blue Cross Formulary National Performance Formulary
DACARBAZINE DACARBAZINE DACOGEN DACOGEN DACTINOMYCIN DACTINOMYCIN DALFAMPRIDIN DALFAMPRIDIN DANYELZA DANYELZA DARAPRIM DARAPRIM DARZALEX DARZALEX DAUNORUBICIN DAURISMO DAURISMO DECITABINE DEPEN DEPEN DEPEN DEPEN DEPEN DEXRAZOXANE DEXRAZOXANE	GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ON-PREFERED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO ORAL-CHEMO GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY OGNERIC-SPECIALTY OGNERIC-SPECIALTY OGNERIC-SPECIALTY OGNERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary
DACARBAZINE DACARBAZINE DACOGEN DACOGEN DACOGEN DACTINOMYCIN DACTINOMYCIN DALFAMPRIDIN DALFAMPRIDIN DANYELZA DANYELZA DARAPRIM DARAPRIM DARAPRIM DARAPRIM DARAZALEX DAUNORUBICIN DAUNORUBICIN DAUNISMO DECITABINE DECITABINE DECITABINE DEPEN DEPEN DEPEN DEPEN DEXTENZA DEXTENZA DEXTENZA DIACOMIT DIACOMIT DIMETHYL DIMETHYL DOCETAXEL DOPTELET DOPTELET DOPTELET DOPTILET	GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO ORAL-CHEMO GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary

DOXORUBICIN	GENERIC-SPECIALTY	National Performance Formulary
DUPIXENT	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
DUPIXENT	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
DUROLANE	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
DUROLANE	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
DYSPORT	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
DYSPORT	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
EGRIFTA	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
EGRIFTA	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
ELAPRASE	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ELAPRASE	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
ELELYSO	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ELELYSO	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
ELIGARD	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ELIGARD	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
ELITEK	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ELITEK	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
ELLENCE	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ELLENCE	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
ELOCTATE	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ELOCTATE	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
ELZONRIS	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ELZONRIS	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
EMFLAZA	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
EMFLAZA	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
EMPLICITI	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
EMPLICITI	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
ENBREL	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ENBREL	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
ENHERTU	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ENHERTU	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
ENOXAPARIN	GENERIC-SPECIALTY	Blue Cross Formulary
ENOXAPARIN	GENERIC-SPECIALTY	National Performance Formulary
ENSPRYNG	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ENSPRYNG	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
ENTECAVIR	GENERIC-SPECIALTY	Blue Cross Formulary
ENTECAVIR	GENERIC-SPECIALTY	National Performance Formulary
ENTYVIO	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ENTYVIO	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
EINTYVIU	NON-PREFERRED-BRAIND-SPECIALIT	reactional refrontiance rothialary
ENVARSUS	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
		·
ENVARSUS	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ENVARSUS ENVARSUS EPCLUSA EPCLUSA	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary
ENVARSUS ENVARSUS EPCLUSA	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary
ENVARSUS ENVARSUS EPCLUSA EPCLUSA	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
ENVARSUS ENVARSUS EPCLUSA EPCLUSA EPIDIOLEX	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
ENVARSUS ENVARSUS EPCLUSA EPCLUSA EPIDIOLEX EPIDIOLEX	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
ENVARSUS ENVARSUS EPCLUSA EPCLUSA EPIDIOLEX EPIDIOLEX EPIDIOLEX EPIRUBICIN	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary
ENVARSUS ENVARSUS EPCLUSA EPCLUSA EPIDIOLEX EPIDIOLEX EPIDIOLEX EPIRUBICIN EPIRUBICIN	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY	Blue Cross Formulary National Performance Formulary National Performance Formulary
ENVARSUS ENVARSUS EPCLUSA EPCLUSA EPIDIOLEX EPIDIOLEX EPIRUBICIN EPIRUBICIN EPIVIR	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary
ENVARSUS ENVARSUS EPCLUSA EPCLUSA EPIDIOLEX EPIDIOLEX EPIRUBICIN EPIRUBICIN EPIVIR EPIVIR	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary
ENVARSUS ENVARSUS EPCLUSA EPCLUSA EPIDIOLEX EPIDIOLEX EPIRUBICIN EPIRUBICIN EPIVIR EPIVIR EPIVIR EPIVIR EPIVIR EPIVIR EPIVIR EPIOGEN	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary
ENVARSUS ENVARSUS EPCLUSA EPCLUSA EPIDIOLEX EPIDIOLEX EPIRUBICIN EPIRUBICIN EPIVIR EPIVIR EPIVIR EPIVIR EPIVIR EPOGEN EPOPROSTENOL	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY RON-PREFERRED-BRAND-SPECIALTY ON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary
ENVARSUS ENVARSUS EPCLUSA EPCLUSA EPIDIOLEX EPIDIOLEX EPIRUBICIN EPIRUBICIN EPIVIR EPIVIR EPIVIR EPIVIR EPIVIR EPIVIR EPIVIR EPIVIR EPOGEN EPOPROSTENOL	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Albue Cross Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary
ENVARSUS ENVARSUS EPCLUSA EPCLUSA EPIDIOLEX EPIDIOLEX EPIRUBICIN EPIRUBICIN EPIVIR EPIVIR EPIVIR EPIVIR EPIVIR EPIVIR EPOGEN EPOPROSTENOL	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY RON-PREFERRED-BRAND-SPECIALTY ON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
ENVARSUS ENVARSUS EPCLUSA EPCLUSA EPIDIOLEX EPIDIOLEX EPIRUBICIN EPIRUBICIN EPIVIR EPIVIR EPIVIR EPIVIR EPIVIR EPIVIR EPIVIR EPIVIR EPOGEN EPOPROSTENOL	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Albue Cross Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary
ENVARSUS ENVARSUS EPCLUSA EPCLUSA EPIDIOLEX EPIDIOLEX EPIRUBICIN EPIRUBICIN EPIVIR EPIVIR EPIVIR EPIVIR EPOGEN EPOPROSTENOL ERBITUX ERBITUX ERIVEDGE	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
ENVARSUS ENVARSUS EPCLUSA EPCLUSA EPIDIOLEX EPIDIOLEX EPIDIOLEX EPIRUBICIN EPIRUBICIN EPIVIR EPIVIR EPIVIR EPIVIR EPIVIR EPOGEN EPOPROSTENOL ERBITUX ERBITUX	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY OFAL-CHEMO ORAL-CHEMO	Blue Cross Formulary National Performance Formulary Indicate Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
ENVARSUS ENVARSUS EPCLUSA EPCLUSA EPIDIOLEX EPIDIOLEX EPIRUBICIN EPIRUBICIN EPIVIR EPIVIR EPIVIR EPIVIR EPOGEN EPOPROSTENOL ERBITUX ERBITUX ERIVEDGE	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary
ENVARSUS ENVARSUS EPCLUSA EPCLUSA EPIDIOLEX EPIDIOLEX EPIRUBICIN EPIRUBICIN EPIVIR EPIVIR EPIVIR EPIVIR EPOGEN EPOPROSTENOL ERBITUX ERBITUX ERIVEDGE ERIVEDGE	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY OFAL-CHEMO ORAL-CHEMO	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
ENVARSUS ENVARSUS EPCLUSA EPCLUSA EPIDIOLEX EPIDIOLEX EPIRUBICIN EPIRUBICIN EPIVIR EPIVIR EPIVIR EPIVIR EPOGEN EPOPROSTENOL ERBITUX ERBITUX ERIVEDGE ERIVEDGE ERIVEDGE ERIVEDGE ERLEADA	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary
ENVARSUS ENVARSUS EPCLUSA EPCLUSA EPIDIOLEX EPIDIOLEX EPIRUBICIN EPIRUBICIN EPIVIR EPIVIR EPIVIR EPIVIR EPOGEN EPOPROSTENOL ERBITUX ERBITUX ERIVEDGE ERIVEDGE ERLEADA ERLOTINIB	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO	Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary
ENVARSUS ENVARSUS EPCLUSA EPCLUSA EPCLUSA EPIDIOLEX EPIDIOLEX EPIRUBICIN EPIRUBICIN EPIVIR EPIVIR EPIVIR EPIVIR EPIVIR EPIVIR EPIVIR EPOGEN EPOPROSTENOL ERBITUX ERBITUX ERBITUX ERIVEDGE ERIVEDGE ERLEADA ERLOTINIB	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
ENVARSUS ENVARSUS EPCLUSA EPCLUSA EPCLUSA EPIDIOLEX EPIDIOLEX EPIRUBICIN EPIRUBICIN EPIVIR ERUSE	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary
ENVARSUS ENVARSUS ENVARSUS EPCLUSA EPCLUSA EPIDIOLEX EPIDIOLEX EPIDIOLEX EPIRUBICIN EPIRUBICIN EPIVIR EPIVIR EPIVIR EPIVIR EPOGEN EPOPROSTENOL ERBITUX ERBITUX ERIVEDGE ERIVEDGE ERIVEDGE ERLEADA ERLOTINIB ESBRIET ESBRIET	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
ENVARSUS ENVARSUS EPCLUSA EPCLUSA EPCLUSA EPIDIOLEX EPIDIOLEX EPIRUBICIN EPIRUBICIN EPIVIR EPIVIR EPIVIR EPIVIR EPIVIR EPIVIR EPIVIR EPIVIR EPICOR EPOPROSTENOL ERBITUX ERBITUX ERBITUX ERIVEDGE ERIVEDGE ERLEADA ERLOTINIB ESBRIET ESPEROCT	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ON-PREFERED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
ENVARSUS ENVARSUS EPCLUSA EPCLUSA EPIDIOLEX EPIDIOLEX EPIRUBICIN EPIRUBICIN EPIVIR EPIVIR EPIVIR EPIVIR EPOGEN EPOPROSTENOL EPOPROSTENOL ERBITUX ERITUX ERITUX ERITUS ERICE ERITUS ERICE ERICE ERICE ERICE ERICE ERLEDA ERLOTINIB ESBRIET ESPEROCT ETOPOPHOS	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary
ENVARSUS ENVARSUS EPCLUSA EPCLUSA EPCLUSA EPIDIOLEX EPIDIOLEX EPIRUBICIN EPIRUBICIN EPIVIR EPIVIR EPIVIR EPIVIR EPOGEN EPOPROSTENOL EPOPROSTENOL ERBITUX ERBITUX ERIVEDGE ERIVEDGE ERLEADA ERLOTINIB ERLOTINIB ESBRIET ESBRIET ESPEROCT ETOPOPHOS	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
ENVARSUS ENVARSUS EPCLUSA EPCLUSA EPCLUSA EPIDIOLEX EPIDIOLEX EPIDIOLEX EPIRUBICIN EPIRUBICIN EPIVIR EPOGEN EPOPROSTENOL ERBITUX ERBITUX ERBITUX ERIVEDGE ERIVEDGE ERIVEDGE ERLEADA ERLOTINIB ESBRIET ESBRIET ESBRIET ESPEROCT ETOPOPHOS ETOPOPHOS ETOPOPHOS	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
ENVARSUS ENVARSUS ENVARSUS EPCLUSA EPCLUSA EPIDIOLEX EPIDIOLEX EPIDIOLEX EPIRUBICIN EPIRUBICIN EPIVIR EPIVIR EPIVIR EPIVIR EPIVIR EPIVIR EPIVIR EPIVIR EPIVIR EPOGEN EPOPROSTENOL ERBITUX ERBITUX ERBITUX ERIVEDGE ERIVEDGE ERIVEDGE ERLEADA ERLOTINIB ERLOTINIB ESBRIET ESBRIET ESPEROCT ETOPOPHOS ETOPOPHOS ETOPOSIDE	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
ENVARSUS ENVARSUS ENVARSUS EPCLUSA EPCLUSA EPIDIOLEX EPIDIOLEX EPIDIOLEX EPIRUBICIN EPIRUBICIN EPIVIR EPIVIR EPIVIR EPIVIR EPOGEN EPOPROSTENOL EPOPROSTENOL ERBITUX ERBITUX ERIVEDGE ERIVEDGE ERIVEDGE ERLEADA ERLOTINIB ESBRIET ESBRIET ESPEROCT ETOPOPHOS ETOPOPHOS ETOPOSIDE ETOPOSIDE ETOPOSIDE	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary
ENVARSUS ENVARSUS ENVARSUS EPCLUSA EPCLUSA EPIDIOLEX EPIDIOLEX EPIDIOLEX EPIRUBICIN EPIRUBICIN EPIVIR EPIVIR EPIVIR EPIVIR EPOGEN EPOPROSTENOL EPOPROSTENOL ERBITUX ERIVEDGE ERIVEDGE ERIVEDGE ERLEADA ERLOTINIB ESBRIET ESBRIET ESPEROCT ETOPOPHOS ETOPOSIDE ETOPOSIDE ETOPOSIDE ETOPOSIDE ETOPOSIDE	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
ENVARSUS ENVARSUS ENVARSUS EPCLUSA EPCLUSA EPIDIOLEX EPIDIOLEX EPIDIOLEX EPIRUBICIN EPIRUBICIN EPIVIR EPIVIR EPIVIR EPIVIR EPOGEN EPOPROSTENOL ERBITUX ERBITUX ERIVEDGE ERIVEDGE ERIVEDGE ERLEADA ERLOTINIB ESBRIET ESBRIET ESPEROCT ETOPOPHOS ETOPOSIDE	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO	Blue Cross Formulary National Performance Formulary
ENVARSUS ENVARSUS ENVARSUS EPCLUSA EPCLUSA EPIDIOLEX EPIDIOLEX EPIRUBICIN EPIRUBICIN EPIRUBICIN EPIVIR EPIVIR EPIVIR EPIVIR EPOGEN EPOPROSTENOL ERBITUX ERBITUX ERIVEDGE ERIVEDGE ERIVEDGE ERLEADA ERLOTINIB ESBRIET ESPEROCT ETOPOPHOS ETOPOSIDE EUFLEXXA	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ON-PREFERED-BRAND-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Slue Cross Formulary Blue Cross Formulary
ENVARSUS ENVARSUS ENVARSUS EPCLUSA EPCLUSA EPCLUSA EPIDIOLEX EPIDIOLEX EPIDIOLEX EPIRUBICIN EPIRUBICIN EPIVIR EPIVIR EPIVIR EPIVIR EPIVIR EPOGEN EPOPROSTENOL ERBITUX ERBITUX ERBITUX ERBITUX ERBITUX ERBITUX ERIVEDGE ERIVEDGE ERIVEDGE ERLEADA ERLOTINIB ESBRIET ESBRIET ESBRIET ESPEROCT ETOPOPHOS ETOPOPHOS ETOPOSIDE	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO NON-PREFERED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary
ENVARSUS ENVARSUS ENVARSUS EPCLUSA EPCLUSA EPIDIOLEX EPIDIOLEX EPIRUBICIN EPIRUBICIN EPIVIR EPIVIR EPIVIR EPOGEN EPOPROSTENOL ERBITUX ERBITUX ERIVEDGE ERIVEDGE ERIVEDGE ERLEADA ERLOTINIB ESBRIET ESBRIET ESBRIET ESPEROCT ETOPOPHOS ETOPOSIDE	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Rough Performance Formulary Blue Cross Formulary Blue Cross Formulary Rough Performance Formulary Blue Cross Formulary Blue Cross Formulary Rough Performance Formulary Rough Perfo

EVEROLIMUS		
EVEROLIMUS	ORAL-CHEMO ORAL-CHEMO	Blue Cross Formulary
EVKEEZA	TIER 03	National Performance Formulary Blue Cross Formulary
EVKEEZA	TIER 03	National Performance Formulary
EVOMELA	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
EVOMELA	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
EVRYSDI	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
EVRYSDI	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
EXONDYS	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
EXTAVIA	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
EYLEA	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
EYLEA	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
FABRAZYME	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
FABRAZYME FARYDAK	PREFERRED-BRAND-SPECIALTY ORAL-CHEMO	National Performance Formulary Blue Cross Formulary
FARYDAK	ORAL-CHEMO	National Performance Formulary
FASENRA	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
FASENRA	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
FASLODEX	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
FASLODEX	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
FEIBA	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
FEIBA	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
FENSOLVI	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
FENSOLVI	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
FIBRYGA	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
FIBRYGA	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
FINTEPLA	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
FINTEPLA	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
FIRAZYR FIRAZYR	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary
FIRDAPSE	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
FIRMAGON	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
FIRMAGON	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
FLEBOGAMMA	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
FLEBOGAMMA	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
FLOLAN	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
FLOLAN	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
FLOXURIDINE	GENERIC-SPECIALTY	Blue Cross Formulary
FLOXURIDINE	GENERIC-SPECIALTY	National Performance Formulary
FLUDARABINE	GENERIC-SPECIALTY	Blue Cross Formulary
FLUDARABINE	GENERIC-SPECIALTY	National Performance Formulary
FLUDARABINE FLUOROURACIL	GENERIC-SPECIALTY GENERIC-SPECIALTY	National Performance Formulary Blue Cross Formulary
FLUDARABINE FLUOROURACIL FLUOROURACIL	GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary
FLUDARABINE FLUOROURACIL FLUOROURACIL FOLLISTIM	GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
FLUDARABINE FLUOROURACIL FLUOROURACIL FOLLISTIM FOLLISTIM	GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
FLUDARABINE FLUOROURACIL FLUOROURACIL FOLLISTIM FOLLISTIM FOLOTYN	GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary
FLUDARABINE FLUOROURACIL FLUOROURACIL FOLLISTIM FOLLISTIM	GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
FLUDARABINE FLUOROURACIL FLUOROURACIL FOLLISTIM FOLLISTIM FOLOTYN FOLOTYN	GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
FLUDARABINE FLUOROURACIL FLUOROURACIL FOLLISTIM FOLLISTIM FOLOTYN FOLOTYN FOLOTYN FONDAPARINUX	GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY	National Performance Formulary Blue Cross Formulary Blue Cross Formulary
FLUDARABINE FLUOROURACIL FLUOROURACIL FOLLISTIM FOLLISTIM FOLOTYN FOLOTYN FONDAPARINUX FONDAPARINUX	GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary
FLUDARABINE FLUOROURACIL FLUOROURACIL FOLLISTIM FOLOTYN FOLOTYN FONDAPARINUX FONDAPARINUX FONDAPARINUX FORTEO	GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary
FLUDARABINE FLUOROURACIL FLUOROURACIL FOLLISTIM FOLLISTIM FOLOTYN FOLOTYN FONDAPARINUX FONDAPARINUX FONTEO FORTEO FRAGMIN FRAGMIN	GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
FLUDARABINE FLUOROURACIL FLUOROURACIL FOLLISTIM FOLLISTIM FOLOTYN FOLOTYN FONDAPARINUX FONDAPARINUX FONTEO FORTEO FRAGMIN FRAGMIN FULPHILA	GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary
FLUDARABINE FLUOROURACIL FLUOROURACIL FOLLISTIM FOLLISTIM FOLOTYN FOLOTYN FONDAPARINUX FONDAPARINUX FORTEO FORTEO FRAGMIN FRAGMIN FULPHILA FULVESTRANT	GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary
FLUDARABINE FLUOROURACIL FLUOROURACIL FOLLISTIM FOLLISTIM FOLOTYN FOLOTYN FONDAPARINUX FONDAPARINUX FORTEO FORTEO FRAGMIN FRAGMIN FULPHILA FULVESTRANT	GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY	National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary
FLUDARABINE FLUOROURACIL FLUOROURACIL FOLLISTIM FOLLISTIM FOLOTYN FOLOTYN FONDAPARINUX FONDAPARINUX FORTEO FORTEO FRAGMIN FRAGMIN FULPHILA FULVESTRANT GALAFOLD	GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary
FLUDARABINE FLUOROURACIL FLUOROURACIL FOLLISTIM FOLLISTIM FOLOTYN FOLOTYN FONDAPARINUX FONDAPARINUX FORTEO FORTEO FRAGMIN FRAGMIN FULPHILA FULVESTRANT GALAFOLD GALAFOLD	GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY OGENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
FLUDARABINE FLUOROURACIL FLUOROURACIL FOLLISTIM FOLLISTIM FOLOTYN FOLOTYN FONDAPARINUX FONDAPARINUX FORTEO FORTEO FRAGMIN FRAGMIN FULPHILA FULVESTRANT GALAFOLD GAMASTAN	GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY OF GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
FLUDARABINE FLUOROURACIL FLUOROURACIL FOLLISTIM FOLLISTIM FOLOTYN FOLOTYN FONDAPARINUX FONDAPARINUX FORTEO FORTEO FRAGMIN FRAGMIN FULPHILA FULVESTRANT FULVESTRANT GALAFOLD GAMASTAN GAMASTAN	GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY OF MORNER OF THE SPECIAL OF TH	National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
FLUDARABINE FLUOROURACIL FLUOROURACIL FOLLISTIM FOLLISTIM FOLOTYN FOLOTYN FONDAPARINUX FONDAPARINUX FORTEO FORTEO FRAGMIN FRAGMIN FULPHILA FULVESTRANT FULVESTRANT GALAFOLD GAMASTAN	GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY TON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
FLUDARABINE FLUOROURACIL FLUOROURACIL FOLLISTIM FOLLISTIM FOLOTYN FOLOTYN FONDAPARINUX FONDAPARINUX FORTEO FORTEO FRAGMIN FRAGMIN FULPHILA FULVESTRANT GALAFOLD GALAFOLD GAMASTAN GAMASTAN GAMISTAN	GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY OF MORNER OF THE SPECIAL OF TH	National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
FLUDARABINE FLUOROURACIL FLUOROURACIL FOLLISTIM FOLLISTIM FOLOTYN FOLOTYN FONDAPARINUX FONDAPARINUX FORTEO FRAGMIN FRAGMIN FRAGMIN FULPHILA FULVESTRANT FULVESTRANT GALAFOLD GAMASTAN GAMASTAN GAMIFANT GAMIFANT	GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
FLUDARABINE FLUOROURACIL FLUOROURACIL FOLLISTIM FOLLISTIM FOLOTYN FOLOTYN FONDAPARINUX FONDAPARINUX FORTEO FRAGMIN FRAGMIN FRAGMIN FULPHILA FULVESTRANT FULVESTRANT GALAFOLD GAMASTAN GAMIFANT GAMIFANT GAMIFANT GAMMAGARD	GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
FLUDARABINE FLUOROURACIL FLUOROURACIL FOLLISTIM FOLLISTIM FOLOTYN FOLOTYN FONDAPARINUX FONDAPARINUX FORTEO FORTEO FRAGMIN FRAGMIN FULPHILA FULVESTRANT GALAFOLD GAMASTAN GAMASTAN GAMIFANT GAMIFANT GAMMAGARD GAMMAGARD	GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary
FLUDARABINE FLUOROURACIL FLUOROURACIL FOLLISTIM FOLLISTIM FOLOTYN FOLOTYN FONDAPARINUX FONDAPARINUX FORTEO FORTEO FRAGMIN FRAGMIN FRAGMIN FULPHILA FULVESTRANT GALAFOLD GAMASTAN GAMASTAN GAMIFANT GAMIFANT GAMIFANT GAMIFANT GAMMAGARD GAMMAGARD GAMMAGARD	GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
FLUDARABINE FLUOROURACIL FLUOROURACIL FOLLISTIM FOLOTYN FOLOTYN FOLOTYN FONDAPARINUX FONDAPARINUX FORTEO FORTEO FRAGMIN FRAGMIN FULPHILA FULVESTRANT GALAFOLD GALAFOLD GAMASTAN GAMASTAN GAMASTAN GAMISANT GAMISANT GAMMAGARD GAMMAGARD GAMMAKED GAMMAKED GAMMARED GAMMAPLEX	GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
FLUDARABINE FLUOROURACIL FLUOROURACIL FOLLISTIM FOLOTYN FOLOTYN FOLOTYN FONDAPARINUX FONDAPARINUX FORTEO FRAGMIN FRAGMIN FRAGMIN FULPHILA FULVESTRANT FULVESTRANT GALAFOLD GAMASTAN GAMASTAN GAMIFANT GAMIFANT GAMMAGARD GAMMAGARD GAMMAKED GAMMAKED GAMMAPLEX GAMMAPLEX GAMMAPLEX GAMMACIL	GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary
FLUDARABINE FLUOROURACIL FLUOROURACIL FOLLISTIM FOLISTIM FOLOTYN FOLOTYN FONDAPARINUX FONDAPARINUX FORTEO FORTEO FRAGMIN FRAGMIN FULPHILA FULVESTRANT FULVESTRANT GALAFOLD GAMASTAN GAMISATAN GAMIFANT GAMIFANT GAMMAGARD GAMMAGARD GAMMAGARD GAMMAGARD GAMMAKED GAMMAPLEX GAMMAPLEX GAMMAPLEX GAMMAPLEX GAMMAPLEX GAMMAPLEX GAMMARCC GAMMAPLEX GAMMAPLEX GAMMAPLEX GAMMARCC	GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
FLUDARABINE FLUOROURACIL FLUOROURACIL FOLLISTIM FOLLISTIM FOLOTYN FOLOTYN FOLOTYN FONDAPARINUX FONDAPARINUX FORTEO FORTEO FRAGMIN FRAGMIN FULPHILA FULVESTRANT GALAFOLD GAMASTAN GAMASTAN GAMASTAN GAMIFANT GAMIFANT GAMMAGARD GAMMAGARD GAMMAGARD GAMMAGARD GAMMAKED GAMMARED GAMMAPLEX GAMMAPLEX GAMMAPLEX GAMUNEX-C GAMUNEX-C GAMINELIX	GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
FLUDARABINE FLUOROURACIL FLUOROURACIL FOLLISTIM FOLLISTIM FOLOTYN FOLOTYN FOLOTYN FONDAPARINUX FONDAPARINUX FORTEO FORTEO FRAGMIN FRAGMIN FULPHILA FULYESTRANT GALAFOLD GAMASTAN GAMASTAN GAMIFANT GAMIFANT GAMIFANT GAMMAGARD GAMMAGARD GAMMAGARD GAMMAGARD GAMMAKED GAMMAKED GAMMARED GAMMAPLEX GAMMAPLEX GAMMAPLEX GAMUNEX-C GAMUNEX-C GAMIRELIX GANIRELIX	GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary
FLUDARABINE FLUOROURACIL FLUOROURACIL FOLLISTIM FOLLISTIM FOLOTYN FOLOTYN FOLOTYN FONDAPARINUX FONDAPARINUX FORTEO FORTEO FRAGMIN FRAGMIN FULPHILA FULVESTRANT GALAFOLD GAMASTAN GAMASTAN GAMISATAN GAMISATAN GAMISATAN GAMASTAN GAMASTAN GAMISANT GAMMAGARD GAMMAGARD GAMMAGARD GAMMAGARD GAMMAKED GAMMAKED GAMMAPLEX GAMMAPLEX GAMUNEX-C GAMUNEX-C GANIRELIX GANIRELIX	GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary
FLUDARABINE FLUOROURACIL FLUOROURACIL FOLLISTIM FOLLISTIM FOLOTYN FOLOTYN FONDAPARINUX FONDAPARINUX FORTEO FORTEO FRAGMIN FRAGMIN FULPHILA FULVESTRANT FULVESTRANT GALAFOLD GAMASTAN GAMASTAN GAMIFANT GAMMAGARD GAMMAGARD GAMMAGARD GAMMAGARD GAMMARED GAMMARED GAMMAPLEX GAMUNEX-C GAMUNEX-C GAMUNEX-C GAMIFANT GAMIFELIX	GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary

GEL-ONE GELSYN-3	NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
GELSYN-3	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary
GEMCITABINE	GENERIC-SPECIALTY	Blue Cross Formulary
GEMCITABINE	GENERIC-SPECIALTY	National Performance Formulary
GENGRAF	GENERIC-SPECIALTY	Blue Cross Formulary
GENGRAF	GENERIC-SPECIALTY	National Performance Formulary
GENOTROPIN	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
GENVISC GILENYA	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary Blue Cross Formulary
GILENYA	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
GILOTRIF	ORAL-CHEMO	Blue Cross Formulary
GILOTRIF	ORAL-CHEMO	National Performance Formulary
GIVLAARI	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
GIVLAARI	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
GLASSIA	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
GLASSIA GLATIRAMER	NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY	National Performance Formulary Blue Cross Formulary
GLATIRAMER	GENERIC-SPECIALTY	National Performance Formulary
GLATOPA	GENERIC-SPECIALTY	Blue Cross Formulary
GLATOPA	GENERIC-SPECIALTY	National Performance Formulary
GLEOSTINE	ORAL-CHEMO	Blue Cross Formulary
GLEOSTINE	ORAL-CHEMO	National Performance Formulary
GONAL-F	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
GRANIX HAEGARDA	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary Blue Cross Formulary
HAEGARDA	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
HALAVEN	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
HALAVEN	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
HARVONI	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
HARVONI	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
HEMLIBRA HEMLIBRA	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary
HEMOFIL	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
HEMOFIL	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
HEPSERA	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
HEPSERA	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
HERCEP	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
HERCEP	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
HERCEPTIN	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
HERCEDTIN	NON-DREEFRRED-RRAND-SDECIALTY	National Performance Formulary
HERCEPTIN HERZUMA	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary
HERCEPTIN HERZUMA HETLIOZ	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary Blue Cross Formulary
HERZUMA	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
HERZUMA HETLIOZ HETLIOZ HIZENTRA	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
HERZUMA HETLIOZ HETLIOZ HIZENTRA HIZENTRA	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
HERZUMA HETLIOZ HETLIOZ HIZENTRA HIZENTRA HUMATE-P	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
HERZUMA HETLIOZ HETLIOZ HIZENTRA HIZENTRA HUMATE-P HUMATE-P	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary
HERZUMA HETLIOZ HETLIOZ HIZENTRA HIZENTRA HUMATE-P HUMATROPE	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary
HERZUMA HETLIOZ HETLIOZ HIZENTRA HIZENTRA HUMATE-P HUMATE-P	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary
HERZUMA HETLIOZ HETLIOZ HIZENTRA HIZENTRA HUMATE-P HUMATE-P HUMATROPE HUMIRA	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary
HERZUMA HETLIOZ HETLIOZ HIZENTRA HIZENTRA HUMATE-P HUMATF-P HUMATROPE HUMIRA HUMIRA HYCAMTIN	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
HERZUMA HETLIOZ HETLIOZ HIZENTRA HIZENTRA HUMATE-P HUMATE-P HUMATROPE HUMIRA HUMIRA HYCAMTIN HYCAMTIN	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO	Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
HERZUMA HETLIOZ HETLIOZ HIZENTRA HIZENTRA HUMATE-P HUMATE-P HUMATROPE HUMIRA HUMIRA HYCAMTIN HYCAMTIN HYCAMTIN	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO	Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
HERZUMA HETLIOZ HETLIOZ HIZENTRA HIZENTRA HUMATE-P HUMATE-P HUMATROPE HUMIRA HUMIRA HYCAMTIN HYCAMTIN HYCAMTIN HYCAMTIN	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO GENERIC-SPECIALTY	Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
HERZUMA HETLIOZ HETLIOZ HIZENTRA HIZENTRA HUMATE-P HUMATE-P HUMATROPE HUMIRA HUMIRA HYCAMTIN HYCAMTIN HYCAMTIN HYCAMTIN HYCAMTIN HYCAMTIN	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO GENERIC-SPECIALTY GENERIC-SPECIALTY	Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
HERZUMA HETLIOZ HETLIOZ HIZENTRA HIZENTRA HUMATE-P HUMATE-P HUMATROPE HUMIRA HUMIRA HYCAMTIN HYCAMTIN HYCAMTIN HYCAMTIN	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO GENERIC-SPECIALTY	Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
HERZUMA HETLIOZ HETLIOZ HIZENTRA HIZENTRA HIZENTRA HUMATE-P HUMATE-P HUMATROPE HUMIRA HUMIRA HYCAMTIN HYCAMTIN HYCAMTIN HYCAMTIN HYCAMTIN HYCAMTIN HYCAMTIN HYCAMTIN	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY	Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
HERZUMA HETLIOZ HETLIOZ HIZENTRA HIZENTRA HIZENTRA HUMATE-P HUMATE-P HUMATOPE HUMIRA HUMIRA HYCAMTIN	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY	Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary
HERZUMA HETLIOZ HETLIOZ HIZENTRA HIZENTRA HIZENTRA HUMATE-P HUMATE-P HUMATFOPE HUMIRA HYCAMTIN HYCAMTIN HYCAMTIN HYCAMTIN HYCAMTIN HYDROXY HYDROXY HYDROXYPROG HYMOVIS HYPERRHO HYPERRHO	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary
HERZUMA HETLIOZ HETLIOZ HIZENTRA HIZENTRA HIZENTRA HUMATE-P HUMATE-P HUMATROPE HUMIRA HYCAMTIN HYCAMTIN HYCAMTIN HYCAMTIN HYCAMTIN HYDROXY HYDROXY HYDROXYPROG HYDROXYPROG HYMOVIS HYPERRHO HYPERRHO HYPERRHO	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary
HERZUMA HETLIOZ HETLIOZ HIZENTRA HIZENTRA HIZENTRA HUMATE-P HUMATE-P HUMATROPE HUMIRA HYCAMTIN HYCAMTIN HYCAMTIN HYCAMTIN HYCAMTIN HYCAMTIN HYCAMTIN HYCROXY HYDROXY HYDROXY HYDROXYPROG HYMOVIS HYPERRHO HYPERRHO HYPERRHO HYQVIA	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary National Performance Formulary
HERZUMA HETLIOZ HETLIOZ HIZENTRA HIZENTRA HIZENTRA HUMATE-P HUMATE-P HUMATFOPE HUMIRA HUMIRA HYCAMTIN HYCAMTIN HYCAMTIN HYCAMTIN HYCAMTIN HYCAMTIN HYCAMTIN HYDROXY HYDROXY HYDROXY HYDROXYPROG HYMOVIS HYPERRHO HYPERRHO HYPERRHO HYQVIA HYQVIA IBRANCE	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
HERZUMA HETLIOZ HETLIOZ HIZENTRA HIZENTRA HIZENTRA HUMATE-P HUMATE-P HUMATROPE HUMIRA HYCAMTIN HYCAMTIN HYCAMTIN HYCAMTIN HYCAMTIN HYCAMTIN HYCAMTIN HYCROXY HYDROXY HYDROXY HYDROXYPROG HYMOVIS HYPERRHO HYPERRHO HYPERRHO HYQVIA	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary National Performance Formulary
HERZUMA HETLIOZ HETLIOZ HIZENTRA HIZENTRA HIZENTRA HUMATE-P HUMATE-P HUMATOPE HUMIRA HUMIRA HYCAMTIN HYCROXY HYDROXY HYDROXY HYDROXY HYDROXYPROG HYMOVIS HYPERRHO HYPERRHO HYPERRHO HYQVIA HYQVIA IBRANCE	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO	Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
HERZUMA HETLIOZ HETLIOZ HIZENTRA HIZENTRA HIZENTRA HUMATE-P HUMATE-P HUMATE-P HUMATROPE HUMIRA HYCAMTIN HYCAMTIN HYCAMTIN HYCAMTIN HYCAMTIN HYCAMTIN HYCAMTIN HYDROXY HYDROXY HYDROXY HYDROXYPROG HYMOVIS HYPERRHO HYPERRHO HYPERRHO HYQVIA HYQVIA IBRANCE IBRANCE	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO GENERIC-SPECIALTY	Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
HERZUMA HETLIOZ HETLIOZ HIZENTRA HIZENTRA HIZENTRA HUMATE-P HUMATE-P HUMATROPE HUMIRA HYCAMTIN HYCAMTIN HYCAMTIN HYCAMTIN HYCAMTIN HYCAMTIN HYCROXY HYDROXY HYDROXY HYDROXY HYDROXYPROG HYDROXYPROG HYMOVIS HYPERRHO HYPERRHO HYPERRHO HYQVIA HRANCE IBRANCE ICATIBANT ICATIBANT ICLUSIG ICLUSIG	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ON-PREFERED-BRAND-SPECIALTY ORN-PREFERED-BRAND-SPECIALTY ORN-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO	Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
HERZUMA HETLIOZ HETLIOZ HIZENTRA HIZENTRA HIZENTRA HUMATE-P HUMATE-P HUMATROPE HUMIRA HYCAMTIN HYCAMTIN HYCAMTIN HYCAMTIN HYCAMTIN HYCAMTIN HYCAMTIN HYCROXY HYDROXY HYDROXY HYDROXYPROG HYMOVIS HYPERRHO HYPERRHO HYPERRHO HYPERRHO HYQVIA IBRANCE IBRANCE ICATIBANT ICLUSIG ICLUSIG IDAMYCIN	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO	Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
HERZUMA HETLIOZ HETLIOZ HIZENTRA HIZENTRA HIZENTRA HUMATE-P HUMATE-P HUMATE-P HUMATROPE HUMIRA HYCAMTIN HYPROXY HYDROXY HYDROXY HYDROXY HYDROXYPROG HYMOVIS HYPERRHO HYPERRHO HYPERRHO HYPERRHO HYPERRHO HYQVIA IBRANCE IBRANCE ICATIBANT ICATIBANT ICLUSIG ICLUSIG IDAMYCIN	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY GENERIC-SPECIALTY NON-PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
HERZUMA HETLIOZ HETLIOZ HIZENTRA HIZENTRA HIZENTRA HUMATE-P HUMATE-P HUMATE-P HUMIRA HUMIRA HYCAMTIN HYCROXY HYDROXY HYDROXY HYDROXY HYDROXYPROG HYMOVIS HYPERRHO HYPERRHO HYPERRHO HYPERRHO HYQVIA IBRANCE IBRANCE ICATIBANT ICATIBANT ICATIBANT ICLUSIG ICLUSIG IDAMYCIN IDAMYCIN IDAMYCIN	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO	Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary
HERZUMA HETLIOZ HETLIOZ HIZENTRA HIZENTRA HIZENTRA HUMATE-P HUMATE-P HUMATE-P HUMIRA HUMIRA HYCAMTIN HYPROXY HYDROXY HYDROXY HYDROXY HYDROXYPROG HYMOVIS HYPERRHO HYPERRHO HYPERRHO HYPERRHO HYPERRHO HYQVIA IBRANCE IBRANCE ICATIBANT ICATIBANT ICATIBANT ICLUSIG ICLUSIG IDAMYCIN	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY GENERIC-SPECIALTY NON-PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary

IDHIFA	ORAL-CHEMO	Blue Cross Formulary
IDHIFA	ORAL-CHEMO	National Performance Formulary
IFEX	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
IFEX	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
IFOSFAMIDE	GENERIC-SPECIALTY	Blue Cross Formulary
IFOSFAMIDE	GENERIC-SPECIALTY	National Performance Formulary
ILARIS	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ILARIS	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
ILUMYA	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ILUMYA	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
ILUVIEN	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ILUVIEN	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
IMATINIB	ORAL-CHEMO	Blue Cross Formulary
IMATINIB	ORAL-CHEMO	National Performance Formulary
IMBRUVICA	ORAL-CHEMO	Blue Cross Formulary
IMBRUVICA	ORAL-CHEMO	National Performance Formulary
IMFINZI	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
IMFINZI	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
IMLYGIC	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
IMLYGIC	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
INBRIJA	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
INBRIJA	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
INCRELEX	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
INCRELEX	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
INFLECTRA	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
INFLECTRA	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
INFUGEM	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
INFUGEM	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
INGREZZA	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
INGREZZA	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
INLYTA	ORAL-CHEMO	Blue Cross Formulary
INLYTA	ORAL-CHEMO	National Performance Formulary
INQOVI	ORAL-CHEMO	Blue Cross Formulary
INQOVI	ORAL-CHEMO	National Performance Formulary
INREBIC	ORAL-CHEMO	Blue Cross Formulary
INREBIC	ORAL-CHEMO	National Performance Formulary
INTRON	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
INTRON	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
IRESSA	ORAL-CHEMO	Blue Cross Formulary
IRESSA IRESSA	ORAL-CHEMO ORAL-CHEMO	Blue Cross Formulary National Performance Formulary
IRESSA IRINOTECAN		
IRESSA	ORAL-CHEMO	National Performance Formulary
IRESSA IRINOTECAN	ORAL-CHEMO GENERIC-SPECIALTY	National Performance Formulary Blue Cross Formulary
IRESSA IRINOTECAN IRINOTECAN	ORAL-CHEMO GENERIC-SPECIALTY GENERIC-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary
IRESSA IRINOTECAN IRINOTECAN ISTODAX	ORAL-CHEMO GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
IRESSA IRINOTECAN IRINOTECAN ISTODAX ISTODAX	ORAL-CHEMO GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
IRESSA IRINOTECAN IRINOTECAN ISTODAX ISTODAX ISTODAX ISTURISA	ORAL-CHEMO GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary
IRESSA IRINOTECAN IRINOTECAN ISTODAX ISTODAX ISTUDAX ISTURISA IXEMPRA	ORAL-CHEMO GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary
IRESSA IRINOTECAN IRINOTECAN ISTODAX ISTODAX ISTURISA IXEMPRA IXEMPRA	ORAL-CHEMO GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary
IRESSA IRINOTECAN IRINOTECAN ISTODAX ISTODAX ISTURISA IXEMPRA IXEMPRA IXINITY	ORAL-CHEMO GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
IRESSA IRINOTECAN IRINOTECAN ISTODAX ISTODAX ISTURISA IXEMPRA IXEMPRA IXINITY IXINITY	ORAL-CHEMO GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary
IRESSA IRINOTECAN IRINOTECAN ISTODAX ISTODAX ISTURISA IXEMPRA IXEMPRA IXINITY IXINITY JAKAFI	ORAL-CHEMO GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
IRESSA IRINOTECAN IRINOTECAN ISTODAX ISTODAX ISTURISA IXEMPRA IXEMPRA IXINITY IXINITY JAKAFI JAKAFI JELMYTO JELMYTO	ORAL-CHEMO GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
IRESSA IRINOTECAN IRINOTECAN ISTODAX ISTODAX ISTURISA IXEMPRA IXEMPRA IXINITY IXINITY JAKAFI JAKAFI JELMYTO JELMYTO JELMYTO JEVTANA	ORAL-CHEMO GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
IRESSA IRINOTECAN IRINOTECAN ISTODAX ISTODAX ISTODAX ISTURISA IXEMPRA IXEMPRA IXINITY IXINITY JAKAFI JAKAFI JJELMYTO JELMYTO JEVTANA JEVTANA	ORAL-CHEMO GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
IRESSA IRINOTECAN IRINOTECAN ISTODAX ISTODAX ISTURISA IXEMPRA IXEMPRA IXINITY IXINITY JAKAFI JAKAFI JELMYTO JELMYTO JELMYTO JEVTANA	ORAL-CHEMO GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary
IRESSA IRINOTECAN IRINOTECAN ISTODAX ISTODAX ISTODAX ISTURISA IXEMPRA IXEMPRA IXINITY IXINITY JAKAFI JAKAFI JJELMYTO JELMYTO JEVTANA JEVTANA	ORAL-CHEMO GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
IRESSA IRINOTECAN IRINOTECAN ISTODAX ISTODAX ISTODAX ISTURISA IXEMPRA IXEMPRA IXINITY IXINITY IXINITY JAKAFI JAKAFI JELMYTO JELMYTO JELMYTO JEVTANA JIVI	ORAL-CHEMO GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary
IRESSA IRINOTECAN IRINOTECAN ISTODAX ISTODAX ISTODAX ISTURISA IXEMPRA IXEMPRA IXINITY IXINITY IXINITY JAKAFI JAKAFI JELMYTO JELMYTO JELMYTO JELMYTO JEVTANA JIVI JIVI	ORAL-CHEMO GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
IRESSA IRINOTECAN IRINOTECAN ISTODAX ISTODAX ISTODAX ISTURISA IXEMPRA IXEMPRA IXINITY IXINITY JAKAFI JAKAFI JELMYTO JELMYTO JELMYTO JEVTANA JIVI JIVI JIVI JUXTAPID	ORAL-CHEMO GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
IRESSA IRINOTECAN IRINOTECAN ISTODAX ISTODAX ISTODAX ISTURISA IXEMPRA IXINITY IXINITY IXINITY JAKAFI JAKAFI JELMYTO JELMYTO JELMYTO JEVTANA JIVI JIVI JUXTAPID	ORAL-CHEMO GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
IRESSA IRINOTECAN IRINOTECAN ISTODAX ISTODAX ISTODAX ISTURISA IXEMPRA IXINITY IXINITY IXINITY JAKAFI JAKAFI JELMYTO JELMYTO JEVTANA JEVTANA JIVI JIVI JUXTAPID JUXTAPID JYNARQUE	ORAL-CHEMO GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
IRESSA IRINOTECAN IRINOTECAN ISTODAX ISTODAX ISTURISA IXEMPRA IXEMPRA IXINITY IXINITY JAKAFI JAKAFI JELMYTO JELMYTO JEVTANA JIVI JIVI JIVI JUXTAPID JUXTAPID JYNARQUE JYNARQUE	ORAL-CHEMO GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
IRESSA IRINOTECAN IRINOTECAN ISTODAX ISTODAX ISTODAX ISTURISA IXEMPRA IXEMPRA IXINITY IXINITY JAKAFI JAKAFI JAKAFI JAKAFI JELMYTO JELMYTO JEVTANA JIVI JIVI JIVI JIVI JUXTAPID JYNARQUE JYNARQUE KADCYLA	ORAL-CHEMO GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
IRESSA IRINOTECAN IRINOTECAN ISTODAX ISTODAX ISTODAX ISTURISA IXEMPRA IXEMPRA IXINITY IXINITY IXINITY JAKAFI JAKAFI JELMYTO JELMYTO JELMYTO JEVTANA JIVI JIVI JIVI JUXTAPID JYNARQUE JYNARQUE KADCYLA	ORAL-CHEMO GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
IRESSA IRINOTECAN IRINOTECAN ISTODAX ISTODAX ISTODAX ISTURISA IXEMPRA IXEMPRA IXINITY IXINITY IXINITY JAKAFI JAKAFI JELMYTO JELMYTO JELMYTO JELMYTO JEVTANA JIVI JIVI JIVI JUXTAPID JUXTAPID JYNARQUE IYNARQUE KADCYLA KADCYLA	ORAL-CHEMO GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary
IRESSA IRINOTECAN IRINOTECAN ISTODAX ISTODAX ISTODAX ISTURISA IXEMPRA IXEMPRA IXINITY IXINITY IXINITY JAKAFI JAKAFI JELMYTO JELMYTO JELMYTO JELMYTO JELYTANA JIVI JIVI JIVI JUXTAPID JUXTAPID JYNARQUE KADCYLA KADCYLA KALBITOR	ORAL-CHEMO GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary
IRESSA IRINOTECAN IRINOTECAN ISTODAX ISTODAX ISTODAX ISTURISA IXEMPRA IXEMPRA IXINITY IXINITY IXINITY JAKAFI JELMYTO JELMYTO JELMYTO JELMYTO JEVTANA JEVTANA JIVI JIVI JIVI JUXTAPID JYNARQUE JYNARQUE KADCYLA KALBITOR KALBITOR	ORAL-CHEMO GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
IRESSA IRINOTECAN IRINOTECAN ISTODAX ISTODAX ISTURISA IXEMPRA IXEMPRA IXINITY IXINITY IXINITY JAKAFI JAKAFI JELMYTO JELMYTO JEVTANA JIVI JIVI JIVI JIVI JIVI JIVI JIVIARQUE JYNARQUE KADCYLA KALBITOR KALBITOR KALBITOR KALBITOR	ORAL-CHEMO GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
IRESSA IRINOTECAN IRINOTECAN ISTODAX ISTODAX ISTODAX ISTURISA IXEMPRA IXEMPRA IXINITY IXINITY JAKAFI JAKAFI JAKAFI JELMYTO JELMYTO JEVTANA JIVI JIVI JIVI JUXTAPID JUXTAPID JYNARQUE JYNARQUE KADCYLA KALBITOR KALBITOR KALBITOR KALYDECO KANJINTI	ORAL-CHEMO GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
IRESSA IRINOTECAN IRINOTECAN ISTODAX ISTODAX ISTODAX ISTURISA IXEMPRA IXEMPRA IXINITY IXINITY IXINITY JAKAFI JAKAFI JAKAFI JELMYTO JELMYTO JEVTANA JIVI JIVI JIVI JUXTAPID JUXTAPID JYNARQUE JYNARQUE KADCYLA KALBITOR KALBITOR KALYDECO KANJINTI KANJINTI	ORAL-CHEMO GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary
IRESSA IRINOTECAN IRINOTECAN ISTODAX ISTODAX ISTODAX ISTURISA IXEMPRA IXEMPRA IXINITY	ORAL-CHEMO GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO NON-PREFERED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary
IRESSA IRINOTECAN IRINOTECAN ISTODAX ISTODAX ISTODAX ISTURISA IXEMPRA IXEMPRA IXINITY	ORAL-CHEMO GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
IRESSA IRINOTECAN IRINOTECAN ISTODAX ISTODAX ISTODAX ISTURISA IXEMPRA IXEMPRA IXINITY IXINITY IXINITY JAKAFI JAKAFI JELMYTO JELMYTO JELMYTO JELMYTO JUVI JIVI JIVI JIVI JIVI JIVI JIVI JUXTAPID JYNARQUE IYNARQUE KADCYLA KADCYLA KALBITOR KALBITOR KALBITOR KALYDECO KANJINTI KANUMA KANUMA KANUMA	ORAL-CHEMO GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary
IRESSA IRINOTECAN IRINOTECAN ISTODAX ISTODAX ISTURISA IXEMPRA IXEMPRA IXINITY IXINITY IXINITY JAKAFI JAKAFI JELMYTO JELMYTO JEVTANA JIVI JIVI JIVI JIVI JIVI JIVI AUXTAPID JYNARQUE JYNARQUE IYNARQUE KADCYLA KALBITOR KALBITOR KALBITOR KALBITOR KALBITOR KALBITOR KANJINTI KANJINTI KANJINTI KANJINTI KANJINTI KANJINTI KANJINTI KANUMA KEPIVANCE KESIMPTA	ORAL-CHEMO GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Rough Performance Formulary Rough Perf
IRESSA IRINOTECAN IRINOTECAN ISTODAX ISTODAX ISTODAX ISTURISA IXEMPRA IXEMPRA IXINITY	ORAL-CHEMO GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary

KEVEYIS	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
KEVZARA	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
KEVZARA	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
KEYTRUDA	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
KEYTRUDA	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
KHAPZORY	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
KHAPZORY	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
KINERET	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
KINERET	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
KISQALI	ORAL-CHEMO	Blue Cross Formulary
KISQALI	ORAL-CHEMO	National Performance Formulary
KITABIS	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
KOATE	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
KOATE	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
KOATE-DVI	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
KOATE-DVI	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
KOGENATE	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
KOGENATE	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
KORLYM	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
KORLYM	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
KOSELUGO	ORAL-CHEMO	Blue Cross Formulary
KOSELUGO	ORAL-CHEMO	National Performance Formulary
KOVALTRY	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
KOVALTRY	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
KRYSTEXXA	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
KRYSTEXXA	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
KUVAN	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
KUVAN	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
KYMRIAH	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
KYMRIAH	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
KYNMOBI	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
KYNMOBI	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
KYPROLIS	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
KYPROLIS	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
LAMIVUDINE	GENERIC-SPECIALTY	Blue Cross Formulary
LAMIVUDINE	GENERIC-SPECIALTY	National Performance Formulary
LAPATINIB	ORAL-CHEMO	Blue Cross Formulary
LAPATINIB	ORAL-CHEMO	National Performance Formulary
LAFATIND	OTT TO CITETION	reactional remormance roundary
LEDIP-SOFOSB	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
		·
LEDIP-SOFOSB	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
LEDIP-SOFOSB LEMTRADA	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary Blue Cross Formulary
LEDIP-SOFOSB LEMTRADA LEMTRADA	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary Blue Cross Formulary National Performance Formulary
LEDIP-SOFOSB LEMTRADA LEMTRADA LENVIMA	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO	Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
LEDIP-SOFOSB LEMTRADA LEMTRADA LENVIMA LENVIMA	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO	Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
LEDIP-SOFOSB LEMTRADA LEMTRADA LENVIMA LENVIMA LEUKINE	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
LEDIP-SOFOSB LEMTRADA LEMTRADA LENVIMA LENVIMA LEUKINE LEUKINE	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
LEDIP-SOFOSB LEMTRADA LEMTRADA LENVIMA LENVIMA LEUKINE LEUKINE LEUPROLIDE	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY	Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary
LEDIP-SOFOSB LEMTRADA LEMTRADA LENVIMA LENVIMA LEUKINE LEUKINE LEUPROLIDE LEUPROLIDE	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY	Blue Cross Formulary Blue Cross Formulary National Performance Formulary Palue Cross Formulary National Performance Formulary
LEDIP-SOFOSB LEMTRADA LEMTRADA LENVIMA LENVIMA LEUKINE LEUKINE LEUPROLIDE LEUPROLIDE LEVOLEUCOVOR	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY	Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Alue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
LEDIP-SOFOSB LEMTRADA LEMTRADA LENVIMA LENVIMA LEUKINE LEUKINE LEUPROLIDE LEUPROLIDE LEVOLEUCOVOR LEVOLEUCOVOR	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY	Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
LEDIP-SOFOSB LEMTRADA LEMTRADA LENVIMA LENVIMA LEUKINE LEUKINE LEUPROLIDE LEUPROLIDE LEVOLEUCOVOR LIBTAYO	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary Blue Cross Formulary National Performance Formulary
LEDIP-SOFOSB LEMTRADA LEMTRADA LENVIMA LENVIMA LEUKINE LEUPROLIDE LEUPROLIDE LEVOLEUCOVOR LEVOLEUCOVOR LIBTAYO LIBTAYO	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
LEDIP-SOFOSB LEMTRADA LEMTRADA LENVIMA LENVIMA LEUKINE LEUKINE LEUPROLIDE LEUPROLIDE LEUPROLIDE LEVOLEUCOVOR LEVOLEUCOVOR LIBTAYO LONSURF	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO	Blue Cross Formulary Blue Cross Formulary National Performance Formulary
LEDIP-SOFOSB LEMTRADA LEMTRADA LENVIMA LENVIMA LEUKINE LEUKINE LEUPROLIDE LEUPROLIDE LEVOLEUCOVOR LIBTAYO LIBTAYO LONSURF LONSURF	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO	Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
LEDIP-SOFOSB LEMTRADA LEMTRADA LENVIMA LENVIMA LEUKINE LEUKINE LEUPROLIDE LEUPROLIDE LEVOLEUCOVOR LIBTAYO LIBTAYO LONSURF LONSURF LONSURF LORSERNA	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO	Blue Cross Formulary Blue Cross Formulary National Performance Formulary
LEDIP-SOFOSB LEMTRADA LEMTRADA LENVIMA LENVIMA LEUKINE LEUKINE LEUPROLIDE LEUPROLIDE LEVOLEUCOVOR LIBTAYO LIBTAYO LONSURF LONSURF LORSURF LORSURF LORSURF	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORN-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO	Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
LEDIP-SOFOSB LEMTRADA LEMTRADA LENVIMA LENVIMA LEUKINE LEUKINE LEUPROLIDE LEUPROLIDE LEVOLEUCOVOR LIBTAYO LIBTAYO LONSURF LONSURF LORSURF LORSURF LORSURFNA LORBRENA LORBRENA LOVENOX	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary Blue Cross Formulary National Performance Formulary
LEDIP-SOFOSB LEMTRADA LEMTRADA LENVIMA LENVIMA LEUKINE LEUKINE LEUPROLIDE LEUPROLIDE LEVOLEUCOVOR LIBTAYO LIBTAYO LONSURF LONSURF LORBRENA LORBRENA LOVENOX LOVENOX	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
LEDIP-SOFOSB LEMTRADA LEMTRADA LENVIMA LENVIMA LEUKINE LEUKINE LEUPROLIDE LEUPROLIDE LEVOLEUCOVOR LIBTAYO LIBTAYO LONSURF LONSURF LORBRENA LORBRENA LORBRENA LOVENOX LUVENOX LUVENOX LUVENOX LUCENTIS	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
LEDIP-SOFOSB LEMTRADA LEMTRADA LENVIMA LENVIMA LEUKINE LEUKINE LEUPROLIDE LEUPROLIDE LEVOLEUCOVOR LIBTAYO LIBTAYO LONSURF LONSURF LONSURF LORBRENA LORBRENA LOVENOX LUCENTIS LUCENTIS	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
LEDIP-SOFOSB LEMTRADA LEMTRADA LENVIMA LENVIMA LEUKINE LEUKINE LEUPROLIDE LEUPROLIDE LEVOLEUCOVOR LIBTAYO LIBTAYO LONSURF LONSURF LORBRENA LORBRENA LOVENOX LUVENOX LUCENTIS LUCENTIS LUCENTIS LUMIZYME	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORN-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
LEDIP-SOFOSB LEMTRADA LEMTRADA LENVIMA LENVIMA LEUKINE LEUKINE LEUPROLIDE LEUPROLIDE LEVOLEUCOVOR LIBTAYO LIBTAYO LONSURF LONSURF LORSURF LOVENOX LUCENTIS LUCENTIS LUCENTIS LUMIZYME	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary National Performance Formulary
LEDIP-SOFOSB LEMTRADA LEMTRADA LENVIMA LENVIMA LEUKINE LEUKINE LEUPROLIDE LEUPROLIDE LEVOLEUCOVOR LIBTAYO LIBTAYO LONSURF LONSURF LONSURF LORSURF LOVENOX LUCENTIS LUCENTIS LUCENTIS LUMIZYME LUMIZYME LUMIZYME	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary Blue Cross Formulary National Performance Formulary
LEDIP-SOFOSB LEMTRADA LEMTRADA LENVIMA LENVIMA LEUKINE LEUKINE LEUPROLIDE LEUPROLIDE LEVOLEUCOVOR LIBTAYO LIBTAYO LONSURF LONSURF LONSURF LORSURF LOWSURF LOWINOX LUCENTIS LUCENTIS LUMIZYME LUMIZYME LUMOXITI LUMOXITI	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO NON-PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary
LEDIP-SOFOSB LEMTRADA LEMTRADA LENVIMA LENVIMA LEUKINE LEUKINE LEUPROLIDE LEUPROLIDE LEVOLEUCOVOR LIBTAYO LIBTAYO LONSURF LONSURF LONSURF LORSURF LOWSURF LOWSURF LUCENTIS LUCENTIS LUCENTIS LUCENTIS LUMIZYME LUMIZYME LUMOXITI LUMOXITI LUMOXITI LUMOXITI LUPANETA	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CSPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
LEDIP-SOFOSB LEMTRADA LEMTRADA LENVIMA LENVIMA LEUKINE LEUKINE LEUPROLIDE LEUPROLIDE LEVOLEUCOVOR LIBTAYO LIBTAYO LONSURF LONSURF LONSURF LORBRENA LORBRENA LORBRENA LOVENOX LUCENTIS LUCENTIS LUMIZYME LUMIOXITI LUMOXITI LUMOXITI LUPANETA	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
LEDIP-SOFOSB LEMTRADA LEMTRADA LENVIMA LENVIMA LEUKINE LEUKINE LEUPROLIDE LEUPROLIDE LEUPROLIDE LEVOLEUCOVOR LIBTAYO LIBTAYO LONSURF LONSURF LONSURF LORBRENA LORBRENA LOVENOX LUCENTIS LUCENTIS LUMIZYME LUMIZYME LUMOXITI LUMOXITI LUMOXITI LUPANETA LUPR	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORN-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary Blue Cross Formulary National Performance Formulary
LEDIP-SOFOSB LEMTRADA LEMTRADA LENVIMA LENVIMA LEUKINE LEUKINE LEUPROLIDE LEUPROLIDE LEVOLEUCOVOR LIBTAYO LIBTAYO LONSURF LONSURF LONSURF LORBRENA LORBRENA LOVENOX LUVENOX LUVENOX LUCENTIS LUCENTIS LUMIZYME LUMIZYME LUMOXITI LUMOXITI LUPANETA LUPR LUPR LUPR	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
LEDIP-SOFOSB LEMTRADA LEMTRADA LENVIMA LENVIMA LEUKINE LEUKINE LEUPROLIDE LEUPROLIDE LEVOLEUCOVOR LIBTAYO LIBTAYO LIBTAYO LONSURF LONSURF LORSURF LORBRENA LORBRENA LOVENOX LUVENOX LUVENOX LUCENTIS LUCENTIS LUMIZYME LUMIZYME LUMOXITI LUMOXITI LUPANETA LUPR LUNIMA LENVIMA LUPR LUMINA LUPANETA LUPR	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY	Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
LEDIP-SOFOSB LEMTRADA LEMTRADA LENVIMA LENVIMA LEUKINE LEUKINE LEUPROLIDE LEUPROLIDE LEVOLEUCOVOR LIBTAYO LIBTAYO LIBTAYO LONSURF LONSURF LONSURF LORBRENA LOVENOX LUCENTIS LUCENTIS LUCENTIS LUMIZYME LUMIZYME LUMOXITI LUMOXITI LUPANETA LUPR LUPANIMA LENVIMA LENVIMA LENTRADA LOPR LUPR	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary Blue Cross Formulary National Performance Formulary
LEDIP-SOFOSB LEMTRADA LEMTRADA LENVIMA LENVIMA LEUKINE LEUKINE LEUPROLIDE LEUPROLIDE LEVOLEUCOVOR LIBTAYO LIBTAYO LIBTAYO LONSURF LONSURF LONSURF LONSURF LORBRENA LOVENOX LUCENTIS LUCENTIS LUCENTIS LUMIZYME LUMIZYME LUMOXITI LUMOXITI LUPANETA LUPR	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO NON-PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY	Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Rotal Performance Formulary
LEDIP-SOFOSB LEMTRADA LEMTRADA LEMTRADA LENVIMA LENVIMA LEUKINE LEUKINE LEUPROLIDE LEUPROLIDE LEVOLEUCOVOR LIBTAYO LIBTAYO LONSURF LONSURF LONSURF LORSURF LORSURF LORSURF LORSURF LURSURF LORSURF LORSURF LORSURF LONSURF LORSURF LURSURF LURSURF LUCENTIS LUCENTIS LUCENTIS LUCENTIS LUCENTIS LUMIZYME LUMIZYME LUMIZYME LUMIZYME LUMIZYME LUMOXITI LUPANETA LUPR LUPR LUPR LUPR LUPR LUPR LUPR LUPR LUPRON LUPRON	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO NON-PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY	Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
LEDIP-SOFOSB LEMTRADA LEMTRADA LEMTRADA LENVIMA LENVIMA LEUKINE LEUKINE LEUPROLIDE LEUPROLIDE LEVOLEUCOVOR LIBTAYO LIBTAYO LONSURF LONSURF LONSURF LORSURF LUCENTIS LUMIZYME LUMIZYME LUMIZYME LUMIZYME LUMOXITI LUPANETA LUPR LUPR LUPR LUPR LUPR LUPR LUPR LUPRON LUPRON LUPRON	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CSPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary Blue Cross Formulary National Performance Formulary
LEDIP-SOFOSB LEMTRADA LEMTRADA LENVIMA LENVIMA LEUKINE LEUKINE LEUPROLIDE LEUPROLIDE LEUPROLIDE LEVOLEUCOVOR LIBTAYO LIBTAYO LONSURF LONSURF LONSURF LORBRENA LOVENOX LOVENOX LUCENTIS LUCENTIS LUMIZYME LUMIZYME LUMIZYME LUMOXITI LUMOXITI LUMOXITI LUPANETA LUPR LUPR LUPR LUPR LUPR LUPR LUPR LUPRON	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY	Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
LEDIP-SOFOSB LEMTRADA LEMTRADA LENVIMA LENVIMA LEUKINE LEUKINE LEUPROLIDE LEUPROLIDE LEVOLEUCOVOR LIBTAYO LIBTAYO LONSURF LONSURF LONSURF LORBRENA LOVENOX LUVENOX LUVENOX LUVENTIS LUCENTIS LUMIZYME LUMIZYME LUMIZYME LUMOXITI LUMOXITI LUMOXITI LUMOXITI LUPANETA LUPR LUPR LUPR LUPR LUPR LUPR LUPR LUPRON LU	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY	Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary

	<u></u>	
LYNPARZA	ORAL-CHEMO	National Performance Formulary
MAKENA	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
MAKENA	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
MARQIBO	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
MARQIBO	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
MATULANE	ORAL-CHEMO	Blue Cross Formulary
MATULANE	ORAL-CHEMO	National Performance Formulary
MAVENCLAD	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
MAVENCLAD	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
MAVYRET	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
MAVYRET	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
MAYZENT	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
MAYZENT	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
MEKINIST	ORAL-CHEMO	Blue Cross Formulary
MEKINIST	ORAL-CHEMO	National Performance Formulary
MEKTOVI	ORAL-CHEMO	Blue Cross Formulary
MEKTOVI	ORAL-CHEMO	National Performance Formulary
		•
MELPHALAN	GENERIC-SPECIALTY	Blue Cross Formulary
MELPHALAN	GENERIC-SPECIALTY	National Performance Formulary
MELPHALAN	ORAL-CHEMO	Blue Cross Formulary
MELPHALAN	ORAL-CHEMO	National Performance Formulary
MENOPUR	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
MENOPUR	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
MEPSEVII	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
MEPSEVII	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
MESNA	GENERIC-SPECIALTY	Blue Cross Formulary
MESNA	GENERIC-SPECIALTY	National Performance Formulary
MESNEX	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
MESNEX	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
MESNEX	ORAL-CHEMO	Blue Cross Formulary
MESNEX	ORAL-CHEMO	National Performance Formulary
	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
MICRHOGAM		,
MICRHOGAM	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
MIGLUSTAT	GENERIC-SPECIALTY	Blue Cross Formulary
MIGLUSTAT	GENERIC-SPECIALTY	National Performance Formulary
MIRCERA	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
MIRCERA	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
MITOMYCIN	GENERIC-SPECIALTY	Blue Cross Formulary
MITOMYCIN	GENERIC-SPECIALTY	National Performance Formulary
MITOMYCIN	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
MITOMYCIN	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
MITOXANTRON	GENERIC-SPECIALTY	Blue Cross Formulary
MITOXANTRON	GENERIC-SPECIALTY	National Performance Formulary
MONJUVI	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
MONJUVI	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
MONJUVI MONONINE	NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	National Performance Formulary Rlue Cross Formulary
MONONINE	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
MONONINE MONONINE	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary
MONONINE MONONINE MONOVISC	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary
MONONINE MONONINE MONOVISC MOZOBIL	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary
MONONINE MONONINE MONOVISC MOZOBIL MOZOBIL	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary
MONONINE MONONINE MONOVISC MOZOBIL MOZOBIL MULPLETA	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
MONONINE MONONINE MONOVISC MOZOBIL MOZOBIL MULPLETA MULPLETA	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
MONONINE MONONINE MONOVISC MOZOBIL MOZOBIL MULPLETA MULPLETA MULPLETA MUTAMYCIN	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary
MONONINE MONONINE MONOVISC MOZOBIL MOZOBIL MULPLETA MULPLETA MUTAMYCIN MUTAMYCIN	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Albue Cross Formulary National Performance Formulary
MONONINE MONONINE MONOVISC MOZOBIL MOZOBIL MULPLETA MULPLETA MUTAMYCIN MUTAMYCIN MVASI	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary
MONONINE MONONINE MONOVISC MOZOBIL MOZOBIL MULPLETA MULPLETA MUTAMYCIN MUTAMYCIN	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary
MONONINE MONONINE MONOVISC MOZOBIL MOZOBIL MULPLETA MULPLETA MULPLETA MUTAMYCIN MUTAMYCIN MVASI MVASI MVASI MYALEPT	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary
MONONINE MONONINE MONOVISC MOZOBIL MOZOBIL MULPLETA MULPLETA MULPLETA MUTAMYCIN MVASI MVASI	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary
MONONINE MONONINE MONOVISC MOZOBIL MOZOBIL MULPLETA MULPLETA MULPLETA MUTAMYCIN MUTAMYCIN MVASI MVASI MVASI MVALEPT	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary
MONONINE MONONINE MONOVISC MOZOBIL MOZOBIL MULPLETA MULPLETA MUTAMYCIN MUTAMYCIN MVASI MVASI MYALEPT MYALEPT	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary
MONONINE MONONINE MONOVISC MOZOBIL MULPLETA MULPLETA MULPLETA MUTAMYCIN MUTAMYCIN MVASI MVASI MYALEPT MYALEPT MYCOPHENOLAT	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY TIER 03 GENERIC-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary
MONONINE MONONINE MONOVISC MOZOBIL MULPLETA MULPLETA MUTAMYCIN MUTAMYCIN MVASI MVASI MYALEPT MYALEPT MYCAPSSA	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY TIER 03 GENERIC-SPECIALTY GENERIC-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
MONONINE MONONINE MONOVISC MOZOBIL MUZOBIL MULPLETA MULPLETA MUTAMYCIN MUTAMYCIN MVASI MVASI MYALEPT MYALEPT MYCAPSSA MYCOPHENOLAT	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY TIER 03 GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
MONONINE MONONINE MONOVISC MOZOBIL MOZOBIL MULPLETA MULPLETA MUTAMYCIN MUTAMYCIN MVASI MVASI MVASI MYALEPT MYCAPSSA MYCOPHENOLAT MYCOPHENOLIC MYCOPHENOLIC	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY TIER 03 GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Alienal Performance Formulary Blue Cross Formulary Blue Cross Formulary
MONONINE MONONINE MONOVISC MOZOBIL MOZOBIL MULPLETA MULPLETA MULPLETA MUTAMYCIN MVASI MVASI MVASI MYALEPT MYCAPSSA MYCOPHENOLAT MYCOPHENOLIC MYCOPHENOLIC MYFORTIC	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY TIER 03 GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
MONONINE MONONINE MONOVISC MOZOBIL MOZOBIL MULPLETA MULPLETA MULPLETA MUTAMYCIN MVASI MVASI MVASI MYALEPT MYALEPT MYCAPSSA MYCOPHENOLAT MYCOPHENOLIC MYFORTIC MYFORTIC	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY INON-PREFERRED-BRAND-SPECIALTY TIER 03 GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
MONONINE MONONINE MONOVISC MOZOBIL MUZOBIL MULPLETA MULPLETA MULPLETA MUTAMYCIN MVASI MVASI MVASI MYALEPT MYCAPSSA MYCOPHENOLAT MYCOPHENOLAT MYCOPHENOLIC MYFORTIC MYFORTIC MYFORTIC MYLOTARG	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY INON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
MONONINE MONONINE MONOVISC MOZOBIL MOZOBIL MULPLETA MULPLETA MULPLETA MUTAMYCIN MYASI MYASI MYASI MYALEPT MYALEPT MYALEPT MYCAPSSA MYCOPHENOLAT MYCOPHENOLIC MYCOPHENOLIC MYFORTIC MYFORTIC MYLOTARG MYLOTARG	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY TIER 03 GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
MONONINE MONONINE MONOVISC MOZOBIL MOZOBIL MULPLETA MULPLETA MULPLETA MUTAMYCIN MVASI MVASI MYALEPT MYALEPT MYALEPT MYCOPHENOLAT MYCOPHENOLIC MYCOPHENOLIC MYFORTIC MYFORTIC MYLOTARG MYOBLOC	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
MONONINE MONONINE MONOVISC MOZOBIL MOZOBIL MULPLETA MULPLETA MULPLETA MUTAMYCIN MVASI MVASI MYALEPT MYALEPT MYALEPT MYCAPSSA MYCOPHENOLAT MYCOPHENOLIC MYFORTIC MYFORTIC MYFORTIC MYLOTARG MYOBLOC MYOBLOC MYOBLOC	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
MONONINE MONONINE MONOVISC MOZOBIL MUZOBIL MULPLETA MULPLETA MULPLETA MUTAMYCIN MVASI MVASI MVASI MYALEPT MYCAPSSA MYCOPHENOLAT MYCOPHENOLIC MYFORTIC MYFORTIC MYFORTIC MYLOTARG MYOBLOC MAGLAZYME	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary
MONONINE MONONINE MONOVISC MOZOBIL MOZOBIL MULPLETA MULPLETA MULPLETA MUTAMYCIN MVASI MVASI MVASI MVASI MYALEPT MYCAPSSA MYCOPHENOLAT MYCOPHENOLAT MYCOPHENOLIC MYFORTIC MYFORTIC MYFORTIC MYLOTARG MYOBLOC MYOBLOC NAGLAZYME	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY TIER 03 GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary
MONONINE MONONINE MONOVISC MOZOBIL MOZOBIL MUZPLETA MULPLETA MULPLETA MULPLETA MUTAMYCIN MVASI MVASI MVASI MVASI MYALEPT MYCAPSSA MYCOPHENOLAT MYCOPHENOLAT MYCOPHENOLIC MYFORTIC MYFORTIC MYFORTIC MYLOTARG MYOBLOC NAGLAZYME NAGLAZYME NAGLAZYME NAGLAZYME	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY TIER 03 GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
MONONINE MONONINE MONOVISC MOZOBIL MOZOBIL MULPLETA MULPLETA MULPLETA MULPLETA MUTAMYCIN MVASI MVASI MVASI MYALEPT MYALEPT MYCAPSSA MYCOPHENOLAT MYCOPHENOLAT MYCOPHENOLIC MYFORTIC MYFORTIC MYFORTIC MYFORTIC MYLOTARG MYULOTARG MYULOTARG MYOBLOC MYOBLOC NAGLAZYME NAGLAZYME NAGLAZYME NATPARA	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
MONONINE MONONINE MONOVISC MOZOBIL MOZOBIL MULPLETA MULPLETA MULPLETA MUTAMYCIN MVASI MVASI MVASI MYALEPT MYALEPT MYCOPHENOLAT MYCOPHENOLAT MYCOPHENOLIC MYCOPHENOLIC MYFORTIC MYLOTARG MYLOTARG MYOBLOC NAGLAZYME NAGLAZYME NAGLAZYME NAFORSC	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY TIER 03 GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
MONONINE MONONINE MONOVISC MOZOBIL MOZOBIL MULPLETA MULPLETA MULPLETA MULPLETA MUTAMYCIN MVASI MVASI MVASI MYALEPT MYALEPT MYCAPSSA MYCOPHENOLAT MYCOPHENOLAT MYCOPHENOLIC MYFORTIC MYFORTIC MYFORTIC MYFORTIC MYLOTARG MYULOTARG MYULOTARG MYOBLOC MYOBLOC NAGLAZYME NAGLAZYME NAGLAZYME NATPARA	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary

NEORAL	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
NERLYNX	ORAL-CHEMO ORAL-CHEMO	Blue Cross Formulary National Performance Formulary
NERLYNX NEULASTA	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
NEULASTA NEULASTA	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
NEUPOGEN	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
NEXAVAR	ORAL-CHEMO	Blue Cross Formulary
NEXAVAR	ORAL-CHEMO	National Performance Formulary
NILANDRON	ORAL-CHEMO	Blue Cross Formulary
NILANDRON	ORAL-CHEMO	National Performance Formulary
NILUTAMIDE	ORAL-CHEMO	Blue Cross Formulary
NILUTAMIDE	ORAL-CHEMO	National Performance Formulary
NINLARO	ORAL-CHEMO	Blue Cross Formulary
NINLARO	ORAL-CHEMO	National Performance Formulary
NIPENT	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
NIPENT	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
NITISINONE	GENERIC-SPECIALTY	Blue Cross Formulary
NITISINONE	GENERIC-SPECIALTY	National Performance Formulary
NITYR NITYR	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary
NIVESTYM	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
NIVESTYM	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
NORDITROPIN	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
NORDITROPIN	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
NORTHERA	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
NORTHERA	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
NOVAREL	GENERIC-SPECIALTY	Blue Cross Formulary
NOVAREL	GENERIC-SPECIALTY	National Performance Formulary
NOVAREL	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
NOVAREL	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
NOVOEIGHT	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
NOVOEIGHT	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
NOVOSEVEN	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
NOVOSEVEN	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
NPLATE NPLATE	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
NUBEQA	ORAL-CHEMO	National Performance Formulary Blue Cross Formulary
NUBEQA	ORAL-CHEMO ORAL-CHEMO	National Performance Formulary
NUCALA	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
NUCALA NULOJIX	PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary
NUCALA		·
NUCALA NULOJIX	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
NUCALA NULOJIX NULOJIX	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary
NUCALA NULOJIX NULOJIX NUTROPIN	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary
NUCALA NULOJIX NULOJIX NUTROPIN NUTROPIN	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
NUCALA NULOJIX NULOJIX NUTROPIN NUTROPIN NUWIQ NUWIQ OBIZUR	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary
NUCALA NULOJIX NULOJIX NUTROPIN NUTROPIN NUTROPIN NUWIQ NUWIQ OBIZUR OBIZUR	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary National Performance Formulary
NUCALA NULOJIX NULOJIX NUTROPIN NUTROPIN NUWIQ NUWIQ OBIZUR OBIZUR OCALIVA	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary
NUCALA NULOJIX NULOJIX NUTROPIN NUTROPIN NUWIQ NUWIQ OBIZUR OBIZUR OCALIVA	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary
NUCALA NULOJIX NULOJIX NUTROPIN NUTROPIN NUWIQ NUWIQ OBIZUR OBIZUR OCALIVA OCALIVA OCREVUS	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary
NUCALA NULOJIX NULOJIX NUTROPIN NUTROPIN NUWIQ NUWIQ OBIZUR OBIZUR OBIZUR OCALIVA OCALIVA OCREVUS OCREVUS	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
NUCALA NULOJIX NULOJIX NUTROPIN NUTROPIN NUWIQ NUWIQ OBIZUR OBIZUR OCALIVA OCALIVA OCREVUS OCREVUS OCTAGAM	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
NUCALA NULOJIX NULOJIX NUTROPIN NUTROPIN NUWIQ NUWIQ OBIZUR OBIZUR OCALIVA OCALIVA OCREVUS OCREVUS OCTAGAM OCTAGAM	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Slue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
NUCALA NULOJIX NULOJIX NUTROPIN NUTROPIN NUWIQ NUWIQ OBIZUR OBIZUR OBIZUR OCALIVA OCALIVA OCREVUS OCREVUS OCTAGAM OCTAGAM OCTREOTIDE	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY RON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
NUCALA NULOJIX NULOJIX NUTROPIN NUTROPIN NUWIQ NUWIQ OBIZUR OBIZUR OCALIVA OCALIVA OCREVUS OCREVUS OCTAGAM OCTAGAM	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary National Performance Formulary
NUCALA NULOJIX NULOJIX NUTROPIN NUTROPIN NUWIQ NUWIQ OBIZUR OBIZUR OCALIVA OCALIVA OCREVUS OCREVUS OCTAGAM OCTAGAM OCTREOTIDE OCTREOTIDE	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY	Blue Cross Formulary National Performance Formulary
NUCALA NULOJIX NULOJIX NUTROPIN NUTROPIN NUWIQ NUWIQ OBIZUR OBIZUR OCALIVA OCALIVA OCREVUS OCREVUS OCTAGAM OCTAGAM OCTREOTIDE ODOMZO	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO	Blue Cross Formulary National Performance Formulary
NUCALA NULOJIX NULOJIX NUTROPIN NUTROPIN NUWIQ NUWIQ OBIZUR OBIZUR OCALIVA OCALIVA OCREVUS OCREVUS OCTAGAM OCTAGAM OCTREOTIDE ODOMZO ODOMZO	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ON-PREFERRED-BRAND-SPECIALTY ON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO	Blue Cross Formulary National Performance Formulary
NUCALA NULOJIX NULOJIX NUTROPIN NUTROPIN NUWIQ NUWIQ OBIZUR OBIZUR OCALIVA OCALIVA OCREVUS OCREVUS OCTAGAM OCTAGAM OCTREOTIDE ODOMZO ODOMZO OFEV	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary
NUCALA NULOJIX NULOJIX NUTROPIN NUTROPIN NUWIQ NUWIQ OBIZUR OBIZUR OBIZUR OCALIVA OCALIVA OCREVUS OCREVUS OCTAGAM OCTAGAM OCTREOTIDE ODOMZO OPEV OFEV	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
NUCALA NULOJIX NULOJIX NUTROPIN NUTROPIN NUWIQ NUWIQ OBIZUR OBIZUR OBIZUR OCALIVA OCALIVA OCREVUS OCREVUS OCTAGAM OCTAGAM OCTREOTIDE ODOMZO ODOMZO OFEV OFEV OGIVRI OLUMIANT OMNITROPE	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY ON-PREFERED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary
NUCALA NULOJIX NULOJIX NUTROPIN NUTROPIN NUWIQ NUWIQ OBIZUR OBIZUR OCALIVA OCALIVA OCREVUS OCTAGAM OCTAGAM OCTREOTIDE OCTREOTIDE ODOMZO ODOMZO OFEV OFEV OGIVRI OLUMIANT OMNITROPE ONCASPAR	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORNO-PREFERED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary
NUCALA NULOJIX NULOJIX NUTROPIN NUTROPIN NUTROPIN NUWIQ NUWIQ OBIZUR OBIZUR OCALIVA OCALIVA OCREVUS OCTAGAM OCTAGAM OCTAGAM OCTAGAM OCTAGOTIDE ODOMZO ODOMZO OFEV OFEV OFEV OGIVRI OLUMIANT OMNITROPE ONCASPAR	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary
NUCALA NULOJIX NULOJIX NUTROPIN NUTROPIN NUTROPIN NUWIQ NUWIQ OBIZUR OBIZUR OBIZUR OCALIVA OCALIVA OCREVUS OCTAGAM OCTAGAM OCTREOTIDE ODOMZO ODOMZO OFEV OFEV OFEV OGIVRI OLUMIANT OMNITROPE ONCASPAR ONIVYDE	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORN-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary
NUCALA NULOJIX NULOJIX NULOJIX NUTROPIN NUTROPIN NUWIQ NUWIQ OBIZUR OBIZUR OBIZUR OCALIVA OCALIVA OCREVUS OCREVUS OCREVUS OCTEGAM OCTAGAM OCTAGAM OCTREOTIDE ODOMZO ODOMZO ODOMZO OFEV OFEV OGIVRI OLUMIANT OMNITROPE ONCASPAR ONCASPAR ONCASPAR ONIVYDE	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary
NUCALA NULOJIX NULOJIX NULOJIX NUTROPIN NUTROPIN NUWIQ NUWIQ OBIZUR OBIZUR OBIZUR OCALIVA OCALIVA OCREVUS OCREVUS OCTREOTIDE OCTAGAM OCTREOTIDE OCTREOTIDE ODOMZO ODOMZO ODOMZO OFEV OFEV OFEV OGIVRI OLUMIANT OMNITROPE ONCASPAR ONICASPAR ONICYDE ONIVYDE ONIVYDE ONIVYDE	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary
NUCALA NULOJIX NULOJIX NUTROPIN NUTROPIN NUWIQ NUWIQ OBIZUR OBIZUR OBIZUR OCALIVA OCALIVA OCREVUS OCREVUS OCTAGAM OCTAGAM OCTREOTIDE ODOMZO ODOMZO OFEV OFEV OFEV OGIVRI OLUMIANT OMNITROPE ONCASPAR ONICYDE	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO ORAL-CHEMO ON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
NUCALA NULOJIX NULOJIX NUTROPIN NUTROPIN NUWIQ NUWIQ OBIZUR OBIZUR OBIZUR OCALIVA OCALIVA OCREVUS OCREVUS OCTAGAM OCTAGAM OCTAGAM OCTREOTIDE ODOMZO ODOMZO OFEV OFEV OGIVRI OLUMIANT OMNITROPE ONCASPAR ONICYDE ONIVYDE ONIVYDE ONIVYDE ONPATTRO ONTRUZANT	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO ORAL-CHEMO OND-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Slue Cross Formulary Blue Cross Formulary Blue Cross Formulary Slue Cross Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary
NUCALA NULOJIX NULOJIX NUTROPIN NUTROPIN NUWIQ NUWIQ OBIZUR OBIZUR OBIZUR OCALIVA OCALIVA OCREVUS OCTAGAM OCTAGAM OCTAGAM OCTREOTIDE ODOMZO ODOMZO ODOMZO OFEV OFEV OGIVRI OLUMIANT OMNITROPE ONCASPAR ONICASPAR ONICYDE ONPATTRO ONPATTRO ONTRUZANT ONUREG	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ON-PREFERED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
NUCALA NULOJIX NULOJIX NUTROPIN NUTROPIN NUTROPIN NUWIQ NUWIQ OBIZUR OBIZUR OBIZUR OCALIVA OCREVUS OCREVUS OCTAGAM OCTAGAM OCTREOTIDE ODOMZO ODOMZO OFEV OFEV OFEV OGIVRI OLUMIANT OMNITROPE ONCASPAR ONICASPAR ONICASPAR ONICASPATORO ONPATTRO ONPATTRO ONPATTRO ONTRUZANT ONUREG ONUREG	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
NUCALA NULOJIX NULOJIX NUTROPIN NUTROPIN NUTROPIN NUWIQ NUWIQ OBIZUR OBIZUR OBIZUR OCALIVA OCALIVA OCREVUS OCTAGAM OCTREOTIDE OCTAGAM OCTREOTIDE ODOMZO OFEV OFEV OFEV OGIVRI OLUMIANT OMNITROPE ONCASPAR ONIVYDE ONPATTRO ONPATTRO ONUREG OPDIVO	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY ON-PREFERED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
NUCALA NULOJIX NULOJIX NUTROPIN NUTROPIN NUTROPIN NUWIQ NUWIQ OBIZUR OBIZUR OBIZUR OCALIVA OCALIVA OCREVUS OCREVUS OCREVUS OCTREOTIDE OCTAGAM OCTAGAM OCTAGAM OCTREOTIDE ODOMZO ODOMZO ODOMZO OFEV OFEV OGIVRI OLUMIANT OMNITROPE ONCASPAR ONICASPAR	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ON-PREFERED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
NUCALA NULOJIX NULOJIX NUTROPIN NUTROPIN NUTROPIN NUWIQ NUWIQ OBIZUR OBIZUR OBIZUR OCALIVA OCREVUS OCREVUS OCTAGAM OCTAGAM OCTAGAM OCTAGOTIDE ODOMZO ODOMZO OFEV OFEV OFEV OGIVRI OLUMIANT OMNITROPE ONCASPAR ONIVYDE ONPATTRO ONPATTRO ONUREG OPDIVO	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY ON-PREFERED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary

ORENCA NON-PREFERED BRAND SPECIALTY ORENTAM NON-PREFERED BRAND SPECIALTY ORENTAM NON-PREFERED BRAND SPECIALTY ORENTAM NON-PREFERED BRAND SPECIALTY ORENTAM OND-PREFERED BRAND SPECIALTY ORENTAM ORD-PREFERED BRAND SPECIALTY ORD-PREFERED BRAND SPECI			
ORENTRAM NON-PREFERSE-BRAND-SPECIALTY ROBERTOR ORRADIN ORRADIN NON-PREFERSE-BRAND-SPECIALTY ROBERTOR ORRADIN OR			
ORENTRAM ORADON NON-PREFERED-BRAND-SPECIALTY ORRADON NON-PREFERED-BRAND-SPECIALTY ORRADON NON-PREFERED-BRAND-SPECIALTY ORRADON NON-PREFERED-BRAND-SPECIALTY ORRADON ORRADON NON-PREFERED-BRAND-SPECIALTY ORRADON ORRADON NON-PREFERED-BRAND-SPECIALTY ORRADON ORRADON ORRADON ORRADON ORRADON NON-PREFERED-BRAND-SPECIALTY ORRADON			
ORADIN ONE PREFERBO BRAND SPECIALTY BILL Cross Formulary ORKAMBI NON PREFERBO BRAND SPECIALTY BILL Cross Formulary ORKAMBI NON PREFERBO BRAND SPECIALTY BILL Cross Formulary ORKAMBI NON PREFERBO BRAND SPECIALTY BILL Cross Formulary ORKAMBI ORKAMBI NON PREFERBO BRAND SPECIALTY BILL Cross Formulary ORKAMBI ORKAMBI NON PREFERBO BRAND SPECIALTY BILL Cross Formulary ORKAMBI ORKAMBI ORKAMBI NON PREFERBO BRAND SPECIALTY BILL Cross Formulary ORKAMBI ORKAMBI NON PREFERBO BRAND SPECIALTY National Performance Formulary ORKAMBI ORKAMBI ORKAMBI NON PREFERBO BRAND SPECIALTY ORKAMBI ORKAMBI ORKAMBI ORKAMBI ORKAMBI NON PREFERBO BRAND SPECIALTY NATIONAL PERFORMANCE ORKAMBI	ORENITRAM		Blue Cross Formulary
ORRADIN ONEADIN ONDELL NON-PREFERED BRAND SPECIALTY Blue Cross Formulary ONDELL NON-PREFERED BRAND SPECIALTY ONDELL NON-PREFERED BRAND SPECIALTY Blue Cross Formulary ONDELL NON-PREFERED BRAND SPECIALTY Blue Cross Formulary ONDELL ONDERL ONEADIN ONE			
ORAMMI NON-PRETERIED-BRAND -SPECIALTY BILLE Cross Formulary ORTHOVISC NON-PRETERIED-BRAND -SPECIALTY BILLE Cross Formulary OFIELA PREFERED-BRAND -SPECIALTY BILLE Cross Formulary OFIELA PREFERED-BRAND -SPECIALTY BILLE Cross Formulary OFIELA PREFERED-BRAND -SPECIALTY SILLE CROSS Formulary OFIELA PREFERED-BRAND -SPECIALTY National Performance Formulary OFIELA NON-PREFERED-BRAND -SPECIALTY SILLE CROSS Formulary PACULTAREL GENERIC-SPECIALTY SILLE CROSS Formulary PACULTAREL GENERIC-SPECIALTY SILLE CROSS Formulary PACULTAREL GENERIC-SPECIALTY SILLE CROSS Formulary PALYDIQ NON-PREFERED-BRAND -SPECIALTY SILLE CROSS Formulary PARAMEN GRAND -SPECIALTY SILLE CROSS Formulary PARAMEN GRAND -SPECIALTY SILLE CROSS Formulary PARAMEN GRAND -SPECIALTY SILLE CROSS Formulary PREFERED-BRAND -SPECIALTY SILLE CROSS Formulary PREFERED-BRAND -SPECIALTY SILLE CROSS Formulary PREFERED-BRAND -SPECIA			
ORKAMBI ORTHOVISC OND PREFERBO BRAND SPECIALTY DYDEAL DYDEAL PREFERBO BRAND SPECIALTY DYDEAL ORTHON ORTHON ORTHON OYDEAL NOW PREFERBO BRAND SPECIALTY DYDEAL NOW PREFERBO BRAND SPECIALTY DYDEAL NOW PREFERBO BRAND SPECIALTY Blue Cross Formulary OYDERL OYDERL NOW PREFERBO BRAND SPECIALTY Blue Cross Formulary OYDERL NOW PREFERBO BRAND SPECIALTY Blue Cross Formulary OYDERLATIN OYDERATIN OYDER SPECIAL S	ORFADIN	NON-PREFERRED-BRAND-SPECIALTY	
ORTHOVISC OFELA PREFERBED-BRAND SPECIALTY OVERL OVERL NON-PREFERBED-BRAND SPECIALTY National Performance formulary OVERL NON-PREFERBED-BRAND SPECIALTY National Performance formulary OVERL NON-PREFERBED-BRAND SPECIALTY OVERL NON-PREFERBED-BRAND SPECIALTY OVERL NON-PREFERBED-BRAND SPECIALTY OVERL OVERLATIN GENERIC-SPECIALTY OVERLATIN OVERLATIN	ORKAMBI	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
OTEZIA PREFERED-BRAND-SPECIALTY National Performance formulary OVERSEL NON-PREFERED-BRAND-SPECIALTY Blue Cross Formulary OVERSEL NON-PREFERED-BRAND-SPECIALTY Blue Cross Formulary OXALIPIATIN GENERIC-SPECIALTY Blue Cross Formulary OXENTA NON-PREFERED-BRAND-SPECIALTY Blue Cross Formulary PROCED NON-PREFERED-BRAND-SPECIALTY Blue Cross Formulary PROMOBONATE GINNEC-SPECIAL SPECIAL	ORKAMBI	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
OVEREL NON-PREFERRED-BRAND-SPECIALTY OVALIPATIN OVALIPATIN ORALIPATIN ORA	ORTHOVISC	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
OVIDREL NON-PREFERRED-BRAND-SPECIALTY OVALIPATIN OXALIPATIN OXARYA NON-PREFERRED-BRAND-SPECIALTY OXBOYTA NON-PREFERRED-BRAND-SPECIALTY OXBOYTA OXERVATE NON-PREFERRED-BRAND-SPECIALTY OXERVATE NON-PREFERRED-BRAND-SPECIALTY OXLIMIO NON-PREFERRED-BRAND-SPECIALTY OXLIMIO NON-PREFERRED-BRAND-SPECIALTY OXLIMIO OXIN-PREFERRED-BRAND-SPECIALTY OXLIMIO OXIN-PREFERRED-BRAND-SPECIALTY DATE OXIN-PRE	OTEZLA	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
OVIDREL NON-PREFERED BRAND-SPECIALTY OXALIPLATIN GENERIC-SPECIALTY NON-PREFERED BRAND-SPECIALTY NON-PREFERED BRAND-SPECIALTY OXENYATE OXENYATE NON-PREFERED BRAND-SPECIALTY OXENYATE NON-PREFERED BRAND-SPECIALTY OXENYATE OXENYATE NON-PREFERED BRAND-SPECIALTY OXENYATE NON-PREFERED BRAND-SPECIALTY OXENYATE OXIUNO NON-PREFERED BRAND-SPECIALTY OXIUNO NON-PREFERED BRAND-SPECIALTY OXIUNO NON-PREFERED BRAND-SPECIALTY OXIUNO NON-PREFERED BRAND-SPECIALTY DIRECTORS formulary OXIUNO NON-PREFERED BRAND-SPECIALTY PROCEV PACILITAREL GENERIC-SPECIALTY PACETY NON-PREFERED BRAND-SPECIALTY PACETY NON-PREFERED BRAND-SPECIALTY Blue Cross formulary PACETY PALETY	OTEZLA	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
OXALIPATIN OXALIPATIN OXALIPATIN OXALIPATIN OXABIYTA NON-PREFERED-BARAND-SPECIALTY NON-PREFERED-BARAND-SPECIALTY NON-PREFERED-BARAND-SPECIALTY NON-PREFERED-BARAND-SPECIALTY OXERVATE NON-PREFERED-BARAND-SPECIALTY OXERVATE OXERVATE OXUMO NON-PREFERED-BARAND-SPECIALTY OXLUMO NON-PREFERED-BARAND-SPECIALTY OXLUMO NON-PREFERED-BARAND-SPECIALTY OXLUMO NON-PREFERED-BARAND-SPECIALTY OXLUMO NON-PREFERED-BARAND-SPECIALTY DATE OXLUMO NON-PREFERED-BARAND-SPECIALTY DATE OXLUMO NON-PREFERED-BARAND-SPECIALTY Buse Cross Formulary PACLITAREL GENERIC-SPECIALTY GENERIC-SPECIALTY Buse Cross Formulary PACLITAREL GENERIC-SPECIALTY DATE PACLITAREL GENERIC-SPECIALTY DATE PALITAREL GENERIC-SPECIALTY DATE PALIT	OVIDREL	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
OXALIPATIN NOP-BEERRED-BRAND SPECIALTY Blue Cross Formulary OXENYATE NON-PREERRED-BRAND SPECIALTY Blue Cross Formulary OXENYATE NON-PREERRED-BRAND SPECIALTY Blue Cross Formulary OXENYATE NON-PREERRED-BRAND SPECIALTY Blue Cross Formulary OXLUMO NON-PREERRED-BRAND SPECIALTY Blue Cross Formulary PACILTAREL GENERIC-SPECIALTY Blue Cross Formulary PACILTAREL GENERIC-SPECIALTY Blue Cross Formulary PACILTAREL GENERIC-SPECIALTY Blue Cross Formulary PADCEV NON-PREERRED-BRAND SPECIALTY Blue Cross Formulary PADCEV NON-PREERRED-BRAND SPECIALTY Blue Cross Formulary PALYNZQ NON-PREERRED-BRAND SPECIALTY Blue Cross Formulary PALYNZQ NON-PREERRED-BRAND SPECIALTY Blue Cross Formulary PALYNZQ NON-PREERRED-BRAND SPECIALTY Blue Cross Formulary PANIDRONATE GENERIC-SPECIALTY Blue Cross Formulary PRESISTS PREERRED-BRAND-SPECIALTY Blue Cross For	OVIDREL	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
OXBITYTA NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY OXLUND NON-PREFERRED-BRAND-SPECIALTY PACELTTAKEL GENERIC-SPECIALTY PACELTAKEL GENERIC-SPECIALTY PADEV NON-PREFERRED-BRAND-SPECIALTY PADEV NON-PREFERRED-BRAND-SPECIALTY PADEV NON-PREFERRED-BRAND-SPECIALTY PALVIZIQ NON-PREFERRED-BRAND-SPECIALTY RIBUE Cross Formulary PARAPITATIN GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PARAPITATIN GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY RIBUE Cross Formulary PRASABILY NON-PREFERRED-BRAND-SPECIALTY RIBUE Cross Formulary PREFERRED-BRAND-SPECIALTY RIBUE Cross Formulary PREFERRED-BRAND-SPECIALTY RIBUE Cross Formulary PREFERRED-BRAND-SPECIALTY RIBUE Cross Formulary PREFERRED-BRAND-SPECIALTY RIBUE Cross Formulary PRESADYS PREFERRED-BRAND-SPECIALTY RIBUE Cross Formulary PREFERRED-BRAND-SPECIALTY RIBUE Cross Formulary RIBUE Cross Formulary RIBUE Cross Formulary PREMAZYRE GRAND-SPECIALTY RIBUE Cross Formulary RIBUE Cross Fo	OXALIPLATIN	GENERIC-SPECIALTY	Blue Cross Formulary
OXBRYTA NON-PREFERRED BRAND SPECIALTY Suc Cross Formulary OXENATE NON-PREFERRED BRAND SPECIALTY OXUMO NON-PREFERRED BRAND SPECIALTY Blue Cross Formulary PACLITAREL GENERIC SPECIALTY Blue Cross Formulary PACLITAREL GENERIC SPECIALTY PADERY NON-PREFERRED BRAND SPECIALTY Blue Cross Formulary PALITAREL GENERIC SPECIALTY PADERY NON-PREFERRED BRAND SPECIALTY Blue Cross Formulary PALITAREL OXIMORATION PALITAREL NON-PREFERRED BRAND SPECIALTY Blue Cross Formulary PALITAREL OXIMORATION NON-PREFERRED BRAND SPECIALTY Blue Cross Formulary PALITAREL GENERIC SPECIALTY PALITAREL OXIMORATION NON-PREFERRED BRAND SPECIALTY Blue Cross Formulary PALITAREL GENERIC SPECIALTY PALITAREL GENERIC SPECIALTY Blue Cross Formulary PARAPITATIN GENERIC SPECIALTY Blue Cross Formulary PREFERRED BRAND SPECIALTY Blue Cross Formulary PREFERR	OXALIPLATIN		National Performance Formulary
OXERVATE NON-PREFERRED BRAND-SPECALTY National Performance Formulary OXLUMO NON-PREFERRED BRAND-SPECALTY Blue Cross Formulary OXLUMO NON-PREFERRED-BRAND-SPECALTY Blue Cross Formulary OXLUMO NON-PREFERRED-BRAND-SPECALTY Blue Cross Formulary OXLUMO NON-PREFERRED-BRAND-SPECALTY Blue Cross Formulary OXLUDEX NON-PREFERRED-BRAND-SPECALTY Blue Cross Formulary OXLUDEX NON-PREFERRED-BRAND-SPECALTY Blue Cross Formulary PACILTAXEL GENERIC-SPECIALTY Blue Cross Formulary PACILTAXEL GENERIC-SPECIALTY Blue Cross Formulary PACICTY NON-PREFERRED-BRAND-SPECALTY Blue Cross Formulary PADECV NON-PREFERRED-BRAND-SPECALTY Blue Cross Formulary PADECV NON-PREFERRED-BRAND-SPECALTY Blue Cross Formulary PALIVAZIO NON-PREFERRED-BRAND-SPECALTY Blue Cross Formulary PANIDRONATE GENERIC-SPECIALTY Blue Cross Formulary PANIDRONATE GENERIC-SPECIALTY Blue Cross Formulary PANIDRONATE GENERIC-SPECIALTY Blue Cross Formulary PANIZY PANIZY GROUND FOR FORMULA PROBLEM FOR FORMULARY PANIZY GROUND FORMULA PROBLEM FOR	OXBRYTA		
OXENATE NON-PREFERED BRAND SPECIALTY Blue Cross Formulary OXLUNIO NON-PREFERED-BRAND SPECIALTY Blue Cross Formulary OXLUNIO NON-PREFERED-BRAND SPECIALTY Blue Cross Formulary OZUNDEX NON-PREFERED-BRAND SPECIALTY Blue Cross Formulary PACUTAXEL GENERIC-SPECIALTY National Performance Formulary PACUTAXEL GENERIC-SPECIALTY Blue Cross Formulary PACUTAXEL GENERIC-SPECIALTY National Performance Formulary PACUTAXEL GENERIC-SPECIALTY National Performance Formulary PADOCEV NON-PREFERED-BRAND-SPECIALTY Blue Cross Formulary PADOCEV NON-PREFERED-BRAND-SPECIALTY Blue Cross Formulary PALIFORZIA NON-PREFERED-BRAND-SPECIALTY Blue Cross Formulary PANIDRONATE GENERIC-SPECIALTY Blue Cross Formulary PANIDRONATE GENERIC-SPECIALTY Blue Cross Formulary PARAPLATIN GENERIC-SPECIALTY Blue Cross Formulary PRESSON PREFERRED-BRAND-SPECIALTY National Performance Formulary PEGASYS PREFERRED-BRAND-SPECIALTY National Performance Formulary PEGASYS PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PEGASYS PREFERRED-BRAND-SPECIALTY National Performance Formulary PENATRE ORAL-CHEMO NATIONAL PERFERRED-BRAND-SPECIALTY			
OXLUNIO NON-PREFERRED-BRAND-SPECIALTY OXUMDO NON-PREFERRED-BRAND-SPECIALTY OXUMDEX NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary OXUMDEX NON-PREFERRED-BRAND-SPECIALTY PACITIAXEL SEMERIC-SPECIALTY PACITIAXEL SEMERIC-SPECIALTY PADECV NON-PREFERRED-BRAND-SPECIALTY PADECV NON-PREFERRED-BRAND-SPECIALTY PADECV NON-PREFERRED-BRAND-SPECIALTY PADECV NON-PREFERRED-BRAND-SPECIALTY PALYDIQ PALYDIQ NON-PREFERRED-BRAND-SPECIALTY PALYDIQ NON-PREFERRED-BRAND-SPECIALTY PALYDIQ NON-PREFERRED-BRAND-SPECIALTY PAMIDRONATE GENERIC-SPECIALTY PAMIDRONATE GENERIC-SPECIALTY PAMIDRONATE GENERIC-SPECIALTY PARAPUATIN GENERIC-SPECIALTY ROUNDED PEGASYS PREFERRED-BRAND-SPECIALTY ROUNDED PEGASYS PREFERRED-BRAND-SPECIALTY ROUNDED PEGASYS PREFERRED-BRAND-SPECIALTY ROUNDED PERMACYRE GORAL-CHEMO Blue Cross Formulary PENACYRE GENERIC-SPECIALTY ROUNDED PENACYRE ROUNDED PENACYRE GENERIC-SPECIALTY ROUNDED PEN			
OXLUNO NON-PREFERRED BRAND-SPECIALTY OZURDEX NON-PREFERRED BRAND-SPECIALTY Blue Cross Formulary OZURDEX NON-PREFERRED BRAND-SPECIALTY Blue Cross Formulary PACLITAKEL GENERIC-SPECIALTY Blue Cross Formulary PACLITAKEL GENERIC-SPECIALTY Blue Cross Formulary PADCEV NON-PREFERRED BRAND-SPECIALTY Blue Cross Formulary PADCEV NON-PREFERRED BRAND-SPECIALTY PADCEV NON-PREFERRED BRAND-SPECIALTY Blue Cross Formulary PALIFORM PALIFORM PALIFORM NON-PREFERRED BRAND-SPECIALTY Blue Cross Formulary PALIFORM PALIFORM NON-PREFERRED BRAND-SPECIALTY PALIFORM PANIDRONATE GENERIC-SPECIALTY PANIDRONATE GENERIC-SPECIALTY Blue Cross Formulary PANIDRONATE GENERIC-SPECIALTY PARAPITATIN GENERIC-SPECIALTY Blue Cross Formulary PARAPITATIN GENERIC-SPECIALTY Blue Cross Formulary PARAPITATIN GENERIC-SPECIALTY Blue Cross Formulary PARAPITATIN GENERIC-SPECIALTY PARAPITATIN GENERIC-SPECIALTY Blue Cross Formulary PARAPITATIN GENERIC-SPECIALTY Blue Cross Formulary PARAPITATIN GENERIC-SPECIALTY Blue Cross Formulary PARAPITATIN GENERIC-SPECIALTY PARAPITATIN GENERIC-SPECIALTY Blue Cross Formulary PARAPITATIN GENERIC-SPECIALTY PARAPITATIN GENERIC-SPECIALTY Blue Cross Formulary PREGASYS PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PEGASYS PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PEGASYS PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PEMAZYRE ORAL-CHEMO Blue Cross Formulary PEMAZYRE ORAL-CHEMO Blue Cross Formulary PEMICILAMIN GENERIC-SPECIALTY Blue Cross Formulary PEMICILAMIN GENERIC-SPECIALTY Blue Cross Formulary PEMICITA PHENYBUTYRA GENERIC-SPECIALTY Blue Cross Formulary PEMICITA PHENYBUTYRA GENERIC-SPECIALTY Blue Cross Formulary PHOTOFRIN NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PHOTOFRIN NON-PREFERRED-			
OZURDEX OZURDEX NON-PREFERRED-BRAND-SPECIALTY PACLITAXEL GENERIC-SPECIALTY PACLITAXEL GENERIC-SPECIALTY PACLITAXEL GENERIC-SPECIALTY PACLITAXEL GENERIC-SPECIALTY PALOCEV NON-PREFERRED-BRAND-SPECIALTY PADCEV NON-PREFERRED-BRAND-SPECIALTY PALORIA NON-PREFERRED-BRAND-SPECIALTY PALORIA NON-PREFERRED-BRAND-SPECIALTY PALIVAZIQ NON-PREFERRED-BRAND-SPECIALTY PALIVAZIQ NON-PREFERRED-BRAND-SPECIALTY PAMIDRONATE GENERIC-SPECIALTY PAMIDRONATE GENERIC-SPECIALTY PAMIDRONATE GENERIC-SPECIALTY PARAPLATIN GENERIC-SPECIALTY PARAPLATIN GENERIC-SPECIALTY PARAPLATIN GENERIC-SPECIALTY PARAPLATIN GENERIC-SPECIALTY PARAPLATIN GENERIC-SPECIALTY PARAPLATIN GENERIC-SPECIALTY PARASABW NON-PREFERRED-BRAND-SPECIALTY PARASABW NON-PREFERED-BRAND-SPECIALTY PEGASYS PREFERED-BRAND-SPECIALTY PEGASYS PREFERED-BRAND-SPECIALTY PERAZYEE ORAL-CHEMO Blue Cross Formulary PERAZYEE ORAL-CHEMO RICHARD-SPECIALTY RICHARD-SP			
OZURDEX NON-PREFERED-BRAND-SPECIALTY PACLITAXEL GENERIC-SPECIALTY Blue Cross Formulary PACLITAXEL GENERIC-SPECIALTY Blue Cross Formulary PADCEV NON-PREFERED-BRAND-SPECIALTY PADCEV NON-PREFERED-BRAND-SPECIALTY PALYNZIQ NON-PREFERED-BRAND-SPECIALTY PALYNZIQ NON-PREFERED-BRAND-SPECIALTY PALYNZIQ NON-PREFERED-BRAND-SPECIALTY PALYNZIQ NON-PREFERED-BRAND-SPECIALTY PAMIDRONATE GENERIC-SPECIALTY PAMIDRONATE GENERIC-SPECIALTY PAMIDRONATE GENERIC-SPECIALTY PARAPIATIN GENERIC-SPECIALTY PARAPIATIN GENERIC-SPECIALTY PARASABIV NON-PREFERED-BRAND-SPECIALTY PARASABIV NON-PREFERED-BRAND-SPECIALTY PARASABIV NON-PREFERED-BRAND-SPECIALTY PEGASYS PREFERED-BRAND-SPECIALTY PEGASYS PREFERED-BRAND-SPECIALTY PEMAZYRE ORAL-CHEMO NON-PREFERED-BRAND-SPECIALTY PEMAZYRE ORAL-CHEMO NON-PREFERED-BRAND-SPECIALTY PENAZYRE ORAL-CHEMO NON-DREFERED-BRAND-SPECIALTY NATIONAL PERFORMED-BRAND-SPECIALTY NATIONAL PERFORMED-BRAND-SPECIALTY NATIONAL PERFORMED-BRAND-SPECIALTY PENAZYRE ORAL-CHEMO NON-PREFERED-BRAND-SPECIALTY NATIONAL PERFORMED-BRAND-SPECIALTY NATIONAL PERFO			
PACLITAXEL GENERIC-SPECIALTY PADCEV NON-PREFERRED-BRAND-SPECIALTY PADCEV NON-PREFERRED-BRAND-SPECIALTY PADCEV NON-PREFERRED-BRAND-SPECIALTY PALORZIA NON-PREFERRED-BRAND-SPECIALTY PALORZIA NON-PREFERRED-BRAND-SPECIALTY PALYNZIQ NON-PREFERRED-BRAND-SPECIALTY PALYNZIQ NON-PREFERRED-BRAND-SPECIALTY PALYNZIQ NON-PREFERRED-BRAND-SPECIALTY PALYNZIQ NON-PREFERRED-BRAND-SPECIALTY PAMIDRONATE GENERIC-SPECIALTY PAMIDRONATE GENERIC-SPECIALTY PAMIDRONATE GENERIC-SPECIALTY PARAPHATIN GENERIC-SPECIALTY PARAPHATIN GENERIC-SPECIALTY ROBER-SPECIALTY PARAPHATIN GENERIC-SPECIALTY ROBER-SPECIALTY PARASABIV NON-PREFERRED-BRAND-SPECIALTY PARASABIV NON-PREFERRED-BRAND-SPECIALTY PARASABIV NON-PREFERRED-BRAND-SPECIALTY PEGASYS PREFERRED-BRAND-SPECIALTY PEGASYS PREFERRED-BRAND-SPECIALTY PEGASYS PREFERRED-BRAND-SPECIALTY PEGASYS PREFERRED-BRAND-SPECIALTY PEGASYS PREFERRED-BRAND-SPECIALTY PEGASYS PREFERRED-BRAND-SPECIALTY PENAZYRE ORAL-CHEMO Blue Cross Formulary PENAZYRE ORAL-CHEMO National Performance Formulary PENAZYRE ORAL-CHEMO ROBINE OF SPECIALTY ROBINE OF SPECIALTY PENETA PREFERRED-BRAND-SPECIALTY ROBINE OF SPECIALTY PENETA PREFERRED-BRAND-SPECIALTY ROBINE OF SPECIALTY ROBINERY PENETA PENETA PREFERRED-BRAND-SPECIALTY ROBINERY PENETA PENETA PREFERRED-BRAND-SPECIALTY ROBINERY PENETA PREFERRED-BRAND-SPECIALTY ROBINERY PENETA ROBINERY PENETA ROBINERY PENETA ROBINERY PENETA ROBINERY R			
PACLITAXEL GEBEIC-SPECIALTY PADCEV NON-PREFERRED-BRAND-SPECIALTY PADCEV NON-PREFERRED-BRAND-SPECIALTY PALORIA NON-PREFERRED-BRAND-SPECIALTY PALORIA NON-PREFERRED-BRAND-SPECIALTY PALIVAZIQ NON-PREFERRED-BRAND-SPECIALTY PALIVAZIQ NON-PREFERRED-BRAND-SPECIALTY PALIVAZIQ NON-PREFERRED-BRAND-SPECIALTY PALIVAZIQ NON-PREFERRED-BRAND-SPECIALTY PALIVAZIQ NON-PREFERRED-BRAND-SPECIALTY PAMIDRONATE GENEIC-SPECIALTY PAMIDRONATE GENEIC-SPECIALTY PAMIDRONATE GENEIC-SPECIALTY PARAPLATIN GENEIC-SPECIALTY PARAPLATIN GENEIC-SPECIALTY PARAPLATIN GENEIC-SPECIALTY PARAPLATIN GENEIC-SPECIALTY PARAPLATIN GENEIC-SPECIALTY PARAPLATIN GENEIC-SPECIALTY PARABABW NON-PREFERRED-BRAND-SPECIALTY PARABABW NON-PREFERRED-BRAND-SPECIALTY PEGASYS PREFERRED-BRAND-SPECIALTY PEGASYS PREFERRED-BRAND-SPECIALTY PEGASYS PREFERRED-BRAND-SPECIALTY PEGASYS PREFERRED-BRAND-SPECIALTY PEGASYS PREFERRED-BRAND-SPECIALTY PENAZYRE ORAL-CHEMO National Performance Formulary PENCILLAMIN GENEIC-SPECIALTY PENCILLAMIN GENEIC-SPECIALTY RATIONAL PREFERRED-BRAND-SPECIALTY RATIONAL PREFERRED-BRAND-SPECIALTY RATIONAL PREFERRED-BRAND-SPECIALTY PHENSED PENCILLAMIN GENEIC-SPECIALTY RATIONAL PREFERRED-BRAND-SPECIALTY RATIO			
PADCEY PADCEY NON-PREFERRED-BRAND-SPECIALTY PADCEY NON-PREFERRED-BRAND-SPECIALTY PALFORZIA NON-PREFERRED-BRAND-SPECIALTY PALYNZIQ NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PALYNZIQ NON-PREFERRED-BRAND-SPECIALTY PALYNZIQ NON-PREFERRED-BRAND-SPECIALTY PAMIDRONATE GENERIC-SPECIALTY PAMIDRONATE GENERIC-SPECIALTY PAMIDRONATE GENERIC-SPECIALTY PAMIDRONATE GENERIC-SPECIALTY PARAPLATIN GENERIC-SPECIALTY PARAPLATIN GENERIC-SPECIALTY PARAPLATIN GENERIC-SPECIALTY PARAPLATIN GENERIC-SPECIALTY PARASABIV NON-PREFERRED-BRAND-SPECIALTY PARASABIV NON-PREFERRED-BRAND-SPECIALTY PARASABIV NON-PREFERRED-BRAND-SPECIALTY PEGASYS PREFERRED-BRAND-SPECIALTY PEGASYS PREFERRED-BRAND-SPECIALTY PEGASYS PREFERRED-BRAND-SPECIALTY PEMAZYRE ORAL-CHEMO SIBUE Cross Formulary PEMAZYRE ORAL-CHEMO Mational Performance Formulary PEMAZYRE ORAL-CHEMO Mational Performance Formulary PENICILLAMIN GENERIC-SPECIALTY PENICILLAMIN GENERIC-SPECIALTY PREFERRED-BRAND-SPECIALTY PHOTOFIRN NON-PREFERRED-BRAND-SPECIALTY BIBLE Cross Formulary PHESGO PREFERRED-BRAND-SPECIALTY BIBLE CROSS Formulary PHOTOFIRN NON-PREFERRED-BRAND-SPECIALTY BIBLE CROSS Formulary PHOTOFIRN NON			
PADCEY NON-PREFERRED-BRAND-SPECIALTY PALYNZIQ NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PALYNZIQ NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PALYNZIQ NON-PREFERRED-BRAND-SPECIALTY PALYNZIQ NON-PREFERRED-BRAND-SPECIALTY PAMIDROMATE GENERIC-SPECIALTY PAMIDROMATE GENERIC-SPECIALTY PAMIDROMATE GENERIC-SPECIALTY PAMIDROMATE GENERIC-SPECIALTY PARAPLATIN GENERIC-SPECIALTY PARAPLATIN GENERIC-SPECIALTY PARAPLATIN GENERIC-SPECIALTY PARASABIV NON-PREFERRED-BRAND-SPECIALTY PARASABIV NON-PREFERRED-BRAND-SPECIALTY PARASABIV NON-PREFERRED-BRAND-SPECIALTY PEGASYS PREFERRED-BRAND-SPECIALTY PEGASYS PREFERRED-BRAND-SPECIALTY PEDAZYRE ORAL-CHEMO Blue Cross Formulary PEMAZYRE ORAL-CHEMO SIBUE CROSS FORMULARY PENICILLAMIN GENERIC-SPECIALTY PENICILLAMIN GENERIC-SPECIALTY PENICILLAMIN GENERIC-SPECIALTY PENICILLAMIN GENERIC-SPECIALTY PERIETA PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PENICILLAMIN GENERIC-SPECIALTY Blue Cross Formulary PENICILLAMIN GENERIC-SPECIALTY PENICILLAMIN GENERIC-SPECIALTY Blue Cross Formulary PENICILLAMIN GENERIC-SPECIALTY PHENYLBUTYRA GENERIC-SPECIALTY Blue Cross Formulary PHOTOPRIN NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PHOTOPRIN NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PHOTOPRIN NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary POMALYST ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary POMALYST ORAL-CHEMO Blue Cross Formulary POMALYST ORAL-CHEMO Blue Cross Formulary POMALYST Blue Cross Formulary POMALYST DON-PREFERRED-BRAND-SP			
PALFORZIA PALYNZIQ NON-PREFERRED-BRAND-SPECIALTY PALYNZIQ NON-PREFERRED-BRAND-SPECIALTY PALYNZIQ NON-PREFERRED-BRAND-SPECIALTY PAMIDRONATE GENERIC-SPECIALTY PAMIDRONATE GENERIC-SPECIALTY PAMIDRONATE GENERIC-SPECIALTY PAMIDRONATE GENERIC-SPECIALTY PAMIDRONATE GENERIC-SPECIALTY PANZYGA NON-PREFERRED-BRAND-SPECIALTY PARAPLATIN GENERIC-SPECIALTY PARAPLATIN GENERIC-SPECIALTY PARAPLATIN GENERIC-SPECIALTY PARAPLATIN GENERIC-SPECIALTY PARASABIV NON-PREFERRED-BRAND-SPECIALTY PARASABIV NON-PREFERRED-BRAND-SPECIALTY PARASABIV NON-PREFERRED-BRAND-SPECIALTY PEGASYS PREFERRED-BRAND-SPECIALTY PEGASYS PREFERRED-BRAND-SPECIALTY PERAZYRE ORAL-CHEMO Blue Cross Formulary PEMAZYRE ORAL-CHEMO Blue Cross Formulary PEMAZYRE ORAL-CHEMO Blue Cross Formulary PENELULAMIN GENERIC-SPECIALTY PENELULAMIN GENERIC-SPECIALTY PENELULAMIN GENERIC-SPECIALTY PENELULAMIN GENERIC-SPECIALTY PERIETA PREFERRED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY PERIETA PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY PHONUBLAMIN GENERIC-SPECIALTY PREFERED-BRAND-SPECIALTY Blue Cross Formulary PREFERED-BRAND-SPECIALTY PROTOFRIN NON-PREFERED-BRAND-SPECIALTY Blue Cross Formulary PREFERED-BRAND-SPECIALTY PROTOFRIN NON-PREFERED-BRAND-SPECIALTY PROTOFRIN NON-PREFERED-BRAND-SPECIALTY Blue Cross Formulary PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY PREFER			
PALYNZIQ NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PALYNZIQ NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PAMIDRONATE GENERIC-SPECIALTY BILLY NATIONAL PROFINE PAMIDRONATE GENERIC-SPECIALTY BILLY BILLY SET OF THE PAMIDRONATE GENERIC-SPECIALTY NATIONAL PROFINATION OF THE PAMIDRONATE GENERIC-SPECIALTY BILLY BI			,
PALYNZIQ NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PAMIDRONATE GENERIC-SPECIALTY Blue Cross Formulary PAMIDRONATE GENERIC-SPECIALTY Blue Cross Formulary PANZYGA NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PARAPLATIN GENERIC-SPECIALTY Blue Cross Formulary PARAPLATIN GENERIC-SPECIALTY Blue Cross Formulary PARAPLATIN GENERIC-SPECIALTY Blue Cross Formulary PARASABIV NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PARASABIV NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PEGASYS PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PEGASYS PREFERRED-BRAND-SPECIALTY National Performance Formulary PEGASYS PREFERRED-BRAND-SPECIALTY National Performance Formulary PEMAZYRE ORAL-CHEMO Blue Cross Formulary PEMAZYRE ORAL-CHEMO National Performance Formulary PEMAZYRE ORAL-CHEMO National Performance Formulary PENICILLAMIN GENERIC-SPECIALTY Blue Cross Formulary PENICILLAMIN GENERIC-SPECIALTY National Performance Formulary PENICILLAMIN GENERIC-SPECIALTY Blue Cross Formulary PENICILLAMIN GENERIC-SPECIALTY Blue Cross Formulary PENICILLAMIN GENERIC-SPECIALTY National Performance Formulary PENICILLAMIN GENERIC-SPECIALTY Blue Cross Formulary PHENYLBUTYRA GENERIC-SPECIALTY Blue Cross Formulary PHENYLBUTYRA GENERIC-SPECIALTY National Performance Formulary PHENYLBUTYRA GENERIC-SPECIALTY Blue Cross Formulary PHENGO PREFERRED-BRAND-SPECIALTY National Performance Formulary PHESGO PREFERRED-BRAND-SPECIALTY National Performance Formulary POULYY NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary POULYY NON-PREFERRE	PALFORZIA		Blue Cross Formulary
PAMIDRONATE GENERIC-SPECIALTY Blue Cross Formulary PAMDRONATE GENERIC-SPECIALTY National Performance Formulary PANATYGA NON-PREFERRED-BRAND-SPECIALTY PARAPLATIN GENERIC-SPECIALTY Blue Cross Formulary PARAPLATIN GENERIC-SPECIALTY Blue Cross Formulary PARAPLATIN GENERIC-SPECIALTY National Performance Formulary PARASABIV NON-PREFERRED-BRAND-SPECIALTY Slue Cross Formulary PARASABIV NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PEGASYS PREFERRED-BRAND-SPECIALTY National Performance Formulary PEGASYS PREFERRED-BRAND-SPECIALTY National Performance Formulary PEMAZYRE ORAL-CHEMO Blue Cross Formulary PEMAZYRE ORAL-CHEMO National Performance Formulary PENICILLAMIN GENERIC-SPECIALTY Blue Cross Formulary PENICILLAMIN GENERIC-SPECIALTY National Performance Formulary PENICILLAMIN GENERIC-SPECIALTY National Performance Formulary PERIETA PREFERRED-BRAND-SPECIALTY National Performance Formulary PERIETA PREFERRED-BRAND-SPECIALTY National Performance Formulary PERIETA PREFERRED-BRAND-SPECIALTY National Performance Formulary PHENYLBUTYRA GENERIC-SPECIALTY National Performance Formulary PHENYLBUTYRA GENERIC-SPECIALTY National Performance Formulary PHESSOO PREFERRED-BRAND-SPECIALTY National Performance Formulary PHESSOO PREFERRED-BRAND-SPECIALTY National Performance Formulary PHESSOO PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PHOTOFRIN NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary POURY NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary POURST ORAL-CHEMO NATIONAL PERFORMAND-SPECIALTY National Performance Formulary POURST ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY National Pe	PALYNZIQ	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
PAMIDRONATE GENERIC-SPECIALTY PARAPLATIN GENERIC-SPECIALTY PARAPLATIN GENERIC-SPECIALTY PARAPLATIN GENERIC-SPECIALTY PARAPLATIN GENERIC-SPECIALTY PARAPLATIN GENERIC-SPECIALTY PARAPLATIN GENERIC-SPECIALTY PARASABIV NON-PREFERED-BRAND-SPECIALTY PARSABIV NON-PREFERED-BRAND-SPECIALTY PARSABIV NON-PREFERED-BRAND-SPECIALTY PEGASYS PREFERED-BRAND-SPECIALTY PEGASYS PREFERED-BRAND-SPECIALTY PEGASYS PREFERED-BRAND-SPECIALTY PEMAZYRE ORAL-CHEMO Blue Cross Formulary PEMAZYRE ORAL-CHEMO PEMAZYRE ORAL-CHEMO RUSTON Blue Cross Formulary PENICILLAMIN GENERIC-SPECIALTY PENICILLAMIN GENERIC-SPECIALTY PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY PHENYLBUTYRA GENERIC-SPECIALTY PHENYLBUTYRA GENERIC-SPECIALTY PHENYLBUTYRA GENERIC-SPECIALTY PHENGO PREFERED-BRAND-SPECIALTY PHESGO PREFERED-BRAND-SPECIALTY PHESGO PREFERED-BRAND-SPECIALTY PHESGO PREFERED-BRAND-SPECIALTY PHESGO PREFERED-BRAND-SPECIALTY PHOTOFRIN NON-PREFERED-BRAND-SPECIALTY	PALYNZIQ	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
PANZYGA NON-PREFERRED-BRAND-SPECIALTY PARAPLATIN GENERIC-SPECIALTY PARAPLATIN GENERIC-SPECIALTY Blue Cross Formulary PARASBIV NON-PREFERRED-BRAND-SPECIALTY PARABIV NON-PREFERRED-BRAND-SPECIALTY PEGASYS PREFERRED-BRAND-SPECIALTY PEGASYS PREFERRED-BRAND-SPECIALTY PEGASYS PREFERRED-BRAND-SPECIALTY PEMAZYRE ORAL-CHEMO Blue Cross Formulary PEMAZYRE ORAL-CHEMO PEMAZYRE ORAL-CHEMO PEMICILLAMIN GENERIC-SPECIALTY PENICILLAMIN GENERIC-SPECIALTY PENICILLAMIN GENERIC-SPECIALTY PERICTA PREFERRED-BRAND-SPECIALTY PENICILLAMIN GENERIC-SPECIALTY PHENYBUTYBA GENERIC-SPECIALTY PHENYBUTYBA GENERIC-SPECIALTY PHENYBUTYBA GENERIC-SPECIALTY PHENYBUTYBA GENERIC-SPECIALTY PHENYBUTYBA GENERIC-SPECIALTY PHENYBUTYBA GENERIC-SPECIALTY PHENGO PREFERRED-BRAND-SPECIALTY PHOTOFRIN NON-PREFERRED-BRAND-SPECIALTY PHOTOFRIN NON-PREFERRED-BRAND-SPECIALTY PHOTOFRIN NON-PREFERRED-BRAND-SPECIALTY PHOTOFRIN NON-PREFERRED-BRAND-SPECIALTY PHOTOFRIN NON-PREFERRED-BRAND-SPECIALTY PHOTOFRIN NON-PREFERRED-BRAND-SPECIALTY POMALYST POLIVY NON-PREFERRED-BRAND-SPECIALTY POMALYST POMALYST ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary POTELIGEO NON-PREFERRED-BRAND-SPECIALTY National Performance Form	PAMIDRONATE	GENERIC-SPECIALTY	Blue Cross Formulary
PANZYGA PARAPLATIN GENERIC-SPECIALTY PARAPLATIN GENERIC-SPECIALTY PARAPLATIN GENERIC-SPECIALTY PARAPLATIN GENERIC-SPECIALTY PARABIV NON-PREFERRED-BRAND-SPECIALTY PARASBIV NON-PREFERRED-BRAND-SPECIALTY PEGASYS PREFERRED-BRAND-SPECIALTY PEGASYS PREFERRED-BRAND-SPECIALTY PEGASYS PREFERRED-BRAND-SPECIALTY PEGASYS PREFERRED-BRAND-SPECIALTY PEMAZYRE ORAL-CHEMO Blue Cross Formulary PEMAZYRE ORAL-CHEMO PEMICILLAMIN GENERIC-SPECIALTY PENICILLAMIN GENERIC-SPECIALTY PERICILAMIN GENERIC-SPECIALTY PERICILAMIN GENERIC-SPECIALTY PERICILAMIN PERICILAMIN GENERIC-SPECIALTY PERICILAMIN PERICILAMIN GENERIC-SPECIALTY PERICILAMIN PERICILAMIN GENERIC-SPECIALTY PERICILAMIN PERICILAMIN GENERIC-SPECIALTY PHENYBUTYRA GENERIC-SPECIALTY PHOTOPRIN NON-PREFERRED-BRAND-SPECIALTY POULYY NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary POULYY NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary POULYS PREGONT PREGONT PREGONT PREFORMED-B	PAMIDRONATE	GENERIC-SPECIALTY	National Performance Formulary
PARAPLATIN GENERIC-SPECIALTY Blue Cross Formulary PARAPLATIN GENERIC-SPECIALTY National Performance Formulary PARSABIV NON-PREFERRED-BRAND-SPECIALTY PARSABIV NON-PREFERRED-BRAND-SPECIALTY PASSABIV NON-PREFERRED-BRAND-SPECIALTY PEGASYS PREFERRED-BRAND-SPECIALTY PEGASYS PREFERRED-BRAND-SPECIALTY PEGASYS PREFERRED-BRAND-SPECIALTY PEGASYS PREFERRED-BRAND-SPECIALTY PEMAZYRE ORAL-CHEMO Blue Cross Formulary PEMAZYRE ORAL-CHEMO National Performance Formulary PEMAZYRE ORAL-CHEMO National Performance Formulary PENICILLAMIN GENERIC-SPECIALTY Blue Cross Formulary PENICILLAMIN GENERIC-SPECIALTY National Performance Formulary PERICTA PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PERICTA PREFERRED-BRAND-SPECIALTY National Performance Formulary PHENYIBUTYRA GENERIC-SPECIALTY Blue Cross Formulary PHENYIBUTYRA GENERIC-SPECIALTY National Performance Formulary PHENYIBUTYRA GENERIC-SPECIALTY National Performance Formulary PHESGO PREFERRED-BRAND-SPECIALTY National Performance Formulary PHESGO PREFERRED-BRAND-SPECIALTY National Performance Formulary PHOTOFRIN NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PHOTOFRIN NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PHOTOFRIN NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PICRAY ORAL-CHEMO Blue Cross Formulary PICRAY ORAL-CHEMO Blue Cross Formulary PICRAY ORAL-CHEMO Blue Cross Formulary POLIVY NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary POLIVY NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary POLIVY NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PORTRAZZA NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PORTRAZZA NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PREGNYL GENERIC-SPECIALTY National Performance Formulary PREGNYL GENERIC	PANZYGA	NON-PREFERRED-BRAND-SPECIALTY	
PARAPLATIN GENERIC-SPECIALTY PARSABIV NON-PREFERRED-BRAND-SPECIALTY PARSABIV NON-PREFERRED-BRAND-SPECIALTY PEGASYS PEFERRED-BRAND-SPECIALTY PEGASYS PREFERRED-BRAND-SPECIALTY PEGASYS PREFERRED-BRAND-SPECIALTY PEGASYS PREFERRED-BRAND-SPECIALTY PEMAZYRE ORAL-CHEMO Blue Cross Formulary PEMAZYRE ORAL-CHEMO Blue Cross Formulary PEMAZYRE ORAL-CHEMO PENICILLAMIN GENERIC-SPECIALTY PENICILLAMIN GENERIC-SPECIALTY PENICILLAMIN GENERIC-SPECIALTY PERICITA PREFERRED-BRAND-SPECIALTY PERICITA PREFERRED-BRAND-SPECIALTY PHENYLBUTYRA GENERIC-SPECIALTY PHENYLBUTYRA GENERIC-SPECIALTY PHENYLBUTYRA GENERIC-SPECIALTY PHESO PREFERRED-BRAND-SPECIALTY PHESO PREFERRED-BRAND-SPECIALTY PHESO PREFERRED-BRAND-SPECIALTY PHOTORRIN NON-PREFERRED-BRAND-SPECIALTY PHOTORRIN PHOTORRIN NON-PREFERRED-BRAND-SPECIALTY PHOTORRIN PHOTORRIN NON-PREFERRED-BRAND-SPECIALTY PHOTORRIN PHOTORRIN PHOTORRIN PHOTORRIN PHOTORRIN PHOTORRIN PHOTORRIN PHOTORRIN PHOTORRIN NON-PREFERRED-BRAND-SPECIALTY PHOTORRIN			
PARSABIV NON-PREFERRED-BRAND-SPECIALTY PARSABIV NON-PREFERRED-BRAND-SPECIALTY PEGASYS PREFERRED-BRAND-SPECIALTY PEGASYS PREFERRED-BRAND-SPECIALTY PEGASYS PREFERRED-BRAND-SPECIALTY PEGASYS PREFERRED-BRAND-SPECIALTY PEGASYS PREFERRED-BRAND-SPECIALTY PEMAZYRE ORAL-CHEMO National Performance Formulary PEMAZYRE ORAL-CHEMO National Performance Formulary PENICILLAMIN GENERIC-SPECIALTY PENICILLAMIN GENERIC-SPECIALTY PERICITA PREFERRED-BRAND-SPECIALTY PERICITA PREFERRED-BRAND-SPECIALTY PERICITA PREFERRED-BRAND-SPECIALTY PERICITA PREFERRED-BRAND-SPECIALTY PERICITA PREFERRED-BRAND-SPECIALTY PHENYLBUTYRA GENERIC-SPECIALTY PHENYLBUTYRA GENERIC-SPECIALTY PHESGO PREFERRED-BRAND-SPECIALTY PHESGO PREFERRED-BRAND-SPECIALTY PHESGO PREFERRED-BRAND-SPECIALTY PHOTOFRIN NON-PREFERRED-BRAND-SPECIALTY POLIVY NON-PREFERRED-BRAND-SPECIALTY POLIVY NON-PREFERRED-BRAND-SPECIALTY POLIVY NON-PREFERRED-BRAND-SPECIALTY POLIVY NON-PREFERRED-BRAND-SPECIALTY PORTIAZZA NON-PREFERRED-BRAND-SPECIALTY NATIONAL PERFORMANCE FORMULARY PREGNYL GENERIC-SPECIALTY Blue Cross Formulary PRECVMIS NON-PREFERRED-BRAND-SPECIALTY NATIONAL PERFORMANCE FORMULARY PRECVMIS NON-PREFERRED-BRAND-SPECIALTY NATIONAL PERFORMANCE FORMUL			
PARSABIV NON-PREFERRED-BRAND-SPECIALTY PEGASYS PREFERRED-BRAND-SPECIALTY PEGASYS PREFERRED-BRAND-SPECIALTY PEGASYS PREFERRED-BRAND-SPECIALTY PEMAZYRE ORAL-CHEMO Blue Cross Formulary PEMAZYRE ORAL-CHEMO National Performance Formulary PENICILLAMIN GENERIC-SPECIALTY PENICILLAMIN GENERIC-SPECIALTY PENICILLAMIN GENERIC-SPECIALTY PERICILLAMIN PERFERRED-BRAND-SPECIALTY PERICILLAMIN GENERIC-SPECIALTY PERICILLAMIN PERFERRED-BRAND-SPECIALTY PERICILLAMIN PERFERRED-BRAND-SPECIALTY PHENYLBUTYRA GENERIC-SPECIALTY PHESGO PREFERRED-BRAND-SPECIALTY PHESGO PREFERRED-BRAND-SPECIALTY PHESGO PREFERRED-BRAND-SPECIALTY PHESGO PREFERRED-BRAND-SPECIALTY PHOTOFRIN NON-PREFERRED-BRAND-SPECIALTY PHOTOFRIN NON-PREFERRED-BRAND-SPECIALTY PIQRAY ORAL-CHEMO RAL-CHEMO National Performance Formulary POLIVY NON-PREFERRED-BRAND-SPECIALTY POLIVY NON-PREFERRED-BRAND-SPECIALTY POLIVY NON-PREFERRED-BRAND-SPECIALTY POUNTY POMALYST ORAL-CHEMO National Performance Formulary POMALYST ORAL-CHEMO NATIONAL PERFORMANCE FORMULARY PORTRAZZA NON-PREFERRED-BRAND-SPECIALTY PREFORMAL PERFORMAL SPECIALTY NATIONAL PERFORMANCE FORMULARY PREFORML GENERIC-SPECIALTY NATIONAL PERFORMANCE FORMULARY PREFORML PROFORMIT PREFORMED-BRAND-SPECIALTY NATIONAL PERFORMANCE FORMULARY PROCRI			
PEGASYS PREFERRED-BRAND-SPECIALTY National Performance Formulary PEGASYS PREFERRED-BRAND-SPECIALTY National Performance Formulary PEMAZYRE ORAL-CHEMO Blue Cross Formulary PEMAZYRE ORAL-CHEMO Blue Cross Formulary PEMAZYRE ORAL-CHEMO National Performance Formulary PEMAZYRE ORAL-CHEMO National Performance Formulary PEMICILLAMIN GENERIC-SPECIALTY Blue Cross Formulary PEMICILLAMIN GENERIC-SPECIALTY National Performance Formulary PEMICILLAMIN GENERIC-SPECIALTY National Performance Formulary PERJETA PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PERJETA PREFERRED-BRAND-SPECIALTY National Performance Formulary PHENYLBUTYRA GENERIC-SPECIALTY National Performance Formulary PHENYLBUTYRA GENERIC-SPECIALTY National Performance Formulary PHESGO PREFERRED-BRAND-SPECIALTY National Performance Formulary PHESGO PREFERRED-BRAND-SPECIALTY National Performance Formulary PHOTOFRIN NON-PREFERRED-BRAND-SPECIALTY NATIONAL PERFORMANCE PROMISERY ORAL-CHEMO Blue Cross Formulary PHOTOFRIN NON-PREFERRED-BRAND-SPECIALTY NATIONAL PERFORMANCE PROMISERY PHOLITY NON-PREFERRED-BRAND-SPECIALTY NATIONAL PERFORMANCE PROMISERY PHOLITY NON-PREFERRED-BRAND-SPECIALTY NATIONAL PERFORMANCE PORMULARY POLITY NON-PREFERRED-BRAND-SPECIALTY NATIONAL PERFORMANCE PORMULARY POLITY NON-PREFERRED-BRAND-SPECIALTY NATIONAL PERFORMANCE PORMULARY POLITY NON-PREFERRED-BRAND-SPECIALTY NATIONAL PERFORMANCE PORMULARY PORTAZZA NON-PREFERRED-BRAND-SPECIALTY NATIONAL PERFORMANCE PORMULARY PREGNYL GENERIC-SPECIALTY NATIONAL PERFORMANCE PORMULARY PREGNYL GENERIC-SPECIALTY NATIONAL PERFORMANCE PORMULARY PREGNYL GENERIC-SPECIALTY NATIONAL PERFORMANCE PORMULARY PREV			
PEGASYS PREFERRED-BRAND-SPECIALTY PEMAZYRE ORAL-CHEMO PEMAZYRE ORAL-CHEMO National Performance Formulary PEMAZYRE ORAL-CHEMO PENICILLAMIN GENERIC-SPECIALTY Blue Cross Formulary PENICILLAMIN GENERIC-SPECIALTY PENICILLAMIN GENERIC-SPECIALTY PERITA PREFERED-BRAND-SPECIALTY PERITA PREFERED-BRAND-SPECIALTY PERITA PREFERED-BRAND-SPECIALTY PHENYLBUTYRA GENERIC-SPECIALTY PHENYLBUTYRA GENERIC-SPECIALTY PHENYLBUTYRA GENERIC-SPECIALTY PHESOO PREFERRED-BRAND-SPECIALTY PHESOO PREFERRED-BRAND-SPECIALTY PHOTOFRIN NON-PREFERRED-BRAND-SPECIALTY PHOTOFRIN NON-PREFERRED-BRAND-SPECIALTY PHOTOFRIN NON-PREFERRED-BRAND-SPECIALTY PHOTOFRIN NON-PREFERRED-BRAND-SPECIALTY PIQRAY ORAL-CHEMO Blue Cross Formulary PIQRAY PICARY PICARY POLIVY NON-PREFERRED-BRAND-SPECIALTY POLIVY NON-PREFERRED-BRAND-SPECIALTY POLIVY NON-PREFERRED-BRAND-SPECIALTY POLIVY NON-PREFERRED-BRAND-SPECIALTY POMALYST ORAL-CHEMO Rational Performance Formulary PORTRAZZA NON-PREFERRED-BRAND-SPECIALTY Rational Performance Formulary PREGNYL GENERIC-SPECIALTY Rational Performance Formulary PRECYMIS NON-PREFERRED-BRAND-SPECIALTY Rational Performance Formulary PRECYMIS NON-PREFERRED-BRAND-SPECIALTY Rational Performance Formulary PRECYMIS NON-PREFERRED-BRAND-SPECIALTY Rational Performance Fo			
PEMAZYRE ORAL-CHEMO National Performance Formulary PENICILLAMIN GENERIC-SPECIALTY Blue Cross Formulary PENICILLAMIN GENERIC-SPECIALTY National Performance Formulary PENICILLAMIN GENERIC-SPECIALTY National Performance Formulary PENETA PREFERRED-BRAND-SPECIALTY National Performance Formulary PENETA PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PHENYLBUTYRA GENERIC-SPECIALTY National Performance Formulary PHENYLBUTYRA GENERIC-SPECIALTY National Performance Formulary PHESGO PREFERRED-BRAND-SPECIALTY National Performance Formulary PHESGO PREFERRED-BRAND-SPECIALTY National Performance Formulary PHOTOFRIN NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PHOTOFRIN NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PHOTORIN NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PIQRAY ORAL-CHEMO Blue Cross Formulary PIQRAY ORAL-CHEMO National Performance Formulary PICRAY ORAL-CHEMO National Performance Formulary POLILYY NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary POLILYY NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary POMALYST ORAL-CHEMO National Performance Formulary PORTRAZZA NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PORTRAZZA NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PORTRAZZA NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary POTELIGEO NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary POTELIGEO NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PREGNYL GENERIC-SPECIALTY National Performance Formulary PREGNIT PREFERRED-BRAND-SPECIALTY National P			,
PEMAZYRE PENICILLAMIN GENERIC-SPECIALTY Blue Cross Formulary PENICILLAMIN GENERIC-SPECIALTY PENICILLAMIN GENERIC-SPECIALTY PENICILLAMIN GENERIC-SPECIALTY PERIETA PREFERRED-BRAND-SPECIALTY PERIETA PREFERRED-BRAND-SPECIALTY PENIETA PREFERRED-BRAND-SPECIALTY PHENYLBUTYRA GENERIC-SPECIALTY PHENYLBUTYRA GENERIC-SPECIALTY PHENYLBUTYRA GENERIC-SPECIALTY PHESGO PREFERRED-BRAND-SPECIALTY PHESGO PREFERRED-BRAND-SPECIALTY PHOTOFRIN NON-PREFERRED-BRAND-SPECIALTY PHOTOFRIN NON-PREFERRED-BRAND-SPECIALTY PHOTOFRIN NON-PREFERRED-BRAND-SPECIALTY PHOTOFRIN NON-PREFERRED-BRAND-SPECIALTY PICRAY ORAL-CHEMO Blue Cross Formulary PICRAY PICRAY ORAL-CHEMO RIGHT PROMISE PROMISE PROMISE POLIVY NON-PREFERRED-BRAND-SPECIALTY POLIVY NON-PREFERRED-BRAND-SPECIALTY POLIVY NON-PREFERRED-BRAND-SPECIALTY POLIVY NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary POMALYST ORAL-CHEMO National Performance Formulary POMALYST ORAL-CHEMO National Performance Formulary POMALYST ORAL-CHEMO RIGHT PROMISE PORTAZZA NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PORTAZZA NON-PREFERRED-BRAND-SPECIALTY PORTAZZA NON-PREFERRED-BRAND-SPECIALTY PORTRAZZA NON-PREFERRED-BRAND-SPECIALTY POTELIGEO NON-PREFERRED-BRAND-SPECIALTY POTELIGEO NON-PREFERRED-BRAND-SPECIALTY POTELIGEO NON-PREFERRED-BRAND-SPECIALTY POTELIGEO NON-PREFERRED-BRAND-SPECIALTY PREGNYL GENERIC-SPECIALTY PREGNYL GENERIC-SPECIALTY RIGHT PREFORMANE PREVYMIS NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PREGNYL GENERIC-SPECIALTY RIGHT PREFORMANE PROCRIT PREFERRED-BRAND-SPECIALTY National Performance Formulary PRIVIGEN NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PREGNYL GENERIC-SPECIALTY RIGHT RIG			
PENICILLAMIN GENERIC-SPECIALTY PENICILLAMIN GENERIC-SPECIALTY PERITA PEFERED PERAND PEFERED PEFERED PERAND PEFERED PEFERED PEFERED PEFERED PERAND PEFERED PEFERED PEFERED PERAND PEFERED PEFERED PEFERED PERAND PEFERED PEFERED PEFERED PERAND PEFERED PEFERED PERAND PEFERED PERAND PEFERED PEFERED PERAND PEFERED PER			
PENICILLAMIN GENERIC-SPECIALTY National Performance Formulary PERIETA PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PERIETA PREFERED-BRAND-SPECIALTY National Performance Formulary PHENYLBUTYRA GENERIC-SPECIALTY Blue Cross Formulary PHENYLBUTYRA GENERIC-SPECIALTY National Performance Formulary PHESGO PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PHESGO PREFERED-BRAND-SPECIALTY National Performance Formulary PHOTOFRIN NON-PREFERED-BRAND-SPECIALTY Blue Cross Formulary PHOTOFRIN NON-PREFERED-BRAND-SPECIALTY National Performance Formulary PIQRAY ORAL-CHEMO Blue Cross Formulary PIQRAY ORAL-CHEMO National Performance Formulary PIEGRIDY NON-PREFERED-BRAND-SPECIALTY Blue Cross Formulary PIEGRIDY NON-PREFERED-BRAND-SPECIALTY Blue Cross Formulary POLIVY NON-PREFERED-BRAND-SPECIALTY Blue Cross Formulary POMALYST ORAL-CHEMO National Performance Formulary POMALYST ORAL-CHEMO Blue Cross Formulary POMALYST ORAL-CHEMO Blue Cross Formulary POMALYST ORAL-CHEMO Blue Cross Formulary PORTRAZZA NON-PREFERED-BRAND-SPECIALTY National Performance Formulary PORTRAZZA NON-PREFERED-BRAND-SPECIALTY Blue Cross Formulary PORTRAZZA NON-PREFERED-BRAND-SPECIALTY Blue Cross Formulary POTELIGEO NON-PREFERED-BRAND-SPECIALTY Blue Cross Formulary POTELIGEO NON-PREFERED-BRAND-SPECIALTY National Performance Formulary POTELIGEO NON-PREFERED-BRAND-SPECIALTY Blue Cross Formulary PREGNYL GENERIC-SPECIALTY National Performance Formulary PREFORMED NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PROCRIT NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PROCRIT PREFERRED-BRAND-SPECIALTY N			
PERJETA PREFERED-BRAND-SPECIALTY Blue Cross Formulary PERPIETA PREFERRED-BRAND-SPECIALTY National Performance Formulary PHENYLBUTYRA GENERIC-SPECIALTY Blue Cross Formulary PHENYLBUTYRA GENERIC-SPECIALTY National Performance Formulary PHESGO PREFERED-BRAND-SPECIALTY Blue Cross Formulary PHESGO PREFERED-BRAND-SPECIALTY National Performance Formulary PHOTOFRIN NON-PREFERED-BRAND-SPECIALTY Blue Cross Formulary PHOTOFRIN NON-PREFERED-BRAND-SPECIALTY National Performance Formulary PHOTOFRIN NON-PREFERED-BRAND-SPECIALTY National Performance Formulary PIQRAY ORAL-CHEMO Blue Cross Formulary PIQRAY ORAL-CHEMO National Performance Formulary PIQRAY ORAL-CHEMO National Performance Formulary POLIVY NON-PREFERED-BRAND-SPECIALTY Blue Cross Formulary POLIVY NON-PREFERED-BRAND-SPECIALTY Blue Cross Formulary POLIVY NON-PREFERED-BRAND-SPECIALTY National Performance Formulary POMALYST ORAL-CHEMO Blue Cross Formulary POMALYST ORAL-CHEMO National Performance Formulary PORTRAZZA NON-PREFERED-BRAND-SPECIALTY Blue Cross Formulary PORTRAZZA NON-PREFERED-BRAND-SPECIALTY Blue Cross Formulary PORTRAZZA NON-PREFERED-BRAND-SPECIALTY National Performance Formulary POTELIGEO NON-PREFERED-BRAND-SPECIALTY National Performance Formulary POTELIGEO NON-PREFERED-BRAND-SPECIALTY National Performance Formulary PREGNYL GENERIC-SPECIALTY Blue Cross Formulary PREGNYL GENERIC-SPECIALTY National Performance Formulary PREGNYL GENERIC-SPECIALTY Non-PREFERED-BRAND-SPECIALTY Non-PREFERED-BRAND-SPECIALT			
PERJETA PREFERED-BRAND-SPECIALTY Blue Cross Formulary PHENYLBUTYRA GENERIC-SPECIALTY Blue Cross Formulary PHESSO PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PHESGO PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PHOTOFRIN NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PHOTOFRIN NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PHOTOFRIN NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PIQRAY ORAL-CHEMO Blue Cross Formulary PIQRAY ORAL-CHEMO National Performance Formulary PLEGRIDY NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary POLIVY NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary POULY NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary POMALYST ORAL-CHEMO Blue Cross Formulary POMALYST ORAL-CHEMO Blue Cross Formulary POMALYST ORAL-CHEMO Blue Cross Formulary PORTRAZZA NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PORTRAZZA NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary POTELIGEO NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary POTELIGEO NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary POTELIGEO NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PREGNYL GENERIC-SPECIALTY Blue Cross Formulary PREGNYL GENERIC-SPECIALTY National Performance Formulary PREGNYL GENERIC-SPECIALTY Blue Cross Formulary PREGNYL GENERIC-SPECIALTY National Performance Formulary PREVYMIS NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PREVYMIS NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PREVYMIS NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PRIVIGEN NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PRIVIGEN NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PRIVIGEN NON-PREFERRED-BRAND-SPECIALTY Selue Cross Formulary PRIVIGEN NON-PREFERRED-BRAND-SPECIALTY Selue Cross Formulary PROCRIT PREFERRED-BRAND-SPECIALTY Selue Cross Formulary PROCRIT PREFERRED-BRAND-SPECIALTY Selue Cross Formulary PROCRIT PREFERRED-BRAND-SPECIALTY Selue Cross Formulary PROCYSBI NON-PREFERRED-BRAND-SPECIALTY Selue Cross Formulary			
PHENYLBUTYRA GENERIC-SPECIALTY PHENYLBUTYRA GENERIC-SPECIALTY PHESGO PREFERRED-BRAND-SPECIALTY PHESGO PREFERRED-BRAND-SPECIALTY PHESGO PREFERRED-BRAND-SPECIALTY PHOTOFRIN NON-PREFERRED-BRAND-SPECIALTY PHOTOFRIN NON-PREFERRED-BRAND-SPECIALTY PHOTOFRIN NON-PREFERRED-BRAND-SPECIALTY PIQRAY PIQRAY ORAL-CHEMO PIQRAY ORAL-CHEMO National Performance Formulary PIQRAY ORAL-CHEMO National Performance Formulary PIQRAY POLIVY NON-PREFERRED-BRAND-SPECIALTY POLIVY NON-PREFERRED-BRAND-SPECIALTY POLIVY NON-PREFERRED-BRAND-SPECIALTY POMALYST ORAL-CHEMO Blue Cross Formulary POMALYST ORAL-CHEMO Blue Cross Formulary POMALYST ORAL-CHEMO Blue Cross Formulary PORTRAZZA NON-PREFERRED-BRAND-SPECIALTY PORTRAZZA NON-PREFERRED-BRAND-SPECIALTY PORTRAZZA NON-PREFERRED-BRAND-SPECIALTY POTELIGEO NON-PREFERRED-BRAND-SPECIALTY POTELIGEO NON-PREFERRED-BRAND-SPECIALTY POTELIGEO NON-PREFERRED-BRAND-SPECIALTY PREGNYL GENERIC-SPECIALTY Blue Cross Formulary PREGNYL GENERIC-SPECIALTY Blue Cross Formulary PREGNYL GENERIC-SPECIALTY Blue Cross Formulary PREGNYL GENERIC-SPECIALTY Rational Performance Formulary PREGNYL GENERIC-SPECIALTY Rational Performance Formulary PREVYMIS NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PROCRIT NON-PREFERRED-BRAND-SPECIALTY PROCRIT NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCRIT PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCRIT PREFERRED-BRAND-SPECIALTY Blue Cross Formulary			
PHENYLBUTYRA GENERIC-SPECIALTY PHESGO PREFERRED-BRAND-SPECIALTY PHESGO PREFERRED-BRAND-SPECIALTY PHOTOFRIN NON-PREFERRED-BRAND-SPECIALTY PHOTOFRIN NON-PREFERRED-BRAND-SPECIALTY PHOTOFRIN NON-PREFERRED-BRAND-SPECIALTY PHOTOFRIN NON-PREFERRED-BRAND-SPECIALTY PIQRAY ORAL-CHEMO Blue Cross Formulary PIQRAY ORAL-CHEMO National Performance Formulary PIQRAY ORAL-CHEMO National Performance Formulary PIQRAY NON-PREFERRED-BRAND-SPECIALTY POLIVY NON-PREFERRED-BRAND-SPECIALTY POLIVY NON-PREFERRED-BRAND-SPECIALTY POLIVY NON-PREFERRED-BRAND-SPECIALTY POMALYST ORAL-CHEMO National Performance Formulary POMALYST ORAL-CHEMO National Performance Formulary PORTRAZZA NON-PREFERRED-BRAND-SPECIALTY PORTRAZZA NON-PREFERRED-BRAND-SPECIALTY PORTRAZZA NON-PREFERRED-BRAND-SPECIALTY POTELIGEO NON-PREFERRED-BRAND-SPECIALTY POTELIGEO NON-PREFERRED-BRAND-SPECIALTY PREGNYL GENERIC-SPECIALTY Blue Cross Formulary PREGNYL GENERIC-SPECIALTY PREGNYL GENERIC-SPECIALTY PREGNYL GENERIC-SPECIALTY PREGNYL GENERIC-SPECIALTY PREGNYL GENERIC-SPECIALTY PREGNYL GENERIC-SPECIALTY PREGNYL National Performance Formulary PREVYMIS NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PROCRIT NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PROCRIT NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PROCRIT NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCRIT NON-PREFERRED-BRAND-SPECIALTY PROCRIT NON-PREFERRED-BRAND-SPECIALTY PROCRIT NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCRIT PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCRIT PROCRIT PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROC			
PHESGO PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PHESGO PREFERRED-BRAND-SPECIALTY National Performance Formulary PHOTOFRIN NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PHOTOFRIN NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PICRAY ORAL-CHEMO Blue Cross Formulary PICRAY ORAL-CHEMO National Performance Formulary PICRAY ORAL-CHEMO National Performance Formulary PLEGRIDY NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary POLIVY NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary POLIVY NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary POMALYST ORAL-CHEMO Blue Cross Formulary POMALYST ORAL-CHEMO National Performance Formulary PORTRAZZA NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PORTRAZZA NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary POTELIGEO NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary POTELIGEO NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PREGNYL GENERIC-SPECIALTY National Performance Formulary PREVYMIS NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PROCRIT NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCRIT NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCRIT NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCRIT PREFERRED-BRAND-SPECIALTY B			
PHESGO PREFERRED-BRAND-SPECIALTY National Performance Formulary PHOTOFRIN NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PHOTOFRIN NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PIQRAY ORAL-CHEMO Blue Cross Formulary PIQRAY ORAL-CHEMO National Performance Formulary PIQRAY ORAL-CHEMO National Performance Formulary PIQRAY ORAL-CHEMO National Performance Formulary POLIVY NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary POLIVY NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary POLIVY NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary POMALYST ORAL-CHEMO Blue Cross Formulary POMALYST ORAL-CHEMO National Performance Formulary PORTRAZZA NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PORTRAZZA NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary POTELIGEO NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary POTELIGEO NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PREGNYL GENERIC-SPECIALTY Blue Cross Formulary PREGNYL GENERIC-SPECIALTY National Performance Formulary PREGNYL GENERIC-SPECIALTY National Performance Formulary PREVYMIS NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PREVYMIS NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PRIVIGEN NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PRIVIGEN NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PRIVIGEN NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCRIT NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCRIT PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCRIT PREFERRED-BRAND-SPECIALTY Blue Cross Formulary Blue Cross	PHENYLBUTYRA	GENERIC-SPECIALTY	National Performance Formulary
PHOTOFRIN NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PHOTOFRIN NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PIQRAY ORAL-CHEMO Blue Cross Formulary PIQRAY ORAL-CHEMO National Performance Formulary PLEGRIDY NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary POLINY NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary POLINY NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary POMALYST ORAL-CHEMO Blue Cross Formulary POMALYST ORAL-CHEMO National Performance Formulary PORTRAZZA NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PORTRAZZA NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary POTELIGEO NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary POTELIGEO NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PREGNYL GENERIC-SPECIALTY National Performance Formulary PREGNYL GENERIC-SPECIALTY Blue Cross Formulary PREGNYL GENERIC-SPECIALTY National Performance Formulary PREVYMIS NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PREVYMIS NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PREVYMIS NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PRIVIGEN NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PRIVIGEN NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCRIT NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCRIT PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCRIT PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCRIT PREFERRED-BRAND-SPECIALTY Blue Cross Formulary	PHESGO	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
PHOTOFRIN NON-PREFERRED-BRAND-SPECIALTY PIQRAY ORAL-CHEMO Blue Cross Formulary PIQRAY ORAL-CHEMO National Performance Formulary PIQRAY ORAL-CHEMO National Performance Formulary PLEGRIDY NON-PREFERRED-BRAND-SPECIALTY POLIVY NON-PREFERRED-BRAND-SPECIALTY POLIVY NON-PREFERRED-BRAND-SPECIALTY POMALYST ORAL-CHEMO National Performance Formulary POMALYST ORAL-CHEMO National Performance Formulary PORTRAZZA NON-PREFERRED-BRAND-SPECIALTY PORTRAZZA NON-PREFERRED-BRAND-SPECIALTY POTELIGEO NON-PREFERRED-BRAND-SPECIALTY POTELIGEO NON-PREFERRED-BRAND-SPECIALTY PREGNYL GENERIC-SPECIALTY Blue Cross Formulary PREGNYL Blue Cross Formulary PREVYMIS NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PREVYMIS NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PRIVIGEN NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PRIVIGEN NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PROCRIT NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCRIT PREFERRED-BRAND-SPECIALTY Blue Cross Formulary Blue Cross Formulary PROCRIT PREFERRED-BRAND-SPECIALTY Blue Cross Formulary Blue Cross Formul	PHESGO	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
PIQRAY ORAL-CHEMO Blue Cross Formulary PIQRAY ORAL-CHEMO National Performance Formulary PLEGRIDY NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary POLIVY NON-PREFERRED-BRAND-SPECIALTY POLIVY NON-PREFERRED-BRAND-SPECIALTY POMALYST ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO National Performance Formulary POMALYST ORAL-CHEMO National Performance Formulary PORTRAZZA NON-PREFERRED-BRAND-SPECIALTY PORTRAZZA NON-PREFERRED-BRAND-SPECIALTY POTELIGEO NON-PREFERRED-BRAND-SPECIALTY POTELIGEO NON-PREFERRED-BRAND-SPECIALTY POTELIGEO NON-PREFERRED-BRAND-SPECIALTY PREGNYL GENERIC-SPECIALTY Blue Cross Formulary PREGNYL GENERIC-SPECIALTY Blue Cross Formulary PREGNYL GENERIC-SPECIALTY Blue Cross Formulary PREVYMIS NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PREVYMIS NON-PREFERRED-BRAND-SPECIALTY PREVYMIS NON-PREFERRED-BRAND-SPECIALTY PRIVIGEN NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PRIVIGEN NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PRIVIGEN NON-PREFERRED-BRAND-SPECIALTY PRIVIGEN NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PROCRIT NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PROCRIT PREFERRED-BRAND-SPECIALTY PROCRIT NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCRIT PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCRISE	PHOTOFRIN	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
PIQRAY ORAL-CHEMO National Performance Formulary PLEGRIDY NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary POLIVY NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary POLIVY NON-PREFERRED-BRAND-SPECIALTY POMALYST ORAL-CHEMO ORAL-CHEMO National Performance Formulary POMALYST ORAL-CHEMO National Performance Formulary PORTRAZZA NON-PREFERRED-BRAND-SPECIALTY PORTRAZZA NON-PREFERRED-BRAND-SPECIALTY POTELIGEO NON-PREFERRED-BRAND-SPECIALTY POTELIGEO NON-PREFERRED-BRAND-SPECIALTY POTELIGEO NON-PREFERRED-BRAND-SPECIALTY PREGNYL GENERIC-SPECIALTY PREGNYL GENERIC-SPECIALTY PREVYMIS NON-PREFERRED-BRAND-SPECIALTY PREVYMIS NON-PREFERRED-BRAND-SPECIALTY PRIVIGEN NON-PREFERRED-BRAND-SPECIALTY PRIVIGEN NON-PREFERRED-BRAND-SPECIALTY PRIVIGEN NON-PREFERRED-BRAND-SPECIALTY PRIVIGEN NON-PREFERRED-BRAND-SPECIALTY PRIVIGEN NON-PREFERRED-BRAND-SPECIALTY PROCRIT NON-PREFERRED-BRAND-SPECIALTY PROCRIT PREFERRED-BRAND-SPECIALTY PROCRIT PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCRIS Blue C	PHOTOFRIN	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
PLEGRIDY NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary POLIVY NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary POLIVY NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary POMALYST ORAL-CHEMO Blue Cross Formulary POMALYST ORAL-CHEMO National Performance Formulary PORTRAZZA NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PORTRAZZA NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary POTELIGEO NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary POTELIGEO NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PREGNYL GENERIC-SPECIALTY Blue Cross Formulary PREGNYL GENERIC-SPECIALTY National Performance Formulary PREVYMIS NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PREVYMIS NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PRIVIGEN NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PRIVIGEN NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PRIVIGEN NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCRIT NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PROCRIT PREFERRED-BRAND-SPECIALTY National Performance Formulary PROCRIT PREFERRED-BRAND-SPECIALTY National Performance Formulary PROCRIT PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCRIT PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCRIT PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCRIS PROCRIS Blue Cross Formulary PROCRIS PROCRIS Blue Cross Formulary	PIQRAY	ORAL-CHEMO	Blue Cross Formulary
POLIVY NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary POLIVY NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary POMALYST ORAL-CHEMO Blue Cross Formulary POMALYST ORAL-CHEMO National Performance Formulary PORTRAZZA NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PORTRAZZA NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary POTELIGEO NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary POTELIGEO NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PREGNYL GENERIC-SPECIALTY Blue Cross Formulary PREGNYL GENERIC-SPECIALTY National Performance Formulary PREGNYL GENERIC-SPECIALTY National Performance Formulary PREVYMIS NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PREVYMIS NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PRIVIGEN NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PRIVIGEN NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PROCRIT NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PROCRIT PREFERRED-BRAND-SPECIALTY National Performance Formulary PROCRIT PREFERRED-BRAND-SPECIALTY Blue Cross Formulary	PIQRAY	ORAL-CHEMO	National Performance Formulary
POLIVY NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary POLIVY NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary POMALYST ORAL-CHEMO Blue Cross Formulary POMALYST ORAL-CHEMO National Performance Formulary PORTRAZZA NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PORTRAZZA NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary POTELIGEO NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary POTELIGEO NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PREGNYL GENERIC-SPECIALTY Blue Cross Formulary PREGNYL GENERIC-SPECIALTY National Performance Formulary PREGNYL GENERIC-SPECIALTY National Performance Formulary PREVYMIS NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PREVYMIS NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PRIVIGEN NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PRIVIGEN NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PROCRIT NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PROCRIT PREFERRED-BRAND-SPECIALTY National Performance Formulary PROCRIT PREFERRED-BRAND-SPECIALTY Blue Cross Formulary	PLEGRIDY	NON-PREFERRED-BRAND-SPECIALTY	
POLIVY NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary POMALYST ORAL-CHEMO National Performance Formulary POMALYST ORAL-CHEMO National Performance Formulary PORTRAZZA NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PORTRAZZA NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary POTELIGEO NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary POTELIGEO NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PREGNYL GENERIC-SPECIALTY Blue Cross Formulary PREGNYL GENERIC-SPECIALTY National Performance Formulary PREGNYL GENERIC-SPECIALTY Blue Cross Formulary PREVYMIS NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PREVYMIS NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PRIVIGEN NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PRIVIGEN NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCRIT NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PROCRIT PREFERRED-BRAND-SPECIALTY Blue Cross Formulary			
POMALYST ORAL-CHEMO Blue Cross Formulary POMALYST ORAL-CHEMO National Performance Formulary PORTRAZZA NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PORTRAZZA NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary POTELIGEO NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary POTELIGEO NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PREGNYL GENERIC-SPECIALTY Blue Cross Formulary PREGNYL GENERIC-SPECIALTY National Performance Formulary PREGNYL GENERIC-SPECIALTY National Performance Formulary PREVYMIS NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PREVYMIS NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PRIVIGEN NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PRIVIGEN NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PROCRIT NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCRIT NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCRIT PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCRIT PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCRIT PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCRIS NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary	POLIVY		
POMALYST ORAL-CHEMO National Performance Formulary PORTRAZZA NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PORTRAZZA NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary POTELIGEO NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary POTELIGEO NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PREGNYL GENERIC-SPECIALTY Blue Cross Formulary PREGNYL GENERIC-SPECIALTY National Performance Formulary PREVYMIS NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PREVYMIS NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PRIVIGEN NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PRIVIGEN NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCRIT NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PROCRIT PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCRIS NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary			
PORTRAZZA NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PORTRAZZA NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary POTELIGEO NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary POTELIGEO NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PREGNYL GENERIC-SPECIALTY Blue Cross Formulary PREGNYL GENERIC-SPECIALTY National Performance Formulary PREVYMIS NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PREVYMIS NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PRIVIGEN NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PRIVIGEN NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PROCRIT NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PROCRIT NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCRIT PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCRIT PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCRIT PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCRIS NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary			
PORTRAZZA NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary POTELIGEO NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary POTELIGEO NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PREGNYL GENERIC-SPECIALTY Blue Cross Formulary PREGNYL GENERIC-SPECIALTY National Performance Formulary PREVYMIS NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PREVYMIS NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PRIVIGEN NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PRIVIGEN NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCRIT NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PROCRIT NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCRIT PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCRIT PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCRIS NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCRIS Blue Cross Formulary PROCRIS Blue Cross Formulary PROCRIS Blue Cross Formulary			
POTELIGEO NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary POTELIGEO NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PREGNYL GENERIC-SPECIALTY Blue Cross Formulary PREGNYL GENERIC-SPECIALTY National Performance Formulary PREVYMIS NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PREVYMIS NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PRIVIGEN NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PRIVIGEN NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCRIT NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PROCRIT NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCRIT PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCRIT PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCRIS NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCYSBI NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary			,
POTELIGEO NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PREGNYL GENERIC-SPECIALTY Blue Cross Formulary PREGNYL GENERIC-SPECIALTY National Performance Formulary PREVYMIS NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PREVYMIS NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PRIVIGEN NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PRIVIGEN NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCRIT NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PROCRIT NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCRIT PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCYSBI NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary			,
PREGNYL GENERIC-SPECIALTY Blue Cross Formulary PREGNYL GENERIC-SPECIALTY National Performance Formulary PREVYMIS NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PREVYMIS NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PRIVIGEN NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PRIVIGEN NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PROCRIT NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCRIT PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCRIT PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCYSBI NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary			
PREGNYL GENERIC-SPECIALTY National Performance Formulary PREVYMIS NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PREVYMIS NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PRIVIGEN NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PRIVIGEN NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PROCRIT NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCRIT PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCRIT PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCYSBI NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary			
PREVYMIS NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PREVYMIS NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PRIVIGEN NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PRIVIGEN NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PROCRIT NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCRIT PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCRIT PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCYSBI NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary			
PREVYMIS NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PRIVIGEN NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PRIVIGEN NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PROCRIT NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCRIT PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCYSBI NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary			
PRIVIGEN NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PRIVIGEN NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PROCRIT NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCRIT PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCYSBI NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary			
PRIVIGEN NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary PROCRIT NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCRIT PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCYSBI NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary			
PROCRIT NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCRIT PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCYSBI NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary			
PROCRIT PREFERRED-BRAND-SPECIALTY Blue Cross Formulary PROCYSBI NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary			
PROCYSBI NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary			
	PROCRIT		Blue Cross Formulary
	PROCYSBI	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
PROCYSBI NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary		NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
PROFILNINE PREFERRED-BRAND-SPECIALTY Blue Cross Formulary	PROCYSBI		
PROFILNINE PREFERRED-BRAND-SPECIALTY National Performance Formulary			Blue Cross Formulary
PROGRAF NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary	PROFILNINE	PREFERRED-BRAND-SPECIALTY	
	PROFILNINE PROFILNINE	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	National Performance Formulary
PROLASTIN-C NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary	PROFILNINE PROFILNINE	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	National Performance Formulary

PROLASTIN-C	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
PROLEUKIN	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
PROLEUKIN	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
PROLIA	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
PROLIA	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
PROMACTA	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
PROMACTA	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
PROVENGE	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
PROVENGE	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
PULMOZYME	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
PULMOZYME	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
PURIXAN	ORAL-CHEMO	Blue Cross Formulary
PURIXAN	ORAL-CHEMO	National Performance Formulary
PYRIMETHAMIN	GENERIC-SPECIALTY	Blue Cross Formulary
PYRIMETHAMIN	GENERIC-SPECIALTY	National Performance Formulary
QINLOCK	ORAL-CHEMO	Blue Cross Formulary
QINLOCK	ORAL-CHEMO	National Performance Formulary
RADICAVA	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
RADICAVA	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
RAPAMUNE	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
RAPAMUNE	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
RAVICTI	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
RAVICTI	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
REBIF	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
REBINYN	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
REBINYN	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
REBLOZYL	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
REBLOZYL	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
RECLAST	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
RECLAST	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
RECOMBINATE	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
RECOMBINATE	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
REMICADE	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
REMODULIN	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
RENFLEXIS	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
RENFLEXIS	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
RETACRIT	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
RETACRIT	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
RETEVMO	ORAL-CHEMO	Blue Cross Formulary
RETEVMO RETEVMO	ORAL-CHEMO ORAL-CHEMO	Blue Cross Formulary National Performance Formulary
	ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY	·
RETEVMO	ORAL-CHEMO	National Performance Formulary
RETEVMO RETISERT	ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary
RETEVMO RETISERT RETISERT	ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
RETEVMO RETISERT RETISERT REVATIO	ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
RETEVMO RETISERT RETISERT REVATIO REVATIO	ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
RETEVMO RETISERT RETISERT REVATIO REVATIO REVATIO	ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
RETEVMO RETISERT RETISERT REVATIO REVATIO REVCOVI REVCOVI	ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
RETEVMO RETISERT RETISERT REVATIO REVATIO REVCOVI REVCOVI REVLIMID	ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO	National Performance Formulary Blue Cross Formulary Blue Cross Formulary
RETEVMO RETISERT RETISERT REVATIO REVATIO REVCOVI REVCOVI REVCOVI REVLIMID REVLIMID RHOGAM RHOGAM	ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary
RETEVMO RETISERT RETISERT REVATIO REVATIO REVCOVI REVCOVI REVLIMID REVLIMID RHOGAM	ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary
RETEVMO RETISERT RETISERT REVATIO REVATIO REVCOVI REVCOVI REVCOVI REVLIMID REVLIMID RHOGAM RHOGAM	ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
RETEVMO RETISERT RETISERT REVATIO REVATIO REVCOVI REVCOVI REVLIMID REVLIMID RHOGAM RHOGAM RIASTAP RIASTAP RIBAVIRIN	ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORNERIC-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
RETEVMO RETISERT RETISERT REVATIO REVATIO REVCOVI REVCOVI REVLIMID REVLIMID RHOGAM RHOGAM RHOGAM RIASTAP RIASTAP RIBAVIRIN RIBAVIRIN	ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary
RETEVMO RETISERT RETISERT REVATIO REVATIO REVATIO REVCOVI REVCOVI REVLIMID REVLIMID RHOGAM RHOGAM RHAGAM RIASTAP RIBAVIRIN RIBAVIRIN RIBAVIRIN	ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary
RETEVMO RETISERT RETISERT REVATIO REVATIO REVCOVI REVCOVI REVLIMID REVLIMID RHOGAM RHOGAM RHOGAM RIASTAP RIASTAP RIBAVIRIN RIBAVIRIN	ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary
RETEVMO RETISERT RETISERT REVATIO REVATIO REVATIO REVCOVI REVCOVI REVLIMID REVLIMID RHOGAM RHOGAM RHAGAM RIASTAP RIBAVIRIN RIBAVIRIN RIBAVIRIN	ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
RETEVMO RETISERT RETISERT REVATIO REVATIO REVCOVI REVCOVI REVLIMID REVLIMID RHOGAM RHOGAM RHOGAM RIASTAP RIASTAP RIBAVIRIN RIBAVIRIN RIBAVIRIN RIDAURA RIDAURA	ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary
RETEVMO RETISERT RETISERT REVATIO REVATIO REVATIO REVCOVI REVCOVI REVLIMID REVLIMID RHOGAM RHOGAM RHOGAM RIASTAP RIBAVIRIN RIBAVIRIN RIBAVIRIN RIBAVIRIN RIDAURA RIDAURA RIDAURA RINVOQ	ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary
RETEVMO RETISERT RETISERT REVATIO REVATIO REVCOVI REVCOVI REVLIMID REVLIMID RHOGAM RHOGAM RHOGAM RIASTAP RIBAVIRIN RIBAVIRIN RIBAVIRIN RIDAURA RIDAURA RINVOQ RINVOQ	ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
RETEVMO RETISERT RETISERT REVATIO REVATIO REVCOVI REVCOVI REVLIMID REVLIMID RHOGAM RHOGAM RHOGAM RIASTAP RIBAVIRIN RIBAVIRIN RIBAVIRIN RIDAURA RIDAURA RINVOQ RINVOQ RITUXAN	ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
RETEVMO RETISERT RETISERT REVATIO REVATIO REVCOVI REVCOVI REVLIMID REVLIMID RHOGAM RHOGAM RHOGAM RIASTAP RIBAVIRIN RIBAVIRIN RIDAURA RIDAURA RINDAURA RINVOQ RINVOQ RITUXAN RITUXAN	ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
RETEVMO RETISERT RETISERT REVATIO REVATIO REVATIO REVCOVI REVCOVI REVLIMID REVLIMID RHOGAM RHOGAM RHOGAM RIASTAP RIBAVIRIN RIBAVIRIN RIBAVIRIN RIDAURA RIDAURA RINVOQ RITUXAN RITUXAN RIXERT	ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
RETEVMO RETISERT RETISERT REVATIO REVATIO REVATIO REVCOVI REVCOVI REVLIMID REVLIMID RHOGAM RHOGAM RHOGAM RIASTAP RIBAVIRIN RIBAVIRIN RIBAVIRIN RIDAURA RIDAURA RINVOQ RINVOQ RITUXAN RITUXAN RIXUBIS RIXUBIS	ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
RETEVMO RETISERT RETISERT REVATIO REVATIO REVATIO REVCOVI REVCOVI REVLIMID REVLIMID RHOGAM RHOGAM RHOGAM RIASTAP RIASTAP RIBAVIRIN RIBAVIRIN RIBAVIRIN RIDAURA RIDAURA RINVOQ RITUXAN RITUXAN RITUXAN RIXUBIS ROMIDEPSIN	ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
RETEVMO RETISERT RETISERT REVATIO REVATIO REVATIO REVCOVI REVCOVI REVLIMID REVLIMID RHOGAM RHOGAM RHOGAM RIASTAP RIBAVIRIN RIBAVIRIN RIBAVIRIN RIBAVIRIN RIDAURA RIDAURA RINVOQ RITUXAN RITUXAN RITUXAN RITUXAN RIXUBIS ROMIDEPSIN ROMIDEPSIN	ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
RETEVMO RETISERT RETISERT REVATIO REVATIO REVATIO REVCOVI REVCOVI REVCOVI REVLIMID RHOGAM RHOGAM RHOGAM RIASTAP RIBAVIRIN RIBAVIRIN RIBAVIRIN RIDAURA RIDAURA RINVOQ RINVOQ RITUXAN RITUXAN RITUXAN RIXUBIS ROMIDEPSIN ROMIDEPSIN ROMIDEPSIN	ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary
RETEVMO RETISERT RETISERT REVATIO REVATIO REVATIO REVCOVI REVCOVI REVCOVI REVLIMID REVLIMID RHOGAM RHOGAM RHOGAM RIASTAP RIBAVIRIN RIBAVIRIN RIBAVIRIN RIBAVIRIN RIDAURA RIDAURA RINVOQ RINVOQ RITUXAN RITUXAN RITUXAN RIXUBIS ROMIDEPSIN ROMIDEPSIN ROMIDEPSIN ROZLYTREK	ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO	National Performance Formulary Blue Cross Formulary National Performance Formulary
RETEVMO RETISERT RETISERT REVATIO REVATIO REVATIO REVCOVI REVCOVI REVLIMID REVLIMID RHOGAM RHOGAM RHOGAM RIASTAP RIBAVIRIN RIBAVIRIN RIBAVIRIN RIDAURA RIDAURA RIDAURA RINVOQ RITUXAN RITUXAN RITUXAN RIXUBIS ROMIDEPSIN ROMIDEPSIN ROZLYTREK ROZLYTREK REVATIO	ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary
RETEVMO RETISERT RETISERT REVATIO REVATIO REVATIO REVCOVI REVCOVI REVLIMID REVLIMID RHOGAM RHOGAM RHOGAM RIASTAP RIBAVIRIN RIBAVIRIN RIBAVIRIN RIBAVIRIN RIDAURA RINVOQ RITUXAN RITUXAN RITUXAN RIXUBIS ROMIDEPSIN ROMIDEPSIN ROZLYTREK ROZLYTREK RUBRACA	ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
RETEVMO RETISERT RETISERT REVATIO REVATIO REVATIO REVCOVI REVCOVI REVLIMID REVLIMID REVLIMID RHOGAM RHOGAM RHAGAM RIASTAP RIBAVIRIN RIBAVIRIN RIBAVIRIN RIBAVIRIN RIDAURA RINVOQ RINVOQ RITUXAN RITUXAN RITUXAN RITUXAN RIXUBIS RIXUBIS ROMIDEPSIN ROMIDEPSIN ROMIDEPSIN ROZLYTREK RUBRACA RUBRACA RUBRACA RUBRACA	ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary
RETEVMO RETISERT RETISERT REVATIO REVATIO REVATIO REVCOVI REVCOVI REVLIMID REVLIMID REVLIMID RHOGAM RHOGAM RHAGAM RIASTAP RIBAVIRIN RIBAVIRIN RIBAVIRIN RIBAVIRIN RIDAURA RINVOQ RITUXAN RITUXAN RITUXAN RIXUBIS RIXUBIS ROMIDEPSIN ROMIDEPSIN ROZLYTREK ROZLYTREK RUBRACA RUBRACA RUCONEST RUCONEST	ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
RETEVMO RETISERT RETISERT REVATIO REVATIO REVATIO REVCOVI REVCOVI REVLIMID REVLIMID RHOGAM RHOGAM RHOGAM RIASTAP RIASTAP RIBAVIRIN RIBAVIRIN RIBAVIRIN RIDAURA RIDAURA RINVOQ RITUXAN RITUXAN RITUXAN RIXUBIS ROMIDEPSIN ROMIDEPSIN ROZLYTREK RUBRACA RUBRACA RUBRACA RUBRACA RUCONEST RUCONEST RUXION REVLIMID REVLIMID REVLIMID REVLIMID REVLIMID REVLIMID REVLIMID ROVID RO	ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Sule Cross Formulary Rotal Performance Formulary Blue Cross Formulary Sule Cross Formulary Rotal Performance Formulary Blue Cross Formulary Sule Cross Formulary
RETEVMO RETISERT RETISERT REVATIO REVATIO REVATIO REVCOVI REVCOVI REVLIMID REVLIMID RHOGAM RHOGAM RHOGAM RIASTAP RIBAVIRIN RIBAVIRIN RIBAVIRIN RIDAURA RINVOQ RITUXAN RITUXAN RITUXAN RITUXAN RITUXAN RITUXAN RITUXER ROMIDEPSIN ROMIDEPSIN ROMIDEPSIN ROZLYTREK RUBRACA RUBRACA RUCONEST RUCONEST RUXINCE	ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
RETEVMO RETISERT RETISERT REVATIO REVATIO REVATIO REVCOVI REVCOVI REVLIMID REVLIMID REVLIMID RHOGAM RHOGAM RHOGAM RIASTAP RIBAVIRIN RIBAVIRIN RIBAVIRIN RIBAVIRIN RIDAURA RIDAURA RINVOQ RITUXAN RITUXAN RIXUBIS RIXUBIS ROMIDEPSIN ROMIDEPSIN ROZLYTREK RUBRACA RUCONEST RUXIENCE RUXIENCE RUXIENCE RUXIENCE RUXIENCE RUZURGI RUZURGI	ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
RETEVMO RETISERT RETISERT REVATIO REVATIO REVATIO REVCOVI REVCOVI REVCOVI REVLIMID RHOGAM RHOGAM RHOGAM RIASTAP RIBAVIRIN RIBAVIRIN RIBAVIRIN RIBAVIRIN RIDAURA RINVOQ RINVOQ RITUXAN RITUXAN RITUXAN RITUXAN RIXUBIS RIXUBIS ROMIDEPSIN ROMIDEPSIN ROMIDEPSIN ROZLYTREK RUBRACA RUBRACA RUBRACA RUCONEST RUCONEST RUCONEST RUXINCE RUXIO	ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary Robus Cross Formulary Sundan Performance Formulary Blue Cross Formulary Robus Cross Form

	I	
SAIZEN	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
SAIZENPREP	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
SAMSCA SAMSCA	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
SAMSCA	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary
SAMSCA	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
SANDIMMUNE	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
SANDIMMUNE	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
SANDIMMUNE	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
SANDIMMUNE	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
SANDOSTATIN	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
SANDOSTATIN	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
SAPROPTERIN	GENERIC-SPECIALTY	Blue Cross Formulary
SAPROPTERIN	GENERIC-SPECIALTY	National Performance Formulary
SARCLISA	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
SARCLISA	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
SCENESSE	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
SCENESSE	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
SEROSTIM	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
SEROSTIM	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
SEVENFACT	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
SEVENFACT	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
SIGNIFOR	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
SIGNIFOR	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
SILDENAFIL	GENERIC-SPECIALTY	Blue Cross Formulary
SILDENAFIL	GENERIC-SPECIALTY	National Performance Formulary
SILIQ	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
SILIQ	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
SIMPONI	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
SIMPONI	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
SIROLIMUS	GENERIC-SPECIALTY	Blue Cross Formulary
SIROLIMUS	GENERIC-SPECIALTY	National Performance Formulary
SKYRIZI	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
SKYRIZI	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
SODIUM	GENERIC-SPECIALTY	Blue Cross Formulary
SODIUM	GENERIC-SPECIALTY	National Performance Formulary
SOFOS/VELPAT	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
COLIDIC		
SOLIRIS	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
SOLIRIS	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
SOLIRIS SOMATULINE	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary
SOLIRIS SOMATULINE SOMATULINE	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary
SOLIRIS SOMATULINE SOMATULINE SOMAVERT	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
SOLIRIS SOMATULINE SOMATULINE SOMAVERT SOMAVERT	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
SOLIRIS SOMATULINE SOMATULINE SOMAVERT SOMAVERT SOVALDI	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary
SOLIRIS SOMATULINE SOMATULINE SOMAVERT SOMAVERT SOVALDI SOVALDI	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
SOLIRIS SOMATULINE SOMATULINE SOMAVERT SOMAVERT SOVALDI SOVALDI SPRAVATO	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary Blue Cross Formulary
SOLIRIS SOMATULINE SOMATULINE SOMAVERT SOMAVERT SOVALDI SOVALDI	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
SOLIRIS SOMATULINE SOMATULINE SOMAVERT SOMAVERT SOVALDI SOVALDI SPRAVATO SPRAVATO	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary
SOLIRIS SOMATULINE SOMATULINE SOMAVERT SOMAVERT SOVALDI SOVALDI SPRAVATO SPRAVATO SPRYCEL	NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO	National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary
SOLIRIS SOMATULINE SOMATULINE SOMAVERT SOMAVERT SOVALDI SOVALDI SPRAVATO SPRAVATO SPRAVATO SPRYCEL SPRYCEL	NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO	National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary
SOLIRIS SOMATULINE SOMATULINE SOMAVERT SOMAVERT SOVALDI SOVALDI SOVALDI SPRAVATO SPRAVATO SPRAVATO SPRYCEL SPRYCEL STELARA	NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO PREFERRED-BRAND-SPECIALTY ORAL-CHEMO PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary
SOLIRIS SOMATULINE SOMATULINE SOMAVERT SOMAVERT SOVALDI SOVALDI SPRAVATO SPRAVATO SPRAVATO SPRAVEL SPRYCEL STELARA STELARA	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
SOLIRIS SOMATULINE SOMATULINE SOMAVERT SOMAVERT SOVALDI SOVALDI SPRAVATO SPRAVATO SPRAVATO SPRYCEL SPRYCEL STELARA STELARA STIVARGA STIVARGA STIVARGA STRENSIQ	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary
SOLIRIS SOMATULINE SOMATULINE SOMAVERT SOMAVERT SOVALDI SOVALDI SPRAVATO SPRAVATO SPRAVEL SPRYCEL STELARA STELARA STELARA STIVARGA STIVARGA STRENSIQ STRENSIQ	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary
SOLIRIS SOMATULINE SOMATULINE SOMAVERT SOMAVERT SOVALDI SOVALDI SOVALDI SPRAVATO SPRAVATO SPRAVEL SPRYCEL STELARA STELARA STELARA STIVARGA STIVARGA STRENSIQ SUBLOCADE	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary
SOLIRIS SOMATULINE SOMATULINE SOMAVERT SOMAVERT SOVALDI SOVALDI SOVALDI SPRAVATO SPRAVATO SPRAVATO SPRYCEL STELARA STELARA STELARA STIVARGA STIVARGA STRENSIQ SUBLOCADE SUBLOCADE	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY ORAL-CHEMO NORAL-CHEMO PREFERRED-BRAND-SPECIALTY NORAL-CHEMO NORAL-CHEMO NORAL-CHEMO NORAL-CHEMO NORAL-CHEMO NORAL-CHEMO PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
SOLIRIS SOMATULINE SOMATULINE SOMAVERT SOMAVERT SOVALDI SOVALDI SOVALDI SPRAVATO SPRAVATO SPRAVATO SPRICEL STELARA STELARA STELARA STIVARGA STIVARGA STIVARGA STRENSIQ STRENSIQ SUBLOCADE SUBLOCADE SUCRAID	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO PREFERRED-BRAND-SPECIALTY ORAL-CHEMO PREFERRED-BRAND-SPECIALTY NORAL-CHEMO NORAL-CHEMO PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
SOLIRIS SOMATULINE SOMATULINE SOMAVERT SOMAVERT SOVALDI SOVALDI SOVALDI SPRAVATO SPRAVATO SPRAVATO SPRYCEL STELARA STELARA STELARA STIVARGA STIVARGA STIVARGA STRENSIQ STRENSIQ SUBLOCADE SUBLOCADE SUCRAID	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
SOLIRIS SOMATULINE SOMATULINE SOMAVERT SOMAVERT SOVALDI SOVALDI SPRAVATO SPRAVATO SPRYCEL SPRYCEL STELARA STELARA STELARA STIVARGA STIVARGA STIVARGA STRENSIQ SUBLOCADE SUBLOCADE SUBLOCADE SUCRAID SUCRAID SUCRAID	NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
SOLIRIS SOMATULINE SOMATULINE SOMAVERT SOMAVERT SOVALDI SOVALDI SPRAVATO SPRAVATO SPRAVATO SPRYCEL SPRYCEL STELARA STELARA STILARA STILARA STIVARGA STIVARGA STIVARGA STRENSIQ SUBLOCADE SUBLOCADE SUBLOCADE SUCRAID SUCRAID SUCRAID SUPARTZ SUPPRELIN	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary
SOLIRIS SOMATULINE SOMATULINE SOMAVERT SOMAVERT SOVALDI SOVALDI SPRAVATO SPRAVATO SPRAVATO SPRYCEL STELARA STELARA STELARA STELARA STELARA STIVARGA STIVARGA STIVARGA STIVARGA SURANIQ SUBLOCADE SUBLOCADE SUBLOCADE SUCRAID SUCRAID SUCRAID SUCRAID SUPARTZ SUPPRELIN	NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary
SOLIRIS SOMATULINE SOMATULINE SOMAVERT SOMAVERT SOVALDI SOVALDI SPRAVATO SPRAVATO SPRAVATO SPRYCEL SPRYCEL STELARA STELARA STELARA STIVARGA STIVARGA STIVARGA STRENSIQ SUBLOCADE SUBLOCADE SUBLOCADE SUBLOCADE SUCRAID SUCRAID SUCRAID SUCPRELIN SUPPRELIN SUPPRELIN SUPPRELIN	NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
SOLIRIS SOMATULINE SOMATULINE SOMAVERT SOMAVERT SOVALDI SOVALDI SOVALDI SPRAVATO SPRAVATO SPRAVATO SPRYCEL STELARA STELARA STIVARGA STIVARGA STIVARGA STRENSIQ SUBLOCADE SUBLOCADE SUBLOCADE SUBLOCADE SUCRAID SUCRAID SUCRAID SUPARTZ SUPPRELIN SUPPRELIN SUPENT	NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO	National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
SOLIRIS SOMATULINE SOMATULINE SOMAVERT SOMAVERT SOVALDI SOVALDI SOVALDI SPRAVATO SPRAVATO SPRAVATO SPRYCEL STELARA STELARA STELARA STELARA STIVARGA STIVARGA STIVARGA STRENSIQ SUBLOCADE SUBLOCADE SUBLOCADE SUBLOCADE SUBLOCADE SUCRAID SUCRAID SUCRAID SUPARTZ SUPPRELIN SUPPRELIN SUPPRELIN SUTENT SUTENT	NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary
SOLIRIS SOMATULINE SOMATULINE SOMAVERT SOMAVERT SOVALDI SOVALDI SOVALDI SPRAVATO SPRAVATO SPRAVATO SPRYCEL STELARA STELARA STELARA STIVARGA STIVARGA STIVARGA STIVARGA SUVANT SUPPRELIN SUPPRELIN SUPPRELIN SUPPRELIN SUPPRELIN SUPPRELIN SUTENT SYLVANT SYLVANT	NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary
SOLIRIS SOMATULINE SOMATULINE SOMAVERT SOMAVERT SOVALDI SOVALDI SOVALDI SPRAVATO SPRAVATO SPRAVATO SPRYCEL SPRYCEL STELARA STILARA STILARA STIVARGA STIVARGA STIVARGA STIVARGA STRENSIQ SUBLOCADE SUBLOCADE SUBLOCADE SUBLOCADE SUBLOCADE SUBLOCADE SUCRAID SUCRAID SUCRAID SUCRAID SUCRAID SUCRAID SUPPRELIN SUPPRELIN SUPPRELIN SUPPRELIN SUTENT SYLVANT SYLVANT SYLVANT	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary
SOLIRIS SOMATULINE SOMATULINE SOMAVERT SOMAVERT SOMAVERT SOVALDI SOVALDI SPRAVATO SPRAVATO SPRAVATO SPRYCEL STELARA STELARA STIVARGA STIVARGA STIVARGA STIVARGA SUVARDI SUBLOCADE SUCRAID SUCRAID SUCRAID SUCRAID SUCRAID SUPPRELIN	NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
SOLIRIS SOMATULINE SOMATULINE SOMAVERT SOMAVERT SOMAVERT SOVALDI SOVALDI SPRAVATO SPRAVATO SPRAVATO SPRYCEL STELARA STELARA STELARA STELARA STIVARGA STIVARGA STIVARGA SUVARGA SUVARID SUCRAID SUCRAID SUCRAID SUCRAID SUCRAID SUPARTZ SUPPRELIN	NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary
SOLIRIS SOMATULINE SOMATULINE SOMAVERT SOMAVERT SOVALDI SOVALDI SPRAVATO SPRAVATO SPRAVATO SPRYCEL STELARA STELARA STELARA STELARA STIVARGA STIVARGA STIVARGA SUVARGA SUVARID SUBLOCADE SUBLOCADE SUBLOCADE SUBLOCADE SUCRAID SUCRAID SUCRAID SUCRAID SUCRAID SUPARTZ SUPPRELIN SU	NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
SOLIRIS SOMATULINE SOMATULINE SOMAVERT SOMAVERT SOMAVERT SOVALDI SOVALDI SOVALDI SPRAVATO SPRAVATO SPRYCEL SPRYCEL STELARA STELARA STELARA STIVARGA STIVARGA STIVARGA STRENSIQ SUBLOCADE SUBLOCADE SUBLOCADE SUBLOCADE SUBLOCADE SUPARTZ SUPARTZ SUPPRELIN SUPPR	NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Rota Cross Formulary Blue Cross Formulary Rota Cross Formulary Blue Cross Formulary Blue Cross Formulary Rota Cross Formulary
SOLIRIS SOMATULINE SOMATULINE SOMAVERT SOMAVERT SOVALDI SOVALDI SPRAVATO SPRAVATO SPRAVATO SPRYCEL STELARA STELARA STELARA STELARA STIVARGA STIVARGA STIVARGA SUVARGA SUVARID SUBLOCADE SUBLOCADE SUBLOCADE SUBLOCADE SUCRAID SUCRAID SUCRAID SUCRAID SUCRAID SUPARTZ SUPPRELIN SU	NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
SOLIRIS SOMATULINE SOMATULINE SOMAVERT SOMAVERT SOMAVERT SOVALDI SOVALDI SOVALDI SPRAVATO SPRAVATO SPRAVATO SPRYCEL STELARA STELARA STIVARGA STIVARGA STIVARGA STIVARGA STRENSIQ SUBLOCADE	NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary
SOLIRIS SOMATULINE SOMATULINE SOMAVERT SOMAVERT SOMAVERT SOVALDI SOVALDI SOVALDI SPRAVATO SPRAVATO SPRAVATO SPRYCEL STELARA STELARA STELARA STIVARGA STIVARGA STIVARGA STIVARGA STIVARGA STRENSIQ SUBLOCADE SUBLOCADE SUBLOCADE SUBLOCADE SUBLOCADE SUBLOCADE SUBLOCADE SUCRAID SUPARTZ SUPPRELIN SUPPRE	NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
SOLIRIS SOMATULINE SOMATULINE SOMAVERT SOMAVERT SOMAVERT SOVALDI SOVALDI SOVALDI SPRAVATO SPRAVATO SPRAVATO SPRYCEL STELARA STELARA STELARA STELARA STIVARGA STIVARGA STIVARGA STIVARGA STRENSIQ SUBLOCADE SUBLOCADE SUBLOCADE SUBLOCADE SUBLOCADE SUBLOCADE SUCRAID SUCRAID SUCRAID SUPARTZ SUPPRELIN SUPPRELIN SUPPRELIN SUPPRELIN SUPPRELIN SUPPRELIN SUTENT SYLVANT SYLVANT SYLVANT SYLVANT SYLVANT SYMDEKO SYNAGIS SYNAGIS SYNAGIS SYNRIBO SYNRIBO SYNRIBO SYNRIBO SYNRIBO	NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary Formulary

TACROLIMUS	GENERIC-SPECIALTY	Blue Cross Formulary
TACROLIMUS	GENERIC SPECIALTY	National Performance Formulary
TADALAFIL TADALAFIL	GENERIC-SPECIALTY GENERIC-SPECIALTY	Blue Cross Formulary National Performance Formulary
TAFINLAR	ORAL-CHEMO	Blue Cross Formulary
TAFINLAR	ORAL-CHEMO	National Performance Formulary
TAGRISSO	ORAL-CHEMO	Blue Cross Formulary
TAGRISSO	ORAL-CHEMO	National Performance Formulary
TAKHZYRO	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
TAKHZYRO	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
TALTZ	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
TALTZ	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
TALZENNA	ORAL-CHEMO	Blue Cross Formulary
TALZENNA	ORAL-CHEMO	National Performance Formulary
TARGRETIN	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
TARGRETIN	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
TASIGNA TASIGNA	ORAL-CHEMO ORAL-CHEMO	Blue Cross Formulary National Performance Formulary
TAVALISSE	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
TAVALISSE	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
TAZVERIK	ORAL-CHEMO	Blue Cross Formulary
TECARTUS	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
TECARTUS	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
TECENTRIQ	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
TECENTRIQ	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
TECFIDERA	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
TECFIDERA	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
TEGSEDI	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
TEGSEDI	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
TEMODAR	ORAL-CHEMO	Blue Cross Formulary
TEMODAR	ORAL-CHEMO	National Performance Formulary
TEMODAR	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
TEMODAR	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
TEMOZOLOMIDE TEMOZOLOMIDE	ORAL-CHEMO ORAL-CHEMO	Blue Cross Formulary National Performance Formulary
TEMSIROLIMUS	GENERIC-SPECIALTY	Blue Cross Formulary
TEMSIROLIMUS	GENERIC-SPECIALTY	National Performance Formulary
TEPADINA	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
TEPADINA	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
TEFADINA		
TEPEZZA	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
TEPEZZA	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
TEPEZZA TEPEZZA TERIPARATIDE TERIPARATIDE	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
TEPEZZA TEPEZZA TERIPARATIDE TERIPARATIDE TETRABENAZIN	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
TEPEZZA TEPEZZA TERIPARATIDE TERIPARATIDE TETRABENAZIN TETRABENAZIN	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
TEPEZZA TEPEZZA TERIPARATIDE TERIPARATIDE TETRABENAZIN TETRABENAZIN THALOMID	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO	Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary
TEPEZZA TEPEZZA TERIPARATIDE TERIPARATIDE TETRABENAZIN TETRABENAZIN THALOMID THALOMID	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO ORAL-CHEMO	Blue Cross Formulary National Performance Formulary National Performance Formulary
TEPEZZA TEPEZZA TERIPARATIDE TERIPARATIDE TETRABENAZIN TETRABENAZIN THALOMID THALOMID THALOMID THOLA	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary
TEPEZZA TEPEZZA TERIPARATIDE TERIPARATIDE TETRABENAZIN TETRABENAZIN THALOMID THALOMID THOLA THIOLA	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary National Performance Formulary
TEPEZZA TEPEZZA TERIPARATIDE TERIPARATIDE TETRABENAZIN TETRABENAZIN THALOMID THALOMID THOLA THIOLA THIOLA THIOLA	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary
TEPEZZA TEPEZZA TERIPARATIDE TERIPARATIDE TETRABENAZIN TETRABENAZIN THALOMID THALOMID THIOLA THIOLA THIOLA THIOTEPA THIOTEPA	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY	Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
TEPEZZA TEPEZZA TERIPARATIDE TERIPARATIDE TETRABENAZIN TETRABENAZIN THALOMID THALOMID THOLA THIOLA THIOLA THIOLA	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary
TEPEZZA TEPEZZA TERIPARATIDE TERIPARATIDE TETRABENAZIN TETRABENAZIN THALOMID THALOMID THALOMID THOLA THIOLA THIOLA THIOTEPA THIOTEPA TIBSOVO	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO	Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
TEPEZZA TEPEZZA TERIPARATIDE TERIPARATIDE TETRABENAZIN TETRABENAZIN THALOMID THALOMID THALOMID THIOLA THIOLA THIOTEPA TIBSOVO TIBSOVO	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO	Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
TEPEZZA TEPEZZA TERIPARATIDE TERIPARATIDE TETRABENAZIN TETRABENAZIN THALOMID THALOMID THIOLA THIOLA THIOTEPA THIOTEPA TIBSOVO TIBSOVO TICE	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary
TEPEZZA TEPEZZA TERIPARATIDE TERIPARATIDE TETRABENAZIN TETRABENAZIN THALOMID THALOMID THOLA THIOLA THIOTEPA THIOTEPA TIBSOVO TIBSOVO TICE TICE TICE TIGLUTIK	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary
TEPEZZA TEPEZZA TERIPARATIDE TERIPARATIDE TETRABENAZIN TETRABENAZIN THALOMID THALOMID THOLA THIOLA THIOLA THIOTEPA TIBSOVO TIBSOVO TICE TICE TICE TIGLUTIK TIGLUTIK TOBI	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
TEPEZZA TEPEZZA TERIPARATIDE TERIPARATIDE TETRABENAZIN TETRABENAZIN THALOMID THALOMID THIOLA THIOLA THIOTEPA TIBSOVO TIBSOVO TICE TICE TIGLUTIK TIGLUTIK TOBI	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
TEPEZZA TEPEZZA TERIPARATIDE TERIPARATIDE TETRABENAZIN TETRABENAZIN THALOMID THALOMID THIOLA THIOLA THIOTEPA THIOTEPA TIBSOVO TIES TICE TICE TIGLUTIK TOBI TOBI	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY ORAL-CHEMO PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
TEPEZZA TEPEZZA TERIPARATIDE TERIPARATIDE TETRABENAZIN TETRABENAZIN THALOMID THALOMID THIOLA THIOLA THIOTEPA THIOTEPA TIBSOVO TIBSOVO TICE TICE TICE TIGLUTIK TOBI TOBI TOBRAMYCIN TOBRAMYCIN	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ON-PREFERRED-BRAND-SPECIALTY ON-PREFERRED-BRAND-SPECIALTY ON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY	Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
TEPEZZA TEPEZZA TERIPARATIDE TERIPARATIDE TETRABENAZIN TETRABENAZIN THALOMID THALOMID THOLA THIOLA THIOTEPA THIOTEPA TIBSOVO TIBSOVO TICE TICE TICE TICE TIGLUTIK TOBI TOBI TOBRAMYCIN TOBRAMYCIN TEPEZZA TERIPAZIN TEPEZZA TICE TOBRAMYCIN TEPEZZA TOBEZA TOBEZA TOBRAMYCIN TOBRAMYCIN	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY ORAL-CHEMO PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY OR-PREFERRED-BRAND-SPECIALTY ON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary
TEPEZZA TEPEZZA TERIPARATIDE TERIPARATIDE TETRABENAZIN TETRABENAZIN THALOMID THALOMID THOLA THIOLA THIOTEPA THIOTEPA THIOTEPA TIBSOVO TICE TICE TICE TICE TIGLUTIK TOBI TOBI TOBRAMYCIN TOBRAMYCIN TOBRAMYCIN TOLVAPTAN	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY ON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary
TEPEZZA TEPEZZA TERIPARATIDE TERIPARATIDE TETRABENAZIN TETRABENAZIN THALOMID THALOMID THALOMID THIOLA THIOLA THIOTEPA TIBSOVO TIESOVO TICE TICE TICE TIGLUTIK TOBI TOBI TOBRAMYCIN TOBRAMYCIN TOBRAMYCIN TOLVAPTAN TOLVAPTAN	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary
TEPEZZA TEPEZZA TERIPARATIDE TERIPARATIDE TETRABENAZIN TETRABENAZIN THALOMID THALOMID THOLA THIOLA THIOTEPA THIOTEPA TIBSOVO TIESOVO TICE TICE TICE TIGLUTIK TIGLUTIK TOBI TOBI TOBRAMYCIN TOBRAMYCIN TOBRAMYCIN TOBRAMYCIN TOLVAPTAN TOLVAPTAN	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
TEPEZZA TEPEZZA TERIPARATIDE TERIPARATIDE TETRABENAZIN TETRABENAZIN THALOMID THALOMID THALOMID THOLA THIOLA THIOTEPA TIBSOVO TIBSOVO TICE TICE TICE TIGLUTIK TIGLUTIK TOBI TOBI TOBRAMYCIN TOBRAMYCIN TOLVAPTAN TOLVAPTAN TOLVAPTAN	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY ON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY ON-PREFERRED-BRAND-SPECIALTY ON-PREFERRED-BRAND-SPECIALTY ON-PREFERRED-BRAND-SPECIALTY ON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
TEPEZZA TEPEZZA TERIPARATIDE TERIPARATIDE TERIPARATIDE TETRABENAZIN THALOMID THALOMID THALOMID THIOLA THIOLA THIOTEPA THIOTEPA TIBSOVO TIESOVO TICE TICE TICE TICE TICE TIGLUTIK TIGLUTIK TOBI TOBI TOBRAMYCIN TOBRAMYCIN TOBRAMYCIN TOLVAPTAN	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
TEPEZZA TEPEZZA TERIPARATIDE TERIPARATIDE TETRABENAZIN TETRABENAZIN THALOMID THALOMID THALOMID THOLA THIOLA THIOTEPA TIBSOVO TIBSOVO TICE TICE TICE TIGLUTIK TIGLUTIK TOBI TOBI TOBRAMYCIN TOBRAMYCIN TOLVAPTAN TOLVAPTAN TOLVAPTAN	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY ON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY ON-PREFERRED-BRAND-SPECIALTY ON-PREFERRED-BRAND-SPECIALTY ON-PREFERRED-BRAND-SPECIALTY ON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
TEPEZZA TEPEZZA TEPEZZA TERIPARATIDE TERIPARATIDE TETRABENAZIN TETRABENAZIN THALOMID THALOMID THIOLA THIOLA THIOTEPA THIOTEPA THIOTEPA TIBSOVO TICE TICE TICE TICE TIGLUTIK TOBI TOBI TOBRAMYCIN TOBRAMYCIN TOBRAMYCIN TOBRAMYCIN TOLVAPTAN	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY GENERIC-SPECIALTY	Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
TEPEZZA TEPEZZA TEPEZZA TERIPARATIDE TERIPARATIDE TETRABENAZIN TETRABENAZIN THALOMID THALOMID THOLA THIOLA THIOTEPA THIOTEPA THIOTEPA TIBSOVO TIESOVO TICE TICE TICE TICE TIGLUTIK TOBI TOBI TOBRAMYCIN TOBRAMYCIN TOBRAMYCIN TOBRAMYCIN TOLVAPTAN TOPOSAR	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ON-PREFERED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ON-PREFERED-BRAND-SPECIALTY GENERIC-SPECIALTY	Blue Cross Formulary National Performance Formulary
TEPEZZA TEPEZZA TEPEZZA TERIPARATIDE TERIPARATIDE TETRABENAZIN TETRABENAZIN THALOMID THALOMID THOLA THIOLA THIOTEPA THIOTEPA THIOTEPA TIBSOVO TICE TICE TICE TICE TIGLUTIK TOBI TOBI TOBI TOBI TOBRAMYCIN TOBRAMYCIN TOBRAMYCIN TOLVAPTAN TOLVAPTAN TOLVAPTAN TOLVAPTAN TOLVAPTAN TOPOSAR TOPOTECAN	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ON-PREFERRED-BRAND-SPECIALTY ON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY	Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
TEPEZZA TEPEZZA TEPEZZA TERIPARATIDE TERIPARATIDE TETRABENAZIN TETRABENAZIN THALOMID THALOMID THALOMID THIOLA THIOLA THIOTEPA TIBSOVO TICE TICE TICE TICE TIGLUTIK TOBI TOBI TOBRAMYCIN TOBRAMYCIN TOBRAMYCIN TOBRAMYCIN TOBRAMYCIN TOLVAPTAN TOLVAPTAN TOLVAPTAN TOLVAPTAN TOLVAPTAN TOPOSAR TOPOSAR TOPOSAR TOPOSCAN TOPOTECAN TORISEL	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORN-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY ORN-PREFERED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERED-BRAND-SPECIALTY GENERIC-SPECIALTY ON-PREFERED-BRAND-SPECIALTY GENERIC-SPECIALTY	Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Sule Cross Formulary Rotional Performance Formulary Blue Cross Formulary Sule Cross Formulary Rotional Performance Formulary Blue Cross Formulary Sule Cross Formulary Rotional Performance Formulary Blue Cross Formulary
TEPEZZA TEPEZZA TEPEZZA TERIPARATIDE TERIPARATIDE TETRABENAZIN TETRABENAZIN THALOMID THALOMID THIOLA THIOLA THIOTEPA THIOTEPA TIBSOVO TIBSOVO TICE TICE TICE TICE TIGLUTIK TOBI TOBI TOBIAMYCIN TOBRAMYCIN TOBRAMYCIN TOBRAMYCIN TOLVAPTAN TOPOSAR TOPOSAR TOPOTECAN TOPOTECAN TORISEL TORISEL TOTECT	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORN-PREFERED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY ON-PREFERRED-BRAND-SPECIALTY ON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
TEPEZZA TEPEZZA TERPEZZA TERIPARATIDE TERIPARATIDE TETRABENAZIN TETRABENAZIN THALOMID THALOMID THOLA THIOLA THIOLA THIOTEPA THIOTEPA THIOTEPA TIBSOVO TICE TICE TICE TICE TIGLUTIK TOBI TOBI TOBI TOBRAMYCIN TOBRAMYCIN TOBRAMYCIN TOBRAMYCIN TOLVAPTAN TOPOSAR TOPOSAR TOPOTECAN TOPOTECAN TORISEL TORISEL TOTECT TRACLEER	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary Rotal Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Rotal Performance Formulary Blue Cross Formulary Rotal Performance Formulary Rotal Perfor
TEPEZZA TEPEZZA TERIPARATIDE TERIPARATIDE TERIPARATIDE TETRABENAZIN TETRABENAZIN THALOMID THALOMID THIOLA THIOLA THIOTEPA THIOTEPA THIOTEPA TIBSOVO TICE TICE TIGLUTIK TIGLUTIK TOBI TOBI TOBRAMYCIN TOBRAMYCIN TOBRAMYCIN TOBRAMYCIN TOBRAMYCIN TOLVAPTAN TOLVAPTAN TOLVAPTAN TOLVAPTAN TOLVAPTAN TOLVAPTAN TOPOSAR TOPOSAR TOPOSAR TOPOTECAN TORISEL TORISEL TOTECT	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY ON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary

TRAZIMERA	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
TRAZIMERA	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
TREANDA	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
TRELSTAR	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
TRELSTAR	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
TREMFYA	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
TREMFYA	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
TREPROSTINIL	GENERIC-SPECIALTY	Blue Cross Formulary
TREPROSTINIL	GENERIC-SPECIALTY	National Performance Formulary
TRETINOIN	ORAL-CHEMO	Blue Cross Formulary
TRETINOIN	ORAL-CHEMO	National Performance Formulary
TRETTEN	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
TRETTEN	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
TRIENTINE	GENERIC-SPECIALTY	Blue Cross Formulary
TRIENTINE	GENERIC-SPECIALTY	National Performance Formulary
TRIKAFTA	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
TRIKAFTA	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
TRILURON	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
TRIPTODUR	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
TRIPTODUR	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
TRISENOX	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
TRISENOX	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
TRIVISC	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
TRODELVY	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
TRODELVY	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
TRUXIMA	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
TUKYSA	ORAL-CHEMO	Blue Cross Formulary
TUKYSA	ORAL-CHEMO	National Performance Formulary
TURALIO	ORAL-CHEMO	Blue Cross Formulary
TURALIO	ORAL-CHEMO	National Performance Formulary
TYKERB	ORAL-CHEMO	Blue Cross Formulary
TYKERB	ORAL-CHEMO	National Performance Formulary
TYMLOS	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
TYMLOS	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
TYSABRI	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
TYSABRI	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
TYVASO	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
TYVASO	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
UDENYCA	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ULTOMIRIS	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ULTOMIRIS ULTOMIRIS	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary
		,
ULTOMIRIS	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
ULTOMIRIS UNITUXIN	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary
ULTOMIRIS UNITUXIN UNITUXIN	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary
ULTOMIRIS UNITUXIN UNITUXIN UPLIZNA	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
ULTOMIRIS UNITUXIN UNITUXIN UPLIZNA UPLIZNA	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
ULTOMIRIS UNITUXIN UNITUXIN UPLIZNA UPLIZNA UPTRAVI	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary
ULTOMIRIS UNITUXIN UNITUXIN UPLIZNA UPLIZNA UPTRAVI UPTRAVI	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary
ULTOMIRIS UNITUXIN UNITUXIN UPLIZNA UPLIZNA UPTRAVI UPTRAVI VALCHLOR	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary
ULTOMIRIS UNITUXIN UNITUXIN UPLIZNA UPLIZNA UPTRAVI UPTRAVI VALCHLOR VALCHLOR	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary
ULTOMIRIS UNITUXIN UNITUXIN UPLIZNA UPLIZNA UPTRAVI UPTRAVI VALCHLOR VALCHLOR VALRUBICIN	NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY	National Performance Formulary Blue Cross Formulary
ULTOMIRIS UNITUXIN UNITUXIN UPLIZNA UPLIZNA UPTRAVI UPTRAVI VALCHLOR VALCHLOR VALRUBICIN VALRUBICIN	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary
ULTOMIRIS UNITUXIN UNITUXIN UPLIZNA UPLIZNA UPTRAVI UPTRAVI VALCHLOR VALCHLOR VALCHLOR VALRUBICIN VALSTAR	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary Slue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Slue Cross Formulary
ULTOMIRIS UNITUXIN UNITUXIN UPLIZNA UPLIZNA UPTRAVI UPTRAVI VALCHLOR VALCHLOR VALCHLOR VALRUBICIN VALSTAR VALSTAR	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
ULTOMIRIS UNITUXIN UNITUXIN UPLIZNA UPLIZNA UPTRAVI UPTRAVI VALCHLOR VALCHLOR VALCHLOR VALCHLOR VALRUBICIN VALSTAR VALSTAR VANTAS	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
ULTOMIRIS UNITUXIN UNITUXIN UPLIZNA UPLIZNA UPTRAVI UPTRAVI VALCHLOR VALCHLOR VALRUBICIN VALRUBICIN VALSTAR VALSTAR VANTAS	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary
ULTOMIRIS UNITUXIN UNITUXIN UPLIZNA UPLIZNA UPTRAVI UPTRAVI VALCHLOR VALCHLOR VALRUBICIN VALRUBICIN VALSTAR VALSTAR VANTAS VANTAS VECTIBIX	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary
ULTOMIRIS UNITUXIN UNITUXIN UPLIZNA UPLIZNA UPTRAVI UPTRAVI VALCHLOR VALCHLOR VALRUBICIN VALRUBICIN VALSTAR VALSTAR VANTAS VANTAS VECTIBIX VECTIBIX	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary
ULTOMIRIS UNITUXIN UNITUXIN UPLIZNA UPLIZNA UPTRAVI UPTRAVI VALCHLOR VALCHLOR VALRUBICIN VALRUBICIN VALSTAR VALSTAR VANTAS VANTAS VECTIBIX VECADE	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
ULTOMIRIS UNITUXIN UNITUXIN UPLIZNA UPLIZNA UPTRAVI UPTRAVI VALCHLOR VALCHLOR VALCHLOR VALRUBICIN VALSTAR VALSTAR VANTAS VANTAS VECTIBIX VECADE VELCADE	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
ULTOMIRIS UNITUXIN UNITUXIN UPLIZNA UPLIZNA UPTRAVI UPTRAVI VALCHLOR VALCHLOR VALCHLOR VALRUBICIN VALSTAR VALSTAR VANTAS VANTAS VECTIBIX VECTIBIX VELCADE VELCADE VELCADE	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
ULTOMIRIS UNITUXIN UNITUXIN UPIZNA UPLIZNA UPLIZNA UPTRAVI UPTRAVI VALCHLOR VALCHLOR VALCHLOR VALRUBICIN VALSTAR VALSTAR VANTAS VANTAS VECTIBIX VECTIBIX VELCADE VELCADE VELETRI	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
ULTOMIRIS UNITUXIN UNITUXIN UPLIZNA UPLIZNA UPLIZNA UPTRAVI VALCHLOR VALCHLOR VALCHLOR VALRUBICIN VALRUBICIN VALSTAR VALSTAR VANTAS VANTAS VECTIBIX VECTIBIX VELCADE VELCADE VELETRI VELETRI VEMLIDY	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
ULTOMIRIS UNITUXIN UNITUXIN UPLIZNA UPLIZNA UPTRAVI UPTRAVI VALCHLOR VALCHLOR VALRUBICIN VALRUBICIN VALSTAR VALSTAR VANTAS VECTIBIX VECTIBIX VELCADE VELCADE VELETRI VELETRI VEMLIDY VEMLIDY	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
ULTOMIRIS UNITUXIN UNITUXIN UPLIZNA UPLIZNA UPTRAVI UPTRAVI VALCHLOR VALCHLOR VALCHLOR VALRUBICIN VALSTAR VALSTAR VALSTAR VANTAS VECTIBIX VECTIBIX VELCADE VELCADE VELETRI VELETRI VEMILIDY VEMLIDY VEMLIDY VENCLEXTA	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
ULTOMIRIS UNITUXIN UNITUXIN UPLIZNA UPLIZNA UPLIZNA UPTRAVI UPTRAVI VALCHLOR VALCHLOR VALRUBICIN VALRUBICIN VALSTAR VANTAS VANTAS VANTAS VECTIBIX VECTIBIX VECTIBIX VELCADE VELCADE VELETRI VEMLIDY VEMLIDY VEMLIDY VEMLIDY VENCLEXTA	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
ULTOMIRIS UNITUXIN UNITUXIN UPLIZNA UPLIZNA UPLIZNA UPTRAVI UPTRAVI VALCHLOR VALCHLOR VALCHLOR VALRUBICIN VALSTAR VALSTAR VALSTAR VALSTAR VANTAS VECTIBIX VECTIBIX VECTIBIX VELCADE VELCADE VELETRI VELETRI VEMLIDY VEMLIDY VENCLEXTA VENCLEXTA VENCLEXTA	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary
ULTOMIRIS UNITUXIN UNITUXIN UPLIZNA UPLIZNA UPLIZNA UPTRAVI UPTRAVI VALCHLOR VALCHLOR VALCHLOR VALRUBICIN VALRUBICIN VALSTAR VANTAS VECTIBIX VECTIBIX VECTIBIX VECTIBIX VELCADE VELCADE VELETRI VELETRI VEMLIDY VEMLIDY VENCLEXTA VENCLEXTA VENCLEXTA VENCLEXTA VENCLEXTA VENTAVIS	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary
ULTOMIRIS UNITUXIN UNITUXIN UPLIZNA UPLIZNA UPLIZNA UPTRAVI VALCHLOR VALCHLOR VALCHLOR VALRUBICIN VALSTAR VALSTAR VALSTAR VANTAS VANTAS VECTIBIX VECTIBIX VECTIBIX VELCADE VELCADE VELCADE VELETRI VEMEIT VENCLEXTA VENTAVIS VENTAVIS VERZENIO	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
ULTOMIRIS UNITUXIN UNITUXIN UPLIZNA UPLIZNA UPLIZNA UPTRAVI UPTRAVI VALCHLOR VALCHLOR VALCHLOR VALRUBICIN VALRUBICIN VALSTAR VANTAS VECTIBIX VECTIBIX VECTIBIX VELCADE VELCADE VELETRI VELETRI VELETRI VEMLIDY VEMLIDY VENCLEXTA VENTAVIS VENTAVIS VENTAVIS VENTAVIS VERZENIO VERZENIO VIDAZA	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
ULTOMIRIS UNITUXIN UNITUXIN UPLIZNA UPLIZNA UPLIZNA UPTRAVI UPTRAVI VALCHLOR VALCHLOR VALCHLOR VALRUBICIN VALRUBICIN VALSTAR VANTAS VALSTAR VANTAS VECTIBIX VECTIBIX VELCADE VELCADE VELETRI VELETRI VELETRI VELETRI VEMILIDY VENCLEXTA VENTAVIS VENTAVIS VERZENIO VERZENIO VERZENIO VIDAZA VIDAZA	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
ULTOMIRIS UNITUXIN UNITUXIN UPLIZNA UPLIZNA UPLIZNA UPTRAVI UPTRAVI VALCHLOR VALCHLOR VALCHLOR VALRUBICIN VALRUBICIN VALSTAR VALSTAR VANTAS VECTIBIX VECTIBIX VECTIBIX VELCADE VELCADE VELETRI VELETRI VELETRI VEMLIDY VEMLIDY VENCLEXTA VENTAVIS VENTAVIS VERZENIO VIDAZA	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary
ULTOMIRIS UNITUXIN UNITUXIN UPLIZNA UPLIZNA UPLIZNA UPTRAVI UPTRAVI VALCHLOR VALCHLOR VALCHLOR VALRUBICIN VALRUBICIN VALSTAR VANTAS VANTAS VECTIBIX VECTIBIX VECTIBIX VECTIBIX VELETRI VELETRI VELETRI VELETRI VEMLIDY VENCLEXTA VENCLEXTA VENTAVIS VERZENIO VIDAZA VIDAZA VIDAZA VIDAZA VIDAZA VIDAZA VIDAZA VIEKIRA	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary
ULTOMIRIS UNITUXIN UNITUXIN UPLIZNA UPLIZNA UPLIZNA UPTRAVI UPTRAVI VALCHLOR VALCHLOR VALCHLOR VALRUBICIN VALRUBICIN VALSTAR VALSTAR VANTAS VECTIBIX VECTIBIX VECTIBIX VECTIBIX VELCADE VELCADE VELETRI VELETRI VELETRI VELETRI VEMLIDY VEMLIDY VEMLIDY VENCLEXTA VENTAVIS VERZENIO VERZENIO VIDAZA VIDAZA VIDAZA VIDAZA VIDAZA VIGABATRIN	NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary
ULTOMIRIS UNITUXIN UNITUXIN UPLIZNA UPLIZNA UPLIZNA UPTRAVI UPTRAVI VALCHLOR VALCHLOR VALCHLOR VALRUBICIN VALRUBICIN VALSTAR VANTAS VANTAS VECTIBIX VECTIBIX VECTIBIX VECTIBIX VELCADE VELCADE VELETRI VELETRI VELETRI VEMLIDY VEMLIDY VENCLEXTA VENCLEXTA VENTAVIS VERZENIO VIDAZA VIDAZA VIDAZA VIDAZA VIDAZA VIEKIRA	NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY GENERIC-SPECIALTY GENERIC-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary Blue Cross Formulary National Performance Formulary

WIGGORDE OFFICERSON ONE-PREVENSES ONNO-SPECIALTY VILTESO NOW-PREVENSES ONNO-SPECIALTY OND-PREVENSES ONNO-SPECIALTY ONNO-PREVENSES ONNO-SPECIALTY WIGGORD NOW-PREVENSES ONNO-SPECIALTY WIGGORD VINBLASTINE ONN-CREEK-SPECIALTY VINBLASTINE GENERAL SPECIALTY VINBLASTINE GENERAL SPECIALTY WIGGORD ONN-CREEK-SPECIALTY WIGGORD VINBLASTINE GENERAL SPECIALTY WIGGORD ONN-CREEK-SPECIALTY WIGGORD VINBLASTINE GENERAL SPECIALTY WIGGORD MON-PREVENSE SANDAS-SPECIALTY WIGGORD VINBLASTINE V		•	
VINITERO NON-PRETERED-BRAND-SPECIALTY VINIDAM NON-PRETERED-BRAND-SPECIALTY VINIDAM NON-PRETERED-BRAND-SPECIALTY VINIDAM NON-PRETERED-BRAND-SPECIALTY VINIDAM NON-PRETERED-BRAND-SPECIALTY VINIDAM NON-PRETERED-BRAND-SPECIALTY VINIDAM VINIDAM ON-PRETERED-BRAND-SPECIALTY VINIDAM VINIDAM VINIDAM VINIDAM VINIDAM VINIDAM VINIDAM VINIDAM CONTROL SPECIALTY VINIDAM V			National Performance Formulary
VMEMAM NON-PREFERED-BRAND-SPECALTY VINBLASTINE GENERIC-SPECALTY GENERIC-SPECALTY WINDLASTINE WINDLASTINE GENERIC-SPECALTY WINDLASTINE WINDLAS	VILTEPSO	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
VIMILATINE GENERIC-SPECALTY WIRDLASTINE WIRDLASTINE GENERIC-SPECALTY WIRDLASTINE WIRDLAS	VILTEPSO		
WIRELASTINE GENERIC-SPECIALTY WINCRESTINE WINCRE			
VINDUSTINE GENERIC-SPECIALTY VINCRESTINE GENERIC-SPECIALTY VINCRESTINE GENERIC-SPECIALTY WINCRESTINE WINCRESTINE WINCRESTINE NON-PREFERENCE-BRAND-SPECIALTY WINCRESTINE WINCRE			
VINCEISTINE GENERIC SPECIALTY NORDELBINE GENERIC SPECIALTY VINDELBINE GENERIC SPECIALTY VINDELBINE GENERIC SPECIALTY NORDELBINE GENERIC SPECIALTY NISCO 3 NOR PREFERED BERAND SPECIALTY VISCO 3 VISC			·
VINCEREINE GENERIC-SPECIATY WINDEREINE GENERIC-SPECIATY OND PRETERIES BARRON SPECIALTY VINCENTER VISUPIVE NON PRETERIES BARRON SPECIALTY NON PRETERIES BARRON SPECIALTY VISUPIVE VISUPIVE NON PRETERIES BARRON SPECIALTY VISUPIVE VIVIAND ORAL CHEMO Not Department of multiply VIVIAND VIVIAND ORAL CHEMO NON PRETERIES BARRON SPECIALTY VIVIAND ORAL CHEMO NON PRETERIES BARRON SPECIALTY VIVIAND VIVIAND ORAL CHEMO ORAL CHEMO NON PRETERIES BARRON SPECIALTY VIVIAND VIVIAND ORAL CHEMO ORAL CHEMO NON PRETERIES BARRON SPECIALTY VIVIAND VIVIAND ORAL CHEMO ORAL CHEMO NON PRETERIES BARRON SPECIALTY NON-PRETERIES BARRON SPECIALTY VIVIAND V			,
VINDELEINE GENERL-SPECIALTY NICOS 3 NON-PREFERED-BRAND-SPECIALTY NICOS 3 NON-PREFERED-BRAND-SPECIALTY NICOS 50 NON-PREFERED-BRAND-SPECIALTY NICOS			
VINDREAD VISCO 3 NON-PRETENBED-BRAND-SPECIALTY WISLUTIVE NON-PRETENBED-BRAND-SPECIALTY WISLUTIVE NON-PRETENBED-BRAND-SPECIALTY NON-PRETENBED-BRAND-SPECIALTY WITRANVI ORAL-CHEMO NON-PRETENBED-BRAND-SPECIALTY			·
VISLOYNE NON-PREFERBO-BRAND-SPECIALTY NON-PREFERBO-BRAND SPECIALTY NON-PREFERBO-BRAND-SPECIALTY NON-PRE	VINORELBINE	GENERIC-SPECIALTY	Blue Cross Formulary
VISIONYE NON-PRETENDED BRAND-SPECIALTY NORTH CONSTRUMENT WITRARY ORAL CHEMO NITRARY ORAL CHEMO NORTH CONSTRUMENT WITROL WITROL NORTH CONSTRUMENT WITROL WITROL NORTH CONSTRUMENT WITROL WITR			National Performance Formulary
VISIONE NON-PRETERBLE BRAND-SPECIALTY ORAL-CHEMO BBLE Cross Formulary VITRAKYI ORAL-CHEMO BRAND-SPECIALTY VINTROL NON-PRETERBLE BRAND-SPECIALTY BRAND RESERBLE BRAND-SPECIALTY BRA			Blue Cross Formulary
VITRAKYI VITRAKYI VITRAKYI VITROL NON-PREERRED BRAND SPECIALTY BIBUC Cross Formulary VITROL NON-PREERRED BRAND SPECIALTY WITROL VIZIMBRO ORAL-CHEMO BIBUC Cross Formulary VIZIMBRO ORAL-CHEMO NON-PREERRED BRAND SPECIALTY BIBUC Cross Formulary VONVENDI NON-PREERRED BRAND SPECIALTY WONVENDI NON-PREERRED BRAND-SPECIALTY VONVENDI NON-PREERRED BRAND-SPECIALTY WOSEVI PREERRED-BRAND-SPECIALTY WOSEVI PREERRED-BRAND-SPECIALTY WOSEVI VORIBRIT ORAL-CHEMO ROAL-CHEMO ROAL-			
VITTROL NON-PRETERBED BRAND-SPECIALTY WINTROL NON-PRETERBED BRAND-SPECIALTY WINTROL NON-PRETERBED BRAND-SPECIALTY WINTROL NON-PRETERBED BRAND-SPECIALTY WINTROL NON-PRETERBED BRAND-SPECIALTY WONVEND NON-PRETERBED BRAND-SPECIALTY WONVEND NON-PRETERBED BRAND-SPECIALTY VONVEND NON-PRETERBED BRAND-SPECIALTY VONVEND NON-PRETERBED BRAND-SPECIALTY WORTENT ORAL-CHEMO WORTENT ORAL-CHEMO WORTENT ORAL-CHEMO WORTENT ORAL-CHEMO NON-PRETERBED BRAND-SPECIALTY VORTENT ORAL-CHEMO WORTENT ORAL-CHEMO NON-PRETERBED BRAND-SPECIALTY WORTENT VORTENT ORAL-CHEMO NON-PRETERBED BRAND-SPECIALTY WORTENT VORTENT VORTENT ORAL-CHEMO NON-PRETERBED BRAND-SPECIALTY WORTENT VORTENT VORTENT WORTENT NON-PRETERBED BRAND-SPECIALTY WORTENT WORTENT PRETERBED BRAND-SPECIALTY WORTENT WORTENT PRETERBED BRAND-SPECIALTY NON-PRETERBED BRAND-SPECIALTY WORTENT PRETERBED BRAND-SPECIALTY WORTENT PRETERBED BRAND-SPECIALTY NON-PRETERBED BRAND-SPECIALTY WORTENT PRETERBED BRAND-SPECIALTY WORTENT PRETERBED BRAND-SPECIALTY WORTENT WORTENT PRETERBED BRAND-SPECIALTY WORTENT WORTENT PRETERBED BRAND-SPECIALTY NON-PRETERBED BRAND-SPECIALTY WORTENT WORTENT WORTENT WORTENT NON-PRETERBED BRAND-SPECIALTY NON-PRETERBED BRAND-SPECIALTY WORTENT WORTENT WORTENT WORTENT WORTENT WORTENT WORTENT WORTENT PRETERBED BRAND-SPECIALTY NON-PRETERBED BRAND-SPECIALTY WORTENT WORTENT	VISUDYNE	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
NIVITEOL NON PREFERED BRAND SPECIALTY WITTEOL NON PREFERED BRAND SPECIALTY WIZEMRO ORAL-CHEMO BRA-CHEMO NON-PREFERED BRAND SPECIALTY WORKYND WORKYND NON-PREFERED BRAND SPECIALTY WORKYND WOR			Blue Cross Formulary
VINTROL VIZIMBRO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO Notional Performance Formulary VONVINDI NON-PREFERBLE-BRAND-SPECIALTY NOOVENDI NON-PREFERBLE-BRAND-SPECIALTY VONVINDI NON-PREFERBLE-BRAND-SPECIALTY VONVINDI NON-PREFERBLE-BRAND-SPECIALTY NOTIONAL VOSEVI PREFERBLE-BRAND-SPECIALTY NOTIONAL VOSEVI VOSEVI PREFERBLE-BRAND-SPECIALTY NOTIONAL VOSEVI VOREINT ORAL-CHEMO NORAL-CHEMO NORAL-CHEMO NON-PREFERBLE-BRAND-SPECIALTY VOREINT VOREINT VOREINT NON-PREFERBLE-BRAND-SPECIALTY VOREINT VOREINT PREFERBLE-BRAND-SPECIALTY NOTIONAL VOREINT PREFERBLE-BRAND-SPECIALTY VOREINT VOREINT PREFERBLE-BRAND-SPECIALTY NORDHAMA NON-PREFERBLE-BRAND-SPECIALTY VOREINT VOREIN	VITRAKVI	ORAL-CHEMO	National Performance Formulary
VZEMPRO ORAL-CHEMO National Performance Formulary VONVENDI NON-PREFERRED BRAND-SPECIALTY NOVENDI NON-PREFERRED BRAND-SPECIALTY VOSEVI PREFERRED BRAND-SPECIALTY VOSEVI PREFERRED BRAND-SPECIALTY VOSEVI PREFERRED BRAND-SPECIALTY VOSEVI VOSEVI PREFERRED BRAND-SPECIALTY VOSEVI VOSEVI PREFERRED BRAND-SPECIALTY VOSEVI VOSEVI ORAL-CHEMO National Performance Formulary VOTRIENT ORAL-CHEMO National Performance Formulary VORIENT VORTIENT ORAL-CHEMO NATIONAL PROFESSIONAL SPECIALTY VORIENT VORIENT VORDER VORTIENT NON-PREFERRED BRAND-SPECIALTY VOMERITY PREFERRED BRAND-SPECIALTY VOMERITY PREFERRED BRAND-SPECIALTY VOMERITY VOMORE NON-PREFERED BRAND-SPECIALTY NON-PREFERRED BRAND-SPECIALTY NON-PREFERRED BRAND-SPECIALTY NON-PREFERRED BRAND-SPECIALTY VOMORE NON-PREFERRED BRAND-SPECIALTY NON-PREFERRED BRAND-SPECIALTY VOMORE NON-PREFERRED BRAND-SPECIALTY NON-PREFERRED BRAND-SPECIALTY VOMORE NON-PREFERRED BRAND-SPECIALTY N	VIVITROL		Blue Cross Formulary
VONENDI NON-PREERRED-BRAND-SPECIALTY NONENDI NON-PREERRED-BRAND-SPECIALTY NATIONAL PREFERRED-BRAND-SPECIALTY NOTHERT ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NONENDER SPECIALTY NONE NONE PREFERRED-BRAND-SPECIALTY NONENDER SPECIALTY NONENDER SPECIALTY NONENDER SPECIALTY NONENDER SPECIALTY NATIONAL PREFERRED-BRAND-SPECIALTY NATIONAL PREFERRED-BRAND-SPECIALTY NONENDER SPECIALTY NONE SP	VIVITROL	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
VONVENDI NON-PREERRED-BRAND-SPECIALTY VOSEVI PREERRED-BRAND-SPECIALTY NOTOREM VOSEVI PREERRED-BRAND-SPECIALTY NOTOREM VOSEVI PREERRED-BRAND-SPECIALTY NOTOREM VOTEENT ORAL-CHEMO DRAL-CHEMO Non-PREERRED-BRAND-SPECIALTY NOTOREM VORTEW VORTEW NON-PREERRED-BRAND-SPECIALTY NON-PREER	VIZIMPRO	ORAL-CHEMO	Blue Cross Formulary
VOSEYI PREFERED BRAND-SPECIALTY VORTON VORTENT ORAL-CHEMO National Performance Formulary VORTON VORTON VORTON VORTON VORTON VON-PREFERED BRAND-SPECIALTY VORTON VORTON VON-PREFERED BRAND-SPECIALTY VONDERTY PREFERED BRAND-SPECIALTY VONDERTY PREFERED BRAND-SPECIALTY VONDERTY PREFERED BRAND-SPECIALTY VONDERTY VONDERTY VONDAMAX NON-PREFERED BRAND-SPECIALTY NON-PREFERED BRAND-SPECIALTY VONDAMAX NON-PREFERED BRAND-SPECIALTY VONDORS NON-PREFERED BRAND-SPECIALTY N	VIZIMPRO	ORAL-CHEMO	National Performance Formulary
VOSEVI PREFERRED BRAND SPECIALTY VOSEVI PREFERED BRAND SPECIALTY ORAL CHEMO ORAL CHEMO National Performance Formulary VOTRIENT ORAL CHEMO National Performance Formulary VOTRIENT ORAL CHEMO National Performance Formulary VPRIV NON-PREFERED BRAND SPECIALTY NON-PREFERED BRAND SPECIALTY NON-PREFERED BRAND SPECIALTY NON-PREFERED BRAND SPECIALTY VINDAMAX NON-PREFERED BRAND SPECIALTY VINDAMAX NON-PREFERED BRAND SPECIALTY NON-	VONVENDI	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
VOSEVI PREFERRED BRAND-SPECIALTY VOTRIENT ORAL-CHEMO Buse Cross Formulary VOTRIENT ORAL-CHEMO Buse Cross Formulary VOTRIENT ORAL-CHEMO National Performance Formulary VPRIV NON-PREFERRED BRAND-SPECIALTY VPRIV NON-PREFERRED BRAND-SPECIALTY VOMERITY PREFERRED-BRAND-SPECIALTY VOMERITY PREFERRED-BRAND-SPECIALTY VOMERITY PREFERRED-BRAND-SPECIALTY VOMERITY PREFERRED-BRAND-SPECIALTY VOMDAMAX NON-PREFERRED-BRAND-SPECIALTY VOMDAMAX NON-PREFERRED-BRAND-SPECIALTY VOMDAMAX NON-PREFERRED-BRAND-SPECIALTY VOMDAMAX NON-PREFERRED-BRAND-SPECIALTY VOMDAGEL NON-PREFERRED-BRAND-SPECIALTY VOMDAGE NON-PREF	VONVENDI	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
VOTRIENT ORAL-CHEMO National Performance Formulary VORIV ORAL-CHEMO National Performance Formulary VPRIV NON-PREFERRED BRAND-SPECIALTY WIND NON-PREFERRED BRAND-SPECIALTY WIND PREFERRED BRAND-SPECIALTY WIND WIND WIND WIND PREFERRED BRAND-SPECIALTY WIND WIND WIND WIND WIND WIND WIND WIND	VOSEVI	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
VOTRIENT VPRIV VON-PREFERRED-BRAND-SPECIALTY VPRIV NON-PREFERRED-BRAND-SPECIALTY VOMERITY PREFERRED-BRAND-SPECIALTY VOMERITY PREFERRED-BRAND-SPECIALTY VOMERITY PREFERRED-BRAND-SPECIALTY VOMERITY PREFERRED-BRAND-SPECIALTY VONDAMAX NON-PREFERRED-BRAND-SPECIALTY VYNDAMAX NON-PREFERRED-BRAND-SPECIALTY VYNDAMAX NON-PREFERRED-BRAND-SPECIALTY NONDAME VYNDAMAX NON-PREFERRED-BRAND-SPECIALTY VYNDAGEL NON-PREFERRED-BRAND-SPECIALTY VYNDAGEL NON-PREFERRED-BRAND-SPECIALTY VYNDAGEL NON-PREFERRED-BRAND-SPECIALTY VYNDAGEL NON-PREFERRED-BRAND-SPECIALTY VYNDAGEL NON-PREFERRED-BRAND-SPECIALTY VYXEOS NON-PREFERRED-BRAND-SPECIALTY VYXEOS NON-PREFERRED-BRAND-SPECIALTY VYXEOS NON-PREFERRED-BRAND-SPECIALTY WAXIX NON-PREFERRED-BRAND-SPECIALTY WILATE PREFERRED-BRAND-SPECIALTY WILATE PREFERRED-BRAND-SPECIALTY WILATE PREFERRED-BRAND-SPECIALTY WILATE PREFERRED-BRAND-SPECIALTY WILATE PREFERRED-BRAND-SPECIALTY WILATE PREFERRED-BRAND-SPECIALTY WINRHO W	VOSEVI	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
VPRIV VPRIV VON-PREFERRED-BRAND-SPECIALTY VOMERITY VON-PREFERRED-BRAND-SPECIALTY VUMERITY VON-PREFERRED-BRAND-SPECIALTY VUMERITY PREFERRED-BRAND-SPECIALTY VON-PREFERRED-BRAND-SPECIALTY VYNDAMAX NON-PREFERRED-BRAND-SPECIALTY VYNDAMAX NON-PREFERRED-BRAND-SPECIALTY VYNDAMAX NON-PREFERRED-BRAND-SPECIALTY VYNDAGEL NON-PREFERRED-BRAND-SPECIALTY VYNDAGEL NON-PREFERRED-BRAND-SPECIALTY VYNDAGEL NON-PREFERRED-BRAND-SPECIALTY VYNDAGEL NON-PREFERRED-BRAND-SPECIALTY VYXEOS NON-PREFERRED-BRAND-SPECIALTY WXXEOS NON-PREFERRED-BRAND-SPECIALTY WXXIX NON-PREFERRED-BRAND-SPECIALTY WXXIX NON-PREFERRED-BRAND-SPECIALTY WILATE PREFERRED-BRAND-SPECIALTY WILATE WILATE PREFERRED-BRAND-SPECIALTY WILATE	VOTRIENT	ORAL-CHEMO	Blue Cross Formulary
VORINY VIMERITY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY Notional Performance formulary VYNDAMAX NON-PREFERRED-BRAND-SPECIALTY VYNDAMAX NON-PREFERRED-BRAND-SPECIALTY VYNDAGEL NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NAKIX NON-PREFERRED-BRAND-SPECIALTY NIN-PREFERRED-BRAND-SPECIALTY NIN-PREF	VOTRIENT	ORAL-CHEMO	National Performance Formulary
VUMERITY VIMERITY PREFERRED BRAND-SPECIALTY VINDAMAX NON-PREFERRED BRAND-SPECIALTY VINDAME VINDAME VINDAME VINDAME NON-PREFERRED BRAND-SPECIALTY National Performance Formulary VINDAME VINDAME	VPRIV	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
VUMERITY PREFERED-BRAND-SPECIALTY VYNDAMAX NON-PREFERED-BRAND-SPECIALTY VYNDAGEL NON-PREFERED-BRAND-SPECIALTY VYNDAGEL NON-PREFERED-BRAND-SPECIALTY VYNDAGEL NON-PREFERED-BRAND-SPECIALTY VYNDAGEL NON-PREFERED-BRAND-SPECIALTY Notional Performance formulary VYNDAGEL NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY VYXEOS NON-PREFERED-BRAND-SPECIALTY NATIONAL Performance formulary VYXEOS NON-PREFERED-BRAND-SPECIALTY NATIONAL NON-PREFERED-BRAND-SPECIALTY WAXIX NON-PREFERED-BRAND-SPECIALTY NATIONAL PERFORMANCE FOR ANY SPECIALTY WILATE PREFERED-BRAND-SPECIALTY NULATE PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY WINRHO PREFERED-BRAND-SPECIALTY WINRHO PREFERED-BRAND-SPECIALTY NATIONAL PERFORMANCE FOR ANY SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NON-PREFERED-BRAND-SPECIALTY NOTIONAL PREFERED-BRAND-SPECIALTY NATIONAL PERFORMANCE FOR ANY SPECIALTY NATIONAL PERFORMANCE FOR ANY SPECIALTY NATIONAL PERFORMANCE FOR ANY SPECIALTY NATIONAL PERF	VPRIV	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
VYNDAMAX NON-PREFERRED-BRAND-SPECIALTY VYNDAGEL NON-PREFERRED SPECIALTY VYNDAGEL NON-PREFERRED BRAND SPECIALTY WINDAGEL NON-PREFERRED-BRAND-SPECIALTY WONDY NON-PREFERRED-BRAND-SPECIALTY WONDY NON-PREFERRED-BRAND-SPECIALTY WONDY NON-PREFERRED-BRAND-SPECIALTY WONDY WAKIX NON-PREFERRED-BRAND-SPECIALTY WAKIX NON-PREFERRED-BRAND-SPECIALTY WAKIX NON-PREFERRED-BRAND-SPECIALTY WILATE PREFERRED-BRAND-SPECIALTY WILATE PREFERRED-BRAND-SPECIALTY WILATE PREFERRED-BRAND-SPECIALTY WILATE PREFERRED-BRAND-SPECIALTY WINSHIO WINSHIO PREFERRED-BRAND-SPECIALTY WINSHIO WINSHIO PREFERRED-BRAND-SPECIALTY WINSHIO PREFERRED-BRAND-SPECIALTY WINSHIO W	VUMERITY	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
VYNDAQEL NON-PREFERRED-BRAND-SPECIALTY VYNDAQEL NON-PREFERRED-BRAND-SPECIALTY VYNDAQEL NON-PREFERRED-BRAND-SPECIALTY VYNONOYS NON-PREFERRED-BRAND-SPECIALTY VYNEOS NON-PREFERRED-BRAND-SPECIALTY VYXEOS NON-PREFERRED-BRAND-SPECIALTY WAKIX NON-PREFERRED-BRAND-SPECIALTY WAKIX NON-PREFERRED-BRAND-SPECIALTY WAKIX NON-PREFERRED-BRAND-SPECIALTY WAKIX NON-PREFERRED-BRAND-SPECIALTY WILATE PREFERRED-BRAND-SPECIALTY WILATE PREFERRED-BRAND-SPECIALTY WINHO WINHO PREFERRED-BRAND-SPECIALTY WINHO WIN	VUMERITY	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
VYNDAQEL NON-PREFERRED-BRAND-SPECIALTY VYNDAGEL NON-PREFERRED-BRAND-SPECIALTY VYNEOS NON-PREFERRED-BRAND-SPECIALTY VYXEOS NON-PREFERRED-BRAND-SPECIALTY VYXEOS NON-PREFERRED-BRAND-SPECIALTY WAKIX NON-PREFERRED-BRAND-SPECIALTY WAKIX NON-PREFERRED-BRAND-SPECIALTY WAKIX NON-PREFERRED-BRAND-SPECIALTY WAKIX NON-PREFERRED-BRAND-SPECIALTY WILATE PREFERRED-BRAND-SPECIALTY WILATE PREFERRED-BRAND-SPECIALTY WILATE PREFERRED-BRAND-SPECIALTY WILATE PREFERRED-BRAND-SPECIALTY WINHOD WALCHEMO WALCH	VYNDAMAX	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
VYNDAGEL NON-PREFERRED-BRAND-SPECIALTY VYNEOS NON-PREFERRED-BRAND-SPECIALTY WARKX NON-PREFERRED-BRAND-SPECIALTY WARKX NON-PREFERRED-BRAND-SPECIALTY WARKX NON-PREFERRED-BRAND-SPECIALTY WARKX NON-PREFERRED-BRAND-SPECIALTY WARKX NON-PREFERRED-BRAND-SPECIALTY WILATE PREFERRED-BRAND-SPECIALTY WILATE PREFERRED-BRAND-SPECIALTY WINSHO WIN	VYNDAMAX	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
VYONDYS NON-PREFERRED-BRAND-SPECIALTY VYXEOS NON-PREFERRED-BRAND-SPECIALTY WAKIX NON-PREFERRED-BRAND-SPECIALTY WAKIX NON-PREFERRED-BRAND-SPECIALTY WAKIX NON-PREFERRED-BRAND-SPECIALTY WAKIX NON-PREFERRED-BRAND-SPECIALTY WILATE PREFERRED-BRAND-SPECIALTY WILATE PREFERRED-BRAND-SPECIALTY WILATE PREFERRED-BRAND-SPECIALTY WILATE PREFERRED-BRAND-SPECIALTY WINRHO WIN	VYNDAQEL	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
VYXEOS NON-PREFERRED-BRAND-SPECIALTY WAKIX NON-PREFERRED-BRAND-SPECIALTY WAKIX NON-PREFERRED-BRAND-SPECIALTY WAKIX NON-PREFERRED-BRAND-SPECIALTY WILATE PREFERRED-BRAND-SPECIALTY WILATE PREFERRED-BRAND-SPECIALTY WILATE PREFERRED-BRAND-SPECIALTY WINRHO WINRHO WIRE WALKORI ORAL-CHEMO WINRHO WINR	VYNDAQEL	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
VYXEOS NON-PREERRED-BRAND-SPECIALTY WAKIX NON-PREERRED-BRAND-SPECIALTY WAKIX NON-PREERRED-BRAND-SPECIALTY WILATE PREFERRED-BRAND-SPECIALTY WILATE PREFERRED-BRAND-SPECIALTY WILATE PREFERRED-BRAND-SPECIALTY WINATO PREFERRED-BRAND-SPECIALTY WINRHO PREFERRED-BRAND-SPECIALTY WINRHO PREFERRED-BRAND-SPECIALTY WINRHO PREFERRED-BRAND-SPECIALTY WINRHO PREFERRED-BRAND-SPECIALTY WINRHO PREFERRED-BRAND-SPECIALTY WINRHO NON-PREFERRED-BRAND-SPECIALTY WINRHO NON-PREFERRED-BRAND-SPECIALTY WINRHO WINRH	VYONDYS	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
WAXIX NON-PREFERED-BRAND-SPECIALTY WIKITE PREFERED-BRAND-SPECIALTY WIKITE PREFERED-BRAND-SPECIALTY WIKITE PREFERED-BRAND-SPECIALTY WIKITE PREFERED-BRAND-SPECIALTY WIKITE PREFERED-BRAND-SPECIALTY WIKITE PREFERED-BRAND-SPECIALTY WIKITO WIK	VYXEOS	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
WAKIX WILATE PREFERRED-BRAND-SPECIALTY WILATE PREFERRED-BRAND-SPECIALTY WILATE PREFERRED-BRAND-SPECIALTY WINRHO PREFERRED-BRAND-SPECIALTY WINRHO PREFERRED-BRAND-SPECIALTY WINRHO PREFERRED-BRAND-SPECIALTY WINRHO PREFERRED-BRAND-SPECIALTY XALKORI ORAL-CHEMO RIBUE Cross Formulary XALKORI ORAL-CHEMO National Performance Formulary XALKORI ORAL-CHEMO NATIONAL PREFERRED-BRAND-SPECIALTY XELIANZ NON-PREFERRED-BRAND-SPECIALTY XELIANZ PREFERRED-BRAND-SPECIALTY XELIANZ PREFERRED-BRAND-SPECIALTY XELIANZ PREFERRED-BRAND-SPECIALTY XELIANZ PREFERRED-BRAND-SPECIALTY XEMBIFY NON-PREFERRED-BRAND-SPECIALTY XEMBIFY XEMBIFY NON-PREFERRED-BRAND-SPECIALTY XEMBIFY XEMBIFY NON-PREFERRED-BRAND-SPECIALTY XEMBIFY XEMBIFY NON-PREFERRED-BRAND-SPECIALTY XEMBIFY XEMBIFY XEMBIFY NON-PREFERRED-BRAND-SPECIALTY XEMBIFY XEMBIFY XEMBIFY XEMBIFY NON-PREFERRED-BRAND-SPECIALTY XEMBIFY XEMBIF	VYXEOS	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
WILATE PREFERRED-BRAND-SPECIALTY National Performance Formulary WINRHO PREFERRED-BRAND-SPECIALTY National Performance Formulary WINRHO PREFERRED-BRAND-SPECIALTY Blue Cross Formulary WINRHO PREFERRED-BRAND-SPECIALTY National Performance Formulary XALKORI ORAL-CHEMO Blue Cross Formulary XALKORI ORAL-CHEMO National Performance Formulary XELIANZ NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XELIANZ NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary XELIANZ PREFERRED-BRAND-SPECIALTY National Performance Formulary XELIANZ PREFERRED-BRAND-SPECIALTY National Performance Formulary XEMBIFY NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary XEMBIFY NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary XEOMIN NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary XEOMIN NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary XEOWIN NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary XEVEVA PREFERRED-BRAND-SPECIALTY National Performance Formulary XIAFLEX PREFERED-BRAND-SPECIALTY National Performance Formulary XIAFLEX PREFERRED-BRAND-SPECIALTY National Performance Formulary XIAFLEX	WAKIX	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
WILATE PREFERED-BRAND-SPECIALTY Blue Cross Formulary WINRHO PREFERED-BRAND-SPECIALTY Blue Cross Formulary WINRHO PREFERED-BRAND-SPECIALTY National Performance Formulary XALKORI ORAL-CHEMO Blue Cross Formulary XALKORI ORAL-CHEMO National Performance Formulary XELIANZ NON-PREFERED-BRAND-SPECIALTY Blue Cross Formulary XELIANZ NON-PREFERED-BRAND-SPECIALTY Blue Cross Formulary XELIANZ PREFERED-BRAND-SPECIALTY National Performance Formulary XEMBIFY NON-PREFERED-BRAND-SPECIALTY Blue Cross Formulary XEOMIN NON-PREFERED-BRAND-SPECIALTY National Performance Formulary XEOMIN NON-PREFERED-BRAND-SPECIALTY National Performance Formulary XEOMIN NON-PREFERED-BRAND-SPECIALTY National Performance Formulary XGEVA PREFERED-BRAND-SPECIALTY National Performance Formulary XGEVA PREFERED-BRAND-SPECIALTY National Performance Formulary XIAFLEX PREFERED-BRAND-SPECIALTY National Performance Formulary XOLAIR PREFERED-BRAND-SPECIALTY National Performance Formulary XOLAIR PREFERED-BRAND-SPECIALTY National Performance Formulary XOSPATA ORAL-CHEMO Blue Cross Formulary XOSPATA ORAL-CHEMO Blue Cross Formulary XOSPATA ORAL-CHEMO National Performance Formulary XOSPATA PREFERED-BRAND-SPECIALTY National Performance Formulary XOSPATA PREFERED-BRAND-SPECIALTY National Performance Formulary XOSPATA PREFERED-BRAND-SPECIALTY National Performance Formulary XOSPATA PREFER	WAKIX	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
WINRHO PREFERRED-BRAND-SPECIALTY WINRHO PREFERRED-BRAND-SPECIALTY WINRHO PREFERRED-BRAND-SPECIALTY XALKORI ORAL-CHEMO Blue Cross Formulary XALKORI ORAL-CHEMO National Performance Formulary XELJANZ NON-PREFERRED-BRAND-SPECIALTY XELJANZ NON-PREFERRED-BRAND-SPECIALTY XELJANZ PREFERRED-BRAND-SPECIALTY XELJANZ PREFERRED-BRAND-SPECIALTY XELJANZ PREFERRED-BRAND-SPECIALTY XELJANZ PREFERRED-BRAND-SPECIALTY XELJANZ PREFERRED-BRAND-SPECIALTY XEMBIFY NON-PREFERRED-BRAND-SPECIALTY XEMBIFY NON-PREFERRED-BRAND-SPECIALTY XEMBIFY NON-PREFERRED-BRAND-SPECIALTY XEOMIN NON-PREFERRED-BRAND-SPECIALTY XEOMIN NON-PREFERRED-BRAND-SPECIALTY XEOMIN NON-PREFERRED-BRAND-SPECIALTY XEOMIN NON-PREFERRED-BRAND-SPECIALTY XEOMIN NON-PREFERRED-BRAND-SPECIALTY XIAFLEX PREFERRED-BRAND-SPECIALTY XIAFLEX XIAFLEX PREFERRED-BRAND-SPECIALTY XIAFLEX	WILATE	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
WINRHO PREFERRED-BRAND-SPECIALTY National Performance Formulary XALKORI ORAL-CHEMO National Performance Formulary XELIANZ NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XELIANZ NON-PREFERRED-BRAND-SPECIALTY XELIANZ NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary XELIANZ PREFERRED-BRAND-SPECIALTY XELIANZ PREFERRED-BRAND-SPECIALTY National Performance Formulary XELIANZ PREFERRED-BRAND-SPECIALTY XEMBIEY NON-PREFERRED-BRAND-SPECIALTY XEMBIEY NON-PREFERRED-BRAND-SPECIALTY XEMBIEY NON-PREFERRED-BRAND-SPECIALTY XEOMIN NON-PREFERRED-BRAND-SPECIALTY XEOMIN NON-PREFERRED-BRAND-SPECIALTY XEOMIN NON-PREFERRED-BRAND-SPECIALTY XEOVIN XEEVA PREFERRED-BRAND-SPECIALTY NATIONAL Performance Formulary XEEVA PREFERRED-BRAND-SPECIALTY NATIONAL PERFORMANCE XIAFLEX NOBATA ORAL-CHEMO NATIONAL PERFORMANCE XIAFLEX XIAFLEX NOBATA ORAL-CHEMO NATIONAL PERFORMANCE XIAFLEX	VA/II ATE	PRESERVED PRANTS CRECIALTY	
XALKORI ORAL-CHEMO National Performance Formulary XELIANZ NON-PREFERRED-BRAND-SPECIALTY XELIANZ NON-PREFERRED-BRAND-SPECIALTY XELIANZ PREFERRED-BRAND-SPECIALTY XELIANZ PREFERRED-BRAND-SPECIALTY XELIANZ PREFERRED-BRAND-SPECIALTY XELIANZ PREFERRED-BRAND-SPECIALTY XELIANZ PREFERRED-BRAND-SPECIALTY XEMBIFY NON-PREFERRED-BRAND-SPECIALTY XEMBIFY NON-PREFERRED-BRAND-SPECIALTY XEMBIFY NON-PREFERRED-BRAND-SPECIALTY XEOMIN NON-PREFERRED-BRAND-SPECIALTY XEOMIN NON-PREFERRED-BRAND-SPECIALTY XEOMIN NON-PREFERRED-BRAND-SPECIALTY XEOWIN NON-PREFERRED-BRAND-SPECIALTY XEOWIN NON-PREFERRED-BRAND-SPECIALTY XEOWIN XEOWA PREFERRED-BRAND-SPECIALTY XIBUE Cross Formulary XIAFLEX PREFERRED-BRAND-SPECIALTY NATIONAL Performance Formulary XOSPATA ORAL-CHEMO NATIONAL Performance Formulary XOSPATA ORAL-CHEMO NATIONAL PErformance Formulary XPOVIO ORAL-CHEMO NATIONAL PErformance Formulary XYANDI ORAL-CHEMO NATIONAL PErformance Formulary XYANDI ORAL-CHEMO NATIONAL PErformance Formulary XYANDI ORAL-CHEMO NATIONAL PERFORMANCE PECIALTY NATIONAL PErformance Formulary XYANDI NON-PREFERRED-BRAND-SPECIALTY NATIONAL PErformance Formulary XYANDI NON-PREFERRED-BRAND-SPECIALTY NATIONAL PERFORMANCE PECIALTY N	WILATE	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
XALKORI ORAL-CHEMO National Performance Formulary XELIANZ NON-PREFERRED-BRAND-SPECIALTY XELIANZ NON-PREFERRED-BRAND-SPECIALTY XELIANZ PREFERRED-BRAND-SPECIALTY XELIANZ PREFERRED-BRAND-SPECIALTY XELIANZ PREFERRED-BRAND-SPECIALTY XELIANZ PREFERRED-BRAND-SPECIALTY XELIANZ PREFERRED-BRAND-SPECIALTY XEMBIFY NON-PREFERRED-BRAND-SPECIALTY XEMBIFY NON-PREFERRED-BRAND-SPECIALTY XEMBIFY NON-PREFERRED-BRAND-SPECIALTY XEOMIN NON-PREFERRED-BRAND-SPECIALTY XEOMIN NON-PREFERRED-BRAND-SPECIALTY XEOMIN NON-PREFERRED-BRAND-SPECIALTY XEOWIN NON-PREFERRED-BRAND-SPECIALTY XEOWIN NON-PREFERRED-BRAND-SPECIALTY XEOWIN XEOWA PREFERRED-BRAND-SPECIALTY XIBUE Cross Formulary XIAFLEX PREFERRED-BRAND-SPECIALTY NATIONAL Performance Formulary XOSPATA ORAL-CHEMO NATIONAL Performance Formulary XOSPATA ORAL-CHEMO NATIONAL PErformance Formulary XPOVIO ORAL-CHEMO NATIONAL PErformance Formulary XYANDI ORAL-CHEMO NATIONAL PErformance Formulary XYANDI ORAL-CHEMO NATIONAL PErformance Formulary XYANDI ORAL-CHEMO NATIONAL PERFORMANCE PECIALTY NATIONAL PErformance Formulary XYANDI NON-PREFERRED-BRAND-SPECIALTY NATIONAL PErformance Formulary XYANDI NON-PREFERRED-BRAND-SPECIALTY NATIONAL PERFORMANCE PECIALTY N			
XALKORI XELJANZ NON-PREFERRED-BRAND-SPECIALTY XELJANZ NON-PREFERRED-BRAND-SPECIALTY XELJANZ PREFERRED-BRAND-SPECIALTY XELJANZ PREFERRED-BRAND-SPECIALTY XELJANZ PREFERRED-BRAND-SPECIALTY XELJANZ PREFERRED-BRAND-SPECIALTY XELJANZ PREFERRED-BRAND-SPECIALTY XEMBIFY NON-PREFERRED-BRAND-SPECIALTY XEMBIFY NON-PREFERRED-BRAND-SPECIALTY XEMBIFY NON-PREFERRED-BRAND-SPECIALTY XEOMIN NON-PREFERRED-BRAND-SPECIALTY XEOMIN NON-PREFERRED-BRAND-SPECIALTY XEOMIN NON-PREFERRED-BRAND-SPECIALTY XIBOURD X	WINRHO	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
XELJANZ NON-PREFERRED-BRAND-SPECIALTY XELJANZ PREFERRED-BRAND-SPECIALTY XELJANZ PREFERRED-BRAND-SPECIALTY XELJANZ PREFERRED-BRAND-SPECIALTY XEMBIFY NON-PREFERRED-BRAND-SPECIALTY XEMBIFY NON-PREFERRED-BRAND-SPECIALTY XEMBIFY NON-PREFERRED-BRAND-SPECIALTY XEMBIFY NON-PREFERRED-BRAND-SPECIALTY XEOMIN XEOMIN XEOMIN NON-PREFERRED-BRAND-SPECIALTY XEOMIN XE	WINRHO WINRHO	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary
XELJANZ NON-PREFERRED-BRAND-SPECIALTY XELJANZ PREFERRED-BRAND-SPECIALTY XELJANZ PREFERRED-BRAND-SPECIALTY XELJANZ PREFERRED-BRAND-SPECIALTY XEMBIFY NON-PREFERRED-BRAND-SPECIALTY XEMBIFY NON-PREFERRED-BRAND-SPECIALTY XEMBIFY NON-PREFERRED-BRAND-SPECIALTY XEMBIFY NON-PREFERRED-BRAND-SPECIALTY XEOMIN XEOMIN XEOMIN NON-PREFERRED-BRAND-SPECIALTY XEOMIN XE	WINRHO WINRHO XALKORI	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO	Blue Cross Formulary National Performance Formulary Blue Cross Formulary
XELJANZ PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XELJANZ PREFERRED-BRAND-SPECIALTY National Performance Formulary XEMBIFY NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XEMBIFY NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary XEOMIN NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XEOMIN NON-PREFERED-BRAND-SPECIALTY Blue Cross Formulary XEOMIN NON-PREFERED-BRAND-SPECIALTY National Performance Formulary XGEVA PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XGEVA PREFERRED-BRAND-SPECIALTY National Performance Formulary XIAFLEX PREFERED-BRAND-SPECIALTY Blue Cross Formulary XIAFLEX PREFERED-BRAND-SPECIALTY National Performance Formulary XIAFLEX PREFERED-BRAND-SPECIALTY Blue Cross Formulary XOLAIR PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XOLAIR PREFERED-BRAND-SPECIALTY National Performance Formulary XOSPATA ORAL-CHEMO Blue Cross Formulary XOSPATA ORAL-CHEMO Blue Cross Formulary XOSPATA ORAL-CHEMO Blue Cross Formulary XPOVIO ORAL-CHEMO Blue Cross Formulary XPOVIO ORAL-CHEMO Blue Cross Formulary XTANDI ORAL-CHEMO National Performance Formulary XTANDI ORAL-CHEMO Blue Cross Formulary XTANDI ORAL-CHEMO National Performance Formulary XTANDI ORAL-CHEMO NATIONAL PERFORMAND-SPECIALTY XTANDI ORAL-CHEMO NATIONAL PERFORMAND-SPECIALTY XTANDI ORAL-CHEMO	WINRHO WINRHO XALKORI XALKORI	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO	Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
XELIANZ PREFERRED-BRAND-SPECIALTY Non-PREFERRED-BRAND-SPECIALTY Non-PREFERRED-BRAND-SPECIALTY XEMBIFY NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary XEOMIN NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XEOMIN NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary XEOMIN NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary XGEVA PREFERRED-BRAND-SPECIALTY National Performance Formulary XIAFLEX PREFERRED-BRAND-SPECIALTY National Performance Formulary XIAFLEX PREFERRED-BRAND-SPECIALTY National Performance Formulary XIAFLEX PREFERRED-BRAND-SPECIALTY National Performance Formulary XOLAIR PREFERRED-BRAND-SPECIALTY National Performance Formulary XOSPATA ORAL-CHEMO National Performance Formulary XOSPATA ORAL-CHEMO National Performance Formulary XOSPATA ORAL-CHEMO National Performance Formulary XPOVIO ORAL-CHEMO National Performance Formulary XPOVIO ORAL-CHEMO National Performance Formulary XTANDI ORAL-CHEMO Non-PREFERRED-BRAND-SPECIALTY National Performance Formulary XTANDI NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary XYNTHA PREFERRED-BRAND-SPECIALTY National Performance Formulary XYNTHA PREFERRED-BRAND-SPECIALTY National Performance Formulary XYNEM NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary XYWAV NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary XYWAV NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary XYWAV NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary YERVOY PREFERRED-BRAND-SPECIALTY National Performance Formulary PERFORMED-BRAND-SPECIALTY National Performance Formulary NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary YERVOY PREFERRED-B	WINRHO WINRHO XALKORI XALKORI XELJANZ	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
XEMBIFY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY XEOMIN XEOMIN NON-PREFERRED-BRAND-SPECIALTY XEOMIN XIAFLEX XEOMIN XIAFLEX XEOMIN XIAFLEX XEOMIN XIAFLEX XEOMIN XIAFLEX XEOMIN XEOMIN XIAFLEX XEOMIN	WINRHO WINRHO XALKORI XALKORI XELJANZ XELJANZ	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
XEOMIN NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XEOMIN NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary XGEVA PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XGEVA PREFERRED-BRAND-SPECIALTY National Performance Formulary XIAFLEX PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XIAFLEX PREFERRED-BRAND-SPECIALTY National Performance Formulary XOLAIR PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XOLAIR PREFERRED-BRAND-SPECIALTY National Performance Formulary XOSPATA ORAL-CHEMO Blue Cross Formulary XOSPATA ORAL-CHEMO National Performance Formulary XPOVIO ORAL-CHEMO National Performance Formulary XPOVIO ORAL-CHEMO Blue Cross Formulary XTANDI ORAL-CHEMO National Performance Formulary XTANDI NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary XYNTHA PREFERRED-BRAND-SPECIALTY National Performance Formulary XYREM NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary XYREM NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary XYWAV NON-PREFERRE	WINRHO WINRHO XALKORI XALKORI XELJANZ XELJANZ XELJANZ XELJANZ	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary
XEOMIN NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XEOMIN NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary XGEVA PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XGEVA PREFERRED-BRAND-SPECIALTY National Performance Formulary XIAFLEX PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XIAFLEX PREFERRED-BRAND-SPECIALTY National Performance Formulary XOLAIR PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XOLAIR PREFERRED-BRAND-SPECIALTY National Performance Formulary XOSPATA ORAL-CHEMO Blue Cross Formulary XOSPATA ORAL-CHEMO National Performance Formulary XPOVIO ORAL-CHEMO National Performance Formulary XPOVIO ORAL-CHEMO Blue Cross Formulary XTANDI ORAL-CHEMO National Performance Formulary XTANDI NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary XYNTHA PREFERRED-BRAND-SPECIALTY National Performance Formulary XYREM NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary XYREM NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary XYWAV NON-PREFERRE	WINRHO WINRHO XALKORI XALKORI XELJANZ XELJANZ XELJANZ XELJANZ XELJANZ XELJANZ	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary National Performance Formulary
XEOMIN NON-PREFERRED-BRAND-SPECIALTY Selve Cross Formulary (XGEVA) PREFERRED-BRAND-SPECIALTY XGEVA PREFERRED-BRAND-SPECIALTY XIAFLEX PREFERRED-BRAND-SPECIALTY XIAFLEX PREFERRED-BRAND-SPECIALTY XIAFLEX PREFERRED-BRAND-SPECIALTY XIAFLEX PREFERRED-BRAND-SPECIALTY XOLAIR PREFERRED-BRAND-SPECIALTY XOLAIR PREFERRED-BRAND-SPECIALTY XOLAIR PREFERRED-BRAND-SPECIALTY XOSPATA ORAL-CHEMO Blue Cross Formulary XOSPATA ORAL-CHEMO National Performance Formulary XPOVIO ORAL-CHEMO National Performance Formulary XPOVIO ORAL-CHEMO National Performance Formulary XPOVIO ORAL-CHEMO National Performance Formulary XTANDI ORAL-CHEMO National Performance Formulary XTANDI ORAL-CHEMO National Performance Formulary XIANDI ORAL-CHEMO National Performance Formulary XIANDI NON-PREFERRED-BRAND-SPECIALTY XURIDEN NON-PREFERRED-BRAND-SPECIALTY XYNTHA PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XYNTHA PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XYNTHA PREFERRED-BRAND-SPECIALTY NATIONAL PERFORMANCE FORMULARY XYNTHA PREFERRED-BRAND-SPECIALTY NATIONAL PERFORMANCE FORMULARY XYNTHA PREFERRED-BRAND-SPECIALTY NATIONAL PERFORMANCE FORMULARY XYNTHA NON-PREFERRED-BRAND-SPECIALTY NATIONAL PERFORMANCE FORMULARY XYNEM NON-PREFERRED-BRAND-SPECIALTY NATIONAL PERFORMANCE FORMULARY XYWAV NON-PREFERRED-BRAND-SPECIALTY NATIONAL PERFORMANCE FORMULARY YERVOY PREFERRED-BRAND-SPECIALTY NATIONAL PERFORMANCE FORMULARY NATIONAL PERFORMANCE FORMU	WINRHO WINRHO XALKORI XALKORI XELIANZ XELIANZ XELIANZ XELIANZ XELIANZ XELIANZ XELIANZ XELIANZ XELIANZ	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary
XGEVA PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XGEVA PREFERRED-BRAND-SPECIALTY National Performance Formulary XIAFLEX PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XIAFLEX PREFERRED-BRAND-SPECIALTY National Performance Formulary XOLAIR PREFERRED-BRAND-SPECIALTY National Performance Formulary XOLAIR PREFERED-BRAND-SPECIALTY National Performance Formulary XOSPATA ORAL-CHEMO Blue Cross Formulary XOSPATA ORAL-CHEMO National Performance Formulary XPOVIO ORAL-CHEMO Blue Cross Formulary XPOVIO ORAL-CHEMO National Performance Formulary XTANDI ORAL-CHEMO Blue Cross Formulary XTANDI ORAL-CHEMO National Performance Formulary XTANDI ORAL-CHEMO National Performance Formulary XURIDEN NON-PREFERRED-BRAND-SPECIALTY XURIDEN NON-PREFERRED-BRAND-SPECIALTY XYNTHA PREFERRED-BRAND-SPECIALTY XYNTHA PREFERRED-BRAND-SPECIALTY XYNTHA PREFERRED-BRAND-SPECIALTY XYNTHA PREFERRED-BRAND-SPECIALTY XYREM NON-PREFERRED-BRAND-SPECIALTY XYREM NON-PREFERRED-BRAND-SPECIALTY XYWAV NO	WINRHO WINRHO XALKORI XALKORI XELJANZ XELJANZ XELJANZ XELJANZ XELJANZ XELJANZ XELJANZ XELJANZ XEMBIFY XEMBIFY	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Alloue Cross Formulary National Performance Formulary
XGEVA PREFERRED-BRAND-SPECIALTY National Performance Formulary XIAFLEX PREFERED-BRAND-SPECIALTY Blue Cross Formulary XIAFLEX PREFERED-BRAND-SPECIALTY National Performance Formulary XOLAIR PREFERED-BRAND-SPECIALTY Blue Cross Formulary XOLAIR PREFERED-BRAND-SPECIALTY Blue Cross Formulary XOSPATA ORAL-CHEMO Blue Cross Formulary XOSPATA ORAL-CHEMO National Performance Formulary XOSPATA ORAL-CHEMO National Performance Formulary XPOVIO ORAL-CHEMO Blue Cross Formulary XPOVIO ORAL-CHEMO National Performance Formulary XTANDI ORAL-CHEMO Blue Cross Formulary XTANDI ORAL-CHEMO National Performance Formulary XVIRIDEN NON-PREFERED-BRAND-SPECIALTY XVIRIDEN NON-PREFERED-BRAND-SPECIALTY XVIRIDEN NON-PREFERED-BRAND-SPECIALTY XYNTHA PREFERED-BRAND-SPECIALTY XYNTHA PREFERED-BRAND-SPECIALTY XYNTHA PREFERED-BRAND-SPECIALTY XYREM NON-PREFERED-BRAND-SPECIALTY XYREM NON-PREFERED-BRAND-SPECIALTY XYWAV NON-PREFERED-BRAND-SPECIALTY XYBENOY PREFERED-BRAND-SPECIALTY X	WINRHO WINRHO XALKORI XALKORI XELJANZ XELJANZ XELJANZ XELJANZ XELJANZ XELJANZ XEMBIFY XEMBIFY XEMBIFY	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary
XIAFLEX PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XIAFLEX PREFERRED-BRAND-SPECIALTY National Performance Formulary XOLAIR PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XOLAIR PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XOLAIR PREFERRED-BRAND-SPECIALTY National Performance Formulary XOSPATA ORAL-CHEMO Blue Cross Formulary XOSPATA ORAL-CHEMO National Performance Formulary XPOVIO ORAL-CHEMO Blue Cross Formulary XPOVIO ORAL-CHEMO National Performance Formulary XTANDI ORAL-CHEMO Blue Cross Formulary XTANDI ORAL-CHEMO National Performance Formulary XURIDEN NON-PREFERRED-BRAND-SPECIALTY XURIDEN NON-PREFERRED-BRAND-SPECIALTY XYNTHA PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XYNTHA PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XYNTHA PREFERRED-BRAND-SPECIALTY National Performance Formulary XYREM NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XYREM NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary XYREM NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XYWAV NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary XYWAV NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XYWAV NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary XYWAV PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XYWAV PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XYWAV PREFERRED-BRAND-SPECIALTY National Performance Formula	WINRHO WINRHO XALKORI XALKORI XELJANZ XELJANZ XELJANZ XELJANZ XELJANZ XEMBIFY XEMBIFY XEMBIFY XEOMIN XEOMIN	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
XIAFLEX PREFERRED-BRAND-SPECIALTY National Performance Formulary XOLAIR PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XOLAIR PREFERRED-BRAND-SPECIALTY National Performance Formulary XOSPATA ORAL-CHEMO Blue Cross Formulary XOSPATA ORAL-CHEMO National Performance Formulary XOSPATA ORAL-CHEMO National Performance Formulary XPOVIO ORAL-CHEMO Blue Cross Formulary XPOVIO ORAL-CHEMO National Performance Formulary XTANDI ORAL-CHEMO Blue Cross Formulary XTANDI ORAL-CHEMO National Performance Formulary XURIDEN NON-PREFERRED-BRAND-SPECIALTY XURIDEN NON-PREFERRED-BRAND-SPECIALTY XYNTHA PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XYNTHA PREFERRED-BRAND-SPECIALTY National Performance Formulary XYREM NON-PREFERRED-BRAND-SPECIALTY XYREM NON-PREFERRED-BRAND-SPECIALTY XYREM NON-PREFERRED-BRAND-SPECIALTY XYREM NON-PREFERRED-BRAND-SPECIALTY XYWAV NON-PREFERRED-B	WINRHO WINRHO XALKORI XALKORI XELJANZ XELJANZ XELJANZ XELJANZ XELJANZ XEMBIFY XEMBIFY XEMBIFY XEMBIN XEOMIN XGEVA	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
XOLAIR PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XOLAIR PREFERRED-BRAND-SPECIALTY National Performance Formulary XOSPATA ORAL-CHEMO Blue Cross Formulary XOSPATA ORAL-CHEMO National Performance Formulary XPOVIO ORAL-CHEMO Blue Cross Formulary XPOVIO ORAL-CHEMO National Performance Formulary XPOVIO ORAL-CHEMO Blue Cross Formulary XTANDI ORAL-CHEMO Blue Cross Formulary XTANDI ORAL-CHEMO National Performance Formulary XURIDEN NON-PREFERRED-BRAND-SPECIALTY XURIDEN NON-PREFERRED-BRAND-SPECIALTY XVINTHA PREFERRED-BRAND-SPECIALTY XYNTHA PREFERRED-BRAND-SPECIALTY XYREM NON-PREFERRED-BRAND-SPECIALTY XYREM NON-PREFERRED-BRAND-SPECIALTY XYREM NON-PREFERRED-BRAND-SPECIALTY XYREM NON-PREFERRED-BRAND-SPECIALTY XYREM NON-PREFERRED-BRAND-SPECIALTY XYWAV NON-PREFERRED-BRAND-SPECIALTY XYWAY NON-PREFERRED-BRAND-SPECIALTY XYWA	WINRHO WINRHO XALKORI XALKORI XELJANZ XELJANZ XELJANZ XELJANZ XELJANZ XEMBIFY XEMBIFY XEMBIFY XEOMIN XEOMIN XGEVA XGEVA	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary National Performance Formulary
XOLAIR PREFERRED-BRAND-SPECIALTY National Performance Formulary XOSPATA ORAL-CHEMO Blue Cross Formulary XOSPATA ORAL-CHEMO National Performance Formulary XPOVIO ORAL-CHEMO Blue Cross Formulary XPOVIO ORAL-CHEMO National Performance Formulary XTANDI ORAL-CHEMO National Performance Formulary XTANDI ORAL-CHEMO Blue Cross Formulary XTANDI ORAL-CHEMO National Performance Formulary XURIDEN NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XURIDEN NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary XYNTHA PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XYNTHA PREFERRED-BRAND-SPECIALTY National Performance Formulary XYREM NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XYREM NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary XYWAV NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XYWAV NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary XYWAV NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XYWAV PREFERRED-BRAND-SPECIALTY National Performance Formulary YERVOY PREFERRED-BRAND-SPECIALTY Blue Cross Formulary YERVOY PREFERRED-BRAND-SPECIALTY National Performance Formulary	WINRHO WINRHO XALKORI XALKORI XELIANZ XELIANZ XELIANZ XELIANZ XELIANZ XELIANZ XEMBIFY XEMBIFY XEOMIN XEOMIN XGEVA XGEVA XIAFLEX	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
XOSPATA ORAL-CHEMO Blue Cross Formulary XOSPATA ORAL-CHEMO National Performance Formulary XPOVIO ORAL-CHEMO Blue Cross Formulary XPOVIO ORAL-CHEMO National Performance Formulary XTANDI ORAL-CHEMO Blue Cross Formulary XTANDI ORAL-CHEMO Blue Cross Formulary XTANDI ORAL-CHEMO National Performance Formulary XURIDEN NON-PREFERRED-BRAND-SPECIALTY XURIDEN NON-PREFERRED-BRAND-SPECIALTY XVYNTHA PREFERRED-BRAND-SPECIALTY XYNTHA PREFERRED-BRAND-SPECIALTY XYNTHA PREFERRED-BRAND-SPECIALTY XYREM NON-PREFERRED-BRAND-SPECIALTY XYREM NON-PREFERRED-BRAND-SPECIALTY XYREM NON-PREFERRED-BRAND-SPECIALTY XYWAV NON-PREFERRED-BRAND-SPECIALTY XYWAV NON-PREFERRED-BRAND-SPECIALTY XYWAV NON-PREFERRED-BRAND-SPECIALTY XYWAV NON-PREFERRED-BRAND-SPECIALTY XYWAV NON-PREFERRED-BRAND-SPECIALTY XYWAV PREFERRED-BRAND-SPECIALTY XYENOY PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XYENOY PREFERRED-BRAND-SPECIALTY National Performance Formulary YERVOY PREFERRED-BRAND-SPECIALTY National Performance Formulary National Performance Formulary National Performance Formulary	WINRHO WINRHO XALKORI XALKORI XELIANZ XELIANZ XELIANZ XELIANZ XELIANZ XEMBIFY XEMBIFY XEMBIFY XEOMIN XEOMIN XGEVA XIAFLEX XIAFLEX	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
XOSPATA ORAL-CHEMO National Performance Formulary XPOVIO ORAL-CHEMO Blue Cross Formulary XPOVIO ORAL-CHEMO National Performance Formulary XPOVIO ORAL-CHEMO National Performance Formulary XTANDI ORAL-CHEMO Blue Cross Formulary XTANDI ORAL-CHEMO National Performance Formulary XURIDEN NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XURIDEN NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary XYNTHA PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XYNTHA PREFERRED-BRAND-SPECIALTY National Performance Formulary XYREM NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XYREM NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary XYWAV NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary XYWAV NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XYWAV NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XYWAV NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary YERVOY PREFERRED-BRAND-SPECIALTY Blue Cross Formulary YERVOY PREFERRED-BRAND-SPECIALTY National Performance Formulary	WINRHO WINRHO XALKORI XALKORI XELJANZ XELJANZ XELJANZ XELJANZ XELJANZ XELJANZ XEMBIFY XEMBIFY XEMBIFY XEOMIN XEOMIN XGEVA XIAFLEX XIAFLEX XOLAIR	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary
XPOVIO ORAL-CHEMO Blue Cross Formulary XPOVIO ORAL-CHEMO National Performance Formulary XTANDI ORAL-CHEMO Blue Cross Formulary XTANDI ORAL-CHEMO Blue Cross Formulary XTANDI ORAL-CHEMO National Performance Formulary XURIDEN NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XURIDEN NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary XYNTHA PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XYNTHA PREFERRED-BRAND-SPECIALTY National Performance Formulary XYREM NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XYREM NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary XYWAV NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XYWAV NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XYWAV NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary YERVOY PREFERRED-BRAND-SPECIALTY Blue Cross Formulary YERVOY PREFERRED-BRAND-SPECIALTY Blue Cross Formulary	WINRHO WINRHO XALKORI XALKORI XELJANZ XELJANZ XELJANZ XELJANZ XELJANZ XELJANZ XEMBIFY XEMBIFY XEMBIFY XEOMIN XEOMIN XGEVA XGEVA XIAFLEX XIAFLEX XOLAIR	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
XPOVIO ORAL-CHEMO National Performance Formulary XTANDI ORAL-CHEMO Blue Cross Formulary XTANDI ORAL-CHEMO National Performance Formulary XTANDI ORAL-CHEMO National Performance Formulary XURIDEN NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XURIDEN NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary XYNTHA PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XYNTHA PREFERRED-BRAND-SPECIALTY National Performance Formulary XYREM NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XYREM NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary XYWAV NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XYWAV NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary XYWAV NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary YERVOY PREFERRED-BRAND-SPECIALTY Blue Cross Formulary YERVOY PREFERRED-BRAND-SPECIALTY National Performance Formulary	WINRHO WINRHO XALKORI XALKORI XELJANZ XELJANZ XELJANZ XELJANZ XELJANZ XELJANZ XEMBIFY XEMBIFY XEMBIFY XEOMIN XEOMIN XGEVA XGEVA XIAFLEX XIAFLEX XOLAIR XOLAIR	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO	Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary
XTANDI ORAL-CHEMO Blue Cross Formulary XTANDI ORAL-CHEMO National Performance Formulary XURIDEN NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XURIDEN NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary XYNTHA PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XYNTHA PREFERRED-BRAND-SPECIALTY National Performance Formulary XYREM NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XYREM NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary XYWAV NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XYWAV NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XYWAV NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary YERVOY PREFERRED-BRAND-SPECIALTY Blue Cross Formulary YERVOY PREFERRED-BRAND-SPECIALTY National Performance Formulary	WINRHO WINRHO XALKORI XALKORI XELJANZ XELJANZ XELJANZ XELJANZ XELJANZ XEMBIFY XEMBIFY XEMBIFY XEOMIN XEOMIN XGEVA XIAFLEX XIAFLEX XOLAIR XOSPATA	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO	Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
XTANDI ORAL-CHEMO National Performance Formulary XURIDEN NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XURIDEN NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary XYNTHA PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XYNTHA PREFERRED-BRAND-SPECIALTY National Performance Formulary XYREM NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XYREM NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary XYWAV NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XYWAV NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary XYWAV NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary YERVOY PREFERRED-BRAND-SPECIALTY Blue Cross Formulary YERVOY PREFERRED-BRAND-SPECIALTY National Performance Formulary	WINRHO WINRHO XALKORI XALKORI XELJANZ XELJANZ XELJANZ XELJANZ XELJANZ XEMBIFY XEMBIFY XEOMIN XEOMIN XEOMIN XGEVA XIAFLEX XIAFLEX XOLAIR XOLAIR XOSPATA XPOVIO	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO	Blue Cross Formulary National Performance Formulary National Performance Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
XURIDEN NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XURIDEN NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary XYNTHA PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XYNTHA PREFERRED-BRAND-SPECIALTY National Performance Formulary XYREM NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XYREM NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary XYWAV NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XYWAV NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary XYWAV PREFERRED-BRAND-SPECIALTY National Performance Formulary YERVOY PREFERRED-BRAND-SPECIALTY Blue Cross Formulary YERVOY PREFERRED-BRAND-SPECIALTY National Performance Formulary	WINRHO WINRHO XALKORI XALKORI XELIANZ XELIANZ XELIANZ XELIANZ XELIANZ XELIANZ XEMBIFY XEMBIFY XEMBIFY XEOMIN XEOMIN XEOMIN XGEVA XIAFLEX XIAFLEX XOLAIR XOLAIR XOSPATA XOSPATA XPOVIO	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO	Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
XURIDEN NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary XYNTHA PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XYNTHA PREFERRED-BRAND-SPECIALTY National Performance Formulary XYREM NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XYREM NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary XYWAV NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XYWAV NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary YERVOY PREFERRED-BRAND-SPECIALTY Blue Cross Formulary YERVOY PREFERRED-BRAND-SPECIALTY National Performance Formulary YERVOY PREFERRED-BRAND-SPECIALTY National Performance Formulary	WINRHO WINRHO XALKORI XALKORI XALKORI XELJANZ XELJANZ XELJANZ XELJANZ XELJANZ XELJANZ XEMBIFY XEMBIFY XEMBIFY XEOMIN XEOMIN XEOMIN XEOVA XIAFLEX XIAFLEX XOLAIR XOLAIR XOSPATA XPOVIO XPOVIO XTANDI	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO	Blue Cross Formulary National Performance Formulary
XYNTHA PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XYNTHA PREFERRED-BRAND-SPECIALTY National Performance Formulary XYREM NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XYREM NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary XYWAV NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XYWAV NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary YERVOY PREFERRED-BRAND-SPECIALTY Blue Cross Formulary YERVOY PREFERRED-BRAND-SPECIALTY National Performance Formulary YERVOY PREFERRED-BRAND-SPECIALTY National Performance Formulary	WINRHO WINRHO XALKORI XALKORI XELJANZ XELJANZ XELJANZ XELJANZ XELJANZ XELJANZ XEMBIFY XEMBIFY XEMBIFY XEOMIN XEOMIN XGEVA XIAFLEX XIAFLEX XOLAIR XOLAIR XOSPATA XOSPATA XPOVIO XPOVIO XTANDI XTANDI	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO	Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
XYNTHA PREFERRED-BRAND-SPECIALTY National Performance Formulary XYREM NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XYREM NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary XYWAV NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XYWAV NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary YERVOY PREFERRED-BRAND-SPECIALTY Blue Cross Formulary YERVOY PREFERRED-BRAND-SPECIALTY National Performance Formulary YERVOY PREFERRED-BRAND-SPECIALTY National Performance Formulary	WINRHO WINRHO XALKORI XALKORI XALKORI XELJANZ XELJANZ XELJANZ XELJANZ XELJANZ XELJANZ XELJANZ XEMBIFY XEMBIFY XEOMIN XEOMIN XEOVA XIAFLEX XIAFLEX XIAFLEX XOLAIR XOSPATA XOSPATA XPOVIO XPOVIO XTANDI XTANDI XURIDEN	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO	Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
XYREM NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XYREM NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary XYWAV NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XYWAV NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary YERVOY PREFERRED-BRAND-SPECIALTY Blue Cross Formulary YERVOY PREFERRED-BRAND-SPECIALTY National Performance Formulary YERVOY PREFERRED-BRAND-SPECIALTY National Performance Formulary	WINRHO WINRHO XALKORI XALKORI XALKORI XELJANZ XELJANZ XELJANZ XELJANZ XELJANZ XELJANZ XELJANZ XEMBIFY XEMBIFY XEMBIFY XEOMIN XGEVA XGEVA XGEVA XGEVA XIAFLEX XIAFLEX XOLAIR XOSPATA XOSPATA XOSPATA XPOVIO XPOVIO XTANDI XTANDI XURIDEN	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary
XYREM NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary XYWAV NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XYWAV NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary YERVOY PREFERRED-BRAND-SPECIALTY Blue Cross Formulary YERVOY PREFERRED-BRAND-SPECIALTY National Performance Formulary	WINRHO WINRHO XALKORI XALKORI XALKORI XELJANZ XELJANZ XELJANZ XELJANZ XELJANZ XELJANZ XELJANZ XEMBIFY XEMBIFY XEMBIFY XEOMIN XGEVA XGEVA XGEVA XIAFLEX XIAFLEX XIAFLEX XOLAIR XOSPATA XOSPATA XPOVIO XPOVIO XTANDI XTANDI XURIDEN XURIDEN XURIDEN	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary
XYWAV NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary XYWAV NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary YERVOY PREFERRED-BRAND-SPECIALTY Blue Cross Formulary YERVOY PREFERRED-BRAND-SPECIALTY National Performance Formulary	WINRHO WINRHO XALKORI XALKORI XALKORI XELIANZ XELIANZ XELIANZ XELIANZ XELIANZ XELIANZ XEMBIFY XEMBIFY XEMBIFY XEOMIN XEOMIN XGEVA XIAFLEX XIAFLEX XIAFLEX XOLAIR XOLAIR XOSPATA XOSPATA XPOVIO XTANDI XTANDI XTANDI XURIDEN XURIDEN XYNTHA	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary
XYWAV NON-PREFERRED-BRAND-SPECIALTY National Performance Formulary YERVOY PREFERRED-BRAND-SPECIALTY Blue Cross Formulary YERVOY PREFERRED-BRAND-SPECIALTY National Performance Formulary	WINRHO WINRHO XALKORI XALKORI XELIANZ XELIANZ XELIANZ XELIANZ XELIANZ XELIANZ XEMBIFY XEMBIFY XEMBIFY XEOMIN XEOMIN XEOMIN XGEVA XIAFLEX XIAFLEX XOLAIR XOLAIR XOSPATA XOSPATA XOSPATA XOSPATA XPOVIO XTANDI XTANDI XTANDI XURIDEN XVNTHA XYNTHA XYNTHA XYNTHA	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary
YERVOY PREFERRED-BRAND-SPECIALTY Blue Cross Formulary YERVOY PREFERRED-BRAND-SPECIALTY National Performance Formulary	WINRHO WINRHO XALKORI XALKORI XALKORI XELIANZ XELIANZ XELIANZ XELIANZ XELIANZ XELIANZ XEMBIFY XEMBIFY XEMBIFY XEOMIN XEOMIN XEOVA XIAFLEX XIAFLEX XIAFLEX XOLAIR XOSPATA XOSPATA XOSPATA XPOVIO XTANDI XTANDI XURIDEN XURIDEN XYNTHA XYNTHA XYNTHA XYREM XYREM	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary National Performance Formulary Blue Cross Formulary National Performance Formulary
YERVOY PREFERRED-BRAND-SPECIALTY National Performance Formulary	WINRHO WINRHO XALKORI XALKORI XELIANZ XELIANZ XELIANZ XELIANZ XELIANZ XELIANZ XEMBIFY XEMBIFY XEMBIFY XEOMIN XEOMIN XEOMIN XGEVA XIAFLEX XIAFLEX XOLAIR XOLAIR XOSPATA XOSPATA XOSPATA XPOVIO XPOVIO XTANDI XTANDI XURIDEN XURIDEN XURIDEN XYNTHA XYNTHA XYNTHA XYREM XYREM XYWAV	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary
	WINRHO WINRHO XALKORI XALKORI XELJANZ XELJANZ XELJANZ XELJANZ XELJANZ XELJANZ XELJANZ XEMBIFY XEMBIFY XEMBIFY XEOMIN XEOMIN XEOVA XIAFLEX XIAFLEX XOLAIR XOSPATA XOSPATA XOSPATA XPOVIO XPOVIO XTANDI XTANDI XURIDEN XURIDEN XYNTHA XYNTHA XYREM XYREM XYWAV XYWAV	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary
YESCAKIA NON-PREFERRED-BRAND-SPECIALTY Blue Cross Formulary	WINRHO WINRHO XALKORI XALKORI XALKORI XELJANZ XELJANZ XELJANZ XELJANZ XELJANZ XELJANZ XELJANZ XEMBIFY XEMBIFY XEMBIFY XEOMIN XEOMIN XGEVA XGEVA XIAFLEX XOLAIR XOLAIR XOSPATA XOSPATA XPOVIO XPOVIO XTANDI XTANDI XURIDEN XURIDEN XURIDEN XYNTHA XYNTHA XYNTHA XYREM XYREM XYREM XYWAV XYWAV YYERVOY	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary
	WINRHO WINRHO XALKORI XALKORI XALKORI XELJANZ XELJANZ XELJANZ XELJANZ XELJANZ XELJANZ XELJANZ XEMBIFY XEMBIFY XEMBIFY XEOMIN XGEVA XGEVA XGEVA XGEVA XIAFLEX XIAFLEX XOLAIR XOSPATA XOSPATA XPOVIO XPOVIO XTANDI XTANDI XTANDI XURIDEN XURIDEN XYNTHA XYNTHA XYREM XYREM XYWAV XYWAV YERVOY	PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO ORAL-CHEMO NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY NON-PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary National Performance Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary Blue Cross Formulary National Performance Formulary

VECCAREA	NON DESCRIPTION OF THE CONTRACTOR	N. C. 10 C. 5 1
YESCARTA	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
YONDELIS	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
YONDELIS	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
YONSA	ORAL-CHEMO	Blue Cross Formulary
YUTIQ	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
YUTIQ	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
ZALTRAP	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ZALTRAP	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
ZANOSAR	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ZANOSAR	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
ZARXIO	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ZARXIO	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
ZAVESCA	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ZAVESCA	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
ZEJULA	ORAL-CHEMO	Blue Cross Formulary
ZEJULA	ORAL-CHEMO	National Performance Formulary
ZELBORAF	ORAL-CHEMO	Blue Cross Formulary
ZELBORAF	ORAL-CHEMO	National Performance Formulary
ZEMAIRA	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ZEMAIRA	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
ZEPATIER	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ZEPATIER	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
ZEPOSIA	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ZEPOSIA	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
ZEPZELCA	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ZEPZELCA	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
ZEVALIN	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ZEVALIN	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
ZIEXTENZO	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ZIEXTENZO	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
ZIRABEV	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ZIRABEV	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
ZOLADEX	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ZOLADEX	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
ZOLADEX	PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ZOLADEX	PREFERRED-BRAND-SPECIALTY	National Performance Formulary
ZOLEDRONIC	GENERIC-SPECIALTY	Blue Cross Formulary
ZOLEDRONIC	GENERIC-SPECIALTY	National Performance Formulary
ZOLGENSMA	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ZOLGENSMA	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
ZOLINZA	ORAL-CHEMO	Blue Cross Formulary
ZOLINZA	ORAL-CHEMO	National Performance Formulary
ZOMACTON	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ZORBTIVE	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ZORBTIVE	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
ZORTRESS	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ZORTRESS	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
ZULRESSO	NON-PREFERRED-BRAND-SPECIALTY	Blue Cross Formulary
ZULRESSO	NON-PREFERRED-BRAND-SPECIALTY	National Performance Formulary
ZYDELIG	ORAL-CHEMO	Blue Cross Formulary
ZYDELIG	ORAL-CHEMO	National Performance Formulary
ZYKADIA	ORAL-CHEMO	Blue Cross Formulary
ZYKADIA	ORAL-CHEMO	National Performance Formulary
ZYTIGA	ORAL-CHEMO	Blue Cross Formulary
ZITIOA	ONAL-CITEIVIO	blue Cross Formulary

Insurance Company Name The Vermont Health Plan

HIOS ID 99852
SERFF Filing Number BCVT-133154563
Market Large Group

Product Name Q3 2022 TVHP Large Group Rating Program Filing

Pharmacy Benefit Manager Information²

Please list any pharmacy benefit managers utilized for the following periods. Include additional lines as necessary.

	Experience Period -1	Experience Period	Projection Period
	09/01/2019-08/31/2020	09/01/2020-08/31/2021	1/01/2023-12/31/202
Pharmacy Benefit Manager #1	Express Scripts (ESI)	Express Scripts (ESI)	Optum Rx (ORx)
Pharmacy Benefit Manager #2		Optum Rx (ORx)	
Pharmacy Benefit Manager #3			
Pharmacy Benefit Manager #4			

For each period, enter the PBM, if applicable, administering pharmacy benefits at a pharmacy, network pharmacy, or mail-order pharmacy for each drug tier.

	Experience Period -1		Experience Period		Projection Period	
	09/01/2019-08/31/2020		09/01/2020-08/31/2021		1/01/2023-12/31/2023	
	Retail	Mail	Retail	Mail	Retail	Mail
Non-Specialty Generic PMPM	ESI	ESI	ESI/ORx	ESI/ORx	ORx	ORx
Non-Specialty Brand PMPM	ESI	ESI	ESI/ORx	ESI/ORx	ORx	ORx
Specialty PMPM	ESI	ESI	ESI/ORx	ESI/ORx	ORx	ORx

For each period, enter the PBM, if applicable, administering drug benefits by a health care provider in an outpatient setting as part of the medical benefit as separate from the pharmacy benefit for each drug tier.

	Experience Period -1		Experience Period		Projection Period	
	09/01/2019-08/31/2020		09/01/2020-08/31/2021		1/01/2023-12/31/2023	
	Retail	Mail	Retail	Mail	Retail	Mail
Non-Specialty Generic PMPM	N/A	N/A	N/A	N/A	N/A	N/A
Non-Specialty Brand PMPM	N/A	N/A	N/A	N/A	N/A	N/A
Specialty PMPM	N/A	N/A	N/A	N/A	N/A	N/A

² Vermont Statute 8 V.S.A. § 4062

(2)(A) In conjunction with a rate filing required by subsection (a) of this section, an insurer shall disclose to the Board:
(C) The insurer shall include information on its use of a pharmacy benefit manager, if any, including which components of the prescription drug coverage described in subdivisions (A) and (B) of this subdivision (2) are managed by the pharmacy benefit manager, as well as the name of the pharmacy benefit manager or managers used.